{"d5ac016c92e3b02870f7761d52e80824c9ed0b14": [["secondary infection risk, to have similar transmission potential to influenza A(H3N2) in 23 the same population.", [["infection", "DISEASE", 10, 19], ["influenza A", "DISEASE", 68, 79], ["influenza A(H3N2", "ORGANISM", 68, 84], ["secondary infection risk", "PROBLEM", 0, 24], ["influenza A(H3N2)", "PROBLEM", 68, 85], ["infection", "OBSERVATION", 10, 19]]], ["24 A c c e p t e d M a n u s c r i p t Coronaviruses, long known to infect a wide variety of species, have been recognized as 25 human respiratory pathogens for more than 60 years.", [["respiratory pathogens", "DISEASE", 135, 156], ["human", "ORGANISM", 129, 134], ["t Coronaviruses", "DNA", 37, 52], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["a n u s", "TEST", 21, 28], ["t Coronaviruses", "PROBLEM", 37, 52], ["a wide variety of species", "PROBLEM", 75, 100], ["human respiratory pathogens", "PROBLEM", 129, 156]]], ["[1] [2] [3] While animal coronaviruses 26 have been associated with severe disease in their respective hosts, human 27 coronaviruses (HCoV) were historically detected in mild respiratory illnesses.", [["respiratory", "ANATOMY", 175, 186], ["respiratory illnesses", "DISEASE", 175, 196], ["[1] [2] [3", "SIMPLE_CHEMICAL", 0, 10], ["coronaviruses", "ORGANISM", 25, 38], ["human", "ORGANISM", 110, 115], ["27 coronaviruses", "ORGANISM", 116, 132], ["HCoV", "CANCER", 134, 138], ["human", "SPECIES", 110, 115], ["human 27 coronaviruses", "SPECIES", 110, 132], ["HCoV", "SPECIES", 134, 138], ["animal coronaviruses", "PROBLEM", 18, 38], ["severe disease in their respective hosts", "PROBLEM", 68, 108], ["mild respiratory illnesses", "PROBLEM", 170, 196], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["disease", "OBSERVATION", 75, 82], ["mild", "OBSERVATION_MODIFIER", 170, 174], ["respiratory illnesses", "OBSERVATION", 175, 196]]], ["4-6 28 Therefore, the identification of Severe Acute Respiratory Syndrome (SARS) as caused 29 by a coronavirus of animal origin in 2002 was a surprise because of its epidemic 30 behavior as well as its severity.", [["Acute Respiratory Syndrome", "DISEASE", 47, 73], ["SARS", "DISEASE", 75, 79], ["coronavirus", "DISEASE", 99, 110], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 40, 80], ["Severe Acute Respiratory Syndrome", "PROBLEM", 40, 73], ["Severe", "OBSERVATION_MODIFIER", 40, 46], ["Acute", "OBSERVATION_MODIFIER", 47, 52], ["Respiratory Syndrome", "OBSERVATION", 53, 73]]], ["7, 8 Also a surprise was ultimate interruption of SARS 31 transmission by public health measures.", [["SARS", "DISEASE", 50, 54], ["public health measures", "TREATMENT", 74, 96]]], ["9 In 2012, another novel coronavirus of animal 32 origin emerged as the causative agent of Middle East Respiratory Syndrome (MERS).", [["Middle East Respiratory Syndrome", "DISEASE", 91, 123], ["MERS", "DISEASE", 125, 129], ["coronavirus", "ORGANISM", 25, 36], ["coronavirus", "SPECIES", 25, 36], ["Middle East Respiratory Syndrome", "PROBLEM", 91, 123], ["coronavirus", "OBSERVATION", 25, 36], ["Middle", "ANATOMY_MODIFIER", 91, 97], ["Respiratory Syndrome", "OBSERVATION", 103, 123]]], ["1033Unlike SARS, human-to-human transmission of MERS has been limited and sporadic 34 cases have continued to occur primarily in Saudi Arabia among those with contact with 35 camels.", [["SARS", "DISEASE", 11, 15], ["MERS", "DISEASE", 48, 52], ["human", "ORGANISM", 17, 22], ["human", "ORGANISM", 26, 31], ["MERS", "CANCER", 48, 52], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 26, 31], ["SARS", "PROBLEM", 11, 15], ["sporadic 34 cases", "PROBLEM", 74, 91]]], ["11 The current outbreak of a novel coronavirus (SARS-CoV-2) has focused 36 attention back to this often forgotten and unstudied group of pathogens.", [["coronavirus", "DISEASE", 35, 46], ["SARS", "DISEASE", 48, 52], ["coronavirus", "ORGANISM", 35, 46], ["SARS-CoV-2", "ORGANISM", 48, 58], ["coronavirus", "SPECIES", 35, 46], ["a novel coronavirus", "PROBLEM", 27, 46], ["pathogens", "PROBLEM", 137, 146], ["pathogens", "OBSERVATION", 137, 146]]], ["1237HCoVs were first recognized when specimens from individuals ill with respiratory 38 illnesses were inoculated into organ cultures.", [["specimens", "ANATOMY", 37, 46], ["organ cultures", "ANATOMY", 119, 133], ["respiratory 38 illnesses", "DISEASE", 73, 97], ["1237HCoVs", "GENE_OR_GENE_PRODUCT", 0, 9], ["organ cultures", "CELL", 119, 133], ["respiratory 38 illnesses", "PROBLEM", 73, 97], ["organ cultures", "TEST", 119, 133]]], ["One of these viruses is now known as OC 39 (organ culture) 43.", [["organ culture", "ANATOMY", 44, 57], ["OC", "CHEMICAL", 37, 39], ["organ", "ORGAN", 44, 49], ["organ culture", "TEST", 44, 57], ["viruses", "OBSERVATION", 13, 20]]], ["13 Another virus, 229E was first grown in primary human kidney 40 culture.", [["kidney", "ANATOMY", 56, 62], ["human", "ORGANISM", 50, 55], ["kidney", "ORGAN", 56, 62], ["primary human kidney 40 culture", "CELL_LINE", 42, 73], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["Another virus", "PROBLEM", 3, 16], ["culture", "TEST", 66, 73], ["kidney", "ANATOMY", 56, 62]]], ["14 Because of the difficulties in isolating them, much of the initial work in 41 understanding their occurrence in was done by serology.", [["serology", "TEST", 127, 135]]], ["15, 16 Following renewed interest 42 after the SARS epidemic, two additional coronaviruses, HKU1 and NL63, were identified 43 in the 2000's, first from persons with severe respiratory illnesses.", [["respiratory", "ANATOMY", 172, 183], ["SARS", "DISEASE", 47, 51], ["respiratory illnesses", "DISEASE", 172, 193], ["coronaviruses", "ORGANISM", 77, 90], ["HKU1", "GENE_OR_GENE_PRODUCT", 92, 96], ["persons", "ORGANISM", 152, 159], ["persons", "SPECIES", 152, 159], ["the SARS epidemic", "PROBLEM", 43, 60], ["HKU1", "TEST", 92, 96], ["severe respiratory illnesses", "PROBLEM", 165, 193], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["respiratory illnesses", "OBSERVATION", 172, 193]]], ["17-20 44 Availability of reverse-transcriptase polymerase chain reaction (RT-PCR) has now made 45 it possible to detect infection easily for each of the 4 known human coronaviruses.", [["infection", "DISEASE", 120, 129], ["human", "ORGANISM", 161, 166], ["coronaviruses", "ORGANISM", 167, 180], ["human", "SPECIES", 161, 166], ["human coronaviruses", "SPECIES", 161, 180], ["reverse-transcriptase polymerase chain reaction", "PROBLEM", 25, 72], ["RT-PCR", "TEST", 74, 80], ["infection", "PROBLEM", 120, 129], ["the 4 known human coronaviruses", "PROBLEM", 149, 180], ["infection", "OBSERVATION", 120, 129]]], ["46 However, as data from population-based studies using molecular methods have A c c e p t e d M a n u s c r i p t accumulated, minimal attention has been paid to these viruses, perhaps because there HCoV type involved in coincident detection was also included in type-specific analyses.102Type-specific coronavirus incidence and corresponding 95% confidence intervals were 103 calculated by age group (<5, 6-11, 12-17, 18-49, and \u226550 years) and by study year.", [["HCoV", "GENE_OR_GENE_PRODUCT", 200, 204], ["coronavirus", "ORGANISM", 304, 315], ["a n u s", "TEST", 97, 104], ["these viruses", "PROBLEM", 163, 176], ["Type-specific coronavirus incidence", "PROBLEM", 290, 325], ["minimal", "OBSERVATION_MODIFIER", 128, 135], ["viruses", "OBSERVATION", 169, 176], ["coronavirus", "OBSERVATION", 304, 315]]], ["Age-adjusted multinomial logistic regression models were then used to compare the 128 odds of being assigned to each latent class between the four HCoV types.130Characteristics of the study population 131 The number of individuals under study ranged from 895 to 1441, and the number of 132 households ranged from 209 to 340 over the 8 years (Table 1)138The number of ARIs reported also varied from year to year, mainly related to the 139 number of individuals on report but also the differential occurrence of influenza and 140 other respiratory viruses (Table 1) person-years was relatively low and did not vary by age, the incidence was consistently 166 highest among children less than 5 years (Figure 3 ).", [["influenza", "DISEASE", 510, 519], ["respiratory viruses", "DISEASE", 534, 553], ["HCoV", "CANCER", 147, 151], ["children", "ORGANISM", 670, 678], ["person", "SPECIES", 564, 570], ["children", "SPECIES", 670, 678], ["the study population", "TEST", 180, 200], ["study", "TEST", 237, 242], ["ARIs", "PROBLEM", 367, 371], ["influenza", "PROBLEM", 510, 519], ["140 other respiratory viruses", "PROBLEM", 524, 553], ["influenza", "OBSERVATION", 510, 519]]], ["Among those older than 5 years, 167 incidence was relatively flat with little consistent variation with increase in age. a n u s c r i p t illnesses in children less than 5 years and adults older than 50 years were most likely to 180 be classified as severe.", [["children", "ORGANISM", 152, 160], ["children", "SPECIES", 152, 160], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["severe", "OBSERVATION_MODIFIER", 251, 257]]], ["In age-adjusted multinomial regression models (Table 2) (Table 3) . has most frequently infected adults to date.", [["adults", "ORGANISM", 97, 103], ["most frequently", "OBSERVATION_MODIFIER", 72, 87], ["infected", "OBSERVATION", 88, 96]]], ["30 Whether the relative sparing of children 236 has largely been driven by contact and exposure patterns or other factors remains 237 unclear.", [["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["sparing", "OBSERVATION_MODIFIER", 24, 31]]], ["However, the frequency of infection in adults suggests that there is likely little 238 cross-protective immunity from prior seasonal HCoV infection.239The MERS coronavirus is limited in its potential for human to human transmission 240 except in the nosocomial setting.", [["infection", "DISEASE", 26, 35], ["HCoV infection", "DISEASE", 133, 147], ["HCoV", "CANCER", 133, 137], ["MERS coronavirus", "ORGANISM", 155, 171], ["human", "ORGANISM", 204, 209], ["human", "ORGANISM", 213, 218], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 213, 218], ["HCoV", "SPECIES", 133, 137], ["MERS coronavirus", "SPECIES", 155, 171], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 213, 218], ["infection", "PROBLEM", 26, 35], ["prior seasonal HCoV infection", "PROBLEM", 118, 147], ["The MERS coronavirus", "PROBLEM", 151, 171], ["infection", "OBSERVATION", 26, 35], ["likely", "UNCERTAINTY", 69, 75], ["little", "OBSERVATION_MODIFIER", 76, 82], ["238 cross-protective immunity", "OBSERVATION_MODIFIER", 83, 112], ["seasonal HCoV", "OBSERVATION_MODIFIER", 124, 137], ["infection", "OBSERVATION", 138, 147]]], ["11 Although the SARS coronavirus more effectively 241 transmitted human to human, transmission was interrupted by public health 242 interventions.", [["SARS coronavirus", "DISEASE", 16, 32], ["SARS coronavirus", "ORGANISM", 16, 32], ["human", "ORGANISM", 66, 71], ["human", "ORGANISM", 75, 80], ["coronavirus", "SPECIES", 21, 32], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 75, 80], ["SARS coronavirus", "SPECIES", 16, 32], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 75, 80], ["the SARS coronavirus", "PROBLEM", 12, 32]]], ["31 The seasonal HCoV viruses are clearly different in their transmission 243 characteristics given their continued seasonal circulation year after year.", [["HCoV viruses", "ORGANISM", 16, 28], ["HCoV", "SPECIES", 16, 20], ["The seasonal HCoV viruses", "PROBLEM", 3, 28], ["seasonal", "OBSERVATION_MODIFIER", 7, 15], ["HCoV viruses", "OBSERVATION", 16, 28], ["different", "OBSERVATION_MODIFIER", 41, 50]]], ["The serial 244 interval between cases and the secondary infection risk in the HIVE cohort was similar 245 to that previously found for A(H3N2).", [["infection", "DISEASE", 56, 65], ["A(H3N2)", "ORGANISM", 135, 142], ["the secondary infection risk", "PROBLEM", 42, 70], ["secondary", "OBSERVATION_MODIFIER", 46, 55], ["infection", "OBSERVATION", 56, 65]]], ["32 Our secondary attack rates may reflect the 246 smaller household structure found in our region.", [["Our secondary attack rates", "PROBLEM", 3, 29], ["smaller", "OBSERVATION_MODIFIER", 50, 57]]], ["A longitudinal study in Kenya found 247 M a n u s c r i p t overall attack rates as high as 34.0% over one season in a study of households of sizes 248 ranging to 37 members.", [["A longitudinal study", "TEST", 0, 20], ["overall attack rates", "TEST", 60, 80]]], ["33249The transition from pandemic to seasonal circulation is well established for influenza, 250 wherein, following an influenza pandemic, the novel virus becomes the new seasonal 251 virus, replacing the previous A subtype.", [["33249", "CHEMICAL", 0, 5], ["influenza", "DISEASE", 82, 91], ["influenza pandemic", "DISEASE", 119, 137], ["33249", "SPECIES", 0, 5], ["seasonal 251 virus", "SPECIES", 171, 189], ["The transition", "PROBLEM", 5, 19], ["influenza", "PROBLEM", 82, 91], ["an influenza pandemic", "PROBLEM", 116, 137], ["the novel virus", "PROBLEM", 139, 154], ["the new seasonal 251 virus", "PROBLEM", 163, 189]]], ["34 The four current HCoVs have been circulating 252 for decades, and it is unclear how they initially emerged or whether they replaced 253 previously circulating viruses.", [["HCoVs", "GENE_OR_GENE_PRODUCT", 20, 25], ["HCoVs", "DNA", 20, 25]]]], "PMC7417848": [["Das Sp\u00fclk\u00e4nnchen darf nicht zur Virusschleuder werden!Nach der verf\u00fcgbaren Evidenz k\u00f6nne man das Nasenduschen mit Salzl\u00f6sung tats\u00e4chlich empfehlen, auch in Gegenwart von COVID-19, wobei man allerdings auch an das m\u00f6gliche Risiko einer Virusverbreitung denken sollte.", [["Nach der verf\u00fcgbaren Evidenz k\u00f6nne man das Nasenduschen mit Salzl\u00f6sung tats\u00e4chlich empfehlen, auch in Gegenwart von COVID-19", "SPECIES", 54, 178]]], ["Das HNO-Team r\u00e4t deshalb, besonders auf Handhygiene zu achten und nach der Anwendung sowohl das Sp\u00fclgef\u00e4\u00df als auch umliegende Oberfl\u00e4chen gr\u00fcndlich zu desinfizieren.", [["besonders auf Handhygiene zu achten und nach der Anwendung sowohl das Sp\u00fclgef\u00e4\u00df als auch umliegende Oberfl\u00e4chen gr\u00fcndlich zu desinfizieren", "SPECIES", 26, 164]]], ["SARS-CoV-2 war auf Plastik \u00fcber mehr als 72 Stunden nachweisbar.", [["SARS", "DISEASE", 0, 4]]], ["Inaktiviert werden k\u00f6nne es mit Diethylether, 75%igem Alkohol, Chlor, UV-Licht oder Hitze (mindesten 56 \u00b0C \u00fcber eine halbe Stunde).Das Sp\u00fclk\u00e4nnchen darf nicht zur Virusschleuder werden!Zum Einsatz in Corona-Zeiten empfehlen die Experten ggf. h\u00f6her konzentrierte L\u00f6sungen, sog.", [["Zum Einsatz", "TREATMENT", 185, 196], ["Corona", "ANATOMY_MODIFIER", 200, 206], ["sog", "ANATOMY", 272, 275]]], ["In einer randomisierten Studie senkte die HS-L\u00f6sung bei Patienten mit gew\u00f6hnlicher Erk\u00e4ltung nicht nur die Krankheitsdauer, sondern reduzierte auch die Virusausscheidung sowie die \u00dcbertragung an Haushaltsmitglieder.", [["HS", "TEST", 42, 44]]]], "23f357476bb9bb9d39af55dbab060f374e831c69": [["IntroductionPuromycin is a potent translational inhibitor that binds to ribosomes from all domains of life and has been used as a chemical probe and selectable marker for decades (Aviner, 2020; Yarmolinsky and Haba, 1959) .", [["ribosomes", "ANATOMY", 72, 81], ["IntroductionPuromycin", "CHEMICAL", 0, 21], ["IntroductionPuromycin", "CHEMICAL", 0, 21], ["IntroductionPuromycin", "SIMPLE_CHEMICAL", 0, 21], ["ribosomes", "CELLULAR_COMPONENT", 72, 81], ["IntroductionPuromycin", "TREATMENT", 0, 21], ["a potent translational inhibitor", "TREATMENT", 25, 57], ["a chemical probe", "TREATMENT", 128, 144]]], ["Puromycin is unique among translational inhibitors in that it is itself a substrate of the ribosomal peptidyl-transferase reaction (Nathans, 1964) .", [["ribosomal", "ANATOMY", 91, 100], ["Puromycin", "CHEMICAL", 0, 9], ["Puromycin", "CHEMICAL", 0, 9], ["Puromycin", "SIMPLE_CHEMICAL", 0, 9], ["ribosomal", "CELLULAR_COMPONENT", 91, 100], ["peptidyl-transferase", "GENE_OR_GENE_PRODUCT", 101, 121], ["ribosomal peptidyl-transferase", "PROTEIN", 91, 121], ["Puromycin", "TREATMENT", 0, 9], ["translational inhibitors", "TREATMENT", 26, 50], ["the ribosomal peptidyl-transferase reaction", "PROBLEM", 87, 130]]], ["Puromycin mimics the 3 0 adenosine of a tRNA charged with a modified tyrosine, which binds in the ribosomal acceptor site ( Figure 1A) .", [["ribosomal", "ANATOMY", 98, 107], ["Puromycin", "CHEMICAL", 0, 9], ["adenosine", "CHEMICAL", 25, 34], ["tyrosine", "CHEMICAL", 69, 77], ["Puromycin", "CHEMICAL", 0, 9], ["adenosine", "CHEMICAL", 25, 34], ["tyrosine", "CHEMICAL", 69, 77], ["Puromycin", "SIMPLE_CHEMICAL", 0, 9], ["adenosine", "SIMPLE_CHEMICAL", 25, 34], ["tyrosine", "AMINO_ACID", 69, 77], ["ribosomal", "CELLULAR_COMPONENT", 98, 107], ["ribosomal acceptor site", "PROTEIN", 98, 121], ["Puromycin mimics", "TREATMENT", 0, 16], ["a tRNA", "TREATMENT", 38, 44], ["a modified tyrosine", "TREATMENT", 58, 77], ["ribosomal", "OBSERVATION", 98, 107], ["acceptor site", "OBSERVATION", 108, 121]]], ["The ribosome transfers the nascent peptide chain on the P-site tRNA to puromycin, leading to spontaneous dissociation of the nascent peptide from the ribosome ( Figure 1B ; Nathans, 1964) .IntroductionThe development of anti-puromycin antibodies and of derivatized analogs of puromycin (Fujiwara et al., 1982; Liu et al., 2012) has led to the commonplace use of puromycin as a metabolic probe to measure the extent of active translation, replacing radioactive tracers such as S35 methionine.", [["puromycin", "CHEMICAL", 71, 80], ["puromycin", "CHEMICAL", 276, 285], ["puromycin", "CHEMICAL", 362, 371], ["S35 methionine", "CHEMICAL", 476, 490], ["puromycin", "CHEMICAL", 71, 80], ["puromycin", "CHEMICAL", 276, 285], ["puromycin", "CHEMICAL", 362, 371], ["S35 methionine", "CHEMICAL", 476, 490], ["ribosome", "CELLULAR_COMPONENT", 4, 12], ["puromycin", "SIMPLE_CHEMICAL", 71, 80], ["ribosome", "CELLULAR_COMPONENT", 150, 158], ["anti-puromycin antibodies", "GENE_OR_GENE_PRODUCT", 220, 245], ["puromycin", "SIMPLE_CHEMICAL", 276, 285], ["puromycin", "SIMPLE_CHEMICAL", 362, 371], ["S35 methionine", "SIMPLE_CHEMICAL", 476, 490], ["P-site tRNA", "DNA", 56, 67], ["anti-puromycin antibodies", "PROTEIN", 220, 245], ["the nascent peptide chain", "TREATMENT", 23, 48], ["the P-site tRNA", "TREATMENT", 52, 67], ["puromycin", "TREATMENT", 71, 80], ["spontaneous dissociation", "PROBLEM", 93, 117], ["anti-puromycin antibodies", "TREATMENT", 220, 245], ["puromycin", "TREATMENT", 276, 285], ["puromycin", "TREATMENT", 362, 371], ["a metabolic probe", "TREATMENT", 375, 392], ["radioactive tracers", "TREATMENT", 448, 467], ["S35 methionine", "TREATMENT", 476, 490], ["chain", "OBSERVATION_MODIFIER", 43, 48], ["spontaneous", "OBSERVATION_MODIFIER", 93, 104], ["dissociation", "OBSERVATION", 105, 117], ["active", "OBSERVATION_MODIFIER", 418, 424], ["translation", "OBSERVATION", 425, 436]]], ["These probes can be used to quantify the amount of active translation from cells in a culture dish, tissue or organism (Schmidt et al., 2009; Chao et al., 2012) .", [["cells", "ANATOMY", 75, 80], ["tissue", "ANATOMY", 100, 106], ["cells", "CELL", 75, 80], ["tissue", "TISSUE", 100, 106], ["These probes", "TREATMENT", 0, 12], ["active translation from cells", "PROBLEM", 51, 80], ["a culture dish, tissue", "PROBLEM", 84, 106], ["amount", "OBSERVATION_MODIFIER", 41, 47], ["active", "OBSERVATION_MODIFIER", 51, 57], ["translation", "OBSERVATION", 58, 69]]], ["Subsequent development of the ribopuromycylation method (RPM) (David et al., 2012; Bastide et al., 2018) pushed the technique a step further, claiming to detect the subcellular localization of actively translating ribosomes using a puromycin-specific antibody.", [["subcellular", "ANATOMY", 165, 176], ["ribosomes", "ANATOMY", 214, 223], ["puromycin", "CHEMICAL", 232, 241], ["puromycin", "CHEMICAL", 232, 241], ["ribosomes", "CELLULAR_COMPONENT", 214, 223], ["puromycin", "SIMPLE_CHEMICAL", 232, 241], ["puromycin-specific antibody", "PROTEIN", 232, 259], ["a puromycin", "TREATMENT", 230, 241]]], ["In these initial publications, the authors argued that the translation elongation inhibitors cycloheximide or emetine prevent dissociation of the puromycylated peptides from the ribosome.", [["ribosome", "ANATOMY", 178, 186], ["cycloheximide", "CHEMICAL", 93, 106], ["emetine", "CHEMICAL", 110, 117], ["cycloheximide", "CHEMICAL", 93, 106], ["emetine", "CHEMICAL", 110, 117], ["cycloheximide", "SIMPLE_CHEMICAL", 93, 106], ["emetine", "SIMPLE_CHEMICAL", 110, 117], ["ribosome", "CELLULAR_COMPONENT", 178, 186], ["the translation elongation inhibitors cycloheximide", "TREATMENT", 55, 106], ["emetine", "TREATMENT", 110, 117], ["the puromycylated peptides", "TREATMENT", 142, 168]]], ["Cycloheximide and emetine, however, bind in the E-site of the ribosome ( Figure 1C ) far from the peptidyl-transferase center (Garreau de Loubresse et al., 2014; Wong et al., 2014) .", [["Cycloheximide", "CHEMICAL", 0, 13], ["emetine", "CHEMICAL", 18, 25], ["Cycloheximide", "CHEMICAL", 0, 13], ["emetine", "CHEMICAL", 18, 25], ["peptidyl", "CHEMICAL", 98, 106], ["Cycloheximide", "SIMPLE_CHEMICAL", 0, 13], ["emetine", "SIMPLE_CHEMICAL", 18, 25], ["ribosome", "CELLULAR_COMPONENT", 62, 70], ["peptidyl-transferase", "GENE_OR_GENE_PRODUCT", 98, 118], ["E-site", "DNA", 48, 54], ["Cycloheximide", "TREATMENT", 0, 13], ["emetine", "TREATMENT", 18, 25]]], ["Previous work (Grollman, 1968; Colombo et al., 1965) established that these inhibitors prevent puromycin-induced splitting of ribosomes into individual subunits, but do not prevent the release of the majority of puromycylated peptides.", [["ribosomes", "ANATOMY", 126, 135], ["puromycin", "CHEMICAL", 95, 104], ["puromycin", "CHEMICAL", 95, 104], ["puromycin", "SIMPLE_CHEMICAL", 95, 104], ["ribosomes", "CELLULAR_COMPONENT", 126, 135], ["these inhibitors", "TREATMENT", 70, 86], ["puromycin", "TREATMENT", 95, 104], ["puromycylated peptides", "TREATMENT", 212, 234]]], ["Cycloheximide and emetine, in fact, are sometimes omitted from in vivo puromycylation assays based on the claim that short (approximately 5 min) labeling times capture peptides near their original site of translation before significant diffusion has taken place (tom Dieck et al., 2015; Biever et al., 2020; Lewis et al., 2018; Glock et al., 2020; Holt et al., 2019) .", [["Cycloheximide", "CHEMICAL", 0, 13], ["emetine", "CHEMICAL", 18, 25], ["Cycloheximide", "CHEMICAL", 0, 13], ["emetine", "CHEMICAL", 18, 25], ["Cycloheximide", "SIMPLE_CHEMICAL", 0, 13], ["emetine", "SIMPLE_CHEMICAL", 18, 25], ["Cycloheximide", "TREATMENT", 0, 13], ["emetine", "TREATMENT", 18, 25], ["significant diffusion", "PROBLEM", 224, 245]]], ["Puromycin-based imaging methods have been widely adopted, particularly in neurobiology, where translation in neuronal processes, far from the cell body, is crucial to neuronal function (tom Dieck et al., 2015; Biever et al., 2020; Lewis et al., 2018; Glock et al., 2020; Holt et al., 2019; V'kovski et al., 2019; Langille et al., 2019; Gonatopoulos-Pournatzis et al., 2020; Graber et al., 2013; Graber et al., 2017) .", [["neuronal", "ANATOMY", 109, 117], ["cell body", "ANATOMY", 142, 151], ["neuronal", "ANATOMY", 167, 175], ["Puromycin", "CHEMICAL", 0, 9], ["Puromycin", "CHEMICAL", 0, 9], ["Puromycin", "SIMPLE_CHEMICAL", 0, 9], ["neuronal", "CELL", 109, 117], ["cell body", "CELLULAR_COMPONENT", 142, 151], ["neuronal", "CELL", 167, 175], ["Puromycin", "TREATMENT", 0, 9], ["imaging methods", "TEST", 16, 31]]], ["Some studies have combined puromycin treatment with proximity-dependent ligation (PLA) to monitor the location of translation of a specific protein (tom Dieck et al., 2015) , but this method again does not address diffusion of puromycylated peptides post-release from the ribosome.IntroductionIn the present work, we establish that puromycin-based methods, as currently implemented, do not accurately localize translation at the subcellular level.", [["ribosome", "ANATOMY", 272, 280], ["subcellular", "ANATOMY", 429, 440], ["puromycin", "CHEMICAL", 27, 36], ["puromycin", "CHEMICAL", 332, 341], ["puromycin", "CHEMICAL", 27, 36], ["puromycin", "CHEMICAL", 332, 341], ["puromycin", "SIMPLE_CHEMICAL", 27, 36], ["ribosome", "CELLULAR_COMPONENT", 272, 280], ["puromycin", "SIMPLE_CHEMICAL", 332, 341], ["Some studies", "TEST", 0, 12], ["combined puromycin treatment", "TREATMENT", 18, 46], ["proximity-dependent ligation", "TREATMENT", 52, 80], ["diffusion of puromycylated peptides", "PROBLEM", 214, 249], ["puromycin-based methods", "TREATMENT", 332, 355], ["ligation", "OBSERVATION", 72, 80]]], ["We used a rabbit reticulocyte lysate system to show that puromycin nearly instantaneously releases nascent proteins from the ribosome, and that this release reaction is completely unaffected by emetine.", [["reticulocyte lysate", "ANATOMY", 17, 36], ["ribosome", "ANATOMY", 125, 133], ["puromycin", "CHEMICAL", 57, 66], ["emetine", "CHEMICAL", 194, 201], ["puromycin", "CHEMICAL", 57, 66], ["emetine", "CHEMICAL", 194, 201], ["rabbit", "ORGANISM", 10, 16], ["reticulocyte", "CELL", 17, 29], ["puromycin", "SIMPLE_CHEMICAL", 57, 66], ["ribosome", "CELLULAR_COMPONENT", 125, 133], ["emetine", "SIMPLE_CHEMICAL", 194, 201], ["nascent proteins", "PROTEIN", 99, 115], ["rabbit", "SPECIES", 10, 16], ["rabbit", "SPECIES", 10, 16], ["a rabbit reticulocyte lysate system", "TREATMENT", 8, 43], ["puromycin", "TREATMENT", 57, 66], ["this release reaction", "PROBLEM", 144, 165]]], ["To validate this finding in cells, we visualized sites of active translation using fixed cell single-molecule imaging with the SunTag reporter system.", [["cells", "ANATOMY", 28, 33], ["sites", "ANATOMY", 49, 54], ["cell", "ANATOMY", 89, 93], ["cells", "CELL", 28, 33], ["cell", "CELL", 89, 93], ["SunTag", "GENE_OR_GENE_PRODUCT", 127, 133], ["active translation", "TREATMENT", 58, 76], ["fixed cell single-molecule imaging", "TREATMENT", 83, 117], ["the SunTag reporter system", "TREATMENT", 123, 149], ["active", "OBSERVATION_MODIFIER", 58, 64]]], ["Brief treatment with puromycin nearly completely dissociated nascent peptides from their mRNAs, again, independent of the presence of emetine.", [["puromycin", "CHEMICAL", 21, 30], ["emetine", "CHEMICAL", 134, 141], ["puromycin", "CHEMICAL", 21, 30], ["emetine", "CHEMICAL", 134, 141], ["puromycin", "SIMPLE_CHEMICAL", 21, 30], ["emetine", "SIMPLE_CHEMICAL", 134, 141], ["mRNAs", "RNA", 89, 94], ["Brief treatment", "TREATMENT", 0, 15], ["puromycin", "TREATMENT", 21, 30], ["emetine", "TREATMENT", 134, 141], ["nascent peptides", "OBSERVATION", 61, 77]]], ["Simple diffusion calculations predict that the released peptides could diffuse to nearly any point within even large mammalian cells within seconds or minutes.", [["cells", "ANATOMY", 127, 132], ["mammalian cells", "CELL", 117, 132], ["mammalian cells", "CELL_TYPE", 117, 132], ["Simple diffusion calculations", "PROBLEM", 0, 29], ["the released peptides", "PROBLEM", 43, 64], ["diffusion calculations", "OBSERVATION", 7, 29], ["large", "OBSERVATION_MODIFIER", 111, 116], ["mammalian cells", "OBSERVATION", 117, 132]]], ["Thus, puromycylation methods described in the literature do not establish subcellular localization of translation.ResultsThe puromycin analog OPP labels nuclei in live C. elegans germlines in the presence or absence of emetine O-propargyl-puromycin (OPP) is a click-reactive cell permeable puromycin analog that is commonly used to localize sites of translation (Liu et al., 2012) .", [["subcellular", "ANATOMY", 74, 85], ["nuclei", "ANATOMY", 153, 159], ["germlines", "ANATOMY", 179, 188], ["cell", "ANATOMY", 275, 279], ["sites", "ANATOMY", 341, 346], ["puromycin", "CHEMICAL", 125, 134], ["OPP", "CHEMICAL", 142, 145], ["emetine O-propargyl-puromycin", "CHEMICAL", 219, 248], ["OPP", "CHEMICAL", 250, 253], ["puromycin", "CHEMICAL", 290, 299], ["puromycin", "CHEMICAL", 125, 134], ["OPP", "CHEMICAL", 142, 145], ["emetine", "CHEMICAL", 219, 226], ["O-propargyl-puromycin", "CHEMICAL", 227, 248], ["OPP", "CHEMICAL", 250, 253], ["puromycin", "CHEMICAL", 290, 299], ["puromycin", "SIMPLE_CHEMICAL", 125, 134], ["OPP", "SIMPLE_CHEMICAL", 142, 145], ["nuclei", "CELLULAR_COMPONENT", 153, 159], ["C. elegans", "ORGANISM", 168, 178], ["emetine O-propargyl-puromycin", "SIMPLE_CHEMICAL", 219, 248], ["OPP", "SIMPLE_CHEMICAL", 250, 253], ["cell", "CELL", 275, 279], ["puromycin", "SIMPLE_CHEMICAL", 290, 299], ["C. elegans", "SPECIES", 168, 178], ["C. elegans", "SPECIES", 168, 178], ["puromycylation methods", "TREATMENT", 6, 28], ["The puromycin analog", "TREATMENT", 121, 141], ["propargyl", "TREATMENT", 229, 238], ["puromycin (OPP", "TREATMENT", 239, 253], ["a click", "PROBLEM", 258, 265], ["reactive cell permeable puromycin analog", "TREATMENT", 266, 306], ["reactive cell", "OBSERVATION", 266, 279]]], ["When incubated with live cells or tissues, OPP reacts with translating ribosomes and becomes covalently attached to elongating peptides.", [["cells", "ANATOMY", 25, 30], ["tissues", "ANATOMY", 34, 41], ["ribosomes", "ANATOMY", 71, 80], ["OPP", "CHEMICAL", 43, 46], ["OPP", "CHEMICAL", 43, 46], ["cells", "CELL", 25, 30], ["tissues", "TISSUE", 34, 41], ["OPP", "SIMPLE_CHEMICAL", 43, 46], ["ribosomes", "CELLULAR_COMPONENT", 71, 80], ["elongating peptides", "PROBLEM", 116, 135]]], ["Postlabeling, OPP is detected by click-reactive chemistry which attaches a fluorescent probe to OPP (Figure 2) .", [["OPP", "CHEMICAL", 14, 17], ["OPP", "CHEMICAL", 14, 17], ["OPP", "CHEMICAL", 96, 99], ["OPP", "SIMPLE_CHEMICAL", 14, 17], ["OPP", "SIMPLE_CHEMICAL", 96, 99], ["reactive chemistry", "PROBLEM", 39, 57], ["reactive", "OBSERVATION_MODIFIER", 39, 47]]], ["Using this method to label translation in live C. elegans gonads, we observed bright labeling of live germlines upon a 5 min incubation with OPP.", [["gonads", "ANATOMY", 58, 64], ["germlines", "ANATOMY", 102, 111], ["OPP", "CHEMICAL", 141, 144], ["OPP", "CHEMICAL", 141, 144], ["C. elegans", "ORGANISM", 47, 57], ["gonads", "ORGAN", 58, 64], ["OPP", "SIMPLE_CHEMICAL", 141, 144], ["C. elegans", "SPECIES", 47, 57], ["C. elegans", "SPECIES", 47, 57], ["this method", "TREATMENT", 6, 17]]], ["The OPP signal was most intense in nuclei, specifically in the chromatin-free center where nucleoli reside.", [["nuclei", "ANATOMY", 35, 41], ["chromatin", "ANATOMY", 63, 72], ["nucleoli", "ANATOMY", 91, 99], ["OPP", "SIMPLE_CHEMICAL", 4, 7], ["nuclei", "CELLULAR_COMPONENT", 35, 41], ["chromatin", "CELLULAR_COMPONENT", 63, 72], ["nucleoli", "CELLULAR_COMPONENT", 91, 99], ["OPP", "PROTEIN", 4, 7], ["chromatin", "DNA", 63, 72], ["The OPP signal", "TEST", 0, 14], ["most intense", "OBSERVATION_MODIFIER", 19, 31]]], ["A lower signal was also observed in the cytoplasm, which contains the majority of (if not all) functional ribosomes (Klinge and Woolford, 2019) .", [["cytoplasm", "ANATOMY", 40, 49], ["cytoplasm", "ORGANISM_SUBSTANCE", 40, 49], ["ribosomes", "CELLULAR_COMPONENT", 106, 115], ["A lower signal", "PROBLEM", 0, 14], ["lower", "OBSERVATION_MODIFIER", 2, 7], ["cytoplasm", "OBSERVATION", 40, 49], ["majority", "OBSERVATION_MODIFIER", 70, 78]]], ["OPP labeling of nuclei was ablated by pre-treatment with anisomycin, a competitive inhibitor of puromycin that stops elongation by binding to the peptidyl-transferase center (Grollman, 1967) , thereby preventing puromycin from reacting with the nascent chain.", [["nuclei", "ANATOMY", 16, 22], ["anisomycin", "CHEMICAL", 57, 67], ["puromycin", "CHEMICAL", 96, 105], ["puromycin", "CHEMICAL", 212, 221], ["OPP", "CHEMICAL", 0, 3], ["anisomycin", "CHEMICAL", 57, 67], ["puromycin", "CHEMICAL", 96, 105], ["peptidyl", "CHEMICAL", 146, 154], ["puromycin", "CHEMICAL", 212, 221], ["OPP", "SIMPLE_CHEMICAL", 0, 3], ["nuclei", "CELLULAR_COMPONENT", 16, 22], ["anisomycin", "SIMPLE_CHEMICAL", 57, 67], ["puromycin", "SIMPLE_CHEMICAL", 96, 105], ["peptidyl-transferase", "GENE_OR_GENE_PRODUCT", 146, 166], ["puromycin", "SIMPLE_CHEMICAL", 212, 221], ["peptidyl-transferase center", "PROTEIN", 146, 173], ["nascent chain", "PROTEIN", 245, 258], ["anisomycin", "TREATMENT", 57, 67], ["a competitive inhibitor", "TREATMENT", 69, 92], ["puromycin", "TREATMENT", 96, 105], ["puromycin", "TREATMENT", 212, 221], ["nuclei", "ANATOMY", 16, 22], ["nascent chain", "OBSERVATION", 245, 258]]], ["In contrast, OPP labeling was unaffected by pre-treatment with emetine ( Figure 2B ).", [["emetine", "CHEMICAL", 63, 70], ["OPP", "CHEMICAL", 13, 16], ["emetine", "CHEMICAL", 63, 70], ["OPP", "SIMPLE_CHEMICAL", 13, 16], ["emetine", "SIMPLE_CHEMICAL", 63, 70], ["OPP labeling", "TEST", 13, 25], ["emetine", "TREATMENT", 63, 70]]], ["Emetine-resistant puromycin labeling of nucleoli has been observed previously in tissue culture cells (David et al., 2012) and may reflect trafficking or diffusion of puromycylated peptides into the nucleolus (Kubota et al., 1999; Schmidt et al., 1995) .", [["nucleoli", "ANATOMY", 40, 48], ["tissue culture cells", "ANATOMY", 81, 101], ["nucleolus", "ANATOMY", 199, 208], ["Emetine", "CHEMICAL", 0, 7], ["puromycin", "CHEMICAL", 18, 27], ["Emetine", "CHEMICAL", 0, 7], ["puromycin", "CHEMICAL", 18, 27], ["Emetine", "SIMPLE_CHEMICAL", 0, 7], ["puromycin", "SIMPLE_CHEMICAL", 18, 27], ["nucleoli", "CELLULAR_COMPONENT", 40, 48], ["tissue culture cells", "CELL", 81, 101], ["nucleolus", "CELLULAR_COMPONENT", 199, 208], ["tissue culture cells", "CELL_LINE", 81, 101], ["Emetine", "TREATMENT", 0, 7], ["resistant puromycin labeling", "TREATMENT", 8, 36], ["nucleoli", "PROBLEM", 40, 48], ["trafficking or diffusion of puromycylated peptides", "PROBLEM", 139, 189], ["resistant puromycin", "OBSERVATION", 8, 27], ["may reflect", "UNCERTAINTY", 127, 138], ["nucleolus", "ANATOMY", 199, 208]]], ["We conclude that OPP labels translational products but does not necessarily identify sites of active translation even in the presence of emetine.Emetine does not prevent release of puromycylated peptides in rabbit reticulocyte lysatesTo determine whether emetine prevents release of puromycylated nascent peptides in vitro, we made use of a previously established real-time translation monitoring assay in rabbit reticulocyte lysate (RRL).", [["reticulocyte lysates", "ANATOMY", 214, 234], ["reticulocyte lysate", "ANATOMY", 413, 432], ["RRL", "ANATOMY", 434, 437], ["OPP", "CHEMICAL", 17, 20], ["emetine", "CHEMICAL", 137, 144], ["Emetine", "CHEMICAL", 145, 152], ["emetine", "CHEMICAL", 255, 262], ["OPP", "CHEMICAL", 17, 20], ["emetine", "CHEMICAL", 137, 144], ["Emetine", "CHEMICAL", 145, 152], ["emetine", "CHEMICAL", 255, 262], ["OPP", "SIMPLE_CHEMICAL", 17, 20], ["emetine", "SIMPLE_CHEMICAL", 137, 144], ["Emetine", "SIMPLE_CHEMICAL", 145, 152], ["rabbit", "ORGANISM", 207, 213], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 214, 234], ["emetine", "SIMPLE_CHEMICAL", 255, 262], ["rabbit", "ORGANISM", 406, 412], ["reticulocyte lysate", "ORGANISM_SUBSTANCE", 413, 432], ["rabbit", "SPECIES", 207, 213], ["rabbit", "SPECIES", 406, 412], ["rabbit", "SPECIES", 207, 213], ["rabbit", "SPECIES", 406, 412], ["OPP labels translational products", "TREATMENT", 17, 50], ["active translation", "PROBLEM", 94, 112], ["emetine", "TREATMENT", 137, 144], ["Emetine", "TREATMENT", 145, 152], ["puromycylated peptides", "PROBLEM", 181, 203], ["reticulocyte lysates", "TEST", 214, 234], ["emetine", "TREATMENT", 255, 262], ["puromycylated nascent peptides", "TREATMENT", 283, 313], ["translation monitoring assay", "TEST", 374, 402], ["active", "OBSERVATION", 94, 100], ["emetine", "OBSERVATION", 137, 144], ["rabbit reticulocyte lysates", "OBSERVATION", 207, 234]]], ["This method relies on the fact that luciferase rapidly folds into an enzymatically active conformation only after release from the ribosome (Kolb et al., 1994; Frydman et al., 1994) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 36, 46], ["ribosome", "CELLULAR_COMPONENT", 131, 139], ["luciferase", "PROTEIN", 36, 46]]], ["By programming RRL with a luciferase mRNA that is truncated (by runoff SP6 transcription of restriction-digested plasmid) just upstream of the stop codon, we accumulate stalled ribosomes at the 3' end of the mRNA, in which the luciferase nascent peptide remains ribosome-bound and enzymatically inactive ( Figure 3A ).", [["ribosomes", "ANATOMY", 177, 186], ["RRL", "GENE_OR_GENE_PRODUCT", 15, 18], ["luciferase", "GENE_OR_GENE_PRODUCT", 26, 36], ["SP6", "GENE_OR_GENE_PRODUCT", 71, 74], ["ribosomes", "CELLULAR_COMPONENT", 177, 186], ["3' end", "CELLULAR_COMPONENT", 194, 200], ["luciferase", "GENE_OR_GENE_PRODUCT", 227, 237], ["RRL", "DNA", 15, 18], ["luciferase mRNA", "RNA", 26, 41], ["restriction-digested plasmid", "DNA", 92, 120], ["stop codon", "DNA", 143, 153], ["stalled ribosomes", "RNA", 169, 186], ["3' end", "RNA", 194, 200], ["mRNA", "RNA", 208, 212], ["luciferase", "PROTEIN", 227, 237], ["a luciferase mRNA", "PROBLEM", 24, 41], ["stalled ribosomes", "PROBLEM", 169, 186], ["stop codon", "OBSERVATION", 143, 153], ["stalled ribosomes", "OBSERVATION", 169, 186], ["inactive", "OBSERVATION_MODIFIER", 295, 303]]], ["RRL programmed with the truncated mRNA (yellow trace) displays little luciferase activity compared to RRL translating full-length mRNA (purple trace).", [["luciferase", "GENE_OR_GENE_PRODUCT", 70, 80], ["truncated mRNA", "RNA", 24, 38], ["luciferase", "PROTEIN", 70, 80], ["full-length mRNA", "RNA", 118, 134], ["the truncated mRNA (yellow trace)", "PROBLEM", 20, 53], ["little luciferase activity", "PROBLEM", 63, 89], ["little", "OBSERVATION_MODIFIER", 63, 69], ["luciferase activity", "OBSERVATION", 70, 89]]], ["Addition of 91 mM puromycin (the same concentration used by David et al., 2012 ) causes a sharp increase in luminescence output from the truncated mRNA, consistent with release of the stalled peptides.Emetine does not prevent release of puromycylated peptides in rabbit reticulocyte lysatesWe reasoned that if emetine prevents release of puromycylated nascent peptides, then emetine should block the increase in luminescence observed upon puromycin addition.", [["reticulocyte lysates", "ANATOMY", 270, 290], ["puromycin", "CHEMICAL", 18, 27], ["Emetine", "CHEMICAL", 201, 208], ["emetine", "CHEMICAL", 310, 317], ["emetine", "CHEMICAL", 375, 382], ["puromycin", "CHEMICAL", 439, 448], ["puromycin", "CHEMICAL", 18, 27], ["Emetine", "CHEMICAL", 201, 208], ["emetine", "CHEMICAL", 310, 317], ["emetine", "CHEMICAL", 375, 382], ["puromycin", "CHEMICAL", 439, 448], ["puromycin", "SIMPLE_CHEMICAL", 18, 27], ["Emetine", "SIMPLE_CHEMICAL", 201, 208], ["rabbit", "ORGANISM", 263, 269], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 270, 290], ["emetine", "SIMPLE_CHEMICAL", 310, 317], ["emetine", "SIMPLE_CHEMICAL", 375, 382], ["puromycin", "SIMPLE_CHEMICAL", 439, 448], ["truncated mRNA", "RNA", 137, 151], ["rabbit", "SPECIES", 263, 269], ["rabbit", "SPECIES", 263, 269], ["91 mM puromycin", "TREATMENT", 12, 27], ["a sharp increase in luminescence output", "PROBLEM", 88, 127], ["the truncated mRNA", "PROBLEM", 133, 151], ["the stalled peptides", "PROBLEM", 180, 200], ["Emetine", "TREATMENT", 201, 208], ["puromycylated peptides", "PROBLEM", 237, 259], ["reticulocyte lysates", "TEST", 270, 290], ["emetine", "TREATMENT", 310, 317], ["puromycylated nascent peptides", "TREATMENT", 338, 368], ["emetine", "TREATMENT", 375, 382], ["the increase in luminescence", "PROBLEM", 396, 424], ["puromycin addition", "TREATMENT", 439, 457], ["sharp", "OBSERVATION_MODIFIER", 90, 95], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["luminescence output", "OBSERVATION", 108, 127], ["truncated mRNA", "OBSERVATION", 137, 151], ["consistent with", "UNCERTAINTY", 153, 168], ["stalled peptides", "OBSERVATION", 184, 200], ["rabbit reticulocyte lysates", "OBSERVATION", 263, 290], ["increase", "OBSERVATION_MODIFIER", 400, 408]]], ["Matching the conditions of David et al., 2012 , we treated the RRL with 208 mM emetine and 91 mM puromycin.", [["emetine", "CHEMICAL", 79, 86], ["puromycin", "CHEMICAL", 97, 106], ["emetine", "CHEMICAL", 79, 86], ["puromycin", "CHEMICAL", 97, 106], ["emetine", "SIMPLE_CHEMICAL", 79, 86], ["puromycin", "SIMPLE_CHEMICAL", 97, 106], ["the RRL", "TREATMENT", 59, 66], ["208 mM emetine", "TREATMENT", 72, 86], ["91 mM puromycin", "TREATMENT", 91, 106]]], ["When added separately, these two drugs effectively inhibit translation of full-length luciferase mRNA encoding a normal stop codon ( addition of puromycin to lysate programmed with truncated mRNA, we noticed the expected steep increase in luminescence (yellow trace) that was not inhibited by simultaneous addition of emetine (blue trace) ( Figure 3B ).", [["lysate", "ANATOMY", 158, 164], ["puromycin", "CHEMICAL", 145, 154], ["emetine", "CHEMICAL", 318, 325], ["puromycin", "CHEMICAL", 145, 154], ["emetine", "CHEMICAL", 318, 325], ["luciferase", "GENE_OR_GENE_PRODUCT", 86, 96], ["puromycin", "SIMPLE_CHEMICAL", 145, 154], ["emetine", "SIMPLE_CHEMICAL", 318, 325], ["luciferase mRNA", "RNA", 86, 101], ["normal stop codon", "DNA", 113, 130], ["truncated mRNA", "RNA", 181, 195], ["these two drugs", "TREATMENT", 23, 38], ["full-length luciferase mRNA", "TREATMENT", 74, 101], ["puromycin", "TREATMENT", 145, 154], ["emetine (blue trace", "TREATMENT", 318, 337], ["steep", "OBSERVATION_MODIFIER", 221, 226], ["increase", "OBSERVATION_MODIFIER", 227, 235]]], ["The luminescence of the no-puromycin control (purple trace) increased slowly over time, likely due to low levels of ribosome rescue activity (Shao et al., 2013) or spontaneous peptidyl-tRNA hydrolysis in the lysate.", [["ribosome", "ANATOMY", 116, 124], ["lysate", "ANATOMY", 208, 214], ["no-puromycin", "CHEMICAL", 24, 36], ["no-puromycin", "CHEMICAL", 24, 36], ["no-puromycin", "SIMPLE_CHEMICAL", 24, 36], ["peptidyl-tRNA", "SIMPLE_CHEMICAL", 176, 189], ["the no-puromycin control", "TREATMENT", 20, 44], ["low levels of ribosome rescue activity", "PROBLEM", 102, 140], ["spontaneous peptidyl-tRNA hydrolysis", "TREATMENT", 164, 200], ["the lysate", "TREATMENT", 204, 214], ["luminescence", "OBSERVATION_MODIFIER", 4, 16], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["slowly", "OBSERVATION_MODIFIER", 70, 76], ["tRNA hydrolysis", "OBSERVATION", 185, 200]]], ["We next considered the possibility that blocking peptide release with emetine requires pre-incubation.", [["emetine", "CHEMICAL", 70, 77], ["emetine", "CHEMICAL", 70, 77], ["emetine", "SIMPLE_CHEMICAL", 70, 77], ["blocking peptide release", "TREATMENT", 40, 64], ["emetine requires pre-incubation", "TREATMENT", 70, 101]]], ["To test this, we pre-treated the lysate with emetine 5 min before addition of puromycin.", [["lysate", "ANATOMY", 33, 39], ["emetine", "CHEMICAL", 45, 52], ["puromycin", "CHEMICAL", 78, 87], ["emetine", "CHEMICAL", 45, 52], ["puromycin", "CHEMICAL", 78, 87], ["emetine", "SIMPLE_CHEMICAL", 45, 52], ["puromycin", "SIMPLE_CHEMICAL", 78, 87], ["the lysate", "TREATMENT", 29, 39], ["emetine", "TREATMENT", 45, 52], ["puromycin", "TREATMENT", 78, 87]]], ["Because pre-treatment would decrease the total translation time and overall luminescence of a sample, it was critical to equalize the total uninhibited reaction time of all samples.", [["samples", "ANATOMY", 173, 180]]], ["In a first experiment, we treated all samples with the nonhydrolyzable GTP analog 5'-guanylyl imidodiphosphate (GDPNP) to inhibit the translational GTPases and prevent (1) (Purple trace) Ribosomes translate the full-length luciferase mRNA and release luciferase which becomes enzymatically active and results in an increase in luminescence.", [["samples", "ANATOMY", 38, 45], ["GTP", "CHEMICAL", 71, 74], ["5'-guanylyl imidodiphosphate", "CHEMICAL", 82, 110], ["GDPNP", "CHEMICAL", 112, 117], ["GTP", "CHEMICAL", 71, 74], ["5'-guanylyl imidodiphosphate", "CHEMICAL", 82, 110], ["GDPNP", "CHEMICAL", 112, 117], ["GTP", "SIMPLE_CHEMICAL", 71, 74], ["5'-guanylyl imidodiphosphate", "SIMPLE_CHEMICAL", 82, 110], ["GDPNP", "SIMPLE_CHEMICAL", 112, 117], ["GTPases", "GENE_OR_GENE_PRODUCT", 148, 155], ["luciferase", "GENE_OR_GENE_PRODUCT", 223, 233], ["luciferase", "GENE_OR_GENE_PRODUCT", 251, 261], ["translational GTPases", "PROTEIN", 134, 155], ["Ribosomes", "PROTEIN", 187, 196], ["full-length luciferase mRNA", "RNA", 211, 238], ["luciferase", "PROTEIN", 251, 261], ["the nonhydrolyzable GTP analog", "TREATMENT", 51, 81], ["guanylyl imidodiphosphate (GDPNP)", "TREATMENT", 85, 118], ["the translational GTPases", "TREATMENT", 130, 155], ["Purple trace) Ribosomes", "PROBLEM", 173, 196], ["the full-length luciferase mRNA", "TREATMENT", 207, 238], ["release luciferase", "TEST", 243, 261], ["an increase in luminescence", "PROBLEM", 312, 339], ["active", "OBSERVATION_MODIFIER", 290, 296], ["increase", "OBSERVATION_MODIFIER", 315, 323]]], ["(Yellow trace) Ribosomes stall at the 3' end of a truncated luciferase mRNA and little to no luminescence is observed as the ribosome-bound luciferase peptides are in an enzymatically inactive conformation.", [["ribosome", "ANATOMY", 125, 133], ["3' end", "CELLULAR_COMPONENT", 38, 44], ["luciferase", "GENE_OR_GENE_PRODUCT", 60, 70], ["ribosome", "CELLULAR_COMPONENT", 125, 133], ["luciferase peptides", "GENE_OR_GENE_PRODUCT", 140, 159], ["3' end", "RNA", 38, 44], ["truncated luciferase mRNA", "RNA", 50, 75], ["Yellow trace) Ribosomes stall", "PROBLEM", 1, 30], ["a truncated luciferase mRNA", "PROBLEM", 48, 75], ["the ribosome-bound luciferase peptides", "TEST", 121, 159], ["Ribosomes stall", "OBSERVATION", 15, 30], ["luciferase mRNA", "OBSERVATION", 60, 75], ["no", "UNCERTAINTY", 90, 92], ["luminescence", "OBSERVATION", 93, 105], ["inactive conformation", "OBSERVATION", 184, 205]]], ["(2) Puromycin (PM) is added to the system, stopping further translation and causing all nascent peptides to release from the ribosomes.", [["ribosomes", "ANATOMY", 125, 134], ["Puromycin", "CHEMICAL", 4, 13], ["PM", "CHEMICAL", 15, 17], ["Puromycin", "CHEMICAL", 4, 13], ["(2) Puromycin", "SIMPLE_CHEMICAL", 0, 13], ["PM", "SIMPLE_CHEMICAL", 15, 17], ["ribosomes", "CELLULAR_COMPONENT", 125, 134], ["Puromycin (PM)", "TREATMENT", 4, 18], ["further translation", "TREATMENT", 52, 71], ["all nascent peptides", "TREATMENT", 84, 104], ["nascent peptides", "OBSERVATION", 88, 104]]], ["(3) (Yellow) The luciferase rapidly folds into an enzymatically active conformation and a substantial increase in luminescence is observed.", [["luciferase", "GENE_OR_GENE_PRODUCT", 17, 27], ["luciferase", "PROTEIN", 17, 27], ["an enzymatically active conformation", "PROBLEM", 47, 83], ["a substantial increase in luminescence", "PROBLEM", 88, 126], ["enzymatically", "OBSERVATION_MODIFIER", 50, 63], ["active", "OBSERVATION_MODIFIER", 64, 70], ["conformation", "OBSERVATION", 71, 83], ["substantial", "OBSERVATION_MODIFIER", 90, 101], ["increase", "OBSERVATION_MODIFIER", 102, 110], ["luminescence", "OBSERVATION", 114, 126]]], ["(B) Either puromycin (blue), H 2 O (purple) or a mixture of emetine (EME) and puromycin (yellow) was added to a reaction containing truncated luciferase mRNA at t = 21 min.", [["puromycin", "CHEMICAL", 11, 20], ["H 2 O", "CHEMICAL", 29, 34], ["emetine", "CHEMICAL", 60, 67], ["EME", "CHEMICAL", 69, 72], ["puromycin", "CHEMICAL", 78, 87], ["puromycin", "CHEMICAL", 11, 20], ["H 2 O", "CHEMICAL", 29, 34], ["emetine", "CHEMICAL", 60, 67], ["EME", "CHEMICAL", 69, 72], ["puromycin", "CHEMICAL", 78, 87], ["puromycin", "SIMPLE_CHEMICAL", 11, 20], ["blue", "SIMPLE_CHEMICAL", 22, 26], ["H 2 O", "SIMPLE_CHEMICAL", 29, 34], ["emetine", "SIMPLE_CHEMICAL", 60, 67], ["EME", "SIMPLE_CHEMICAL", 69, 72], ["puromycin", "SIMPLE_CHEMICAL", 78, 87], ["luciferase", "GENE_OR_GENE_PRODUCT", 142, 152], ["truncated luciferase mRNA", "RNA", 132, 157], ["puromycin (blue", "TREATMENT", 11, 26], ["emetine (EME)", "TREATMENT", 60, 73], ["puromycin", "TREATMENT", 78, 87], ["a reaction", "PROBLEM", 110, 120]]], ["Experiment was performed in duplicate; mean traces shown as solid lines and range of replicates shaded.", [["solid lines", "CELL", 60, 71], ["solid lines", "TREATMENT", 60, 71], ["solid lines", "OBSERVATION", 60, 71]]], ["(C) GDPNP was added to a reaction containing truncated luciferase mRNA at t = 16 min for 5 min to inhibit translation across samples.", [["samples", "ANATOMY", 125, 132], ["GDPNP", "CHEMICAL", 4, 9], ["(C) GDPNP", "CHEMICAL", 0, 9], ["(C) GDPNP", "SIMPLE_CHEMICAL", 0, 9], ["luciferase", "GENE_OR_GENE_PRODUCT", 55, 65], ["luciferase mRNA", "RNA", 55, 70], ["GDPNP", "PROBLEM", 4, 9], ["a reaction", "PROBLEM", 23, 33]]], ["Then, either emetine (blue, purple), anisomycin (ANS) (green) or H 2 O (yellow) was added to the reaction followed by puromycin (blue, yellow, green) or H 2 O (purple) 5 min later.", [["emetine", "CHEMICAL", 13, 20], ["anisomycin", "CHEMICAL", 37, 47], ["H 2 O", "CHEMICAL", 65, 70], ["puromycin", "CHEMICAL", 118, 127], ["H 2 O", "CHEMICAL", 153, 158], ["emetine", "CHEMICAL", 13, 20], ["anisomycin", "CHEMICAL", 37, 47], ["ANS", "CHEMICAL", 49, 52], ["H 2 O", "CHEMICAL", 65, 70], ["puromycin", "CHEMICAL", 118, 127], ["H 2 O", "CHEMICAL", 153, 158], ["emetine", "SIMPLE_CHEMICAL", 13, 20], ["blue", "SIMPLE_CHEMICAL", 22, 26], ["anisomycin", "SIMPLE_CHEMICAL", 37, 47], ["ANS", "SIMPLE_CHEMICAL", 49, 52], ["green)", "SIMPLE_CHEMICAL", 55, 61], ["H 2 O", "SIMPLE_CHEMICAL", 65, 70], ["puromycin", "SIMPLE_CHEMICAL", 118, 127], ["blue", "SIMPLE_CHEMICAL", 129, 133], ["H 2 O", "SIMPLE_CHEMICAL", 153, 158], ["emetine (blue", "TREATMENT", 13, 26], ["anisomycin", "TREATMENT", 37, 47], ["the reaction", "PROBLEM", 93, 105], ["puromycin (blue", "TREATMENT", 118, 133]]], ["Experiment was performed in duplicate; mean traces shown as solid lines and range of replicates shaded.", [["solid lines", "CELL", 60, 71], ["solid lines", "TREATMENT", 60, 71], ["solid lines", "OBSERVATION", 60, 71]]], ["Note that the experiments in (A and B), and Figure 3-figure supplement 1B were done in the same batch, and the yellow traces (PM treated) in these panels are the same.", [["Figure 3-figure supplement 1B", "TREATMENT", 44, 73], ["the yellow traces", "PROBLEM", 107, 124], ["these panels", "TEST", 141, 153]]], ["The online version of this article includes the following source data and figure supplement(s) for figure 3:Emetine does not prevent release of puromycylated peptides in rabbit reticulocyte lysatesSource data 1.", [["reticulocyte lysates", "ANATOMY", 177, 197], ["Emetine", "CHEMICAL", 108, 115], ["Emetine", "CHEMICAL", 108, 115], ["Emetine", "SIMPLE_CHEMICAL", 108, 115], ["rabbit", "ORGANISM", 170, 176], ["reticulocyte lysates", "ORGANISM_SUBSTANCE", 177, 197], ["rabbit", "SPECIES", 170, 176], ["rabbit", "SPECIES", 170, 176], ["Emetine", "TREATMENT", 108, 115], ["puromycylated peptides", "PROBLEM", 144, 166], ["reticulocyte lysates", "TEST", 177, 197], ["rabbit reticulocyte lysates", "OBSERVATION", 170, 197]]], ["Source data for Figure 3A , B and C. ongoing translation while leaving the ribosome free to react with emetine and puromycin ( Figure 3C ).", [["ribosome", "ANATOMY", 75, 83], ["emetine", "CHEMICAL", 103, 110], ["puromycin", "CHEMICAL", 115, 124], ["emetine", "CHEMICAL", 103, 110], ["puromycin", "CHEMICAL", 115, 124], ["emetine", "SIMPLE_CHEMICAL", 103, 110], ["puromycin", "SIMPLE_CHEMICAL", 115, 124], ["emetine", "TREATMENT", 103, 110], ["puromycin", "TREATMENT", 115, 124]]], ["Again, puromycin treatment (yellow trace) caused a sharp increase in luminescence that was not affected by emetine pre-treatment (blue trace) but was inhibited by anisomycin pre-treatment (green trace).", [["puromycin", "CHEMICAL", 7, 16], ["emetine", "CHEMICAL", 107, 114], ["anisomycin", "CHEMICAL", 163, 173], ["puromycin", "CHEMICAL", 7, 16], ["emetine", "CHEMICAL", 107, 114], ["anisomycin", "CHEMICAL", 163, 173], ["puromycin", "SIMPLE_CHEMICAL", 7, 16], ["emetine", "SIMPLE_CHEMICAL", 107, 114], ["anisomycin", "SIMPLE_CHEMICAL", 163, 173], ["puromycin treatment", "TREATMENT", 7, 26], ["a sharp increase in luminescence", "PROBLEM", 49, 81], ["emetine pre-treatment (blue trace)", "PROBLEM", 107, 141], ["anisomycin pre-treatment", "TREATMENT", 163, 187], ["sharp", "OBSERVATION_MODIFIER", 51, 56], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["luminescence", "OBSERVATION", 69, 81]]], ["The residual slow increase in the anisomycin trace is likely due to incomplete inhibition by anisomycin resulting from its stochastic dissociation during the reaction.", [["anisomycin", "CHEMICAL", 34, 44], ["anisomycin", "CHEMICAL", 93, 103], ["anisomycin", "CHEMICAL", 34, 44], ["anisomycin", "CHEMICAL", 93, 103], ["anisomycin", "SIMPLE_CHEMICAL", 34, 44], ["anisomycin", "SIMPLE_CHEMICAL", 93, 103], ["The residual slow increase", "PROBLEM", 0, 26], ["the anisomycin trace", "TREATMENT", 30, 50], ["incomplete inhibition", "PROBLEM", 68, 89], ["anisomycin", "TREATMENT", 93, 103], ["its stochastic dissociation", "PROBLEM", 119, 146], ["the reaction", "PROBLEM", 154, 166], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["slow", "OBSERVATION_MODIFIER", 13, 17], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["anisomycin trace", "OBSERVATION", 34, 50], ["likely due to", "UNCERTAINTY", 54, 67], ["stochastic dissociation", "OBSERVATION", 123, 146]]], ["In a second experiment, we added puromycin for the puromycin-only control at the same time that we started pretreating the other samples with inhibitors.", [["samples", "ANATOMY", 129, 136], ["puromycin", "CHEMICAL", 33, 42], ["puromycin", "CHEMICAL", 51, 60], ["puromycin", "CHEMICAL", 33, 42], ["puromycin", "CHEMICAL", 51, 60], ["puromycin", "SIMPLE_CHEMICAL", 33, 42], ["puromycin", "SIMPLE_CHEMICAL", 51, 60], ["puromycin", "TREATMENT", 33, 42], ["the puromycin", "TREATMENT", 47, 60], ["inhibitors", "TREATMENT", 142, 152]]], ["This effectively inhibited translation in all samples at the same time ( Figure 3-figure supplement 1B) .", [["samples", "ANATOMY", 46, 53]]], ["While the increase in luminescence for the puromycin-only control (yellow trace) occurred earlier than for the pretreated samples, once the puromycin was added, the luminescence activity of the emetine pretreated sample (blue trace) matched that of the puromycin-only control.", [["samples", "ANATOMY", 122, 129], ["sample", "ANATOMY", 213, 219], ["puromycin", "CHEMICAL", 43, 52], ["puromycin", "CHEMICAL", 140, 149], ["emetine", "CHEMICAL", 194, 201], ["puromycin", "CHEMICAL", 253, 262], ["puromycin", "CHEMICAL", 43, 52], ["puromycin", "CHEMICAL", 140, 149], ["emetine", "CHEMICAL", 194, 201], ["puromycin", "CHEMICAL", 253, 262], ["puromycin", "SIMPLE_CHEMICAL", 43, 52], ["puromycin", "SIMPLE_CHEMICAL", 140, 149], ["emetine", "SIMPLE_CHEMICAL", 194, 201], ["puromycin", "SIMPLE_CHEMICAL", 253, 262], ["the increase in luminescence", "PROBLEM", 6, 34], ["the puromycin", "TREATMENT", 39, 52], ["the puromycin", "TREATMENT", 136, 149], ["the emetine pretreated sample (blue trace)", "TREATMENT", 190, 232], ["the puromycin", "TREATMENT", 249, 262], ["increase", "OBSERVATION_MODIFIER", 10, 18]]], ["Taken together, these results show that pretreating translating ribosomes with emetine does not prevent the release of nascent peptides by puromycin in vitro.Emetine does not prevent release of puromycylated peptides in cellsTo directly test whether emetine blocks release of puromycylated nascent chains in vivo, we implemented the SunTag method for monitoring translation on single mRNAs (Pichon et al., 2016; Wu et al., 2016; Morisaki et al., 2016; Wang et al., 2016; Yan et al., 2016) .", [["ribosomes", "ANATOMY", 64, 73], ["cells", "ANATOMY", 220, 225], ["emetine", "CHEMICAL", 79, 86], ["puromycin", "CHEMICAL", 139, 148], ["Emetine", "CHEMICAL", 158, 165], ["emetine", "CHEMICAL", 250, 257], ["emetine", "CHEMICAL", 79, 86], ["puromycin", "CHEMICAL", 139, 148], ["Emetine", "CHEMICAL", 158, 165], ["emetine", "CHEMICAL", 250, 257], ["ribosomes", "CELLULAR_COMPONENT", 64, 73], ["emetine", "SIMPLE_CHEMICAL", 79, 86], ["puromycin", "SIMPLE_CHEMICAL", 139, 148], ["Emetine", "SIMPLE_CHEMICAL", 158, 165], ["cells", "CELL", 220, 225], ["emetine", "SIMPLE_CHEMICAL", 250, 257], ["puromycylated nascent chains", "PROTEIN", 276, 304], ["mRNAs", "RNA", 384, 389], ["emetine", "TREATMENT", 79, 86], ["nascent peptides", "TREATMENT", 119, 135], ["puromycin in vitro", "TREATMENT", 139, 157], ["Emetine", "TREATMENT", 158, 165], ["puromycylated peptides in cells", "PROBLEM", 194, 225], ["emetine blocks", "TREATMENT", 250, 264], ["the SunTag method", "TREATMENT", 329, 346], ["nascent peptides", "OBSERVATION", 119, 135]]], ["This technique relies on a reporter mRNA encoding tandem repeats of the SunTag epitope near the 5 0 end of the coding sequence ( Figure 4A ).", [["SunTag", "GENE_OR_GENE_PRODUCT", 72, 78], ["reporter mRNA", "RNA", 27, 40], ["SunTag epitope", "PROTEIN", 72, 86], ["5 0 end", "DNA", 96, 103], ["coding sequence", "DNA", 111, 126], ["the SunTag epitope", "TREATMENT", 68, 86]]], ["When translated, each SunTag peptide is bound by a single chain variable fragment (scFV) of a GCN4 antibody fused to super folder GFP (scFV-sfGFP).", [["SunTag", "GENE_OR_GENE_PRODUCT", 22, 28], ["GFP", "GENE_OR_GENE_PRODUCT", 130, 133], ["scFV-sfGFP", "GENE_OR_GENE_PRODUCT", 135, 145], ["single chain variable fragment", "PROTEIN", 51, 81], ["scFV", "PROTEIN", 83, 87], ["GCN4 antibody", "PROTEIN", 94, 107], ["super folder GFP", "PROTEIN", 117, 133], ["scFV", "PROTEIN", 135, 139], ["sfGFP", "PROTEIN", 140, 145], ["each SunTag peptide", "TREATMENT", 17, 36], ["a single chain variable fragment (scFV", "TREATMENT", 49, 87], ["a GCN4 antibody", "TEST", 92, 107], ["scFV", "TEST", 135, 139], ["fragment", "OBSERVATION", 73, 81]]], ["An auxin-inducible degron (AID) near the 3 0 end of the coding sequence allows controlled degradation of the fully-synthesized SunTag array, reducing fluorescence background and enabling detection of single fully-synthesized polypeptides.", [["auxin", "CHEMICAL", 3, 8], ["auxin", "CHEMICAL", 3, 8], ["auxin", "SIMPLE_CHEMICAL", 3, 8], ["degron", "GENE_OR_GENE_PRODUCT", 19, 25], ["AID", "GENE_OR_GENE_PRODUCT", 27, 30], ["SunTag", "SIMPLE_CHEMICAL", 127, 133], ["degron", "PROTEIN", 19, 25], ["AID", "PROTEIN", 27, 30], ["3 0 end", "DNA", 41, 48], ["coding sequence", "DNA", 56, 71], ["SunTag", "PROTEIN", 127, 133], ["An auxin-inducible degron (AID)", "PROBLEM", 0, 31], ["the coding sequence", "TEST", 52, 71], ["single fully-synthesized polypeptides", "TREATMENT", 200, 237], ["inducible degron", "OBSERVATION", 9, 25]]], ["We performed fixed-cell imaging of U-2OS cells stably expressing both the SunTag reporter and scFV-sfGFP, detecting mRNA by fluorescence in-situ hybridization (FISH) and SunTag signal by immunofluorescence (IF).", [["cell", "ANATOMY", 19, 23], ["U-2OS cells", "ANATOMY", 35, 46], ["cell", "CELL", 19, 23], ["U-2OS cells", "CELL", 35, 46], ["SunTag", "GENE_OR_GENE_PRODUCT", 74, 80], ["scFV-sfGFP", "GENE_OR_GENE_PRODUCT", 94, 104], ["U-2OS cells", "CELL_LINE", 35, 46], ["SunTag reporter", "DNA", 74, 89], ["scFV", "PROTEIN", 94, 98], ["sfGFP", "DNA", 99, 104], ["mRNA", "RNA", 116, 120], ["SunTag", "PROTEIN", 170, 176], ["fixed-cell imaging", "TEST", 13, 31], ["scFV", "TEST", 94, 98], ["fluorescence", "TEST", 124, 136]]], ["With this single-molecule FISH and IF hybrid assay (smFISH-IF), we quantified the association of SunTag nascent chains with their encoding mRNAs under various treatment conditions.Emetine does not prevent release of puromycylated peptides in cellsIn untreated cells, an average of 63% of single mRNAs (red foci) per cell co-localize with bright SunTag signal (green foci) ( Figure 4B , top row and 4C); these co-localized spots reflect mRNAs bound by ribosomes synthesizing the SunTag reporter, while weaker isolated green spots reflect single fully synthesized SunTag polypeptides that have been released from the ribosome (Wu et al., 2016) .", [["cells", "ANATOMY", 242, 247], ["cells", "ANATOMY", 260, 265], ["red foci", "ANATOMY", 302, 310], ["cell", "ANATOMY", 316, 320], ["Emetine", "CHEMICAL", 180, 187], ["Emetine", "CHEMICAL", 180, 187], ["SunTag", "GENE_OR_GENE_PRODUCT", 97, 103], ["Emetine", "SIMPLE_CHEMICAL", 180, 187], ["cells", "CELL", 242, 247], ["cells", "CELL", 260, 265], ["cell", "CELL", 316, 320], ["SunTag", "GENE_OR_GENE_PRODUCT", 345, 351], ["green foci", "CELLULAR_COMPONENT", 360, 370], ["ribosomes", "CELLULAR_COMPONENT", 451, 460], ["SunTag", "GENE_OR_GENE_PRODUCT", 478, 484], ["SunTag polypeptides", "GENE_OR_GENE_PRODUCT", 562, 581], ["ribosome", "CELLULAR_COMPONENT", 615, 623], ["smFISH", "PROTEIN", 52, 58], ["SunTag nascent chains", "PROTEIN", 97, 118], ["encoding mRNAs", "RNA", 130, 144], ["mRNAs", "RNA", 295, 300], ["SunTag", "PROTEIN", 345, 351], ["4C", "PROTEIN", 398, 400], ["mRNAs", "RNA", 436, 441], ["SunTag reporter", "DNA", 478, 493], ["SunTag polypeptides", "PROTEIN", 562, 581], ["hybrid assay", "TEST", 38, 50], ["SunTag nascent chains", "TREATMENT", 97, 118], ["various treatment conditions", "TREATMENT", 151, 179], ["Emetine", "TREATMENT", 180, 187], ["puromycylated peptides in cells", "PROBLEM", 216, 247], ["untreated cells", "PROBLEM", 250, 265], ["single mRNAs (red foci", "PROBLEM", 288, 310], ["bright SunTag signal", "TEST", 338, 358], ["green foci", "PROBLEM", 360, 370], ["Figure 4B", "TEST", 374, 383], ["these co-localized spots", "PROBLEM", 403, 427], ["mRNAs bound", "PROBLEM", 436, 447], ["weaker isolated green spots", "PROBLEM", 501, 528], ["single fully synthesized SunTag polypeptides", "TREATMENT", 537, 581], ["untreated cells", "OBSERVATION", 250, 265], ["foci", "OBSERVATION_MODIFIER", 306, 310], ["bright SunTag", "OBSERVATION_MODIFIER", 338, 351], ["green foci", "OBSERVATION_MODIFIER", 360, 370], ["green spots", "OBSERVATION", 517, 528]]], ["Upon treatment with 91 mM puromycin for 5 min, an average of only 3% of mRNAs per cell colocalize with green signal, consistent with release of nascent chains upon puromycin treatment.", [["cell", "ANATOMY", 82, 86], ["puromycin", "CHEMICAL", 26, 35], ["puromycin", "CHEMICAL", 164, 173], ["puromycin", "CHEMICAL", 26, 35], ["puromycin", "CHEMICAL", 164, 173], ["puromycin", "SIMPLE_CHEMICAL", 26, 35], ["cell", "CELL", 82, 86], ["puromycin", "SIMPLE_CHEMICAL", 164, 173], ["mRNAs", "RNA", 72, 77], ["treatment", "TREATMENT", 5, 14], ["91 mM puromycin", "TREATMENT", 20, 35], ["green signal", "TEST", 103, 115], ["nascent chains", "TREATMENT", 144, 158], ["puromycin treatment", "TREATMENT", 164, 183], ["green signal", "OBSERVATION", 103, 115], ["consistent with", "UNCERTAINTY", 117, 132], ["nascent chains", "OBSERVATION", 144, 158], ["puromycin treatment", "OBSERVATION", 164, 183]]], ["Remarkably, pre-treatment with 208 mM emetine for 15 min yielded similar results: only 5% of mRNAs on average colocalized with SunTag signal.", [["emetine", "CHEMICAL", 38, 45], ["emetine", "CHEMICAL", 38, 45], ["emetine", "SIMPLE_CHEMICAL", 38, 45], ["SunTag", "GENE_OR_GENE_PRODUCT", 127, 133], ["mRNAs", "RNA", 93, 98], ["SunTag", "PROTEIN", 127, 133], ["208 mM emetine", "TREATMENT", 31, 45]]], ["Importantly, pre-treatment for 5 min with elongation inhibitor anisomycin (37 mM), resulted in an average of 50% of mRNAs co-localized with green foci, as seen in untreated cells.", [["green foci", "ANATOMY", 140, 150], ["cells", "ANATOMY", 173, 178], ["anisomycin", "CHEMICAL", 63, 73], ["anisomycin", "CHEMICAL", 63, 73], ["anisomycin", "SIMPLE_CHEMICAL", 63, 73], ["cells", "CELL", 173, 178], ["mRNAs", "RNA", 116, 121], ["untreated cells", "CELL_TYPE", 163, 178], ["elongation inhibitor anisomycin", "TREATMENT", 42, 73], ["green foci", "PROBLEM", 140, 150], ["green foci", "OBSERVATION", 140, 150], ["untreated cells", "OBSERVATION", 163, 178]]], ["Together, these data indicate that 5 min of puromycin treatment causes release of nascent polypeptides and diffusion away from ribosomes.", [["ribosomes", "ANATOMY", 127, 136], ["puromycin", "CHEMICAL", 44, 53], ["puromycin", "CHEMICAL", 44, 53], ["puromycin", "SIMPLE_CHEMICAL", 44, 53], ["ribosomes", "CELLULAR_COMPONENT", 127, 136], ["puromycin treatment", "TREATMENT", 44, 63], ["nascent polypeptides", "PROBLEM", 82, 102], ["nascent polypeptides", "OBSERVATION", 82, 102]]], ["Pre-treatment with emetine has no effect on puromycin-induced release.Emetine does not prevent release of puromycylated peptides in cellsPuromycylation treatment times are long compared to protein diffusion rates While initial reports argued that emetine was required to stabilize the interaction of puromycylated peptides with ribosomes, some recent studies of local protein synthesis via the puromycylation method relied on treatment with puromycin alone for~5-10 min, with the implication that detected nascent proteins do not appreciably diffuse away from their site of synthesis (i.e. ribosome) within the treatment time (Colombo et al., 1965; tom Dieck et al., 2015; Morisaki et al., 2016) .", [["cells", "ANATOMY", 132, 137], ["emetine", "CHEMICAL", 19, 26], ["puromycin", "CHEMICAL", 44, 53], ["Emetine", "CHEMICAL", 70, 77], ["Puromycylation", "CHEMICAL", 137, 151], ["emetine", "CHEMICAL", 247, 254], ["puromycin", "CHEMICAL", 441, 450], ["emetine", "CHEMICAL", 19, 26], ["puromycin", "CHEMICAL", 44, 53], ["Emetine", "CHEMICAL", 70, 77], ["emetine", "CHEMICAL", 247, 254], ["puromycin", "CHEMICAL", 441, 450], ["emetine", "SIMPLE_CHEMICAL", 19, 26], ["puromycin", "SIMPLE_CHEMICAL", 44, 53], ["Emetine", "SIMPLE_CHEMICAL", 70, 77], ["cells", "CELL", 132, 137], ["emetine", "SIMPLE_CHEMICAL", 247, 254], ["ribosomes", "CELLULAR_COMPONENT", 328, 337], ["puromycin", "SIMPLE_CHEMICAL", 441, 450], ["ribosome", "CELLULAR_COMPONENT", 590, 598], ["nascent proteins", "PROTEIN", 506, 522], ["emetine", "TREATMENT", 19, 26], ["puromycin", "TREATMENT", 44, 53], ["Emetine", "TREATMENT", 70, 77], ["puromycylated peptides in cells", "PROBLEM", 106, 137], ["Puromycylation treatment", "TREATMENT", 137, 161], ["protein diffusion rates", "TEST", 189, 212], ["emetine", "TREATMENT", 247, 254], ["puromycylated peptides", "TREATMENT", 300, 322], ["ribosomes", "TREATMENT", 328, 337], ["local protein synthesis", "TREATMENT", 362, 385], ["the puromycylation method", "TREATMENT", 390, 415], ["puromycin", "TREATMENT", 441, 450], ["nascent proteins", "PROBLEM", 506, 522]]], ["To determine how far a nascent protein might diffuse on these timescales (i.e. the spatial resolution of the method), we calculated the expected displacement as a function of time, based on the previously measured diffusion coefficient of GFP in the cytosol (Di Rienzo et al., 2014; Figure 5 ).", [["cytosol", "ANATOMY", 250, 257], ["GFP", "GENE_OR_GENE_PRODUCT", 239, 242], ["cytosol", "CELLULAR_COMPONENT", 250, 257], ["nascent protein", "PROTEIN", 23, 38], ["GFP", "PROTEIN", 239, 242], ["a nascent protein", "PROBLEM", 21, 38], ["diffuse", "OBSERVATION_MODIFIER", 45, 52], ["displacement", "OBSERVATION_MODIFIER", 145, 157]]], ["This calculation depends on the dimensionality of space in which the molecule is confined.", [["This calculation", "TEST", 0, 16], ["molecule", "OBSERVATION", 69, 77]]], ["However, even in the most limiting case of one-dimensional diffusion-approximating movement along a very narrow neural projection-a protein is expected to diffuse~100 mm in less than 1 min.", [["neural", "ANATOMY", 112, 118], ["diffuse", "OBSERVATION_MODIFIER", 155, 162], ["100 mm", "OBSERVATION_MODIFIER", 163, 169]]], ["This distance is large compared to both the scale of the relevant structures to which protein synthesis was localized in neurons (tens of microns) (tom Dieck et al., 2015; Biever et al., 2020) , and to the diameter of HeLa cells (~20 microns) (Borle, 1969) , in which the method was demonstrated (David et al., 2012) .", [["neurons", "ANATOMY", 121, 128], ["HeLa cells", "ANATOMY", 218, 228], ["neurons", "CELL", 121, 128], ["HeLa cells", "CELL", 218, 228], ["HeLa cells", "CELL_LINE", 218, 228], ["protein synthesis", "PROBLEM", 86, 103], ["large", "OBSERVATION_MODIFIER", 17, 22], ["neurons", "ANATOMY", 121, 128], ["diameter", "OBSERVATION_MODIFIER", 206, 214], ["HeLa cells", "ANATOMY", 218, 228]]], ["Thus, limiting puromycin treatment time to a few minutes does not ensure that nascent proteins remain confined to the subcellular region in which they are synthesized.DiscussionIn this work, we have demonstrated that the puromycin method for visualizing localized translation does not faithfully detect nascent polypeptides at the site of their synthesis.", [["subcellular", "ANATOMY", 118, 129], ["puromycin", "CHEMICAL", 15, 24], ["puromycin", "CHEMICAL", 221, 230], ["puromycin", "CHEMICAL", 15, 24], ["puromycin", "CHEMICAL", 221, 230], ["puromycin", "SIMPLE_CHEMICAL", 15, 24], ["puromycin", "SIMPLE_CHEMICAL", 221, 230], ["nascent proteins", "PROTEIN", 78, 94], ["limiting puromycin treatment", "TREATMENT", 6, 34], ["nascent proteins", "PROBLEM", 78, 94], ["the puromycin method", "TREATMENT", 217, 237], ["nascent polypeptides", "PROBLEM", 303, 323], ["subcellular", "ANATOMY_MODIFIER", 118, 129], ["region", "ANATOMY_MODIFIER", 130, 136]]], ["Puromycylated polypeptides are released from the ribosome and can diffuse far away from the site of synthesis, even following short treatment times.", [["ribosome", "ANATOMY", 49, 57], ["Puromycylated polypeptides", "GENE_OR_GENE_PRODUCT", 0, 26], ["ribosome", "CELLULAR_COMPONENT", 49, 57], ["Puromycylated polypeptides", "TREATMENT", 0, 26], ["diffuse", "OBSERVATION_MODIFIER", 66, 73], ["synthesis", "OBSERVATION", 100, 109]]], ["Additionally, treatment with emetine does not prevent release of puromycylated peptides from the ribosome.", [["ribosome", "ANATOMY", 97, 105], ["emetine", "CHEMICAL", 29, 36], ["emetine", "CHEMICAL", 29, 36], ["emetine", "SIMPLE_CHEMICAL", 29, 36], ["ribosome", "CELLULAR_COMPONENT", 97, 105], ["emetine", "TREATMENT", 29, 36], ["puromycylated peptides", "PROBLEM", 65, 87]]], ["This is in agreement with previous polysome gradient analysis (Colombo et al., 1965; Grollman, 1968 ) and real-time SunTag imaging (Wang et al., 2016) that has shown that neither emetine nor cycloheximide ultimately prevent release of these peptides.", [["emetine", "CHEMICAL", 179, 186], ["cycloheximide", "CHEMICAL", 191, 204], ["emetine", "CHEMICAL", 179, 186], ["cycloheximide", "CHEMICAL", 191, 204], ["emetine", "SIMPLE_CHEMICAL", 179, 186], ["cycloheximide", "SIMPLE_CHEMICAL", 191, 204], ["previous polysome gradient analysis", "TEST", 26, 61], ["SunTag imaging", "TEST", 116, 130], ["emetine", "TREATMENT", 179, 186], ["cycloheximide", "TREATMENT", 191, 204], ["these peptides", "TREATMENT", 235, 249]]], ["It is therefore likely that the specific subcellular localizations detected by this method are in many cases the end result of trafficking or diffusion of partially-synthesized puromycylated proteins.", [["subcellular", "ANATOMY", 41, 52], ["puromycylated proteins", "PROTEIN", 177, 199], ["the specific subcellular localizations", "PROBLEM", 28, 66], ["partially-synthesized puromycylated proteins", "PROBLEM", 155, 199], ["therefore likely", "UNCERTAINTY", 6, 22]]], ["For example, the bright nucleolar labeling detected in David et al., 2012 likely does not reflect nucleolar translation, but the trafficking of puromycylated N-terminal fragments of highly abundant ribosomal proteins (which have N-terminal nucleolar localization signals) to the nucleolus (Kubota et al., 1999; Schmidt et al., 1995) .", [["nucleolar", "ANATOMY", 24, 33], ["nucleolar", "ANATOMY", 98, 107], ["ribosomal", "ANATOMY", 198, 207], ["nucleolar", "ANATOMY", 240, 249], ["nucleolus", "ANATOMY", 279, 288], ["N", "CHEMICAL", 158, 159], ["N", "CHEMICAL", 229, 230], ["nucleolar", "CELLULAR_COMPONENT", 24, 33], ["nucleolar", "CELLULAR_COMPONENT", 98, 107], ["ribosomal", "CELLULAR_COMPONENT", 198, 207], ["nucleolus", "CELLULAR_COMPONENT", 279, 288], ["puromycylated N-terminal fragments", "PROTEIN", 144, 178], ["ribosomal proteins", "PROTEIN", 198, 216], ["N", "PROTEIN", 229, 230], ["nucleolar translation", "PROBLEM", 98, 119], ["terminal fragments", "PROBLEM", 160, 178], ["highly abundant ribosomal proteins", "PROBLEM", 182, 216], ["terminal nucleolar localization signals", "PROBLEM", 231, 270], ["bright", "OBSERVATION_MODIFIER", 17, 23], ["nucleolar labeling", "OBSERVATION", 24, 42], ["likely does not reflect", "UNCERTAINTY", 74, 97], ["nucleolar translation", "OBSERVATION", 98, 119], ["highly", "OBSERVATION_MODIFIER", 182, 188], ["abundant", "OBSERVATION_MODIFIER", 189, 197], ["ribosomal proteins", "OBSERVATION", 198, 216], ["nucleolus", "ANATOMY", 279, 288]]], ["Thus, conclusions reached using this method should be treated cautiously, even in neurons, where cellular projections protrude relatively far from the cell body.", [["neurons", "ANATOMY", 82, 89], ["cellular", "ANATOMY", 97, 105], ["cell body", "ANATOMY", 151, 160], ["neurons", "CELL", 82, 89], ["cellular", "CELL", 97, 105], ["cell body", "CELLULAR_COMPONENT", 151, 160], ["this method", "TREATMENT", 32, 43], ["cell body", "OBSERVATION", 151, 160]]], ["We note that other reporter-based methods that rely on rapid, single turnover chemistry, such as the 'flash' activity of some luciferases, may allow for more accurate localization of the sites of protein synthesis (Na et al., 2016) .", [["Na", "CHEMICAL", 215, 217], ["protein synthesis", "PROBLEM", 196, 213]]], ["Additionally, in principle, derivatizing puromycin with a chemical moiety large enough to obstruct its passage through the ribosome exit tunnel would immobilize reacted nascent chains on the ribosome.", [["ribosome", "ANATOMY", 123, 131], ["ribosome", "ANATOMY", 191, 199], ["puromycin", "CHEMICAL", 41, 50], ["puromycin", "CHEMICAL", 41, 50], ["puromycin", "SIMPLE_CHEMICAL", 41, 50], ["ribosome", "CELLULAR_COMPONENT", 123, 131], ["ribosome", "CELLULAR_COMPONENT", 191, 199], ["derivatizing puromycin", "TREATMENT", 28, 50], ["a chemical moiety", "TREATMENT", 56, 73], ["the ribosome exit tunnel", "PROBLEM", 119, 143], ["ribosome", "OBSERVATION", 123, 131], ["exit tunnel", "OBSERVATION", 132, 143], ["nascent", "OBSERVATION_MODIFIER", 169, 176], ["chains", "OBSERVATION_MODIFIER", 177, 183]]], ["The viability of this concept is demonstrated by the RiboLace method (Clamer et al., 2018) , which uses a puromycin-biotin conjugate bound to magnetic beads to capture translating ribosomes from cellular lysates.", [["ribosomes", "ANATOMY", 180, 189], ["cellular lysates", "ANATOMY", 195, 211], ["puromycin-biotin", "CHEMICAL", 106, 122], ["puromycin", "CHEMICAL", 106, 115], ["biotin", "CHEMICAL", 116, 122], ["puromycin", "SIMPLE_CHEMICAL", 106, 115], ["biotin", "SIMPLE_CHEMICAL", 116, 122], ["ribosomes", "CELLULAR_COMPONENT", 180, 189], ["cellular lysates", "ORGANISM_SUBSTANCE", 195, 211], ["a puromycin-biotin conjugate bound", "TREATMENT", 104, 138], ["magnetic beads", "TREATMENT", 142, 156], ["cellular lysates", "PROBLEM", 195, 211], ["viability", "OBSERVATION_MODIFIER", 4, 13], ["cellular lysates", "OBSERVATION", 195, 211]]], ["Of course, these beads are not cell permeable and are unsuitable for in vivo imaging.", [["cell", "ANATOMY", 31, 35], ["cell", "CELL", 31, 35], ["these beads", "TREATMENT", 11, 22], ["vivo imaging", "TEST", 72, 84]]], ["The methods outlined here will be useful for screening cellpermeable puromycin derivatives for their ability to faithfully localize protein synthesis.Materials and methodsKey resourcesPlasmid constructionA Kozak consensus sequence (GCCACC) was inserted immediately upstream of the start codon of luciferase reporter plasmid pGEM-luc (GenBank X65316.2) to generate pSL312.", [["puromycin", "CHEMICAL", 69, 78], ["puromycin", "CHEMICAL", 69, 78], ["puromycin derivatives", "SIMPLE_CHEMICAL", 69, 90], ["luciferase", "GENE_OR_GENE_PRODUCT", 296, 306], ["pGEM-luc", "GENE_OR_GENE_PRODUCT", 324, 332], ["pSL312", "GENE_OR_GENE_PRODUCT", 364, 370], ["Plasmid constructionA Kozak consensus sequence", "DNA", 184, 230], ["GCCACC", "DNA", 232, 238], ["start codon", "DNA", 281, 292], ["luciferase reporter plasmid", "DNA", 296, 323], ["pGEM", "DNA", 324, 328], ["luc", "DNA", 329, 332], ["GenBank X65316.2", "DNA", 334, 350], ["pSL312", "DNA", 364, 370], ["screening cellpermeable puromycin derivatives", "TREATMENT", 45, 90]]], ["This was used as the template for full-length firefly luciferase mRNA transcription and was linearized with a StuI restriction digest.", [["luciferase", "GENE_OR_GENE_PRODUCT", 54, 64], ["luciferase mRNA", "RNA", 54, 69], ["StuI restriction digest", "DNA", 110, 133], ["full-length firefly luciferase mRNA transcription", "TREATMENT", 34, 83], ["a StuI restriction digest", "TREATMENT", 108, 133]]], ["For reasons unrelated to the current work, a disabled 2A peptide sequence was fused downstream of the luciferase sequence to generate P3.28_pGEM_ luc_2A_AGP|_kozak_RC, which was further modified by inserting an HpaI restriction site 2 nt 3 0 of the final codon of luciferase (TTGtt|aac, where TTG is the final luciferase sense codon) through site-directed mutagenesis to make P3.35_pGEM_luc_trunc_kozak_RC.", [["luciferase", "GENE_OR_GENE_PRODUCT", 102, 112], ["luciferase", "GENE_OR_GENE_PRODUCT", 264, 274], ["TTGtt|aac", "GENE_OR_GENE_PRODUCT", 276, 285], ["luciferase", "GENE_OR_GENE_PRODUCT", 310, 320], ["luciferase sequence", "DNA", 102, 121], ["P3", "DNA", 134, 136], ["HpaI restriction site 2 nt 3 0", "DNA", 211, 241], ["luciferase", "PROTEIN", 264, 274], ["TTGtt", "DNA", 276, 281], ["aac", "DNA", 282, 285], ["TTG", "DNA", 293, 296], ["luciferase sense codon", "DNA", 310, 332], ["a disabled 2A peptide sequence", "PROBLEM", 43, 73], ["an HpaI restriction site", "TREATMENT", 208, 232], ["TTG", "TEST", 293, 296]]], ["This plasmid was linearized with an HpaI restriction digest such that transcription of this template would terminate at TTGtt and would exclude the 2A peptide sequence.", [["plasmid", "ANATOMY", 5, 12], ["HpaI", "GENE_OR_GENE_PRODUCT", 36, 40], ["HpaI restriction digest", "DNA", 36, 59], ["TTGtt", "PROTEIN", 120, 125], ["This plasmid", "TREATMENT", 0, 12], ["an HpaI restriction digest", "TREATMENT", 33, 59], ["this template", "TREATMENT", 87, 100], ["HpaI", "OBSERVATION", 36, 40]]], ["For SunTag experiments, the plasmid pcDNA_CMV_ST was used to generate a stable cell line using the Flp-In method. pcDNA_CMV_ST contains an open reading frame coding for 23x Sun-Tag repeats, Nano Luciferase, BFP and an auxin-inducible degron, expressed from a pcDNA5 vector.Plasmid constructionOPP-click C. elegans was cultured according to standard methods at 20\u02daC. N2 adult germlines were dissected into egg buffer with 1 mM levamisole.", [["plasmid", "ANATOMY", 28, 35], ["cell line", "ANATOMY", 79, 88], ["adult germlines", "ANATOMY", 369, 384], ["auxin", "CHEMICAL", 218, 223], ["levamisole", "CHEMICAL", 426, 436], ["levamisole", "CHEMICAL", 426, 436], ["cell line", "CELL", 79, 88], ["Flp", "GENE_OR_GENE_PRODUCT", 99, 102], ["pcDNA_CMV_ST", "GENE_OR_GENE_PRODUCT", 114, 126], ["Tag", "GENE_OR_GENE_PRODUCT", 177, 180], ["Luciferase", "GENE_OR_GENE_PRODUCT", 195, 205], ["BFP", "GENE_OR_GENE_PRODUCT", 207, 210], ["auxin", "SIMPLE_CHEMICAL", 218, 223], ["degron", "GENE_OR_GENE_PRODUCT", 234, 240], ["pcDNA5", "GENE_OR_GENE_PRODUCT", 259, 265], ["egg", "ORGANISM_SUBSTANCE", 405, 408], ["levamisole", "SIMPLE_CHEMICAL", 426, 436], ["plasmid pcDNA_CMV_ST", "DNA", 28, 48], ["stable cell line", "CELL_LINE", 72, 88], ["Flp", "PROTEIN", 99, 102], ["pcDNA_CMV_ST", "DNA", 114, 126], ["open reading frame", "DNA", 139, 157], ["23x Sun-Tag repeats", "DNA", 169, 188], ["Nano Luciferase", "DNA", 190, 205], ["BFP", "DNA", 207, 210], ["auxin-inducible degron", "DNA", 218, 240], ["pcDNA5 vector", "DNA", 259, 272], ["C. elegans", "SPECIES", 303, 313], ["C. elegans", "SPECIES", 303, 313], ["SunTag experiments", "TREATMENT", 4, 22], ["the plasmid pcDNA_CMV_ST", "TREATMENT", 24, 48], ["a stable cell line", "TREATMENT", 70, 88], ["the Flp", "TREATMENT", 95, 102], ["Nano Luciferase", "TREATMENT", 190, 205], ["BFP", "TEST", 207, 210], ["an auxin-inducible degron", "TREATMENT", 215, 240], ["a pcDNA5 vector", "TREATMENT", 257, 272], ["Plasmid constructionOPP-click C. elegans", "TREATMENT", 273, 313], ["N2 adult germlines", "PROBLEM", 366, 384], ["1 mM levamisole", "TREATMENT", 421, 436], ["stable cell line", "OBSERVATION", 72, 88], ["inducible degron", "OBSERVATION", 224, 240], ["adult", "OBSERVATION_MODIFIER", 369, 374], ["germlines", "OBSERVATION", 375, 384], ["1 mM", "OBSERVATION_MODIFIER", 421, 425]]], ["Germlines were incubated with 45 mM emetine, or 37 mM anisomycin (Bastide et al., 2018) , or egg buffer alone for 15 min.", [["emetine", "CHEMICAL", 36, 43], ["anisomycin", "CHEMICAL", 54, 64], ["emetine", "CHEMICAL", 36, 43], ["anisomycin", "CHEMICAL", 54, 64], ["emetine", "SIMPLE_CHEMICAL", 36, 43], ["anisomycin", "SIMPLE_CHEMICAL", 54, 64], ["egg", "ORGANISM_SUBSTANCE", 93, 96], ["37 mM anisomycin", "TREATMENT", 48, 64], ["egg buffer", "TREATMENT", 93, 103]]], ["OPP was added at a concentration of 20 mM while maintaining concentrations of emetine and anisomycin for the 5 min incubation.", [["OPP", "CHEMICAL", 0, 3], ["emetine", "CHEMICAL", 78, 85], ["anisomycin", "CHEMICAL", 90, 100], ["OPP", "CHEMICAL", 0, 3], ["emetine", "CHEMICAL", 78, 85], ["anisomycin", "CHEMICAL", 90, 100], ["OPP", "SIMPLE_CHEMICAL", 0, 3], ["emetine", "SIMPLE_CHEMICAL", 78, 85], ["anisomycin", "SIMPLE_CHEMICAL", 90, 100], ["emetine", "TREATMENT", 78, 85], ["anisomycin", "TREATMENT", 90, 100]]], ["Germlines were rinsed once with PBS and fixed in 4% paraformaldehyde.", [["paraformaldehyde", "CHEMICAL", 52, 68], ["paraformaldehyde", "SIMPLE_CHEMICAL", 52, 68], ["Germlines", "TEST", 0, 9], ["PBS", "TEST", 32, 35], ["fixed", "OBSERVATION_MODIFIER", 40, 45]]], ["Click reaction was carried out with Click-iT Plus OPP Alexa Fluor 488 Protein Synthesis Assay kit (Thermo Fisher C10456) according to the manufacturer's directions.C. elegans imagingImages were taken with a Zeiss Axio Observer equipped with a CSU-W1 SoRA spinning disk scan head (Yokogawa) and Slidebook v6.0 software (Intelligent Imaging Innovations).", [["Alexa Fluor 488", "CHEMICAL", 54, 69], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 54, 69], ["C. elegans", "ORGANISM", 164, 174], ["Zeiss Axio Observer", "DNA", 207, 226], ["C. elegans", "SPECIES", 164, 174], ["C. elegans", "SPECIES", 164, 174], ["Click reaction", "PROBLEM", 0, 14], ["Click", "TEST", 36, 41], ["Protein Synthesis", "TEST", 70, 87], ["C. elegans imagingImages", "TEST", 164, 188], ["a CSU", "TEST", 241, 246], ["disk scan head", "TEST", 264, 278], ["head", "ANATOMY", 274, 278]]], ["Germline images are 10 mm z-stacks starting at the bottom of the distal germline with 0.27 mm step size using a 63X objective.", [["distal germline", "DNA", 65, 80], ["Germline images", "TEST", 0, 15], ["10 mm", "OBSERVATION_MODIFIER", 20, 25], ["bottom", "ANATOMY_MODIFIER", 51, 57], ["distal", "ANATOMY_MODIFIER", 65, 71], ["germline", "OBSERVATION", 72, 80], ["0.27 mm", "OBSERVATION_MODIFIER", 86, 93], ["step", "OBSERVATION_MODIFIER", 94, 98], ["size", "OBSERVATION_MODIFIER", 99, 103]]], ["An ROI was drawn around the mitotic zone of each germline and fluorescence in the 488 nm channel was measured.", [["germline", "DNA", 49, 57], ["488 nm channel", "PROTEIN", 82, 96], ["An ROI", "TEST", 0, 6], ["mitotic zone", "OBSERVATION", 28, 40]]], ["Fluorescence intensity of each germline was normalized to the average intensity of the germlines treated with OPP alone.Luciferase-based real-time translation monitoring assayLuciferase plasmids were linearized with a blunt-end restriction enzyme just upstream (truncated) or downstream (full-length) of the stop codon, followed by transcription with the mMESSAGE mMA-CHINE SP6 transcription kit (Invitrogen AM1340).", [["germlines", "ANATOMY", 87, 96], ["OPP", "CHEMICAL", 110, 113], ["OPP", "CHEMICAL", 110, 113], ["OPP", "SIMPLE_CHEMICAL", 110, 113], ["SP6", "GENE_OR_GENE_PRODUCT", 374, 377], ["Invitrogen AM1340", "GENE_OR_GENE_PRODUCT", 397, 414], ["germline", "DNA", 31, 39], ["assayLuciferase plasmids", "DNA", 170, 194], ["blunt-end restriction enzyme", "DNA", 218, 246], ["stop codon", "DNA", 308, 318], ["mMESSAGE mMA-CHINE SP6", "DNA", 355, 377], ["OPP alone", "TREATMENT", 110, 119], ["Luciferase", "TEST", 120, 130], ["assayLuciferase plasmids", "TREATMENT", 170, 194], ["a blunt-end restriction enzyme", "PROBLEM", 216, 246], ["germline", "OBSERVATION", 31, 39], ["average", "OBSERVATION_MODIFIER", 62, 69], ["intensity", "OBSERVATION_MODIFIER", 70, 79]]], ["Synthesized mRNA was quantified using a Nanodrop 1000.", [["mRNA", "RNA", 12, 16], ["a Nanodrop", "TREATMENT", 38, 48]]], ["Nuclease-treated rabbit reticulocyte lysate translation reactions (Promega L4960) were set up in a 384-well plate (Thermo Scientific 164610) on ice.", [["reticulocyte lysate", "ANATOMY", 24, 43], ["Nuclease", "GENE_OR_GENE_PRODUCT", 0, 8], ["rabbit", "ORGANISM", 17, 23], ["reticulocyte", "CELL", 24, 36], ["rabbit", "SPECIES", 17, 23], ["rabbit", "SPECIES", 17, 23], ["Nuclease", "TEST", 0, 8], ["rabbit reticulocyte lysate translation reactions", "TREATMENT", 17, 65], ["rabbit reticulocyte lysate", "OBSERVATION", 17, 43]]], ["Luciferin (PerkinElmer 122799) was added to each reaction well to a concentration of 0.5 mM followed by 12 units of Superase-In RNase Inhibitor (Invitrogen AM2696).", [["Luciferin", "CHEMICAL", 0, 9], ["PerkinElmer 122799", "CHEMICAL", 11, 29], ["Luciferin", "CHEMICAL", 0, 9], ["PerkinElmer 122799", "CHEMICAL", 11, 29], ["Luciferin", "SIMPLE_CHEMICAL", 0, 9], ["PerkinElmer 122799", "SIMPLE_CHEMICAL", 11, 29], ["RNase", "GENE_OR_GENE_PRODUCT", 128, 133], ["Invitrogen AM2696", "SIMPLE_CHEMICAL", 145, 162], ["RNase", "PROTEIN", 128, 133], ["Luciferin", "TREATMENT", 0, 9], ["Superase-In RNase Inhibitor", "TREATMENT", 116, 143]]], ["SP6-transcribed truncated or full-length firefly luciferase mRNA was added to a concentration of 40 mg/mL using a multichannel pipette and the plate was immediately inserted into a luminometer microplate reader (Biotek Synergy H1MD) regulated at 30\u02daC. Luminescence readings were taken every few seconds, depending on the number of reaction wells.", [["SP6", "GENE_OR_GENE_PRODUCT", 0, 3], ["luciferase", "GENE_OR_GENE_PRODUCT", 49, 59], ["SP6-transcribed truncated or full-length firefly luciferase mRNA", "RNA", 0, 64], ["SP6", "PROBLEM", 0, 3], ["full-length firefly luciferase mRNA", "TREATMENT", 29, 64], ["a multichannel pipette", "TREATMENT", 112, 134], ["the plate", "TREATMENT", 139, 148], ["a luminometer microplate reader (Biotek Synergy H1MD", "TREATMENT", 179, 231], ["Luminescence readings", "TEST", 252, 273]]], ["5'-guanylyl imidodiphosphate (GDPNP; Jena Bioscience NU-401-50) was added to the wells 16 min after the start of the reaction for 5 min at a concentration of 100 mM followed by a 5-min pretreatment of either 208 mM emetine (Cayman Chemical 21048) or 9.4 mM anisomycin (Sigma A9789).", [["5'-guanylyl imidodiphosphate", "CHEMICAL", 0, 28], ["GDPNP", "CHEMICAL", 30, 35], ["NU-401-50", "CHEMICAL", 53, 62], ["emetine", "CHEMICAL", 215, 222], ["Cayman Chemical 21048", "CHEMICAL", 224, 245], ["anisomycin", "CHEMICAL", 257, 267], ["5'-guanylyl imidodiphosphate", "CHEMICAL", 0, 28], ["GDPNP", "CHEMICAL", 30, 35], ["NU-401-50", "CHEMICAL", 53, 62], ["emetine", "CHEMICAL", 215, 222], ["anisomycin", "CHEMICAL", 257, 267], ["5'-guanylyl imidodiphosphate", "SIMPLE_CHEMICAL", 0, 28], ["GDPNP", "SIMPLE_CHEMICAL", 30, 35], ["emetine", "SIMPLE_CHEMICAL", 215, 222], ["anisomycin", "SIMPLE_CHEMICAL", 257, 267], ["Sigma A9789", "SIMPLE_CHEMICAL", 269, 280], ["guanylyl imidodiphosphate", "TREATMENT", 3, 28], ["GDPNP", "TEST", 30, 35], ["Jena Bioscience NU", "TEST", 37, 55], ["the reaction", "PROBLEM", 113, 125]]], ["Puromycin (Sigma Aldrich P7255) was added to wells at a concentration of 91 mM.", [["Puromycin", "CHEMICAL", 0, 9], ["Sigma Aldrich P7255", "CHEMICAL", 11, 30], ["Puromycin", "CHEMICAL", 0, 9], ["Puromycin", "SIMPLE_CHEMICAL", 0, 9], ["Sigma Aldrich P7255", "SIMPLE_CHEMICAL", 11, 30], ["Puromycin (Sigma Aldrich P7255)", "TREATMENT", 0, 31]]], ["In experiments where GDPNP was not used, the first translation inhibitors were added to the reaction wells at 21 min following the start of the reaction.", [["GDPNP", "CHEMICAL", 21, 26], ["GDPNP", "CHEMICAL", 21, 26], ["GDPNP", "SIMPLE_CHEMICAL", 21, 26], ["GDPNP", "PROTEIN", 21, 26], ["GDPNP", "TREATMENT", 21, 26], ["the first translation inhibitors", "TREATMENT", 41, 73], ["the reaction", "PROBLEM", 140, 152]]], ["Reagents were added to the wells by first ejecting the microplate from the luminometer and pipetting the reagents in using a multichannel pipette.", [["the luminometer", "TREATMENT", 71, 86], ["a multichannel pipette", "TREATMENT", 123, 145]]], ["The microplate was then promptly inserted again.Stable cell lineU-2OS cells stably expressing the SunTag reporter were generated using the Flp-In system with the pcDNA_CMV_ST plasmid, as described in Goldman et al., 2020 .", [["cell lineU-2OS cells", "ANATOMY", 55, 75], ["plasmid", "ANATOMY", 175, 182], ["cell lineU-2OS cells", "CELL", 55, 75], ["SunTag", "GENE_OR_GENE_PRODUCT", 98, 104], ["Flp", "GENE_OR_GENE_PRODUCT", 139, 142], ["Stable cell lineU", "CELL_LINE", 48, 65], ["2OS cells", "CELL_LINE", 66, 75], ["SunTag reporter", "DNA", 98, 113], ["Flp", "DNA", 139, 142], ["pcDNA_CMV_ST plasmid", "DNA", 162, 182], ["The microplate", "TREATMENT", 0, 14], ["the pcDNA_CMV_ST plasmid", "TREATMENT", 158, 182], ["cell lineU", "OBSERVATION", 55, 65]]], ["The cell line was a kind gift from Dr. Andrew Holland (Johns Hopkins University).", [["cell line", "ANATOMY", 4, 13], ["cell line", "CELL", 4, 13], ["cell line", "CELL_LINE", 4, 13], ["cell line", "OBSERVATION", 4, 13]]], ["While the cell line's identity has not recently been authenticated via STR profiling, it has frequently been tested for mycoplasma contamination and is mycoplasma free. smFISH Probe Labeling smFISH probes targeting the SunTag region of the mRNA reporter transcript were synthesized as described (Goldman et al., 2020; Gaspar et al., 2017) .", [["cell line", "ANATOMY", 10, 19], ["mycoplasma contamination", "DISEASE", 120, 144], ["smFISH", "CHEMICAL", 169, 175], ["cell line", "CELL", 10, 19], ["smFISH probes", "DNA", 191, 204], ["SunTag region", "DNA", 219, 232], ["mRNA reporter transcript", "RNA", 240, 264], ["STR profiling", "TEST", 71, 84], ["mycoplasma contamination", "PROBLEM", 120, 144], ["mycoplasma", "PROBLEM", 152, 162], ["Probe Labeling smFISH probes", "TREATMENT", 176, 204], ["cell line", "OBSERVATION", 10, 19]]], ["20mer oligonucleotides (Supplementary file 1) were ordered from IDT in an arrayed format, pooled, and labeled on the 3'-end with amino-11-12 ddUTP (Lumiprobe A5040) using deoxynucleotidyl transferase (TdT, Thermo Fisher EP0162).", [["amino-11-12 ddUTP", "CHEMICAL", 129, 146], ["amino", "CHEMICAL", 129, 134], ["amino-11-12 ddUTP", "SIMPLE_CHEMICAL", 129, 146], ["deoxynucleotidyl transferase", "GENE_OR_GENE_PRODUCT", 171, 199], ["TdT", "SIMPLE_CHEMICAL", 201, 204], ["3'-end", "DNA", 117, 123], ["Lumiprobe A5040", "DNA", 148, 163], ["deoxynucleotidyl transferase", "PROTEIN", 171, 199], ["TdT", "PROTEIN", 201, 204], ["oligonucleotides (Supplementary file", "TREATMENT", 6, 42], ["amino", "TEST", 129, 134]]], ["After size exclusion purification on a Spin-X centrifuge column (Corning 8161) with Bio Gel P-4 Beads (Bio Rad 1504124), the oligonucleotide was labeled with Cy3-NHS ester (Lumiprobe 41020).", [["Rad 1504124", "CHEMICAL", 107, 118], ["Cy3-NHS ester", "CHEMICAL", 158, 171], ["Lumiprobe 41020", "CHEMICAL", 173, 188], ["Cy3-NHS ester", "CHEMICAL", 158, 171], ["Lumiprobe 41020", "CHEMICAL", 173, 188], ["Cy3-NHS ester", "SIMPLE_CHEMICAL", 158, 171], ["Lumiprobe 41020", "SIMPLE_CHEMICAL", 173, 188], ["a Spin-X centrifuge column", "TREATMENT", 37, 63], ["Bio Gel P-4 Beads", "TREATMENT", 84, 101], ["the oligonucleotide", "TREATMENT", 121, 140], ["Cy3-NHS ester (Lumiprobe", "TREATMENT", 158, 182], ["size", "OBSERVATION_MODIFIER", 6, 10]]], ["Following the labeling reaction, the probes were again purified over a Spin-X column to remove excessive dyes. smFISH-IF smFISH-IF was performed similarly as described (Goldman et al., 2020; Latallo et al., 2019) . smFISH-IF was performed on U-2OS cells stably expressing the SunTag mRNA reporter and scFV-sfGFP.", [["U-2OS cells", "ANATOMY", 242, 253], ["smFISH-IF", "GENE_OR_GENE_PRODUCT", 215, 224], ["U-2OS cells", "CELL", 242, 253], ["SunTag", "GENE_OR_GENE_PRODUCT", 276, 282], ["scFV-sfGFP", "GENE_OR_GENE_PRODUCT", 301, 311], ["smFISH", "PROTEIN", 111, 117], ["smFISH", "PROTEIN", 121, 127], ["IF", "PROTEIN", 128, 130], ["smFISH", "PROTEIN", 215, 221], ["IF", "PROTEIN", 222, 224], ["U-2OS cells", "CELL_LINE", 242, 253], ["SunTag mRNA reporter", "DNA", 276, 296], ["scFV-sfGFP", "PROTEIN", 301, 311], ["the labeling reaction", "PROBLEM", 10, 31], ["the probes", "TREATMENT", 33, 43], ["a Spin-X column", "TREATMENT", 69, 84], ["excessive dyes", "PROBLEM", 95, 109], ["smFISH", "TEST", 111, 117], ["U", "TEST", 242, 243], ["scFV-sfGFP", "TEST", 301, 311]]], ["18 mm #1 coverslips (Fisher 12-545-100) were etched in 3M sodium hydroxide (Millipore Sigma 221465) prior to cell plating.", [["cell", "ANATOMY", 109, 113], ["sodium hydroxide", "CHEMICAL", 58, 74], ["Sigma 221465", "CHEMICAL", 86, 98], ["sodium hydroxide", "CHEMICAL", 58, 74], ["3M sodium hydroxide", "SIMPLE_CHEMICAL", 55, 74], ["cell", "CELL", 109, 113], ["1 coverslips (Fisher", "TREATMENT", 7, 27], ["3M sodium hydroxide (Millipore Sigma", "TREATMENT", 55, 91], ["cell plating", "TREATMENT", 109, 121], ["cell plating", "OBSERVATION", 109, 121]]], ["The coverslips were then washed 3x with PBS (Corning 21-031-CV) and then coated for 30 min at 37\u02daC with 0.25 mg/mL rat tail collagen I (Gibco A1048301) diluted in 20 mM sodium acetate (Sigma-Aldrich S2889).", [["Corning 21-031-CV", "CHEMICAL", 45, 62], ["Gibco A1048301", "CHEMICAL", 136, 150], ["sodium acetate", "CHEMICAL", 169, 183], ["Sigma-Aldrich S2889", "CHEMICAL", 185, 204], ["sodium acetate", "CHEMICAL", 169, 183], ["rat", "ORGANISM", 115, 118], ["collagen", "GENE_OR_GENE_PRODUCT", 124, 132], ["sodium acetate", "SIMPLE_CHEMICAL", 169, 183], ["Sigma-Aldrich S2889", "SIMPLE_CHEMICAL", 185, 204], ["collagen I", "PROTEIN", 124, 134], ["rat", "SPECIES", 115, 118], ["The coverslips", "TREATMENT", 0, 14], ["PBS", "TEST", 40, 43], ["20 mM sodium acetate", "TREATMENT", 163, 183]]], ["After another 2x PBS wash, 18,000 cells were plated per well and grown for 24 hr in DMEM supplemented with 10% FBS.", [["cells", "ANATOMY", 34, 39], ["FBS", "ANATOMY", 111, 114], ["cells", "CELL", 34, 39], ["FBS", "ORGANISM_SUBSTANCE", 111, 114], ["another 2x PBS wash", "TREATMENT", 6, 25], ["10% FBS", "TREATMENT", 107, 114]]], ["24 hr following plating, the media was supplemented with 1 mg/mL doxycycline hyclate (Millipore Sigma, #D9891) and 500 mM 3-indole acetic acid (IAA) (Sigma-Aldrich I2886).Stable cell lineApproximately, 24 hr following induction, cells were treated with either 91 mM puromycin in the medium for 5 min, 208 mM emetine in the medium for 15 min followed by 91 mM puromycin in the medium for 5 min, or 37 mM anisomycin in the medium for 5 min followed by 91 mM puromycin in the medium for 5 min.", [["cell", "ANATOMY", 178, 182], ["cells", "ANATOMY", 229, 234], ["doxycycline", "CHEMICAL", 65, 76], ["3-indole acetic acid", "CHEMICAL", 122, 142], ["IAA", "CHEMICAL", 144, 147], ["puromycin", "CHEMICAL", 266, 275], ["emetine", "CHEMICAL", 308, 315], ["puromycin", "CHEMICAL", 359, 368], ["anisomycin", "CHEMICAL", 403, 413], ["puromycin", "CHEMICAL", 456, 465], ["doxycycline hyclate", "CHEMICAL", 65, 84], ["3-indole acetic acid", "CHEMICAL", 122, 142], ["IAA", "CHEMICAL", 144, 147], ["puromycin", "CHEMICAL", 266, 275], ["emetine", "CHEMICAL", 308, 315], ["puromycin", "CHEMICAL", 359, 368], ["anisomycin", "CHEMICAL", 403, 413], ["puromycin", "CHEMICAL", 456, 465], ["doxycycline hyclate", "SIMPLE_CHEMICAL", 65, 84], ["3-indole acetic acid", "SIMPLE_CHEMICAL", 122, 142], ["IAA", "SIMPLE_CHEMICAL", 144, 147], ["Sigma-Aldrich I2886", "SIMPLE_CHEMICAL", 150, 169], ["cell", "CELL", 178, 182], ["cells", "CELL", 229, 234], ["puromycin", "SIMPLE_CHEMICAL", 266, 275], ["emetine", "SIMPLE_CHEMICAL", 308, 315], ["puromycin", "SIMPLE_CHEMICAL", 359, 368], ["anisomycin", "SIMPLE_CHEMICAL", 403, 413], ["puromycin", "SIMPLE_CHEMICAL", 456, 465], ["plating", "TREATMENT", 16, 23], ["91 mM puromycin in the medium", "TREATMENT", 260, 289], ["91 mM puromycin in the medium", "TREATMENT", 353, 382], ["37 mM anisomycin", "TREATMENT", 397, 413], ["91 mM puromycin in the medium", "TREATMENT", 450, 479], ["cell lineApproximately", "OBSERVATION", 178, 200]]], ["Control cells were left untreated.", [["cells", "ANATOMY", 8, 13], ["Control cells", "CELL", 0, 13], ["left", "ANATOMY_MODIFIER", 19, 23]]], ["Following treatment, samples were prepared for smFISH-IF.", [["samples", "ANATOMY", 21, 28], ["treatment", "TREATMENT", 10, 19], ["samples", "TEST", 21, 28]]], ["All solutions were prepared in nuclease free water (Quality Biological 351-029-131CS).", [["All solutions", "TREATMENT", 0, 13]]], ["Cells were washed 3x with 1x PBS (Corning 46-013 CM) + 5 mM magnesium chloride (Sigma-Aldrich M2670-500G) (PBSM).", [["Cells", "ANATOMY", 0, 5], ["magnesium chloride", "CHEMICAL", 60, 78], ["Sigma-Aldrich M2670-500G", "CHEMICAL", 80, 104], ["magnesium chloride", "CHEMICAL", 60, 78], ["Sigma-Aldrich M2670-500G", "CHEMICAL", 80, 104], ["PBSM", "CHEMICAL", 107, 111], ["Cells", "CELL", 0, 5], ["magnesium chloride", "SIMPLE_CHEMICAL", 60, 78], ["Sigma-Aldrich M2670-500G", "SIMPLE_CHEMICAL", 80, 104], ["PBSM", "SIMPLE_CHEMICAL", 107, 111], ["Cells", "TEST", 0, 5], ["magnesium chloride", "TEST", 60, 78]]], ["Cell were then fixed for 10 min at room temperature in PBSM + 4% paraformaldehyde (Electron Microscopy Sciences 50-980-492).", [["Cell", "ANATOMY", 0, 4], ["PBSM", "CHEMICAL", 55, 59], ["paraformaldehyde", "CHEMICAL", 65, 81], ["Cell", "CELL", 0, 4], ["paraformaldehyde", "SIMPLE_CHEMICAL", 65, 81], ["PBSM", "TEST", 55, 59]]], ["Following fixation, samples were washed for 3 \u00c2 5 min in PBSM and permeabilized for 10 min in PBSM + 5 mg/mL BSA (VWR VWRV0332-25G) + 0.1% Triton-X100 (Sigma-Aldrich T8787-100mL).", [["samples", "ANATOMY", 20, 27], ["PBSM", "CHEMICAL", 57, 61], ["PBSM", "CHEMICAL", 94, 98], ["VWRV0332-25G", "CHEMICAL", 118, 130], ["Triton-X100", "CHEMICAL", 139, 150], ["Triton-X100", "CHEMICAL", 139, 150], ["PBSM", "SIMPLE_CHEMICAL", 57, 61], ["PBSM", "SIMPLE_CHEMICAL", 94, 98], ["BSA", "SIMPLE_CHEMICAL", 109, 112], ["VWRV0332-25G", "SIMPLE_CHEMICAL", 118, 130], ["Triton-X100", "SIMPLE_CHEMICAL", 139, 150], ["Sigma-Aldrich T8787-100mL", "SIMPLE_CHEMICAL", 152, 177], ["fixation", "TREATMENT", 10, 18], ["samples", "TEST", 20, 27], ["PBSM", "TEST", 94, 98], ["VWR", "TEST", 114, 117], ["VWRV0332", "TEST", 118, 126], ["fixation", "OBSERVATION", 10, 18]]], ["After 3 \u00c2 5 min washes in PBSM, cells were incubated for 30 min at room temperature in 2xSSC (Corning 46-020 CM), 10% formamide (Sigma-Aldrich F9037-100ML), and 5 mg/mL BSA (VWR VWRV0332-25G).", [["cells", "ANATOMY", 32, 37], ["2xSSC", "CHEMICAL", 87, 92], ["formamide", "CHEMICAL", 118, 127], ["Sigma-Aldrich F9037-100ML", "CHEMICAL", 129, 154], ["VWRV0332-25G", "CHEMICAL", 178, 190], ["formamide", "CHEMICAL", 118, 127], ["cells", "CELL", 32, 37], ["formamide", "SIMPLE_CHEMICAL", 118, 127], ["Sigma-Aldrich F9037-100ML", "SIMPLE_CHEMICAL", 129, 154], ["BSA", "SIMPLE_CHEMICAL", 169, 172], ["VWR", "TEST", 174, 177]]], ["Following prehybridization incubation, samples were incubated for 3 hr at 37\u02daC in 2xSSC (Corning 46-020 CM), 10% formamide (Sigma-Aldrich F9037-100ML), 1 mg/mL competitor E. coli tRNA (Sigma-Aldrich 10109541001), 10% w/v dextran sulfate (Sigma-Aldrich D8906-100G), 2 mM ribonucleoside vanadyl complex (NEB S1402S), 100 units/mL SUPERase In (Thermo Fisher AM2694), 60 nM SunTag_v4-Cy3 smFISH probes, and 1:1000 chicken anti-GFP (Aves Labs GFP-1010).", [["samples", "ANATOMY", 39, 46], ["2xSSC", "CHEMICAL", 82, 87], ["formamide", "CHEMICAL", 113, 122], ["Sigma-Aldrich 10109541001", "CHEMICAL", 185, 210], ["dextran sulfate", "CHEMICAL", 221, 236], ["ribonucleoside vanadyl", "CHEMICAL", 270, 292], ["formamide", "CHEMICAL", 113, 122], ["sulfate", "CHEMICAL", 229, 236], ["ribonucleoside vanadyl", "CHEMICAL", 270, 292], ["formamide", "SIMPLE_CHEMICAL", 113, 122], ["Sigma-Aldrich F9037-100ML", "SIMPLE_CHEMICAL", 124, 149], ["Sigma-Aldrich 10109541001", "SIMPLE_CHEMICAL", 185, 210], ["w/v dextran sulfate", "SIMPLE_CHEMICAL", 217, 236], ["Sigma-Aldrich D8906-100G", "SIMPLE_CHEMICAL", 238, 262], ["ribonucleoside vanadyl complex", "SIMPLE_CHEMICAL", 270, 300], ["NEB S1402S", "SIMPLE_CHEMICAL", 302, 312], ["chicken", "ORGANISM", 410, 417], ["anti-GFP", "GENE_OR_GENE_PRODUCT", 418, 426], ["1:1000 chicken anti-GFP (Aves Labs GFP-1010", "PROTEIN", 403, 446], ["E. coli", "SPECIES", 171, 178], ["chicken", "SPECIES", 410, 417], ["E. coli", "SPECIES", 171, 178], ["chicken", "SPECIES", 410, 417], ["samples", "TEST", 39, 46], ["formamide (Sigma-Aldrich F9037", "TREATMENT", 113, 143], ["E. coli tRNA (Sigma-Aldrich", "TREATMENT", 171, 198], ["v dextran sulfate", "TREATMENT", 219, 236], ["Sigma-Aldrich D8906", "TREATMENT", 238, 257], ["2 mM ribonucleoside vanadyl complex (NEB S1402S)", "TREATMENT", 265, 313]]], ["The coverslips were then washed 4x with 2xSSC (Corning 46-020 CM) + 10% formamide (Sigma-Aldrich F9037-100ML).", [["2xSSC", "CHEMICAL", 40, 45], ["CM", "DISEASE", 62, 64], ["formamide", "CHEMICAL", 72, 81], ["formamide", "CHEMICAL", 72, 81], ["formamide", "SIMPLE_CHEMICAL", 72, 81], ["The coverslips", "TREATMENT", 0, 14]]], ["The samples were then incubated with 2 \u00c2 20 min with a goat anti-chicken IgY secondary antibody labeled with Alexa Fluor 488 (Thermo Fisher A-11039).", [["samples", "ANATOMY", 4, 11], ["Alexa Fluor 488", "CHEMICAL", 109, 124], ["A-11039", "CHEMICAL", 140, 147], ["Alexa Fluor 488", "CHEMICAL", 109, 124], ["goat", "ORGANISM", 55, 59], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 109, 124], ["goat anti-chicken IgY secondary antibody", "PROTEIN", 55, 95], ["Alexa Fluor 488", "PROTEIN", 109, 124], ["goat", "SPECIES", 55, 59], ["goat", "SPECIES", 55, 59], ["Alexa Fluor 488", "SPECIES", 109, 124], ["a goat anti-chicken IgY", "TREATMENT", 53, 76]]], ["After 3x washes in 2xSCC, cells were mounted on pre-cleaned frosted glass cover slides (Fisher 12-552-3) with ProLong Diamond antifade reagent with DAPI (Invitrogen P36962).", [["cells", "ANATOMY", 26, 31], ["DAPI", "CHEMICAL", 148, 152], ["cells", "CELL", 26, 31], ["DAPI", "SIMPLE_CHEMICAL", 148, 152], ["Invitrogen P36962", "SIMPLE_CHEMICAL", 154, 171], ["3x washes in 2xSCC", "TREATMENT", 6, 24], ["cells", "PROBLEM", 26, 31], ["ProLong Diamond antifade reagent", "TREATMENT", 110, 142], ["DAPI", "TREATMENT", 148, 152]]], ["After curing for 24 hr, the samples were imaged on a custom Nikon Ti-2 wide-field microscope equipped with a 60 \u00c2 1.4 NA oil immersion objective lens (Nikon), a Spectra X LED light engine (Lumencor), and an Orca 4.0 v2 scMOS camera (Hamamatsu).", [["samples", "ANATOMY", 28, 35], ["the samples", "TEST", 24, 35], ["a 60 \u00c2 1.4 NA oil immersion objective lens", "TREATMENT", 107, 149], ["an Orca", "TEST", 204, 211]]], ["The microscope was under automated control by Nikon Elements software. x-y pixel size: 107.5 nm. z-step: 300 nm.smFISH AnalysisFixed cell image analysis was performed as described (Goldman et al., 2020) with existing or custom MATLAB software.", [["cell", "ANATOMY", 133, 137], ["cell", "CELL", 133, 137], ["Nikon Elements software", "DNA", 46, 69], ["smFISH", "PROTEIN", 112, 118], ["The microscope", "TEST", 0, 14], ["AnalysisFixed cell image analysis", "TEST", 119, 152], ["size", "OBSERVATION_MODIFIER", 81, 85], ["107.5 nm", "OBSERVATION_MODIFIER", 87, 95], ["300 nm", "OBSERVATION_MODIFIER", 105, 111]]], ["Spot detection of the mRNA and proteins channels were performed independently in FISH-Quant (Mueller et al., 2013) .", [["mRNA", "RNA", 22, 26], ["Spot detection", "TEST", 0, 14], ["the mRNA and proteins channels", "TEST", 18, 48]]], ["In the protein channel, all released single peptides in the cytoplasm were detected and thresholded based on their Gaussian fitting parameters (intensity and width) and inspected to ensure accuracy.", [["cytoplasm", "ANATOMY", 60, 69], ["cytoplasm", "ORGANISM_SUBSTANCE", 60, 69], ["protein channel", "PROTEIN", 7, 22], ["accuracy", "TEST", 189, 197], ["protein channel", "ANATOMY", 7, 22]]], ["All released single peptides were then averaged into an idealized point spread function to calculate the integrated intensity of a single SunTag array.", [["SunTag array", "DNA", 138, 150], ["All released single peptides", "TREATMENT", 0, 28], ["a single SunTag array", "TREATMENT", 129, 150]]], ["In the mRNA channel, only cytoplasmic RNAs were included for analysis.", [["cytoplasmic", "ANATOMY", 26, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 26, 37], ["mRNA channel", "RNA", 7, 19], ["cytoplasmic RNAs", "RNA", 26, 42], ["cytoplasmic RNAs", "TEST", 26, 42], ["analysis", "TEST", 61, 69], ["cytoplasmic RNAs", "OBSERVATION", 26, 42]]], ["After determining all cytoplasmic mRNA positions, FISH-Quant's transcription site quantification algorithm was employed to quantify the integrated intensity of the associated translation site.", [["cytoplasmic", "ANATOMY", 22, 33], ["cytoplasmic", "ORGANISM_SUBSTANCE", 22, 33], ["cytoplasmic mRNA positions", "RNA", 22, 48], ["associated translation site", "DNA", 164, 191], ["FISH", "TEST", 50, 54], ["translation site", "OBSERVATION", 175, 191]]], ["Briefly, a 11 \u00c2 11 bounding box was drawn at the position of each mRNA and Gaussian fitting was performed centered on the brightest pixel within this box.", [["11 \u00c2 11 bounding box", "DNA", 11, 31], ["mRNA", "RNA", 66, 70], ["a 11 \u00c2 11 bounding box", "TREATMENT", 9, 31], ["Gaussian fitting", "TREATMENT", 75, 91]]], ["The integrated intensity of the translation site was then normalized against the intensity of the idealized single peptide to calculate the number of nascent chains associated with a given mRNA.", [["translation site", "DNA", 32, 48], ["mRNA", "RNA", 189, 193], ["nascent chains", "PROBLEM", 150, 164], ["intensity", "OBSERVATION_MODIFIER", 15, 24], ["nascent chains", "OBSERVATION", 150, 164]]], ["The translation sites were filtered based on shape, intensity, and distance from the mRNA.", [["translation sites", "DNA", 4, 21], ["mRNA", "RNA", 85, 89], ["The translation sites", "PROBLEM", 0, 21], ["filtered", "OBSERVATION", 27, 35], ["shape", "OBSERVATION_MODIFIER", 45, 50], ["intensity", "OBSERVATION_MODIFIER", 52, 61], ["mRNA", "ANATOMY", 85, 89]]], ["Failure to converge on an accurate fit given these parameters resulted in the associated translation site intensity to have an intensity value of 0.", [["Failure to converge", "PROBLEM", 0, 19], ["an intensity value", "TEST", 124, 142]]], ["Translation sites with an integrated intensity of less than one idealized single peptide were determined to be unassociated with SunTag signal.", [["SunTag", "GENE_OR_GENE_PRODUCT", 129, 135], ["SunTag", "PROTEIN", 129, 135], ["intensity", "OBSERVATION_MODIFIER", 37, 46], ["less", "OBSERVATION_MODIFIER", 50, 54]]], ["Only cells with greater than five and fewer than 35 mRNAs were considered.", [["cells", "ANATOMY", 5, 10], ["cells", "CELL", 5, 10], ["35 mRNAs", "RNA", 49, 57], ["greater", "OBSERVATION_MODIFIER", 16, 23]]]], "515dd4e4106ae000e759cc372410e12b66d2f982": [["Resistance rates (RR) over a period of 5 years were generally better than those reported for a total of 40 ICUs.", [["Resistance rates", "TEST", 0, 16], ["RR", "TEST", 18, 20]]], ["The mean MRSA RR was 22.1%, for all the SARI ICUs, whereas it was only 2.7% in the study ICU.", [["SARI", "DISEASE", 40, 44], ["MRSA", "SPECIES", 9, 13], ["The mean MRSA RR", "TEST", 0, 16]]], ["By the end of 2003 duration of treatment for pneumonia had been reduced to 5-7 days and written guidelines on empiric antibiotic treatment and prophylaxis were revised with respect to the resistance situation of the study ICU.", [["pneumonia", "DISEASE", 45, 54], ["treatment", "TREATMENT", 31, 40], ["pneumonia", "PROBLEM", 45, 54], ["empiric antibiotic treatment", "TREATMENT", 110, 138], ["prophylaxis", "TREATMENT", 143, 154], ["pneumonia", "OBSERVATION", 45, 54]]], ["The significant decrease between 2000 and 2004 in total antimicrobial AD from 1,099 to 607 in the study ICU resulted mainly from the reduced consumption of 2nd generation cephalosporins, carbapenems and imidazoles.", [["AD", "DISEASE", 70, 72], ["cephalosporins", "CHEMICAL", 171, 185], ["carbapenems", "CHEMICAL", 187, 198], ["imidazoles", "CHEMICAL", 203, 213], ["cephalosporins", "CHEMICAL", 171, 185], ["carbapenems", "CHEMICAL", 187, 198], ["imidazoles", "CHEMICAL", 203, 213], ["cephalosporins", "SIMPLE_CHEMICAL", 171, 185], ["carbapenems", "SIMPLE_CHEMICAL", 187, 198], ["imidazoles", "SIMPLE_CHEMICAL", 203, 213], ["2nd generation cephalosporins", "TREATMENT", 156, 185], ["carbapenems", "TREATMENT", 187, 198], ["imidazoles", "TREATMENT", 203, 213], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["decrease", "OBSERVATION_MODIFIER", 16, 24]]], ["NI did not change significantly over time.", [["not", "UNCERTAINTY", 7, 10], ["change", "OBSERVATION_MODIFIER", 11, 17], ["significantly", "OBSERVATION_MODIFIER", 18, 31]]], ["Compared to the year 2000, the costs for antibiotics were halved from \u20ac51,102 to 22,324, which corresponds to \u20ac18.7/pd and \u20ac6.6/pd, respectively.", [["antibiotics", "TREATMENT", 41, 52], ["\u20ac", "TEST", 110, 111], ["pd", "TEST", 116, 118], ["\u20ac", "TEST", 123, 124], ["pd", "TEST", 128, 130]]], ["The percentage of antibiotics in the total ICU budget for pharmaceuticals decreased from 14.6% to 10.4%.", [["antibiotics", "TREATMENT", 18, 29], ["pharmaceuticals", "TREATMENT", 58, 73], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Conclusion: Surveillance and feedback of antibiotic use and resistance can serve as a valuable quality control instrument and can have an impact on antibiotic treatment.", [["Surveillance", "TEST", 12, 24], ["antibiotic use", "TREATMENT", 41, 55], ["antibiotic treatment", "TREATMENT", 148, 168]]], ["From 2000 to 2004, antibiotic use was reduced by 45% and costs for antibiotics/pd were cut by two third in the ICU study without any increase in device associated nosocomial infection rates.", [["nosocomial infection", "DISEASE", 163, 183], ["antibiotic use", "TREATMENT", 19, 33], ["antibiotics/pd", "TREATMENT", 67, 81], ["the ICU study", "TEST", 107, 120], ["device associated nosocomial infection rates", "PROBLEM", 145, 189], ["nosocomial", "OBSERVATION_MODIFIER", 163, 173], ["infection", "OBSERVATION", 174, 183]]], ["The resistance situation was generally better than in all SARI ICUs, but showed heavy fluctuations.P1463Similar illness burden but different antibiotic prescription to children: a population-based study K. Hedin, M. Andre, A. H\u00e5kansson, N. Rodhe, S. M\u00f6 lstad, C. Petersson (V\u00e4xj\u00f6, Falun, Malm\u00f6, Link\u00f6ping, SE) Objectives: Respiratory tract infections are the most common reason for antibiotic prescription in Sweden as in other countries.", [["Respiratory tract", "ANATOMY", 322, 339], ["illness", "DISEASE", 112, 119], ["Respiratory tract infections", "DISEASE", 322, 350], ["children", "ORGANISM", 168, 176], ["Respiratory tract", "ORGANISM", 322, 339], ["children", "SPECIES", 168, 176], ["The resistance situation", "PROBLEM", 0, 24], ["P1463Similar illness burden", "PROBLEM", 99, 126], ["Respiratory tract infections", "PROBLEM", 322, 350], ["antibiotic prescription", "TREATMENT", 382, 405], ["resistance", "OBSERVATION_MODIFIER", 4, 14], ["heavy fluctuations", "OBSERVATION", 80, 98], ["Respiratory tract", "ANATOMY", 322, 339]]], ["The prescription rates vary markedly in different countries, counties and municipalities.", [["The prescription rates", "TREATMENT", 0, 22]]], ["The reasons for these variations in prescription rates are not obvious.", [["these variations in prescription rates", "PROBLEM", 16, 54]]], ["The aim of the study was to find possible explanations for different antibiotic prescription rates in children.", [["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["the study", "TEST", 11, 20], ["different antibiotic prescription rates", "TREATMENT", 59, 98]]], ["Therefore a prospective population based log book study was conducted in four municipalities which, according to official statistics, had high and three municipalities which had low antibiotic prescription rates.", [["log book study", "TEST", 41, 55], ["low antibiotic prescription rates", "TREATMENT", 178, 211]]], ["Methods: During one month, parents recorded all infectious symptoms, physician consultations and antibiotic treatments, from 848 18-month-old children in a log book.", [["children", "ORGANISM", 142, 150], ["children", "SPECIES", 142, 150], ["all infectious symptoms", "PROBLEM", 44, 67], ["antibiotic treatments", "TREATMENT", 97, 118], ["infectious", "OBSERVATION_MODIFIER", 48, 58]]], ["The children's parents also answered a questionnaire about socioeconomic factors and concern about infectious illness.", [["infectious illness", "DISEASE", 99, 117], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["infectious illness", "PROBLEM", 99, 117]]], ["Results: Antibiotics were prescribed to 11.6% of the children in the high prescription area and 4.7% in the low prescription area (crude OR 2.67 (95% ).", [["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["Antibiotics", "TREATMENT", 9, 20]]], ["After multiple logistic regression analyses taking account of socioeconomic factors, concern about infectious illness, number of symptom days and physician consultations, differences in antibiotic prescription rates remained (adjusted OR 2.61 (95%CI 1.14-5.98)).", [["infectious illness", "DISEASE", 99, 117], ["antibiotic prescription", "TREATMENT", 186, 209], ["CI", "TEST", 247, 249]]], ["The variable that impacted most on antibiotic prescription rates although it was not relevant to the geographical differences was a high level of concern about infectious illness in the family.", [["infectious illness", "DISEASE", 160, 178], ["antibiotic prescription", "TREATMENT", 35, 58], ["variable", "OBSERVATION_MODIFIER", 4, 12]]], ["Conclusion: The differences in antibiotic prescription rates could not be explained by socioeconomic factors, concern about infectious illness, number of symptom days and physician consultations.", [["infectious illness", "DISEASE", 124, 142], ["antibiotic prescription rates", "TREATMENT", 31, 60], ["infectious illness", "PROBLEM", 124, 142]]], ["The differences may be attributable to different prescription customs, in which case physician\u015b prescription patterns are not always rational.P1464Decreasing outpatient antibiotic prescribing in Germany, 1995 Germany, -2004 , does not include newer macrolides, fluoroquinolones and extendedspectrum beta-lactams W.V. Kern, K. de With, K. Nink, H. Schr\u00f6 der (Freiburg, Bonn, DE) Objective: The ESAC (European Surveillance of Antibiotic Consumption, www.ua.ac.be/ESAC) project has shown that outpatient antibiotic prescribing in Germany has been comparatively low among European countries.", [["macrolides", "CHEMICAL", 249, 259], ["fluoroquinolones", "CHEMICAL", 261, 277], ["beta-lactams", "CHEMICAL", 299, 311], ["macrolides", "CHEMICAL", 249, 259], ["fluoroquinolones", "CHEMICAL", 261, 277], ["fluoroquinolones", "SIMPLE_CHEMICAL", 261, 277], ["newer macrolides", "TREATMENT", 243, 259], ["fluoroquinolones", "TREATMENT", 261, 277], ["extendedspectrum beta-lactams", "TREATMENT", 282, 311], ["Antibiotic Consumption", "TREATMENT", 424, 446], ["outpatient antibiotic", "TREATMENT", 490, 511], ["may be attributable to", "UNCERTAINTY", 16, 38]]], ["We assessed trends over time and regional variation of outpatient antibiotic use in Germany, and wondered if the observable decreasing trend included all drug classes to a similar extent.", [["outpatient antibiotic use", "TREATMENT", 55, 80], ["similar extent", "OBSERVATION_MODIFIER", 172, 186]]], ["Methods: Prescription data (compulsory health insurance covering >90% of the population, sample of 0.4% until the year 2000, all prescriptions thereafter) were analysed using the ATC/WHO methodology and current DDD definitions.", [["the ATC/WHO methodology", "TREATMENT", 175, 198], ["current DDD definitions", "TREATMENT", 203, 226]]], ["We specifically defined the following drug groups: ''basic'' penicillins (BPENs, oral penicillin or aminopenicillins), extended-spectrum betalactams (ESBLs, oral cephalosporins, staphylococcal penicillins, aminopenicillin/betalactamse inhibitor combinations, parenteral cephalosporins and broadspectrum betalactams), newer macrolides (NMLs, roxithromycin, clarithromycin, azithromycin) versus older macrolides (OMLs).", [["oral", "ANATOMY", 81, 85], ["oral", "ANATOMY", 157, 161], ["penicillins", "CHEMICAL", 61, 72], ["BPENs", "CHEMICAL", 74, 79], ["penicillin", "CHEMICAL", 86, 96], ["aminopenicillins", "CHEMICAL", 100, 116], ["betalactams", "CHEMICAL", 137, 148], ["ESBLs", "CHEMICAL", 150, 155], ["cephalosporins", "CHEMICAL", 162, 176], ["penicillins", "CHEMICAL", 193, 204], ["aminopenicillin/betalactamse inhibitor", "CHEMICAL", 206, 244], ["cephalosporins", "CHEMICAL", 270, 284], ["broadspectrum betalactams", "CHEMICAL", 289, 314], ["macrolides", "CHEMICAL", 323, 333], ["NMLs", "CHEMICAL", 335, 339], ["roxithromycin", "CHEMICAL", 341, 354], ["clarithromycin", "CHEMICAL", 356, 370], ["azithromycin", "CHEMICAL", 372, 384], ["macrolides", "CHEMICAL", 399, 409], ["penicillins", "CHEMICAL", 61, 72], ["BPENs", "CHEMICAL", 74, 79], ["penicillin", "CHEMICAL", 86, 96], ["aminopenicillins", "CHEMICAL", 100, 116], ["betalactams", "CHEMICAL", 137, 148], ["cephalosporins", "CHEMICAL", 162, 176], ["penicillins", "CHEMICAL", 193, 204], ["aminopenicillin", "CHEMICAL", 206, 221], ["betalactamse", "CHEMICAL", 222, 234], ["cephalosporins", "CHEMICAL", 270, 284], ["broadspectrum betalactams", "CHEMICAL", 289, 314], ["macrolides", "CHEMICAL", 323, 333], ["NMLs", "CHEMICAL", 335, 339], ["roxithromycin", "CHEMICAL", 341, 354], ["clarithromycin", "CHEMICAL", 356, 370], ["azithromycin", "CHEMICAL", 372, 384], ["macrolides", "CHEMICAL", 399, 409], ["OMLs", "CHEMICAL", 411, 415], ["penicillins", "SIMPLE_CHEMICAL", 61, 72], ["BPENs", "SIMPLE_CHEMICAL", 74, 79], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["penicillin", "SIMPLE_CHEMICAL", 86, 96], ["aminopenicillins", "SIMPLE_CHEMICAL", 100, 116], ["extended-spectrum betalactams", "SIMPLE_CHEMICAL", 119, 148], ["ESBLs", "SIMPLE_CHEMICAL", 150, 155], ["oral cephalosporins", "SIMPLE_CHEMICAL", 157, 176], ["staphylococcal penicillins", "SIMPLE_CHEMICAL", 178, 204], ["aminopenicillin", "SIMPLE_CHEMICAL", 206, 221], ["betalactamse", "SIMPLE_CHEMICAL", 222, 234], ["parenteral cephalosporins", "SIMPLE_CHEMICAL", 259, 284], ["broadspectrum", "SIMPLE_CHEMICAL", 289, 302], ["betalactams", "SIMPLE_CHEMICAL", 303, 314], ["macrolides", "SIMPLE_CHEMICAL", 323, 333], ["NMLs", "SIMPLE_CHEMICAL", 335, 339], ["roxithromycin", "SIMPLE_CHEMICAL", 341, 354], ["clarithromycin", "SIMPLE_CHEMICAL", 356, 370], ["azithromycin", "SIMPLE_CHEMICAL", 372, 384], ["macrolides", "SIMPLE_CHEMICAL", 399, 409], ["OMLs", "SIMPLE_CHEMICAL", 411, 415], ["basic'' penicillins", "TREATMENT", 53, 72], ["BPENs", "TREATMENT", 74, 79], ["oral penicillin", "TREATMENT", 81, 96], ["aminopenicillins", "TREATMENT", 100, 116], ["extended-spectrum betalactams", "TREATMENT", 119, 148], ["ESBLs", "TREATMENT", 150, 155], ["oral cephalosporins", "TREATMENT", 157, 176], ["staphylococcal penicillins", "TREATMENT", 178, 204], ["aminopenicillin", "TREATMENT", 206, 221], ["betalactamse inhibitor combinations", "TREATMENT", 222, 257], ["parenteral cephalosporins", "TREATMENT", 259, 284], ["broadspectrum betalactams", "TREATMENT", 289, 314], ["newer macrolides", "TREATMENT", 317, 333], ["NMLs", "TREATMENT", 335, 339], ["roxithromycin", "TREATMENT", 341, 354], ["clarithromycin", "TREATMENT", 356, 370], ["azithromycin", "TREATMENT", 372, 384], ["older macrolides", "TREATMENT", 393, 409]]], ["Quinolones (FQs), folate synthesis inhibitors (T/Ss) and tetracyclines (TETs) were also assessed.", [["Quinolones", "CHEMICAL", 0, 10], ["FQs", "CHEMICAL", 12, 15], ["folate", "CHEMICAL", 18, 24], ["T/Ss", "CHEMICAL", 47, 51], ["tetracyclines", "CHEMICAL", 57, 70], ["Quinolones", "CHEMICAL", 0, 10], ["FQs", "CHEMICAL", 12, 15], ["folate", "CHEMICAL", 18, 24], ["tetracyclines", "CHEMICAL", 57, 70], ["Quinolones", "SIMPLE_CHEMICAL", 0, 10], ["FQs", "SIMPLE_CHEMICAL", 12, 15], ["folate", "SIMPLE_CHEMICAL", 18, 24], ["T/Ss", "SIMPLE_CHEMICAL", 47, 51], ["tetracyclines", "SIMPLE_CHEMICAL", 57, 70], ["TETs", "SIMPLE_CHEMICAL", 72, 76], ["Quinolones (FQs", "TREATMENT", 0, 15], ["folate synthesis inhibitors", "TREATMENT", 18, 45], ["T/Ss)", "TREATMENT", 47, 52], ["tetracyclines (TETs)", "TREATMENT", 57, 77]]], ["Data were expressed in yearly DDD/1000 persons covered by the insurance (DDD/1000).", [["persons", "SPECIES", 39, 46]]], ["The decreasing trend over the last 4 years was observed in all regions.", [["decreasing", "OBSERVATION_MODIFIER", 4, 14], ["trend", "OBSERVATION_MODIFIER", 15, 20]]], ["The decrease was most significant for OMLs ()55%), T/Ss ()48%), TETs ()36%), and BPENs ()13%) while there was no decreasing use of ESBLs (\u00b10%) and increases in the rate of prescribing NMLs (+13%) and FQs (+43%).", [["OMLs", "TEST", 38, 42], ["T/Ss", "TEST", 51, 55], ["TETs", "TEST", 64, 68], ["BPENs", "TEST", 81, 86], ["ESBLs", "TEST", 131, 136], ["FQs", "TEST", 200, 203], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["no", "UNCERTAINTY", 110, 112], ["decreasing", "OBSERVATION_MODIFIER", 113, 123]]], ["TETs and BPENs, however remained the most prescribed antibiotics in 2004.", [["BPENs", "SIMPLE_CHEMICAL", 9, 14], ["antibiotics", "TREATMENT", 53, 64]]], ["Regional variations in 2004 remained large for BPENs (>3-fold) with very low prescribing rates in the Eastern region, but were small for T/Ss, NMLs and FQs (<2-fold).", [["T/Ss", "GENE_OR_GENE_PRODUCT", 137, 141], ["Regional variations", "TEST", 0, 19], ["BPENs", "TEST", 47, 52], ["very low prescribing rates", "PROBLEM", 68, 94], ["T/Ss", "TEST", 137, 141], ["NMLs", "TEST", 143, 147], ["FQs", "TEST", 152, 155], ["variations", "OBSERVATION_MODIFIER", 9, 19], ["large", "OBSERVATION_MODIFIER", 37, 42], ["very", "OBSERVATION_MODIFIER", 68, 72], ["low", "OBSERVATION_MODIFIER", 73, 76], ["Eastern", "ANATOMY_MODIFIER", 102, 109], ["region", "ANATOMY_MODIFIER", 110, 116], ["small", "OBSERVATION_MODIFIER", 127, 132]]], ["Conclusions: Over a decade we observed a 24% decreasing outpatient antibiotic prescribing that included relevant antibiotic drug classes except ESBLs, NMLs and FQs.", [["NMLs", "SIMPLE_CHEMICAL", 151, 155], ["a 24% decreasing outpatient antibiotic prescribing", "TREATMENT", 39, 89], ["relevant antibiotic drug classes", "TREATMENT", 104, 136], ["ESBLs", "PROBLEM", 144, 149]]], ["The relative increase was most significant for FQs.P1465Severe community-acquired pneumonia admitted to the intensive care unit: impact of antibiotic therapy delay on hospital mortality antibiotic therapy were enrolled in the study.", [["P1465", "CHEMICAL", 51, 56], ["pneumonia", "DISEASE", 82, 91], ["FQs", "PROBLEM", 47, 50], ["Severe community-acquired pneumonia", "PROBLEM", 56, 91], ["antibiotic therapy delay", "TREATMENT", 139, 163], ["hospital mortality antibiotic therapy", "TREATMENT", 167, 204], ["the study", "TEST", 222, 231], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["pneumonia", "OBSERVATION", 82, 91]]], ["Pts were divided in 4 Groups according to time to treatment (<2 h GI, [2] [3] [4] [4] [5] [6] [7] [8] .", [["[2] [3] [4] [4] [5] [6] [7]", "CHEMICAL", 70, 97], ["[2] [3] [4] [4] [5] [6", "SIMPLE_CHEMICAL", 70, 92]]], ["Baseline severity scores (APACHE II, SOFA, PSI, CURB-65), microbiological documentation, and hospital outcome were compared for all groups.", [["Baseline severity scores", "PROBLEM", 0, 24], ["APACHE II", "TEST", 26, 35], ["SOFA", "TEST", 37, 41], ["PSI", "TEST", 43, 46], ["CURB", "TEST", 48, 52], ["microbiological documentation", "TEST", 58, 87]]], ["Results: 152 pts were included in the study.", [["the study", "TEST", 34, 43]]], ["Microbiological documentation was achieved in 80% of all pts, positive blood cultures in 54/152 (35.5%), S. Pneumoniae in 64/152 (42%).", [["blood cultures", "ANATOMY", 71, 85], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["S. Pneumoniae", "ORGANISM", 105, 118], ["S. Pneumoniae", "SPECIES", 105, 118], ["S. Pneumoniae", "SPECIES", 105, 118], ["Microbiological documentation", "TEST", 0, 29], ["blood cultures", "TEST", 71, 85], ["S. Pneumoniae", "TEST", 105, 118], ["Pneumoniae", "OBSERVATION", 108, 118]]], ["Mean age was 66 \u00b1 13, APACHE II 25.8 \u00b1 7.6, SOFA 8.8 \u00b1 3.7, PSI 158 \u00b1 40, CURB-65 3.2 \u00b1 1, mechanical ventilation in 67.7% and vasopressors use in 63.1%.", [["Mean age", "TEST", 0, 8], ["APACHE II", "TEST", 22, 31], ["SOFA", "TEST", 44, 48], ["PSI", "TEST", 60, 63], ["CURB", "TEST", 74, 78], ["mechanical ventilation", "TEST", 91, 113], ["vasopressors", "TREATMENT", 127, 139]]], ["Overall ICU and Hospital all-cause mortality were 27.5% and 35.5%, respectively.", [["mortality", "TEST", 35, 44]]], ["Baseline severity scores were comparable in all 4 Groups and their respective Hospital mortality is provided in Table 1 .P1465Conclusions: In severe CAP, treated with a combination therapy, time to treatment seems to have an impact on hospital all-cause mortality.", [["CAP", "DISEASE", 149, 152], ["Baseline severity scores", "PROBLEM", 0, 24], ["severe CAP", "PROBLEM", 142, 152], ["a combination therapy", "TREATMENT", 167, 188], ["treatment", "TREATMENT", 198, 207], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["CAP", "OBSERVATION", 149, 152]]], ["Based on our results, antibiotic treatment should be initiated within the first 2 hours after hospital admission.", [["antibiotic treatment", "TREATMENT", 22, 42]]], ["(Period II) -cefoperazone/ sulbactam (8 g a day) as monotherapy were used as the empirical antibacterial therapy of VAP.", [["cefoperazone", "CHEMICAL", 13, 25], ["sulbactam", "CHEMICAL", 27, 36], ["VAP", "DISEASE", 116, 119], ["cefoperazone", "CHEMICAL", 13, 25], ["sulbactam", "CHEMICAL", 27, 36], ["cefoperazone", "SIMPLE_CHEMICAL", 13, 25], ["sulbactam", "SIMPLE_CHEMICAL", 27, 36], ["cefoperazone", "TREATMENT", 13, 25], ["sulbactam", "TREATMENT", 27, 36], ["monotherapy", "TREATMENT", 52, 63], ["the empirical antibacterial therapy", "TREATMENT", 77, 112], ["VAP", "PROBLEM", 116, 119]]], ["The rotation from cefepime to cefoperazone/sulbactam was performed due to our previous study demonstrated high frequency of ESBL producers among Enterobacteriaceae.", [["cefepime", "CHEMICAL", 18, 26], ["cefoperazone", "CHEMICAL", 30, 42], ["sulbactam", "CHEMICAL", 43, 52], ["cefepime", "CHEMICAL", 18, 26], ["cefoperazone", "CHEMICAL", 30, 42], ["sulbactam", "CHEMICAL", 43, 52], ["cefepime", "SIMPLE_CHEMICAL", 18, 26], ["cefoperazone", "SIMPLE_CHEMICAL", 30, 42], ["sulbactam", "SIMPLE_CHEMICAL", 43, 52], ["The rotation", "TREATMENT", 0, 12], ["cefepime", "TREATMENT", 18, 26], ["cefoperazone", "TREATMENT", 30, 42], ["sulbactam", "TREATMENT", 43, 52], ["our previous study", "TEST", 74, 92], ["ESBL producers", "PROBLEM", 124, 138], ["Enterobacteriaceae", "PROBLEM", 145, 163], ["ESBL producers", "OBSERVATION", 124, 138]]], ["The samples from the lower respiratory tract were obtained by mini-BAL.", [["samples", "ANATOMY", 4, 11], ["lower respiratory tract", "ANATOMY", 21, 44], ["lower respiratory", "ORGANISM_SUBDIVISION", 21, 38], ["tract", "ORGANISM_SUBDIVISION", 39, 44], ["The samples from the lower respiratory tract", "TEST", 0, 44], ["lower", "ANATOMY_MODIFIER", 21, 26], ["respiratory tract", "ANATOMY", 27, 44]]], ["The sensitivity of microorganisms to the antibiotics studied (ceftazidime, cefepime, cefoperazone/sulbactam and carbapenems) was determined by the disk diffusion method.", [["ceftazidime", "CHEMICAL", 62, 73], ["cefepime", "CHEMICAL", 75, 83], ["cefoperazone", "CHEMICAL", 85, 97], ["sulbactam", "CHEMICAL", 98, 107], ["carbapenems", "CHEMICAL", 112, 123], ["ceftazidime", "CHEMICAL", 62, 73], ["cefepime", "CHEMICAL", 75, 83], ["cefoperazone", "CHEMICAL", 85, 97], ["sulbactam", "CHEMICAL", 98, 107], ["carbapenems", "CHEMICAL", 112, 123], ["ceftazidime", "SIMPLE_CHEMICAL", 62, 73], ["cefepime", "SIMPLE_CHEMICAL", 75, 83], ["cefoperazone", "SIMPLE_CHEMICAL", 85, 97], ["sulbactam", "SIMPLE_CHEMICAL", 98, 107], ["carbapenems", "SIMPLE_CHEMICAL", 112, 123], ["microorganisms", "PROBLEM", 19, 33], ["the antibiotics", "TREATMENT", 37, 52], ["ceftazidime", "TREATMENT", 62, 73], ["cefepime", "TREATMENT", 75, 83], ["cefoperazone", "TREATMENT", 85, 97], ["sulbactam", "TREATMENT", 98, 107], ["carbapenems", "TREATMENT", 112, 123], ["the disk diffusion method", "TEST", 143, 168]]], ["Results: The main pathogens of VAP were S. aureus (20%), P. aeruginosa (19%), Enterobacteriaceae (23%) and this structure did not changed during both periods.", [["VAP", "DISEASE", 31, 34], ["S. aureus", "DISEASE", 40, 49], ["P. aeruginosa", "DISEASE", 57, 70], ["S. aureus", "ORGANISM", 40, 49], ["P. aeruginosa", "ORGANISM", 57, 70], ["S. aureus", "SPECIES", 40, 49], ["P. aeruginosa", "SPECIES", 57, 70], ["S. aureus", "SPECIES", 40, 49], ["P. aeruginosa", "SPECIES", 57, 70], ["VAP", "PROBLEM", 31, 34], ["S. aureus", "TEST", 40, 49], ["P. aeruginosa", "TEST", 57, 70], ["Enterobacteriaceae", "TEST", 78, 96], ["VAP", "OBSERVATION", 31, 34], ["aureus", "OBSERVATION", 43, 49]]], ["The antibiotic sensitivity of P. aeruginosa and Enterobacteriaceae (K. pneumoniae and E. coli), was studied separately.", [["P. aeruginosa", "ORGANISM", 30, 43], ["Enterobacteriaceae", "ORGANISM", 48, 66], ["K. pneumoniae", "ORGANISM", 68, 81], ["E. coli", "ORGANISM", 86, 93], ["P. aeruginosa", "SPECIES", 30, 43], ["K. pneumoniae", "SPECIES", 68, 81], ["E. coli", "SPECIES", 86, 93], ["P. aeruginosa", "SPECIES", 30, 43], ["K. pneumoniae", "SPECIES", 68, 81], ["E. coli", "SPECIES", 86, 93], ["The antibiotic sensitivity", "TEST", 0, 26], ["P. aeruginosa", "PROBLEM", 30, 43], ["Enterobacteriaceae", "PROBLEM", 48, 66], ["pneumoniae", "PROBLEM", 71, 81], ["E. coli", "PROBLEM", 86, 93]]], ["A high level of resistance of Enterobacteriaceae to cefepime can be explained by the strains prevailing in the given ICU, which produced extended spectrum beta-lactamases (CTX-M).", [["Enterobacteriaceae", "CHEMICAL", 30, 48], ["cefepime", "CHEMICAL", 52, 60], ["cefepime", "CHEMICAL", 52, 60], ["cefepime", "SIMPLE_CHEMICAL", 52, 60], ["Enterobacteriaceae", "PROBLEM", 30, 48], ["cefepime", "TREATMENT", 52, 60], ["the strains", "PROBLEM", 81, 92], ["high", "OBSERVATION_MODIFIER", 2, 6], ["Enterobacteriaceae", "OBSERVATION", 30, 48], ["beta-lactamases", "OBSERVATION", 155, 170]]], ["The resistance of Enterobacteriaceae to cefepime was 57.5% in I period and 80.5% in II period, to ceftazidime -90.0 and 100%, meropenem -0 and 0%, imipenem -5.1 and 2.1%, cefoperazone/sulbactam -10.9 and 20.8%, respectively.", [["Enterobacteriaceae", "CHEMICAL", 18, 36], ["cefepime", "CHEMICAL", 40, 48], ["ceftazidime", "CHEMICAL", 98, 109], ["meropenem", "CHEMICAL", 126, 135], ["imipenem", "CHEMICAL", 147, 155], ["cefoperazone", "CHEMICAL", 171, 183], ["sulbactam", "CHEMICAL", 184, 193], ["cefepime", "CHEMICAL", 40, 48], ["ceftazidime", "CHEMICAL", 98, 109], ["meropenem", "CHEMICAL", 126, 135], ["imipenem", "CHEMICAL", 147, 155], ["cefoperazone", "CHEMICAL", 171, 183], ["sulbactam", "CHEMICAL", 184, 193], ["cefepime", "SIMPLE_CHEMICAL", 40, 48], ["ceftazidime", "SIMPLE_CHEMICAL", 98, 109], ["meropenem -0", "SIMPLE_CHEMICAL", 126, 138], ["imipenem", "SIMPLE_CHEMICAL", 147, 155], ["cefoperazone", "SIMPLE_CHEMICAL", 171, 183], ["sulbactam", "SIMPLE_CHEMICAL", 184, 193], ["Enterobacteriaceae to cefepime", "TREATMENT", 18, 48], ["ceftazidime", "TREATMENT", 98, 109], ["meropenem", "TREATMENT", 126, 135], ["imipenem", "TREATMENT", 147, 155], ["cefoperazone", "TREATMENT", 171, 183], ["sulbactam", "TREATMENT", 184, 193]]], ["A change of cefepime for cefoperazone/sulbactam was not followed by any decrease of Enterobacteriaceae resistance level to cefepime during II period.", [["cefepime", "CHEMICAL", 12, 20], ["cefoperazone", "CHEMICAL", 25, 37], ["sulbactam", "CHEMICAL", 38, 47], ["cefepime", "CHEMICAL", 123, 131], ["cefepime", "CHEMICAL", 12, 20], ["cefoperazone", "CHEMICAL", 25, 37], ["sulbactam", "CHEMICAL", 38, 47], ["cefepime", "CHEMICAL", 123, 131], ["cefepime", "SIMPLE_CHEMICAL", 12, 20], ["cefoperazone", "SIMPLE_CHEMICAL", 25, 37], ["sulbactam", "SIMPLE_CHEMICAL", 38, 47], ["cefepime", "SIMPLE_CHEMICAL", 123, 131], ["cefepime", "TREATMENT", 12, 20], ["cefoperazone", "TREATMENT", 25, 37], ["sulbactam", "TREATMENT", 38, 47], ["Enterobacteriaceae resistance level", "PROBLEM", 84, 119], ["cefepime", "TREATMENT", 123, 131], ["Enterobacteriaceae resistance", "OBSERVATION", 84, 113]]], ["The resistance level of P. aeruginosa to cefepime was 20.5% in I period and 24.1% in II period, to ceftazidime -22.", [["cefepime", "CHEMICAL", 41, 49], ["ceftazidime -22", "CHEMICAL", 99, 114], ["cefepime", "CHEMICAL", 41, 49], ["ceftazidime -22", "CHEMICAL", 99, 114], ["P. aeruginosa", "ORGANISM", 24, 37], ["cefepime", "SIMPLE_CHEMICAL", 41, 49], ["ceftazidime -22", "SIMPLE_CHEMICAL", 99, 114], ["P. aeruginosa", "SPECIES", 24, 37], ["P. aeruginosa", "SPECIES", 24, 37], ["P. aeruginosa", "PROBLEM", 24, 37], ["cefepime", "TREATMENT", 41, 49], ["ceftazidime", "TREATMENT", 99, 110]]], ["5 and 33.0%, meropenem -44.7 and 39.5%, imipenem -50.1 and 39.5%, cefoperazone/ sulbactam -16.9 and 12.5%, respectively.", [["meropenem", "CHEMICAL", 13, 22], ["imipenem", "CHEMICAL", 40, 48], ["cefoperazone", "CHEMICAL", 66, 78], ["sulbactam", "CHEMICAL", 80, 89], ["meropenem", "CHEMICAL", 13, 22], ["imipenem", "CHEMICAL", 40, 48], ["cefoperazone", "CHEMICAL", 66, 78], ["sulbactam", "CHEMICAL", 80, 89], ["meropenem", "SIMPLE_CHEMICAL", 13, 22], ["imipenem", "SIMPLE_CHEMICAL", 40, 48], ["cefoperazone", "SIMPLE_CHEMICAL", 66, 78], ["sulbactam", "SIMPLE_CHEMICAL", 80, 89], ["meropenem", "TREATMENT", 13, 22], ["imipenem", "TREATMENT", 40, 48], ["cefoperazone", "TREATMENT", 66, 78], ["sulbactam", "TREATMENT", 80, 89]]], ["Conclusion: The exclusion of cefepime for 9 months didn't improved the sensitivity of Enterobacteriaceae to this medication.", [["cefepime", "CHEMICAL", 29, 37], ["cefepime", "CHEMICAL", 29, 37], ["cefepime", "SIMPLE_CHEMICAL", 29, 37], ["cefepime", "TREATMENT", 29, 37], ["Enterobacteriaceae", "PROBLEM", 86, 104], ["this medication", "TREATMENT", 108, 123]]], ["The level of resistance of P. aeruginosa and Enterobacteriaceae to cefoperazone/sulbactam did not increased despite a wide use of this antibiotic during 9 months.P1467Antibiotic consumption in German acute care hospitals M. Steib-Bauert, K. de With, E. Meyer, P. Straach, W.V. Kern (Freiburg, Frankfurt, DE) Objective: Outpatient antibiotic use in Germany differs substantially between Eastern and Southern parts of the country (relatively low use) and Western part (relatively high use).", [["cefoperazone", "CHEMICAL", 67, 79], ["sulbactam", "CHEMICAL", 80, 89], ["cefoperazone", "CHEMICAL", 67, 79], ["sulbactam", "CHEMICAL", 80, 89], ["P. aeruginosa", "ORGANISM", 27, 40], ["Enterobacteriaceae", "CANCER", 45, 63], ["cefoperazone", "SIMPLE_CHEMICAL", 67, 79], ["sulbactam", "SIMPLE_CHEMICAL", 80, 89], ["P1467Antibiotic", "SIMPLE_CHEMICAL", 162, 177], ["P. aeruginosa", "SPECIES", 27, 40], ["P. aeruginosa", "SPECIES", 27, 40], ["P. aeruginosa", "PROBLEM", 27, 40], ["Enterobacteriaceae", "PROBLEM", 45, 63], ["cefoperazone", "TREATMENT", 67, 79], ["sulbactam", "TREATMENT", 80, 89], ["this antibiotic", "TREATMENT", 130, 145]]], ["There is no nationwide estimate of hospital antibiotic use and its geographic variation if any.", [["hospital antibiotic use", "TREATMENT", 35, 58], ["no", "UNCERTAINTY", 9, 11]]], ["Methods: Data on hospital consumption of systemic antibiotics in Anatomical Therapeutic Chemical (ATC) class J01 were obtained from a convenience sample of 145 acute care hospitals in Germany that participated in an IMS survey in the year 2003 and had complete data (dispensed drugs and patient-days per year) for at least one non-paediatric, non-psychiatric department or ward.", [["patient", "ORGANISM", 287, 294], ["patient", "SPECIES", 287, 294], ["systemic antibiotics", "TREATMENT", 41, 61], ["Anatomical Therapeutic Chemical (ATC)", "TREATMENT", 65, 102]]], ["A total of 275 non-ICU surgical departments/wards, 229 non-ICU non-surgical (general medicine, oncologyhaematology, neurology/stroke) departments/wards, and 184 ICUs covering >16 million patient-days were analysed.", [["stroke", "DISEASE", 126, 132], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194]]], ["Data were expressed in DDD (WHO/ATC definition version 2001) or ''prescribed/recommended daily doses'' (PDD, better reflecting [high] dosages given to hospitalized patients) per 100 patient days (DDD/100 and PDD/100).", [["patients", "ORGANISM", 164, 172], ["patient", "ORGANISM", 182, 189], ["patients", "SPECIES", 164, 172], ["patient", "SPECIES", 182, 189], ["PDD", "PROBLEM", 104, 107]]], ["ICUs was 49.8 DDD/100 (31.4 PDD/100).", [["ICUs", "TEST", 0, 4], ["DDD", "TEST", 14, 17], ["PDD", "TEST", 28, 31]]], ["As expected, ICU antibiotic use density was much higher than use in non-ICU areas, and use in haematology-oncology was higher than in other non-surgical departments/wards.", [["ICU antibiotic use density", "TREATMENT", 13, 39]]], ["In univariate analyses, bed-size category and university affiliation (ICUs, surgical wards), region (ICU, surgical and non-surgical wards) and haematology-oncology as specialty (non-surgical wards) were associated with use density, but these associations were only partly confirmed in multivariate logistic regression analyses of factors associated with excess ( \u202175%) use density which showed university affiliation and haematology-oncology to be independently associated with high use.", [["univariate analyses", "TEST", 3, 22]]], ["Conclusions: Based on this hospital sample, antibiotic use in German hospitals shows little, non-significant regional variation and appears to be similar to what has been described from other European countries.", [["non-significant regional variation", "PROBLEM", 93, 127], ["little", "OBSERVATION_MODIFIER", 85, 91], ["non-significant", "OBSERVATION_MODIFIER", 93, 108], ["regional variation", "OBSERVATION", 109, 127]]], ["Adjustment of the data at least for university affiliation and haematology-oncology is important in comparative analyses of hospital antibiotic consumption.P1468Impact of formulary change in medical intensive care unit on outcome of infection and antimicrobial resistance sought to evaluate a formulary change and impact it has on infection and resistant.", [["infection", "DISEASE", 233, 242], ["infection", "DISEASE", 331, 340], ["hospital antibiotic consumption", "TREATMENT", 124, 155], ["infection", "PROBLEM", 233, 242], ["antimicrobial resistance", "TREATMENT", 247, 271], ["a formulary change", "TREATMENT", 291, 309], ["infection", "PROBLEM", 331, 340], ["change", "OBSERVATION_MODIFIER", 181, 187], ["infection", "OBSERVATION", 233, 242], ["infection", "OBSERVATION", 331, 340]]], ["Methods: Prospectively, all patients in a 20-bed ICU were followed for a period of 4 months in Phase I (390 patients per 2379 patient days) and to collect baseline data after a decrease in the use of piperacillin-tazobactam (PT) when substituted by cefepime for a period of 4 months in Phase II (383 patients per 2260 patient days).", [["piperacillin-tazobactam", "CHEMICAL", 200, 223], ["cefepime", "CHEMICAL", 249, 257], ["piperacillin-tazobactam", "CHEMICAL", 200, 223], ["cefepime", "CHEMICAL", 249, 257], ["patients", "ORGANISM", 28, 36], ["patients", "ORGANISM", 108, 116], ["patient", "ORGANISM", 126, 133], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 200, 223], ["PT", "SIMPLE_CHEMICAL", 225, 227], ["cefepime", "SIMPLE_CHEMICAL", 249, 257], ["patients", "ORGANISM", 300, 308], ["patient", "ORGANISM", 318, 325], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 108, 116], ["patient", "SPECIES", 126, 133], ["patients", "SPECIES", 300, 308], ["patient", "SPECIES", 318, 325], ["piperacillin-tazobactam", "TREATMENT", 200, 223], ["cefepime", "TREATMENT", 249, 257]]], ["Results: Total infections in Phase I vs. Phase II were lower respiratory tract (LRTI) 214 patients (55%) vs. 203 patients (53%); urinary tract infection (UTI) 94 patients (24%) vs. 96 patients (25%); and sepsis of undetermined aetiology 70 patients (18%) vs. 65 patients (17%), respectively.", [["lower respiratory tract", "ANATOMY", 55, 78], ["urinary tract", "ANATOMY", 129, 142], ["infections", "DISEASE", 15, 25], ["lower respiratory tract", "DISEASE", 55, 78], ["LRTI", "DISEASE", 80, 84], ["urinary tract infection", "DISEASE", 129, 152], ["UTI", "DISEASE", 154, 157], ["sepsis", "DISEASE", 204, 210], ["lower", "ORGANISM_SUBDIVISION", 55, 60], ["respiratory tract", "ORGANISM_SUBDIVISION", 61, 78], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 113, 121], ["urinary tract", "ORGANISM_SUBDIVISION", 129, 142], ["patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 184, 192], ["patients", "ORGANISM", 240, 248], ["patients", "ORGANISM", 262, 270], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 240, 248], ["patients", "SPECIES", 262, 270], ["Total infections", "PROBLEM", 9, 25], ["urinary tract infection (UTI)", "PROBLEM", 129, 158], ["sepsis", "PROBLEM", 204, 210], ["Total", "OBSERVATION_MODIFIER", 9, 14], ["infections", "OBSERVATION", 15, 25], ["lower", "ANATOMY_MODIFIER", 55, 60], ["respiratory tract", "ANATOMY", 61, 78], ["urinary tract", "ANATOMY", 129, 142], ["infection", "OBSERVATION", 143, 152], ["sepsis", "OBSERVATION", 204, 210]]], ["There were no significant differences in death (22% vs. 19%) , cure or improvement of infection (53% vs. 56%), readmission to the unit (3.5% vs. 3.2%), hospital risk of death (29.8% vs. 30.2%), mean length of ICU stay (6.1 days vs. 5.9 days), or rates of nosocomial infection (6.3% vs. 5.1% for LRTI; 4.0% vs. 4.2% for UTI; 0.8% vs. 0.0% for soft tissue infection; 0.8% vs. 1.0% for bacteremia; 2.1 vs. 1.0 per 1000 patient days for intravenous catheter infection) in Phase I and II respectively.", [["soft tissue", "ANATOMY", 342, 353], ["intravenous", "ANATOMY", 433, 444], ["death", "DISEASE", 41, 46], ["infection", "DISEASE", 86, 95], ["death", "DISEASE", 169, 174], ["nosocomial infection", "DISEASE", 255, 275], ["LRTI", "DISEASE", 295, 299], ["UTI", "DISEASE", 319, 322], ["soft tissue infection", "DISEASE", 342, 363], ["bacteremia", "DISEASE", 383, 393], ["intravenous catheter infection", "DISEASE", 433, 463], ["soft tissue", "TISSUE", 342, 353], ["patient", "ORGANISM", 416, 423], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 433, 444], ["patient", "SPECIES", 416, 423], ["significant differences in death", "PROBLEM", 14, 46], ["infection", "PROBLEM", 86, 95], ["death", "PROBLEM", 169, 174], ["nosocomial infection", "PROBLEM", 255, 275], ["LRTI", "TEST", 295, 299], ["UTI", "PROBLEM", 319, 322], ["soft tissue infection", "PROBLEM", 342, 363], ["bacteremia", "PROBLEM", 383, 393], ["intravenous catheter infection", "TREATMENT", 433, 463], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["infection", "OBSERVATION", 86, 95], ["nosocomial", "OBSERVATION_MODIFIER", 255, 265], ["infection", "OBSERVATION", 266, 275], ["soft tissue", "ANATOMY", 342, 353], ["infection", "OBSERVATION", 354, 363]]], ["The cost of antimicrobial acquisition in Phase I and II were $548 and $433 per patient respectively (p < 0.001).", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["antimicrobial acquisition", "TEST", 12, 37]]], ["The mean antimicrobial treatment costs per patient for PT were $145 vs. $100 and cefepime were $80 vs. $105 in Phase I and II respectively (p < 0.01).", [["cefepime", "CHEMICAL", 81, 89], ["cefepime", "CHEMICAL", 81, 89], ["patient", "ORGANISM", 43, 50], ["cefepime", "SIMPLE_CHEMICAL", 81, 89], ["patient", "SPECIES", 43, 50], ["The mean antimicrobial treatment costs", "TREATMENT", 0, 38], ["PT", "TEST", 55, 57], ["cefepime", "TREATMENT", 81, 89]]], ["The in vitro susceptibility and rate of infection and colonization with Escherichia coli were unchanged in both study periods.", [["infection", "DISEASE", 40, 49], ["Escherichia coli", "ORGANISM", 72, 88], ["Escherichia coli", "SPECIES", 72, 88], ["Escherichia coli", "SPECIES", 72, 88], ["infection", "PROBLEM", 40, 49], ["colonization", "PROBLEM", 54, 66], ["Escherichia coli", "PROBLEM", 72, 88], ["infection", "OBSERVATION", 40, 49], ["Escherichia coli", "OBSERVATION", 72, 88], ["unchanged", "OBSERVATION_MODIFIER", 94, 103]]], ["There were 68 vs. 39 Staphylococcus aureus (p < 0.001); of these 94percnt vs. 87percnt were methicillinresistant S. aureus and 11 vs. 9 Enterococcus faecium (82% vs. 77% vancomycin-resistant enterococci) in Phase I and II respectively.", [["Staphylococcus aureus", "DISEASE", 21, 42], ["9 Enterococcus faecium", "CHEMICAL", 134, 156], ["vancomycin", "CHEMICAL", 170, 180], ["vancomycin", "CHEMICAL", 170, 180], ["Staphylococcus aureus", "ORGANISM", 21, 42], ["S. aureus", "ORGANISM", 113, 122], ["Enterococcus faecium", "ORGANISM", 136, 156], ["vancomycin", "SIMPLE_CHEMICAL", 170, 180], ["Staphylococcus aureus", "SPECIES", 21, 42], ["S. aureus", "SPECIES", 113, 122], ["Enterococcus faecium", "SPECIES", 136, 156], ["Staphylococcus aureus", "SPECIES", 21, 42], ["S. aureus", "SPECIES", 113, 122], ["Enterococcus faecium", "SPECIES", 136, 156], ["Staphylococcus aureus", "TEST", 21, 42], ["methicillinresistant S. aureus", "PROBLEM", 92, 122], ["Enterococcus faecium", "PROBLEM", 136, 156], ["vancomycin", "TEST", 170, 180], ["resistant enterococci", "PROBLEM", 181, 202], ["Staphylococcus aureus", "OBSERVATION", 21, 42], ["aureus", "OBSERVATION", 116, 122], ["Enterococcus faecium", "OBSERVATION", 136, 156]]], ["There were 73% vs. 31% Pseudomonas aeruginosa and 70% vs. 4% Klebsiella pneumoniae extended spectrum beta lactamases in Phase I and II respectively.", [["Pseudomonas aeruginosa", "ORGANISM", 23, 45], ["Klebsiella pneumoniae", "ORGANISM", 61, 82], ["extended spectrum beta lactamases", "GENE_OR_GENE_PRODUCT", 83, 116], ["Phase I and II", "PROTEIN", 120, 134], ["Pseudomonas aeruginosa", "SPECIES", 23, 45], ["Klebsiella pneumoniae", "SPECIES", 61, 82], ["Pseudomonas aeruginosa", "SPECIES", 23, 45], ["Klebsiella pneumoniae", "SPECIES", 61, 82], ["Pseudomonas aeruginosa", "TEST", 23, 45], ["Klebsiella pneumoniae", "PROBLEM", 61, 82], ["beta lactamases", "TEST", 101, 116]]], ["Conclusion: The implementation of formulary substitution of PT to cefepime in the medical ICU had resulted in a decrease in the use of PT.", [["cefepime", "CHEMICAL", 66, 74], ["cefepime", "CHEMICAL", 66, 74], ["cefepime", "SIMPLE_CHEMICAL", 66, 74], ["formulary substitution", "TREATMENT", 34, 56], ["PT", "TREATMENT", 60, 62], ["cefepime", "TREATMENT", 66, 74], ["PT", "TREATMENT", 135, 137], ["decrease", "OBSERVATION_MODIFIER", 112, 120]]], ["In addition, there were decreased costs and less S. aureus infections without adversely affecting the outcome of infection or antimicrobial resistance.P1469Intravenous antibiotic use in Scottish hospitals; evaluation of the Glasgow antimicrobial audit tool R.A. Seaton, D. Nathwani, P. Burton, E. Douglas (Glasgow, Dundee, UK)P1469Introduction: There are few data on antibiotic prescribing within Scottish hospitals and a coordinated multisite point prevalence survey had not been performed before.", [["S. aureus infections", "DISEASE", 49, 69], ["infection", "DISEASE", 113, 122], ["S. aureus", "ORGANISM", 49, 58], ["S. aureus", "SPECIES", 49, 58], ["S. aureus", "SPECIES", 49, 58], ["decreased costs", "PROBLEM", 24, 39], ["less S. aureus infections", "PROBLEM", 44, 69], ["infection", "PROBLEM", 113, 122], ["antimicrobial resistance", "PROBLEM", 126, 150], ["evaluation", "TEST", 206, 216], ["antibiotic", "TREATMENT", 367, 377], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["costs", "OBSERVATION_MODIFIER", 34, 39], ["less", "OBSERVATION_MODIFIER", 44, 48], ["aureus", "OBSERVATION_MODIFIER", 52, 58], ["infections", "OBSERVATION", 59, 69], ["infection", "OBSERVATION", 113, 122], ["antimicrobial resistance", "OBSERVATION", 126, 150]]], ["There is concern that antimicrobials are overused in hospitals.", [["antimicrobials", "TREATMENT", 22, 36], ["antimicrobials", "OBSERVATION", 22, 36]]], ["Appropriateness of the IV route of administration was determined by review of data by an infectious diseases physician (IDP) and compared with a specifically designed computerised algorithm.", [["infectious diseases", "DISEASE", 89, 108], ["computerised algorithm", "TEST", 167, 189]]], ["The IDP also judged the appropriateness of the chosen IV agent against local guidelines.", [["the chosen IV agent", "TREATMENT", 43, 62], ["local guidelines", "TREATMENT", 71, 87]]], ["3826 patients from 10 hospitals in 5 regions were surveyed on a single day.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["1079 (28.3%) were receiving an antibiotic, 381 (35.3%) intravenously.", [["intravenously", "ANATOMY", 55, 68], ["an antibiotic", "TREATMENT", 28, 41]]], ["197 receiving oral antibiotics had received an IV previously.", [["oral", "ANATOMY", 14, 18], ["oral", "ORGANISM_SUBDIVISION", 14, 18], ["oral antibiotics", "TREATMENT", 14, 30], ["an IV", "TREATMENT", 44, 49]]], ["Median duration of IV therapy was 4 days (IQR 2-7 days) and time from IV to oral switch was 3.5 (2) (3) (4) (5) (6) .", [["oral", "ANATOMY", 76, 80], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["IV therapy", "TREATMENT", 19, 29], ["IV to oral switch", "TREATMENT", 70, 87]]], ["The IDP judged appropriate IV route in 84% patients compared with 84.8% by the algorithm.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["the algorithm", "TEST", 75, 88]]], ["The sensitivity of the algorithm was 93.4% and specificity 60.7%.", [["the algorithm", "TEST", 19, 32], ["specificity", "TEST", 47, 58]]], ["The positive predictive value was 92.6% and the negative predictive value was 63.8%.", [["The positive predictive value", "TEST", 0, 29], ["positive", "OBSERVATION_MODIFIER", 4, 12]]], ["The IDP judged IV agents to have been chosen and administered appropriately in 80%.", [["The IDP judged IV agents", "TREATMENT", 0, 24]]], ["Most frequently prescribed IV agents were 3rd generation cephalosporins (3GC) (28.3%), Co-amoxiclav (20.2%), Metronidazole (19.2%), Glycopeptides (18.6%).", [["cephalosporins", "CHEMICAL", 57, 71], ["3GC", "CHEMICAL", 73, 76], ["Co-amoxiclav", "CHEMICAL", 87, 99], ["Metronidazole", "CHEMICAL", 109, 122], ["Glycopeptides", "CHEMICAL", 132, 145], ["cephalosporins", "CHEMICAL", 57, 71], ["3GC", "CHEMICAL", 73, 76], ["Co-amoxiclav", "CHEMICAL", 87, 99], ["Metronidazole", "CHEMICAL", 109, 122], ["Glycopeptides", "CHEMICAL", 132, 145], ["IV agents", "SIMPLE_CHEMICAL", 27, 36], ["3rd generation cephalosporins", "SIMPLE_CHEMICAL", 42, 71], ["3GC", "SIMPLE_CHEMICAL", 73, 76], ["Co-amoxiclav", "SIMPLE_CHEMICAL", 87, 99], ["Metronidazole", "SIMPLE_CHEMICAL", 109, 122], ["Glycopeptides", "SIMPLE_CHEMICAL", 132, 145], ["IV agents", "TREATMENT", 27, 36], ["3rd generation cephalosporins (3GC)", "TREATMENT", 42, 77], ["Co-amoxiclav", "TREATMENT", 87, 99], ["Metronidazole", "TREATMENT", 109, 122], ["Glycopeptides", "TREATMENT", 132, 145]]], ["Significant regional differences were seen for most antibiotic groups including 3GCs (49.2% (site 3) vs 24.4% (sites 1, 2, 4, 5) , p < 0.001) and Glycopeptides [31.8% (site 1) vs 9.3% (site 2, 3, 4, 5) , p < 0.001].", [["Glycopeptides", "SIMPLE_CHEMICAL", 146, 159], ["Significant regional differences", "PROBLEM", 0, 32], ["most antibiotic groups", "TREATMENT", 47, 69], ["3GCs", "TEST", 80, 84], ["vs", "TEST", 101, 103], ["sites", "TEST", 111, 116], ["Glycopeptides", "TEST", 146, 159], ["vs", "TEST", 176, 178]]], ["The GAAT gives a good estimate of the appropriateness of IV therapy.", [["GAAT", "PROTEIN", 4, 8], ["IV therapy", "TREATMENT", 57, 67]]], ["Significant differences in prescribing patterns between similar patient groups across different hospital sites were demonstrated.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["Significant differences in prescribing patterns", "PROBLEM", 0, 47]]], ["Associations between continuous variables were tested in univariate analysis with the Spearman correlation test (r).", [["univariate analysis", "TEST", 57, 76], ["the Spearman correlation test", "TEST", 82, 111]]], ["Multiple linear regression analysis was performed in a backward stepwise approach.", [["Multiple linear regression analysis", "TEST", 0, 35], ["a backward stepwise approach", "TREATMENT", 53, 81], ["linear", "OBSERVATION_MODIFIER", 9, 15], ["regression", "OBSERVATION", 16, 26]]], ["Results: The median rate of total hospital glycopeptides use was 4.11 (range 0.21 to 27.22) DDDs per 1,000 PD with higher consumption in large public hospitals.", [["PD", "DISEASE", 107, 109], ["total hospital glycopeptides", "TREATMENT", 28, 56], ["large", "OBSERVATION_MODIFIER", 137, 142]]], ["Consumption was higher in intensive care areas (median 46.51; range 7.19 to 134) than in surgery areas (median 4.5; range 0.17 to 24.76 ) and in medicine (median 4.26 ; range 0 to 41).", [["higher", "OBSERVATION_MODIFIER", 16, 22]]], ["Glycopeptides use correlated with number of central line per 1,000 PD (r: 0.44; p: 0.03) and with size of the various areas in the hospital (for intensive care, r: 0.50; for medicine areas, r: 0.33 and for surgery areas, r: 0.42; p < 0.05).", [["Glycopeptides", "CHEMICAL", 0, 13], ["Glycopeptides", "CHEMICAL", 0, 13], ["Glycopeptides", "TREATMENT", 0, 13], ["central line", "TREATMENT", 44, 56], ["surgery areas", "TEST", 206, 219], ["central line", "OBSERVATION", 44, 56]]], ["Median incidence of MRSA was 0.87 per 1,000 PD.", [["MRSA", "DISEASE", 20, 24], ["PD", "DISEASE", 44, 46], ["MRSA", "SPECIES", 20, 24], ["MRSA", "SPECIES", 20, 24], ["MRSA", "PROBLEM", 20, 24], ["MRSA", "OBSERVATION", 20, 24]]], ["Incidence of MRSA explained a small proportion of the variation in hospital glycopeptides consumption (R2: 0.13).", [["MRSA", "DISEASE", 13, 17], ["MRSA", "SPECIES", 13, 17], ["MRSA", "PROBLEM", 13, 17], ["MRSA", "OBSERVATION", 13, 17], ["small", "OBSERVATION_MODIFIER", 30, 35], ["variation", "OBSERVATION_MODIFIER", 54, 63]]], ["In a multivariate linear regression model, incidence of MRSA and number of beds in surgery areas were independent predictors of total glycopeptides use in the hospital (R2 adjusted: 0.39).", [["MRSA", "DISEASE", 56, 60], ["MRSA", "SPECIES", 56, 60], ["MRSA", "SPECIES", 56, 60], ["MRSA", "PROBLEM", 56, 60], ["beds in surgery", "TREATMENT", 75, 90], ["total glycopeptides", "TREATMENT", 128, 147], ["MRSA", "OBSERVATION", 56, 60], ["beds", "OBSERVATION_MODIFIER", 75, 79]]], ["After controlling for these factors, number of central-line per 1,000 PD was no more associated with glycopeptides use.", [["PD", "DISEASE", 70, 72], ["central-line", "TREATMENT", 47, 59], ["glycopeptides use", "TREATMENT", 101, 118]]], ["Conclusion: In our hospitals, total glycopeptides use was not heavily determined by incidence of MRSA.", [["MRSA", "DISEASE", 97, 101], ["MRSA", "SPECIES", 97, 101], ["MRSA", "SPECIES", 97, 101], ["total glycopeptides", "TREATMENT", 30, 49], ["MRSA", "PROBLEM", 97, 101], ["MRSA", "OBSERVATION", 97, 101]]], ["Although glycopeptides use in surgery areas was not the highest, the total number of surgery beds in the hospital explained a large variation of the total hospital glycopeptides use.", [["glycopeptides", "TREATMENT", 9, 22], ["surgery", "TREATMENT", 30, 37], ["surgery beds", "TREATMENT", 85, 97], ["the total hospital glycopeptides", "TREATMENT", 145, 177], ["large", "OBSERVATION_MODIFIER", 126, 131]]], ["Therefore we had to take it into account to interpret these consumption and to decide further evaluation.P1471Antibiotic management of acute lower respiratory tract infections among Dutch elderly patients in primary care J. Bont, C. Birkhoff, T. Verheij, E. Hak on behalf of ESPRIT Objectives: Acute lower respiratory tract infection (LRTI) can cause various complications leading to morbidity as well as mortality notably among elderly patients.", [["lower respiratory tract", "ANATOMY", 141, 164], ["lower respiratory tract", "ANATOMY", 300, 323], ["lower respiratory tract infections", "DISEASE", 141, 175], ["lower respiratory tract infection", "DISEASE", 300, 333], ["LRTI", "DISEASE", 335, 339], ["tract", "ORGANISM_SUBDIVISION", 159, 164], ["patients", "ORGANISM", 196, 204], ["patients", "ORGANISM", 437, 445], ["patients", "SPECIES", 196, 204], ["patients", "SPECIES", 437, 445], ["further evaluation", "TEST", 86, 104], ["P1471Antibiotic management", "TREATMENT", 105, 131], ["acute lower respiratory tract infections", "PROBLEM", 135, 175], ["Acute lower respiratory tract infection", "PROBLEM", 294, 333], ["various complications", "PROBLEM", 351, 372], ["morbidity", "PROBLEM", 384, 393], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["lower", "ANATOMY_MODIFIER", 141, 146], ["respiratory tract", "ANATOMY", 147, 164], ["Acute", "OBSERVATION_MODIFIER", 294, 299], ["lower", "ANATOMY_MODIFIER", 300, 305], ["respiratory tract", "ANATOMY", 306, 323], ["infection", "OBSERVATION", 324, 333]]], ["Antibiotic treatment of LRTI is common, despite Dutch clinical guidelines recommending antibiotics only in case of pneumonia or high risk of serious complications.", [["LRTI", "DISEASE", 24, 28], ["pneumonia", "DISEASE", 115, 124], ["Antibiotic treatment", "TREATMENT", 0, 20], ["LRTI", "PROBLEM", 24, 28], ["antibiotics", "TREATMENT", 87, 98], ["pneumonia", "PROBLEM", 115, 124], ["serious complications", "PROBLEM", 141, 162], ["LRTI", "OBSERVATION", 24, 28], ["pneumonia", "OBSERVATION", 115, 124], ["serious", "OBSERVATION_MODIFIER", 141, 148], ["complications", "OBSERVATION", 149, 162]]], ["We assessed the course of illness and outcome of pneumonia, acute bronchitis and exacerbations of COPD or asthma among Dutch elderly patients in primary care and assessed whether GPs were inclined to prescribe antibiotics more readily to patients with potential risk factors for complications in acute bronchitis or exacerbations of COPD/ asthma.", [["illness", "DISEASE", 26, 33], ["pneumonia", "DISEASE", 49, 58], ["bronchitis", "DISEASE", 66, 76], ["COPD", "DISEASE", 98, 102], ["asthma", "DISEASE", 106, 112], ["bronchitis", "DISEASE", 302, 312], ["COPD", "DISEASE", 333, 337], ["asthma", "DISEASE", 339, 345], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 238, 246], ["illness", "PROBLEM", 26, 33], ["pneumonia", "PROBLEM", 49, 58], ["acute bronchitis", "PROBLEM", 60, 76], ["exacerbations", "PROBLEM", 81, 94], ["COPD", "PROBLEM", 98, 102], ["asthma", "PROBLEM", 106, 112], ["antibiotics", "TREATMENT", 210, 221], ["complications", "PROBLEM", 279, 292], ["acute bronchitis", "PROBLEM", 296, 312], ["exacerbations", "PROBLEM", 316, 329], ["COPD", "PROBLEM", 333, 337], ["asthma", "PROBLEM", 339, 345], ["pneumonia", "OBSERVATION", 49, 58], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["bronchitis", "OBSERVATION", 66, 76], ["COPD", "OBSERVATION", 98, 102], ["acute", "OBSERVATION_MODIFIER", 296, 301], ["bronchitis", "OBSERVATION", 302, 312], ["COPD", "OBSERVATION", 333, 337], ["asthma", "OBSERVATION", 339, 345]]], ["Methods: We retrospectively analysed medical data from 3,166 episodes of LRTI among patients \u202165 years of age presenting in primary care to describe the course of illness and outcome.", [["LRTI", "DISEASE", 73, 77], ["illness", "DISEASE", 163, 170], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["illness", "PROBLEM", 163, 170]]], ["The relation between prescriptions of antibiotics and patients with risk factors for a complicated course was assessed by means of multivariate logistic regression.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["antibiotics", "TREATMENT", 38, 49], ["multivariate logistic regression", "PROBLEM", 131, 163]]], ["Risk factors for a complicated course included heart failure, history of myocardial infarction, angina pectoris, diabetes, history of stroke, dementia, malignancy, and history of pneumonia or hospitalisation in preceding year.", [["heart", "ANATOMY", 47, 52], ["myocardial", "ANATOMY", 73, 83], ["heart failure", "DISEASE", 47, 60], ["myocardial infarction", "DISEASE", 73, 94], ["angina pectoris", "DISEASE", 96, 111], ["diabetes", "DISEASE", 113, 121], ["stroke", "DISEASE", 134, 140], ["dementia", "DISEASE", 142, 150], ["malignancy", "DISEASE", 152, 162], ["pneumonia", "DISEASE", 179, 188], ["heart", "ORGAN", 47, 52], ["myocardial", "MULTI-TISSUE_STRUCTURE", 73, 83], ["Risk factors", "PROBLEM", 0, 12], ["heart failure", "PROBLEM", 47, 60], ["myocardial infarction", "PROBLEM", 73, 94], ["angina pectoris", "PROBLEM", 96, 111], ["diabetes", "PROBLEM", 113, 121], ["stroke", "PROBLEM", 134, 140], ["dementia", "PROBLEM", 142, 150], ["malignancy", "PROBLEM", 152, 162], ["pneumonia", "PROBLEM", 179, 188], ["heart", "ANATOMY", 47, 52], ["failure", "OBSERVATION", 53, 60], ["myocardial", "ANATOMY", 73, 83], ["infarction", "OBSERVATION", 84, 94], ["angina", "OBSERVATION_MODIFIER", 96, 102], ["pectoris", "OBSERVATION", 103, 111], ["diabetes", "OBSERVATION", 113, 121], ["stroke", "OBSERVATION", 134, 140], ["dementia", "OBSERVATION", 142, 150], ["malignancy", "OBSERVATION", 152, 162], ["pneumonia", "OBSERVATION", 179, 188]]], ["Results: One or more complications arose in 17% of episodes of LRTI.", [["LRTI", "DISEASE", 63, 67], ["LRTI", "PROBLEM", 63, 67], ["LRTI", "OBSERVATION", 63, 67]]], ["Among these, 8% suffered from pulmonary complications, 5% had cardiovascular complications (heart failure, myocardial infarction etc.), 5% had a protracted course and 0.6% had a diabetes event.", [["pulmonary", "ANATOMY", 30, 39], ["cardiovascular", "ANATOMY", 62, 76], ["heart", "ANATOMY", 92, 97], ["myocardial", "ANATOMY", 107, 117], ["pulmonary complications", "DISEASE", 30, 53], ["cardiovascular complications", "DISEASE", 62, 90], ["heart failure", "DISEASE", 92, 105], ["myocardial infarction", "DISEASE", 107, 128], ["diabetes", "DISEASE", 178, 186], ["pulmonary", "ORGAN", 30, 39], ["heart", "ORGAN", 92, 97], ["myocardial", "MULTI-TISSUE_STRUCTURE", 107, 117], ["pulmonary complications", "PROBLEM", 30, 53], ["cardiovascular complications", "PROBLEM", 62, 90], ["heart failure", "PROBLEM", 92, 105], ["myocardial infarction", "PROBLEM", 107, 128], ["a diabetes event", "PROBLEM", 176, 192], ["pulmonary", "ANATOMY", 30, 39], ["complications", "OBSERVATION", 40, 53], ["complications", "OBSERVATION", 77, 90], ["heart", "ANATOMY", 92, 97], ["failure", "OBSERVATION", 98, 105], ["myocardial", "ANATOMY", 107, 117], ["infarction", "OBSERVATION", 118, 128], ["diabetes", "OBSERVATION", 178, 186]]], ["In 6.9% of the patients complications led to hospital admission and in 2.4% LRTI were fatal.", [["LRTI", "DISEASE", 76, 80], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Antibiotics were more readily prescribed to patients aged \u202190 years, when heart failure was present and in patients with diabetes.", [["heart", "ANATOMY", 74, 79], ["heart failure", "DISEASE", 74, 87], ["diabetes", "DISEASE", 121, 129], ["patients", "ORGANISM", 44, 52], ["heart", "ORGAN", 74, 79], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 107, 115], ["Antibiotics", "TREATMENT", 0, 11], ["heart failure", "PROBLEM", 74, 87], ["diabetes", "PROBLEM", 121, 129], ["heart", "ANATOMY", 74, 79], ["failure", "OBSERVATION", 80, 87]]], ["No significant association was observed in patients with other co-morbid conditions.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["other co-morbid conditions", "PROBLEM", 57, 83], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["Patients diagnosed with an exacerbation of COPD or acute bronchitis with a history of pneumonia or hospitalisation in the preceding year were not more likely to receive antibiotics.", [["COPD", "DISEASE", 43, 47], ["bronchitis", "DISEASE", 57, 67], ["pneumonia", "DISEASE", 86, 95], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COPD", "PROBLEM", 43, 47], ["acute bronchitis", "PROBLEM", 51, 67], ["pneumonia", "PROBLEM", 86, 95], ["antibiotics", "TREATMENT", 169, 180], ["exacerbation", "OBSERVATION", 27, 39], ["COPD", "OBSERVATION", 43, 47], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["bronchitis", "OBSERVATION", 57, 67], ["pneumonia", "OBSERVATION", 86, 95]]], ["Conclusions: A considerable part of elderly patients with a LRTI suffers from a severely complicated course in primary care.", [["LRTI", "DISEASE", 60, 64], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["a LRTI", "PROBLEM", 58, 64], ["severely", "OBSERVATION_MODIFIER", 80, 88], ["complicated", "OBSERVATION", 89, 100]]], ["Although GPs are inclined to prescribe more readily antibiotics in the very old and those with heart failure or diabetes, other potential risk factors are not taken into account.", [["heart", "ANATOMY", 95, 100], ["heart failure", "DISEASE", 95, 108], ["diabetes", "DISEASE", 112, 120], ["heart", "ORGAN", 95, 100], ["readily antibiotics", "TREATMENT", 44, 63], ["heart failure", "PROBLEM", 95, 108], ["diabetes", "PROBLEM", 112, 120], ["heart", "ANATOMY", 95, 100], ["failure", "OBSERVATION", 101, 108], ["diabetes", "OBSERVATION", 112, 120]]], ["Objectives: In this study it was aimed to analyse the infectious diseases (ID) trainees' night/weekend shift consultation process in terms of patient and consultant characteristics, types of recommendations, and compliance with recommendations.", [["infectious diseases", "DISEASE", 54, 73], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 142, 149], ["this study", "TEST", 15, 25]]], ["Methods: All consultations performed by ID trainees in night shift and at the weekends between June 10th-August 10th 2004 were analysed in terms of consultation type [treatment continuation (TC), consultation for surgical antibiotic prophylaxis (PA), and consultation with or without a request of a specific antibiotic (others)].", [["treatment continuation (TC)", "TREATMENT", 167, 194], ["surgical antibiotic prophylaxis", "TREATMENT", 213, 244], ["a specific antibiotic", "TREATMENT", 297, 318]]], ["Appropriateness of recommendations was assessed the day after the consultation by infectious diseases specialists (IDS).", [["infectious diseases", "DISEASE", 82, 101]]], ["Recommendations including antibiotics were considered appropriate, if they were appropriate according to national and international guidelines.", [["antibiotics", "TREATMENT", 26, 37]]], ["Recommendations were considered complied, if they were done in up to 72 hours after the consultation (except the consultations in the emergency medicine and the consultations in which antibiotics were started by the counselling IDSs).", [["antibiotics", "TREATMENT", 184, 195]]], ["Results: Of 436 consultations 79 was for TC, 74 was for PA and 290 was for others.", [["TC", "TEST", 41, 43], ["PA", "TEST", 56, 58]]], ["Overall 146 consultations (74 for SP, 69 for a clinical infectious disease diagnosed clinically, 9 for an infectious disease diagnosed microbiologically) were for requesting spesific antibiotic(s).", [["infectious disease", "DISEASE", 56, 74], ["a clinical infectious disease", "PROBLEM", 45, 74], ["an infectious disease", "PROBLEM", 103, 124]]], ["PA were approved in 68 of 74 consultations.", [["PA", "GENE_OR_GENE_PRODUCT", 0, 2], ["PA", "TEST", 0, 2]]], ["Antibiotic was not recommended in 14 of 290 other consultations.", [["Antibiotic", "TREATMENT", 0, 10]]], ["In six of 74 consultations for PA antibiotic was changed for a clinically diagnosed infectious disease.", [["infectious disease", "DISEASE", 84, 102], ["PA", "GENE_OR_GENE_PRODUCT", 31, 33], ["PA antibiotic", "TREATMENT", 31, 44], ["a clinically diagnosed infectious disease", "PROBLEM", 61, 102], ["infectious", "OBSERVATION", 84, 94]]], ["In one of 79 consultations for TC antibiotic was changed due to lack of response to the given antibiotic, in others TC was approved.", [["TC", "CHEMICAL", 31, 33], ["TC", "SIMPLE_CHEMICAL", 31, 33], ["TC antibiotic", "TREATMENT", 31, 44], ["antibiotic", "TREATMENT", 94, 104]]], ["Inappropriate antibiotic recommendation rate was 2.4% (8/32, 4 inappropriate choice, 3 inappropriate dosage, one antibiotic unnecessary).", [["Inappropriate antibiotic recommendation rate", "TREATMENT", 0, 44], ["one antibiotic unnecessary", "TREATMENT", 109, 135]]], ["Rate of compliance to antibiotic recommendations was evaluated in 240 consultations and was found 98.2% (277/282) and was higher than compliance to other (microbiology etc.) recommendations (60.8%, 199/327, chi square p < 0.05).", [["antibiotic recommendations", "TREATMENT", 22, 48], ["chi square p", "TEST", 207, 219]]], ["Conclusion: Methodologies to improve the compliance to nontreatment based recommendations and optimizing antibiotic selection is necessary.P1473Study of the influence of online practice guidelines on the appropriateness of antibiotic prescribing in a university-affiliated psychiatric hospital J.F. Westphal, C. Nonnenmacher, D. Gregoire, M. Hittinger, C. Oulerich, F. Jehl (Brumath, Strasbourg, FR) Background: Problems with the dissemination of guidelines are frequently cited as a major reason for failure to impact practice.", [["psychiatric", "DISEASE", 273, 284], ["optimizing antibiotic selection", "TREATMENT", 94, 125], ["antibiotic", "TREATMENT", 223, 233], ["failure to impact practice", "PROBLEM", 501, 527]]], ["Reviews of the effectiveness of various methods of guideline dissemination show that the most predictable impact is achieved when the guideline is made accessible through computer-based reminders that are integrated into the clinician's workflow.", [["guideline dissemination", "TREATMENT", 51, 74]]], ["We report a time-series prospective investigation aimed at comparing the appropriateness of antibiotic (AB) orders for pneumonia at the treatment initiation level after vs. before having embedded our current AB guidelines for pneumonia in the computerized physician drug-order entry system of our teaching psychiatric hospital comprising 410 adult beds.", [["pneumonia", "DISEASE", 119, 128], ["pneumonia", "DISEASE", 226, 235], ["psychiatric", "DISEASE", 306, 317], ["prospective investigation", "TEST", 24, 49], ["antibiotic (AB) orders", "TREATMENT", 92, 114], ["pneumonia", "PROBLEM", 119, 128], ["current AB guidelines", "TREATMENT", 200, 221], ["pneumonia", "PROBLEM", 226, 235], ["pneumonia", "OBSERVATION", 119, 128], ["pneumonia", "OBSERVATION", 226, 235]]], ["Methods: In total, 160 consecutive AB orders for pneumonia were evaluated by the pharmacy department, including 80 orders just before and 80 orders just after implementation of online AB guidelines.", [["pneumonia", "DISEASE", 49, 58], ["pneumonia", "PROBLEM", 49, 58], ["online AB guidelines", "TREATMENT", 177, 197], ["pneumonia", "OBSERVATION", 49, 58]]], ["Appropriateness of AB orders relative to the guidelines was assessed according to 3 criteria: (1) the choice of AB with respect to the mode of acquisition (community-or hospital-acquired) of pneumonia or the presence of clinical risk factors for involvement of gramnegative bacilli, (2) the daily dosage, (3) the planned duration of treatment.", [["pneumonia", "DISEASE", 191, 200], ["pneumonia", "PROBLEM", 191, 200], ["gramnegative bacilli", "PROBLEM", 261, 281], ["treatment", "TREATMENT", 333, 342], ["pneumonia", "OBSERVATION", 191, 200]]], ["Data were extracted from the computerized infection declaration system that recorded all AB-requiring infections in our hospital.P1473Results: The number of AB orders with at least 1 criterion of inappropriateness tended to decrease, yet not significantly (p = 0.11), after vs. before implementation of online guidelines: 30/80 (36.5%) and 40/80 (50.0%), respectively.", [["infection", "DISEASE", 42, 51], ["infections", "DISEASE", 102, 112], ["infections", "PROBLEM", 102, 112], ["AB orders", "TEST", 157, 166], ["infection", "OBSERVATION", 42, 51], ["infections", "OBSERVATION", 102, 112], ["decrease", "OBSERVATION_MODIFIER", 224, 232]]], ["The number of criteria of inappropriateness relative to all AB orders for pneumonia was significantly lower in the post-implementation period: 43.8% vs. 65.0% before implementation (difference 21.2%, 95% CI 6.", [["pneumonia", "DISEASE", 74, 83], ["all AB orders", "TEST", 56, 69], ["pneumonia", "PROBLEM", 74, 83], ["difference", "TEST", 182, 192], ["CI", "TEST", 204, 206], ["pneumonia", "OBSERVATION", 74, 83]]], ["1-36.3, p < 0.01) , with a trend to a decreased number of orders containing more than 1 criterion of inappropriateness.", [["p", "TEST", 8, 9]]], ["Analyzed separately, the numbers of inappropriate orders for the choice of the AB, or the daily dosage, or the planned duration of treatment decreased, yet not significantly (p > 0.1 for each criterion), in the post-vs. preimplementation period : 11 vs. 18, 12 vs.15, 12 vs.19, respectively.", [["the AB", "TREATMENT", 75, 81], ["treatment", "TREATMENT", 131, 140]]], ["Conclusion: In this study, the moderate impact on AB prescribing practices of online guidelines available at the time of drug order shows that additional types of intervention are needed to improve further the quality of AB prescribing.", [["this study", "TEST", 15, 25], ["AB prescribing practices", "TREATMENT", 50, 74], ["online guidelines", "TREATMENT", 78, 95], ["intervention", "TREATMENT", 163, 175], ["AB prescribing", "TREATMENT", 221, 235], ["moderate", "OBSERVATION_MODIFIER", 31, 39]]], ["Material: The pilot hospitals had a median capacity of 654 (range, 154 to 1597) beds; their regional distribution was representative of population size; 18 were general hospitals, 8 teaching hospitals and 10 general hospitals with teaching beds.", [["a median capacity", "TEST", 34, 51], ["teaching beds", "TREATMENT", 231, 244], ["size", "OBSERVATION_MODIFIER", 147, 151]]], ["Results: AMs were Internists (28), Microbiologists (13) and Pharmacists (13).", [["AMs", "CELL", 9, 12], ["AMs", "CELL_TYPE", 9, 12]]], ["All hospitals irrespective of size or affiliation had undertaken a wide range of antibiotic management interventions in 2003, which increased in 2004; These included (in 2003 and 2004, respectively) : major review of formulary (in 10 and 23 hospitals), development of clinical guidelines (69 and 215 topics), restricted access to selected antibiotics (carbapenems, glycopeptides, quinolones, new drugs; in 25 and 33 hospitals).", [["carbapenems", "CHEMICAL", 352, 363], ["quinolones", "CHEMICAL", 380, 390], ["carbapenems", "CHEMICAL", 352, 363], ["quinolones", "CHEMICAL", 380, 390], ["carbapenems", "SIMPLE_CHEMICAL", 352, 363], ["quinolones", "SIMPLE_CHEMICAL", 380, 390], ["antibiotic management interventions", "TREATMENT", 81, 116], ["selected antibiotics", "TREATMENT", 330, 350], ["carbapenems", "TREATMENT", 352, 363], ["glycopeptides", "TREATMENT", 365, 378], ["quinolones", "TREATMENT", 380, 390], ["new drugs", "TREATMENT", 392, 401], ["size", "OBSERVATION_MODIFIER", 30, 34]]], ["In 2003, antibiotic consumption databases were established in 35 hospitals and antibacterial susceptibility databases in 31 hospitals.", [["antibiotic consumption databases", "TEST", 9, 41], ["antibacterial susceptibility databases", "PROBLEM", 79, 117]]], ["In 2004, cross-analysis of these databases was performed in 28 hospitals.", [["cross-analysis", "TEST", 9, 23], ["these databases", "TEST", 27, 42]]], ["In 2004, prescribing assistance, antibiotic stop orders, treatment streamlining and IV/PO therapy switch were implemented in 32, 21, 24 and 24 hospitals, respectively.", [["antibiotic", "TREATMENT", 33, 43], ["treatment streamlining", "TREATMENT", 57, 79], ["IV/PO therapy", "TREATMENT", 84, 97]]], ["In 2004, 26 hospitals reported a better use of target antibiotics, 15 hospitals a decrease in consumption of restricted antibiotics, 5 hospitals a decrease of total antibiotic consumption, 2 hospitals a decrease in high consumer departments.", [["target antibiotics", "TREATMENT", 47, 65], ["restricted antibiotics", "TREATMENT", 109, 131], ["total antibiotic consumption", "TREATMENT", 159, 187]]], ["Conclusion: All hospitals participating in the AMT pilot scheme have developed multiple antibiotic policy interventions and established monitoring and guidance of antibiotic prescription.", [["the AMT pilot scheme", "TREATMENT", 43, 63], ["multiple antibiotic policy interventions", "TREATMENT", 79, 119], ["antibiotic prescription", "TREATMENT", 163, 186]]], ["Preliminary data from some hospitals indicated success in meeting self-defined targets of appropriate use and reducing the consumption of selected antimicrobial agents.", [["Preliminary data", "TEST", 0, 16], ["selected antimicrobial agents", "TREATMENT", 138, 167]]], ["More systematic evaluation using standard quantitative and qualitative indicators is planned.P1475Antibiotic prescribing practices at two linked London teaching hospitals P1476 Comparison of different antibiotic consumption measurement methods in large multidisciplinary hospital E. Pujate, I. Apine, U. Dumpis (Riga, LV)P1475Objectives: Antibiotic selection pressure is determined by the total amount of antibiotics, number and density of patients treated with antibiotics in the particular geographical area.", [["patients", "ORGANISM", 440, 448], ["patients", "SPECIES", 440, 448], ["More systematic evaluation", "TEST", 0, 26], ["different antibiotic consumption", "TREATMENT", 191, 223], ["Apine", "TEST", 294, 299], ["Antibiotic selection pressure", "TREATMENT", 338, 367], ["antibiotics", "TREATMENT", 405, 416], ["antibiotics", "TREATMENT", 462, 473], ["LV", "ANATOMY", 318, 320], ["density", "OBSERVATION_MODIFIER", 429, 436]]], ["Several antibiotic consumption detection methods should be combined in the hospital setting.", [["Several antibiotic consumption detection methods", "TREATMENT", 0, 48]]], ["Our objective was to evaluate efficacy of different approaches in large multidisciplinary hospital.", [["large", "OBSERVATION_MODIFIER", 66, 71]]], ["All patients receiving antibiotics on the day of the survey were identified and their medical records were reviewed.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["antibiotics", "TREATMENT", 23, 34]]], ["Data on antibiotics, dose and route of administration were collected.", [["antibiotics", "TREATMENT", 8, 19], ["administration", "TREATMENT", 39, 53]]], ["In addition, annual data on antibiotics dispensed to the departments were collected from pharmacy.", [["antibiotics", "TREATMENT", 28, 39]]], ["Total used grams for each antibiotic were expressed into defined daily doses (DDD-WHO).", [["Total used grams", "TREATMENT", 0, 16], ["each antibiotic", "TREATMENT", 21, 36]]], ["Bed days (BD) and admission days (AD) were used as denominators.P1475Results: Table 1 Total use of antibiotics in Stradins University Hospital 2002 Hospital -2004 The most commonly used antibiotic groups in the pharmacy study were 1st generation cephalosporins (13.35 DDD/100 BD in 2002 , 11.6 in 2003 , 10.8 in 2004 ) and penicillin's with extended spectrum (11.20, 11.98, 13.15 ) followed by fluoroquinolones (6.26, 8.13, 8.69 ) and metronidazole (4.42, 4.59, 5.61 ).", [["AD", "DISEASE", 34, 36], ["cephalosporins", "CHEMICAL", 246, 260], ["penicillin", "CHEMICAL", 323, 333], ["fluoroquinolones", "CHEMICAL", 394, 410], ["metronidazole", "CHEMICAL", 435, 448], ["cephalosporins", "CHEMICAL", 246, 260], ["penicillin", "CHEMICAL", 323, 333], ["fluoroquinolones", "CHEMICAL", 394, 410], ["metronidazole", "CHEMICAL", 435, 448], ["cephalosporins", "SIMPLE_CHEMICAL", 246, 260], ["penicillin", "SIMPLE_CHEMICAL", 323, 333], ["fluoroquinolones", "SIMPLE_CHEMICAL", 394, 410], ["metronidazole", "SIMPLE_CHEMICAL", 435, 448], ["antibiotics", "TREATMENT", 99, 110], ["antibiotic groups", "TREATMENT", 186, 203], ["the pharmacy study", "TEST", 207, 225], ["1st generation cephalosporins", "TREATMENT", 231, 260], ["DDD", "TEST", 268, 271], ["penicillin's", "TREATMENT", 323, 335], ["fluoroquinolones", "TREATMENT", 394, 410], ["metronidazole", "TREATMENT", 435, 448]]], ["There was no significant difference between distribution of different antibiotics from prevalence and pharmacy studies if calculated in DDDs.", [["different antibiotics", "TREATMENT", 60, 81], ["pharmacy studies", "TEST", 102, 118], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["In contrast, distribution of antibiotics calculated per patient in the prevalence study was quite different; 1st generation cephalosporins (8.", [["cephalosporins", "CHEMICAL", 124, 138], ["cephalosporins", "CHEMICAL", 124, 138], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["antibiotics", "TREATMENT", 29, 40], ["the prevalence study", "TEST", 67, 87], ["1st generation cephalosporins", "TREATMENT", 109, 138]]], ["71%, 8.63%, 5.84% in 2002, 2003, 2004 respectively) and fluoroquinolones (3.05%, 6.69%, 5.63%) with smaller proportion of extended spectrum penicillins (4.36%, 3.88%, 3.93%) and metronidazole (4.03%, 3.56%, 4.68%).", [["fluoroquinolones", "CHEMICAL", 56, 72], ["penicillins", "CHEMICAL", 140, 151], ["metronidazole", "CHEMICAL", 178, 191], ["fluoroquinolones", "CHEMICAL", 56, 72], ["penicillins", "CHEMICAL", 140, 151], ["metronidazole", "CHEMICAL", 178, 191], ["fluoroquinolones", "SIMPLE_CHEMICAL", 56, 72], ["penicillins", "SIMPLE_CHEMICAL", 140, 151], ["metronidazole", "SIMPLE_CHEMICAL", 178, 191], ["fluoroquinolones", "TREATMENT", 56, 72], ["extended spectrum penicillins", "TREATMENT", 122, 151], ["metronidazole", "TREATMENT", 178, 191]]], ["Conclusions: There were no differences in the distribution of antibiotics calculated in DDDs per bed days and admissions.", [["antibiotics", "TREATMENT", 62, 73]]], ["Distribution of antibiotics in annual pharmacy studies and point prevalence studies if calculated in DDDs were also similar.", [["antibiotics", "TREATMENT", 16, 27], ["annual pharmacy studies", "TEST", 31, 54], ["point prevalence studies", "TEST", 59, 83], ["antibiotics", "OBSERVATION_MODIFIER", 16, 27]]], ["In contrast, the prevalence data expressed as a proportion of patients with selected antibiotics showed quite different distribution.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["selected antibiotics", "TREATMENT", 76, 96]]], ["Studies using only DDDs may overestimate use of certain antibiotic groups in our setting where WHO DDDs are significantly different from actual PDDs used.P1477A study of prescribing patterns and errors of antibiotics in a Saudi hospital M. Al-Jamal, M. Al-Barrak (Riyadh, SA) Background: The term ''prescribing patterns'' has been used extensively in studies to describe different aspects of the prescribing process.", [["certain antibiotic groups", "TREATMENT", 48, 73], ["antibiotics", "TREATMENT", 205, 216], ["The term ''prescribing patterns", "TREATMENT", 288, 319]]], ["Antibiotics as well as other drugs are prescribed for the purpose of achieving definite therapeutic outcomes that improve a patient's quality of life while minimizing risk.", [["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["Antibiotics", "TREATMENT", 0, 11], ["other drugs", "TREATMENT", 23, 34]]], ["In the clinical literature, the incidence of antibiotics prescribing errors ranges between 0.5% and 18.8%.", [["antibiotics", "TREATMENT", 45, 56]]], ["Objective: In this study we will address antibiotics prescribing patterns and the incidence of prescribing errors in a tertiary hospital and the potential relationship between them.", [["this study", "TEST", 14, 24], ["antibiotics", "TREATMENT", 41, 52]]], ["Methods: A prospective study of all prescriptions in a 3-month period (June to August 2003) in a tertiary hospital has been analysed.", [["A prospective study", "TEST", 9, 28]]], ["Criteria used include frequency of selected prescribed drugs, average number of items per prescription, compliance to the hospital formulary, frequency of prescriptions for antibiotics, generic prescribing and diagnosis.", [["selected prescribed drugs", "TREATMENT", 35, 60], ["antibiotics", "TREATMENT", 173, 184]]], ["The average number of items per prescription is 2.1.", [["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["The most prescribed drugs by primary care (25.3% errors), emergency are antibiotics (28.2%), medicine (3.7), ophthalmology (22.3), gynaecology (7.8), and paediatrics (17.8).", [["antibiotics", "TREATMENT", 72, 83]]], ["Discussions and conclusions: Over 24000 prescriptions were included in this study.", [["this study", "TEST", 71, 81]]], ["The incidence of prescribing errors was 18.8% the average number of items per prescription was 2.1.", [["prescribing errors", "TEST", 17, 35]]], ["Total Prescription errors are also related to frequency of prescribing antibiotics.", [["prescribing antibiotics", "TREATMENT", 59, 82]]], ["There was a relation between prescribing of antibiotics and prescribing of trade names (p < 0.01), and compliance to the hospital formulary (p < 0.001).", [["antibiotics", "TREATMENT", 44, 55]]], ["Several factors influence prescribing patterns and variations in prescribing rates has been identified.", [["variations in prescribing rates", "PROBLEM", 51, 82]]], ["These include general physician behavior, differences in morbidity and mortality patterns, social perception toward illness, and physician clinical skills, experience and qualification, as well as physician continuing education and training.", [["illness", "DISEASE", 116, 123]]], ["Special antibiotic prescribing guidelines and restrictions should target primary care and emergency department physicians.P1478Effect of a policy for restriction of selected classes of antibiotics on antimicrobial drug cost and resistance of the non-restricted antibiotics.", [["Special antibiotic prescribing guidelines", "TREATMENT", 0, 41], ["antibiotics", "TREATMENT", 185, 196], ["antimicrobial drug cost", "TREATMENT", 200, 223], ["the non-restricted antibiotics", "TREATMENT", 242, 272]]], ["The logistic regression model we performed showed that the new policy had an independent positive effect on the in vitro antimicrobial susceptibility of Pseudomonas aeruginosa (p = 0.051) but not of Acinetobacter baumannii and Escherichia coli isolates.", [["Pseudomonas aeruginosa", "DISEASE", 153, 175], ["Pseudomonas aeruginosa", "ORGANISM", 153, 175], ["Acinetobacter baumannii", "ORGANISM", 199, 222], ["Escherichia coli", "ORGANISM", 227, 243], ["isolates", "ORGANISM", 244, 252], ["Pseudomonas aeruginosa", "SPECIES", 153, 175], ["Acinetobacter baumannii", "SPECIES", 199, 222], ["Escherichia coli", "SPECIES", 227, 243], ["Pseudomonas aeruginosa", "SPECIES", 153, 175], ["Acinetobacter baumannii", "SPECIES", 199, 222], ["Escherichia coli", "SPECIES", 227, 243], ["The logistic regression model", "TEST", 0, 29], ["an independent positive effect", "PROBLEM", 74, 104], ["Pseudomonas aeruginosa", "PROBLEM", 153, 175], ["Acinetobacter baumannii", "PROBLEM", 199, 222], ["Escherichia coli isolates", "PROBLEM", 227, 252], ["positive effect", "OBSERVATION", 89, 104], ["Escherichia coli", "OBSERVATION", 227, 243]]], ["Conclusion: Our data suggest that there are considerable limitations of the programs aiming to reduce the consumption of restricted antibiotics through the approval of their use by specialists, at least in a proportion of settings.", [["Our data", "TEST", 12, 20], ["the programs", "TREATMENT", 72, 84], ["restricted antibiotics", "TREATMENT", 121, 143]]], ["Education programs that aim to involve the medical staff directly responsible for the care of patients in voluntary decisions regarding the appropriate use of antimicrobial agents may have more profound and sustainable success, and thus, deserve to be studied.P1479Estimating hospital versus ambulatory care consumption of antibiotics in southwestern Germany K. de With, M. Steib-Bauert, H. Schr\u00f6 der, K. Nink, W.V. Kern (Freiburg, Bonn, DE) Objective: Preliminary data from the ESAC (European Surveillance of Antibiotic Consumption, www.ua.ac.be/ESAC) project indicated that the proportion of hospital care (HC) antibiotic use on total antibiotic use in several European countries ranges between 5 and 20%.", [["P1479Estimating", "CHEMICAL", 260, 275], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["Education programs", "TREATMENT", 0, 18], ["antimicrobial agents", "TREATMENT", 159, 179], ["antibiotics", "TREATMENT", 323, 334], ["Antibiotic Consumption", "TREATMENT", 510, 532], ["hospital care (HC) antibiotic", "TREATMENT", 594, 623], ["total antibiotic use", "TREATMENT", 631, 651]]], ["Only few countries, however, have so far been able to report representative countrywide information on both HC and ambulatory care (HC) antibiotic consumption.", [["ambulatory care (HC) antibiotic consumption", "TREATMENT", 115, 158], ["few", "OBSERVATION_MODIFIER", 5, 8]]], ["We estimated AC versus HC consumption of antibiotics for one of the 16 German federal states located in the Southwestern part of the country with a 10.5 million population.", [["AC versus HC consumption of antibiotics", "TREATMENT", 13, 52], ["a 10.5 million population", "TREATMENT", 146, 171]]], ["Methods: Data on HC consumption (ATC class J01) were obtained from a convenience sample of acute care general hospitals (n = 42), extrapolated to state-wide consumption (using official statistics for the total state-wide 152 general plus 77 special non-psychiatric/non-paediatric/non-radiotherapy hospitals), expressed in defined daily doses per 1000 inhabitants and day (DID), and finally compared to ambulatory care antibiotic use density in the same region and period of time (years 2001 and 2002) .", [["HC consumption", "TEST", 17, 31], ["ambulatory care antibiotic", "TREATMENT", 402, 428]]], ["Findings: The estimated state-wide HC consumption of antibiotics was 2.1 DID (95% confidence interval, 1.9 to 2.2 DID) in both years.", [["antibiotics", "TREATMENT", 53, 64]]], ["State-wide antibiotic consumption in the AC setting during the same time was 12 DID (~85% of total consumption).", [["wide antibiotic consumption", "TREATMENT", 6, 33]]], ["AC consumption of fluoroquinolones (1.1-1.2 DID, 79%) and macrolides/clindamycin (1.8 DID, 95%) made up a major proportion of total use of that drug classes.", [["fluoroquinolones", "CHEMICAL", 18, 34], ["macrolides", "CHEMICAL", 58, 68], ["clindamycin", "CHEMICAL", 69, 80], ["fluoroquinolones", "CHEMICAL", 18, 34], ["macrolides", "CHEMICAL", 58, 68], ["clindamycin", "CHEMICAL", 69, 80], ["fluoroquinolones", "SIMPLE_CHEMICAL", 18, 34], ["macrolides", "SIMPLE_CHEMICAL", 58, 68], ["clindamycin", "SIMPLE_CHEMICAL", 69, 80], ["fluoroquinolones", "TREATMENT", 18, 34], ["macrolides", "TREATMENT", 58, 68], ["clindamycin", "TREATMENT", 69, 80]]], ["Conclusions: Hospital antibiotic use in the Southwestern part of Germany can be estimated to contribute~15% to overall antibiotic consumption in the general population.P1480Antibiotic use profile and temporal trends during a 5-year period at a Greek university hospital: implications for antibiotic policy changes E.I. Kritsotakis, P. Assithianakis, P. Kanellos, N. Tzagarakis, M.C. Ioannides, A. Gikas (Heraklion, GR)P1480Objectives: To investigate the profile and temporal trends of inpatient antimicrobial use over a 5-year period at the University Hospital of Heraklion Crete, Greece.", [["Hospital antibiotic use", "TREATMENT", 13, 36], ["overall antibiotic consumption", "TREATMENT", 111, 141], ["antibiotic policy", "TREATMENT", 288, 305]]], ["Further, to examine the way in which frequency of data collection and stratification by different patient-care areas provides guidance to antibiotic policy changes.", [["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["data collection", "TEST", 50, 65], ["different patient-care areas", "TREATMENT", 88, 116], ["antibiotic policy changes", "TREATMENT", 138, 163]]], ["Methods: Retrospective monitoring of antimicrobial consumption was carried out according to the WHO anatomic therapeutic chemical classification (ATC) and defined daily dose (DDD) measurement methodology.", [["antimicrobial consumption", "TREATMENT", 37, 62]]], ["Linear regression was used in order to assess the statistical significance of a temporal trend in usage densities.", [["Linear regression", "PROBLEM", 0, 17], ["a temporal trend in usage densities", "PROBLEM", 78, 113], ["regression", "OBSERVATION", 7, 17], ["temporal", "OBSERVATION_MODIFIER", 80, 88]]], ["Results: During 1998 -2002 , hospital-wide antimicrobial use (ATC group J01) significantly increased by 22%, from 86.97 to 106.24 DDD/100BD.", [["ATC group J01", "TREATMENT", 62, 75]]], ["The annual average increase rate was 4.8 DDD/100BD.", [["rate", "TEST", 28, 32]]], ["Pooled usage rates in DDD/100BD, overall percentage increases and annual average increase rates were respectively 109.", [["DDD", "TREATMENT", 22, 25], ["percentage", "OBSERVATION_MODIFIER", 41, 51], ["increases", "OBSERVATION_MODIFIER", 52, 61]]], ["97, 35.6%, 8.1 for Medical wards; 98.21, 48.7%, 9.1 for ICU's; and 74.46, 34.3%, 5.7 for Haemato-oncology wards.", [["ICU's", "TEST", 56, 61]]], ["A shift towards the newer broad-spectrum antibiotics to the detriment of the older penicillins and cephalosporins was noted in all hospital areas.P1480Conclusion: Surveillance of aggregate data on the consumption of antimicrobials using the ATC/DDD system provided a clear picture of the profile of hospital usage.", [["penicillins", "CHEMICAL", 83, 94], ["cephalosporins", "CHEMICAL", 99, 113], ["penicillins", "CHEMICAL", 83, 94], ["cephalosporins", "CHEMICAL", 99, 113], ["penicillins", "SIMPLE_CHEMICAL", 83, 94], ["cephalosporins", "SIMPLE_CHEMICAL", 99, 113], ["A shift", "PROBLEM", 0, 7], ["the newer broad-spectrum antibiotics", "TREATMENT", 16, 52], ["the older penicillins", "TREATMENT", 73, 94], ["cephalosporins", "TREATMENT", 99, 113], ["antimicrobials", "TREATMENT", 216, 230], ["the ATC/DDD system", "TREATMENT", 237, 255]]], ["Monthly data over a sufficient surveillance period allowed the assessment of temporal trends.", [["the assessment", "TEST", 59, 73]]], ["Thus, surveillance of monthly antimicrobial consumption rates stratified by patientcare area can provide a simple, rapid and efficient tool for triggering antibiotic policy changes in the hospital and targeting more detailed quality-of-use audits.P1481Appropriate use of aminoglycosides: the impact of an antibiotic control team C. Rioux, P. Lesprit, J.R. Zahar, A. Hulin, A. Bernier-Combes, C. Brun-Buisson, E. Girou (Cr\u00e9teil, Paris, FR) Objectives: Many factors are involved in the appropriate use of aminoglycosides (AG), such as modalities of administration, serum monitoring and duration of treatment.", [["serum", "ANATOMY", 563, 568], ["aminoglycosides", "CHEMICAL", 271, 286], ["aminoglycosides", "CHEMICAL", 503, 518], ["AG", "CHEMICAL", 520, 522], ["aminoglycosides", "CHEMICAL", 271, 286], ["aminoglycosides", "CHEMICAL", 503, 518], ["aminoglycosides", "SIMPLE_CHEMICAL", 271, 286], ["aminoglycosides", "SIMPLE_CHEMICAL", 503, 518], ["AG", "SIMPLE_CHEMICAL", 520, 522], ["serum", "ORGANISM_SUBSTANCE", 563, 568], ["monthly antimicrobial consumption rates", "TREATMENT", 22, 61], ["triggering antibiotic policy", "TREATMENT", 144, 172], ["aminoglycosides", "TREATMENT", 271, 286], ["an antibiotic control", "TREATMENT", 302, 323], ["aminoglycosides (AG)", "TREATMENT", 503, 523], ["administration", "TREATMENT", 547, 561], ["serum monitoring", "TEST", 563, 579], ["treatment", "TREATMENT", 596, 605]]], ["We assessed prospectively the risk factors and the impact of an antibiotic control team on the appropriateness of AG prescriptions.", [["AG", "CHEMICAL", 114, 116], ["AG", "SIMPLE_CHEMICAL", 114, 116], ["the risk factors", "PROBLEM", 26, 42], ["an antibiotic control", "TREATMENT", 61, 82], ["AG prescriptions", "TREATMENT", 114, 130]]], ["Methods: In a setting of a restricted delivery system of AG in our hospital, we first performed an observational audit (OA) to assess the appropriateness of prescriptions including justification of prescribing, adequacy of drug choice, adequacy of administration modalities, modalities of serum monitoring and duration of treatment.", [["serum", "ANATOMY", 289, 294], ["AG", "CHEMICAL", 57, 59], ["serum", "ORGANISM_SUBSTANCE", 289, 294], ["prescriptions", "TREATMENT", 157, 170], ["drug choice", "TREATMENT", 223, 234], ["administration modalities", "TREATMENT", 248, 273], ["serum monitoring", "TEST", 289, 305], ["treatment", "TREATMENT", 322, 331]]], ["After implementation of specific guidelines hospital wide, we then performed an interventional audit (IA) where an antibiotic control team could interfere when AG prescriptions were considered inappropriate.", [["AG", "CHEMICAL", 160, 162], ["an antibiotic control team", "TREATMENT", 112, 138], ["AG prescriptions", "TREATMENT", 160, 176]]], ["Appropriateness of AG prescriptions between the 2 audits was then compared.", [["AG", "MULTI-TISSUE_STRUCTURE", 19, 21]]], ["During the IA, 32% of prescriptions were modified by the control team.", [["prescriptions", "TREATMENT", 22, 35]]], ["As compared to the OA, prescriptions in the IA were significantly more appropriate with regard to treatment duration (73 vs 55%, p = 0.009) and serum monitoring (61 vs 40%, p = 0.05).", [["serum", "ANATOMY", 144, 149], ["OA", "DISEASE", 19, 21], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["p", "TEST", 129, 130], ["serum monitoring", "TEST", 144, 160], ["vs", "TEST", 165, 167], ["p", "TEST", 173, 174]]], ["Median treatment duration was shorter in the IA (4 d) than in the OA (6 d) (p < 0.0001).", [["OA", "DISEASE", 66, 68], ["Median treatment duration", "TREATMENT", 0, 25], ["OA", "ANATOMY", 66, 68]]], ["A logistic regression model showed that risk factors for appropriate treatment duration were (adjusted OR, 95% CI, p value): hospitalization in intensive care unit (4.39, 1.57-12.2, 0.005) , polymicrobial infection (4.08, 1.38-12.08, 0.01) and antibiotic control team intervention (2.41, 1.23-4.72, 0.01) .", [["polymicrobial infection", "DISEASE", 191, 214], ["A logistic regression model", "TEST", 0, 27], ["polymicrobial infection", "PROBLEM", 191, 214], ["antibiotic control team intervention", "TREATMENT", 244, 280], ["polymicrobial", "OBSERVATION_MODIFIER", 191, 204], ["infection", "OBSERVATION", 205, 214]]], ["Table: Conclusions: Despite a restricted delivery system, AG use was frequently associated with excessive treatment duration and errors in monitoring modalities.", [["AG", "CHEMICAL", 58, 60], ["AG", "SIMPLE_CHEMICAL", 58, 60], ["a restricted delivery system", "TREATMENT", 28, 56], ["excessive treatment duration", "PROBLEM", 96, 124], ["errors in monitoring modalities", "PROBLEM", 129, 160]]], ["Reinforcing practice guidelines through direct counselling improved appropriateness of prescriptions.P1482Hospital antibiotic consumption in southern and eastern mediterranean countries: preliminary results from the ARMed project P. Zarb, M.A. Borg, H. Goossens, M. Ferech for the ARMed Participants Introduction: ARMed is an international research project investigating antimicrobial resistance and consumption in 7 southern and eastern Mediterranean countries through the collection of comparable and validated antimicrobial resistance data as well as information about antibiotic consumption patterns and infection control initiatives.", [["P1482Hospital", "CHEMICAL", 101, 114], ["infection", "DISEASE", 608, 617], ["Participants", "SPECIES", 287, 299], ["practice guidelines", "TREATMENT", 12, 31], ["P1482Hospital antibiotic consumption", "TREATMENT", 101, 137], ["antimicrobial resistance", "TREATMENT", 371, 395], ["antimicrobial resistance data", "TREATMENT", 513, 542], ["antibiotic consumption patterns", "TREATMENT", 572, 603], ["infection control initiatives", "TREATMENT", 608, 637], ["antimicrobial resistance", "OBSERVATION", 371, 395]]], ["Objectives: The consumption part of the study aims to collect data on antimicrobial use within participating hospitals in the region, which information is currently unavailable.", [["the study", "TEST", 36, 45], ["antimicrobial use", "TREATMENT", 70, 87]]], ["Methods: Data collection is planned over a 24-month period using Anatomical Therapeutic Chemical (ATC) classification, a validated methodology adopted by the European Surveillance of Antimicrobial Consumption (ESAC -www.ua.ac.be/esac).", [["Anatomical Therapeutic Chemical (ATC)", "TREATMENT", 65, 102], ["Antimicrobial Consumption", "TREATMENT", 183, 208]]], ["Results: Data from 2004, the first year of data collection, indicates that Turkish hospitals seem to show the lowest overall consumption [230-480 DDD/1000Bed Days], whilst the Cypriot hospitals show highest values [2900-7500 DDD/ 1000Bed Days].", [["data collection", "TEST", 43, 58]]], ["The most common antibiotics used are the beta-lactams, especially the penicillins although in Jordan and Turkey cephalosporin consumption is very close to the penicillins.", [["beta-lactams", "CHEMICAL", 41, 53], ["penicillins", "CHEMICAL", 70, 81], ["cephalosporin", "CHEMICAL", 112, 125], ["penicillins", "CHEMICAL", 159, 170], ["penicillins", "CHEMICAL", 70, 81], ["cephalosporin", "CHEMICAL", 112, 125], ["penicillins", "CHEMICAL", 159, 170], ["beta-lactams", "SIMPLE_CHEMICAL", 41, 53], ["penicillins", "SIMPLE_CHEMICAL", 70, 81], ["cephalosporin", "SIMPLE_CHEMICAL", 112, 125], ["penicillins", "SIMPLE_CHEMICAL", 159, 170], ["The most common antibiotics", "TREATMENT", 0, 27], ["the beta-lactams", "TEST", 37, 53], ["the penicillins", "TREATMENT", 66, 81], ["Turkey cephalosporin consumption", "TREATMENT", 105, 137], ["the penicillins", "TREATMENT", 155, 170]]], ["Broad-spectrum penicillins [J01CA] are the mostly utilised penicillins in Cyprus, Jordan and Tunisia whereas in Malta and Turkey the combination penicillins [J01CR] are the most widely used.", [["penicillins", "CHEMICAL", 15, 26], ["J01CA", "CHEMICAL", 28, 33], ["penicillins", "CHEMICAL", 59, 70], ["penicillins", "CHEMICAL", 145, 156], ["J01CR", "CHEMICAL", 158, 163], ["penicillins", "CHEMICAL", 15, 26], ["J01CA", "CHEMICAL", 28, 33], ["penicillins", "CHEMICAL", 59, 70], ["penicillins", "CHEMICAL", 145, 156], ["J01CR", "CHEMICAL", 158, 163], ["Broad-spectrum penicillins", "SIMPLE_CHEMICAL", 0, 26], ["J01CA", "SIMPLE_CHEMICAL", 28, 33], ["penicillins", "SIMPLE_CHEMICAL", 59, 70], ["penicillins", "SIMPLE_CHEMICAL", 145, 156], ["Broad-spectrum penicillins [J01CA]", "TREATMENT", 0, 34], ["penicillins", "TREATMENT", 59, 70], ["penicillins [J01CR]", "TREATMENT", 145, 164]]], ["There is more variability where cephalosporin consumption is concerned.", [["cephalosporin", "CHEMICAL", 32, 45], ["cephalosporin", "CHEMICAL", 32, 45], ["cephalosporin", "SIMPLE_CHEMICAL", 32, 45], ["cephalosporin consumption", "PROBLEM", 32, 57], ["more", "OBSERVATION_MODIFIER", 9, 13], ["variability", "OBSERVATION_MODIFIER", 14, 25], ["cephalosporin consumption", "OBSERVATION", 32, 57]]], ["In Egypt, Tunisia and Turkey there is significant variability between hospitals; nevertheless use of third generation cephalosporins appears to be significant.", [["cephalosporins", "CHEMICAL", 118, 132], ["cephalosporins", "CHEMICAL", 118, 132], ["cephalosporins", "SIMPLE_CHEMICAL", 118, 132], ["third generation cephalosporins", "TREATMENT", 101, 132], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["variability", "OBSERVATION_MODIFIER", 50, 61]]], ["Conclusion: A significant variability was evident between countries.", [["A significant variability", "PROBLEM", 12, 37], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["variability", "OBSERVATION", 26, 37]]], ["This is likely to be multifactorial depending on the antibiotics licensed in a country, the national and/or hospital formulary, the type of hospital as well as any antibiotic donations that are relevant in some of the study hospitals.", [["the antibiotics", "TREATMENT", 49, 64], ["any antibiotic donations", "TREATMENT", 160, 184], ["likely to be", "UNCERTAINTY", 8, 20], ["multifactorial", "OBSERVATION", 21, 35]]], ["Furthermore, the region as a whole seems to utilise a considerable quantity of broad-spectrum antimicrobials.", [["broad-spectrum antimicrobials", "TREATMENT", 79, 108]]], ["This can be a factor in the high prevalence of resistance already documented in the study.P1483Russian pharmacoepidemiology study of the antibiotic prescription during pregnancy Results: Mean age of the patients was 25.6 \u00b1 6.0 (min -14, max -52) years, mean gestational ages at admission to hospital was 27.", [["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["the study", "TEST", 80, 89], ["the antibiotic prescription", "TREATMENT", 133, 160], ["max", "TEST", 237, 240]]], ["Most often (77.5%) infection was community acquired and 2.1% -nosocomial, in 20% patients there was not to estimate origin of the infection.", [["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 130, 139], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["infection", "PROBLEM", 19, 28], ["nosocomial", "PROBLEM", 62, 72], ["the infection", "PROBLEM", 126, 139], ["infection", "OBSERVATION", 130, 139]]], ["The most prevalent infections during pregnancy in Russia was urinary tract infections -39.9%, STD -19.3%, candidiasis -17.4%, RTI -6.6% Therefore the most interest was analysing the antibiotic prescription for UTI in pregnancy (table) .", [["urinary tract", "ANATOMY", 61, 74], ["infections", "DISEASE", 19, 29], ["urinary tract infections", "DISEASE", 61, 85], ["STD", "DISEASE", 94, 97], ["candidiasis", "DISEASE", 106, 117], ["UTI", "DISEASE", 210, 213], ["urinary tract", "ORGANISM_SUBDIVISION", 61, 74], ["The most prevalent infections", "PROBLEM", 0, 29], ["urinary tract infections", "TEST", 61, 85], ["STD", "TEST", 94, 97], ["candidiasis", "TEST", 106, 117], ["RTI", "TEST", 126, 129], ["the antibiotic prescription", "TREATMENT", 178, 205], ["UTI in pregnancy", "PROBLEM", 210, 226], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["infections", "OBSERVATION", 19, 29], ["urinary tract", "ANATOMY", 61, 74]]], ["In 28% cases were used topical (intravaginal) antimicrobial administration.", [["topical (intravaginal) antimicrobial administration", "TREATMENT", 23, 74]]], ["Most often of topically administrated antimicrobials (19.02% of all prescriptions) were prescribed combined drugs included antibacterials and amtimycotics.", [["amtimycotics", "DISEASE", 142, 154], ["amtimycotics", "SIMPLE_CHEMICAL", 142, 154], ["topically administrated antimicrobials", "TREATMENT", 14, 52], ["all prescriptions", "TREATMENT", 64, 81], ["combined drugs", "TREATMENT", 99, 113], ["antibacterials", "TREATMENT", 123, 137], ["amtimycotics", "TREATMENT", 142, 154]]], ["In 80.98% cases antimicrobials were prescribed systemically.", [["antimicrobials", "TREATMENT", 16, 30]]], ["Mostly prescribed antimicrobials were beta-lactams (16.2% for outpatients and 57.7% for inpatients), ampicillin was prescribed more often (4.6% for outpatients and 31.5% for inpatients).", [["beta-lactams", "CHEMICAL", 38, 50], ["ampicillin", "CHEMICAL", 101, 111], ["ampicillin", "CHEMICAL", 101, 111], ["ampicillin", "SIMPLE_CHEMICAL", 101, 111], ["antimicrobials", "TREATMENT", 18, 32], ["beta-lactams", "TREATMENT", 38, 50], ["ampicillin", "TREATMENT", 101, 111]]], ["Amoxicillin + clavulanic acid was prescribed in 6.4% of outpatients and 5.6% inpatients pregnant women with UTI.", [["Amoxicillin + clavulanic acid", "CHEMICAL", 0, 29], ["UTI", "DISEASE", 108, 111], ["Amoxicillin", "CHEMICAL", 0, 11], ["clavulanic acid", "CHEMICAL", 14, 29], ["Amoxicillin + clavulanic acid", "SIMPLE_CHEMICAL", 0, 29], ["outpatients", "ORGANISM", 56, 67], ["women", "ORGANISM", 97, 102], ["outpatients", "SPECIES", 56, 67], ["women", "SPECIES", 97, 102], ["Amoxicillin", "TREATMENT", 0, 11], ["clavulanic acid", "TREATMENT", 14, 29], ["UTI", "PROBLEM", 108, 111], ["UTI", "OBSERVATION", 108, 111]]], ["Cephalosporins were prescribed in 5.2% and 20.6% for outpatient and inpatient UTI (mainly III-and Ist generations).", [["Cephalosporins", "CHEMICAL", 0, 14], ["UTI", "DISEASE", 78, 81], ["Cephalosporins", "CHEMICAL", 0, 14], ["Cephalosporins", "SIMPLE_CHEMICAL", 0, 14], ["Cephalosporins", "TREATMENT", 0, 14], ["inpatient UTI", "PROBLEM", 68, 81], ["III-and Ist generations", "TREATMENT", 90, 113], ["UTI", "OBSERVATION", 78, 81]]], ["Mitroimidazoles -1.8-7.4% (in general metronidasole), nitro-furanes -8.", [["Mitroimidazoles", "CHEMICAL", 0, 15], ["metronidasole", "CHEMICAL", 38, 51], ["nitro-furanes -8", "CHEMICAL", 54, 70], ["Mitroimidazoles", "CHEMICAL", 0, 15], ["metronidasole", "CHEMICAL", 38, 51], ["nitro-furanes -8", "CHEMICAL", 54, 70], ["Mitroimidazoles", "SIMPLE_CHEMICAL", 0, 15], ["metronidasole", "SIMPLE_CHEMICAL", 38, 51], ["nitro-furanes -8", "SIMPLE_CHEMICAL", 54, 70], ["Mitroimidazoles", "TREATMENT", 0, 15], ["general metronidasole)", "TREATMENT", 30, 52], ["nitro-furanes", "TREATMENT", 54, 67]]], ["[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .0%, aminolglycosides -4.6-3.8% were prescribed quite often but unjustified.", [["[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]", "CHEMICAL", 0, 56], ["aminolglycosides", "CHEMICAL", 67, 83], ["aminolglycosides", "CHEMICAL", 67, 83], ["[2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .0", "SIMPLE_CHEMICAL", 0, 64], ["aminolglycosides", "SIMPLE_CHEMICAL", 67, 83], ["3] [4] [5] [6] [7] [8] [9] [10] [11", "TEST", 5, 40], ["aminolglycosides", "TEST", 67, 83]]], ["Other antimicrobials (fluoroquinolones, doxicicline, antiviral drugs, antifungals) were prescribed relatively rarely.", [["fluoroquinolones", "CHEMICAL", 22, 38], ["doxicicline", "CHEMICAL", 40, 51], ["fluoroquinolones", "CHEMICAL", 22, 38], ["doxicicline", "CHEMICAL", 40, 51], ["fluoroquinolones", "SIMPLE_CHEMICAL", 22, 38], ["doxicicline", "SIMPLE_CHEMICAL", 40, 51], ["Other antimicrobials", "TREATMENT", 0, 20], ["fluoroquinolones", "TREATMENT", 22, 38], ["doxicicline", "TREATMENT", 40, 51], ["antiviral drugs", "TREATMENT", 53, 68], ["antifungals", "TREATMENT", 70, 81]]], ["Despite the fact that most prescribed drugs were class B by FDA, 5.8% all antimicrobials prescribed to pregnancy were class C, 0.8% class D and 9.1% were unclassified.P1483Conclusions: Most often prescribed antimicrobials for UTI (the most prevalent infections during pregnancy in Russia) are betalactams and combined topical antibacterials.", [["UTI", "DISEASE", 226, 229], ["infections", "DISEASE", 250, 260], ["betalactams", "CHEMICAL", 293, 304], ["betalactams", "CHEMICAL", 293, 304], ["betalactams", "SIMPLE_CHEMICAL", 293, 304], ["all antimicrobials", "TREATMENT", 70, 88], ["C", "TEST", 124, 125], ["antimicrobials", "TREATMENT", 207, 221], ["UTI", "PROBLEM", 226, 229], ["betalactams", "TREATMENT", 293, 304], ["combined topical antibacterials", "TREATMENT", 309, 340], ["UTI", "OBSERVATION", 226, 229]]], ["In 15.7% cases were prescribed antimicrobials of class C, D or unclassified by FDA.", [["D", "SIMPLE_CHEMICAL", 58, 59], ["antimicrobials", "TREATMENT", 31, 45]]], ["In 25% outpatient and 53.6% inpatient were used antibiotics with low in vitro activity for uropathogens.", [["antibiotics", "TREATMENT", 48, 59], ["uropathogens", "PROBLEM", 91, 103]]], ["Objectives: To study the dynamics of the antibiotic usage in children from orphanages located in different Russian cities as the result of interventions with the increased use of the most active antimicrobials and restrictions on use of the least active.", [["children", "ORGANISM", 61, 69], ["children", "SPECIES", 61, 69], ["the antibiotic usage", "TREATMENT", 37, 57], ["interventions", "TREATMENT", 139, 152], ["the most active antimicrobials", "TREATMENT", 179, 209]]], ["Methods: The study was performed in 12 orphanages (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) from 5 cities of European Russia (Moscow, Saint-Petersburg, Smolensk, Karachev, Bryansk) .", [["The study", "TEST", 9, 18]]], ["Use of antimicrobials during the previous 12 months was analysed upon reviews of medical records of 743 children <7 years in 2003.", [["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112], ["antimicrobials", "TREATMENT", 7, 21]]], ["Appropriate recommendations on predominant use of selected beta-lactams (e.g. amoxicillin/clavulanate -AMC) with restriction of antimicrobials of other classes (e.g. co-trimoxazole -SXT) were made where applicable on the basis of the expert analysis of antibiotic usage and pneumococcal nasopharyngeal resistance rates.", [["nasopharyngeal", "ANATOMY", 287, 301], ["beta-lactams", "CHEMICAL", 59, 71], ["amoxicillin/clavulanate -AMC", "CHEMICAL", 78, 106], ["co-trimoxazole -SXT", "CHEMICAL", 166, 185], ["amoxicillin", "CHEMICAL", 78, 89], ["clavulanate -AMC", "CHEMICAL", 90, 106], ["co-trimoxazole -SXT", "CHEMICAL", 166, 185], ["beta-lactams", "SIMPLE_CHEMICAL", 59, 71], ["amoxicillin", "SIMPLE_CHEMICAL", 78, 89], ["clavulanate", "SIMPLE_CHEMICAL", 90, 101], ["co-trimoxazole -SXT", "SIMPLE_CHEMICAL", 166, 185], ["nasopharyngeal", "ORGAN", 287, 301], ["pneumococcal", "SPECIES", 274, 286], ["selected beta-lactams", "TREATMENT", 50, 71], ["amoxicillin", "TREATMENT", 78, 89], ["clavulanate", "TREATMENT", 90, 101], ["antimicrobials", "TREATMENT", 128, 142], ["co-trimoxazole -SXT", "TREATMENT", 166, 185], ["antibiotic usage", "TREATMENT", 253, 269], ["pneumococcal nasopharyngeal resistance rates", "TREATMENT", 274, 318], ["nasopharyngeal resistance", "OBSERVATION", 287, 312]]], ["Repeated antibiotic usage analysis was performed 7 months later in 2004 upon reviews of medical records of 752 children <7 years.", [["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119], ["Repeated antibiotic usage analysis", "TEST", 0, 34]]], ["Results: Total usage of antimicrobials increased 1. increase of resistance to PEN and aminopenicillins.", [["PEN", "CHEMICAL", 78, 81], ["aminopenicillins", "CHEMICAL", 86, 102], ["PEN", "CHEMICAL", 78, 81], ["aminopenicillins", "CHEMICAL", 86, 102], ["PEN", "SIMPLE_CHEMICAL", 78, 81], ["aminopenicillins", "SIMPLE_CHEMICAL", 86, 102], ["Total usage of antimicrobials", "TREATMENT", 9, 38], ["PEN", "TREATMENT", 78, 81], ["aminopenicillins", "TREATMENT", 86, 102], ["resistance", "OBSERVATION", 64, 74]]], ["Enhanced use of cephalosporins led to increase of resistance to these drugs.", [["cephalosporins", "CHEMICAL", 16, 30], ["cephalosporins", "CHEMICAL", 16, 30], ["cephalosporins", "SIMPLE_CHEMICAL", 16, 30], ["cephalosporins", "TREATMENT", 16, 30], ["these drugs", "TREATMENT", 64, 75]]], ["In spite of recommendations to restrict usage of AM/OX, aminoglycosides and SXT, the analysis showed that these antimicrobials still accounted for 13.2%, 7.8% and 7.5% of all prescriptions, respectively, thus dictating the need for further enforcement measures.P1485Antibiotic consumption in ambulatory care in Latvia, 2004 S. Berzina, M. Ferech, G. Ozolins, H. Goosens (Riga, LV; Antwerp, BE) Objectives: To collect data on antibiotic consumption in ambulatory care (AC) in Latvia according to the ESAC data collection protocol.", [["AM", "CHEMICAL", 49, 51], ["OX", "CHEMICAL", 52, 54], ["aminoglycosides", "CHEMICAL", 56, 71], ["SXT", "CHEMICAL", 76, 79], ["aminoglycosides", "CHEMICAL", 56, 71], ["SXT", "CHEMICAL", 76, 79], ["AM", "SIMPLE_CHEMICAL", 49, 51], ["OX", "SIMPLE_CHEMICAL", 52, 54], ["aminoglycosides", "SIMPLE_CHEMICAL", 56, 71], ["SXT", "SIMPLE_CHEMICAL", 76, 79], ["P1485Antibiotic", "SIMPLE_CHEMICAL", 261, 276], ["AM/OX", "TREATMENT", 49, 54], ["aminoglycosides", "TREATMENT", 56, 71], ["SXT", "TREATMENT", 76, 79], ["the analysis", "TEST", 81, 93], ["these antimicrobials", "TEST", 106, 126], ["further enforcement measures", "TREATMENT", 232, 260], ["antibiotic consumption", "TREATMENT", 425, 447], ["ambulatory care (AC)", "TREATMENT", 451, 471], ["LV", "ANATOMY", 377, 379]]], ["ESAC (European Surveillance of Antimicrobial Consumption, granted by DG SANCO of the EC) is an international network of national surveillance systems, aiming to collect reliable and comparable data on antibiotic consumption in Europe.", [["ESAC", "CHEMICAL", 0, 4], ["EC", "CELL", 85, 87], ["Antimicrobial Consumption", "TREATMENT", 31, 56], ["antibiotic consumption", "TREATMENT", 201, 223]]], ["Methods: The data on AC antibiotic consumption for 2004 have been collected using ATC/DDD classification (WHO, version 2005) and expressed in Defined Daily Doses per 1000 inhabitants per day (DID).", [["AC antibiotic consumption", "TREATMENT", 21, 46], ["ATC/DDD classification", "TREATMENT", 82, 104]]], ["Data were obtained from the State Medicinal Agencybased on the reports of the wholesalers for AC.", [["AC", "TREATMENT", 94, 96]]], ["Results: The overall use of antibiotics in AC was 11.7 DID in 2004, which positions Latvia to countries with comparatively low antibiotic consumption in Europe.", [["antibiotics in AC", "TREATMENT", 28, 45], ["comparatively low antibiotic consumption", "TREATMENT", 109, 149]]], ["The mostly used class of antibiotics in AC were penicillins with extended spectrum (mainly amoxicillin) -3.97 DID (33.9%).", [["AC", "CHEMICAL", 40, 42], ["penicillins", "CHEMICAL", 48, 59], ["amoxicillin", "CHEMICAL", 91, 102], ["penicillins", "CHEMICAL", 48, 59], ["amoxicillin", "CHEMICAL", 91, 102], ["AC", "SIMPLE_CHEMICAL", 40, 42], ["penicillins", "SIMPLE_CHEMICAL", 48, 59], ["amoxicillin", "SIMPLE_CHEMICAL", 91, 102], ["antibiotics in AC", "TREATMENT", 25, 42], ["penicillins", "TREATMENT", 48, 59], ["extended spectrum (mainly amoxicillin", "TREATMENT", 65, 102]]], ["Other frequently used antibiotics were tetracyclines (mainly doxycycline), representing 2.41 DID (20.6%), combinations of penicillins/with betalactamase inhibitors (essentially co-amoxiclav) -1.18 DID (10.1%), macrolides (mainly clarithromycin) 0.85 DID (7.26%), fluoroquinolones (essentially ciprofloxacin) -0.84 DID (7.17%) and combinations of sulphonamides and trimethroprim, incl.derivatives -1.02 DID (8.71%).", [["tetracyclines", "CHEMICAL", 39, 52], ["doxycycline", "CHEMICAL", 61, 72], ["penicillins", "CHEMICAL", 122, 133], ["betalactamase", "CHEMICAL", 139, 152], ["co-amoxiclav", "CHEMICAL", 177, 189], ["macrolides", "CHEMICAL", 210, 220], ["clarithromycin", "CHEMICAL", 229, 243], ["DID", "CHEMICAL", 250, 253], ["fluoroquinolones", "CHEMICAL", 263, 279], ["ciprofloxacin", "CHEMICAL", 293, 306], ["sulphonamides", "CHEMICAL", 346, 359], ["trimethroprim", "CHEMICAL", 364, 377], ["tetracyclines", "CHEMICAL", 39, 52], ["doxycycline", "CHEMICAL", 61, 72], ["penicillins", "CHEMICAL", 122, 133], ["macrolides", "CHEMICAL", 210, 220], ["clarithromycin", "CHEMICAL", 229, 243], ["fluoroquinolones", "CHEMICAL", 263, 279], ["ciprofloxacin", "CHEMICAL", 293, 306], ["sulphonamides", "CHEMICAL", 346, 359], ["trimethroprim", "CHEMICAL", 364, 377], ["tetracyclines", "SIMPLE_CHEMICAL", 39, 52], ["doxycycline", "SIMPLE_CHEMICAL", 61, 72], ["penicillins", "SIMPLE_CHEMICAL", 122, 133], ["betalactamase inhibitors", "SIMPLE_CHEMICAL", 139, 163], ["co-amoxiclav", "SIMPLE_CHEMICAL", 177, 189], ["macrolides", "SIMPLE_CHEMICAL", 210, 220], ["clarithromycin", "SIMPLE_CHEMICAL", 229, 243], ["fluoroquinolones", "SIMPLE_CHEMICAL", 263, 279], ["ciprofloxacin", "SIMPLE_CHEMICAL", 293, 306], ["sulphonamides", "SIMPLE_CHEMICAL", 346, 359], ["trimethroprim", "SIMPLE_CHEMICAL", 364, 377], ["antibiotics", "TREATMENT", 22, 33], ["tetracyclines", "TREATMENT", 39, 52], ["doxycycline", "TREATMENT", 61, 72], ["penicillins", "TREATMENT", 122, 133], ["betalactamase inhibitors", "TREATMENT", 139, 163], ["essentially co-amoxiclav", "TREATMENT", 165, 189], ["macrolides (mainly clarithromycin)", "TREATMENT", 210, 244], ["fluoroquinolones", "TREATMENT", 263, 279], ["ciprofloxacin", "TREATMENT", 293, 306], ["sulphonamides", "TREATMENT", 346, 359], ["trimethroprim", "TREATMENT", 364, 377], ["incl", "TREATMENT", 379, 383], ["derivatives", "TEST", 384, 395]]], ["The most frequently used antibiotics in AC in Latvia, in 2004, were amoxicillin (3.97 DID) , doxycycline (2.41 DID) , and co-amoxiclav (1.18 DID) .", [["AC", "CHEMICAL", 40, 42], ["amoxicillin", "CHEMICAL", 68, 79], ["doxycycline", "CHEMICAL", 93, 104], ["co-amoxiclav", "CHEMICAL", 122, 134], ["amoxicillin", "CHEMICAL", 68, 79], ["doxycycline", "CHEMICAL", 93, 104], ["co-amoxiclav", "CHEMICAL", 122, 134], ["amoxicillin", "SIMPLE_CHEMICAL", 68, 79], ["doxycycline", "SIMPLE_CHEMICAL", 93, 104], ["co-amoxiclav", "SIMPLE_CHEMICAL", 122, 134], ["antibiotics in AC", "TREATMENT", 25, 42], ["amoxicillin", "TREATMENT", 68, 79], ["doxycycline", "TREATMENT", 93, 104], ["co-amoxiclav", "TREATMENT", 122, 134]]], ["Conclusions: Valid data on outpatient antibiotic use in Latvia has been for the first time collected and delivered to European Surveillance of Antimicrobial Consumption.", [["outpatient antibiotic use", "TREATMENT", 27, 52], ["Antimicrobial Consumption", "TREATMENT", 143, 168], ["Antimicrobial Consumption", "OBSERVATION", 143, 168]]], ["This allows international comparison of the pattern of antibiotic consumption in Latvia with other European countries.P1486Trends in glycopeptide antibiotics consumption over a 6-year period in a general hospital, Athens, Greece Introduction: Glycopeptide use is under restriction in Hellenic hospitals since late '80s.", [["Glycopeptide", "CHEMICAL", 243, 255], ["antibiotic consumption", "TREATMENT", 55, 77], ["glycopeptide antibiotics consumption", "TREATMENT", 133, 169], ["Glycopeptide use", "TREATMENT", 243, 259]]], ["The aim of our study was to record trends in their consumption over the last 6 years in our Hospital (''A. Fleming'' General Hospital -300 beds) and to correlate these data with the numbers of important Gram (+) strains isolated in our hospital during the same time period.", [["Gram", "GENE_OR_GENE_PRODUCT", 203, 207], ["our study", "TEST", 11, 20], ["strains", "PROBLEM", 212, 219]]], ["Methods: We measured glycopeptide use for the period 1999-2004 by using data from the pharmacy computer.", [["glycopeptide use", "TREATMENT", 21, 37]]], ["Consumption was expressed as DDDs/1000 patient days (ABC calc 3.0).", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["ABC calc", "TEST", 53, 61]]], ["Furthermore we correlated these data with data from the microbiology department concerning numbers of MRSA, MRSE and enterococci isolated during the same period.", [["MRSA", "SPECIES", 102, 106], ["MRSA", "SPECIES", 102, 106], ["MRSE", "SPECIES", 108, 112], ["MRSA", "PROBLEM", 102, 106], ["MRSE", "PROBLEM", 108, 112], ["enterococci", "PROBLEM", 117, 128], ["MRSA", "OBSERVATION", 102, 106]]], ["Results: Glycopeptide consumption was 1.3, 6.1, 6.3, 7.9, 4.5 and 13 DDDs/1000 patient days for the years 1999, 2000, 2001, 2002, 2003, 2004 (900% increase) .", [["Glycopeptide", "CHEMICAL", 9, 21], ["Glycopeptide", "CHEMICAL", 9, 21], ["Glycopeptide", "SIMPLE_CHEMICAL", 9, 21], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["Glycopeptide consumption", "TEST", 9, 33]]], ["At the same time the cumulative number of MRSA, MRSE and enterococci isolated were 175, 224, 207, 415, 338, 479 respectively (170% increase) .", [["MRSA", "DISEASE", 42, 46], ["MRSA", "SPECIES", 42, 46], ["MRSA", "SPECIES", 42, 46], ["MRSE", "SPECIES", 48, 52], ["MRSA", "PROBLEM", 42, 46], ["MRSE", "TEST", 48, 52], ["enterococci", "TEST", 57, 68], ["MRSA", "OBSERVATION", 42, 46]]], ["When both types of data were put on the same graph, glycopeptide consumption correlated well with the number of important Gram(+) strains isolated (figure).", [["Gram(+)", "GENE_OR_GENE_PRODUCT", 122, 129], ["glycopeptide consumption", "TREATMENT", 52, 76], ["important Gram", "TEST", 112, 126], ["strains", "PROBLEM", 130, 137]]], ["Furthermore VRE percentage among enterococci was 0, 0, 3.0, 0.6, 3.5, 1 for the study years respectively.", [["Furthermore VRE percentage", "TEST", 0, 26], ["enterococci", "TEST", 33, 44], ["the study", "TEST", 76, 85], ["enterococci", "OBSERVATION", 33, 44]]], ["It is worth noting that 87% of our MRSA strains were sensitive to rifampin, 83% to clindamycin, 74% to cotrimoxazole, 80% to clindamycin + rifampin and 74% to cotrimoxazole + rifampin.", [["MRSA", "DISEASE", 35, 39], ["rifampin", "CHEMICAL", 66, 74], ["clindamycin", "CHEMICAL", 83, 94], ["cotrimoxazole", "CHEMICAL", 103, 116], ["clindamycin", "CHEMICAL", 125, 136], ["rifampin", "CHEMICAL", 139, 147], ["cotrimoxazole", "CHEMICAL", 159, 172], ["rifampin", "CHEMICAL", 175, 183], ["rifampin", "CHEMICAL", 66, 74], ["clindamycin", "CHEMICAL", 83, 94], ["cotrimoxazole", "CHEMICAL", 103, 116], ["clindamycin", "CHEMICAL", 125, 136], ["rifampin", "CHEMICAL", 139, 147], ["cotrimoxazole", "CHEMICAL", 159, 172], ["rifampin", "CHEMICAL", 175, 183], ["rifampin", "SIMPLE_CHEMICAL", 66, 74], ["clindamycin", "SIMPLE_CHEMICAL", 83, 94], ["cotrimoxazole", "SIMPLE_CHEMICAL", 103, 116], ["clindamycin", "SIMPLE_CHEMICAL", 125, 136], ["rifampin", "SIMPLE_CHEMICAL", 139, 147], ["cotrimoxazole", "SIMPLE_CHEMICAL", 159, 172], ["rifampin", "SIMPLE_CHEMICAL", 175, 183], ["MRSA", "SPECIES", 35, 39], ["MRSA", "SPECIES", 35, 39], ["our MRSA strains", "PROBLEM", 31, 47], ["rifampin", "TREATMENT", 66, 74], ["clindamycin", "TREATMENT", 83, 94], ["cotrimoxazole", "TREATMENT", 103, 116], ["clindamycin", "TREATMENT", 125, 136], ["rifampin", "TREATMENT", 139, 147], ["cotrimoxazole", "TREATMENT", 159, 172], ["rifampin", "TREATMENT", 175, 183]]], ["Linezolid has not been introduced in our hospital yet.", [["Linezolid", "CHEMICAL", 0, 9], ["Linezolid", "CHEMICAL", 0, 9], ["Linezolid", "SIMPLE_CHEMICAL", 0, 9], ["Linezolid", "TREATMENT", 0, 9]]], ["Conclusions: (A) Despite the restriction policy, a tremendous increase in glycopeptide use was recorded in our hospital during the study period and this correlated to the number of the important Gram(+) strains isolated; (B) Nevertheless, VRE is not a significant problem for our hospital yet; and C. The huge increase in glycopeptide use could be avoided at least in part, since other, older and simpler antibiotics could substitute for glycopeptides in many cases.P1487An audit of linezolid use in a university teaching hospital, Galway, Ireland Objective: To audit linezolid use over a six-month period among the in-patient population of a 504-bed teaching hospital that includes most medical and surgical specialties with the exception of nephrology, rheumatology and orthopaedics.", [["VRE", "DISEASE", 239, 242], ["linezolid", "CHEMICAL", 483, 492], ["linezolid", "CHEMICAL", 568, 577], ["linezolid", "CHEMICAL", 483, 492], ["linezolid", "CHEMICAL", 568, 577], ["Gram", "GENE_OR_GENE_PRODUCT", 195, 199], ["linezolid", "SIMPLE_CHEMICAL", 483, 492], ["linezolid", "SIMPLE_CHEMICAL", 568, 577], ["patient", "ORGANISM", 619, 626], ["patient", "SPECIES", 619, 626], ["the restriction policy", "TREATMENT", 25, 47], ["glycopeptide use", "TREATMENT", 74, 90], ["the study", "TEST", 127, 136], ["strains", "PROBLEM", 203, 210], ["VRE", "PROBLEM", 239, 242], ["glycopeptide use", "TREATMENT", 322, 338], ["simpler antibiotics", "TREATMENT", 397, 416], ["glycopeptides", "TREATMENT", 438, 451], ["linezolid", "TREATMENT", 483, 492], ["audit linezolid", "TREATMENT", 562, 577], ["tremendous", "OBSERVATION_MODIFIER", 51, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["huge", "OBSERVATION_MODIFIER", 305, 309], ["increase", "OBSERVATION_MODIFIER", 310, 318]]], ["Methods: A prospective audit was carried out of the prescribing of linezolid to in-patients from October 2004 to April 2005.", [["linezolid", "CHEMICAL", 67, 76], ["linezolid", "CHEMICAL", 67, 76], ["linezolid", "SIMPLE_CHEMICAL", 67, 76], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["linezolid", "TREATMENT", 67, 76]]], ["The ward pharmacist recorded the details of all patients who were prescribed linezolid.", [["linezolid", "CHEMICAL", 77, 86], ["linezolid", "CHEMICAL", 77, 86], ["patients", "ORGANISM", 48, 56], ["linezolid", "SIMPLE_CHEMICAL", 77, 86], ["patients", "SPECIES", 48, 56], ["linezolid", "TREATMENT", 77, 86]]], ["A chart review was performed to assess the profile of patients prescribed linezolid, clinical and microbiological indications for treatment, adherence to treatment guidelines and documented adverse events.", [["linezolid", "CHEMICAL", 74, 83], ["linezolid", "CHEMICAL", 74, 83], ["patients", "ORGANISM", 54, 62], ["linezolid", "SIMPLE_CHEMICAL", 74, 83], ["patients", "SPECIES", 54, 62], ["A chart review", "TEST", 0, 14], ["linezolid", "TREATMENT", 74, 83], ["treatment", "TREATMENT", 130, 139], ["treatment guidelines", "TREATMENT", 154, 174], ["documented adverse events", "PROBLEM", 179, 204]]], ["Results: Over the 6-month period 53 courses of linezolid were prescribed.", [["linezolid", "CHEMICAL", 47, 56], ["linezolid", "CHEMICAL", 47, 56], ["linezolid", "SIMPLE_CHEMICAL", 47, 56], ["linezolid", "TREATMENT", 47, 56]]], ["Fifty two percent of the patients for whom linezolid was prescribed were from surgical specialties; half of these patients were under the care of one surgeon.", [["linezolid", "CHEMICAL", 43, 52], ["linezolid", "CHEMICAL", 43, 52], ["patients", "ORGANISM", 25, 33], ["linezolid", "SIMPLE_CHEMICAL", 43, 52], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 114, 122], ["linezolid", "TREATMENT", 43, 52]]], ["Pneumonia was the clinical indication for use in 32% of cases and soft tissue infection in 36% of cases.", [["soft tissue", "ANATOMY", 66, 77], ["Pneumonia", "DISEASE", 0, 9], ["infection", "DISEASE", 78, 87], ["soft tissue", "TISSUE", 66, 77], ["Pneumonia", "PROBLEM", 0, 9], ["soft tissue infection", "PROBLEM", 66, 87], ["soft tissue", "OBSERVATION_MODIFIER", 66, 77], ["infection", "OBSERVATION", 78, 87]]], ["The microbiological indication was clear in 64% of cases where MRSA or VRE had been isolated.", [["MRSA", "CHEMICAL", 63, 67], ["VRE", "DISEASE", 71, 74], ["MRSA", "SPECIES", 63, 67], ["MRSA", "SPECIES", 63, 67], ["MRSA", "PROBLEM", 63, 67], ["VRE", "PROBLEM", 71, 74]]], ["In 36% of cases therapy was either (1) empiric with no significant organisms isolated prior to prescription of linezolid or (2) therapy was directed against an organism that could have been treated with an alternative agent.", [["linezolid", "CHEMICAL", 111, 120], ["linezolid", "CHEMICAL", 111, 120], ["linezolid", "SIMPLE_CHEMICAL", 111, 120], ["cases therapy", "TREATMENT", 10, 23], ["empiric", "TREATMENT", 39, 46], ["significant organisms", "PROBLEM", 55, 76], ["linezolid", "TREATMENT", 111, 120], ["therapy", "TREATMENT", 128, 135], ["an alternative agent", "TREATMENT", 203, 223]]], ["Duration of treatment exceeded 10 to 14 days in 40% of courses.", [["treatment", "TREATMENT", 12, 21]]], ["An adverse event was recorded in the case of only one course of linezolid.", [["linezolid", "CHEMICAL", 64, 73], ["linezolid", "CHEMICAL", 64, 73], ["linezolid", "SIMPLE_CHEMICAL", 64, 73], ["An adverse event", "PROBLEM", 0, 16], ["linezolid", "TREATMENT", 64, 73], ["adverse", "OBSERVATION_MODIFIER", 3, 10]]], ["Conclusion: In more than a third of cases linezolid use was prescribed without clear justification.", [["linezolid", "CHEMICAL", 42, 51], ["linezolid", "CHEMICAL", 42, 51], ["linezolid", "SIMPLE_CHEMICAL", 42, 51], ["cases linezolid use", "TREATMENT", 36, 55]]], ["Avoidable use of linezolid is associated with increased costs and risks of acquired resistance. participants prior to on an oral interview during which the interviewer filled in the answers.", [["oral", "ANATOMY", 124, 128], ["linezolid", "CHEMICAL", 17, 26], ["linezolid", "CHEMICAL", 17, 26], ["linezolid", "SIMPLE_CHEMICAL", 17, 26], ["oral", "ORGANISM_SUBDIVISION", 124, 128], ["participants", "SPECIES", 96, 108], ["linezolid", "TREATMENT", 17, 26], ["increased costs", "PROBLEM", 46, 61], ["acquired resistance", "PROBLEM", 75, 94], ["linezolid", "OBSERVATION", 17, 26]]], ["Results: A total of 62 CM specialists completed the inquiry.", [["CM", "DISEASE", 23, 25]]], ["This represents approximately 25% of the national quorum.", [["approximately", "OBSERVATION_MODIFIER", 16, 29], ["25%", "OBSERVATION_MODIFIER", 30, 33]]], ["Mean age was 48 years (32-63).", [["Mean age", "TEST", 0, 8]]], ["22 of the 62 interviewed CM specialists worked full-time with more full-time employment in hospital labs (HL).", [["CM", "DISEASE", 25, 27]]], ["Next to routine microbiology, other activities performed by CM specialists are mainly the other domains of clinical biology, hospital hygiene and to a lesser extent quality control and lab management.", [["CM", "DISEASE", 60, 62], ["routine microbiology", "TEST", 8, 28], ["a lesser extent quality control", "TREATMENT", 149, 180], ["lab management", "TREATMENT", 185, 199]]], ["Almost two thirds of the interviewed CM specialists believes that their training hasn't prepared them properly for the tasks they are performing now.", [["CM", "DISEASE", 37, 39]]], ["Most desired changes include more emphasis on the clinical aspect of infectious diseases and on antibiotic treatment counselling.", [["infectious diseases", "DISEASE", 69, 88], ["infectious diseases", "PROBLEM", 69, 88], ["antibiotic treatment counselling", "TREATMENT", 96, 128], ["infectious", "OBSERVATION", 69, 79]]], ["CM does not exist as a separate speciality in Belgium but is included in the 'clinical biology' speciality training.", [["CM", "DISEASE", 0, 2]]], ["The majority of the respondents thinks that CM should become a sub-speciality (still part of clinical biology) but with a specific minimal training that needs to be defined.", [["CM", "DISEASE", 44, 46], ["a specific minimal training", "TREATMENT", 120, 147], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The majority of the CM specialists also believes that CM can share lab infrastructure with other disciplines and that the essential aspect of CM lies predominantly in the medical expertise.", [["CM", "DISEASE", 20, 22], ["CM", "DISEASE", 54, 56], ["CM", "DISEASE", 142, 144], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["essential", "OBSERVATION_MODIFIER", 122, 131], ["CM", "OBSERVATION", 142, 144]]], ["Conclusion: CM training should put more emphasis on the clinical aspect of infectious diseases and on antibiotic treatment counselling.", [["CM", "DISEASE", 12, 14], ["infectious diseases", "DISEASE", 75, 94], ["CM training", "TREATMENT", 12, 23], ["infectious diseases", "PROBLEM", 75, 94], ["antibiotic treatment counselling", "TREATMENT", 102, 134], ["infectious", "OBSERVATION", 75, 85]]], ["The majority of the respondents feels that CM should become a sub-specialty (still part of clinical biology), with a well defined training curriculum.", [["CM", "DISEASE", 43, 45]]], ["Here we report on 1163 consultations of a fellow, conducted during 1 year, compared with 5708 consultations conducted by two veteran board-certified infectious disease consultants during the same period.", [["infectious disease", "DISEASE", 149, 167], ["infectious", "OBSERVATION", 149, 159]]], ["Methods: We analysed computerized consultation records, including demographic details of patients; referring department; initiative for, route and purpose of the consultation; and recommendations; and compared between the different consultants.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["Results: A larger percentage of veterans' compared to the fellow's consultations, were requested by attending physicians (72% vs. 50%, p < 0.001), while follow-up (15% vs. 23%, p < 0.001), laboratory results (11% vs. 23%, p < 0.001) or prescription for a restricted antimicrobial agent (1.3% vs. 3 .3%, p < 0.001) were more prevalent in fellow consultations.", [["p", "TEST", 177, 178], ["laboratory results", "TEST", 189, 207], ["p", "TEST", 222, 223], ["a restricted antimicrobial agent", "TREATMENT", 253, 285], ["larger", "OBSERVATION_MODIFIER", 11, 17]]], ["The fellow had a higher rate of additional consultations (in which the patient was seen more than once) (40% vs. 30%, p < 0.001), and performed more bedside consultations (68% vs. 47%, p < 0.001) or consultation by curb side discussion (25% vs. 13.2%, p < 0.001), and less consultations by telephone (6.6% vs. 40.1%, p < 0.001).", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78]]], ["Diagnosis and prophylaxis were more often the purposes of the veterans' consultations (44.8% vs. 36.1%, p < 0.001, 3.9% vs. 2.1%, p < 0.01, respectively), and they also offered new diagnoses more frequently (p < 0.005).", [["prophylaxis", "TREATMENT", 14, 25], ["p", "TEST", 104, 105], ["p", "TEST", 130, 131]]], ["The veteran consultants more often conducted consultation for communityacquired infections (53% vs. 44%, p < 0.001), and more often started antibiotic treatment (19% vs. 8 .9%, p < 0.001).P1487Conclusions: Significant differences were detected between consultations conducted during the first year of a fellow compared to those of veteran infectious disease consultants.", [["infections", "DISEASE", 80, 90], ["infectious disease", "DISEASE", 339, 357], ["communityacquired infections", "PROBLEM", 62, 90], ["antibiotic treatment", "TREATMENT", 140, 160], ["Significant", "OBSERVATION_MODIFIER", 206, 217]]], ["Periodic analysis of computerized data of consultations facilitates supervision as well as direction of consultants' work, addressing issues such as antibiotic use and patterns of microbial resistance.P1490Bridging the gap between health care and public health; capacity building in infectious disease control Objectives: In recent years, the European Union (EU) has developed and supported many activities in the field of communicable diseases.", [["P1490", "CHEMICAL", 201, 206], ["infectious disease", "DISEASE", 283, 301], ["communicable diseases", "DISEASE", 423, 444], ["antibiotic use", "TREATMENT", 149, 163], ["microbial resistance", "PROBLEM", 180, 200], ["communicable diseases", "PROBLEM", 423, 444], ["microbial resistance", "OBSERVATION", 180, 200], ["infectious", "OBSERVATION_MODIFIER", 283, 293]]], ["These activities not only concern surveillance networks of specific infectious diseases (e.g. Enter-net for Salmonella and Escherichia coli infections, EWGLI for Legionella infections, EISS for Influenza infections), but also EU training programmes like EPIET (European Programme for Intervention Epidemiology Training) and a EU communicable disease bulletin.", [["infectious diseases", "DISEASE", 68, 87], ["Escherichia coli infections", "DISEASE", 123, 150], ["EWGLI", "DISEASE", 152, 157], ["Legionella infections", "DISEASE", 162, 183], ["EISS", "DISEASE", 185, 189], ["Influenza infections", "DISEASE", 194, 214], ["communicable disease", "DISEASE", 329, 349], ["Escherichia coli", "ORGANISM", 123, 139], ["Escherichia coli", "SPECIES", 123, 139], ["Salmonella", "SPECIES", 108, 118], ["Escherichia coli", "SPECIES", 123, 139], ["specific infectious diseases", "PROBLEM", 59, 87], ["Salmonella", "PROBLEM", 108, 118], ["Escherichia coli infections", "PROBLEM", 123, 150], ["Legionella infections", "PROBLEM", 162, 183], ["Influenza infections", "PROBLEM", 194, 214], ["Intervention Epidemiology Training", "TREATMENT", 284, 318], ["a EU communicable disease bulletin", "PROBLEM", 324, 358], ["Escherichia coli", "OBSERVATION", 123, 139]]], ["Even more recent are the EU's initiative BICHAT to improve preparedness and response to bioterrorism, and the development of a EU CDC.", [["bioterrorism", "PROBLEM", 88, 100]]], ["Moreover, a major part of the new programme of Community action in the field of public health (PH) (2003) (2004) (2005) (2006) (2007) (2008) concerns ID, with not only a commitment to improve information and information exchange, but particularly to strengthen the international rapid response capacity.All this, to illustrate the importance of IDC on the EU agenda.", [["IDC", "CANCER", 345, 348], ["new", "OBSERVATION_MODIFIER", 30, 33], ["Community", "OBSERVATION_MODIFIER", 47, 56], ["response capacity", "OBSERVATION", 285, 302]]], ["In 2003 EUPHA has created an EUPHA section IDC bringing together EUPHA members with expertise in this field and representatives of the various above mentioned EU initiatives in order to: promote and strengthen research in the field of IDC; provide a platform for the exchange of information, experience and research in IDC; bring together researchers, PH practitioners and policymakers active in IDC; encourage joint activities in IDC; and improve IDC training.", [["IDC", "CANCER", 235, 238], ["IDC", "CANCER", 319, 322], ["IDC", "CANCER", 396, 399], ["joint", "MULTI-TISSUE_STRUCTURE", 411, 416], ["IDC", "CANCER", 431, 434], ["IDC", "CANCER", 448, 451], ["PH practitioners", "TREATMENT", 352, 368], ["IDC training", "TREATMENT", 448, 460], ["joint", "ANATOMY", 411, 416]]], ["Primary purpose is to aid in the reduction of MRSA-rates and limit the cross-border transmission of MRSA.", [["MRSA", "DISEASE", 46, 50], ["MRSA", "DISEASE", 100, 104], ["MRSA", "CANCER", 100, 104], ["MRSA", "SPECIES", 46, 50], ["MRSA", "SPECIES", 100, 104], ["MRSA", "SPECIES", 100, 104], ["MRSA", "PROBLEM", 46, 50], ["MRSA", "PROBLEM", 100, 104], ["MRSA", "OBSERVATION", 46, 50], ["MRSA", "OBSERVATION", 100, 104]]], ["Cross-border (CA-) MRSA guidelines will be redesigned according to international standards and socio-cultural differences between the nations.", [["MRSA", "SPECIES", 19, 23], ["Cross-border (CA-) MRSA guidelines", "TREATMENT", 0, 34]]], ["Methods: Based on quality standards for safety and healthcare documentation used in high risk chemical organizations, a framework for a systematic content analysis of national MRSAguidelines was developed.", [["healthcare documentation", "TEST", 51, 75], ["a systematic content analysis", "TEST", 134, 163]]], ["Results: A content analysis of the current national MRSAguidelines showed five dominating MRSA-perspectives: rule-, expert-, risk-, demand-and community-driven.", [["MRSA", "SPECIES", 90, 94], ["A content analysis", "TEST", 9, 27], ["the current national MRSAguidelines", "TEST", 31, 66], ["MRSA", "OBSERVATION", 90, 94]]], ["German guidelines are mainly dominated by the rule-and expertdriven perspectives (guidelines are literally derived from law and follow the infection transmission route), in contrast to the Dutch which focus on the demand of the user and the community (addressed to public health and acceptability of guidelines by users).", [["infection", "DISEASE", 139, 148]]], ["Conclusion: The analysis showed that the fact that there are different guideline-perspectives results in an enormous, confusing set of guidelines.", [["The analysis", "TEST", 12, 24], ["enormous", "OBSERVATION_MODIFIER", 108, 116]]], ["The management and use of guidelines becomes uncontrollable and leads to an illusory organisation where healthcare workers don't act in accordance with the guidelines and start applying their own insights.", [["The management", "TREATMENT", 0, 14], ["uncontrollable", "PROBLEM", 45, 59]]], ["This might lead to cost-increasing and contrasting situations.", [["cost-increasing and contrasting situations", "PROBLEM", 19, 61]]], ["To implement guidelines successfully in a cross-border situation, a cultural and technical synchronisation alongside an integrated approach of the different perspectives of guidelines is necessary, inline with the current disease management models.", [["a cultural", "TEST", 66, 76], ["the current disease management", "TREATMENT", 210, 240]]], ["Further research about the redesign and the evaluation of those guidelines in practice will help achieving this.P1492 Prevention of rabies in GeorgiaR.", [["P1492", "CHEMICAL", 112, 117], ["rabies", "DISEASE", 132, 138], ["rabies", "ORGANISM", 132, 138], ["rabies", "SPECIES", 132, 138], ["the evaluation", "TEST", 40, 54]]], ["Tsiklauri (Tbilisi, GE) Background: Animal bites are a common but under recognized public health problem.", [["Animal bites", "DISEASE", 36, 48], ["Tsiklauri", "TEST", 0, 9], ["Animal bites", "PROBLEM", 36, 48]]], ["Despite the frequency and expense of these injuries, there is little information about the incidence of animal bites because of a lack systematic reporting and a lack of measurement of the quality and completeness of reported data.", [["injuries", "DISEASE", 43, 51], ["these injuries", "PROBLEM", 37, 51], ["animal bites", "PROBLEM", 104, 116], ["injuries", "OBSERVATION", 43, 51]]], ["Objectives: To investigate animal bites and rabies reported cases, revealed unreported cases, analyse and based on study results find more effective epidemiological measures of animal bites and deaths (due to rabies) prevention in Georgia.", [["rabies", "DISEASE", 44, 50], ["animal bites", "DISEASE", 177, 189], ["deaths", "DISEASE", 194, 200], ["rabies", "DISEASE", 209, 215], ["rabies", "ORGANISM", 44, 50], ["rabies", "SPECIES", 44, 50], ["rabies", "SPECIES", 209, 215], ["study results", "TEST", 115, 128]]], ["Methods: The capture-recapture method was used, along with log-linear modelling.", [["The capture-recapture method", "TREATMENT", 9, 37]]], ["Results: In 1980-2001 years 150 700 dog and other animal bites were reported.", [["dog", "ORGANISM", 36, 39], ["dog", "SPECIES", 36, 39]]], ["The capture-recapture method estimated that there were 146 200 unreported bites.", [["The capture", "TEST", 0, 11], ["recapture method", "TEST", 12, 28]]], ["During these period 118 deaths due to rabies was registered in Georgia and 67 (57%) cases among them have been registered during the last 6 years.", [["deaths", "DISEASE", 24, 30], ["rabies", "DISEASE", 38, 44], ["rabies", "ORGANISM", 38, 44], ["rabies", "SPECIES", 38, 44], ["rabies", "PROBLEM", 38, 44]]], ["The reasons of fatal cases were untreated (47%), uncompleted treated (34%) and late began post-exposure treated (19%) cases of bites (mostly dog bites).", [["bites", "DISEASE", 127, 132], ["dog", "ORGANISM", 141, 144], ["dog", "SPECIES", 141, 144], ["fatal cases", "PROBLEM", 15, 26], ["bites", "PROBLEM", 127, 132], ["fatal", "OBSERVATION_MODIFIER", 15, 20]]], ["About 56% of bitted persons did not know about rabies and it's prevention measures.", [["rabies", "DISEASE", 47, 53], ["persons", "ORGANISM", 20, 27], ["rabies", "ORGANISM", 47, 53], ["persons", "SPECIES", 20, 27], ["rabies", "SPECIES", 47, 53]]], ["About 32% had incorrect information about prevention and only 12% of them knew epidemiological and clinical aspects of disease.", [["disease", "PROBLEM", 119, 126], ["disease", "OBSERVATION", 119, 126]]], ["About 16% of physicians who were responsible on quality post-exposure treatment had not an adequate knowledge.", [["quality post-exposure treatment", "TREATMENT", 48, 79]]], ["Conclusion: Dog and other animal bites are common but preventable injuries.", [["Dog", "ORGANISM", 12, 15], ["preventable injuries", "PROBLEM", 54, 74], ["injuries", "OBSERVATION", 66, 74]]], ["To improve surveillance and prevention of rabies in Georgia, the focus should be on educating the general public about the serious consequences of animal bite injuries and developing the animal's vaccination strategy.P1492 Prevention of rabies in GeorgiaPharmacoeconomics and electronic resources P1493 The expected economic burden of methicillinresistant Staphylococcus aureus in complicated skin and skin structure infections: a modelling approach A. Kuznik, R. Mallick, D. Weber (Collegeville, Chapel Hill, US) Objective: To model the expected rate of clinical failure of initial empiric therapy and economic burden likely to be associated with the increasing prevalence of methicillinresistant Staphylococcus aureus (MRSA) in patients hospitalised with complicated skin and skin structure infections (cSSSI) in the United States.", [["skin", "ANATOMY", 393, 397], ["skin", "ANATOMY", 402, 406], ["skin", "ANATOMY", 769, 773], ["skin", "ANATOMY", 778, 782], ["rabies", "DISEASE", 42, 48], ["bite injuries", "DISEASE", 154, 167], ["P1492", "CHEMICAL", 217, 222], ["rabies", "DISEASE", 237, 243], ["P1493", "CHEMICAL", 297, 302], ["methicillinresistant", "CHEMICAL", 335, 355], ["Staphylococcus aureus", "DISEASE", 356, 377], ["skin and skin structure infections", "DISEASE", 393, 427], ["Staphylococcus aureus", "DISEASE", 698, 719], ["MRSA", "DISEASE", 721, 725], ["skin and skin structure infections", "DISEASE", 769, 803], ["cSSSI", "DISEASE", 805, 810], ["P1493", "CHEMICAL", 297, 302], ["methicillinresistant Staphylococcus aureus", "ORGANISM", 335, 377], ["skin", "ORGAN", 393, 397], ["skin", "ORGAN", 402, 406], ["methicillinresistant Staphylococcus aureus", "ORGANISM", 677, 719], ["MRSA", "CANCER", 721, 725], ["patients", "ORGANISM", 730, 738], ["skin", "ORGAN", 769, 773], ["skin", "ORGAN", 778, 782], ["Staphylococcus aureus", "SPECIES", 356, 377], ["Staphylococcus aureus", "SPECIES", 698, 719], ["MRSA", "SPECIES", 721, 725], ["patients", "SPECIES", 730, 738], ["rabies", "SPECIES", 42, 48], ["rabies", "SPECIES", 237, 243], ["Staphylococcus aureus", "SPECIES", 356, 377], ["Staphylococcus aureus", "SPECIES", 698, 719], ["MRSA", "SPECIES", 721, 725], ["surveillance", "TEST", 11, 23], ["rabies", "PROBLEM", 42, 48], ["animal bite injuries", "PROBLEM", 147, 167], ["the animal's vaccination strategy", "TREATMENT", 183, 216], ["methicillinresistant Staphylococcus aureus", "PROBLEM", 335, 377], ["complicated skin and skin structure infections", "PROBLEM", 381, 427], ["clinical failure", "PROBLEM", 555, 571], ["initial empiric therapy", "TREATMENT", 575, 598], ["economic burden", "PROBLEM", 603, 618], ["methicillinresistant Staphylococcus aureus", "PROBLEM", 677, 719], ["MRSA", "PROBLEM", 721, 725], ["complicated skin and skin structure infections", "PROBLEM", 757, 803], ["economic", "OBSERVATION_MODIFIER", 316, 324], ["burden", "OBSERVATION_MODIFIER", 325, 331], ["methicillinresistant Staphylococcus aureus", "OBSERVATION", 335, 377], ["complicated", "OBSERVATION_MODIFIER", 381, 392], ["skin", "ANATOMY", 393, 397], ["skin", "ANATOMY", 402, 406], ["structure infections", "OBSERVATION", 407, 427], ["Staphylococcus aureus", "OBSERVATION", 698, 719], ["complicated", "OBSERVATION_MODIFIER", 757, 768], ["skin", "ANATOMY", 769, 773], ["skin", "ANATOMY", 778, 782], ["structure infections", "OBSERVATION", 783, 803]]], ["Methods: Using published data on (1) the prevalence of MRSA and other bacterial pathogens causing cSSSI in the US, (2) the in-vitro susceptibility rates of commonly used regimens in cSSSI in the US in relation to the most pervasive pathogens identified above, and (3) estimated costs of failure of initial, empiric treatment from a recent study of a large US multi-hospital database, we developed a model to predict the expected clinical and economic impact of increasing prevalence of MRSA.", [["MRSA", "DISEASE", 55, 59], ["cSSSI", "DISEASE", 98, 103], ["MRSA", "DISEASE", 486, 490], ["MRSA", "SPECIES", 55, 59], ["MRSA", "SPECIES", 486, 490], ["MRSA", "SPECIES", 55, 59], ["MRSA", "SPECIES", 486, 490], ["MRSA", "PROBLEM", 55, 59], ["other bacterial pathogens", "PROBLEM", 64, 89], ["regimens", "TREATMENT", 170, 178], ["the most pervasive pathogens", "PROBLEM", 213, 241], ["empiric treatment", "TREATMENT", 307, 324], ["a recent study", "TEST", 330, 344], ["MRSA", "PROBLEM", 486, 490], ["MRSA", "OBSERVATION", 55, 59], ["MRSA", "OBSERVATION", 486, 490]]], ["Specifically, clinical failure of 5 of the more commonly used initial regimens in cSSSI was modeled in terms of their in-vitro susceptibility rates with respect to MRSA, weighted by MRSA prevalence.", [["MRSA", "SPECIES", 164, 168], ["MRSA", "SPECIES", 182, 186], ["MRSA", "SPECIES", 164, 168], ["MRSA", "SPECIES", 182, 186], ["clinical failure", "PROBLEM", 14, 30], ["initial regimens", "TREATMENT", 62, 78], ["MRSA", "PROBLEM", 164, 168], ["MRSA", "OBSERVATION", 164, 168]]], ["Varying the rate of MRSA further yielded projected clinical failure rates and costs attributable to increasing levels of methicillin resistance over time.", [["methicillin", "CHEMICAL", 121, 132], ["methicillin", "CHEMICAL", 121, 132], ["methicillin", "SIMPLE_CHEMICAL", 121, 132], ["MRSA", "SPECIES", 20, 24], ["MRSA", "SPECIES", 20, 24], ["MRSA", "PROBLEM", 20, 24], ["projected clinical failure rates", "PROBLEM", 41, 73], ["methicillin resistance", "TREATMENT", 121, 143], ["MRSA", "OBSERVATION", 20, 24], ["methicillin resistance", "OBSERVATION", 121, 143]]], ["Results: Given current 55% prevalence of S. aureus pathogens in cSSSI, half of them methicillin-resistant (base case MRSA = 27%), the model projected an overall clinical failure rate of 35.9% for 5 of the more commonly used initial regimens, with an expected overall treatment cost (in US dollars) of $5,492 per patient (range, $4,566-5,633) .", [["S. aureus pathogens", "DISEASE", 41, 60], ["cSSSI", "DISEASE", 64, 69], ["methicillin", "CHEMICAL", 84, 95], ["methicillin", "CHEMICAL", 84, 95], ["S. aureus pathogens", "ORGANISM", 41, 60], ["methicillin", "SIMPLE_CHEMICAL", 84, 95], ["patient", "ORGANISM", 312, 319], ["S. aureus", "SPECIES", 41, 50], ["MRSA", "SPECIES", 117, 121], ["patient", "SPECIES", 312, 319], ["S. aureus", "SPECIES", 41, 50], ["S. aureus pathogens", "PROBLEM", 41, 60], ["them methicillin", "TEST", 79, 95], ["base case MRSA", "TEST", 107, 121], ["clinical failure rate", "TEST", 161, 182], ["initial regimens", "TREATMENT", 224, 240], ["aureus", "OBSERVATION", 44, 50]]], ["If none of the S. aureus pathogens were resistant (MRSA = 0%), clinical failure rate was projected to be 18.4% and treatment cost to be $4,869 per patient.", [["S. aureus pathogens", "ORGANISM", 15, 34], ["patient", "ORGANISM", 147, 154], ["S. aureus", "SPECIES", 15, 24], ["MRSA", "SPECIES", 51, 55], ["patient", "SPECIES", 147, 154], ["S. aureus", "SPECIES", 15, 24], ["the S. aureus pathogens", "PROBLEM", 11, 34], ["MRSA", "TEST", 51, 55], ["clinical failure rate", "TEST", 63, 84], ["aureus", "OBSERVATION", 18, 24]]], ["The differences in the two scenarios translated to an expected clinical failure rate of 17.5%, an incremental cost of $623 per patient, and for the 800,000 patients hospitalised for cSSSI annually in the US, an expected health care system burden of $498 million attributable to MRSA.", [["cSSSI", "DISEASE", 182, 187], ["MRSA", "DISEASE", 278, 282], ["patient", "ORGANISM", 127, 134], ["patients", "ORGANISM", 156, 164], ["patient", "SPECIES", 127, 134], ["patients", "SPECIES", 156, 164], ["MRSA", "SPECIES", 278, 282], ["an expected clinical failure rate", "TEST", 51, 84], ["MRSA", "PROBLEM", 278, 282], ["MRSA", "OBSERVATION", 278, 282]]], ["Under a \"worst-case\" scenario in which MRSA was the only causative pathogen (MRSA = 100%) in cSSSI, clinical failure rate was projected to be 79.3%, and treatment cost per patient was expected to be $7,035.", [["MRSA", "DISEASE", 39, 43], ["cSSSI", "DISEASE", 93, 98], ["patient", "ORGANISM", 172, 179], ["MRSA", "SPECIES", 39, 43], ["MRSA", "SPECIES", 77, 81], ["patient", "SPECIES", 172, 179], ["MRSA", "SPECIES", 39, 43], ["MRSA", "PROBLEM", 39, 43], ["causative pathogen", "PROBLEM", 57, 75], ["MRSA", "PROBLEM", 77, 81], ["clinical failure rate", "TEST", 100, 121]]], ["Conclusions: Going beyond existing estimates, our model generated a substantial expected clinical failure rate and economic impact attributable to current MRSA levels, as well as simulations of the expected impact of increasing MRSA prevalence over time, varying levels of MRSA across regions and choice of initial empiric regimens.P1494Treatment of complicated skin and skin structure infections in the US: expected cost differences between tigecycline and vancomycin/aztreonam R. Mallick, A. Kuznik, D. Weber (Collegeville, Chapel Hill, US) Objective: To compare tigecycline and vancomycin/aztreonam in terms of treatment-related costs for patients hospitalised in the United States with complicated skin and skin structure infections (cSSSI).", [["skin", "ANATOMY", 362, 366], ["skin", "ANATOMY", 371, 375], ["skin", "ANATOMY", 702, 706], ["skin", "ANATOMY", 711, 715], ["MRSA", "DISEASE", 228, 232], ["MRSA", "DISEASE", 273, 277], ["skin and skin structure infections", "DISEASE", 362, 396], ["tigecycline", "CHEMICAL", 442, 453], ["vancomycin", "CHEMICAL", 458, 468], ["aztreonam", "CHEMICAL", 469, 478], ["tigecycline", "CHEMICAL", 565, 576], ["vancomycin", "CHEMICAL", 581, 591], ["aztreonam", "CHEMICAL", 592, 601], ["skin and skin structure infections", "DISEASE", 702, 736], ["SSSI", "DISEASE", 739, 743], ["tigecycline", "CHEMICAL", 442, 453], ["vancomycin", "CHEMICAL", 458, 468], ["aztreonam", "CHEMICAL", 469, 478], ["tigecycline", "CHEMICAL", 565, 576], ["vancomycin", "CHEMICAL", 581, 591], ["aztreonam", "CHEMICAL", 592, 601], ["skin", "ORGAN", 362, 366], ["skin", "ORGAN", 371, 375], ["tigecycline", "SIMPLE_CHEMICAL", 442, 453], ["vancomycin", "SIMPLE_CHEMICAL", 458, 468], ["tigecycline", "SIMPLE_CHEMICAL", 565, 576], ["vancomycin", "SIMPLE_CHEMICAL", 581, 591], ["aztreonam", "SIMPLE_CHEMICAL", 592, 601], ["patients", "ORGANISM", 642, 650], ["skin", "ORGAN", 702, 706], ["skin", "ORGAN", 711, 715], ["MRSA", "SPECIES", 155, 159], ["MRSA", "SPECIES", 228, 232], ["MRSA", "SPECIES", 273, 277], ["patients", "SPECIES", 642, 650], ["MRSA", "SPECIES", 273, 277], ["a substantial expected clinical failure rate", "PROBLEM", 66, 110], ["economic impact", "PROBLEM", 115, 130], ["current MRSA levels", "PROBLEM", 147, 166], ["increasing MRSA prevalence", "PROBLEM", 217, 243], ["MRSA", "PROBLEM", 273, 277], ["initial empiric regimens", "TREATMENT", 307, 331], ["complicated skin and skin structure infections", "PROBLEM", 350, 396], ["tigecycline", "TREATMENT", 442, 453], ["vancomycin", "TREATMENT", 458, 468], ["aztreonam", "TREATMENT", 469, 478], ["tigecycline", "TREATMENT", 565, 576], ["vancomycin", "TREATMENT", 581, 591], ["aztreonam", "TREATMENT", 592, 601], ["treatment", "TREATMENT", 614, 623], ["complicated skin and skin structure infections", "PROBLEM", 690, 736], ["substantial", "OBSERVATION_MODIFIER", 68, 79], ["MRSA", "OBSERVATION", 155, 159], ["increasing", "OBSERVATION_MODIFIER", 217, 227], ["MRSA", "OBSERVATION", 228, 232], ["MRSA", "OBSERVATION", 273, 277], ["complicated", "OBSERVATION_MODIFIER", 350, 361], ["skin", "ANATOMY", 362, 366], ["skin", "ANATOMY", 371, 375], ["structure", "OBSERVATION_MODIFIER", 376, 385], ["infections", "OBSERVATION", 386, 396], ["complicated", "OBSERVATION_MODIFIER", 690, 701], ["skin", "ANATOMY", 702, 706], ["skin", "ANATOMY", 711, 715], ["structure infections", "OBSERVATION", 716, 736]]], ["Methods: We conducted a retrospective analysis of pooled data from US centres in two randomized, double-blind clinical studies comparing tigecycline and vancomycin/aztreonam in the treatment of cSSSI.", [["tigecycline", "CHEMICAL", 137, 148], ["vancomycin", "CHEMICAL", 153, 163], ["aztreonam", "CHEMICAL", 164, 173], ["cSSSI", "DISEASE", 194, 199], ["tigecycline", "CHEMICAL", 137, 148], ["vancomycin", "CHEMICAL", 153, 163], ["aztreonam", "CHEMICAL", 164, 173], ["tigecycline", "SIMPLE_CHEMICAL", 137, 148], ["vancomycin", "SIMPLE_CHEMICAL", 153, 163], ["aztreonam", "SIMPLE_CHEMICAL", 164, 173], ["a retrospective analysis", "TEST", 22, 46], ["pooled data", "TEST", 50, 61], ["US centres", "TEST", 67, 77], ["blind clinical studies", "TEST", 104, 126], ["tigecycline", "TREATMENT", 137, 148], ["vancomycin", "TREATMENT", 153, 163], ["aztreonam", "TREATMENT", 164, 173], ["cSSSI", "TREATMENT", 194, 199]]], ["Using regression analysis, we estimated the effect of tigecycline treatment on hospital length of stay (LOS), controlling for other significant predictors.", [["tigecycline", "CHEMICAL", 54, 65], ["tigecycline", "CHEMICAL", 54, 65], ["tigecycline", "SIMPLE_CHEMICAL", 54, 65], ["regression analysis", "TEST", 6, 25], ["tigecycline treatment", "TREATMENT", 54, 75]]], ["Using published estimates of daily hospitalisation cost of cSSSI in the US from a multi-hospital audit, we then translated the estimated impact on LOS into economic terms.", [["cSSSI", "TREATMENT", 59, 64]]], ["This analysis was repeated for the subgroup of patients in which the primary pathogen was methicillin-resistant Staphylococcus aureus (MRSA).", [["methicillin", "CHEMICAL", 90, 101], ["Staphylococcus aureus", "DISEASE", 112, 133], ["methicillin", "CHEMICAL", 90, 101], ["patients", "ORGANISM", 47, 55], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 90, 133], ["MRSA", "CANCER", 135, 139], ["patients", "SPECIES", 47, 55], ["Staphylococcus aureus", "SPECIES", 112, 133], ["MRSA", "SPECIES", 135, 139], ["Staphylococcus aureus", "SPECIES", 112, 133], ["MRSA", "SPECIES", 135, 139], ["This analysis", "TEST", 0, 13], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 90, 133], ["MRSA", "PROBLEM", 135, 139], ["Staphylococcus aureus", "OBSERVATION", 112, 133]]], ["Clinical efficacy (tigecycline 81%, vancomycin/aztreonam 83.1%; p = 0.376) was similar across treatments and was not included as a model parameter.", [["tigecycline", "CHEMICAL", 19, 30], ["vancomycin", "CHEMICAL", 36, 46], ["aztreonam", "CHEMICAL", 47, 56], ["tigecycline", "CHEMICAL", 19, 30], ["vancomycin", "CHEMICAL", 36, 46], ["aztreonam", "CHEMICAL", 47, 56], ["tigecycline", "SIMPLE_CHEMICAL", 19, 30], ["vancomycin", "SIMPLE_CHEMICAL", 36, 46], ["aztreonam", "SIMPLE_CHEMICAL", 47, 56], ["tigecycline", "TREATMENT", 19, 30], ["vancomycin", "TREATMENT", 36, 46], ["aztreonam", "TREATMENT", 47, 56]]], ["Results: Our retrospective analysis of the pooled clinical data from US centres found that tigecycline was associated with a shorter LOS [)1.85 days (p = 0.015)] compared with the combination of vancomycin/aztreonam in the treatment of patients with cSSSI.", [["tigecycline", "CHEMICAL", 91, 102], ["vancomycin", "CHEMICAL", 195, 205], ["aztreonam", "CHEMICAL", 206, 215], ["cSSSI", "DISEASE", 250, 255], ["tigecycline", "CHEMICAL", 91, 102], ["vancomycin", "CHEMICAL", 195, 205], ["aztreonam", "CHEMICAL", 206, 215], ["tigecycline", "SIMPLE_CHEMICAL", 91, 102], ["vancomycin", "SIMPLE_CHEMICAL", 195, 205], ["aztreonam", "SIMPLE_CHEMICAL", 206, 215], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 236, 244], ["Our retrospective analysis", "TEST", 9, 35], ["tigecycline", "TREATMENT", 91, 102], ["vancomycin", "TREATMENT", 195, 205], ["aztreonam", "TREATMENT", 206, 215], ["cSSSI", "TREATMENT", 250, 255]]], ["At a mean daily hospitalisation cost (in US $) of $794, excluding antibiotic costs, this translated into expected medical cost savings of $1,469 per patient for tigecycline compared with vancomycin/aztreonam.", [["tigecycline", "CHEMICAL", 161, 172], ["vancomycin", "CHEMICAL", 187, 197], ["aztreonam", "CHEMICAL", 198, 207], ["tigecycline", "CHEMICAL", 161, 172], ["vancomycin", "CHEMICAL", 187, 197], ["aztreonam", "CHEMICAL", 198, 207], ["patient", "ORGANISM", 149, 156], ["tigecycline", "SIMPLE_CHEMICAL", 161, 172], ["vancomycin", "SIMPLE_CHEMICAL", 187, 197], ["aztreonam", "SIMPLE_CHEMICAL", 198, 207], ["patient", "SPECIES", 149, 156], ["antibiotic costs", "TREATMENT", 66, 82], ["tigecycline", "TREATMENT", 161, 172], ["vancomycin", "TREATMENT", 187, 197], ["aztreonam", "TREATMENT", 198, 207]]], ["In the MRSA subgroup, comprising 26% of the clinical study sample, tigecycline was associated with a greater reduction in LOS [)2.82 days (p = 0.011)] compared with vancomycin/ aztreonam, translating to expected medical cost savings of $2,239 per patient treated with tigecycline.", [["tigecycline", "CHEMICAL", 67, 78], ["vancomycin", "CHEMICAL", 165, 175], ["aztreonam", "CHEMICAL", 177, 186], ["tigecycline", "CHEMICAL", 268, 279], ["tigecycline", "CHEMICAL", 67, 78], ["vancomycin", "CHEMICAL", 165, 175], ["aztreonam", "CHEMICAL", 177, 186], ["tigecycline", "CHEMICAL", 268, 279], ["tigecycline", "SIMPLE_CHEMICAL", 67, 78], ["vancomycin", "SIMPLE_CHEMICAL", 165, 175], ["aztreonam", "SIMPLE_CHEMICAL", 177, 186], ["patient", "ORGANISM", 247, 254], ["tigecycline", "SIMPLE_CHEMICAL", 268, 279], ["MRSA", "SPECIES", 7, 11], ["patient", "SPECIES", 247, 254], ["the clinical study sample", "TEST", 40, 65], ["tigecycline", "TREATMENT", 67, 78], ["vancomycin", "TREATMENT", 165, 175], ["aztreonam", "TREATMENT", 177, 186], ["tigecycline", "TREATMENT", 268, 279], ["greater", "OBSERVATION_MODIFIER", 101, 108], ["reduction", "OBSERVATION_MODIFIER", 109, 118]]], ["These expected medical cost savings more than offset the higher average daily drug acquisition costs of tigecycline ($118/day) relative to the vancomycin/aztreonam combination ($110/day).", [["tigecycline", "CHEMICAL", 104, 115], ["vancomycin", "CHEMICAL", 143, 153], ["aztreonam", "CHEMICAL", 154, 163], ["tigecycline", "CHEMICAL", 104, 115], ["vancomycin", "CHEMICAL", 143, 153], ["aztreonam", "CHEMICAL", 154, 163], ["tigecycline", "SIMPLE_CHEMICAL", 104, 115], ["vancomycin", "SIMPLE_CHEMICAL", 143, 153], ["aztreonam", "SIMPLE_CHEMICAL", 154, 163], ["tigecycline", "TREATMENT", 104, 115], ["the vancomycin", "TREATMENT", 139, 153], ["aztreonam", "TREATMENT", 154, 163]]], ["Conclusion: In a retrospective analysis of pooled clinical data of patients with cSSSI treated at US centres, tigecycline was associated with a significantly reduced length of hospital stay relative to vancomycin/aztreonam; this translated into substantial cost savings, especially in the subset of cSSSI patients with MRSA.P1495The economic impact of linezolid in the treatment of skin and soft tissue MRSA infections in Italy M. Eandi, P. Dale, S. Sorensen, T. Baker, M. Procaccini, S. Duttagupta (Turin, IT; London, UK; Bethesda, US; Rome, IT; New York, US) Objective: Linezolid has been shown to be highly effective against infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in patients with complicated skin and soft tissue infections (cSSTI).", [["skin", "ANATOMY", 382, 386], ["skin", "ANATOMY", 729, 733], ["soft tissue", "ANATOMY", 738, 749], ["cSSSI", "DISEASE", 81, 86], ["tigecycline", "CHEMICAL", 110, 121], ["vancomycin", "CHEMICAL", 202, 212], ["aztreonam", "CHEMICAL", 213, 222], ["cSSSI", "DISEASE", 299, 304], ["MRSA", "DISEASE", 319, 323], ["P1495", "CHEMICAL", 324, 329], ["linezolid", "CHEMICAL", 352, 361], ["skin and soft tissue MRSA infections", "DISEASE", 382, 418], ["Linezolid", "CHEMICAL", 572, 581], ["infections", "DISEASE", 628, 638], ["methicillin", "CHEMICAL", 649, 660], ["Staphylococcus aureus", "DISEASE", 671, 692], ["skin and soft tissue infections", "DISEASE", 729, 760], ["cSSTI", "DISEASE", 762, 767], ["tigecycline", "CHEMICAL", 110, 121], ["vancomycin", "CHEMICAL", 202, 212], ["aztreonam", "CHEMICAL", 213, 222], ["linezolid", "CHEMICAL", 352, 361], ["Linezolid", "CHEMICAL", 572, 581], ["methicillin", "CHEMICAL", 649, 660], ["patients", "ORGANISM", 67, 75], ["tigecycline", "SIMPLE_CHEMICAL", 110, 121], ["vancomycin", "SIMPLE_CHEMICAL", 202, 212], ["aztreonam", "SIMPLE_CHEMICAL", 213, 222], ["patients", "ORGANISM", 305, 313], ["P1495", "SIMPLE_CHEMICAL", 324, 329], ["linezolid", "SIMPLE_CHEMICAL", 352, 361], ["skin", "ORGAN", 382, 386], ["M. Procaccini", "ORGANISM", 470, 483], ["S. Duttagupta", "ORGANISM", 485, 498], ["Linezolid", "SIMPLE_CHEMICAL", 572, 581], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 649, 692], ["MRSA", "CANCER", 694, 698], ["patients", "ORGANISM", 703, 711], ["skin", "ORGAN", 729, 733], ["soft tissue", "TISSUE", 738, 749], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 305, 313], ["MRSA", "SPECIES", 319, 323], ["MRSA", "SPECIES", 403, 407], ["Staphylococcus aureus", "SPECIES", 671, 692], ["MRSA", "SPECIES", 694, 698], ["patients", "SPECIES", 703, 711], ["Staphylococcus aureus", "SPECIES", 671, 692], ["MRSA", "SPECIES", 694, 698], ["cSSSI", "TREATMENT", 81, 86], ["tigecycline", "TREATMENT", 110, 121], ["vancomycin", "TREATMENT", 202, 212], ["aztreonam", "TREATMENT", 213, 222], ["substantial cost savings", "PROBLEM", 245, 269], ["MRSA", "PROBLEM", 319, 323], ["linezolid", "TREATMENT", 352, 361], ["the treatment", "TREATMENT", 365, 378], ["soft tissue MRSA infections", "PROBLEM", 391, 418], ["Linezolid", "TREATMENT", 572, 581], ["infections", "PROBLEM", 628, 638], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 649, 692], ["MRSA", "PROBLEM", 694, 698], ["complicated skin and soft tissue infections", "PROBLEM", 717, 760], ["substantial", "OBSERVATION_MODIFIER", 245, 256], ["cost savings", "OBSERVATION", 257, 269], ["MRSA", "OBSERVATION", 319, 323], ["skin", "ANATOMY", 382, 386], ["soft tissue", "ANATOMY", 391, 402], ["MRSA", "OBSERVATION", 403, 407], ["Staphylococcus aureus", "OBSERVATION", 671, 692], ["complicated", "OBSERVATION_MODIFIER", 717, 728], ["skin", "ANATOMY", 729, 733], ["soft tissue", "ANATOMY", 738, 749], ["infections", "OBSERVATION", 750, 760]]], ["The objective of this study was to evaluate the clinical and economic consequences of using linezolid for the empiric treatment of cSSTI from the Italian hospital perspective.", [["linezolid", "CHEMICAL", 92, 101], ["cSSTI", "DISEASE", 131, 136], ["linezolid", "CHEMICAL", 92, 101], ["linezolid", "SIMPLE_CHEMICAL", 92, 101], ["this study", "TEST", 17, 27], ["linezolid", "TREATMENT", 92, 101], ["the empiric treatment", "TREATMENT", 106, 127], ["cSSTI", "TREATMENT", 131, 136]]], ["Methods: A decision-analytic model was developed to calculate the clinical and cost outcomes of empiric treatment of hospitalized patients with cSSTI in Italy prescribed linezolid, vancomycin or teicoplanin.", [["cSSTI", "DISEASE", 144, 149], ["linezolid", "CHEMICAL", 170, 179], ["vancomycin", "CHEMICAL", 181, 191], ["teicoplanin", "CHEMICAL", 195, 206], ["linezolid", "CHEMICAL", 170, 179], ["vancomycin", "CHEMICAL", 181, 191], ["teicoplanin", "CHEMICAL", 195, 206], ["patients", "ORGANISM", 130, 138], ["linezolid", "SIMPLE_CHEMICAL", 170, 179], ["vancomycin", "SIMPLE_CHEMICAL", 181, 191], ["teicoplanin", "SIMPLE_CHEMICAL", 195, 206], ["patients", "SPECIES", 130, 138], ["empiric treatment", "TREATMENT", 96, 113], ["cSSTI", "TREATMENT", 144, 149], ["linezolid", "TREATMENT", 170, 179], ["vancomycin", "TREATMENT", 181, 191], ["teicoplanin", "TREATMENT", 195, 206]]], ["Efficacy data were derived from clinical trials.", [["Efficacy data", "TEST", 0, 13]]], ["Costs from published sources were applied to tests, adverse events, and days of intravenous and oral (linezolid only) treatment and hospitalization by ward type (general, intensive-care).", [["intravenous", "ANATOMY", 80, 91], ["oral", "ANATOMY", 96, 100], ["linezolid", "CHEMICAL", 102, 111], ["linezolid", "CHEMICAL", 102, 111], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 91], ["oral", "ORGANISM_SUBDIVISION", 96, 100], ["linezolid", "SIMPLE_CHEMICAL", 102, 111], ["tests", "TEST", 45, 50], ["adverse events", "PROBLEM", 52, 66], ["intravenous", "TREATMENT", 80, 91], ["oral (linezolid", "TREATMENT", 96, 111], ["treatment", "TREATMENT", 118, 127]]], ["Resource use and utilization patterns were obtained from a combination of clinical trial data and expert opinion.", [["clinical trial data", "TEST", 74, 93]]], ["Outcomes included total costs per patient, cost per cure and cost per death avoided.", [["death", "DISEASE", 70, 75], ["patient", "ORGANISM", 34, 41], ["patient", "SPECIES", 34, 41]]], ["Uncertainty surrounding the CE ratio was tested using one-way sensitivity analysis.", [["the CE ratio", "TEST", 24, 36], ["one-way sensitivity analysis", "TEST", 54, 82]]], ["Results: Starting empiric treatment with linezolid resulted in 98.4% of patients cured from MRSA compared to 98.0% with vancomycin.", [["linezolid", "CHEMICAL", 41, 50], ["MRSA", "DISEASE", 92, 96], ["vancomycin", "CHEMICAL", 120, 130], ["linezolid", "CHEMICAL", 41, 50], ["vancomycin", "CHEMICAL", 120, 130], ["linezolid", "SIMPLE_CHEMICAL", 41, 50], ["patients", "ORGANISM", 72, 80], ["vancomycin", "SIMPLE_CHEMICAL", 120, 130], ["patients", "SPECIES", 72, 80], ["MRSA", "SPECIES", 92, 96], ["empiric treatment", "TREATMENT", 18, 35], ["linezolid", "TREATMENT", 41, 50], ["MRSA", "PROBLEM", 92, 96], ["vancomycin", "TREATMENT", 120, 130], ["MRSA", "OBSERVATION", 92, 96]]], ["The average cost per patient treated with linezolid was \u20ac6,305 versus \u20ac6,228 for patients treated with vancomycin.", [["linezolid", "CHEMICAL", 42, 51], ["vancomycin", "CHEMICAL", 103, 113], ["linezolid", "CHEMICAL", 42, 51], ["vancomycin", "CHEMICAL", 103, 113], ["patient", "ORGANISM", 21, 28], ["linezolid", "SIMPLE_CHEMICAL", 42, 51], ["patients", "ORGANISM", 81, 89], ["vancomycin", "SIMPLE_CHEMICAL", 103, 113], ["patient", "SPECIES", 21, 28], ["patients", "SPECIES", 81, 89], ["linezolid", "TREATMENT", 42, 51], ["vancomycin", "TREATMENT", 103, 113], ["average", "OBSERVATION_MODIFIER", 4, 11]]], ["In a separate analysis more patients were cured using linezolid (97.6%) compared to teicoplanin (94.7%).", [["linezolid", "CHEMICAL", 54, 63], ["teicoplanin", "CHEMICAL", 84, 95], ["linezolid", "CHEMICAL", 54, 63], ["teicoplanin", "CHEMICAL", 84, 95], ["patients", "ORGANISM", 28, 36], ["linezolid", "SIMPLE_CHEMICAL", 54, 63], ["teicoplanin", "SIMPLE_CHEMICAL", 84, 95], ["patients", "SPECIES", 28, 36], ["linezolid", "TREATMENT", 54, 63], ["teicoplanin", "TEST", 84, 95]]], ["The average total cost per episode was \u20ac6,401 for linezolid treated patients versus \u20ac5,897 for teicoplanin treated patients, resulting in a cost per cure of \u20ac17,100.", [["linezolid", "CHEMICAL", 50, 59], ["teicoplanin", "CHEMICAL", 95, 106], ["linezolid", "CHEMICAL", 50, 59], ["teicoplanin", "CHEMICAL", 95, 106], ["linezolid", "SIMPLE_CHEMICAL", 50, 59], ["patients", "ORGANISM", 68, 76], ["teicoplanin", "SIMPLE_CHEMICAL", 95, 106], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 115, 123], ["linezolid", "TREATMENT", 50, 59], ["teicoplanin", "TREATMENT", 95, 106], ["average", "OBSERVATION_MODIFIER", 4, 11], ["total", "OBSERVATION_MODIFIER", 12, 17]]], ["The most sensitive parameters included hospital LOS and MRSA resistance rate.", [["MRSA", "SPECIES", 56, 60], ["hospital LOS", "TEST", 39, 51], ["MRSA resistance rate", "TEST", 56, 76], ["MRSA resistance", "OBSERVATION", 56, 71]]], ["Conclusions: In the treatment of cSSTI due to suspected MRSA in Italy, the empiric use of linezolid is cost-effective when compared to vancomycin and teicoplanin P1496 Outpatient and home parenteral antimicrobial therapy for the treatment of cellulitis: evaluation of efficacy and cost H. Ziglam, R. Tilley, C. Wootton, J. Morrison, D. Nathwani (Dundee, UK)P1495Objective: Outpatient and home parenteral antibiotic therapy (OHPAT) programmes are effective, well tolerated and economically advantageous in carefully selected patient populations.", [["cSSTI", "DISEASE", 33, 38], ["MRSA", "DISEASE", 56, 60], ["linezolid", "CHEMICAL", 90, 99], ["vancomycin", "CHEMICAL", 135, 145], ["teicoplanin P1496", "CHEMICAL", 150, 167], ["cellulitis", "DISEASE", 242, 252], ["linezolid", "CHEMICAL", 90, 99], ["vancomycin", "CHEMICAL", 135, 145], ["teicoplanin", "CHEMICAL", 150, 161], ["linezolid", "SIMPLE_CHEMICAL", 90, 99], ["vancomycin", "SIMPLE_CHEMICAL", 135, 145], ["teicoplanin", "SIMPLE_CHEMICAL", 150, 161], ["patient", "ORGANISM", 524, 531], ["MRSA", "SPECIES", 56, 60], ["patient", "SPECIES", 524, 531], ["MRSA", "SPECIES", 56, 60], ["cSSTI", "PROBLEM", 33, 38], ["MRSA", "PROBLEM", 56, 60], ["linezolid", "TREATMENT", 90, 99], ["vancomycin", "TREATMENT", 135, 145], ["teicoplanin", "TREATMENT", 150, 161], ["home parenteral antimicrobial therapy", "TREATMENT", 183, 220], ["cellulitis", "PROBLEM", 242, 252], ["evaluation", "TEST", 254, 264], ["home parenteral antibiotic therapy (OHPAT) programmes", "TREATMENT", 388, 441], ["MRSA", "OBSERVATION", 56, 60], ["cellulitis", "OBSERVATION", 242, 252]]], ["Skin and soft tissue infections represent a high burden disease which in amenable to treatment by OPHAT programmes.", [["Skin", "ANATOMY", 0, 4], ["soft tissue", "ANATOMY", 9, 20], ["Skin and soft tissue infections", "DISEASE", 0, 31], ["Skin", "ORGAN", 0, 4], ["soft tissue", "TISSUE", 9, 20], ["soft tissue infections", "PROBLEM", 9, 31], ["a high burden disease", "PROBLEM", 42, 63], ["treatment", "TREATMENT", 85, 94], ["OPHAT programmes", "TREATMENT", 98, 114], ["soft tissue", "OBSERVATION_MODIFIER", 9, 20], ["infections", "OBSERVATION", 21, 31], ["high", "OBSERVATION_MODIFIER", 44, 48], ["burden", "OBSERVATION_MODIFIER", 49, 55], ["disease", "OBSERVATION", 56, 63]]], ["We retrospectively analysed our outcomes registry to evaluate the clinical and health economic impact of treating cellulitis in this setting.", [["cellulitis", "DISEASE", 114, 124], ["treating cellulitis", "PROBLEM", 105, 124], ["cellulitis", "OBSERVATION", 114, 124]]], ["Methods: We have reviewed 465 patients with cellulitis and erysipelas who were treated with OHPAT.", [["cellulitis", "DISEASE", 44, 54], ["erysipelas", "DISEASE", 59, 69], ["OHPAT", "CHEMICAL", 92, 97], ["OHPAT", "CHEMICAL", 92, 97], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["cellulitis", "PROBLEM", 44, 54], ["erysipelas", "PROBLEM", 59, 69], ["OHPAT", "TREATMENT", 92, 97], ["cellulitis", "OBSERVATION", 44, 54], ["erysipelas", "OBSERVATION", 59, 69]]], ["Each patient treatment has a full integrated care pathway (ICP).", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["The ICP documents the microbiological outcome, drug and vascular access complication rates, impact on drug costs and in-patient bed days on the 465 number of patients treated from April 1998 to March 2005 are presented here.", [["vascular", "ANATOMY", 56, 64], ["vascular", "MULTI-TISSUE_STRUCTURE", 56, 64], ["patient", "ORGANISM", 120, 127], ["patients", "ORGANISM", 158, 166], ["patient", "SPECIES", 120, 127], ["patients", "SPECIES", 158, 166], ["The ICP", "TEST", 0, 7], ["vascular access complication rates", "TREATMENT", 56, 90], ["drug costs", "TREATMENT", 102, 112], ["microbiological outcome", "OBSERVATION", 22, 45], ["vascular", "ANATOMY", 56, 64]]], ["We also reviewed using the SMR1O inpatient discharge diagnosis data from the Information Statistics Division Scotland (ISD) and the Dundee Infectious Diseases Units (DIDU) Outcomes Registry Database.", [["Infectious Diseases", "DISEASE", 139, 158]]], ["The key diagnosis (ICD 10 codes) groups considered were cellulitis (LO30, 31, 32, 33, 38, 39) and erysipelas (A46X) over eight consecutive years (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) .", [["cellulitis", "DISEASE", 56, 66], ["erysipelas", "DISEASE", 98, 108], ["ICD 10 codes) groups", "TREATMENT", 19, 39], ["cellulitis", "PROBLEM", 56, 66], ["erysipelas", "PROBLEM", 98, 108], ["cellulitis", "OBSERVATION", 56, 66], ["erysipelas", "OBSERVATION", 98, 108]]], ["Results: The patients received intravenous antibiotic therapy for a mean duration of 5.64 days.", [["intravenous", "ANATOMY", 31, 42], ["patients", "ORGANISM", 13, 21], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 42], ["patients", "SPECIES", 13, 21], ["intravenous antibiotic therapy", "TREATMENT", 31, 61]]], ["The two primary agents administered were once-daily ceftriaxone in 84%of patients and teicoplanin in 9.8% of patients.", [["ceftriaxone", "CHEMICAL", 52, 63], ["teicoplanin", "CHEMICAL", 86, 97], ["ceftriaxone", "CHEMICAL", 52, 63], ["teicoplanin", "CHEMICAL", 86, 97], ["ceftriaxone", "SIMPLE_CHEMICAL", 52, 63], ["patients", "ORGANISM", 73, 81], ["teicoplanin", "SIMPLE_CHEMICAL", 86, 97], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 73, 81], ["patients", "SPECIES", 109, 117], ["The two primary agents", "TREATMENT", 0, 22], ["ceftriaxone", "TREATMENT", 52, 63], ["teicoplanin", "TREATMENT", 86, 97]]], ["Of the 465 patients, 431 (92.6%) were cured or improved; 5 worsened and required surgery.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["surgery", "TREATMENT", 81, 88], ["improved", "OBSERVATION_MODIFIER", 47, 55], ["worsened", "OBSERVATION_MODIFIER", 59, 67]]], ["Tinea pedis was found in 31% of patients treated for cellulitis.", [["pedis", "ANATOMY", 6, 11], ["Tinea pedis", "DISEASE", 0, 11], ["cellulitis", "DISEASE", 53, 63], ["Tinea pedis", "ORGAN", 0, 11], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["Tinea pedis", "SPECIES", 0, 11], ["Tinea pedis", "PROBLEM", 0, 11], ["cellulitis", "PROBLEM", 53, 63], ["pedis", "ANATOMY", 6, 11], ["cellulitis", "OBSERVATION", 53, 63]]], ["Economic benefits were realized despite use of more expensive agents.", [["more expensive agents", "TREATMENT", 47, 68]]], ["Data from the Dundee outcomes registry revealed a mean reduction in length of hospitalization from 5.8 days (1996/ 1997) to3.2 in 2003-2004-a reduction of 48% compared to Scottish data from ISD which did not show any changes in length of hospitalization between year 1996/1997 (5.33 days) and year 2003-2004 (5.92 days) .", [["a mean reduction", "PROBLEM", 48, 64], ["a reduction", "TEST", 140, 151], ["Scottish data", "TEST", 171, 184], ["mean", "OBSERVATION_MODIFIER", 50, 54], ["reduction", "OBSERVATION_MODIFIER", 55, 64], ["length", "OBSERVATION_MODIFIER", 68, 74]]], ["Conclusions: We have found that OHPAT is clinically effective and can be administered safely and successfully in an outpatient setting.", [["OHPAT", "CHEMICAL", 32, 37], ["OHPAT", "CHEMICAL", 32, 37], ["OHPAT", "SIMPLE_CHEMICAL", 32, 37]]], ["The majority of complications were minor, and 93% of patients were cured.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["complications", "PROBLEM", 16, 29], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["complications", "OBSERVATION", 16, 29]]], ["Tinea pedis and were found to be significant risk factors for acute cellulitis and indicate that improved awareness and management of toe web intertrigo might reduce the incidence of cellulitis.", [["Tinea pedis", "DISEASE", 0, 11], ["cellulitis", "DISEASE", 68, 78], ["cellulitis", "DISEASE", 183, 193], ["pedis", "ORGAN", 6, 11], ["toe", "ORGANISM_SUBDIVISION", 134, 137], ["cellulitis", "PATHOLOGICAL_FORMATION", 183, 193], ["Tinea pedis", "PROBLEM", 0, 11], ["significant risk factors", "PROBLEM", 33, 57], ["acute cellulitis", "PROBLEM", 62, 78], ["management", "TREATMENT", 120, 130], ["toe web intertrigo", "PROBLEM", 134, 152], ["cellulitis", "PROBLEM", 183, 193], ["pedis", "ANATOMY", 6, 11], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["cellulitis", "OBSERVATION", 68, 78], ["improved", "OBSERVATION_MODIFIER", 97, 105], ["toe", "ANATOMY", 134, 137], ["cellulitis", "OBSERVATION", 183, 193]]], ["This analysis also supports the premise that an adult OHPAT programme can substantially reduce healthcare resource use in the European healthcare setting.P1497Cost-effectiveness analysis of intravenous moxifloxacin compared to levofloxacin in hospitalised elderly patients with communityacquired pneumonia Objective: To evaluate the cost-effectiveness of moxifloxacin compared to levofloxacin in hospitalised patients aged \u202165 with community acquired pneumonia (CAP).", [["intravenous", "ANATOMY", 190, 201], ["moxifloxacin", "CHEMICAL", 202, 214], ["levofloxacin", "CHEMICAL", 227, 239], ["pneumonia", "DISEASE", 296, 305], ["moxifloxacin", "CHEMICAL", 355, 367], ["levofloxacin", "CHEMICAL", 380, 392], ["pneumonia", "DISEASE", 451, 460], ["CAP", "DISEASE", 462, 465], ["moxifloxacin", "CHEMICAL", 202, 214], ["levofloxacin", "CHEMICAL", 227, 239], ["moxifloxacin", "CHEMICAL", 355, 367], ["levofloxacin", "CHEMICAL", 380, 392], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 201], ["moxifloxacin", "SIMPLE_CHEMICAL", 202, 214], ["levofloxacin", "SIMPLE_CHEMICAL", 227, 239], ["patients", "ORGANISM", 264, 272], ["moxifloxacin", "SIMPLE_CHEMICAL", 355, 367], ["levofloxacin", "SIMPLE_CHEMICAL", 380, 392], ["patients", "ORGANISM", 409, 417], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 409, 417], ["This analysis", "TEST", 0, 13], ["an adult OHPAT programme", "TREATMENT", 45, 69], ["intravenous moxifloxacin", "TREATMENT", 190, 214], ["levofloxacin", "TREATMENT", 227, 239], ["communityacquired pneumonia", "PROBLEM", 278, 305], ["moxifloxacin", "TREATMENT", 355, 367], ["levofloxacin", "TREATMENT", 380, 392], ["community acquired pneumonia (CAP)", "PROBLEM", 432, 466], ["pneumonia", "OBSERVATION", 296, 305], ["pneumonia", "OBSERVATION", 451, 460]]], ["Methods: A randomised double-blind parallel group study was conducted in 47 US hospitals.", [["blind parallel group study", "TEST", 29, 55]]], ["Patients had radiological evidence of bacterial pneumonia confirmed by at least 2 other signs, were aged \u202165 years and were managed as inpatients on initiation of treatment.", [["pneumonia", "DISEASE", 48, 57], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["bacterial pneumonia", "PROBLEM", 38, 57], ["treatment", "TREATMENT", 163, 172], ["evidence of", "UNCERTAINTY", 26, 37], ["bacterial", "OBSERVATION_MODIFIER", 38, 47], ["pneumonia", "OBSERVATION", 48, 57]]], ["Patients initially received moxifloxacin 400 mg IV O.D. or levofloxacin 500 mg IV O.D., and once stabilised were switched to oral therapy with the same agent.", [["oral", "ANATOMY", 125, 129], ["moxifloxacin", "CHEMICAL", 28, 40], ["levofloxacin", "CHEMICAL", 59, 71], ["moxifloxacin", "CHEMICAL", 28, 40], ["levofloxacin", "CHEMICAL", 59, 71], ["Patients", "ORGANISM", 0, 8], ["moxifloxacin", "SIMPLE_CHEMICAL", 28, 40], ["levofloxacin", "SIMPLE_CHEMICAL", 59, 71], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["Patients", "SPECIES", 0, 8], ["moxifloxacin", "TREATMENT", 28, 40], ["levofloxacin", "TREATMENT", 59, 71], ["oral therapy", "TREATMENT", 125, 137], ["the same agent", "TREATMENT", 143, 157]]], ["The effectiveness endpoint for the economic analysis was the percentage of patients successfully treated, defined as patients with marked improvement, resolution or clinical cure at test of cure visit after 7-14 days of therapy who did not experience a serious cardiac adverse event.", [["cardiac", "ANATOMY", 261, 268], ["cardiac adverse event", "DISEASE", 261, 282], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 117, 125], ["cardiac", "ORGAN", 261, 268], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 117, 125], ["the economic analysis", "TEST", 31, 52], ["therapy", "TREATMENT", 220, 227], ["a serious cardiac adverse event", "PROBLEM", 251, 282], ["marked", "OBSERVATION_MODIFIER", 131, 137], ["improvement", "OBSERVATION_MODIFIER", 138, 149]]], ["Total costs were estimated from the perspective of the treating hospital and included antibiotic drugs, hospital stay, hospital re-admission within 28 days and cost of managing treatment failures.", [["antibiotic drugs", "TREATMENT", 86, 102], ["managing treatment failures", "TREATMENT", 168, 195]]], ["Results: 394 patients were included in this analysis, 195 randomised to moxifloxacin and 199 to levofloxacin.", [["moxifloxacin", "CHEMICAL", 72, 84], ["levofloxacin", "CHEMICAL", 96, 108], ["moxifloxacin", "CHEMICAL", 72, 84], ["levofloxacin", "CHEMICAL", 96, 108], ["patients", "ORGANISM", 13, 21], ["moxifloxacin", "SIMPLE_CHEMICAL", 72, 84], ["levofloxacin", "SIMPLE_CHEMICAL", 96, 108], ["patients", "SPECIES", 13, 21], ["this analysis", "TEST", 39, 52], ["moxifloxacin", "TREATMENT", 72, 84], ["levofloxacin", "TREATMENT", 96, 108]]], ["82% (95% CI: 77-88%) of moxifloxacin and 75% (69-81%) of levofloxacin treated patients were successfully treated (resolution, clinical cure at TOC and no serious drug related AEs).", [["moxifloxacin", "CHEMICAL", 24, 36], ["levofloxacin", "CHEMICAL", 57, 69], ["TOC", "CHEMICAL", 143, 146], ["moxifloxacin", "CHEMICAL", 24, 36], ["levofloxacin", "CHEMICAL", 57, 69], ["moxifloxacin", "SIMPLE_CHEMICAL", 24, 36], ["levofloxacin", "SIMPLE_CHEMICAL", 57, 69], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["CI", "TEST", 9, 11], ["moxifloxacin", "TREATMENT", 24, 36], ["levofloxacin", "TREATMENT", 57, 69], ["serious drug related AEs", "PROBLEM", 154, 178]]], ["In the moxifloxacin group patients reported a mean of 3.5 days of IV antibiotic treatment and 5.7 days inpatient stay with 3.4 days IV antibiotic treatment and 6.1 days inpatient stay in the levofloxacin group.", [["moxifloxacin", "CHEMICAL", 7, 19], ["levofloxacin", "CHEMICAL", 191, 203], ["moxifloxacin", "CHEMICAL", 7, 19], ["levofloxacin", "CHEMICAL", 191, 203], ["moxifloxacin", "SIMPLE_CHEMICAL", 7, 19], ["patients", "ORGANISM", 26, 34], ["levofloxacin", "SIMPLE_CHEMICAL", 191, 203], ["patients", "SPECIES", 26, 34], ["IV antibiotic treatment", "TREATMENT", 66, 89], ["3.4 days IV antibiotic treatment", "TREATMENT", 123, 155], ["the levofloxacin group", "TREATMENT", 187, 209]]], ["Mean per patient drug cost was $257 in the moxifloxacin group, $222 in the levofloxacin group.", [["moxifloxacin", "CHEMICAL", 43, 55], ["levofloxacin", "CHEMICAL", 75, 87], ["moxifloxacin", "CHEMICAL", 43, 55], ["levofloxacin", "CHEMICAL", 75, 87], ["patient", "ORGANISM", 9, 16], ["moxifloxacin", "SIMPLE_CHEMICAL", 43, 55], ["levofloxacin", "SIMPLE_CHEMICAL", 75, 87], ["patient", "SPECIES", 9, 16], ["the moxifloxacin group", "TREATMENT", 39, 61], ["the levofloxacin group", "TREATMENT", 71, 93]]], ["Mean total cost was $8,339 in the moxifloxacin group and $8,354 in the levofloxacin group.", [["moxifloxacin", "CHEMICAL", 34, 46], ["levofloxacin", "CHEMICAL", 71, 83], ["moxifloxacin", "CHEMICAL", 34, 46], ["levofloxacin", "CHEMICAL", 71, 83], ["moxifloxacin", "SIMPLE_CHEMICAL", 34, 46], ["levofloxacin", "SIMPLE_CHEMICAL", 71, 83], ["Mean total cost", "TEST", 0, 15], ["the moxifloxacin group", "TREATMENT", 30, 52], ["the levofloxacin group", "TREATMENT", 67, 89]]], ["Findings were consistent across a range of patient subgroups.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50]]], ["Conclusions: Patients in the moxifloxacin group had higher rates of successful treatment at slightly lower average costs than the levofloxacin group.", [["moxifloxacin", "CHEMICAL", 29, 41], ["levofloxacin", "CHEMICAL", 130, 142], ["moxifloxacin", "CHEMICAL", 29, 41], ["levofloxacin", "CHEMICAL", 130, 142], ["Patients", "ORGANISM", 13, 21], ["moxifloxacin", "SIMPLE_CHEMICAL", 29, 41], ["levofloxacin", "SIMPLE_CHEMICAL", 130, 142], ["Patients", "SPECIES", 13, 21], ["the moxifloxacin group", "TREATMENT", 25, 47], ["successful treatment", "TREATMENT", 68, 88], ["slightly lower average costs", "PROBLEM", 92, 120], ["the levofloxacin group", "TREATMENT", 126, 148], ["lower average", "OBSERVATION_MODIFIER", 101, 114]]], ["This confirms the results of the TARGET study where moxifloxacin showed superior clinical efficacy in comparison to co-amoxiclav with or without clarithromycin in hospitalised CAP patients.", [["moxifloxacin", "CHEMICAL", 52, 64], ["co-amoxiclav", "CHEMICAL", 116, 128], ["clarithromycin", "CHEMICAL", 145, 159], ["CAP", "DISEASE", 176, 179], ["moxifloxacin", "CHEMICAL", 52, 64], ["co-amoxiclav", "CHEMICAL", 116, 128], ["clarithromycin", "CHEMICAL", 145, 159], ["moxifloxacin", "SIMPLE_CHEMICAL", 52, 64], ["co-amoxiclav", "SIMPLE_CHEMICAL", 116, 128], ["clarithromycin", "SIMPLE_CHEMICAL", 145, 159], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["the TARGET study", "TEST", 29, 45], ["moxifloxacin", "TREATMENT", 52, 64], ["co-amoxiclav", "TREATMENT", 116, 128], ["clarithromycin", "TREATMENT", 145, 159]]], ["Antibiotic costs were slightly higher in the moxifloxacin group than the levofloxacin group but total costs were slightly lower, due to reduced hospital stay.P1498Economic impact of invasive fungal infections in ICU patients in a tertiary care hospital in Switzerland A. Imhof, W. Zingg, R. Laffer, C. Ruef (Zurich, CH)P1498Objectives: Invasive fungal infections (IFI) cause significant morbidity and mortality.", [["moxifloxacin", "CHEMICAL", 45, 57], ["levofloxacin", "CHEMICAL", 73, 85], ["fungal infections", "DISEASE", 191, 208], ["Invasive fungal infections", "DISEASE", 336, 362], ["IFI", "DISEASE", 364, 367], ["moxifloxacin", "CHEMICAL", 45, 57], ["levofloxacin", "CHEMICAL", 73, 85], ["moxifloxacin", "SIMPLE_CHEMICAL", 45, 57], ["levofloxacin", "SIMPLE_CHEMICAL", 73, 85], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 216, 224], ["Antibiotic costs", "TREATMENT", 0, 16], ["the moxifloxacin group", "TREATMENT", 41, 63], ["the levofloxacin group", "TREATMENT", 69, 91], ["total costs", "TEST", 96, 107], ["slightly lower", "PROBLEM", 113, 127], ["invasive fungal infections", "PROBLEM", 182, 208], ["Invasive fungal infections", "PROBLEM", 336, 362], ["significant morbidity", "PROBLEM", 375, 396], ["slightly", "OBSERVATION_MODIFIER", 22, 30], ["higher", "OBSERVATION_MODIFIER", 31, 37], ["invasive", "OBSERVATION_MODIFIER", 182, 190], ["fungal", "OBSERVATION_MODIFIER", 191, 197], ["infections", "OBSERVATION", 198, 208], ["Invasive", "OBSERVATION_MODIFIER", 336, 344], ["fungal infections", "OBSERVATION", 345, 362], ["significant", "OBSERVATION_MODIFIER", 375, 386], ["morbidity", "OBSERVATION", 387, 396]]], ["The management of invasive fungal infections is currently undergoing important changes due to the availability of new therapeutic agents with improved safety profiles but the acquisition costs of these new agents are high.", [["fungal infections", "DISEASE", 27, 44], ["invasive fungal infections", "PROBLEM", 18, 44], ["new therapeutic agents", "TREATMENT", 114, 136], ["these new agents", "TREATMENT", 196, 212], ["invasive", "OBSERVATION_MODIFIER", 18, 26], ["fungal", "OBSERVATION_MODIFIER", 27, 33], ["infections", "OBSERVATION", 34, 44]]], ["We evaluated the average overall cost of management (microbiological diagnosis and treatment) of invasive fungal infection in critically ill patients at a large university hospital.", [["fungal infection", "DISEASE", 106, 122], ["critically ill", "DISEASE", 126, 140], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["management", "TREATMENT", 41, 51], ["treatment", "TREATMENT", 83, 92], ["invasive fungal infection", "PROBLEM", 97, 122], ["invasive", "OBSERVATION_MODIFIER", 97, 105], ["fungal", "OBSERVATION_MODIFIER", 106, 112], ["infection", "OBSERVATION", 113, 122]]], ["Methods: A retrospective (2003) (2004) , pairwise-matched cohort study was performed on 4 surgical ICUs and one medical ICU at our university hospital.", [["matched cohort study", "TEST", 50, 70]]], ["ICU patients with documented IFI (n = 23) were matched with control subjects (n = 46) on the basis of disease severity, sex and age (\u00b15 years).", [["IFI", "DISEASE", 29, 32], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["disease severity", "PROBLEM", 102, 118], ["disease", "OBSERVATION", 102, 109]]], ["The economic impact of microbiological studies and antibiotic treatment was assessed.", [["microbiological studies", "TEST", 23, 46], ["antibiotic treatment", "TREATMENT", 51, 71]]], ["Calculations were based on the period between admission and diagnosis of IFI in cases and the duration of hospital stay in controls, respectively.", [["IFI", "DISEASE", 73, 76], ["Calculations", "TEST", 0, 12], ["IFI", "PROBLEM", 73, 76]]], ["Results: The median length of hospital and ICU stay differed significantly between cases and controls (43 vs 14 days, 19 vs 3 days, P < 0.001, respectively).", [["P", "TEST", 132, 133]]], ["IFI occurred after a median hospital stay of 22 (range 2-95) days.", [["IFI", "DISEASE", 0, 3]]], ["The mortality rate for patients with IFI and matched control subjects were 30.4% and 10.9%, respectively (p = 0.04).", [["IFI", "DISEASE", 37, 40], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["The mortality rate", "TEST", 0, 18], ["IFI", "TREATMENT", 37, 40]]], ["There was no significant difference between cases and controls for Charlson index, McCabe and SAPS II score.", [["significant difference between cases", "PROBLEM", 13, 49], ["Charlson index", "TEST", 67, 81], ["SAPS II score", "TEST", 94, 107], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35]]], ["Median number of antibiotic treatment courses was 3 for cases and 1 for controls (p = 0.003), with a median duration of therapy of 6 days vs 1 day (p < 0.0001), respectively.", [["antibiotic treatment courses", "TREATMENT", 17, 45], ["a median duration of therapy", "TREATMENT", 99, 127]]], ["Microbiological studies (MiS) were conducted 78 times/100 patient-days (pd) in cases and 17 times/100 pd in the control group (p = 0.03).", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["Microbiological studies", "TEST", 0, 23]]], ["The most frequent samples were bloodcultures in both groups.", [["samples", "ANATOMY", 18, 25], ["samples", "CANCER", 18, 25], ["The most frequent samples", "PROBLEM", 0, 25]]], ["Swabs were ordered significantly more frequently in cases (median 25 (range: 1-150) vs. 2 (0-23); p = 0.04).", [["Swabs", "TEST", 0, 5]]], ["The cost for MiS was 13'728 Euro/100 pd in cases vs. 3742 Euro/100 pd in controls, and the costs for antifungal therapy 4'373 Euro/100 pd vs. 99 Euro/100 pd, respectively.", [["MiS", "TEST", 13, 16], ["Euro/100 pd in controls", "TREATMENT", 58, 81], ["antifungal therapy", "TREATMENT", 101, 119]]], ["Conclusions: IFI is associated with excess length of ICU and hospital stay, increased use of antibiotics and microbiological diagnostics.", [["IFI", "DISEASE", 13, 16], ["IFI", "PROBLEM", 13, 16], ["antibiotics", "TREATMENT", 93, 104], ["microbiological diagnostics", "TEST", 109, 136], ["IFI", "OBSERVATION", 13, 16]]], ["The microbiological studies have a significant economic impact on the treatment of IFI.P1499Cost-effectiveness of voriconazole to amphotericin B deoxycholate in early and late treatment of invasive aspergillosis R. Greene, J. Mauskopf, C. Roberts, T. Zyczynski, H. Schlamm (Boston, Research Triangle Park, New York, US) Objective: We estimate the cost-effectiveness of alternative initial drug treatments of invasive pulmonary aspergillosis (IPA) in suspected earlier and later lung involvement, based on the presence or absence of the halo sign on thoracic computed tomography (CT).", [["invasive pulmonary aspergillosis", "ANATOMY", 408, 440], ["lung", "ANATOMY", 478, 482], ["IFI", "DISEASE", 83, 86], ["voriconazole", "CHEMICAL", 114, 126], ["amphotericin B deoxycholate", "CHEMICAL", 130, 157], ["aspergillosis", "DISEASE", 198, 211], ["invasive pulmonary aspergillosis", "DISEASE", 408, 440], ["IPA", "DISEASE", 442, 445], ["voriconazole", "CHEMICAL", 114, 126], ["amphotericin B deoxycholate", "CHEMICAL", 130, 157], ["voriconazole", "SIMPLE_CHEMICAL", 114, 126], ["amphotericin B deoxycholate", "SIMPLE_CHEMICAL", 130, 157], ["pulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 417, 440], ["lung", "ORGAN", 478, 482], ["The microbiological studies", "TEST", 0, 27], ["the treatment of IFI", "TREATMENT", 66, 86], ["voriconazole", "TREATMENT", 114, 126], ["amphotericin B deoxycholate", "TREATMENT", 130, 157], ["invasive aspergillosis", "PROBLEM", 189, 211], ["alternative initial drug treatments", "TREATMENT", 369, 404], ["invasive pulmonary aspergillosis", "PROBLEM", 408, 440], ["later lung involvement", "PROBLEM", 472, 494], ["the halo sign", "PROBLEM", 532, 545], ["thoracic computed tomography", "TEST", 549, 577], ["CT", "TEST", 579, 581], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["IFI", "OBSERVATION", 83, 86], ["invasive", "OBSERVATION_MODIFIER", 189, 197], ["aspergillosis", "OBSERVATION", 198, 211], ["invasive", "OBSERVATION_MODIFIER", 408, 416], ["pulmonary", "ANATOMY", 417, 426], ["aspergillosis", "OBSERVATION", 427, 440], ["lung", "ANATOMY", 478, 482], ["involvement", "OBSERVATION", 483, 494], ["thoracic", "ANATOMY", 549, 557]]], ["Methods: We constructed a decision analysis model comparing 12-week treatment outcomes for a subset of patients enrolled in a clinical trial of initial treatment of IPA with amphotericin B dexoycholate (AmBd) vs voriconazole (VOR).", [["IPA", "CHEMICAL", 165, 168], ["amphotericin B dexoycholate", "CHEMICAL", 174, 201], ["AmBd", "CHEMICAL", 203, 207], ["voriconazole", "CHEMICAL", 212, 224], ["amphotericin B dexoycholate", "CHEMICAL", 174, 201], ["AmBd", "CHEMICAL", 203, 207], ["voriconazole", "CHEMICAL", 212, 224], ["VOR", "CHEMICAL", 226, 229], ["patients", "ORGANISM", 103, 111], ["amphotericin B dexoycholate", "SIMPLE_CHEMICAL", 174, 201], ["AmBd", "SIMPLE_CHEMICAL", 203, 207], ["voriconazole", "SIMPLE_CHEMICAL", 212, 224], ["VOR", "SIMPLE_CHEMICAL", 226, 229], ["patients", "SPECIES", 103, 111], ["initial treatment of IPA", "TREATMENT", 144, 168], ["amphotericin B dexoycholate (AmBd)", "TREATMENT", 174, 208], ["voriconazole", "TREATMENT", 212, 224]]], ["Patients included those with suspected lung involvement who underwent a baseline thoracic CT.", [["lung", "ANATOMY", 39, 43], ["thoracic", "ANATOMY", 81, 89], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 39, 43], ["Patients", "SPECIES", 0, 8], ["suspected lung involvement", "PROBLEM", 29, 55], ["a baseline thoracic CT", "TEST", 70, 92], ["lung", "ANATOMY", 39, 43], ["involvement", "OBSERVATION", 44, 55], ["thoracic", "ANATOMY", 81, 89]]], ["The subset was subdivided into two groups based on the presence or absence of a characteristic CT halo sign, a perimeter of ground glass CT opacity surrounding a solid lung nodule \u20211 cm diameter, known as an early indicator of IPA.", [["solid lung nodule", "ANATOMY", 162, 179], ["IPA", "CHEMICAL", 227, 230], ["lung", "ORGAN", 168, 172], ["a characteristic CT halo sign", "TEST", 78, 107], ["ground glass CT opacity", "PROBLEM", 124, 147], ["a solid lung nodule", "PROBLEM", 160, 179], ["perimeter", "OBSERVATION_MODIFIER", 111, 120], ["ground glass", "OBSERVATION", 124, 136], ["opacity", "OBSERVATION", 140, 147], ["solid", "OBSERVATION_MODIFIER", 162, 167], ["lung", "ANATOMY", 168, 172], ["nodule", "OBSERVATION", 173, 179], ["\u20211 cm", "OBSERVATION_MODIFIER", 180, 185], ["diameter", "OBSERVATION_MODIFIER", 186, 194], ["early", "OBSERVATION_MODIFIER", 208, 213], ["IPA", "OBSERVATION", 227, 230]]], ["Healthcare resource use and survival data were obtained directly from the clinical trial.", [["survival data", "TEST", 28, 41]]], ["US unit costs for drugs and health care services were applied from standard data sources.", [["drugs", "TREATMENT", 18, 23], ["health care services", "TREATMENT", 28, 48]]], ["Cost and survival at 12-weeks were estimated for those with and without a halo sign at baseline.", [["survival", "TREATMENT", 9, 17]]], ["Incremental cost-effectiveness ratios comparing VOR to AmBd were calculated for both patient subgroups.", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["Incremental cost-effectiveness ratios", "PROBLEM", 0, 37]]], ["Sensitivity of results to uncertainty in health care use and cost estimates was tested.", [["cost estimates", "TEST", 61, 75]]], ["Results: Patients in the halo subgroup had better survival than those in the no-halo subgroup (70.6% vs 54.4%), with lower total treatment cost ($44,352 vs $47,077) .", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17], ["lower total treatment cost", "TREATMENT", 117, 143]]], ["Survival was higher for VOR than for AmBd in both patient subgroups (halo: 75.3% vs 65.2%; no-halo: 68.3% vs 39.5%).", [["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["no-halo", "TEST", 91, 98]]], ["In the halo subgroup, total costs were lower for those treated with VOR than for those treated with AmBd ($40,380 vs $48,985) .", [["AmBd", "CHEMICAL", 100, 104], ["AmBd", "CHEMICAL", 100, 104]]], ["In the no-halo subgroup, total cost per patient was slightly higher for those treated with VOR ($48,133 vs $45,938) .", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["Conclusions: Earlier identification and treatment of IPA appears to result in better survival and potentially lower costs than later treatment.", [["IPA", "CHEMICAL", 53, 56], ["Earlier identification", "TEST", 13, 35], ["treatment of IPA", "TREATMENT", 40, 56], ["later treatment", "TREATMENT", 127, 142], ["lower", "OBSERVATION_MODIFIER", 110, 115], ["costs", "OBSERVATION", 116, 121]]], ["Initial treatment of IPA with VOR improves survival in patients with early or late disease compared with AmBd, is cost saving in the halo sub-group, and is cost-effective in the no-halo subgroup, within the constraints of our analysis.", [["IPA", "CHEMICAL", 21, 24], ["AmBd", "CHEMICAL", 105, 109], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["IPA", "PROBLEM", 21, 24], ["early or late disease", "PROBLEM", 69, 90], ["our analysis", "TEST", 222, 234], ["late", "OBSERVATION_MODIFIER", 78, 82], ["disease", "OBSERVATION", 83, 90]]], ["Objective: To describe and compare the nursing labor time required for preparation and administration of liposomal amphotericin B (L-AmB), amphotericin B deoxycholate (AmBd), and voriconazole (VOR).", [["amphotericin B", "CHEMICAL", 115, 129], ["L-AmB", "CHEMICAL", 131, 136], ["amphotericin B deoxycholate", "CHEMICAL", 139, 166], ["AmBd", "CHEMICAL", 168, 172], ["voriconazole", "CHEMICAL", 179, 191], ["amphotericin B", "CHEMICAL", 115, 129], ["L-AmB", "CHEMICAL", 131, 136], ["amphotericin B deoxycholate", "CHEMICAL", 139, 166], ["AmBd", "CHEMICAL", 168, 172], ["voriconazole", "CHEMICAL", 179, 191], ["VOR", "CHEMICAL", 193, 196], ["liposomal", "SIMPLE_CHEMICAL", 105, 114], ["amphotericin B", "SIMPLE_CHEMICAL", 115, 129], ["L-AmB", "SIMPLE_CHEMICAL", 131, 136], ["amphotericin B deoxycholate", "SIMPLE_CHEMICAL", 139, 166], ["AmBd", "SIMPLE_CHEMICAL", 168, 172], ["voriconazole", "SIMPLE_CHEMICAL", 179, 191], ["VOR", "SIMPLE_CHEMICAL", 193, 196], ["liposomal amphotericin B (L-AmB)", "TREATMENT", 105, 137], ["amphotericin B deoxycholate (AmBd)", "TREATMENT", 139, 173], ["voriconazole", "TREATMENT", 179, 191]]], ["Methods: Activities associated with nurse preparation and administration of the three study drugs were timed by trained observers at five hospitals (one in Italy, three in France, and one in the United Kingdom).", [["nurse preparation", "TREATMENT", 36, 53], ["the three study drugs", "TREATMENT", 76, 97]]], ["Target tasks were classified as those likely to be affected by the difference between the drugs and excluded those tasks likely to differ because of site-specific factors (e.g., travel time to a patient room in different hospitals).", [["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202], ["the drugs", "TREATMENT", 86, 95]]], ["Target tasks included: obtain supplies and medications; prepare medications; educate patient; administer medications; monitor for adverse events; and prepare follow-up medications.", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["medications", "TREATMENT", 43, 54], ["medications", "TREATMENT", 64, 75], ["medications", "TREATMENT", 105, 116], ["adverse events", "PROBLEM", 130, 144], ["medications", "TREATMENT", 168, 179]]], ["The mean times for administration of a single day of study drug were summarised and compared, accounting for a single daily dose of L-AmB and AmBd and 2 daily doses of VOR IV or oral.", [["oral", "ANATOMY", 178, 182], ["L-AmB", "CHEMICAL", 132, 137], ["AmBd", "CHEMICAL", 142, 146], ["L-AmB", "CHEMICAL", 132, 137], ["AmBd", "CHEMICAL", 142, 146], ["L-AmB", "SIMPLE_CHEMICAL", 132, 137], ["AmBd", "SIMPLE_CHEMICAL", 142, 146], ["oral", "ORGANISM_SUBDIVISION", 178, 182], ["study drug", "TEST", 53, 63], ["L-AmB", "TREATMENT", 132, 137], ["AmBd", "TREATMENT", 142, 146], ["VOR IV", "TREATMENT", 168, 174]]], ["Results: Sixty-nine patients were observed receiving 256 doses of study medications at the five hospitals.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["study medications", "TREATMENT", 66, 83]]], ["Time of administration in minutes per day was 20, 16, 14, and 3 for L-AmB, AmBd, VOR IV, and VOR oral, respectively.", [["oral", "ANATOMY", 97, 101], ["AmB", "CHEMICAL", 70, 73], ["L-AmB", "CHEMICAL", 68, 73], ["AmBd", "CHEMICAL", 75, 79], ["VOR IV", "CHEMICAL", 81, 87], ["VOR", "CHEMICAL", 93, 96], ["L-AmB", "SIMPLE_CHEMICAL", 68, 73], ["AmBd", "SIMPLE_CHEMICAL", 75, 79], ["VOR IV", "SIMPLE_CHEMICAL", 81, 87], ["oral", "ORGANISM_SUBDIVISION", 97, 101]]], ["Administration time was significantly lower for VOR IV compared with L-AmB (P < 0.05) and for VOR oral compared to all IV regimens (P < 0.05).", [["oral", "ANATOMY", 98, 102], ["L-AmB", "CHEMICAL", 69, 74], ["L-AmB", "CHEMICAL", 69, 74], ["VOR", "CHEMICAL", 94, 97], ["L-AmB", "SIMPLE_CHEMICAL", 69, 74], ["oral", "ORGANISM_SUBDIVISION", 98, 102], ["VOR IV", "TREATMENT", 48, 54], ["VOR oral", "PROBLEM", 94, 102], ["all IV regimens", "TREATMENT", 115, 130]]], ["The task of preparation of medications required the most time for IV formulations, and was longer in the L-AmB group than the others (L-AmB: 12 mins vs AmBd: 7 mins; VOR IV: 9 mins).", [["AmB", "CHEMICAL", 107, 110], ["AmB", "CHEMICAL", 136, 139], ["L-AmB", "CHEMICAL", 105, 110], ["L-AmB", "CHEMICAL", 134, 139], ["L-AmB", "SIMPLE_CHEMICAL", 105, 110], ["L-AmB", "SIMPLE_CHEMICAL", 134, 139], ["medications", "TREATMENT", 27, 38], ["IV formulations", "TREATMENT", 66, 81]]], ["AmBd required more time for patient monitoring and administration of followup drugs than other formulations (AmBd: 7 mins vs L-AmB: 4 mins; VOR IV: 2 mins).", [["AmB", "CHEMICAL", 127, 130], ["L-AmB", "CHEMICAL", 125, 130], ["AmBd", "SIMPLE_CHEMICAL", 0, 4], ["patient", "ORGANISM", 28, 35], ["L-AmB", "SIMPLE_CHEMICAL", 125, 130], ["patient", "SPECIES", 28, 35], ["patient monitoring", "TEST", 28, 46], ["followup drugs", "TREATMENT", 69, 83]]], ["Conclusion: VOR IV required significantly less time to prepare and administer on a daily basis compared to L-AmB.", [["L-AmB", "SIMPLE_CHEMICAL", 107, 112], ["VOR IV", "PROTEIN", 12, 18], ["L-AmB", "TREATMENT", 107, 112]]], ["Measurements of IV antifungal versus oral VOR administration suggest the opportunity to save 10-17 minutes per day by switching to oral therapy when possible.P1501Need of cost-effectiveness investigation focused on diagnosis, management and prevention of osteopenia and osteoporosis in the setting of HIV disease treated with HAART: when to act, how to act, which patients are the first target of intervention R. Manfredi, L. Calza, F. Chiodo (Bologna, IT) Background: Osteopenia/osteoporosis are emerging untoward effects of HIV infection/HAART.", [["oral", "ANATOMY", 37, 41], ["oral", "ANATOMY", 131, 135], ["osteopenia", "DISEASE", 255, 265], ["osteoporosis", "DISEASE", 270, 282], ["HIV disease", "DISEASE", 301, 312], ["Osteopenia", "DISEASE", 469, 479], ["osteoporosis", "DISEASE", 480, 492], ["HIV infection", "DISEASE", 526, 539], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["oral", "ORGANISM_SUBDIVISION", 131, 135], ["HIV", "ORGANISM", 301, 304], ["patients", "ORGANISM", 364, 372], ["HIV", "ORGANISM", 526, 529], ["patients", "SPECIES", 364, 372], ["HIV", "SPECIES", 301, 304], ["HIV", "SPECIES", 526, 529], ["IV antifungal", "TREATMENT", 16, 29], ["oral VOR administration", "TREATMENT", 37, 60], ["oral therapy", "TREATMENT", 131, 143], ["cost-effectiveness investigation", "TEST", 171, 203], ["management", "TREATMENT", 226, 236], ["osteopenia", "PROBLEM", 255, 265], ["osteoporosis", "PROBLEM", 270, 282], ["HIV disease", "PROBLEM", 301, 312], ["HAART", "TREATMENT", 326, 331], ["Osteopenia", "PROBLEM", 469, 479], ["osteoporosis", "PROBLEM", 480, 492], ["HIV infection", "PROBLEM", 526, 539], ["HAART", "TREATMENT", 540, 545], ["osteopenia", "OBSERVATION", 255, 265], ["osteoporosis", "OBSERVATION", 270, 282], ["L. Calza", "ANATOMY", 423, 431], ["Osteopenia", "OBSERVATION", 469, 479], ["osteoporosis", "OBSERVATION", 480, 492], ["infection", "OBSERVATION", 530, 539]]], ["The pathogenesis is multifactorial, involving all classes of anti-HIV drugs, although protease inhibitor use, overall HAART duration, and the male sex, seem related to a greater risk.Epidemiologicalclinical data.", [["multifactorial", "PROBLEM", 20, 34], ["anti-HIV drugs", "TREATMENT", 61, 75], ["protease inhibitor", "TREATMENT", 86, 104], ["multifactorial", "OBSERVATION_MODIFIER", 20, 34], ["anti-HIV drugs", "OBSERVATION", 61, 75]]], ["In an ongoing study at our Centre where >1000 HIV-infected patients (p) are followed, bone mineral density was assessed in lumbar spine/femural head by a dual energy Xray absorptiometry (DEXA) exam to estimate the prevalence of osteopenia/osteoporosis.", [["bone", "ANATOMY", 86, 90], ["lumbar spine", "ANATOMY", 123, 135], ["femural head", "ANATOMY", 136, 148], ["HIV-infected", "DISEASE", 46, 58], ["osteopenia", "DISEASE", 228, 238], ["osteoporosis", "DISEASE", 239, 251], ["HIV", "ORGANISM", 46, 49], ["patients", "ORGANISM", 59, 67], ["bone mineral", "MULTI-TISSUE_STRUCTURE", 86, 98], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 123, 135], ["head", "ORGAN", 144, 148], ["HIV", "SPECIES", 46, 49], ["patients", "SPECIES", 59, 67], ["HIV", "SPECIES", 46, 49], ["an ongoing study", "TEST", 3, 19], ["bone mineral density", "TEST", 86, 106], ["a dual energy Xray absorptiometry", "TEST", 152, 185], ["DEXA) exam", "TEST", 187, 197], ["osteopenia", "PROBLEM", 228, 238], ["osteoporosis", "PROBLEM", 239, 251], ["bone", "ANATOMY", 86, 90], ["mineral density", "OBSERVATION", 91, 106], ["lumbar spine", "ANATOMY", 123, 135], ["head", "ANATOMY", 144, 148], ["osteopenia", "OBSERVATION", 228, 238], ["osteoporosis", "OBSERVATION", 239, 251]]], ["In a screening of~100 p, the frequency of osteopenia and osteoporosis (based on lumbar T-score) was 38% and~10%, respectively.", [["lumbar", "ANATOMY", 80, 86], ["osteopenia", "DISEASE", 42, 52], ["osteoporosis", "DISEASE", 57, 69], ["a screening", "TEST", 3, 14], ["osteopenia", "PROBLEM", 42, 52], ["osteoporosis", "PROBLEM", 57, 69], ["lumbar T-score", "TEST", 80, 94], ["osteopenia", "OBSERVATION", 42, 52], ["osteoporosis", "OBSERVATION", 57, 69], ["lumbar", "ANATOMY", 80, 86]]], ["An increased risk was found in p treated with protease inhibitors versus those receiving nonnucleoside reverse transcriptase inhibitors or triple nucleoside/ nucleotide combinations.", [["nucleoside", "CHEMICAL", 146, 156], ["nucleotide", "CHEMICAL", 158, 168], ["nucleoside", "CHEMICAL", 146, 156], ["nucleotide", "CHEMICAL", 158, 168], ["nonnucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 89, 124], ["triple nucleoside", "SIMPLE_CHEMICAL", 139, 156], ["nonnucleoside reverse transcriptase", "PROTEIN", 89, 124], ["An increased risk", "PROBLEM", 0, 17], ["protease inhibitors", "TREATMENT", 46, 65], ["nonnucleoside reverse transcriptase inhibitors", "TREATMENT", 89, 135], ["triple nucleoside", "TREATMENT", 139, 156], ["nucleotide combinations", "TREATMENT", 158, 181], ["increased", "OBSERVATION_MODIFIER", 3, 12]]], ["Discussion and future insights: Prospective studies of extensive p samples are needed, to elucidate the epidemiology, pathogenesis, clinical issues and evolution of HIV-associated bone metabolism anomalies.", [["samples", "ANATOMY", 67, 74], ["bone", "ANATOMY", 180, 184], ["bone metabolism anomalies", "DISEASE", 180, 205], ["HIV", "ORGANISM", 165, 168], ["bone", "TISSUE", 180, 184], ["HIV", "SPECIES", 165, 168], ["Prospective studies", "TEST", 32, 51], ["extensive p samples", "TEST", 55, 74], ["pathogenesis", "PROBLEM", 118, 130], ["HIV", "PROBLEM", 165, 168], ["bone metabolism anomalies", "PROBLEM", 180, 205], ["HIV", "OBSERVATION", 165, 168], ["bone", "ANATOMY", 180, 184], ["metabolism anomalies", "OBSERVATION", 185, 205]]], ["When planning strategies for their early diagnosis, prevention and management also cost-effectiveness issues should be considered, since no pharmacoeconomic data still exist in this setting.", [["management", "TREATMENT", 67, 77], ["cost-effectiveness issues", "PROBLEM", 83, 108], ["pharmacoeconomic data", "TEST", 140, 161]]], ["Although severe consequences (e.g. pathological fractures, prosthetic implants) are expected to be infrequent their consequences in terms of length and intensity of hospitalization, related costs, and especially severe consequences on the p's quality of life, play a notable role.", [["fractures", "DISEASE", 48, 57], ["severe consequences (e.g. pathological fractures", "PROBLEM", 9, 57], ["prosthetic implants", "TREATMENT", 59, 78], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["fractures", "OBSERVATION", 48, 57], ["prosthetic implants", "OBSERVATION", 59, 78]]], ["Anyway, the most reliable diagnostic procedure (DEXA) has affordable costs (around Eur 43.40 for a total-body scan which also offers a body composition assessment), as well as the first-line drugs for osteopenia, e.g. supplementation with calcium (Eur 5-6.5/month), and vitamin D (Eur 7/month).", [["body", "ANATOMY", 135, 139], ["osteopenia", "DISEASE", 201, 211], ["calcium", "CHEMICAL", 239, 246], ["vitamin D", "CHEMICAL", 270, 279], ["calcium", "CHEMICAL", 239, 246], ["vitamin D", "CHEMICAL", 270, 279], ["body", "ORGANISM_SUBDIVISION", 105, 109], ["body", "ORGANISM_SUBDIVISION", 135, 139], ["calcium", "SIMPLE_CHEMICAL", 239, 246], ["vitamin D", "SIMPLE_CHEMICAL", 270, 279], ["a total-body scan", "TEST", 97, 114], ["a body composition assessment", "TEST", 133, 162], ["the first-line drugs", "TREATMENT", 176, 196], ["osteopenia", "PROBLEM", 201, 211], ["calcium", "TREATMENT", 239, 246], ["vitamin D", "TREATMENT", 270, 279], ["osteopenia", "OBSERVATION", 201, 211]]], ["These costs cannot be compared with the costs of a standard care of an asymptomatic HAART-treated p (Eur 471 to 774/month) and the immunological, virologic, laboratory and clinical controls made at least quarterly.", [["an asymptomatic HAART", "TREATMENT", 68, 89]]], ["Like postmenopausal osteopenia/osteoporosis (burdened by a greater risk of bone mass anomalies) also HIV disease should be investigated from multiple cost-effectiveness points of view to establish which p are the preferred candidates for a DEXA screening when this examination is more useful during HIV disease course and therapy, when the exam should be repeated and when and how to intervene pharmacologically to prevent serious and potentially invalidating complications.P1502A comparative study on the cost of new drugs in different therapeutic categories M. Falagas, K. Fragoulis, G. Zouglakis, I. Karydis (Athens, GR)P1502Objectives: Drug treatment is becoming more expensive due to the increased cost for the introduction of new drugs and there seems to be an uneven distribution of medication cost for different therapeutic categories.", [["bone mass", "ANATOMY", 75, 84], ["osteopenia", "DISEASE", 20, 30], ["osteoporosis", "DISEASE", 31, 43], ["bone mass anomalies", "DISEASE", 75, 94], ["HIV disease", "DISEASE", 101, 112], ["bone", "TISSUE", 75, 79], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 299, 302], ["postmenopausal osteopenia", "PROBLEM", 5, 30], ["osteoporosis", "PROBLEM", 31, 43], ["bone mass anomalies", "PROBLEM", 75, 94], ["HIV disease", "PROBLEM", 101, 112], ["a DEXA screening", "TEST", 238, 254], ["this examination", "TEST", 260, 276], ["HIV disease course", "TREATMENT", 299, 317], ["therapy", "TREATMENT", 322, 329], ["the exam", "TEST", 336, 344], ["serious and potentially invalidating complications", "PROBLEM", 423, 473], ["comparative study", "TEST", 481, 498], ["new drugs", "TREATMENT", 514, 523], ["Drug treatment", "TREATMENT", 640, 654], ["the increased cost", "PROBLEM", 689, 707], ["new drugs", "TREATMENT", 732, 741], ["medication cost", "TREATMENT", 790, 805], ["different therapeutic categories", "PROBLEM", 810, 842], ["postmenopausal", "OBSERVATION_MODIFIER", 5, 19], ["osteopenia", "OBSERVATION", 20, 30], ["osteoporosis", "OBSERVATION", 31, 43], ["bone", "ANATOMY", 75, 79], ["mass", "OBSERVATION", 80, 84]]], ["We hypothesized that the cost of new antimicrobial agents may differ from that of other therapeutic categories and this may play a role in the stagnation of development of new antibiotics.", [["new antimicrobial agents", "TREATMENT", 33, 57], ["new antibiotics", "TREATMENT", 172, 187], ["new", "OBSERVATION_MODIFIER", 172, 175], ["antibiotics", "OBSERVATION", 176, 187]]], ["Methods: We performed a pharmaco-economical comparative analysis of the drug cost of treatment for new agents introduced in the United States drug market in various therapeutic categories.", [["treatment", "TREATMENT", 85, 94], ["new agents", "TREATMENT", 99, 109]]], ["We calculated the drug cost [in US dollars (USD)] of a 10-day treatment of all new drugs approved by the FDA during the period between January 1997 and July 2003, according to the 2004 Red Book Pharmacy's Fundamental Reference.", [["all new drugs", "TREATMENT", 75, 88]]], ["Results: New anti-neoplastic agents were found to be the most expensive drugs in comparison to all other therapeutic categories with a median 10-day drug-treatment cost of 848 USD compared to the median 10-day drug-treatment costs of all other categories ranging from 29 to 301 USD (Table) .", [["New anti-neoplastic agents", "TREATMENT", 9, 35], ["all other categories", "TEST", 234, 254]]], ["On the other hand, new antimicrobial drugs were found to be much less expensive with a median 10-day drug-treatment cost of 137 and 85 USD for all anti-microbial agents and for anti-microbial agents excluding anti-HIV medications, respectively.", [["new antimicrobial drugs", "TREATMENT", 19, 42], ["all anti-microbial agents", "TREATMENT", 143, 168], ["anti-microbial agents", "TREATMENT", 177, 198], ["anti-HIV medications", "TREATMENT", 209, 229]]], ["Conclusion: The drug-treatment cost of new medications varies considerably by different therapeutic categories.", [["The drug-treatment", "TREATMENT", 12, 30], ["new medications", "TREATMENT", 39, 54]]], ["This fact may influence industry decisions regarding the development of new drugs and may play a role in the shortage of new anti-microbial agents in the fight against the serious problem of anti-microbial resistance.P1503Usage and expenditure of 4f-quinolones in a tertiary hospital in 2004 T.A. Peppas, K. Malengou, N. Zachos, D. Voutsinas, O. Kosmopoulou, N. Galanakis (Piraeus, Athens, GR) Objective: Our aim was to assess 4-F-quinolone (4FQ) usage, distribution and expenditure over 2 years.", [["4f-quinolones", "CHEMICAL", 247, 260], ["4-F-quinolone", "CHEMICAL", 427, 440], ["4FQ", "CHEMICAL", 442, 445], ["4f-quinolones", "CHEMICAL", 247, 260], ["4-F-quinolone", "CHEMICAL", 427, 440], ["4FQ", "CHEMICAL", 442, 445], ["4f-quinolones", "SIMPLE_CHEMICAL", 247, 260], ["4-F-quinolone", "SIMPLE_CHEMICAL", 427, 440], ["4FQ", "SIMPLE_CHEMICAL", 442, 445], ["new drugs", "TREATMENT", 72, 81], ["new anti-microbial agents", "TREATMENT", 121, 146], ["anti-microbial resistance", "PROBLEM", 191, 216], ["quinolones", "TREATMENT", 250, 260], ["quinolone", "TREATMENT", 431, 440], ["anti-microbial resistance", "OBSERVATION", 191, 216]]], ["Objective: To analyse antiobiotic utilization in Croatia using Anatomical-Therapeutic-Chemical (ATC) drug classification system and number of defined daily doses (DDD).", [["Chemical (ATC) drug classification system", "TREATMENT", 86, 127]]], ["Methods: Data on the number of packages and purchase price were collected for each individual drug.", [["purchase price", "TREATMENT", 44, 58]]], ["These data were used to calculate the number of defined daily doses (DDD) and DDD per 1000 inhabitants per day (DDD/TID).", [["DDD", "TREATMENT", 78, 81]]], ["Drug utilization 90% (DU90%) segment was used as a prescribing quality indicator.", [["Drug utilization", "TREATMENT", 0, 16], ["DU90%) segment", "TREATMENT", 22, 36]]], ["Results: In 2004, the overall utilization of antibiotics in Croatia amounted to 23.35DDD/TID.", [["antibiotics", "TREATMENT", 45, 56]]], ["According to drug groups, penicillins (J01C) showed highest utilization (12.24 DDD/TID), predominated by the subgroup of penicillin combinations (including beta-lactamase inhibitors, J01CR) with6.86 DDD/ TID, within which the combination of amoxicillin + clavulanic acid accounted for99.9% with 6.85DDD/TID.", [["penicillins", "CHEMICAL", 26, 37], ["J01C", "CHEMICAL", 39, 43], ["penicillin", "CHEMICAL", 121, 131], ["J01CR", "CHEMICAL", 183, 188], ["TID", "CHEMICAL", 204, 207], ["amoxicillin + clavulanic acid", "CHEMICAL", 241, 270], ["penicillins", "CHEMICAL", 26, 37], ["J01C", "CHEMICAL", 39, 43], ["penicillin", "CHEMICAL", 121, 131], ["amoxicillin", "CHEMICAL", 241, 252], ["clavulanic acid", "CHEMICAL", 255, 270], ["penicillins", "SIMPLE_CHEMICAL", 26, 37], ["J01C", "SIMPLE_CHEMICAL", 39, 43], ["penicillin", "SIMPLE_CHEMICAL", 121, 131], ["beta-lactamase inhibitors", "SIMPLE_CHEMICAL", 156, 181], ["J01CR", "SIMPLE_CHEMICAL", 183, 188], ["amoxicillin + clavulanic acid", "SIMPLE_CHEMICAL", 241, 270], ["penicillins (J01C", "TREATMENT", 26, 43], ["penicillin combinations", "TREATMENT", 121, 144], ["beta-lactamase inhibitors", "TREATMENT", 156, 181], ["J01CR", "TREATMENT", 183, 188], ["DDD", "TREATMENT", 199, 202], ["amoxicillin", "TREATMENT", 241, 252], ["clavulanic acid", "TREATMENT", 255, 270]]], ["Broad-spectrum penicillins (J01CA) accounted for 43.2%(5.28 DDD/TID) of total penicillin utilization, with a 97.7% predominance of amoxicillin (5.16 DDD/TID).", [["penicillins", "CHEMICAL", 15, 26], ["J01CA", "CHEMICAL", 28, 33], ["penicillin", "CHEMICAL", 78, 88], ["amoxicillin", "CHEMICAL", 131, 142], ["penicillins", "CHEMICAL", 15, 26], ["J01CA", "CHEMICAL", 28, 33], ["penicillin", "CHEMICAL", 78, 88], ["amoxicillin", "CHEMICAL", 131, 142], ["Broad-spectrum penicillins", "SIMPLE_CHEMICAL", 0, 26], ["J01CA", "SIMPLE_CHEMICAL", 28, 33], ["penicillin", "SIMPLE_CHEMICAL", 78, 88], ["amoxicillin", "SIMPLE_CHEMICAL", 131, 142], ["Broad-spectrum penicillins (J01CA", "TREATMENT", 0, 33], ["DDD", "TEST", 60, 63], ["total penicillin utilization", "TREATMENT", 72, 100], ["amoxicillin", "TREATMENT", 131, 142]]], ["Cephalosporins (J01D) ranked second with 4.00DDD/TID, followed by macrolides and lincosamides (J01F) with 2.41 DDD/TID, with an 86.84%predominance of macrolides (J01FA) with 2.09DDD/TID.", [["Cephalosporins", "CHEMICAL", 0, 14], ["J01D", "CHEMICAL", 16, 20], ["TID", "CHEMICAL", 49, 52], ["macrolides", "CHEMICAL", 66, 76], ["lincosamides", "CHEMICAL", 81, 93], ["J01F", "CHEMICAL", 95, 99], ["macrolides", "CHEMICAL", 150, 160], ["J01FA", "CHEMICAL", 162, 167], ["Cephalosporins", "CHEMICAL", 0, 14], ["macrolides", "CHEMICAL", 66, 76], ["lincosamides", "CHEMICAL", 81, 93], ["J01F", "CHEMICAL", 95, 99], ["macrolides", "CHEMICAL", 150, 160], ["J01FA", "CHEMICAL", 162, 167], ["Cephalosporins", "SIMPLE_CHEMICAL", 0, 14], ["macrolides", "SIMPLE_CHEMICAL", 66, 76], ["lincosamides", "SIMPLE_CHEMICAL", 81, 93], ["macrolides", "SIMPLE_CHEMICAL", 150, 160], ["Cephalosporins (J01D)", "TREATMENT", 0, 21], ["DDD/TID", "TREATMENT", 45, 52], ["macrolides", "TREATMENT", 66, 76], ["lincosamides", "TREATMENT", 81, 93], ["macrolides", "TREATMENT", 150, 160]]], ["Among the latter, azithromycin showed highest utilization with 1.44 DDD/TID, accounting for 68.66% of total macrolide utilization.", [["azithromycin", "CHEMICAL", 18, 30], ["macrolide", "CHEMICAL", 108, 117], ["azithromycin", "CHEMICAL", 18, 30], ["macrolide", "CHEMICAL", 108, 117], ["azithromycin", "SIMPLE_CHEMICAL", 18, 30], ["macrolide", "SIMPLE_CHEMICAL", 108, 117], ["azithromycin", "TREATMENT", 18, 30], ["DDD/TID", "TREATMENT", 68, 75], ["total macrolide utilization", "TREATMENT", 102, 129]]], ["Tetracyclines (J01A) ranked fourth with 2.02DDD/TID, accounting for 8.65% of overall antibiotic utilization, followed by quinolones with 1.65 DDD/TID, other antimicrobials with 0.91 DDD/TID, and aminoglycosides with 0.16DDD/TID.", [["Tetracyclines", "CHEMICAL", 0, 13], ["J01A", "CHEMICAL", 15, 19], ["quinolones", "CHEMICAL", 121, 131], ["DDD", "CHEMICAL", 142, 145], ["TID", "CHEMICAL", 146, 149], ["DDD", "CHEMICAL", 182, 185], ["TID", "CHEMICAL", 186, 189], ["aminoglycosides", "CHEMICAL", 195, 210], ["Tetracyclines", "CHEMICAL", 0, 13], ["quinolones", "CHEMICAL", 121, 131], ["TID", "CHEMICAL", 186, 189], ["aminoglycosides", "CHEMICAL", 195, 210], ["TID", "CHEMICAL", 224, 227], ["Tetracyclines", "SIMPLE_CHEMICAL", 0, 13], ["J01A", "SIMPLE_CHEMICAL", 15, 19], ["quinolones", "SIMPLE_CHEMICAL", 121, 131], ["TID", "SIMPLE_CHEMICAL", 186, 189], ["aminoglycosides", "SIMPLE_CHEMICAL", 195, 210], ["Tetracyclines (J01A)", "TREATMENT", 0, 20], ["overall antibiotic utilization", "TREATMENT", 77, 107], ["quinolones", "TREATMENT", 121, 131], ["other antimicrobials", "TREATMENT", 151, 171], ["aminoglycosides", "TREATMENT", 195, 210]]], ["Sulfonamides (J01E) accounted for a negligible proportion of overall utilization.", [["Sulfonamides", "CHEMICAL", 0, 12], ["J01E", "CHEMICAL", 14, 18], ["Sulfonamides", "CHEMICAL", 0, 12], ["J01E", "CHEMICAL", 14, 18], ["Sulfonamides", "SIMPLE_CHEMICAL", 0, 12], ["J01E", "SIMPLE_CHEMICAL", 14, 18], ["Sulfonamides (J01E)", "TREATMENT", 0, 19]]], ["DU 90% segment included 9 of 43 antibiotics registered in Croatia, with amoxicillin + clavulanic acid as the leading one, followed by cephalexin with 1.83, cefuroxime with 1.53, azithromycin and norfloxacin with 1.3each, nitrofurantoin with 0.56 and clarithromycin with 0.53DDD/TID.", [["amoxicillin + clavulanic acid", "CHEMICAL", 72, 101], ["cephalexin", "CHEMICAL", 134, 144], ["cefuroxime", "CHEMICAL", 156, 166], ["azithromycin", "CHEMICAL", 178, 190], ["norfloxacin", "CHEMICAL", 195, 206], ["nitrofurantoin", "CHEMICAL", 221, 235], ["clarithromycin", "CHEMICAL", 250, 264], ["TID", "CHEMICAL", 278, 281], ["amoxicillin", "CHEMICAL", 72, 83], ["clavulanic acid", "CHEMICAL", 86, 101], ["cephalexin", "CHEMICAL", 134, 144], ["cefuroxime", "CHEMICAL", 156, 166], ["azithromycin", "CHEMICAL", 178, 190], ["norfloxacin", "CHEMICAL", 195, 206], ["nitrofurantoin", "CHEMICAL", 221, 235], ["clarithromycin", "CHEMICAL", 250, 264], ["TID", "CHEMICAL", 278, 281], ["amoxicillin + clavulanic acid", "SIMPLE_CHEMICAL", 72, 101], ["cephalexin", "SIMPLE_CHEMICAL", 134, 144], ["cefuroxime", "SIMPLE_CHEMICAL", 156, 166], ["azithromycin", "SIMPLE_CHEMICAL", 178, 190], ["norfloxacin", "SIMPLE_CHEMICAL", 195, 206], ["nitrofurantoin", "SIMPLE_CHEMICAL", 221, 235], ["clarithromycin", "SIMPLE_CHEMICAL", 250, 264], ["43 antibiotics", "TREATMENT", 29, 43], ["amoxicillin", "TREATMENT", 72, 83], ["clavulanic acid", "TREATMENT", 86, 101], ["cephalexin", "TREATMENT", 134, 144], ["cefuroxime", "TREATMENT", 156, 166], ["azithromycin", "TREATMENT", 178, 190], ["norfloxacin", "TREATMENT", 195, 206], ["nitrofurantoin", "TREATMENT", 221, 235], ["clarithromycin", "TREATMENT", 250, 264]]], ["Hospital utilization accounted for 7.1% of overall antibiotic utilization expressed in DDD/TID and 22.7% of the respective financial cost, predominated by aminoglycosides (J01G) with 72% and 94.2%, and lowest proportion of tetracyclines (J01A) with 4.3%, and 2.4%, respectively.", [["TID", "CHEMICAL", 91, 94], ["aminoglycosides", "CHEMICAL", 155, 170], ["J01G", "CHEMICAL", 172, 176], ["tetracyclines", "CHEMICAL", 223, 236], ["J01A", "CHEMICAL", 238, 242], ["aminoglycosides", "CHEMICAL", 155, 170], ["tetracyclines", "CHEMICAL", 223, 236], ["aminoglycosides", "SIMPLE_CHEMICAL", 155, 170], ["tetracyclines", "SIMPLE_CHEMICAL", 223, 236], ["overall antibiotic utilization", "TREATMENT", 43, 73], ["DDD/TID", "TREATMENT", 87, 94], ["aminoglycosides", "TEST", 155, 170], ["tetracyclines", "TREATMENT", 223, 236]]], ["Conclusion: The utilization of antibiotics in Croatia is among the highest in Europe, mostly due to overuse of amoxicillin + clavulanic acid, which has no rational ground in professional guidelines.", [["amoxicillin + clavulanic acid", "CHEMICAL", 111, 140], ["amoxicillin", "CHEMICAL", 111, 122], ["clavulanic acid", "CHEMICAL", 125, 140], ["amoxicillin + clavulanic acid", "SIMPLE_CHEMICAL", 111, 140], ["antibiotics", "TREATMENT", 31, 42], ["amoxicillin", "TREATMENT", 111, 122], ["clavulanic acid", "TREATMENT", 125, 140]]], ["The data was collected from two randomly chosen pharmacies in the city of Zabrze that supply the citizens of the Silesian agglomeration from various social backgrounds.", [["The data", "TEST", 0, 8], ["Zabrze", "TREATMENT", 74, 80], ["Silesian agglomeration", "OBSERVATION", 113, 135], ["social backgrounds", "OBSERVATION", 149, 167]]], ["Taking into account the value of a single antibiotics package and the price a patient has to pay for it an average price of medications prescribed by family and specialist doctors was calculated.", [["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["a single antibiotics package", "TREATMENT", 33, 61], ["medications", "TREATMENT", 124, 135]]], ["Results: A total of 30793 prescriptions were analysed out of which 24834 dated from 1999 and 5959 from 2005.In the first half-year of 1999 the percentage of prescriptions for antibiotics reached 7.76% on average, and in the year 2005 -the average was 11.6%.", [["antibiotics", "TREATMENT", 175, 186]]], ["In the first half-year of 1999 family doctors mostly prescribed: penicyllins (43%), makrolids (26%), cephalosporins (16%), tetracyclins (11%), chinolons (3%).", [["penicyllins", "CHEMICAL", 65, 76], ["makrolids", "CHEMICAL", 84, 93], ["cephalosporins", "CHEMICAL", 101, 115], ["tetracyclins", "CHEMICAL", 123, 135], ["penicyllins", "CHEMICAL", 65, 76], ["makrolids", "CHEMICAL", 84, 93], ["cephalosporins", "CHEMICAL", 101, 115], ["tetracyclins", "CHEMICAL", 123, 135], ["penicyllins", "SIMPLE_CHEMICAL", 65, 76], ["makrolids", "SIMPLE_CHEMICAL", 84, 93], ["cephalosporins", "SIMPLE_CHEMICAL", 101, 115], ["penicyllins", "TREATMENT", 65, 76], ["makrolids", "TREATMENT", 84, 93], ["cephalosporins", "TREATMENT", 101, 115], ["tetracyclins", "TREATMENT", 123, 135]]], ["In the same period spcialist doctors prescribed: penicyllins (41%), cephalosporins (17%), makrolids (15%), tetracyclins (13%), lincozamids (9%), chinolons (4%).", [["penicyllins", "CHEMICAL", 49, 60], ["cephalosporins", "CHEMICAL", 68, 82], ["makrolids", "CHEMICAL", 90, 99], ["tetracyclins", "CHEMICAL", 107, 119], ["lincozamids", "CHEMICAL", 127, 138], ["chinolons", "CHEMICAL", 145, 154], ["penicyllins", "CHEMICAL", 49, 60], ["cephalosporins", "CHEMICAL", 68, 82], ["makrolids", "CHEMICAL", 90, 99], ["tetracyclins", "CHEMICAL", 107, 119], ["lincozamids", "CHEMICAL", 127, 138], ["penicyllins", "SIMPLE_CHEMICAL", 49, 60], ["cephalosporins", "SIMPLE_CHEMICAL", 68, 82], ["makrolids", "SIMPLE_CHEMICAL", 90, 99], ["tetracyclins", "SIMPLE_CHEMICAL", 107, 119], ["penicyllins", "TREATMENT", 49, 60], ["cephalosporins", "TREATMENT", 68, 82], ["makrolids", "TREATMENT", 90, 99], ["tetracyclins", "TREATMENT", 107, 119], ["lincozamids", "TREATMENT", 127, 138]]], ["In the first half-year of 2005 family doctors most often prescribed penicyllins -(44.8%), makrolids -(27.1%), cephalosporins -(12.5%), tetracyclins -(9.4%) and lincozamidsbased (3.1%) treatments Specialist doctors, on the other hand, prescribed penicllins (41.7%), makrolids (17.9%), cephalosporins (17.7%), tetracyclins (12.1%), lincozamids (5.2%) and chinolons (3%).", [["penicyllins", "CHEMICAL", 68, 79], ["makrolids", "CHEMICAL", 90, 99], ["cephalosporins", "CHEMICAL", 110, 124], ["tetracyclins", "CHEMICAL", 135, 147], ["lincozamidsbased", "CHEMICAL", 160, 176], ["penicllins", "CHEMICAL", 245, 255], ["makrolids", "CHEMICAL", 265, 274], ["cephalosporins", "CHEMICAL", 284, 298], ["tetracyclins", "CHEMICAL", 308, 320], ["lincozamids", "CHEMICAL", 330, 341], ["penicyllins", "CHEMICAL", 68, 79], ["makrolids", "CHEMICAL", 90, 99], ["cephalosporins", "CHEMICAL", 110, 124], ["tetracyclins", "CHEMICAL", 135, 147], ["lincozamidsbased", "CHEMICAL", 160, 176], ["penicllins", "CHEMICAL", 245, 255], ["makrolids", "CHEMICAL", 265, 274], ["cephalosporins", "CHEMICAL", 284, 298], ["tetracyclins", "CHEMICAL", 308, 320], ["lincozamids", "CHEMICAL", 330, 341], ["penicyllins", "SIMPLE_CHEMICAL", 68, 79], ["makrolids", "SIMPLE_CHEMICAL", 90, 99], ["cephalosporins", "SIMPLE_CHEMICAL", 110, 124], ["tetracyclins", "SIMPLE_CHEMICAL", 135, 147], ["makrolids", "SIMPLE_CHEMICAL", 265, 274], ["cephalosporins", "SIMPLE_CHEMICAL", 284, 298], ["tetracyclins", "SIMPLE_CHEMICAL", 308, 320], ["lincozamids", "SIMPLE_CHEMICAL", 330, 341], ["penicyllins", "TEST", 68, 79], ["makrolids", "TEST", 90, 99], ["cephalosporins", "TREATMENT", 110, 124], ["tetracyclins", "TREATMENT", 135, 147], ["lincozamidsbased", "TREATMENT", 160, 176], ["penicllins", "TREATMENT", 245, 255], ["makrolids", "TREATMENT", 265, 274], ["cephalosporins", "TREATMENT", 284, 298], ["tetracyclins", "TREATMENT", 308, 320], ["lincozamids", "TREATMENT", 330, 341], ["hand", "ANATOMY", 228, 232]]], ["The average prices of the prescribed medications in the years 1999 and 2005 were, respectively: for family doctors-EU 3.08 and 4.01, for specialist doctors EU 4.44 and 3.87.", [["the prescribed medications", "TREATMENT", 22, 48]]], ["Conclusions: There has been a considerable increase in the percentage of prescriptions for antibiotics from 7.45% (in 1999) to 11.3% (in 2005).", [["antibiotics", "TREATMENT", 91, 102], ["considerable", "OBSERVATION_MODIFIER", 30, 42], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["percentage", "OBSERVATION_MODIFIER", 59, 69]]], ["The tendency towards prescribing antibiotics in the specific groups of doctors has not changed significantly.", [["The tendency", "PROBLEM", 0, 12], ["prescribing antibiotics", "TREATMENT", 21, 44], ["tendency", "OBSERVATION_MODIFIER", 4, 12]]], ["In both years prescriptions for antibiotics were in line with the recommendations.", [["antibiotics", "TREATMENT", 32, 43]]], ["Also, prices of medications prescribed by family doctors have risen.P1507Internet guide on antimicrobial resistance A. Sosa, F. Traub, S. Valovic, P. Chea (Boston, US)P1507Objectives: (1) To organize the plethora of information available, providing clinicians the tools to easily access available online resources that include academic institutions, professional societies as well as sites maintained by private individuals; (2) to inform clinicians of new advances in the epidemiology, diagnosis, treatment, and prevention of most common infections; (3) to inform on subjects such as clinical trials in antimicrobial resistance, information about specific pathogens and their infections, genomic resources, culture collections, electronic images of pathogens and antimicrobial agents, antimicrobial resistance lecture and teaching materials, environmental health and safety information, and a listing of websites of infectious disease and clinical microbiology professional societies.", [["infections", "DISEASE", 539, 549], ["infections", "DISEASE", 677, 687], ["infectious disease", "DISEASE", 917, 935], ["P1507", "SIMPLE_CHEMICAL", 68, 73], ["medications", "TREATMENT", 16, 27], ["treatment", "TREATMENT", 498, 507], ["most common infections", "PROBLEM", 527, 549], ["antimicrobial resistance", "TREATMENT", 604, 628], ["specific pathogens", "PROBLEM", 648, 666], ["their infections", "PROBLEM", 671, 687], ["culture collections", "TEST", 708, 727], ["electronic images", "TEST", 729, 746], ["pathogens", "PROBLEM", 750, 759], ["antimicrobial agents", "TREATMENT", 764, 784], ["antimicrobial resistance lecture", "TREATMENT", 786, 818]]], ["Methods: We defined four inclusion criteria after extensive consulting with APUA staff and scientific advisory members: (1) Recognized/reputable source; (2) High quality of information presented; (3) Potential usefulness to medical professionals and the general public; and (4) Ease of navigation.", [["navigation", "TREATMENT", 286, 296]]], ["Ideal parameters were determined for the guide's scope and the appropriate sources identified online were subsequently reviewed.", [["the guide's scope", "TEST", 37, 54]]], ["Results: With use of popular search engines, such as Google, Yahoo!, and AltaVista, we initially identified a great number of websites.", [["great", "OBSERVATION_MODIFIER", 110, 115]]], ["Using broad search terms, such as \"antibiotic resistance,\" we identified 1,310,000 web addresses.", [["\"antibiotic resistance", "TREATMENT", 34, 56]]], ["The term \"antimicrobial resistance\" generated 578,000 hits, and the term \"drug resistance\" generated 6,190,000 hits.", [["antimicrobial resistance", "OBSERVATION", 10, 34]]], ["Each website listed describes: (1) Full citation of the resource: author/editor and title of website;P1507(2) Date of publication or last revision; (3) Methods and results: The portal is free to use but requires registration and has more than 1850 registered users as of November 2005.", [["portal", "MULTI-TISSUE_STRUCTURE", 177, 183], ["last revision", "TREATMENT", 133, 146], ["registration", "TEST", 212, 224], ["portal", "ANATOMY", 177, 183], ["free", "OBSERVATION", 187, 191]]], ["Of these, 20% are in-training positions, 28% hold a faculty position in infectious diseases (ID), microbiology or hemato-oncology, 24% are specialists in a non-university, but a teaching setting.", [["infectious diseases", "DISEASE", 72, 91], ["ID", "DISEASE", 93, 95], ["infectious", "OBSERVATION_MODIFIER", 72, 82]]], ["Running costs of the portal are partially covered by educational grants from pharmaceutical sponsors who have no role in organization of the site, but their names are acknowledged.", [["portal", "MULTI-TISSUE_STRUCTURE", 21, 27], ["portal", "ANATOMY", 21, 27]]], ["Other materials included guidelines, free slide sets, study protocols and updates from the Group, CME activities and meeting announcements.", [["study protocols", "TEST", 54, 69]]], ["Approximately 5.5 Gb material was downloaded.", [["5.5 Gb", "OBSERVATION_MODIFIER", 14, 20]]], ["The frequency of readings are related with the time (highest between 9.00-11.00 am during weekdays and lowest during weekends), the type of documents (i.e. educational materials and guidelines), popularity of the news (e.g. peaked during an epidemic of avian influenza when related news and articles announced).", [["influenza", "DISEASE", 259, 268], ["influenza", "PROBLEM", 259, 268]]], ["Our results also indicated that, a web page gets ''old'' after about a month of publishing, emphasizing the importance of well-timed announcements of the Portal material.P1509NeLI and NRIC survey: information needs of infectious disease professionals P. Kostkova, S. D'Souza, G. Madle, J. Mani-Saada, S. Wiseman, A. Roy, J. Weinberg (London, UK)P1509Healthcare professionals are increasingly facing the problem of information overflow.", [["infectious disease", "DISEASE", 218, 236], ["Portal material", "MULTI-TISSUE_STRUCTURE", 154, 169], ["Portal", "ANATOMY", 154, 160]]], ["National Internet libraries in the UK are addressing this problem: the umbrella portal National electronic Library of Infection NeLI (http://www.neli.org.uk) providing a single access portal to quality-assured information on treatment, diagnosis, prevention and management of infection diseases, and the National Resource for Infection Control NRIC (http:// www.nric.org.uk) -a single-stop shop for policies, guidelines and research around infection control, hosted by NeLI.", [["infection diseases", "DISEASE", 276, 294], ["Infection", "DISEASE", 326, 335], ["infection", "DISEASE", 440, 449], ["NeLI", "PROTEIN", 469, 473], ["Infection NeLI", "PROBLEM", 118, 132], ["treatment", "TREATMENT", 225, 234], ["management", "TREATMENT", 262, 272], ["infection diseases", "PROBLEM", 276, 294], ["Infection", "PROBLEM", 326, 335], ["research around infection control", "TREATMENT", 424, 457], ["umbrella", "ANATOMY_MODIFIER", 71, 79], ["portal", "ANATOMY", 80, 86], ["Infection", "OBSERVATION", 118, 127], ["portal", "ANATOMY", 184, 190], ["infection", "OBSERVATION", 276, 285], ["infection", "OBSERVATION", 440, 449]]], ["A pilot qualitative online questionnaire-based study revealed that our users come from the variety of professionals: clinical scientist, consultant, registrar, psychotherapist, lecturer, GP, medical librarian, information scientist, health protection.", [["A pilot qualitative online questionnaire", "TEST", 0, 40], ["based study", "TEST", 41, 52]]], ["These have questions mainly around HIV, tinea, molluscum contagio, meningitis, cold, MRSA, Lyme, Toxoplasma, chicken pox, Influenza, diarrhoea and vomiting, rash, Staph. aureus, traveller infections antibiotics resistance, malaria, MMR, meningitis, viral myocarditis, anthrax, smallpox, and TB.", [["tinea", "DISEASE", 40, 45], ["molluscum contagio", "DISEASE", 47, 65], ["meningitis", "DISEASE", 67, 77], ["MRSA", "DISEASE", 85, 89], ["Lyme", "DISEASE", 91, 95], ["Toxoplasma, chicken pox", "DISEASE", 97, 120], ["Influenza", "DISEASE", 122, 131], ["diarrhoea", "DISEASE", 133, 142], ["vomiting", "DISEASE", 147, 155], ["rash", "DISEASE", 157, 161], ["infections", "DISEASE", 188, 198], ["malaria", "DISEASE", 223, 230], ["meningitis", "DISEASE", 237, 247], ["viral myocarditis", "DISEASE", 249, 266], ["anthrax", "DISEASE", 268, 275], ["smallpox", "DISEASE", 277, 285], ["TB", "DISEASE", 291, 293], ["HIV", "ORGANISM", 35, 38], ["molluscum contagio", "ORGANISM", 47, 65], ["Toxoplasma", "ORGANISM", 97, 107], ["chicken", "ORGANISM", 109, 116], ["pox", "ORGANISM", 117, 120], ["Influenza", "ORGANISM", 122, 131], ["aureus", "ORGANISM", 170, 176], ["HIV", "SPECIES", 35, 38], ["MRSA", "SPECIES", 85, 89], ["chicken", "SPECIES", 109, 116], ["pox", "SPECIES", 117, 120], ["Influenza", "SPECIES", 122, 131], ["aureus", "SPECIES", 170, 176], ["HIV", "SPECIES", 35, 38], ["MRSA", "SPECIES", 85, 89], ["chicken", "SPECIES", 109, 116], ["aureus", "SPECIES", 170, 176], ["HIV", "PROBLEM", 35, 38], ["tinea", "PROBLEM", 40, 45], ["molluscum contagio", "PROBLEM", 47, 65], ["meningitis", "PROBLEM", 67, 77], ["cold", "PROBLEM", 79, 83], ["MRSA", "PROBLEM", 85, 89], ["Lyme", "PROBLEM", 91, 95], ["Toxoplasma", "PROBLEM", 97, 107], ["chicken pox", "PROBLEM", 109, 120], ["Influenza", "PROBLEM", 122, 131], ["diarrhoea", "PROBLEM", 133, 142], ["vomiting", "PROBLEM", 147, 155], ["rash", "PROBLEM", 157, 161], ["Staph", "PROBLEM", 163, 168], ["aureus", "PROBLEM", 170, 176], ["antibiotics resistance", "TREATMENT", 199, 221], ["malaria", "PROBLEM", 223, 230], ["MMR", "PROBLEM", 232, 235], ["meningitis", "PROBLEM", 237, 247], ["viral myocarditis", "PROBLEM", 249, 266], ["anthrax", "PROBLEM", 268, 275], ["smallpox", "PROBLEM", 277, 285], ["TB", "PROBLEM", 291, 293], ["tinea", "OBSERVATION", 40, 45], ["molluscum", "OBSERVATION", 47, 56], ["meningitis", "OBSERVATION", 67, 77], ["MRSA", "OBSERVATION", 85, 89], ["Staph", "OBSERVATION", 163, 168], ["traveller infections", "OBSERVATION", 178, 198], ["malaria", "OBSERVATION", 223, 230], ["meningitis", "OBSERVATION", 237, 247], ["viral myocarditis", "OBSERVATION", 249, 266], ["TB", "OBSERVATION", 291, 293]]], ["This is in line with our quantitative weblog-based evaluation of the most commonly access topics on NeLI by NHS-based users: Antimicrobial resistance and HAE (10.27%), TB (9.54%), meningitis (9.47%), HIV (8.95%), chlamydia (6.31%), E. coli (5.54%), Staph. aureus (5.26%), adenovirus (4.84%), blood borne infections (4.44%).", [["blood", "ANATOMY", 292, 297], ["NeLI", "CHEMICAL", 100, 104], ["HAE", "DISEASE", 154, 157], ["TB", "DISEASE", 168, 170], ["meningitis", "DISEASE", 180, 190], ["HIV (8.95%), chlamydia", "DISEASE", 200, 222], ["blood borne infections", "DISEASE", 292, 314], ["NeLI", "SIMPLE_CHEMICAL", 100, 104], ["E. coli", "ORGANISM", 232, 239], ["aureus", "ORGANISM", 256, 262], ["adenovirus", "ORGANISM", 272, 282], ["blood", "ORGANISM_SUBSTANCE", 292, 297], ["HIV", "SPECIES", 200, 203], ["E. coli", "SPECIES", 232, 239], ["aureus", "SPECIES", 256, 262], ["HIV", "SPECIES", 200, 203], ["E. coli", "SPECIES", 232, 239], ["aureus", "SPECIES", 256, 262], ["based evaluation", "TEST", 45, 61], ["Antimicrobial resistance", "TEST", 125, 149], ["HAE", "TEST", 154, 157], ["TB", "TEST", 168, 170], ["meningitis", "PROBLEM", 180, 190], ["HIV", "TEST", 200, 203], ["chlamydia", "TEST", 213, 222], ["E. coli", "TEST", 232, 239], ["Staph", "PROBLEM", 249, 254], ["aureus", "PROBLEM", 256, 262], ["adenovirus", "TEST", 272, 282], ["blood borne infections", "PROBLEM", 292, 314], ["Antimicrobial resistance", "OBSERVATION", 125, 149], ["meningitis", "OBSERVATION", 180, 190], ["Staph", "OBSERVATION", 249, 254], ["infections", "OBSERVATION", 304, 314]]], ["Further results identifying the needs specific to the infection disease professions will be discussed in relation to differences in the national variations in information needs and priorities.P1510Training in infection S. D'Souza, P. Kostkova, F. Cooke, A. Holmes (London, UK)P1510Specialists today require prompt access to quality information in order to work effectively.", [["infection", "DISEASE", 54, 63], ["infection", "DISEASE", 209, 218], ["the infection disease professions", "PROBLEM", 50, 83], ["infection", "OBSERVATION", 54, 63]]], ["The diversity of specialist interests in the field of infection has led to the formation of a large number of professional and scientific societies.", [["infection", "DISEASE", 54, 63], ["infection", "PROBLEM", 54, 63], ["diversity", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 54, 63], ["large", "OBSERVATION_MODIFIER", 94, 99]]], ["Training In Infection (TII -www.trainingininfection.org.uk) is an online resource, primarily aimed at infection specialist trainees but useful throughout the career path, which brings together this information into one central access point, so that users from all infection specialties can find the appropriate information for their specialty quickly and easily.", [["infection", "DISEASE", 102, 111], ["infection", "DISEASE", 264, 273], ["Infection", "OBSERVATION", 12, 21]]], ["It identifies and links to the key relevant resources covering a broad range of infection related disciplines in a dynamic database structure.", [["infection", "DISEASE", 80, 89], ["infection", "PROBLEM", 80, 89], ["infection", "OBSERVATION", 80, 89]]], ["Information on societies, conferences, grants, journals, textbooks and more are available on the site, and have been put together to create a one-stop infection training portal.", [["infection", "DISEASE", 151, 160], ["infection", "OBSERVATION", 151, 160], ["portal", "ANATOMY", 170, 176]]], ["Training in Infection is endorsed by the National electronic Library of Infection (NeLI -www.neli.org.uk), an established digital library bringing together the best available online evidence-based resources on the investigation, treatment, prevention and control of infectious diseases.P1511Research designs and statistical methods in medical abstracts M. Kompoti, M. Matsagoura, A. Koutsovasilis, A. Koutsovasili, S. Drimis (Athens, GR) Statistical methods used in biomedical research articles are being increasingly scrutinized in medical journals.", [["Infection", "DISEASE", 72, 81], ["infectious diseases", "DISEASE", 266, 285], ["Infection", "PROBLEM", 12, 21], ["Infection", "PROBLEM", 72, 81], ["the investigation", "TEST", 210, 227], ["treatment", "TREATMENT", 229, 238], ["prevention", "TREATMENT", 240, 250], ["infectious diseases", "PROBLEM", 266, 285], ["Statistical methods", "TREATMENT", 438, 457], ["Infection", "OBSERVATION", 12, 21], ["Infection", "OBSERVATION", 72, 81], ["infectious", "OBSERVATION", 266, 276]]], ["However, no such strict policy is generally applied in abstracts presented in medical congresses.", [["no", "UNCERTAINTY", 9, 11]]], ["Objective: This study aimed at assessing the frequency of research designs and statistical methods reported in abstracts presented in two successive years of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).", [["Infectious Diseases", "DISEASE", 209, 228], ["This study", "TEST", 11, 21]]], ["Material and methods: We reviewed all abstracts included in the abstract book of the 14th ECCMID (Prague 2004) (PG) and the 15th ECCMID (Copenhagen 2005) (CP).", [["PG", "CHEMICAL", 112, 114]]], ["All abstracts of original research studies but no abstracts of lectures were included in our study.", [["original research studies", "TEST", 17, 42], ["our study", "TEST", 89, 98]]], ["Two independent investigators read all abstracts and extracted information concerning origin, type (clinical, laboratory, animal model), research design, sample size and statistical methods used in the study.", [["statistical methods", "TEST", 170, 189], ["the study", "TEST", 198, 207], ["size", "OBSERVATION_MODIFIER", 161, 165]]], ["Data analysis was performed with logistic regression and Pearson's chi-square test for categorical variables and Student's t-test for continuous variables.", [["Data analysis", "TEST", 0, 13], ["logistic regression", "TEST", 33, 52], ["Pearson's chi-square test", "TEST", 57, 82], ["categorical variables", "TEST", 87, 108], ["Student's t-test", "TEST", 113, 129]]], ["Statistical significance level was set at p < 0.05.", [["Statistical significance level", "TEST", 0, 30]]], ["Results: A total of 4178 abstracts were included in the analysis according to eligibility criteria (2110 from PG and 2068 from CP).", [["PG", "CHEMICAL", 110, 112], ["the analysis", "TEST", 52, 64], ["CP", "PROBLEM", 127, 129]]], ["Laboratory studies prevailed (61%) followed by clinical studies (35%) and experimental studies with animal models (4%).", [["Laboratory studies", "TEST", 0, 18], ["clinical studies", "TEST", 47, 63], ["experimental studies", "TEST", 74, 94], ["animal models", "TEST", 100, 113]]], ["The majority (79.3%) of the studies were observational (retrospective, prospective, cross-sectional) of which 6.3% concerned diagnostic accuracy testing of laboratory methods and 2.3% were pharmacological studies, 3.8% were randomized controlled trials.", [["the studies", "TEST", 24, 35], ["laboratory methods", "TEST", 156, 174], ["pharmacological studies", "TEST", 189, 212]]], ["Statistical evaluation was clearly described in 26.5% of abstracts (26.1% in PG and 19.8% in CP, p < 0.001), while the rest of abstracts included only descriptive statistics or no statistics at all.", [["PG", "CHEMICAL", 77, 79], ["Statistical evaluation", "TEST", 0, 22], ["PG", "TEST", 77, 79], ["CP", "TEST", 93, 95]]], ["The proportion of statistical methods reporting varied according to the type of the study (animal model studies 49.4%, clinical studies 38.9% and laboratory studies 12.0%, p < 0.001).", [["the study", "TEST", 80, 89], ["animal model studies", "TEST", 91, 111], ["clinical studies", "TEST", 119, 135], ["laboratory studies", "TEST", 146, 164]]], ["Multicentre research studies reported statistics more frequently than single-center studies (26.5% vs. 21.5%, respectively, p = 0.005).", [["Multicentre research studies", "TEST", 0, 28]]], ["Conclusions: Statistical analysis is an inseparable part of original research.", [["Statistical analysis", "TEST", 13, 33]]], ["Research design as well as the implemented statistical methods should always be reported in an adequate manner, thus improving the scientific quality of abstracts.P1511Antimicrobial PK/PD P1512 NXL103-Oral Streptogramin: a phase I, doubleblind, single escalating oral dose study to evaluate safety, tolerability and pharmacokinetics in healthy adult male volunteers M. Rangaraju, J. Rey, J. Hodgson (Romainville, Vitry sur Seine, FR)P1511Background: NXL 103 (formerly XRP 2868) is a novel semisynthetic oral streptogramin that consists of a 30/70 (w/w ratio) association of a pristinamycin IA (PI) derivative and a pristinamycin IIB (PII) derivative.", [["oral", "ANATOMY", 263, 267], ["oral", "ANATOMY", 503, 507], ["Streptogramin", "CHEMICAL", 206, 219], ["NXL 103", "CHEMICAL", 450, 457], ["XRP 2868", "CHEMICAL", 468, 476], ["streptogramin", "CHEMICAL", 508, 521], ["pristinamycin IA", "CHEMICAL", 576, 592], ["PI", "CHEMICAL", 594, 596], ["pristinamycin", "CHEMICAL", 615, 628], ["streptogramin", "CHEMICAL", 508, 521], ["pristinamycin IA", "CHEMICAL", 576, 592], ["pristinamycin IIB", "CHEMICAL", 615, 632], ["oral", "ORGANISM_SUBDIVISION", 263, 267], ["NXL 103", "SIMPLE_CHEMICAL", 450, 457], ["XRP 2868", "SIMPLE_CHEMICAL", 468, 476], ["oral", "ORGANISM_SUBDIVISION", 503, 507], ["streptogramin", "SIMPLE_CHEMICAL", 508, 521], ["pristinamycin IA", "SIMPLE_CHEMICAL", 576, 592], ["PI", "SIMPLE_CHEMICAL", 594, 596], ["pristinamycin IIB", "SIMPLE_CHEMICAL", 615, 632], ["PII) derivative", "SIMPLE_CHEMICAL", 634, 649], ["PII", "PROTEIN", 634, 637], ["PK", "TEST", 182, 184], ["PD", "TEST", 185, 187], ["doubleblind", "TREATMENT", 232, 243], ["single escalating oral dose study", "TREATMENT", 245, 278], ["a novel semisynthetic oral streptogramin", "PROBLEM", 481, 521], ["w/w ratio)", "TREATMENT", 548, 558], ["a pristinamycin IA (PI) derivative", "TREATMENT", 574, 608], ["a pristinamycin IIB (PII) derivative", "TREATMENT", 613, 649]]], ["NXL 103 is being developed for the treatment of respiratory tract and skin and skin structure infections.P1511Methods: 60 healthy male subjects were enrolled in this study.", [["respiratory tract", "ANATOMY", 48, 65], ["skin", "ANATOMY", 70, 74], ["skin", "ANATOMY", 79, 83], ["NXL 103", "CHEMICAL", 0, 7], ["respiratory tract and skin and skin structure infections", "DISEASE", 48, 104], ["respiratory tract", "ORGANISM_SUBDIVISION", 48, 65], ["skin", "ORGAN", 70, 74], ["skin", "ORGAN", 79, 83], ["subjects", "ORGANISM", 135, 143], ["respiratory tract", "PROBLEM", 48, 65], ["skin and skin structure infections", "PROBLEM", 70, 104], ["this study", "TEST", 161, 171], ["respiratory tract", "ANATOMY", 48, 65], ["skin", "ANATOMY", 70, 74], ["skin", "ANATOMY", 79, 83], ["structure", "OBSERVATION_MODIFIER", 84, 93], ["infections", "OBSERVATION", 94, 104]]], ["10 subjects in each of 6 cohorts (125 mg, 250 mg, 500 mg, 1000 mg, 1500 mg and 2000 mg) received either NXL103 (8) or placebo (2) .", [["NXL103", "CHEMICAL", 104, 110], ["NXL103", "CHEMICAL", 104, 110], ["NXL103", "SIMPLE_CHEMICAL", 104, 110]]], ["An additional cohort of 10 subjects received a single dose of 500 mg NXL103 in fasting and fed conditions.", [["NXL103", "CHEMICAL", 69, 75], ["NXL103", "CHEMICAL", 69, 75], ["NXL103", "SIMPLE_CHEMICAL", 69, 75]]], ["Blood and urine samples for PK analysis were collected at multiple time points.", [["Blood", "ANATOMY", 0, 5], ["urine samples", "ANATOMY", 10, 23], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urine samples", "ORGANISM_SUBSTANCE", 10, 23], ["PK", "GENE_OR_GENE_PRODUCT", 28, 30], ["Blood and urine samples", "TEST", 0, 23], ["PK analysis", "TEST", 28, 39], ["urine", "ANATOMY", 10, 15]]], ["Safety was assessed via adverse events, physical examination, clinical laboratory data, ECG and cardiac monitoring.", [["cardiac", "ANATOMY", 96, 103], ["cardiac", "ORGAN", 96, 103], ["adverse events", "PROBLEM", 24, 38], ["physical examination", "TEST", 40, 60], ["clinical laboratory data", "TEST", 62, 86], ["ECG", "TEST", 88, 91], ["cardiac monitoring", "TEST", 96, 114], ["cardiac", "ANATOMY", 96, 103]]], ["Results: NXL103 administered as 125 mg capsules at single doses from 125 mg to 2000 mg was well tolerated and safe.", [["NXL103", "CHEMICAL", 9, 15], ["NXL103", "CHEMICAL", 9, 15], ["NXL103", "SIMPLE_CHEMICAL", 9, 15], ["NXL103", "TREATMENT", 9, 15]]], ["There was no serious or severe adverse event, no dosedependency in the number of AEs or their severity, no significant variation in blood pressure or heart rate, no abnormality on ECG recording, and no clinically significant changes compared to baseline for laboratory parameters.", [["blood", "ANATOMY", 132, 137], ["heart", "ANATOMY", 150, 155], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["heart", "ORGAN", 150, 155], ["serious or severe adverse event", "PROBLEM", 13, 44], ["dosedependency", "PROBLEM", 49, 63], ["blood pressure", "TEST", 132, 146], ["heart rate", "TEST", 150, 160], ["abnormality", "PROBLEM", 165, 176], ["ECG recording", "TEST", 180, 193], ["clinically significant changes", "PROBLEM", 202, 232], ["laboratory parameters", "TEST", 258, 279], ["no", "UNCERTAINTY", 10, 12], ["serious", "OBSERVATION_MODIFIER", 13, 20], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["adverse", "OBSERVATION", 31, 38], ["no", "UNCERTAINTY", 104, 106], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["variation", "OBSERVATION", 119, 128], ["heart", "ANATOMY", 150, 155], ["no", "UNCERTAINTY", 162, 164], ["abnormality", "OBSERVATION", 165, 176], ["no", "UNCERTAINTY", 199, 201]]], ["Both components were rapidly absorbed; PI being slightly more rapidly absorbed than PII.", [["PI", "SIMPLE_CHEMICAL", 39, 41], ["PII", "GENE_OR_GENE_PRODUCT", 84, 87], ["PII", "PROTEIN", 84, 87], ["PI", "PROBLEM", 39, 41]]], ["The Cmax and AUC (0-t) increased approximately in proportion with dose.", [["Cmax", "CHEMICAL", 4, 8], ["Cmax", "SIMPLE_CHEMICAL", 4, 8], ["The Cmax", "TEST", 0, 8], ["AUC", "TEST", 13, 16]]], ["The proportion of PI and PII components estimated on mean exposure values was approximately comparable to that administered (30/70), indicating that the relative bioavailabilities of PI and PII are simila.", [["PI", "SIMPLE_CHEMICAL", 18, 20], ["PI", "SIMPLE_CHEMICAL", 183, 185], ["PII", "GENE_OR_GENE_PRODUCT", 190, 193], ["PII", "PROTEIN", 25, 28], ["PII", "PROTEIN", 190, 193], ["PI and PII components", "PROBLEM", 18, 39], ["mean exposure values", "TEST", 53, 73], ["PI and PII", "PROBLEM", 183, 193], ["PI", "OBSERVATION", 18, 20], ["PII components", "OBSERVATION", 25, 39]]], ["Elimination half-life ranged from between 2 to 3 hours for PI to 4 to 6 hours for PII.", [["PII", "PROTEIN", 82, 85], ["PII", "PROBLEM", 82, 85]]], ["Food increased the bioavailability of PI and PII by approximately 20%.", [["PI", "SIMPLE_CHEMICAL", 38, 40], ["PII", "GENE_OR_GENE_PRODUCT", 45, 48], ["PII", "PROTEIN", 45, 48], ["PI and PII", "TREATMENT", 38, 48]]], ["Conclusions: NXL103 is safe, well tolerated and exhibits predictable PK properties in healthy volunteers in doses up to 2000 mg administered as a single dose.P1513Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator polymorphism and function W. Rose, M. Rybak, B. Tsuji, G. Kaatz, G. Sakoulas (Detroit, New York, US) Objective: Polymorphism at the accessory gene regulator (agr) locus in S. aureus (SA) defines 4 groups (I-IV).", [["NXL103", "CHEMICAL", 13, 19], ["vancomycin", "CHEMICAL", 178, 188], ["daptomycin", "CHEMICAL", 193, 203], ["Staphylococcus aureus", "DISEASE", 222, 243], ["NXL103", "CHEMICAL", 13, 19], ["vancomycin", "CHEMICAL", 178, 188], ["daptomycin", "CHEMICAL", 193, 203], ["NXL103", "SIMPLE_CHEMICAL", 13, 19], ["PK", "GENE_OR_GENE_PRODUCT", 69, 71], ["volunteers", "ORGANISM", 94, 104], ["vancomycin", "SIMPLE_CHEMICAL", 178, 188], ["daptomycin", "SIMPLE_CHEMICAL", 193, 203], ["Staphylococcus aureus", "ORGANISM", 222, 243], ["agr", "GENE_OR_GENE_PRODUCT", 443, 446], ["S. aureus", "ORGANISM", 457, 466], ["I-IV", "GENE_OR_GENE_PRODUCT", 490, 494], ["accessory gene regulator (agr) locus", "DNA", 417, 453], ["Staphylococcus aureus", "SPECIES", 222, 243], ["S. aureus", "SPECIES", 457, 466], ["Staphylococcus aureus", "SPECIES", 222, 243], ["S. aureus", "SPECIES", 457, 466], ["vancomycin", "TREATMENT", 178, 188], ["daptomycin", "TREATMENT", 193, 203], ["Staphylococcus aureus", "PROBLEM", 222, 243], ["Polymorphism", "PROBLEM", 397, 409], ["S. aureus", "PROBLEM", 457, 466], ["Staphylococcus aureus", "OBSERVATION", 222, 243], ["aureus", "OBSERVATION", 460, 466]]], ["Agr group II SA have been associated with glycopeptide treatment failure in patients.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["glycopeptide treatment failure", "TREATMENT", 42, 72]]], ["SA with loss of agr function appear to have a higher tendency to become vancomycin (V) resistant.", [["vancomycin", "CHEMICAL", 72, 82], ["vancomycin (V)", "CHEMICAL", 72, 86], ["agr", "GENE_OR_GENE_PRODUCT", 16, 19], ["vancomycin", "SIMPLE_CHEMICAL", 72, 82], ["agr", "DNA", 16, 19], ["loss of agr function", "PROBLEM", 8, 28], ["a higher tendency", "PROBLEM", 44, 61], ["vancomycin", "TREATMENT", 72, 82], ["vancomycin", "OBSERVATION", 72, 82]]], ["It is unknown whether this association only pertains to glycopeptides.", [["glycopeptides", "TREATMENT", 56, 69]]], ["We examined the effect of varying V and Daptomycin (D) against agr+ and agr null pairs in an in vitro pharmacodynamic model (IVPM).", [["Daptomycin", "CHEMICAL", 40, 50], ["Daptomycin", "CHEMICAL", 40, 50], ["Daptomycin", "SIMPLE_CHEMICAL", 40, 50], ["D", "SIMPLE_CHEMICAL", 52, 53], ["agr+", "GENE_OR_GENE_PRODUCT", 63, 67], ["agr", "DNA", 63, 66], ["varying V", "TREATMENT", 26, 35], ["Daptomycin (D)", "TREATMENT", 40, 54], ["agr", "PROBLEM", 63, 66], ["agr null pairs", "PROBLEM", 72, 86]]], ["Methods: Agr group I and II wild-type prototype and knockout (tetM::agr) pairs were evaluated.", [["Agr group I and II wild-type prototype and knockout (tetM::agr) pairs", "CELL_LINE", 9, 78]]], ["MIC values were determined according to Clinical Laboratory Standards Institute.", [["MIC values", "TEST", 0, 10]]], ["IVPM glass and hollow fibre models were used to simulate dosages and AUC/MIC exposures for V ranging from 62.5 mg-1 g q 12 h fAUC/MIC range 31-665 mg/LMIC)(100/DI) <<ln: natural logarithm, Dose: 1 dose (mg), Vd: distribution volume (L), T1/2: plasma half-life (h), DI: dosing interval (h)>>.", [["plasma", "ANATOMY", 243, 249], ["plasma", "ORGANISM_SUBSTANCE", 243, 249], ["IVPM glass and hollow fibre models", "TREATMENT", 0, 34], ["AUC/MIC exposures", "TREATMENT", 69, 86]]], ["Based on Craig's data, the maximum bactericidal effect on Gram negative bacilli is attained when %T>MIC is approximately 50%.", [["Gram", "SIMPLE_CHEMICAL", 58, 62], ["Craig's data", "TEST", 9, 21], ["the maximum bactericidal effect", "PROBLEM", 23, 54], ["Gram negative bacilli", "TEST", 58, 79], ["bacilli", "OBSERVATION", 72, 79]]], ["Results: The probability of achieving T>MIC50% was 43.2% for MEPM 500 mg bid, followed by 4.2% for IPM 500 mg bid and 3.6% for PAPM 500 mg bid.", [["MIC50", "CHEMICAL", 40, 45], ["MEPM", "CHEMICAL", 61, 65], ["IPM", "CHEMICAL", 99, 102], ["PAPM", "CHEMICAL", 127, 131], ["IPM", "CHEMICAL", 99, 102], ["MEPM", "TREATMENT", 61, 65], ["IPM", "TREATMENT", 99, 102], ["PAPM", "TREATMENT", 127, 131]]], ["When the dose was increased from 500 mg to 1000 mg, it was 60.7% for MEPM 1000 mg bid, followed by 10.3% for IPM 1000 mg bid and 9.9% for PAPM 1000 mg bid.", [["MEPM", "CHEMICAL", 69, 73], ["IPM", "CHEMICAL", 109, 112], ["PAPM", "CHEMICAL", 138, 142], ["IPM", "CHEMICAL", 109, 112], ["PAPM", "SIMPLE_CHEMICAL", 138, 142], ["MEPM", "TREATMENT", 69, 73], ["IPM", "TREATMENT", 109, 112], ["PAPM", "TREATMENT", 138, 142]]], ["When the dose remained at 500 mg and the dosing frequency was increased to three times daily, it was 76.5% for MEPM 500 mg tid, followed by 43.0% for IPM 500 mg tid and 18.8% for PAPM 500 mg tid.", [["MEPM", "CHEMICAL", 111, 115], ["PAPM", "CHEMICAL", 179, 183], ["IPM", "CHEMICAL", 150, 153], ["tid", "CHEMICAL", 161, 164], ["tid", "CHEMICAL", 191, 194], ["the dosing frequency", "TREATMENT", 37, 57], ["MEPM", "TREATMENT", 111, 115], ["IPM", "TREATMENT", 150, 153], ["PAPM", "TREATMENT", 179, 183]]], ["Regarding MEPM, it was 85.9% for 500 mg gid? and 86.7% for 1000 mg tid showing higher probabilities.", [["MEPM", "TREATMENT", 10, 14], ["higher probabilities", "PROBLEM", 79, 99]]], ["Discussion: In severe sepsis caused by Pseudomonas aeruginosa, remarkably higher T>MIC50% was achieved with carbapenems at 500 mg tid, although the daily dose (1500 mg) was lower, compared to 1000 mg bid.", [["sepsis", "DISEASE", 22, 28], ["carbapenems", "CHEMICAL", 108, 119], ["carbapenems", "CHEMICAL", 108, 119], ["tid", "CHEMICAL", 130, 133], ["Pseudomonas aeruginosa", "ORGANISM", 39, 61], ["carbapenems", "SIMPLE_CHEMICAL", 108, 119], ["Pseudomonas aeruginosa", "SPECIES", 39, 61], ["Pseudomonas aeruginosa", "SPECIES", 39, 61], ["severe sepsis", "PROBLEM", 15, 28], ["Pseudomonas aeruginosa", "PROBLEM", 39, 61], ["carbapenems", "TREATMENT", 108, 119], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["sepsis", "OBSERVATION", 22, 28]]], ["Carbapenems with a low MIC distribution, i.e. a superior antibacterial activity, showed higher probability of achieving T>MIC.", [["Carbapenems", "CHEMICAL", 0, 11], ["Carbapenems", "CHEMICAL", 0, 11], ["Carbapenems", "SIMPLE_CHEMICAL", 0, 11], ["Carbapenems", "TREATMENT", 0, 11], ["a low MIC distribution", "TREATMENT", 17, 39], ["low MIC", "OBSERVATION_MODIFIER", 19, 26]]], ["Therefore, the optimal treatment for such sepsis is MEPM 500 mg tid.", [["sepsis", "DISEASE", 42, 48], ["MEPM", "CHEMICAL", 52, 56], ["the optimal treatment", "TREATMENT", 11, 32], ["such sepsis", "PROBLEM", 37, 48], ["MEPM", "TREATMENT", 52, 56]]], ["MEPM 500 mg qid appeared to provide comparable therapeutic effects with those at 100 mg tid, the usual dose in foreign countries.P1545Penetration of moxifloxacin into normal and infected subcutaneous tissue in patients with spinal cord injury measured by microdialysis Background: Skin breakdowns, also termed decubitus ulcers or pressure sores, are a major complication associated with spinal cord injury, resulting in infection and tissue death.", [["subcutaneous tissue", "ANATOMY", 187, 206], ["spinal cord", "ANATOMY", 224, 235], ["Skin", "ANATOMY", 281, 285], ["decubitus ulcers", "ANATOMY", 310, 326], ["spinal cord", "ANATOMY", 387, 398], ["tissue", "ANATOMY", 434, 440], ["MEPM", "CHEMICAL", 0, 4], ["moxifloxacin", "CHEMICAL", 149, 161], ["cord injury", "DISEASE", 231, 242], ["ulcers", "DISEASE", 320, 326], ["pressure sores", "DISEASE", 330, 344], ["cord injury", "DISEASE", 394, 405], ["infection", "DISEASE", 420, 429], ["death", "DISEASE", 441, 446], ["tid", "CHEMICAL", 88, 91], ["moxifloxacin", "CHEMICAL", 149, 161], ["MEPM", "SIMPLE_CHEMICAL", 0, 4], ["moxifloxacin", "SIMPLE_CHEMICAL", 149, 161], ["subcutaneous tissue", "TISSUE", 187, 206], ["patients", "ORGANISM", 210, 218], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 224, 235], ["Skin", "ORGAN", 281, 285], ["spinal cord", "ORGANISM_SUBDIVISION", 387, 398], ["tissue", "TISSUE", 434, 440], ["patients", "SPECIES", 210, 218], ["MEPM", "TREATMENT", 0, 4], ["those", "TREATMENT", 72, 77], ["moxifloxacin", "TREATMENT", 149, 161], ["infected subcutaneous tissue", "PROBLEM", 178, 206], ["spinal cord injury", "PROBLEM", 224, 242], ["Skin breakdowns", "PROBLEM", 281, 296], ["decubitus ulcers", "PROBLEM", 310, 326], ["pressure sores", "PROBLEM", 330, 344], ["a major complication", "PROBLEM", 350, 370], ["spinal cord injury", "PROBLEM", 387, 405], ["infection", "PROBLEM", 420, 429], ["tissue death", "PROBLEM", 434, 446], ["infected", "OBSERVATION_MODIFIER", 178, 186], ["subcutaneous tissue", "ANATOMY", 187, 206], ["spinal cord", "ANATOMY", 224, 235], ["injury", "OBSERVATION", 236, 242], ["Skin", "ANATOMY", 281, 285], ["breakdowns", "OBSERVATION", 286, 296], ["decubitus", "ANATOMY", 310, 319], ["ulcers", "OBSERVATION", 320, 326], ["pressure sores", "OBSERVATION", 330, 344], ["spinal cord", "ANATOMY", 387, 398], ["injury", "OBSERVATION", 399, 405], ["infection", "OBSERVATION", 420, 429], ["tissue death", "OBSERVATION", 434, 446]]], ["Moxifloxacin (MFX) is approved for the treatment of SSSI.", [["Moxifloxacin", "CHEMICAL", 0, 12], ["MFX", "CHEMICAL", 14, 17], ["SSSI", "DISEASE", 52, 56], ["Moxifloxacin", "CHEMICAL", 0, 12], ["MFX", "CHEMICAL", 14, 17], ["Moxifloxacin", "SIMPLE_CHEMICAL", 0, 12], ["MFX", "SIMPLE_CHEMICAL", 14, 17], ["Moxifloxacin (MFX)", "TREATMENT", 0, 18], ["SSSI", "TREATMENT", 52, 56]]], ["Our objective was to construct a population PK model for MFX disposition in plasma, normal and infected subcutaneous tissue in spinal cord injured patients with infected decubitus ulcer.", [["plasma", "ANATOMY", 76, 82], ["subcutaneous tissue", "ANATOMY", 104, 123], ["spinal cord", "ANATOMY", 127, 138], ["decubitus ulcer", "ANATOMY", 170, 185], ["MFX", "CHEMICAL", 57, 60], ["infected decubitus ulcer", "DISEASE", 161, 185], ["MFX", "SIMPLE_CHEMICAL", 57, 60], ["plasma", "ORGANISM_SUBSTANCE", 76, 82], ["subcutaneous tissue", "TISSUE", 104, 123], ["spinal cord", "ORGAN", 127, 138], ["patients", "ORGANISM", 147, 155], ["decubitus ulcer", "PATHOLOGICAL_FORMATION", 170, 185], ["patients", "SPECIES", 147, 155], ["a population PK model", "TEST", 31, 52], ["MFX disposition in plasma", "PROBLEM", 57, 82], ["infected subcutaneous tissue in spinal cord", "PROBLEM", 95, 138], ["infected decubitus ulcer", "PROBLEM", 161, 185], ["normal", "OBSERVATION", 84, 90], ["infected", "OBSERVATION_MODIFIER", 95, 103], ["subcutaneous tissue", "ANATOMY", 104, 123], ["spinal cord", "ANATOMY", 127, 138], ["infected", "OBSERVATION_MODIFIER", 161, 169], ["decubitus ulcer", "OBSERVATION", 170, 185]]], ["Methods: 4 patients receiving 400 mg MFX orally daily were enrolled in this study.", [["MFX", "CHEMICAL", 37, 40], ["MFX", "CHEMICAL", 37, 40], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["this study", "TEST", 71, 81]]], ["Blood, saliva and interstitial tissue fluid samples (microdialysis in normal and infected tissue) were collected over a time period of 8 hrs.", [["Blood", "ANATOMY", 0, 5], ["saliva", "ANATOMY", 7, 13], ["interstitial tissue fluid samples", "ANATOMY", 18, 51], ["tissue", "ANATOMY", 90, 96], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["saliva", "ORGANISM_SUBSTANCE", 7, 13], ["interstitial tissue fluid samples", "ORGANISM_SUBSTANCE", 18, 51], ["tissue", "TISSUE", 90, 96], ["Blood, saliva and interstitial tissue fluid samples", "TEST", 0, 51], ["microdialysis", "TEST", 53, 66], ["saliva", "ANATOMY", 7, 13], ["interstitial tissue", "ANATOMY", 18, 37], ["fluid", "OBSERVATION", 38, 43], ["infected tissue", "OBSERVATION_MODIFIER", 81, 96]]], ["MFX concentrations were measured by a validated HPLC.", [["MFX", "CHEMICAL", 0, 3], ["MFX", "CHEMICAL", 0, 3], ["MFX", "SIMPLE_CHEMICAL", 0, 3], ["MFX concentrations", "TREATMENT", 0, 18]]], ["Concentration-time data obtained in the present study were pooled with previously published MFX data (n = 12).", [["the present study", "TEST", 36, 53]]], ["Population PK modelling was performed with NONMEM.", [["Population PK modelling", "TEST", 0, 23]]], ["Results: The concentrations of MFX achieved in plasma, saliva, normal subcutaneous tissues and infected decubitus ulcers showed parallel profiles versus time.", [["plasma", "ANATOMY", 47, 53], ["saliva", "ANATOMY", 55, 61], ["subcutaneous tissues", "ANATOMY", 70, 90], ["decubitus ulcers", "ANATOMY", 104, 120], ["MFX", "CHEMICAL", 31, 34], ["ulcers", "DISEASE", 114, 120], ["MFX", "CHEMICAL", 31, 34], ["MFX", "SIMPLE_CHEMICAL", 31, 34], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["saliva", "ORGANISM_SUBSTANCE", 55, 61], ["subcutaneous tissues", "TISSUE", 70, 90], ["decubitus ulcers", "PATHOLOGICAL_FORMATION", 104, 120], ["MFX", "TREATMENT", 31, 34], ["infected decubitus ulcers", "PROBLEM", 95, 120], ["subcutaneous tissues", "ANATOMY", 70, 90], ["infected", "OBSERVATION_MODIFIER", 95, 103], ["decubitus ulcers", "OBSERVATION", 104, 120]]], ["The PK was best described by a 2-compartment model with a link to interstitial tissue fluid.", [["interstitial tissue fluid", "ANATOMY", 66, 91], ["PK", "GENE_OR_GENE_PRODUCT", 4, 6], ["interstitial tissue fluid", "ORGANISM_SUBSTANCE", 66, 91], ["The PK", "TEST", 0, 6], ["interstitial tissue fluid", "PROBLEM", 66, 91], ["interstitial tissue", "ANATOMY", 66, 85], ["fluid", "OBSERVATION", 86, 91]]], ["The population PK parameters were as follows (given as estimate with percent interindividual variability in parentheses): CL 10.2 L/h (3%); central VD 83.2 L (15%); intercompartmental CL 31.9 L/h (16%); peripheral VD 92.2 L (17%); and elimination rate constant for interstitial tissue fluid 1.57 h)1 (17%).", [["interstitial tissue", "ANATOMY", 265, 284], ["The population PK parameters", "TEST", 0, 28], ["CL", "TEST", 122, 124], ["central VD", "TEST", 140, 150], ["intercompartmental CL", "TEST", 165, 186], ["L/h", "TEST", 192, 195], ["peripheral VD", "TEST", 203, 216], ["elimination rate", "TEST", 235, 251], ["interstitial tissue fluid", "TEST", 265, 290], ["peripheral", "ANATOMY_MODIFIER", 203, 213]]], ["With a conservative MIC90 of 0.25 mg/L, the Peak/MIC ratios were higher than 10 and the AUC24/MIC ratios were higher than 100 for plasma, saliva and interstitial tissue fluids.", [["plasma", "ANATOMY", 130, 136], ["saliva", "ANATOMY", 138, 144], ["interstitial tissue fluids", "ANATOMY", 149, 175], ["plasma", "ORGANISM_SUBSTANCE", 130, 136], ["saliva", "ORGANISM_SUBSTANCE", 138, 144], ["interstitial tissue fluids", "ORGANISM_SUBSTANCE", 149, 175], ["a conservative MIC90", "TREATMENT", 5, 25], ["the Peak/MIC ratios", "TEST", 40, 59], ["the AUC24/MIC ratios", "TEST", 84, 104], ["plasma, saliva and interstitial tissue fluids", "PROBLEM", 130, 175], ["interstitial tissue", "ANATOMY", 149, 168], ["fluids", "OBSERVATION", 169, 175]]], ["Conclusions: This study showed the good diffusion of MFX into subcutaneous tissue in spinal cord injured patients with decubitus ulcers.", [["subcutaneous tissue", "ANATOMY", 62, 81], ["spinal cord", "ANATOMY", 85, 96], ["MFX", "CHEMICAL", 53, 56], ["ulcers", "DISEASE", 129, 135], ["MFX", "SIMPLE_CHEMICAL", 53, 56], ["subcutaneous tissue", "TISSUE", 62, 81], ["spinal cord", "ORGAN", 85, 96], ["patients", "ORGANISM", 105, 113], ["decubitus ulcers", "PATHOLOGICAL_FORMATION", 119, 135], ["MFX", "PROTEIN", 53, 56], ["patients", "SPECIES", 105, 113], ["This study", "TEST", 13, 23], ["decubitus ulcers", "PROBLEM", 119, 135], ["subcutaneous tissue", "ANATOMY", 62, 81], ["spinal cord", "ANATOMY", 85, 96], ["decubitus", "ANATOMY", 119, 128], ["ulcers", "OBSERVATION", 129, 135]]], ["The interstitial tissue fluids reached bactericidal levels for common bacteria found in infected skin lesions.", [["interstitial tissue fluids", "ANATOMY", 4, 30], ["skin lesions", "ANATOMY", 97, 109], ["infected skin lesions", "DISEASE", 88, 109], ["interstitial tissue fluids", "TISSUE", 4, 30], ["skin lesions", "PATHOLOGICAL_FORMATION", 97, 109], ["The interstitial tissue fluids", "PROBLEM", 0, 30], ["bactericidal levels", "TEST", 39, 58], ["common bacteria", "PROBLEM", 63, 78], ["infected skin lesions", "PROBLEM", 88, 109], ["interstitial", "ANATOMY_MODIFIER", 4, 16], ["tissue", "ANATOMY", 17, 23], ["fluids", "OBSERVATION", 24, 30], ["infected", "OBSERVATION_MODIFIER", 88, 96], ["skin", "ANATOMY", 97, 101], ["lesions", "OBSERVATION", 102, 109]]], ["Objective: Investigations of pharmacodynamic parameters such as postantibiotic effect and postantibiotic subminimum inhibitory concentration effect have been employed for design of dosing schedules of antimicrobial agents.", [["pharmacodynamic parameters", "TEST", 29, 55], ["postantibiotic effect", "TREATMENT", 64, 85], ["postantibiotic subminimum inhibitory concentration effect", "TREATMENT", 90, 147], ["antimicrobial agents", "TREATMENT", 201, 221]]], ["In this study we compared postantibiotic effect and postantibiotic subminimum inhibitory concentration effect of ciprofloxacin, levofloxacin, and moxifloxacin for clinical isolates of methicillin susceptible Staphylococcus aureus, methicillin resistant Staphylococcus aureus and Pseudomonas aureginosa.", [["ciprofloxacin", "CHEMICAL", 113, 126], ["levofloxacin", "CHEMICAL", 128, 140], ["moxifloxacin", "CHEMICAL", 146, 158], ["methicillin", "CHEMICAL", 184, 195], ["Staphylococcus aureus", "DISEASE", 208, 229], ["methicillin", "CHEMICAL", 231, 242], ["Staphylococcus aureus", "DISEASE", 253, 274], ["ciprofloxacin", "CHEMICAL", 113, 126], ["levofloxacin", "CHEMICAL", 128, 140], ["moxifloxacin", "CHEMICAL", 146, 158], ["methicillin", "CHEMICAL", 184, 195], ["methicillin", "CHEMICAL", 231, 242], ["ciprofloxacin", "SIMPLE_CHEMICAL", 113, 126], ["levofloxacin", "SIMPLE_CHEMICAL", 128, 140], ["moxifloxacin", "SIMPLE_CHEMICAL", 146, 158], ["methicillin susceptible Staphylococcus aureus", "ORGANISM", 184, 229], ["methicillin resistant Staphylococcus aureus", "ORGANISM", 231, 274], ["Pseudomonas aureginosa", "ORGANISM", 279, 301], ["Staphylococcus aureus", "SPECIES", 208, 229], ["Staphylococcus aureus", "SPECIES", 253, 274], ["Pseudomonas aureginosa", "SPECIES", 279, 301], ["Staphylococcus aureus", "SPECIES", 208, 229], ["Staphylococcus aureus", "SPECIES", 253, 274], ["Pseudomonas aureginosa", "SPECIES", 279, 301], ["this study", "TEST", 3, 13], ["postantibiotic effect", "PROBLEM", 26, 47], ["postantibiotic subminimum inhibitory concentration effect", "TREATMENT", 52, 109], ["ciprofloxacin", "TREATMENT", 113, 126], ["levofloxacin", "TREATMENT", 128, 140], ["moxifloxacin", "TREATMENT", 146, 158], ["methicillin susceptible Staphylococcus aureus", "PROBLEM", 184, 229], ["methicillin resistant Staphylococcus aureus", "PROBLEM", 231, 274], ["Pseudomonas aureginosa", "PROBLEM", 279, 301]]], ["Methods: The following strains were tested in this study: methicilline-susceptible Staphylococcus aureus (n:4), methicilline resistant -Staphylococcus aureus (n:2) and Pseudomonas aeruginosa (n:2).", [["methicilline", "CHEMICAL", 58, 70], ["Staphylococcus aureus", "DISEASE", 83, 104], ["methicilline", "CHEMICAL", 112, 124], ["Staphylococcus aureus", "DISEASE", 136, 157], ["methicilline", "CHEMICAL", 58, 70], ["methicilline-susceptible Staphylococcus aureus", "ORGANISM", 58, 104], ["methicilline resistant -Staphylococcus aureus", "ORGANISM", 112, 157], ["n:2", "ORGANISM", 159, 162], ["Pseudomonas aeruginosa", "ORGANISM", 168, 190], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Staphylococcus aureus", "SPECIES", 136, 157], ["Pseudomonas aeruginosa", "SPECIES", 168, 190], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Staphylococcus aureus", "SPECIES", 136, 157], ["Pseudomonas aeruginosa", "SPECIES", 168, 190], ["this study", "TEST", 46, 56], ["methicilline", "TEST", 58, 70], ["susceptible Staphylococcus aureus", "PROBLEM", 71, 104], ["methicilline resistant -Staphylococcus aureus", "PROBLEM", 112, 157], ["Pseudomonas aeruginosa", "PROBLEM", 168, 190], ["Staphylococcus aureus", "OBSERVATION", 136, 157]]], ["The PAE was determined by viable plate count method using Mueller Hinton broth.", [["PAE", "SIMPLE_CHEMICAL", 4, 7], ["Mueller Hinton broth", "TREATMENT", 58, 78], ["PAE", "OBSERVATION", 4, 7]]], ["Tubes containing 5 ml of broth and the antibiotic to be tested at 1, 2, 4 and 8x the MIC were inoculated with approximately 5 \u00b7 106 CFU/ml.", [["Tubes", "TREATMENT", 0, 5], ["broth", "TREATMENT", 25, 30], ["the antibiotic", "TREATMENT", 35, 49]]], ["Growth controls with an inoculum but not antibiotic were included with each experiment.", [["an inoculum", "TREATMENT", 21, 32], ["antibiotic", "TREATMENT", 41, 51]]], ["Result: Postantibiotic effects of ciprofloxacin, levofloxacin and moxifloxacin increased with increasing concentration of the drug.", [["ciprofloxacin", "CHEMICAL", 34, 47], ["levofloxacin", "CHEMICAL", 49, 61], ["moxifloxacin", "CHEMICAL", 66, 78], ["ciprofloxacin", "CHEMICAL", 34, 47], ["levofloxacin", "CHEMICAL", 49, 61], ["moxifloxacin", "CHEMICAL", 66, 78], ["ciprofloxacin", "SIMPLE_CHEMICAL", 34, 47], ["levofloxacin", "SIMPLE_CHEMICAL", 49, 61], ["moxifloxacin", "SIMPLE_CHEMICAL", 66, 78], ["ciprofloxacin", "TREATMENT", 34, 47], ["levofloxacin", "TREATMENT", 49, 61], ["moxifloxacin", "TREATMENT", 66, 78]]], ["The longest postantibiotic effect was observed for moxifloxacin.", [["moxifloxacin", "CHEMICAL", 51, 63], ["moxifloxacin", "CHEMICAL", 51, 63], ["moxifloxacin", "SIMPLE_CHEMICAL", 51, 63], ["The longest postantibiotic effect", "PROBLEM", 0, 33], ["moxifloxacin", "TREATMENT", 51, 63]]], ["Moxifloxacin showed no postantibiotic effect one P. aureginosa at all concentration and had no post antibiotic effect to another P. aureginosa at x2MIC and MIC.", [["Moxifloxacin", "CHEMICAL", 0, 12], ["Moxifloxacin", "CHEMICAL", 0, 12], ["Moxifloxacin", "SIMPLE_CHEMICAL", 0, 12], ["P. aureginosa", "ORGANISM", 49, 62], ["P. aureginosa", "ORGANISM", 129, 142], ["x2MIC", "SIMPLE_CHEMICAL", 146, 151], ["P. aureginosa", "SPECIES", 49, 62], ["P. aureginosa", "SPECIES", 129, 142], ["P. aureginosa", "SPECIES", 49, 62], ["P. aureginosa", "SPECIES", 129, 142], ["Moxifloxacin", "TREATMENT", 0, 12], ["postantibiotic effect", "PROBLEM", 23, 44], ["post antibiotic effect", "PROBLEM", 95, 117], ["no", "UNCERTAINTY", 20, 22]]], ["In our study the longest postantibiotic subminimum inhibitory concentration effect against MSSA was determined with moxifloxacin.", [["MSSA", "CHEMICAL", 91, 95], ["moxifloxacin", "CHEMICAL", 116, 128], ["moxifloxacin", "CHEMICAL", 116, 128], ["MSSA", "SIMPLE_CHEMICAL", 91, 95], ["moxifloxacin", "SIMPLE_CHEMICAL", 116, 128], ["MSSA", "SPECIES", 91, 95], ["our study", "TEST", 3, 12], ["the longest postantibiotic subminimum inhibitory concentration effect", "TREATMENT", 13, 82], ["MSSA", "PROBLEM", 91, 95], ["moxifloxacin", "TREATMENT", 116, 128]]], ["Similarly the moxifloxacin induced the longest effect against MRSA.", [["moxifloxacin", "CHEMICAL", 14, 26], ["MRSA", "DISEASE", 62, 66], ["moxifloxacin", "CHEMICAL", 14, 26], ["moxifloxacin", "SIMPLE_CHEMICAL", 14, 26], ["MRSA", "SPECIES", 62, 66], ["MRSA", "SPECIES", 62, 66], ["the moxifloxacin", "TREATMENT", 10, 26], ["MRSA", "PROBLEM", 62, 66], ["moxifloxacin", "OBSERVATION", 14, 26]]], ["However, this time frame was shorter than that of MSSA.", [["MSSA", "PROBLEM", 50, 54], ["MSSA", "OBSERVATION", 50, 54]]], ["Conclusions: All three antibiotics, showed for longer postantibiotic subminimum inhibitory concentration effect in all subMIC concentrations, immeasurable within the study period i.e. 24 hours.P1547Lack of horizontal transmission of fluoroquinolone resistance between S. mitis and S. pneumoniae Objectives: Fluoroquinolone (FQ) resistance can arise in S. pneumoniae through acquisition of DNA from S. mitis and subsequent homologous recombination.", [["fluoroquinolone", "CHEMICAL", 233, 248], ["Fluoroquinolone", "CHEMICAL", 307, 322], ["FQ", "CHEMICAL", 324, 326], ["fluoroquinolone", "CHEMICAL", 233, 248], ["Fluoroquinolone", "CHEMICAL", 307, 322], ["subMIC", "SIMPLE_CHEMICAL", 119, 125], ["fluoroquinolone", "SIMPLE_CHEMICAL", 233, 248], ["S. mitis", "ORGANISM", 268, 276], ["S. pneumoniae", "ORGANISM", 281, 294], ["Fluoroquinolone", "SIMPLE_CHEMICAL", 307, 322], ["FQ", "SIMPLE_CHEMICAL", 324, 326], ["S. pneumoniae", "ORGANISM", 352, 365], ["DNA", "CELLULAR_COMPONENT", 389, 392], ["S. mitis", "ORGANISM", 398, 406], ["S. mitis", "SPECIES", 268, 276], ["S. pneumoniae", "SPECIES", 281, 294], ["S. pneumoniae", "SPECIES", 352, 365], ["S. mitis", "SPECIES", 398, 406], ["S. mitis", "SPECIES", 268, 276], ["S. pneumoniae", "SPECIES", 281, 294], ["S. pneumoniae", "SPECIES", 352, 365], ["S. mitis", "SPECIES", 398, 406], ["All three antibiotics", "TREATMENT", 13, 34], ["longer postantibiotic subminimum inhibitory concentration effect", "TREATMENT", 47, 111], ["all subMIC concentrations", "PROBLEM", 115, 140], ["fluoroquinolone resistance", "TREATMENT", 233, 259], ["S. mitis", "PROBLEM", 268, 276], ["S. pneumoniae", "PROBLEM", 281, 294], ["Fluoroquinolone (FQ) resistance", "TREATMENT", 307, 338], ["S. pneumoniae", "PROBLEM", 352, 365], ["DNA", "PROBLEM", 389, 392], ["S. mitis", "PROBLEM", 398, 406], ["subsequent homologous recombination", "TREATMENT", 411, 446], ["subMIC concentrations", "OBSERVATION", 119, 140], ["fluoroquinolone resistance", "OBSERVATION", 233, 259], ["mitis", "OBSERVATION", 271, 276], ["pneumoniae", "OBSERVATION", 355, 365], ["mitis", "OBSERVATION", 401, 406]]], ["The frequency at which this occurs is unknown, and while likely a rare event, increases in FQ resistance among S. mitis may increase the rate at which horizontal transmission occurs.", [["FQ", "CHEMICAL", 91, 93], ["FQ", "SIMPLE_CHEMICAL", 91, 93], ["S. mitis", "ORGANISM", 111, 119], ["S. mitis", "SPECIES", 111, 119], ["S. mitis", "SPECIES", 111, 119], ["a rare event", "PROBLEM", 64, 76], ["S. mitis", "PROBLEM", 111, 119], ["FQ resistance", "OBSERVATION", 91, 104], ["mitis", "OBSERVATION", 114, 119]]], ["We sought to determine the frequency at which FQ resistance could be transferred from S. mitis to S. pneumoniae or from S. pneumoniae to S. mitis.", [["FQ", "CHEMICAL", 46, 48], ["FQ", "SIMPLE_CHEMICAL", 46, 48], ["S. mitis", "ORGANISM", 86, 94], ["S. pneumoniae", "ORGANISM", 98, 111], ["S. pneumoniae", "ORGANISM", 120, 133], ["S. mitis", "ORGANISM", 137, 145], ["S. mitis", "SPECIES", 86, 94], ["S. pneumoniae", "SPECIES", 98, 111], ["S. pneumoniae", "SPECIES", 120, 133], ["S. mitis", "SPECIES", 137, 145], ["S. mitis", "SPECIES", 86, 94], ["S. pneumoniae", "SPECIES", 98, 111], ["S. pneumoniae", "SPECIES", 120, 133], ["S. mitis", "SPECIES", 137, 145], ["S. pneumoniae", "PROBLEM", 98, 111], ["S. pneumoniae", "PROBLEM", 120, 133], ["S. mitis", "PROBLEM", 137, 145], ["pneumoniae", "OBSERVATION", 101, 111], ["pneumoniae", "OBSERVATION", 123, 133], ["mitis", "OBSERVATION", 140, 145]]], ["Methods: S. mitis (either FQ^R,Tetracycline[Tet^S], FQ^R,Penicillin[Pen^S], or FQR) and S. pneumoniae (either FQR, FQR or FQS) were grown in co-culture using a pharmacodynamic model in the presence of either moxifloxacin (MXF) or levofloxacin (LFX) at salivary drug concentrations.", [["salivary", "ANATOMY", 252, 260], ["FQ", "CHEMICAL", 26, 28], ["Tetracycline", "CHEMICAL", 31, 43], ["Tet", "CHEMICAL", 44, 47], ["FQ", "CHEMICAL", 52, 54], ["Penicillin", "CHEMICAL", 57, 67], ["moxifloxacin", "CHEMICAL", 208, 220], ["MXF", "CHEMICAL", 222, 225], ["levofloxacin", "CHEMICAL", 230, 242], ["LFX", "CHEMICAL", 244, 247], ["Tetracycline", "CHEMICAL", 31, 43], ["Penicillin", "CHEMICAL", 57, 67], ["Pen^S", "CHEMICAL", 68, 73], ["moxifloxacin", "CHEMICAL", 208, 220], ["MXF", "CHEMICAL", 222, 225], ["levofloxacin", "CHEMICAL", 230, 242], ["LFX", "CHEMICAL", 244, 247], ["S. mitis", "ORGANISM", 9, 17], ["FQ^R", "SIMPLE_CHEMICAL", 26, 30], ["Tetracycline", "SIMPLE_CHEMICAL", 31, 43], ["Tet^S", "SIMPLE_CHEMICAL", 44, 49], ["FQ^R", "SIMPLE_CHEMICAL", 52, 56], ["Penicillin", "SIMPLE_CHEMICAL", 57, 67], ["Pen^S", "SIMPLE_CHEMICAL", 68, 73], ["FQR", "SIMPLE_CHEMICAL", 79, 82], ["S. pneumoniae", "ORGANISM", 88, 101], ["moxifloxacin", "SIMPLE_CHEMICAL", 208, 220], ["MXF", "SIMPLE_CHEMICAL", 222, 225], ["levofloxacin", "SIMPLE_CHEMICAL", 230, 242], ["LFX", "SIMPLE_CHEMICAL", 244, 247], ["salivary", "ORGAN", 252, 260], ["S. mitis", "SPECIES", 9, 17], ["S. pneumoniae", "SPECIES", 88, 101], ["S. mitis", "SPECIES", 9, 17], ["S. pneumoniae", "SPECIES", 88, 101], ["mitis", "PROBLEM", 12, 17], ["Tetracycline", "TREATMENT", 31, 43], ["Tet^S", "TREATMENT", 44, 49], ["FQ^R", "TREATMENT", 52, 56], ["Penicillin", "TREATMENT", 57, 67], ["S. pneumoniae", "PROBLEM", 88, 101], ["FQS", "PROBLEM", 122, 125], ["a pharmacodynamic model", "TREATMENT", 158, 181], ["moxifloxacin (MXF", "TREATMENT", 208, 225], ["levofloxacin", "TREATMENT", 230, 242], ["pneumoniae", "OBSERVATION", 91, 101]]], ["After incubation, aliquots were plated onto either Tet or Pen containing SBA plates to select for the recipient strains.", [["Tet", "CHEMICAL", 51, 54], ["aliquots", "TREATMENT", 18, 26], ["Tet or Pen containing SBA plates", "TREATMENT", 51, 83], ["the recipient strains", "PROBLEM", 98, 119]]], ["FQ susceptibility was performed using microbroth dilution.", [["FQ", "CHEMICAL", 0, 2], ["FQ", "SIMPLE_CHEMICAL", 0, 2], ["FQ susceptibility", "TEST", 0, 17], ["microbroth dilution", "TREATMENT", 38, 57]]], ["The entire parC and gyrA genes were amplified and sequenced to determine if horizontal transmission occurred.", [["parC", "GENE_OR_GENE_PRODUCT", 11, 15], ["gyrA", "GENE_OR_GENE_PRODUCT", 20, 24], ["parC and gyrA genes", "DNA", 11, 30], ["horizontal transmission", "PROBLEM", 76, 99], ["gyrA genes", "OBSERVATION", 20, 30]]], ["Results: In initial experiments Tet was used as the selective agent.", [["Tet", "CHEMICAL", 32, 35], ["Tet", "GENE_OR_GENE_PRODUCT", 32, 35], ["Tet", "TREATMENT", 32, 35], ["the selective agent", "TREATMENT", 48, 67]]], ["However Tet resistance was transferred and therefore Pen^R was used as a selective marker.", [["Tet", "CHEMICAL", 8, 11], ["Tet", "GENE_OR_GENE_PRODUCT", 8, 11], ["Pen^R", "GENE_OR_GENE_PRODUCT", 53, 58], ["Tet resistance", "PROBLEM", 8, 22], ["Pen^R", "TREATMENT", 53, 58], ["a selective marker", "TREATMENT", 71, 89], ["resistance", "OBSERVATION_MODIFIER", 12, 22]]], ["An increase in the LFX MIC in was observed in 3 S. pneumoniae and 1 S. mitis strain.", [["LFX", "CHEMICAL", 19, 22], ["LFX", "GENE_OR_GENE_PRODUCT", 19, 22], ["S. pneumoniae", "ORGANISM", 48, 61], ["S. mitis strain", "ORGANISM", 68, 83], ["S. pneumoniae", "SPECIES", 48, 61], ["S. mitis", "SPECIES", 68, 76], ["S. pneumoniae", "SPECIES", 48, 61], ["S. mitis", "SPECIES", 68, 76], ["An increase in the LFX MIC", "PROBLEM", 0, 26], ["3 S. pneumoniae", "PROBLEM", 46, 61], ["mitis strain", "PROBLEM", 71, 83], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["LFX", "OBSERVATION_MODIFIER", 19, 22], ["MIC", "OBSERVATION_MODIFIER", 23, 26], ["pneumoniae", "OBSERVATION", 51, 61], ["mitis strain", "OBSERVATION", 71, 83]]], ["Sequencing of the parC gene revealed the selection of 2 Ser79Phe and 1 Ser79Tyr mutations in S. pneumoniae and Ser79Phe in S. mitis consistent with FQ resistance.", [["FQ", "CHEMICAL", 148, 150], ["Ser", "CHEMICAL", 56, 59], ["parC", "GENE_OR_GENE_PRODUCT", 18, 22], ["2 Ser79Phe", "GENE_OR_GENE_PRODUCT", 54, 64], ["Ser79Tyr", "GENE_OR_GENE_PRODUCT", 71, 79], ["S. pneumoniae", "ORGANISM", 93, 106], ["Ser79Phe", "GENE_OR_GENE_PRODUCT", 111, 119], ["S. mitis", "ORGANISM", 123, 131], ["FQ", "SIMPLE_CHEMICAL", 148, 150], ["parC gene", "DNA", 18, 27], ["S. pneumoniae", "SPECIES", 93, 106], ["S. mitis", "SPECIES", 123, 131], ["S. pneumoniae", "SPECIES", 93, 106], ["S. mitis", "SPECIES", 123, 131], ["the parC gene", "TEST", 14, 27], ["1 Ser79Tyr mutations", "PROBLEM", 69, 89], ["S. pneumoniae", "PROBLEM", 93, 106], ["S. mitis", "PROBLEM", 123, 131], ["FQ resistance", "PROBLEM", 148, 161], ["pneumoniae", "OBSERVATION", 96, 106], ["mitis", "OBSERVATION", 126, 131], ["consistent with", "UNCERTAINTY", 132, 147], ["FQ resistance", "OBSERVATION", 148, 161]]], ["Sequencing of the entire gene failed to uncover evidence of horizontal transmission.", [["horizontal transmission", "PROBLEM", 60, 83], ["horizontal", "OBSERVATION_MODIFIER", 60, 70]]], ["No mutations were detected in gyrA.", [["gyrA", "GENE_OR_GENE_PRODUCT", 30, 34], ["gyrA", "DNA", 30, 34], ["mutations", "PROBLEM", 3, 12], ["mutations", "OBSERVATION", 3, 12]]], ["Selection of 1st step parC Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006 mutations occurred only after exposure to LFX.", [["Infection", "DISEASE", 53, 62], ["LFX", "CHEMICAL", 136, 139], ["LFX", "CHEMICAL", 136, 139], ["Infection", "PROBLEM", 53, 62], ["Volume", "TEST", 64, 70], ["Infection", "OBSERVATION", 53, 62]]], ["MXF eradicated both S. mitis and S. pneumoniae and failed to either select for resistance or support horizontal transmission.", [["MXF", "CHEMICAL", 0, 3], ["MXF", "SIMPLE_CHEMICAL", 0, 3], ["S. mitis", "ORGANISM", 20, 28], ["S. pneumoniae", "ORGANISM", 33, 46], ["S. mitis", "SPECIES", 20, 28], ["S. pneumoniae", "SPECIES", 33, 46], ["S. mitis", "SPECIES", 20, 28], ["S. pneumoniae", "SPECIES", 33, 46], ["mitis", "PROBLEM", 23, 28], ["S. pneumoniae", "PROBLEM", 33, 46], ["resistance", "PROBLEM", 79, 89], ["mitis", "OBSERVATION", 23, 28], ["pneumoniae", "OBSERVATION", 36, 46]]], ["Conclusions: Although 1st step parC mutations were selected in 4 strains (3 S. pneumoniae, 1 S. mitis), we failed to find evidence of horizontal transmission between S. pneumoniae and S. mitis under our laboratory conditions.", [["S. pneumoniae", "ORGANISM", 76, 89], ["S. mitis", "ORGANISM", 93, 101], ["S. pneumoniae", "ORGANISM", 166, 179], ["S. mitis", "ORGANISM", 184, 192], ["S. pneumoniae", "SPECIES", 76, 89], ["S. mitis", "SPECIES", 93, 101], ["S. pneumoniae", "SPECIES", 166, 179], ["S. mitis", "SPECIES", 184, 192], ["S. pneumoniae", "SPECIES", 76, 89], ["S. mitis", "SPECIES", 93, 101], ["S. pneumoniae", "SPECIES", 166, 179], ["S. mitis", "SPECIES", 184, 192], ["1st step parC mutations", "PROBLEM", 22, 45], ["pneumoniae", "PROBLEM", 79, 89], ["mitis", "PROBLEM", 96, 101], ["horizontal transmission", "PROBLEM", 134, 157], ["S. pneumoniae", "PROBLEM", 166, 179], ["S. mitis", "PROBLEM", 184, 192], ["pneumoniae", "OBSERVATION", 169, 179], ["mitis", "OBSERVATION", 187, 192]]], ["The phenomenon of horizontal transfer resulting in FQ resistance has been described, however, based on our results, we must speculate that it is an extremely rare event and not likely to be a major driver of FQ resistance.", [["FQ", "CHEMICAL", 51, 53], ["FQ", "CHEMICAL", 208, 210], ["FQ", "SIMPLE_CHEMICAL", 51, 53], ["FQ", "SIMPLE_CHEMICAL", 208, 210], ["FQ resistance", "PROBLEM", 51, 64], ["horizontal", "OBSERVATION_MODIFIER", 18, 28], ["FQ resistance", "OBSERVATION", 51, 64], ["FQ resistance", "OBSERVATION", 208, 221]]], ["Of interest, the parC mutations were selected only under the selective pressure of LFX.", [["LFX", "CHEMICAL", 83, 86], ["parC", "GENE_OR_GENE_PRODUCT", 17, 21], ["LFX", "SIMPLE_CHEMICAL", 83, 86], ["parC mutations", "DNA", 17, 31], ["LFX", "PROTEIN", 83, 86], ["the parC mutations", "PROBLEM", 13, 31]]], ["MXF completely eradicated both S. pneumoniae and S. mitis and did not select for the development of FQ^R mutations.", [["MXF", "CHEMICAL", 0, 3], ["FQ", "CHEMICAL", 100, 102], ["MXF", "SIMPLE_CHEMICAL", 0, 3], ["S. pneumoniae", "ORGANISM", 31, 44], ["S. mitis", "ORGANISM", 49, 57], ["R", "GENE_OR_GENE_PRODUCT", 103, 104], ["S. pneumoniae", "SPECIES", 31, 44], ["S. mitis", "SPECIES", 49, 57], ["S. pneumoniae", "SPECIES", 31, 44], ["S. mitis", "SPECIES", 49, 57], ["pneumoniae", "PROBLEM", 34, 44], ["S. mitis", "PROBLEM", 49, 57], ["FQ", "PROBLEM", 100, 102], ["R mutations", "PROBLEM", 103, 114], ["pneumoniae", "OBSERVATION", 34, 44], ["mitis", "OBSERVATION", 52, 57], ["mutations", "OBSERVATION", 105, 114]]], ["Objectives: The aim of the present study was to assess the killing activity of ertapenem (ERT) and metronidazole (MTR) against four selected Bacteroides fragilis strains with different MIC values in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model.", [["strains", "ANATOMY", 162, 169], ["ertapenem", "CHEMICAL", 79, 88], ["ERT", "CHEMICAL", 90, 93], ["metronidazole", "CHEMICAL", 99, 112], ["MTR", "CHEMICAL", 114, 117], ["ertapenem", "CHEMICAL", 79, 88], ["ERT", "CHEMICAL", 90, 93], ["metronidazole", "CHEMICAL", 99, 112], ["MTR", "CHEMICAL", 114, 117], ["ertapenem", "SIMPLE_CHEMICAL", 79, 88], ["ERT", "SIMPLE_CHEMICAL", 90, 93], ["metronidazole", "SIMPLE_CHEMICAL", 99, 112], ["MTR", "SIMPLE_CHEMICAL", 114, 117], ["Bacteroides fragilis", "ORGANISM", 141, 161], ["Bacteroides fragilis", "SPECIES", 141, 161], ["Bacteroides fragilis", "SPECIES", 141, 161], ["the present study", "TEST", 23, 40], ["ertapenem", "TREATMENT", 79, 88], ["ERT)", "TREATMENT", 90, 94], ["metronidazole (MTR)", "TREATMENT", 99, 118], ["four selected Bacteroides fragilis strains", "PROBLEM", 127, 169], ["different MIC values", "TEST", 175, 195], ["an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model", "TREATMENT", 199, 256]]], ["Since anaerobes are often present in mixed infections, kill kinetics were also established for mixed inocula employing the B. fragilis strains together with four selected Escherichia coli strains.", [["infections", "DISEASE", 43, 53], ["B. fragilis strains", "ORGANISM", 123, 142], ["Escherichia coli", "ORGANISM", 171, 187], ["B. fragilis", "SPECIES", 123, 134], ["Escherichia coli", "SPECIES", 171, 187], ["B. fragilis", "SPECIES", 123, 134], ["Escherichia coli", "SPECIES", 171, 187], ["anaerobes", "PROBLEM", 6, 15], ["mixed infections", "PROBLEM", 37, 53], ["mixed inocula", "PROBLEM", 95, 108], ["the B. fragilis strains", "PROBLEM", 119, 142], ["four selected Escherichia coli strains", "PROBLEM", 157, 195], ["anaerobes", "OBSERVATION", 6, 15], ["mixed", "OBSERVATION_MODIFIER", 37, 42], ["infections", "OBSERVATION", 43, 53], ["Escherichia coli strains", "OBSERVATION", 171, 195]]], ["The killing activity was analysed for kinetic concentrations of the antimicrobial agents simulating human serum kinetics.", [["serum", "ANATOMY", 106, 111], ["human", "ORGANISM", 100, 105], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["the antimicrobial agents", "TREATMENT", 64, 88]]], ["Methods: A PK/PD in vitro model was established by adding appropriate amounts of broth every half hour.", [["PK", "GENE_OR_GENE_PRODUCT", 11, 13], ["A PK/PD in vitro model", "TREATMENT", 9, 31]]], ["At the same time intervals samples were obtained and plated.", [["samples", "ANATOMY", 27, 34], ["intervals samples", "TEST", 17, 34]]], ["After incubation colony forming units were counted.", [["colony", "ANATOMY", 17, 23]]], ["Human serum concentrations were simulated with Cmax = 100 mg/L and t1/2 of 5 hours for ERT and Cmax = 14.0 mg/L and t1/2 of 7 hours for MTR.", [["serum", "ANATOMY", 6, 11], ["Cmax", "CHEMICAL", 47, 51], ["Cmax", "CHEMICAL", 95, 99], ["Human", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["MTR", "SIMPLE_CHEMICAL", 136, 139], ["MTR", "PROTEIN", 136, 139], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human serum concentrations", "TEST", 0, 26], ["Cmax", "TREATMENT", 47, 51], ["ERT", "TREATMENT", 87, 90], ["Cmax", "TEST", 95, 99], ["MTR", "PROBLEM", 136, 139]]], ["Mann trend test was used for statistical analysis.", [["Mann trend test", "TEST", 0, 15], ["statistical analysis", "TEST", 29, 49]]], ["Results: As to be expected the E. coli strains were not killed by MTR both in pure as well as in mixed cultures whereas the susceptible E. coli strains were effectively killed by ERT.", [["MTR", "CHEMICAL", 66, 69], ["E. coli", "ORGANISM", 31, 38], ["strains", "ORGANISM", 39, 46], ["MTR", "SIMPLE_CHEMICAL", 66, 69], ["E. coli", "ORGANISM", 136, 143], ["strains", "ORGANISM", 144, 151], ["MTR", "PROTEIN", 66, 69], ["mixed cultures", "CELL_LINE", 97, 111], ["E. coli", "SPECIES", 31, 38], ["E. coli", "SPECIES", 136, 143], ["E. coli", "SPECIES", 31, 38], ["E. coli", "SPECIES", 136, 143], ["the E. coli strains", "PROBLEM", 27, 46], ["mixed cultures", "TEST", 97, 111], ["the susceptible E. coli strains", "PROBLEM", 120, 151], ["coli strains", "OBSERVATION", 139, 151]]], ["In pure cultures the B. fragilis strains were effectively killed by MTR and the growth of the susceptible B. fragilis strains was reduced by ERT by about two to four logs.", [["strains", "ANATOMY", 33, 40], ["MTR", "CHEMICAL", 68, 71], ["B. fragilis strains", "ORGANISM", 21, 40], ["MTR", "SIMPLE_CHEMICAL", 68, 71], ["B. fragilis strains", "ORGANISM", 106, 125], ["MTR", "PROTEIN", 68, 71], ["B. fragilis", "SPECIES", 21, 32], ["B. fragilis", "SPECIES", 106, 117], ["B. fragilis", "SPECIES", 21, 32], ["B. fragilis", "SPECIES", 106, 117], ["pure cultures", "TEST", 3, 16], ["the B. fragilis strains", "PROBLEM", 17, 40], ["the susceptible B. fragilis strains", "PROBLEM", 90, 125], ["fragilis strains", "OBSERVATION", 109, 125]]], ["However, in some mixed cultures the killing activity of MTR against the B. fragilis strains was significantly reduced.", [["cultures", "ANATOMY", 23, 31], ["MTR", "CHEMICAL", 56, 59], ["MTR", "SIMPLE_CHEMICAL", 56, 59], ["B. fragilis strains", "ORGANISM", 72, 91], ["MTR", "PROTEIN", 56, 59], ["B. fragilis", "SPECIES", 72, 83], ["B. fragilis", "SPECIES", 72, 83], ["some mixed cultures", "PROBLEM", 12, 31], ["the B. fragilis strains", "PROBLEM", 68, 91], ["reduced", "OBSERVATION_MODIFIER", 110, 117]]], ["Conclusion: The in part moderate in vitro activity of ERT against the B. fragilis strains and the reduced activity of metronidazole in mixed cultures against the B. fragilis strains may explain some of the difficulties in treating mixed aerobic/ anaerobic infections.P1549Penetration of ciprofloxacin into human cerebrospinal fluid and brain tissue A. Tsona, S. Metallidis, E. Koumentaki, J. Nikolaidis, P. Kollaras, G. Lazaraki, P. Nikolaidis (Thessaloniki, GR)P1549Objectives: The aim of the present study was to determine the penetration of ciprofloxacin into cerebrospinal fluid (CSF) and brain tissue of humans.P1549Methods: A total of 10 patients undergoing brain tumor excision were evaluated.", [["cerebrospinal fluid", "ANATOMY", 312, 331], ["brain tissue", "ANATOMY", 336, 348], ["cerebrospinal fluid", "ANATOMY", 563, 582], ["CSF", "ANATOMY", 584, 587], ["brain tissue", "ANATOMY", 593, 605], ["brain tumor", "ANATOMY", 664, 675], ["ERT", "CHEMICAL", 54, 57], ["metronidazole", "CHEMICAL", 118, 131], ["infections", "DISEASE", 256, 266], ["ciprofloxacin", "CHEMICAL", 287, 300], ["ciprofloxacin", "CHEMICAL", 544, 557], ["tumor", "DISEASE", 670, 675], ["metronidazole", "CHEMICAL", 118, 131], ["ciprofloxacin", "CHEMICAL", 287, 300], ["ciprofloxacin", "CHEMICAL", 544, 557], ["ERT", "SIMPLE_CHEMICAL", 54, 57], ["B. fragilis strains", "ORGANISM", 70, 89], ["metronidazole", "SIMPLE_CHEMICAL", 118, 131], ["B. fragilis strains", "ORGANISM", 162, 181], ["ciprofloxacin", "SIMPLE_CHEMICAL", 287, 300], ["human", "ORGANISM", 306, 311], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 312, 331], ["brain tissue", "TISSUE", 336, 348], ["ciprofloxacin", "SIMPLE_CHEMICAL", 544, 557], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 563, 582], ["CSF", "ORGANISM_SUBSTANCE", 584, 587], ["brain tissue", "TISSUE", 593, 605], ["humans", "ORGANISM", 609, 615], ["patients", "ORGANISM", 644, 652], ["brain tumor", "CANCER", 664, 675], ["mixed cultures", "CELL_LINE", 135, 149], ["B. fragilis", "SPECIES", 70, 81], ["B. fragilis", "SPECIES", 162, 173], ["human", "SPECIES", 306, 311], ["humans", "SPECIES", 609, 615], ["patients", "SPECIES", 644, 652], ["B. fragilis", "SPECIES", 70, 81], ["B. fragilis", "SPECIES", 162, 173], ["human", "SPECIES", 306, 311], ["humans", "SPECIES", 609, 615], ["ERT", "TREATMENT", 54, 57], ["the B. fragilis strains", "PROBLEM", 66, 89], ["metronidazole", "TREATMENT", 118, 131], ["mixed cultures", "TEST", 135, 149], ["the B. fragilis strains", "PROBLEM", 158, 181], ["the difficulties", "PROBLEM", 202, 218], ["mixed aerobic/ anaerobic infections", "PROBLEM", 231, 266], ["ciprofloxacin", "TREATMENT", 287, 300], ["human cerebrospinal fluid", "TEST", 306, 331], ["the present study", "TEST", 490, 507], ["ciprofloxacin", "TREATMENT", 544, 557], ["cerebrospinal fluid (CSF", "TEST", 563, 587], ["brain tumor excision", "TREATMENT", 664, 684], ["fragilis", "OBSERVATION", 73, 81], ["reduced", "OBSERVATION_MODIFIER", 98, 105], ["activity", "OBSERVATION_MODIFIER", 106, 114], ["anaerobic infections", "OBSERVATION", 246, 266], ["cerebrospinal fluid", "OBSERVATION", 312, 331], ["brain", "ANATOMY", 336, 341], ["brain tissue", "ANATOMY", 593, 605], ["brain", "ANATOMY", 664, 669], ["tumor", "OBSERVATION", 670, 675]]], ["The patients received a single intravenous dose of 400 mg ciprofloxacin.", [["intravenous", "ANATOMY", 31, 42], ["ciprofloxacin", "CHEMICAL", 58, 71], ["ciprofloxacin", "CHEMICAL", 58, 71], ["patients", "ORGANISM", 4, 12], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 42], ["ciprofloxacin", "SIMPLE_CHEMICAL", 58, 71], ["patients", "SPECIES", 4, 12], ["a single intravenous dose of 400 mg ciprofloxacin", "TREATMENT", 22, 71]]], ["Samples of blood, cerebrospinal fluid and brain (brain-adjacent tumour tissue) were collected during surgery 2 h after drug administration.", [["Samples", "ANATOMY", 0, 7], ["blood", "ANATOMY", 11, 16], ["cerebrospinal fluid", "ANATOMY", 18, 37], ["brain", "ANATOMY", 42, 47], ["brain", "ANATOMY", 49, 54], ["tumour tissue", "ANATOMY", 64, 77], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 18, 37], ["brain", "ORGAN", 42, 47], ["brain", "ORGAN", 49, 54], ["tumour tissue", "TISSUE", 64, 77], ["Samples of blood", "TEST", 0, 16], ["cerebrospinal fluid", "TEST", 18, 37], ["surgery", "TREATMENT", 101, 108], ["drug administration", "TREATMENT", 119, 138], ["blood", "ANATOMY", 11, 16], ["cerebrospinal fluid", "OBSERVATION", 18, 37], ["brain", "ANATOMY", 42, 47], ["brain", "ANATOMY", 49, 54], ["tumour tissue", "OBSERVATION", 64, 77]]], ["Ciprofloxacin concentrations in serum, cerebrospinal fluid and brain homogenate were analysed by means of a validated HPLC method.", [["serum", "ANATOMY", 32, 37], ["cerebrospinal fluid", "ANATOMY", 39, 58], ["brain homogenate", "ANATOMY", 63, 79], ["Ciprofloxacin", "CHEMICAL", 0, 13], ["Ciprofloxacin", "CHEMICAL", 0, 13], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 39, 58], ["brain homogenate", "ORGANISM_SUBSTANCE", 63, 79], ["Ciprofloxacin concentrations", "TREATMENT", 0, 28], ["serum, cerebrospinal fluid", "TEST", 32, 58], ["brain homogenate", "TEST", 63, 79], ["a validated HPLC method", "TREATMENT", 106, 129], ["cerebrospinal", "ANATOMY", 39, 52], ["fluid", "OBSERVATION", 53, 58], ["brain", "ANATOMY", 63, 68]]], ["Results: Ciprofloxacin concentrations in plasma (mcg/ml), cerebrospinal fluid (mcg/ml) and tissue homogenate (mcg/g), respectively, after 2 h ranged 0.87-2.67 mcg/ml, 0.07-0.37 mcg/ ml and 0.65-4.02 mcg/g.", [["plasma", "ANATOMY", 41, 47], ["cerebrospinal fluid", "ANATOMY", 58, 77], ["tissue homogenate", "ANATOMY", 91, 108], ["Ciprofloxacin", "CHEMICAL", 9, 22], ["Ciprofloxacin", "CHEMICAL", 9, 22], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 9, 22], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 58, 77], ["tissue homogenate", "TISSUE", 91, 108], ["Ciprofloxacin concentrations in plasma", "TREATMENT", 9, 47], ["cerebrospinal fluid", "TREATMENT", 58, 77], ["tissue homogenate", "TREATMENT", 91, 108], ["cerebrospinal", "ANATOMY", 58, 71]]], ["CSF-to-serum ratio ranged between 0.06 and 0.14.", [["serum", "ANATOMY", 7, 12], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["CSF", "PROTEIN", 0, 3], ["CSF", "TEST", 0, 3], ["serum ratio", "TEST", 7, 18]]], ["Tissue-to-serum ratio ranged between 0.41 and 4.25.", [["Tissue", "ANATOMY", 0, 6], ["serum", "ANATOMY", 10, 15], ["Tissue", "TISSUE", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["Tissue", "TEST", 0, 6], ["serum ratio", "TEST", 10, 21]]], ["CSF/serum concentration ratios and brain tissue/serum concentration ratios were respectively 0.10 \u00b1 0.03 and 1.70 \u00b1 1.17.", [["serum", "ANATOMY", 4, 9], ["brain tissue", "ANATOMY", 35, 47], ["serum", "ANATOMY", 48, 53], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["brain tissue", "TISSUE", 35, 47], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["CSF", "PROTEIN", 0, 3], ["CSF/serum concentration ratios", "TEST", 0, 30], ["brain tissue", "TEST", 35, 47], ["serum concentration ratios", "TEST", 48, 74], ["brain tissue", "ANATOMY", 35, 47]]], ["Conclusion: These findings suggest that valuable informations on brain tissue penetration can be obtained only from brain material.", [["brain tissue", "ANATOMY", 65, 77], ["brain", "ANATOMY", 116, 121], ["brain tissue", "TISSUE", 65, 77], ["brain material", "MULTI-TISSUE_STRUCTURE", 116, 130], ["brain tissue penetration", "TEST", 65, 89]]], ["Data from CSF penetration cannot be extrapolated to the brain since the blood: SF barrier differs from the blood:brain barrier.", [["brain", "ANATOMY", 56, 61], ["blood", "ANATOMY", 72, 77], ["blood", "ANATOMY", 107, 112], ["brain", "ANATOMY", 113, 118], ["CSF", "ORGANISM_SUBSTANCE", 10, 13], ["brain", "ORGAN", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["SF barrier", "TISSUE", 79, 89], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 113, 126], ["CSF penetration", "TEST", 10, 25], ["brain barrier", "TREATMENT", 113, 126], ["brain", "ANATOMY", 56, 61], ["brain", "ANATOMY", 113, 118]]], ["Concentrations of ciprofloxacin in cerebrospinal fluid were lower than those in serum, in contrast to the brain tissue concentrations that exceeded serum concentrations.", [["cerebrospinal fluid", "ANATOMY", 35, 54], ["serum", "ANATOMY", 80, 85], ["brain tissue", "ANATOMY", 106, 118], ["serum", "ANATOMY", 148, 153], ["ciprofloxacin", "CHEMICAL", 18, 31], ["ciprofloxacin", "CHEMICAL", 18, 31], ["ciprofloxacin", "SIMPLE_CHEMICAL", 18, 31], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 35, 54], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["brain tissue", "TISSUE", 106, 118], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["ciprofloxacin", "TREATMENT", 18, 31], ["cerebrospinal fluid", "TEST", 35, 54], ["serum concentrations", "TEST", 148, 168], ["cerebrospinal fluid", "OBSERVATION", 35, 54], ["brain tissue", "ANATOMY", 106, 118]]], ["The achieved concentrations in brain tissue were generally above the MIC90 of common pathogens in central nervous system infections (H. influenze, N. meningitidis, S. pneumoniae, L. monocytogenes, Escherichia coli, aerobic gram-negative bacilli, Group B Streptococci, MSSA).", [["brain tissue", "ANATOMY", 31, 43], ["central nervous system", "ANATOMY", 98, 120], ["central nervous system infections", "DISEASE", 98, 131], ["brain tissue", "TISSUE", 31, 43], ["central nervous system", "ANATOMICAL_SYSTEM", 98, 120], ["H. influenze", "ORGANISM", 133, 145], ["N. meningitidis", "ORGANISM", 147, 162], ["S. pneumoniae", "ORGANISM", 164, 177], ["L. monocytogenes", "ORGANISM", 179, 195], ["Escherichia coli", "ORGANISM", 197, 213], ["Group B Streptococci", "ORGANISM", 246, 266], ["MSSA", "CANCER", 268, 272], ["H. influenze", "SPECIES", 133, 145], ["N. meningitidis", "SPECIES", 147, 162], ["S. pneumoniae", "SPECIES", 164, 177], ["L. monocytogenes", "SPECIES", 179, 195], ["Escherichia coli", "SPECIES", 197, 213], ["H. influenze", "SPECIES", 133, 145], ["N. meningitidis", "SPECIES", 147, 162], ["S. pneumoniae", "SPECIES", 164, 177], ["L. monocytogenes", "SPECIES", 179, 195], ["Escherichia coli", "SPECIES", 197, 213], ["The achieved concentrations in brain tissue", "PROBLEM", 0, 43], ["common pathogens", "PROBLEM", 78, 94], ["central nervous system infections", "PROBLEM", 98, 131], ["H. influenze", "TEST", 133, 145], ["meningitidis", "PROBLEM", 150, 162], ["S. pneumoniae", "PROBLEM", 164, 177], ["L. monocytogenes", "PROBLEM", 179, 195], ["Escherichia coli", "PROBLEM", 197, 213], ["aerobic gram", "TEST", 215, 227], ["bacilli", "PROBLEM", 237, 244], ["Group B Streptococci", "PROBLEM", 246, 266], ["MSSA", "PROBLEM", 268, 272], ["concentrations", "OBSERVATION_MODIFIER", 13, 27], ["brain tissue", "ANATOMY", 31, 43], ["central", "ANATOMY_MODIFIER", 98, 105], ["nervous system", "ANATOMY", 106, 120], ["Escherichia coli", "OBSERVATION", 197, 213], ["negative bacilli", "OBSERVATION", 228, 244]]], ["Cerebrospinal fluid concentrations exceed the MICs of Neisseria meningitidis and most gram-negative aerobic bacilli.", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["Neisseria meningitidis", "DISEASE", 54, 76], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["Neisseria meningitidis", "ORGANISM", 54, 76], ["Neisseria meningitidis", "SPECIES", 54, 76], ["Neisseria meningitidis", "SPECIES", 54, 76], ["Cerebrospinal fluid concentrations", "TEST", 0, 34], ["the MICs", "TEST", 42, 50], ["Neisseria meningitidis", "PROBLEM", 54, 76], ["most gram", "TEST", 81, 90], ["fluid concentrations", "OBSERVATION", 14, 34], ["aerobic bacilli", "OBSERVATION", 100, 115]]], ["Our findings suggests that ciprofloxacin may be an acceptable alternative for the treatment of meningitis due to susceptible gram-negative aerobic organisms and for the treatment of brain abscesses.", [["brain abscesses", "ANATOMY", 182, 197], ["ciprofloxacin", "CHEMICAL", 27, 40], ["meningitis", "DISEASE", 95, 105], ["brain abscesses", "DISEASE", 182, 197], ["ciprofloxacin", "CHEMICAL", 27, 40], ["ciprofloxacin", "SIMPLE_CHEMICAL", 27, 40], ["brain abscesses", "PATHOLOGICAL_FORMATION", 182, 197], ["ciprofloxacin", "TREATMENT", 27, 40], ["meningitis", "PROBLEM", 95, 105], ["susceptible gram-negative aerobic organisms", "PROBLEM", 113, 156], ["brain abscesses", "PROBLEM", 182, 197], ["meningitis", "OBSERVATION", 95, 105], ["negative aerobic organisms", "OBSERVATION", 130, 156], ["brain", "ANATOMY", 182, 187], ["abscesses", "OBSERVATION", 188, 197]]], ["Objective: To model the performance of imipenem (IMI), meropenem (MEM), and ertapenem (ETM) against ESBL producing E. coli and Klebsiella spp in order to identify possible PD differences among compounds.", [["imipenem", "CHEMICAL", 39, 47], ["IMI", "CHEMICAL", 49, 52], ["meropenem", "CHEMICAL", 55, 64], ["MEM", "CHEMICAL", 66, 69], ["ertapenem", "CHEMICAL", 76, 85], ["ETM", "CHEMICAL", 87, 90], ["ESBL", "CHEMICAL", 100, 104], ["imipenem", "CHEMICAL", 39, 47], ["IMI", "CHEMICAL", 49, 52], ["meropenem", "CHEMICAL", 55, 64], ["MEM", "CHEMICAL", 66, 69], ["ertapenem", "CHEMICAL", 76, 85], ["ETM", "CHEMICAL", 87, 90], ["imipenem", "SIMPLE_CHEMICAL", 39, 47], ["IMI", "SIMPLE_CHEMICAL", 49, 52], ["meropenem", "SIMPLE_CHEMICAL", 55, 64], ["MEM", "SIMPLE_CHEMICAL", 66, 69], ["ertapenem", "SIMPLE_CHEMICAL", 76, 85], ["ETM", "SIMPLE_CHEMICAL", 87, 90], ["ESBL producing", "ORGANISM", 100, 114], ["E. coli", "ORGANISM", 115, 122], ["Klebsiella spp", "ORGANISM", 127, 141], ["E. coli", "SPECIES", 115, 122], ["E. coli", "SPECIES", 115, 122], ["imipenem (IMI", "TREATMENT", 39, 52], ["meropenem (MEM)", "TREATMENT", 55, 70], ["ertapenem", "TREATMENT", 76, 85], ["ESBL", "PROBLEM", 100, 104], ["E. coli", "PROBLEM", 115, 122], ["Klebsiella spp", "PROBLEM", 127, 141], ["PD differences among compounds", "PROBLEM", 172, 202]]], ["Methods: Minimal inhibitory concentrations (MICs) were generated for 133 randomly selected ESBL producing isolates of EC (n = 29) and KL (n = 104) collected during 2004 from Brazilian hospitals as part of the MYSTIC program.", [["EC", "ANATOMY", 118, 120], ["EC", "CELL", 118, 120], ["EC", "CELL_TYPE", 118, 120], ["Minimal inhibitory concentrations (MICs)", "TREATMENT", 9, 49], ["EC", "TEST", 118, 120], ["KL", "TEST", 134, 136], ["the MYSTIC program", "TREATMENT", 205, 223]]], ["MIC testing for IMI, MEM, ETM, ceftazidime (CTZ), and cefotaxime (CTX) were done by E-test methodology.", [["MIC", "CHEMICAL", 0, 3], ["IMI", "CHEMICAL", 16, 19], ["MEM", "CHEMICAL", 21, 24], ["ETM", "CHEMICAL", 26, 29], ["ceftazidime", "CHEMICAL", 31, 42], ["CTZ", "CHEMICAL", 44, 47], ["cefotaxime", "CHEMICAL", 54, 64], ["CTX", "CHEMICAL", 66, 69], ["ETM", "CHEMICAL", 26, 29], ["ceftazidime", "CHEMICAL", 31, 42], ["CTZ", "CHEMICAL", 44, 47], ["cefotaxime", "CHEMICAL", 54, 64], ["CTX", "CHEMICAL", 66, 69], ["ETM", "SIMPLE_CHEMICAL", 26, 29], ["ceftazidime", "SIMPLE_CHEMICAL", 31, 42], ["CTZ", "SIMPLE_CHEMICAL", 44, 47], ["cefotaxime", "SIMPLE_CHEMICAL", 54, 64], ["CTX", "SIMPLE_CHEMICAL", 66, 69], ["MIC testing", "TEST", 0, 11], ["IMI", "PROBLEM", 16, 19], ["ceftazidime (CTZ)", "TREATMENT", 31, 48], ["cefotaxime", "TREATMENT", 54, 64], ["CTX", "TREATMENT", 66, 69]]], ["ESBLs were confirmed via CTZ/clavulanate and CTX/clavulanate E-Test.", [["CTZ/clavulanate", "CHEMICAL", 25, 40], ["CTX", "CHEMICAL", 45, 48], ["clavulanate", "CHEMICAL", 49, 60], ["CTZ", "CHEMICAL", 25, 28], ["clavulanate", "CHEMICAL", 29, 40], ["CTX", "CHEMICAL", 45, 48], ["clavulanate", "CHEMICAL", 49, 60], ["ESBLs", "GENE_OR_GENE_PRODUCT", 0, 5], ["CTZ", "SIMPLE_CHEMICAL", 25, 28], ["clavulanate", "SIMPLE_CHEMICAL", 29, 40], ["CTX/clavulanate E", "SIMPLE_CHEMICAL", 45, 62], ["ESBLs", "TEST", 0, 5], ["CTZ", "TEST", 25, 28], ["clavulanate", "TREATMENT", 29, 40], ["CTX", "TEST", 45, 48], ["clavulanate E", "TEST", 49, 62]]], ["PD exposure, measured as percent time above the MIC for free drug (fT>MIC), was modelled via a 5000 subject Monte Carlo simulation for the following 30-minute infusions:IMI 1 gram every 8 hours, MEM 1 gram every 8 hours, and ETM 1 gram every 24 hours, using pharmacokinetics from healthy volunteers.", [["PD", "DISEASE", 0, 2], ["volunteers", "ORGANISM", 288, 298], ["PD exposure", "PROBLEM", 0, 11], ["free drug (fT>MIC", "TREATMENT", 56, 73], ["IMI", "TREATMENT", 169, 172], ["MEM", "TREATMENT", 195, 198]]], ["The bactericidal cumulative fraction of response (CFR) was calculated for each regimen against the populations of EC, KL, and against all ESBL isolates together.", [["EC", "ANATOMY", 114, 116], ["EC", "CELL", 114, 116], ["KL", "CELL", 118, 120], ["EC", "CELL_TYPE", 114, 116], ["The bactericidal cumulative fraction", "TEST", 0, 36], ["CFR", "TEST", 50, 53], ["each regimen", "TREATMENT", 74, 86], ["all ESBL isolates", "TEST", 134, 151], ["bactericidal", "OBSERVATION_MODIFIER", 4, 16]]], ["Bactericidal CFR was defined as 40% fT>MIC for all agents.", [["Bactericidal CFR", "TEST", 0, 16], ["all agents", "TREATMENT", 47, 57]]], ["Results are reported as CFR (95% Confidence Interval).P1549Results: Isolates were 100% susceptible (S) to IMI and MEM (MIC range 0.125-1.5 and 0.023-4 mg/L, respectively), and 97% S to ETM (MIC range 0.008-32 mg/L Conclusions: These findings support other data that although ETM is likely to be an effective empiric agent against most ESBL producing EC and KL, its ability to achieve high bactericidal PD exposure will be dependent on the presence of less susceptible organisms in the population.", [["EC", "ANATOMY", 350, 352], ["IMI", "CHEMICAL", 106, 109], ["MEM", "CHEMICAL", 114, 117], ["ETM", "CHEMICAL", 185, 188], ["ETM", "CHEMICAL", 275, 278], ["PD", "DISEASE", 402, 404], ["ETM", "SIMPLE_CHEMICAL", 275, 278], ["EC", "CELL", 350, 352], ["EC", "CELL_TYPE", 350, 352], ["CFR", "TEST", 24, 27], ["Isolates", "TEST", 68, 76], ["IMI", "TEST", 106, 109], ["MEM", "TEST", 114, 117], ["MIC range", "TEST", 119, 128], ["ETM", "TEST", 185, 188], ["MIC range", "TEST", 190, 199], ["an effective empiric agent", "TREATMENT", 295, 321], ["most ESBL producing EC and KL", "PROBLEM", 330, 359], ["high bactericidal PD exposure", "PROBLEM", 384, 413], ["less susceptible organisms in the population", "PROBLEM", 451, 495]]], ["IMI and MEM should remain first line for ESBL infections.", [["IMI", "CHEMICAL", 0, 3], ["infections", "DISEASE", 46, 56], ["IMI", "PROBLEM", 0, 3], ["ESBL infections", "PROBLEM", 41, 56], ["infections", "OBSERVATION", 46, 56]]], ["Objectives: This study analyses eradication and resistance selection in Streptococcus pneumoniae with moxifloxacin, levofloxacin and azithromycin, using a parental serotype 3 infecting strain (A) and subsequent resistant step-mutants (isolates B, C and D) selected in vivo in a patient with pneumonia.", [["moxifloxacin", "CHEMICAL", 102, 114], ["levofloxacin", "CHEMICAL", 116, 128], ["azithromycin", "CHEMICAL", 133, 145], ["pneumonia", "DISEASE", 291, 300], ["moxifloxacin", "CHEMICAL", 102, 114], ["levofloxacin", "CHEMICAL", 116, 128], ["azithromycin", "CHEMICAL", 133, 145], ["Streptococcus pneumoniae", "ORGANISM", 72, 96], ["moxifloxacin", "SIMPLE_CHEMICAL", 102, 114], ["levofloxacin", "SIMPLE_CHEMICAL", 116, 128], ["azithromycin", "SIMPLE_CHEMICAL", 133, 145], ["serotype 3", "ORGANISM", 164, 174], ["A", "CANCER", 193, 194], ["B", "CELL", 244, 245], ["C", "CELL", 247, 248], ["D", "CELL", 253, 254], ["patient", "ORGANISM", 278, 285], ["Streptococcus pneumoniae", "SPECIES", 72, 96], ["patient", "SPECIES", 278, 285], ["Streptococcus pneumoniae", "SPECIES", 72, 96], ["This study", "TEST", 12, 22], ["resistance selection", "TREATMENT", 48, 68], ["Streptococcus pneumoniae", "PROBLEM", 72, 96], ["moxifloxacin", "TREATMENT", 102, 114], ["levofloxacin", "TREATMENT", 116, 128], ["azithromycin", "TREATMENT", 133, 145], ["a parental serotype", "TREATMENT", 153, 172], ["subsequent resistant step-mutants", "PROBLEM", 200, 233], ["pneumonia", "PROBLEM", 291, 300], ["pneumonia", "OBSERVATION", 291, 300]]], ["Methods: Moxifloxacin, levofloxacin and azithromycin MICs were 1, 2 and 0.5 lg/ml for the parental strain, 4, 16, and 4 lg/ ml for isolate B, and 4, 16 and >128 lg/ml for isolates C and D, respectively.", [["Moxifloxacin", "CHEMICAL", 9, 21], ["levofloxacin", "CHEMICAL", 23, 35], ["azithromycin", "CHEMICAL", 40, 52], ["Moxifloxacin", "CHEMICAL", 9, 21], ["levofloxacin", "CHEMICAL", 23, 35], ["azithromycin", "CHEMICAL", 40, 52], ["Moxifloxacin", "SIMPLE_CHEMICAL", 9, 21], ["levofloxacin", "SIMPLE_CHEMICAL", 23, 35], ["azithromycin", "SIMPLE_CHEMICAL", 40, 52], ["B", "CELL", 139, 140], ["D", "SIMPLE_CHEMICAL", 186, 187], ["Moxifloxacin", "TREATMENT", 9, 21], ["levofloxacin", "TREATMENT", 23, 35], ["azithromycin MICs", "TREATMENT", 40, 57], ["the parental strain", "TEST", 86, 105], ["isolate B", "TEST", 131, 140]]], ["A pharmacokinetic computerized device was used to simulate serum and epithelial lining fluid (ELF) concentrations.", [["serum", "ANATOMY", 59, 64], ["epithelial lining fluid", "ANATOMY", 69, 92], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["epithelial lining fluid", "TISSUE", 69, 92], ["A pharmacokinetic computerized device", "TREATMENT", 0, 37], ["epithelial", "ANATOMY_MODIFIER", 69, 79], ["lining fluid", "OBSERVATION", 80, 92]]], ["Initial inocula was approx.", [["inocula", "OBSERVATION", 8, 15]]], ["Population analysis profiles were performed using plates with increasing antimicrobial concentrations on a MIC basis.", [["Population analysis profiles", "TEST", 0, 28], ["plates", "TREATMENT", 50, 56], ["increasing antimicrobial concentrations", "TREATMENT", 62, 101], ["a MIC basis", "TREATMENT", 105, 116]]], ["Results: In serum, moxifloxacin eradicated the parental isolate (isolate A), with an AUC0-24 h/MIC value of 39.6.", [["serum", "ANATOMY", 12, 17], ["moxifloxacin", "CHEMICAL", 19, 31], ["moxifloxacin", "CHEMICAL", 19, 31], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["moxifloxacin", "SIMPLE_CHEMICAL", 19, 31], ["serum", "TEST", 12, 17], ["moxifloxacin", "TREATMENT", 19, 31], ["an AUC0", "TEST", 82, 89], ["MIC value", "TEST", 95, 104]]], ["Serum AUC0-24 h/MIC values of 26.5 and 5.5 for levofloxacin and azithromycin, respectively, were not able to eradicate isolate A. In ELF, moxifloxacin showed a bactericidal pattern against all isolates with a minority (approx.", [["Serum", "ANATOMY", 0, 5], ["levofloxacin", "CHEMICAL", 47, 59], ["azithromycin", "CHEMICAL", 64, 76], ["moxifloxacin", "CHEMICAL", 138, 150], ["levofloxacin", "CHEMICAL", 47, 59], ["azithromycin", "CHEMICAL", 64, 76], ["moxifloxacin", "CHEMICAL", 138, 150], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["levofloxacin", "SIMPLE_CHEMICAL", 47, 59], ["azithromycin", "SIMPLE_CHEMICAL", 64, 76], ["moxifloxacin", "SIMPLE_CHEMICAL", 138, 150], ["Serum AUC0", "TEST", 0, 10], ["MIC values", "TEST", 16, 26], ["levofloxacin", "TREATMENT", 47, 59], ["azithromycin", "TREATMENT", 64, 76], ["moxifloxacin", "TREATMENT", 138, 150], ["a bactericidal pattern", "PROBLEM", 158, 180]]], ["100 cfu/ml) of the survival population (isolates B, C and D) growing in plates with moxifloxacin concentrations higher than those obtained in ELF.", [["moxifloxacin", "CHEMICAL", 84, 96], ["moxifloxacin", "CHEMICAL", 84, 96], ["B, C", "CELL", 49, 53], ["moxifloxacin", "SIMPLE_CHEMICAL", 84, 96], ["the survival population", "TREATMENT", 15, 38], ["isolates B, C and D)", "TEST", 40, 60], ["moxifloxacin concentrations", "TREATMENT", 84, 111]]], ["Levofloxacin and azithromycin showed a bactericidal pattern only against isolate A, with the whole population of isolates B, C and D growing in plates with levofloxacin concentrations higher (16-64 lg/ml) than those obtained in ELF, and in plates with azithromycin concentrations as high as 2048 lg/ml (for isolates C and D).", [["Levofloxacin", "CHEMICAL", 0, 12], ["azithromycin", "CHEMICAL", 17, 29], ["levofloxacin", "CHEMICAL", 156, 168], ["azithromycin", "CHEMICAL", 252, 264], ["Levofloxacin", "CHEMICAL", 0, 12], ["azithromycin", "CHEMICAL", 17, 29], ["levofloxacin", "CHEMICAL", 156, 168], ["azithromycin", "CHEMICAL", 252, 264], ["Levofloxacin", "SIMPLE_CHEMICAL", 0, 12], ["azithromycin", "SIMPLE_CHEMICAL", 17, 29], ["B, C", "CELL", 122, 126], ["D", "SIMPLE_CHEMICAL", 131, 132], ["levofloxacin", "SIMPLE_CHEMICAL", 156, 168], ["azithromycin", "SIMPLE_CHEMICAL", 252, 264], ["Levofloxacin", "TREATMENT", 0, 12], ["azithromycin", "TREATMENT", 17, 29], ["a bactericidal pattern", "PROBLEM", 37, 59], ["isolates B, C and D growing in plates", "PROBLEM", 113, 150], ["levofloxacin concentrations", "TREATMENT", 156, 183], ["azithromycin concentrations", "TREATMENT", 252, 279]]], ["In ELF, moxifloxacin AUC0-24 h/MIC values were 201.0 for isolate A, and 50.3 for isolates B, C and D. Levofloxacin AUC0-24 h/MIC values were 94.0 for isolate A, and 11.8 for isolates B, C and D. Azithromycin AUC0-24 h/MIC values were 8.0 for isolate A; 10.0 for isolate B; and 0 for isolates C and D. Conclusion: If prevention of resistance depends more on the eradication of possible emerging mutants in pulmonary tissues than of the parental susceptible strain, moxifloxacin concentrations in ELF may provide advantages over previous quinolones and macrolides in preventing clinical failures.", [["pulmonary tissues", "ANATOMY", 405, 422], ["moxifloxacin", "CHEMICAL", 8, 20], ["Azithromycin", "CHEMICAL", 195, 207], ["moxifloxacin", "CHEMICAL", 464, 476], ["quinolones", "CHEMICAL", 536, 546], ["macrolides", "CHEMICAL", 551, 561], ["moxifloxacin", "CHEMICAL", 8, 20], ["moxifloxacin", "CHEMICAL", 464, 476], ["quinolones", "CHEMICAL", 536, 546], ["macrolides", "CHEMICAL", 551, 561], ["moxifloxacin", "SIMPLE_CHEMICAL", 8, 20], ["C", "SIMPLE_CHEMICAL", 93, 94], ["Levofloxacin", "SIMPLE_CHEMICAL", 102, 114], ["C", "SIMPLE_CHEMICAL", 186, 187], ["pulmonary tissues", "TISSUE", 405, 422], ["moxifloxacin", "SIMPLE_CHEMICAL", 464, 476], ["quinolones", "SIMPLE_CHEMICAL", 536, 546], ["macrolides", "SIMPLE_CHEMICAL", 551, 561], ["moxifloxacin AUC0", "TREATMENT", 8, 25], ["MIC values", "TEST", 31, 41], ["isolates B", "TEST", 81, 91], ["C", "TEST", 93, 94], ["Levofloxacin AUC0", "TEST", 102, 119], ["MIC values", "TEST", 125, 135], ["isolates B", "TEST", 174, 184], ["C", "TEST", 186, 187], ["Azithromycin AUC0", "TEST", 195, 212], ["MIC values", "TEST", 218, 228], ["resistance", "PROBLEM", 330, 340], ["emerging mutants in pulmonary tissues", "PROBLEM", 385, 422], ["the parental susceptible strain", "PROBLEM", 431, 462], ["moxifloxacin concentrations in ELF", "TREATMENT", 464, 498], ["previous quinolones", "TREATMENT", 527, 546], ["macrolides", "TREATMENT", 551, 561], ["clinical failures", "PROBLEM", 576, 593], ["pulmonary tissues", "ANATOMY", 405, 422]]], ["Objectives: To explore how antimicrobial pressure influences the evolution of Streptococcus pneumoniae populations sharing the same ecological niche.", [["Streptococcus pneumoniae", "ORGANISM", 78, 102], ["Streptococcus pneumoniae", "SPECIES", 78, 102], ["Streptococcus pneumoniae", "SPECIES", 78, 102], ["antimicrobial pressure", "TEST", 27, 49], ["Streptococcus pneumoniae populations", "PROBLEM", 78, 114], ["Streptococcus pneumoniae", "OBSERVATION", 78, 102]]], ["Methods: An in vitro computerized pharmacodynamic model simulating physiological concentrations obtained over 24 h after 500 mg o.d levofloxacin, 750 mg b.i.d ciprofloxacin, and 500 mg o.d azithromycin was used to investigate its effect on a mixed culture of five S. pneumoniae serotypes (S) as an approach to ecology of population dynamics.", [["levofloxacin", "CHEMICAL", 132, 144], ["ciprofloxacin", "CHEMICAL", 159, 172], ["azithromycin", "CHEMICAL", 189, 201], ["levofloxacin", "CHEMICAL", 132, 144], ["ciprofloxacin", "CHEMICAL", 159, 172], ["azithromycin", "CHEMICAL", 189, 201], ["levofloxacin", "SIMPLE_CHEMICAL", 132, 144], ["ciprofloxacin", "SIMPLE_CHEMICAL", 159, 172], ["azithromycin", "SIMPLE_CHEMICAL", 189, 201], ["S. pneumoniae", "ORGANISM", 264, 277], ["S. pneumoniae", "SPECIES", 264, 277], ["S. pneumoniae", "SPECIES", 264, 277], ["levofloxacin", "TREATMENT", 132, 144], ["ciprofloxacin", "TREATMENT", 159, 172], ["azithromycin", "TREATMENT", 189, 201], ["a mixed culture", "TEST", 240, 255], ["five S. pneumoniae serotypes", "PROBLEM", 259, 287]]], ["Resistance patterns were: S12 was susceptible to study drugs, S31 was low-level macrolideresistant (efflux phenotype), S11 was high-level macrolideresistant (erm genotype), S9V was low-level quinoloneresistant, and S3 was high-level quinolone-resistant.", [["S31", "CHEMICAL", 62, 65], ["macrolideresistant", "CHEMICAL", 80, 98], ["quinolone", "CHEMICAL", 233, 242], ["quinolone", "CHEMICAL", 233, 242], ["S31", "SIMPLE_CHEMICAL", 62, 65], ["macrolideresistant", "SIMPLE_CHEMICAL", 80, 98], ["quinolone", "SIMPLE_CHEMICAL", 233, 242], ["Resistance patterns", "TEST", 0, 19], ["S12", "PROBLEM", 26, 29], ["study drugs", "TEST", 49, 60], ["S31", "TEST", 62, 65], ["low-level macrolideresistant (efflux phenotype)", "PROBLEM", 70, 117], ["high-level macrolideresistant (erm genotype)", "PROBLEM", 127, 171], ["S9V", "TEST", 173, 176], ["low-level quinoloneresistant", "PROBLEM", 181, 209], ["S3", "TEST", 215, 217], ["level quinolone", "TREATMENT", 227, 242], ["S3", "ANATOMY", 215, 217]]], ["Initial mixed inocula (time 0) included similar percentages of each serotype.", [["each serotype", "PROBLEM", 63, 76], ["mixed", "OBSERVATION_MODIFIER", 8, 13], ["inocula", "OBSERVATION", 14, 21]]], ["Results: Mean colony counts in antibiotic-free plates (whole pneumococcal population) increased (from 0 to 24 h) from log10 6.9 to 8.8 in drug-free simulations (control), from log10 6.8 to 7.9 in levofloxacin simulations, from log10 6.8 to 8.6 in ciprofloxacin simulations, and from log10 7.1 to 8.8 in azithromycin simulations.", [["colony", "ANATOMY", 14, 20], ["levofloxacin", "CHEMICAL", 196, 208], ["ciprofloxacin", "CHEMICAL", 247, 260], ["azithromycin", "CHEMICAL", 303, 315], ["levofloxacin", "CHEMICAL", 196, 208], ["ciprofloxacin", "CHEMICAL", 247, 260], ["azithromycin", "CHEMICAL", 303, 315], ["levofloxacin", "SIMPLE_CHEMICAL", 196, 208], ["ciprofloxacin", "SIMPLE_CHEMICAL", 247, 260], ["azithromycin", "SIMPLE_CHEMICAL", 303, 315], ["pneumococcal", "SPECIES", 61, 73], ["Mean colony counts", "TEST", 9, 27], ["antibiotic-free plates", "TREATMENT", 31, 53], ["whole pneumococcal population", "TREATMENT", 55, 84], ["levofloxacin simulations", "TREATMENT", 196, 220], ["ciprofloxacin simulations", "TEST", 247, 272], ["azithromycin simulations", "TREATMENT", 303, 327], ["Mean colony", "OBSERVATION_MODIFIER", 9, 20]]], ["At 24 h of control drug-free experiments, dominant strains were S9V (57.4%) and S12 (41.8%) with marginal populations of S31, S3 and S11.", [["S11", "GENE_OR_GENE_PRODUCT", 133, 136], ["S31", "PROTEIN", 121, 124], ["S3", "PROTEIN", 126, 128], ["S11", "PROTEIN", 133, 136], ["control drug", "TREATMENT", 11, 23], ["dominant strains", "PROBLEM", 42, 58], ["S9V", "TEST", 64, 67], ["S12", "TEST", 80, 83], ["marginal populations of S31", "PROBLEM", 97, 124], ["marginal populations", "OBSERVATION", 97, 117]]], ["Azithromycin selected in a much higher extent the strain with low-level resistance to macrolides (S31) than the strain with high-level resistance (S11) (accounting for 99.9% vs. 0.1% of total population at 24 h).", [["Azithromycin", "CHEMICAL", 0, 12], ["macrolides", "CHEMICAL", 86, 96], ["S31", "CHEMICAL", 98, 101], ["Azithromycin", "CHEMICAL", 0, 12], ["macrolides", "CHEMICAL", 86, 96], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["macrolides", "SIMPLE_CHEMICAL", 86, 96], ["S31", "SIMPLE_CHEMICAL", 98, 101], ["Azithromycin", "TREATMENT", 0, 12], ["the strain", "PROBLEM", 46, 56], ["macrolides", "TREATMENT", 86, 96], ["the strain", "PROBLEM", 108, 118], ["high-level resistance", "PROBLEM", 124, 145], ["high", "OBSERVATION_MODIFIER", 124, 128], ["level resistance", "OBSERVATION_MODIFIER", 129, 145]]], ["Ciprofloxacin selected in a higher extent low-level (S9V) than high-level (S3) quinolone resistance (72.4% vs. 27.6%).", [["Ciprofloxacin", "CHEMICAL", 0, 13], ["quinolone", "CHEMICAL", 79, 88], ["Ciprofloxacin", "CHEMICAL", 0, 13], ["quinolone", "CHEMICAL", 79, 88], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 0, 13], ["quinolone", "SIMPLE_CHEMICAL", 79, 88], ["Ciprofloxacin", "TREATMENT", 0, 13], ["quinolone resistance", "TEST", 79, 99]]], ["Levofloxacin decreased the proportion of the predominant S9V in controls to 22.2% (an intermediateresistant strain with MIC = 4 lg/ml), and unmasked the highlevel resistant strain (MIC = 32 lg/ml) up to 77.8%.", [["Levofloxacin", "CHEMICAL", 0, 12], ["Levofloxacin", "CHEMICAL", 0, 12], ["Levofloxacin", "SIMPLE_CHEMICAL", 0, 12], ["Levofloxacin", "TREATMENT", 0, 12], ["an intermediateresistant strain", "PROBLEM", 83, 114], ["MIC", "TEST", 120, 123], ["the highlevel resistant strain", "PROBLEM", 149, 179], ["MIC", "TEST", 181, 184], ["predominant", "OBSERVATION_MODIFIER", 45, 56], ["S9V", "OBSERVATION_MODIFIER", 57, 60]]], ["Conclusion: Strain distribution in antibiotic-free environment depends on bacterial fitness in mono-and multi-strain niches.", [["antibiotic", "TREATMENT", 35, 45], ["bacterial fitness in mono", "PROBLEM", 74, 99], ["bacterial fitness", "OBSERVATION", 74, 91]]], ["The selective pressure of antimicrobial regimens eradicate some populations and unmask minor populations, thus redistributing the whole population.", [["The selective pressure of antimicrobial regimens", "TREATMENT", 0, 48], ["unmask minor populations", "PROBLEM", 80, 104], ["selective", "OBSERVATION_MODIFIER", 4, 13], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["antimicrobial", "OBSERVATION_MODIFIER", 26, 39]]], ["Selective potential only for resistance phenotypes with very low prevalence (as high-level quinolone resistance) in the community should be preferred to that selecting more prevalent resistance phenotypes.P1553Re-evaluation of the role of broad-spectrum cephalosporins against staphylococci applying contemporary in vitro results and pharmacokinetic-pharmacodynamic principals H. Sader, S.M. Bhavnani, P.G. Ambrose, R. Jones (North Liberty, US)P1553Objectives: To re-evaluate the current in vitro activity and to assess the PK-PD target attainment of cefepime (CPM), ceftriaxone (CRO) and ceftazidime (CAZ) against Staphylococcus spp.", [["quinolone", "CHEMICAL", 91, 100], ["cephalosporins", "CHEMICAL", 254, 268], ["staphylococci", "DISEASE", 277, 290], ["cefepime", "CHEMICAL", 551, 559], ["CPM", "CHEMICAL", 561, 564], ["ceftriaxone", "CHEMICAL", 567, 578], ["CRO", "CHEMICAL", 580, 583], ["ceftazidime", "CHEMICAL", 589, 600], ["CAZ", "CHEMICAL", 602, 605], ["Staphylococcus spp", "DISEASE", 615, 633], ["quinolone", "CHEMICAL", 91, 100], ["cephalosporins", "CHEMICAL", 254, 268], ["cefepime", "CHEMICAL", 551, 559], ["CPM", "CHEMICAL", 561, 564], ["ceftriaxone", "CHEMICAL", 567, 578], ["CRO", "CHEMICAL", 580, 583], ["ceftazidime", "CHEMICAL", 589, 600], ["CAZ", "CHEMICAL", 602, 605], ["broad-spectrum cephalosporins", "SIMPLE_CHEMICAL", 239, 268], ["staphylococci", "SIMPLE_CHEMICAL", 277, 290], ["cefepime", "SIMPLE_CHEMICAL", 551, 559], ["CPM", "SIMPLE_CHEMICAL", 561, 564], ["ceftriaxone", "SIMPLE_CHEMICAL", 567, 578], ["CRO", "SIMPLE_CHEMICAL", 580, 583], ["ceftazidime", "SIMPLE_CHEMICAL", 589, 600], ["CAZ", "SIMPLE_CHEMICAL", 602, 605], ["Staphylococcus spp", "ORGANISM", 615, 633], ["Staphylococcus spp", "SPECIES", 615, 633], ["Staphylococcus spp", "SPECIES", 615, 633], ["resistance phenotypes", "PROBLEM", 29, 50], ["very low prevalence", "PROBLEM", 56, 75], ["high-level quinolone resistance", "TREATMENT", 80, 111], ["broad-spectrum cephalosporins", "TREATMENT", 239, 268], ["staphylococci", "PROBLEM", 277, 290], ["pharmacokinetic", "TEST", 334, 349], ["the PK", "TEST", 520, 526], ["PD", "TREATMENT", 527, 529], ["cefepime (CPM)", "TREATMENT", 551, 565], ["ceftriaxone (CRO)", "TREATMENT", 567, 584], ["ceftazidime (CAZ", "TREATMENT", 589, 605], ["Staphylococcus spp", "PROBLEM", 615, 633]]], ["Methods: The potency of CPM, CRO and CAZ against staphylococci was accessed through the SENTRY Antimicrobial Surveillance Program database, worldwide.P1553During the 1998-2004 period 41,883 S. aureus (SA; 63% oxacillin [OXA]-susceptible [S]) and 14,349 coagulase-negative staphylococci (CoNS; 22% OXA-S) were S tested against CPM, CRO, CAZ and numerous comparators by CLSI broth microdilution methods.", [["CPM", "CHEMICAL", 24, 27], ["CRO", "CHEMICAL", 29, 32], ["CAZ", "CHEMICAL", 37, 40], ["SA", "CHEMICAL", 201, 203], ["oxacillin", "CHEMICAL", 209, 218], ["OXA", "CHEMICAL", 220, 223], ["CoNS", "DISEASE", 287, 291], ["OXA", "CHEMICAL", 297, 300], ["CPM", "CHEMICAL", 326, 329], ["CRO", "CHEMICAL", 331, 334], ["CAZ", "CHEMICAL", 336, 339], ["CRO", "CHEMICAL", 29, 32], ["oxacillin", "CHEMICAL", 209, 218], ["OXA", "CHEMICAL", 220, 223], ["CPM", "SIMPLE_CHEMICAL", 24, 27], ["CRO", "SIMPLE_CHEMICAL", 29, 32], ["CAZ", "SIMPLE_CHEMICAL", 37, 40], ["staphylococci", "CANCER", 49, 62], ["S. aureus", "ORGANISM", 190, 199], ["oxacillin", "SIMPLE_CHEMICAL", 209, 218], ["OXA", "SIMPLE_CHEMICAL", 220, 223], ["OXA-S", "SIMPLE_CHEMICAL", 297, 302], ["CPM", "SIMPLE_CHEMICAL", 326, 329], ["CRO", "SIMPLE_CHEMICAL", 331, 334], ["CAZ", "SIMPLE_CHEMICAL", 336, 339], ["S. aureus", "SPECIES", 190, 199], ["S. aureus", "SPECIES", 190, 199], ["CPM, CRO", "TREATMENT", 24, 32], ["CAZ", "TREATMENT", 37, 40], ["staphylococci", "PROBLEM", 49, 62], ["S. aureus", "TEST", 190, 199], ["SA", "TEST", 201, 203], ["oxacillin", "TEST", 209, 218], ["OXA", "TEST", 220, 223], ["coagulase", "TEST", 253, 262], ["staphylococci", "TEST", 272, 285], ["CoNS", "TEST", 287, 291], ["OXA", "TEST", 297, 300], ["CPM", "TEST", 326, 329], ["CRO", "TEST", 331, 334], ["CAZ", "TEST", 336, 339], ["aureus", "OBSERVATION", 193, 199]]], ["Using volunteer PK data and a linear intermittent intravenous infusion model, and an animal-derived PK-PD target of 25% time above MIC, expected probabilities of target attainment (PTA) for cephems were evaluated using Monte Carlo simulation.", [["intravenous", "ANATOMY", 50, 61], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 61], ["volunteer PK data", "TEST", 6, 23], ["a linear intermittent intravenous infusion model", "TREATMENT", 28, 76], ["PD target", "TEST", 103, 112], ["cephems", "TREATMENT", 190, 197]]], ["PTA were determined for the following dosing regimens: CPM 1gm q12 and q8 hours, CAZ 1 gm q8 hours and CRO 1 gm q24 hours, each representing the most common dosing patterns applied clinically.", [["CAZ", "CHEMICAL", 81, 84], ["PTA", "SIMPLE_CHEMICAL", 0, 3], ["CPM", "TREATMENT", 55, 58], ["CAZ", "TREATMENT", 81, 84], ["CRO", "TREATMENT", 103, 106]]], ["Cephem susceptibility (%S) was calculated based on the current CLSI (2006) breakpoints (BKPs) and also on BKPs derived from a PTA >90%.", [["Cephem susceptibility", "TEST", 0, 21], ["the current CLSI", "TEST", 51, 67], ["a PTA", "TEST", 124, 129]]], ["Results: Against OXA-S SA, MIC50/90 values were (in mg/L): 2/4 for CPM, 4/4 for CRO and 8/16 for CAZ, respectively; and against OXA-S CoNS MIC50/90 values were (in mg/L) 0.5/2 for CPM, 2/4 for CRO, and 4/8 for CAZ, respectively.", [["OXA-S SA", "CHEMICAL", 17, 25], ["MIC50", "CHEMICAL", 27, 32], ["CPM", "CHEMICAL", 67, 70], ["OXA", "CHEMICAL", 128, 131], ["CPM", "CHEMICAL", 180, 183], ["OXA-S SA", "SIMPLE_CHEMICAL", 17, 25], ["MIC50/90", "SIMPLE_CHEMICAL", 27, 35], ["CAZ", "SIMPLE_CHEMICAL", 97, 100], ["OXA-S CoNS", "SIMPLE_CHEMICAL", 128, 138], ["CAZ", "SIMPLE_CHEMICAL", 210, 213], ["OXA", "TEST", 17, 20], ["MIC50", "TEST", 27, 32], ["CPM", "TEST", 67, 70], ["CAZ", "TEST", 97, 100], ["OXA", "TEST", 128, 131]]], ["The calculated %S of these cephems are summarized in the Table: Twenty year-old CLSI BKPs would rank the tested agents CPM \u2021 CRO > CAZ and by PK-PD PTA CPM \u2021 CAZ > CRO.", [["CPM", "CHEMICAL", 119, 122], ["CAZ", "CHEMICAL", 158, 161], ["CAZ", "SIMPLE_CHEMICAL", 131, 134], ["CAZ", "SIMPLE_CHEMICAL", 158, 161], ["these cephems", "TEST", 21, 34], ["CRO", "TEST", 125, 128]]], ["CPM has a potency advantage over CAZ (4-to 8-fold) and superiority at the usual dosing over CRO (22.7-66.1%) for OXA-S staphylococci.", [["CPM", "CHEMICAL", 0, 3], ["CAZ", "CHEMICAL", 33, 36], ["CRO", "CHEMICAL", 92, 95], ["OXA-S", "CHEMICAL", 113, 118], ["CRO", "CHEMICAL", 92, 95], ["CAZ", "SIMPLE_CHEMICAL", 33, 36], ["CRO", "SIMPLE_CHEMICAL", 92, 95], ["OXA-S staphylococci", "SIMPLE_CHEMICAL", 113, 132], ["CPM", "PROBLEM", 0, 3], ["CRO", "TEST", 92, 95], ["OXA", "PROBLEM", 113, 116], ["staphylococci", "PROBLEM", 119, 132], ["staphylococci", "OBSERVATION", 119, 132]]], ["CAZ PK overcomes by-weight activity disadvantages, while a low proportion (<5%) of active freedrug penalizes CRO in the PTA calculations.", [["CAZ", "CHEMICAL", 0, 3], ["CRO", "CHEMICAL", 109, 112], ["CRO", "CHEMICAL", 109, 112], ["CAZ PK", "GENE_OR_GENE_PRODUCT", 0, 6], ["CRO", "SIMPLE_CHEMICAL", 109, 112], ["CAZ PK overcomes", "TEST", 0, 16]]], ["PTA remained at >90% to a BKP of 16 mg/L for CPM (1 gm q8) and CAZ and to a BKP of 2 mg/L for CRO.P1553Conclusions: Regardless of applied BKP (CLSI or PK-PD), CPM has the widest and more potent anti-staphylococcal activity among commonly used ''third-or fourth-generation'' cephems.", [["CPM", "CHEMICAL", 45, 48], ["CAZ", "CHEMICAL", 63, 66], ["BKP", "CHEMICAL", 76, 79], ["CRO", "CHEMICAL", 94, 97], ["BKP", "CHEMICAL", 138, 141], ["CPM", "CHEMICAL", 159, 162], ["PTA", "SIMPLE_CHEMICAL", 0, 3], ["CAZ", "SIMPLE_CHEMICAL", 63, 66], ["BKP", "SIMPLE_CHEMICAL", 138, 141], ["anti-staphylococcal", "CANCER", 194, 213], ["PTA", "TEST", 0, 3], ["a BKP", "TEST", 24, 29], ["CPM", "TREATMENT", 45, 48], ["CAZ", "TREATMENT", 63, 66], ["CLSI", "TEST", 143, 147], ["CPM", "TREATMENT", 159, 162]]], ["When used at doses \u2021 3 gm/day, CPM assures maximal coverage of OXA-S staphylococci whether using existing (CLSI) or modified (PK/PD) BKPs.", [["CPM", "CHEMICAL", 31, 34], ["OXA-S", "CHEMICAL", 63, 68], ["OXA-S staphylococci", "SIMPLE_CHEMICAL", 63, 82], ["CPM assures", "TREATMENT", 31, 42], ["OXA", "PROBLEM", 63, 66], ["staphylococci", "PROBLEM", 69, 82], ["existing (CLSI)", "TREATMENT", 97, 112], ["modified (PK/PD)", "TREATMENT", 116, 132]]], ["CRO should be used with caution.", [["CRO", "CHEMICAL", 0, 3], ["CRO", "SIMPLE_CHEMICAL", 0, 3], ["CRO", "TREATMENT", 0, 3]]], ["Methods: The MIC for all strains were determined by serial two-fold macrodilutions.", [["The MIC", "TREATMENT", 9, 16], ["all strains", "PROBLEM", 21, 32], ["serial two-fold macrodilutions", "TREATMENT", 52, 82]]], ["An in vitro kinetic model was used to investigate the antibacterial efficacy of constant drug concentrations during 6 hours.", [["constant drug concentrations", "TREATMENT", 80, 108]]], ["The selection of the doses of azithromycin tested in each bacterial strains was based on their MIC values.", [["azithromycin", "CHEMICAL", 30, 42], ["azithromycin", "CHEMICAL", 30, 42], ["azithromycin", "SIMPLE_CHEMICAL", 30, 42], ["azithromycin", "TREATMENT", 30, 42], ["each bacterial strains", "PROBLEM", 53, 75], ["their MIC values", "TEST", 89, 105]]], ["Bacterial counts were determined on appropriate agar plates using an adapted drop-plate method.", [["Bacterial", "ANATOMY", 0, 9], ["Bacterial counts", "TEST", 0, 16], ["appropriate agar plates", "TREATMENT", 36, 59], ["an adapted drop-plate method", "TREATMENT", 66, 94]]], ["Twelve different PK/PD models were fitted and compared to the time-kill data by using non-linear regression.", [["PK", "GENE_OR_GENE_PRODUCT", 17, 19], ["Twelve different PK/PD models", "TEST", 0, 29]]], ["Results: A simple PK-PD model was not sufficient to describe the pharmacodynamic effects for the four bacterial strains.", [["A simple PK-PD model", "TEST", 9, 29], ["the four bacterial strains", "PROBLEM", 93, 119]]], ["Appropriate models that gave good curve fits included a saturation term for the number of bacteria (Nmax), delay terms (1-e-zt) for the initial bacterial growth phase and/or the onset of anti-infective activity as well as a Hill factor (h) to capture the steepness of the concentration-response relationship.", [["Hill factor", "PROTEIN", 224, 235], ["bacteria", "PROBLEM", 90, 98], ["the initial bacterial growth phase", "PROBLEM", 132, 166], ["anti-infective activity", "TREATMENT", 187, 210], ["anti-infective activity", "OBSERVATION", 187, 210]]], ["Azithromycin had high potency against S. pneumoniae strains and M. catarrhalis while the potency of azithromycin against H. influenzae was poor.", [["Azithromycin", "CHEMICAL", 0, 12], ["azithromycin", "CHEMICAL", 100, 112], ["H. influenzae", "DISEASE", 121, 134], ["Azithromycin", "CHEMICAL", 0, 12], ["azithromycin", "CHEMICAL", 100, 112], ["Azithromycin", "SIMPLE_CHEMICAL", 0, 12], ["S. pneumoniae", "ORGANISM", 38, 51], ["strains", "ORGANISM", 52, 59], ["M. catarrhalis", "ORGANISM", 64, 78], ["azithromycin", "SIMPLE_CHEMICAL", 100, 112], ["H. influenzae", "ORGANISM", 121, 134], ["S. pneumoniae", "SPECIES", 38, 51], ["M. catarrhalis", "SPECIES", 64, 78], ["H. influenzae", "SPECIES", 121, 134], ["S. pneumoniae", "SPECIES", 38, 51], ["M. catarrhalis", "SPECIES", 64, 78], ["H. influenzae", "SPECIES", 121, 134], ["Azithromycin", "TREATMENT", 0, 12], ["S. pneumoniae strains", "PROBLEM", 38, 59], ["M. catarrhalis", "PROBLEM", 64, 78], ["azithromycin", "TREATMENT", 100, 112], ["H. influenzae", "PROBLEM", 121, 134], ["high potency", "OBSERVATION_MODIFIER", 17, 29], ["catarrhalis", "OBSERVATION", 67, 78]]], ["Conclusions: The developed PK/PD models are suitable for describing the pharmacodynamics of azithromycin.", [["azithromycin", "CHEMICAL", 92, 104], ["azithromycin", "CHEMICAL", 92, 104], ["azithromycin", "SIMPLE_CHEMICAL", 92, 104], ["PK/PD models", "TREATMENT", 27, 39], ["azithromycin", "TREATMENT", 92, 104]]], ["Applications of these PK-PD models will eventually provide a tool for rational antibiotic dosing decisions.", [["PK", "GENE_OR_GENE_PRODUCT", 22, 24], ["these PK-PD models", "TREATMENT", 16, 34], ["rational antibiotic dosing decisions", "TREATMENT", 70, 106]]], ["Objectives: Optimal antimicrobial dosage regimens aim to achieve successful clinical outcomes without drug toxicity or emergence of bacterial resistance.", [["toxicity", "DISEASE", 107, 115], ["Optimal antimicrobial dosage regimens", "TREATMENT", 12, 49], ["drug toxicity", "PROBLEM", 102, 115], ["bacterial resistance", "PROBLEM", 132, 152], ["bacterial resistance", "OBSERVATION", 132, 152]]], ["For concentration dependent antibiotics, such as the fluoroquinolones, in humans a Cmax:MIC ratio of >10 is considered more important for efficacy and reduced selection of resistance than prolonged antibiotic concentrations just above the MIC.", [["fluoroquinolones", "CHEMICAL", 53, 69], ["Cmax", "CHEMICAL", 83, 87], ["fluoroquinolones", "CHEMICAL", 53, 69], ["fluoroquinolones", "SIMPLE_CHEMICAL", 53, 69], ["humans", "ORGANISM", 74, 80], ["Cmax", "SIMPLE_CHEMICAL", 83, 87], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["concentration dependent antibiotics", "TREATMENT", 4, 39], ["the fluoroquinolones", "TREATMENT", 49, 69], ["MIC ratio", "TEST", 88, 97], ["prolonged antibiotic concentrations", "TREATMENT", 188, 223]]], ["Fluoroquinolone resistance in zoonotic bacteria is a matter of public health concern, and fluoroquinolone treatment of poultry can rapidly select for bacteria with reduced fluoroquinolone susceptibility.", [["Fluoroquinolone", "CHEMICAL", 0, 15], ["zoonotic bacteria", "DISEASE", 30, 47], ["fluoroquinolone", "CHEMICAL", 90, 105], ["fluoroquinolone", "CHEMICAL", 172, 187], ["Fluoroquinolone", "CHEMICAL", 0, 15], ["fluoroquinolone", "CHEMICAL", 90, 105], ["fluoroquinolone", "CHEMICAL", 172, 187], ["Fluoroquinolone", "SIMPLE_CHEMICAL", 0, 15], ["fluoroquinolone", "SIMPLE_CHEMICAL", 90, 105], ["fluoroquinolone", "SIMPLE_CHEMICAL", 172, 187], ["poultry", "SPECIES", 119, 126], ["Fluoroquinolone resistance in zoonotic bacteria", "PROBLEM", 0, 47], ["fluoroquinolone treatment of poultry", "TREATMENT", 90, 126], ["bacteria", "PROBLEM", 150, 158], ["reduced fluoroquinolone susceptibility", "PROBLEM", 164, 202], ["zoonotic", "OBSERVATION_MODIFIER", 30, 38], ["fluoroquinolone susceptibility", "OBSERVATION", 172, 202]]], ["In this study we compared basic pharmacokinetic parameters for the recommended dose of Baytril (enrofloxacin) 10% oral solution in poultry to 2.5x this dose for birds dosed by continuous water (standard) compared to pulsed water treatments and dosing by gavage.Methods.", [["oral", "ANATOMY", 114, 118], ["Baytril", "CHEMICAL", 87, 94], ["enrofloxacin", "CHEMICAL", 96, 108], ["Baytril", "CHEMICAL", 87, 94], ["enrofloxacin", "CHEMICAL", 96, 108], ["Baytril", "SIMPLE_CHEMICAL", 87, 94], ["enrofloxacin", "SIMPLE_CHEMICAL", 96, 108], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["poultry", "SPECIES", 131, 138], ["this study", "TEST", 3, 13], ["basic pharmacokinetic parameters", "TEST", 26, 58], ["Baytril (enrofloxacin)", "TREATMENT", 87, 109], ["pulsed water treatments", "TREATMENT", 216, 239]]], ["For the pulsed versus continuous water treatments, groups of chickens received Baytril 10% oral solution at 50 (recommended) or 125 ppm continuously in the water or at 10 (recommended) or 25 mg/kg pulsed in the water.", [["oral", "ANATOMY", 91, 95], ["Baytril", "CHEMICAL", 79, 86], ["chickens", "ORGANISM", 61, 69], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["chickens", "SPECIES", 61, 69], ["chickens", "SPECIES", 61, 69], ["the pulsed versus continuous water treatments", "TREATMENT", 4, 49], ["chickens", "TREATMENT", 61, 69], ["Baytril", "TREATMENT", 79, 86]]], ["For each group, three birds were killed at 0, 2, 4, 6, 8, 10 and 24 hours after start of antibiotic treatment and caecal contents, liver, lung and sera were taken and the concentration of fluoroquinolone determined by fluorescence HPLC.", [["caecal", "ANATOMY", 114, 120], ["liver", "ANATOMY", 131, 136], ["lung", "ANATOMY", 138, 142], ["sera", "ANATOMY", 147, 151], ["fluoroquinolone", "CHEMICAL", 188, 203], ["fluoroquinolone", "CHEMICAL", 188, 203], ["birds", "ORGANISM", 22, 27], ["caecal", "ORGANISM_SUBDIVISION", 114, 120], ["liver", "ORGAN", 131, 136], ["lung", "ORGAN", 138, 142], ["sera", "ORGANISM_SUBSTANCE", 147, 151], ["fluoroquinolone", "SIMPLE_CHEMICAL", 188, 203], ["antibiotic treatment", "TREATMENT", 89, 109], ["caecal contents", "TEST", 114, 129], ["fluoroquinolone", "TREATMENT", 188, 203], ["fluorescence HPLC", "TEST", 218, 235], ["caecal", "ANATOMY", 114, 120], ["liver", "ANATOMY", 131, 136], ["lung", "ANATOMY", 138, 142]]], ["For gavage treatment, dosing was at 10 and 25 mg/kg by crop intubation and four birds were killed in each group at 2, 6 and 24 hours after gavage; caecal contents, liver and sera were taken and analysed as above.", [["caecal", "ANATOMY", 147, 153], ["liver", "ANATOMY", 164, 169], ["sera", "ANATOMY", 174, 178], ["birds", "ORGANISM", 80, 85], ["caecal", "ORGANISM_SUBDIVISION", 147, 153], ["liver", "ORGAN", 164, 169], ["sera", "ORGANISM_SUBSTANCE", 174, 178], ["gavage treatment", "TREATMENT", 4, 20], ["crop intubation", "TREATMENT", 55, 70], ["caecal contents, liver and sera", "TEST", 147, 178], ["caecal", "ANATOMY", 147, 153], ["liver", "ANATOMY", 164, 169]]], ["Basic pharmacokinetic parameters were determined using PK solutions software.", [["Basic pharmacokinetic parameters", "TEST", 0, 32], ["PK solutions software", "TREATMENT", 55, 76]]], ["Results: The mean fluoroquinolone Cmax in caecal contents (and sera) for gavage, pulsed water and continuous water treatments respectively was 78.01 (1.81), 53.19 (1.17) and 24.73 (0.73) mg/ml after the recommended dose and 115.86 (3.86), 115.63 (2.74) and 68.02 (1.17) mg/ml after 2.5x the recommended dose.", [["caecal", "ANATOMY", 42, 48], ["sera", "ANATOMY", 63, 67], ["fluoroquinolone", "CHEMICAL", 18, 33], ["Cmax", "CHEMICAL", 34, 38], ["fluoroquinolone", "CHEMICAL", 18, 33], ["fluoroquinolone", "SIMPLE_CHEMICAL", 18, 33], ["Cmax", "SIMPLE_CHEMICAL", 34, 38], ["caecal", "ORGANISM_SUBDIVISION", 42, 48], ["sera", "ORGANISM_SUBSTANCE", 63, 67], ["The mean fluoroquinolone Cmax in caecal contents", "TREATMENT", 9, 57], ["gavage", "TREATMENT", 73, 79], ["pulsed water", "TREATMENT", 81, 93], ["continuous water treatments", "TREATMENT", 98, 125]]], ["Cmax of antibiotic in liver and lung was increased by the modified regimens in similar proportions to above.", [["liver", "ANATOMY", 22, 27], ["lung", "ANATOMY", 32, 36], ["Cmax", "CHEMICAL", 0, 4], ["Cmax", "SIMPLE_CHEMICAL", 0, 4], ["liver", "ORGAN", 22, 27], ["lung", "ORGAN", 32, 36], ["antibiotic in liver", "TREATMENT", 8, 27], ["the modified regimens", "TREATMENT", 54, 75], ["antibiotic", "OBSERVATION", 8, 18], ["liver", "ANATOMY", 22, 27], ["lung", "ANATOMY", 32, 36], ["increased", "OBSERVATION_MODIFIER", 41, 50]]], ["Both pulsed water and gavage treatment not only resulted in higher Cmax values, but also a faster rate of fluoroquinolone clearance than continuous water treatment ( Figure 1 ).Conclusion:Dosing by gavage is not practical for thousands of chickens.", [["fluoroquinolone", "CHEMICAL", 106, 121], ["fluoroquinolone", "CHEMICAL", 106, 121], ["Cmax", "SIMPLE_CHEMICAL", 67, 71], ["fluoroquinolone", "SIMPLE_CHEMICAL", 106, 121], ["chickens", "ORGANISM", 239, 247], ["chickens", "SPECIES", 239, 247], ["chickens", "SPECIES", 239, 247], ["Both pulsed water", "TREATMENT", 0, 17], ["gavage treatment", "TREATMENT", 22, 38], ["fluoroquinolone clearance", "TREATMENT", 106, 131], ["continuous water treatment", "TREATMENT", 137, 163]]], ["However, pulsed dosing at 2.5x the recommended dose can increase Cmax values about fourfold and so could improve efficacy and reduce selection of resistance, compared to the current recommended treatment regime.", [["Cmax", "CHEMICAL", 65, 69], ["Cmax", "SIMPLE_CHEMICAL", 65, 69], ["pulsed dosing", "TREATMENT", 9, 22], ["Cmax values", "TEST", 65, 76], ["resistance", "PROBLEM", 146, 156], ["treatment regime", "TREATMENT", 194, 210]]], ["Objectives: Nephrotoxicity is the major concern arising with the use of intravenous colistimethate sodium.Conclusion:Methods: A prospective cohort study was performed at ''Henry Dunant'' Hospital, a 450-bed tertiary care center in Athens, Greece.", [["intravenous", "ANATOMY", 72, 83], ["Nephrotoxicity", "DISEASE", 12, 26], ["colistimethate sodium", "CHEMICAL", 84, 105], ["colistimethate sodium", "CHEMICAL", 84, 105], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 83], ["colistimethate sodium", "SIMPLE_CHEMICAL", 84, 105], ["Nephrotoxicity", "PROBLEM", 12, 26], ["intravenous colistimethate sodium", "TREATMENT", 72, 105], ["A prospective cohort study", "TEST", 126, 152], ["Nephrotoxicity", "OBSERVATION", 12, 26]]], ["Patients who received intravenous colistin for at least 7 days for the treatment of multidrug resistant Gram-negative bacterial infections were included in the study.", [["intravenous", "ANATOMY", 22, 33], ["colistin", "CHEMICAL", 34, 42], ["bacterial infections", "DISEASE", 118, 138], ["colistin", "CHEMICAL", 34, 42], ["Patients", "ORGANISM", 0, 8], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 33], ["colistin", "SIMPLE_CHEMICAL", 34, 42], ["Gram", "GENE_OR_GENE_PRODUCT", 104, 108], ["Patients", "SPECIES", 0, 8], ["intravenous colistin", "TREATMENT", 22, 42], ["multidrug resistant Gram-negative bacterial infections", "PROBLEM", 84, 138], ["the study", "TEST", 156, 165], ["negative bacterial infections", "OBSERVATION", 109, 138]]], ["The development of nephrotoxicity through evaluations of serum creatinine, blood urea, serum electrolytes, urinalysis, and creatinine and sodium in 24-hour urine collection during intravenous colistin therapy was the primary end point of the study.", [["serum", "ANATOMY", 57, 62], ["blood", "ANATOMY", 75, 80], ["serum", "ANATOMY", 87, 92], ["urine", "ANATOMY", 156, 161], ["intravenous", "ANATOMY", 180, 191], ["nephrotoxicity", "DISEASE", 19, 33], ["creatinine", "CHEMICAL", 63, 73], ["blood urea", "CHEMICAL", 75, 85], ["creatinine", "CHEMICAL", 123, 133], ["sodium", "CHEMICAL", 138, 144], ["colistin", "CHEMICAL", 192, 200], ["creatinine", "CHEMICAL", 63, 73], ["urea", "CHEMICAL", 81, 85], ["creatinine", "CHEMICAL", 123, 133], ["sodium", "CHEMICAL", 138, 144], ["colistin", "CHEMICAL", 192, 200], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["creatinine", "SIMPLE_CHEMICAL", 63, 73], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["urea", "SIMPLE_CHEMICAL", 81, 85], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["electrolytes", "SIMPLE_CHEMICAL", 93, 105], ["creatinine", "SIMPLE_CHEMICAL", 123, 133], ["sodium", "SIMPLE_CHEMICAL", 138, 144], ["urine", "ORGANISM_SUBSTANCE", 156, 161], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 191], ["colistin", "SIMPLE_CHEMICAL", 192, 200], ["nephrotoxicity", "PROBLEM", 19, 33], ["evaluations", "TEST", 42, 53], ["serum creatinine", "TEST", 57, 73], ["blood urea", "TEST", 75, 85], ["serum electrolytes", "TEST", 87, 105], ["urinalysis", "TEST", 107, 117], ["creatinine", "TEST", 123, 133], ["sodium", "TEST", 138, 144], ["urine collection", "TEST", 156, 172], ["intravenous colistin therapy", "TREATMENT", 180, 208], ["the study", "TEST", 238, 247], ["nephrotoxicity", "OBSERVATION", 19, 33]]], ["Results: Twenty-six patients were included in the study, 21 of whom received colistimethate sodium (CMS) for at least 7 days and were evaluated further.", [["colistimethate sodium", "CHEMICAL", 77, 98], ["colistimethate sodium", "CHEMICAL", 77, 98], ["patients", "ORGANISM", 20, 28], ["colistimethate sodium", "SIMPLE_CHEMICAL", 77, 98], ["patients", "SPECIES", 20, 28], ["the study", "TEST", 46, 55], ["colistimethate sodium", "TREATMENT", 77, 98]]], ["The mean (\u00b1 SD)/median daily dose, cumulative dose, and duration of treatment of intravenous CMS was 5.5 (\u00b1 1.9)/6 million IU, 90.2 (\u00b152.0)/72 million IU, and 17.7 (\u00b111.7)/15 days (range 7-54 days), respectively.", [["intravenous", "ANATOMY", 81, 92], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 92], ["The mean (\u00b1 SD)/median daily dose", "TREATMENT", 0, 33], ["cumulative dose", "TREATMENT", 35, 50], ["intravenous CMS", "TEST", 81, 96]]], ["Three of the 21 evaluable patients (14.3%) developed nephrotoxicity during the intravenous treatment with CMS.", [["intravenous", "ANATOMY", 79, 90], ["nephrotoxicity", "DISEASE", 53, 67], ["patients", "ORGANISM", 26, 34], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 90], ["patients", "SPECIES", 26, 34], ["nephrotoxicity", "PROBLEM", 53, 67], ["the intravenous treatment", "TREATMENT", 75, 100], ["nephrotoxicity", "OBSERVATION", 53, 67]]], ["The cumulative dose of the administered CMS was statistically correlated with the difference between the end and start of CMS treatment values of serum creatinine (r = 0.6, p = 0.004 by Spearman's test).", [["serum", "ANATOMY", 146, 151], ["creatinine", "CHEMICAL", 152, 162], ["creatinine", "CHEMICAL", 152, 162], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["creatinine", "SIMPLE_CHEMICAL", 152, 162], ["the administered CMS", "TREATMENT", 23, 43], ["CMS treatment", "TREATMENT", 122, 135], ["serum creatinine", "TEST", 146, 162], ["r", "TEST", 164, 165], ["p", "TEST", 173, 174], ["Spearman's test", "TEST", 186, 201]]], ["A statistically but not clinically significant decrease of the mean baseline serum sodium concentration was observed between start and end of treatment [mean 144.2 (\u00b16.9) to 142.1 (\u00b16.1) mmol/L, p = 0.04].", [["serum", "ANATOMY", 77, 82], ["sodium", "CHEMICAL", 83, 89], ["sodium", "CHEMICAL", 83, 89], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["sodium", "SIMPLE_CHEMICAL", 83, 89], ["the mean baseline serum sodium concentration", "PROBLEM", 59, 103], ["treatment", "TREATMENT", 142, 151], ["mean", "TEST", 153, 157], ["p", "TEST", 195, 196], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["decrease", "OBSERVATION_MODIFIER", 47, 55]]], ["No other toxic events were noted during the intravenous administration of colistimethate sodium.", [["intravenous", "ANATOMY", 44, 55], ["colistimethate sodium", "CHEMICAL", 74, 95], ["colistimethate sodium", "CHEMICAL", 74, 95], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 55], ["colistimethate sodium", "SIMPLE_CHEMICAL", 74, 95], ["other toxic events", "PROBLEM", 3, 21], ["the intravenous administration of colistimethate sodium", "TREATMENT", 40, 95], ["toxic", "OBSERVATION_MODIFIER", 9, 14]]], ["Conclusion: Although this is an evaluation of a small number of patients, our prospective study shows that nephrotoxicity was not commonly observed in this group of patients who received intravenous colistimethate sodium.", [["intravenous", "ANATOMY", 187, 198], ["nephrotoxicity", "DISEASE", 107, 121], ["colistimethate sodium", "CHEMICAL", 199, 220], ["colistimethate sodium", "CHEMICAL", 199, 220], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 165, 173], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 198], ["colistimethate sodium", "SIMPLE_CHEMICAL", 199, 220], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 165, 173], ["an evaluation", "TEST", 29, 42], ["our prospective study", "TEST", 74, 95], ["nephrotoxicity", "PROBLEM", 107, 121], ["intravenous colistimethate sodium", "TREATMENT", 187, 220], ["small", "OBSERVATION_MODIFIER", 48, 53], ["nephrotoxicity", "OBSERVATION", 107, 121]]], ["However, caution should be taken to avoid the prolonged administration of the antibiotic.", [["the antibiotic", "TREATMENT", 74, 88]]], ["Objectives: The objective of the present work is Quantitative Structure-Activity Relationship (QSAR) analysis of antimicrobial activity of the 4-thiazolidone derivatives and consequent computational design of new antimicrobials.", [["4-thiazolidone", "CHEMICAL", 143, 157], ["4-thiazolidone", "CHEMICAL", 143, 157], ["4-thiazolidone derivatives", "SIMPLE_CHEMICAL", 143, 169], ["antimicrobial activity", "TREATMENT", 113, 135], ["the 4-thiazolidone derivatives", "TREATMENT", 139, 169], ["new antimicrobials", "TREATMENT", 209, 227]]], ["Methods: For the achievement of the formulated objectives the QSAR investigation has been carried out using computational chemistry approach based on Simplex Representation of Molecular Structure (SiRMS).", [["the QSAR investigation", "TEST", 58, 80], ["computational chemistry approach", "TREATMENT", 108, 140], ["Molecular Structure", "OBSERVATION", 176, 195]]], ["On the framework of SiRMS it is possible to develop the molecular design of the new effective antimicrobials.", [["the new effective antimicrobials", "TREATMENT", 76, 108], ["new", "OBSERVATION_MODIFIER", 80, 83], ["effective", "OBSERVATION_MODIFIER", 84, 93], ["antimicrobials", "OBSERVATION", 94, 108]]], ["Results: Systematic researches of relationship between antimicrobial activity (Staphylococcus aureus -methicillin-sensitive (MSSA) strain, Pseudomonas aeruginosa -R and S strain, Klebsiella pneumoniae, Candida albicans S and \u00d1 itrobacter freundii) and a structure of about one hundred fifty compounds (4-thiazolidone derivatives and analogs).", [["Staphylococcus aureus -", "CHEMICAL", 79, 102], ["methicillin", "CHEMICAL", 102, 113], ["MSSA", "CHEMICAL", 125, 129], ["Klebsiella pneumoniae", "DISEASE", 179, 200], ["4-thiazolidone", "CHEMICAL", 302, 316], ["methicillin", "CHEMICAL", 102, 113], ["4-thiazolidone", "CHEMICAL", 302, 316], ["Staphylococcus aureus -methicillin-sensitive (MSSA) strain", "ORGANISM", 79, 137], ["Pseudomonas aeruginosa -R", "ORGANISM", 139, 164], ["S strain", "ORGANISM", 169, 177], ["Klebsiella pneumoniae", "ORGANISM", 179, 200], ["Candida albicans S", "ORGANISM", 202, 220], ["\u00d1 itrobacter freundii", "ORGANISM", 225, 246], ["4-thiazolidone derivatives", "SIMPLE_CHEMICAL", 302, 328], ["Staphylococcus aureus", "SPECIES", 79, 100], ["Pseudomonas aeruginosa", "SPECIES", 139, 161], ["Klebsiella pneumoniae", "SPECIES", 179, 200], ["Candida albicans", "SPECIES", 202, 218], ["\u00d1 itrobacter freundii", "SPECIES", 225, 246], ["Staphylococcus aureus", "SPECIES", 79, 100], ["MSSA", "SPECIES", 125, 129], ["Pseudomonas aeruginosa -R", "SPECIES", 139, 164], ["Klebsiella pneumoniae", "SPECIES", 179, 200], ["Candida albicans", "SPECIES", 202, 218], ["\u00d1 itrobacter freundii", "SPECIES", 225, 246], ["antimicrobial activity", "TEST", 55, 77], ["Staphylococcus aureus", "TEST", 79, 100], ["methicillin-sensitive (MSSA) strain", "PROBLEM", 102, 137], ["Pseudomonas aeruginosa", "PROBLEM", 139, 161], ["R and S strain", "PROBLEM", 163, 177], ["Klebsiella pneumoniae", "PROBLEM", 179, 200], ["Candida albicans S", "TEST", 202, 220], ["\u00d1 itrobacter freundii", "PROBLEM", 225, 246], ["4-thiazolidone derivatives", "TREATMENT", 302, 328], ["analogs", "TREATMENT", 333, 340], ["Klebsiella pneumoniae", "OBSERVATION", 179, 200]]], ["The elucidation of structure-activity relations allows predicting biological properties of such compounds, to execute their direct synthesis and to receive the indispensable information for research of mechanisms of their biological effect.", [["such compounds", "PROBLEM", 91, 105]]], ["Completely adequate statistical partial least squares models (R2 = 0.841-0.990, Q2 = 0.600-0.814) have been obtained for all of the studied cultures.", [["R2", "TEST", 62, 64], ["the studied cultures", "TEST", 128, 148]]], ["On the base of the first ones the molecular fragments both promoting and interfering the given antimicrobial activity have been determined.", [["antimicrobial activity", "TREATMENT", 95, 117], ["base", "ANATOMY_MODIFIER", 7, 11], ["molecular", "OBSERVATION_MODIFIER", 34, 43], ["fragments", "OBSERVATION", 44, 53]]], ["They give a possibility to realize the computer high throughput screening and molecular design of active compounds.", [["the computer high throughput screening", "PROBLEM", 35, 73], ["active compounds", "PROBLEM", 98, 114], ["active", "OBSERVATION_MODIFIER", 98, 104], ["compounds", "OBSERVATION", 105, 114]]], ["The results of prognosis are verifying by the experimental investigations.", [["the experimental investigations", "TEST", 42, 73]]], ["Also the influence of heterocycle system evolution on antimicrobial activity has been revealed.", [["heterocycle", "CHEMICAL", 22, 33], ["heterocycle system", "TREATMENT", 22, 40], ["antimicrobial activity", "TEST", 54, 76]]], ["Conclusion: QSAR analysis of antimicrobial activity of 4-thiazolidone derivatives allows us to discover that the presence of naphthalene-substituted fragment (independently on its location in molecule) has distinctly negative influence on antimicrobial action.", [["4-thiazolidone", "CHEMICAL", 55, 69], ["naphthalene", "CHEMICAL", 125, 136], ["4-thiazolidone", "CHEMICAL", 55, 69], ["naphthalene", "CHEMICAL", 125, 136], ["4-thiazolidone derivatives", "SIMPLE_CHEMICAL", 55, 81], ["naphthalene", "SIMPLE_CHEMICAL", 125, 136], ["QSAR analysis", "TEST", 12, 25], ["antimicrobial activity", "TEST", 29, 51], ["thiazolidone derivatives", "TREATMENT", 57, 81], ["naphthalene-substituted fragment", "PROBLEM", 125, 157], ["antimicrobial action", "TREATMENT", 239, 259], ["substituted fragment", "OBSERVATION", 137, 157], ["negative", "OBSERVATION", 217, 225]]], ["For example, high active compounds must include 3-indolyl fragment.P1558Computational design of the new antimicrobials based on the substituted crown ethers activity of the row of substituted crown ethers and consequent molecular design of new antimicrobials.", [["3-indolyl", "CHEMICAL", 48, 57], ["crown ethers", "CHEMICAL", 144, 156], ["crown ethers", "CHEMICAL", 192, 204], ["3-indolyl", "CHEMICAL", 48, 57], ["crown ethers", "CHEMICAL", 144, 156], ["crown ethers", "CHEMICAL", 192, 204], ["3-indolyl fragment", "SIMPLE_CHEMICAL", 48, 66], ["crown ethers", "SIMPLE_CHEMICAL", 144, 156], ["crown ethers", "SIMPLE_CHEMICAL", 192, 204], ["high active compounds", "PROBLEM", 13, 34], ["3-indolyl fragment", "PROBLEM", 48, 66], ["the new antimicrobials", "TREATMENT", 96, 118], ["substituted crown ethers", "TREATMENT", 180, 204], ["new antimicrobials", "TREATMENT", 240, 258], ["high", "OBSERVATION_MODIFIER", 13, 17], ["active", "OBSERVATION_MODIFIER", 18, 24], ["compounds", "OBSERVATION", 25, 34], ["indolyl fragment", "OBSERVATION", 50, 66], ["new", "OBSERVATION_MODIFIER", 100, 103], ["new", "OBSERVATION_MODIFIER", 240, 243], ["antimicrobials", "OBSERVATION_MODIFIER", 244, 258]]], ["Methods: The well-known Hierarchic System of QSAR Models based on simplex representation of molecular structure has been used for the solution of the formulated problem, within the framework of which one it is possible to develop the molecular design of the new effective antimicrobial agents.", [["QSAR Models", "TREATMENT", 45, 56], ["molecular structure", "PROBLEM", 92, 111], ["the new effective antimicrobial agents", "TREATMENT", 254, 292], ["molecular structure", "OBSERVATION", 92, 111], ["new", "OBSERVATION_MODIFIER", 258, 261], ["effective", "OBSERVATION_MODIFIER", 262, 271], ["antimicrobial agents", "OBSERVATION", 272, 292]]], ["Results: We tried to conduct systematic researches of relationship between antimicrobial activity (Planococcus citreus, Streptococcus lactis, Micrococcus lysodeiktious, Staphylococcus aureus, Streptococcus faecalis, Bacillus subtillum) about two hundred fifty crowns ethers including aromatic, cyclic and heterocyclic etc. fragments and a structure of these molecules, in particular -macro cycle size, it dentacy, lipophily, nature of the substituents, and other factors.", [["fragments", "ANATOMY", 323, 332], ["crowns ethers", "CHEMICAL", 260, 273], ["crowns ethers", "CHEMICAL", 260, 273], ["Planococcus citreus", "ORGANISM", 99, 118], ["Streptococcus lactis", "ORGANISM", 120, 140], ["Micrococcus lysodeiktious", "ORGANISM", 142, 167], ["Staphylococcus aureus", "ORGANISM", 169, 190], ["Streptococcus faecalis", "ORGANISM", 192, 214], ["Bacillus subtillum", "ORGANISM", 216, 234], ["crowns ethers", "SIMPLE_CHEMICAL", 260, 273], ["aromatic", "SIMPLE_CHEMICAL", 284, 292], ["cyclic", "SIMPLE_CHEMICAL", 294, 300], ["heterocyclic etc", "SIMPLE_CHEMICAL", 305, 321], ["lipophily", "SIMPLE_CHEMICAL", 414, 423], ["Planococcus citreus", "SPECIES", 99, 118], ["Streptococcus lactis", "SPECIES", 120, 140], ["Micrococcus lysodeiktious", "SPECIES", 142, 167], ["Staphylococcus aureus", "SPECIES", 169, 190], ["Streptococcus faecalis", "SPECIES", 192, 214], ["Bacillus subtillum", "SPECIES", 216, 234], ["Planococcus citreus", "SPECIES", 99, 118], ["Streptococcus lactis", "SPECIES", 120, 140], ["Micrococcus lysodeiktious", "SPECIES", 142, 167], ["Staphylococcus aureus", "SPECIES", 169, 190], ["Streptococcus faecalis", "SPECIES", 192, 214], ["Bacillus subtillum", "SPECIES", 216, 234], ["antimicrobial activity", "TREATMENT", 75, 97], ["Planococcus citreus", "TREATMENT", 99, 118], ["Streptococcus lactis", "TREATMENT", 120, 140], ["Micrococcus lysodeiktious", "TREATMENT", 142, 167], ["Staphylococcus aureus", "PROBLEM", 169, 190], ["Streptococcus faecalis", "PROBLEM", 192, 214], ["Bacillus subtillum", "PROBLEM", 216, 234], ["aromatic, cyclic and heterocyclic etc", "PROBLEM", 284, 321], ["fragments", "PROBLEM", 323, 332], ["a structure of these molecules", "PROBLEM", 337, 367], ["the substituents", "PROBLEM", 435, 451], ["molecules", "OBSERVATION_MODIFIER", 358, 367], ["macro cycle", "OBSERVATION_MODIFIER", 384, 395], ["size", "OBSERVATION_MODIFIER", 396, 400], ["substituents", "OBSERVATION_MODIFIER", 439, 451]]], ["The elucidation of similar relations allows predicting biological properties of crown compounds, to execute their direct synthesis and to receive the indispensable information for research of mechanisms of biological effect of such kind of compounds.", [["crown compounds", "PROBLEM", 80, 95]]], ["Completely adequate QSAR models (R2 = 0.841-0.995, Q2 = 0.660-0.954) have been obtained using partial least squares method for all of the studied cultures.", [["R2", "TEST", 33, 35], ["the studied cultures", "TEST", 134, 154]]], ["On the base of the first ones the molecular fragments with positive or negative influence on the explored properties have been determined.", [["base", "ANATOMY_MODIFIER", 7, 11], ["molecular", "OBSERVATION_MODIFIER", 34, 43], ["fragments", "OBSERVATION", 44, 53], ["positive", "OBSERVATION_MODIFIER", 59, 67], ["negative", "OBSERVATION_MODIFIER", 71, 79], ["influence", "OBSERVATION_MODIFIER", 80, 89]]], ["They give a possibility to realize the virtual screening and molecular design of compounds with the high level of target activity.", [["the virtual screening", "TEST", 35, 56], ["molecular design of compounds", "PROBLEM", 61, 90]]], ["The results of prognosis are verifying by the experimental investigations.", [["the experimental investigations", "TEST", 42, 73]]], ["Conclusion: QSAR analysis of antimicrobial activity of crown ethers allows us to suppose the presence of two different mechanisms of their antimicrobial action.", [["crown ethers", "CHEMICAL", 55, 67], ["crown ethers", "CHEMICAL", 55, 67], ["crown ethers", "SIMPLE_CHEMICAL", 55, 67], ["QSAR analysis", "TEST", 12, 25], ["their antimicrobial action", "TREATMENT", 133, 159]]], ["It is discovered that the presence of diphenyloxide and tert-butyl fragments promotes; diphenyl-sulphide and diamino-biphenyl -prevents the antimicrobial action.", [["diphenyloxide", "CHEMICAL", 38, 51], ["tert-butyl", "CHEMICAL", 56, 66], ["diphenyl-sulphide", "CHEMICAL", 87, 104], ["diamino-biphenyl", "CHEMICAL", 109, 125], ["diphenyloxide", "CHEMICAL", 38, 51], ["tert-butyl", "CHEMICAL", 56, 66], ["diphenyl-sulphide", "CHEMICAL", 87, 104], ["diamino-biphenyl", "CHEMICAL", 109, 125], ["diphenyloxide", "SIMPLE_CHEMICAL", 38, 51], ["tert-butyl fragments", "SIMPLE_CHEMICAL", 56, 76], ["diphenyl-sulphide", "SIMPLE_CHEMICAL", 87, 104], ["diamino-biphenyl", "SIMPLE_CHEMICAL", 109, 125], ["diphenyloxide", "TREATMENT", 38, 51], ["tert-butyl fragments promotes", "TREATMENT", 56, 85], ["diphenyl", "TREATMENT", 87, 95], ["sulphide", "TREATMENT", 96, 104], ["diamino", "TREATMENT", 109, 116], ["biphenyl", "TREATMENT", 117, 125], ["the antimicrobial action", "TREATMENT", 136, 160]]], ["It is shown that the hexadenthal crown ethers containing aromatic fragments with a tert-butyl group are the most perspective antimicrobials.", [["hexadenthal crown ethers", "CHEMICAL", 21, 45], ["tert-butyl", "CHEMICAL", 83, 93], ["hexadenthal crown ethers", "CHEMICAL", 21, 45], ["tert-butyl", "CHEMICAL", 83, 93], ["hexadenthal crown ethers", "SIMPLE_CHEMICAL", 21, 45], ["tert-butyl", "SIMPLE_CHEMICAL", 83, 93], ["the hexadenthal crown ethers", "TREATMENT", 17, 45], ["aromatic fragments", "PROBLEM", 57, 75], ["a tert-butyl group", "TREATMENT", 81, 99], ["aromatic fragments", "OBSERVATION", 57, 75]]], ["Objectives: Methionyl tRNA synthetase (MRS) catalyses the covalent attachment of methionine to its cognate tRNA.", [["Methionyl tRNA", "CHEMICAL", 12, 26], ["methionine", "CHEMICAL", 81, 91], ["Methionyl", "CHEMICAL", 12, 21], ["methionine", "CHEMICAL", 81, 91], ["Methionyl tRNA synthetase", "GENE_OR_GENE_PRODUCT", 12, 37], ["MRS", "SIMPLE_CHEMICAL", 39, 42], ["methionine", "AMINO_ACID", 81, 91], ["Methionyl tRNA synthetase", "PROTEIN", 12, 37], ["cognate tRNA", "PROTEIN", 99, 111], ["Methionyl tRNA synthetase (MRS)", "TREATMENT", 12, 43], ["the covalent attachment of methionine", "TREATMENT", 54, 91]]], ["REP8839 is a synthetic inhibitor of MRS with potent antibacterial activity against Staphylococcus aureus including clinically-relevant resistant strains (MIC90 equals 0.06 to 0.5 lg/mL).", [["strains", "ANATOMY", 145, 152], ["REP8839", "CHEMICAL", 0, 7], ["MRS", "CHEMICAL", 36, 39], ["Staphylococcus aureus", "DISEASE", 83, 104], ["REP8839", "CHEMICAL", 0, 7], ["REP8839", "SIMPLE_CHEMICAL", 0, 7], ["MRS", "SIMPLE_CHEMICAL", 36, 39], ["Staphylococcus aureus", "ORGANISM", 83, 104], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Staphylococcus aureus", "SPECIES", 83, 104], ["a synthetic inhibitor of MRS", "TREATMENT", 11, 39], ["potent antibacterial activity", "TREATMENT", 45, 74], ["Staphylococcus aureus", "PROBLEM", 83, 104], ["relevant resistant strains", "PROBLEM", 126, 152], ["MIC90 equals", "TEST", 154, 166]]], ["We determined the biochemical potency and mechanism of action of REP8839 and related compounds with respect to S. aureus MRS enzymatic activity.", [["REP8839", "CHEMICAL", 65, 72], ["REP8839", "CHEMICAL", 65, 72], ["REP8839", "SIMPLE_CHEMICAL", 65, 72], ["S. aureus", "ORGANISM", 111, 120], ["S. aureus", "SPECIES", 111, 120], ["S. aureus", "SPECIES", 111, 120], ["S. aureus MRS enzymatic activity", "PROBLEM", 111, 143]]], ["We also evaluated the enzyme kinetic properties of mutated forms of S. aureus MRS. Methods: The metS gene from S. aureus was expressed in E. coli and MRS was purified to near homogeneity by ammonium sulfate fractionation and anion exchange chromatography.", [["ammonium sulfate", "CHEMICAL", 190, 206], ["anion", "CHEMICAL", 225, 230], ["ammonium sulfate", "CHEMICAL", 190, 206], ["S. aureus", "ORGANISM", 68, 77], ["metS", "GENE_OR_GENE_PRODUCT", 96, 100], ["S. aureus", "ORGANISM", 111, 120], ["E. coli", "ORGANISM", 138, 145], ["MRS", "SIMPLE_CHEMICAL", 150, 153], ["ammonium sulfate", "SIMPLE_CHEMICAL", 190, 206], ["anion", "SIMPLE_CHEMICAL", 225, 230], ["metS gene", "DNA", 96, 105], ["S. aureus", "SPECIES", 68, 77], ["S. aureus", "SPECIES", 111, 120], ["E. coli", "SPECIES", 138, 145], ["S. aureus", "SPECIES", 68, 77], ["S. aureus", "SPECIES", 111, 120], ["E. coli", "SPECIES", 138, 145], ["the enzyme", "TEST", 18, 28], ["S. aureus MRS", "PROBLEM", 68, 81], ["The metS gene", "PROBLEM", 92, 105], ["S. aureus", "PROBLEM", 111, 120], ["E. coli", "PROBLEM", 138, 145], ["MRS", "TEST", 150, 153], ["ammonium sulfate fractionation", "TREATMENT", 190, 220], ["anion exchange chromatography", "TEST", 225, 254], ["aureus", "OBSERVATION", 71, 77], ["metS", "OBSERVATION", 96, 100], ["aureus", "OBSERVATION", 114, 120]]], ["Aminoacylation of tRNAmet was measured using scintillation proximity assays (SPA).", [["tRNAmet", "GENE_OR_GENE_PRODUCT", 18, 25], ["tRNAmet", "PROTEIN", 18, 25], ["Aminoacylation of tRNAmet", "TREATMENT", 0, 25]]], ["The kinetics of the ATP:PPi exchange were determined using thin layer chromatography (TLC).", [["ATP", "CHEMICAL", 20, 23], ["PPi", "CHEMICAL", 24, 27], ["ATP", "CHEMICAL", 20, 23], ["PPi", "CHEMICAL", 24, 27], ["ATP", "SIMPLE_CHEMICAL", 20, 23], ["PPi", "SIMPLE_CHEMICAL", 24, 27], ["PPi exchange", "TREATMENT", 24, 36], ["thin layer chromatography (TLC", "TREATMENT", 59, 89], ["PPi exchange", "OBSERVATION", 24, 36]]], ["Mutants of S. aureus MRS were selected by serial passage and spontaneous resistance in the presence of REP8839.", [["REP8839", "CHEMICAL", 103, 110], ["REP8839", "CHEMICAL", 103, 110], ["S. aureus MRS", "ORGANISM", 11, 24], ["REP8839", "SIMPLE_CHEMICAL", 103, 110], ["S. aureus", "SPECIES", 11, 20], ["S. aureus", "SPECIES", 11, 20], ["S. aureus MRS", "PROBLEM", 11, 24], ["serial passage", "TEST", 42, 56], ["aureus", "OBSERVATION", 14, 20]]], ["Results: REP8839 exhibited strong inhibition of S. aureus MRS in the aminoacylation reaction, having an IC50 limited by the enzyme concentration.", [["REP8839", "CHEMICAL", 9, 16], ["REP8839", "CHEMICAL", 9, 16], ["REP8839", "SIMPLE_CHEMICAL", 9, 16], ["S. aureus", "ORGANISM", 48, 57], ["S. aureus", "SPECIES", 48, 57], ["S. aureus", "SPECIES", 48, 57], ["S. aureus MRS", "PROBLEM", 48, 61], ["the aminoacylation reaction", "PROBLEM", 65, 92], ["an IC50", "TEST", 101, 108], ["the enzyme concentration", "TEST", 120, 144], ["aureus", "OBSERVATION", 51, 57], ["aminoacylation reaction", "OBSERVATION", 69, 92]]], ["In order to estimate the true inhibition constant (Ki), we utilized an ATP:PPi exchange assay.", [["ATP", "CHEMICAL", 71, 74], ["PPi", "CHEMICAL", 75, 78], ["ATP", "CHEMICAL", 71, 74], ["PPi", "CHEMICAL", 75, 78], ["ATP", "SIMPLE_CHEMICAL", 71, 74], ["PPi", "SIMPLE_CHEMICAL", 75, 78], ["an ATP", "TREATMENT", 68, 74], ["PPi exchange assay", "TREATMENT", 75, 93]]], ["REP8839 showed potent inhibition of S. aureus MRS, with a Ki of 10 pM.P1558Related inhibitors were analysed, and a correlation was observed between the Ki for MRS and the MIC for S. aureus.", [["REP8839", "CHEMICAL", 0, 7], ["REP8839", "CHEMICAL", 0, 7], ["REP8839", "SIMPLE_CHEMICAL", 0, 7], ["S. aureus", "ORGANISM", 36, 45], ["P1558Related", "GENE_OR_GENE_PRODUCT", 70, 82], ["S. aureus", "ORGANISM", 179, 188], ["S. aureus", "SPECIES", 36, 45], ["S. aureus", "SPECIES", 179, 188], ["S. aureus", "SPECIES", 36, 45], ["S. aureus", "SPECIES", 179, 188], ["S. aureus MRS", "PROBLEM", 36, 49], ["P1558Related inhibitors", "TREATMENT", 70, 93], ["MRS", "TEST", 159, 162], ["S. aureus", "PROBLEM", 179, 188], ["potent inhibition", "OBSERVATION_MODIFIER", 15, 32], ["aureus", "OBSERVATION", 39, 45], ["aureus", "OBSERVATION", 182, 188]]], ["REP8839 was found to be competitive with methionine binding, but uncompetitive with ATP binding (i.e., increasing the ATP concentration resulted in tighter binding of REP8839).", [["REP8839", "CHEMICAL", 0, 7], ["methionine", "CHEMICAL", 41, 51], ["ATP", "CHEMICAL", 84, 87], ["ATP", "CHEMICAL", 118, 121], ["REP8839", "CHEMICAL", 0, 7], ["methionine", "CHEMICAL", 41, 51], ["ATP", "CHEMICAL", 84, 87], ["ATP", "CHEMICAL", 118, 121], ["REP8839", "CHEMICAL", 167, 174], ["REP8839", "SIMPLE_CHEMICAL", 0, 7], ["methionine", "SIMPLE_CHEMICAL", 41, 51], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["ATP", "SIMPLE_CHEMICAL", 118, 121], ["REP8839", "GENE_OR_GENE_PRODUCT", 167, 174], ["REP8839", "PROTEIN", 167, 174], ["methionine binding", "PROBLEM", 41, 59], ["uncompetitive", "PROBLEM", 65, 78], ["ATP binding", "PROBLEM", 84, 95], ["increasing the ATP concentration", "PROBLEM", 103, 135]]], ["Mutated S. aureus MRS variants (derived from strains with elevated MICs) showed substantially weaker binding by REP8839.", [["MICs", "CHEMICAL", 67, 71], ["REP8839", "CHEMICAL", 112, 119], ["REP8839", "CHEMICAL", 112, 119], ["S. aureus MRS", "ORGANISM", 8, 21], ["REP8839", "SIMPLE_CHEMICAL", 112, 119], ["REP8839", "PROTEIN", 112, 119], ["S. aureus", "SPECIES", 8, 17], ["S. aureus", "SPECIES", 8, 17], ["Mutated S. aureus MRS variants", "PROBLEM", 0, 30], ["elevated MICs", "PROBLEM", 58, 71], ["substantially weaker binding", "PROBLEM", 80, 108], ["aureus", "OBSERVATION", 11, 17]]], ["All of the mutated enzymes exhibited impaired tRNA aminoacylation activity, with defects ranging from reduced turnover rates to weaker affinities for one or more substrates.", [["mutated enzymes", "PROTEIN", 11, 26], ["the mutated enzymes", "TEST", 7, 26], ["impaired tRNA aminoacylation activity", "PROBLEM", 37, 74], ["defects", "PROBLEM", 81, 88], ["reduced turnover rates", "PROBLEM", 102, 124], ["impaired", "OBSERVATION_MODIFIER", 37, 45], ["tRNA aminoacylation activity", "OBSERVATION", 46, 74]]], ["Conclusions: REP8839 is a potent inhibitor of S. aureus MRS. Enzymatic potency of this class of inhibitors correlates with microbiological potency.", [["REP8839", "CHEMICAL", 13, 20], ["REP8839", "CHEMICAL", 13, 20], ["REP8839", "SIMPLE_CHEMICAL", 13, 20], ["S. aureus", "ORGANISM", 46, 55], ["S. aureus", "SPECIES", 46, 55], ["S. aureus", "SPECIES", 46, 55], ["S. aureus MRS", "PROBLEM", 46, 59], ["aureus", "OBSERVATION", 49, 55]]], ["Mutations that confer resistance to REP8839 result in functionally impaired MRS, encompassing a wide variety of enzymatic phenotypes.", [["REP8839", "CHEMICAL", 36, 43], ["REP8839", "CHEMICAL", 36, 43], ["REP8839", "GENE_OR_GENE_PRODUCT", 36, 43], ["REP8839", "PROTEIN", 36, 43], ["Mutations", "PROBLEM", 0, 9], ["functionally impaired MRS", "PROBLEM", 54, 79], ["enzymatic phenotypes", "PROBLEM", 112, 132], ["enzymatic phenotypes", "OBSERVATION", 112, 132]]], ["We report here the antibacterial and antifungal activity of 8 newly synthesized and physico-chemically characterised thioureides of 2-(4-chlorophenoxy)-benzoic acid.", [["thioureides", "CHEMICAL", 117, 128], ["2-(4-chlorophenoxy)-benzoic acid", "CHEMICAL", 132, 164], ["thioureides", "CHEMICAL", 117, 128], ["2-(4-chlorophenoxy)-benzoic acid", "CHEMICAL", 132, 164], ["thioureides", "SIMPLE_CHEMICAL", 117, 128], ["2-(4-chlorophenoxy)-benzoic acid", "SIMPLE_CHEMICAL", 132, 164], ["the antibacterial", "TREATMENT", 15, 32], ["antifungal activity", "TREATMENT", 37, 56], ["benzoic acid", "TREATMENT", 152, 164]]], ["The new compounds were prepared in three stage.", [["new", "OBSERVATION_MODIFIER", 4, 7], ["compounds", "OBSERVATION_MODIFIER", 8, 17]]], ["Firstly, the 2-(4-chlorophenoxymethyl)-benzoic acid was prepared by treating the phtalide with p-chlorophenol potassium salt in xylene.", [["2-(4-chlorophenoxymethyl)-benzoic acid", "CHEMICAL", 13, 51], ["phtalide", "CHEMICAL", 81, 89], ["p-chlorophenol potassium", "CHEMICAL", 95, 119], ["xylene", "CHEMICAL", 128, 134], ["2-(4-chlorophenoxymethyl)-benzoic acid", "CHEMICAL", 13, 51], ["phtalide", "CHEMICAL", 81, 89], ["p-chlorophenol potassium salt", "CHEMICAL", 95, 124], ["xylene", "CHEMICAL", 128, 134], ["2-(4-chlorophenoxymethyl)-benzoic acid", "SIMPLE_CHEMICAL", 13, 51], ["phtalide", "SIMPLE_CHEMICAL", 81, 89], ["p-chlorophenol potassium salt", "SIMPLE_CHEMICAL", 95, 124], ["xylene", "SIMPLE_CHEMICAL", 128, 134], ["4-chlorophenoxymethyl)-benzoic acid", "TREATMENT", 16, 51], ["the phtalide", "TREATMENT", 77, 89], ["p-chlorophenol potassium salt in xylene", "TREATMENT", 95, 134]]], ["The second stage was the synthesis of 2-(4-chlorophenoxymethyl)benzoyl chloride by treating the corresponding acid with thionyl chloride using anhydrous 1,2-dichloroethane as solvent, followed in the third stage, by the treatment of the above-mentioned chloride with ammonium thiocyanate.", [["2-(4-chlorophenoxymethyl)benzoyl chloride", "CHEMICAL", 38, 79], ["thionyl chloride", "CHEMICAL", 120, 136], ["anhydrous 1,2-dichloroethane", "CHEMICAL", 143, 171], ["ammonium thiocyanate", "CHEMICAL", 267, 287], ["2-(4-chlorophenoxymethyl)benzoyl chloride", "CHEMICAL", 38, 79], ["thionyl chloride", "CHEMICAL", 120, 136], ["anhydrous 1,2-dichloroethane", "CHEMICAL", 143, 171], ["chloride", "CHEMICAL", 253, 261], ["ammonium thiocyanate", "CHEMICAL", 267, 287], ["2-(4-chlorophenoxymethyl)benzoyl chloride", "SIMPLE_CHEMICAL", 38, 79], ["thionyl chloride", "SIMPLE_CHEMICAL", 120, 136], ["anhydrous 1,2-dichloroethane", "SIMPLE_CHEMICAL", 143, 171], ["chloride", "SIMPLE_CHEMICAL", 253, 261], ["ammonium thiocyanate", "SIMPLE_CHEMICAL", 267, 287], ["the synthesis", "TEST", 21, 34], ["chlorophenoxymethyl)benzoyl chloride", "TREATMENT", 43, 79], ["the corresponding acid with thionyl chloride", "TREATMENT", 92, 136], ["anhydrous", "TREATMENT", 143, 152], ["dichloroethane", "TREATMENT", 157, 171], ["ammonium thiocyanate", "TREATMENT", 267, 287]]], ["The 2-(4-chlorophenoxymethyl)-benzoyl isothiocyanate resulted after refluxing the reaction mixture in dry acetone.", [["2-(4-chlorophenoxymethyl)-benzoyl isothiocyanate", "CHEMICAL", 4, 52], ["dry acetone", "CHEMICAL", 102, 113], ["2-(4-chlorophenoxymethyl)-benzoyl isothiocyanate", "CHEMICAL", 4, 52], ["acetone", "CHEMICAL", 106, 113], ["2-(4-chlorophenoxymethyl)-benzoyl isothiocyanate", "SIMPLE_CHEMICAL", 4, 52], ["acetone", "SIMPLE_CHEMICAL", 106, 113], ["4-chlorophenoxymethyl)", "TREATMENT", 7, 29], ["benzoyl isothiocyanate", "TREATMENT", 30, 52], ["refluxing the reaction mixture", "PROBLEM", 68, 98]]], ["The new compounds were prepared by refluxing the isothiocyanate with primary aromatic amines in dry acetone.", [["aromatic amines", "CHEMICAL", 77, 92], ["dry acetone", "CHEMICAL", 96, 107], ["isothiocyanate", "CHEMICAL", 49, 63], ["primary aromatic amines", "CHEMICAL", 69, 92], ["acetone", "CHEMICAL", 100, 107], ["isothiocyanate", "SIMPLE_CHEMICAL", 49, 63], ["primary aromatic amines", "SIMPLE_CHEMICAL", 69, 92], ["dry acetone", "SIMPLE_CHEMICAL", 96, 107], ["The new compounds", "PROBLEM", 0, 17], ["refluxing the isothiocyanate", "TREATMENT", 35, 63], ["primary aromatic amines", "TREATMENT", 69, 92], ["new", "OBSERVATION_MODIFIER", 4, 7], ["compounds", "OBSERVATION", 8, 17]]], ["The obtained compounds have been characterized by their physical properties and their chemical structures were confirmed using the spectral analysis.", [["the spectral analysis", "TEST", 127, 148]]], ["The aim of this study was also to evaluate the in vitro antimicrobial activity of the new compounds.", [["this study", "TEST", 11, 21], ["new", "OBSERVATION_MODIFIER", 86, 89], ["compounds", "OBSERVATION", 90, 99]]], ["The in vitro antimicrobial testing was performed by binary microdilution method, in 96 multi-well plates, in order to establish the minimal inhibitory concentration (MIC), against Gram-positive (Listeria (L.) monocytogenes, Staphylococcus (S.) aureus, Bacillus (B.) subtilis), Gram-negative (Psedomonas (P.) aeruginosa, Escherichia (E.) coli, Salmonella (S.) enteritidis), as well as Candida sp., using both reference and clinical, multidrug resistant strains.", [["Gram-", "CHEMICAL", 180, 185], ["Gram-", "ORGANISM", 180, 185], ["Listeria (", "ORGANISM", 195, 205], ["L.) monocytogenes", "ORGANISM", 205, 222], ["Staphylococcus (S.) aureus", "ORGANISM", 224, 250], ["Bacillus (B.) subtilis", "ORGANISM", 252, 274], ["Gram-", "GENE_OR_GENE_PRODUCT", 277, 282], ["Psedomonas (P.) aeruginosa", "ORGANISM", 292, 318], ["Escherichia (E.) coli", "ORGANISM", 320, 341], ["Salmonella (S.) enteritidis", "ORGANISM", 343, 370], ["Candida sp.", "ORGANISM", 384, 395], ["L.) monocytogenes", "SPECIES", 205, 222], ["Staphylococcus", "SPECIES", 224, 238], ["S.) aureus", "SPECIES", 240, 250], ["Bacillus", "SPECIES", 252, 260], ["B.) subtilis", "SPECIES", 262, 274], ["Psedomonas", "SPECIES", 292, 302], ["P.) aeruginosa", "SPECIES", 304, 318], ["Escherichia", "SPECIES", 320, 331], ["E.) coli", "SPECIES", 333, 341], ["Salmonella", "SPECIES", 343, 353], ["S.) enteritidis", "SPECIES", 355, 370], ["Candida sp.", "SPECIES", 384, 395], ["Listeria (L.) monocytogenes", "SPECIES", 195, 222], ["Staphylococcus (S.) aureus", "SPECIES", 224, 250], ["B.) subtilis", "SPECIES", 262, 274], ["P.) aeruginosa", "SPECIES", 304, 318], ["E.) coli", "SPECIES", 333, 341], ["S.) enteritidis", "SPECIES", 355, 370], ["Candida sp.", "SPECIES", 384, 395], ["The in vitro antimicrobial testing", "TEST", 0, 34], ["Gram-positive (Listeria (L.) monocytogenes", "PROBLEM", 180, 222], ["Staphylococcus (S.)", "TEST", 224, 243], ["aureus", "PROBLEM", 244, 250], ["Bacillus (B.) subtilis", "TEST", 252, 274], ["Gram-negative (Psedomonas (P.) aeruginosa", "PROBLEM", 277, 318], ["Escherichia (E.) coli", "PROBLEM", 320, 341], ["Salmonella (S.) enteritidis", "PROBLEM", 343, 370], ["Candida sp.", "PROBLEM", 384, 395], ["multidrug resistant strains", "PROBLEM", 432, 459]]], ["Our results showed that the tested compounds exhibited a specific antimicrobial activity, depending on the nature of the substituents and their position on the benzene ring, both concerning the microbial spectrum and the MIC value.", [["benzene", "CHEMICAL", 160, 167], ["benzene", "CHEMICAL", 160, 167], ["benzene", "SIMPLE_CHEMICAL", 160, 167], ["the tested compounds", "PROBLEM", 24, 44], ["the benzene ring", "TREATMENT", 156, 172], ["the MIC value", "TEST", 217, 230], ["antimicrobial activity", "OBSERVATION", 66, 88], ["benzene ring", "OBSERVATION", 160, 172]]], ["The MICs values widely ranged between 1024 mcg/ml and 32 mcg/ml.", [["The MICs values", "TREATMENT", 0, 15]]], ["The most active proved to be N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(2,6-dichloro-phenyl)-thiourea and N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(4-bromo-phenyl)-thiourea, showing a large spectrum of antimicrobial activity against enterobacterial strains (E. coli and S. enteritidis), L. monocytogenes, S. aureus and Candida sp.", [["N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(2,6-dichloro-phenyl)-thiourea", "CHEMICAL", 29, 100], ["N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(4-bromo-phenyl)-thiourea", "CHEMICAL", 105, 171], ["N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(2,6-dichloro-phenyl)-thiourea", "CHEMICAL", 29, 100], ["N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(4-bromo-phenyl)-thiourea", "CHEMICAL", 105, 171], ["N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(2,6-dichloro-phenyl)-thiourea", "SIMPLE_CHEMICAL", 29, 100], ["N-[2-(4-chlorophenoxymethyl)-benzoyl]-N'-(4-bromo-phenyl)-thiourea", "SIMPLE_CHEMICAL", 105, 171], ["enterobacterial strains", "ORGANISM", 232, 255], ["E. coli", "ORGANISM", 257, 264], ["S. enteritidis", "ORGANISM", 269, 283], ["L. monocytogenes", "ORGANISM", 286, 302], ["S. aureus", "ORGANISM", 304, 313], ["Candida sp", "ORGANISM", 318, 328], ["E. coli", "SPECIES", 257, 264], ["S. enteritidis", "SPECIES", 269, 283], ["L. monocytogenes", "SPECIES", 286, 302], ["S. aureus", "SPECIES", 304, 313], ["E. coli", "SPECIES", 257, 264], ["S. enteritidis", "SPECIES", 269, 283], ["L. monocytogenes", "SPECIES", 286, 302], ["S. aureus", "SPECIES", 304, 313], ["N", "TEST", 29, 30], ["chlorophenoxymethyl", "TREATMENT", 37, 56], ["benzoyl", "TREATMENT", 58, 65], ["dichloro-phenyl)", "TREATMENT", 75, 91], ["thiourea", "TREATMENT", 92, 100], ["chlorophenoxymethyl", "TREATMENT", 113, 132], ["benzoyl", "TREATMENT", 134, 141], ["thiourea", "TREATMENT", 163, 171], ["antimicrobial activity", "TREATMENT", 201, 223], ["enterobacterial strains", "PROBLEM", 232, 255], ["E. coli", "PROBLEM", 257, 264], ["S. enteritidis", "PROBLEM", 269, 283], ["L. monocytogenes", "PROBLEM", 286, 302], ["S. aureus", "PROBLEM", 304, 313], ["Candida sp", "PROBLEM", 318, 328], ["E. coli", "OBSERVATION_MODIFIER", 257, 264], ["aureus", "OBSERVATION", 307, 313], ["Candida sp", "OBSERVATION", 318, 328]]], ["All the tested compounds were highly active against S. aureus (MIC = 32 mcg/ml).", [["S. aureus", "ORGANISM", 52, 61], ["S. aureus", "SPECIES", 52, 61], ["S. aureus", "SPECIES", 52, 61], ["S. aureus", "PROBLEM", 52, 61], ["MIC", "TEST", 63, 66]]], ["Four of the tested compounds exhibited antifungal activity (MIC = 256-32 mcg/ml), and P. aeruginosa as well as B. subtilis were resistant to all tested compounds.P1561In vitro antimicrobial activities of novel dianthraquinones produced by a marine Streptomyces sp. against clinical Staphylococcus aureus and Enterococcus faecium isolates K.L. LaPlante, K. Lor, A. Socha, D.C. Rowley (Providence, North Kingston, US)P1561Objectives: The escalation of antibiotic resistance among grampositive pathogens presents increasing treatment challenges and requires the development of new therapeutic agents.", [["dianthraquinones", "CHEMICAL", 210, 226], ["Staphylococcus aureus", "DISEASE", 282, 303], ["dianthraquinones", "CHEMICAL", 210, 226], ["P. aeruginosa", "ORGANISM", 86, 99], ["B. subtilis", "ORGANISM", 111, 122], ["dianthraquinones", "SIMPLE_CHEMICAL", 210, 226], ["Streptomyces sp", "ORGANISM", 248, 263], ["Staphylococcus aureus", "ORGANISM", 282, 303], ["Enterococcus faecium", "ORGANISM", 308, 328], ["P. aeruginosa", "SPECIES", 86, 99], ["B. subtilis", "SPECIES", 111, 122], ["Staphylococcus aureus", "SPECIES", 282, 303], ["Enterococcus faecium", "SPECIES", 308, 328], ["P. aeruginosa", "SPECIES", 86, 99], ["B. subtilis", "SPECIES", 111, 122], ["Staphylococcus aureus", "SPECIES", 282, 303], ["Enterococcus faecium", "SPECIES", 308, 328], ["the tested compounds", "TEST", 8, 28], ["antifungal activity", "TREATMENT", 39, 58], ["MIC", "TEST", 60, 63], ["P. aeruginosa", "PROBLEM", 86, 99], ["B. subtilis", "PROBLEM", 111, 122], ["novel dianthraquinones", "TREATMENT", 204, 226], ["clinical Staphylococcus aureus", "PROBLEM", 273, 303], ["Enterococcus faecium", "PROBLEM", 308, 328], ["antibiotic resistance", "TREATMENT", 450, 471], ["grampositive pathogens", "PROBLEM", 478, 500], ["increasing treatment challenges", "TREATMENT", 510, 541], ["new therapeutic agents", "TREATMENT", 574, 596], ["Staphylococcus aureus", "OBSERVATION", 282, 303], ["Enterococcus faecium", "OBSERVATION", 308, 328]]], ["Recently we discovered a new class of dianthraquinone antibiotics produced by a marine streptomycete.", [["dianthraquinone", "CHEMICAL", 38, 53], ["dianthraquinone", "CHEMICAL", 38, 53], ["dianthraquinone", "SIMPLE_CHEMICAL", 38, 53], ["dianthraquinone antibiotics", "TREATMENT", 38, 65], ["a marine streptomycete", "TREATMENT", 78, 100], ["new", "OBSERVATION_MODIFIER", 25, 28]]], ["The inhibitory and bactericidal activity of four dianthraquinone secondary metabolites and four semi-synthetic derivatives were measured against clinical strains of vancomycin resistant E. faecium (VRE), methicillin susceptible and methicillin resistant S. aureus (MSSA and MRSA, respectively).", [["dianthraquinone", "CHEMICAL", 49, 64], ["vancomycin", "CHEMICAL", 165, 175], ["VRE", "CHEMICAL", 198, 201], ["methicillin", "CHEMICAL", 204, 215], ["methicillin", "CHEMICAL", 232, 243], ["MSSA", "CHEMICAL", 265, 269], ["dianthraquinone", "CHEMICAL", 49, 64], ["vancomycin", "CHEMICAL", 165, 175], ["methicillin", "CHEMICAL", 204, 215], ["methicillin", "CHEMICAL", 232, 243], ["dianthraquinone", "SIMPLE_CHEMICAL", 49, 64], ["vancomycin", "SIMPLE_CHEMICAL", 165, 175], ["E. faecium", "ORGANISM", 186, 196], ["methicillin resistant", "ORGANISM", 232, 253], ["S. aureus", "ORGANISM", 254, 263], ["MSSA", "CANCER", 265, 269], ["E. faecium", "SPECIES", 186, 196], ["S. aureus", "SPECIES", 254, 263], ["MRSA", "SPECIES", 274, 278], ["E. faecium", "SPECIES", 186, 196], ["S. aureus", "SPECIES", 254, 263], ["MSSA", "SPECIES", 265, 269], ["MRSA", "SPECIES", 274, 278], ["The inhibitory", "TREATMENT", 0, 14], ["four semi-synthetic derivatives", "TREATMENT", 91, 122], ["vancomycin resistant E. faecium", "PROBLEM", 165, 196], ["VRE", "PROBLEM", 198, 201], ["methicillin susceptible and methicillin resistant S. aureus", "PROBLEM", 204, 263], ["MSSA", "PROBLEM", 265, 269], ["MRSA", "PROBLEM", 274, 278], ["bactericidal activity", "OBSERVATION", 19, 40], ["aureus", "OBSERVATION", 257, 263]]], ["Two compounds, DAQ550a and DAQ552, were tested against an expanded panel of pathogens.", [["DAQ550a", "CHEMICAL", 15, 22], ["DAQ552", "CHEMICAL", 27, 33], ["DAQ550a", "CHEMICAL", 15, 22], ["DAQ552", "CHEMICAL", 27, 33], ["DAQ550a", "SIMPLE_CHEMICAL", 15, 22], ["DAQ552", "SIMPLE_CHEMICAL", 27, 33], ["DAQ552", "TREATMENT", 27, 33], ["pathogens", "PROBLEM", 76, 85], ["pathogens", "OBSERVATION", 76, 85]]], ["Methods: Thirty-two clinical strains of VRE (n = 10), MSSA (n = 12) and MRSA (n = 12) were obtained from patients at the Veterans Affairs Medical Center in Providence, RI.", [["VRE", "DISEASE", 40, 43], ["MSSA", "DISEASE", 54, 58], ["MRSA", "DISEASE", 72, 76], ["patients", "ORGANISM", 105, 113], ["MRSA", "SPECIES", 72, 76], ["patients", "SPECIES", 105, 113], ["MRSA", "SPECIES", 72, 76], ["VRE", "PROBLEM", 40, 43], ["MSSA", "PROBLEM", 54, 58], ["MRSA", "PROBLEM", 72, 76]]], ["MIC's were performed using methodologies described by CLSI.", [["MIC's", "TEST", 0, 5]]], ["Control isolates were ATCC52923 and ATCC29213.", [["ATCC52923", "CHEMICAL", 22, 31], ["ATCC29213", "CHEMICAL", 36, 45], ["ATCC52923", "CHEMICAL", 22, 31], ["ATCC29213", "CHEMICAL", 36, 45], ["ATCC29213", "SIMPLE_CHEMICAL", 36, 45], ["Control isolates", "TEST", 0, 16]]], ["The bactericidal activity of each antimicrobial agent was evaluated with time-kill experiments using 6 randomly selected MSSA (n = 2), MRSA (n = 2), and VRE (n = 2) isolates tested at 4 times the respective MIC.", [["MSSA", "CHEMICAL", 121, 125], ["MRSA", "DISEASE", 135, 139], ["VRE", "DISEASE", 153, 156], ["MRSA", "SPECIES", 135, 139], ["each antimicrobial agent", "TREATMENT", 29, 53], ["selected MSSA", "TEST", 112, 125], ["MRSA", "PROBLEM", 135, 139], ["VRE", "PROBLEM", 153, 156], ["bactericidal", "OBSERVATION_MODIFIER", 4, 16], ["activity", "OBSERVATION_MODIFIER", 17, 25]]], ["Conclusions: The potent activities and unusual structures of the dianthraquinones tested here suggest that these may provide a new molecular scaffold for the development of novel antimicrobial agents.", [["dianthraquinones", "CHEMICAL", 65, 81], ["dianthraquinones", "SIMPLE_CHEMICAL", 65, 81], ["a new molecular scaffold", "TREATMENT", 125, 149], ["novel antimicrobial agents", "TREATMENT", 173, 199], ["antimicrobial agents", "OBSERVATION", 179, 199]]], ["More biological testing is warranted to more fully explore the clinical potential of these antibiotics.P1562Efficacy of the novel antimicrobial peptide plectasin to staphylococci Objective: The purpose of the investigation was to investigate the in vitro efficacy and kill kinetics of Plectasin against Staphylococcus aureus.", [["Plectasin", "CHEMICAL", 285, 294], ["Staphylococcus aureus", "DISEASE", 303, 324], ["Plectasin", "SIMPLE_CHEMICAL", 285, 294], ["Staphylococcus aureus", "ORGANISM", 303, 324], ["Staphylococcus aureus", "SPECIES", 303, 324], ["Staphylococcus aureus", "SPECIES", 303, 324], ["More biological testing", "TEST", 0, 23], ["these antibiotics", "TREATMENT", 85, 102], ["the novel antimicrobial peptide", "TREATMENT", 120, 151], ["staphylococci", "PROBLEM", 165, 178], ["the investigation", "TEST", 205, 222], ["Plectasin", "TREATMENT", 285, 294], ["Staphylococcus aureus", "PROBLEM", 303, 324], ["staphylococci", "OBSERVATION", 165, 178], ["Staphylococcus aureus", "OBSERVATION", 303, 324]]], ["Plectasin is a newly discovered defensintype antimicrobial peptide found in the fungus Pseudoplectania nigrella which showed activity against several Gram-positive bacteria including drug resistant strains (Mygind PH. et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus.", [["Plectasin", "CHEMICAL", 0, 9], ["Plectasin", "CHEMICAL", 225, 234], ["Plectasin", "CHEMICAL", 0, 9], ["Plectasin", "CHEMICAL", 225, 234], ["Plectasin", "GENE_OR_GENE_PRODUCT", 0, 9], ["fungus", "ORGANISM", 80, 86], ["Pseudoplectania nigrella", "ORGANISM", 87, 111], ["Plectasin", "SIMPLE_CHEMICAL", 225, 234], ["Pseudoplectania nigrella", "SPECIES", 87, 111], ["Pseudoplectania nigrella", "SPECIES", 87, 111], ["a newly discovered defensintype antimicrobial peptide", "PROBLEM", 13, 66], ["the fungus Pseudoplectania nigrella", "TEST", 76, 111], ["several Gram-positive bacteria", "PROBLEM", 142, 172], ["drug resistant strains (Mygind PH", "PROBLEM", 183, 216], ["Plectasin", "TREATMENT", 225, 234], ["a peptide antibiotic", "TREATMENT", 238, 258], ["a saprophytic fungus", "PROBLEM", 291, 311], ["antimicrobial peptide", "OBSERVATION", 45, 66], ["fungus", "OBSERVATION", 80, 86], ["activity", "OBSERVATION_MODIFIER", 125, 133], ["positive bacteria", "OBSERVATION", 155, 172], ["drug resistant strains", "OBSERVATION", 183, 205], ["saprophytic fungus", "OBSERVATION", 293, 311]]], ["Bactericidal activity was characterized by time kill experiments at 2 and 10 times the MIC.", [["Bactericidal activity", "PROBLEM", 0, 21]]], ["Staphylococcus aureus (S. aureus) ATCC29213 were used as the test organism and vancomycin was used for comparison.", [["Staphylococcus aureus", "DISEASE", 0, 21], ["ATCC29213", "CHEMICAL", 34, 43], ["vancomycin", "CHEMICAL", 79, 89], ["vancomycin", "CHEMICAL", 79, 89], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["S. aureus", "ORGANISM", 23, 32], ["ATCC29213", "ORGANISM", 34, 43], ["vancomycin", "SIMPLE_CHEMICAL", 79, 89], ["Staphylococcus aureus", "SPECIES", 0, 21], ["S. aureus", "SPECIES", 23, 32], ["Staphylococcus aureus", "SPECIES", 0, 21], ["S. aureus", "SPECIES", 23, 32], ["Staphylococcus aureus (S. aureus)", "PROBLEM", 0, 33], ["the test organism", "TEST", 57, 74], ["vancomycin", "TREATMENT", 79, 89], ["aureus", "OBSERVATION", 15, 21]]], ["The kill kinetics and post antibiotic effect (PAE) were evaluated by CFU determination.", [["PAE", "CHEMICAL", 46, 49], ["The kill kinetics", "TREATMENT", 0, 17], ["post antibiotic effect", "TREATMENT", 22, 44]]], ["Inoculum sizes ranging from 10E4 to 10E7 cells were used to test the inoculum effect.", [["10E7 cells", "ANATOMY", 36, 46], ["10E7 cells", "CELL", 36, 46], ["10E7 cells", "CELL_LINE", 36, 46], ["Inoculum sizes", "TEST", 0, 14], ["sizes", "OBSERVATION_MODIFIER", 9, 14], ["ranging", "OBSERVATION_MODIFIER", 15, 22], ["inoculum effect", "OBSERVATION", 69, 84]]], ["10E10 cells were employed for determination of mutant prevention concentration (MPC) and the frequency of spontaneous resistance.", [["10E10 cells", "ANATOMY", 0, 11], ["10E10 cells", "CELL", 0, 11], ["10E10 cells", "CELL_LINE", 0, 11], ["mutant prevention concentration", "TREATMENT", 47, 78], ["spontaneous resistance", "PROBLEM", 106, 128], ["spontaneous resistance", "OBSERVATION", 106, 128]]], ["Results: Plectasin is bactericidal as evidenced by kill kinetics showing a 2.1 log reduction in CFU/ml after 1 hour of incubation and a reduction of 3.1 log CFU/ml after 2 hours.", [["Plectasin", "CHEMICAL", 9, 18], ["Plectasin", "CHEMICAL", 9, 18], ["Plectasin", "GENE_OR_GENE_PRODUCT", 9, 18], ["bactericidal", "PROBLEM", 22, 34], ["kill kinetics", "TEST", 51, 64], ["a 2.1 log reduction", "TREATMENT", 73, 92], ["a reduction", "TREATMENT", 134, 145]]], ["This is superior compared to the activity of vancomycin.", [["vancomycin", "CHEMICAL", 45, 55], ["vancomycin", "CHEMICAL", 45, 55], ["vancomycin", "SIMPLE_CHEMICAL", 45, 55], ["vancomycin", "TREATMENT", 45, 55], ["superior", "OBSERVATION_MODIFIER", 8, 16]]], ["No inoculum effect was observed in the employed range of cells.", [["cells", "ANATOMY", 57, 62], ["cells", "CELL", 57, 62], ["inoculum effect", "PROBLEM", 3, 18], ["inoculum effect", "OBSERVATION", 3, 18]]], ["The observed PAE had a duration of 2 hours and 42 minutes.", [["PAE", "CHEMICAL", 13, 16], ["PAE", "OBSERVATION_MODIFIER", 13, 16]]], ["No spontaneously resistance mutation was observed among 10E10 cells of staphylococci and the MPC were determined to be 8 times MIC.", [["10E10 cells", "ANATOMY", 56, 67], ["staphylococci", "ANATOMY", 71, 84], ["10E10 cells", "CELL", 56, 67], ["staphylococci", "CANCER", 71, 84], ["MPC", "CANCER", 93, 96], ["10E10 cells", "CELL_LINE", 56, 67], ["spontaneously resistance mutation", "PROBLEM", 3, 36], ["staphylococci", "PROBLEM", 71, 84], ["the MPC", "TREATMENT", 89, 96], ["spontaneously", "OBSERVATION_MODIFIER", 3, 16], ["resistance", "OBSERVATION", 17, 27], ["staphylococci", "OBSERVATION", 71, 84]]], ["Conclusions: Plectasin is a novel antimicrobial peptide that shows potent antimicrobial activity against Gram-positive bacteria including drug-resistant organisms.", [["Plectasin", "CHEMICAL", 13, 22], ["Plectasin", "CHEMICAL", 13, 22], ["Plectasin", "GENE_OR_GENE_PRODUCT", 13, 22], ["Gram-positive bacteria", "SIMPLE_CHEMICAL", 105, 127], ["a novel antimicrobial peptide", "PROBLEM", 26, 55], ["potent antimicrobial activity", "PROBLEM", 67, 96], ["Gram-positive bacteria", "PROBLEM", 105, 127], ["drug-resistant organisms", "PROBLEM", 138, 162]]], ["The potent, excellent bactericidal activity in vitro, lack of cross-resistance to clinical used antibiotics, low spontaneously resistance mutation frequency and good PAE properties, suggest that Plectasin may have potential as a therapeutic agent against staphylococci.P1563In vitro antimicrobial activity of the novel polymeric guanidine Akacid plus \u00d2 C. Kratzer, S. Tobudic, W. Graninger, A. Buxbaum, A. Georgopoulos (Vienna, AT)P1563Objectives: Cationic antimicrobials are widely used for disinfection within clinical settings.", [["Plectasin", "CHEMICAL", 195, 204], ["staphylococci", "DISEASE", 255, 268], ["polymeric guanidine", "CHEMICAL", 319, 338], ["guanidine", "CHEMICAL", 329, 338], ["Plectasin", "SIMPLE_CHEMICAL", 195, 204], ["staphylococci", "CANCER", 255, 268], ["polymeric guanidine Akacid", "SIMPLE_CHEMICAL", 319, 345], ["Cationic antimicrobials", "SIMPLE_CHEMICAL", 448, 471], ["antibiotics", "TREATMENT", 96, 107], ["low spontaneously resistance mutation frequency", "PROBLEM", 109, 156], ["Plectasin", "TREATMENT", 195, 204], ["a therapeutic agent", "TREATMENT", 227, 246], ["staphylococci", "PROBLEM", 255, 268], ["vitro antimicrobial activity", "TREATMENT", 277, 305], ["the novel polymeric guanidine Akacid", "TREATMENT", 309, 345], ["Cationic antimicrobials", "TREATMENT", 448, 471], ["potent", "OBSERVATION_MODIFIER", 4, 10], ["excellent", "OBSERVATION_MODIFIER", 12, 21], ["bactericidal activity", "OBSERVATION", 22, 43], ["good PAE", "OBSERVATION_MODIFIER", 161, 169]]], ["In the present study the bactericidal and fungicidal activity of Akacid plus \u00d2 , a novel polymeric compound of the cationic family of disinfectants, was evaluated against quality control strains of Staphylococcus aureus, Enterococcus hirae, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and Aspergillus niger in comparison to chlorhexidine digluconate.", [["Akacid", "CHEMICAL", 65, 71], ["\u00d2", "CHEMICAL", 77, 78], ["Staphylococcus aureus", "DISEASE", 198, 219], ["chlorhexidine digluconate", "CHEMICAL", 339, 364], ["Akacid", "CHEMICAL", 65, 71], ["chlorhexidine digluconate", "CHEMICAL", 339, 364], ["Akacid", "SIMPLE_CHEMICAL", 65, 71], ["\u00d2", "SIMPLE_CHEMICAL", 77, 78], ["Staphylococcus aureus", "ORGANISM", 198, 219], ["Enterococcus hirae", "ORGANISM", 221, 239], ["Escherichia coli", "ORGANISM", 241, 257], ["Pseudomonas aeruginosa", "ORGANISM", 259, 281], ["Candida albicans", "ORGANISM", 283, 299], ["Aspergillus niger", "ORGANISM", 304, 321], ["chlorhexidine digluconate", "SIMPLE_CHEMICAL", 339, 364], ["Staphylococcus aureus", "SPECIES", 198, 219], ["Enterococcus hirae", "SPECIES", 221, 239], ["Escherichia coli", "SPECIES", 241, 257], ["Pseudomonas aeruginosa", "SPECIES", 259, 281], ["Candida albicans", "SPECIES", 283, 299], ["Aspergillus niger", "SPECIES", 304, 321], ["Staphylococcus aureus", "SPECIES", 198, 219], ["Enterococcus hirae", "SPECIES", 221, 239], ["Escherichia coli", "SPECIES", 241, 257], ["Pseudomonas aeruginosa", "SPECIES", 259, 281], ["Candida albicans", "SPECIES", 283, 299], ["Aspergillus niger", "SPECIES", 304, 321], ["the bactericidal", "TEST", 21, 37], ["Staphylococcus aureus", "PROBLEM", 198, 219], ["Enterococcus hirae", "PROBLEM", 221, 239], ["Escherichia coli", "PROBLEM", 241, 257], ["Pseudomonas aeruginosa", "PROBLEM", 259, 281], ["Candida albicans", "PROBLEM", 283, 299], ["Aspergillus niger", "TREATMENT", 304, 321], ["chlorhexidine digluconate", "TREATMENT", 339, 364], ["bactericidal", "OBSERVATION_MODIFIER", 25, 37], ["fungicidal activity", "OBSERVATION", 42, 61], ["Staphylococcus aureus", "OBSERVATION", 198, 219], ["Enterococcus hirae", "OBSERVATION", 221, 239], ["Escherichia coli", "OBSERVATION", 241, 257]]], ["Methods: The in vitro activity of Akacid plus \u00d2 and chlorhexidine was determined by quantitative suspensions tests according to the European Committee for Standardization at concentrations of 0.01-0.5% against bacterial strains and C. albicans and at concentrations of 0.5-4% against A. niger after exposure for 5, 15 and 60 min in the presence and absence of 0.3% bovine albumin and dilution in distilled and hard water.", [["Akacid", "CHEMICAL", 34, 40], ["chlorhexidine", "CHEMICAL", 52, 65], ["Akacid", "CHEMICAL", 34, 40], ["chlorhexidine", "CHEMICAL", 52, 65], ["Akacid", "SIMPLE_CHEMICAL", 34, 40], ["\u00d2", "SIMPLE_CHEMICAL", 46, 47], ["chlorhexidine", "SIMPLE_CHEMICAL", 52, 65], ["C. albicans", "ORGANISM", 232, 243], ["A. niger", "ORGANISM", 284, 292], ["bovine", "ORGANISM", 365, 371], ["albumin", "GENE_OR_GENE_PRODUCT", 372, 379], ["C. albicans", "SPECIES", 232, 243], ["A. niger", "SPECIES", 284, 292], ["bovine", "SPECIES", 365, 371], ["C. albicans", "SPECIES", 232, 243], ["A. niger", "SPECIES", 284, 292], ["bovine", "SPECIES", 365, 371], ["Akacid", "TREATMENT", 34, 40], ["chlorhexidine", "TREATMENT", 52, 65], ["quantitative suspensions tests", "TEST", 84, 114], ["Standardization at concentrations", "TREATMENT", 155, 188], ["bacterial strains", "PROBLEM", 210, 227], ["C. albicans", "PROBLEM", 232, 243], ["0.3% bovine albumin", "TREATMENT", 360, 379], ["dilution", "TREATMENT", 384, 392]]], ["Results: In the basic quantitative suspension test Akacid plus \u00d2 destroyed all bacterial pathogens at a concentration of \u20210.1% in \u00a35 min contact time.", [["Akacid", "CHEMICAL", 51, 57], ["Akacid", "SIMPLE_CHEMICAL", 51, 57], ["the basic quantitative suspension test", "TEST", 12, 50], ["Akacid", "TEST", 51, 57], ["all bacterial pathogens", "PROBLEM", 75, 98], ["a concentration of \u2021", "TREATMENT", 102, 122], ["bacterial pathogens", "OBSERVATION", 79, 98]]], ["Chlorhexidine was also highly active against S. aureus, E. coli and P. aeruginosa, but failed to eliminate E. hirae within 5 min.", [["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "SIMPLE_CHEMICAL", 0, 13], ["S. aureus", "ORGANISM", 45, 54], ["E. coli", "ORGANISM", 56, 63], ["P. aeruginosa", "ORGANISM", 68, 81], ["E. hirae", "ORGANISM", 107, 115], ["S. aureus", "SPECIES", 45, 54], ["E. coli", "SPECIES", 56, 63], ["P. aeruginosa", "SPECIES", 68, 81], ["E. hirae", "SPECIES", 107, 115], ["S. aureus", "SPECIES", 45, 54], ["E. coli", "SPECIES", 56, 63], ["P. aeruginosa", "SPECIES", 68, 81], ["E. hirae", "SPECIES", 107, 115], ["Chlorhexidine", "TREATMENT", 0, 13], ["S. aureus", "PROBLEM", 45, 54], ["E. coli", "PROBLEM", 56, 63], ["P. aeruginosa", "PROBLEM", 68, 81], ["E. hirae", "PROBLEM", 107, 115], ["aureus", "OBSERVATION", 48, 54], ["E. coli", "OBSERVATION", 56, 63]]], ["Under high organic burden, the bactericidal activity of both disinfectants was slightly reduced.", [["high organic burden", "PROBLEM", 6, 25], ["slightly reduced", "PROBLEM", 79, 95], ["high", "OBSERVATION_MODIFIER", 6, 10], ["organic burden", "OBSERVATION", 11, 25], ["bactericidal", "OBSERVATION_MODIFIER", 31, 43], ["activity", "OBSERVATION_MODIFIER", 44, 52], ["both", "OBSERVATION_MODIFIER", 56, 60], ["disinfectants", "OBSERVATION", 61, 74], ["slightly", "OBSERVATION_MODIFIER", 79, 87], ["reduced", "OBSERVATION_MODIFIER", 88, 95]]], ["Akacid plus \u00d2 showed fungicidal activity against C. albicans within 15-60 min and eliminated A. niger at a concentration of \u20211% in 5 min contact time.", [["Akacid", "CHEMICAL", 0, 6], ["\u00d2", "CHEMICAL", 12, 13], ["Akacid", "SIMPLE_CHEMICAL", 0, 6], ["\u00d2", "SIMPLE_CHEMICAL", 12, 13], ["C. albicans", "ORGANISM", 49, 60], ["A. niger", "ORGANISM", 93, 101], ["C. albicans", "SPECIES", 49, 60], ["A. niger", "SPECIES", 93, 101], ["C. albicans", "SPECIES", 49, 60], ["A. niger", "SPECIES", 93, 101], ["fungicidal activity", "PROBLEM", 21, 40], ["C. albicans", "PROBLEM", 49, 60], ["fungicidal activity", "OBSERVATION", 21, 40]]], ["Chlorhexidine was fungicidal against C. albicans, but did not achieve biocidal activity against A. niger.", [["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "CHEMICAL", 0, 13], ["Chlorhexidine", "SIMPLE_CHEMICAL", 0, 13], ["C. albicans", "ORGANISM", 37, 48], ["A. niger", "ORGANISM", 96, 104], ["C. albicans", "SPECIES", 37, 48], ["A. niger", "SPECIES", 96, 104], ["C. albicans", "SPECIES", 37, 48], ["A. niger", "SPECIES", 96, 104], ["Chlorhexidine", "TREATMENT", 0, 13], ["fungicidal", "TREATMENT", 18, 28], ["C. albicans", "PROBLEM", 37, 48]]], ["Conclusion: The novel polymeric guanidine Akacid plus \u00d2 when compared to chlorhexidine digluconate showed similar bactericidal activity against S. aureus, E. coli and P. aeruginosa and superior biocidal activity against E. hirae and A. niger.P1564Investigation of emergence of bacterial resistance to the novel antibacterial photodynamic agent XF-42 are novel, light activated antibacterial agents (1) active against Gram-positive bacteria, which have greater potency than antibiotics.", [["guanidine Akacid", "CHEMICAL", 32, 48], ["chlorhexidine digluconate", "CHEMICAL", 73, 98], ["XF-42", "CHEMICAL", 344, 349], ["guanidine Akacid", "CHEMICAL", 32, 48], ["chlorhexidine digluconate", "CHEMICAL", 73, 98], ["XF-42", "CHEMICAL", 344, 349], ["polymeric guanidine Akacid", "SIMPLE_CHEMICAL", 22, 48], ["\u00d2", "SIMPLE_CHEMICAL", 54, 55], ["chlorhexidine digluconate", "SIMPLE_CHEMICAL", 73, 98], ["S. aureus", "ORGANISM", 144, 153], ["E. coli", "ORGANISM", 155, 162], ["P. aeruginosa", "ORGANISM", 167, 180], ["E. hirae", "ORGANISM", 220, 228], ["A. niger", "ORGANISM", 233, 241], ["XF-42", "SIMPLE_CHEMICAL", 344, 349], ["Gram", "GENE_OR_GENE_PRODUCT", 417, 421], ["S. aureus", "SPECIES", 144, 153], ["E. coli", "SPECIES", 155, 162], ["P. aeruginosa", "SPECIES", 167, 180], ["E. hirae", "SPECIES", 220, 228], ["A. niger", "SPECIES", 233, 241], ["S. aureus", "SPECIES", 144, 153], ["E. coli", "SPECIES", 155, 162], ["P. aeruginosa", "SPECIES", 167, 180], ["E. hirae", "SPECIES", 220, 228], ["A. niger", "SPECIES", 233, 241], ["The novel polymeric guanidine Akacid", "TREATMENT", 12, 48], ["chlorhexidine digluconate", "TREATMENT", 73, 98], ["similar bactericidal activity", "PROBLEM", 106, 135], ["S. aureus", "PROBLEM", 144, 153], ["E. coli", "PROBLEM", 155, 162], ["P. aeruginosa", "PROBLEM", 167, 180], ["bacterial resistance", "PROBLEM", 277, 297], ["the novel antibacterial photodynamic agent XF", "TREATMENT", 301, 346], ["light activated antibacterial agents", "TREATMENT", 361, 397], ["Gram-positive bacteria", "PROBLEM", 417, 439], ["antibiotics", "TREATMENT", 473, 484], ["bactericidal activity", "OBSERVATION", 114, 135], ["aureus", "OBSERVATION", 147, 153], ["E. coli", "OBSERVATION", 155, 162], ["bacterial resistance", "OBSERVATION", 277, 297], ["positive bacteria", "OBSERVATION_MODIFIER", 422, 439]]], ["The emergence of resistance to XF-42 has been investigated.", [["XF-42", "CHEMICAL", 31, 36], ["XF-42", "CHEMICAL", 31, 36], ["XF-42", "SIMPLE_CHEMICAL", 31, 36], ["XF", "DNA", 31, 33]]], ["Methods: 0.382 mg/L of XF-42 was added to 108 cells/mL of MRSA.", [["cells", "ANATOMY", 46, 51], ["XF-42", "CHEMICAL", 23, 28], ["XF-42", "CHEMICAL", 23, 28], ["XF-42", "SIMPLE_CHEMICAL", 23, 28], ["cells", "CELL", 46, 51], ["MRSA", "SPECIES", 58, 62], ["MRSA", "PROBLEM", 58, 62], ["MRSA", "OBSERVATION", 58, 62]]], ["After 5 minutes incubation in the dark the unbound XF-42 was removed and the culture illuminated with 13.7 J/cm 2 of light at 422 nm and CFU analysis undertaken to determine the number of viable cells remaining.", [["cells", "ANATOMY", 195, 200], ["XF-42", "CHEMICAL", 51, 56], ["XF-42", "CHEMICAL", 51, 56], ["cells", "CELL", 195, 200], ["the culture", "TEST", 73, 84], ["CFU analysis", "TEST", 137, 149], ["viable cells", "OBSERVATION", 188, 200]]], ["5 surviving clones of the treatment were cultured and subjected to further treatment.", [["clones", "ANATOMY", 12, 18], ["the treatment", "TREATMENT", 22, 35], ["further treatment", "TREATMENT", 67, 84]]], ["10 cycles were undertaken to determine whether the number of surviving cells increased, suggesting resistance build up to XF-42.", [["cells", "ANATOMY", 71, 76], ["XF-42", "CHEMICAL", 122, 127], ["cells", "CELL", 71, 76], ["surviving cells", "CELL_TYPE", 61, 76], ["surviving cells", "PROBLEM", 61, 76], ["surviving cells", "OBSERVATION", 61, 76]]], ["Results: The survival of methicillin-resistant Staphylococcus aureus (MRSA) (ATCC BAA-44) is expressed as log N0/N, where N0 and N are the CFU of untreated and treated suspensions, respectively.Conclusions:The results demonstrate that no detectable resistance build up to the activity of XF-42 was seen after 10 successive treatments.", [["methicillin", "CHEMICAL", 25, 36], ["Staphylococcus aureus", "DISEASE", 47, 68], ["BAA-44", "CHEMICAL", 82, 88], ["XF-42", "CHEMICAL", 288, 293], ["methicillin", "CHEMICAL", 25, 36], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 25, 68], ["MRSA", "CANCER", 70, 74], ["ATCC BAA-44", "CELL", 77, 88], ["XF-42", "GENE_OR_GENE_PRODUCT", 288, 293], ["XF", "DNA", 288, 290], ["Staphylococcus aureus", "SPECIES", 47, 68], ["MRSA", "SPECIES", 70, 74], ["Staphylococcus aureus", "SPECIES", 47, 68], ["MRSA", "SPECIES", 70, 74], ["ATCC BAA-44", "SPECIES", 77, 88], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 25, 68], ["MRSA", "PROBLEM", 70, 74], ["ATCC BAA", "TEST", 77, 85], ["N0", "PROBLEM", 122, 124], ["detectable resistance", "PROBLEM", 238, 259], ["Staphylococcus aureus", "OBSERVATION", 47, 68], ["no", "UNCERTAINTY", 235, 237], ["detectable", "OBSERVATION_MODIFIER", 238, 248], ["resistance", "OBSERVATION", 249, 259]]], ["A low propensity for emergence of resistance is a valuable attribute for new anti-bacterial agents.", [["new anti-bacterial agents", "TREATMENT", 73, 98], ["low propensity", "OBSERVATION_MODIFIER", 2, 16]]], ["XF-42 might be effectively employed in the clinical setting for prophylactic use to decolonise skin and nares and therapeutic use to treat infected wounds/ulcers.", [["skin", "ANATOMY", 95, 99], ["nares", "ANATOMY", 104, 109], ["wounds", "ANATOMY", 148, 154], ["XF-42", "CHEMICAL", 0, 5], ["infected wounds", "DISEASE", 139, 154], ["ulcers", "DISEASE", 155, 161], ["XF-42", "CHEMICAL", 0, 5], ["XF-42", "SIMPLE_CHEMICAL", 0, 5], ["skin", "ORGAN", 95, 99], ["nares", "ORGANISM_SUBDIVISION", 104, 109], ["wounds", "PATHOLOGICAL_FORMATION", 148, 154], ["ulcers", "PATHOLOGICAL_FORMATION", 155, 161], ["prophylactic use", "TREATMENT", 64, 80], ["decolonise skin and nares", "TREATMENT", 84, 109], ["infected wounds", "PROBLEM", 139, 154], ["ulcers", "PROBLEM", 155, 161], ["skin", "ANATOMY", 95, 99], ["nares", "ANATOMY", 104, 109], ["infected", "OBSERVATION_MODIFIER", 139, 147], ["wounds", "OBSERVATION", 148, 154], ["ulcers", "OBSERVATION", 155, 161]]], ["Objectives: The XF drugs are novel, light activated antibacterial agents (1) active against Gram-positive bacteria which have superior potency to antibiotics but possess a low propensity to induce resistant bacterial strain emergence.", [["XF drugs", "SIMPLE_CHEMICAL", 16, 24], ["Gram", "GENE_OR_GENE_PRODUCT", 92, 96], ["The XF drugs", "TREATMENT", 12, 24], ["light activated antibacterial agents", "TREATMENT", 36, 72], ["Gram-positive bacteria", "PROBLEM", 92, 114], ["antibiotics", "TREATMENT", 146, 157], ["a low propensity", "PROBLEM", 170, 186], ["resistant bacterial strain emergence", "PROBLEM", 197, 233], ["low propensity", "OBSERVATION_MODIFIER", 172, 186], ["bacterial strain", "OBSERVATION", 207, 223]]], ["A novel ex-vivo porcine skin model has been developed to test the antibacterial activity of XF-73 on the surface of skin.", [["skin", "ANATOMY", 24, 28], ["surface", "ANATOMY", 105, 112], ["skin", "ANATOMY", 116, 120], ["XF-73", "CHEMICAL", 92, 97], ["XF-73", "CHEMICAL", 92, 97], ["porcine", "ORGANISM", 16, 23], ["skin", "ORGAN", 24, 28], ["XF-73", "SIMPLE_CHEMICAL", 92, 97], ["surface", "CELLULAR_COMPONENT", 105, 112], ["skin", "ORGAN", 116, 120], ["A novel ex-vivo porcine skin model", "TREATMENT", 0, 34], ["antibacterial activity", "OBSERVATION_MODIFIER", 66, 88], ["skin", "ANATOMY", 116, 120]]], ["Methods: 10x7 cells of methicillin-resistant Staphylococcus aureus (MRSA) were inoculated onto a 1.32 cm 2 area of ex-vivo porcine skin samples, immobilised in agar.", [["10x7 cells", "ANATOMY", 9, 19], ["skin samples", "ANATOMY", 131, 143], ["methicillin", "CHEMICAL", 23, 34], ["methicillin", "CHEMICAL", 23, 34], ["10x7 cells", "CELL", 9, 19], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 23, 66], ["MRSA", "ORGANISM", 68, 72], ["porcine", "ORGANISM", 123, 130], ["skin samples", "TISSUE", 131, 143], ["10x7 cells", "CELL_LINE", 9, 19], ["Staphylococcus aureus", "SPECIES", 45, 66], ["MRSA", "SPECIES", 68, 72], ["porcine", "SPECIES", 123, 130], ["Staphylococcus aureus", "SPECIES", 45, 66], ["MRSA", "SPECIES", 68, 72], ["porcine", "SPECIES", 123, 130], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 23, 66], ["MRSA", "PROBLEM", 68, 72], ["ex-vivo porcine skin samples", "TREATMENT", 115, 143], ["Staphylococcus aureus", "OBSERVATION", 45, 66], ["ex-vivo porcine", "OBSERVATION", 115, 130], ["skin", "ANATOMY", 131, 135]]], ["After drying, solutions of XF-73 were applied and after 60 minutes, the samples were illuminated for 15 minutes with blue light (422 nm) with various total light doses using a LumaCare TM LC-122M lamp.", [["samples", "ANATOMY", 72, 79], ["XF-73", "CHEMICAL", 27, 32], ["XF-73", "CHEMICAL", 27, 32], ["XF-73", "SIMPLE_CHEMICAL", 27, 32], ["solutions of XF", "TREATMENT", 14, 29], ["the samples", "TEST", 68, 79], ["various total light doses", "TREATMENT", 142, 167], ["a LumaCare TM LC", "TREATMENT", 174, 190]]], ["CFU analysis were undertaken to determine the number of viable cells remaining after treatment.", [["cells", "ANATOMY", 63, 68], ["cells", "CELL", 63, 68], ["CFU analysis", "TEST", 0, 12], ["treatment", "TREATMENT", 85, 94], ["viable cells", "OBSERVATION", 56, 68]]], ["Controls of drug alone and light alone were included.", [["drug alone", "TREATMENT", 12, 22]]], ["Results: Using 7.64 mg/L of XF-73, CFU analysis demonstrated that at a total light dose of 5 J/cm 2 , there was~90% kill of bacteria.", [["XF-73", "CHEMICAL", 28, 33], ["XF-73", "CHEMICAL", 28, 33], ["XF-73", "SIMPLE_CHEMICAL", 28, 33], ["CFU analysis", "TEST", 35, 47], ["bacteria", "PROBLEM", 124, 132]]], ["At 10 J/cm 2 , there was 99.9% kill of bacteria, and 99.99% at 20 J/cm 2 and 40 J/cm 2 .", [["bacteria", "PROBLEM", 39, 47]]], ["At a total light dose of 20 J/ cm 2 , it was found that there was a <99% kill by XF-73 at concentrations of 0.76, 1.53 and 3.8 mg/L. At a concentration of 7.64 mg/L, there was a >99.9% kill.", [["XF-73", "CHEMICAL", 81, 86], ["XF-73", "CHEMICAL", 81, 86], ["XF-73", "SIMPLE_CHEMICAL", 81, 86], ["XF", "TEST", 81, 83]]], ["This kill did not significantly increase at 22.93 and 76.4 mg/L. Conclusions: The results demonstrate that XF-73 has exceptional activity at low concentrations against MRSA on the surface of porcine skin.", [["surface", "ANATOMY", 180, 187], ["skin", "ANATOMY", 199, 203], ["XF-73", "CHEMICAL", 107, 112], ["MRSA", "CHEMICAL", 168, 172], ["XF-73", "CHEMICAL", 107, 112], ["XF-73", "SIMPLE_CHEMICAL", 107, 112], ["surface", "CELLULAR_COMPONENT", 180, 187], ["porcine", "ORGANISM", 191, 198], ["skin", "ORGAN", 199, 203], ["MRSA", "SPECIES", 168, 172], ["porcine", "SPECIES", 191, 198], ["MRSA", "SPECIES", 168, 172], ["porcine", "SPECIES", 191, 198], ["XF", "TEST", 107, 109], ["MRSA", "PROBLEM", 168, 172], ["low concentrations", "OBSERVATION_MODIFIER", 141, 159], ["MRSA", "OBSERVATION", 168, 172], ["porcine", "ANATOMY_MODIFIER", 191, 198], ["skin", "ANATOMY", 199, 203]]], ["XF-73 and light are non-toxic to skin at therapeutic concentrations.", [["skin", "ANATOMY", 33, 37], ["XF-73", "CHEMICAL", 0, 5], ["XF-73", "CHEMICAL", 0, 5], ["XF-73", "SIMPLE_CHEMICAL", 0, 5], ["skin", "ORGAN", 33, 37], ["skin", "ANATOMY", 33, 37]]], ["Work is in progress to clinically evaluate the effectiveness of this compound in eradicating staphylococcal nasal carriage.", [["nasal", "ANATOMY", 108, 113], ["staphylococcal nasal carriage", "DISEASE", 93, 122], ["staphylococcal", "ORGANISM", 93, 107], ["nasal", "ORGANISM_SUBDIVISION", 108, 113], ["this compound", "PROBLEM", 64, 77], ["eradicating staphylococcal nasal carriage", "PROBLEM", 81, 122], ["nasal", "ANATOMY", 108, 113], ["carriage", "OBSERVATION", 114, 122]]], ["Objectives: The rise of epidemic methicillin-resistant Staphylococcus aureus (EMRSA) and the emergence of mupirocin resistance means that it is essential to develop new therapies that cannot be readily overcome by microorganisms.", [["methicillin", "CHEMICAL", 33, 44], ["Staphylococcus aureus", "DISEASE", 55, 76], ["EMRSA", "DISEASE", 78, 83], ["mupirocin", "CHEMICAL", 106, 115], ["methicillin", "CHEMICAL", 33, 44], ["mupirocin", "CHEMICAL", 106, 115], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 33, 76], ["EMRSA", "CANCER", 78, 83], ["mupirocin", "SIMPLE_CHEMICAL", 106, 115], ["Staphylococcus aureus", "SPECIES", 55, 76], ["Staphylococcus aureus", "SPECIES", 55, 76], ["EMRSA", "SPECIES", 78, 83], ["epidemic methicillin-resistant Staphylococcus aureus", "PROBLEM", 24, 76], ["mupirocin resistance", "TREATMENT", 106, 126], ["new therapies", "TREATMENT", 165, 178], ["Staphylococcus aureus", "OBSERVATION", 55, 76]]], ["The XF series of novel light activated antibacterial agents (1) active against Gram-positive bacteria addresses this issue and have superior levels of activity to antibiotics but with less likelihood of resistance emergence.", [["Gram", "GENE_OR_GENE_PRODUCT", 79, 83], ["novel light activated antibacterial agents", "TREATMENT", 17, 59], ["Gram", "TEST", 79, 83], ["positive bacteria", "PROBLEM", 84, 101], ["antibiotics", "TREATMENT", 163, 174], ["resistance emergence", "PROBLEM", 203, 223]]], ["The antibacterial activity of the XF Drugs against EMRSA has been investigated.", [["EMRSA", "CHEMICAL", 51, 56], ["XF Drugs", "SIMPLE_CHEMICAL", 34, 42], ["EMRSA", "SIMPLE_CHEMICAL", 51, 56], ["the XF Drugs", "TREATMENT", 30, 42], ["EMRSA", "TREATMENT", 51, 56], ["antibacterial activity", "OBSERVATION", 4, 26]]], ["Methods: MIC and MBC assays were used to investigate the antibacterial activity of XF-73, a novel antimicrobial photodynamic agent against a range of Staphylococcus aureus strains.", [["MBC", "CHEMICAL", 17, 20], ["XF-73", "CHEMICAL", 83, 88], ["Staphylococcus aureus", "DISEASE", 150, 171], ["XF-73", "CHEMICAL", 83, 88], ["XF-73", "SIMPLE_CHEMICAL", 83, 88], ["Staphylococcus aureus", "ORGANISM", 150, 171], ["strains", "ORGANISM", 172, 179], ["Staphylococcus aureus", "SPECIES", 150, 171], ["XF-73", "SPECIES", 83, 88], ["Staphylococcus aureus", "SPECIES", 150, 171], ["MIC and MBC assays", "TEST", 9, 27], ["a novel antimicrobial photodynamic agent", "TREATMENT", 90, 130], ["Staphylococcus aureus strains", "PROBLEM", 150, 179], ["Staphylococcus aureus", "OBSERVATION", 150, 171]]], ["A concentration range of 2-0.001 mg/L was investigated.", [["A concentration range", "TREATMENT", 0, 21]]], ["15 minutes of 420 nm light activation (13 J/cm 2 ) was applied.", [["420 nm light activation (13 J/cm 2 )", "TREATMENT", 14, 50]]], ["Results:Conclusions:Conclusions: The results demonstrate that XF-73 has exceptionally low MIC and MBC values against all of the S. aureus strains tested.", [["XF-73", "CHEMICAL", 62, 67], ["MBC", "CHEMICAL", 98, 101], ["XF-73", "CHEMICAL", 62, 67], ["XF-73", "SIMPLE_CHEMICAL", 62, 67], ["MBC", "SIMPLE_CHEMICAL", 98, 101], ["S. aureus strains", "ORGANISM", 128, 145], ["S. aureus", "SPECIES", 128, 137], ["S. aureus", "SPECIES", 128, 137], ["XF", "TEST", 62, 64], ["exceptionally low MIC", "PROBLEM", 72, 93], ["MBC values", "TEST", 98, 108], ["the S. aureus strains", "PROBLEM", 124, 145], ["aureus", "OBSERVATION", 131, 137]]], ["The results also demonstrate that XF-73 is equally effective against MRSA and methicillin-sensitive Staphylococcus aureus (MSSA) indicating its mode of action is independent of antibiotic resistance.", [["XF-73", "CHEMICAL", 34, 39], ["MRSA", "CHEMICAL", 69, 73], ["methicillin", "CHEMICAL", 78, 89], ["Staphylococcus aureus", "DISEASE", 100, 121], ["XF-73", "CHEMICAL", 34, 39], ["methicillin", "CHEMICAL", 78, 89], ["XF-73", "SIMPLE_CHEMICAL", 34, 39], ["methicillin-sensitive Staphylococcus aureus", "ORGANISM", 78, 121], ["MSSA", "CANCER", 123, 127], ["MRSA", "SPECIES", 69, 73], ["Staphylococcus aureus", "SPECIES", 100, 121], ["MRSA", "SPECIES", 69, 73], ["Staphylococcus aureus", "SPECIES", 100, 121], ["MSSA", "SPECIES", 123, 127], ["XF", "TEST", 34, 36], ["MRSA", "PROBLEM", 69, 73], ["methicillin-sensitive Staphylococcus aureus", "PROBLEM", 78, 121], ["MSSA", "PROBLEM", 123, 127], ["antibiotic resistance", "TREATMENT", 177, 198], ["Staphylococcus aureus", "OBSERVATION", 100, 121], ["antibiotic resistance", "OBSERVATION", 177, 198]]], ["XF-73 may therefore be useful in prevention and treatment of EMRSA.", [["XF-73", "CHEMICAL", 0, 5], ["EMRSA", "DISEASE", 61, 66], ["XF-73", "CHEMICAL", 0, 5], ["XF-73", "GENE_OR_GENE_PRODUCT", 0, 5], ["EMRSA", "CANCER", 61, 66], ["treatment", "TREATMENT", 48, 57], ["EMRSA", "PROBLEM", 61, 66]]], ["XF-73 is non-toxic to skin at prophylactic/therapeutic concentrations and has potential for the treatment of skin sepsis and the eradication of nasal and skin MRSA carriage.", [["skin", "ANATOMY", 22, 26], ["skin", "ANATOMY", 109, 113], ["nasal", "ANATOMY", 144, 149], ["skin", "ANATOMY", 154, 158], ["XF-73", "CHEMICAL", 0, 5], ["skin sepsis", "DISEASE", 109, 120], ["XF-73", "CHEMICAL", 0, 5], ["XF-73", "SIMPLE_CHEMICAL", 0, 5], ["skin", "ORGAN", 22, 26], ["skin", "ORGAN", 109, 113], ["nasal", "ORGANISM_SUBDIVISION", 144, 149], ["skin", "ORGAN", 154, 158], ["MRSA", "SPECIES", 159, 163], ["MRSA", "SPECIES", 159, 163], ["prophylactic/therapeutic concentrations", "TREATMENT", 30, 69], ["skin sepsis", "PROBLEM", 109, 120], ["nasal and skin MRSA carriage", "PROBLEM", 144, 172], ["skin", "ANATOMY", 22, 26], ["skin", "ANATOMY", 109, 113], ["sepsis", "OBSERVATION", 114, 120], ["nasal", "ANATOMY", 144, 149], ["skin", "ANATOMY", 154, 158], ["MRSA", "OBSERVATION", 159, 163]]], ["Work is in progress to evaluate the effectiveness of this compound in eradicating staphylococcal nasal carriage.", [["nasal", "ANATOMY", 97, 102], ["staphylococcal nasal carriage", "DISEASE", 82, 111], ["staphylococcal", "ORGANISM", 82, 96], ["nasal", "ORGANISM_SUBDIVISION", 97, 102], ["this compound", "PROBLEM", 53, 66], ["eradicating staphylococcal nasal carriage", "PROBLEM", 70, 111], ["nasal", "ANATOMY", 97, 102], ["carriage", "OBSERVATION", 103, 111]]], ["Objective: NXL101 is a novel antibacterial currently in preclinical development.", [["NXL101", "CHEMICAL", 11, 17], ["NXL101", "SIMPLE_CHEMICAL", 11, 17], ["a novel antibacterial", "TREATMENT", 21, 42]]], ["The mechanism of action is directed against topoisomerase, and the spectrum of activity is exclusively against Gram positive organisms.", [["topoisomerase", "GENE_OR_GENE_PRODUCT", 44, 57], ["topoisomerase", "PROTEIN", 44, 57], ["topoisomerase", "PROBLEM", 44, 57], ["Gram positive organisms", "PROBLEM", 111, 134]]], ["The goal of the study was to characterise the activity and time/kill kinetics against common aerobic cocci in comparison to currently marketed molecules: linezolid (LIN), vancomycin (VAN), quinupristin/dalfopristin (Q/D) and moxifloxacin (MOX).", [["linezolid", "CHEMICAL", 154, 163], ["LIN", "CHEMICAL", 165, 168], ["vancomycin", "CHEMICAL", 171, 181], ["VAN", "CHEMICAL", 183, 186], ["quinupristin", "CHEMICAL", 189, 201], ["dalfopristin", "CHEMICAL", 202, 214], ["Q/D", "CHEMICAL", 216, 219], ["moxifloxacin", "CHEMICAL", 225, 237], ["MOX", "CHEMICAL", 239, 242], ["linezolid", "CHEMICAL", 154, 163], ["LIN", "CHEMICAL", 165, 168], ["vancomycin", "CHEMICAL", 171, 181], ["VAN", "CHEMICAL", 183, 186], ["quinupristin", "CHEMICAL", 189, 201], ["dalfopristin", "CHEMICAL", 202, 214], ["moxifloxacin", "CHEMICAL", 225, 237], ["MOX", "CHEMICAL", 239, 242], ["linezolid", "SIMPLE_CHEMICAL", 154, 163], ["LIN", "SIMPLE_CHEMICAL", 165, 168], ["vancomycin", "SIMPLE_CHEMICAL", 171, 181], ["VAN", "SIMPLE_CHEMICAL", 183, 186], ["quinupristin", "SIMPLE_CHEMICAL", 189, 201], ["dalfopristin", "SIMPLE_CHEMICAL", 202, 214], ["Q/D", "SIMPLE_CHEMICAL", 216, 219], ["moxifloxacin", "SIMPLE_CHEMICAL", 225, 237], ["MOX", "SIMPLE_CHEMICAL", 239, 242], ["the study", "TEST", 12, 21], ["common aerobic cocci", "PROBLEM", 86, 106], ["linezolid (LIN)", "TREATMENT", 154, 169], ["vancomycin (VAN)", "TREATMENT", 171, 187], ["quinupristin", "TREATMENT", 189, 201], ["dalfopristin", "TREATMENT", 202, 214], ["moxifloxacin (MOX)", "TREATMENT", 225, 243], ["cocci", "OBSERVATION", 101, 106]]], ["Methods: (i) In vitro susceptibility tests: The strains used were from the culture collection of Novexel and were of clinical origin.", [["Novexel", "CHEMICAL", 97, 104], ["The strains", "PROBLEM", 44, 55], ["the culture collection", "TEST", 71, 93], ["Novexel", "TREATMENT", 97, 104]]], ["MICs were determined by an agar dilution technique.", [["MICs", "TREATMENT", 0, 4], ["an agar dilution technique", "TEST", 24, 50]]], ["Mueller Hinton agar medium was used, supplemented with 5% horse blood for Group A streptococci (GAS), Group B streptococci and S. pneumoniae.", [["blood", "ANATOMY", 64, 69], ["horse", "ORGANISM", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["GAS", "ORGANISM", 96, 99], ["Group B streptococci", "ORGANISM", 102, 122], ["S. pneumoniae", "ORGANISM", 127, 140], ["horse", "SPECIES", 58, 63], ["S. pneumoniae", "SPECIES", 127, 140], ["S. pneumoniae", "SPECIES", 127, 140], ["Mueller Hinton agar medium", "TREATMENT", 0, 26], ["Group A streptococci (GAS", "TEST", 74, 99], ["Group B streptococci", "PROBLEM", 102, 122], ["S. pneumoniae", "PROBLEM", 127, 140], ["pneumoniae", "OBSERVATION", 130, 140]]], ["Overnight cultures were diluted to obtain the final inoculum of 10 4 CFU/spot.", [["cultures", "ANATOMY", 10, 18], ["Overnight cultures", "TEST", 0, 18]]], ["The MIC was the lowest concentration which inhibited all visual growth (3 or less colonies were ignored). (ii) Time/kill kinetics: Experiments were performed against strains of S. aureus (n = 8) and S. pneumoniae (n = 4) in 20 ml volumes of appropriate growth medium with initial inoculum of around 10 6 CFU/ml of logarithmically growing culture.", [["colonies", "ANATOMY", 82, 90], ["S. aureus", "ORGANISM", 177, 186], ["S. pneumoniae", "ORGANISM", 199, 212], ["S. aureus", "SPECIES", 177, 186], ["S. pneumoniae", "SPECIES", 199, 212], ["S. aureus", "SPECIES", 177, 186], ["S. pneumoniae", "SPECIES", 199, 212], ["The MIC", "TREATMENT", 0, 7], ["S. aureus", "PROBLEM", 177, 186], ["S. pneumoniae", "PROBLEM", 199, 212], ["appropriate growth medium", "PROBLEM", 241, 266], ["initial inoculum", "PROBLEM", 272, 288], ["logarithmically growing culture", "PROBLEM", 314, 345], ["aureus", "OBSERVATION", 180, 186], ["pneumoniae", "OBSERVATION", 202, 212], ["growth medium", "OBSERVATION_MODIFIER", 253, 266]]], ["Timed samples over a 24 hour period were enumerated using a spiral plating method.", [["samples", "ANATOMY", 6, 13], ["a spiral plating method", "TREATMENT", 58, 81]]], ["NXL101 was compared to linezolid and vancomycin and the concentrations tested were 4, 8 and 16-fold the MIC90 for both species.Conclusions:Results: (i) The MIC90s of NXL101 versus comparators are shown in the table. (ii) Time kill experiments showed that NXL101 was bactericidal against S. aureus, including methicillin resistant strains (>3log10 reduction within 6-8 hours) compared to a slowly bactericidal effect for vancomycin (24 hours).", [["strains", "ANATOMY", 330, 337], ["NXL101", "CHEMICAL", 0, 6], ["linezolid", "CHEMICAL", 23, 32], ["vancomycin", "CHEMICAL", 37, 47], ["NXL101", "CHEMICAL", 166, 172], ["NXL101", "CHEMICAL", 255, 261], ["methicillin", "CHEMICAL", 308, 319], ["vancomycin", "CHEMICAL", 420, 430], ["linezolid", "CHEMICAL", 23, 32], ["vancomycin", "CHEMICAL", 37, 47], ["NXL101", "CHEMICAL", 166, 172], ["NXL101", "CHEMICAL", 255, 261], ["methicillin", "CHEMICAL", 308, 319], ["vancomycin", "CHEMICAL", 420, 430], ["NXL101", "SIMPLE_CHEMICAL", 0, 6], ["linezolid", "SIMPLE_CHEMICAL", 23, 32], ["vancomycin", "SIMPLE_CHEMICAL", 37, 47], ["NXL101", "SIMPLE_CHEMICAL", 166, 172], ["NXL101", "SIMPLE_CHEMICAL", 255, 261], ["S. aureus", "ORGANISM", 287, 296], ["vancomycin", "SIMPLE_CHEMICAL", 420, 430], ["S. aureus", "SPECIES", 287, 296], ["S. aureus", "SPECIES", 287, 296], ["NXL101", "TREATMENT", 0, 6], ["linezolid", "TREATMENT", 23, 32], ["vancomycin", "TREATMENT", 37, 47], ["the concentrations", "TEST", 52, 70], ["NXL101 versus comparators", "TREATMENT", 166, 191], ["bactericidal", "PROBLEM", 266, 278], ["S. aureus", "PROBLEM", 287, 296], ["methicillin resistant strains", "PROBLEM", 308, 337], ["3log10 reduction", "TREATMENT", 340, 356], ["vancomycin", "TREATMENT", 420, 430], ["aureus", "OBSERVATION", 290, 296]]], ["NXL101 and vancomycin were both bactericidal against S. pneumoniae within 6-8 hours.", [["NXL101", "CHEMICAL", 0, 6], ["vancomycin", "CHEMICAL", 11, 21], ["NXL101", "CHEMICAL", 0, 6], ["vancomycin", "CHEMICAL", 11, 21], ["NXL101", "SIMPLE_CHEMICAL", 0, 6], ["vancomycin", "SIMPLE_CHEMICAL", 11, 21], ["S. pneumoniae", "ORGANISM", 53, 66], ["S. pneumoniae", "SPECIES", 53, 66], ["S. pneumoniae", "SPECIES", 53, 66], ["NXL101", "TREATMENT", 0, 6], ["vancomycin", "TREATMENT", 11, 21], ["S. pneumoniae", "PROBLEM", 53, 66], ["pneumoniae", "OBSERVATION", 56, 66]]], ["Linezolid was bacteriostatic against all strains tested.Conclusions:Conclusion: NXL101 exhibits bactericidal activity against common Gram positive cocci, including strains which exhibit resistance to methicillin, vancomycin and fluoroquinolones.", [["Linezolid", "CHEMICAL", 0, 9], ["NXL101", "CHEMICAL", 80, 86], ["methicillin", "CHEMICAL", 200, 211], ["vancomycin", "CHEMICAL", 213, 223], ["fluoroquinolones", "CHEMICAL", 228, 244], ["Linezolid", "CHEMICAL", 0, 9], ["methicillin", "CHEMICAL", 200, 211], ["vancomycin", "CHEMICAL", 213, 223], ["fluoroquinolones", "CHEMICAL", 228, 244], ["Linezolid", "SIMPLE_CHEMICAL", 0, 9], ["NXL101", "SIMPLE_CHEMICAL", 80, 86], ["methicillin", "SIMPLE_CHEMICAL", 200, 211], ["vancomycin", "SIMPLE_CHEMICAL", 213, 223], ["fluoroquinolones", "SIMPLE_CHEMICAL", 228, 244], ["Linezolid", "TREATMENT", 0, 9], ["bacteriostatic", "PROBLEM", 14, 28], ["all strains tested", "PROBLEM", 37, 55], ["bactericidal activity", "PROBLEM", 96, 117], ["common Gram positive cocci", "PROBLEM", 126, 152], ["strains", "PROBLEM", 164, 171], ["methicillin", "TREATMENT", 200, 211], ["vancomycin", "TREATMENT", 213, 223], ["fluoroquinolones", "TREATMENT", 228, 244], ["bactericidal activity", "OBSERVATION", 96, 117], ["positive cocci", "OBSERVATION", 138, 152]]], ["NXL101 warrants further investigation.", [["NXL101", "CHEMICAL", 0, 6], ["NXL101", "SIMPLE_CHEMICAL", 0, 6], ["further investigation", "TEST", 16, 37]]], ["Objectives: The aim of this study was to identify bacterial proteins as targets of the endogenous antiseptic N-chlorotaurine (NCT), which is a promising microbicidal agent for topical treatment of infections.", [["N-chlorotaurine", "CHEMICAL", 109, 124], ["NCT", "CHEMICAL", 126, 129], ["infections", "DISEASE", 197, 207], ["N-chlorotaurine", "CHEMICAL", 109, 124], ["NCT", "CHEMICAL", 126, 129], ["antiseptic N-chlorotaurine", "SIMPLE_CHEMICAL", 98, 124], ["NCT", "SIMPLE_CHEMICAL", 126, 129], ["bacterial proteins", "PROTEIN", 50, 68], ["this study", "TEST", 23, 33], ["bacterial proteins", "PROBLEM", 50, 68], ["the endogenous antiseptic N-chlorotaurine (NCT)", "TREATMENT", 83, 130], ["a promising microbicidal agent", "TREATMENT", 141, 171], ["topical treatment", "TREATMENT", 176, 193], ["infections", "PROBLEM", 197, 207], ["infections", "OBSERVATION", 197, 207]]], ["In addition, a combination of NCT with ammonium chloride which enhances the microbicidal activity significantly was investigated.", [["ammonium chloride", "CHEMICAL", 39, 56], ["ammonium chloride", "CHEMICAL", 39, 56], ["NCT", "SIMPLE_CHEMICAL", 30, 33], ["ammonium chloride", "SIMPLE_CHEMICAL", 39, 56], ["NCT with ammonium chloride", "TREATMENT", 30, 56], ["microbicidal activity", "OBSERVATION", 76, 97]]], ["Methods: Escherichia coli and Staphylococcus aureus were treated with NCT and NCT plus ammonium chloride for different incubation times between 1 and 30 min -a period where killing takes place.", [["ammonium chloride", "CHEMICAL", 87, 104], ["ammonium chloride", "CHEMICAL", 87, 104], ["Escherichia coli", "ORGANISM", 9, 25], ["Staphylococcus aureus", "ORGANISM", 30, 51], ["NCT", "SIMPLE_CHEMICAL", 70, 73], ["NCT", "SIMPLE_CHEMICAL", 78, 81], ["ammonium chloride", "SIMPLE_CHEMICAL", 87, 104], ["Escherichia coli", "SPECIES", 9, 25], ["Staphylococcus aureus", "SPECIES", 30, 51], ["Escherichia coli", "SPECIES", 9, 25], ["Staphylococcus aureus", "SPECIES", 30, 51], ["Escherichia coli", "PROBLEM", 9, 25], ["Staphylococcus aureus", "PROBLEM", 30, 51], ["NCT and NCT plus ammonium chloride", "TREATMENT", 70, 104], ["Escherichia coli", "OBSERVATION", 9, 25], ["Staphylococcus aureus", "OBSERVATION", 30, 51]]], ["To find out protein changes, 2D-PAGE of bacterial proteins followed by mass spectrometry was performed.", [["bacterial proteins", "PROTEIN", 40, 58], ["protein changes", "PROBLEM", 12, 27], ["bacterial proteins", "PROBLEM", 40, 58], ["mass spectrometry", "TEST", 71, 88]]], ["Results: Incubation in 1% NCT revealed a change of the charge and a separation of numerous proteins into a series of spots with a different isoelectric point.", [["NCT", "SIMPLE_CHEMICAL", 26, 29], ["Incubation", "TEST", 9, 19], ["a change of the charge", "PROBLEM", 39, 61]]], ["Moreover, in E. coli heat shock protein 60 appeared, while ribosome releasing factor, D-ribose periplasmic binding protein, and malonyl-CoA transacylase spots decreased.", [["D-ribose", "CHEMICAL", 86, 94], ["malonyl-CoA", "CHEMICAL", 128, 139], ["ribose", "CHEMICAL", 88, 94], ["malonyl-CoA", "CHEMICAL", 128, 139], ["E. coli", "ORGANISM", 13, 20], ["heat shock protein 60", "GENE_OR_GENE_PRODUCT", 21, 42], ["ribosome releasing factor", "GENE_OR_GENE_PRODUCT", 59, 84], ["D-ribose periplasmic binding protein", "GENE_OR_GENE_PRODUCT", 86, 122], ["malonyl-CoA transacylase", "SIMPLE_CHEMICAL", 128, 152], ["E. coli heat shock protein 60", "PROTEIN", 13, 42], ["ribosome releasing factor, D-ribose periplasmic binding protein", "PROTEIN", 59, 122], ["malonyl-CoA transacylase spots", "PROTEIN", 128, 158], ["E. coli", "SPECIES", 13, 20], ["E. coli", "SPECIES", 13, 20], ["E. coli heat shock protein", "TEST", 13, 39], ["ribosome releasing factor", "TEST", 59, 84], ["D-ribose periplasmic binding protein", "TEST", 86, 122], ["malonyl-CoA transacylase spots", "TEST", 128, 158], ["decreased", "OBSERVATION_MODIFIER", 159, 168]]], ["In S. aureus, enolase and a translation elongation factor decreased.", [["S. aureus", "ORGANISM", 3, 12], ["enolase", "GENE_OR_GENE_PRODUCT", 14, 21], ["enolase", "PROTEIN", 14, 21], ["translation elongation factor", "PROTEIN", 28, 57], ["S. aureus", "SPECIES", 3, 12], ["S. aureus", "SPECIES", 3, 12], ["S. aureus", "PROBLEM", 3, 12], ["enolase", "PROBLEM", 14, 21], ["a translation elongation factor", "PROBLEM", 26, 57], ["aureus", "OBSERVATION", 6, 12], ["elongation", "OBSERVATION_MODIFIER", 40, 50], ["decreased", "OBSERVATION_MODIFIER", 58, 67]]], ["These changes appeared more rapidly in the presence of ammonium chloride, which can be explained by formation of the more lipophilic and microbicidal monochloramine.", [["ammonium chloride", "CHEMICAL", 55, 72], ["monochloramine", "CHEMICAL", 150, 164], ["ammonium chloride", "CHEMICAL", 55, 72], ["monochloramine", "CHEMICAL", 150, 164], ["ammonium chloride", "SIMPLE_CHEMICAL", 55, 72], ["lipophilic", "SIMPLE_CHEMICAL", 122, 132], ["monochloramine", "SIMPLE_CHEMICAL", 150, 164], ["ammonium chloride", "PROBLEM", 55, 72], ["microbicidal monochloramine", "TREATMENT", 137, 164], ["more", "OBSERVATION_MODIFIER", 23, 27], ["rapidly", "OBSERVATION_MODIFIER", 28, 35]]], ["Molecular mechanisms of attack comprised mainly oxidation of thio and amino groups as confirmed with model peptides.", [["thio and amino", "CHEMICAL", 61, 75], ["thio", "CHEMICAL", 61, 65], ["amino", "CHEMICAL", 70, 75], ["thio", "SIMPLE_CHEMICAL", 61, 65], ["amino", "AMINO_ACID", 70, 75], ["Molecular mechanisms of attack", "PROBLEM", 0, 30], ["thio and amino groups", "TREATMENT", 61, 82]]], ["They indicate both surface attack and penetration of oxidation capacity into the bacteria and destruction of essential proteins by NCT and NCT plus ammonium chloride, respectively.", [["surface", "ANATOMY", 19, 26], ["ammonium chloride", "CHEMICAL", 148, 165], ["ammonium chloride", "CHEMICAL", 148, 165], ["NCT", "SIMPLE_CHEMICAL", 131, 134], ["NCT", "SIMPLE_CHEMICAL", 139, 142], ["ammonium chloride", "SIMPLE_CHEMICAL", 148, 165], ["essential proteins", "PROTEIN", 109, 127], ["NCT", "PROTEIN", 131, 134], ["NCT", "PROTEIN", 139, 142], ["both surface attack", "PROBLEM", 14, 33], ["penetration of oxidation capacity", "PROBLEM", 38, 71], ["the bacteria", "PROBLEM", 77, 89], ["destruction of essential proteins", "PROBLEM", 94, 127], ["NCT plus ammonium chloride", "TREATMENT", 139, 165], ["both", "OBSERVATION_MODIFIER", 14, 18], ["surface", "OBSERVATION_MODIFIER", 19, 26]]], ["Objectives: Ceftobiprole is a new extended-spectrum cephalosporin with activity against methicillin-susceptible and methicillin-resistant Staphylococci, as well as against most Enterobacteriaceae.", [["Ceftobiprole", "CHEMICAL", 12, 24], ["cephalosporin", "CHEMICAL", 52, 65], ["methicillin", "CHEMICAL", 88, 99], ["methicillin", "CHEMICAL", 116, 127], ["Staphylococci", "DISEASE", 138, 151], ["Ceftobiprole", "CHEMICAL", 12, 24], ["cephalosporin", "CHEMICAL", 52, 65], ["methicillin", "CHEMICAL", 88, 99], ["methicillin", "CHEMICAL", 116, 127], ["Ceftobiprole", "SIMPLE_CHEMICAL", 12, 24], ["cephalosporin", "SIMPLE_CHEMICAL", 52, 65], ["methicillin", "SIMPLE_CHEMICAL", 88, 99], ["methicillin", "SIMPLE_CHEMICAL", 116, 127], ["Ceftobiprole", "TREATMENT", 12, 24], ["a new extended-spectrum cephalosporin", "TREATMENT", 28, 65], ["methicillin", "PROBLEM", 88, 99], ["methicillin-resistant Staphylococci", "PROBLEM", 116, 151], ["most Enterobacteriaceae", "PROBLEM", 172, 195]]], ["In this study the anti-staphylococcal activity of ceftobiprole is reported from a set of isolates from a recent clinical trial.", [["ceftobiprole", "CHEMICAL", 50, 62], ["ceftobiprole", "CHEMICAL", 50, 62], ["ceftobiprole", "SIMPLE_CHEMICAL", 50, 62], ["this study", "TEST", 3, 13], ["ceftobiprole", "TREATMENT", 50, 62], ["anti-staphylococcal activity", "OBSERVATION", 18, 46]]], ["Methods: Consecutive clinical isolates of Staphylococci from 340 patients enrolled in a multicentre clinical trial involving complicated skin infections were examined for their susceptibility to ceftobiprole and selected anti-Gram-positive agents.", [["skin", "ANATOMY", 137, 141], ["skin infections", "DISEASE", 137, 152], ["ceftobiprole", "CHEMICAL", 195, 207], ["ceftobiprole", "CHEMICAL", 195, 207], ["Staphylococci", "CANCER", 42, 55], ["patients", "ORGANISM", 65, 73], ["skin", "ORGAN", 137, 141], ["ceftobiprole", "SIMPLE_CHEMICAL", 195, 207], ["patients", "SPECIES", 65, 73], ["Staphylococci", "PROBLEM", 42, 55], ["a multicentre clinical trial", "TREATMENT", 86, 114], ["complicated skin infections", "PROBLEM", 125, 152], ["ceftobiprole", "TREATMENT", 195, 207], ["selected anti-Gram-positive agents", "TREATMENT", 212, 246], ["skin", "ANATOMY", 137, 141], ["infections", "OBSERVATION", 142, 152]]], ["Results: Among these isolates, 525 Staphylococcus aureus and 84 coagulase-negative Staphylococci (CoNS) were identified.", [["Staphylococcus aureus", "DISEASE", 35, 56], ["Staphylococcus aureus", "ORGANISM", 35, 56], ["coagulase-negative Staphylococci", "GENE_OR_GENE_PRODUCT", 64, 96], ["CoNS", "CANCER", 98, 102], ["Staphylococcus aureus", "SPECIES", 35, 56], ["Staphylococcus aureus", "SPECIES", 35, 56], ["these isolates", "TEST", 15, 29], ["Staphylococcus aureus", "TEST", 35, 56], ["coagulase", "TEST", 64, 73], ["Staphylococci", "PROBLEM", 83, 96]]], ["The percentages of methicillin-resistant strains were 43% for S. aureus and 50% for CoNS.", [["methicillin", "CHEMICAL", 19, 30], ["S. aureus", "DISEASE", 62, 71], ["CoNS", "DISEASE", 84, 88], ["methicillin", "CHEMICAL", 19, 30], ["methicillin", "SIMPLE_CHEMICAL", 19, 30], ["S. aureus", "ORGANISM", 62, 71], ["S. aureus", "SPECIES", 62, 71], ["S. aureus", "SPECIES", 62, 71], ["methicillin-resistant strains", "TREATMENT", 19, 48], ["S. aureus", "PROBLEM", 62, 71], ["CoNS", "PROBLEM", 84, 88]]], ["All strains (except one CoNS with a linezolid MIC of 8 mg/L) were susceptible to vancomycin and linezolid, with MICs <2 mg/L.Against methicillin-susceptible S. aureus, ceftobiprole MIC50 and MIC90 values were 0.25 and 0.5 mg/L, respectively, and against methicillin-resistant S. aureus, ceftobiprole MIC50 and MIC90 values were 0.5 and 2 mg/L, respectively.", [["linezolid", "CHEMICAL", 36, 45], ["vancomycin", "CHEMICAL", 81, 91], ["linezolid", "CHEMICAL", 96, 105], ["MICs", "CHEMICAL", 112, 116], ["methicillin", "CHEMICAL", 133, 144], ["ceftobiprole", "CHEMICAL", 168, 180], ["MIC50", "CHEMICAL", 181, 186], ["MIC90", "CHEMICAL", 191, 196], ["methicillin", "CHEMICAL", 254, 265], ["ceftobiprole", "CHEMICAL", 287, 299], ["MIC50", "CHEMICAL", 300, 305], ["MIC90", "CHEMICAL", 310, 315], ["linezolid", "CHEMICAL", 36, 45], ["vancomycin", "CHEMICAL", 81, 91], ["linezolid", "CHEMICAL", 96, 105], ["methicillin", "CHEMICAL", 133, 144], ["ceftobiprole", "CHEMICAL", 168, 180], ["methicillin", "CHEMICAL", 254, 265], ["linezolid", "SIMPLE_CHEMICAL", 36, 45], ["vancomycin", "SIMPLE_CHEMICAL", 81, 91], ["linezolid", "SIMPLE_CHEMICAL", 96, 105], ["methicillin", "SIMPLE_CHEMICAL", 133, 144], ["S. aureus", "ORGANISM", 157, 166], ["ceftobiprole MIC50", "SIMPLE_CHEMICAL", 168, 186], ["MIC90", "SIMPLE_CHEMICAL", 191, 196], ["methicillin", "SIMPLE_CHEMICAL", 254, 265], ["S. aureus", "ORGANISM", 276, 285], ["ceftobiprole MIC50", "SIMPLE_CHEMICAL", 287, 305], ["MIC90", "SIMPLE_CHEMICAL", 310, 315], ["S. aureus", "SPECIES", 157, 166], ["S. aureus", "SPECIES", 276, 285], ["S. aureus", "SPECIES", 157, 166], ["S. aureus", "SPECIES", 276, 285], ["All strains", "PROBLEM", 0, 11], ["a linezolid MIC", "TREATMENT", 34, 49], ["vancomycin", "TREATMENT", 81, 91], ["linezolid", "TREATMENT", 96, 105], ["MICs", "TREATMENT", 112, 116], ["methicillin-susceptible S. aureus", "PROBLEM", 133, 166], ["ceftobiprole MIC50", "TREATMENT", 168, 186], ["MIC90 values", "TEST", 191, 203], ["methicillin", "TEST", 254, 265], ["resistant S. aureus", "PROBLEM", 266, 285], ["ceftobiprole MIC50", "TREATMENT", 287, 305], ["MIC90 values", "TEST", 310, 322], ["aureus", "OBSERVATION", 160, 166], ["aureus", "OBSERVATION", 279, 285]]], ["Ceftobiprole MICs ranged from \u00a30.06 to 1 mg/L against methicillin-susceptible-CoNS (MS-CoNS) and Methods: Consecutive, non-duplicate bacterial isolates (10,068 strains) acquired from patients with bloodstream, respiratory, and skin and skin structure infections both nosocomial and community acquired were submitted from >70 medical centres in Europe, the Americas and the Asia-Pacific region.", [["strains", "ANATOMY", 160, 167], ["bloodstream", "ANATOMY", 197, 208], ["respiratory", "ANATOMY", 210, 221], ["skin", "ANATOMY", 227, 231], ["skin structure", "ANATOMY", 236, 250], ["Ceftobiprole", "CHEMICAL", 0, 12], ["methicillin", "CHEMICAL", 54, 65], ["bloodstream, respiratory, and skin and skin structure infections", "DISEASE", 197, 261], ["Ceftobiprole", "CHEMICAL", 0, 12], ["methicillin", "CHEMICAL", 54, 65], ["Ceftobiprole", "SIMPLE_CHEMICAL", 0, 12], ["methicillin", "SIMPLE_CHEMICAL", 54, 65], ["patients", "ORGANISM", 183, 191], ["skin", "ORGAN", 227, 231], ["skin", "ORGAN", 236, 240], ["patients", "SPECIES", 183, 191], ["Ceftobiprole MICs", "TREATMENT", 0, 17], ["methicillin", "TREATMENT", 54, 65], ["non-duplicate bacterial isolates", "PROBLEM", 119, 151], ["bloodstream", "PROBLEM", 197, 208], ["respiratory, and skin and skin structure infections", "PROBLEM", 210, 261], ["respiratory", "ANATOMY", 210, 221], ["skin", "ANATOMY", 227, 231], ["skin", "ANATOMY", 236, 240]]], ["All isolates were tested using CLSI/NCCLS broth microdilution methods against GRN, the currently marketed fluoroquinolones (FQ) including CIPRO, levofloxacin (LEVO), gatifloxacin (GATI) and representative comparator agents.", [["fluoroquinolones", "CHEMICAL", 106, 122], ["FQ", "CHEMICAL", 124, 126], ["CIPRO", "CHEMICAL", 138, 143], ["levofloxacin", "CHEMICAL", 145, 157], ["LEVO", "CHEMICAL", 159, 163], ["gatifloxacin", "CHEMICAL", 166, 178], ["GATI", "CHEMICAL", 180, 184], ["fluoroquinolones", "CHEMICAL", 106, 122], ["CIPRO", "CHEMICAL", 138, 143], ["levofloxacin", "CHEMICAL", 145, 157], ["LEVO", "CHEMICAL", 159, 163], ["gatifloxacin", "CHEMICAL", 166, 178], ["GATI", "CHEMICAL", 180, 184], ["fluoroquinolones", "SIMPLE_CHEMICAL", 106, 122], ["FQ", "SIMPLE_CHEMICAL", 124, 126], ["CIPRO", "SIMPLE_CHEMICAL", 138, 143], ["levofloxacin", "SIMPLE_CHEMICAL", 145, 157], ["LEVO", "SIMPLE_CHEMICAL", 159, 163], ["gatifloxacin", "SIMPLE_CHEMICAL", 166, 178], ["GATI", "SIMPLE_CHEMICAL", 180, 184], ["All isolates", "TREATMENT", 0, 12], ["CLSI/NCCLS broth microdilution methods", "TREATMENT", 31, 69], ["GRN", "PROBLEM", 78, 81], ["fluoroquinolones (FQ", "TREATMENT", 106, 126], ["CIPRO", "TREATMENT", 138, 143], ["levofloxacin", "TREATMENT", 145, 157], ["LEVO", "TREATMENT", 159, 163], ["gatifloxacin (GATI)", "TREATMENT", 166, 185], ["representative comparator agents", "TREATMENT", 190, 222]]], ["OXA-and CIPRO-S and -R subsets were included.", [["OXA", "CHEMICAL", 0, 3], ["OXA", "GENE_OR_GENE_PRODUCT", 0, 3], ["CIPRO-S", "GENE_OR_GENE_PRODUCT", 8, 15], ["-R", "GENE_OR_GENE_PRODUCT", 20, 22], ["OXA-and CIPRO-S and -R subsets", "CELL_LINE", 0, 30], ["OXA", "TEST", 0, 3], ["CIPRO", "TREATMENT", 8, 13], ["S and -R subsets", "TREATMENT", 14, 30]]], ["A GRN-S breakpoint of \u00a30.12 mg/L was applied for comparative purposes only and was based upon the MIC population distributions of strains that included quinoloneresistance determining region (QRDR) mutations.", [["quinoloneresistance", "CHEMICAL", 152, 171], ["quinoloneresistance", "CHEMICAL", 152, 171], ["GRN", "DNA", 2, 5], ["quinoloneresistance determining region", "PROTEIN", 152, 190], ["A GRN-S breakpoint of \u00a3", "TREATMENT", 0, 23], ["comparative purposes", "TEST", 49, 69], ["strains", "PROBLEM", 130, 137]]], ["Results: Potency for GRN and comparator FQs tested against SA: (See Table) .", [["GRN and comparator FQs", "TEST", 21, 43]]], ["Key resistance patterns (%) among this SA collection included OXA (40.3), CIPRO (36.4), erythromycin (47.5), clindamycin (13.4), tetracycline (9.7), and trimethoprim/ sulfamethoxazole (4.8%); Gram-positive-targeted comparator including vancomycin, linezolid, daptomycin and quinupristin/dalfopristin all remained >99% S. Compared with currently marketed FQs when tested against all SA, GRN was 2-to 16-fold more active (MIC50, \u00a30.03 vs. 0.06 or 0.5 mg/ L).", [["OXA", "CHEMICAL", 62, 65], ["CIPRO", "CHEMICAL", 74, 79], ["erythromycin", "CHEMICAL", 88, 100], ["clindamycin", "CHEMICAL", 109, 120], ["tetracycline", "CHEMICAL", 129, 141], ["trimethoprim/ sulfamethoxazole", "CHEMICAL", 153, 183], ["vancomycin", "CHEMICAL", 236, 246], ["linezolid", "CHEMICAL", 248, 257], ["daptomycin", "CHEMICAL", 259, 269], ["quinupristin", "CHEMICAL", 274, 286], ["dalfopristin", "CHEMICAL", 287, 299], ["SA", "CHEMICAL", 382, 384], ["OXA", "CHEMICAL", 62, 65], ["CIPRO", "CHEMICAL", 74, 79], ["erythromycin", "CHEMICAL", 88, 100], ["clindamycin", "CHEMICAL", 109, 120], ["tetracycline", "CHEMICAL", 129, 141], ["trimethoprim", "CHEMICAL", 153, 165], ["sulfamethoxazole", "CHEMICAL", 167, 183], ["vancomycin", "CHEMICAL", 236, 246], ["linezolid", "CHEMICAL", 248, 257], ["daptomycin", "CHEMICAL", 259, 269], ["quinupristin", "CHEMICAL", 274, 286], ["dalfopristin", "CHEMICAL", 287, 299], ["OXA", "SIMPLE_CHEMICAL", 62, 65], ["CIPRO", "SIMPLE_CHEMICAL", 74, 79], ["erythromycin", "SIMPLE_CHEMICAL", 88, 100], ["clindamycin", "SIMPLE_CHEMICAL", 109, 120], ["tetracycline", "SIMPLE_CHEMICAL", 129, 141], ["trimethoprim/ sulfamethoxazole", "SIMPLE_CHEMICAL", 153, 183], ["vancomycin", "SIMPLE_CHEMICAL", 236, 246], ["linezolid", "SIMPLE_CHEMICAL", 248, 257], ["daptomycin", "SIMPLE_CHEMICAL", 259, 269], ["quinupristin", "SIMPLE_CHEMICAL", 274, 286], ["dalfopristin", "SIMPLE_CHEMICAL", 287, 299], ["FQs", "SIMPLE_CHEMICAL", 354, 357], ["Key resistance patterns", "PROBLEM", 0, 23], ["this SA collection", "PROBLEM", 34, 52], ["OXA", "TEST", 62, 65], ["CIPRO", "TREATMENT", 74, 79], ["erythromycin", "TREATMENT", 88, 100], ["clindamycin", "TREATMENT", 109, 120], ["tetracycline", "TREATMENT", 129, 141], ["trimethoprim", "TREATMENT", 153, 165], ["sulfamethoxazole", "TREATMENT", 167, 183], ["Gram-positive", "PROBLEM", 192, 205], ["vancomycin", "TREATMENT", 236, 246], ["linezolid", "TREATMENT", 248, 257], ["daptomycin", "TREATMENT", 259, 269], ["quinupristin", "TREATMENT", 274, 286], ["dalfopristin", "TREATMENT", 287, 299], ["all SA", "TEST", 378, 384], ["GRN", "TEST", 386, 389], ["MIC50", "TEST", 420, 425]]], ["Against both OXA-S and -R SA, GRN displayed markedly enhanced potency compared with CIPRO and LEVO ( \u20214-fold), and GATI (2-to 4-fold).", [["OXA", "CHEMICAL", 13, 16], ["CIPRO", "CHEMICAL", 84, 89], ["OXA-S", "SIMPLE_CHEMICAL", 13, 18], ["-R SA", "SIMPLE_CHEMICAL", 23, 28], ["CIPRO", "SIMPLE_CHEMICAL", 84, 89], ["LEVO", "SIMPLE_CHEMICAL", 94, 98], ["GATI", "GENE_OR_GENE_PRODUCT", 115, 119], ["GRN", "DNA", 30, 33], ["CIPRO", "PROTEIN", 84, 89], ["LEVO", "PROTEIN", 94, 98], ["\u20214", "PROTEIN", 101, 103], ["GATI", "PROTEIN", 115, 119], ["both OXA", "TEST", 8, 16], ["markedly enhanced potency", "PROBLEM", 44, 69], ["CIPRO", "TREATMENT", 84, 89], ["LEVO", "TREATMENT", 94, 98], ["GATI", "TEST", 115, 119]]], ["Among CIPRO-R isolates, GRN also maintained \u20214-fold greater potency (MIC50, 1 vs. \u20214 mg/L) although overall S for all FQs was 0-1%.Conclusions:Compared to the FQ agents tested against SA, GRN was the most potent agent and maintained the broadest coverage against OXA-and CIPRO-R strains even when applying a very conservative epidemiologic breakpoint.", [["FQ", "CHEMICAL", 159, 161], ["SA", "CHEMICAL", 184, 186], ["OXA", "CHEMICAL", 263, 266], ["CIPRO-R", "GENE_OR_GENE_PRODUCT", 6, 13], ["SA", "SIMPLE_CHEMICAL", 184, 186], ["OXA", "SIMPLE_CHEMICAL", 263, 266], ["CIPRO-R", "GENE_OR_GENE_PRODUCT", 271, 278], ["CIPRO", "TREATMENT", 6, 11], ["R isolates", "TREATMENT", 12, 22], ["overall S", "TEST", 100, 109], ["all FQs", "TEST", 114, 121], ["the FQ agents", "TEST", 155, 168], ["SA", "PROBLEM", 184, 186], ["OXA", "PROBLEM", 263, 266], ["CIPRO", "TREATMENT", 271, 276], ["R strains", "PROBLEM", 277, 286], ["most potent", "OBSERVATION_MODIFIER", 200, 211]]], ["When a FQ is indicated for staphylococcal coverage, this des-F(6) quinolone may represent a superior alternative among FQ class agents, while minimizing selection of resistance.", [["FQ", "CHEMICAL", 7, 9], ["des-F(6) quinolone", "CHEMICAL", 57, 75], ["quinolone", "CHEMICAL", 66, 75], ["des-F(6) quinolone", "SIMPLE_CHEMICAL", 57, 75], ["staphylococcal coverage", "TREATMENT", 27, 50], ["quinolone", "TREATMENT", 66, 75], ["a superior alternative among FQ class agents", "TREATMENT", 90, 134], ["resistance", "PROBLEM", 166, 176]]], ["Objective: To assess the garenoxacin (GRN) potency against a vast number of international respiratory tract infection (RTI) pathogens, especially versus phenotypic (high MIC) or genotypic (sequence change) QRDR mutants.", [["garenoxacin", "CHEMICAL", 25, 36], ["respiratory tract infection", "DISEASE", 90, 117], ["RTI", "DISEASE", 119, 122], ["garenoxacin", "CHEMICAL", 25, 36], ["garenoxacin", "SIMPLE_CHEMICAL", 25, 36], ["tract", "ORGANISM_SUBDIVISION", 102, 107], ["QRDR", "GENE_OR_GENE_PRODUCT", 206, 210], ["QRDR mutants", "PROTEIN", 206, 218], ["the garenoxacin (GRN)", "TREATMENT", 21, 42], ["international respiratory tract infection", "PROBLEM", 76, 117], ["RTI) pathogens", "PROBLEM", 119, 133], ["phenotypic (high MIC)", "PROBLEM", 153, 174], ["genotypic (sequence change", "PROBLEM", 178, 204], ["QRDR mutants", "PROBLEM", 206, 218], ["respiratory tract", "ANATOMY", 90, 107]]], ["A total of 40,423 isolates from 6 continents were analysed (1999) (2000) (2001) (2002) (2003) (2004) (2005) Table) Conclusions: GRN maintains clinically usable activity (MIC, \u00a31 mg/L) against important community-acquired RTI pathogens having R to presently marketed fluoroquinolones and against those isolates with documented QRDR mutations.", [["RTI", "DISEASE", 221, 224], ["fluoroquinolones", "CHEMICAL", 266, 282], ["fluoroquinolones", "CHEMICAL", 266, 282], ["fluoroquinolones", "SIMPLE_CHEMICAL", 266, 282], ["QRDR", "GENE_OR_GENE_PRODUCT", 326, 330], ["acquired RTI pathogens", "PROBLEM", 212, 234], ["fluoroquinolones", "TREATMENT", 266, 282], ["those isolates", "TREATMENT", 295, 309], ["documented QRDR mutations", "PROBLEM", 315, 340]]], ["Continued development of this novel des-F(6) quinolone agent appears desirable.P1574In vitro activity of garenoxacin tested against ciprofloxacin-susceptible and -resistant Enterobacteriaceae and Acinetobacter spp. strains collected worldwide by the SENTRY Antimicrobial Surveillance Program (2004) (2005) H. Sader, T. Fritsche, P. Strabala, R. Jones (North Liberty, US)P1574Objective: To evaluate the contemporary activity of garenoxacin (GRN) against ciprofloxacin (CIPRO)-susceptible (S) and CIPRO-resistant (R) Enterobacteriaceae (ENT) and Acinetobacter spp.", [["des-F(6) quinolone", "CHEMICAL", 36, 54], ["garenoxacin", "CHEMICAL", 105, 116], ["ciprofloxacin", "CHEMICAL", 132, 145], ["Enterobacteriaceae", "CHEMICAL", 173, 191], ["garenoxacin", "CHEMICAL", 427, 438], ["ciprofloxacin", "CHEMICAL", 453, 466], ["CIPRO", "CHEMICAL", 468, 473], ["CIPRO", "CHEMICAL", 495, 500], ["des-F(6) quinolone", "CHEMICAL", 36, 54], ["garenoxacin", "CHEMICAL", 105, 116], ["ciprofloxacin", "CHEMICAL", 132, 145], ["garenoxacin", "CHEMICAL", 427, 438], ["ciprofloxacin", "CHEMICAL", 453, 466], ["CIPRO", "CHEMICAL", 468, 473], ["des-F(6) quinolone", "SIMPLE_CHEMICAL", 36, 54], ["garenoxacin", "SIMPLE_CHEMICAL", 105, 116], ["ciprofloxacin", "SIMPLE_CHEMICAL", 132, 145], ["Acinetobacter spp", "ORGANISM", 196, 213], ["garenoxacin", "SIMPLE_CHEMICAL", 427, 438], ["GRN", "SIMPLE_CHEMICAL", 440, 443], ["ciprofloxacin", "SIMPLE_CHEMICAL", 453, 466], ["CIPRO", "SIMPLE_CHEMICAL", 468, 473], ["CIPRO", "SIMPLE_CHEMICAL", 495, 500], ["R) Enterobacteriaceae", "ORGANISM", 512, 533], ["Acinetobacter spp", "ORGANISM", 544, 561], ["Acinetobacter spp", "SPECIES", 196, 213], ["Acinetobacter spp", "SPECIES", 196, 213], ["Acinetobacter spp", "SPECIES", 544, 561], ["this novel des-F(6) quinolone agent", "TREATMENT", 25, 60], ["garenoxacin", "TREATMENT", 105, 116], ["ciprofloxacin", "TREATMENT", 132, 145], ["susceptible", "PROBLEM", 146, 157], ["-resistant Enterobacteriaceae", "PROBLEM", 162, 191], ["Acinetobacter spp", "PROBLEM", 196, 213], ["garenoxacin (GRN)", "TREATMENT", 427, 444], ["ciprofloxacin", "TREATMENT", 453, 466], ["CIPRO", "TREATMENT", 468, 473], ["CIPRO", "TREATMENT", 495, 500], ["Enterobacteriaceae", "PROBLEM", 515, 533], ["Acinetobacter spp", "PROBLEM", 544, 561], ["Acinetobacter spp", "OBSERVATION", 196, 213]]], ["Unlike recently marketed fluoroquinolones (FQ), GRN, a des-F(6) quinolone lacks the C-6 fluorine.P1574Methods: A total of 9,017 isolates (8,247 ENT and 770 ASP) were consecutively collected from > 70 medical centres from bloodstream, respiratory, urinary and skin and soft tissue infections and tested by reference broth microdilution methods according to CLSI/NCCLS methods and interpretative criteria.", [["bloodstream", "ANATOMY", 221, 232], ["respiratory", "ANATOMY", 234, 245], ["urinary", "ANATOMY", 247, 254], ["skin", "ANATOMY", 259, 263], ["soft tissue", "ANATOMY", 268, 279], ["fluoroquinolones", "CHEMICAL", 25, 41], ["FQ", "CHEMICAL", 43, 45], ["des-F(6) quinolone", "CHEMICAL", 55, 73], ["C-6 fluorine", "CHEMICAL", 84, 96], ["respiratory, urinary and skin and soft tissue infections", "DISEASE", 234, 290], ["fluoroquinolones", "CHEMICAL", 25, 41], ["des-F(6) quinolone", "CHEMICAL", 55, 73], ["fluorine", "CHEMICAL", 88, 96], ["fluoroquinolones", "SIMPLE_CHEMICAL", 25, 41], ["FQ", "SIMPLE_CHEMICAL", 43, 45], ["des-F(6) quinolone", "SIMPLE_CHEMICAL", 55, 73], ["C-6 fluorine", "SIMPLE_CHEMICAL", 84, 96], ["urinary", "ORGANISM_SUBDIVISION", 247, 254], ["skin", "ORGAN", 259, 263], ["soft tissue", "TISSUE", 268, 279], ["fluoroquinolones (FQ)", "TREATMENT", 25, 46], ["quinolone", "TREATMENT", 64, 73], ["the C-6 fluorine", "TREATMENT", 80, 96], ["ASP", "TEST", 156, 159], ["respiratory, urinary and skin and soft tissue infections", "PROBLEM", 234, 290], ["respiratory", "ANATOMY", 234, 245], ["urinary", "ANATOMY", 247, 254], ["skin", "ANATOMY", 259, 263], ["soft tissue", "ANATOMY", 268, 279], ["infections", "OBSERVATION", 280, 290]]], ["A GRN S breakpoint of \u00a31 mg/L was applied for comparison purposes only.P1574Results: The results of the major organism groups tested: (See table) .", [["GRN S breakpoint", "DNA", 2, 18], ["A GRN S breakpoint", "TREATMENT", 0, 18], ["comparison purposes", "TEST", 46, 65]]], ["GRN showed excellent activity against this large collection of ENT (MIC50, 0.12 mg/L) and 82.7% of isolates were inhibited at \u00a31 mg/L. Objectives: Garenoxacin (GRN) is a novel, broad-spectrum des-F(6)-quinolone with activity against Gram-negative and Grampositive aerobes and anaerobes including quinolone-resistant Staphylococcus aureus.", [["MIC50", "CHEMICAL", 68, 73], ["Garenoxacin", "CHEMICAL", 147, 158], ["des-F(6)-quinolone", "CHEMICAL", 192, 210], ["quinolone", "CHEMICAL", 296, 305], ["Staphylococcus aureus", "DISEASE", 316, 337], ["Garenoxacin", "CHEMICAL", 147, 158], ["des-F(6)-quinolone", "CHEMICAL", 192, 210], ["quinolone", "CHEMICAL", 296, 305], ["Garenoxacin", "SIMPLE_CHEMICAL", 147, 158], ["GRN", "SIMPLE_CHEMICAL", 160, 163], ["des-F(6)-quinolone", "SIMPLE_CHEMICAL", 192, 210], ["Gram", "SIMPLE_CHEMICAL", 233, 237], ["Grampositive aerobes", "SIMPLE_CHEMICAL", 251, 271], ["quinolone-resistant", "SIMPLE_CHEMICAL", 296, 315], ["Staphylococcus aureus", "ORGANISM", 316, 337], ["GRN", "DNA", 0, 3], ["Staphylococcus aureus", "SPECIES", 316, 337], ["Staphylococcus aureus", "SPECIES", 316, 337], ["ENT (MIC50", "TREATMENT", 63, 73], ["isolates", "TREATMENT", 99, 107], ["Garenoxacin (GRN)", "TREATMENT", 147, 164], ["broad-spectrum des", "TREATMENT", 177, 195], ["quinolone", "TREATMENT", 201, 210], ["Gram", "TEST", 233, 237], ["Grampositive aerobes", "PROBLEM", 251, 271], ["anaerobes", "PROBLEM", 276, 285], ["quinolone", "TREATMENT", 296, 305], ["resistant Staphylococcus aureus", "PROBLEM", 306, 337], ["excellent activity", "OBSERVATION", 11, 29], ["Staphylococcus aureus", "OBSERVATION", 316, 337]]], ["The objective of this analysis was to compare the microbiologic efficacy of GRN to that of comparators against common pathogens involved in complicated skin and skin structure infections (cSSSI).", [["skin", "ANATOMY", 152, 156], ["skin", "ANATOMY", 161, 165], ["skin and skin structure infections", "DISEASE", 152, 186], ["skin", "ORGAN", 152, 156], ["skin", "ORGAN", 161, 165], ["this analysis", "TEST", 17, 30], ["common pathogens", "PROBLEM", 111, 127], ["complicated skin and skin structure infections", "PROBLEM", 140, 186], ["complicated", "OBSERVATION_MODIFIER", 140, 151], ["skin", "ANATOMY", 152, 156], ["skin", "ANATOMY", 161, 165], ["structure", "OBSERVATION_MODIFIER", 166, 175], ["infections", "OBSERVATION", 176, 186]]], ["Methods: Two multinational, double-blind, randomized studies were conducted.", [["randomized studies", "TEST", 42, 60]]], ["In the first study, subjects received GRN (600 mg IV to PO qd) or piperacillin/tazobactam (3.375 g IV q6h) with transition to PO amoxicillin/clavulanate (500 mg PO q8h).", [["piperacillin/tazobactam", "CHEMICAL", 66, 89], ["PO amoxicillin/clavulanate", "CHEMICAL", 126, 152], ["piperacillin", "CHEMICAL", 66, 78], ["tazobactam", "CHEMICAL", 79, 89], ["amoxicillin", "CHEMICAL", 129, 140], ["clavulanate", "CHEMICAL", 141, 152], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 66, 89], ["PO", "SIMPLE_CHEMICAL", 126, 128], ["amoxicillin", "SIMPLE_CHEMICAL", 129, 140], ["clavulanate", "SIMPLE_CHEMICAL", 141, 152], ["GRN", "TREATMENT", 38, 41], ["piperacillin", "TREATMENT", 66, 78], ["tazobactam", "TREATMENT", 79, 89], ["PO amoxicillin", "TREATMENT", 126, 140], ["clavulanate", "TREATMENT", 141, 152]]], ["In the second study, subjects received GRN (600 mg PO qd) or ciprofloxacin/metronidazole (500 mg q12h/500 mg q8h).", [["ciprofloxacin", "CHEMICAL", 61, 74], ["metronidazole", "CHEMICAL", 75, 88], ["ciprofloxacin", "CHEMICAL", 61, 74], ["metronidazole", "CHEMICAL", 75, 88], ["ciprofloxacin", "SIMPLE_CHEMICAL", 61, 74], ["metronidazole", "SIMPLE_CHEMICAL", 75, 88], ["the second study", "TEST", 3, 19], ["GRN (", "TREATMENT", 39, 44], ["ciprofloxacin", "TREATMENT", 61, 74], ["metronidazole", "TREATMENT", 75, 88]]], ["All antimicrobials were administered for 7 to 14 days.", [["All antimicrobials", "TREATMENT", 0, 18]]], ["Subjects were adults ( \u202118 y) newly hospitalized or ambulatory outpatients with evidence of cSSSI who did not have underlying osteomyelitis.", [["cSSSI", "DISEASE", 92, 97], ["osteomyelitis", "DISEASE", 126, 139], ["Subjects", "ORGANISM", 0, 8], ["outpatients", "ORGANISM", 63, 74], ["underlying osteomyelitis", "PROBLEM", 115, 139], ["osteomyelitis", "OBSERVATION", 126, 139]]], ["Microbiologic efficacy was determined 5 to18 days post-therapy.P1574Results: A total of 567 subjects were microbiologically evaluable (GRN, n = 283; comparators, n = 284).", [["subjects", "ORGANISM", 92, 100], ["Microbiologic efficacy", "TEST", 0, 22], ["therapy", "TREATMENT", 55, 62], ["GRN", "TEST", 135, 138], ["comparators", "TEST", 149, 160]]], ["The disease diagnosis was similar between GRN and comparators and included infected pressure sore (5% vs 3%), infected diabetic foot ulcer (18% vs 19%), major abscess (66% vs 67%), or postsurgical wound infection (11% vs 12%).", [["foot", "ANATOMY", 128, 132], ["abscess", "ANATOMY", 159, 166], ["wound", "ANATOMY", 197, 202], ["infected pressure sore", "DISEASE", 75, 97], ["infected diabetic foot ulcer", "DISEASE", 110, 138], ["abscess", "DISEASE", 159, 166], ["wound infection", "DISEASE", 197, 212], ["foot", "ORGANISM_SUBDIVISION", 128, 132], ["abscess", "PATHOLOGICAL_FORMATION", 159, 166], ["wound", "PATHOLOGICAL_FORMATION", 197, 202], ["The disease diagnosis", "PROBLEM", 0, 21], ["infected pressure sore", "PROBLEM", 75, 97], ["infected diabetic foot ulcer", "PROBLEM", 110, 138], ["major abscess", "PROBLEM", 153, 166], ["postsurgical wound infection", "PROBLEM", 184, 212], ["disease", "OBSERVATION", 4, 11], ["infected", "OBSERVATION_MODIFIER", 75, 83], ["pressure", "OBSERVATION_MODIFIER", 84, 92], ["sore", "OBSERVATION", 93, 97], ["infected", "OBSERVATION_MODIFIER", 110, 118], ["diabetic", "OBSERVATION_MODIFIER", 119, 127], ["foot", "ANATOMY", 128, 132], ["ulcer", "OBSERVATION", 133, 138], ["major", "OBSERVATION_MODIFIER", 153, 158], ["abscess", "OBSERVATION", 159, 166], ["postsurgical", "OBSERVATION_MODIFIER", 184, 196], ["wound", "OBSERVATION_MODIFIER", 197, 202], ["infection", "OBSERVATION", 203, 212]]], ["The majority of common skin pathogens were eradicated by GRN Background: Acute bacterial sinusitis (ABS) is a common infection world-wide, with many patients having an associated an allergic component/history.", [["skin", "ANATOMY", 23, 27], ["bacterial sinusitis", "DISEASE", 79, 98], ["ABS", "DISEASE", 100, 103], ["infection", "DISEASE", 117, 126], ["skin", "ORGAN", 23, 27], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["common skin pathogens", "PROBLEM", 16, 37], ["Acute bacterial sinusitis", "PROBLEM", 73, 98], ["a common infection", "PROBLEM", 108, 126], ["an allergic component", "PROBLEM", 179, 200], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["common", "OBSERVATION_MODIFIER", 16, 22], ["skin", "ANATOMY", 23, 27], ["pathogens", "OBSERVATION", 28, 37], ["Acute", "OBSERVATION_MODIFIER", 73, 78], ["bacterial", "OBSERVATION_MODIFIER", 79, 88], ["sinusitis", "OBSERVATION", 89, 98], ["common", "OBSERVATION_MODIFIER", 110, 116], ["infection", "OBSERVATION", 117, 126], ["allergic", "OBSERVATION", 182, 190]]], ["However the role of antibacterials in these patients (pts) has not been examined.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["antibacterials", "TREATMENT", 20, 34]]], ["As some fluoroquinolones (FQ) have an in-vitro immunomodulatory effect (IE) the clinical efficacy of GEM was compared other agents in ABS pts with or without allergic rhinitis (AR).", [["fluoroquinolones", "CHEMICAL", 8, 24], ["FQ", "CHEMICAL", 26, 28], ["GEM", "CHEMICAL", 101, 104], ["allergic rhinitis", "DISEASE", 158, 175], ["fluoroquinolones", "CHEMICAL", 8, 24], ["GEM", "CHEMICAL", 101, 104], ["fluoroquinolones", "SIMPLE_CHEMICAL", 8, 24], ["FQ", "SIMPLE_CHEMICAL", 26, 28], ["GEM", "SIMPLE_CHEMICAL", 101, 104], ["some fluoroquinolones (FQ", "TREATMENT", 3, 28], ["an in-vitro immunomodulatory effect", "TREATMENT", 35, 70], ["GEM", "PROBLEM", 101, 104], ["allergic rhinitis", "PROBLEM", 158, 175], ["rhinitis", "OBSERVATION", 167, 175]]], ["Methods: 5 phase 3 clinical trials were pooled and pts where allergic rhinitis was identified (584 pts) were compared with pts not reporting AR (1834 pts).", [["allergic rhinitis", "DISEASE", 61, 78], ["AR", "PROTEIN", 141, 143], ["allergic rhinitis", "PROBLEM", 61, 78], ["rhinitis", "OBSERVATION", 70, 78]]], ["Clinical response (success or failure) at end of therapy (EOT) & at follow-up (FU, approx.", [["failure)", "PROBLEM", 30, 38], ["therapy (EOT", "TREATMENT", 49, 61]]], ["1-3 weeks after treatment) was studied.", [["treatment", "TREATMENT", 16, 25]]], ["Comparators (CMP) were cefuroxime (CEF) and trovafloxacin (TRO).", [["CMP", "CHEMICAL", 13, 16], ["cefuroxime", "CHEMICAL", 23, 33], ["CEF", "CHEMICAL", 35, 38], ["trovafloxacin", "CHEMICAL", 44, 57], ["TRO", "CHEMICAL", 59, 62], ["cefuroxime", "CHEMICAL", 23, 33], ["CEF", "CHEMICAL", 35, 38], ["trovafloxacin", "CHEMICAL", 44, 57], ["TRO", "CHEMICAL", 59, 62], ["cefuroxime", "SIMPLE_CHEMICAL", 23, 33], ["CEF", "SIMPLE_CHEMICAL", 35, 38], ["trovafloxacin", "SIMPLE_CHEMICAL", 44, 57], ["TRO", "SIMPLE_CHEMICAL", 59, 62], ["Comparators (CMP)", "TREATMENT", 0, 17], ["cefuroxime (CEF)", "TREATMENT", 23, 39], ["trovafloxacin (TRO)", "TREATMENT", 44, 63]]], ["Results: % Success based on clinical outcome at EOT and FU for AR and non AR pts are shown in the table.", [["FU", "CHEMICAL", 56, 58], ["AR", "PROTEIN", 63, 65], ["FU", "TEST", 56, 58], ["AR", "PROBLEM", 63, 65]]], ["For all treatments EOT success was high for the non AR pts, but at FU this was reduced, especially with both FQs.", [["FU", "CHEMICAL", 67, 69], ["all treatments EOT success", "TREATMENT", 4, 30]]], ["In contrast, GEM retained a high clinical success rate in pts with AR unlike CEF or TRO.P1574Conclusion: GEM has been shown to be very efficacious in a sub group of problematic ABS pts.", [["CEF", "ANATOMY", 77, 80], ["GEM", "CHEMICAL", 13, 16], ["TRO", "CHEMICAL", 84, 87], ["P1574Conclusion", "CHEMICAL", 88, 103], ["GEM", "CHEMICAL", 105, 108], ["GEM", "CHEMICAL", 13, 16], ["GEM", "CHEMICAL", 105, 108], ["GEM", "SIMPLE_CHEMICAL", 13, 16], ["CEF", "CELL", 77, 80], ["AR", "PROTEIN", 67, 69], ["high", "OBSERVATION_MODIFIER", 28, 32]]], ["This advantage may be due to the high antibacterial activity of GEM vs key ABS pathogens and/or a stimulatory IE.", [["GEM", "CHEMICAL", 64, 67], ["GEM", "CHEMICAL", 64, 67], ["GEM", "SIMPLE_CHEMICAL", 64, 67], ["the high antibacterial activity of GEM", "PROBLEM", 29, 67], ["key ABS pathogens", "PROBLEM", 71, 88]]], ["Both being important with pts having decreased local immune defences.", [["decreased local immune defences", "PROBLEM", 37, 68], ["local immune defences", "OBSERVATION", 47, 68]]], ["These data also show that not all fluoroquinolones have immuno-stimulatory properties.P1577Garenoxacin efficacy against multidrug-resistant Streptococcus pneumoniae: retrospective analysis of community-acquired pneumoniae isolates obtained from nine phase II and III clinical studies (1999) (2000) (2001) (2002) (2003) T. Black, H. Waskin, R. Hare (Kenilworth, US)P1577Objective: Garenoxacin (GRN) is a novel, des-F(6)-quinolone with excellent activity against S. pneumoniae, one of the most common pathogens causing community-acquired pneumoniae (CAP).", [["fluoroquinolones", "CHEMICAL", 34, 50], ["Garenoxacin", "CHEMICAL", 91, 102], ["Streptococcus pneumoniae", "DISEASE", 140, 164], ["Garenoxacin", "CHEMICAL", 380, 391], ["des-F(6)-quinolone", "CHEMICAL", 410, 428], ["S. pneumoniae", "DISEASE", 461, 474], ["community-acquired pneumoniae", "DISEASE", 517, 546], ["CAP", "DISEASE", 548, 551], ["fluoroquinolones", "CHEMICAL", 34, 50], ["Garenoxacin", "CHEMICAL", 91, 102], ["Garenoxacin", "CHEMICAL", 380, 391], ["des-F(6)-quinolone", "CHEMICAL", 410, 428], ["fluoroquinolones", "SIMPLE_CHEMICAL", 34, 50], ["P1577", "SIMPLE_CHEMICAL", 86, 91], ["multidrug-resistant Streptococcus pneumoniae", "ORGANISM", 120, 164], ["Garenoxacin", "SIMPLE_CHEMICAL", 380, 391], ["des-F(6)-quinolone", "SIMPLE_CHEMICAL", 410, 428], ["S. pneumoniae", "ORGANISM", 461, 474], ["Streptococcus pneumoniae", "SPECIES", 140, 164], ["S. pneumoniae", "SPECIES", 461, 474], ["Streptococcus pneumoniae", "SPECIES", 140, 164], ["S. pneumoniae", "SPECIES", 461, 474], ["These data", "TEST", 0, 10], ["all fluoroquinolones", "TREATMENT", 30, 50], ["immuno-stimulatory properties", "TREATMENT", 56, 85], ["Garenoxacin efficacy", "TREATMENT", 91, 111], ["multidrug-resistant Streptococcus pneumoniae", "PROBLEM", 120, 164], ["retrospective analysis", "TEST", 166, 188], ["community-acquired pneumoniae isolates", "PROBLEM", 192, 230], ["III clinical studies", "TEST", 263, 283], ["Garenoxacin (GRN)", "TREATMENT", 380, 397], ["quinolone", "TREATMENT", 419, 428], ["S. pneumoniae", "PROBLEM", 461, 474], ["community-acquired pneumoniae (CAP)", "PROBLEM", 517, 552], ["Streptococcus pneumoniae", "OBSERVATION", 140, 164], ["pneumoniae", "OBSERVATION", 464, 474], ["pneumoniae", "OBSERVATION", 536, 546]]], ["The incidence of infections caused by antibiotic-resistant isolates of Streptococcus pneumoniae is on the increase, therefore information regarding the activity of new anti-infective drugs against populations of S. pneumoniae that are multi-drug resistant (MDR) is critical.", [["infections", "DISEASE", 17, 27], ["Streptococcus pneumoniae", "DISEASE", 71, 95], ["Streptococcus pneumoniae", "ORGANISM", 71, 95], ["S. pneumoniae", "ORGANISM", 212, 225], ["Streptococcus pneumoniae", "SPECIES", 71, 95], ["S. pneumoniae", "SPECIES", 212, 225], ["Streptococcus pneumoniae", "SPECIES", 71, 95], ["S. pneumoniae", "SPECIES", 212, 225], ["infections", "PROBLEM", 17, 27], ["antibiotic", "TREATMENT", 38, 48], ["Streptococcus pneumoniae", "PROBLEM", 71, 95], ["new anti-infective drugs", "TREATMENT", 164, 188], ["S. pneumoniae", "PROBLEM", 212, 225], ["multi-drug resistant (MDR", "PROBLEM", 235, 260], ["infections", "OBSERVATION", 17, 27], ["Streptococcus pneumoniae", "OBSERVATION", 71, 95], ["pneumoniae", "OBSERVATION", 215, 225]]], ["MDR S. pneumoniae (MDRSP) includes isolates previously known as PRSP (penicillinresistant S. pneumoniae), as well as strains resistant to two or more of the following antibiotics: second-generation cephalosporins, macrolides, tetracyclines, and trimethoprim/ sulfamethoxazole.", [["PRSP", "CHEMICAL", 64, 68], ["cephalosporins", "CHEMICAL", 198, 212], ["macrolides", "CHEMICAL", 214, 224], ["tetracyclines", "CHEMICAL", 226, 239], ["trimethoprim/ sulfamethoxazole", "CHEMICAL", 245, 275], ["cephalosporins", "CHEMICAL", 198, 212], ["macrolides", "CHEMICAL", 214, 224], ["tetracyclines", "CHEMICAL", 226, 239], ["trimethoprim", "CHEMICAL", 245, 257], ["sulfamethoxazole", "CHEMICAL", 259, 275], ["MDR S. pneumoniae", "ORGANISM", 0, 17], ["MDRSP", "GENE_OR_GENE_PRODUCT", 19, 24], ["PRSP", "GENE_OR_GENE_PRODUCT", 64, 68], ["penicillinresistant S. pneumoniae", "ORGANISM", 70, 103], ["second-generation cephalosporins", "SIMPLE_CHEMICAL", 180, 212], ["macrolides", "SIMPLE_CHEMICAL", 214, 224], ["tetracyclines", "SIMPLE_CHEMICAL", 226, 239], ["trimethoprim/ sulfamethoxazole", "SIMPLE_CHEMICAL", 245, 275], ["S. pneumoniae", "SPECIES", 4, 17], ["S. pneumoniae", "SPECIES", 90, 103], ["S. pneumoniae", "SPECIES", 4, 17], ["S. pneumoniae", "SPECIES", 90, 103], ["MDR S. pneumoniae", "PROBLEM", 0, 17], ["isolates", "PROBLEM", 35, 43], ["PRSP", "PROBLEM", 64, 68], ["penicillinresistant S. pneumoniae", "PROBLEM", 70, 103], ["the following antibiotics", "TREATMENT", 153, 178], ["second-generation cephalosporins", "TREATMENT", 180, 212], ["macrolides", "TREATMENT", 214, 224], ["tetracyclines", "TREATMENT", 226, 239], ["trimethoprim", "TREATMENT", 245, 257], ["sulfamethoxazole", "TREATMENT", 259, 275], ["pneumoniae", "OBSERVATION", 7, 17]]], ["Methods: Pretreatment sputum and blood isolates collected worldwide during GRN phase 2/3 clinical CAP trials (1999) (2000) (2001) (2002) (2003) were retrospectively analysed for the MDRSP phenotype.", [["sputum", "ANATOMY", 22, 28], ["blood", "ANATOMY", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["Pretreatment sputum", "TEST", 9, 28], ["blood isolates", "TEST", 33, 47], ["clinical CAP trials", "TEST", 89, 108], ["the MDRSP phenotype", "PROBLEM", 178, 197]]], ["Of the 352 S. pneumoniae isolates originally identified, 208 from 180 subjects were subjected to secondary MDR susceptibility testing by central laboratories.", [["S. pneumoniae", "ORGANISM", 11, 24], ["subjects", "ORGANISM", 70, 78], ["S. pneumoniae", "SPECIES", 11, 24], ["S. pneumoniae", "SPECIES", 11, 24], ["pneumoniae isolates", "PROBLEM", 14, 33], ["secondary MDR susceptibility testing", "PROBLEM", 97, 133], ["pneumoniae", "OBSERVATION", 14, 24]]], ["Confirmed MDRSP isolates were matched to individual subjects to assess clinical and microbiological outcomes for MDRSP-infections treated with GRN.", [["MDRSP-infections", "DISEASE", 113, 129], ["MDRSP isolates", "CELL", 10, 24], ["MDRSP isolates", "PROBLEM", 10, 24], ["MDRSP", "PROBLEM", 113, 118], ["infections", "PROBLEM", 119, 129], ["infections", "OBSERVATION", 119, 129]]], ["Results: Expanded susceptibility testing identified 53/208 MDRSP isolates from 44 unique subjects.", [["Expanded susceptibility testing", "TEST", 9, 40], ["MDRSP isolates", "TEST", 59, 73]]], ["The lowest MIC50 and MIC90 values for MDRSP isolates tested against a panel of representative drugs were observed for GRN (Table 1 ; 0.03 lg/ ml and 0.06 lg/ml, respectively).", [["MIC90", "SIMPLE_CHEMICAL", 21, 26], ["The lowest MIC50", "TEST", 0, 16], ["MIC90 values", "TEST", 21, 33], ["MDRSP isolates", "TEST", 38, 52], ["representative drugs", "TREATMENT", 79, 99], ["GRN (Table", "TEST", 118, 128]]], ["The incidence of resistance to the five classes of drugs was 11%, 12%, 21%, 19% and 18% for penicillin, 2nd Generation Cep., macrolides, tetracycline and Tri/Sulf, respectively.", [["penicillin", "CHEMICAL", 92, 102], ["macrolides", "CHEMICAL", 125, 135], ["tetracycline", "CHEMICAL", 137, 149], ["penicillin", "CHEMICAL", 92, 102], ["macrolides", "CHEMICAL", 125, 135], ["tetracycline", "CHEMICAL", 137, 149], ["penicillin", "SIMPLE_CHEMICAL", 92, 102], ["macrolides", "SIMPLE_CHEMICAL", 125, 135], ["tetracycline", "SIMPLE_CHEMICAL", 137, 149], ["drugs", "TEST", 51, 56], ["penicillin", "TREATMENT", 92, 102], ["2nd Generation Cep.", "TREATMENT", 104, 123], ["macrolides", "TREATMENT", 125, 135], ["tetracycline", "TREATMENT", 137, 149], ["Tri/Sulf", "TREATMENT", 154, 162], ["resistance", "OBSERVATION", 17, 27]]], ["No isolates were resistant to GRN using a proposed susceptibility breakpoint value of \u00a31 lg/ml.", [["GRN", "DNA", 30, 33], ["isolates", "PROBLEM", 3, 11], ["a proposed susceptibility breakpoint value", "TEST", 40, 82], ["isolates", "OBSERVATION", 3, 11]]], ["Thirtyfive percent, 28%, 15%, 9% and 13% of isolates were resistant to 1, 2, 3, 4 and 5 drug classes, respectively.", [["isolates", "TREATMENT", 44, 52]]], ["The worldwide incidence of MDRSP was 18% with an equivalent geographic distribution of 19%, 21% and 16% among North America, Europe and the Rest of World.", [["MDRSP", "DISEASE", 27, 32], ["MDRSP", "CANCER", 27, 32], ["MDRSP", "TEST", 27, 32]]], ["Overall, GRN provided clinical and bacteriological success for 32/35 (91%) CAP evaluable subjects with MDR infection, which was similar to clinical success for evaluable subjects with non-MDRSP CAP infections 151/165 (92%).P1577Conclusions: These data demonstrate the ability of GRN to successfully eradicate MDRSP associated with CAP. .", [["CAP", "DISEASE", 75, 78], ["MDR infection", "DISEASE", 103, 116], ["infections", "DISEASE", 198, 208], ["MDRSP", "DISEASE", 309, 314], ["CAP", "DISEASE", 331, 334], ["MDRSP", "CANCER", 309, 314], ["MDRSP", "PROTEIN", 309, 314], ["CAP evaluable subjects", "PROBLEM", 75, 97], ["MDR infection", "PROBLEM", 103, 116], ["non-MDRSP CAP infections", "PROBLEM", 184, 208], ["These data", "TEST", 241, 251], ["CAP", "PROBLEM", 331, 334], ["infection", "OBSERVATION", 107, 116]]], ["Per cent success is shown in the table (AB, antibiotics, COPD, chronic bronchitis and obstructive lung disease, HD, heart disease).", [["lung", "ANATOMY", 98, 102], ["heart", "ANATOMY", 116, 121], ["COPD", "DISEASE", 57, 61], ["chronic bronchitis and obstructive lung disease", "DISEASE", 63, 110], ["HD", "DISEASE", 112, 114], ["heart disease", "DISEASE", 116, 129], ["lung", "ORGAN", 98, 102], ["heart", "ORGAN", 116, 121], ["AB, antibiotics", "TREATMENT", 40, 55], ["COPD", "PROBLEM", 57, 61], ["chronic bronchitis", "PROBLEM", 63, 81], ["obstructive lung disease", "PROBLEM", 86, 110], ["HD", "TREATMENT", 112, 114], ["heart disease)", "PROBLEM", 116, 130], ["COPD", "OBSERVATION", 57, 61], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["bronchitis", "OBSERVATION", 71, 81], ["obstructive", "OBSERVATION_MODIFIER", 86, 97], ["lung", "ANATOMY", 98, 102], ["disease", "OBSERVATION", 103, 110], ["heart", "ANATOMY", 116, 121], ["disease", "OBSERVATION", 122, 129]]], ["Results: Although gemifloxacin showed lower % success than comparator against CAP patients with no defined risk factor, gemifloxacin was considerably more successful than comparator against patients associated with risk factors, especially diabetic patients where comparator success was low.", [["gemifloxacin", "CHEMICAL", 18, 30], ["CAP", "DISEASE", 78, 81], ["gemifloxacin", "CHEMICAL", 120, 132], ["diabetic", "DISEASE", 240, 248], ["gemifloxacin", "CHEMICAL", 18, 30], ["gemifloxacin", "CHEMICAL", 120, 132], ["gemifloxacin", "SIMPLE_CHEMICAL", 18, 30], ["patients", "ORGANISM", 82, 90], ["gemifloxacin", "SIMPLE_CHEMICAL", 120, 132], ["patients", "ORGANISM", 190, 198], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 249, 257], ["gemifloxacin", "TREATMENT", 18, 30], ["defined risk factor", "PROBLEM", 99, 118], ["gemifloxacin", "TREATMENT", 120, 132], ["risk factors", "PROBLEM", 215, 227]]], ["This advantage was often more prominent at FU than at EOT.", [["FU", "SIMPLE_CHEMICAL", 43, 45], ["more prominent", "OBSERVATION_MODIFIER", 25, 39]]], ["Patients with other comorbidities such as renal failure or malignancy were not recruited in sufficient number for analysis.P1577Conclusions: These data support the use of gemifloxacin in the treatment of CAP, especially where the patient has recognised IDSA risk factors.P1579Microbiologic efficacy of garenoxacin vs. comparators against common pathogens associated with community-acquired pneumonia Objectives: Garenoxacin (GRN) a novel, broad-spectrum des-F(6)-quinolone is active against many clinically important respiratory pathogens including penicillin-resistant strains of Streptococcus pneumoniae.", [["renal", "ANATOMY", 42, 47], ["renal failure", "DISEASE", 42, 55], ["malignancy", "DISEASE", 59, 69], ["gemifloxacin", "CHEMICAL", 171, 183], ["CAP", "DISEASE", 204, 207], ["garenoxacin", "CHEMICAL", 302, 313], ["pneumonia", "DISEASE", 390, 399], ["Garenoxacin", "CHEMICAL", 412, 423], ["des-F(6)-quinolone", "CHEMICAL", 454, 472], ["penicillin", "CHEMICAL", 549, 559], ["Streptococcus pneumoniae", "DISEASE", 581, 605], ["gemifloxacin", "CHEMICAL", 171, 183], ["garenoxacin", "CHEMICAL", 302, 313], ["Garenoxacin", "CHEMICAL", 412, 423], ["des-F(6)-quinolone", "CHEMICAL", 454, 472], ["penicillin", "CHEMICAL", 549, 559], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 42, 47], ["gemifloxacin", "SIMPLE_CHEMICAL", 171, 183], ["patient", "ORGANISM", 230, 237], ["IDSA", "CANCER", 253, 257], ["garenoxacin", "SIMPLE_CHEMICAL", 302, 313], ["Garenoxacin", "SIMPLE_CHEMICAL", 412, 423], ["des-F(6)-quinolone", "SIMPLE_CHEMICAL", 454, 472], ["penicillin", "SIMPLE_CHEMICAL", 549, 559], ["Streptococcus pneumoniae", "ORGANISM", 581, 605], ["IDSA risk factors", "PROTEIN", 253, 270], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 230, 237], ["Streptococcus pneumoniae", "SPECIES", 581, 605], ["Streptococcus pneumoniae", "SPECIES", 581, 605], ["other comorbidities", "PROBLEM", 14, 33], ["renal failure", "PROBLEM", 42, 55], ["malignancy", "PROBLEM", 59, 69], ["analysis", "TEST", 114, 122], ["gemifloxacin", "TREATMENT", 171, 183], ["CAP", "PROBLEM", 204, 207], ["IDSA risk factors", "PROBLEM", 253, 270], ["garenoxacin", "TREATMENT", 302, 313], ["common pathogens", "PROBLEM", 338, 354], ["community-acquired pneumonia", "PROBLEM", 371, 399], ["Garenoxacin (GRN)", "TREATMENT", 412, 429], ["broad-spectrum des", "TREATMENT", 439, 457], ["quinolone", "TREATMENT", 463, 472], ["respiratory pathogens", "PROBLEM", 517, 538], ["penicillin", "TREATMENT", 549, 559], ["Streptococcus pneumoniae", "PROBLEM", 581, 605], ["renal", "ANATOMY", 42, 47], ["failure", "OBSERVATION", 48, 55], ["malignancy", "OBSERVATION", 59, 69], ["pneumonia", "OBSERVATION", 390, 399], ["Streptococcus pneumoniae", "OBSERVATION", 581, 605]]], ["GRN has dual sites of inhibition (DNA gyrase and topoisomerase IV) and may be less likely to promote resistance.", [["DNA", "CELLULAR_COMPONENT", 34, 37], ["gyrase", "GENE_OR_GENE_PRODUCT", 38, 44], ["topoisomerase IV", "GENE_OR_GENE_PRODUCT", 49, 65], ["GRN", "DNA", 0, 3], ["DNA gyrase", "PROTEIN", 34, 44], ["topoisomerase IV", "PROTEIN", 49, 65], ["inhibition (DNA gyrase", "TREATMENT", 22, 44], ["topoisomerase IV", "TREATMENT", 49, 65], ["dual sites", "OBSERVATION_MODIFIER", 8, 18], ["resistance", "OBSERVATION", 101, 111]]], ["The objective of this analysis was to compare the microbiologic efficacy of GRN to that of comparators against common pathogens involved in community-acquired pneumonia (CAP).", [["pneumonia", "DISEASE", 159, 168], ["CAP", "DISEASE", 170, 173], ["this analysis", "TEST", 17, 30], ["common pathogens", "PROBLEM", 111, 127], ["community-acquired pneumonia", "PROBLEM", 140, 168], ["pneumonia", "OBSERVATION", 159, 168]]], ["Methods: Two multinational, double-blind, randomized studies were conducted.", [["randomized studies", "TEST", 42, 60]]], ["In the first study, subjects received GRN (400 mg PO qd for 5 d) or amoxicillin/clavulanate (A/C; 500 mg PO q8h for 7-10 d).", [["amoxicillin/clavulanate", "CHEMICAL", 68, 91], ["amoxicillin", "CHEMICAL", 68, 79], ["clavulanate", "CHEMICAL", 80, 91], ["amoxicillin", "SIMPLE_CHEMICAL", 68, 79], ["clavulanate", "SIMPLE_CHEMICAL", 80, 91], ["GRN", "TREATMENT", 38, 41], ["amoxicillin", "TREATMENT", 68, 79], ["clavulanate", "TREATMENT", 80, 91], ["A/C", "TREATMENT", 93, 96]]], ["In the second study, subjects received GRN (400 mg PO qd for 7-10 d) or levofloxacin (LEV; 500 mg PO qd for 7-10 d).", [["levofloxacin", "CHEMICAL", 72, 84], ["LEV", "CHEMICAL", 86, 89], ["levofloxacin", "CHEMICAL", 72, 84], ["LEV", "CHEMICAL", 86, 89], ["levofloxacin", "SIMPLE_CHEMICAL", 72, 84], ["GRN (", "TREATMENT", 39, 44], ["levofloxacin (LEV", "TREATMENT", 72, 89]]], ["Adults (18 years of age or older) were enrolled with clinical and radiologic evidence of CAP [new infiltrate(s) on chest radiograph and fever, leukocytosis, cough, chest pain, auscultatory findings, or sputum production].", [["chest", "ANATOMY", 115, 120], ["chest", "ANATOMY", 164, 169], ["sputum", "ANATOMY", 202, 208], ["CAP", "DISEASE", 89, 92], ["fever", "DISEASE", 136, 141], ["leukocytosis", "DISEASE", 143, 155], ["cough", "DISEASE", 157, 162], ["chest pain", "DISEASE", 164, 174], ["Adults", "ORGANISM", 0, 6], ["Adults", "SPECIES", 0, 6], ["CAP", "PROBLEM", 89, 92], ["new infiltrate", "PROBLEM", 94, 108], ["chest radiograph", "TEST", 115, 131], ["fever", "PROBLEM", 136, 141], ["leukocytosis", "PROBLEM", 143, 155], ["cough", "PROBLEM", 157, 162], ["chest pain", "PROBLEM", 164, 174], ["auscultatory findings", "PROBLEM", 176, 197], ["sputum production", "PROBLEM", 202, 219], ["CAP", "OBSERVATION_MODIFIER", 89, 92], ["new", "OBSERVATION_MODIFIER", 94, 97], ["infiltrate", "OBSERVATION", 98, 108], ["chest", "ANATOMY", 115, 120], ["chest", "ANATOMY", 164, 169]]], ["Bacteriologic eradication was assessed 5 to18 days post therapy.", [["Bacteriologic eradication", "TREATMENT", 0, 25], ["therapy", "TREATMENT", 56, 63], ["eradication", "OBSERVATION", 14, 25]]], ["Results: A total of 377 treated subjects had pretreatment pathogens (GRN, n = 179; comparators, n = 198) .", [["subjects", "ORGANISM", 32, 40], ["pretreatment pathogens", "PROBLEM", 45, 67], ["comparators", "TEST", 83, 94]]], ["The overall eradication rate in all treated subjects was 91% (129/142) for GRN and 85% (123/145) for the comparators.", [["The overall eradication rate", "TEST", 0, 28], ["GRN", "TEST", 75, 78], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["eradication", "OBSERVATION", 12, 23]]], ["Eradication rates for S pneumoniae were 92% (24/26) for garenoxacin and 96% (49/ 51) for the comparators.", [["garenoxacin", "CHEMICAL", 56, 67], ["garenoxacin", "CHEMICAL", 56, 67], ["S pneumoniae", "ORGANISM", 22, 34], ["S pneumoniae", "SPECIES", 22, 34], ["S pneumoniae", "SPECIES", 22, 34], ["Eradication rates", "TEST", 0, 17], ["S pneumoniae", "TEST", 22, 34], ["garenoxacin", "TREATMENT", 56, 67]]], ["Eradication of S pneumoniae was 100% and 89% for A/C and LEV, respectively.", [["LEV", "CHEMICAL", 57, 60], ["S pneumoniae", "ORGANISM", 15, 27], ["LEV", "SIMPLE_CHEMICAL", 57, 60], ["S pneumoniae", "SPECIES", 15, 27], ["S pneumoniae", "SPECIES", 15, 27], ["Eradication of S pneumoniae", "TEST", 0, 27], ["A/C and LEV", "TREATMENT", 49, 60], ["pneumoniae", "OBSERVATION", 17, 27]]], ["In strains with reduced susceptibility to penicillin eradication rates were 86% (6/7) vs 67% (2/3) in favour of GRN.", [["penicillin", "CHEMICAL", 42, 52], ["penicillin", "CHEMICAL", 42, 52], ["penicillin", "SIMPLE_CHEMICAL", 42, 52], ["reduced susceptibility", "PROBLEM", 16, 38], ["penicillin eradication rates", "TEST", 42, 70]]], ["Eradication rates for H. influenzae were 89% (40/45) and 75% (30/40) for GRN and comparators, respectively.", [["H. influenzae", "ORGANISM", 22, 35], ["H. influenzae", "SPECIES", 22, 35], ["H. influenzae", "SPECIES", 22, 35], ["Eradication rates", "TEST", 0, 17], ["H. influenzae", "TEST", 22, 35]]], ["LEV eradicated 71% of H. influenzae isolates and A/C eradicated 77% of the strains isolated.", [["LEV", "CHEMICAL", 0, 3], ["H. influenzae isolates", "ORGANISM", 22, 44], ["A/C", "ORGANISM", 49, 52], ["H. influenzae", "SPECIES", 22, 35], ["H. influenzae", "SPECIES", 22, 35], ["LEV", "TREATMENT", 0, 3], ["H. influenzae isolates", "TEST", 22, 44], ["A/C", "TEST", 49, 52], ["the strains", "PROBLEM", 71, 82]]], ["There were very few isolates (4) of Moraxella catarrhalis in the 2 studies.", [["Moraxella catarrhalis", "DISEASE", 36, 57], ["Moraxella catarrhalis", "ORGANISM", 36, 57], ["Moraxella catarrhalis", "SPECIES", 36, 57], ["Moraxella catarrhalis", "SPECIES", 36, 57], ["Moraxella catarrhalis", "PROBLEM", 36, 57], ["very", "OBSERVATION_MODIFIER", 11, 15], ["few", "OBSERVATION_MODIFIER", 16, 19], ["isolates", "OBSERVATION_MODIFIER", 20, 28], ["Moraxella catarrhalis", "OBSERVATION", 36, 57]]], ["In 1 study GRN was 100% effective against 3 strains of M. catarrhalis and in the other A/C was 100% effective against the 1 strain isolated.", [["M. catarrhalis", "ORGANISM", 55, 69], ["M. catarrhalis", "SPECIES", 55, 69], ["M. catarrhalis", "SPECIES", 55, 69], ["M. catarrhalis", "PROBLEM", 55, 69], ["the 1 strain", "PROBLEM", 118, 130], ["catarrhalis", "OBSERVATION", 58, 69]]], ["GRN eradicated 95% (19/20) of the Staphylococcus aureus isolates vs 100% (11/11) for the comparators.", [["Staphylococcus aureus", "DISEASE", 34, 55], ["Staphylococcus aureus", "ORGANISM", 34, 55], ["Staphylococcus aureus", "SPECIES", 34, 55], ["Staphylococcus aureus", "SPECIES", 34, 55], ["the Staphylococcus aureus isolates", "TEST", 30, 64], ["Staphylococcus aureus", "OBSERVATION", 34, 55]]], ["Conclusions: GRN was highly active against pathogens commonly associated with CAP including drug-resistant strains of S pneumoniae and represents an effective therapeutic option for this patient population.", [["CAP", "CHEMICAL", 78, 81], ["S pneumoniae", "ORGANISM", 118, 130], ["patient", "ORGANISM", 187, 194], ["S pneumoniae", "SPECIES", 118, 130], ["patient", "SPECIES", 187, 194], ["S pneumoniae", "SPECIES", 118, 130], ["pathogens", "PROBLEM", 43, 52], ["CAP", "PROBLEM", 78, 81], ["drug-resistant strains of S pneumoniae", "PROBLEM", 92, 130], ["this patient population", "TREATMENT", 182, 205]]], ["Objectives: Garenoxacin (GRN) a novel, broad-spectrum des-F(6)-quinolone is active against many clinically important respiratory pathogens including penicillin-resistant strains of Streptococcus pneumoniae.", [["Garenoxacin", "CHEMICAL", 12, 23], ["des-F(6)-quinolone", "CHEMICAL", 54, 72], ["penicillin", "CHEMICAL", 149, 159], ["Streptococcus pneumoniae", "DISEASE", 181, 205], ["Garenoxacin", "CHEMICAL", 12, 23], ["des-F(6)-quinolone", "CHEMICAL", 54, 72], ["penicillin", "CHEMICAL", 149, 159], ["Garenoxacin", "SIMPLE_CHEMICAL", 12, 23], ["des-F(6)-quinolone", "SIMPLE_CHEMICAL", 54, 72], ["penicillin", "SIMPLE_CHEMICAL", 149, 159], ["Streptococcus pneumoniae", "ORGANISM", 181, 205], ["Streptococcus pneumoniae", "SPECIES", 181, 205], ["Streptococcus pneumoniae", "SPECIES", 181, 205], ["Garenoxacin (GRN)", "TREATMENT", 12, 29], ["broad-spectrum des", "TREATMENT", 39, 57], ["quinolone", "TREATMENT", 63, 72], ["respiratory pathogens", "PROBLEM", 117, 138], ["penicillin", "TREATMENT", 149, 159], ["Streptococcus pneumoniae", "PROBLEM", 181, 205], ["Streptococcus pneumoniae", "OBSERVATION", 181, 205]]], ["There is a growing problem of resistance in strains of S pneumoniae, with multi-drug-resistant S pneumoniae (MDRSP) becoming increasingly more common.", [["S pneumoniae", "ORGANISM", 55, 67], ["multi-drug-resistant S pneumoniae", "ORGANISM", 74, 107], ["MDRSP", "CANCER", 109, 114], ["S pneumoniae", "SPECIES", 55, 67], ["S pneumoniae", "SPECIES", 95, 107], ["S pneumoniae", "SPECIES", 55, 67], ["S pneumoniae", "SPECIES", 95, 107], ["S pneumoniae", "PROBLEM", 55, 67], ["multi-drug-resistant S pneumoniae", "PROBLEM", 74, 107], ["growing", "OBSERVATION_MODIFIER", 11, 18], ["resistance", "OBSERVATION_MODIFIER", 30, 40], ["pneumoniae", "OBSERVATION", 57, 67], ["pneumoniae", "OBSERVATION", 97, 107], ["more common", "OBSERVATION_MODIFIER", 138, 149]]], ["The objective of this study was to evaluate the clinical and microbiologic efficacy of GRN in the treatment of communityacquired pneumonia (CAP) caused by MDRSP.", [["pneumonia", "DISEASE", 129, 138], ["CAP", "DISEASE", 140, 143], ["this study", "TEST", 17, 27], ["GRN", "PROBLEM", 87, 90], ["communityacquired pneumonia", "PROBLEM", 111, 138], ["pneumonia", "OBSERVATION", 129, 138]]], ["Methods: This was a multinational, open-label, noncomparative study.", [["noncomparative study", "TEST", 47, 67]]], ["Subjects were adults ( \u202118 and <75 y) with clinical (clinical signs, sputum production), radiologic (new infiltrates on chest radiograph), or microbiologic (predominance of Gram-positive cocci in pairs on sputum Gram-stain or a positive blood culture for S. pneumoniae) evidence of CAP caused by S. pneumoniae.", [["sputum", "ANATOMY", 69, 75], ["chest", "ANATOMY", 120, 125], ["blood", "ANATOMY", 237, 242], ["CAP", "DISEASE", 282, 285], ["Subjects", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["S. pneumoniae", "ORGANISM", 255, 268], ["S. pneumoniae", "ORGANISM", 296, 309], ["S. pneumoniae", "SPECIES", 255, 268], ["S. pneumoniae", "SPECIES", 296, 309], ["S. pneumoniae", "SPECIES", 255, 268], ["S. pneumoniae", "SPECIES", 296, 309], ["clinical (clinical signs", "PROBLEM", 43, 67], ["sputum production", "PROBLEM", 69, 86], ["radiologic (new infiltrates", "PROBLEM", 89, 116], ["chest radiograph", "TEST", 120, 136], ["microbiologic", "PROBLEM", 142, 155], ["Gram-positive cocci in pairs", "PROBLEM", 173, 201], ["sputum Gram", "TEST", 205, 216], ["stain", "TEST", 217, 222], ["a positive blood culture", "PROBLEM", 226, 250], ["S. pneumoniae", "PROBLEM", 255, 268], ["CAP", "PROBLEM", 282, 285], ["S. pneumoniae", "PROBLEM", 296, 309], ["new", "OBSERVATION_MODIFIER", 101, 104], ["infiltrates", "OBSERVATION", 105, 116], ["chest", "ANATOMY", 120, 125], ["positive cocci", "OBSERVATION", 178, 192], ["CAP", "OBSERVATION_MODIFIER", 282, 285], ["pneumoniae", "OBSERVATION", 299, 309]]], ["Subjects received GRN 400 mg PO qd or GRN 400 mg IV with transition to 400 mg PO qd for 7 to 14 days.", [["GRN", "TREATMENT", 18, 21]]], ["Results: A total of 121 subjects were enrolled.", [["subjects", "ORGANISM", 24, 32]]], ["Clinical and microbiologic success rates were 91% (43/47) and 89% (42/47), respectively.", [["microbiologic success rates", "TEST", 13, 40]]], ["Clinical success rates were 94% (16/17) and 90% (27/30) for PO and IV to PO, respectively.", [["Clinical success rates", "TEST", 0, 22], ["PO and IV to PO", "TREATMENT", 60, 75]]], ["Documented S. pneumoniae bacteremia was present in 28% (n = 13) of subjects with a clinical success rate of 92%.", [["S. pneumoniae bacteremia", "DISEASE", 11, 35], ["S. pneumoniae", "ORGANISM", 11, 24], ["S. pneumoniae", "SPECIES", 11, 24], ["S. pneumoniae", "SPECIES", 11, 24], ["S. pneumoniae bacteremia", "PROBLEM", 11, 35], ["a clinical success rate", "TEST", 81, 104], ["pneumoniae", "OBSERVATION_MODIFIER", 14, 24], ["bacteremia", "OBSERVATION", 25, 35]]], ["Among evaluable subjects, resistance rates for S. pneumoniae were penicillin 13%, second-generation cephalosporin 17%, macrolides 21%, tetracyclines 21%, and trimethoprim/ sulfamethoxazole 17%.", [["penicillin", "CHEMICAL", 66, 76], ["cephalosporin", "CHEMICAL", 100, 113], ["macrolides", "CHEMICAL", 119, 129], ["tetracyclines", "CHEMICAL", 135, 148], ["trimethoprim/ sulfamethoxazole", "CHEMICAL", 158, 188], ["penicillin", "CHEMICAL", 66, 76], ["cephalosporin", "CHEMICAL", 100, 113], ["macrolides", "CHEMICAL", 119, 129], ["tetracyclines", "CHEMICAL", 135, 148], ["trimethoprim", "CHEMICAL", 158, 170], ["sulfamethoxazole", "CHEMICAL", 172, 188], ["S. pneumoniae", "ORGANISM", 47, 60], ["penicillin", "SIMPLE_CHEMICAL", 66, 76], ["cephalosporin", "SIMPLE_CHEMICAL", 100, 113], ["macrolides", "SIMPLE_CHEMICAL", 119, 129], ["tetracyclines", "SIMPLE_CHEMICAL", 135, 148], ["trimethoprim/ sulfamethoxazole", "SIMPLE_CHEMICAL", 158, 188], ["S. pneumoniae", "SPECIES", 47, 60], ["S. pneumoniae", "SPECIES", 47, 60], ["resistance rates", "PROBLEM", 26, 42], ["S. pneumoniae", "PROBLEM", 47, 60], ["penicillin", "TREATMENT", 66, 76], ["second-generation cephalosporin", "TREATMENT", 82, 113], ["macrolides", "TREATMENT", 119, 129], ["tetracyclines", "TREATMENT", 135, 148], ["trimethoprim", "TREATMENT", 158, 170], ["sulfamethoxazole", "TREATMENT", 172, 188]]], ["Twelve evaluable subjects had pneumonia caused by MDRSP.", [["pneumonia", "DISEASE", 30, 39], ["subjects", "ORGANISM", 17, 25], ["pneumonia", "PROBLEM", 30, 39], ["MDRSP", "PROBLEM", 50, 55], ["pneumonia", "OBSERVATION", 30, 39]]], ["Clinical success rate was 92% (11/12) in subjects with MDRSP and 91% (32/35) in non-MDRSP subjects.", [["MDRSP", "DISEASE", 55, 60], ["MDRSP", "CANCER", 55, 60], ["Clinical success rate", "TEST", 0, 21], ["MDRSP", "TEST", 55, 60]]], ["Clinical success of GRN for strains resistant to 2, 3, 4, or 5 antimicrobial drug classes, were 100% (5/5), 100% (1/1), 100% (2/2), and 75% (3/4), respectively.", [["strains", "PROBLEM", 28, 35]]], ["Microbiologic success was 83% (10/12) and 91% (32/35) for MDRSP and non-MDRSP (susceptible or resistant to 1 class) strains, respectively.", [["Microbiologic success", "TEST", 0, 21], ["MDRSP", "TEST", 58, 63], ["non-MDRSP", "PROBLEM", 68, 77]]], ["GRN was generally well tolerated with drug-related adverse events (AE) reported in 14% (8/58; PO) and 21% (13/63; IV to PO) of subjects.", [["adverse events", "PROBLEM", 51, 65]]], ["Conclusions: GRN (PO or IV to PO) is an effective treatment for CAP caused by MDRSP and non-MDRSP.", [["CAP", "DISEASE", 64, 67], ["MDRSP", "PROTEIN", 78, 83], ["non-MDRSP", "PROTEIN", 88, 97], ["GRN (PO or IV to PO", "TREATMENT", 13, 32], ["an effective treatment", "TREATMENT", 37, 59], ["CAP", "PROBLEM", 64, 67], ["MDRSP", "PROBLEM", 78, 83]]], ["GRN is well tolerated.P1581In vitro bactericidal activity of daptomycin against Staphylococcus aureus and Enterococcus spp.: comparison with vancomycin, teicoplanin and linezolid H. Drugeon, M. Juvin (Nantes, FR)P1581Objectives: The aim of this study was to evaluate the bactericidal activity (by killing kinetics) of daptomycin (DAP) against Staphylococcus aureus (SA) clinical isolates with different teicoplanin MICs and against Enterococcus faecalis (EFL) and E. faecium (EFM) with different mechanisms of glycopeptide resistance.", [["P1581In", "CHEMICAL", 22, 29], ["daptomycin", "CHEMICAL", 61, 71], ["Staphylococcus aureus", "DISEASE", 80, 101], ["vancomycin", "CHEMICAL", 141, 151], ["teicoplanin", "CHEMICAL", 153, 164], ["linezolid", "CHEMICAL", 169, 178], ["daptomycin", "CHEMICAL", 318, 328], ["DAP", "CHEMICAL", 330, 333], ["Staphylococcus aureus", "DISEASE", 343, 364], ["teicoplanin", "CHEMICAL", 403, 414], ["daptomycin", "CHEMICAL", 61, 71], ["vancomycin", "CHEMICAL", 141, 151], ["teicoplanin", "CHEMICAL", 153, 164], ["linezolid", "CHEMICAL", 169, 178], ["daptomycin", "CHEMICAL", 318, 328], ["DAP", "CHEMICAL", 330, 333], ["teicoplanin", "CHEMICAL", 403, 414], ["P1581In", "SIMPLE_CHEMICAL", 22, 29], ["daptomycin", "SIMPLE_CHEMICAL", 61, 71], ["Staphylococcus aureus", "ORGANISM", 80, 101], ["Enterococcus spp.", "ORGANISM", 106, 123], ["vancomycin", "SIMPLE_CHEMICAL", 141, 151], ["teicoplanin", "SIMPLE_CHEMICAL", 153, 164], ["daptomycin", "SIMPLE_CHEMICAL", 318, 328], ["DAP", "SIMPLE_CHEMICAL", 330, 333], ["Staphylococcus aureus", "ORGANISM", 343, 364], ["teicoplanin", "SIMPLE_CHEMICAL", 403, 414], ["Enterococcus faecalis", "ORGANISM", 432, 453], ["E. faecium", "ORGANISM", 464, 474], ["GRN", "DNA", 0, 3], ["Staphylococcus aureus", "SPECIES", 80, 101], ["Enterococcus spp.", "SPECIES", 106, 123], ["Staphylococcus aureus", "SPECIES", 343, 364], ["Enterococcus faecalis", "SPECIES", 432, 453], ["E. faecium", "SPECIES", 464, 474], ["Staphylococcus aureus", "SPECIES", 80, 101], ["Enterococcus spp.", "SPECIES", 106, 123], ["Staphylococcus aureus", "SPECIES", 343, 364], ["Enterococcus faecalis", "SPECIES", 432, 453], ["E. faecium", "SPECIES", 464, 474], ["vitro bactericidal activity", "TREATMENT", 30, 57], ["daptomycin", "TREATMENT", 61, 71], ["Staphylococcus aureus", "PROBLEM", 80, 101], ["Enterococcus spp.", "PROBLEM", 106, 123], ["vancomycin", "TREATMENT", 141, 151], ["teicoplanin", "TREATMENT", 153, 164], ["linezolid", "TREATMENT", 169, 178], ["this study", "TEST", 240, 250], ["the bactericidal activity", "PROBLEM", 267, 292], ["daptomycin (DAP", "TREATMENT", 318, 333], ["Staphylococcus aureus (SA) clinical isolates", "PROBLEM", 343, 387], ["different teicoplanin MICs", "TREATMENT", 393, 419], ["Enterococcus faecalis", "PROBLEM", 432, 453], ["E. faecium", "PROBLEM", 464, 474], ["EFM", "TEST", 476, 479], ["glycopeptide resistance", "TREATMENT", 510, 533], ["well tolerated", "OBSERVATION", 7, 21], ["Enterococcus faecalis", "OBSERVATION", 432, 453], ["glycopeptide resistance", "OBSERVATION", 510, 533]]], ["DAP has been compared with teicoplanin (TEI), vancomycin (VAN) and linezolid (LIN).", [["DAP", "CHEMICAL", 0, 3], ["teicoplanin", "CHEMICAL", 27, 38], ["TEI", "CHEMICAL", 40, 43], ["vancomycin", "CHEMICAL", 46, 56], ["VAN", "CHEMICAL", 58, 61], ["linezolid", "CHEMICAL", 67, 76], ["LIN", "CHEMICAL", 78, 81], ["DAP", "CHEMICAL", 0, 3], ["teicoplanin", "CHEMICAL", 27, 38], ["TEI", "CHEMICAL", 40, 43], ["vancomycin", "CHEMICAL", 46, 56], ["VAN", "CHEMICAL", 58, 61], ["linezolid", "CHEMICAL", 67, 76], ["LIN", "CHEMICAL", 78, 81], ["DAP", "SIMPLE_CHEMICAL", 0, 3], ["teicoplanin", "SIMPLE_CHEMICAL", 27, 38], ["TEI", "SIMPLE_CHEMICAL", 40, 43], ["vancomycin", "SIMPLE_CHEMICAL", 46, 56], ["VAN", "SIMPLE_CHEMICAL", 58, 61], ["linezolid", "SIMPLE_CHEMICAL", 67, 76], ["LIN", "SIMPLE_CHEMICAL", 78, 81], ["teicoplanin (TEI", "TREATMENT", 27, 43], ["vancomycin (VAN)", "TREATMENT", 46, 62], ["linezolid (LIN)", "TREATMENT", 67, 82]]], ["Methods: 6 SA strains (2 MSSA and 4 MRSA) with TEI MIC distributed from 0.5 to 8 mg/L, 6 Enterococcus (3 EFL and 3 EFM) with glycopeptide phenotypes [S, R-vanA, R-vanB] were studied using a killing curve method.", [["TEI", "CHEMICAL", 47, 50], ["Enterococcus", "CHEMICAL", 89, 101], ["R-vanA", "SIMPLE_CHEMICAL", 153, 159], ["R-vanB", "SIMPLE_CHEMICAL", 161, 167], ["MRSA", "SPECIES", 36, 40], ["SA strains", "PROBLEM", 11, 21], ["MSSA", "PROBLEM", 25, 29], ["TEI MIC", "TEST", 47, 54], ["Enterococcus", "PROBLEM", 89, 101], ["glycopeptide phenotypes", "PROBLEM", 125, 148], ["R-vanA", "TEST", 153, 159], ["a killing curve method", "TREATMENT", 188, 210]]], ["7 antibiotic concentrations were used from 1 mg/l to 64 mg/l in two fold dilutions.", [["antibiotic concentrations", "TREATMENT", 2, 27]]], ["Surviving bacteria were counted at T0, T30', T1, T3, T6, T12 and T24 hours using agar plates with inhibitors to prevent antibiotic carry-over.", [["T24", "ANATOMY", 65, 68], ["Surviving bacteria", "PROBLEM", 0, 18], ["agar plates", "TREATMENT", 81, 92], ["inhibitors", "TREATMENT", 98, 108], ["antibiotic carry", "TREATMENT", 120, 136], ["bacteria", "OBSERVATION", 10, 18], ["T3", "ANATOMY", 49, 51], ["T6", "ANATOMY", 53, 55], ["T12", "ANATOMY", 57, 60]]], ["Antibiotics tested were daptomycin (DAP), teicoplanin (TEI), vancomycin (VAN) and linezolid (LIN).", [["daptomycin", "CHEMICAL", 24, 34], ["DAP", "CHEMICAL", 36, 39], ["teicoplanin", "CHEMICAL", 42, 53], ["TEI", "CHEMICAL", 55, 58], ["vancomycin", "CHEMICAL", 61, 71], ["VAN", "CHEMICAL", 73, 76], ["linezolid", "CHEMICAL", 82, 91], ["LIN", "CHEMICAL", 93, 96], ["daptomycin", "CHEMICAL", 24, 34], ["DAP", "CHEMICAL", 36, 39], ["teicoplanin", "CHEMICAL", 42, 53], ["TEI", "CHEMICAL", 55, 58], ["vancomycin", "CHEMICAL", 61, 71], ["VAN", "CHEMICAL", 73, 76], ["linezolid", "CHEMICAL", 82, 91], ["LIN", "CHEMICAL", 93, 96], ["daptomycin", "SIMPLE_CHEMICAL", 24, 34], ["DAP", "SIMPLE_CHEMICAL", 36, 39], ["teicoplanin", "SIMPLE_CHEMICAL", 42, 53], ["TEI", "SIMPLE_CHEMICAL", 55, 58], ["vancomycin", "SIMPLE_CHEMICAL", 61, 71], ["VAN", "SIMPLE_CHEMICAL", 73, 76], ["linezolid", "SIMPLE_CHEMICAL", 82, 91], ["LIN", "SIMPLE_CHEMICAL", 93, 96], ["Antibiotics", "TREATMENT", 0, 11], ["daptomycin (DAP)", "TREATMENT", 24, 40], ["teicoplanin (TEI", "TREATMENT", 42, 58], ["vancomycin (VAN)", "TREATMENT", 61, 77], ["linezolid (LIN)", "TREATMENT", 82, 97]]], ["Results: All the SA isolates were susceptible to DAP (MIC = 0.25-1 mg/l), to LIN (MIC = 1-2 mg/L), to VAN (MIC = 1-2 mg/L) regardless of susceptibility to methicillin.", [["DAP", "CHEMICAL", 49, 52], ["MIC", "CHEMICAL", 54, 57], ["LIN", "CHEMICAL", 77, 80], ["VAN", "CHEMICAL", 102, 105], ["MIC", "CHEMICAL", 107, 110], ["methicillin", "CHEMICAL", 155, 166], ["DAP", "CHEMICAL", 49, 52], ["methicillin", "CHEMICAL", 155, 166], ["DAP", "SIMPLE_CHEMICAL", 49, 52], ["LIN", "SIMPLE_CHEMICAL", 77, 80], ["VAN", "SIMPLE_CHEMICAL", 102, 105], ["methicillin", "SIMPLE_CHEMICAL", 155, 166], ["the SA isolates", "TEST", 13, 28], ["DAP (MIC", "TREATMENT", 49, 57], ["VAN (MIC", "TREATMENT", 102, 110], ["methicillin", "TREATMENT", 155, 166]]], ["DAP showed the same strong concentration dependent bactericidal activity with MSSA and MRSA: at T30' bactericidal activity (BA) (decrease of 3 log10 cfu/mL) was observed with 8-16 mg/L of DAP; at T3 hours, 1-4 mg/L of DAP was sufficient and at T6 hours, BA was obtained with 1 mg/L of DAP.", [["DAP", "CHEMICAL", 0, 3], ["MSSA", "CHEMICAL", 78, 82], ["MRSA", "CHEMICAL", 87, 91], ["BA", "CHEMICAL", 124, 126], ["DAP", "CHEMICAL", 188, 191], ["DAP", "CHEMICAL", 218, 221], ["BA", "CHEMICAL", 254, 256], ["DAP", "CHEMICAL", 285, 288], ["DAP", "CHEMICAL", 0, 3], ["DAP", "CHEMICAL", 188, 191], ["DAP", "CHEMICAL", 218, 221], ["DAP", "CHEMICAL", 285, 288], ["DAP", "SIMPLE_CHEMICAL", 0, 3], ["MSSA", "SIMPLE_CHEMICAL", 78, 82], ["BA", "SIMPLE_CHEMICAL", 124, 126], ["DAP", "SIMPLE_CHEMICAL", 188, 191], ["DAP", "SIMPLE_CHEMICAL", 218, 221], ["BA", "SIMPLE_CHEMICAL", 254, 256], ["DAP", "SIMPLE_CHEMICAL", 285, 288], ["MRSA", "SPECIES", 87, 91], ["DAP", "TEST", 0, 3], ["the same strong concentration dependent bactericidal activity", "PROBLEM", 11, 72], ["MSSA", "PROBLEM", 78, 82], ["MRSA", "PROBLEM", 87, 91], ["DAP", "TREATMENT", 188, 191], ["DAP", "PROBLEM", 218, 221], ["DAP", "TREATMENT", 285, 288], ["strong", "OBSERVATION_MODIFIER", 20, 26], ["concentration dependent", "OBSERVATION_MODIFIER", 27, 50], ["bactericidal activity", "OBSERVATION", 51, 72], ["MSSA", "OBSERVATION", 78, 82], ["MRSA", "OBSERVATION", 87, 91]]], ["The other antibiotics showed a time dependent bactericidal activity but BA was observed only with long exposure ( \u202112 hours) and with high concentrations.", [["BA", "CHEMICAL", 72, 74], ["BA", "SIMPLE_CHEMICAL", 72, 74], ["The other antibiotics", "TREATMENT", 0, 21], ["a time dependent bactericidal activity", "PROBLEM", 29, 67], ["high concentrations", "PROBLEM", 134, 153], ["bactericidal activity", "OBSERVATION", 46, 67], ["high concentrations", "OBSERVATION_MODIFIER", 134, 153]]], ["All the Enterococcus isolates were susceptible to DAP (MIC = 1-2 mg/ L) and to LIN (MIC = 1-2 mg/L) regardless of the resistance to glycopeptides.", [["Enterococcus", "CHEMICAL", 8, 20], ["DAP", "CHEMICAL", 50, 53], ["MIC", "CHEMICAL", 55, 58], ["LIN", "CHEMICAL", 79, 82], ["DAP", "CHEMICAL", 50, 53], ["Enterococcus isolates", "ORGANISM", 8, 29], ["DAP", "SIMPLE_CHEMICAL", 50, 53], ["LIN", "SIMPLE_CHEMICAL", 79, 82], ["All the Enterococcus isolates", "TREATMENT", 0, 29], ["DAP (MIC", "TREATMENT", 50, 58], ["glycopeptides", "TREATMENT", 132, 145], ["Enterococcus isolates", "OBSERVATION", 8, 29]]], ["BA of DAP was also concentration dependent.", [["BA", "CHEMICAL", 0, 2], ["DAP", "CHEMICAL", 6, 9], ["DAP", "CHEMICAL", 6, 9], ["BA", "SIMPLE_CHEMICAL", 0, 2], ["DAP", "SIMPLE_CHEMICAL", 6, 9], ["concentration dependent", "PROBLEM", 19, 42], ["concentration dependent", "OBSERVATION", 19, 42]]], ["BA was obtained with 4-8 mg/L after 6 hours of contact and with 1 mg/L after 12 hours of contact for EFL.", [["BA", "CHEMICAL", 0, 2], ["BA", "SIMPLE_CHEMICAL", 0, 2], ["EFL", "PROBLEM", 101, 104]]], ["BA was observed with 8-16 mg/L after 6 hours of contact and with 1-2 mg/L after 24 hours of contact for EFM.", [["BA", "CHEMICAL", 0, 2], ["BA", "SIMPLE_CHEMICAL", 0, 2]]], ["The other antibiotics had a time dependant activity but didn't show bactericidal activity with concentrations 32 mg/L. Conclusion: The bactericidal activity of daptomycin was very strong, concentration dependent, and not influenced by the level or mechanism of glycopeptide resistance The bactericidal activity of linezolid was time dependent and observed only with the highest concentration and the bactericidal activity of vancomycin and teicoplanin was time dependent but was influenced by the mechanism of glycopeptide resistance.", [["daptomycin", "CHEMICAL", 160, 170], ["linezolid", "CHEMICAL", 314, 323], ["vancomycin", "CHEMICAL", 425, 435], ["teicoplanin", "CHEMICAL", 440, 451], ["daptomycin", "CHEMICAL", 160, 170], ["linezolid", "CHEMICAL", 314, 323], ["vancomycin", "CHEMICAL", 425, 435], ["teicoplanin", "CHEMICAL", 440, 451], ["daptomycin", "SIMPLE_CHEMICAL", 160, 170], ["linezolid", "SIMPLE_CHEMICAL", 314, 323], ["vancomycin", "SIMPLE_CHEMICAL", 425, 435], ["teicoplanin", "SIMPLE_CHEMICAL", 440, 451], ["The other antibiotics", "TREATMENT", 0, 21], ["The bactericidal activity of daptomycin", "TREATMENT", 131, 170], ["glycopeptide resistance", "PROBLEM", 261, 284], ["linezolid", "TREATMENT", 314, 323], ["the highest concentration", "TREATMENT", 366, 391], ["vancomycin", "TREATMENT", 425, 435], ["teicoplanin", "TREATMENT", 440, 451], ["glycopeptide resistance", "TREATMENT", 510, 533], ["glycopeptide resistance", "OBSERVATION", 261, 284], ["bactericidal", "OBSERVATION_MODIFIER", 289, 301], ["activity", "OBSERVATION_MODIFIER", 302, 310], ["glycopeptide resistance", "OBSERVATION", 510, 533]]], ["Objectives: Telavancin (TLV) is a bactericidal lipoglycopeptide with multiple mechanisms of action that is in phase 3 clinical trials for the treatment of complicated skin and skin structure infections and hospital-acquired pneumonia with a focus on infections due to methicillin-resistant Staphylococcus aureus (MRSA).", [["skin", "ANATOMY", 167, 171], ["skin", "ANATOMY", 176, 180], ["Telavancin", "CHEMICAL", 12, 22], ["TLV", "CHEMICAL", 24, 27], ["skin and skin structure infections", "DISEASE", 167, 201], ["pneumonia", "DISEASE", 224, 233], ["infections", "DISEASE", 250, 260], ["methicillin", "CHEMICAL", 268, 279], ["Staphylococcus aureus", "DISEASE", 290, 311], ["Telavancin", "CHEMICAL", 12, 22], ["TLV", "CHEMICAL", 24, 27], ["methicillin", "CHEMICAL", 268, 279], ["Telavancin", "SIMPLE_CHEMICAL", 12, 22], ["TLV", "SIMPLE_CHEMICAL", 24, 27], ["lipoglycopeptide", "SIMPLE_CHEMICAL", 47, 63], ["skin", "ORGAN", 167, 171], ["skin", "ORGAN", 176, 180], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 268, 311], ["MRSA", "CANCER", 313, 317], ["Staphylococcus aureus", "SPECIES", 290, 311], ["MRSA", "SPECIES", 313, 317], ["Staphylococcus aureus", "SPECIES", 290, 311], ["MRSA", "SPECIES", 313, 317], ["Telavancin (TLV)", "TREATMENT", 12, 28], ["a bactericidal lipoglycopeptide", "TREATMENT", 32, 63], ["the treatment", "TREATMENT", 138, 151], ["complicated skin and skin structure infections", "PROBLEM", 155, 201], ["hospital-acquired pneumonia", "PROBLEM", 206, 233], ["infections", "PROBLEM", 250, 260], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 268, 311], ["MRSA", "PROBLEM", 313, 317], ["skin", "ANATOMY", 167, 171], ["skin", "ANATOMY", 176, 180], ["structure infections", "OBSERVATION", 181, 201], ["pneumonia", "OBSERVATION", 224, 233], ["Staphylococcus aureus", "OBSERVATION", 290, 311]]], ["This study evaluated and compared the antibacterial activity of TLV with that of other antibacterial agents against recent gram-positive clinical isolates from Germany.", [["TLV", "CHEMICAL", 64, 67], ["TLV", "CHEMICAL", 64, 67], ["This study", "TEST", 0, 10], ["TLV", "TREATMENT", 64, 67], ["other antibacterial agents", "TREATMENT", 81, 107], ["recent gram", "TEST", 116, 127]]], ["Methods: A total of 363 aerobic gram-positive bacterial strains recently collected were included.", [["strains", "ANATOMY", 56, 63], ["aerobic gram", "TEST", 24, 36], ["positive bacterial strains", "PROBLEM", 37, 63], ["bacterial strains", "OBSERVATION", 46, 63]]], ["Antibiotics tested were TLV, vancomycin (VAN), teicoplanin, penicillin, oxacillin, ampicillin, cefuroxime, ceftriaxone, daptomycin (DAP), linezolid (LZD), quinupristin-dalfopristin, clindamycin, ciprofloxacin, levofloxacin, gentamicin, streptomycin, erythromycin, telithromycin, co-trimoxazole and tetracycline.", [["TLV", "CHEMICAL", 24, 27], ["vancomycin", "CHEMICAL", 29, 39], ["VAN", "CHEMICAL", 41, 44], ["teicoplanin", "CHEMICAL", 47, 58], ["penicillin", "CHEMICAL", 60, 70], ["oxacillin", "CHEMICAL", 72, 81], ["ampicillin", "CHEMICAL", 83, 93], ["cefuroxime", "CHEMICAL", 95, 105], ["ceftriaxone", "CHEMICAL", 107, 118], ["daptomycin", "CHEMICAL", 120, 130], ["DAP", "CHEMICAL", 132, 135], ["linezolid", "CHEMICAL", 138, 147], ["LZD", "CHEMICAL", 149, 152], ["quinupristin-dalfopristin", "CHEMICAL", 155, 180], ["clindamycin", "CHEMICAL", 182, 193], ["ciprofloxacin", "CHEMICAL", 195, 208], ["levofloxacin", "CHEMICAL", 210, 222], ["gentamicin", "CHEMICAL", 224, 234], ["streptomycin", "CHEMICAL", 236, 248], ["erythromycin", "CHEMICAL", 250, 262], ["telithromycin", "CHEMICAL", 264, 277], ["co-trimoxazole", "CHEMICAL", 279, 293], ["tetracycline", "CHEMICAL", 298, 310], ["TLV", "CHEMICAL", 24, 27], ["vancomycin", "CHEMICAL", 29, 39], ["VAN", "CHEMICAL", 41, 44], ["teicoplanin", "CHEMICAL", 47, 58], ["penicillin", "CHEMICAL", 60, 70], ["oxacillin", "CHEMICAL", 72, 81], ["ampicillin", "CHEMICAL", 83, 93], ["cefuroxime", "CHEMICAL", 95, 105], ["ceftriaxone", "CHEMICAL", 107, 118], ["daptomycin", "CHEMICAL", 120, 130], ["DAP", "CHEMICAL", 132, 135], ["linezolid", "CHEMICAL", 138, 147], ["LZD", "CHEMICAL", 149, 152], ["quinupristin", "CHEMICAL", 155, 167], ["dalfopristin", "CHEMICAL", 168, 180], ["clindamycin", "CHEMICAL", 182, 193], ["ciprofloxacin", "CHEMICAL", 195, 208], ["levofloxacin", "CHEMICAL", 210, 222], ["gentamicin", "CHEMICAL", 224, 234], ["streptomycin", "CHEMICAL", 236, 248], ["erythromycin", "CHEMICAL", 250, 262], ["telithromycin", "CHEMICAL", 264, 277], ["co-trimoxazole", "CHEMICAL", 279, 293], ["tetracycline", "CHEMICAL", 298, 310], ["vancomycin", "SIMPLE_CHEMICAL", 29, 39], ["VAN", "SIMPLE_CHEMICAL", 41, 44], ["teicoplanin", "SIMPLE_CHEMICAL", 47, 58], ["penicillin", "SIMPLE_CHEMICAL", 60, 70], ["oxacillin", "SIMPLE_CHEMICAL", 72, 81], ["ampicillin", "SIMPLE_CHEMICAL", 83, 93], ["cefuroxime", "SIMPLE_CHEMICAL", 95, 105], ["ceftriaxone", "SIMPLE_CHEMICAL", 107, 118], ["daptomycin", "SIMPLE_CHEMICAL", 120, 130], ["DAP", "SIMPLE_CHEMICAL", 132, 135], ["linezolid", "SIMPLE_CHEMICAL", 138, 147], ["LZD", "SIMPLE_CHEMICAL", 149, 152], ["quinupristin-dalfopristin", "SIMPLE_CHEMICAL", 155, 180], ["clindamycin", "SIMPLE_CHEMICAL", 182, 193], ["ciprofloxacin", "SIMPLE_CHEMICAL", 195, 208], ["levofloxacin", "SIMPLE_CHEMICAL", 210, 222], ["gentamicin", "SIMPLE_CHEMICAL", 224, 234], ["streptomycin", "SIMPLE_CHEMICAL", 236, 248], ["erythromycin", "SIMPLE_CHEMICAL", 250, 262], ["telithromycin", "SIMPLE_CHEMICAL", 264, 277], ["co-trimoxazole", "SIMPLE_CHEMICAL", 279, 293], ["tetracycline", "SIMPLE_CHEMICAL", 298, 310], ["Antibiotics", "TREATMENT", 0, 11], ["TLV", "TREATMENT", 24, 27], ["vancomycin (VAN)", "TREATMENT", 29, 45], ["teicoplanin", "TREATMENT", 47, 58], ["penicillin", "TREATMENT", 60, 70], ["oxacillin", "TREATMENT", 72, 81], ["ampicillin", "TREATMENT", 83, 93], ["cefuroxime", "TREATMENT", 95, 105], ["ceftriaxone", "TREATMENT", 107, 118], ["daptomycin", "TREATMENT", 120, 130], ["linezolid", "TREATMENT", 138, 147], ["LZD)", "TREATMENT", 149, 153], ["quinupristin", "TREATMENT", 155, 167], ["dalfopristin", "TREATMENT", 168, 180], ["clindamycin", "TREATMENT", 182, 193], ["ciprofloxacin", "TREATMENT", 195, 208], ["levofloxacin", "TREATMENT", 210, 222], ["gentamicin", "TREATMENT", 224, 234], ["streptomycin", "TREATMENT", 236, 248], ["erythromycin", "TREATMENT", 250, 262], ["telithromycin", "TREATMENT", 264, 277], ["co-trimoxazole", "TREATMENT", 279, 293], ["tetracycline", "TREATMENT", 298, 310]]], ["MICs were determined by the broth microdilution procedure according to the guidelines of the CLSI.", [["MICs", "TREATMENT", 0, 4], ["the broth microdilution procedure", "TREATMENT", 24, 57], ["the CLSI", "TEST", 89, 97]]], ["Results: TLV exhibited potent activity against all grampositive bacteria including resistant isolates such as MRSA, VAN-resistant enterococci, pneumococci (including multiple resistant strains with various antibiotic resistance phenotypes) and other streptococcal species.", [["TLV", "CHEMICAL", 9, 12], ["MRSA", "CHEMICAL", 110, 114], ["VAN", "CHEMICAL", 116, 119], ["enterococci", "DISEASE", 130, 141], ["pneumococci", "DISEASE", 143, 154], ["VAN", "SIMPLE_CHEMICAL", 116, 119], ["MRSA", "SPECIES", 110, 114], ["MRSA", "SPECIES", 110, 114], ["all grampositive bacteria", "PROBLEM", 47, 72], ["resistant isolates", "PROBLEM", 83, 101], ["MRSA", "PROBLEM", 110, 114], ["VAN-resistant enterococci", "PROBLEM", 116, 141], ["pneumococci", "PROBLEM", 143, 154], ["multiple resistant strains", "PROBLEM", 166, 192], ["various antibiotic resistance phenotypes", "TREATMENT", 198, 238], ["other streptococcal species", "PROBLEM", 244, 271], ["potent activity", "OBSERVATION_MODIFIER", 23, 38], ["MRSA", "OBSERVATION", 110, 114], ["antibiotic resistance", "OBSERVATION", 206, 227], ["streptococcal species", "OBSERVATION", 250, 271]]], ["TLV showed excellent in vitro activity against the species irrespective of the antibiotic phenotype tested.", [["TLV", "TREATMENT", 0, 3], ["the antibiotic phenotype", "TREATMENT", 75, 99], ["excellent", "OBSERVATION_MODIFIER", 11, 20], ["vitro activity", "OBSERVATION", 24, 38]]], ["For methicillin-susceptible S. aureus (MSSA, n = 33) and MRSA (n = 42) MIC90 of TLV for both phenotypes were 0.5 mg/L. For coagulase-negative Staphylococci (n = 72, incl.", [["methicillin", "CHEMICAL", 4, 15], ["MRSA", "DISEASE", 57, 61], ["MIC90", "CHEMICAL", 71, 76], ["methicillin", "CHEMICAL", 4, 15], ["methicillin-susceptible S. aureus", "ORGANISM", 4, 37], ["MSSA", "CANCER", 39, 43], ["S. aureus", "SPECIES", 28, 37], ["MRSA", "SPECIES", 57, 61], ["S. aureus", "SPECIES", 28, 37], ["MSSA", "SPECIES", 39, 43], ["MRSA", "SPECIES", 57, 61], ["methicillin", "TEST", 4, 15], ["susceptible S. aureus", "PROBLEM", 16, 37], ["MSSA", "PROBLEM", 39, 43], ["MRSA", "PROBLEM", 57, 61], ["TLV", "TREATMENT", 80, 83], ["both phenotypes", "PROBLEM", 88, 103], ["coagulase", "TEST", 123, 132], ["Staphylococci", "TEST", 142, 155], ["aureus", "OBSERVATION", 31, 37], ["negative Staphylococci", "OBSERVATION", 133, 155]]], ["MSSE, MRSE, MSSH, MRSH and others) MIC90s were 0.5 or 1 mg/L. MIC90s of TLV for Enterococcus faecalis (n = 30) and E. faecium (n = 32) were 1 and 2 mg/L, respectively.", [["Enterococcus faecalis", "ORGANISM", 80, 101], ["E. faecium", "ORGANISM", 115, 125], ["Enterococcus faecalis", "SPECIES", 80, 101], ["E. faecium", "SPECIES", 115, 125], ["Enterococcus faecalis", "SPECIES", 80, 101], ["E. faecium", "SPECIES", 115, 125], ["MRSE", "TEST", 6, 10], ["MRSH", "TEST", 18, 22], ["MIC90s", "TEST", 35, 41], ["TLV", "TREATMENT", 72, 75], ["Enterococcus faecalis", "PROBLEM", 80, 101], ["E. faecium", "TEST", 115, 125]]], ["For VAN-resistant strains of E. faecalis (n = 2) or E. faecium (n = 7) MICs for TLV ranged from 0.12 to 4 mg/L. Against Streptococcus pneumoniae (n = 60) TLV MICs ranged from \u00a30.001 to 0.03 mg/L. All Streptococcus pyogenes, Streptococcus agalactiae and all viridans group streptococci (n = 94) had MICs of \u00a30.125 mg/L. Conclusion: Based on MIC90, TLV was more potent than VAN, DAP or LZD against Staphylococci, streptococci and E. faecalis.", [["VAN", "CHEMICAL", 4, 7], ["Streptococcus pneumoniae", "DISEASE", 120, 144], ["Streptococcus pyogenes", "DISEASE", 200, 222], ["Streptococcus agalactiae", "DISEASE", 224, 248], ["MIC90", "CHEMICAL", 340, 345], ["VAN", "CHEMICAL", 372, 375], ["DAP", "CHEMICAL", 377, 380], ["LZD", "CHEMICAL", 384, 387], ["VAN", "CHEMICAL", 4, 7], ["TLV", "CHEMICAL", 347, 350], ["VAN", "CHEMICAL", 372, 375], ["DAP", "CHEMICAL", 377, 380], ["LZD", "CHEMICAL", 384, 387], ["VAN", "SIMPLE_CHEMICAL", 4, 7], ["E. faecalis", "ORGANISM", 29, 40], ["E. faecium", "ORGANISM", 52, 62], ["Streptococcus pneumoniae", "ORGANISM", 120, 144], ["Streptococcus pyogenes", "ORGANISM", 200, 222], ["Streptococcus agalactiae", "ORGANISM", 224, 248], ["MIC90", "SIMPLE_CHEMICAL", 340, 345], ["TLV", "SIMPLE_CHEMICAL", 347, 350], ["VAN", "SIMPLE_CHEMICAL", 372, 375], ["DAP", "SIMPLE_CHEMICAL", 377, 380], ["LZD", "SIMPLE_CHEMICAL", 384, 387], ["streptococci", "CELL", 411, 423], ["E. faecalis", "ORGANISM", 428, 439], ["E. faecalis", "SPECIES", 29, 40], ["E. faecium", "SPECIES", 52, 62], ["Streptococcus pneumoniae", "SPECIES", 120, 144], ["Streptococcus pyogenes", "SPECIES", 200, 222], ["Streptococcus agalactiae", "SPECIES", 224, 248], ["viridans group streptococci", "SPECIES", 257, 284], ["E. faecalis", "SPECIES", 428, 439], ["E. faecalis", "SPECIES", 29, 40], ["E. faecium", "SPECIES", 52, 62], ["TLV", "SPECIES", 80, 83], ["Streptococcus pneumoniae", "SPECIES", 120, 144], ["Streptococcus pyogenes", "SPECIES", 200, 222], ["Streptococcus agalactiae", "SPECIES", 224, 248], ["E. faecalis", "SPECIES", 428, 439], ["E. faecalis", "PROBLEM", 29, 40], ["E. faecium", "PROBLEM", 52, 62], ["TLV", "TREATMENT", 80, 83], ["Streptococcus pneumoniae", "PROBLEM", 120, 144], ["TLV MICs", "TEST", 154, 162], ["All Streptococcus pyogenes", "TEST", 196, 222], ["Streptococcus agalactiae", "PROBLEM", 224, 248], ["all viridans group streptococci", "TEST", 253, 284], ["MICs", "TEST", 298, 302], ["TLV", "TREATMENT", 347, 350], ["DAP", "TEST", 377, 380], ["LZD", "TREATMENT", 384, 387], ["Staphylococci", "PROBLEM", 396, 409], ["streptococci", "PROBLEM", 411, 423], ["E. faecalis", "PROBLEM", 428, 439], ["Streptococcus pyogenes", "OBSERVATION", 200, 222], ["E. faecalis", "OBSERVATION", 428, 439]]], ["It was superior to DAP and LZD against E. faecium and at least as active as DAP or LZD against most VAN-resistant enterococci.", [["DAP", "CHEMICAL", 19, 22], ["LZD", "CHEMICAL", 27, 30], ["DAP", "CHEMICAL", 76, 79], ["LZD", "CHEMICAL", 83, 86], ["VAN", "CHEMICAL", 100, 103], ["DAP", "CHEMICAL", 19, 22], ["DAP", "CHEMICAL", 76, 79], ["LZD", "CHEMICAL", 83, 86], ["VAN", "CHEMICAL", 100, 103], ["DAP", "SIMPLE_CHEMICAL", 19, 22], ["LZD", "SIMPLE_CHEMICAL", 27, 30], ["E. faecium", "ORGANISM", 39, 49], ["DAP", "SIMPLE_CHEMICAL", 76, 79], ["LZD", "SIMPLE_CHEMICAL", 83, 86], ["VAN", "SIMPLE_CHEMICAL", 100, 103], ["E. faecium", "SPECIES", 39, 49], ["E. faecium", "SPECIES", 39, 49], ["DAP", "TEST", 19, 22], ["LZD", "TREATMENT", 27, 30], ["E. faecium", "PROBLEM", 39, 49], ["LZD", "TREATMENT", 83, 86], ["resistant enterococci", "PROBLEM", 104, 125], ["enterococci", "OBSERVATION", 114, 125]]], ["TLV appears to be a promising new antimicrobial agent for the treatment of infections caused by gram-positive organisms including multiply resistant isolates.", [["TLV", "CHEMICAL", 0, 3], ["infections", "DISEASE", 75, 85], ["TLV", "CHEMICAL", 0, 3], ["TLV", "TREATMENT", 0, 3], ["a promising new antimicrobial agent", "TREATMENT", 18, 53], ["infections", "PROBLEM", 75, 85], ["gram-positive organisms", "PROBLEM", 96, 119], ["multiply resistant isolates", "PROBLEM", 130, 157], ["appears to be", "UNCERTAINTY", 4, 17], ["new", "OBSERVATION_MODIFIER", 30, 33], ["antimicrobial agent", "OBSERVATION", 34, 53], ["infections", "OBSERVATION", 75, 85], ["positive organisms", "OBSERVATION", 101, 119], ["resistant isolates", "OBSERVATION", 139, 157]]], ["The extent of protein binding (PB) of DAP is still under investigation and data available so far indicate PB of either 92% or 63%.", [["DAP", "CHEMICAL", 38, 41], ["DAP", "CHEMICAL", 38, 41], ["DAP", "SIMPLE_CHEMICAL", 38, 41], ["protein binding", "PROBLEM", 14, 29], ["DAP", "PROBLEM", 38, 41], ["PB", "TEST", 106, 108], ["protein binding", "OBSERVATION", 14, 29]]], ["Therefore we tested two FSCs: 22.0 (corresponding to 63% PB) and 4.8 (corresponding to 92% PB).", [["two FSCs", "TEST", 20, 28], ["PB", "TEST", 57, 59]]], ["The activity of DAP was determined in Mueller-Hinton broth supplemented with 50 mg/l calcium.", [["DAP", "CHEMICAL", 16, 19], ["calcium", "CHEMICAL", 85, 92], ["DAP", "CHEMICAL", 16, 19], ["calcium", "CHEMICAL", 85, 92], ["DAP", "SIMPLE_CHEMICAL", 16, 19], ["calcium", "SIMPLE_CHEMICAL", 85, 92], ["DAP", "TEST", 16, 19], ["l calcium", "TREATMENT", 83, 92]]], ["Viability counts were performed at 0.25, 0.5, 1, 3, 6, 12 and 24 h.", [["Viability counts", "TEST", 0, 16]]], ["One methicillin-susceptible Staphylococcus aureus (MSSA), two methicillin-resistant S. aureus (MRSA), one vancomycin-susceptible (VAN-S) and one VAN-resistant (VAN-R) Enterococcus faecalis, one VAN-S and one VAN-R Enterococcus faecium were tested.", [["methicillin", "CHEMICAL", 4, 15], ["Staphylococcus aureus", "DISEASE", 28, 49], ["MSSA", "CHEMICAL", 51, 55], ["methicillin", "CHEMICAL", 62, 73], ["MRSA", "CHEMICAL", 95, 99], ["vancomycin", "CHEMICAL", 106, 116], ["VAN-S", "CHEMICAL", 130, 135], ["VAN", "CHEMICAL", 145, 148], ["VAN", "CHEMICAL", 160, 163], ["VAN", "CHEMICAL", 194, 197], ["VAN", "CHEMICAL", 208, 211], ["methicillin", "CHEMICAL", 4, 15], ["methicillin", "CHEMICAL", 62, 73], ["vancomycin", "CHEMICAL", 106, 116], ["methicillin-susceptible Staphylococcus aureus", "ORGANISM", 4, 49], ["MSSA", "CANCER", 51, 55], ["methicillin-resistant S. aureus", "ORGANISM", 62, 93], ["MRSA", "CANCER", 95, 99], ["vancomycin", "SIMPLE_CHEMICAL", 106, 116], ["VAN", "SIMPLE_CHEMICAL", 145, 148], ["VAN-R) Enterococcus faecalis", "ORGANISM", 160, 188], ["VAN-R Enterococcus faecium", "ORGANISM", 208, 234], ["Staphylococcus aureus", "SPECIES", 28, 49], ["S. aureus", "SPECIES", 84, 93], ["MRSA", "SPECIES", 95, 99], ["Enterococcus faecalis", "SPECIES", 167, 188], ["R Enterococcus faecium", "SPECIES", 212, 234], ["Staphylococcus aureus", "SPECIES", 28, 49], ["MSSA", "SPECIES", 51, 55], ["S. aureus", "SPECIES", 84, 93], ["MRSA", "SPECIES", 95, 99], ["Enterococcus faecalis", "SPECIES", 167, 188], ["Enterococcus faecium", "SPECIES", 214, 234], ["One methicillin", "TEST", 0, 15], ["susceptible Staphylococcus aureus", "PROBLEM", 16, 49], ["MSSA", "TEST", 51, 55], ["two methicillin", "TEST", 58, 73], ["resistant S. aureus", "PROBLEM", 74, 93], ["MRSA", "PROBLEM", 95, 99], ["one vancomycin", "TREATMENT", 102, 116], ["Enterococcus faecalis", "PROBLEM", 167, 188], ["one VAN-R Enterococcus faecium", "TREATMENT", 204, 234], ["Staphylococcus aureus", "OBSERVATION", 28, 49], ["aureus", "OBSERVATION", 87, 93]]], ["Bactericidal activity was defined as >99.9% killing during incubation.", [["Bactericidal activity", "TEST", 0, 21]]], ["Results: DAP was bactericidal at concentrations of 60.0 mg/l and 22.0 mg/l in all seven strains.", [["DAP", "CHEMICAL", 9, 12], ["DAP", "CHEMICAL", 9, 12], ["DAP", "SIMPLE_CHEMICAL", 9, 12], ["bactericidal", "TREATMENT", 17, 29]]], ["The concentration of 4.8 mg/l was bactericidal against the two MRSA and against the VAN-S E. faecium.", [["MRSA", "CHEMICAL", 63, 67], ["VAN", "CHEMICAL", 84, 87], ["VAN-S E. faecium", "ORGANISM", 84, 100], ["MRSA", "SPECIES", 63, 67], ["S E. faecium", "SPECIES", 88, 100], ["MRSA", "SPECIES", 63, 67], ["E. faecium", "SPECIES", 90, 100], ["The concentration", "TREATMENT", 0, 17], ["bactericidal", "PROBLEM", 34, 46], ["the two MRSA", "PROBLEM", 55, 67], ["MRSA", "OBSERVATION", 63, 67]]], ["In the other four strains the maximum reduction of initial inoculum ranged from 1.52 to 2.53 log10 CFU/ml.", [["initial inoculum", "TEST", 51, 67], ["maximum", "OBSERVATION_MODIFIER", 30, 37], ["reduction", "OBSERVATION_MODIFIER", 38, 47]]], ["In six strains a bactericidal effect at 60.0 mg/l and 22.0 mg/l of DAP, respectively, occurred between 15 minutes and 3 h and after 6 h in the VAN-S E. faecalis.", [["DAP", "CHEMICAL", 67, 70], ["VAN", "CHEMICAL", 143, 146], ["DAP", "CHEMICAL", 67, 70], ["DAP", "SIMPLE_CHEMICAL", 67, 70], ["E. faecalis", "ORGANISM", 149, 160], ["E. faecalis", "SPECIES", 149, 160], ["E. faecalis", "SPECIES", 149, 160], ["a bactericidal effect", "PROBLEM", 15, 36], ["bactericidal", "OBSERVATION_MODIFIER", 17, 29]]], ["VAN at 40.0 mg/l or 18.0 mg/l was bactericidal in only two strains after 24 h (1 MSSA, 1 MRSA).", [["VAN", "CHEMICAL", 0, 3], ["VAN", "SIMPLE_CHEMICAL", 0, 3], ["MRSA", "SPECIES", 89, 93], ["VAN", "TREATMENT", 0, 3], ["bactericidal", "PROBLEM", 34, 46], ["MSSA", "PROBLEM", 81, 85], ["MRSA", "PROBLEM", 89, 93]]], ["Against the other five strains, VAN was bacteriostatic with maximum reduction of initial inoculum between 1.91 and 2.78 log10 CFU/ml at 40 mg/l after 24 h, respectively.", [["VAN", "CHEMICAL", 32, 35], ["VAN", "SIMPLE_CHEMICAL", 32, 35], ["bacteriostatic", "PROBLEM", 40, 54], ["maximum reduction of initial inoculum", "TREATMENT", 60, 97], ["maximum", "OBSERVATION_MODIFIER", 60, 67], ["reduction", "OBSERVATION_MODIFIER", 68, 77]]], ["Both TPL and LZD were consistently bacteriostatic against the test strains.", [["TPL", "CHEMICAL", 5, 8], ["LZD", "CHEMICAL", 13, 16], ["TPL", "SIMPLE_CHEMICAL", 5, 8], ["LZD", "SIMPLE_CHEMICAL", 13, 16], ["Both TPL", "TREATMENT", 0, 8], ["LZD", "TREATMENT", 13, 16], ["the test strains", "TEST", 58, 74], ["TPL", "ANATOMY", 5, 8], ["LZD", "OBSERVATION", 13, 16], ["bacteriostatic", "OBSERVATION_MODIFIER", 35, 49]]], ["Conclusion: DAP at PSC of 60.0 mg/l as well as at FSC of 22.0 mg/l showed a pronounced bactericidal effect within 3 h in 6/7 strains.", [["DAP", "CHEMICAL", 12, 15], ["DAP", "SIMPLE_CHEMICAL", 12, 15], ["DAP at PSC", "TREATMENT", 12, 22], ["FSC", "TEST", 50, 53], ["a pronounced bactericidal effect", "PROBLEM", 74, 106], ["pronounced", "OBSERVATION_MODIFIER", 76, 86], ["bactericidal effect", "OBSERVATION", 87, 106]]], ["VAN was bactericidal in only 2/7 strains after 24 h.", [["VAN", "CHEMICAL", 0, 3], ["VAN", "SIMPLE_CHEMICAL", 0, 3]]], ["Compared to VAN bacterial killing by DAP was very rapid.", [["VAN", "CHEMICAL", 12, 15], ["DAP", "CHEMICAL", 37, 40], ["DAP", "CHEMICAL", 37, 40], ["VAN", "SIMPLE_CHEMICAL", 12, 15], ["DAP", "SIMPLE_CHEMICAL", 37, 40], ["VAN bacterial killing", "TEST", 12, 33], ["DAP", "TEST", 37, 40], ["rapid", "OBSERVATION_MODIFIER", 50, 55]]], ["TPL and LZD were bacteriostatic only.P1584The effect of human serum on the bactericidal activity of daptomycin and comparators against Staphylococcus aureus and Enterococcus spp.", [["serum", "ANATOMY", 62, 67], ["TPL", "CHEMICAL", 0, 3], ["LZD", "CHEMICAL", 8, 11], ["P1584", "CHEMICAL", 37, 42], ["daptomycin", "CHEMICAL", 100, 110], ["Staphylococcus aureus", "DISEASE", 135, 156], ["daptomycin", "CHEMICAL", 100, 110], ["TPL", "SIMPLE_CHEMICAL", 0, 3], ["LZD", "SIMPLE_CHEMICAL", 8, 11], ["P1584", "SIMPLE_CHEMICAL", 37, 42], ["human", "ORGANISM", 56, 61], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["daptomycin", "SIMPLE_CHEMICAL", 100, 110], ["Staphylococcus aureus", "ORGANISM", 135, 156], ["Enterococcus spp", "ORGANISM", 161, 177], ["human", "SPECIES", 56, 61], ["Staphylococcus aureus", "SPECIES", 135, 156], ["Enterococcus spp", "SPECIES", 161, 177], ["human", "SPECIES", 56, 61], ["Staphylococcus aureus", "SPECIES", 135, 156], ["Enterococcus spp", "SPECIES", 161, 177], ["TPL", "TREATMENT", 0, 3], ["LZD", "TREATMENT", 8, 11], ["bacteriostatic", "PROBLEM", 17, 31], ["human serum", "TEST", 56, 67], ["the bactericidal activity", "TREATMENT", 71, 96], ["daptomycin", "TREATMENT", 100, 110], ["comparators", "TREATMENT", 115, 126], ["Staphylococcus aureus", "PROBLEM", 135, 156], ["Enterococcus spp", "PROBLEM", 161, 177], ["LZD", "OBSERVATION", 8, 11], ["bacteriostatic", "OBSERVATION_MODIFIER", 17, 31], ["Enterococcus spp", "OBSERVATION", 161, 177]]], ["Background: Daptomycin is a new cyclic lipopeptide antibiotic that shows rapid bactericidal activity and has high protein binding when assessed by standard methodology.", [["Daptomycin", "CHEMICAL", 12, 22], ["Daptomycin", "CHEMICAL", 12, 22], ["Daptomycin", "SIMPLE_CHEMICAL", 12, 22], ["Daptomycin", "TREATMENT", 12, 22], ["a new cyclic lipopeptide antibiotic", "TREATMENT", 26, 61], ["rapid bactericidal activity", "PROBLEM", 73, 100], ["high protein binding", "PROBLEM", 109, 129], ["Daptomycin", "OBSERVATION", 12, 22], ["rapid", "OBSERVATION_MODIFIER", 73, 78], ["bactericidal activity", "OBSERVATION", 79, 100], ["high protein binding", "OBSERVATION", 109, 129]]], ["This study investigated the bactericidal activity of daptomycin and the effect of protein binding by the addition of 50% human serum (HS).", [["serum", "ANATOMY", 127, 132], ["daptomycin", "CHEMICAL", 53, 63], ["daptomycin", "CHEMICAL", 53, 63], ["daptomycin", "SIMPLE_CHEMICAL", 53, 63], ["human", "ORGANISM", 121, 126], ["serum", "ORGANISM_SUBSTANCE", 127, 132], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["This study", "TEST", 0, 10], ["daptomycin", "TREATMENT", 53, 63], ["protein binding", "PROBLEM", 82, 97], ["50% human serum (HS)", "TREATMENT", 117, 137]]], ["Methods: Exponentially-growing methicillin-susceptible andresistant S. aureus (MSSA, MRSA) and vancomycin-susceptible Enterococcus faecium (VSE) and -resistant Enterococcus faecium (VRE) (ca.", [["methicillin", "CHEMICAL", 31, 42], ["MSSA", "CHEMICAL", 79, 83], ["MRSA", "CHEMICAL", 85, 89], ["vancomycin", "CHEMICAL", 95, 105], ["Enterococcus faecium", "CHEMICAL", 118, 138], ["VSE", "CHEMICAL", 140, 143], ["Enterococcus faecium", "CHEMICAL", 160, 180], ["VRE", "CHEMICAL", 182, 185], ["methicillin", "CHEMICAL", 31, 42], ["vancomycin", "CHEMICAL", 95, 105], ["methicillin", "SIMPLE_CHEMICAL", 31, 42], ["andresistant", "ORGANISM", 55, 67], ["S. aureus", "ORGANISM", 68, 77], ["MSSA", "CANCER", 79, 83], ["vancomycin-susceptible Enterococcus faecium", "SIMPLE_CHEMICAL", 95, 138], ["VSE", "SIMPLE_CHEMICAL", 140, 143], ["-resistant Enterococcus faecium", "ORGANISM", 149, 180], ["S. aureus", "SPECIES", 68, 77], ["MRSA", "SPECIES", 85, 89], ["Enterococcus faecium", "SPECIES", 118, 138], ["Enterococcus faecium", "SPECIES", 160, 180], ["S. aureus", "SPECIES", 68, 77], ["MSSA", "SPECIES", 79, 83], ["MRSA", "SPECIES", 85, 89], ["Enterococcus faecium", "SPECIES", 118, 138], ["VSE", "SPECIES", 140, 143], ["Enterococcus faecium", "SPECIES", 160, 180], ["methicillin", "TEST", 31, 42], ["S. aureus", "PROBLEM", 68, 77], ["MSSA", "PROBLEM", 79, 83], ["MRSA", "PROBLEM", 85, 89], ["vancomycin", "TEST", 95, 105], ["susceptible Enterococcus faecium", "PROBLEM", 106, 138], ["-resistant Enterococcus faecium", "PROBLEM", 149, 180], ["VRE", "PROBLEM", 182, 185], ["aureus", "OBSERVATION", 71, 77], ["Enterococcus faecium", "OBSERVATION", 160, 180]]], ["106 CFU/mL) were exposed to daptomycin (DAP), vancomycin (VAN), teicoplanin (TEI), piperacillin-tazobactam (PTZ) or linezolid (LZD) at peak (P) and trough (T) serum concentrations in Mueller Hinton broth supplemented with Ca2+ to 50 mg/L with or without HS.", [["serum", "ANATOMY", 159, 164], ["daptomycin", "CHEMICAL", 28, 38], ["DAP", "CHEMICAL", 40, 43], ["vancomycin", "CHEMICAL", 46, 56], ["VAN", "CHEMICAL", 58, 61], ["teicoplanin", "CHEMICAL", 64, 75], ["TEI", "CHEMICAL", 77, 80], ["piperacillin-tazobactam", "CHEMICAL", 83, 106], ["PTZ", "CHEMICAL", 108, 111], ["linezolid", "CHEMICAL", 116, 125], ["LZD", "CHEMICAL", 127, 130], ["Ca2", "CHEMICAL", 222, 225], ["daptomycin", "CHEMICAL", 28, 38], ["DAP", "CHEMICAL", 40, 43], ["vancomycin", "CHEMICAL", 46, 56], ["VAN", "CHEMICAL", 58, 61], ["teicoplanin", "CHEMICAL", 64, 75], ["TEI", "CHEMICAL", 77, 80], ["piperacillin-tazobactam", "CHEMICAL", 83, 106], ["PTZ", "CHEMICAL", 108, 111], ["linezolid", "CHEMICAL", 116, 125], ["LZD", "CHEMICAL", 127, 130], ["Ca2+", "CHEMICAL", 222, 226], ["daptomycin", "SIMPLE_CHEMICAL", 28, 38], ["DAP", "SIMPLE_CHEMICAL", 40, 43], ["vancomycin", "SIMPLE_CHEMICAL", 46, 56], ["VAN", "SIMPLE_CHEMICAL", 58, 61], ["teicoplanin", "SIMPLE_CHEMICAL", 64, 75], ["TEI", "SIMPLE_CHEMICAL", 77, 80], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 83, 106], ["PTZ", "SIMPLE_CHEMICAL", 108, 111], ["linezolid", "SIMPLE_CHEMICAL", 116, 125], ["LZD", "SIMPLE_CHEMICAL", 127, 130], ["serum", "ORGANISM_SUBSTANCE", 159, 164], ["Ca2+", "SIMPLE_CHEMICAL", 222, 226], ["Ca2", "PROTEIN", 222, 225], ["daptomycin (DAP", "TREATMENT", 28, 43], ["vancomycin (VAN)", "TREATMENT", 46, 62], ["teicoplanin (TEI", "TREATMENT", 64, 80], ["piperacillin-tazobactam", "TREATMENT", 83, 106], ["linezolid (LZD", "TREATMENT", 116, 130], ["trough (T) serum concentrations", "TEST", 148, 179], ["Mueller Hinton broth", "TREATMENT", 183, 203], ["Ca2+", "TREATMENT", 222, 226]]], ["Viable count was determined at 0.25, 0.5, 3, 6 & 24 h.", [["Viable count", "TEST", 0, 12]]], ["Plots were made of log reduction in viable count over time and the area-under-thecurve measured to calculate bactericidal indices (BIs) from these plots (J Antimicrob Chemother 1997, 39: 713-717).", [["log reduction", "TREATMENT", 19, 32], ["viable count", "TEST", 36, 48], ["bactericidal indices", "TEST", 109, 129], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["viable count", "OBSERVATION", 36, 48]]], ["Results: Daptomycin reduced viable count of MSSA & MRSA by approx.", [["Daptomycin", "CHEMICAL", 9, 19], ["MSSA", "CHEMICAL", 44, 48], ["MRSA", "DISEASE", 51, 55], ["Daptomycin", "CHEMICAL", 9, 19], ["Daptomycin", "SIMPLE_CHEMICAL", 9, 19], ["MRSA", "SPECIES", 51, 55], ["Daptomycin", "TREATMENT", 9, 19], ["MSSA", "PROBLEM", 44, 48], ["MRSA", "PROBLEM", 51, 55], ["MSSA", "OBSERVATION", 44, 48], ["MRSA", "OBSERVATION", 51, 55]]], ["5 logs or more within 0.25 h and VSE or VRE within 3 h at P. Other agents either did not achieve this or required 24 h to do so (not shown).", [["VRE", "PROBLEM", 40, 43]]], ["BI data are shown below (>represents kill beyond the limit of detection).", [["BI data", "TEST", 0, 7]]], ["HS had little effect on DAP kill, except against the VRE at T. Nevertheless, DAP at T against VRE was more bactericidal than any other antibacterial except DAP at P.P1584Conclusions: DAP was the most bactericidal agent tested as measured either by BI or rate of kill.", [["DAP", "CHEMICAL", 24, 27], ["DAP", "CHEMICAL", 77, 80], ["VRE", "CHEMICAL", 94, 97], ["DAP", "CHEMICAL", 156, 159], ["DAP", "CHEMICAL", 183, 186], ["DAP", "CHEMICAL", 24, 27], ["DAP", "CHEMICAL", 77, 80], ["DAP", "CHEMICAL", 156, 159], ["DAP", "CHEMICAL", 183, 186], ["DAP", "SIMPLE_CHEMICAL", 24, 27], ["DAP", "SIMPLE_CHEMICAL", 77, 80], ["DAP", "SIMPLE_CHEMICAL", 156, 159], ["P.P1584Conclusions", "SIMPLE_CHEMICAL", 163, 181], ["DAP", "SIMPLE_CHEMICAL", 183, 186], ["DAP kill", "TREATMENT", 24, 32], ["the VRE at T.", "PROBLEM", 49, 62], ["VRE", "PROBLEM", 94, 97], ["bactericidal", "PROBLEM", 107, 119], ["DAP", "PROBLEM", 183, 186], ["the most bactericidal agent", "TREATMENT", 191, 218], ["little effect", "OBSERVATION_MODIFIER", 7, 20]]], ["Dap at P reduced MSSA and MRSA to below detection within 15 min.", [["Dap", "CHEMICAL", 0, 3], ["MSSA", "CHEMICAL", 17, 21], ["Dap", "SIMPLE_CHEMICAL", 0, 3], ["MRSA", "SPECIES", 26, 30], ["Dap", "TEST", 0, 3], ["MSSA", "PROBLEM", 17, 21], ["MRSA", "PROBLEM", 26, 30], ["MSSA", "OBSERVATION", 17, 21]]], ["The effect of HS was minimal which suggests that protein binding is either weak or highly reversible.", [["protein binding", "PROBLEM", 49, 64], ["weak", "PROBLEM", 75, 79], ["protein binding", "OBSERVATION", 49, 64]]], ["These data support the use of DAP in the treatment of infections caused by these organisms.P1585Daptomycin activity against multi-resistant Staphylococcus haemolyticus bloodstream isolates from severe infections Objectives: Daptomycin, a new cyclic lipopeptide with activity against multidrug-resistant Gram-positive pathogens including MRSA, is approved for use in cSSST infections (US-FDA) and is being reviewed by EMEA for approval in EU member countries.", [["DAP", "CHEMICAL", 30, 33], ["infections", "DISEASE", 54, 64], ["P1585Daptomycin", "CHEMICAL", 91, 106], ["Staphylococcus haemolyticus bloodstream", "DISEASE", 140, 179], ["infections", "DISEASE", 201, 211], ["Daptomycin", "CHEMICAL", 224, 234], ["cyclic lipopeptide", "CHEMICAL", 242, 260], ["Gram-", "CHEMICAL", 303, 308], ["MRSA", "CHEMICAL", 337, 341], ["cSSST infections", "DISEASE", 366, 382], ["DAP", "CHEMICAL", 30, 33], ["Daptomycin", "CHEMICAL", 224, 234], ["DAP", "SIMPLE_CHEMICAL", 30, 33], ["P1585Daptomycin", "SIMPLE_CHEMICAL", 91, 106], ["Staphylococcus haemolyticus", "ORGANISM", 140, 167], ["Daptomycin", "SIMPLE_CHEMICAL", 224, 234], ["Staphylococcus haemolyticus", "SPECIES", 140, 167], ["MRSA", "SPECIES", 337, 341], ["Staphylococcus haemolyticus", "SPECIES", 140, 167], ["MRSA", "SPECIES", 337, 341], ["DAP", "TREATMENT", 30, 33], ["infections", "PROBLEM", 54, 64], ["these organisms", "PROBLEM", 75, 90], ["P1585Daptomycin", "TREATMENT", 91, 106], ["multi-resistant Staphylococcus haemolyticus bloodstream isolates", "PROBLEM", 124, 188], ["severe infections", "PROBLEM", 194, 211], ["Daptomycin", "TREATMENT", 224, 234], ["a new cyclic lipopeptide", "TREATMENT", 236, 260], ["multidrug-resistant Gram-positive pathogens", "PROBLEM", 283, 326], ["MRSA", "PROBLEM", 337, 341], ["cSSST infections", "PROBLEM", 366, 382], ["infections", "OBSERVATION", 54, 64], ["severe", "OBSERVATION_MODIFIER", 194, 200], ["infections", "OBSERVATION", 201, 211], ["positive pathogens", "OBSERVATION", 308, 326], ["MRSA", "OBSERVATION", 337, 341]]], ["The rapid bactericidal activity of daptomycin, due to its unique mechanism of action, makes it an attractive antibiotic for serious Gram-positive infections.", [["daptomycin", "CHEMICAL", 35, 45], ["infections", "DISEASE", 146, 156], ["daptomycin", "CHEMICAL", 35, 45], ["daptomycin", "SIMPLE_CHEMICAL", 35, 45], ["The rapid bactericidal activity", "TREATMENT", 0, 31], ["daptomycin", "TREATMENT", 35, 45], ["an attractive antibiotic", "TREATMENT", 95, 119], ["serious Gram-positive infections", "PROBLEM", 124, 156], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["bactericidal activity", "OBSERVATION", 10, 31], ["positive", "OBSERVATION_MODIFIER", 137, 145], ["infections", "OBSERVATION", 146, 156]]], ["The study was performed: (i) to evaluate the activity of daptomycin and other drugs against 50 multi-resistant clinically relevant Staphylococcus haemolyticus (MRSH), isolated from bloodstream infections in various hospitals in Italy (ii) to determine epidemiologic and genetic correlation among strains, and (iii) to characterize the SCCmec DNA of these strains.", [["bloodstream", "ANATOMY", 181, 192], ["daptomycin", "CHEMICAL", 57, 67], ["multi-", "CHEMICAL", 95, 101], ["Staphylococcus haemolyticus", "DISEASE", 131, 158], ["bloodstream infections", "DISEASE", 181, 203], ["daptomycin", "CHEMICAL", 57, 67], ["daptomycin", "SIMPLE_CHEMICAL", 57, 67], ["Staphylococcus haemolyticus", "ORGANISM", 131, 158], ["MRSH", "CANCER", 160, 164], ["DNA", "CELLULAR_COMPONENT", 342, 345], ["SCCmec DNA", "DNA", 335, 345], ["Staphylococcus haemolyticus", "SPECIES", 131, 158], ["Staphylococcus haemolyticus", "SPECIES", 131, 158], ["MRSH", "SPECIES", 160, 164], ["The study", "TEST", 0, 9], ["daptomycin", "TREATMENT", 57, 67], ["other drugs", "TREATMENT", 72, 83], ["Staphylococcus haemolyticus (MRSH)", "PROBLEM", 131, 165], ["bloodstream infections", "PROBLEM", 181, 203], ["these strains", "PROBLEM", 349, 362], ["Staphylococcus haemolyticus", "OBSERVATION", 131, 158], ["bloodstream infections", "OBSERVATION", 181, 203]]], ["Methods: The MRSH strains were tested against a panel of antimicrobial agents, by broth microdilution method performed according to CLSI (Clinical Laboratory Standards Institute) guidelines, including supplementation of 50 mg/L calcium for daptomycin.", [["calcium", "CHEMICAL", 228, 235], ["daptomycin", "CHEMICAL", 240, 250], ["calcium", "CHEMICAL", 228, 235], ["daptomycin", "CHEMICAL", 240, 250], ["calcium", "SIMPLE_CHEMICAL", 228, 235], ["daptomycin", "SIMPLE_CHEMICAL", 240, 250], ["The MRSH strains", "PROBLEM", 9, 25], ["antimicrobial agents", "TREATMENT", 57, 77], ["broth microdilution method", "TEST", 82, 108], ["supplementation", "TREATMENT", 201, 216], ["calcium", "TREATMENT", 228, 235], ["daptomycin", "TREATMENT", 240, 250]]], ["Moreover, phenotypic tests and antibiotic susceptibility profiling were carried out and the results compared with molecular typing analysis by using SmaI-PFGE fingerprints and PCR to characterize the mec-complex.", [["SmaI", "GENE_OR_GENE_PRODUCT", 149, 153], ["SmaI", "DNA", 149, 153], ["mec-complex", "DNA", 200, 211], ["phenotypic tests", "TEST", 10, 26], ["antibiotic susceptibility profiling", "TEST", 31, 66], ["molecular typing analysis", "TEST", 114, 139], ["SmaI-PFGE fingerprints", "TEST", 149, 171], ["PCR", "TEST", 176, 179]]], ["Results: All isolates were resistant to erythromycin, gentamicin, ciprofloxacin, 16 strains showed reduced susceptibility to vancomycin (MICs 2 mg/L), 24 strains were resistant to cotrimoxazole, 16 strains to clindamycin, 6 strains to chloramphenicol and 3 strains to tetracycline.", [["erythromycin", "CHEMICAL", 40, 52], ["gentamicin", "CHEMICAL", 54, 64], ["ciprofloxacin", "CHEMICAL", 66, 79], ["vancomycin", "CHEMICAL", 125, 135], ["MICs", "CHEMICAL", 137, 141], ["cotrimoxazole", "CHEMICAL", 180, 193], ["clindamycin", "CHEMICAL", 209, 220], ["chloramphenicol", "CHEMICAL", 235, 250], ["tetracycline", "CHEMICAL", 268, 280], ["erythromycin", "CHEMICAL", 40, 52], ["gentamicin", "CHEMICAL", 54, 64], ["ciprofloxacin", "CHEMICAL", 66, 79], ["vancomycin", "CHEMICAL", 125, 135], ["cotrimoxazole", "CHEMICAL", 180, 193], ["clindamycin", "CHEMICAL", 209, 220], ["chloramphenicol", "CHEMICAL", 235, 250], ["tetracycline", "CHEMICAL", 268, 280], ["erythromycin", "SIMPLE_CHEMICAL", 40, 52], ["gentamicin", "SIMPLE_CHEMICAL", 54, 64], ["ciprofloxacin", "SIMPLE_CHEMICAL", 66, 79], ["vancomycin", "SIMPLE_CHEMICAL", 125, 135], ["cotrimoxazole", "SIMPLE_CHEMICAL", 180, 193], ["clindamycin", "SIMPLE_CHEMICAL", 209, 220], ["chloramphenicol", "SIMPLE_CHEMICAL", 235, 250], ["tetracycline", "SIMPLE_CHEMICAL", 268, 280], ["All isolates", "PROBLEM", 9, 21], ["erythromycin", "TREATMENT", 40, 52], ["gentamicin", "TREATMENT", 54, 64], ["ciprofloxacin", "TREATMENT", 66, 79], ["reduced susceptibility", "PROBLEM", 99, 121], ["vancomycin (MICs", "TREATMENT", 125, 141], ["24 strains", "PROBLEM", 151, 161], ["cotrimoxazole", "TREATMENT", 180, 193], ["clindamycin", "TREATMENT", 209, 220], ["chloramphenicol", "TREATMENT", 235, 250], ["tetracycline", "TREATMENT", 268, 280]]], ["Almost all isolates were inhibited by \u00a31 mg/L of daptomycin, and only four strains exhibited a MIC value of 2 mg/L. PFGE analyses showed the existence of at least two multi-resistant S. haemolyticus clones widespread in different hospitals.", [["daptomycin", "CHEMICAL", 49, 59], ["daptomycin", "CHEMICAL", 49, 59], ["daptomycin", "SIMPLE_CHEMICAL", 49, 59], ["S. haemolyticus clones", "CELL", 183, 205], ["S. haemolyticus", "SPECIES", 183, 198], ["S. haemolyticus", "SPECIES", 183, 198], ["daptomycin", "TREATMENT", 49, 59], ["a MIC value", "TEST", 93, 104], ["PFGE analyses", "TEST", 116, 129], ["two multi-resistant S. haemolyticus clones", "PROBLEM", 163, 205], ["multi-resistant", "OBSERVATION_MODIFIER", 167, 182], ["haemolyticus clones", "OBSERVATION", 186, 205]]], ["Methicillin-resistance was correlated to the presence of the mecA and preliminary results regarding the genetic element carrying the gene, showed an organization of the mec-complex of class A and class C. Conclusions: Our results suggest that daptomycin has excellent activity against multiresistant MR S. haemolyticus isolates, which represent a serious threat in catheter-related bloodstream infections.", [["bloodstream", "ANATOMY", 382, 393], ["Methicillin", "CHEMICAL", 0, 11], ["daptomycin", "CHEMICAL", 243, 253], ["bloodstream infections", "DISEASE", 382, 404], ["Methicillin", "CHEMICAL", 0, 11], ["daptomycin", "CHEMICAL", 243, 253], ["Methicillin", "SIMPLE_CHEMICAL", 0, 11], ["mecA", "GENE_OR_GENE_PRODUCT", 61, 65], ["daptomycin", "SIMPLE_CHEMICAL", 243, 253], ["MR S. haemolyticus", "ORGANISM", 300, 318], ["mecA", "DNA", 61, 65], ["S. haemolyticus", "SPECIES", 303, 318], ["S. haemolyticus", "SPECIES", 303, 318], ["Methicillin", "TREATMENT", 0, 11], ["the mecA", "TEST", 57, 65], ["daptomycin", "TREATMENT", 243, 253], ["multiresistant MR S. haemolyticus isolates", "PROBLEM", 285, 327], ["a serious threat in catheter", "PROBLEM", 345, 373], ["bloodstream infections", "PROBLEM", 382, 404], ["haemolyticus isolates", "OBSERVATION", 306, 327], ["serious", "OBSERVATION_MODIFIER", 347, 354], ["catheter", "OBSERVATION", 365, 373], ["bloodstream infections", "OBSERVATION", 382, 404]]], ["Furthermore, the emergence of S. haemolyticus exhibiting reduced susceptibility to vancomycin is of particular concern, probably due to the common use of vancomycin as initial therapy for such infections.", [["vancomycin", "CHEMICAL", 83, 93], ["vancomycin", "CHEMICAL", 154, 164], ["infections", "DISEASE", 193, 203], ["vancomycin", "CHEMICAL", 83, 93], ["vancomycin", "CHEMICAL", 154, 164], ["S. haemolyticus", "ORGANISM", 30, 45], ["vancomycin", "SIMPLE_CHEMICAL", 83, 93], ["vancomycin", "SIMPLE_CHEMICAL", 154, 164], ["S. haemolyticus", "SPECIES", 30, 45], ["S. haemolyticus", "SPECIES", 30, 45], ["S. haemolyticus", "PROBLEM", 30, 45], ["reduced susceptibility", "PROBLEM", 57, 79], ["vancomycin", "TREATMENT", 83, 93], ["vancomycin", "TREATMENT", 154, 164], ["initial therapy", "TREATMENT", 168, 183], ["such infections", "PROBLEM", 188, 203], ["probably due to", "UNCERTAINTY", 120, 135]]], ["Moreover, the use of additional molecular techniques to fingerprint isolates makes this study of clinically important CoNS more accurate.", [["CoNS", "CANCER", 118, 122], ["additional molecular techniques", "TREATMENT", 21, 52], ["fingerprint isolates", "TEST", 56, 76], ["this study", "TEST", 83, 93]]], ["Objectives: Ceftobiprole is a new cephalosporin with a broad spectrum of action including methicillin-resistant Staphylococci (MRS) as well as many other Gram-positive and Gram-negative pathogenic bacteria.", [["Ceftobiprole", "CHEMICAL", 12, 24], ["cephalosporin", "CHEMICAL", 34, 47], ["methicillin", "CHEMICAL", 90, 101], ["Ceftobiprole", "CHEMICAL", 12, 24], ["cephalosporin", "CHEMICAL", 34, 47], ["methicillin", "CHEMICAL", 90, 101], ["Ceftobiprole", "SIMPLE_CHEMICAL", 12, 24], ["cephalosporin", "SIMPLE_CHEMICAL", 34, 47], ["methicillin-resistant Staphylococci", "SIMPLE_CHEMICAL", 90, 125], ["Gram-", "GENE_OR_GENE_PRODUCT", 154, 159], ["Gram-", "GENE_OR_GENE_PRODUCT", 172, 177], ["Ceftobiprole", "TREATMENT", 12, 24], ["a new cephalosporin", "TREATMENT", 28, 47], ["methicillin-resistant Staphylococci", "PROBLEM", 90, 125], ["MRS", "TEST", 127, 130], ["many other Gram-positive and Gram-negative pathogenic bacteria", "PROBLEM", 143, 205], ["pathogenic bacteria", "OBSERVATION", 186, 205]]], ["This study investigates the structural basis for the good activity against MRS. Methods: The primary beta-lactam resistance determinant of MRS, penicillin-binding protein PBP 2' (or 2a) has been cloned and expressed as a soluble form in which the amino-terminal residues forming a membrane-anchor have been deleted.", [["membrane", "ANATOMY", 281, 289], ["beta-lactam", "CHEMICAL", 101, 112], ["MRS", "CHEMICAL", 139, 142], ["penicillin", "CHEMICAL", 144, 154], ["amino-terminal", "CHEMICAL", 247, 261], ["beta-lactam", "CHEMICAL", 101, 112], ["penicillin", "CHEMICAL", 144, 154], ["amino", "CHEMICAL", 247, 252], ["MRS", "SIMPLE_CHEMICAL", 139, 142], ["penicillin-binding protein PBP 2", "GENE_OR_GENE_PRODUCT", 144, 176], ["membrane", "CELLULAR_COMPONENT", 281, 289], ["penicillin-binding protein PBP 2'", "PROTEIN", 144, 177], ["amino-terminal residues", "PROTEIN", 247, 270], ["membrane-anchor", "PROTEIN", 281, 296], ["This study", "TEST", 0, 10], ["MRS", "TEST", 139, 142], ["penicillin", "TREATMENT", 144, 154], ["binding protein PBP", "TEST", 155, 174], ["the amino-terminal residues", "TREATMENT", 243, 270], ["a membrane-anchor", "TREATMENT", 279, 296]]], ["The soluble form has been crystallized and the structure of the complex formed after soaking crystals in a solution containing ceftobiprole has been determined at 2.8 Angstrom resolution.", [["ceftobiprole", "CHEMICAL", 127, 139], ["ceftobiprole", "CHEMICAL", 127, 139], ["ceftobiprole", "SIMPLE_CHEMICAL", 127, 139], ["soaking crystals", "TREATMENT", 85, 101], ["a solution containing ceftobiprole", "TREATMENT", 105, 139], ["complex", "OBSERVATION_MODIFIER", 64, 71], ["formed", "OBSERVATION_MODIFIER", 72, 78]]], ["Additional data on the structure of the ceftobiprole-PBP2' complex formed in solution has been obtained using spectroscopic methods such as UV-circular dichroism.", [["ceftobiprole", "CHEMICAL", 40, 52], ["PBP2", "CHEMICAL", 53, 57], ["ceftobiprole", "CHEMICAL", 40, 52], ["PBP2", "CHEMICAL", 53, 57], ["ceftobiprole", "SIMPLE_CHEMICAL", 40, 52], ["PBP2", "SIMPLE_CHEMICAL", 53, 57], ["ceftobiprole-PBP2' complex", "PROTEIN", 40, 66], ["Additional data", "TEST", 0, 15], ["the ceftobiprole-PBP2' complex", "TREATMENT", 36, 66], ["spectroscopic methods", "TREATMENT", 110, 131], ["UV-circular dichroism", "TREATMENT", 140, 161], ["circular dichroism", "OBSERVATION", 143, 161]]], ["Results: Ceftobiprole reacts rapidly with PBP2' to form a stable acyl-enzyme complex.", [["Ceftobiprole", "CHEMICAL", 9, 21], ["PBP2", "CHEMICAL", 42, 46], ["Ceftobiprole", "CHEMICAL", 9, 21], ["acyl", "CHEMICAL", 65, 69], ["Ceftobiprole", "SIMPLE_CHEMICAL", 9, 21], ["PBP2", "SIMPLE_CHEMICAL", 42, 46], ["acyl-enzyme complex", "PROTEIN", 65, 84], ["Ceftobiprole", "TREATMENT", 9, 21], ["PBP2'", "TEST", 42, 47], ["stable", "OBSERVATION_MODIFIER", 58, 64]]], ["The ceftobiprole moiety is positioned deep within the active site of the acyl-enzyme complex formed with PBP2', where it forms several hydrogen bonds and hydrophobic interactions.", [["ceftobiprole", "CHEMICAL", 4, 16], ["PBP2", "CHEMICAL", 105, 109], ["ceftobiprole", "CHEMICAL", 4, 16], ["acyl", "CHEMICAL", 73, 77], ["PBP2", "CHEMICAL", 105, 109], ["hydrogen", "CHEMICAL", 135, 143], ["ceftobiprole", "SIMPLE_CHEMICAL", 4, 16], ["PBP2", "SIMPLE_CHEMICAL", 105, 109], ["acyl-enzyme complex", "PROTEIN", 73, 92], ["PBP2", "PROTEIN", 105, 109], ["The ceftobiprole moiety", "TREATMENT", 0, 23], ["PBP2'", "TREATMENT", 105, 110], ["ceftobiprole moiety", "OBSERVATION", 4, 23], ["deep", "OBSERVATION_MODIFIER", 38, 42], ["active", "OBSERVATION_MODIFIER", 54, 60], ["site", "OBSERVATION_MODIFIER", 61, 65], ["several", "OBSERVATION_MODIFIER", 127, 134], ["hydrogen bonds", "OBSERVATION", 135, 149], ["hydrophobic interactions", "OBSERVATION", 154, 178]]], ["In particular, the 7-aminothiadiazolylhyroxyiminoacetyl side chain of ceftobiprole sits more deeply within the side-chain binding pocket of PBP 2' than does the 7-acylamino side chain of nitrocefin in the previously determined complex structure.", [["7-aminothiadiazolylhyroxyiminoacetyl", "CHEMICAL", 19, 55], ["ceftobiprole", "CHEMICAL", 70, 82], ["nitrocefin", "CHEMICAL", 187, 197], ["7-aminothiadiazolylhyroxyiminoacetyl", "CHEMICAL", 19, 55], ["ceftobiprole", "CHEMICAL", 70, 82], ["7-acylamino", "CHEMICAL", 161, 172], ["nitrocefin", "CHEMICAL", 187, 197], ["7-aminothiadiazolylhyroxyiminoacetyl", "SIMPLE_CHEMICAL", 19, 55], ["ceftobiprole", "SIMPLE_CHEMICAL", 70, 82], ["PBP 2", "GENE_OR_GENE_PRODUCT", 140, 145], ["7-acylamino", "SIMPLE_CHEMICAL", 161, 172], ["nitrocefin", "SIMPLE_CHEMICAL", 187, 197], ["7-acylamino side chain", "PROTEIN", 161, 183], ["complex structure", "PROTEIN", 227, 244], ["the 7-aminothiadiazolylhyroxyiminoacetyl side chain of ceftobiprole sits", "TREATMENT", 15, 87], ["PBP", "TEST", 140, 143], ["nitrocefin", "TREATMENT", 187, 197], ["pocket", "OBSERVATION_MODIFIER", 130, 136]]], ["The additional interactions probably add to the enhanced stability of the acyl-enzyme complex formed with ceftobiprole, compared to complexes formed with other betalactams that are inactive against MRS. Significant structural rearrangements between apo-enzyme and acyl-enzyme are evident in the crystal structure and in solution.", [["acyl", "CHEMICAL", 74, 78], ["ceftobiprole", "CHEMICAL", 106, 118], ["acyl", "CHEMICAL", 264, 268], ["acyl", "CHEMICAL", 74, 78], ["ceftobiprole", "CHEMICAL", 106, 118], ["betalactams", "CHEMICAL", 160, 171], ["acyl", "CHEMICAL", 264, 268], ["ceftobiprole", "SIMPLE_CHEMICAL", 106, 118], ["betalactams", "SIMPLE_CHEMICAL", 160, 171], ["apo-enzyme", "SIMPLE_CHEMICAL", 249, 259], ["acyl-enzyme", "SIMPLE_CHEMICAL", 264, 275], ["acyl-enzyme complex", "PROTEIN", 74, 93], ["apo-enzyme and acyl-enzyme", "PROTEIN", 249, 275], ["ceftobiprole", "TREATMENT", 106, 118], ["other betalactams", "PROBLEM", 154, 171], ["Significant structural rearrangements between apo-enzyme", "PROBLEM", 203, 259], ["acyl-enzyme", "TREATMENT", 264, 275], ["structural rearrangements", "OBSERVATION", 215, 240], ["acyl-enzyme", "OBSERVATION", 264, 275], ["crystal structure", "OBSERVATION", 295, 312]]], ["Conclusion: Ceftobiprole readily forms a stable inhibitory acylenzyme complex with the PBP 2', the beta-lactam resistance determinant of MRS. This, together with potent inhibition of the normal complement of beta-lactam sensitive penicillin-binding proteins, accounts for its excellent activity against Staphylococci and probably accounts for the low rates of resistance development observed in experimental conditions.P1587Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in a French hospital (November 2004 -April 2005 C. Morate, A. Charron, C. Bebear, J. Maugein (Bordeaux, FR) Staphylococcus aureus are a major cause of nosocomial infections around the world.", [["Ceftobiprole", "CHEMICAL", 12, 24], ["beta-lactam", "CHEMICAL", 99, 110], ["beta-lactam", "CHEMICAL", 208, 219], ["penicillin", "CHEMICAL", 230, 240], ["Staphylococci", "DISEASE", 303, 316], ["Staphylococcus aureus", "DISEASE", 437, 458], ["Staphylococcus aureus", "DISEASE", 612, 633], ["nosocomial infections", "DISEASE", 655, 676], ["Ceftobiprole", "CHEMICAL", 12, 24], ["beta-lactam", "CHEMICAL", 99, 110], ["beta-lactam", "CHEMICAL", 208, 219], ["penicillin", "CHEMICAL", 230, 240], ["Ceftobiprole", "SIMPLE_CHEMICAL", 12, 24], ["acylenzyme", "SIMPLE_CHEMICAL", 59, 69], ["PBP 2", "GENE_OR_GENE_PRODUCT", 87, 92], ["penicillin-binding proteins", "GENE_OR_GENE_PRODUCT", 230, 257], ["Staphylococcus aureus", "ORGANISM", 437, 458], ["Bordeaux, FR) Staphylococcus aureus", "ORGANISM", 598, 633], ["inhibitory acylenzyme complex", "PROTEIN", 48, 77], ["beta-lactam sensitive penicillin-binding proteins", "PROTEIN", 208, 257], ["Staphylococcus aureus", "SPECIES", 437, 458], ["Staphylococcus aureus", "SPECIES", 612, 633], ["Staphylococcus aureus", "SPECIES", 437, 458], ["Staphylococcus aureus", "SPECIES", 612, 633], ["Ceftobiprole", "TREATMENT", 12, 24], ["the PBP", "TEST", 83, 90], ["the beta-lactam resistance", "TEST", 95, 121], ["beta-lactam sensitive penicillin-binding proteins", "PROBLEM", 208, 257], ["Staphylococci", "PROBLEM", 303, 316], ["the low rates of resistance development", "PROBLEM", 343, 382], ["Staphylococcus aureus", "PROBLEM", 437, 458], ["reduced susceptibility to glycopeptides", "PROBLEM", 464, 503], ["Staphylococcus aureus", "PROBLEM", 612, 633], ["nosocomial infections", "PROBLEM", 655, 676], ["stable", "OBSERVATION", 41, 47], ["Staphylococcus aureus", "OBSERVATION", 437, 458], ["reduced", "OBSERVATION_MODIFIER", 464, 471], ["Staphylococcus aureus", "OBSERVATION", 612, 633], ["nosocomial", "OBSERVATION_MODIFIER", 655, 665], ["infections", "OBSERVATION", 666, 676]]], ["Glycopeptides remain the drug of choice for severe infections caused by MRSA.", [["Glycopeptides", "CHEMICAL", 0, 13], ["infections", "DISEASE", 51, 61], ["MRSA", "DISEASE", 72, 76], ["Glycopeptides", "CHEMICAL", 0, 13], ["Glycopeptides", "SIMPLE_CHEMICAL", 0, 13], ["MRSA", "SPECIES", 72, 76], ["MRSA", "SPECIES", 72, 76], ["Glycopeptides", "TREATMENT", 0, 13], ["severe infections", "PROBLEM", 44, 61], ["MRSA", "PROBLEM", 72, 76], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["infections", "OBSERVATION", 51, 61], ["MRSA", "OBSERVATION", 72, 76]]], ["However, after the emergence of vancomycin resistance in Enterococcus and in the coagulase negative staphylococcus, strains of Staphylococcus aureus with reduced susceptibility to glycopeptides (GISA) have been reported in different countries like Japan, France, Spain, the UK and the United States.", [["vancomycin", "CHEMICAL", 32, 42], ["Enterococcus", "CHEMICAL", 57, 69], ["Staphylococcus aureus", "DISEASE", 127, 148], ["vancomycin", "CHEMICAL", 32, 42], ["vancomycin", "SIMPLE_CHEMICAL", 32, 42], ["Staphylococcus aureus", "ORGANISM", 127, 148], ["Staphylococcus aureus", "SPECIES", 127, 148], ["Staphylococcus aureus", "SPECIES", 127, 148], ["vancomycin resistance", "TREATMENT", 32, 53], ["Enterococcus", "PROBLEM", 57, 69], ["the coagulase negative staphylococcus", "PROBLEM", 77, 114], ["Staphylococcus aureus", "PROBLEM", 127, 148], ["reduced susceptibility to glycopeptides", "PROBLEM", 154, 193], ["Enterococcus", "OBSERVATION", 57, 69], ["coagulase negative staphylococcus", "OBSERVATION", 81, 114], ["Staphylococcus aureus", "OBSERVATION", 127, 148]]], ["The aim of our study was to determine the proportion of vancomycin resistance in clinical S. aureus isolates in a french university hospital, between November 2004 and April 2005, then we wanted to define if there was an epidemic clone and study the clinical impact of these GISA strains.", [["vancomycin", "CHEMICAL", 56, 66], ["vancomycin", "CHEMICAL", 56, 66], ["vancomycin", "SIMPLE_CHEMICAL", 56, 66], ["S. aureus", "ORGANISM", 90, 99], ["clone", "CELL", 230, 235], ["S. aureus", "SPECIES", 90, 99], ["S. aureus", "SPECIES", 90, 99], ["our study", "TEST", 11, 20], ["vancomycin resistance", "PROBLEM", 56, 77], ["an epidemic clone", "PROBLEM", 218, 235], ["these GISA strains", "PROBLEM", 269, 287], ["vancomycin resistance", "OBSERVATION", 56, 77]]], ["The protocol of detection was, first, a screening test on BHI agar containing 4 mg/L of teicoplanin, then, the vancomycin and teicoplanin MICs were determined by the method of Etest with an inoculum of 2.0 McF on the selected strains.", [["teicoplanin", "CHEMICAL", 88, 99], ["vancomycin", "CHEMICAL", 111, 121], ["teicoplanin", "CHEMICAL", 126, 137], ["teicoplanin", "CHEMICAL", 88, 99], ["vancomycin", "CHEMICAL", 111, 121], ["teicoplanin", "CHEMICAL", 126, 137], ["teicoplanin", "SIMPLE_CHEMICAL", 88, 99], ["vancomycin", "SIMPLE_CHEMICAL", 111, 121], ["teicoplanin", "SIMPLE_CHEMICAL", 126, 137], ["a screening test", "TEST", 38, 54], ["BHI agar", "TREATMENT", 58, 66], ["teicoplanin", "TREATMENT", 88, 99], ["the vancomycin", "TREATMENT", 107, 121], ["teicoplanin MICs", "TREATMENT", 126, 142], ["Etest", "TEST", 176, 181], ["an inoculum", "TREATMENT", 187, 198], ["the selected strains", "TREATMENT", 213, 233]]], ["Finally, the isolates with MIC of the teicoplanin \u20218 mg/ L and MIC of the vancomycin \u20214 mg/L or MIC of the teicoplanin \u202112 mg/L and MIC of the vancomycin \u00a34 mg/L were studied on population analysis.", [["teicoplanin", "CHEMICAL", 38, 49], ["vancomycin", "CHEMICAL", 74, 84], ["teicoplanin", "CHEMICAL", 107, 118], ["vancomycin", "CHEMICAL", 143, 153], ["teicoplanin", "CHEMICAL", 38, 49], ["vancomycin", "CHEMICAL", 74, 84], ["teicoplanin", "CHEMICAL", 107, 118], ["vancomycin", "CHEMICAL", 143, 153], ["teicoplanin", "SIMPLE_CHEMICAL", 38, 49], ["vancomycin", "SIMPLE_CHEMICAL", 74, 84], ["teicoplanin", "SIMPLE_CHEMICAL", 107, 118], ["vancomycin", "SIMPLE_CHEMICAL", 143, 153], ["the teicoplanin", "TREATMENT", 34, 49], ["the vancomycin \u2021", "TREATMENT", 70, 86], ["the teicoplanin \u2021", "TREATMENT", 103, 120], ["the vancomycin", "TREATMENT", 139, 153], ["population analysis", "TEST", 178, 197]]], ["After that, pulsed-field gel electrophoresis (PFGE) was performed on the different isolates and the pulsotypes were compared.", [["pulsed-field gel electrophoresis (PFGE", "TEST", 12, 50], ["the pulsotypes", "TEST", 96, 110]]], ["From November 2004 to April 2005, 468 S. aureus isolates were collected from 331 patients and screened for glycopeptide resistance on an initial agar screening test containing 4 mg/L of teicoplanin.", [["teicoplanin", "CHEMICAL", 186, 197], ["teicoplanin", "CHEMICAL", 186, 197], ["S. aureus", "ORGANISM", 38, 47], ["patients", "ORGANISM", 81, 89], ["teicoplanin", "SIMPLE_CHEMICAL", 186, 197], ["S. aureus", "SPECIES", 38, 47], ["patients", "SPECIES", 81, 89], ["S. aureus", "SPECIES", 38, 47], ["S. aureus isolates", "PROBLEM", 38, 56], ["glycopeptide resistance", "TREATMENT", 107, 130], ["an initial agar screening test", "TEST", 134, 164], ["teicoplanin", "TREATMENT", 186, 197]]], ["The teicoplanin MIC was >4 mg/L for 65 isolates (13.9%) from 59 patients and these strains were selected for the determination of the MICs by ''macromethod'' Etest.", [["teicoplanin", "CHEMICAL", 4, 15], ["teicoplanin", "CHEMICAL", 4, 15], ["teicoplanin", "SIMPLE_CHEMICAL", 4, 15], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["The teicoplanin MIC", "TREATMENT", 0, 19], ["these strains", "PROBLEM", 77, 90]]], ["By this technique, 39 strains were selected and studied by population analysis.", [["39 strains", "PROBLEM", 19, 29], ["population analysis", "TEST", 59, 78]]], ["This procedure detected 5 isolates (from 5 patients) with heterogeneous reduced susceptibility to glycopeptides (hGISA).", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["This procedure", "TREATMENT", 0, 14], ["heterogeneous reduced susceptibility to glycopeptides", "PROBLEM", 58, 111], ["heterogeneous", "OBSERVATION_MODIFIER", 58, 71], ["reduced", "OBSERVATION_MODIFIER", 72, 79]]], ["So the incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in our hospital was found to be 1.1%.", [["Staphylococcus aureus", "DISEASE", 20, 41], ["Staphylococcus aureus", "ORGANISM", 20, 41], ["Staphylococcus aureus", "SPECIES", 20, 41], ["Staphylococcus aureus", "SPECIES", 20, 41], ["Staphylococcus aureus", "PROBLEM", 20, 41], ["reduced susceptibility to glycopeptides", "PROBLEM", 47, 86], ["Staphylococcus aureus", "OBSERVATION", 20, 41], ["reduced", "OBSERVATION_MODIFIER", 47, 54]]], ["Four strains were resistant to methicillin and 3 were also resistant to gentamicin.", [["methicillin", "CHEMICAL", 31, 42], ["gentamicin", "CHEMICAL", 72, 82], ["methicillin", "CHEMICAL", 31, 42], ["gentamicin", "CHEMICAL", 72, 82], ["methicillin", "SIMPLE_CHEMICAL", 31, 42], ["gentamicin", "SIMPLE_CHEMICAL", 72, 82], ["Four strains", "PROBLEM", 0, 12], ["methicillin", "TREATMENT", 31, 42], ["gentamicin", "TREATMENT", 72, 82]]], ["The diversity of the strains was confirmed by PFGE: there was not an epidemic clone in the hospital.", [["clone", "CELL", 78, 83], ["the strains", "PROBLEM", 17, 28], ["an epidemic clone", "PROBLEM", 66, 83], ["diversity", "OBSERVATION_MODIFIER", 4, 13], ["epidemic", "OBSERVATION_MODIFIER", 69, 77], ["clone", "OBSERVATION", 78, 83]]], ["The clinical history showed that 4 patients had received a prior treatment with vancomycin, and that 3 patients had a failure in treatment: 2 of them had cystic fibrosis.", [["cystic", "ANATOMY", 154, 160], ["vancomycin", "CHEMICAL", 80, 90], ["fibrosis", "DISEASE", 161, 169], ["vancomycin", "CHEMICAL", 80, 90], ["patients", "ORGANISM", 35, 43], ["vancomycin", "SIMPLE_CHEMICAL", 80, 90], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 103, 111], ["a prior treatment", "TREATMENT", 57, 74], ["vancomycin", "TREATMENT", 80, 90], ["a failure in treatment", "PROBLEM", 116, 138], ["cystic fibrosis", "PROBLEM", 154, 169], ["failure", "OBSERVATION", 118, 125], ["cystic", "OBSERVATION_MODIFIER", 154, 160], ["fibrosis", "OBSERVATION", 161, 169]]], ["Objectives: Enterococcus faecalis was the most prevalent organism (72.5%) involved in enterococcal infections at Tehran Hospitals followed by E. faecium (22.5%).", [["enterococcal infections", "DISEASE", 86, 109], ["Enterococcus faecalis", "ORGANISM", 12, 33], ["E. faecium", "ORGANISM", 142, 152], ["Enterococcus faecalis", "SPECIES", 12, 33], ["E. faecium", "SPECIES", 142, 152], ["Enterococcus faecalis", "SPECIES", 12, 33], ["E. faecium", "SPECIES", 142, 152], ["Enterococcus faecalis", "PROBLEM", 12, 33], ["enterococcal infections", "PROBLEM", 86, 109], ["Enterococcus faecalis", "OBSERVATION", 12, 33], ["enterococcal", "OBSERVATION_MODIFIER", 86, 98], ["infections", "OBSERVATION", 99, 109]]], ["Due to widespread expansion of aminoglycoside modifiying Enzymes (AGMEs) genes, the rate of resistance to high level concentration of aminoglycosides has increased in these years.", [["aminoglycoside", "CHEMICAL", 31, 45], ["aminoglycosides", "CHEMICAL", 134, 149], ["aminoglycoside", "CHEMICAL", 31, 45], ["aminoglycosides", "CHEMICAL", 134, 149], ["aminoglycoside modifiying Enzymes", "GENE_OR_GENE_PRODUCT", 31, 64], ["AGMEs", "GENE_OR_GENE_PRODUCT", 66, 71], ["aminoglycosides", "SIMPLE_CHEMICAL", 134, 149], ["aminoglycoside modifiying Enzymes (AGMEs) genes", "DNA", 31, 78], ["widespread expansion of aminoglycoside modifiying Enzymes (AGMEs) genes", "PROBLEM", 7, 78], ["the rate of resistance", "PROBLEM", 80, 102], ["aminoglycosides", "TREATMENT", 134, 149], ["widespread", "OBSERVATION_MODIFIER", 7, 17], ["expansion", "OBSERVATION_MODIFIER", 18, 27], ["aminoglycoside", "OBSERVATION", 31, 45], ["increased", "OBSERVATION_MODIFIER", 154, 163]]], ["The rate of high level gentamicin resistant isolates of enterococci (HLGR) is high in Iran (46%).", [["gentamicin", "CHEMICAL", 23, 33], ["gentamicin", "CHEMICAL", 23, 33], ["gentamicin", "SIMPLE_CHEMICAL", 23, 33], ["The rate", "TEST", 0, 8], ["high level gentamicin", "TREATMENT", 12, 33], ["enterococci", "PROBLEM", 56, 67], ["enterococci", "OBSERVATION", 56, 67], ["high", "OBSERVATION_MODIFIER", 78, 82]]], ["The aim of this study was to determine the genes encoding resistance to aminoglycosides among enterococci in Iran.", [["aminoglycosides", "CHEMICAL", 72, 87], ["aminoglycosides", "CHEMICAL", 72, 87], ["aminoglycosides", "SIMPLE_CHEMICAL", 72, 87], ["this study", "TEST", 11, 21], ["aminoglycosides", "TREATMENT", 72, 87], ["enterococci", "PROBLEM", 94, 105]]], ["Methods: Disks containing 120 lg gentamicin were used to detect HLGR isolates.", [["gentamicin", "CHEMICAL", 33, 43], ["gentamicin", "CHEMICAL", 33, 43], ["gentamicin", "SIMPLE_CHEMICAL", 33, 43], ["HLGR", "GENE_OR_GENE_PRODUCT", 64, 68], ["lg gentamicin", "TREATMENT", 30, 43], ["HLGR isolates", "PROBLEM", 64, 77]]], ["Primers specific for aac (6') aph (2\") and aph (3') IIIa genes were used in PCR to possibly detect acetyltransferases and phosphotransferas, the common AGMEs among 113 isolates of enetrococci.", [["enetrococci", "DISEASE", 180, 191], ["aac (6') aph", "GENE_OR_GENE_PRODUCT", 21, 33], ["aph (3') IIIa", "GENE_OR_GENE_PRODUCT", 43, 56], ["phosphotransferas", "GENE_OR_GENE_PRODUCT", 122, 139], ["AGMEs", "CANCER", 152, 157], ["enetrococci", "CANCER", 180, 191], ["aph (3') IIIa genes", "DNA", 43, 62], ["acetyltransferases", "PROTEIN", 99, 117], ["aac", "TEST", 21, 24], ["aph", "TEST", 30, 33], ["aph (3') IIIa genes", "PROBLEM", 43, 62], ["PCR", "TEST", 76, 79], ["phosphotransferas", "TEST", 122, 139], ["enetrococci", "PROBLEM", 180, 191]]], ["Theses isolates were resistance to different concentration of gentamicin.", [["gentamicin", "CHEMICAL", 62, 72], ["gentamicin", "CHEMICAL", 62, 72], ["gentamicin", "SIMPLE_CHEMICAL", 62, 72], ["Theses isolates", "TREATMENT", 0, 15], ["gentamicin", "TREATMENT", 62, 72]]], ["Results: A 222 bp region of the aac (6')-aph (2\") gene was amplified by PCR in 95% HLGR isolates as well as in 40% of low level getamicin resistant isolates (LLGR).", [["getamicin", "CHEMICAL", 128, 137], ["getamicin", "CHEMICAL", 128, 137], ["aac (6')-aph (2\")", "GENE_OR_GENE_PRODUCT", 32, 49], ["222 bp region", "DNA", 11, 24], ["aac (6')-aph (2\") gene", "DNA", 32, 54], ["the aac", "TEST", 28, 35], ["PCR", "TEST", 72, 75], ["HLGR isolates", "TEST", 83, 96], ["low level getamicin resistant isolates", "PROBLEM", 118, 156]]], ["Moreover the gene aph (3') IIIa was detected in 92.5% and 72% of isolates of HLGR and LLGR respectively.", [["aph (3') IIIa", "GENE_OR_GENE_PRODUCT", 18, 31], ["gene aph (3') IIIa", "DNA", 13, 31], ["IIIa", "TEST", 27, 31], ["HLGR", "TEST", 77, 81]]], ["Differences between isolates of E. faecalis and E. faecium were found in term of prevalence of aph (3') IIIa gene.", [["E. faecalis", "ORGANISM", 32, 43], ["E. faecium", "ORGANISM", 48, 58], ["aph (3') IIIa", "GENE_OR_GENE_PRODUCT", 95, 108], ["aph (3') IIIa gene", "DNA", 95, 113], ["E. faecalis", "SPECIES", 32, 43], ["E. faecium", "SPECIES", 48, 58], ["E. faecalis", "SPECIES", 32, 43], ["E. faecium", "SPECIES", 48, 58], ["E. faecalis", "PROBLEM", 32, 43], ["E. faecium", "PROBLEM", 48, 58], ["E. faecalis", "OBSERVATION", 32, 43]]], ["Conclusion: The bifunctional enzyme AAC (6')-APH (2\") is the main cause of resistance to high concentration of aminoglycosides in our collection of enterococci.", [["aminoglycosides", "CHEMICAL", 111, 126], ["aminoglycosides", "CHEMICAL", 111, 126], ["AAC (6')-APH", "SIMPLE_CHEMICAL", 36, 48], ["aminoglycosides", "SIMPLE_CHEMICAL", 111, 126], ["enterococci", "CANCER", 148, 159], ["The bifunctional enzyme AAC", "TEST", 12, 39], ["APH", "TEST", 45, 48], ["resistance", "PROBLEM", 75, 85], ["aminoglycosides", "TREATMENT", 111, 126], ["enterococci", "PROBLEM", 148, 159], ["resistance", "OBSERVATION", 75, 85], ["high concentration", "OBSERVATION_MODIFIER", 89, 107], ["enterococci", "OBSERVATION", 148, 159]]], ["This enzyme confers resistance to all clinically useful aminoglycosides with the exception of streptomycin.", [["aminoglycosides", "CHEMICAL", 56, 71], ["streptomycin", "CHEMICAL", 94, 106], ["aminoglycosides", "CHEMICAL", 56, 71], ["streptomycin", "CHEMICAL", 94, 106], ["aminoglycosides", "SIMPLE_CHEMICAL", 56, 71], ["streptomycin", "SIMPLE_CHEMICAL", 94, 106], ["This enzyme", "TEST", 0, 11], ["aminoglycosides", "TREATMENT", 56, 71], ["streptomycin", "TREATMENT", 94, 106]]], ["In the absence of AAC (6')-APH (2\"), gentamicin could be used in combination therapy.P1589Prevalence and genetic analysis of methicillinresistant Staphylococcus aureus expressing highlevel and low-level mupirocin resistance M. Kural, T. Us, Y. Akgun (Eskisehir, TR)P1589Objectives: To investigate the genetic location of mupA gene which encoded mupirocin resistance and characterize mupirocin-resistant methicillin resistant Staphylococcus aureus (MRSA) isolated from patients in a Turkish University hospital by polymerase chain reaction (PCR) and plasmid analysis.", [["gentamicin", "CHEMICAL", 37, 47], ["mupirocin", "CHEMICAL", 203, 212], ["mupirocin", "CHEMICAL", 345, 354], ["mupirocin", "CHEMICAL", 383, 392], ["methicillin", "CHEMICAL", 403, 414], ["Staphylococcus aureus", "DISEASE", 425, 446], ["AAC (6')-APH", "CHEMICAL", 18, 30], ["gentamicin", "CHEMICAL", 37, 47], ["mupirocin", "CHEMICAL", 203, 212], ["mupirocin", "CHEMICAL", 345, 354], ["mupirocin", "CHEMICAL", 383, 392], ["methicillin", "CHEMICAL", 403, 414], ["AAC (6')-APH", "SIMPLE_CHEMICAL", 18, 30], ["gentamicin", "SIMPLE_CHEMICAL", 37, 47], ["methicillinresistant Staphylococcus aureus", "ORGANISM", 125, 167], ["mupirocin", "SIMPLE_CHEMICAL", 203, 212], ["mupA", "GENE_OR_GENE_PRODUCT", 321, 325], ["mupirocin", "SIMPLE_CHEMICAL", 345, 354], ["mupirocin", "SIMPLE_CHEMICAL", 383, 392], ["methicillin resistant Staphylococcus aureus", "ORGANISM", 403, 446], ["MRSA", "CANCER", 448, 452], ["patients", "ORGANISM", 468, 476], ["mupA gene", "DNA", 321, 330], ["Staphylococcus aureus", "SPECIES", 146, 167], ["Staphylococcus aureus", "SPECIES", 425, 446], ["MRSA", "SPECIES", 448, 452], ["patients", "SPECIES", 468, 476], ["Staphylococcus aureus", "SPECIES", 146, 167], ["Staphylococcus aureus", "SPECIES", 425, 446], ["MRSA", "SPECIES", 448, 452], ["AAC", "TEST", 18, 21], ["gentamicin", "TREATMENT", 37, 47], ["combination therapy", "TREATMENT", 65, 84], ["genetic analysis", "TEST", 105, 121], ["methicillinresistant Staphylococcus aureus", "PROBLEM", 125, 167], ["highlevel", "TEST", 179, 188], ["low-level mupirocin resistance", "TREATMENT", 193, 223], ["T. Us", "TEST", 234, 239], ["mupA gene", "TREATMENT", 321, 330], ["mupirocin resistance", "TREATMENT", 345, 365], ["mupirocin", "TREATMENT", 383, 392], ["resistant methicillin resistant Staphylococcus aureus", "PROBLEM", 393, 446], ["MRSA", "PROBLEM", 448, 452], ["polymerase chain reaction", "PROBLEM", 513, 538], ["PCR", "TEST", 540, 543], ["plasmid analysis", "TEST", 549, 565], ["methicillin resistant", "OBSERVATION_MODIFIER", 403, 424], ["Staphylococcus aureus", "OBSERVATION", 425, 446]]], ["Methods: Methicillin and mupirocin resistance were detected by disk diffusion (Oxoid, UK).", [["Methicillin", "CHEMICAL", 9, 20], ["mupirocin", "CHEMICAL", 25, 34], ["Methicillin", "CHEMICAL", 9, 20], ["mupirocin", "CHEMICAL", 25, 34], ["Methicillin", "SIMPLE_CHEMICAL", 9, 20], ["mupirocin", "SIMPLE_CHEMICAL", 25, 34], ["Methicillin", "TREATMENT", 9, 20], ["mupirocin resistance", "TREATMENT", 25, 45]]], ["The Etest (AB Biodisk, Sweden) was performed to determine mupirocin minimum inhibitory concentrations (MICs).", [["mupirocin", "CHEMICAL", 58, 67], ["mupirocin", "CHEMICAL", 58, 67], ["mupirocin", "SIMPLE_CHEMICAL", 58, 67], ["The Etest", "TEST", 0, 9], ["mupirocin minimum inhibitory concentrations", "TREATMENT", 58, 101]]], ["The presence of mupA and mecA were detected by PCR using specific primers.", [["mupA", "GENE_OR_GENE_PRODUCT", 16, 20], ["mecA", "GENE_OR_GENE_PRODUCT", 25, 29], ["mupA", "DNA", 16, 20], ["mecA", "DNA", 25, 29], ["mupA", "PROBLEM", 16, 20], ["mecA", "PROBLEM", 25, 29], ["PCR", "TEST", 47, 50], ["specific primers", "TREATMENT", 57, 73]]], ["Plasmid analysis were used to study the genetic location of mupA gene.", [["mupA", "GENE_OR_GENE_PRODUCT", 60, 64], ["mupA gene", "DNA", 60, 69], ["Plasmid analysis", "TEST", 0, 16]]], ["Results: A total of 595 (44.9%) MRSA strains were identified by disk diffusion in 1324 S. aureus.", [["S. aureus", "ORGANISM", 87, 96], ["MRSA", "SPECIES", 32, 36], ["S. aureus", "SPECIES", 87, 96], ["S. aureus", "SPECIES", 87, 96], ["MRSA strains", "PROBLEM", 32, 44], ["disk diffusion", "TEST", 64, 78], ["S. aureus", "PROBLEM", 87, 96], ["aureus", "OBSERVATION", 90, 96]]], ["Of the 595 clinical isolates 394 (66.2%) were from wound, 91 (15.3%) from blood, 41 (6.9%) from catheter, 36 (6.1%) from lower respirator tract (bronchoalveolar lavage, pleural fluid and transtracheal aspirates), 13 (2.2%) from sputum, 12 (2.0%) from urine and 8 (1.3%) from other (serebrospinal fluid, parasynthesis fluid, peritoneal fluid, and bone marrow) clinical samples.", [["wound", "ANATOMY", 51, 56], ["blood", "ANATOMY", 74, 79], ["catheter", "ANATOMY", 96, 104], ["lower respirator tract", "ANATOMY", 121, 143], ["bronchoalveolar lavage", "ANATOMY", 145, 167], ["pleural fluid", "ANATOMY", 169, 182], ["transtracheal aspirates", "ANATOMY", 187, 210], ["sputum", "ANATOMY", 228, 234], ["urine", "ANATOMY", 251, 256], ["serebrospinal fluid", "ANATOMY", 282, 301], ["parasynthesis fluid", "ANATOMY", 303, 322], ["peritoneal fluid", "ANATOMY", 324, 340], ["bone marrow", "ANATOMY", 346, 357], ["samples", "ANATOMY", 368, 375], ["wound", "PATHOLOGICAL_FORMATION", 51, 56], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["tract", "ORGANISM_SUBDIVISION", 138, 143], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 145, 167], ["pleural fluid", "MULTI-TISSUE_STRUCTURE", 169, 182], ["transtracheal aspirates", "MULTI-TISSUE_STRUCTURE", 187, 210], ["urine", "ORGANISM_SUBSTANCE", 251, 256], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 324, 340], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 346, 357], ["clinical isolates", "TEST", 11, 28], ["wound", "TEST", 51, 56], ["blood", "TEST", 74, 79], ["catheter", "TEST", 96, 104], ["lower respirator tract", "TEST", 121, 143], ["bronchoalveolar lavage", "TEST", 145, 167], ["pleural fluid", "TEST", 169, 182], ["transtracheal aspirates", "TEST", 187, 210], ["sputum", "TEST", 228, 234], ["urine", "TEST", 251, 256], ["other (serebrospinal fluid, parasynthesis fluid", "TEST", 275, 322], ["peritoneal fluid", "TEST", 324, 340], ["clinical samples", "TEST", 359, 375], ["wound", "ANATOMY", 51, 56], ["respirator tract", "ANATOMY", 127, 143], ["bronchoalveolar lavage", "OBSERVATION", 145, 167], ["pleural", "ANATOMY", 169, 176], ["fluid", "OBSERVATION", 177, 182], ["transtracheal", "ANATOMY", 187, 200], ["peritoneal", "ANATOMY", 324, 334], ["bone marrow", "ANATOMY", 346, 357]]], ["Among the MRSA isolates, mupirocin resistance was detected in 35 (5.9%) strains with disk diffusion and Etest.", [["mupirocin", "CHEMICAL", 25, 34], ["mupirocin", "CHEMICAL", 25, 34], ["mupirocin", "SIMPLE_CHEMICAL", 25, 34], ["MRSA", "SPECIES", 10, 14], ["MRSA", "SPECIES", 10, 14], ["the MRSA isolates", "TEST", 6, 23], ["mupirocin resistance", "TEST", 25, 45], ["disk diffusion", "TEST", 85, 99], ["Etest", "TEST", 104, 109]]], ["Of the 35 mupirosin-resistant isolates 23 (3.9%) expressed high-level (MuH) and 12 (2%) expressed lowlevel (MuL) mupirocin resistance.", [["mupirosin", "CHEMICAL", 10, 19], ["mupirocin", "CHEMICAL", 113, 122], ["mupirosin", "CHEMICAL", 10, 19], ["mupirocin", "CHEMICAL", 113, 122], ["mupirosin", "GENE_OR_GENE_PRODUCT", 10, 19], ["mupirocin", "SIMPLE_CHEMICAL", 113, 122], ["resistant isolates", "TEST", 20, 38], ["mupirocin resistance", "TREATMENT", 113, 133]]], ["All isolates were vancomycin, teicoplannin susceptible and chloramphenicol resistant with disk diffusion.", [["vancomycin", "CHEMICAL", 18, 28], ["teicoplannin", "CHEMICAL", 30, 42], ["chloramphenicol", "CHEMICAL", 59, 74], ["vancomycin", "CHEMICAL", 18, 28], ["teicoplannin", "CHEMICAL", 30, 42], ["chloramphenicol", "CHEMICAL", 59, 74], ["vancomycin", "SIMPLE_CHEMICAL", 18, 28], ["teicoplannin", "SIMPLE_CHEMICAL", 30, 42], ["chloramphenicol", "SIMPLE_CHEMICAL", 59, 74], ["All isolates", "TREATMENT", 0, 12], ["vancomycin", "TREATMENT", 18, 28], ["teicoplannin", "TREATMENT", 30, 42], ["chloramphenicol", "TREATMENT", 59, 74], ["disk diffusion", "PROBLEM", 90, 104]]], ["Isolates with high-level and low level mupirocin resistance due to the mupA gene were also detected with PCR.", [["mupirocin", "CHEMICAL", 39, 48], ["mupirocin", "CHEMICAL", 39, 48], ["mupirocin", "SIMPLE_CHEMICAL", 39, 48], ["mupA", "GENE_OR_GENE_PRODUCT", 71, 75], ["mupA gene", "DNA", 71, 80], ["Isolates", "TEST", 0, 8], ["low level mupirocin resistance", "TREATMENT", 29, 59], ["the mupA gene", "PROBLEM", 67, 80], ["PCR", "TEST", 105, 108], ["low level", "OBSERVATION_MODIFIER", 29, 38], ["mupirocin resistance", "OBSERVATION", 39, 59]]], ["Plasmids were detected in all of the 35 isolates.", [["Plasmids", "TREATMENT", 0, 8]]], ["However only the MuH isolates contained a 38 kb plasmid that encoded highlevel resistance.", [["plasmid", "ANATOMY", 48, 55], ["38 kb plasmid", "DNA", 42, 55], ["the MuH isolates", "TEST", 13, 29], ["a 38 kb plasmid", "TREATMENT", 40, 55], ["highlevel resistance", "OBSERVATION", 69, 89]]], ["All of the isolates contained a 4.4 kb plasmid and resistant to chloramphenicol.", [["plasmid", "ANATOMY", 39, 46], ["chloramphenicol", "CHEMICAL", 64, 79], ["chloramphenicol", "CHEMICAL", 64, 79], ["chloramphenicol", "SIMPLE_CHEMICAL", 64, 79], ["4.4 kb plasmid", "DNA", 32, 46], ["the isolates", "TEST", 7, 19], ["a 4.4 kb plasmid", "TREATMENT", 30, 46], ["chloramphenicol", "TREATMENT", 64, 79]]], ["Conclusion: Our results indicated that the MRSA clones detected in the hospital had acquired a high-level mupirocin resistant plasmid.", [["MRSA clones", "ANATOMY", 43, 54], ["plasmid", "ANATOMY", 126, 133], ["mupirocin", "CHEMICAL", 106, 115], ["mupirocin", "CHEMICAL", 106, 115], ["MRSA clones", "CELL", 43, 54], ["mupirocin", "SIMPLE_CHEMICAL", 106, 115], ["MRSA clones", "CELL_LINE", 43, 54], ["mupirocin resistant plasmid", "DNA", 106, 133], ["MRSA", "SPECIES", 43, 47], ["MRSA", "SPECIES", 43, 47], ["the MRSA clones", "PROBLEM", 39, 54], ["a high-level mupirocin resistant plasmid", "TREATMENT", 93, 133], ["MRSA clones", "OBSERVATION", 43, 54]]], ["The past observations and recent studies suggested that the numbers of such strians have increased following extensive topical use of mupirocin.", [["mupirocin", "CHEMICAL", 134, 143], ["mupirocin", "CHEMICAL", 134, 143], ["mupirocin", "SIMPLE_CHEMICAL", 134, 143], ["recent studies", "TEST", 26, 40], ["such strians", "PROBLEM", 71, 83], ["mupirocin", "TREATMENT", 134, 143], ["increased", "OBSERVATION_MODIFIER", 89, 98]]], ["The usage of mupirocin in our hospital has not yet been systematically implemented.", [["mupirocin", "CHEMICAL", 13, 22], ["mupirocin", "CHEMICAL", 13, 22], ["mupirocin", "SIMPLE_CHEMICAL", 13, 22], ["mupirocin", "TREATMENT", 13, 22]]], ["It is frequently prescribed for the treatment of staphylococcal skin infections and less to eliminate nasal carriage of MRSA.", [["skin", "ANATOMY", 64, 68], ["nasal", "ANATOMY", 102, 107], ["staphylococcal skin infections", "DISEASE", 49, 79], ["MRSA", "DISEASE", 120, 124], ["staphylococcal", "ORGANISM", 49, 63], ["skin", "ORGAN", 64, 68], ["nasal", "ORGANISM_SUBDIVISION", 102, 107], ["MRSA", "SPECIES", 120, 124], ["MRSA", "SPECIES", 120, 124], ["staphylococcal skin infections", "PROBLEM", 49, 79], ["nasal carriage of MRSA", "PROBLEM", 102, 124], ["staphylococcal", "OBSERVATION_MODIFIER", 49, 63], ["skin", "ANATOMY", 64, 68], ["infections", "OBSERVATION", 69, 79], ["MRSA", "OBSERVATION", 120, 124]]], ["In our hospital we should be aware of the possible emergence and increase of mupirocin highly resistant MRSA strains in the future so that we should be considered when using mupirocin to control the spread of MRSA in hospital.P1590Emergence and spread of acquired fusidic acid resistance in Staphylococcus aureus Objectives: A major route to fusidic acid resistance (fusR) in S. aureus involves acquisition of fusB, a resistance determinant first Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006 identified on plasmid pUB101.", [["plasmid", "ANATOMY", 528, 535], ["mupirocin", "CHEMICAL", 77, 86], ["MRSA", "DISEASE", 104, 108], ["mupirocin", "CHEMICAL", 174, 183], ["MRSA", "DISEASE", 209, 213], ["P1590", "CHEMICAL", 226, 231], ["fusidic acid", "CHEMICAL", 264, 276], ["Staphylococcus aureus", "DISEASE", 291, 312], ["fusidic acid", "CHEMICAL", 342, 354], ["Infection", "DISEASE", 473, 482], ["mupirocin", "CHEMICAL", 77, 86], ["mupirocin", "CHEMICAL", 174, 183], ["P1590", "CHEMICAL", 226, 231], ["fusidic acid", "CHEMICAL", 264, 276], ["fusidic acid", "CHEMICAL", 342, 354], ["mupirocin", "SIMPLE_CHEMICAL", 77, 86], ["mupirocin", "SIMPLE_CHEMICAL", 174, 183], ["fusidic acid", "SIMPLE_CHEMICAL", 264, 276], ["Staphylococcus aureus", "ORGANISM", 291, 312], ["fusidic acid", "SIMPLE_CHEMICAL", 342, 354], ["fusR", "SIMPLE_CHEMICAL", 367, 371], ["S. aureus", "ORGANISM", 376, 385], ["fusB", "GENE_OR_GENE_PRODUCT", 410, 414], ["pUB101", "GENE_OR_GENE_PRODUCT", 536, 542], ["P1590", "PROTEIN", 226, 231], ["fusB", "PROTEIN", 410, 414], ["plasmid pUB101", "DNA", 528, 542], ["MRSA", "SPECIES", 104, 108], ["MRSA", "SPECIES", 209, 213], ["Staphylococcus aureus", "SPECIES", 291, 312], ["S. aureus", "SPECIES", 376, 385], ["MRSA", "SPECIES", 104, 108], ["MRSA", "SPECIES", 209, 213], ["Staphylococcus aureus", "SPECIES", 291, 312], ["S. aureus", "SPECIES", 376, 385], ["mupirocin", "TREATMENT", 77, 86], ["highly resistant MRSA strains", "PROBLEM", 87, 116], ["mupirocin", "TREATMENT", 174, 183], ["MRSA", "PROBLEM", 209, 213], ["acquired fusidic acid resistance", "PROBLEM", 255, 287], ["Staphylococcus aureus", "PROBLEM", 291, 312], ["fusidic acid resistance", "PROBLEM", 342, 365], ["S. aureus", "PROBLEM", 376, 385], ["a resistance determinant", "PROBLEM", 416, 440], ["Infection", "PROBLEM", 473, 482], ["Volume", "TEST", 484, 490], ["MRSA", "OBSERVATION", 209, 213], ["Staphylococcus aureus", "OBSERVATION", 291, 312], ["aureus", "OBSERVATION", 379, 385], ["Infection", "OBSERVATION", 473, 482]]], ["Here we show that (i) the two currently-circulating major clones of fusR S. aureus identified to date have acquired fusB from pUB101 (or from the same ancestral source as pUB101), and (ii) that the pUB101-encoded FusB is only one of at least three lineages of this protein that appear to have evolved since recruitment of the original, ancestral fusB to the Staphylococci.", [["fusR S. aureus", "ORGANISM", 68, 82], ["fusB", "GENE_OR_GENE_PRODUCT", 116, 120], ["pUB101", "GENE_OR_GENE_PRODUCT", 126, 132], ["pUB101", "GENE_OR_GENE_PRODUCT", 171, 177], ["pUB101", "GENE_OR_GENE_PRODUCT", 198, 204], ["FusB", "GENE_OR_GENE_PRODUCT", 213, 217], ["fusB", "GENE_OR_GENE_PRODUCT", 346, 350], ["fusB", "PROTEIN", 116, 120], ["pUB101", "PROTEIN", 126, 132], ["pUB101", "PROTEIN", 171, 177], ["pUB101", "PROTEIN", 198, 204], ["FusB", "PROTEIN", 213, 217], ["fusB", "DNA", 346, 350], ["S. aureus", "SPECIES", 73, 82], ["S. aureus", "SPECIES", 73, 82], ["fusR S. aureus", "PROBLEM", 68, 82], ["acquired fusB from pUB101", "PROBLEM", 107, 132], ["the pUB101", "TEST", 194, 204], ["this protein", "PROBLEM", 260, 272], ["the Staphylococci", "PROBLEM", 354, 371], ["aureus", "OBSERVATION", 76, 82], ["Staphylococci", "OBSERVATION", 358, 371]]], ["Methods: Plasmid purification, DNA sequencing, PCR amplification, and cloning in S. aureus RN4220 using shuttlevector pCU1, were all performed using established methods.", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["S. aureus RN4220", "ORGANISM", 81, 97], ["shuttlevector pCU1", "GENE_OR_GENE_PRODUCT", 104, 122], ["shuttlevector pCU1", "DNA", 104, 122], ["S. aureus", "SPECIES", 81, 90], ["S. aureus", "SPECIES", 81, 90], ["Plasmid purification", "TREATMENT", 9, 29], ["DNA sequencing", "TEST", 31, 45], ["PCR amplification", "TEST", 47, 64], ["shuttlevector pCU1", "TREATMENT", 104, 122]]], ["Antibiotic susceptibility testing was performed by agar dilution.", [["Antibiotic susceptibility testing", "TEST", 0, 33]]], ["Results: The Epidemic European Fusidic acid-resistant Impetigo Clone (EEFIC) and community-acquired MRSA strain ST80 have been shown to carry chromosomal and plasmid-encoded fusB, respectively.", [["chromosomal", "ANATOMY", 142, 153], ["ST80", "CHEMICAL", 112, 116], ["chromosomal", "CELLULAR_COMPONENT", 142, 153], ["fusB", "GENE_OR_GENE_PRODUCT", 174, 178], ["plasmid", "DNA", 158, 165], ["fusB", "DNA", 174, 178], ["MRSA", "SPECIES", 100, 104], ["MRSA strain ST80", "SPECIES", 100, 116], ["The Epidemic European Fusidic acid-resistant Impetigo Clone", "PROBLEM", 9, 68], ["MRSA strain ST80", "PROBLEM", 100, 116]]], ["DNA sequencing of fusB and its surrounding regions in these backgrounds revealed that they are identical to sequences on pUB101.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["fusB", "GENE_OR_GENE_PRODUCT", 18, 22], ["pUB101", "GENE_OR_GENE_PRODUCT", 121, 127], ["fusB", "DNA", 18, 22], ["pUB101", "DNA", 121, 127], ["DNA sequencing of fusB", "TEST", 0, 22], ["pUB101", "TEST", 121, 127]]], ["However, acquired fusR does not always result from acquisition of the prototypical fusB gene.", [["fusR", "GENE_OR_GENE_PRODUCT", 18, 22], ["fusB", "GENE_OR_GENE_PRODUCT", 83, 87], ["fusR", "PROTEIN", 18, 22], ["fusB gene", "DNA", 83, 92]]], ["A gene encoding a FusB homologue was recently identified during sequencing of S. aureus strain MSSA476, and we identified an additional homologue encoded in the genome of S. saprophyticus strain ATCC15305.", [["FusB", "GENE_OR_GENE_PRODUCT", 18, 22], ["S. aureus strain", "ORGANISM", 78, 94], ["MSSA476", "ORGANISM", 95, 102], ["S. saprophyticus strain", "ORGANISM", 171, 194], ["ATCC15305", "ORGANISM", 195, 204], ["FusB homologue", "DNA", 18, 32], ["S. aureus", "SPECIES", 78, 87], ["S. saprophyticus", "SPECIES", 171, 187], ["S. aureus strain MSSA476", "SPECIES", 78, 102], ["S. saprophyticus", "SPECIES", 171, 187], ["S. aureus strain MSSA476", "PROBLEM", 78, 102], ["aureus", "OBSERVATION", 81, 87], ["saprophyticus strain", "OBSERVATION", 174, 194]]], ["The products of these genes exhibit~40% homology to FusB and to each other.", [["FusB", "GENE_OR_GENE_PRODUCT", 52, 56], ["FusB", "PROTEIN", 52, 56]]], ["Cloning of PCR amplicons corresponding to these genes and their upstream expression signals into S. aureus established that they both confer resistance to fus.", [["S. aureus", "ORGANISM", 97, 106], ["PCR amplicons", "DNA", 11, 24], ["S. aureus", "SPECIES", 97, 106], ["S. aureus", "SPECIES", 97, 106], ["Cloning of PCR amplicons", "TREATMENT", 0, 24], ["S. aureus", "PROBLEM", 97, 106]]], ["Since these functional homologues are more closely related to each other than to those from other Gram-positive organisms, it is highly likely that they evolved from an ancestral FusB after its recruitment to the Staphylococci.", [["Gram", "GENE_OR_GENE_PRODUCT", 98, 102], ["FusB", "GENE_OR_GENE_PRODUCT", 179, 183], ["FusB", "DNA", 179, 183], ["other Gram-positive organisms", "PROBLEM", 92, 121], ["an ancestral FusB", "PROBLEM", 166, 183], ["the Staphylococci", "PROBLEM", 209, 226], ["positive organisms", "OBSERVATION", 103, 121], ["highly likely", "UNCERTAINTY", 129, 142], ["ancestral FusB", "OBSERVATION", 169, 183], ["Staphylococci", "OBSERVATION", 213, 226]]], ["Conclusions: The three members of the staphylococcal family of FusB proteins appear to have evolved from the same ancestral protein, which, based on the low level of sequence homology between fusB genes at the nucleotide level, clearly occurred well before the introduction of fus into the clinic.", [["nucleotide", "CHEMICAL", 210, 220], ["FusB", "GENE_OR_GENE_PRODUCT", 63, 67], ["fusB", "GENE_OR_GENE_PRODUCT", 192, 196], ["staphylococcal family", "PROTEIN", 38, 59], ["FusB proteins", "PROTEIN", 63, 76], ["ancestral protein", "PROTEIN", 114, 131], ["fusB genes", "DNA", 192, 202], ["FusB proteins", "PROBLEM", 63, 76]]], ["Of the three, the FusB protein encoded by pUB101 is by far the most successful, and this gene/plasmid represents the source of (or shares a source with) the major fusR strain lineages.P1591Telithromycin activity is reduced by efflux in Streptococcus pneumoniae C. Benvenuti, R. Koncan, G. Bahar, A. Mazzariol, G. Cornaglia (Verona, IT; Ankara, TR)P1591Objectives: Telithromycin shows an excellent activity against M-type erythromycin-resistant Streptococcus pneumoniae, thus is commonly regarded as being capable of overcoming the efflux resistance mechanism.", [["P1591Telithromycin", "CHEMICAL", 184, 202], ["Telithromycin", "CHEMICAL", 364, 377], ["erythromycin", "CHEMICAL", 421, 433], ["Streptococcus pneumoniae", "DISEASE", 444, 468], ["P1591Telithromycin", "CHEMICAL", 184, 202], ["Telithromycin", "CHEMICAL", 364, 377], ["erythromycin", "CHEMICAL", 421, 433], ["FusB", "GENE_OR_GENE_PRODUCT", 18, 22], ["pUB101", "GENE_OR_GENE_PRODUCT", 42, 48], ["fusR", "GENE_OR_GENE_PRODUCT", 163, 167], ["P1591Telithromycin", "SIMPLE_CHEMICAL", 184, 202], ["Streptococcus pneumoniae", "ORGANISM", 236, 260], ["Telithromycin", "SIMPLE_CHEMICAL", 364, 377], ["M-type erythromycin", "SIMPLE_CHEMICAL", 414, 433], ["Streptococcus pneumoniae", "ORGANISM", 444, 468], ["FusB protein", "PROTEIN", 18, 30], ["pUB101", "PROTEIN", 42, 48], ["plasmid", "DNA", 94, 101], ["Streptococcus pneumoniae", "SPECIES", 236, 260], ["Streptococcus pneumoniae", "SPECIES", 444, 468], ["Streptococcus pneumoniae", "SPECIES", 236, 260], ["Streptococcus pneumoniae", "SPECIES", 444, 468], ["the FusB protein", "TEST", 14, 30], ["this gene/plasmid", "TREATMENT", 84, 101], ["the major fusR strain lineages", "PROBLEM", 153, 183], ["Streptococcus pneumoniae", "PROBLEM", 236, 260], ["Telithromycin", "TREATMENT", 364, 377], ["type erythromycin", "TREATMENT", 416, 433], ["resistant Streptococcus pneumoniae", "PROBLEM", 434, 468], ["the efflux resistance mechanism", "PROBLEM", 527, 558], ["Streptococcus pneumoniae", "OBSERVATION", 236, 260], ["Streptococcus pneumoniae", "OBSERVATION", 444, 468], ["efflux resistance", "OBSERVATION", 531, 548]]], ["Nevertheless, telithromycin MIC values in those strains appear to be distinctly higher than in the erythromycin-susceptible ones.", [["telithromycin", "CHEMICAL", 14, 27], ["erythromycin", "CHEMICAL", 99, 111], ["telithromycin", "CHEMICAL", 14, 27], ["erythromycin", "CHEMICAL", 99, 111], ["telithromycin", "SIMPLE_CHEMICAL", 14, 27], ["erythromycin", "SIMPLE_CHEMICAL", 99, 111], ["telithromycin MIC values", "TEST", 14, 38], ["those strains", "PROBLEM", 42, 55], ["the erythromycin", "TREATMENT", 95, 111], ["distinctly", "OBSERVATION_MODIFIER", 69, 79], ["higher", "OBSERVATION_MODIFIER", 80, 86]]], ["The possibility of telithromycin acting as an actual efflux substrate, as it was already demonstrated in Streptococcus pyogenes, seemed worth investigating.", [["telithromycin", "CHEMICAL", 19, 32], ["Streptococcus pyogenes", "DISEASE", 105, 127], ["telithromycin", "CHEMICAL", 19, 32], ["telithromycin", "SIMPLE_CHEMICAL", 19, 32], ["Streptococcus pyogenes", "ORGANISM", 105, 127], ["Streptococcus pyogenes", "SPECIES", 105, 127], ["Streptococcus pyogenes", "SPECIES", 105, 127], ["telithromycin", "TREATMENT", 19, 32], ["an actual efflux substrate", "TEST", 43, 69], ["Streptococcus pyogenes", "PROBLEM", 105, 127], ["telithromycin", "OBSERVATION", 19, 32], ["Streptococcus pyogenes", "OBSERVATION", 105, 127]]], ["Methods: Telithromycin MIC distribution was analysed in a collection of 423 Italian S. pneumoniae strains originating from multi-centre studies (2000) (2001) (2002) (2003) .", [["Telithromycin", "CHEMICAL", 9, 22], ["Telithromycin", "CHEMICAL", 9, 22], ["Telithromycin", "SIMPLE_CHEMICAL", 9, 22], ["S. pneumoniae", "ORGANISM", 84, 97], ["S. pneumoniae", "SPECIES", 84, 97], ["S. pneumoniae", "SPECIES", 84, 97], ["Telithromycin MIC distribution", "TREATMENT", 9, 39], ["pneumoniae strains", "PROBLEM", 87, 105], ["multi-centre studies", "TEST", 123, 143]]], ["The effect of an efflux mechanism was investigated using [3H]-telithromycin.", [["[3H]-telithromycin", "CHEMICAL", 57, 75], ["[3H]-telithromycin", "CHEMICAL", 57, 75], ["[3H]-telithromycin", "SIMPLE_CHEMICAL", 57, 75], ["an efflux mechanism", "PROBLEM", 14, 33], ["telithromycin", "TREATMENT", 62, 75], ["efflux mechanism", "OBSERVATION", 17, 33]]], ["Results: Telithromycin MIC ranges were \u00a30.002-0.12 mg/l (MIC50 0.008 mg/l and MIC90 0.03 mg/l) in erythromycinsusceptible strains (lacking both mef and erm genes) and 0.016-1 mg/l (MIC50 0.25 mg/l and MIC90 0.5 mg/l) in strains endowed with the M phenotype.", [["Telithromycin", "CHEMICAL", 9, 22], ["Telithromycin", "CHEMICAL", 9, 22], ["Telithromycin", "SIMPLE_CHEMICAL", 9, 22], ["erm", "GENE_OR_GENE_PRODUCT", 152, 155], ["Telithromycin MIC ranges", "TEST", 9, 33], ["MIC50", "TREATMENT", 57, 62], ["MIC90", "TREATMENT", 78, 83], ["erythromycinsusceptible strains", "TREATMENT", 98, 129], ["lacking both mef and erm genes", "TREATMENT", 131, 161], ["MIC50", "TREATMENT", 181, 186], ["MIC90", "TREATMENT", 201, 206], ["strains", "PROBLEM", 220, 227]]], ["A distinct telithromycin efflux was detected in the strains expressing the mef gene, but not in those expressing the erm(B) gene, nor in the susceptible strains lacking mef or erm genes.", [["telithromycin", "CHEMICAL", 11, 24], ["telithromycin", "CHEMICAL", 11, 24], ["telithromycin", "SIMPLE_CHEMICAL", 11, 24], ["mef", "GENE_OR_GENE_PRODUCT", 75, 78], ["erm(B)", "GENE_OR_GENE_PRODUCT", 117, 123], ["mef", "GENE_OR_GENE_PRODUCT", 169, 172], ["erm", "GENE_OR_GENE_PRODUCT", 176, 179], ["mef gene", "DNA", 75, 83], ["erm(B) gene", "DNA", 117, 128], ["mef or erm genes", "DNA", 169, 185], ["A distinct telithromycin efflux", "PROBLEM", 0, 31], ["distinct", "OBSERVATION_MODIFIER", 2, 10], ["telithromycin efflux", "OBSERVATION", 11, 31], ["erm genes", "OBSERVATION", 176, 185]]], ["Efflux reversibility by addition of an inhibiting compound (sodium arsenate) was demonstrated.", [["sodium arsenate", "CHEMICAL", 60, 75], ["sodium arsenate", "CHEMICAL", 60, 75], ["sodium arsenate", "SIMPLE_CHEMICAL", 60, 75], ["Efflux reversibility", "PROBLEM", 0, 20], ["an inhibiting compound (sodium arsenate", "TREATMENT", 36, 75]]], ["An msr-like sequence was also found in all strains effluxing telithromycin, but not in the others.", [["telithromycin", "CHEMICAL", 61, 74], ["telithromycin", "CHEMICAL", 61, 74], ["msr-", "GENE_OR_GENE_PRODUCT", 3, 7], ["telithromycin", "SIMPLE_CHEMICAL", 61, 74], ["msr-like sequence", "DNA", 3, 20], ["An msr-like sequence", "TEST", 0, 20], ["telithromycin", "TREATMENT", 61, 74]]], ["Conclusions: This is the first time that telithromycin has been shown to be effluxed by S. pyogenes isolates.", [["telithromycin", "CHEMICAL", 41, 54], ["telithromycin", "CHEMICAL", 41, 54], ["telithromycin", "SIMPLE_CHEMICAL", 41, 54], ["S. pyogenes isolates", "ORGANISM", 88, 108], ["S. pyogenes", "SPECIES", 88, 99], ["S. pyogenes", "SPECIES", 88, 99], ["telithromycin", "TREATMENT", 41, 54], ["S. pyogenes isolates", "PROBLEM", 88, 108]]], ["That the efflux is related to the presence of both the mef and the msr-like genes is clearly demonstrated, but -owing to the increasingly evident complexity of S. pneumoniae efflux systems -other genes might also contribute to the efflux.P1592An unusual phenotype of Enterococcus faecalis in Greece expressing low-level resistance to clindamycin and dalfopristin but susceptibility to quinupristin-dalfopristin M. Maniati, F. Kontos, P. Liakos, E. Petinaki, I. Spiliopoulou, A. Maniatis (Larissa, Patras, GR)P1592Objectives: To investigate the resistance mechanism of a new described phenotype among Enterococcus faecalis expressing lowlevel resistance to clindamycin and dalfopristin but susceptibility to quinupristin-dalfopristin (Q-D).", [["clindamycin", "CHEMICAL", 334, 345], ["dalfopristin", "CHEMICAL", 350, 362], ["quinupristin", "CHEMICAL", 385, 397], ["clindamycin", "CHEMICAL", 656, 667], ["dalfopristin", "CHEMICAL", 672, 684], ["quinupristin-dalfopristin", "CHEMICAL", 707, 732], ["Q-D", "CHEMICAL", 734, 737], ["clindamycin", "CHEMICAL", 334, 345], ["dalfopristin", "CHEMICAL", 350, 362], ["quinupristin", "CHEMICAL", 385, 397], ["clindamycin", "CHEMICAL", 656, 667], ["dalfopristin", "CHEMICAL", 672, 684], ["quinupristin", "CHEMICAL", 707, 719], ["dalfopristin", "CHEMICAL", 720, 732], ["Q-D", "CHEMICAL", 734, 737], ["mef", "GENE_OR_GENE_PRODUCT", 55, 58], ["msr-like", "GENE_OR_GENE_PRODUCT", 67, 75], ["S. pneumoniae", "ORGANISM", 160, 173], ["Enterococcus faecalis", "ORGANISM", 267, 288], ["clindamycin", "SIMPLE_CHEMICAL", 334, 345], ["dalfopristin", "SIMPLE_CHEMICAL", 350, 362], ["quinupristin", "SIMPLE_CHEMICAL", 385, 397], ["Enterococcus faecalis", "ORGANISM", 600, 621], ["clindamycin", "SIMPLE_CHEMICAL", 656, 667], ["dalfopristin", "SIMPLE_CHEMICAL", 672, 684], ["quinupristin-dalfopristin", "SIMPLE_CHEMICAL", 707, 732], ["Q-D", "SIMPLE_CHEMICAL", 734, 737], ["mef", "DNA", 55, 58], ["msr-like genes", "DNA", 67, 81], ["S. pneumoniae", "SPECIES", 160, 173], ["Enterococcus faecalis", "SPECIES", 267, 288], ["Enterococcus faecalis", "SPECIES", 600, 621], ["S. pneumoniae", "SPECIES", 160, 173], ["Enterococcus faecalis", "SPECIES", 267, 288], ["Enterococcus faecalis", "SPECIES", 600, 621], ["the efflux", "PROBLEM", 5, 15], ["S. pneumoniae efflux systems", "PROBLEM", 160, 188], ["the efflux", "PROBLEM", 227, 237], ["Enterococcus faecalis", "PROBLEM", 267, 288], ["clindamycin", "TREATMENT", 334, 345], ["dalfopristin", "TREATMENT", 350, 362], ["quinupristin", "TEST", 385, 397], ["a new described phenotype", "PROBLEM", 568, 593], ["Enterococcus faecalis", "PROBLEM", 600, 621], ["clindamycin", "TREATMENT", 656, 667], ["dalfopristin", "TREATMENT", 672, 684], ["quinupristin", "TREATMENT", 707, 719], ["dalfopristin", "TREATMENT", 720, 732], ["efflux", "OBSERVATION", 9, 15], ["mef", "OBSERVATION", 55, 58], ["pneumoniae", "OBSERVATION", 163, 173], ["Enterococcus faecalis", "OBSERVATION", 267, 288]]], ["Methods: In Greece, during 2005, three Enterococcus faecalis isolates, expressing this unusual phenotype, were recovered from urine samples.", [["urine samples", "ANATOMY", 126, 139], ["Enterococcus faecalis", "ORGANISM", 39, 60], ["urine samples", "ORGANISM_SUBSTANCE", 126, 139], ["Enterococcus faecalis", "SPECIES", 39, 60], ["Enterococcus faecalis", "SPECIES", 39, 60], ["three Enterococcus faecalis isolates", "TREATMENT", 33, 69], ["this unusual phenotype", "PROBLEM", 82, 104], ["urine samples", "TEST", 126, 139]]], ["The isolates were studied by PCR for the lsa-gene and by PFGE.", [["lsa-gene", "DNA", 41, 49], ["The isolates", "TEST", 0, 12]]], ["Nucleotide sequencing analysis of lsa and 309 bp of the upstream region was performed.", [["lsa", "GENE_OR_GENE_PRODUCT", 34, 37], ["lsa", "DNA", 34, 37], ["upstream region", "DNA", 56, 71], ["Nucleotide sequencing analysis", "TEST", 0, 30], ["lsa", "TEST", 34, 37], ["lsa", "ANATOMY", 34, 37]]], ["The isolates were also tested by RT-PCR for the expression of the lsa-gene.", [["lsa-gene", "GENE_OR_GENE_PRODUCT", 66, 74], ["lsa-gene", "DNA", 66, 74], ["The isolates", "TEST", 0, 12], ["PCR", "TEST", 36, 39], ["the lsa-gene", "TREATMENT", 62, 74]]], ["Results: The isolates belonged to three distinct clones and carried the lsa-gene.", [["clones", "CELL", 49, 55], ["lsa-gene", "DNA", 72, 80]]], ["No stop codons were found in any strain, while some point mutations in the lsa-gene were detected.", [["lsa-gene", "GENE_OR_GENE_PRODUCT", 75, 83], ["lsa-gene", "DNA", 75, 83], ["stop codons", "PROBLEM", 3, 14], ["any strain", "PROBLEM", 29, 39], ["some point mutations", "PROBLEM", 47, 67]]], ["Comparing the lsa mRNA production of these unusual strains with that obtained from fully Q-D resistant ones no quantitative differences were found.", [["lsa", "GENE_OR_GENE_PRODUCT", 14, 17], ["lsa mRNA", "RNA", 14, 22], ["these unusual strains", "PROBLEM", 37, 58], ["quantitative differences", "PROBLEM", 111, 135]]], ["Conclusions: The findings of the present study clearly show that the resistance mechanism of quinupristin-dalfopristin is not only correlated with the presence and the expression of the lsagene.", [["quinupristin", "CHEMICAL", 93, 105], ["dalfopristin", "CHEMICAL", 106, 118], ["quinupristin", "CHEMICAL", 93, 105], ["dalfopristin", "CHEMICAL", 106, 118], ["quinupristin-dalfopristin", "SIMPLE_CHEMICAL", 93, 118], ["lsagene", "GENE_OR_GENE_PRODUCT", 186, 193], ["lsagene", "PROTEIN", 186, 193], ["the present study", "TEST", 29, 46], ["the resistance mechanism of quinupristin-dalfopristin", "PROBLEM", 65, 118]]], ["Some mutations detected in the lsa gene probably are responsible for the production of an Lsa protein with decreased activity, resulting to the Q-D susceptibility.P1593The presence of erm TR gene is responsible for the macrolide-resistance of Streptococcus agalactiaeP1593Objectives: To investigate the mechanism of resistance to macrolides in strains of Streptococcus agalactiae in the area of Thessalia, Greece during the period 2000-2005.P1593Methods: The subject of this study were 147 strains of S. agalactiae which were collected from clinical specimens (90% vaginal swabs) from pregnant and non pregnant women.", [["specimens", "ANATOMY", 550, 559], ["vaginal swabs", "ANATOMY", 565, 578], ["macrolide", "CHEMICAL", 219, 228], ["macrolides", "CHEMICAL", 330, 340], ["Streptococcus agalactiae", "DISEASE", 355, 379], ["macrolide", "CHEMICAL", 219, 228], ["macrolides", "CHEMICAL", 330, 340], ["lsa", "GENE_OR_GENE_PRODUCT", 31, 34], ["Lsa", "GENE_OR_GENE_PRODUCT", 90, 93], ["Q-D", "GENE_OR_GENE_PRODUCT", 144, 147], ["erm TR", "GENE_OR_GENE_PRODUCT", 184, 190], ["macrolide", "SIMPLE_CHEMICAL", 219, 228], ["Streptococcus agalactiae", "ORGANISM", 243, 267], ["macrolides", "SIMPLE_CHEMICAL", 330, 340], ["Streptococcus agalactiae", "ORGANISM", 355, 379], ["S. agalactiae", "ORGANISM", 501, 514], ["vaginal swabs", "MULTI-TISSUE_STRUCTURE", 565, 578], ["women", "ORGANISM", 611, 616], ["lsa gene", "DNA", 31, 39], ["Lsa protein", "PROTEIN", 90, 101], ["erm TR gene", "DNA", 184, 195], ["Streptococcus agalactiae", "SPECIES", 243, 267], ["Streptococcus agalactiae", "SPECIES", 355, 379], ["S. agalactiae", "SPECIES", 501, 514], ["women", "SPECIES", 611, 616], ["Streptococcus agalactiae", "SPECIES", 243, 267], ["Streptococcus agalactiae", "SPECIES", 355, 379], ["S. agalactiae", "SPECIES", 501, 514], ["Some mutations", "PROBLEM", 0, 14], ["an Lsa protein", "PROBLEM", 87, 101], ["decreased activity", "PROBLEM", 107, 125], ["the Q-D susceptibility", "PROBLEM", 140, 162], ["erm TR gene", "PROBLEM", 184, 195], ["the macrolide", "TREATMENT", 215, 228], ["Streptococcus agalactiae", "PROBLEM", 243, 267], ["macrolides", "TREATMENT", 330, 340], ["Streptococcus agalactiae", "PROBLEM", 355, 379], ["this study", "TEST", 470, 480], ["S. agalactiae", "PROBLEM", 501, 514], ["clinical specimens", "TEST", 541, 559], ["mutations", "OBSERVATION", 5, 14], ["erm", "OBSERVATION", 184, 187], ["Streptococcus agalactiae", "OBSERVATION", 355, 379]]], ["The strains were identified by Gram stain, the Lancefield B antigen, and by API Strep System (BioMerieux, France).", [["Lancefield B antigen", "GENE_OR_GENE_PRODUCT", 47, 67], ["Lancefield B antigen", "PROTEIN", 47, 67], ["The strains", "PROBLEM", 0, 11], ["Gram stain", "TEST", 31, 41], ["the Lancefield B antigen", "TEST", 43, 67]]], ["Susceptibility to macrolides, lincosamides and streptogrammines B was studied by the disk diffusion method.", [["macrolides", "CHEMICAL", 18, 28], ["lincosamides", "CHEMICAL", 30, 42], ["streptogrammines B", "CHEMICAL", 47, 65], ["macrolides", "CHEMICAL", 18, 28], ["lincosamides", "CHEMICAL", 30, 42], ["streptogrammines B", "CHEMICAL", 47, 65], ["macrolides", "SIMPLE_CHEMICAL", 18, 28], ["lincosamides", "SIMPLE_CHEMICAL", 30, 42], ["streptogrammines B", "SIMPLE_CHEMICAL", 47, 65], ["macrolides", "TREATMENT", 18, 28], ["lincosamides", "TREATMENT", 30, 42], ["streptogrammines B", "TREATMENT", 47, 65], ["the disk diffusion method", "TEST", 81, 106], ["macrolides", "OBSERVATION", 18, 28]]], ["The MICs were also measured by the use of E-test.", [["The MICs", "TREATMENT", 0, 8], ["E-test", "TEST", 42, 48]]], ["The detection of the genes mef A, erm TR, and erm B was performed by Polymerase Chain Reaction (PCR).", [["mef A", "GENE_OR_GENE_PRODUCT", 27, 32], ["erm TR", "GENE_OR_GENE_PRODUCT", 34, 40], ["erm B", "GENE_OR_GENE_PRODUCT", 46, 51], ["genes mef A", "DNA", 21, 32], ["erm TR", "DNA", 34, 40], ["erm B", "DNA", 46, 51], ["The detection", "TEST", 0, 13], ["erm TR", "TEST", 34, 40], ["PCR", "TEST", 96, 99]]], ["The clonality of the resistant strains was studied by pulse-field gel electrophoresis.P1593Results: Of the 147 strains, 15 were resistant to erythromycin, lincosamid and streptogrammines B. None was found to be resistant to erythromycin only (M-phenopype).", [["strains", "ANATOMY", 31, 38], ["erythromycin", "CHEMICAL", 141, 153], ["lincosamid", "CHEMICAL", 155, 165], ["erythromycin", "CHEMICAL", 224, 236], ["erythromycin", "CHEMICAL", 141, 153], ["lincosamid", "CHEMICAL", 155, 165], ["erythromycin", "CHEMICAL", 224, 236], ["erythromycin", "SIMPLE_CHEMICAL", 141, 153], ["lincosamid", "SIMPLE_CHEMICAL", 155, 165], ["erythromycin", "SIMPLE_CHEMICAL", 224, 236], ["M-phenopype", "SIMPLE_CHEMICAL", 243, 254], ["the resistant strains", "PROBLEM", 17, 38], ["pulse-field gel electrophoresis", "TEST", 54, 85], ["erythromycin", "TREATMENT", 141, 153], ["lincosamid", "TREATMENT", 155, 165], ["streptogrammines B.", "PROBLEM", 170, 189], ["erythromycin", "TREATMENT", 224, 236], ["resistant strains", "OBSERVATION", 21, 38]]], ["60% of the strains were MLSB constitutive phenotype, while 40% were MLSB inducible.", [["MLSB", "GENE_OR_GENE_PRODUCT", 24, 28], ["the strains", "PROBLEM", 7, 18], ["MLSB constitutive phenotype", "PROBLEM", 24, 51], ["constitutive phenotype", "OBSERVATION", 29, 51]]], ["All strains were found to carry the erm TR gene.", [["erm TR", "GENE_OR_GENE_PRODUCT", 36, 42], ["erm TR gene", "DNA", 36, 47], ["All strains", "PROBLEM", 0, 11], ["erm", "OBSERVATION", 36, 39]]], ["Only one strain was found to carry both erm TR and erm B genes.", [["erm TR", "GENE_OR_GENE_PRODUCT", 40, 46], ["erm B", "GENE_OR_GENE_PRODUCT", 51, 56], ["erm TR and erm B genes", "DNA", 40, 62]]], ["PFGE analysis revealed the emergence of multiple resistant clones.", [["clones", "ANATOMY", 59, 65], ["clones", "CELL", 59, 65], ["multiple resistant clones", "CELL_LINE", 40, 65], ["PFGE analysis", "TEST", 0, 13], ["multiple resistant clones", "PROBLEM", 40, 65], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["resistant clones", "OBSERVATION", 49, 65]]], ["Conclusions: The resistance of S. agalactiae to MLSB antibiotics is related with the presence of erm TR gene in Central Greece.P1594Emergence of novel clindamycin resistance phenotype among invasive Streptococcus pyogenes isolates in Sweden A. Jasir, B. Luca, C. Schalen (Lund, SE)P1594Objectives: In some recent throat group A streptococci (GAS) isolates from our diagnostic laboratory total resistance to clindamycin but susceptibility to erythromycin and other 14-as well as 15-membered macrolides was found.", [["MLSB", "CHEMICAL", 48, 52], ["clindamycin", "CHEMICAL", 151, 162], ["Streptococcus pyogenes", "DISEASE", 199, 221], ["clindamycin", "CHEMICAL", 407, 418], ["erythromycin", "CHEMICAL", 441, 453], ["macrolides", "CHEMICAL", 490, 500], ["clindamycin", "CHEMICAL", 151, 162], ["clindamycin", "CHEMICAL", 407, 418], ["erythromycin", "CHEMICAL", 441, 453], ["macrolides", "CHEMICAL", 490, 500], ["S. agalactiae", "ORGANISM", 31, 44], ["MLSB", "SIMPLE_CHEMICAL", 48, 52], ["erm TR", "GENE_OR_GENE_PRODUCT", 97, 103], ["clindamycin", "SIMPLE_CHEMICAL", 151, 162], ["Streptococcus pyogenes", "ORGANISM", 199, 221], ["C. Schalen", "ORGANISM", 260, 270], ["clindamycin", "SIMPLE_CHEMICAL", 407, 418], ["erythromycin", "SIMPLE_CHEMICAL", 441, 453], ["15-membered macrolides", "SIMPLE_CHEMICAL", 478, 500], ["erm TR gene", "DNA", 97, 108], ["S. agalactiae", "SPECIES", 31, 44], ["Streptococcus pyogenes", "SPECIES", 199, 221], ["S. agalactiae", "SPECIES", 31, 44], ["Streptococcus pyogenes", "SPECIES", 199, 221], ["S. agalactiae", "PROBLEM", 31, 44], ["MLSB antibiotics", "TREATMENT", 48, 64], ["novel clindamycin resistance phenotype", "TREATMENT", 145, 183], ["invasive Streptococcus pyogenes", "PROBLEM", 190, 221], ["some recent throat group A streptococci (GAS) isolates", "PROBLEM", 301, 355], ["clindamycin", "TREATMENT", 407, 418], ["erythromycin", "TREATMENT", 441, 453], ["15-membered macrolides", "TREATMENT", 478, 500], ["erm", "OBSERVATION", 97, 100], ["throat", "ANATOMY", 313, 319]]], ["The isolates were susceptible to 16-membered macrolides and streptogramin B. These atypical strains thus did not agree with previously known MLS resistance phenotypes.", [["macrolides", "CHEMICAL", 45, 55], ["streptogramin", "CHEMICAL", 60, 73], ["macrolides", "CHEMICAL", 45, 55], ["streptogramin", "CHEMICAL", 60, 73], ["16-membered macrolides", "SIMPLE_CHEMICAL", 33, 55], ["streptogramin B.", "SIMPLE_CHEMICAL", 60, 76], ["The isolates", "TEST", 0, 12], ["16-membered macrolides", "TREATMENT", 33, 55], ["streptogramin", "TREATMENT", 60, 73], ["These atypical strains", "PROBLEM", 77, 99], ["previously known MLS resistance phenotypes", "PROBLEM", 124, 166]]], ["The main objective was to characterize theses resistance phenotype and genotypes.", [["theses resistance phenotype and genotypes", "PROBLEM", 39, 80], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Method and results: The isolates were examined for resistance genes by PCR.", [["resistance genes", "DNA", 51, 67], ["The isolates", "TEST", 20, 32], ["resistance genes by PCR", "PROBLEM", 51, 74]]], ["Out of 14 strains one harboured an ermA gene.", [["ermA", "GENE_OR_GENE_PRODUCT", 35, 39], ["ermA gene", "DNA", 35, 44]]], ["The gene was sequenced and showed a mutation in regulatory part and was localized on a transposons.", [["transposons", "DNA", 87, 98], ["a mutation in regulatory part", "PROBLEM", 34, 63]]], ["All other strains were negative for any erm genes and were also tested for 23s rRNA mutations with negative outcome.", [["erm", "GENE_OR_GENE_PRODUCT", 40, 43], ["erm genes", "DNA", 40, 49], ["23s rRNA mutations", "DNA", 75, 93], ["All other strains", "TEST", 0, 17], ["any erm genes", "PROBLEM", 36, 49], ["23s rRNA mutations", "PROBLEM", 75, 93]]], ["Strains were T-and emm typed and showed to belong to different types.", [["T", "CELL", 13, 14], ["Strains", "PROBLEM", 0, 7]]], ["Conclusions: GAS account for common human infections such as acute pharyngotonsillitis and impetigo, which untreated may be followed by the nonsuppurative complications rheumatic fever and acute poststreptococcal glomerulonephritis GAS may also give rise to invasive, often life-threatening acute disease, such as scarlatina, erysipelas, endometritis, necrotising fasciitis and sepsis, often accompanied by toxic shock.", [["infections", "DISEASE", 42, 52], ["pharyngotonsillitis", "DISEASE", 67, 86], ["impetigo", "DISEASE", 91, 99], ["rheumatic fever", "DISEASE", 169, 184], ["glomerulonephritis", "DISEASE", 213, 231], ["erysipelas", "DISEASE", 326, 336], ["endometritis", "DISEASE", 338, 350], ["necrotising fasciitis", "DISEASE", 352, 373], ["sepsis", "DISEASE", 378, 384], ["shock", "DISEASE", 413, 418], ["human", "ORGANISM", 36, 41], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["common human infections", "PROBLEM", 29, 52], ["acute pharyngotonsillitis", "PROBLEM", 61, 86], ["impetigo", "PROBLEM", 91, 99], ["the nonsuppurative complications rheumatic fever", "PROBLEM", 136, 184], ["acute poststreptococcal glomerulonephritis GAS", "PROBLEM", 189, 235], ["threatening acute disease", "PROBLEM", 279, 304], ["scarlatina", "PROBLEM", 314, 324], ["erysipelas", "PROBLEM", 326, 336], ["endometritis", "PROBLEM", 338, 350], ["necrotising fasciitis", "PROBLEM", 352, 373], ["sepsis", "PROBLEM", 378, 384], ["toxic shock", "PROBLEM", 407, 418], ["GAS", "OBSERVATION", 13, 16], ["infections", "OBSERVATION", 42, 52], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["pharyngotonsillitis", "OBSERVATION", 67, 86], ["impetigo", "OBSERVATION", 91, 99], ["nonsuppurative", "OBSERVATION_MODIFIER", 140, 154], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["poststreptococcal", "OBSERVATION_MODIFIER", 195, 212], ["glomerulonephritis", "OBSERVATION", 213, 231], ["invasive", "OBSERVATION_MODIFIER", 258, 266], ["threatening", "OBSERVATION_MODIFIER", 279, 290], ["acute", "OBSERVATION_MODIFIER", 291, 296], ["disease", "OBSERVATION", 297, 304], ["erysipelas", "OBSERVATION", 326, 336], ["endometritis", "OBSERVATION", 338, 350], ["necrotising", "OBSERVATION_MODIFIER", 352, 363], ["fasciitis", "OBSERVATION", 364, 373], ["sepsis", "OBSERVATION", 378, 384], ["toxic", "OBSERVATION_MODIFIER", 407, 412], ["shock", "OBSERVATION", 413, 418]]], ["Without known exceptions, GAS are fully susceptible to betalactams, which are first-choice drugs for treatment.", [["betalactams", "CHEMICAL", 55, 66], ["betalactams", "CHEMICAL", 55, 66], ["GAS", "GENE_OR_GENE_PRODUCT", 26, 29], ["betalactams", "SIMPLE_CHEMICAL", 55, 66], ["GAS", "DNA", 26, 29], ["known exceptions", "PROBLEM", 8, 24], ["GAS", "PROBLEM", 26, 29], ["betalactams", "PROBLEM", 55, 66], ["treatment", "TREATMENT", 101, 110], ["GAS", "OBSERVATION", 26, 29]]], ["In cases of allergy or intolerance to penicillins, macrolides are most used, and possibly as a consequence, a significant resistance development to these agents has evolved in many parts of the world.", [["allergy", "DISEASE", 12, 19], ["penicillins", "CHEMICAL", 38, 49], ["macrolides", "CHEMICAL", 51, 61], ["penicillins", "CHEMICAL", 38, 49], ["macrolides", "CHEMICAL", 51, 61], ["penicillins", "SIMPLE_CHEMICAL", 38, 49], ["macrolides", "SIMPLE_CHEMICAL", 51, 61], ["allergy", "PROBLEM", 12, 19], ["intolerance", "PROBLEM", 23, 34], ["penicillins", "TREATMENT", 38, 49], ["macrolides", "TREATMENT", 51, 61], ["these agents", "TREATMENT", 148, 160], ["significant", "OBSERVATION_MODIFIER", 110, 121], ["resistance", "OBSERVATION", 122, 132]]], ["Though the role of clindamycin for treatment of streptococcal disease is more limited this drug was shown to be particularly effective in eradicating streptococci after penicillin treatment failure of pharyngotonsillitis.", [["clindamycin", "CHEMICAL", 19, 30], ["streptococcal disease", "DISEASE", 48, 69], ["penicillin", "CHEMICAL", 169, 179], ["pharyngotonsillitis", "DISEASE", 201, 220], ["clindamycin", "CHEMICAL", 19, 30], ["penicillin", "CHEMICAL", 169, 179], ["clindamycin", "SIMPLE_CHEMICAL", 19, 30], ["streptococci", "CELL", 150, 162], ["penicillin", "SIMPLE_CHEMICAL", 169, 179], ["pharyngotonsillitis", "CANCER", 201, 220], ["clindamycin", "TREATMENT", 19, 30], ["streptococcal disease", "PROBLEM", 48, 69], ["eradicating streptococci", "PROBLEM", 138, 162], ["penicillin treatment", "TREATMENT", 169, 189], ["pharyngotonsillitis", "PROBLEM", 201, 220], ["streptococcal disease", "OBSERVATION", 48, 69]]], ["Clindamycin, often as a supplement to betalactams, also may have a life-saving effect in the treatment of fulminant streptococcal infections.", [["Clindamycin", "CHEMICAL", 0, 11], ["betalactams", "CHEMICAL", 38, 49], ["streptococcal infections", "DISEASE", 116, 140], ["Clindamycin", "CHEMICAL", 0, 11], ["betalactams", "CHEMICAL", 38, 49], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["betalactams", "SIMPLE_CHEMICAL", 38, 49], ["Clindamycin", "TREATMENT", 0, 11], ["betalactams", "TREATMENT", 38, 49], ["fulminant streptococcal infections", "PROBLEM", 106, 140], ["fulminant", "OBSERVATION_MODIFIER", 106, 115], ["streptococcal", "OBSERVATION_MODIFIER", 116, 129], ["infections", "OBSERVATION", 130, 140]]], ["Due to its important role in the treatment of invasive streptococcal disease, resistance development to clindamycin in GAS is considered highly undesirable.", [["streptococcal disease", "DISEASE", 55, 76], ["clindamycin", "CHEMICAL", 104, 115], ["clindamycin", "CHEMICAL", 104, 115], ["clindamycin", "SIMPLE_CHEMICAL", 104, 115], ["invasive streptococcal disease", "PROBLEM", 46, 76], ["clindamycin", "TREATMENT", 104, 115], ["invasive", "OBSERVATION_MODIFIER", 46, 54], ["streptococcal disease", "OBSERVATION", 55, 76]]], ["The alarming finding of a possibly new phenotype of selective clindamycin resistance in GAS will motivate a thorough analysis of the phenotype as well as identification of its resistance determinants.P1595 Resistance mechanisms of telithromycin-resistant clinical isolates of Streptococcus pneumoniae in EuropeA.", [["clindamycin", "CHEMICAL", 62, 73], ["P1595", "CHEMICAL", 200, 205], ["telithromycin", "CHEMICAL", 231, 244], ["Streptococcus pneumoniae", "DISEASE", 276, 300], ["clindamycin", "CHEMICAL", 62, 73], ["telithromycin", "CHEMICAL", 231, 244], ["clindamycin", "SIMPLE_CHEMICAL", 62, 73], ["P1595", "SIMPLE_CHEMICAL", 200, 205], ["telithromycin", "SIMPLE_CHEMICAL", 231, 244], ["Streptococcus pneumoniae", "ORGANISM", 276, 300], ["Streptococcus pneumoniae", "SPECIES", 276, 300], ["Streptococcus pneumoniae", "SPECIES", 276, 300], ["selective clindamycin resistance", "TREATMENT", 52, 84], ["a thorough analysis", "TEST", 106, 125], ["telithromycin", "TREATMENT", 231, 244], ["Streptococcus pneumoniae in EuropeA", "PROBLEM", 276, 311], ["possibly", "UNCERTAINTY", 26, 34], ["new", "OBSERVATION_MODIFIER", 35, 38], ["selective", "OBSERVATION_MODIFIER", 52, 61], ["clindamycin resistance", "OBSERVATION", 62, 84], ["telithromycin", "OBSERVATION_MODIFIER", 231, 244], ["Streptococcus pneumoniae", "OBSERVATION", 276, 300]]], ["Al-Lahham, M. van der Linden, R.R. Reinert (Aachen, DE)P1595 Resistance mechanisms of telithromycin-resistant clinical isolates of Streptococcus pneumoniae in EuropeObjectives: Telithromycin is a novel ketolide antibiotic with significant in-vitro activity against Streptococcus pneumoniae.", [["telithromycin", "CHEMICAL", 86, 99], ["Streptococcus pneumoniae", "DISEASE", 131, 155], ["Telithromycin", "CHEMICAL", 177, 190], ["ketolide", "CHEMICAL", 202, 210], ["Streptococcus pneumoniae", "DISEASE", 265, 289], ["telithromycin", "CHEMICAL", 86, 99], ["Telithromycin", "CHEMICAL", 177, 190], ["ketolide", "CHEMICAL", 202, 210], ["telithromycin", "SIMPLE_CHEMICAL", 86, 99], ["Streptococcus pneumoniae", "ORGANISM", 131, 155], ["Telithromycin", "SIMPLE_CHEMICAL", 177, 190], ["ketolide", "SIMPLE_CHEMICAL", 202, 210], ["Streptococcus pneumoniae", "ORGANISM", 265, 289], ["Streptococcus pneumoniae", "SPECIES", 131, 155], ["Streptococcus pneumoniae", "SPECIES", 265, 289], ["Streptococcus pneumoniae", "SPECIES", 131, 155], ["Streptococcus pneumoniae", "SPECIES", 265, 289], ["telithromycin", "TREATMENT", 86, 99], ["Streptococcus pneumoniae", "PROBLEM", 131, 155], ["Telithromycin", "TREATMENT", 177, 190], ["a novel ketolide antibiotic", "TREATMENT", 194, 221], ["Streptococcus pneumoniae", "PROBLEM", 265, 289], ["Streptococcus pneumoniae", "OBSERVATION", 131, 155], ["Streptococcus pneumoniae", "OBSERVATION", 265, 289]]], ["The aim of this study is to characterize the resistance mechanisms of clinical isolates of S. pneumoniae with reduced susceptibility to telithromycin (>1 mg/l) and to perform the time-kill kinetics with telithromycin.", [["telithromycin", "CHEMICAL", 136, 149], ["telithromycin", "CHEMICAL", 203, 216], ["telithromycin", "CHEMICAL", 136, 149], ["telithromycin", "CHEMICAL", 203, 216], ["S. pneumoniae", "ORGANISM", 91, 104], ["telithromycin", "SIMPLE_CHEMICAL", 136, 149], ["telithromycin", "SIMPLE_CHEMICAL", 203, 216], ["S. pneumoniae", "SPECIES", 91, 104], ["S. pneumoniae", "SPECIES", 91, 104], ["this study", "TEST", 11, 21], ["S. pneumoniae", "PROBLEM", 91, 104], ["telithromycin", "TREATMENT", 136, 149], ["telithromycin", "TREATMENT", 203, 216], ["pneumoniae", "OBSERVATION", 94, 104]]], ["Methods: Determination of MICs was performed by the microbroth dilution method according to the CLSI and the serotyping by the Neufeld Quellung reaction.", [["MICs", "TREATMENT", 26, 30], ["the microbroth dilution method", "TREATMENT", 48, 78], ["the CLSI", "TEST", 92, 100], ["the serotyping", "TEST", 105, 119]]], ["Multilocus sequence typing, sequencing of the 23S rRNA, sequencing of genes encoding ribosomal proteins (L4 and L22), and ermB were performed according to standard methods.", [["ribosomal", "ANATOMY", 85, 94], ["ribosomal", "CELLULAR_COMPONENT", 85, 94], ["L22", "GENE_OR_GENE_PRODUCT", 112, 115], ["ermB", "GENE_OR_GENE_PRODUCT", 122, 126], ["23S rRNA", "DNA", 46, 54], ["ribosomal proteins", "PROTEIN", 85, 103], ["L4", "PROTEIN", 105, 107], ["L22", "PROTEIN", 112, 115], ["ermB", "PROTEIN", 122, 126], ["Multilocus sequence typing", "TEST", 0, 26], ["sequencing", "TEST", 28, 38], ["the 23S rRNA", "TEST", 42, 54], ["genes encoding ribosomal proteins (L4 and L22)", "PROBLEM", 70, 116], ["ermB", "PROBLEM", 122, 126], ["L4", "ANATOMY", 105, 107]]], ["Four isolates were selected for time-kill, two of which with a telithromycin MIC 2 mg/l and two strains with a telithromycin MIC of 8 mg/l.", [["telithromycin", "CHEMICAL", 63, 76], ["telithromycin", "CHEMICAL", 111, 124], ["telithromycin", "CHEMICAL", 63, 76], ["telithromycin", "CHEMICAL", 111, 124], ["telithromycin", "SIMPLE_CHEMICAL", 63, 76], ["telithromycin", "SIMPLE_CHEMICAL", 111, 124], ["Four isolates", "TEST", 0, 13], ["a telithromycin MIC", "TREATMENT", 61, 80], ["a telithromycin MIC", "TREATMENT", 109, 128]]], ["Results: In two nation-wide studies and one European surveillance study (n = 6604) performed at the National Reference Center for Streptococci (NRCS) in Germany, reduced susceptibility to telithromycin (>1 mg/l) was detected in 17 isolates (0.3%).", [["telithromycin", "CHEMICAL", 188, 201], ["telithromycin", "CHEMICAL", 188, 201], ["telithromycin", "SIMPLE_CHEMICAL", 188, 201], ["European surveillance study", "TEST", 44, 71], ["Streptococci", "PROBLEM", 130, 142], ["telithromycin", "TREATMENT", 188, 201]]], ["MIC50/MIC90 (mg/L) of the strains to other antibiotics were as follows: Telithromycin 2/8, penicillin G 2/2, cefuroxime 8/8, erythromycin A >32/>32, clindamycin >32/>32, tetracycline 32/32, and gatifloxacin 0.25/0.25.", [["MIC50", "CHEMICAL", 0, 5], ["Telithromycin", "CHEMICAL", 72, 85], ["penicillin", "CHEMICAL", 91, 101], ["cefuroxime", "CHEMICAL", 109, 119], ["erythromycin", "CHEMICAL", 125, 137], ["clindamycin", "CHEMICAL", 149, 160], ["tetracycline", "CHEMICAL", 170, 182], ["gatifloxacin", "CHEMICAL", 194, 206], ["Telithromycin", "CHEMICAL", 72, 85], ["penicillin G", "CHEMICAL", 91, 103], ["cefuroxime", "CHEMICAL", 109, 119], ["erythromycin A", "CHEMICAL", 125, 139], ["clindamycin", "CHEMICAL", 149, 160], ["tetracycline", "CHEMICAL", 170, 182], ["gatifloxacin", "CHEMICAL", 194, 206], ["Telithromycin", "SIMPLE_CHEMICAL", 72, 85], ["penicillin G 2", "SIMPLE_CHEMICAL", 91, 105], ["cefuroxime 8/8", "SIMPLE_CHEMICAL", 109, 123], ["erythromycin A", "SIMPLE_CHEMICAL", 125, 139], ["clindamycin", "SIMPLE_CHEMICAL", 149, 160], ["tetracycline 32/32", "SIMPLE_CHEMICAL", 170, 188], ["gatifloxacin", "SIMPLE_CHEMICAL", 194, 206], ["MIC50", "TREATMENT", 0, 5], ["the strains", "PROBLEM", 22, 33], ["other antibiotics", "TREATMENT", 37, 54], ["Telithromycin", "TREATMENT", 72, 85], ["penicillin G", "TREATMENT", 91, 103], ["cefuroxime", "TREATMENT", 109, 119], ["erythromycin A", "TREATMENT", 125, 139], ["clindamycin", "TREATMENT", 149, 160], ["tetracycline", "TREATMENT", 170, 182], ["gatifloxacin", "TREATMENT", 194, 206]]], ["Two major serotypes were observed, serotype 14 (58.8%) and serotype 19A (29.4%).", [["Two major serotypes", "PROBLEM", 0, 19], ["serotype", "TEST", 35, 43], ["serotype 19A", "TEST", 59, 71], ["serotypes", "OBSERVATION", 10, 19]]], ["All isolates possess the cMLSB phenotype (ermB positive).", [["cMLSB", "GENE_OR_GENE_PRODUCT", 25, 30], ["ermB", "GENE_OR_GENE_PRODUCT", 42, 46], ["All isolates", "TEST", 0, 12], ["the cMLSB phenotype", "TEST", 21, 40]]], ["The isolates showed a wide range of combinations of resistance determinants including multiple alterations in the 23S rRNA (A138G, C150T, A260G, A1745T, and C2216T), a S20N alteration in the ribosomal protein L4 (n = 9), and a N100S alteration in the erm(B) gene (n = 14).", [["ribosomal", "ANATOMY", 191, 200], ["23S", "GENE_OR_GENE_PRODUCT", 114, 117], ["rRNA", "CELLULAR_COMPONENT", 118, 122], ["ribosomal protein L4", "GENE_OR_GENE_PRODUCT", 191, 211], ["erm(B)", "GENE_OR_GENE_PRODUCT", 251, 257], ["23S rRNA", "DNA", 114, 122], ["ribosomal protein L4", "PROTEIN", 191, 211], ["erm(B) gene", "DNA", 251, 262], ["The isolates", "TEST", 0, 12], ["resistance determinants", "PROBLEM", 52, 75], ["multiple alterations", "PROBLEM", 86, 106], ["the 23S rRNA", "TEST", 110, 122], ["C150T", "TEST", 131, 136], ["A1745T", "TEST", 145, 151], ["a S20N alteration in the ribosomal protein L4", "PROBLEM", 166, 211], ["a N100S alteration", "PROBLEM", 225, 243], ["wide range", "OBSERVATION_MODIFIER", 22, 32], ["multiple", "OBSERVATION_MODIFIER", 86, 94], ["alterations", "OBSERVATION", 95, 106], ["23S rRNA", "OBSERVATION", 114, 122], ["L4", "ANATOMY", 209, 211]]], ["The predominant clone was serotype 14 sequence type 143 (8 of 17 isolates), which was seen in France (n = 7) and Germany (n = 1).", [["clone", "CELL", 16, 21], ["serotype 14 sequence type", "TEST", 26, 51], ["predominant", "OBSERVATION_MODIFIER", 4, 15], ["clone", "OBSERVATION_MODIFIER", 16, 21]]], ["Telithromycin-resistance has also spread to the Spain23F-1 clone (ST 81; n = 1) and its serotype 19A variant.", [["Spain23F-1 clone", "ANATOMY", 48, 64], ["Telithromycin", "CHEMICAL", 0, 13], ["Telithromycin", "CHEMICAL", 0, 13], ["Telithromycin", "SIMPLE_CHEMICAL", 0, 13], ["ST 81", "ORGANISM", 66, 71], ["Spain23F-1 clone", "DNA", 48, 64], ["Telithromycin", "TREATMENT", 0, 13], ["the Spain23F", "TEST", 44, 56], ["ST", "TEST", 66, 68], ["its serotype 19A variant", "PROBLEM", 84, 108]]], ["Bactericidal activity was achieved only with 8 times the MIC in all strains.", [["Bactericidal activity", "PROBLEM", 0, 21]]], ["Conclusions: Although the incidence of telithromycin resistance remains rare world-wide, the spread of telithromycin resistance to multi-drug resistance clones with world-wide distribution is worrisome.", [["telithromycin", "CHEMICAL", 39, 52], ["telithromycin", "CHEMICAL", 103, 116], ["telithromycin", "CHEMICAL", 39, 52], ["telithromycin", "CHEMICAL", 103, 116], ["telithromycin", "SIMPLE_CHEMICAL", 39, 52], ["telithromycin", "SIMPLE_CHEMICAL", 103, 116], ["telithromycin resistance", "PROBLEM", 39, 63], ["telithromycin resistance", "TREATMENT", 103, 127], ["multi-drug resistance clones", "TREATMENT", 131, 159], ["telithromycin resistance", "OBSERVATION", 103, 127]]], ["GBS obtained from non-pregnant women.", [["women", "ORGANISM", 31, 36], ["women", "SPECIES", 31, 36], ["GBS", "TEST", 0, 3]]], ["The erythromycin resistant-GBS were identified, phenotypically analysed, screened by PCR for mre(A) gene and for erythromycin resistance genes: erm(B), erm(TR), mef(A) and mef(E), and serotyped with type specific antisera for serotypes Ia, Ib, II, III, IV, and V. Results: Among the total of GBS, 161 (28.65%) were erythromycin-resistant: 86 (24.29%) erythromycin-resistant GBS were isolated from vaginal swabs of pregnant women and 75 (36.06%) from non-pregnant women.", [["vaginal swabs", "ANATOMY", 397, 410], ["erythromycin", "CHEMICAL", 4, 16], ["erythromycin", "CHEMICAL", 113, 125], ["GBS", "DISEASE", 292, 295], ["erythromycin", "CHEMICAL", 315, 327], ["erythromycin", "CHEMICAL", 351, 363], ["GBS", "DISEASE", 374, 377], ["erythromycin", "CHEMICAL", 4, 16], ["erythromycin", "CHEMICAL", 113, 125], ["erythromycin", "CHEMICAL", 315, 327], ["erythromycin", "CHEMICAL", 351, 363], ["erythromycin", "SIMPLE_CHEMICAL", 4, 16], ["mre(A)", "GENE_OR_GENE_PRODUCT", 93, 99], ["erythromycin", "SIMPLE_CHEMICAL", 113, 125], ["erm(B)", "GENE_OR_GENE_PRODUCT", 144, 150], ["erm(TR)", "GENE_OR_GENE_PRODUCT", 152, 159], ["mef(A)", "GENE_OR_GENE_PRODUCT", 161, 167], ["mef(E)", "GENE_OR_GENE_PRODUCT", 172, 178], ["erythromycin", "SIMPLE_CHEMICAL", 315, 327], ["erythromycin", "SIMPLE_CHEMICAL", 351, 363], ["vaginal swabs", "ORGANISM_SUBSTANCE", 397, 410], ["women", "ORGANISM", 423, 428], ["women", "ORGANISM", 463, 468], ["mre(A) gene", "DNA", 93, 104], ["erythromycin resistance genes", "DNA", 113, 142], ["erm", "DNA", 144, 147], ["B", "DNA", 148, 149], ["erm", "DNA", 152, 155], ["TR", "DNA", 156, 158], ["mef", "DNA", 161, 164], ["A", "DNA", 165, 166], ["mef", "DNA", 172, 175], ["E", "DNA", 176, 177], ["women", "SPECIES", 423, 428], ["women", "SPECIES", 463, 468], ["The erythromycin resistant", "TEST", 0, 26], ["GBS", "PROBLEM", 27, 30], ["mre", "TEST", 93, 96], ["erythromycin resistance genes", "PROBLEM", 113, 142], ["serotypes", "PROBLEM", 226, 235], ["GBS", "TEST", 292, 295], ["erythromycin", "TEST", 315, 327], ["erythromycin", "TEST", 351, 363], ["resistant GBS", "PROBLEM", 364, 377], ["vaginal swabs", "TEST", 397, 410]]], ["The frequency of serotypes in 151 erythromycin-resistant GBS tested, the distribu-tion of their resistance genes and the distribution of serotypes among the different genotypes are illustrated in the table.", [["erythromycin", "CHEMICAL", 34, 46], ["GBS", "DISEASE", 57, 60], ["erythromycin", "CHEMICAL", 34, 46], ["erythromycin", "SIMPLE_CHEMICAL", 34, 46], ["resistance genes", "DNA", 96, 112], ["serotypes", "PROBLEM", 17, 26], ["erythromycin", "TREATMENT", 34, 46], ["resistant GBS", "PROBLEM", 47, 60], ["their resistance genes", "PROBLEM", 90, 112], ["serotypes", "PROBLEM", 137, 146], ["serotypes", "OBSERVATION_MODIFIER", 17, 26], ["resistance genes", "OBSERVATION", 96, 112], ["distribution", "OBSERVATION_MODIFIER", 121, 133], ["serotypes", "OBSERVATION", 137, 146]]], ["NT, nontypeable, The mre(A) gene was found in all the GBS strains tested.", [["GBS", "DISEASE", 54, 57], ["NT", "GENE_OR_GENE_PRODUCT", 0, 2], ["mre(A)", "GENE_OR_GENE_PRODUCT", 21, 27], ["mre(A) gene", "DNA", 21, 32], ["NT", "PROBLEM", 0, 2], ["nontypeable", "PROBLEM", 4, 15], ["the GBS strains", "TEST", 50, 65], ["nontypeable", "OBSERVATION", 4, 15], ["GBS strains", "OBSERVATION", 54, 65]]], ["MICs of erythromycin in erythromycin-resistant GBS were: MIC50 and MIC90, >128 mg/L; range, 4 to >128 mg/L for GBS harbouring erm(B) and erm(B)+erm(TR) and MIC50 and MIC90, 8 mg/L and >128 mg/L, respectively; range, 0.5 to >128 mg/L for GBS harbouring erm(TR).P1595 Resistance mechanisms of telithromycin-resistant clinical isolates of Streptococcus pneumoniae in EuropeConclusion: Erm(B) was the erythromycin-resistant gene most prevalent among the GBS isolates and these isolates showed the highest MICs of erythromycin.", [["erythromycin", "CHEMICAL", 8, 20], ["erythromycin", "CHEMICAL", 24, 36], ["GBS", "DISEASE", 47, 50], ["MIC50", "CHEMICAL", 57, 62], ["MIC90", "CHEMICAL", 67, 72], ["MIC50", "CHEMICAL", 156, 161], ["MIC90", "CHEMICAL", 166, 171], ["P1595", "CHEMICAL", 260, 265], ["telithromycin", "CHEMICAL", 291, 304], ["Streptococcus pneumoniae", "DISEASE", 336, 360], ["Erm", "CHEMICAL", 382, 385], ["erythromycin", "CHEMICAL", 397, 409], ["GBS", "DISEASE", 450, 453], ["erythromycin", "CHEMICAL", 509, 521], ["erythromycin", "CHEMICAL", 8, 20], ["erythromycin", "CHEMICAL", 24, 36], ["telithromycin", "CHEMICAL", 291, 304], ["erythromycin", "CHEMICAL", 397, 409], ["erythromycin", "CHEMICAL", 509, 521], ["erythromycin", "SIMPLE_CHEMICAL", 8, 20], ["erythromycin", "SIMPLE_CHEMICAL", 24, 36], ["MIC50", "SIMPLE_CHEMICAL", 57, 62], ["erm(B)+erm", "GENE_OR_GENE_PRODUCT", 137, 147], ["P1595", "SIMPLE_CHEMICAL", 260, 265], ["telithromycin", "SIMPLE_CHEMICAL", 291, 304], ["Streptococcus pneumoniae", "ORGANISM", 336, 360], ["Erm(B)", "ORGANISM", 382, 388], ["erythromycin", "SIMPLE_CHEMICAL", 397, 409], ["erythromycin", "SIMPLE_CHEMICAL", 509, 521], ["TR", "PROTEIN", 256, 258], ["Streptococcus pneumoniae", "SPECIES", 336, 360], ["Streptococcus pneumoniae", "SPECIES", 336, 360], ["erythromycin", "TREATMENT", 8, 20], ["erythromycin", "TREATMENT", 24, 36], ["resistant GBS", "PROBLEM", 37, 50], ["MIC50", "TEST", 57, 62], ["MIC90", "TEST", 67, 72], ["range", "TEST", 85, 90], ["GBS harbouring erm", "PROBLEM", 111, 129], ["TR", "TEST", 148, 150], ["MIC50", "TEST", 156, 161], ["MIC90", "TEST", 166, 171], ["range", "TEST", 209, 214], ["GBS harbouring erm", "PROBLEM", 237, 255], ["telithromycin", "TREATMENT", 291, 304], ["Streptococcus pneumoniae", "PROBLEM", 336, 360], ["the erythromycin", "TREATMENT", 393, 409], ["the GBS isolates", "TEST", 446, 462], ["these isolates", "TEST", 467, 481], ["erythromycin", "TREATMENT", 509, 521], ["Streptococcus pneumoniae", "OBSERVATION", 336, 360]]], ["The commonest serotypes among erythromycin-resistant GBS isolated were III, II and I, and showed genotypic variability harbouring either of the two most prevalent genes, erm(B) or/and erm(TR).", [["erythromycin", "CHEMICAL", 30, 42], ["GBS", "DISEASE", 53, 56], ["erythromycin", "CHEMICAL", 30, 42], ["erythromycin", "SIMPLE_CHEMICAL", 30, 42], ["erm(B)", "GENE_OR_GENE_PRODUCT", 170, 176], ["erm(TR)", "GENE_OR_GENE_PRODUCT", 184, 191], ["erm", "DNA", 170, 173], ["TR", "DNA", 188, 190], ["The commonest serotypes", "TEST", 0, 23], ["erythromycin", "TREATMENT", 30, 42], ["resistant GBS", "PROBLEM", 43, 56], ["genotypic variability harbouring", "PROBLEM", 97, 129]]], ["Methods: We studied the rates of resistance to tetracycline and minocycline among 161 erythromycin-resistant GBS strains isolated at the University Hospital Lozano Blesa of Zaragoza, Spain.", [["strains", "ANATOMY", 113, 120], ["tetracycline", "CHEMICAL", 47, 59], ["minocycline", "CHEMICAL", 64, 75], ["erythromycin", "CHEMICAL", 86, 98], ["GBS", "DISEASE", 109, 112], ["tetracycline", "CHEMICAL", 47, 59], ["minocycline", "CHEMICAL", 64, 75], ["erythromycin", "CHEMICAL", 86, 98], ["tetracycline", "SIMPLE_CHEMICAL", 47, 59], ["minocycline", "SIMPLE_CHEMICAL", 64, 75], ["erythromycin", "SIMPLE_CHEMICAL", 86, 98], ["tetracycline", "TREATMENT", 47, 59], ["minocycline", "TREATMENT", 64, 75], ["erythromycin", "TREATMENT", 86, 98], ["resistant GBS strains", "PROBLEM", 99, 120]]], ["Isolates were subsequently phenotypically analysed by means of the disk diffusion method and screened by PCR for erythromycin and tetracycline resistance genes [erm(B), erm(TR), mef(A/E), tet(M) and tet(O)].", [["erythromycin", "CHEMICAL", 113, 125], ["tetracycline", "CHEMICAL", 130, 142], ["erythromycin", "CHEMICAL", 113, 125], ["tetracycline", "CHEMICAL", 130, 142], ["erythromycin", "SIMPLE_CHEMICAL", 113, 125], ["tetracycline", "SIMPLE_CHEMICAL", 130, 142], ["erm(B)", "GENE_OR_GENE_PRODUCT", 161, 167], ["erm(TR)", "GENE_OR_GENE_PRODUCT", 169, 176], ["tet(M)", "GENE_OR_GENE_PRODUCT", 188, 194], ["tet(O)", "GENE_OR_GENE_PRODUCT", 199, 205], ["tetracycline resistance genes", "DNA", 130, 159], ["erm", "DNA", 161, 164], ["erm", "DNA", 169, 172], ["TR", "DNA", 173, 175], ["mef", "DNA", 178, 181], ["A", "DNA", 182, 183], ["E", "DNA", 184, 185], ["tet", "DNA", 188, 191], ["tet(O)", "DNA", 199, 205], ["Isolates", "TEST", 0, 8], ["the disk diffusion method", "TEST", 63, 88], ["PCR", "TEST", 105, 108], ["erythromycin", "TREATMENT", 113, 125], ["tetracycline resistance genes", "TREATMENT", 130, 159]]], ["The susceptibility to erythromycin, josamycin, tetracycline and minocycline was tested by the agar dilution method according to the NCCLS.", [["erythromycin", "CHEMICAL", 22, 34], ["josamycin", "CHEMICAL", 36, 45], ["tetracycline", "CHEMICAL", 47, 59], ["minocycline", "CHEMICAL", 64, 75], ["erythromycin", "CHEMICAL", 22, 34], ["josamycin", "CHEMICAL", 36, 45], ["tetracycline", "CHEMICAL", 47, 59], ["minocycline", "CHEMICAL", 64, 75], ["erythromycin", "SIMPLE_CHEMICAL", 22, 34], ["josamycin", "SIMPLE_CHEMICAL", 36, 45], ["tetracycline", "SIMPLE_CHEMICAL", 47, 59], ["minocycline", "SIMPLE_CHEMICAL", 64, 75], ["erythromycin", "TREATMENT", 22, 34], ["josamycin", "TREATMENT", 36, 45], ["tetracycline", "TREATMENT", 47, 59], ["minocycline", "TREATMENT", 64, 75]]], ["The strains were serotyped with type specific antisera for serotypes Ia, Ib, II, III, IV, and V. Results: Among the total of 161 isolates of macrolide-resistant GBS collected from May 2002 to April 2004 in our hospital (28.6% of the total SGB isolated), 124 (78.85%) were tetracyclineresistant.", [["macrolide", "CHEMICAL", 141, 150], ["GBS", "DISEASE", 161, 164], ["tetracyclineresistant", "CHEMICAL", 272, 293], ["macrolide", "CHEMICAL", 141, 150], ["Ib", "GENE_OR_GENE_PRODUCT", 73, 75], ["macrolide", "SIMPLE_CHEMICAL", 141, 150], ["The strains", "PROBLEM", 0, 11], ["macrolide", "TREATMENT", 141, 150], ["resistant GBS", "PROBLEM", 151, 164], ["the total SGB", "TEST", 229, 242]]], ["The distribution of tet(M) and tet(O) among the erythromycin-resistant GBS harbouring erm(B) was (66.1% and 54.2%, repectively) and harbouring erm(TR) was (63.8% and 34.5%).", [["erythromycin", "CHEMICAL", 48, 60], ["GBS", "DISEASE", 71, 74], ["erythromycin", "CHEMICAL", 48, 60], ["tet(M)", "GENE_OR_GENE_PRODUCT", 20, 26], ["tet(O)", "GENE_OR_GENE_PRODUCT", 31, 37], ["erythromycin", "SIMPLE_CHEMICAL", 48, 60], ["erm(B)", "GENE_OR_GENE_PRODUCT", 86, 92], ["TR", "PROTEIN", 147, 149], ["the erythromycin", "TEST", 44, 60], ["resistant GBS harbouring erm", "PROBLEM", 61, 89], ["TR", "TEST", 147, 149]]], ["The distribution of tetracycline resistance genes and serotypes among the different genotypes in 121 GBS are illustrated in the table.), encoding a secondary betaine uptake system.", [["tetracycline", "CHEMICAL", 20, 32], ["GBS", "DISEASE", 101, 104], ["betaine", "CHEMICAL", 158, 165], ["tetracycline", "CHEMICAL", 20, 32], ["betaine", "CHEMICAL", 158, 165], ["tetracycline", "SIMPLE_CHEMICAL", 20, 32], ["betaine", "SIMPLE_CHEMICAL", 158, 165], ["tetracycline resistance genes", "DNA", 20, 49], ["tetracycline resistance genes", "TREATMENT", 20, 49], ["serotypes", "PROBLEM", 54, 63], ["the different genotypes", "PROBLEM", 70, 93], ["GBS", "TEST", 101, 104], ["a secondary betaine uptake system", "PROBLEM", 146, 179], ["tetracycline resistance", "OBSERVATION", 20, 43], ["secondary betaine", "OBSERVATION", 148, 165], ["uptake system", "OBSERVATION", 166, 179]]], ["The mutant betL* promotes a dramatic increase in resistance to a number of biologically relevant stresses when expressed in a variety of different surrogate hosts.", [["betL", "GENE_OR_GENE_PRODUCT", 11, 15], ["mutant betL*", "PROTEIN", 4, 16], ["dramatic", "OBSERVATION_MODIFIER", 28, 36], ["increase", "OBSERVATION_MODIFIER", 37, 45]]], ["Using a luciferase (Lux) reporter system in combination with the IVIS Imager System (Xenogen Corporation, Alameda, CA), we tracked betL* expression, in real time, both in vitro under various environmental stresses and in vivo in animal models of infection.", [["infection", "DISEASE", 246, 255], ["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["Lux", "GENE_OR_GENE_PRODUCT", 20, 23], ["betL", "GENE_OR_GENE_PRODUCT", 131, 135], ["luciferase (Lux) reporter", "DNA", 8, 33], ["betL", "PROTEIN", 131, 135], ["a luciferase (Lux) reporter system", "TREATMENT", 6, 40], ["the IVIS Imager System", "TREATMENT", 61, 83], ["infection", "PROBLEM", 246, 255], ["environmental stresses", "OBSERVATION", 191, 213], ["infection", "OBSERVATION", 246, 255]]], ["In each case strains expressing betL* demonstrated a marked improvement over those expressing wild type betL, both in terms of gene expression and bacterial growth.", [["betL", "GENE_OR_GENE_PRODUCT", 32, 36], ["betL", "GENE_OR_GENE_PRODUCT", 104, 108], ["betL*", "PROTEIN", 32, 37], ["wild type betL", "PROTEIN", 94, 108], ["bacterial growth", "PROBLEM", 147, 163], ["marked", "OBSERVATION_MODIFIER", 53, 59], ["improvement", "OBSERVATION_MODIFIER", 60, 71], ["bacterial growth", "OBSERVATION", 147, 163]]], ["Sequence analysis of the mutated gene revealed a single nucleotide deletion in the spacer region between the -10 and )35 promoter elements upstream of the betL coding region.", [["nucleotide", "CHEMICAL", 56, 66], ["betL", "GENE_OR_GENE_PRODUCT", 155, 159], ["mutated gene", "DNA", 25, 37], ["spacer region", "DNA", 83, 96], ["35 promoter elements", "DNA", 118, 138], ["betL coding region", "DNA", 155, 173], ["Sequence analysis", "TEST", 0, 17], ["a single nucleotide deletion in the spacer region", "TREATMENT", 47, 96], ["spacer", "ANATOMY_MODIFIER", 83, 89]]], ["This deletion presumably introduces a conformational 'twist' in the putative promoter, thereby increasing its transcriptional output.", [["putative promoter", "DNA", 68, 85], ["This deletion", "PROBLEM", 0, 13], ["a conformational 'twist' in the putative promoter", "TREATMENT", 36, 85], ["transcriptional output", "OBSERVATION", 110, 132]]], ["Furthermore, the betL* mutation appears to counter the heretofore unreported 'twisted' cell morphology observed using scanning electron microscopy of L. monocytogenes grown at elevated osmolarities.", [["cell", "ANATOMY", 87, 91], ["betL", "GENE_OR_GENE_PRODUCT", 17, 21], ["cell", "CELL", 87, 91], ["L. monocytogenes", "ORGANISM", 150, 166], ["betL* mutation", "DNA", 17, 31], ["L. monocytogenes", "SPECIES", 150, 166], ["L. monocytogenes", "SPECIES", 150, 166], ["scanning electron microscopy", "TEST", 118, 146], ["L. monocytogenes", "PROBLEM", 150, 166], ["elevated osmolarities", "PROBLEM", 176, 197]]], ["Conclusions: It is possible to selectively improve genes required for bacterial stress survival both inside and outside the host.", [["bacterial stress survival", "TREATMENT", 70, 95]]], ["Such mutated genes systems may ultimately be used for the construction of more physiologically robust bacterial based vaccine and drug delivery platforms.P1693 Application of fluorescent in situ hybridization for detection of Helicobacter pyloriA.R. Samarbaf-Zadeh, S. Tajbakhsh, S.M. Moosavian (Ahwaz, IR) Introduction: Peptic ulceration following infection of stomach with H. pylori is a common disease.", [["Peptic", "ANATOMY", 321, 327], ["stomach", "ANATOMY", 362, 369], ["Peptic ulceration", "DISEASE", 321, 338], ["infection", "DISEASE", 349, 358], ["H. pylori", "DISEASE", 375, 384], ["stomach", "ORGAN", 362, 369], ["H. pylori", "ORGANISM", 375, 384], ["H. pylori", "SPECIES", 375, 384], ["H. pylori", "SPECIES", 375, 384], ["Such mutated genes systems", "PROBLEM", 0, 26], ["physiologically robust bacterial based vaccine", "TREATMENT", 79, 125], ["drug delivery platforms", "TREATMENT", 130, 153], ["Helicobacter pyloriA.R. Samarbaf", "TREATMENT", 226, 258], ["Moosavian (Ahwaz", "TREATMENT", 285, 301], ["Peptic ulceration", "PROBLEM", 321, 338], ["infection of stomach", "PROBLEM", 349, 369], ["H. pylori", "PROBLEM", 375, 384], ["a common disease", "PROBLEM", 388, 404], ["Peptic", "OBSERVATION_MODIFIER", 321, 327], ["ulceration", "OBSERVATION", 328, 338], ["infection", "OBSERVATION", 349, 358], ["stomach", "ANATOMY", 362, 369], ["H. pylori", "OBSERVATION", 375, 384]]], ["Accurate and rapid detection of the bacteria can lead to implementation of appropriate treatment and recovery.", [["the bacteria", "PROBLEM", 32, 44], ["appropriate treatment", "TREATMENT", 75, 96], ["bacteria", "OBSERVATION", 36, 44]]], ["This research was undertaken to evaluate the sensivity and specificity of Fluorescent In-Situ Hybridization (FISH) in the detection of H. pylori in patients who were suffering from dyspepsia.", [["H. pylori", "DISEASE", 135, 144], ["dyspepsia", "DISEASE", 181, 190], ["H. pylori", "ORGANISM", 135, 144], ["patients", "ORGANISM", 148, 156], ["H. pylori", "SPECIES", 135, 144], ["patients", "SPECIES", 148, 156], ["H. pylori", "SPECIES", 135, 144], ["Fluorescent", "TEST", 74, 85], ["H. pylori", "PROBLEM", 135, 144], ["dyspepsia", "PROBLEM", 181, 190], ["dyspepsia", "OBSERVATION", 181, 190]]], ["Methods: For this purpose, one hundred gastric biopsy samples taken from antrum and corpus of stomach by endoscopy were tested by FISH and compared with conventional culture method complemented with biochemical tests.", [["gastric biopsy samples", "ANATOMY", 39, 61], ["antrum", "ANATOMY", 73, 79], ["corpus", "ANATOMY", 84, 90], ["stomach", "ANATOMY", 94, 101], ["gastric biopsy samples", "CANCER", 39, 61], ["antrum", "MULTI-TISSUE_STRUCTURE", 73, 79], ["corpus", "ORGAN", 84, 90], ["stomach", "ORGAN", 94, 101], ["one hundred gastric biopsy samples", "TEST", 27, 61], ["endoscopy", "TEST", 105, 114], ["conventional culture method", "TEST", 153, 180], ["biochemical tests", "TEST", 199, 216], ["gastric", "ANATOMY", 39, 46], ["biopsy", "OBSERVATION", 47, 53], ["antrum", "ANATOMY", 73, 79], ["corpus", "ANATOMY_MODIFIER", 84, 90], ["stomach", "ANATOMY", 94, 101]]], ["Results: FISH detected H. pylori in 48 clinical samples while conventional method detected 42 samples.", [["samples", "ANATOMY", 48, 55], ["samples", "ANATOMY", 94, 101], ["H. pylori", "ORGANISM", 23, 32], ["samples", "CANCER", 48, 55], ["H. pylori", "SPECIES", 23, 32], ["H. pylori", "SPECIES", 23, 32], ["H. pylori", "PROBLEM", 23, 32], ["clinical samples", "TEST", 39, 55], ["conventional method", "TEST", 62, 81]]], ["The sensivity and specificity of FISH for detection of H. pylori were calculated as 98% and 100% respectively.", [["H. pylori", "ORGANISM", 55, 64], ["H. pylori", "SPECIES", 55, 64], ["H. pylori", "SPECIES", 55, 64], ["H. pylori", "PROBLEM", 55, 64]]], ["Conclusion: The findings of this study suggest that FISH is a highly suitable and rapid method for diagnosis of H. pylori, especially when the samples are taken from the antrum and the corpus of the stomach this technique potentially can be applied routinely for detection of this bacterium in clinical samples.", [["samples", "ANATOMY", 143, 150], ["antrum", "ANATOMY", 170, 176], ["corpus", "ANATOMY", 185, 191], ["stomach", "ANATOMY", 199, 206], ["samples", "ANATOMY", 303, 310], ["H. pylori", "DISEASE", 112, 121], ["H. pylori", "ORGANISM", 112, 121], ["antrum", "MULTI-TISSUE_STRUCTURE", 170, 176], ["corpus", "ORGAN", 185, 191], ["stomach", "ORGAN", 199, 206], ["H. pylori", "SPECIES", 112, 121], ["H. pylori", "SPECIES", 112, 121], ["this study", "TEST", 28, 38], ["H. pylori", "PROBLEM", 112, 121], ["the samples", "TEST", 139, 150], ["this bacterium", "PROBLEM", 276, 290], ["antrum", "ANATOMY", 170, 176], ["corpus", "ANATOMY_MODIFIER", 185, 191], ["stomach", "ANATOMY", 199, 206]]], ["Objective: Numerous studies have demonstrated that H. pylori is ubiquitous; approximately 50% of the world's population is infected with the organism.", [["H. pylori", "DISEASE", 51, 60], ["H. pylori", "ORGANISM", 51, 60], ["H. pylori", "SPECIES", 51, 60], ["H. pylori", "SPECIES", 51, 60], ["Numerous studies", "TEST", 11, 27], ["H. pylori", "PROBLEM", 51, 60], ["the organism", "PROBLEM", 137, 149], ["pylori", "OBSERVATION", 54, 60], ["infected", "OBSERVATION", 123, 131]]], ["Gastroduodenal diseases associated with H. pylori infection are manifested principally in adults.", [["Gastroduodenal", "ANATOMY", 0, 14], ["Gastroduodenal diseases", "DISEASE", 0, 23], ["H. pylori infection", "DISEASE", 40, 59], ["H. pylori", "ORGANISM", 40, 49], ["H. pylori", "SPECIES", 40, 49], ["H. pylori", "SPECIES", 40, 49], ["Gastroduodenal diseases", "PROBLEM", 0, 23], ["H. pylori infection", "PROBLEM", 40, 59], ["diseases", "OBSERVATION", 15, 23], ["H. pylori infection", "OBSERVATION", 40, 59]]], ["However, it's usually during chilhood that the infection is acquired, and it is possibile that mucosal and humoral responses at this time may determine, at least in part, the course of the natural infection.", [["mucosal", "ANATOMY", 95, 102], ["infection", "DISEASE", 47, 56], ["infection", "DISEASE", 197, 206], ["mucosal", "PATHOLOGICAL_FORMATION", 95, 102], ["the infection", "PROBLEM", 43, 56], ["mucosal and humoral responses", "PROBLEM", 95, 124], ["the natural infection", "PROBLEM", 185, 206], ["infection", "OBSERVATION", 47, 56], ["mucosal", "ANATOMY", 95, 102], ["natural", "OBSERVATION_MODIFIER", 189, 196], ["infection", "OBSERVATION", 197, 206]]], ["Our study will describe the prevalence of the H. pylori oral carriage in children resident in Bari, south of Italy, using the PCR method.", [["oral", "ANATOMY", 56, 60], ["H. pylori", "ORGANISM", 46, 55], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["children", "ORGANISM", 73, 81], ["H. pylori", "SPECIES", 46, 55], ["children", "SPECIES", 73, 81], ["H. pylori", "SPECIES", 46, 55], ["Our study", "TEST", 0, 9], ["the H. pylori", "PROBLEM", 42, 55], ["the PCR method", "TREATMENT", 122, 136]]], ["Methods: The evaluation was performed in 404 children, with ages ranging from 6 to 11 years, from primary school district of Local Health Unit of Bari, Italy (AUSL BA/4).", [["children", "ORGANISM", 45, 53], ["children", "SPECIES", 45, 53], ["The evaluation", "TEST", 9, 23]]], ["The school and the class have been selected using the cluster sampling method.", [["the cluster sampling method", "TREATMENT", 50, 77]]], ["A standardized questionnaire was used to verify socio-economic standard, hygiene and history of previous gastrointestinal disorder.", [["gastrointestinal", "ANATOMY", 105, 121], ["gastrointestinal disorder", "DISEASE", 105, 130], ["gastrointestinal", "ORGANISM_SUBDIVISION", 105, 121], ["previous gastrointestinal disorder", "PROBLEM", 96, 130], ["gastrointestinal", "ANATOMY", 105, 121], ["disorder", "OBSERVATION", 122, 130]]], ["A standard full-mouth examination was made to detect periodontal diseases, then dental plaque and saliva collected from children were placed in PBS and transported in laboratory.", [["periodontal", "ANATOMY", 53, 64], ["dental plaque", "ANATOMY", 80, 93], ["saliva", "ANATOMY", 98, 104], ["periodontal diseases", "DISEASE", 53, 73], ["dental plaque", "PATHOLOGICAL_FORMATION", 80, 93], ["saliva", "ORGANISM_SUBSTANCE", 98, 104], ["children", "ORGANISM", 120, 128], ["children", "SPECIES", 120, 128], ["A standard full-mouth examination", "TEST", 0, 33], ["periodontal diseases", "PROBLEM", 53, 73], ["dental plaque", "PROBLEM", 80, 93], ["PBS", "TREATMENT", 144, 147], ["periodontal", "ANATOMY", 53, 64], ["diseases", "OBSERVATION", 65, 73], ["plaque", "OBSERVATION", 87, 93]]], ["H. pylori infection status was checked by PCR method.", [["H. pylori infection", "DISEASE", 0, 19], ["H. pylori", "ORGANISM", 0, 9], ["H. pylori", "SPECIES", 0, 9], ["H. pylori", "SPECIES", 0, 9], ["H. pylori infection", "PROBLEM", 0, 19], ["pylori", "OBSERVATION_MODIFIER", 3, 9], ["infection", "OBSERVATION", 10, 19]]], ["DNA was extracted from oral samples by the boiling method and evaluated for the presence of H. pylori CagA and UreA genes using commercial kit (AB Analitica, Padova).", [["oral samples", "ANATOMY", 23, 35], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["oral samples", "ORGANISM_SUBSTANCE", 23, 35], ["H. pylori", "ORGANISM", 92, 101], ["CagA", "GENE_OR_GENE_PRODUCT", 102, 106], ["UreA", "GENE_OR_GENE_PRODUCT", 111, 115], ["H. pylori CagA and UreA genes", "DNA", 92, 121], ["H. pylori", "SPECIES", 92, 101], ["H. pylori", "SPECIES", 92, 101], ["DNA", "PROBLEM", 0, 3], ["oral samples", "TEST", 23, 35], ["the boiling method", "TEST", 39, 57], ["H. pylori CagA", "PROBLEM", 92, 106], ["commercial kit (AB Analitica", "TREATMENT", 128, 156]]], ["Results: A total of 404 children (212 females and 192 males) partecipated to the study.", [["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32], ["the study", "TEST", 77, 86]]], ["The presence of gene coding for CagA was found in 57 children (14%), but gene UreA was detected only in 22 (5%).", [["CagA", "GENE_OR_GENE_PRODUCT", 32, 36], ["children", "ORGANISM", 53, 61], ["UreA", "GENE_OR_GENE_PRODUCT", 78, 82], ["CagA", "PROTEIN", 32, 36], ["UreA", "DNA", 78, 82], ["children", "SPECIES", 53, 61], ["CagA", "PROBLEM", 32, 36], ["gene UreA", "TEST", 73, 82]]], ["The bacteria was detected in saliva, supragingival and subgingival plaque, suggested that these sites may be considered reservoirs for H. pylori in ureasi-positive patients.", [["saliva", "ANATOMY", 29, 35], ["supragingival", "ANATOMY", 37, 50], ["subgingival plaque", "ANATOMY", 55, 73], ["sites", "ANATOMY", 96, 101], ["H. pylori", "DISEASE", 135, 144], ["saliva", "ORGANISM_SUBSTANCE", 29, 35], ["supragingival", "ORGANISM_SUBSTANCE", 37, 50], ["subgingival plaque", "PATHOLOGICAL_FORMATION", 55, 73], ["H. pylori", "ORGANISM", 135, 144], ["patients", "ORGANISM", 164, 172], ["H. pylori", "SPECIES", 135, 144], ["patients", "SPECIES", 164, 172], ["H. pylori", "SPECIES", 135, 144], ["The bacteria", "PROBLEM", 0, 12], ["saliva", "PROBLEM", 29, 35], ["supragingival and subgingival plaque", "PROBLEM", 37, 73], ["H. pylori", "PROBLEM", 135, 144], ["bacteria", "OBSERVATION", 4, 12], ["supragingival", "OBSERVATION_MODIFIER", 37, 50], ["subgingival", "OBSERVATION_MODIFIER", 55, 66], ["plaque", "OBSERVATION", 67, 73]]], ["There was statistically significant relationship between who didn't wash their hands frequently and the presence of UreA gene (O.R. 1.71).", [["UreA", "GENE_OR_GENE_PRODUCT", 116, 120], ["UreA gene", "DNA", 116, 125]]], ["Conclusions: Current knowledge implies that acquisition of H. pylori seems to occur predominantly in childhood and that once acquired the infection persists life-long in most infected subjects.", [["H. pylori", "DISEASE", 59, 68], ["infection", "DISEASE", 138, 147], ["H. pylori", "ORGANISM", 59, 68], ["H. pylori", "SPECIES", 59, 68], ["H. pylori", "SPECIES", 59, 68], ["H. pylori", "PROBLEM", 59, 68], ["the infection", "PROBLEM", 134, 147], ["infection", "OBSERVATION", 138, 147]]], ["It has been reported at a worldwide level that H. pylori infection prevalence in children varies between 10% and 80% and increases with low socio-economic and educational levels and age.", [["H. pylori infection", "DISEASE", 47, 66], ["H. pylori", "ORGANISM", 47, 56], ["children", "ORGANISM", 81, 89], ["H. pylori", "SPECIES", 47, 56], ["children", "SPECIES", 81, 89], ["H. pylori", "SPECIES", 47, 56], ["H. pylori infection prevalence", "PROBLEM", 47, 77], ["pylori", "OBSERVATION_MODIFIER", 50, 56], ["infection", "OBSERVATION", 57, 66]]], ["The results of this study suggest that oral carriage of H. pylori may play a role in the transmission of infection and that the hand may be instrumental in transmission.P1695The role of Helicobacter pylori in otitis media with effusion T. Yilmaz, M. Ceylan, Y. Akyon, O. Ozcakir, B. Gursel (Ankara, TR)P1695Objectives: Otitis media with effusion (OME) is such a common disease of childhood and its pathogenesis still remains unsettled.", [["oral", "ANATOMY", 39, 43], ["hand", "ANATOMY", 128, 132], ["infection", "DISEASE", 105, 114], ["P1695", "CHEMICAL", 169, 174], ["Helicobacter pylori", "DISEASE", 186, 205], ["otitis", "DISEASE", 209, 215], ["effusion", "DISEASE", 227, 235], ["Otitis media", "DISEASE", 319, 331], ["effusion", "DISEASE", 337, 345], ["OME", "DISEASE", 347, 350], ["oral", "ORGANISM_SUBDIVISION", 39, 43], ["H. pylori", "ORGANISM", 56, 65], ["hand", "ORGANISM_SUBDIVISION", 128, 132], ["P1695", "GENE_OR_GENE_PRODUCT", 169, 174], ["Helicobacter pylori", "ORGANISM", 186, 205], ["H. pylori", "SPECIES", 56, 65], ["Helicobacter pylori", "SPECIES", 186, 205], ["H. pylori", "SPECIES", 56, 65], ["Helicobacter pylori", "SPECIES", 186, 205], ["this study", "TEST", 15, 25], ["H. pylori", "PROBLEM", 56, 65], ["infection", "PROBLEM", 105, 114], ["Helicobacter pylori", "PROBLEM", 186, 205], ["otitis media", "PROBLEM", 209, 221], ["effusion", "PROBLEM", 227, 235], ["Otitis media", "PROBLEM", 319, 331], ["effusion (OME", "PROBLEM", 337, 350], ["a common disease of childhood", "PROBLEM", 360, 389], ["infection", "OBSERVATION", 105, 114], ["instrumental", "OBSERVATION", 140, 152], ["Helicobacter pylori", "OBSERVATION", 186, 205], ["otitis", "OBSERVATION", 209, 215], ["effusion", "OBSERVATION", 227, 235], ["Otitis", "OBSERVATION", 319, 325], ["effusion", "OBSERVATION", 337, 345]]], ["Pepsinogen and pepsin has been shown in the middle ear fluid of patients with OME, indicating that gastric juice could reach as far as middle ear.", [["middle ear fluid", "ANATOMY", 44, 60], ["gastric juice", "ANATOMY", 99, 112], ["middle ear", "ANATOMY", 135, 145], ["Pepsinogen", "CHEMICAL", 0, 10], ["OME", "DISEASE", 78, 81], ["Pepsinogen", "SIMPLE_CHEMICAL", 0, 10], ["pepsin", "GENE_OR_GENE_PRODUCT", 15, 21], ["ear", "ORGAN", 51, 54], ["patients", "ORGANISM", 64, 72], ["gastric juice", "ORGANISM_SUBSTANCE", 99, 112], ["ear", "ORGAN", 142, 145], ["Pepsinogen", "PROTEIN", 0, 10], ["pepsin", "PROTEIN", 15, 21], ["patients", "SPECIES", 64, 72], ["Pepsinogen", "TEST", 0, 10], ["pepsin", "TREATMENT", 15, 21], ["OME", "PROBLEM", 78, 81], ["gastric juice", "TREATMENT", 99, 112], ["middle", "ANATOMY_MODIFIER", 44, 50], ["ear", "ANATOMY", 51, 54], ["fluid", "OBSERVATION", 55, 60], ["gastric", "ANATOMY", 99, 106], ["juice", "OBSERVATION", 107, 112], ["middle ear", "ANATOMY", 135, 145]]], ["If gastric juice could enter the middle ear, Helicobacter pylori, a common inhabitant of gastric juice and mucosa, would also be expected to be found in the middle ear of patients with OME.", [["gastric juice", "ANATOMY", 3, 16], ["middle ear", "ANATOMY", 33, 43], ["gastric juice", "ANATOMY", 89, 102], ["mucosa", "ANATOMY", 107, 113], ["middle ear", "ANATOMY", 157, 167], ["Helicobacter pylori", "DISEASE", 45, 64], ["OME", "DISEASE", 185, 188], ["gastric juice", "ORGANISM_SUBSTANCE", 3, 16], ["ear", "ORGAN", 40, 43], ["Helicobacter pylori", "ORGANISM", 45, 64], ["gastric juice", "MULTI-TISSUE_STRUCTURE", 89, 102], ["mucosa", "MULTI-TISSUE_STRUCTURE", 107, 113], ["ear", "ORGAN", 164, 167], ["patients", "ORGANISM", 171, 179], ["Helicobacter pylori", "SPECIES", 45, 64], ["patients", "SPECIES", 171, 179], ["Helicobacter pylori", "SPECIES", 45, 64], ["gastric juice", "PROBLEM", 3, 16], ["Helicobacter pylori", "PROBLEM", 45, 64], ["gastric juice", "TREATMENT", 89, 102], ["OME", "PROBLEM", 185, 188], ["gastric", "ANATOMY", 3, 10], ["juice", "OBSERVATION", 11, 16], ["middle ear", "ANATOMY", 33, 43], ["Helicobacter pylori", "OBSERVATION", 45, 64], ["gastric", "ANATOMY", 89, 96], ["juice", "OBSERVATION", 97, 102], ["mucosa", "ANATOMY", 107, 113], ["middle ear", "ANATOMY", 157, 167], ["OME", "OBSERVATION", 185, 188]]], ["The objective of this study was to evaluate possible role of Helicobacter pylori in pathogenesis of otitis media with effusion.", [["Helicobacter pylori", "DISEASE", 61, 80], ["otitis media", "DISEASE", 100, 112], ["effusion", "DISEASE", 118, 126], ["Helicobacter pylori", "ORGANISM", 61, 80], ["Helicobacter pylori", "SPECIES", 61, 80], ["Helicobacter pylori", "SPECIES", 61, 80], ["this study", "TEST", 17, 27], ["Helicobacter pylori", "PROBLEM", 61, 80], ["otitis media", "PROBLEM", 100, 112], ["effusion", "PROBLEM", 118, 126], ["Helicobacter pylori", "OBSERVATION", 61, 80], ["otitis", "OBSERVATION", 100, 106], ["effusion", "OBSERVATION", 118, 126]]], ["Methods: The study group consisted of 22 children who are to undergo bilateral ventilation tube insertion, adenoidectomy, tonsillectomy with a diagnosis of OME, adenoid hypertrophy and chronic tonsillitis.", [["adenoid", "ANATOMY", 161, 168], ["OME", "DISEASE", 156, 159], ["adenoid hypertrophy", "DISEASE", 161, 180], ["tonsillitis", "DISEASE", 193, 204], ["children", "ORGANISM", 41, 49], ["tube", "TISSUE", 91, 95], ["adenoid", "ORGAN", 161, 168], ["children", "SPECIES", 41, 49], ["bilateral ventilation tube insertion", "TREATMENT", 69, 105], ["adenoidectomy", "TREATMENT", 107, 120], ["tonsillectomy", "TREATMENT", 122, 135], ["OME", "PROBLEM", 156, 159], ["adenoid hypertrophy", "PROBLEM", 161, 180], ["chronic tonsillitis", "PROBLEM", 185, 204], ["bilateral", "ANATOMY_MODIFIER", 69, 78], ["ventilation", "OBSERVATION", 79, 90], ["tube insertion", "OBSERVATION", 91, 105], ["adenoidectomy", "OBSERVATION", 107, 120], ["tonsillectomy", "OBSERVATION", 122, 135], ["adenoid", "ANATOMY", 161, 168], ["hypertrophy", "OBSERVATION", 169, 180], ["chronic", "OBSERVATION_MODIFIER", 185, 192], ["tonsillitis", "OBSERVATION", 193, 204]]], ["The control group consisted of 20 children who are to undergo adenoidectomy, tonsillectomy with a diagnosis of adenoid hypertrophy and chronic tonsillitis.", [["adenoid", "ANATOMY", 111, 118], ["adenoid hypertrophy", "DISEASE", 111, 130], ["tonsillitis", "DISEASE", 143, 154], ["children", "ORGANISM", 34, 42], ["adenoid", "ORGAN", 111, 118], ["children", "SPECIES", 34, 42], ["adenoidectomy", "TREATMENT", 62, 75], ["tonsillectomy", "TREATMENT", 77, 90], ["adenoid hypertrophy", "PROBLEM", 111, 130], ["chronic tonsillitis", "PROBLEM", 135, 154], ["adenoidectomy", "OBSERVATION", 62, 75], ["tonsillectomy", "OBSERVATION", 77, 90], ["adenoid", "ANATOMY", 111, 118], ["hypertrophy", "OBSERVATION", 119, 130], ["chronic", "OBSERVATION_MODIFIER", 135, 142], ["tonsillitis", "OBSERVATION", 143, 154]]], ["For the study group, middle ear fluid was aspirated and a small biopsy was taken from the promontorium mucosa.", [["ear fluid", "ANATOMY", 28, 37], ["promontorium mucosa", "ANATOMY", 90, 109], ["ear", "ORGAN", 28, 31], ["fluid", "ORGANISM_SUBSTANCE", 32, 37], ["promontorium mucosa", "MULTI-TISSUE_STRUCTURE", 90, 109], ["the study", "TEST", 4, 13], ["middle ear fluid", "PROBLEM", 21, 37], ["a small biopsy", "TEST", 56, 70], ["middle ear", "ANATOMY", 21, 31], ["fluid", "OBSERVATION", 32, 37], ["small", "OBSERVATION_MODIFIER", 58, 63], ["promontorium mucosa", "ANATOMY", 90, 109]]], ["For the control group, myringotomy was done and a small biopsy was taken from the promontorium mucosa.", [["promontorium mucosa", "ANATOMY", 82, 101], ["promontorium mucosa", "MULTI-TISSUE_STRUCTURE", 82, 101], ["myringotomy", "TREATMENT", 23, 34], ["a small biopsy", "TEST", 48, 62], ["myringotomy", "OBSERVATION", 23, 34], ["small", "OBSERVATION_MODIFIER", 50, 55], ["biopsy", "OBSERVATION", 56, 62], ["promontorium mucosa", "ANATOMY", 82, 101]]], ["For both groups, 5 mm deep tissue specimens were obtained from tonsil and adenoid.", [["tissue specimens", "ANATOMY", 27, 43], ["tonsil", "ANATOMY", 63, 69], ["adenoid", "ANATOMY", 74, 81], ["tissue specimens", "CANCER", 27, 43], ["tonsil", "ORGAN", 63, 69], ["adenoid", "ORGAN", 74, 81], ["5 mm deep tissue specimens", "TEST", 17, 43], ["tonsil", "ANATOMY", 63, 69], ["adenoid", "ANATOMY", 74, 81]]], ["For all the specimens taken from the patients, culture and a Nested-PCR were performed to show Helicobacter pylori.", [["specimens", "ANATOMY", 12, 21], ["Helicobacter pylori", "DISEASE", 95, 114], ["patients", "ORGANISM", 37, 45], ["Helicobacter pylori", "ORGANISM", 95, 114], ["patients", "SPECIES", 37, 45], ["Helicobacter pylori", "SPECIES", 95, 114], ["Helicobacter pylori", "SPECIES", 95, 114], ["all the specimens", "TEST", 4, 21], ["culture", "TEST", 47, 54], ["a Nested-PCR", "TEST", 59, 71], ["Helicobacter pylori", "PROBLEM", 95, 114], ["Helicobacter pylori", "OBSERVATION", 95, 114]]], ["Results: Middle ear fluid culture was positive for H. pylori in 2 patients and mucosa culture was positive in 1 patient only.", [["ear fluid", "ANATOMY", 16, 25], ["mucosa", "ANATOMY", 79, 85], ["ear", "ORGAN", 16, 19], ["H. pylori", "ORGANISM", 51, 60], ["patients", "ORGANISM", 66, 74], ["mucosa", "MULTI-TISSUE_STRUCTURE", 79, 85], ["patient", "ORGANISM", 112, 119], ["H. pylori", "SPECIES", 51, 60], ["patients", "SPECIES", 66, 74], ["patient", "SPECIES", 112, 119], ["H. pylori", "SPECIES", 51, 60], ["Middle ear fluid culture", "TEST", 9, 33], ["H. pylori", "PROBLEM", 51, 60], ["mucosa culture", "TEST", 79, 93], ["Middle", "ANATOMY_MODIFIER", 9, 15], ["ear", "ANATOMY", 16, 19], ["fluid", "OBSERVATION", 20, 25], ["mucosa", "ANATOMY", 79, 85]]], ["In the control group middle ear mucosa cultures were always negative.", [["middle ear mucosa", "ANATOMY", 21, 38], ["ear mucosa", "MULTI-TISSUE_STRUCTURE", 28, 38], ["the control group middle ear mucosa cultures", "TEST", 3, 47], ["middle", "ANATOMY_MODIFIER", 21, 27], ["ear mucosa", "ANATOMY", 28, 38]]], ["When culture and PCR results were combined together; the middle ear was positive for H. pylori in 10 patients in the study group and in 2 patients in the control group.", [["middle ear", "ANATOMY", 57, 67], ["H. pylori", "DISEASE", 85, 94], ["ear", "ORGAN", 64, 67], ["H. pylori", "ORGANISM", 85, 94], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 138, 146], ["H. pylori", "SPECIES", 85, 94], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 138, 146], ["H. pylori", "SPECIES", 85, 94], ["culture", "TEST", 5, 12], ["PCR", "TEST", 17, 20], ["H. pylori", "PROBLEM", 85, 94], ["middle ear", "ANATOMY", 57, 67]]], ["This difference was statistically significant.", [["significant", "OBSERVATION_MODIFIER", 34, 45]]], ["H. pylori presence in the tonsillar and adenoid tissues by culture and PCR was also significantly more frequent in the study group compared to the control group.", [["tonsillar", "ANATOMY", 26, 35], ["adenoid tissues", "ANATOMY", 40, 55], ["H. pylori", "ORGANISM", 0, 9], ["tonsillar", "TISSUE", 26, 35], ["adenoid tissues", "TISSUE", 40, 55], ["H. pylori", "SPECIES", 0, 9], ["H. pylori", "SPECIES", 0, 9], ["H. pylori presence in the tonsillar and adenoid tissues", "PROBLEM", 0, 55], ["culture", "TEST", 59, 66], ["PCR", "TEST", 71, 74], ["pylori", "OBSERVATION", 3, 9], ["tonsillar", "ANATOMY", 26, 35], ["adenoid tissues", "ANATOMY", 40, 55], ["more frequent", "OBSERVATION_MODIFIER", 98, 111]]], ["Conclusion: This study is the first to grow H. pylori in the middle ear in OME.", [["middle ear", "ANATOMY", 61, 71], ["OME", "DISEASE", 75, 78], ["H. pylori", "ORGANISM", 44, 53], ["ear", "ORGAN", 68, 71], ["H. pylori", "SPECIES", 44, 53], ["H. pylori", "SPECIES", 44, 53], ["This study", "TEST", 12, 22], ["H. pylori", "PROBLEM", 44, 53], ["pylori", "OBSERVATION", 47, 53], ["middle ear", "ANATOMY", 61, 71], ["OME", "OBSERVATION", 75, 78]]], ["Significantly increased colonization by H. pylori of the middle ear, tonsillar and adenoid tissue in patients with OME indicates that the bacteria reaching the middle ear through gastroesophageal reflux might be involved in the pathogenesis of OME.", [["middle ear", "ANATOMY", 57, 67], ["tonsillar", "ANATOMY", 69, 78], ["adenoid tissue", "ANATOMY", 83, 97], ["middle ear", "ANATOMY", 160, 170], ["gastroesophageal", "ANATOMY", 179, 195], ["OME", "DISEASE", 115, 118], ["gastroesophageal reflux", "DISEASE", 179, 202], ["OME", "DISEASE", 244, 247], ["H. pylori", "ORGANISM", 40, 49], ["ear", "ORGAN", 64, 67], ["tonsillar", "TISSUE", 69, 78], ["adenoid tissue", "TISSUE", 83, 97], ["patients", "ORGANISM", 101, 109], ["ear", "ORGAN", 167, 170], ["gastroesophageal", "ORGAN", 179, 195], ["H. pylori", "SPECIES", 40, 49], ["patients", "SPECIES", 101, 109], ["H. pylori", "SPECIES", 40, 49], ["Significantly increased colonization", "PROBLEM", 0, 36], ["H. pylori of the middle ear, tonsillar and adenoid tissue", "PROBLEM", 40, 97], ["OME", "PROBLEM", 115, 118], ["the bacteria", "PROBLEM", 134, 146], ["gastroesophageal reflux", "PROBLEM", 179, 202], ["OME", "PROBLEM", 244, 247], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["colonization", "OBSERVATION", 24, 36], ["H. pylori", "OBSERVATION", 40, 49], ["middle ear", "ANATOMY", 57, 67], ["tonsillar", "ANATOMY", 69, 78], ["adenoid tissue", "ANATOMY", 83, 97], ["bacteria", "OBSERVATION", 138, 146], ["middle ear", "ANATOMY", 160, 170], ["gastroesophageal", "ANATOMY", 179, 195], ["reflux", "OBSERVATION", 196, 202], ["OME", "OBSERVATION", 244, 247]]], ["For OME cases resistant to medical treatment it may meaningful to evaluate the patient for gastroesophageal reflux and H. pylori.P1696Distribution of the serine-aspartate repeat protein-encoding sdr genes among nasal carriage and invasive Staphylococcus aureus strains Objectives: This study was designed to examine the distribution of the sdr genes among nasal carriage and invasive Staphylococcus aureus strains as well as methicillinsensitive S. aureus (MSSA) and methicillin-resistant S aureus (MRSA).", [["gastroesophageal", "ANATOMY", 91, 107], ["nasal", "ANATOMY", 211, 216], ["nasal", "ANATOMY", 356, 361], ["OME", "DISEASE", 4, 7], ["gastroesophageal reflux and H. pylori", "DISEASE", 91, 128], ["aspartate", "CHEMICAL", 161, 170], ["Staphylococcus aureus", "DISEASE", 239, 260], ["Staphylococcus aureus", "DISEASE", 384, 405], ["MSSA", "CHEMICAL", 457, 461], ["methicillin", "CHEMICAL", 467, 478], ["serine", "CHEMICAL", 154, 160], ["aspartate", "CHEMICAL", 161, 170], ["methicillin", "CHEMICAL", 467, 478], ["patient", "ORGANISM", 79, 86], ["gastroesophageal", "ORGAN", 91, 107], ["H. pylori", "ORGANISM", 119, 128], ["serine", "AMINO_ACID", 154, 160], ["aspartate", "AMINO_ACID", 161, 170], ["sdr", "GENE_OR_GENE_PRODUCT", 195, 198], ["Staphylococcus aureus", "ORGANISM", 239, 260], ["sdr", "GENE_OR_GENE_PRODUCT", 340, 343], ["nasal", "ORGANISM_SUBDIVISION", 356, 361], ["Staphylococcus aureus", "ORGANISM", 384, 405], ["methicillinsensitive S. aureus", "ORGANISM", 425, 455], ["MSSA", "CANCER", 457, 461], ["methicillin-resistant S aureus", "ORGANISM", 467, 497], ["MRSA", "CANCER", 499, 503], ["serine-aspartate repeat protein", "PROTEIN", 154, 185], ["sdr genes", "DNA", 195, 204], ["sdr genes", "DNA", 340, 349], ["patient", "SPECIES", 79, 86], ["H. pylori", "SPECIES", 119, 128], ["Staphylococcus aureus", "SPECIES", 239, 260], ["Staphylococcus aureus", "SPECIES", 384, 405], ["S. aureus", "SPECIES", 446, 455], ["S aureus", "SPECIES", 489, 497], ["MRSA", "SPECIES", 499, 503], ["H. pylori", "SPECIES", 119, 128], ["Staphylococcus aureus", "SPECIES", 239, 260], ["Staphylococcus aureus", "SPECIES", 384, 405], ["S. aureus", "SPECIES", 446, 455], ["MSSA", "SPECIES", 457, 461], ["S aureus", "SPECIES", 489, 497], ["MRSA", "SPECIES", 499, 503], ["OME cases", "PROBLEM", 4, 13], ["medical treatment", "TREATMENT", 27, 44], ["gastroesophageal reflux", "PROBLEM", 91, 114], ["H. pylori", "PROBLEM", 119, 128], ["the serine", "TEST", 150, 160], ["aspartate repeat protein", "TEST", 161, 185], ["encoding sdr genes", "PROBLEM", 186, 204], ["nasal carriage", "PROBLEM", 211, 225], ["invasive Staphylococcus aureus strains", "PROBLEM", 230, 268], ["This study", "TEST", 281, 291], ["the sdr genes", "PROBLEM", 336, 349], ["nasal carriage", "PROBLEM", 356, 370], ["invasive Staphylococcus aureus strains", "PROBLEM", 375, 413], ["methicillinsensitive S. aureus", "PROBLEM", 425, 455], ["MSSA", "PROBLEM", 457, 461], ["methicillin-resistant S aureus", "PROBLEM", 467, 497], ["MRSA", "PROBLEM", 499, 503], ["gastroesophageal", "ANATOMY", 91, 107], ["reflux", "OBSERVATION", 108, 114], ["nasal", "ANATOMY", 211, 216], ["nasal", "ANATOMY", 356, 361], ["Staphylococcus aureus", "OBSERVATION", 384, 405], ["aureus", "OBSERVATION", 449, 455]]], ["Methods: The presence or absence of the sdr genes using DNA from 497 S. aureus strains was determined by a novel triplex PCR procedure.", [["sdr", "GENE_OR_GENE_PRODUCT", 40, 43], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["S. aureus", "ORGANISM", 69, 78], ["strains", "ORGANISM", 79, 86], ["sdr genes", "DNA", 40, 49], ["S. aureus", "SPECIES", 69, 78], ["S. aureus", "SPECIES", 69, 78], ["DNA", "TEST", 56, 59], ["S. aureus strains", "PROBLEM", 69, 86], ["a novel triplex PCR procedure", "TREATMENT", 105, 134]]], ["The two-tailed Fisher's exact test was used to analyse the distribution of the sdr genes among S. aureus strains originating from different hosts.", [["sdr", "GENE_OR_GENE_PRODUCT", 79, 82], ["S. aureus strains", "ORGANISM", 95, 112], ["sdr genes", "DNA", 79, 88], ["S. aureus", "SPECIES", 95, 104], ["S. aureus", "SPECIES", 95, 104], ["Fisher's exact test", "TEST", 15, 34], ["S. aureus strains", "PROBLEM", 95, 112], ["aureus strains", "OBSERVATION", 98, 112]]], ["P values less than 0.05 were considered a statistically significant difference.", [["P values", "TEST", 0, 8], ["a statistically significant difference", "PROBLEM", 40, 78]]], ["Results: The sdr locus was found in all 497 investigated S. aureus strains although in 29 strains it contained only the sdrC gene (sdrD -sdrE-).", [["strains", "ANATOMY", 67, 74], ["sdr", "GENE_OR_GENE_PRODUCT", 13, 16], ["S. aureus strains", "ORGANISM", 57, 74], ["sdrC", "GENE_OR_GENE_PRODUCT", 120, 124], ["sdrD -sdrE", "GENE_OR_GENE_PRODUCT", 131, 141], ["sdr locus", "DNA", 13, 22], ["sdrC gene", "DNA", 120, 129], ["sdrD", "DNA", 131, 135], ["sdrE", "DNA", 137, 141], ["S. aureus", "SPECIES", 57, 66], ["S. aureus", "SPECIES", 57, 66], ["The sdr locus", "TEST", 9, 22], ["S. aureus strains", "PROBLEM", 57, 74], ["aureus", "OBSERVATION", 60, 66]]], ["The sdrC + sdrD -sdrE-gene profile was exclusive to MSSA strains (Fisher's exact test; P = 0.0005) and was not found in the strains collected from bone infections (P = 0.0019).", [["bone", "ANATOMY", 147, 151], ["bone infections", "DISEASE", 147, 162], ["sdrC", "GENE_OR_GENE_PRODUCT", 4, 8], ["bone", "TISSUE", 147, 151], ["sdrC", "PROTEIN", 4, 8], ["sdrD", "PROTEIN", 11, 15], ["sdrE", "PROTEIN", 17, 21], ["The sdrC", "TEST", 0, 8], ["MSSA strains", "PROBLEM", 52, 64], ["Fisher's exact test", "TEST", 66, 85], ["P", "TEST", 87, 88], ["the strains", "PROBLEM", 120, 131], ["bone infections", "PROBLEM", 147, 162], ["bone", "ANATOMY", 147, 151], ["infections", "OBSERVATION", 152, 162]]], ["We also found a strong association between the presence of the sdrD gene and MRSA strains (P < 0.0001).", [["sdrD", "GENE_OR_GENE_PRODUCT", 63, 67], ["sdrD gene", "DNA", 63, 72], ["MRSA", "SPECIES", 77, 81], ["the sdrD gene and MRSA strains", "PROBLEM", 59, 89], ["strong", "OBSERVATION_MODIFIER", 16, 22], ["MRSA", "OBSERVATION", 77, 81]]], ["Conclusion: Our findings suggest that MSSA strains with the newly uncovered sdrC + sdrD -sdrE-gene profile have a substantially decreased potential to establish bone infection.P1697Sequencing of lukS-PV and lukF-PV in methicillin-sensitive and methicillin-resistant Staphylococcus aureus of diverse genetic backgrounds in a Swedish county C. Berglund, B. S\u00f6 derquist (\u00d6 rebro, SE)P1697Objectives: Community-aquired methicillin-resistant Staphylococcus aureus (CA-MRSA) have been reported to carry the loci for Panton-Valentine leukocidin (PVL) in high frequency.", [["bone", "ANATOMY", 161, 165], ["MSSA", "CHEMICAL", 38, 42], ["bone infection", "DISEASE", 161, 175], ["methicillin", "CHEMICAL", 218, 229], ["methicillin", "CHEMICAL", 244, 255], ["Staphylococcus aureus", "DISEASE", 266, 287], ["methicillin", "CHEMICAL", 415, 426], ["Staphylococcus aureus", "DISEASE", 437, 458], ["Panton-Valentine leukocidin", "CHEMICAL", 510, 537], ["methicillin", "CHEMICAL", 218, 229], ["methicillin", "CHEMICAL", 244, 255], ["methicillin", "CHEMICAL", 415, 426], ["MSSA strains", "ORGANISM", 38, 50], ["sdrC", "GENE_OR_GENE_PRODUCT", 76, 80], ["sdrD", "GENE_OR_GENE_PRODUCT", 83, 87], ["bone", "TISSUE", 161, 165], ["lukS-PV", "GENE_OR_GENE_PRODUCT", 195, 202], ["lukF-PV", "GENE_OR_GENE_PRODUCT", 207, 214], ["methicillin", "ORGANISM", 218, 229], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 244, 287], ["Community-aquired methicillin-resistant Staphylococcus aureus", "ORGANISM", 397, 458], ["CA-MRSA", "ORGANISM", 460, 467], ["Panton-Valentine leukocidin", "GENE_OR_GENE_PRODUCT", 510, 537], ["sdrC", "PROTEIN", 76, 80], ["sdrD", "PROTEIN", 83, 87], ["sdrE", "PROTEIN", 89, 93], ["lukS", "PROTEIN", 195, 199], ["PV", "PROTEIN", 200, 202], ["lukF", "PROTEIN", 207, 211], ["Staphylococcus aureus", "SPECIES", 266, 287], ["Staphylococcus aureus", "SPECIES", 437, 458], ["MRSA", "SPECIES", 463, 467], ["Staphylococcus aureus", "SPECIES", 266, 287], ["B. S\u00f6 derquist", "SPECIES", 352, 366], ["Staphylococcus aureus", "SPECIES", 437, 458], ["Panton-Valentine leukocidin", "SPECIES", 510, 537], ["MSSA strains", "PROBLEM", 38, 50], ["the newly uncovered sdrC + sdrD -sdrE-gene profile", "PROBLEM", 56, 106], ["bone infection", "PROBLEM", 161, 175], ["lukS", "TEST", 195, 199], ["PV", "TEST", 200, 202], ["lukF", "TEST", 207, 211], ["PV", "TEST", 212, 214], ["methicillin", "TEST", 218, 229], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 244, 287], ["aquired methicillin-resistant Staphylococcus aureus", "PROBLEM", 407, 458], ["MRSA", "PROBLEM", 463, 467], ["Panton", "TEST", 510, 516], ["Valentine leukocidin", "TREATMENT", 517, 537], ["MSSA", "OBSERVATION", 38, 42], ["bone", "ANATOMY", 161, 165], ["infection", "OBSERVATION", 166, 175], ["PV", "ANATOMY", 200, 202], ["PV", "ANATOMY", 212, 214], ["Staphylococcus aureus", "OBSERVATION", 266, 287], ["Staphylococcus aureus", "OBSERVATION", 437, 458], ["high frequency", "OBSERVATION_MODIFIER", 547, 561]]], ["The aim of this study was to describe variations within the PVL genes (lukS-PV and lukF-PV) in methicillinsensitive and methicillin-resistant S. aureus of diverse genetic backgrounds.", [["methicillin", "CHEMICAL", 120, 131], ["methicillin", "CHEMICAL", 120, 131], ["PVL", "GENE_OR_GENE_PRODUCT", 60, 63], ["lukS-PV", "GENE_OR_GENE_PRODUCT", 71, 78], ["lukF-PV", "GENE_OR_GENE_PRODUCT", 83, 90], ["methicillin", "ORGANISM", 120, 131], ["S. aureus", "ORGANISM", 142, 151], ["PVL genes", "DNA", 60, 69], ["lukS", "DNA", 71, 75], ["PV", "DNA", 76, 78], ["lukF", "DNA", 83, 87], ["PV", "DNA", 88, 90], ["S. aureus", "SPECIES", 142, 151], ["S. aureus", "SPECIES", 142, 151], ["this study", "TEST", 11, 21], ["the PVL genes", "TEST", 56, 69], ["lukS", "TEST", 71, 75], ["PV", "TEST", 76, 78], ["lukF", "TEST", 83, 87], ["methicillin", "TEST", 120, 131], ["PV", "ANATOMY", 88, 90], ["aureus", "OBSERVATION", 145, 151], ["diverse genetic backgrounds", "OBSERVATION", 155, 182]]], ["Methods: Twelve PVL-positive S. aureus were characterised by multilocus sequence typing (MLST) and MRSA also by staphylococcal cassette chromosome mec (SCCmec) typing.", [["PVL", "GENE_OR_GENE_PRODUCT", 16, 19], ["S. aureus", "ORGANISM", 29, 38], ["staphylococcal cassette chromosome mec", "GENE_OR_GENE_PRODUCT", 112, 150], ["staphylococcal cassette chromosome mec", "DNA", 112, 150], ["SCCmec", "DNA", 152, 158], ["S. aureus", "SPECIES", 29, 38], ["MRSA", "SPECIES", 99, 103], ["S. aureus", "SPECIES", 29, 38], ["MRSA", "SPECIES", 99, 103], ["Twelve PVL", "TEST", 9, 19], ["positive S. aureus", "PROBLEM", 20, 38], ["multilocus sequence typing", "TEST", 61, 87], ["MRSA", "PROBLEM", 99, 103], ["staphylococcal cassette chromosome mec", "TREATMENT", 112, 150], ["aureus", "OBSERVATION", 32, 38]]], ["Oligonucleotide primers were designed to yield a product size of~2500 bp including lukS-PV and lukF-PV and flanking regions by PCR amplification.", [["lukS-PV", "GENE_OR_GENE_PRODUCT", 83, 90], ["lukF-PV", "GENE_OR_GENE_PRODUCT", 95, 102], ["lukS-PV and lukF-PV and flanking regions", "DNA", 83, 123], ["Oligonucleotide primers", "TEST", 0, 23], ["bp", "TEST", 70, 72], ["lukS", "TEST", 83, 87], ["PV", "TEST", 88, 90], ["lukF", "TEST", 95, 99], ["PCR amplification", "TEST", 127, 144], ["size", "OBSERVATION_MODIFIER", 57, 61], ["PV", "ANATOMY", 88, 90], ["PV", "ANATOMY", 100, 102]]], ["Cyclic sequencing was performed with several sets of primers to overlap the sequences on both strands and was separated on ABI PRISM \u00d2 3100 Genetic Analyzer (Applied Biosystems).", [["Cyclic sequencing", "TEST", 0, 17], ["the sequences", "TEST", 72, 85], ["ABI PRISM", "TEST", 123, 132], ["Genetic Analyzer", "TEST", 140, 156]]], ["The nucleotide sequences were analysed using ABI PRISM \u00d2 AutoAssembler TM DNA Sequence Assembly 1.4.0 software and compared using BioEdit 7.0.1.P1697Results: Analysis with MLST differentiated the PVL-positive CA-MRSA into six different sequence types (ST8, 36, 80, 152, 154 and 256) with either SCCmec type IV, IV c, V or unknown types.", [["nucleotide", "CHEMICAL", 4, 14], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["PVL", "GENE_OR_GENE_PRODUCT", 196, 199], ["CA", "GENE_OR_GENE_PRODUCT", 209, 211], ["IV c, V", "GENE_OR_GENE_PRODUCT", 311, 318], ["MRSA", "SPECIES", 212, 216], ["The nucleotide sequences", "TEST", 0, 24], ["ABI PRISM", "TEST", 45, 54], ["software", "TEST", 102, 110], ["BioEdit", "TEST", 130, 137], ["Analysis", "TEST", 158, 166], ["MLST", "TEST", 172, 176], ["the PVL", "TEST", 192, 199], ["positive CA", "PROBLEM", 200, 211], ["MRSA", "PROBLEM", 212, 216], ["ST8", "TEST", 252, 255], ["SCCmec type IV", "PROBLEM", 295, 309], ["PVL", "OBSERVATION", 196, 199]]], ["Six additional STs (ST5, 22, 25, 30, 88 and new) were detected among the PVL-positive methicillin-sensitive S. aureus.", [["methicillin", "CHEMICAL", 86, 97], ["methicillin", "CHEMICAL", 86, 97], ["PVL", "GENE_OR_GENE_PRODUCT", 73, 76], ["S. aureus", "ORGANISM", 108, 117], ["S. aureus", "SPECIES", 108, 117], ["S. aureus", "SPECIES", 108, 117], ["Six additional STs", "TEST", 0, 18], ["ST5", "TEST", 20, 23], ["the PVL", "TEST", 69, 76], ["positive methicillin-sensitive S. aureus", "PROBLEM", 77, 117], ["aureus", "OBSERVATION", 111, 117]]], ["Sequencing lukS-PV and lukF-PV revealed eight point mutations among these isolates with twelve different origins.", [["lukS-PV", "GENE_OR_GENE_PRODUCT", 11, 18], ["lukF-PV", "GENE_OR_GENE_PRODUCT", 23, 30], ["lukS", "DNA", 11, 15], ["PV", "DNA", 16, 18], ["lukF", "DNA", 23, 27], ["PV", "DNA", 28, 30], ["Sequencing lukS", "TEST", 0, 15], ["PV", "TEST", 16, 18], ["lukF", "TEST", 23, 27], ["eight point mutations", "PROBLEM", 40, 61], ["PV", "ANATOMY", 16, 18]]], ["Five substitutions had occurred in lukS-PV and three in lukF-PV.", [["lukS-PV", "GENE_OR_GENE_PRODUCT", 35, 42], ["lukF-PV", "GENE_OR_GENE_PRODUCT", 56, 63], ["lukS", "PROTEIN", 35, 39], ["lukF", "PROTEIN", 56, 60], ["Five substitutions", "PROBLEM", 0, 18], ["PV", "ANATOMY", 40, 42], ["PV", "ANATOMY", 61, 63]]], ["Only one substitution was nonsynonymous (histidine fi arginine).", [["histidine fi arginine", "CHEMICAL", 41, 62], ["histidine fi arginine", "CHEMICAL", 41, 62], ["histidine fi arginine", "SIMPLE_CHEMICAL", 41, 62], ["nonsynonymous (histidine fi arginine", "TREATMENT", 26, 62]]], ["Conclusion: The PVL-genes were well conserved despite the different genetic origins of the isolates analysed.", [["PVL", "GENE_OR_GENE_PRODUCT", 16, 19], ["PVL-genes", "DNA", 16, 25], ["The PVL", "TEST", 12, 19], ["the isolates", "TEST", 87, 99], ["PVL", "OBSERVATION", 16, 19]]], ["The PVL is an extracellular product and the genes are not subject to any selective forces and thereby diversify very slowly.", [["extracellular", "ANATOMY", 14, 27], ["PVL", "GENE_OR_GENE_PRODUCT", 4, 7], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["PVL", "OBSERVATION", 4, 7], ["extracellular product", "OBSERVATION", 14, 35]]], ["Additional nonsynonymous mutations might result in a non-functional toxin.P1698The first case of Staphylococcus pseudintermedius in humans isolated from an ICD lead L. Van Hoovels, A. Vankeerberghen, K. Van Vaerenbergh, A. Boel, H. De Beenhouwer (Aalst, BE) Introduction: Staphylococcus pseudintermedius is recently described as a new coagulase-positive species from animals (Devriese et al., 2005) .", [["Staphylococcus pseudintermedius", "DISEASE", 97, 128], ["BE", "CHEMICAL", 254, 256], ["Staphylococcus pseudintermedius", "DISEASE", 272, 303], ["Staphylococcus pseudintermedius", "ORGANISM", 97, 128], ["humans", "ORGANISM", 132, 138], ["Staphylococcus pseudintermedius", "ORGANISM", 272, 303], ["non-functional toxin", "PROTEIN", 53, 73], ["Staphylococcus pseudintermedius", "SPECIES", 97, 128], ["humans", "SPECIES", 132, 138], ["Staphylococcus pseudintermedius", "SPECIES", 272, 303], ["Staphylococcus pseudintermedius", "SPECIES", 97, 128], ["humans", "SPECIES", 132, 138], ["Staphylococcus pseudintermedius", "SPECIES", 272, 303], ["Additional nonsynonymous mutations", "PROBLEM", 0, 34], ["a non-functional toxin", "PROBLEM", 51, 73], ["Staphylococcus pseudintermedius", "PROBLEM", 97, 128], ["Staphylococcus pseudintermedius", "PROBLEM", 272, 303], ["a new coagulase", "TEST", 329, 344], ["nonsynonymous mutations", "OBSERVATION", 11, 34], ["Staphylococcus pseudintermedius", "OBSERVATION", 97, 128], ["ICD", "OBSERVATION", 156, 159], ["Staphylococcus pseudintermedius", "OBSERVATION", 272, 303], ["positive species", "OBSERVATION_MODIFIER", 345, 361]]], ["The pathogenic significance of this novel species remains unclear and to our knowledge no human infection due to S. pseudintermedius has been reported to date.", [["infection", "DISEASE", 96, 105], ["S. pseudintermedius", "DISEASE", 113, 132], ["human", "ORGANISM", 90, 95], ["S. pseudintermedius", "ORGANISM", 113, 132], ["human", "SPECIES", 90, 95], ["S. pseudintermedius", "SPECIES", 113, 132], ["human", "SPECIES", 90, 95], ["S. pseudintermedius", "SPECIES", 113, 132], ["this novel species", "PROBLEM", 31, 49], ["human infection", "PROBLEM", 90, 105], ["S. pseudintermedius", "PROBLEM", 113, 132], ["infection", "OBSERVATION", 96, 105], ["pseudintermedius", "OBSERVATION", 116, 132]]], ["Here, we present the first isolation of S. pseudintermedius in humans with important clinical significance.", [["S. pseudintermedius", "DISEASE", 40, 59], ["S. pseudintermedius", "ORGANISM", 40, 59], ["humans", "ORGANISM", 63, 69], ["S. pseudintermedius", "SPECIES", 40, 59], ["humans", "SPECIES", 63, 69], ["S. pseudintermedius", "SPECIES", 40, 59], ["humans", "SPECIES", 63, 69], ["pseudintermedius", "OBSERVATION", 43, 59]]], ["Patient and methods: A 60-year old male patient was referred to our centre for an ischemic cardiomyopathy and ventricle tachycardia for which he recieved an implantable cardioverterdefibrillator (ICD) in January 2004.", [["ventricle", "ANATOMY", 110, 119], ["ischemic cardiomyopathy", "DISEASE", 82, 105], ["ventricle tachycardia", "DISEASE", 110, 131], ["patient", "ORGANISM", 40, 47], ["ventricle", "MULTI-TISSUE_STRUCTURE", 110, 119], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 40, 47], ["an ischemic cardiomyopathy", "PROBLEM", 79, 105], ["ventricle tachycardia", "PROBLEM", 110, 131], ["an implantable cardioverterdefibrillator (ICD", "TREATMENT", 154, 199], ["ischemic", "OBSERVATION_MODIFIER", 82, 90], ["cardiomyopathy", "OBSERVATION", 91, 105], ["ventricle", "ANATOMY", 110, 119], ["tachycardia", "OBSERVATION", 120, 131]]], ["In August 2005 he presented with complaints of migration of the ICD device.", [["the ICD device", "TREATMENT", 60, 74], ["migration", "OBSERVATION_MODIFIER", 47, 56], ["ICD device", "OBSERVATION", 64, 74]]], ["Clinical examination revealed perforation of the ICD pocket.", [["perforation of the ICD pocket", "DISEASE", 30, 59], ["Clinical examination", "TEST", 0, 20], ["perforation of the ICD pocket", "PROBLEM", 30, 59], ["perforation", "OBSERVATION", 30, 41], ["ICD pocket", "OBSERVATION", 49, 59]]], ["Infection was suspected and confirmed by the presence of pus in the pocket.", [["pus", "ORGANISM_SUBSTANCE", 57, 60], ["Infection", "PROBLEM", 0, 9], ["pus in the pocket", "PROBLEM", 57, 74], ["pus", "OBSERVATION", 57, 60], ["pocket", "OBSERVATION_MODIFIER", 68, 74]]], ["The infected ICD was completely removed and several samples (ventricular lead, pus and a tissue sample from the pocket) were sent for culture.Bacteria obtained by routine culture were further characterised by phenotypical identification, Pastorex \u00d2 Staph-Plus (BioRad), API Staph \u00d2 (BioM\u00e9rieux) and Phoenix \u00d2 (BD).", [["samples", "ANATOMY", 52, 59], ["ventricular", "ANATOMY", 61, 72], ["pus", "ANATOMY", 79, 82], ["tissue sample", "ANATOMY", 89, 102], ["ventricular", "MULTI-TISSUE_STRUCTURE", 61, 72], ["pus", "ORGANISM_SUBSTANCE", 79, 82], ["tissue", "TISSUE", 89, 95], ["Bacteria", "CELL", 142, 150], ["The infected ICD", "TREATMENT", 0, 16], ["several samples (ventricular lead", "PROBLEM", 44, 77], ["pus", "PROBLEM", 79, 82], ["a tissue sample", "TEST", 87, 102], ["culture", "TEST", 134, 141], ["Bacteria", "PROBLEM", 142, 150], ["routine culture", "TEST", 163, 178], ["phenotypical identification", "TEST", 209, 236], ["Pastorex", "TEST", 238, 246], ["Staph", "TEST", 249, 254], ["API", "TEST", 270, 273], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["ICD", "OBSERVATION", 13, 16], ["ventricular", "ANATOMY", 61, 72], ["pus", "OBSERVATION", 79, 82]]], ["For molecular analysis, PCRs were performed targeting the nuclease (Nuc) and coagulase (Coag) genes of S. aureus.", [["Nuc", "GENE_OR_GENE_PRODUCT", 68, 71], ["coagulase (Coag)", "GENE_OR_GENE_PRODUCT", 77, 93], ["S. aureus", "ORGANISM", 103, 112], ["nuclease (Nuc) and coagulase (Coag) genes", "DNA", 58, 99], ["S. aureus", "SPECIES", 103, 112], ["S. aureus", "SPECIES", 103, 112], ["molecular analysis", "TEST", 4, 22], ["PCRs", "TEST", 24, 28], ["the nuclease", "TEST", 54, 66], ["coagulase", "TEST", 77, 86], ["Coag", "TEST", 88, 92], ["S. aureus", "PROBLEM", 103, 112], ["aureus", "OBSERVATION", 106, 112]]], ["Additionally, sequencing of the 16S rRNA gene was performed and further analysed using BLAST.", [["16S", "GENE_OR_GENE_PRODUCT", 32, 35], ["rRNA", "CELLULAR_COMPONENT", 36, 40], ["16S rRNA gene", "DNA", 32, 45], ["the 16S rRNA gene", "TEST", 28, 45], ["BLAST", "TEST", 87, 92]]], ["Results: Staphylococci with identical phenotypical appearance were isolated from 2 of the 3 ICD samples (lead and pus).", [["samples", "ANATOMY", 96, 103], ["pus", "ANATOMY", 114, 117], ["Staphylococci", "CANCER", 9, 22], ["Staphylococci", "PROBLEM", 9, 22], ["the 3 ICD samples", "TREATMENT", 86, 103], ["pus", "PROBLEM", 114, 117], ["Staphylococci", "OBSERVATION", 9, 22], ["pus", "OBSERVATION", 114, 117]]], ["Colonies were beta-hemolytic on sheep blood agar, DNase and coagulase positive but clumping factor, mannitol and Pastorex \u00d2 negative.", [["Colonies", "ANATOMY", 0, 8], ["blood", "ANATOMY", 38, 43], ["mannitol", "CHEMICAL", 100, 108], ["Pastorex", "CHEMICAL", 113, 121], ["mannitol", "CHEMICAL", 100, 108], ["sheep", "ORGANISM", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["DNase", "GENE_OR_GENE_PRODUCT", 50, 55], ["coagulase positive but clumping factor", "GENE_OR_GENE_PRODUCT", 60, 98], ["mannitol", "SIMPLE_CHEMICAL", 100, 108], ["Pastorex", "SIMPLE_CHEMICAL", 113, 121], ["DNase", "PROTEIN", 50, 55], ["coagulase positive but clumping factor", "PROTEIN", 60, 98], ["sheep", "SPECIES", 32, 37], ["sheep", "SPECIES", 32, 37], ["beta-hemolytic", "PROBLEM", 14, 28], ["sheep blood agar", "TEST", 32, 48], ["DNase", "TEST", 50, 55], ["coagulase", "TEST", 60, 69], ["clumping factor", "PROBLEM", 83, 98], ["mannitol", "TREATMENT", 100, 108], ["Pastorex", "TEST", 113, 121], ["beta-hemolytic", "OBSERVATION_MODIFIER", 14, 28]]], ["Biochemical identification by API Staph \u00d2 and Phoenix \u00d2 gave a presumptive identification of S. aureus with a confidence value of respectively 88,5% and 97%.The PCRs for the Nuc and Coag genes were both negative.", [["S. aureus", "ORGANISM", 93, 102], ["Nuc", "GENE_OR_GENE_PRODUCT", 174, 177], ["Coag", "GENE_OR_GENE_PRODUCT", 182, 186], ["Nuc and Coag genes", "DNA", 174, 192], ["S. aureus", "SPECIES", 93, 102], ["S. aureus", "SPECIES", 93, 102], ["Biochemical identification", "TEST", 0, 26], ["API Staph", "TEST", 30, 39], ["S. aureus", "PROBLEM", 93, 102], ["a confidence value", "TEST", 108, 126], ["The PCRs", "TEST", 157, 165], ["the Nuc and Coag genes", "TEST", 170, 192], ["API", "ANATOMY", 30, 33], ["Staph", "OBSERVATION", 34, 39], ["aureus", "OBSERVATION", 96, 102]]], ["16S rRNA gene sequencing resulted in the identification of S. pseudintermedius based on a 100% sequence similarity with a previous reported sequence by Devriese et al. Conclusion: This case report describes the first identification of S. pseudintermedius as a significant pathogen in human.", [["S. pseudintermedius", "DISEASE", 235, 254], ["S. pseudintermedius", "ORGANISM", 59, 78], ["S. pseudintermedius", "ORGANISM", 235, 254], ["human", "ORGANISM", 284, 289], ["16S rRNA gene", "DNA", 0, 13], ["S. pseudintermedius", "SPECIES", 59, 78], ["S. pseudintermedius", "SPECIES", 235, 254], ["human", "SPECIES", 284, 289], ["S. pseudintermedius", "SPECIES", 59, 78], ["S. pseudintermedius", "SPECIES", 235, 254], ["human", "SPECIES", 284, 289], ["16S rRNA gene sequencing", "TEST", 0, 24], ["S. pseudintermedius", "PROBLEM", 59, 78], ["S. pseudintermedius", "PROBLEM", 235, 254], ["a significant pathogen in human", "PROBLEM", 258, 289], ["pseudintermedius", "OBSERVATION", 62, 78], ["pseudintermedius", "OBSERVATION", 238, 254], ["significant", "OBSERVATION_MODIFIER", 260, 271], ["pathogen", "OBSERVATION", 272, 280]]], ["Growth characteristics and commercial identification systems misidentify the organism as S. aureus.", [["S. aureus", "ORGANISM", 89, 98], ["S. aureus", "SPECIES", 89, 98], ["S. aureus", "SPECIES", 89, 98], ["commercial identification systems", "TEST", 27, 60], ["S. aureus", "PROBLEM", 89, 98], ["aureus", "OBSERVATION", 92, 98]]], ["When confronted with an inconsistent phenotypical identification pattern, clinical labs should consider the use of 16S rRNA gene sequencing for final confirmation.P1699Characterisation of Staphylococcus aureus isolates recovered from dairy sheep farms (agr group, adherence, slime, resistance to antibiotics) E. Vautor, M. Sabah, G. Mancini, M. Pepin, H. Carsenti-Dellamonica (Sophia-Antipolis, Nice, FR)P1699Objectives: The purpose of this study was to investigate 46 Staphylococcus aureus natural isolates associated with dairy sheep mastitis for epidemiological key features (agr group, adherence, slime production and antibiotics resistance).", [["Staphylococcus aureus", "DISEASE", 188, 209], ["Staphylococcus aureus", "DISEASE", 469, 490], ["sheep mastitis", "DISEASE", 530, 544], ["Staphylococcus aureus", "ORGANISM", 188, 209], ["H. Carsenti-Dellamonica", "ORGANISM", 352, 375], ["Sophia-Antipolis", "ORGANISM", 377, 393], ["Staphylococcus aureus", "ORGANISM", 469, 490], ["16S rRNA gene", "DNA", 115, 128], ["Staphylococcus aureus", "SPECIES", 188, 209], ["sheep", "SPECIES", 240, 245], ["Staphylococcus aureus", "SPECIES", 469, 490], ["sheep", "SPECIES", 530, 535], ["Staphylococcus aureus", "SPECIES", 188, 209], ["sheep", "SPECIES", 240, 245], ["Staphylococcus aureus", "SPECIES", 469, 490], ["sheep", "SPECIES", 530, 535], ["clinical labs", "TEST", 74, 87], ["16S rRNA", "TREATMENT", 115, 123], ["final confirmation", "TEST", 144, 162], ["Staphylococcus aureus isolates", "PROBLEM", 188, 218], ["antibiotics", "TREATMENT", 296, 307], ["this study", "TEST", 436, 446], ["Staphylococcus aureus natural isolates", "PROBLEM", 469, 507], ["dairy sheep mastitis", "PROBLEM", 524, 544], ["epidemiological key features", "PROBLEM", 549, 577], ["slime production", "TREATMENT", 601, 617], ["antibiotics resistance", "TREATMENT", 622, 644], ["Staphylococcus aureus isolates", "OBSERVATION", 188, 218], ["sheep mastitis", "OBSERVATION", 530, 544]]], ["Methods: The S. aureus isolates (n = 46) were recovered from a field study in the southeast of France in 2001-2004 (28 from subclinical mastitis, 10 from clinical mastitis, 8 from the environment of the dairy sheep farm).", [["mastitis", "DISEASE", 136, 144], ["mastitis", "DISEASE", 163, 171], ["S. aureus", "ORGANISM", 13, 22], ["S. aureus", "SPECIES", 13, 22], ["sheep", "SPECIES", 209, 214], ["S. aureus", "SPECIES", 13, 22], ["sheep", "SPECIES", 209, 214], ["The S. aureus isolates", "TEST", 9, 31], ["a field study", "TEST", 61, 74], ["subclinical mastitis", "PROBLEM", 124, 144], ["clinical mastitis", "PROBLEM", 154, 171], ["mastitis", "OBSERVATION", 136, 144], ["mastitis", "OBSERVATION", 163, 171]]], ["A total of thirteen dairy sheep farms, producing cheeses manufactured with raw ewe's milk, were involved.", [["milk", "ANATOMY", 85, 89], ["sheep", "ORGANISM", 26, 31], ["ewe", "ORGANISM_SUBDIVISION", 79, 82], ["milk", "ORGANISM_SUBSTANCE", 85, 89], ["sheep", "SPECIES", 26, 31], ["milk", "SPECIES", 85, 89], ["sheep", "SPECIES", 26, 31]]], ["The agr group were determined by multiplex and real-time PCR.", [["agr", "GENE_OR_GENE_PRODUCT", 4, 7], ["multiplex", "TEST", 33, 42]]], ["The evaluation of adherence and slime production were assessed with methods previously described by Christensen et al. (1982) .", [["The evaluation", "TEST", 0, 14], ["slime production", "PROBLEM", 32, 48]]], ["The susceptibility patterns to 11 antibiotics were determined using the discdiffusion method on Mueller-Hinton agar plates.", [["antibiotics", "TREATMENT", 34, 45], ["the discdiffusion method", "TREATMENT", 68, 92], ["Mueller-Hinton agar plates", "TREATMENT", 96, 122]]], ["Oxacillin susceptibility testing was performed on all the isolates.", [["Oxacillin", "CHEMICAL", 0, 9], ["Oxacillin", "CHEMICAL", 0, 9], ["Oxacillin", "SIMPLE_CHEMICAL", 0, 9], ["Oxacillin susceptibility testing", "TEST", 0, 32]]], ["The 10 others antibiotics susceptibility was only studied on the 28 isolates recovered from subclinical mastitis as they represent the major source of cheese contamination.", [["mastitis", "DISEASE", 104, 112], ["cheese", "ORGANISM_SUBDIVISION", 151, 157], ["antibiotics susceptibility", "TEST", 14, 40], ["subclinical mastitis", "PROBLEM", 92, 112], ["cheese contamination", "PROBLEM", 151, 171], ["subclinical mastitis", "OBSERVATION", 92, 112], ["cheese contamination", "OBSERVATION", 151, 171]]], ["Results: 80% (37/46) of the isolates belonged to agr group 3, regardless of clinical findings.", [["the isolates", "TEST", 24, 36]]], ["39% (18/46) were adherent, strongly adherent or with maximal adherence (biofilm producers).", [["maximal adherence (biofilm producers", "TREATMENT", 53, 89]]], ["26% (12/46) were slime producers (moderate or strong producers).", [["slime producers", "TEST", 17, 32], ["moderate", "OBSERVATION_MODIFIER", 34, 42]]], ["All the isolates (n = 46), but seven, were susceptible to all the antibiotics tested.", [["All the isolates", "TEST", 0, 16], ["all the antibiotics", "TREATMENT", 58, 77]]], ["Two isolates recovered from subclinical mastitis were resistant to oxacillin and partly resistant to ampicillin and penicillin-G.", [["mastitis", "DISEASE", 40, 48], ["oxacillin", "CHEMICAL", 67, 76], ["ampicillin", "CHEMICAL", 101, 111], ["penicillin", "CHEMICAL", 116, 126], ["oxacillin", "CHEMICAL", 67, 76], ["ampicillin", "CHEMICAL", 101, 111], ["penicillin", "CHEMICAL", 116, 126], ["oxacillin", "SIMPLE_CHEMICAL", 67, 76], ["ampicillin", "SIMPLE_CHEMICAL", 101, 111], ["penicillin-G.", "SIMPLE_CHEMICAL", 116, 129], ["Two isolates", "PROBLEM", 0, 12], ["subclinical mastitis", "PROBLEM", 28, 48], ["oxacillin", "TREATMENT", 67, 76], ["ampicillin", "TREATMENT", 101, 111], ["penicillin", "TREATMENT", 116, 126], ["subclinical mastitis", "OBSERVATION", 28, 48]]], ["The five other isolates were found: partly resistant to erythromycin (n = 1), cefoperazone and penicillin-G (n = 1), erythromycin (n = 1), neomycin (n = 1) or resistant to enrofloxaxin and partly resistant to ampicillin and penicillin (n = 1).", [["erythromycin", "CHEMICAL", 56, 68], ["cefoperazone", "CHEMICAL", 78, 90], ["penicillin", "CHEMICAL", 95, 105], ["-G", "CHEMICAL", 105, 107], ["erythromycin", "CHEMICAL", 117, 129], ["neomycin", "CHEMICAL", 139, 147], ["enrofloxaxin", "CHEMICAL", 172, 184], ["ampicillin", "CHEMICAL", 209, 219], ["penicillin", "CHEMICAL", 224, 234], ["erythromycin", "CHEMICAL", 56, 68], ["cefoperazone", "CHEMICAL", 78, 90], ["penicillin-G", "CHEMICAL", 95, 107], ["erythromycin", "CHEMICAL", 117, 129], ["neomycin", "CHEMICAL", 139, 147], ["enrofloxaxin", "CHEMICAL", 172, 184], ["ampicillin", "CHEMICAL", 209, 219], ["penicillin", "CHEMICAL", 224, 234], ["erythromycin", "SIMPLE_CHEMICAL", 56, 68], ["cefoperazone", "SIMPLE_CHEMICAL", 78, 90], ["penicillin-G", "SIMPLE_CHEMICAL", 95, 107], ["erythromycin", "SIMPLE_CHEMICAL", 117, 129], ["neomycin", "SIMPLE_CHEMICAL", 139, 147], ["enrofloxaxin", "SIMPLE_CHEMICAL", 172, 184], ["ampicillin", "SIMPLE_CHEMICAL", 209, 219], ["penicillin", "SIMPLE_CHEMICAL", 224, 234], ["erythromycin (n", "TREATMENT", 56, 71], ["cefoperazone", "TREATMENT", 78, 90], ["penicillin", "TREATMENT", 95, 105], ["erythromycin (n", "TREATMENT", 117, 132], ["neomycin", "TREATMENT", 139, 147], ["enrofloxaxin", "TREATMENT", 172, 184], ["ampicillin", "TREATMENT", 209, 219], ["penicillin", "TREATMENT", 224, 234]]], ["Conclusions: S. aureus isolates recovered from sheep mastitis in the southeast of France are mainly related to agr group 3 suggesting a role for agr-regulated proteins in the persistence of this bacteria in the sheep udders.", [["sheep mastitis", "DISEASE", 47, 61], ["S. aureus isolates", "ORGANISM", 13, 31], ["sheep", "ORGANISM", 47, 52], ["agr group 3", "GENE_OR_GENE_PRODUCT", 111, 122], ["agr", "GENE_OR_GENE_PRODUCT", 145, 148], ["sheep", "ORGANISM", 211, 216], ["agr-regulated proteins", "PROTEIN", 145, 167], ["S. aureus", "SPECIES", 13, 22], ["sheep", "SPECIES", 47, 52], ["sheep", "SPECIES", 211, 216], ["S. aureus", "SPECIES", 13, 22], ["sheep", "SPECIES", 47, 52], ["sheep", "SPECIES", 211, 216], ["S. aureus isolates", "PROBLEM", 13, 31], ["sheep mastitis", "PROBLEM", 47, 61], ["agr-regulated proteins", "PROBLEM", 145, 167], ["this bacteria", "PROBLEM", 190, 203], ["aureus", "OBSERVATION", 16, 22], ["sheep mastitis", "OBSERVATION", 47, 61], ["bacteria", "OBSERVATION", 195, 203]]], ["Biofilm and slime production may also be an important aspect for intracellular survival of S. aureus which could promote the development of persistent intramammary infections.", [["Biofilm", "ANATOMY", 0, 7], ["slime", "ANATOMY", 12, 17], ["intracellular", "ANATOMY", 65, 78], ["intramammary infections", "DISEASE", 151, 174], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 78], ["S. aureus", "ORGANISM", 91, 100], ["S. aureus", "SPECIES", 91, 100], ["S. aureus", "SPECIES", 91, 100], ["Biofilm", "PROBLEM", 0, 7], ["S. aureus", "PROBLEM", 91, 100], ["persistent intramammary infections", "PROBLEM", 140, 174], ["slime production", "OBSERVATION", 12, 28], ["may also be", "UNCERTAINTY", 29, 40], ["aureus", "OBSERVATION", 94, 100], ["persistent", "OBSERVATION_MODIFIER", 140, 150], ["intramammary", "OBSERVATION_MODIFIER", 151, 163], ["infections", "OBSERVATION", 164, 174]]], ["Finally, ewe's milk does not appear to represent a source of resistant S. aureus and specially methicillin (oxacillin)-resistant S. aureus (MRSA) for human health.P1700Detection of virulence genes in Staphylococus aureus isolates from dairy sheep, goats and cows mastitis, using single-dye DNA microarray E. Vautor, V. Magnone, G. Rios, M. Pepin, P. Barbry (Sophia-Antipolis, FR)P1700Objectives: Staphylococcus aureus is a common cause of mastitis in dairy farms animals.", [["milk", "ANATOMY", 15, 19], ["methicillin", "CHEMICAL", 95, 106], ["oxacillin", "CHEMICAL", 108, 117], ["MRSA", "CHEMICAL", 140, 144], ["mastitis", "DISEASE", 263, 271], ["Staphylococcus aureus", "DISEASE", 396, 417], ["mastitis", "DISEASE", 439, 447], ["methicillin", "CHEMICAL", 95, 106], ["oxacillin", "CHEMICAL", 108, 117], ["ewe", "ORGANISM", 9, 12], ["milk", "ORGANISM_SUBSTANCE", 15, 19], ["S. aureus", "ORGANISM", 71, 80], ["methicillin", "SIMPLE_CHEMICAL", 95, 106], ["oxacillin", "SIMPLE_CHEMICAL", 108, 117], ["S. aureus", "ORGANISM", 129, 138], ["MRSA", "CANCER", 140, 144], ["human", "ORGANISM", 150, 155], ["Staphylococus aureus", "ORGANISM", 200, 220], ["sheep", "ORGANISM", 241, 246], ["goats", "ORGANISM", 248, 253], ["DNA", "CELLULAR_COMPONENT", 290, 293], ["P. Barbry", "ORGANISM", 347, 356], ["Sophia-Antipolis, FR)P1700Objectives", "ORGANISM", 358, 394], ["Staphylococcus aureus", "ORGANISM", 396, 417], ["virulence genes", "DNA", 181, 196], ["S. aureus", "SPECIES", 71, 80], ["S. aureus", "SPECIES", 129, 138], ["MRSA", "SPECIES", 140, 144], ["human", "SPECIES", 150, 155], ["Staphylococus aureus", "SPECIES", 200, 220], ["sheep", "SPECIES", 241, 246], ["goats", "SPECIES", 248, 253], ["cows", "SPECIES", 258, 262], ["Staphylococcus aureus", "SPECIES", 396, 417], ["S. aureus", "SPECIES", 71, 80], ["S. aureus", "SPECIES", 129, 138], ["MRSA", "SPECIES", 140, 144], ["human", "SPECIES", 150, 155], ["Staphylococus aureus", "SPECIES", 200, 220], ["sheep", "SPECIES", 241, 246], ["goats", "SPECIES", 248, 253], ["cows", "SPECIES", 258, 262], ["Staphylococcus aureus", "SPECIES", 396, 417], ["resistant S. aureus", "PROBLEM", 61, 80], ["methicillin (oxacillin", "TREATMENT", 95, 117], ["resistant S. aureus", "PROBLEM", 119, 138], ["MRSA", "PROBLEM", 140, 144], ["virulence genes", "PROBLEM", 181, 196], ["Staphylococus aureus isolates", "PROBLEM", 200, 229], ["cows mastitis", "PROBLEM", 258, 271], ["Staphylococcus aureus", "PROBLEM", 396, 417], ["mastitis", "PROBLEM", 439, 447], ["aureus", "OBSERVATION", 74, 80], ["aureus", "OBSERVATION", 132, 138], ["Staphylococcus aureus", "OBSERVATION", 396, 417], ["mastitis", "OBSERVATION", 439, 447]]], ["Although many putative virulence factors have been identified in S. aureus genomes (Kuroda et al., 2001) , the differences in pathogenic potential between naturally occurring isolates remain largely unaddressed.", [["S. aureus", "ORGANISM", 65, 74], ["virulence factors", "PROTEIN", 23, 40], ["S. aureus", "SPECIES", 65, 74], ["S. aureus", "SPECIES", 65, 74], ["many putative virulence factors", "PROBLEM", 9, 40], ["S. aureus genomes", "PROBLEM", 65, 82], ["isolates", "PROBLEM", 175, 183], ["aureus genomes", "OBSERVATION", 68, 82]]], ["The relative importance of host (tissue) factors versus bacterial virulence determinants in disease pathogenesis is not well known, but it is widely accepted that bacterial factors including toxins, cell wall-associated adhesions, and secreted exoproteins are involved in the process.", [["tissue", "ANATOMY", 33, 39], ["cell wall", "ANATOMY", 199, 208], ["adhesions", "ANATOMY", 220, 229], ["tissue", "TISSUE", 33, 39], ["cell wall", "CELLULAR_COMPONENT", 199, 208], ["exoproteins", "GENE_OR_GENE_PRODUCT", 244, 255], ["host (tissue) factors", "PROTEIN", 27, 48], ["bacterial factors", "PROTEIN", 163, 180], ["secreted exoproteins", "PROTEIN", 235, 255], ["host (tissue) factors", "TREATMENT", 27, 48], ["bacterial virulence determinants in disease pathogenesis", "PROBLEM", 56, 112], ["bacterial factors", "PROBLEM", 163, 180], ["toxins", "PROBLEM", 191, 197], ["cell wall-associated adhesions", "PROBLEM", 199, 229], ["secreted exoproteins", "PROBLEM", 235, 255], ["adhesions", "OBSERVATION", 220, 229]]], ["In this study, we use a single-dye DNA microarray assay to investigate the presence or absence of 196 putatives virulence genes in 75 S. aureus isolates recovered from cases of ovine, caprine and bovine mastitis.", [["bovine mastitis", "DISEASE", 196, 211], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["S. aureus", "ORGANISM", 134, 143], ["ovine", "ORGANISM", 177, 182], ["caprine", "ORGANISM", 184, 191], ["bovine", "ORGANISM", 196, 202], ["196 putatives virulence genes", "DNA", 98, 127], ["S. aureus", "SPECIES", 134, 143], ["ovine", "SPECIES", 177, 182], ["caprine", "SPECIES", 184, 191], ["bovine", "SPECIES", 196, 202], ["S. aureus", "SPECIES", 134, 143], ["ovine", "SPECIES", 177, 182], ["caprine", "SPECIES", 184, 191], ["bovine", "SPECIES", 196, 202], ["this study", "TEST", 3, 13], ["a single-dye DNA microarray assay", "TEST", 22, 55], ["196 putatives virulence genes", "PROBLEM", 98, 127], ["aureus isolates", "PROBLEM", 137, 152], ["ovine, caprine", "TREATMENT", 177, 191], ["bovine mastitis", "PROBLEM", 196, 211], ["bovine mastitis", "OBSERVATION", 196, 211]]], ["Methods: Mastitis S. aureus isolates: sheep (n = 25), goats (n= 22), cows (n = 20).DNA microarray: the arrays were spotted with long oligonucleotides (65-mer) representing 192 known virulence genes and new candidates identified in Mu 50 genome (a human strain) and other S. aureus genomes.", [["strain", "ANATOMY", 253, 259], ["Mastitis S. aureus", "ORGANISM", 9, 27], ["sheep", "ORGANISM", 38, 43], ["goats", "ORGANISM", 54, 59], ["cows", "ORGANISM", 69, 73], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["Mu 50 genome", "ORGANISM", 231, 243], ["human", "ORGANISM", 247, 252], ["S. aureus", "ORGANISM", 271, 280], ["long oligonucleotides", "DNA", 128, 149], ["virulence genes", "DNA", 182, 197], ["Mu 50 genome", "DNA", 231, 243], ["S. aureus", "SPECIES", 18, 27], ["sheep", "SPECIES", 38, 43], ["goats", "SPECIES", 54, 59], ["cows", "SPECIES", 69, 73], ["human", "SPECIES", 247, 252], ["S. aureus", "SPECIES", 271, 280], ["S. aureus", "SPECIES", 18, 27], ["sheep", "SPECIES", 38, 43], ["goats", "SPECIES", 54, 59], ["Mu 50", "SPECIES", 231, 236], ["human", "SPECIES", 247, 252], ["S. aureus", "SPECIES", 271, 280], ["Mastitis S. aureus isolates", "PROBLEM", 9, 36], ["cows", "TEST", 69, 73], ["DNA microarray", "TEST", 83, 97], ["the arrays", "TEST", 99, 109], ["long oligonucleotides", "TREATMENT", 128, 149], ["known virulence genes", "PROBLEM", 176, 197], ["a human strain)", "PROBLEM", 245, 260], ["other S. aureus genomes", "PROBLEM", 265, 288], ["Mastitis", "OBSERVATION", 9, 17], ["virulence genes", "OBSERVATION", 182, 197], ["aureus genomes", "OBSERVATION", 274, 288]]], ["DNA extracted from the strains were labelled with fluorescent Cy5 using the BioPrime \u00d2 Array CGH (Invitrogen).", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["Cy5", "SIMPLE_CHEMICAL", 62, 65], ["DNA", "PROBLEM", 0, 3], ["the strains", "PROBLEM", 19, 30], ["fluorescent Cy5", "TREATMENT", 50, 65], ["the BioPrime \u00d2 Array CGH (Invitrogen)", "TREATMENT", 72, 109]]], ["Control strains with known genetic and phenotypic characteristics were used to normalize the data.", [["Control strains", "PROBLEM", 0, 15], ["known genetic and phenotypic characteristics", "PROBLEM", 21, 65]]], ["Results: (i) The majority of the virulence gene was detected in all the isolates (e.g. coa, ica ADBC operon, htrA, hysA, nuc, sbi, sdrE, ssp, feoB, fnb, sib, spa). (ii) genes were not detected in the majority of the isolates (e.g. cna, edin, lukF-PV, SAV1999,\u2026). (iii) genes were not found in isolates, depending on the herd (e.g. aur or SAV1038 absent in isolates from some dairy sheep farm), on the isolates whatever the species (i.g. bsaP, capH, entK, eta, fnbB, hsdS, lpl2, lukD, \u2026) .", [["ica ADBC operon", "GENE_OR_GENE_PRODUCT", 92, 107], ["htrA", "GENE_OR_GENE_PRODUCT", 109, 113], ["hysA", "GENE_OR_GENE_PRODUCT", 115, 119], ["nuc", "GENE_OR_GENE_PRODUCT", 121, 124], ["sbi", "GENE_OR_GENE_PRODUCT", 126, 129], ["sdrE", "GENE_OR_GENE_PRODUCT", 131, 135], ["ssp", "GENE_OR_GENE_PRODUCT", 137, 140], ["feoB", "GENE_OR_GENE_PRODUCT", 142, 146], ["fnb", "GENE_OR_GENE_PRODUCT", 148, 151], ["spa", "GENE_OR_GENE_PRODUCT", 158, 161], ["cna", "GENE_OR_GENE_PRODUCT", 231, 234], ["edin", "GENE_OR_GENE_PRODUCT", 236, 240], ["lukF-PV", "GENE_OR_GENE_PRODUCT", 242, 249], ["aur", "GENE_OR_GENE_PRODUCT", 331, 334], ["bsaP", "GENE_OR_GENE_PRODUCT", 437, 441], ["capH", "GENE_OR_GENE_PRODUCT", 443, 447], ["entK", "GENE_OR_GENE_PRODUCT", 449, 453], ["eta", "GENE_OR_GENE_PRODUCT", 455, 458], ["fnbB", "GENE_OR_GENE_PRODUCT", 460, 464], ["hsdS", "GENE_OR_GENE_PRODUCT", 466, 470], ["lpl2", "GENE_OR_GENE_PRODUCT", 472, 476], ["lukD", "GENE_OR_GENE_PRODUCT", 478, 482], ["virulence gene", "DNA", 33, 47], ["coa, ica ADBC operon", "DNA", 87, 107], ["htrA", "DNA", 109, 113], ["hysA", "DNA", 115, 119], ["nuc", "DNA", 121, 124], ["sbi", "DNA", 126, 129], ["sdrE", "DNA", 131, 135], ["ssp", "DNA", 137, 140], ["feoB", "DNA", 142, 146], ["fnb", "DNA", 148, 151], ["sib", "DNA", 153, 156], ["spa", "DNA", 158, 161], ["bsaP", "PROTEIN", 437, 441], ["capH", "PROTEIN", 443, 447], ["entK", "DNA", 449, 453], ["eta", "DNA", 455, 458], ["fnbB", "DNA", 460, 464], ["hsdS", "DNA", 466, 470], ["lpl2", "DNA", 472, 476], ["lukD", "DNA", 478, 482], ["sheep", "SPECIES", 381, 386], ["sheep", "SPECIES", 381, 386], ["coa", "TEST", 87, 90], ["htrA", "PROBLEM", 109, 113], ["sbi", "TEST", 126, 129], ["ssp", "TEST", 137, 140], ["lukF", "TEST", 242, 246], ["aur", "PROBLEM", 331, 334], ["SAV1038", "PROBLEM", 338, 345], ["the species", "TEST", 419, 430], ["bsaP", "TEST", 437, 441], ["capH", "TEST", 443, 447], ["entK", "TEST", 449, 453], ["hsdS", "TEST", 466, 470], ["spa", "ANATOMY", 158, 161]]], ["But we found gene mainly related to species (e.g. agrIII, SAV2496,\u2026) Comprehensive results will be given in the poster.", [["agrIII", "DNA", 50, 56], ["agrIII", "TEST", 50, 56]]], ["Conclusions: The present study indicated that the prevalence of virulence genes among S. aureus isolates recovered from dairy farm species depends on the gene.", [["S. aureus isolates", "ORGANISM", 86, 104], ["virulence genes", "DNA", 64, 79], ["S. aureus", "SPECIES", 86, 95], ["S. aureus", "SPECIES", 86, 95], ["The present study", "TEST", 13, 30], ["virulence genes", "PROBLEM", 64, 79], ["S. aureus isolates", "PROBLEM", 86, 104], ["dairy farm species", "PROBLEM", 120, 138], ["aureus", "OBSERVATION", 89, 95], ["farm species", "OBSERVATION", 126, 138]]], ["These observations suggest a common occurrence of host-adapted (or tissueadapted) S. aureus strains in which particular virulence genes may play a significant role.", [["S. aureus strains", "ORGANISM", 82, 99], ["virulence genes", "DNA", 120, 135], ["S. aureus", "SPECIES", 82, 91], ["S. aureus", "SPECIES", 82, 91], ["S. aureus strains", "PROBLEM", 82, 99], ["aureus strains", "OBSERVATION", 85, 99]]], ["When taken with complementary methods such as PCR or/and Southern hybridisation, singledye DNA microarrays may provide a powerful tool to type S. aureus strains for epidemiological and possibly pathogenesis studies.P1701Detection of DNA sequences distinguishing two closely related genomes of Staphylococcus aureus from subclinical versus gangrenous ewe mastitis strains N. Chevalier, C. Huard, R. Thiery, E. Vautor (Sophia-Antipolis, FR)P1701Objectives: Staphylococcus aureus is a common cause of mastitis in dairy sheep.", [["Staphylococcus aureus", "DISEASE", 293, 314], ["ewe mastitis", "DISEASE", 350, 362], ["Staphylococcus aureus", "DISEASE", 455, 476], ["mastitis", "DISEASE", 498, 506], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["S. aureus strains", "ORGANISM", 143, 160], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["Staphylococcus aureus", "ORGANISM", 293, 314], ["Staphylococcus aureus", "ORGANISM", 455, 476], ["sheep", "ORGANISM", 516, 521], ["DNA sequences", "DNA", 233, 246], ["S. aureus", "SPECIES", 143, 152], ["Staphylococcus aureus", "SPECIES", 293, 314], ["Staphylococcus aureus", "SPECIES", 455, 476], ["sheep", "SPECIES", 516, 521], ["S. aureus", "SPECIES", 143, 152], ["Staphylococcus aureus", "SPECIES", 293, 314], ["Staphylococcus aureus", "SPECIES", 455, 476], ["sheep", "SPECIES", 516, 521], ["complementary methods", "TREATMENT", 16, 37], ["PCR", "TEST", 46, 49], ["Southern hybridisation", "TREATMENT", 57, 79], ["singledye DNA microarrays", "TREATMENT", 81, 106], ["type S. aureus strains", "PROBLEM", 138, 160], ["pathogenesis studies", "TEST", 194, 214], ["DNA sequences", "TEST", 233, 246], ["Staphylococcus aureus", "PROBLEM", 293, 314], ["gangrenous ewe mastitis strains", "PROBLEM", 339, 370], ["Staphylococcus aureus", "PROBLEM", 455, 476], ["mastitis", "PROBLEM", 498, 506], ["aureus", "OBSERVATION", 146, 152], ["Staphylococcus aureus", "OBSERVATION", 293, 314], ["gangrenous", "OBSERVATION_MODIFIER", 339, 349], ["ewe mastitis", "OBSERVATION", 350, 362], ["Staphylococcus aureus", "OBSERVATION", 455, 476], ["mastitis", "OBSERVATION", 498, 506]]], ["The severity of mastitis ranges from subclinical to gangrenous forms.", [["mastitis", "DISEASE", 16, 24], ["mastitis ranges", "PROBLEM", 16, 31], ["subclinical to gangrenous forms", "PROBLEM", 37, 68], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["mastitis", "OBSERVATION", 16, 24], ["gangrenous", "OBSERVATION", 52, 62]]], ["Subclinical mastitis is an inflammation that is not readily detected clinically whereas gangrenous form is an acute necrotizing mastitis.", [["mastitis", "DISEASE", 12, 20], ["inflammation", "DISEASE", 27, 39], ["mastitis", "DISEASE", 128, 136], ["Subclinical mastitis", "PROBLEM", 0, 20], ["an inflammation", "PROBLEM", 24, 39], ["an acute necrotizing mastitis", "PROBLEM", 107, 136], ["mastitis", "OBSERVATION", 12, 20], ["inflammation", "OBSERVATION", 27, 39], ["not readily detected", "UNCERTAINTY", 48, 68], ["gangrenous", "OBSERVATION", 88, 98], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["necrotizing", "OBSERVATION_MODIFIER", 116, 127], ["mastitis", "OBSERVATION", 128, 136]]], ["With the ain to find genetic markers or virulence factors that are only present in gangrenous strains a suppression substractive hybridisation (SSH) method was used in the present study to compare two strains of S. aureus respectively recovered from subclinical or gangrenous mastitis in the same dairy sheep herd.", [["mastitis", "DISEASE", 276, 284], ["S. aureus", "ORGANISM", 212, 221], ["sheep", "ORGANISM", 303, 308], ["herd", "ORGANISM_SUBDIVISION", 309, 313], ["virulence factors", "PROTEIN", 40, 57], ["S. aureus", "SPECIES", 212, 221], ["sheep", "SPECIES", 303, 308], ["S. aureus", "SPECIES", 212, 221], ["sheep", "SPECIES", 303, 308], ["virulence factors", "PROBLEM", 40, 57], ["gangrenous strains", "PROBLEM", 83, 101], ["a suppression substractive hybridisation (SSH) method", "TREATMENT", 102, 155], ["the present study", "TEST", 168, 185], ["S. aureus", "PROBLEM", 212, 221], ["subclinical or gangrenous mastitis", "PROBLEM", 250, 284], ["gangrenous", "OBSERVATION_MODIFIER", 83, 93], ["aureus", "OBSERVATION", 215, 221], ["subclinical", "OBSERVATION_MODIFIER", 250, 261], ["gangrenous", "OBSERVATION_MODIFIER", 265, 275], ["mastitis", "OBSERVATION", 276, 284]]], ["Methods: 42 ewes were held in the investigated farm.", [["ewes", "ORGANISM", 12, 16]]], ["The subclinical strain was recovered in January 2002 from the milk of 6 ewes.", [["milk", "ANATOMY", 62, 66], ["milk", "ORGANISM_SUBSTANCE", 62, 66], ["The subclinical strain", "PROBLEM", 0, 22], ["subclinical", "OBSERVATION_MODIFIER", 4, 15], ["strain", "OBSERVATION_MODIFIER", 16, 22]]], ["The gangrenous strain was recovered in December 2002 from an primipare dairy sheep that subsequently died from this acute mastitis.", [["mastitis", "DISEASE", 122, 130], ["sheep", "ORGANISM", 77, 82], ["sheep", "SPECIES", 77, 82], ["sheep", "SPECIES", 77, 82], ["The gangrenous strain", "PROBLEM", 0, 21], ["this acute mastitis", "PROBLEM", 111, 130], ["gangrenous", "OBSERVATION", 4, 14], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["mastitis", "OBSERVATION", 122, 130]]], ["DNA extracted from the strains were first compared by pulsed field gel electrophoresis (PFGE).", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["the strains", "PROBLEM", 19, 30], ["pulsed field gel electrophoresis", "TEST", 54, 86]]], ["Then, SSH was performed by using DNA from the subclinical strain (driver), as described in a commercial kit (Clontech PCR-Select Bacterial Genome Substraction Kit).", [["DNA", "CELLULAR_COMPONENT", 33, 36], ["Clontech PCR", "TEST", 109, 121], ["Select Bacterial Genome Substraction Kit", "TREATMENT", 122, 162]]], ["Results: Using PFGE, four band differences were found between the two strains.", [["PFGE", "TEST", 15, 19]]], ["Two DNA fragments, presumably specific from the gangrenous strain were detected by SSH and sequenced: (i) a 262 bp (98% of homology with the sulfide quinone reductase contained in Orf 11 pathogenicity island of the MRSA 252 strain) (ii) 280 bp (98% homology with a gene coding a bacteriophage holine contained in the S. aureus N315 genome).", [["fragments", "ANATOMY", 8, 17], ["sulfide", "CHEMICAL", 141, 148], ["sulfide", "CHEMICAL", 141, 148], ["quinone", "CHEMICAL", 149, 156], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["sulfide quinone reductase", "GENE_OR_GENE_PRODUCT", 141, 166], ["S. aureus N315", "ORGANISM", 317, 331], ["DNA fragments", "DNA", 4, 17], ["sulfide quinone reductase", "PROTEIN", 141, 166], ["Orf 11 pathogenicity island", "DNA", 180, 207], ["bacteriophage holine", "DNA", 279, 299], ["S. aureus N315 genome", "DNA", 317, 338], ["MRSA", "SPECIES", 215, 219], ["S. aureus", "SPECIES", 317, 326], ["S. aureus", "SPECIES", 317, 326], ["Two DNA fragments", "PROBLEM", 0, 17], ["the gangrenous strain", "PROBLEM", 44, 65], ["bp", "TEST", 112, 114], ["the sulfide quinone reductase", "TREATMENT", 137, 166], ["bp", "TEST", 241, 243], ["a bacteriophage holine", "TREATMENT", 277, 299], ["DNA fragments", "OBSERVATION", 4, 17], ["gangrenous", "OBSERVATION", 48, 58], ["aureus", "OBSERVATION", 320, 326]]], ["Control PCR tests using primers designed from these specific gene candidates confirmed that they were only present in the S. aureus gangrenous strain.", [["S. aureus gangrenous strain", "ORGANISM", 122, 149], ["S. aureus", "SPECIES", 122, 131], ["S. aureus", "SPECIES", 122, 131], ["Control PCR tests", "TEST", 0, 17], ["primers", "TREATMENT", 24, 31], ["the S. aureus gangrenous strain", "PROBLEM", 118, 149], ["aureus", "OBSERVATION_MODIFIER", 125, 131], ["gangrenous strain", "OBSERVATION", 132, 149]]], ["Conclusions: According to Tenover et al. (1995) , a 4 band difference using PFGE indicates that the strains may possibly be related genetically.", [["a 4 band difference using PFGE", "PROBLEM", 50, 80], ["the strains", "PROBLEM", 96, 107], ["may possibly be", "UNCERTAINTY", 108, 123]]], ["Although genes classically involved in the virulence of S. aureus were not detected in the present study, two putative virulence factors were detected.", [["S. aureus", "ORGANISM", 56, 65], ["virulence factors", "PROTEIN", 119, 136], ["S. aureus", "SPECIES", 56, 65], ["S. aureus", "SPECIES", 56, 65], ["S. aureus", "PROBLEM", 56, 65], ["two putative virulence factors", "PROBLEM", 106, 136], ["aureus", "OBSERVATION", 59, 65]]], ["The sulfide quinone reductase allows S. aureus to growth on sulfide (found in animal manure).", [["sulfide", "CHEMICAL", 4, 11], ["sulfide", "CHEMICAL", 60, 67], ["sulfide quinone", "CHEMICAL", 4, 19], ["sulfide", "CHEMICAL", 60, 67], ["sulfide quinone reductase", "SIMPLE_CHEMICAL", 4, 29], ["S. aureus", "ORGANISM", 37, 46], ["sulfide", "SIMPLE_CHEMICAL", 60, 67], ["sulfide quinone reductase", "PROTEIN", 4, 29], ["S. aureus", "SPECIES", 37, 46], ["S. aureus", "SPECIES", 37, 46], ["The sulfide quinone reductase", "TREATMENT", 0, 29], ["S. aureus", "PROBLEM", 37, 46], ["sulfide", "TREATMENT", 60, 67], ["sulfide", "OBSERVATION", 4, 11], ["quinone reductase", "OBSERVATION", 12, 29], ["aureus", "OBSERVATION", 40, 46]]], ["The holine protein breaks the internal membrane of S. aureus to release daughter phages suggesting that a mechanism of horizontal gene transfer could have been mediated by bacteriophages and could explain the acquisition of virulence factors.P1701Antimicrobial clinical trials P1702 Outpatient treatment of acute pyelonephritis in pregnancy after 24 weeks.", [["internal membrane", "ANATOMY", 30, 47], ["holine", "CHEMICAL", 4, 10], ["P1702", "CHEMICAL", 277, 282], ["pyelonephritis", "DISEASE", 313, 327], ["P1702", "CHEMICAL", 277, 282], ["holine protein", "GENE_OR_GENE_PRODUCT", 4, 18], ["internal membrane", "CELLULAR_COMPONENT", 30, 47], ["S. aureus", "ORGANISM", 51, 60], ["holine protein", "PROTEIN", 4, 18], ["virulence factors", "PROTEIN", 224, 241], ["S. aureus", "SPECIES", 51, 60], ["S. aureus", "SPECIES", 51, 60], ["The holine protein breaks", "PROBLEM", 0, 25], ["S. aureus", "PROBLEM", 51, 60], ["horizontal gene transfer", "PROBLEM", 119, 143], ["virulence factors", "PROBLEM", 224, 241], ["Outpatient treatment", "TREATMENT", 283, 303], ["acute pyelonephritis", "PROBLEM", 307, 327], ["protein breaks", "OBSERVATION", 11, 25], ["internal membrane", "ANATOMY", 30, 47], ["aureus", "OBSERVATION", 54, 60], ["acute", "OBSERVATION_MODIFIER", 307, 312], ["pyelonephritis", "OBSERVATION", 313, 327]]], ["A randomised controlled trial Z. Ahmadinejad, S. Hantooshzadeh (Tehran, IR)P1701Objectives: The purpose of this study was to compare the safety and efficacy of outpatient and inpatient treatment of acute pyelonephritis in pregnancy.P1701Methods: This was a randomized controlled, clinical trial.", [["pyelonephritis", "DISEASE", 204, 218], ["this study", "TEST", 107, 117], ["acute pyelonephritis in pregnancy", "PROBLEM", 198, 231], ["acute", "OBSERVATION_MODIFIER", 198, 203], ["pyelonephritis", "OBSERVATION", 204, 218]]], ["One hundred twenty eight gravidas past 24 weeks' gestation admitted in IMAM KHOMEINI hospital, Tehran & SAHID Dr BAHONAR hospital, Kerman, divided by random blocks to outpatient or inpatient therapy, received two 1-g doses of intramuscular ceftriaxone at 24-hour intervals while hospitalized, then were discharged and reevaluated within 48-72 hours or remained hospitalized until afebrile for 48 hours.", [["intramuscular", "ANATOMY", 226, 239], ["ceftriaxone", "CHEMICAL", 240, 251], ["ceftriaxone", "CHEMICAL", 240, 251], ["ceftriaxone", "SIMPLE_CHEMICAL", 240, 251], ["inpatient therapy", "TREATMENT", 181, 198], ["intramuscular ceftriaxone", "TREATMENT", 226, 251], ["afebrile", "PROBLEM", 380, 388]]], ["All patients completed a 14-day course of oral cephalexin.", [["oral", "ANATOMY", 42, 46], ["cephalexin", "CHEMICAL", 47, 57], ["cephalexin", "CHEMICAL", 47, 57], ["patients", "ORGANISM", 4, 12], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["cephalexin", "SIMPLE_CHEMICAL", 47, 57], ["patients", "SPECIES", 4, 12], ["oral cephalexin", "TREATMENT", 42, 57]]], ["We performed urine cultures on admission and 10-14 days after therapy.", [["urine cultures", "ANATOMY", 13, 27], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["urine cultures", "TEST", 13, 27], ["therapy", "TREATMENT", 62, 69]]], ["Results: The two groups were similar with respect to age, parity, temperature, estimated gestational age, initial white blood cell count, and incidence of bacteremia.", [["white blood cell", "ANATOMY", 114, 130], ["bacteremia", "DISEASE", 155, 165], ["blood cell", "CELL", 120, 130], ["initial white blood cell count", "TEST", 106, 136], ["bacteremia", "PROBLEM", 155, 165], ["bacteremia", "OBSERVATION", 155, 165]]], ["There were not any significant differences between two groups about the clinical improvement after 48-72 hours, bacteriuria 10-14 days after treatment, relapse of pyelonephritis, requirement to change in antibiotic, date of pregnancy at delivery and preterm labor.", [["bacteriuria", "DISEASE", 112, 123], ["pyelonephritis", "DISEASE", 163, 177], ["preterm labor", "DISEASE", 250, 263], ["bacteriuria", "PROBLEM", 112, 123], ["treatment", "TREATMENT", 141, 150], ["pyelonephritis", "PROBLEM", 163, 177], ["antibiotic", "TREATMENT", 204, 214], ["pregnancy at delivery", "TREATMENT", 224, 245], ["preterm labor", "PROBLEM", 250, 263], ["pyelonephritis", "OBSERVATION", 163, 177]]], ["The relapse of bacteriuria and preterm labor in inpatients were significantly more than outpatients (PV = 0.0077 and 0.030 respectively).", [["bacteriuria", "DISEASE", 15, 26], ["preterm labor", "DISEASE", 31, 44], ["inpatients", "ORGANISM", 48, 58], ["bacteriuria", "PROBLEM", 15, 26], ["preterm labor", "PROBLEM", 31, 44], ["PV", "TEST", 101, 103], ["relapse", "OBSERVATION_MODIFIER", 4, 11], ["bacteriuria", "OBSERVATION", 15, 26], ["preterm", "OBSERVATION_MODIFIER", 31, 38], ["labor", "OBSERVATION_MODIFIER", 39, 44]]], ["The birth weight of neonate in outpatients were significantly more than inpatients (PV = 0.013).", [["neonate", "ORGANISM", 20, 27], ["outpatients", "ORGANISM", 31, 42], ["outpatients", "SPECIES", 31, 42], ["The birth weight", "TEST", 0, 16], ["PV", "TEST", 84, 86]]], ["Conclusion: Outpatient antibiotic therapy is effective and safe in selected pregnant women with pyelonephritis.", [["pyelonephritis", "DISEASE", 96, 110], ["women", "ORGANISM", 85, 90], ["women", "SPECIES", 85, 90], ["Outpatient antibiotic therapy", "TREATMENT", 12, 41], ["pyelonephritis", "PROBLEM", 96, 110], ["pyelonephritis", "OBSERVATION", 96, 110]]], ["However in this study, the neonatal outcomes were better in outpatients and the maternal outcomes in inpatients.P1703Experience with daptomycin in patients with renal insufficiency Investigators collected demographic, disease state, clinical and microbiological data; outcomes were defined using standard definitions.", [["renal", "ANATOMY", 161, 166], ["P1703Experience", "CHEMICAL", 112, 127], ["daptomycin", "CHEMICAL", 133, 143], ["renal insufficiency", "DISEASE", 161, 180], ["daptomycin", "CHEMICAL", 133, 143], ["outpatients", "ORGANISM", 60, 71], ["daptomycin", "SIMPLE_CHEMICAL", 133, 143], ["patients", "ORGANISM", 147, 155], ["renal", "ORGAN", 161, 166], ["outpatients", "SPECIES", 60, 71], ["patients", "SPECIES", 147, 155], ["this study", "TEST", 11, 21], ["daptomycin", "TREATMENT", 133, 143], ["renal insufficiency", "PROBLEM", 161, 180], ["clinical and microbiological data", "TEST", 233, 266], ["daptomycin", "OBSERVATION", 133, 143], ["renal", "ANATOMY", 161, 166], ["insufficiency", "OBSERVATION", 167, 180]]], ["Patients nonevaluable for outcome were excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["CORE data were divided and data on cohorts of pts with a creatinine clearance (CrCl) \u202130 or <30 ml/min were examined.", [["creatinine", "CHEMICAL", 57, 67], ["creatinine", "CHEMICAL", 57, 67], ["creatinine", "SIMPLE_CHEMICAL", 57, 67], ["CORE data", "TEST", 0, 9], ["a creatinine clearance", "TEST", 55, 77], ["CrCl", "TEST", 79, 83]]], ["Results: Of the 1160 pts enrolled, 770 (66%) had evaluable pt outcomes and either CrCl \u202130 ml/min (NML, n = 598) or CrCl <30 ml/min not yet requiring renal replacement therapy (RI, n = 172).", [["renal", "ANATOMY", 150, 155], ["renal", "ORGAN", 150, 155], ["CrCl", "TEST", 82, 86], ["CrCl", "TEST", 116, 120], ["renal replacement therapy", "TREATMENT", 150, 175], ["renal", "ANATOMY", 150, 155], ["replacement", "OBSERVATION", 156, 167]]], ["The distribution of males and females was equal in both groups.", [["distribution", "OBSERVATION_MODIFIER", 4, 16], ["males", "OBSERVATION", 20, 25]]], ["RI pts were older (45% \u202166 yrs vs 29%, p < 0.01).", [["p", "TEST", 39, 40]]], ["The groups did not differ in the percent coming from the community setting prior to starting DAP (NML 46%, RI 49%).", [["DAP", "TEST", 93, 96], ["NML", "TEST", 98, 101], ["RI", "TEST", 107, 109]]], ["NML had more frequent history of fractures/orthopaedic procedures (11 vs 4%, p < 0.01) and haematological cancers (6 vs 1%, p < 0.02) while RI had higher rates of any renal disease (4 vs 17%, p < 0.01), CHF (6 vs 12%, p < 0.05) and other immunologic/ inflammatory disease (2 vs 11%, p < 0.01).", [["haematological cancers", "ANATOMY", 91, 113], ["renal", "ANATOMY", 167, 172], ["NML", "DISEASE", 0, 3], ["fractures", "DISEASE", 33, 42], ["haematological cancers", "DISEASE", 91, 113], ["renal disease", "DISEASE", 167, 180], ["CHF", "DISEASE", 203, 206], ["immunologic/ inflammatory disease", "DISEASE", 238, 271], ["NML", "CANCER", 0, 3], ["haematological cancers", "CANCER", 91, 113], ["renal", "ORGAN", 167, 172], ["fractures", "PROBLEM", 33, 42], ["orthopaedic procedures", "TEST", 43, 65], ["haematological cancers", "PROBLEM", 91, 113], ["any renal disease", "PROBLEM", 163, 180], ["p", "TEST", 192, 193], ["CHF", "PROBLEM", 203, 206], ["p", "TEST", 218, 219], ["other immunologic/ inflammatory disease", "PROBLEM", 232, 271], ["p", "TEST", 283, 284], ["fractures", "OBSERVATION", 33, 42], ["haematological", "ANATOMY", 91, 105], ["cancers", "OBSERVATION", 106, 113], ["renal", "ANATOMY", 167, 172], ["disease", "OBSERVATION", 173, 180], ["CHF", "OBSERVATION", 203, 206], ["inflammatory disease", "OBSERVATION", 251, 271]]], ["RI had higher rates of skin infections (60 vs 69%, p < 0.05) and endocarditis (3 vs 6%, p < 0.05).", [["skin", "ANATOMY", 23, 27], ["skin infections", "DISEASE", 23, 38], ["endocarditis", "DISEASE", 65, 77], ["skin", "ORGAN", 23, 27], ["RI", "TEST", 0, 2], ["skin infections", "PROBLEM", 23, 38], ["p", "TEST", 51, 52], ["endocarditis", "PROBLEM", 65, 77], ["p", "TEST", 88, 89], ["higher", "OBSERVATION_MODIFIER", 7, 13], ["rates", "OBSERVATION_MODIFIER", 14, 19], ["skin", "ANATOMY", 23, 27], ["infections", "OBSERVATION", 28, 38], ["endocarditis", "OBSERVATION", 65, 77]]], ["Infections that were frequently reported for NML and RI were bacteremia, non-catheter-related (10 vs 10%), bacteremia, catheter-related (10 vs 4%), osteomyelitis (14 vs 7%), and foreign body-orthopaedic (6 vs 5%), all p > 0.05.", [["body", "ANATOMY", 186, 190], ["Infections", "DISEASE", 0, 10], ["NML", "DISEASE", 45, 48], ["bacteremia", "DISEASE", 61, 71], ["bacteremia", "DISEASE", 107, 117], ["osteomyelitis", "DISEASE", 148, 161], ["Infections", "PROBLEM", 0, 10], ["NML and RI", "PROBLEM", 45, 55], ["bacteremia", "PROBLEM", 61, 71], ["bacteremia", "PROBLEM", 107, 117], ["catheter", "TREATMENT", 119, 127], ["osteomyelitis", "PROBLEM", 148, 161], ["foreign body", "PROBLEM", 178, 190], ["bacteremia", "OBSERVATION", 61, 71], ["bacteremia", "OBSERVATION", 107, 117], ["catheter", "OBSERVATION", 119, 127], ["osteomyelitis", "OBSERVATION", 148, 161], ["foreign body", "OBSERVATION", 178, 190]]], ["Methicillin-resistant Staphylococcus aureus was the most common pathogen; NML 41%, RI 38%.", [["Methicillin", "CHEMICAL", 0, 11], ["Staphylococcus aureus", "DISEASE", 22, 43], ["Methicillin", "CHEMICAL", 0, 11], ["Methicillin-resistant Staphylococcus aureus", "ORGANISM", 0, 43], ["Staphylococcus aureus", "SPECIES", 22, 43], ["Staphylococcus aureus", "SPECIES", 22, 43], ["Methicillin", "TEST", 0, 11], ["resistant Staphylococcus aureus", "PROBLEM", 12, 43], ["NML", "TEST", 74, 77], ["RI", "TEST", 83, 85], ["resistant", "OBSERVATION_MODIFIER", 12, 21], ["Staphylococcus aureus", "OBSERVATION", 22, 43]]], ["RI had higher rates of coagulase-negative staphylococci (9 vs 15%, p < 0.02) and viridans streptococci (0.3 vs 1.7%, p < 0.05).", [["coagulase-negative staphylococci", "DISEASE", 23, 55], ["viridans streptococci", "DISEASE", 81, 102], ["coagulase-negative staphylococci", "GENE_OR_GENE_PRODUCT", 23, 55], ["coagulase", "PROTEIN", 23, 32], ["RI", "TEST", 0, 2], ["coagulase", "TEST", 23, 32], ["staphylococci", "TEST", 42, 55], ["p", "TEST", 67, 68], ["viridans streptococci", "TEST", 81, 102], ["p", "TEST", 117, 118], ["negative staphylococci", "OBSERVATION", 33, 55]]], ["There was no difference in the percentage receiving antibiotics prior to DAP; NML 75%, RI 68%.", [["antibiotics", "TREATMENT", 52, 63], ["DAP", "TEST", 73, 76], ["NML", "TEST", 78, 81], ["RI", "TEST", 87, 89], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23]]], ["The mean DAP dose and duration were similar; NML 4.7 mg/kg for 18 d, RI 4.6 mg/kg for 16 d.", [["DAP", "CHEMICAL", 9, 12], ["The mean DAP dose", "TREATMENT", 0, 17], ["NML", "TEST", 45, 48]]], ["The most frequent dose was 4 mg/kg; NML 58%, RI 39%.", [["NML", "TEST", 36, 39], ["RI", "TEST", 45, 47]]], ["RI initial DAP dosing was more frequent than recommended (q 48 h) in 76%.", [["DAP", "CHEMICAL", 11, 14], ["RI initial DAP dosing", "TREATMENT", 0, 21]]], ["The mean time to clinical response was similar; NML 5.2 d, RI 5.4 d.", [["NML", "TEST", 48, 51], ["RI", "TEST", 59, 61]]], ["More pts in NML received concomitant antibiotics with DAP; 53 vs 35%, p < 0.01).", [["NML", "CANCER", 12, 15], ["concomitant antibiotics", "TREATMENT", 25, 48], ["DAP", "TEST", 54, 57], ["vs", "TEST", 62, 64], ["p", "TEST", 70, 71]]], ["The clinical success (cure and improved) rates were; NML 95%, RI 96%.", [["rates", "TEST", 41, 46], ["NML", "TEST", 53, 56], ["RI", "TEST", 62, 64]]], ["Conclusion: DAP shows favourable clinical success rates in pts regardless of the presence of renal insufficiency.P1704In vitro activity of second line antibiotics against Helicobacter pylori infection Objective: The aim of our study was to determine the in vitro activity of levofloxacin, ciprofloxacin and rifampicin in clinical strains of H. pylori.", [["renal", "ANATOMY", 93, 98], ["DAP", "CHEMICAL", 12, 15], ["renal insufficiency", "DISEASE", 93, 112], ["Helicobacter pylori infection", "DISEASE", 171, 200], ["levofloxacin", "CHEMICAL", 275, 287], ["ciprofloxacin", "CHEMICAL", 289, 302], ["rifampicin", "CHEMICAL", 307, 317], ["H. pylori", "DISEASE", 341, 350], ["levofloxacin", "CHEMICAL", 275, 287], ["ciprofloxacin", "CHEMICAL", 289, 302], ["rifampicin", "CHEMICAL", 307, 317], ["renal", "ORGAN", 93, 98], ["Helicobacter pylori", "ORGANISM", 171, 190], ["levofloxacin", "SIMPLE_CHEMICAL", 275, 287], ["ciprofloxacin", "SIMPLE_CHEMICAL", 289, 302], ["rifampicin", "SIMPLE_CHEMICAL", 307, 317], ["H. pylori", "ORGANISM", 341, 350], ["Helicobacter pylori", "SPECIES", 171, 190], ["H. pylori", "SPECIES", 341, 350], ["Helicobacter pylori", "SPECIES", 171, 190], ["H. pylori", "SPECIES", 341, 350], ["renal insufficiency", "PROBLEM", 93, 112], ["second line antibiotics", "TREATMENT", 139, 162], ["Helicobacter pylori infection", "PROBLEM", 171, 200], ["our study", "TEST", 223, 232], ["levofloxacin", "TREATMENT", 275, 287], ["ciprofloxacin", "TREATMENT", 289, 302], ["rifampicin", "TREATMENT", 307, 317], ["H. pylori", "PROBLEM", 341, 350], ["favourable", "OBSERVATION_MODIFIER", 22, 32], ["renal", "ANATOMY", 93, 98], ["insufficiency", "OBSERVATION", 99, 112], ["H. pylori", "OBSERVATION", 341, 350]]], ["Material and methods: 40 isolates of H. pylori from biopsies of dyspeptic patients were obtained following standard methodology.P1704In vitro activity of metronidazole, clarithromycin, levofloxacin, ciprofloxacin and rifampicin was determined by E-Test using 5% sheep blood agar and incubated at 37ordm;C during 3-5 days in a CO2 atmosphere.", [["biopsies", "ANATOMY", 52, 60], ["blood", "ANATOMY", 268, 273], ["dyspeptic", "DISEASE", 64, 73], ["metronidazole", "CHEMICAL", 154, 167], ["clarithromycin", "CHEMICAL", 169, 183], ["levofloxacin", "CHEMICAL", 185, 197], ["ciprofloxacin", "CHEMICAL", 199, 212], ["rifampicin", "CHEMICAL", 217, 227], ["CO2", "CHEMICAL", 326, 329], ["metronidazole", "CHEMICAL", 154, 167], ["clarithromycin", "CHEMICAL", 169, 183], ["levofloxacin", "CHEMICAL", 185, 197], ["ciprofloxacin", "CHEMICAL", 199, 212], ["rifampicin", "CHEMICAL", 217, 227], ["CO2", "CHEMICAL", 326, 329], ["H. pylori", "ORGANISM", 37, 46], ["biopsies", "CANCER", 52, 60], ["patients", "ORGANISM", 74, 82], ["P1704In", "SIMPLE_CHEMICAL", 128, 135], ["metronidazole", "SIMPLE_CHEMICAL", 154, 167], ["clarithromycin", "SIMPLE_CHEMICAL", 169, 183], ["levofloxacin", "SIMPLE_CHEMICAL", 185, 197], ["ciprofloxacin", "SIMPLE_CHEMICAL", 199, 212], ["rifampicin", "SIMPLE_CHEMICAL", 217, 227], ["sheep", "ORGANISM", 262, 267], ["blood", "ORGANISM_SUBSTANCE", 268, 273], ["CO2", "SIMPLE_CHEMICAL", 326, 329], ["H. pylori", "SPECIES", 37, 46], ["patients", "SPECIES", 74, 82], ["sheep", "SPECIES", 262, 267], ["H. pylori", "SPECIES", 37, 46], ["sheep", "SPECIES", 262, 267], ["H. pylori", "PROBLEM", 37, 46], ["biopsies", "TEST", 52, 60], ["dyspeptic patients", "PROBLEM", 64, 82], ["metronidazole", "TREATMENT", 154, 167], ["clarithromycin", "TREATMENT", 169, 183], ["levofloxacin", "TREATMENT", 185, 197], ["ciprofloxacin", "TREATMENT", 199, 212], ["rifampicin", "TREATMENT", 217, 227], ["5% sheep blood agar", "TREATMENT", 259, 278], ["a CO2 atmosphere", "TREATMENT", 324, 340]]], ["MIC was determined as the point of complete inhibition of growth.", [["MIC", "CHEMICAL", 0, 3], ["complete inhibition of growth", "PROBLEM", 35, 64]]], ["Breakpoint of the NCCLS for other microorganisms were considered for fluorquinolones: resistant if MIC > 4 mg/ l.", [["fluorquinolones", "CHEMICAL", 69, 84], ["MIC", "CHEMICAL", 99, 102], ["fluorquinolones", "CHEMICAL", 69, 84], ["fluorquinolones", "SIMPLE_CHEMICAL", 69, 84], ["the NCCLS", "TEST", 14, 23], ["other microorganisms", "PROBLEM", 28, 48], ["fluorquinolones", "PROBLEM", 69, 84], ["MIC", "TEST", 99, 102]]], ["For rifampicin we considered the strain susceptible if MIC <32 mg/ l, as same studies reported.", [["rifampicin", "CHEMICAL", 4, 14], ["MIC", "CHEMICAL", 55, 58], ["rifampicin", "CHEMICAL", 4, 14], ["rifampicin", "SIMPLE_CHEMICAL", 4, 14], ["rifampicin", "TREATMENT", 4, 14], ["MIC", "TEST", 55, 58], ["same studies", "TEST", 73, 85]]], ["Results: 42.5% of the strains were resistant to metronidazole and 50% to clarithromycin.", [["metronidazole", "CHEMICAL", 48, 61], ["clarithromycin", "CHEMICAL", 73, 87], ["metronidazole", "CHEMICAL", 48, 61], ["clarithromycin", "CHEMICAL", 73, 87], ["metronidazole", "SIMPLE_CHEMICAL", 48, 61], ["clarithromycin", "SIMPLE_CHEMICAL", 73, 87], ["the strains", "PROBLEM", 18, 29], ["metronidazole", "TREATMENT", 48, 61], ["clarithromycin", "TREATMENT", 73, 87]]], ["MIC50, MIC90 and range (mg/l) was: 0.064, 0.125 and 0.012 fi 32 for levofloxacin, 0.064, 0.25 and 0.006 fi 32 for ciprofloxacin and 0.75, 1.5, and <0.002-4 for rifampicin.", [["MIC50", "CHEMICAL", 0, 5], ["MIC90", "CHEMICAL", 7, 12], ["levofloxacin", "CHEMICAL", 68, 80], ["ciprofloxacin", "CHEMICAL", 114, 127], ["rifampicin", "CHEMICAL", 160, 170], ["levofloxacin", "CHEMICAL", 68, 80], ["ciprofloxacin", "CHEMICAL", 114, 127], ["rifampicin", "CHEMICAL", 160, 170], ["MIC50", "SIMPLE_CHEMICAL", 0, 5], ["levofloxacin", "SIMPLE_CHEMICAL", 68, 80], ["ciprofloxacin", "SIMPLE_CHEMICAL", 114, 127], ["rifampicin", "SIMPLE_CHEMICAL", 160, 170], ["MIC50", "TEST", 0, 5], ["levofloxacin", "TREATMENT", 68, 80], ["ciprofloxacin", "TREATMENT", 114, 127], ["rifampicin", "TREATMENT", 160, 170]]], ["All the strains were susceptible to rifampicin and only 2% of them were resistant to fluorquinolones.", [["rifampicin", "CHEMICAL", 36, 46], ["fluorquinolones", "CHEMICAL", 85, 100], ["rifampicin", "CHEMICAL", 36, 46], ["fluorquinolones", "CHEMICAL", 85, 100], ["rifampicin", "SIMPLE_CHEMICAL", 36, 46], ["fluorquinolones", "SIMPLE_CHEMICAL", 85, 100], ["All the strains", "PROBLEM", 0, 15], ["rifampicin", "TREATMENT", 36, 46], ["fluorquinolones", "TREATMENT", 85, 100]]], ["Conclusions: The fluorquinolones tested and rifampicin showed an excellent in vitro activity against H. pylori, despite the high resistance rate to metronidazole and clarithromycin.", [["fluorquinolones", "CHEMICAL", 17, 32], ["rifampicin", "CHEMICAL", 44, 54], ["H. pylori", "DISEASE", 101, 110], ["metronidazole", "CHEMICAL", 148, 161], ["clarithromycin", "CHEMICAL", 166, 180], ["fluorquinolones", "CHEMICAL", 17, 32], ["rifampicin", "CHEMICAL", 44, 54], ["metronidazole", "CHEMICAL", 148, 161], ["clarithromycin", "CHEMICAL", 166, 180], ["fluorquinolones", "SIMPLE_CHEMICAL", 17, 32], ["rifampicin", "SIMPLE_CHEMICAL", 44, 54], ["H. pylori", "ORGANISM", 101, 110], ["metronidazole", "SIMPLE_CHEMICAL", 148, 161], ["clarithromycin", "SIMPLE_CHEMICAL", 166, 180], ["H. pylori", "SPECIES", 101, 110], ["H. pylori", "SPECIES", 101, 110], ["The fluorquinolones", "TREATMENT", 13, 32], ["rifampicin", "TREATMENT", 44, 54], ["H. pylori", "PROBLEM", 101, 110], ["the high resistance rate", "TREATMENT", 120, 144], ["metronidazole", "TREATMENT", 148, 161], ["clarithromycin", "TREATMENT", 166, 180]]], ["However, in vitro susceptibility test should be done before the use in clinical practice.P1705Vibrio antibodies in serum and breast milk samples of parturient women in Calabar, NigeriaS.", [["serum", "ANATOMY", 115, 120], ["breast milk samples", "ANATOMY", 125, 144], ["P1705Vibrio antibodies", "GENE_OR_GENE_PRODUCT", 89, 111], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["breast milk samples", "ORGANISM_SUBSTANCE", 125, 144], ["women", "ORGANISM", 159, 164], ["P1705Vibrio antibodies", "PROTEIN", 89, 111], ["women", "SPECIES", 159, 164], ["vitro susceptibility test", "TEST", 12, 37], ["P1705Vibrio antibodies", "TEST", 89, 111], ["serum", "TEST", 115, 120], ["breast milk samples", "TEST", 125, 144], ["breast", "ANATOMY", 125, 131]]], ["Utsalo (Calabar, NG)Objectives: Serum and breast milk samples from 335 parturient women and serum from non-parturient controls were analysed for prevalence and titres of vibrio antibodies.", [["Serum", "ANATOMY", 32, 37], ["breast milk samples", "ANATOMY", 42, 61], ["serum", "ANATOMY", 92, 97], ["Serum", "ORGANISM_SUBSTANCE", 32, 37], ["breast milk samples", "ORGANISM_SUBSTANCE", 42, 61], ["women", "ORGANISM", 82, 87], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["controls", "ORGANISM", 118, 126], ["vibrio antibodies", "GENE_OR_GENE_PRODUCT", 170, 187], ["vibrio antibodies", "PROTEIN", 170, 187], ["women", "SPECIES", 82, 87], ["Serum and breast milk samples", "TEST", 32, 61], ["serum from non-parturient controls", "TEST", 92, 126], ["vibrio antibodies", "PROBLEM", 170, 187], ["breast", "ANATOMY", 42, 48]]], ["Methods: V. cholerae agglutinins and vibriocidal antibodies in serum samples were analysed by direct agglutination and immune bacteriolysis techniques respectively, using 96 well microtitre plates.", [["serum samples", "ANATOMY", 63, 76], ["V. cholerae", "ORGANISM", 9, 20], ["agglutinins", "ORGANISM", 21, 32], ["vibriocidal antibodies", "GENE_OR_GENE_PRODUCT", 37, 59], ["serum samples", "ORGANISM_SUBSTANCE", 63, 76], ["V. cholerae agglutinins", "PROTEIN", 9, 32], ["vibriocidal antibodies", "PROTEIN", 37, 59], ["V. cholerae", "SPECIES", 9, 20], ["V. cholerae", "SPECIES", 9, 20], ["V. cholerae agglutinins", "TEST", 9, 32], ["vibriocidal antibodies", "TEST", 37, 59], ["serum samples", "TEST", 63, 76], ["direct agglutination", "TEST", 94, 114], ["immune bacteriolysis techniques", "TREATMENT", 119, 150]]], ["The protective value of breast milk was evaluated by haemagglutination inhibition and rabbit intestinal mucosal attachment of V. cholerae cells.", [["breast milk", "ANATOMY", 24, 35], ["intestinal mucosal", "ANATOMY", 93, 111], ["cells", "ANATOMY", 138, 143], ["breast milk", "ORGANISM_SUBSTANCE", 24, 35], ["rabbit", "ORGANISM", 86, 92], ["intestinal mucosal", "MULTI-TISSUE_STRUCTURE", 93, 111], ["V. cholerae cells", "CELL", 126, 143], ["V. cholerae cells", "CELL_TYPE", 126, 143], ["rabbit", "SPECIES", 86, 92], ["V. cholerae", "SPECIES", 126, 137], ["rabbit", "SPECIES", 86, 92], ["V. cholerae", "SPECIES", 126, 137], ["breast milk", "TREATMENT", 24, 35], ["haemagglutination inhibition", "TREATMENT", 53, 81], ["rabbit intestinal mucosal attachment of V. cholerae cells", "PROBLEM", 86, 143], ["breast", "ANATOMY", 24, 30], ["intestinal mucosal", "ANATOMY", 93, 111], ["cholerae cells", "OBSERVATION", 129, 143]]], ["Results: Vibrio agglutinins were detected in serum samples of 191(57.0%) parturient and 78 (33.9%) non-parturient subjects (p < 0.05).", [["serum samples", "ANATOMY", 45, 58], ["Vibrio agglutinins", "ORGANISM", 9, 27], ["serum samples", "ORGANISM_SUBSTANCE", 45, 58], ["Vibrio agglutinins", "TEST", 9, 27], ["serum samples", "TEST", 45, 58], ["parturient", "TEST", 73, 83], ["non-parturient subjects", "TEST", 99, 122]]], ["High prevalence rates of 68.9% and 39.1% occurred among parturient and control subjects of 21-25 years of age respectively.", [["High prevalence rates", "TEST", 0, 21]]], ["At 1:160 cut off titre to evaluate Vibrio cholerae specific bacteriocidal antibodies, activity was detected in samples of 31 (57.1%) and 9 (56.3%) parturients and controls respectively aged 26-30 years.", [["samples", "ANATOMY", 111, 118], ["Vibrio cholerae", "ORGANISM", 35, 50], ["bacteriocidal antibodies", "GENE_OR_GENE_PRODUCT", 60, 84], ["parturients", "ORGANISM", 147, 158], ["Vibrio cholerae specific bacteriocidal antibodies", "PROTEIN", 35, 84], ["Vibrio cholerae", "SPECIES", 35, 50], ["Vibrio cholerae", "SPECIES", 35, 50], ["Vibrio cholerae specific bacteriocidal antibodies", "TEST", 35, 84]]], ["Breast milk from 67 (20.0%) parturients contained vibrio agglutinins with titres ranging between 1:20 and 1:320, while milk samples from 32 subjects showed haemagglutination inhibition (HI) activity titres of P 1:40.", [["Breast milk", "ANATOMY", 0, 11], ["milk samples", "ANATOMY", 119, 131], ["Breast milk", "ORGANISM_SUBSTANCE", 0, 11], ["parturients", "ORGANISM", 28, 39], ["vibrio", "ORGANISM", 50, 56], ["milk samples", "ORGANISM_SUBSTANCE", 119, 131], ["P 1:40", "PROTEIN", 209, 215], ["milk", "SPECIES", 7, 11], ["Breast milk", "TEST", 0, 11], ["vibrio agglutinins", "PROBLEM", 50, 68], ["milk samples", "TEST", 119, 131], ["haemagglutination inhibition", "PROBLEM", 156, 184]]], ["Of the 19 HI positive milk samples 17 (89.5%) showed inhibition of V. cholerae adherence to rabbit intestinal mucosa at titres P 1:80, and 53-92% reductions in cell attachment.", [["milk samples", "ANATOMY", 22, 34], ["intestinal mucosa", "ANATOMY", 99, 116], ["cell", "ANATOMY", 160, 164], ["V. cholerae", "ORGANISM", 67, 78], ["rabbit", "ORGANISM", 92, 98], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 99, 116], ["cell", "CELL", 160, 164], ["V. cholerae", "SPECIES", 67, 78], ["rabbit", "SPECIES", 92, 98], ["V. cholerae", "SPECIES", 67, 78], ["rabbit", "SPECIES", 92, 98], ["milk samples", "TEST", 22, 34], ["inhibition of V. cholerae adherence", "PROBLEM", 53, 88], ["intestinal mucosa", "ANATOMY", 99, 116], ["cell attachment", "OBSERVATION", 160, 175]]], ["Conclusion: Our study confirms that parturient women in Calabar may benefit from significant serum titres of V. cholerae antibodies and provide immune protection for their babies through breast milk secretions.P1706Moxifloxacin vs clarithromycin for treatment of community-acquired pneumonia associated with common respiratory pathogens: a pooled analysis Objectives: Streptococcus pneumoniae and Haemophilus influenzae are pathogens commonly associated with community-acquired pneumonia (CAP).", [["serum", "ANATOMY", 93, 98], ["breast milk", "ANATOMY", 187, 198], ["respiratory", "ANATOMY", 315, 326], ["breast milk secretions", "DISEASE", 187, 209], ["P1706", "CHEMICAL", 210, 215], ["Moxifloxacin", "CHEMICAL", 215, 227], ["clarithromycin", "CHEMICAL", 231, 245], ["pneumonia", "DISEASE", 282, 291], ["respiratory pathogens", "DISEASE", 315, 336], ["Streptococcus pneumoniae", "DISEASE", 368, 392], ["Haemophilus influenzae", "DISEASE", 397, 419], ["pneumonia", "DISEASE", 478, 487], ["CAP", "DISEASE", 489, 492], ["Moxifloxacin", "CHEMICAL", 215, 227], ["clarithromycin", "CHEMICAL", 231, 245], ["women", "ORGANISM", 47, 52], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["V. cholerae", "ORGANISM", 109, 120], ["babies", "ORGANISM", 172, 178], ["breast milk secretions", "ORGANISM_SUBSTANCE", 187, 209], ["P1706", "SIMPLE_CHEMICAL", 210, 215], ["clarithromycin", "SIMPLE_CHEMICAL", 231, 245], ["Streptococcus pneumoniae", "ORGANISM", 368, 392], ["Haemophilus influenzae", "ORGANISM", 397, 419], ["V. cholerae antibodies", "PROTEIN", 109, 131], ["women", "SPECIES", 47, 52], ["V. cholerae", "SPECIES", 109, 120], ["Streptococcus pneumoniae", "SPECIES", 368, 392], ["Haemophilus influenzae", "SPECIES", 397, 419], ["V. cholerae", "SPECIES", 109, 120], ["Streptococcus pneumoniae", "SPECIES", 368, 392], ["Haemophilus influenzae", "SPECIES", 397, 419], ["Our study", "TEST", 12, 21], ["significant serum titres of V. cholerae antibodies", "PROBLEM", 81, 131], ["immune protection", "TREATMENT", 144, 161], ["breast milk secretions", "PROBLEM", 187, 209], ["Moxifloxacin", "TREATMENT", 215, 227], ["clarithromycin", "TREATMENT", 231, 245], ["community-acquired pneumonia", "PROBLEM", 263, 291], ["common respiratory pathogens", "PROBLEM", 308, 336], ["a pooled analysis", "TEST", 338, 355], ["Streptococcus pneumoniae", "PROBLEM", 368, 392], ["Haemophilus influenzae", "PROBLEM", 397, 419], ["pathogens", "PROBLEM", 424, 433], ["community-acquired pneumonia (CAP)", "PROBLEM", 459, 493], ["breast", "ANATOMY", 187, 193], ["pneumonia", "OBSERVATION", 282, 291], ["Streptococcus pneumoniae", "OBSERVATION", 368, 392], ["Haemophilus influenzae", "OBSERVATION", 397, 419], ["pneumonia", "OBSERVATION", 478, 487]]], ["This study compared the clinical and bacteriologic efficacy of moxifloxacin (MXF) to clarithromycin (CLAR) in CAP patients with these pathogens.P1706Patients and methods: Data were pooled from three doubleblind, multicenter, Phase III trials comparing oral MXF 400 mg QD to CLAR 500 mg BID for 10 days.", [["oral", "ANATOMY", 252, 256], ["moxifloxacin", "CHEMICAL", 63, 75], ["MXF", "CHEMICAL", 77, 80], ["clarithromycin", "CHEMICAL", 85, 99], ["CLAR", "CHEMICAL", 101, 105], ["CAP", "DISEASE", 110, 113], ["MXF", "CHEMICAL", 257, 260], ["CLAR", "CHEMICAL", 274, 278], ["moxifloxacin", "CHEMICAL", 63, 75], ["MXF", "CHEMICAL", 77, 80], ["clarithromycin", "CHEMICAL", 85, 99], ["CLAR", "CHEMICAL", 101, 105], ["BID", "CHEMICAL", 286, 289], ["moxifloxacin", "SIMPLE_CHEMICAL", 63, 75], ["MXF", "SIMPLE_CHEMICAL", 77, 80], ["clarithromycin", "SIMPLE_CHEMICAL", 85, 99], ["CLAR", "SIMPLE_CHEMICAL", 101, 105], ["patients", "ORGANISM", 114, 122], ["oral", "ORGANISM_SUBDIVISION", 252, 256], ["MXF", "SIMPLE_CHEMICAL", 257, 260], ["BID", "SIMPLE_CHEMICAL", 286, 289], ["patients", "SPECIES", 114, 122], ["This study", "TEST", 0, 10], ["moxifloxacin (MXF)", "TREATMENT", 63, 81], ["clarithromycin", "TREATMENT", 85, 99], ["these pathogens", "PROBLEM", 128, 143], ["Phase III trials", "TREATMENT", 225, 241], ["oral MXF", "TREATMENT", 252, 260], ["CLAR", "TREATMENT", 274, 278], ["pathogens", "OBSERVATION", 134, 143]]], ["All patients included had mild-to-moderate CAP.", [["CAP", "DISEASE", 43, 46], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["mild-to-moderate CAP", "PROBLEM", 26, 46], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["-to-moderate", "OBSERVATION_MODIFIER", 30, 42], ["CAP", "OBSERVATION", 43, 46]]], ["Clinical and bacteriologic success rates were identified for S. pneumoniae and H. influenzae isolated from these studies.", [["S. pneumoniae", "ORGANISM", 61, 74], ["H. influenzae", "ORGANISM", 79, 92], ["S. pneumoniae", "SPECIES", 61, 74], ["H. influenzae", "SPECIES", 79, 92], ["S. pneumoniae", "SPECIES", 61, 74], ["H. influenzae", "SPECIES", 79, 92], ["Clinical and bacteriologic success rates", "TEST", 0, 40], ["S. pneumoniae", "PROBLEM", 61, 74], ["H. influenzae", "PROBLEM", 79, 92], ["these studies", "TEST", 107, 120]]], ["Data for the efficacy-valid population was recorded at the test-of-cure (TOC) visit (7-35 days post-therapy).", [["valid population", "PROBLEM", 22, 38]]], ["Results: 1437 patients were entered, of which 356 were microbiologically evaluable.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Infection with S. pneumoniae and/or H. influenzae was documented in 149 (42%) of patients (5 MXF and 2 CLAR patients had mixed infection).", [["S. pneumoniae and/or H. influenzae", "DISEASE", 15, 49], ["infection", "DISEASE", 127, 136], ["S. pneumoniae", "ORGANISM", 15, 28], ["H. influenzae", "ORGANISM", 36, 49], ["patients", "ORGANISM", 81, 89], ["MXF", "CANCER", 93, 96], ["patients", "ORGANISM", 108, 116], ["S. pneumoniae", "SPECIES", 15, 28], ["H. influenzae", "SPECIES", 36, 49], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 108, 116], ["S. pneumoniae", "SPECIES", 15, 28], ["H. influenzae", "SPECIES", 36, 49], ["Infection", "PROBLEM", 0, 9], ["S. pneumoniae", "PROBLEM", 15, 28], ["H. influenzae", "PROBLEM", 36, 49], ["mixed infection", "PROBLEM", 121, 136], ["pneumoniae", "OBSERVATION", 18, 28], ["mixed", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136]]], ["Within this cohort, the two treatment groups were well balanced based on demographic/baseline medical characteristics (55% male, mean age 50 yrs, 41% smokers, 8% recent antimicrobial therapy).", [["8% recent antimicrobial therapy", "TREATMENT", 159, 190]]], ["Clinical success and bacteriologic eradication rates (one response per patient) at TOC are presented in the Table.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["Clinical success", "TREATMENT", 0, 16], ["bacteriologic eradication rates", "TEST", 21, 52]]], ["Conclusions: In CAP associated with S. pneumoniae and H. influenzae there was a trend towards greater bacterial eradication for MXF vs CLAR.", [["CAP", "DISEASE", 16, 19], ["S. pneumoniae and H. influenzae", "DISEASE", 36, 67], ["S. pneumoniae", "ORGANISM", 36, 49], ["H. influenzae", "ORGANISM", 54, 67], ["S. pneumoniae", "SPECIES", 36, 49], ["H. influenzae", "SPECIES", 54, 67], ["S. pneumoniae", "SPECIES", 36, 49], ["H. influenzae", "SPECIES", 54, 67], ["S. pneumoniae", "PROBLEM", 36, 49], ["H. influenzae", "PROBLEM", 54, 67], ["greater bacterial eradication", "TREATMENT", 94, 123], ["MXF", "PROBLEM", 128, 131], ["CLAR", "PROBLEM", 135, 139], ["pneumoniae", "OBSERVATION", 39, 49]]], ["Clinical success rates were significantly higher for MXF monotherapy vs CLAR.P1707Variability of creatinine clearance measurements in inpatients with community-acquired pneumonia R. Grossman, S. Choudhri, D. Haverstock (Mississauga, CA; West Haven, US)P1707Objectives: Moxifloxacin, levofloxacin and gatifloxacin have been recommended as empiric therapies for patients with community-acquired pneumonia (CAP).", [["MXF", "CHEMICAL", 53, 56], ["creatinine", "CHEMICAL", 97, 107], ["pneumonia", "DISEASE", 169, 178], ["Moxifloxacin", "CHEMICAL", 269, 281], ["levofloxacin", "CHEMICAL", 283, 295], ["gatifloxacin", "CHEMICAL", 300, 312], ["pneumonia", "DISEASE", 393, 402], ["CAP", "DISEASE", 404, 407], ["MXF", "CHEMICAL", 53, 56], ["creatinine", "CHEMICAL", 97, 107], ["Moxifloxacin", "CHEMICAL", 269, 281], ["levofloxacin", "CHEMICAL", 283, 295], ["gatifloxacin", "CHEMICAL", 300, 312], ["MXF", "SIMPLE_CHEMICAL", 53, 56], ["creatinine", "SIMPLE_CHEMICAL", 97, 107], ["Moxifloxacin", "SIMPLE_CHEMICAL", 269, 281], ["levofloxacin", "SIMPLE_CHEMICAL", 283, 295], ["gatifloxacin", "SIMPLE_CHEMICAL", 300, 312], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 360, 368], ["Clinical success rates", "TEST", 0, 22], ["MXF monotherapy", "TREATMENT", 53, 68], ["CLAR", "PROBLEM", 72, 76], ["creatinine clearance measurements", "TEST", 97, 130], ["community-acquired pneumonia", "PROBLEM", 150, 178], ["Moxifloxacin", "TREATMENT", 269, 281], ["levofloxacin", "TREATMENT", 283, 295], ["gatifloxacin", "TREATMENT", 300, 312], ["empiric therapies", "TREATMENT", 338, 355], ["community-acquired pneumonia", "PROBLEM", 374, 402], ["pneumonia", "OBSERVATION", 169, 178], ["pneumonia", "OBSERVATION", 393, 402]]], ["Levofloxacin and gatifloxacin require dose-adjustment for renal insufficiency while no dose adjustment is required for moxifloxacin.", [["renal", "ANATOMY", 58, 63], ["Levofloxacin", "CHEMICAL", 0, 12], ["gatifloxacin", "CHEMICAL", 17, 29], ["renal insufficiency", "DISEASE", 58, 77], ["moxifloxacin", "CHEMICAL", 119, 131], ["Levofloxacin", "CHEMICAL", 0, 12], ["gatifloxacin", "CHEMICAL", 17, 29], ["moxifloxacin", "CHEMICAL", 119, 131], ["Levofloxacin", "SIMPLE_CHEMICAL", 0, 12], ["gatifloxacin", "SIMPLE_CHEMICAL", 17, 29], ["renal", "ORGAN", 58, 63], ["moxifloxacin", "SIMPLE_CHEMICAL", 119, 131], ["Levofloxacin", "TREATMENT", 0, 12], ["gatifloxacin", "TREATMENT", 17, 29], ["dose-adjustment", "TREATMENT", 38, 53], ["renal insufficiency", "PROBLEM", 58, 77], ["dose adjustment", "TREATMENT", 87, 102], ["moxifloxacin", "TREATMENT", 119, 131], ["renal", "ANATOMY", 58, 63], ["insufficiency", "OBSERVATION", 64, 77]]], ["This study was designed to determine the frequency and underlying variability of renal insufficiency in patients with CAP.", [["renal", "ANATOMY", 81, 86], ["renal insufficiency", "DISEASE", 81, 100], ["CAP", "DISEASE", 118, 121], ["renal", "ORGAN", 81, 86], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["This study", "TEST", 0, 10], ["renal insufficiency", "PROBLEM", 81, 100], ["CAP", "PROBLEM", 118, 121], ["renal", "ANATOMY", 81, 86], ["insufficiency", "OBSERVATION", 87, 100], ["CAP", "OBSERVATION_MODIFIER", 118, 121]]], ["Methods: A pooled analysis of data from 2211 patients with mild to moderate or severe CAP entered into one of six randomized, controlled clinical trials was undertaken.", [["CAP", "DISEASE", 86, 89], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["A pooled analysis of data", "TEST", 9, 34], ["mild to moderate or severe CAP", "PROBLEM", 59, 89], ["mild", "OBSERVATION_MODIFIER", 59, 63], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["CAP", "OBSERVATION_MODIFIER", 86, 89]]], ["Renal function (calculated creatinine clearance; CrCl) was assessed in each patient prior to treatment with MXF and then again during and post-treatment.", [["Renal", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 27, 37], ["creatinine", "CHEMICAL", 27, 37], ["Renal", "ORGAN", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 27, 37], ["CrCl", "SIMPLE_CHEMICAL", 49, 53], ["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["Renal function", "TEST", 0, 14], ["calculated creatinine clearance", "TEST", 16, 47], ["CrCl", "TEST", 49, 53], ["treatment", "TREATMENT", 93, 102], ["MXF", "TREATMENT", 108, 111]]], ["Results: Baseline CrCl levels in this pooled population of patients with CAP were: <25 mL/min in 47 (2.1%) of patients, 25-49.9 mL/min in 436 (19.7%) and \u202150 mL/min in 1728 (78.2%) patients.", [["CAP", "DISEASE", 73, 76], ["CrCl", "GENE_OR_GENE_PRODUCT", 18, 22], ["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 181, 189], ["CrCl", "PROTEIN", 18, 22], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 181, 189], ["Baseline CrCl levels", "TEST", 9, 29], ["CAP", "TEST", 73, 76]]], ["After the pre-treatment CrCl measurement 88 patients (4%) were lost to follow-up, so there was no during or post treatment value.", [["CrCl", "SIMPLE_CHEMICAL", 24, 28], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["the pre-treatment CrCl measurement", "TEST", 6, 40], ["treatment value", "TEST", 113, 128]]], ["In patients with CAP the CrCl improved from baseline in many patients during or post-treatment, while some patients experienced a worsening of renal function (see Table) .P1707Conclusions: Renal function (CrCl) is highly variable in CAP patients with baseline evidence of renal insufficiency.", [["renal", "ANATOMY", 143, 148], ["Renal", "ANATOMY", 189, 194], ["renal", "ANATOMY", 272, 277], ["CAP", "DISEASE", 17, 20], ["CAP", "DISEASE", 233, 236], ["renal insufficiency", "DISEASE", 272, 291], ["patients", "ORGANISM", 3, 11], ["CrCl", "SIMPLE_CHEMICAL", 25, 29], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 107, 115], ["renal", "ORGAN", 143, 148], ["Renal", "ORGAN", 189, 194], ["patients", "ORGANISM", 237, 245], ["renal", "ORGAN", 272, 277], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 237, 245], ["CAP the CrCl", "TEST", 17, 29], ["a worsening of renal function", "PROBLEM", 128, 157], ["CrCl", "TEST", 205, 209], ["renal insufficiency", "PROBLEM", 272, 291], ["CrCl", "OBSERVATION", 25, 29], ["improved", "OBSERVATION_MODIFIER", 30, 38], ["worsening", "OBSERVATION_MODIFIER", 130, 139], ["renal", "ANATOMY", 143, 148], ["Renal", "ANATOMY", 189, 194], ["renal", "ANATOMY", 272, 277], ["insufficiency", "OBSERVATION", 278, 291]]], ["Renal function should be monitored closely to permit appropriate dose adjustments if levofloxacin or gatifloxacin is used in this patient population.", [["Renal", "ANATOMY", 0, 5], ["levofloxacin", "CHEMICAL", 85, 97], ["gatifloxacin", "CHEMICAL", 101, 113], ["levofloxacin", "CHEMICAL", 85, 97], ["gatifloxacin", "CHEMICAL", 101, 113], ["Renal", "ORGAN", 0, 5], ["levofloxacin", "SIMPLE_CHEMICAL", 85, 97], ["gatifloxacin", "SIMPLE_CHEMICAL", 101, 113], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137], ["Renal function", "TEST", 0, 14], ["appropriate dose adjustments", "TREATMENT", 53, 81], ["levofloxacin", "TREATMENT", 85, 97], ["gatifloxacin", "TREATMENT", 101, 113]]], ["Moxifloxacin may be a better empiric choice in this setting as it does not require dose adjustment in patients with renal insufficiency or renal failure.P1708A prospective, controlled, randomised, nonblind, comparative study of the efficacy and safety of high-dose single daily ceftriaxone plus ciprofloxacin versus thrice-daily ceftazidime plus amikacin in the empirical therapy of febrile neutropenic patients Objective: Empirical antibiotic treatment for febrile neutropenia is well established.", [["renal", "ANATOMY", 116, 121], ["renal", "ANATOMY", 139, 144], ["Moxifloxacin", "CHEMICAL", 0, 12], ["renal insufficiency", "DISEASE", 116, 135], ["renal failure", "DISEASE", 139, 152], ["ceftriaxone", "CHEMICAL", 278, 289], ["ciprofloxacin", "CHEMICAL", 295, 308], ["ceftazidime", "CHEMICAL", 329, 340], ["amikacin", "CHEMICAL", 346, 354], ["febrile neutropenic", "DISEASE", 383, 402], ["febrile neutropenia", "DISEASE", 458, 477], ["Moxifloxacin", "CHEMICAL", 0, 12], ["ceftriaxone", "CHEMICAL", 278, 289], ["ciprofloxacin", "CHEMICAL", 295, 308], ["ceftazidime", "CHEMICAL", 329, 340], ["amikacin", "CHEMICAL", 346, 354], ["Moxifloxacin", "SIMPLE_CHEMICAL", 0, 12], ["patients", "ORGANISM", 102, 110], ["renal", "ORGAN", 116, 121], ["renal", "ORGAN", 139, 144], ["ceftriaxone", "SIMPLE_CHEMICAL", 278, 289], ["ciprofloxacin", "SIMPLE_CHEMICAL", 295, 308], ["ceftazidime", "SIMPLE_CHEMICAL", 329, 340], ["amikacin", "SIMPLE_CHEMICAL", 346, 354], ["patients", "ORGANISM", 403, 411], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 403, 411], ["Moxifloxacin", "TREATMENT", 0, 12], ["dose adjustment", "TREATMENT", 83, 98], ["renal insufficiency", "PROBLEM", 116, 135], ["renal failure", "PROBLEM", 139, 152], ["comparative study", "TEST", 207, 224], ["high-dose single daily ceftriaxone", "TREATMENT", 255, 289], ["ciprofloxacin", "TREATMENT", 295, 308], ["thrice", "TREATMENT", 316, 322], ["ceftazidime", "TREATMENT", 329, 340], ["amikacin", "TREATMENT", 346, 354], ["the empirical therapy", "TREATMENT", 358, 379], ["febrile neutropenic patients", "TREATMENT", 383, 411], ["Empirical antibiotic treatment", "TREATMENT", 423, 453], ["febrile neutropenia", "PROBLEM", 458, 477], ["renal", "ANATOMY", 116, 121], ["insufficiency", "OBSERVATION", 122, 135], ["renal", "ANATOMY", 139, 144], ["failure", "OBSERVATION", 145, 152]]], ["The best regimen is still controversial.", [["The best regimen", "TREATMENT", 0, 16]]], ["The purpose of this study was to evaluate the efficacy, safety and cost of high-dose single daily ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in neutropenic febrile patients.", [["ceftriaxone", "CHEMICAL", 98, 109], ["ciprofloxacin", "CHEMICAL", 115, 128], ["ceftazidime", "CHEMICAL", 149, 160], ["amikacin", "CHEMICAL", 166, 174], ["febrile", "DISEASE", 190, 197], ["ceftriaxone", "CHEMICAL", 98, 109], ["ciprofloxacin", "CHEMICAL", 115, 128], ["ceftazidime", "CHEMICAL", 149, 160], ["amikacin", "CHEMICAL", 166, 174], ["ceftriaxone", "SIMPLE_CHEMICAL", 98, 109], ["ciprofloxacin", "SIMPLE_CHEMICAL", 115, 128], ["ceftazidime", "SIMPLE_CHEMICAL", 149, 160], ["amikacin", "SIMPLE_CHEMICAL", 166, 174], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["this study", "TEST", 15, 25], ["high-dose single daily ceftriaxone", "TREATMENT", 75, 109], ["ciprofloxacin", "TREATMENT", 115, 128], ["ceftazidime", "TREATMENT", 149, 160], ["amikacin", "TREATMENT", 166, 174], ["neutropenic febrile patients", "TREATMENT", 178, 206]]], ["Patients and methods: Ninety-five patients with febrile neutropenia were included in a prospective, controlled, randomized, non-blind, comparative study.", [["febrile neutropenia", "DISEASE", 48, 67], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 34, 42], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 34, 42], ["febrile neutropenia", "PROBLEM", 48, 67], ["comparative study", "TEST", 135, 152]]], ["Patients were randomly assigned to either treatment group (63 in the Ceftriaxone/Ciprofloxacin group and 32 in the Ceftazidime/ Amikacin group) and evaluated as successes or failures according to defined criteria.", [["Ceftriaxone", "CHEMICAL", 69, 80], ["Ciprofloxacin", "CHEMICAL", 81, 94], ["Ceftazidime", "CHEMICAL", 115, 126], ["Amikacin", "CHEMICAL", 128, 136], ["Ceftriaxone", "CHEMICAL", 69, 80], ["Ciprofloxacin", "CHEMICAL", 81, 94], ["Ceftazidime", "CHEMICAL", 115, 126], ["Patients", "ORGANISM", 0, 8], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 81, 94], ["Patients", "SPECIES", 0, 8], ["treatment group", "TREATMENT", 42, 57], ["the Ceftriaxone/Ciprofloxacin group", "TREATMENT", 65, 100], ["the Ceftazidime/ Amikacin group", "TREATMENT", 111, 142]]], ["Daily assessments were made on all patients all adverse events were record.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["Daily assessments", "TEST", 0, 17]]], ["Results: The overall incidence of documented infections was 45.9%: 24/47 (51.1%) in the Ceftriaxone/Ciprofloxacin group and 10/27 (37%) in the Ceftazidime/Amikacin group.", [["infections", "DISEASE", 45, 55], ["Ceftriaxone", "CHEMICAL", 88, 99], ["Ciprofloxacin", "CHEMICAL", 100, 113], ["Ceftazidime", "CHEMICAL", 143, 154], ["Amikacin", "CHEMICAL", 155, 163], ["Ceftriaxone", "CHEMICAL", 88, 99], ["Ciprofloxacin", "CHEMICAL", 100, 113], ["Ceftazidime", "CHEMICAL", 143, 154], ["Amikacin", "CHEMICAL", 155, 163], ["Ceftriaxone", "SIMPLE_CHEMICAL", 88, 99], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 100, 113], ["Ceftazidime", "SIMPLE_CHEMICAL", 143, 154], ["Amikacin", "SIMPLE_CHEMICAL", 155, 163], ["documented infections", "PROBLEM", 34, 55], ["the Ceftriaxone", "TREATMENT", 84, 99], ["Ciprofloxacin", "TREATMENT", 100, 113], ["the Ceftazidime", "TREATMENT", 139, 154], ["Amikacin group", "TREATMENT", 155, 169], ["infections", "OBSERVATION", 45, 55]]], ["There was significant difference in clinical efficacy between groups (p = 0.011) at the end of therapy.", [["therapy", "TREATMENT", 95, 102], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["difference", "OBSERVATION_MODIFIER", 22, 32]]], ["Ceftriaxone/Ciprofloxacin group had an overall incidence of resolution and improvement of 95,7% in comparison to the 75% of the Ceftazidime/Amikacin group.", [["Ceftriaxone", "CHEMICAL", 0, 11], ["Ciprofloxacin", "CHEMICAL", 12, 25], ["Ceftazidime", "CHEMICAL", 128, 139], ["Amikacin", "CHEMICAL", 140, 148], ["Ceftriaxone", "CHEMICAL", 0, 11], ["Ciprofloxacin", "CHEMICAL", 12, 25], ["Ceftazidime", "CHEMICAL", 128, 139], ["Amikacin", "CHEMICAL", 140, 148], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["Ciprofloxacin", "SIMPLE_CHEMICAL", 12, 25], ["Ceftazidime", "SIMPLE_CHEMICAL", 128, 139], ["Amikacin", "SIMPLE_CHEMICAL", 140, 148], ["Ceftriaxone", "TREATMENT", 0, 11], ["Ciprofloxacin", "TREATMENT", 12, 25], ["the Ceftazidime", "TREATMENT", 124, 139], ["Amikacin group", "TREATMENT", 140, 154], ["resolution", "OBSERVATION_MODIFIER", 60, 70], ["improvement", "OBSERVATION_MODIFIER", 75, 86]]], ["Thirty-nine organisms were isolated, 26 (66.67%) gramnegative and 13 (33,33%) gram-positive.", [["Thirty-nine organisms", "TEST", 0, 21], ["gramnegative", "TEST", 49, 61], ["gram-positive", "PROBLEM", 78, 91]]], ["There was low incidence of adverse events in both groups.", [["adverse events", "PROBLEM", 27, 41], ["low incidence", "OBSERVATION_MODIFIER", 10, 23], ["adverse events", "OBSERVATION", 27, 41]]], ["Conclusion: The combination of high dose single daily ceftriaxone plus ciprofloxacin was more effective than the standard combination of thrice daily ceftazidime plus amikacn with no significant adverse events in either group.", [["ceftriaxone", "CHEMICAL", 54, 65], ["ciprofloxacin", "CHEMICAL", 71, 84], ["ceftazidime", "CHEMICAL", 150, 161], ["amikacn", "CHEMICAL", 167, 174], ["ceftriaxone", "CHEMICAL", 54, 65], ["ciprofloxacin", "CHEMICAL", 71, 84], ["ceftazidime", "CHEMICAL", 150, 161], ["amikacn", "CHEMICAL", 167, 174], ["ceftriaxone", "SIMPLE_CHEMICAL", 54, 65], ["ciprofloxacin", "SIMPLE_CHEMICAL", 71, 84], ["ceftazidime", "SIMPLE_CHEMICAL", 150, 161], ["amikacn", "SIMPLE_CHEMICAL", 167, 174], ["high dose single daily ceftriaxone", "TREATMENT", 31, 65], ["ciprofloxacin", "TREATMENT", 71, 84], ["ceftazidime", "TREATMENT", 150, 161], ["amikacn", "TREATMENT", 167, 174], ["significant adverse events", "PROBLEM", 183, 209]]], ["Objective: In past studies of azithromycin in children, a posttreatment (PT) benefit was observed at Day 28.", [["azithromycin", "CHEMICAL", 30, 42], ["azithromycin", "CHEMICAL", 30, 42], ["azithromycin", "SIMPLE_CHEMICAL", 30, 42], ["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["azithromycin", "TREATMENT", 30, 42], ["a posttreatment (PT)", "TREATMENT", 56, 76]]], ["In 5 recent phase 3 trials in adults, single-dose Zmax was at least as effective as standard comparators for treatment of respiratory tract infections (RTIs), including CAP.", [["respiratory tract", "ANATOMY", 122, 139], ["Zmax", "CHEMICAL", 50, 54], ["respiratory tract infections", "DISEASE", 122, 150], ["RTIs", "DISEASE", 152, 156], ["CAP", "DISEASE", 169, 172], ["adults", "ORGANISM", 30, 36], ["Zmax", "SIMPLE_CHEMICAL", 50, 54], ["respiratory tract", "ORGANISM_SUBDIVISION", 122, 139], ["single-dose Zmax", "TREATMENT", 38, 54], ["respiratory tract infections", "PROBLEM", 122, 150], ["RTIs", "PROBLEM", 152, 156], ["CAP", "PROBLEM", 169, 172], ["respiratory tract", "ANATOMY", 122, 139], ["CAP", "OBSERVATION_MODIFIER", 169, 172]]], ["Methods: Post-hoc analyses, including respiratory adverse event burden (RAEB), were conducted on the All Treated population (N = 2596; 1292 AZ-M, 1304 comparators) in the 5 phase 3 studies.", [["respiratory", "ANATOMY", 38, 49], ["respiratory adverse event", "DISEASE", 38, 63], ["RAEB", "DISEASE", 72, 76], ["Post-hoc analyses", "TEST", 9, 26], ["respiratory adverse event burden", "PROBLEM", 38, 70]]], ["The RAEB is the sum of duration, in days, of all respiratory adverse events, divided by total number of observation days of all patients, normalized to 1 year.", [["respiratory", "ANATOMY", 49, 60], ["RAEB", "DISEASE", 4, 8], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["all respiratory adverse events", "PROBLEM", 45, 75], ["RAEB", "OBSERVATION", 4, 8]]], ["The overall and per study day RAEB were calculated for Zmax and the pooled comparators for the 5 studies combined.", [["RAEB", "DISEASE", 30, 34], ["RAEB", "TEST", 30, 34], ["Zmax", "TREATMENT", 55, 59], ["the 5 studies", "TEST", 91, 104]]], ["Results: RAEB, in days/patient year, was 15.5 for AZ-M patients vs 20.2 for comparator patients (p = 0.08).", [["RAEB", "DISEASE", 9, 13], ["patient", "ORGANISM", 23, 30], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 87, 95], ["patient", "SPECIES", 23, 30], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 87, 95], ["vs", "TEST", 64, 66], ["RAEB", "OBSERVATION", 9, 13]]], ["The difference in RAEB consistently and progressively favoured Zmax, beginning at Day 11 and achieving statistical significance between Days 29 and 35, when the upper limits of the 95% CIs around the differences were below zero (figure).", [["RAEB", "DISEASE", 18, 22], ["The difference in RAEB", "PROBLEM", 0, 22], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["RAEB consistently", "OBSERVATION", 18, 35], ["upper limits", "OBSERVATION_MODIFIER", 161, 173]]], ["Faropenem medoxomil (FM) is an oral penem with potent activity against Streptococcus pneumoniae and Haemophilus influenzae.", [["oral", "ANATOMY", 31, 35], ["Faropenem medoxomil", "CHEMICAL", 0, 19], ["FM", "CHEMICAL", 21, 23], ["Streptococcus pneumoniae", "DISEASE", 71, 95], ["Haemophilus influenzae", "DISEASE", 100, 122], ["Faropenem medoxomil", "CHEMICAL", 0, 19], ["Faropenem medoxomil", "SIMPLE_CHEMICAL", 0, 19], ["FM", "SIMPLE_CHEMICAL", 21, 23], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["Streptococcus pneumoniae", "ORGANISM", 71, 95], ["Haemophilus influenzae", "ORGANISM", 100, 122], ["Streptococcus pneumoniae", "SPECIES", 71, 95], ["Haemophilus influenzae", "SPECIES", 100, 122], ["Streptococcus pneumoniae", "SPECIES", 71, 95], ["Haemophilus influenzae", "SPECIES", 100, 122], ["Faropenem medoxomil (FM)", "TREATMENT", 0, 24], ["an oral penem", "TREATMENT", 28, 41], ["Streptococcus pneumoniae", "PROBLEM", 71, 95], ["Haemophilus influenzae", "PROBLEM", 100, 122], ["Haemophilus influenzae", "OBSERVATION", 100, 122]]], ["This integrated analysis was conducted to summarize the efficacy of 10 days of 300 mg BID of FM compared with other beta lactams in the management of community acquired pneumonia (CAP).", [["FM", "CHEMICAL", 93, 95], ["beta lactams", "CHEMICAL", 116, 128], ["pneumonia", "DISEASE", 169, 178], ["CAP", "DISEASE", 180, 183], ["BID", "CHEMICAL", 86, 89], ["FM", "SIMPLE_CHEMICAL", 93, 95], ["beta lactams", "GENE_OR_GENE_PRODUCT", 116, 128], ["This integrated analysis", "TEST", 0, 24], ["FM", "TREATMENT", 93, 95], ["other beta lactams", "TREATMENT", 110, 128], ["the management", "TREATMENT", 132, 146], ["community acquired pneumonia", "PROBLEM", 150, 178], ["pneumonia", "OBSERVATION", 169, 178]]], ["Methods: Efficacy was determined in three multicenter randomized double-blind controlled trials (RCT) and a single uncontrolled study of faropenem medoxomil.", [["faropenem medoxomil", "CHEMICAL", 137, 156], ["faropenem medoxomil", "CHEMICAL", 137, 156], ["faropenem medoxomil", "SIMPLE_CHEMICAL", 137, 156], ["double-blind controlled trials (RCT)", "TREATMENT", 65, 101], ["a single uncontrolled study", "TEST", 106, 133], ["faropenem medoxomil", "TREATMENT", 137, 156]]], ["Comparators were 14 days of cefpodoxime (C), 10 days of amoxicillinclavulanate (AC), or 10 days of amoxicillin (A).", [["cefpodoxime", "CHEMICAL", 28, 39], ["amoxicillinclavulanate", "CHEMICAL", 56, 78], ["AC", "CHEMICAL", 80, 82], ["amoxicillin", "CHEMICAL", 99, 110], ["cefpodoxime", "CHEMICAL", 28, 39], ["amoxicillinclavulanate", "CHEMICAL", 56, 78], ["amoxicillin", "CHEMICAL", 99, 110], ["cefpodoxime", "SIMPLE_CHEMICAL", 28, 39], ["C", "SIMPLE_CHEMICAL", 41, 42], ["amoxicillinclavulanate", "SIMPLE_CHEMICAL", 56, 78], ["amoxicillin", "SIMPLE_CHEMICAL", 99, 110], ["cefpodoxime (C)", "TREATMENT", 28, 43], ["amoxicillinclavulanate (AC)", "TREATMENT", 56, 83], ["amoxicillin", "TREATMENT", 99, 110]]], ["The analysis allowed examination of treatment effects by age, race, gender and study site subgroups.", [["The analysis", "TEST", 0, 12], ["examination", "TEST", 21, 32], ["treatment effects", "TREATMENT", 36, 53]]], ["Results: A total of 2267 subjects were studied.", [["subjects", "ORGANISM", 25, 33]]], ["Studies 1 and 4 were conducted in N. America, studies 2 and 3 in Europe, Latin America, Israel, and S. Africa.", [["Studies", "TEST", 0, 7]]], ["N. American vs. other studies included subjects at least 12 (vs. at least 18) years of age and only out patient (vs. outpatient and hospitalized) subjects.", [["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["other studies", "TEST", 16, 29]]], ["The clinical responses for FM in both Per Protocol and Intention-to-Treat populations were non-inferior to comparator for each study and for the three trials combined.", [["Treat populations", "TREATMENT", 68, 85], ["each study", "TEST", 122, 132]]], ["Recovery of an etiologic agent from initial respiratory or blood culture varied between 9.4 and 17.5% of cases in the 4 studies for a total of 236 microbiologically evaluable subjects.", [["respiratory", "ANATOMY", 44, 55], ["blood", "ANATOMY", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["initial respiratory or blood culture", "TEST", 36, 72]]], ["S. pneumoniae was eradicated or presumed eradicated in 82/90 (91.1%) and 49/52 (94.2%), H. influenzae in 49/61 (80.3%) and 30/32 (93.8%), S. aureus in 13/14 (93%) and 8/10 (80%), H. parainfluenzae in 6/8 (75%) and 0/2 (0%), and M. catarrhalis in 6/7 (85.7%) and 4/4(100%) FM and comparator recipients, respectively.", [["FM", "ANATOMY", 272, 274], ["H. parainfluenzae", "DISEASE", 179, 196], ["S. pneumoniae", "ORGANISM", 0, 13], ["H. influenzae", "ORGANISM", 88, 101], ["S. aureus", "ORGANISM", 138, 147], ["H. parainfluenzae", "ORGANISM", 179, 196], ["M. catarrhalis", "ORGANISM", 228, 242], ["recipients", "ORGANISM", 290, 300], ["S. pneumoniae", "SPECIES", 0, 13], ["H. influenzae", "SPECIES", 88, 101], ["S. aureus", "SPECIES", 138, 147], ["H. parainfluenzae", "SPECIES", 179, 196], ["M. catarrhalis", "SPECIES", 228, 242], ["S. pneumoniae", "SPECIES", 0, 13], ["H. influenzae", "SPECIES", 88, 101], ["S. aureus", "SPECIES", 138, 147], ["H. parainfluenzae", "SPECIES", 179, 196], ["M. catarrhalis", "SPECIES", 228, 242], ["S. pneumoniae", "PROBLEM", 0, 13], ["H. influenzae", "TEST", 88, 101], ["S. aureus", "TEST", 138, 147], ["H. parainfluenzae", "TEST", 179, 196], ["M. catarrhalis", "TEST", 228, 242], ["pneumoniae", "OBSERVATION", 3, 13], ["aureus", "OBSERVATION", 141, 147], ["parainfluenzae", "OBSERVATION", 182, 196], ["catarrhalis", "OBSERVATION", 231, 242]]], ["Clinical response for S. pneumoniae bacteremic patients was 18/21 (85.7%) for FM.P1708Conclusions: FM efficacy was consistent across studies, within subgroups, and non-inferior to comparators.", [["S. pneumoniae bacteremic", "DISEASE", 22, 46], ["S. pneumoniae", "ORGANISM", 22, 35], ["patients", "ORGANISM", 47, 55], ["FM", "MULTI-TISSUE_STRUCTURE", 99, 101], ["S. pneumoniae", "SPECIES", 22, 35], ["patients", "SPECIES", 47, 55], ["S. pneumoniae", "SPECIES", 22, 35], ["S. pneumoniae bacteremic", "PROBLEM", 22, 46]]], ["It is efficacious against the most common bacterial pathogens and in the most severe form (bacteremic) disease.", [["bacteremic) disease", "DISEASE", 91, 110], ["the most common bacterial pathogens", "PROBLEM", 26, 61], ["bacteremic) disease", "PROBLEM", 91, 110], ["efficacious", "OBSERVATION_MODIFIER", 6, 17], ["most common", "OBSERVATION_MODIFIER", 30, 41], ["bacterial", "OBSERVATION_MODIFIER", 42, 51], ["pathogens", "OBSERVATION", 52, 61], ["most severe", "OBSERVATION_MODIFIER", 73, 84], ["bacteremic", "OBSERVATION", 91, 101]]], ["FM is a good option for the treatment of CAP.P1711Propionibacterium acnes strains isolated from acne vulgaris and severe infections C. Oprica, C.E. Nord (Stockholm, SE) Propionibacterium acnes is a member of the resident flora of the skin and is an important factor involved in inflammatory reactions in acne patients.", [["skin", "ANATOMY", 234, 238], ["CAP", "DISEASE", 41, 44], ["P1711Propionibacterium", "CHEMICAL", 45, 67], ["acne vulgaris", "DISEASE", 96, 109], ["infections", "DISEASE", 121, 131], ["Propionibacterium acnes", "DISEASE", 169, 192], ["acne", "DISEASE", 304, 308], ["FM", "MULTI-TISSUE_STRUCTURE", 0, 2], ["P1711Propionibacterium acnes", "ORGANISM", 45, 73], ["acne vulgaris", "ORGANISM", 96, 109], ["Propionibacterium acnes", "ORGANISM", 169, 192], ["skin", "ORGAN", 234, 238], ["patients", "ORGANISM", 309, 317], ["P1711Propionibacterium acnes", "SPECIES", 45, 73], ["C. Oprica", "SPECIES", 132, 141], ["Propionibacterium acnes", "SPECIES", 169, 192], ["patients", "SPECIES", 309, 317], ["P1711Propionibacterium acnes", "SPECIES", 45, 73], ["acne vulgaris", "SPECIES", 96, 109], ["Propionibacterium acnes", "SPECIES", 169, 192], ["CAP", "PROBLEM", 41, 44], ["acnes strains", "PROBLEM", 68, 81], ["acne vulgaris", "PROBLEM", 96, 109], ["severe infections", "PROBLEM", 114, 131], ["Propionibacterium acnes", "PROBLEM", 169, 192], ["inflammatory reactions", "PROBLEM", 278, 300], ["CAP", "OBSERVATION", 41, 44], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["infections", "OBSERVATION", 121, 131], ["skin", "ANATOMY", 234, 238], ["inflammatory", "OBSERVATION_MODIFIER", 278, 290]]], ["During the last years the prevalence of different severe infections due to P. acnes has increased.", [["infections", "DISEASE", 57, 67], ["P. acnes", "DISEASE", 75, 83], ["P. acnes", "ORGANISM", 75, 83], ["P. acnes", "SPECIES", 75, 83], ["P. acnes", "SPECIES", 75, 83], ["different severe infections", "PROBLEM", 40, 67], ["P. acnes", "PROBLEM", 75, 83], ["different", "OBSERVATION_MODIFIER", 40, 49], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["infections", "OBSERVATION", 57, 67], ["acnes", "OBSERVATION", 78, 83], ["increased", "OBSERVATION_MODIFIER", 88, 97]]], ["Objectives: 1) To detect the prevalence of resistant P. acnes strains isolated from acne patients in Stockholm and different severe infections in Europe; 2) To identify the mechanisms of resistance and the genetic diversity among resistant strains.", [["P. acnes", "DISEASE", 53, 61], ["acne", "DISEASE", 84, 88], ["infections", "DISEASE", 132, 142], ["P. acnes", "ORGANISM", 53, 61], ["patients", "ORGANISM", 89, 97], ["P. acnes", "SPECIES", 53, 61], ["patients", "SPECIES", 89, 97], ["P. acnes", "SPECIES", 53, 61], ["resistant P. acnes strains", "PROBLEM", 43, 69], ["different severe infections", "PROBLEM", 115, 142], ["resistance", "PROBLEM", 187, 197], ["resistant strains", "PROBLEM", 230, 247], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["infections", "OBSERVATION", 132, 142]]], ["Methods: P. acnes strains isolated from acne vulgaris and severe infections were tested against clindamycin, erythromycin, linezolid and tetracycline and pulsed-field gel electrophoresis was used for further characterization.", [["acne vulgaris", "DISEASE", 40, 53], ["infections", "DISEASE", 65, 75], ["clindamycin", "CHEMICAL", 96, 107], ["erythromycin", "CHEMICAL", 109, 121], ["linezolid", "CHEMICAL", 123, 132], ["tetracycline", "CHEMICAL", 137, 149], ["clindamycin", "CHEMICAL", 96, 107], ["erythromycin", "CHEMICAL", 109, 121], ["linezolid", "CHEMICAL", 123, 132], ["tetracycline", "CHEMICAL", 137, 149], ["P. acnes strains", "ORGANISM", 9, 25], ["acne vulgaris", "ORGANISM", 40, 53], ["clindamycin", "SIMPLE_CHEMICAL", 96, 107], ["erythromycin", "SIMPLE_CHEMICAL", 109, 121], ["linezolid", "SIMPLE_CHEMICAL", 123, 132], ["tetracycline", "SIMPLE_CHEMICAL", 137, 149], ["P. acnes", "SPECIES", 9, 17], ["P. acnes", "SPECIES", 9, 17], ["acne vulgaris", "SPECIES", 40, 53], ["P. acnes strains", "PROBLEM", 9, 25], ["acne vulgaris", "PROBLEM", 40, 53], ["severe infections", "PROBLEM", 58, 75], ["clindamycin", "TREATMENT", 96, 107], ["erythromycin", "TREATMENT", 109, 121], ["linezolid", "TREATMENT", 123, 132], ["tetracycline", "TREATMENT", 137, 149], ["pulsed-field gel electrophoresis", "TREATMENT", 154, 186], ["further characterization", "TEST", 200, 224], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["infections", "OBSERVATION", 65, 75]]], ["PCR and sequencing of the genes encoding domain V of 23S rRNA for clindamycin and erythromycin resistant strains and 16S rRNA for tetracycline resistant strains were performed.", [["clindamycin", "CHEMICAL", 66, 77], ["erythromycin", "CHEMICAL", 82, 94], ["tetracycline", "CHEMICAL", 130, 142], ["clindamycin", "CHEMICAL", 66, 77], ["erythromycin", "CHEMICAL", 82, 94], ["tetracycline", "CHEMICAL", 130, 142], ["23S rRNA", "GENE_OR_GENE_PRODUCT", 53, 61], ["clindamycin", "SIMPLE_CHEMICAL", 66, 77], ["erythromycin", "SIMPLE_CHEMICAL", 82, 94], ["tetracycline", "SIMPLE_CHEMICAL", 130, 142], ["domain V", "PROTEIN", 41, 49], ["23S rRNA", "DNA", 53, 61], ["16S rRNA", "DNA", 117, 125], ["PCR", "TEST", 0, 3], ["23S rRNA", "TREATMENT", 53, 61], ["clindamycin", "TREATMENT", 66, 77], ["erythromycin resistant strains", "TREATMENT", 82, 112], ["16S rRNA", "TREATMENT", 117, 125], ["tetracycline resistant strains", "PROBLEM", 130, 160]]], ["Results: i) Antibiotic-resistant strains were more often isolated from antibiotic treated patients with moderate to severe acne area than from non-antibiotic treated acne patients.", [["acne", "DISEASE", 123, 127], ["acne", "DISEASE", 166, 170], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 171, 179], ["Antibiotic", "TREATMENT", 12, 22], ["resistant strains", "PROBLEM", 23, 40], ["antibiotic", "TREATMENT", 71, 81], ["moderate to severe acne area", "PROBLEM", 104, 132], ["non-antibiotic treated acne", "TREATMENT", 143, 170], ["moderate", "OBSERVATION_MODIFIER", 104, 112], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acne", "OBSERVATION", 123, 127]]], ["An individual might harbor different pulsotypes of P. acnes with various degrees of resistance. ii) Among the 304 clinical isolates from 13 European countries were found resistant strains to tetracycline, clindamycin, and erythromycin.", [["tetracycline", "CHEMICAL", 191, 203], ["clindamycin", "CHEMICAL", 205, 216], ["erythromycin", "CHEMICAL", 222, 234], ["tetracycline", "CHEMICAL", 191, 203], ["clindamycin", "CHEMICAL", 205, 216], ["erythromycin", "CHEMICAL", 222, 234], ["P. acnes", "ORGANISM", 51, 59], ["tetracycline", "SIMPLE_CHEMICAL", 191, 203], ["clindamycin", "SIMPLE_CHEMICAL", 205, 216], ["erythromycin", "SIMPLE_CHEMICAL", 222, 234], ["P. acnes", "SPECIES", 51, 59], ["P. acnes", "SPECIES", 51, 59], ["P. acnes", "PROBLEM", 51, 59], ["resistance", "PROBLEM", 84, 94], ["clinical isolates", "TEST", 114, 131], ["resistant strains", "PROBLEM", 170, 187], ["tetracycline", "TREATMENT", 191, 203], ["clindamycin", "TREATMENT", 205, 216], ["erythromycin", "TREATMENT", 222, 234], ["acnes", "OBSERVATION", 54, 59], ["various degrees", "OBSERVATION_MODIFIER", 65, 80], ["resistance", "OBSERVATION", 84, 94]]], ["Overall, in the southern Europe a higher prevalence of erythromycin-resistant strains was noticed and in southern and eastern Europe a higher prevalence of resistance to clindamycin.", [["erythromycin", "CHEMICAL", 55, 67], ["clindamycin", "CHEMICAL", 170, 181], ["erythromycin", "CHEMICAL", 55, 67], ["clindamycin", "CHEMICAL", 170, 181], ["erythromycin", "SIMPLE_CHEMICAL", 55, 67], ["clindamycin", "SIMPLE_CHEMICAL", 170, 181], ["erythromycin", "TREATMENT", 55, 67], ["resistant strains", "PROBLEM", 68, 85], ["clindamycin", "TREATMENT", 170, 181]]], ["It was noticed a high genomic diversity and the geographical spread of some clones in related areas but also in geographically distant countries.", [["clones", "CELL", 76, 82], ["a high genomic diversity", "PROBLEM", 15, 39], ["some clones", "PROBLEM", 71, 82], ["high", "OBSERVATION_MODIFIER", 17, 21], ["genomic diversity", "OBSERVATION", 22, 39], ["geographical", "OBSERVATION_MODIFIER", 48, 60], ["spread", "OBSERVATION_MODIFIER", 61, 67], ["some", "OBSERVATION_MODIFIER", 71, 75], ["clones", "OBSERVATION", 76, 82], ["areas", "OBSERVATION_MODIFIER", 94, 99], ["geographically", "OBSERVATION_MODIFIER", 112, 126]]], ["Most clindamycin or erythromycin resistant P. acnes isolates, were found to be members of a single clone that has spread in different geographically countries. iii) P. acnes clindamycin and erythromycin resistant strains carrying one of the described mutations within the 23S rRNA were predominantly isolated from Swedish acne patients compared to strains from other infections.", [["clindamycin", "CHEMICAL", 5, 16], ["erythromycin", "CHEMICAL", 20, 32], ["clindamycin", "CHEMICAL", 174, 185], ["erythromycin", "CHEMICAL", 190, 202], ["acne", "DISEASE", 322, 326], ["infections", "DISEASE", 367, 377], ["clindamycin", "CHEMICAL", 5, 16], ["erythromycin", "CHEMICAL", 20, 32], ["clindamycin", "CHEMICAL", 174, 185], ["erythromycin", "CHEMICAL", 190, 202], ["clindamycin", "SIMPLE_CHEMICAL", 5, 16], ["erythromycin", "SIMPLE_CHEMICAL", 20, 32], ["P. acnes", "ORGANISM", 43, 51], ["clone", "CELL", 99, 104], ["P. acnes", "ORGANISM", 165, 173], ["clindamycin", "SIMPLE_CHEMICAL", 174, 185], ["erythromycin", "SIMPLE_CHEMICAL", 190, 202], ["23S", "GENE_OR_GENE_PRODUCT", 272, 275], ["rRNA", "CELLULAR_COMPONENT", 276, 280], ["patients", "ORGANISM", 327, 335], ["23S rRNA", "DNA", 272, 280], ["P. acnes", "SPECIES", 43, 51], ["P. acnes", "SPECIES", 165, 173], ["patients", "SPECIES", 327, 335], ["P. acnes", "SPECIES", 43, 51], ["P. acnes", "SPECIES", 165, 173], ["Most clindamycin", "TREATMENT", 0, 16], ["erythromycin resistant P. acnes isolates", "TREATMENT", 20, 60], ["a single clone", "PROBLEM", 90, 104], ["P. acnes clindamycin", "TREATMENT", 165, 185], ["erythromycin resistant strains", "TREATMENT", 190, 220], ["the described mutations", "PROBLEM", 237, 260], ["the 23S rRNA", "PROBLEM", 268, 280], ["strains", "PROBLEM", 348, 355], ["other infections", "PROBLEM", 361, 377], ["spread", "OBSERVATION_MODIFIER", 114, 120], ["different", "OBSERVATION_MODIFIER", 124, 133], ["geographically", "OBSERVATION_MODIFIER", 134, 148], ["infections", "OBSERVATION", 367, 377]]], ["Forty-four per cent of tetracycline resistant strains were found to carry a mutation in the 16S rRNA.", [["tetracycline", "CHEMICAL", 23, 35], ["tetracycline", "CHEMICAL", 23, 35], ["tetracycline", "SIMPLE_CHEMICAL", 23, 35], ["16S", "GENE_OR_GENE_PRODUCT", 92, 95], ["rRNA", "CELLULAR_COMPONENT", 96, 100], ["16S rRNA", "DNA", 92, 100], ["tetracycline resistant strains", "PROBLEM", 23, 53], ["a mutation in the 16S rRNA", "PROBLEM", 74, 100]]], ["These strains were isolated from Swedish acne patients, were highly resistant and were clustered in one pulsotype.", [["acne", "DISEASE", 41, 45], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["These strains", "PROBLEM", 0, 13]]], ["Conclusion: Surveillance of both the prevalence of resistant P. acnes strains and associated resistance mechanisms is important due to the rapid variation in resistance patterns, both in acne patients and other severe infections.P1712Antimicrobial activity of Unisepta quick and Deconex solarsept on the surface contamination and dental instrument in dental clinics in Iran F. Shahcheraghi (Tehran, IR)P1712Objectives: Quaternary ammonium compounds (QACs) are amphoteric surfactants that are widely used for the control of bacterial growth in clinical and industrial invironment.Unisepta quick and deconex solarsept are new generation of QACs is widely used as adjuncts in Iran to hygine in dental clinics.The aim of present study was to investigate clinical efficiency of these substances on the surface and instruments in dental clinics.", [["surface", "ANATOMY", 304, 311], ["surface", "ANATOMY", 797, 804], ["P. acnes", "DISEASE", 61, 69], ["acne", "DISEASE", 187, 191], ["infections", "DISEASE", 218, 228], ["Deconex solarsept", "CHEMICAL", 279, 296], ["Quaternary ammonium", "CHEMICAL", 419, 438], ["QACs", "CHEMICAL", 450, 454], ["Quaternary ammonium", "CHEMICAL", 419, 438], ["P. acnes", "ORGANISM", 61, 69], ["patients", "ORGANISM", 192, 200], ["Quaternary ammonium compounds", "SIMPLE_CHEMICAL", 419, 448], ["QACs", "SIMPLE_CHEMICAL", 450, 454], ["amphoteric surfactants", "SIMPLE_CHEMICAL", 460, 482], ["QACs", "SIMPLE_CHEMICAL", 638, 642], ["surface", "CELLULAR_COMPONENT", 797, 804], ["P. acnes", "SPECIES", 61, 69], ["patients", "SPECIES", 192, 200], ["P. acnes", "SPECIES", 61, 69], ["resistant P. acnes strains", "PROBLEM", 51, 77], ["associated resistance mechanisms", "PROBLEM", 82, 114], ["the rapid variation in resistance patterns", "PROBLEM", 135, 177], ["other severe infections", "PROBLEM", 205, 228], ["Unisepta quick", "PROBLEM", 260, 274], ["Deconex solarsept", "PROBLEM", 279, 296], ["the surface contamination", "PROBLEM", 300, 325], ["dental instrument", "TREATMENT", 330, 347], ["Quaternary ammonium compounds (QACs)", "TREATMENT", 419, 455], ["amphoteric surfactants", "TREATMENT", 460, 482], ["bacterial growth", "PROBLEM", 523, 539], ["Unisepta", "TREATMENT", 579, 587], ["deconex solarsept", "TREATMENT", 598, 615], ["new generation of QACs", "TREATMENT", 620, 642], ["present study", "TEST", 717, 730], ["acnes", "OBSERVATION", 64, 69], ["rapid", "OBSERVATION_MODIFIER", 139, 144], ["variation", "OBSERVATION", 145, 154], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["infections", "OBSERVATION", 218, 228], ["substances", "OBSERVATION", 779, 789]]], ["Material and methods: The following bacteria and fungi on the base of AOAC standard were used.Pseudomonas aeruginosa (ATCC 27853), Staphylococcus aureus (ATCC 25923) Bacillus. subtilis ATCC (6051), Mycobacterium bovis ATCC (35443) and wild types of Trichophyton mentagraphit, P. aeruginosa and Salmonella typhimorium (a common fungi in IRAN).", [["ATCC 27853", "CHEMICAL", 118, 128], ["Staphylococcus aureus", "DISEASE", 131, 152], ["Pseudomonas aeruginosa", "ORGANISM", 94, 116], ["ATCC 27853", "ORGANISM", 118, 128], ["Staphylococcus aureus", "ORGANISM", 131, 152], ["ATCC 25923", "ORGANISM", 154, 164], ["subtilis ATCC (6051)", "ORGANISM", 176, 196], ["Mycobacterium bovis ATCC (35443", "ORGANISM", 198, 229], ["Trichophyton mentagraphit", "ORGANISM", 249, 274], ["P. aeruginosa", "ORGANISM", 276, 289], ["Salmonella typhimorium", "ORGANISM", 294, 316], ["IRAN", "CANCER", 336, 340], ["Pseudomonas aeruginosa", "SPECIES", 94, 116], ["Staphylococcus aureus", "SPECIES", 131, 152], ["subtilis ATCC", "SPECIES", 176, 189], ["Mycobacterium bovis", "SPECIES", 198, 217], ["Trichophyton mentagraphit", "SPECIES", 249, 274], ["P. aeruginosa", "SPECIES", 276, 289], ["Salmonella typhimorium", "SPECIES", 294, 316], ["Pseudomonas aeruginosa", "SPECIES", 94, 116], ["ATCC 27853)", "SPECIES", 118, 129], ["Staphylococcus aureus (ATCC 25923)", "SPECIES", 131, 165], ["subtilis", "SPECIES", 176, 184], ["Mycobacterium bovis ATCC (35443)", "SPECIES", 198, 230], ["Trichophyton mentagraphit", "SPECIES", 249, 274], ["P. aeruginosa", "SPECIES", 276, 289], ["Salmonella typhimorium", "SPECIES", 294, 316], ["The following bacteria", "TEST", 22, 44], ["fungi", "TEST", 49, 54], ["Pseudomonas aeruginosa", "PROBLEM", 94, 116], ["ATCC", "TEST", 118, 122], ["Staphylococcus aureus", "PROBLEM", 131, 152], ["Bacillus", "PROBLEM", 166, 174], ["subtilis ATCC", "TEST", 176, 189], ["Mycobacterium bovis ATCC", "TEST", 198, 222], ["Trichophyton mentagraphit", "TEST", 249, 274], ["P. aeruginosa", "PROBLEM", 276, 289], ["Salmonella typhimorium", "PROBLEM", 294, 316], ["Staphylococcus aureus", "OBSERVATION", 131, 152], ["Trichophyton mentagraphit", "OBSERVATION", 249, 274]]], ["A stock solution of deconex solarsept (BORER chemie) and unisepta quick (micro 10 unident) was prepared as recommended by the manufacturer.", [["deconex solarsept", "CHEMICAL", 20, 37], ["A stock solution", "TREATMENT", 0, 16], ["deconex solarsept (BORER chemie", "TREATMENT", 20, 51], ["unisepta quick (micro", "TREATMENT", 57, 78]]], ["The concentration of Bacterial suspention was 0.5 MacFarland and the results were reported on the base of decreasing in (CFU) colony forming unit from 107 to 102.", [["Bacterial suspention", "TREATMENT", 21, 41], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["Bacterial suspention", "OBSERVATION", 21, 41], ["decreasing", "OBSERVATION_MODIFIER", 106, 116]]], ["Results: The results shows that Both of these disinfectants have bactericidal and fungicidal activity on the standard P. aeruginosa, S. aureus, S. typhimurium and Trichophyton mentagraphit, The number of bacteria decreased significantly (P < 0.05), but no significant difference was seen with B. subtilis, wild type of P. aeruginosa and M. bovis.", [["P. aeruginosa", "ORGANISM", 118, 131], ["S. aureus", "ORGANISM", 133, 142], ["S. typhimurium", "ORGANISM", 144, 158], ["Trichophyton mentagraphit", "ORGANISM", 163, 188], ["B. subtilis", "ORGANISM", 293, 304], ["P. aeruginosa", "ORGANISM", 319, 332], ["M. bovis", "ORGANISM", 337, 345], ["P. aeruginosa", "SPECIES", 118, 131], ["S. aureus", "SPECIES", 133, 142], ["S. typhimurium", "SPECIES", 144, 158], ["Trichophyton mentagraphit", "SPECIES", 163, 188], ["B. subtilis", "SPECIES", 293, 304], ["P. aeruginosa", "SPECIES", 319, 332], ["M. bovis", "SPECIES", 337, 345], ["P. aeruginosa", "SPECIES", 118, 131], ["S. aureus", "SPECIES", 133, 142], ["S. typhimurium", "SPECIES", 144, 158], ["Trichophyton mentagraphit", "SPECIES", 163, 188], ["B. subtilis", "SPECIES", 293, 304], ["P. aeruginosa", "SPECIES", 319, 332], ["M. bovis", "SPECIES", 337, 345], ["bactericidal", "PROBLEM", 65, 77], ["fungicidal activity", "PROBLEM", 82, 101], ["the standard P. aeruginosa", "TEST", 105, 131], ["S. aureus", "PROBLEM", 133, 142], ["S. typhimurium", "PROBLEM", 144, 158], ["Trichophyton mentagraphit", "PROBLEM", 163, 188], ["bacteria", "PROBLEM", 204, 212], ["significant difference", "PROBLEM", 256, 278], ["B. subtilis", "PROBLEM", 293, 304], ["P. aeruginosa", "PROBLEM", 319, 332], ["bactericidal", "OBSERVATION_MODIFIER", 65, 77], ["fungicidal activity", "OBSERVATION", 82, 101], ["aureus", "OBSERVATION", 136, 142], ["Trichophyton mentagraphit", "OBSERVATION", 163, 188], ["bacteria", "OBSERVATION_MODIFIER", 204, 212], ["decreased", "OBSERVATION_MODIFIER", 213, 222], ["no", "UNCERTAINTY", 253, 255], ["significant", "OBSERVATION_MODIFIER", 256, 267], ["difference", "OBSERVATION", 268, 278]]], ["Conclusion: The results confirm that these QACs are not able to sterilize or disinfect medical and dental instruments, and they can not be used lonely, and it must be used with the other methods for sterilization of surface and dental instruments.P1713Macrolide as long-term treatment in patients with bronchiectasis colonised by P. aeruginosa Background: A certain efficacy of macrolide against P. aeruginosa has been described in vitro, mainly through mechanisms such disruption of quorum sensing and suppression of inflammation.", [["surface", "ANATOMY", 216, 223], ["P1713", "CHEMICAL", 247, 252], ["Macrolide", "CHEMICAL", 252, 261], ["bronchiectasis", "DISEASE", 302, 316], ["macrolide", "CHEMICAL", 378, 387], ["P. aeruginosa", "DISEASE", 396, 409], ["inflammation", "DISEASE", 518, 530], ["Macrolide", "CHEMICAL", 252, 261], ["macrolide", "CHEMICAL", 378, 387], ["QACs", "SIMPLE_CHEMICAL", 43, 47], ["surface", "CELLULAR_COMPONENT", 216, 223], ["P1713", "SIMPLE_CHEMICAL", 247, 252], ["Macrolide", "SIMPLE_CHEMICAL", 252, 261], ["patients", "ORGANISM", 288, 296], ["P. aeruginosa", "ORGANISM", 330, 343], ["macrolide", "SIMPLE_CHEMICAL", 378, 387], ["P. aeruginosa", "ORGANISM", 396, 409], ["patients", "SPECIES", 288, 296], ["P. aeruginosa", "SPECIES", 330, 343], ["P. aeruginosa", "SPECIES", 396, 409], ["P. aeruginosa", "SPECIES", 330, 343], ["P. aeruginosa", "SPECIES", 396, 409], ["sterilization of surface and dental instruments", "TREATMENT", 199, 246], ["Macrolide", "TREATMENT", 252, 261], ["long-term treatment", "TREATMENT", 265, 284], ["bronchiectasis colonised", "PROBLEM", 302, 326], ["macrolide", "TREATMENT", 378, 387], ["P. aeruginosa", "PROBLEM", 396, 409], ["inflammation", "PROBLEM", 518, 530], ["long-term", "OBSERVATION_MODIFIER", 265, 274], ["bronchiectasis", "OBSERVATION", 302, 316], ["inflammation", "OBSERVATION", 518, 530]]], ["Aim: To evaluate the efficacy of macrolide in patients with bronchiectasis colonised by P. aeruginosa.", [["macrolide", "CHEMICAL", 33, 42], ["bronchiectasis", "DISEASE", 60, 74], ["macrolide", "CHEMICAL", 33, 42], ["macrolide", "SIMPLE_CHEMICAL", 33, 42], ["patients", "ORGANISM", 46, 54], ["P. aeruginosa", "ORGANISM", 88, 101], ["patients", "SPECIES", 46, 54], ["P. aeruginosa", "SPECIES", 88, 101], ["P. aeruginosa", "SPECIES", 88, 101], ["macrolide", "TREATMENT", 33, 42], ["bronchiectasis", "PROBLEM", 60, 74], ["P. aeruginosa", "PROBLEM", 88, 101], ["bronchiectasis", "OBSERVATION", 60, 74]]], ["Methods: The study prospectively included patients with bronchiectasis and P. aeruginosa isolated in sputum in stable state.P1713All subjects received either azithromycin 250 mg \u00b7 3 days/week or clarithromycin 500 mg daily on long term and completed daily diary cards for symptoms and PEF values until the end of therapy.", [["sputum", "ANATOMY", 101, 107], ["bronchiectasis", "DISEASE", 56, 70], ["azithromycin", "CHEMICAL", 158, 170], ["clarithromycin", "CHEMICAL", 195, 209], ["azithromycin", "CHEMICAL", 158, 170], ["clarithromycin", "CHEMICAL", 195, 209], ["patients", "ORGANISM", 42, 50], ["P. aeruginosa", "ORGANISM", 75, 88], ["sputum", "ORGANISM_SUBSTANCE", 101, 107], ["azithromycin", "SIMPLE_CHEMICAL", 158, 170], ["clarithromycin", "SIMPLE_CHEMICAL", 195, 209], ["patients", "SPECIES", 42, 50], ["P. aeruginosa", "SPECIES", 75, 88], ["P. aeruginosa", "SPECIES", 75, 88], ["The study prospectively", "TEST", 9, 32], ["bronchiectasis", "PROBLEM", 56, 70], ["P. aeruginosa", "PROBLEM", 75, 88], ["sputum", "PROBLEM", 101, 107], ["azithromycin", "TREATMENT", 158, 170], ["clarithromycin", "TREATMENT", 195, 209], ["symptoms", "PROBLEM", 272, 280], ["PEF values", "TEST", 285, 295], ["therapy", "TREATMENT", 313, 320], ["bronchiectasis", "OBSERVATION", 56, 70], ["stable", "OBSERVATION_MODIFIER", 111, 117]]], ["Results: 26 patients with bronchiectasis and P. aeruginosa evidence in sputum were included (17 men, mean age 55.0 \u00b1 12.1 yrs.).", [["sputum", "ANATOMY", 71, 77], ["bronchiectasis", "DISEASE", 26, 40], ["patients", "ORGANISM", 12, 20], ["P. aeruginosa", "ORGANISM", 45, 58], ["sputum", "ORGANISM_SUBSTANCE", 71, 77], ["men", "ORGANISM", 96, 99], ["patients", "SPECIES", 12, 20], ["P. aeruginosa", "SPECIES", 45, 58], ["men", "SPECIES", 96, 99], ["P. aeruginosa", "SPECIES", 45, 58], ["bronchiectasis", "PROBLEM", 26, 40], ["P. aeruginosa", "PROBLEM", 45, 58], ["sputum", "PROBLEM", 71, 77], ["bronchiectasis", "OBSERVATION", 26, 40], ["aeruginosa", "OBSERVATION", 48, 58]]], ["12 patients received azithromycin and 14 patients clarithromycin, with a mean duration of 4.5 \u00b1 1.7 months.", [["azithromycin", "CHEMICAL", 21, 33], ["clarithromycin", "CHEMICAL", 50, 64], ["azithromycin", "CHEMICAL", 21, 33], ["clarithromycin", "CHEMICAL", 50, 64], ["patients", "ORGANISM", 3, 11], ["azithromycin", "SIMPLE_CHEMICAL", 21, 33], ["patients", "ORGANISM", 41, 49], ["clarithromycin", "SIMPLE_CHEMICAL", 50, 64], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 41, 49], ["azithromycin", "TREATMENT", 21, 33], ["14 patients clarithromycin", "TREATMENT", 38, 64]]], ["Five (19.2%) patients discontinued treatment after less than 2 weeks because of adverse events.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["treatment", "TREATMENT", 35, 44], ["adverse events", "PROBLEM", 80, 94]]], ["At the end of therapy, 12 (46.1%) patients showed no evidence of P. aeruginosa in sputum while 9 (34.6%) patients still had Ps. aeruginosa in sputum.", [["sputum", "ANATOMY", 82, 88], ["sputum", "ANATOMY", 142, 148], ["P. aeruginosa in sputum", "DISEASE", 65, 88], ["patients", "ORGANISM", 34, 42], ["P. aeruginosa", "ORGANISM", 65, 78], ["sputum", "ORGANISM_SUBSTANCE", 82, 88], ["patients", "ORGANISM", 105, 113], ["Ps. aeruginosa", "ORGANISM", 124, 138], ["sputum", "ORGANISM_SUBSTANCE", 142, 148], ["patients", "SPECIES", 34, 42], ["P. aeruginosa", "SPECIES", 65, 78], ["patients", "SPECIES", 105, 113], ["Ps. aeruginosa", "SPECIES", 124, 138], ["P. aeruginosa", "SPECIES", 65, 78], ["Ps. aeruginosa", "SPECIES", 124, 138], ["therapy", "TREATMENT", 14, 21], ["P. aeruginosa in sputum", "PROBLEM", 65, 88], ["Ps. aeruginosa in sputum", "PROBLEM", 124, 148], ["no evidence of", "UNCERTAINTY", 50, 64], ["aeruginosa", "OBSERVATION", 68, 78]]], ["An improvement in the following parameters could be observed in all patients: sputum volume (75.5 ml/day before therapy versus 31.6 ml/day after therapy, p = 0.04); PEF (311.2\u00b177.1 l/min before therapy versus 476.2 \u00b1 30.2 l/min after therapy, p = 0.03); number of exacerbations/year (2.8 in the previous year versus 1.7 in the follow-up year, p = 0.01).", [["sputum", "ANATOMY", 78, 84], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["sputum volume", "TEST", 78, 91], ["therapy", "TREATMENT", 112, 119], ["therapy", "TREATMENT", 145, 152], ["PEF", "TEST", 165, 168], ["therapy", "TREATMENT", 194, 201], ["therapy", "TREATMENT", 234, 241], ["p", "TEST", 243, 244], ["exacerbations", "PROBLEM", 264, 277], ["improvement", "OBSERVATION_MODIFIER", 3, 14]]], ["Conclusion: The study shows that macrolide may be an effective therapy in patients with bronchiectasis colonised by P. aeruginosa.", [["macrolide", "CHEMICAL", 33, 42], ["bronchiectasis", "DISEASE", 88, 102], ["macrolide", "CHEMICAL", 33, 42], ["macrolide", "SIMPLE_CHEMICAL", 33, 42], ["patients", "ORGANISM", 74, 82], ["P. aeruginosa", "ORGANISM", 116, 129], ["patients", "SPECIES", 74, 82], ["P. aeruginosa", "SPECIES", 116, 129], ["P. aeruginosa", "SPECIES", 116, 129], ["The study", "TEST", 12, 21], ["macrolide", "TREATMENT", 33, 42], ["an effective therapy", "TREATMENT", 50, 70], ["bronchiectasis", "PROBLEM", 88, 102], ["P. aeruginosa", "PROBLEM", 116, 129], ["effective", "OBSERVATION_MODIFIER", 53, 62], ["therapy", "OBSERVATION", 63, 70], ["bronchiectasis", "OBSERVATION", 88, 102]]], ["Independently of the microbial eradication, an improvement of the clinical symptoms and a reduction of exacerbations were observed in all patients.P1714Fungal pathogens from haematoncology patients and their susceptibility to new and old antifungal drugsM.A. Petrou (London, UK)The expanding population of immunocompromised hosts has been infected with many established and emerging opportunistic fungi.", [["exacerbations", "DISEASE", 103, 116], ["haematoncology", "DISEASE", 174, 188], ["opportunistic fungi", "DISEASE", 383, 402], ["patients", "ORGANISM", 138, 146], ["P1714Fungal", "GENE_OR_GENE_PRODUCT", 147, 158], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 189, 197], ["the microbial eradication", "TREATMENT", 17, 42], ["the clinical symptoms", "PROBLEM", 62, 83], ["exacerbations", "PROBLEM", 103, 116], ["old antifungal drugs", "TREATMENT", 234, 254], ["immunocompromised hosts", "PROBLEM", 306, 329], ["improvement", "OBSERVATION_MODIFIER", 47, 58], ["exacerbations", "OBSERVATION", 103, 116], ["immunocompromised hosts", "OBSERVATION", 306, 329], ["opportunistic fungi", "OBSERVATION", 383, 402]]], ["Most pathogens can be treated empirically whereas for an increasing number of species proper treatment starts once the MIC becomes available.", [["species proper treatment", "TREATMENT", 78, 102], ["increasing", "OBSERVATION_MODIFIER", 57, 67]]], ["Though invasive Aspergillosis remains the principle life threatening complication in the haematoncology patients (HOP) other pathogens cannot be ignored as selection and resistance during prophylaxis increases the risk of treatment failure.In order to understand the frequency of rare fungal pathogens, selection and emergence of resistance in our trust all fungi from HOP were identified using standard mycological techniques and the MICs to amphotericin B (AMB), flucytosine (5FC), fluconazole (FCZ), itraconazole (ITZ), voriconazole (VCZ) and caspofungin (CFG) were determined using the NCCLS method.", [["Aspergillosis", "DISEASE", 16, 29], ["haematoncology", "DISEASE", 89, 103], ["amphotericin B", "CHEMICAL", 443, 457], ["AMB", "CHEMICAL", 459, 462], ["flucytosine", "CHEMICAL", 465, 476], ["5FC", "CHEMICAL", 478, 481], ["fluconazole", "CHEMICAL", 484, 495], ["FCZ", "CHEMICAL", 497, 500], ["itraconazole", "CHEMICAL", 503, 515], ["ITZ", "CHEMICAL", 517, 520], ["voriconazole", "CHEMICAL", 523, 535], ["VCZ", "CHEMICAL", 537, 540], ["caspofungin", "CHEMICAL", 546, 557], ["CFG", "CHEMICAL", 559, 562], ["amphotericin B", "CHEMICAL", 443, 457], ["AMB", "CHEMICAL", 459, 462], ["flucytosine", "CHEMICAL", 465, 476], ["5FC", "CHEMICAL", 478, 481], ["fluconazole", "CHEMICAL", 484, 495], ["FCZ", "CHEMICAL", 497, 500], ["itraconazole", "CHEMICAL", 503, 515], ["ITZ", "CHEMICAL", 517, 520], ["voriconazole", "CHEMICAL", 523, 535], ["VCZ", "CHEMICAL", 537, 540], ["caspofungin", "CHEMICAL", 546, 557], ["CFG", "CHEMICAL", 559, 562], ["Aspergillosis", "CANCER", 16, 29], ["patients", "ORGANISM", 104, 112], ["HOP", "GENE_OR_GENE_PRODUCT", 114, 117], ["HOP", "GENE_OR_GENE_PRODUCT", 369, 372], ["amphotericin B", "SIMPLE_CHEMICAL", 443, 457], ["AMB", "SIMPLE_CHEMICAL", 459, 462], ["flucytosine", "SIMPLE_CHEMICAL", 465, 476], ["5FC", "SIMPLE_CHEMICAL", 478, 481], ["fluconazole", "SIMPLE_CHEMICAL", 484, 495], ["FCZ", "SIMPLE_CHEMICAL", 497, 500], ["itraconazole", "SIMPLE_CHEMICAL", 503, 515], ["ITZ", "SIMPLE_CHEMICAL", 517, 520], ["voriconazole", "SIMPLE_CHEMICAL", 523, 535], ["VCZ", "SIMPLE_CHEMICAL", 537, 540], ["caspofungin", "SIMPLE_CHEMICAL", 546, 557], ["CFG", "SIMPLE_CHEMICAL", 559, 562], ["HOP", "PROTEIN", 369, 372], ["patients", "SPECIES", 104, 112], ["invasive Aspergillosis", "PROBLEM", 7, 29], ["other pathogens", "PROBLEM", 119, 134], ["prophylaxis", "TREATMENT", 188, 199], ["treatment failure", "PROBLEM", 222, 239], ["rare fungal pathogens", "PROBLEM", 280, 301], ["standard mycological techniques", "TREATMENT", 395, 426], ["the MICs", "TREATMENT", 431, 439], ["amphotericin B (AMB)", "TREATMENT", 443, 463], ["flucytosine (5FC)", "TREATMENT", 465, 482], ["fluconazole (FCZ)", "TREATMENT", 484, 501], ["itraconazole (ITZ)", "TREATMENT", 503, 521], ["voriconazole (VCZ)", "TREATMENT", 523, 541], ["caspofungin (CFG)", "TREATMENT", 546, 563], ["the NCCLS method", "TREATMENT", 586, 602], ["invasive", "OBSERVATION_MODIFIER", 7, 15], ["Aspergillosis", "OBSERVATION", 16, 29], ["treatment failure", "OBSERVATION", 222, 239]]], ["513 specimens were processed, 53% respiratory, 17.5% blood, 12.8% oral, 8.4% other sterile (bile, CSF, drains, lines and tissue biopsies) and 8.3% nonsterile sites.", [["specimens", "ANATOMY", 4, 13], ["respiratory", "ANATOMY", 34, 45], ["blood", "ANATOMY", 53, 58], ["oral", "ANATOMY", 66, 70], ["bile", "ANATOMY", 92, 96], ["lines", "ANATOMY", 111, 116], ["tissue biopsies", "ANATOMY", 121, 136], ["sites", "ANATOMY", 158, 163], ["specimens", "CANCER", 4, 13], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["bile", "MULTI-TISSUE_STRUCTURE", 92, 96], ["tissue biopsies", "TISSUE", 121, 136], ["specimens", "TEST", 4, 13], ["respiratory", "TEST", 34, 45], ["blood", "TEST", 53, 58], ["oral", "TEST", 66, 70], ["CSF", "TEST", 98, 101], ["drains", "TREATMENT", 103, 109], ["tissue biopsies", "TEST", 121, 136], ["8.3% nonsterile sites", "TREATMENT", 142, 163], ["bile", "ANATOMY", 92, 96], ["drains", "OBSERVATION", 103, 109]]], ["Yeasts accounted for 85% and filamentous fungi (FF) for 15%, representing 12 Candida sp, 7 other types of yeast, 6 Aspergillus sp and 8 other types of FF.", [["Yeasts", "ANATOMY", 0, 6], ["yeast", "SPECIES", 106, 111], ["yeast", "SPECIES", 106, 111], ["Yeasts", "TEST", 0, 6], ["filamentous fungi", "TEST", 29, 46], ["Candida sp", "TEST", 77, 87], ["yeast", "TEST", 106, 111], ["6 Aspergillus sp", "PROBLEM", 113, 129]]], ["C. albicans represented 35.7%, C. glabrata 29.3%, C. krusei 8.6%, A. fumigatus 10% and other Aspergillus sp 2% of all isolates.", [["C. albicans", "ORGANISM", 0, 11], ["C. glabrata", "ORGANISM", 31, 42], ["C. krusei", "ORGANISM", 50, 59], ["A. fumigatus", "ORGANISM", 66, 78], ["C. albicans", "SPECIES", 0, 11], ["C. glabrata", "SPECIES", 31, 42], ["C. krusei", "SPECIES", 50, 59], ["A. fumigatus", "SPECIES", 66, 78], ["C. albicans", "SPECIES", 0, 11], ["C. glabrata", "SPECIES", 31, 42], ["C. krusei", "SPECIES", 50, 59], ["A. fumigatus", "SPECIES", 66, 78], ["C. albicans", "TEST", 0, 11], ["C. glabrata", "TEST", 31, 42], ["C. krusei", "TEST", 50, 59], ["A. fumigatus", "TEST", 66, 78], ["other Aspergillus sp", "TREATMENT", 87, 107]]], ["The MIC 90s for all isolates were AMB 0.5, 5FC 2, FCZ >64, ITZ 1, VCZ 1 and CFG 0.06 mg/ L. With the exception of Acremonium sp, A. versicolor, A. terreus and Scedosporium apiospermum all isolates including the 15 isolates of C. lusitaniae were sensitive to AMB.", [["AMB 0.5, 5FC 2, FCZ >64, ITZ 1, VCZ 1 and CFG", "CHEMICAL", 34, 79], ["Scedosporium apiospermum", "DISEASE", 159, 183], ["AMB", "CHEMICAL", 258, 261], ["AMB", "CHEMICAL", 34, 37], ["AMB", "CHEMICAL", 258, 261], ["AMB", "SIMPLE_CHEMICAL", 34, 37], ["CFG", "SIMPLE_CHEMICAL", 76, 79], ["Acremonium sp", "ORGANISM", 114, 127], ["A. versicolor", "ORGANISM", 129, 142], ["A. terreus", "ORGANISM", 144, 154], ["Scedosporium apiospermum", "ORGANISM", 159, 183], ["C. lusitaniae", "ORGANISM", 226, 239], ["AMB", "SIMPLE_CHEMICAL", 258, 261], ["A. versicolor", "SPECIES", 129, 142], ["A. terreus", "SPECIES", 144, 154], ["Scedosporium apiospermum", "SPECIES", 159, 183], ["C. lusitaniae", "SPECIES", 226, 239], ["A. versicolor", "SPECIES", 129, 142], ["A. terreus", "SPECIES", 144, 154], ["Scedosporium apiospermum", "SPECIES", 159, 183], ["C. lusitaniae", "SPECIES", 226, 239], ["The MIC", "TEST", 0, 7], ["all isolates", "TEST", 16, 28], ["AMB", "TEST", 34, 37], ["5FC", "TEST", 43, 46], ["FCZ", "TEST", 50, 53], ["ITZ", "TEST", 59, 62], ["VCZ", "TEST", 66, 69], ["CFG", "TEST", 76, 79], ["Acremonium sp", "PROBLEM", 114, 127], ["A. terreus", "TREATMENT", 144, 154], ["Scedosporium apiospermum", "PROBLEM", 159, 183], ["C. lusitaniae", "PROBLEM", 226, 239]]], ["Most but not all FF and only one isolate of C. albicans from the yeasts were resistant to 5FC.", [["5FC", "CHEMICAL", 90, 93], ["C. albicans", "ORGANISM", 44, 55], ["C. albicans", "SPECIES", 44, 55], ["C. albicans", "SPECIES", 44, 55], ["C. albicans", "PROBLEM", 44, 55], ["the yeasts", "PROBLEM", 61, 71], ["5FC", "TREATMENT", 90, 93]]], ["All FF, Rhodotorula sp, C. albicans 3%, C. glabrata 53% and C. krusei 41% were resistant to FCZ.", [["FCZ", "CHEMICAL", 92, 95], ["FCZ", "CHEMICAL", 92, 95], ["Rhodotorula sp", "ORGANISM", 8, 22], ["C. albicans 3", "ORGANISM", 24, 37], ["C. glabrata", "ORGANISM", 40, 51], ["C. krusei", "ORGANISM", 60, 69], ["FCZ", "SIMPLE_CHEMICAL", 92, 95], ["C. albicans", "SPECIES", 24, 35], ["C. glabrata", "SPECIES", 40, 51], ["C. krusei", "SPECIES", 60, 69], ["C. albicans", "SPECIES", 24, 35], ["C. glabrata", "SPECIES", 40, 51], ["C. krusei", "SPECIES", 60, 69], ["All FF", "TEST", 0, 6], ["Rhodotorula sp", "TEST", 8, 22], ["C. albicans", "TEST", 24, 35], ["C. glabrata", "TEST", 40, 51], ["C. krusei", "TEST", 60, 69], ["Rhodotorula sp", "OBSERVATION", 8, 22]]], ["Only Absidia corymbifera, Acremonium sp 25%, C. albicans 1%, C glabrata 33% and Saccharomyces cerevisiae 4% were resistant to ITZ.", [["ITZ", "CHEMICAL", 126, 129], ["ITZ", "CHEMICAL", 126, 129], ["Absidia corymbifera", "ORGANISM", 5, 24], ["Acremonium sp 25", "ORGANISM", 26, 42], ["C. albicans 1", "ORGANISM", 45, 58], ["C glabrata", "ORGANISM", 61, 71], ["Saccharomyces cerevisiae", "ORGANISM", 80, 104], ["ITZ", "SIMPLE_CHEMICAL", 126, 129], ["Absidia corymbifera", "SPECIES", 5, 24], ["C. albicans", "SPECIES", 45, 56], ["C glabrata", "SPECIES", 61, 71], ["Saccharomyces cerevisiae", "SPECIES", 80, 104], ["Absidia corymbifera", "SPECIES", 5, 24], ["Acremonium sp 25", "SPECIES", 26, 42], ["C. albicans", "SPECIES", 45, 56], ["C glabrata", "SPECIES", 61, 71], ["Saccharomyces cerevisiae", "SPECIES", 80, 104], ["Absidia corymbifera", "TEST", 5, 24], ["Acremonium sp", "TEST", 26, 39], ["C. albicans", "TEST", 45, 56], ["C glabrata", "TREATMENT", 61, 71], ["Saccharomyces cerevisiae", "TREATMENT", 80, 104]]], ["For VCZ A. corymbifera, Acremonium sp 25%, C. albicans 2%, C. glabrata 31%, C. krusei 2%, C. tropicalis 10%, Rhodotorula sp 66.6% and P. aecilomyces variotii 50% had an MIC \u20212 mg/L. With CFG the effective concentration was \u20210.5 mg/L for A. corymbifera, Fusarium solani, Geotrichum capitatum, Sporobolomyces salmonicolor, Acremonium sp 50% and C. parapsilosis 25%.The data show that HOP are exposed to many different fungal pathogens some of which are resistant to the old and the new antifungals and that AMB is still the drug with the broader spectrum and less developed resistance for both yeasts and FF.P1715Faropenem medoxomil in the treatment of acute bacterial sinusitis: an integrated analysis S. Kowalsky, R. Tosiello, R. Echols (Milford, US)P1715Background: Faropenem medoxomil (FM) is an orally absorbed, synthetic, penem antibacterial agent with in vitro activity against community-acquired respiratory pathogens.", [["respiratory", "ANATOMY", 902, 913], ["CFG", "CHEMICAL", 187, 190], ["AMB", "CHEMICAL", 505, 508], ["P1715", "CHEMICAL", 606, 611], ["Faropenem medoxomil", "CHEMICAL", 611, 630], ["bacterial sinusitis", "DISEASE", 657, 676], ["Faropenem medoxomil", "CHEMICAL", 767, 786], ["FM", "CHEMICAL", 788, 790], ["respiratory pathogens", "DISEASE", 902, 923], ["AMB", "CHEMICAL", 505, 508], ["Faropenem medoxomil", "CHEMICAL", 611, 630], ["Faropenem medoxomil", "CHEMICAL", 767, 786], ["VCZ", "ORGANISM", 4, 7], ["A. corymbifera", "ORGANISM", 8, 22], ["Acremonium sp 25", "ORGANISM", 24, 40], ["C. albicans", "ORGANISM", 43, 54], ["C. glabrata", "ORGANISM", 59, 70], ["C. krusei", "ORGANISM", 76, 85], ["C. tropicalis", "ORGANISM", 90, 103], ["Rhodotorula sp", "ORGANISM", 109, 123], ["P. aecilomyces variotii", "ORGANISM", 134, 157], ["CFG", "SIMPLE_CHEMICAL", 187, 190], ["A. corymbifera", "ORGANISM", 237, 251], ["Fusarium solani", "ORGANISM", 253, 268], ["Geotrichum capitatum", "ORGANISM", 270, 290], ["Sporobolomyces salmonicolor", "ORGANISM", 292, 319], ["Acremonium sp", "ORGANISM", 321, 334], ["50", "ORGANISM", 335, 337], ["C. parapsilosis", "ORGANISM", 343, 358], ["HOP", "GENE_OR_GENE_PRODUCT", 382, 385], ["AMB", "SIMPLE_CHEMICAL", 505, 508], ["Faropenem medoxomil", "SIMPLE_CHEMICAL", 767, 786], ["FM", "SIMPLE_CHEMICAL", 788, 790], ["penem", "SIMPLE_CHEMICAL", 826, 831], ["HOP", "PROTEIN", 382, 385], ["A. corymbifera", "SPECIES", 8, 22], ["C. albicans", "SPECIES", 43, 54], ["C. glabrata", "SPECIES", 59, 70], ["C. krusei", "SPECIES", 76, 85], ["C. tropicalis", "SPECIES", 90, 103], ["Rhodotorula sp", "SPECIES", 109, 123], ["P. aecilomyces variotii", "SPECIES", 134, 157], ["A. corymbifera", "SPECIES", 237, 251], ["Fusarium solani", "SPECIES", 253, 268], ["Geotrichum capitatum", "SPECIES", 270, 290], ["Sporobolomyces salmonicolor", "SPECIES", 292, 319], ["C. parapsilosis", "SPECIES", 343, 358], ["A. corymbifera", "SPECIES", 8, 22], ["Acremonium sp 25", "SPECIES", 24, 40], ["C. albicans", "SPECIES", 43, 54], ["C. glabrata", "SPECIES", 59, 70], ["C. krusei", "SPECIES", 76, 85], ["C. tropicalis", "SPECIES", 90, 103], ["Rhodotorula sp 66.6", "SPECIES", 109, 128], ["P. aecilomyces variotii", "SPECIES", 134, 157], ["A. corymbifera", "SPECIES", 237, 251], ["Fusarium solani", "SPECIES", 253, 268], ["Geotrichum capitatum", "SPECIES", 270, 290], ["Sporobolomyces salmonicolor", "SPECIES", 292, 319], ["Acremonium sp 50", "SPECIES", 321, 337], ["C. parapsilosis", "SPECIES", 343, 358], ["VCZ", "TEST", 4, 7], ["Acremonium sp", "TREATMENT", 24, 37], ["C. albicans", "TEST", 43, 54], ["C. glabrata", "TEST", 59, 70], ["C. krusei", "PROBLEM", 76, 85], ["C. tropicalis", "TEST", 90, 103], ["Rhodotorula sp", "TEST", 109, 123], ["P. aecilomyces variotii", "TREATMENT", 134, 157], ["an MIC", "TREATMENT", 166, 172], ["CFG the effective concentration", "TREATMENT", 187, 218], ["Fusarium solani", "TREATMENT", 253, 268], ["Geotrichum capitatum", "TREATMENT", 270, 290], ["Sporobolomyces salmonicolor", "TREATMENT", 292, 319], ["Acremonium sp", "TREATMENT", 321, 334], ["C. parapsilosis", "TREATMENT", 343, 358], ["The data", "TEST", 363, 371], ["many different fungal pathogens", "PROBLEM", 401, 432], ["the new antifungals", "TREATMENT", 476, 495], ["AMB", "TREATMENT", 505, 508], ["both yeasts", "PROBLEM", 587, 598], ["Faropenem medoxomil", "TREATMENT", 611, 630], ["acute bacterial sinusitis", "PROBLEM", 651, 676], ["an integrated analysis", "TEST", 678, 700], ["Faropenem medoxomil (FM", "TREATMENT", 767, 790], ["synthetic, penem antibacterial agent", "TREATMENT", 815, 851], ["acquired respiratory pathogens", "PROBLEM", 893, 923], ["fungal", "OBSERVATION_MODIFIER", 416, 422], ["pathogens", "OBSERVATION", 423, 432], ["new", "OBSERVATION_MODIFIER", 480, 483], ["antifungals", "OBSERVATION", 484, 495], ["acute", "OBSERVATION_MODIFIER", 651, 656], ["bacterial sinusitis", "OBSERVATION", 657, 676], ["respiratory", "ANATOMY", 902, 913], ["pathogens", "OBSERVATION", 914, 923]]], ["Methods: The efficacy of FM in subjects with acute bacterial sinusitis (ABS) was evaluated in 3 Phase III trials; 100288, 10186, and 100287.", [["acute bacterial sinusitis", "DISEASE", 45, 70], ["ABS", "DISEASE", 72, 75], ["FM", "MULTI-TISSUE_STRUCTURE", 25, 27], ["acute bacterial sinusitis", "PROBLEM", 45, 70], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["bacterial", "OBSERVATION_MODIFIER", 51, 60], ["sinusitis", "OBSERVATION", 61, 70]]], ["100288 and 10186 were prospective, randomized, double-blind, active comparator trials and 100287 was an open-label ''sinus tap'' trial.", [["an open-label ''sinus tap", "TREATMENT", 101, 126]]], ["The dose of FM was 300 mg BID in all 3 studies.", [["FM", "CHEMICAL", 12, 14], ["BID", "CHEMICAL", 26, 29], ["FM", "MULTI-TISSUE_STRUCTURE", 12, 14], ["The dose of FM", "TREATMENT", 0, 14]]], ["The comparator in 100288 and 10186 was cefuroxime axetil (CFX) 250 mg BID.", [["cefuroxime axetil", "CHEMICAL", 39, 56], ["CFX", "CHEMICAL", 58, 61], ["cefuroxime axetil", "CHEMICAL", 39, 56], ["CFX", "CHEMICAL", 58, 61], ["BID", "CHEMICAL", 70, 73], ["cefuroxime axetil", "SIMPLE_CHEMICAL", 39, 56], ["CFX", "SIMPLE_CHEMICAL", 58, 61], ["BID", "SIMPLE_CHEMICAL", 70, 73], ["cefuroxime axetil (CFX)", "TREATMENT", 39, 62]]], ["The duration of FM treatment in 100288 was 7 days and 10 days vs CFX for 10 days.", [["CFX", "CHEMICAL", 65, 68], ["FM treatment", "TREATMENT", 16, 28], ["CFX", "TREATMENT", 65, 68]]], ["In 10186, FM or CFX were given for 7 days.", [["CFX", "CHEMICAL", 16, 19], ["CFX", "SIMPLE_CHEMICAL", 16, 19], ["CFX", "TREATMENT", 16, 19]]], ["In 100287, FM was administered for 7 days.", [["FM", "MULTI-TISSUE_STRUCTURE", 11, 13]]], ["The primary efficacy variable in all 3 studies was clinical response at the Test-of-Cure (TOC).", [["all 3 studies", "TEST", 33, 46], ["the Test", "TEST", 72, 80]]], ["Microbiologic response at the TOC was a secondary efficacy variable in 10186 (sinus puncture and endoscopic collection) and 100287 (sinus puncture and aspiration).", [["sinus", "ANATOMY", 78, 83], ["sinus", "ANATOMY", 132, 137], ["TOC", "CHEMICAL", 30, 33], ["TOC", "CHEMICAL", 30, 33], ["sinus puncture", "MULTI-TISSUE_STRUCTURE", 78, 92], ["sinus puncture", "MULTI-TISSUE_STRUCTURE", 132, 146], ["the TOC", "TEST", 26, 33], ["sinus puncture", "TEST", 78, 92], ["endoscopic collection", "TEST", 97, 118], ["sinus puncture", "TEST", 132, 146], ["aspiration", "PROBLEM", 151, 161], ["sinus", "ANATOMY", 78, 83], ["sinus", "ANATOMY", 132, 137], ["aspiration", "OBSERVATION", 151, 161]]], ["Non-inferiority was defined as the difference in cure rates (FM minus comparator) where the lower boundary of the 95% CI was greater than -10%.", [["cure rates", "TEST", 49, 59], ["CI", "TEST", 118, 120], ["lower", "ANATOMY_MODIFIER", 92, 97]]], ["Results: The cure rates at the TOC are shown in the table for the valid per protocol (vPP) and the Intent-to-Treat (ITT) populations.", [["vPP", "TEST", 86, 89]]], ["The frequency of isolation of key pathogens and the rate of eradication in samples obtained by endoscopicallyguided swab and in samples obtained by TAP were consistent across studies.", [["samples", "ANATOMY", 75, 82], ["swab", "ANATOMY", 116, 120], ["samples", "ANATOMY", 128, 135], ["samples", "CANCER", 75, 82], ["TAP", "GENE_OR_GENE_PRODUCT", 148, 151], ["TAP", "PROTEIN", 148, 151], ["key pathogens", "PROBLEM", 30, 43], ["endoscopicallyguided swab", "TEST", 95, 120], ["TAP", "TEST", 148, 151]]], ["The eradication rates for S. pneumoniae, H. influenzae, and M. catarrhalis were 94.8% vs. 96.3% (FM 7/ 10 d vs. CFX 7/10 d), 82.4% vs. 90.5% (FM vs. CFX) and 96.2% vs. 83.3% (FM vs. CFX), respectively.P1715Conclusions: FM 300 mg BID x 7 days was shown to be noninferior to CFX in clinical efficacy in two prospective, doubleblind, comparative trials.", [["CFX", "CHEMICAL", 273, 276], ["BID", "CHEMICAL", 229, 232], ["S. pneumoniae", "ORGANISM", 26, 39], ["H. influenzae", "ORGANISM", 41, 54], ["M. catarrhalis", "ORGANISM", 60, 74], ["CFX", "SIMPLE_CHEMICAL", 273, 276], ["S. pneumoniae", "SPECIES", 26, 39], ["H. influenzae", "SPECIES", 41, 54], ["M. catarrhalis", "SPECIES", 60, 74], ["S. pneumoniae", "SPECIES", 26, 39], ["H. influenzae", "SPECIES", 41, 54], ["M. catarrhalis", "SPECIES", 60, 74], ["The eradication rates", "TEST", 0, 21], ["S. pneumoniae", "PROBLEM", 26, 39], ["H. influenzae", "PROBLEM", 41, 54], ["M. catarrhalis", "TEST", 60, 74], ["FM", "TEST", 97, 99], ["CFX", "TEST", 112, 115], ["FM", "TEST", 142, 144], ["CFX", "TEST", 149, 152], ["FM", "TEST", 175, 177], ["CFX", "TEST", 182, 185], ["FM", "TREATMENT", 219, 221], ["pneumoniae", "OBSERVATION", 29, 39], ["CFX", "OBSERVATION", 273, 276]]], ["A third, open-label trial, demonstrated similar efficacy in microbiologically documented ABS caused by key pathogens.", [["ABS", "DISEASE", 89, 92], ["microbiologically documented ABS", "PROBLEM", 60, 92], ["key pathogens", "PROBLEM", 103, 116], ["pathogens", "OBSERVATION", 107, 116]]], ["Longer (10 d treatment) with FM provided no additional efficacy.P1716Faropenem medoxomil in the treatment of acute exacerbation of chronic bronchitis: an integrated analysis S. Kowalsky, R. Tosiello, R. Echols (Milford, US)P1716Background: Faropenem medoxomil (FM) is an orally absorbed, synthetic, penem antibacterial with in vitro activity against community-acquired respiratory pathogens.", [["respiratory", "ANATOMY", 369, 380], ["P1716Faropenem medoxomil", "CHEMICAL", 64, 88], ["chronic bronchitis", "DISEASE", 131, 149], ["Faropenem medoxomil", "CHEMICAL", 240, 259], ["FM", "CHEMICAL", 261, 263], ["respiratory pathogens", "DISEASE", 369, 390], ["P1716Faropenem medoxomil", "CHEMICAL", 64, 88], ["Faropenem medoxomil", "CHEMICAL", 240, 259], ["P1716Faropenem medoxomil", "SIMPLE_CHEMICAL", 64, 88], ["Faropenem medoxomil", "SIMPLE_CHEMICAL", 240, 259], ["FM", "SIMPLE_CHEMICAL", 261, 263], ["FM", "TREATMENT", 29, 31], ["medoxomil", "TREATMENT", 79, 88], ["acute exacerbation", "PROBLEM", 109, 127], ["chronic bronchitis", "PROBLEM", 131, 149], ["an integrated analysis", "TEST", 151, 173], ["Faropenem medoxomil (FM", "TREATMENT", 240, 263], ["synthetic, penem antibacterial", "TREATMENT", 288, 318], ["acquired respiratory pathogens", "PROBLEM", 360, 390], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["exacerbation", "OBSERVATION", 115, 127], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["bronchitis", "OBSERVATION", 139, 149], ["respiratory", "ANATOMY", 369, 380], ["pathogens", "OBSERVATION", 381, 390]]], ["Methods: The efficacy of FM in subjects with acute exacerbation of chronic bronchitis (AECB) was evaluated in 2 Phase III trials.", [["chronic bronchitis", "DISEASE", 67, 85], ["AECB", "DISEASE", 87, 91], ["FM", "MULTI-TISSUE_STRUCTURE", 25, 27], ["acute exacerbation", "PROBLEM", 45, 63], ["chronic bronchitis", "PROBLEM", 67, 85], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["exacerbation", "OBSERVATION", 51, 63], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["bronchitis", "OBSERVATION", 75, 85]]], ["Study 10187 was conducted in Europe, Israel, Mexico, and South Africa.", [["Study", "TEST", 0, 5]]], ["Study 100291 was conducted in the US and Argentina.", [["Study", "TEST", 0, 5]]], ["Both were prospective, randomized, double-blind, active comparator trials.", [["active comparator trials", "TREATMENT", 49, 73]]], ["The dose of FM was 300 mg BID for 5 days in both studies.", [["FM", "CHEMICAL", 12, 14], ["BID", "CHEMICAL", 26, 29], ["FM", "SIMPLE_CHEMICAL", 12, 14], ["The dose of FM", "TREATMENT", 0, 14]]], ["The comparators were clarithromycin (CLR) 500 mg BID for 7 days and azithromycin (AZI) QD for 5 days (500 mg on Day 1 and 250 mg on .", [["clarithromycin", "CHEMICAL", 21, 35], ["CLR", "CHEMICAL", 37, 40], ["azithromycin", "CHEMICAL", 68, 80], ["AZI", "CHEMICAL", 82, 85], ["QD", "CHEMICAL", 87, 89], ["clarithromycin", "CHEMICAL", 21, 35], ["CLR", "CHEMICAL", 37, 40], ["BID", "CHEMICAL", 49, 52], ["azithromycin", "CHEMICAL", 68, 80], ["clarithromycin", "SIMPLE_CHEMICAL", 21, 35], ["CLR", "SIMPLE_CHEMICAL", 37, 40], ["BID", "SIMPLE_CHEMICAL", 49, 52], ["azithromycin", "SIMPLE_CHEMICAL", 68, 80], ["AZI", "SIMPLE_CHEMICAL", 82, 85], ["The comparators", "TREATMENT", 0, 15], ["clarithromycin (CLR)", "TREATMENT", 21, 41], ["azithromycin (AZI)", "TREATMENT", 68, 86]]], ["The primary efficacy variable was clinical response at the Test-of-Cure (TOC).", [["the Test", "TEST", 55, 63]]], ["Microbiologic response at the TOC, in subjects with a baseline pathogen was a secondary variable.", [["TOC", "CHEMICAL", 30, 33], ["a baseline pathogen", "PROBLEM", 52, 71]]], ["Non-inferiority was defined as the difference in cure rate (FM minus comparator) where the lower boundary of the 95% CI was greater than )10%.", [["cure rate", "TEST", 49, 58], ["CI", "TEST", 117, 119], ["lower", "ANATOMY_MODIFIER", 91, 96]]], ["Results: The cure rates are shown below for the valid per protocol (vPP), Intent-to-Treat (ITT) and modified ITT populations (all ITT subjects who met inclusion/exclusion criteria).", [["The cure rates", "TEST", 9, 23], ["vPP", "TEST", 68, 71], ["modified ITT populations", "TREATMENT", 100, 124]]], ["In both the individual studies and the pooled analyses, for all populations, treatment with FM was not less effective than either comparator.", [["FM", "SIMPLE_CHEMICAL", 92, 94], ["the individual studies", "TEST", 8, 30], ["the pooled analyses", "TEST", 35, 54], ["treatment with FM", "TREATMENT", 77, 94]]], ["In 10187, the eradication rates for the microbiologically evaluable population was higher in the CLR group (77.1%) compared with the FM group (68.6%) (95% CI )23.", [["the eradication rates", "TEST", 10, 31], ["the microbiologically evaluable population", "TEST", 36, 78], ["the FM group", "TEST", 129, 141]]], ["In contrast, the eradication rate in 100291 was similar in the FM (80.0%) and AZI (78.9%) groups (95% CI -9.7, 11.8).", [["the eradication rate", "TEST", 13, 33], ["AZI", "TEST", 78, 81], ["CI", "TEST", 102, 104]]], ["When the data were pooled across studies, the response rates were similar with FM (75.8%) and combined comparator (78.2%) groups (95% CI -11.0, 6.3).", [["pooled across studies", "TEST", 19, 40], ["the response rates", "TEST", 42, 60], ["FM", "TEST", 79, 81], ["CI", "TEST", 134, 136]]], ["The combined eradication/presumed eradication rates in the pooled FM and comparator groups were 81.8% vs. 86.6%, respectively for S. pneumoniae and 76.0% vs. 77.6%, respectively, for H. influenzae.", [["S. pneumoniae", "ORGANISM", 130, 143], ["H. influenzae", "ORGANISM", 183, 196], ["S. pneumoniae", "SPECIES", 130, 143], ["H. influenzae", "SPECIES", 183, 196], ["S. pneumoniae", "SPECIES", 130, 143], ["H. influenzae", "SPECIES", 183, 196], ["The combined eradication", "TREATMENT", 0, 24], ["eradication rates", "TEST", 34, 51], ["the pooled FM", "TEST", 55, 68], ["comparator groups", "TEST", 73, 90], ["S. pneumoniae", "PROBLEM", 130, 143], ["H. influenzae", "PROBLEM", 183, 196], ["eradication", "OBSERVATION", 13, 24], ["eradication", "OBSERVATION_MODIFIER", 34, 45]]], ["Conclusions: FM was shown to be non-inferior to either AZI or CLR in clinical efficacy in two adequate and well-controlled trials.", [["AZI", "CHEMICAL", 55, 58], ["CLR", "CHEMICAL", 62, 65], ["FM", "MULTI-TISSUE_STRUCTURE", 13, 15], ["AZI", "SIMPLE_CHEMICAL", 55, 58], ["either AZI", "PROBLEM", 48, 58], ["CLR", "PROBLEM", 62, 65], ["CLR", "OBSERVATION", 62, 65]]], ["Pooled analysis further strengthened the clinical noninferiority conclusion.", [["Pooled analysis", "TEST", 0, 15]]], ["The difference in eradication rates observed in Study 10187 (CLR) was not supported by Study 100291 (AZI).P1717An integrated safety analysis of faropenem medoxomil: results of 5,023 subjects from phase II/III clinical trials R. Echols, R. Tosiello (Milford, US)P1717Objective: To evaluate the safety profile of faropenem medoxomil (FM), a novel oral penem antibiotic.", [["oral", "ANATOMY", 345, 349], ["faropenem medoxomil", "CHEMICAL", 144, 163], ["faropenem medoxomil", "CHEMICAL", 311, 330], ["FM", "CHEMICAL", 332, 334], ["penem", "CHEMICAL", 350, 355], ["faropenem medoxomil", "CHEMICAL", 144, 163], ["faropenem medoxomil", "CHEMICAL", 311, 330], ["faropenem medoxomil", "SIMPLE_CHEMICAL", 144, 163], ["faropenem medoxomil", "SIMPLE_CHEMICAL", 311, 330], ["FM", "SIMPLE_CHEMICAL", 332, 334], ["oral", "ORGANISM_SUBDIVISION", 345, 349], ["eradication rates", "TEST", 18, 35], ["Study", "TEST", 48, 53], ["faropenem medoxomil", "TREATMENT", 144, 163], ["Echols", "TEST", 228, 234], ["faropenem medoxomil (FM", "TREATMENT", 311, 334], ["a novel oral penem antibiotic", "TREATMENT", 337, 366], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Methods: 5,023 subjects from 3 phase II and 14 phase III clinical trials received FM, 300 mg BID for 3-10 days for treatment of acute bacterial infections.", [["bacterial infections", "DISEASE", 134, 154], ["BID", "CHEMICAL", 93, 96], ["FM", "TREATMENT", 82, 84], ["acute bacterial infections", "PROBLEM", 128, 154], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["bacterial", "OBSERVATION_MODIFIER", 134, 143], ["infections", "OBSERVATION", 144, 154]]], ["Randomized controlled trials (RCTs) included 4,223 FM and 3795 comparator treated subjects.", [["Randomized controlled trials (RCTs", "TREATMENT", 0, 34]]], ["Analyses were conducted to identify possible disparate adverse event (AE) reporting based on type of infection, subject age (12-17, 18-45, 4664, 65-75, >75) and gender, duration of treatment (3/5 d v. 7/10 d), geography (NA, EU, ROW), study design (open label v RCT), relationship to treatment.", [["infection", "DISEASE", 101, 110], ["Analyses", "TEST", 0, 8], ["disparate adverse event", "PROBLEM", 45, 68], ["infection", "PROBLEM", 101, 110], ["treatment", "TREATMENT", 181, 190], ["treatment", "TREATMENT", 284, 293], ["infection", "OBSERVATION", 101, 110]]], ["Comparisons were made to control treatment based on antibiotic class (b-lactam v. Other), and individual antibiotic treatments.", [["control treatment", "TREATMENT", 25, 42], ["antibiotic class", "TREATMENT", 52, 68], ["individual antibiotic treatments", "TREATMENT", 94, 126]]], ["Results: FM compared favourably to penicillins, cephalosporins and macrolides.", [["penicillins", "CHEMICAL", 35, 46], ["cephalosporins", "CHEMICAL", 48, 62], ["macrolides", "CHEMICAL", 67, 77], ["penicillins", "CHEMICAL", 35, 46], ["cephalosporins", "CHEMICAL", 48, 62], ["macrolides", "CHEMICAL", 67, 77], ["penicillins", "SIMPLE_CHEMICAL", 35, 46], ["cephalosporins", "SIMPLE_CHEMICAL", 48, 62], ["macrolides", "SIMPLE_CHEMICAL", 67, 77], ["FM", "PROBLEM", 9, 11], ["penicillins", "TREATMENT", 35, 46], ["cephalosporins", "TREATMENT", 48, 62], ["macrolides", "TREATMENT", 67, 77]]], ["FM was better tolerated than TMP/SMX and co-amoxiclav.", [["TMP", "CHEMICAL", 29, 32], ["SMX", "CHEMICAL", 33, 36], ["co-amoxiclav", "CHEMICAL", 41, 53], ["TMP", "CHEMICAL", 29, 32], ["SMX", "CHEMICAL", 33, 36], ["co-amoxiclav", "CHEMICAL", 41, 53], ["FM", "SIMPLE_CHEMICAL", 0, 2], ["TMP", "SIMPLE_CHEMICAL", 29, 32], ["SMX", "SIMPLE_CHEMICAL", 33, 36], ["co-amoxiclav", "SIMPLE_CHEMICAL", 41, 53], ["TMP/SMX", "TREATMENT", 29, 36], ["co-amoxiclav", "TREATMENT", 41, 53]]], ["Open labeled trials had higher AEs reported v. RCTs.", [["higher AEs", "PROBLEM", 24, 34]]], ["AEs reporting NA = ROW > EU except serious AEs and deaths where ROW = EU>NA.", [["deaths", "DISEASE", 51, 57], ["serious AEs", "PROBLEM", 35, 46]]], ["Underlying infection did influence AE reporting.", [["infection", "DISEASE", 11, 20], ["Underlying infection", "PROBLEM", 0, 20], ["infection", "OBSERVATION", 11, 20]]], ["FM was tolerated equally well across age ranges, although deaths and SAEs were more common in >75 age group.", [["deaths", "DISEASE", 58, 64], ["SAEs", "DISEASE", 69, 73], ["SAEs", "PROBLEM", 69, 73]]], ["Common AEs (>1%/related from RCTs) were diarrhoea, nausea, fungal vaginosis and headache and were generally less frequent with FM than control Rx.", [["diarrhoea", "DISEASE", 40, 49], ["nausea", "DISEASE", 51, 57], ["fungal vaginosis", "DISEASE", 59, 75], ["headache", "DISEASE", 80, 88], ["Common AEs", "PROBLEM", 0, 10], ["diarrhoea", "PROBLEM", 40, 49], ["nausea", "PROBLEM", 51, 57], ["fungal vaginosis", "PROBLEM", 59, 75], ["headache", "PROBLEM", 80, 88], ["fungal vaginosis", "OBSERVATION", 59, 75]]], ["No evidence of neuro or cardio toxicity was identified.", [["neuro", "ANATOMY", 15, 20], ["cardio toxicity", "DISEASE", 24, 39], ["neuro", "CANCER", 15, 20], ["neuro or cardio toxicity", "PROBLEM", 15, 39], ["evidence of", "UNCERTAINTY", 3, 14], ["neuro", "OBSERVATION", 15, 20], ["cardio", "ANATOMY", 24, 30], ["toxicity", "OBSERVATION", 31, 39]]], ["Laboratory tests identified no hepatic, renal or hematopoietic signals.P1717Conclusion: Faropenem medoxomil, a novel oral penem antibiotic, has the safety profile expected of a b-lactam but is better tolerated than co-amoxiclav with approximately one-third the GI side effects.P1718The efficacy of non-surgical and systemic antibiotic treatment regimens in smoking and non-smoking patients E. P\u00e4hkla, K. L\u00f5 ivukene, P. Naaber, M. Saag (Tartu, EE)P1718Periodontitis is a chronic infectious disease, which leads to the destruction of periodontal ligament fibres and alveolar bone until tooth loss.", [["hepatic", "ANATOMY", 31, 38], ["renal", "ANATOMY", 40, 45], ["hematopoietic", "ANATOMY", 49, 62], ["oral", "ANATOMY", 117, 121], ["GI", "ANATOMY", 261, 263], ["periodontal ligament fibres", "ANATOMY", 532, 559], ["alveolar bone", "ANATOMY", 564, 577], ["tooth", "ANATOMY", 584, 589], ["Faropenem medoxomil", "CHEMICAL", 88, 107], ["penem", "CHEMICAL", 122, 127], ["b-lactam", "CHEMICAL", 177, 185], ["co-amoxiclav", "CHEMICAL", 215, 227], ["smoking", "CHEMICAL", 357, 364], ["EE", "CHEMICAL", 443, 445], ["P1718Periodontitis", "CHEMICAL", 446, 464], ["infectious disease", "DISEASE", 478, 496], ["tooth loss", "DISEASE", 584, 594], ["Faropenem medoxomil", "CHEMICAL", 88, 107], ["b-lactam", "CHEMICAL", 177, 185], ["co-amoxiclav", "CHEMICAL", 215, 227], ["hepatic", "MULTI-TISSUE_STRUCTURE", 31, 38], ["renal", "CANCER", 40, 45], ["Faropenem medoxomil", "SIMPLE_CHEMICAL", 88, 107], ["oral", "ORGANISM_SUBDIVISION", 117, 121], ["b-lactam", "SIMPLE_CHEMICAL", 177, 185], ["co-amoxiclav", "SIMPLE_CHEMICAL", 215, 227], ["patients", "ORGANISM", 381, 389], ["periodontal ligament fibres", "TISSUE", 532, 559], ["alveolar bone", "TISSUE", 564, 577], ["tooth", "ORGAN", 584, 589], ["patients", "SPECIES", 381, 389], ["Laboratory tests", "TEST", 0, 16], ["hepatic, renal or hematopoietic signals", "PROBLEM", 31, 70], ["Faropenem medoxomil", "TREATMENT", 88, 107], ["a novel oral penem antibiotic", "TREATMENT", 109, 138], ["a b-lactam", "TREATMENT", 175, 185], ["co-amoxiclav", "TREATMENT", 215, 227], ["non-surgical", "TREATMENT", 298, 310], ["systemic antibiotic treatment regimens", "TREATMENT", 315, 353], ["a chronic infectious disease", "PROBLEM", 468, 496], ["the destruction of periodontal ligament fibres", "PROBLEM", 513, 559], ["alveolar bone", "PROBLEM", 564, 577], ["tooth loss", "PROBLEM", 584, 594], ["no", "UNCERTAINTY", 28, 30], ["hepatic", "ANATOMY", 31, 38], ["renal", "ANATOMY", 40, 45], ["hematopoietic signals", "OBSERVATION", 49, 70], ["chronic", "OBSERVATION_MODIFIER", 470, 477], ["infectious", "OBSERVATION", 478, 488], ["destruction", "OBSERVATION", 517, 528], ["periodontal ligament", "ANATOMY", 532, 552], ["fibres", "ANATOMY_MODIFIER", 553, 559], ["alveolar", "ANATOMY_MODIFIER", 564, 572], ["bone", "ANATOMY", 573, 577], ["tooth loss", "OBSERVATION", 584, 594]]], ["The objective of this study was to compare the longitudinal effect of combination of non-surgical periodontal therapy with systemic antibiotics in smoking (S) and nonsmoking (NS) patients.", [["periodontal", "ANATOMY", 98, 109], ["smoking", "CHEMICAL", 147, 154], ["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["this study", "TEST", 17, 27], ["non-surgical periodontal therapy", "TREATMENT", 85, 117], ["systemic antibiotics", "TREATMENT", 123, 143], ["nonsmoking (NS)", "TREATMENT", 163, 178], ["periodontal therapy", "OBSERVATION", 98, 117]]], ["Methods: There were total of 28 patients with severe generalized chronic periodontitis involved in this study (14 S, 14 NS), who did not respond well to previous mechanical periodontal treatment.", [["periodontal", "ANATOMY", 173, 184], ["periodontitis", "DISEASE", 73, 86], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["severe generalized chronic periodontitis", "PROBLEM", 46, 86], ["this study", "TEST", 99, 109], ["previous mechanical periodontal treatment", "TREATMENT", 153, 194], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["generalized", "OBSERVATION_MODIFIER", 53, 64], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["periodontitis", "OBSERVATION", 73, 86]]], ["The clinical examination included recordings of visible plaque index (VPI), modified gingival index (MGI), bleeding on probing (BOP) and suppuration after probing (SUP), probing pocket depths (PD) and clinical attachment levels (CAL).", [["plaque", "ANATOMY", 56, 62], ["gingival", "ANATOMY", 85, 93], ["bleeding", "DISEASE", 107, 115], ["suppuration", "DISEASE", 137, 148], ["gingival", "TISSUE", 85, 93], ["The clinical examination", "TEST", 0, 24], ["visible plaque index", "PROBLEM", 48, 68], ["bleeding on probing (BOP)", "PROBLEM", 107, 132], ["suppuration", "PROBLEM", 137, 148], ["probing pocket depths", "PROBLEM", 170, 191], ["clinical attachment levels", "TEST", 201, 227], ["visible", "OBSERVATION_MODIFIER", 48, 55], ["plaque", "OBSERVATION", 56, 62], ["gingival index", "ANATOMY", 85, 99], ["bleeding", "OBSERVATION", 107, 115], ["suppuration", "OBSERVATION", 137, 148]]], ["The non-surgical periodontal therapy was performed within 4 weeks.", [["periodontal", "ANATOMY", 17, 28], ["The non-surgical periodontal therapy", "TREATMENT", 0, 36]]], ["Clinical parameters were recorded at baseline, 2-3 weeks after the first mechanical treatment and 14 months after combined treatment, during a regular check-up visit.", [["Clinical parameters", "TEST", 0, 19], ["the first mechanical treatment", "TREATMENT", 63, 93], ["combined treatment", "TREATMENT", 114, 132]]], ["As the patients did not respond to the conventional periodontal therapy, the microbiological analyses were taken and a combination of systemic amoxicillin 500 mg \u00b7 3 and metronidazole 250 mg \u00b7 2 for 7 days, was prescribed.", [["periodontal", "ANATOMY", 52, 63], ["amoxicillin", "CHEMICAL", 143, 154], ["metronidazole", "CHEMICAL", 170, 183], ["amoxicillin", "CHEMICAL", 143, 154], ["metronidazole", "CHEMICAL", 170, 183], ["patients", "ORGANISM", 7, 15], ["amoxicillin", "SIMPLE_CHEMICAL", 143, 154], ["metronidazole", "SIMPLE_CHEMICAL", 170, 183], ["patients", "SPECIES", 7, 15], ["the conventional periodontal therapy", "TREATMENT", 35, 71], ["the microbiological analyses", "TEST", 73, 101], ["systemic amoxicillin", "TREATMENT", 134, 154], ["metronidazole", "TREATMENT", 170, 183]]], ["Results: The results suggested that the combined systemic antibiotic therapy is effective in case of severe generalized chronic periodontitis, as VPI, BOP, SUP, CAL, and MGI improved significantly after the treatment.", [["periodontitis", "DISEASE", 128, 141], ["VPI", "DISEASE", 146, 149], ["the combined systemic antibiotic therapy", "TREATMENT", 36, 76], ["severe generalized chronic periodontitis", "PROBLEM", 101, 141], ["VPI", "TEST", 146, 149], ["BOP", "TEST", 151, 154], ["the treatment", "TREATMENT", 203, 216], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["generalized", "OBSERVATION_MODIFIER", 108, 119], ["chronic", "OBSERVATION_MODIFIER", 120, 127], ["periodontitis", "OBSERVATION", 128, 141]]], ["In the NS group all parameters, except CAL, improved significantly after the treatment.", [["the treatment", "TREATMENT", 73, 86]]], ["The S showed markedly smaller reduction in SUP, MGI, and CAL.After instrumentation, no periodontal pathogens were isolated in 11 (39%) patients, while 17 patients (61%) were infected with one to three different pathogens.", [["periodontal", "ANATOMY", 87, 98], ["patients", "ORGANISM", 135, 143], ["patients", "ORGANISM", 154, 162], ["SUP", "PROTEIN", 43, 46], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 154, 162], ["The S", "TEST", 0, 5], ["markedly smaller reduction", "PROBLEM", 13, 39], ["instrumentation", "TREATMENT", 67, 82], ["periodontal pathogens", "PROBLEM", 87, 108], ["markedly", "OBSERVATION_MODIFIER", 13, 21], ["smaller", "OBSERVATION_MODIFIER", 22, 29], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["no", "UNCERTAINTY", 84, 86], ["periodontal", "ANATOMY", 87, 98], ["pathogens", "OBSERVATION", 99, 108], ["pathogens", "OBSERVATION", 211, 220]]], ["Among the pathogens, Prevotella intermedia/nigrescens (10 patients) and Actinobacillus actinomycetemcomitans (8 patients) were dominating.", [["Prevotella intermedia", "DISEASE", 21, 42], ["Actinobacillus actinomycetemcomitans", "DISEASE", 72, 108], ["Prevotella intermedia/nigrescens", "ORGANISM", 21, 53], ["patients", "ORGANISM", 58, 66], ["Actinobacillus actinomycetemcomitans", "ORGANISM", 72, 108], ["patients", "ORGANISM", 112, 120], ["Prevotella intermedia", "SPECIES", 21, 42], ["/nigrescens", "SPECIES", 42, 53], ["patients", "SPECIES", 58, 66], ["Actinobacillus actinomycetemcomitans", "SPECIES", 72, 108], ["patients", "SPECIES", 112, 120], ["Prevotella intermedia/nigrescens", "SPECIES", 21, 53], ["Actinobacillus actinomycetemcomitans", "SPECIES", 72, 108], ["the pathogens", "PROBLEM", 6, 19], ["Prevotella intermedia/nigrescens", "TREATMENT", 21, 53], ["Actinobacillus actinomycetemcomitans", "TREATMENT", 72, 108], ["pathogens", "OBSERVATION_MODIFIER", 10, 19]]], ["The total level of microbial load (log10 CFU/ml) as well as the spectrum of pathogens in S and NS patients remained similar.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["microbial load", "TEST", 19, 33], ["pathogens", "PROBLEM", 76, 85], ["NS", "TREATMENT", 95, 97], ["pathogens", "OBSERVATION", 76, 85]]], ["Conclusions: Despite of positive treatment effect in general, there were insignificant improvements in any clinical parameters in the smoking group.", [["positive treatment", "OBSERVATION", 24, 42], ["insignificant", "OBSERVATION_MODIFIER", 73, 86], ["improvements", "OBSERVATION", 87, 99]]], ["Smoking has adverse effect on periodontal therapy; therefore the dentist should cooperate with patients in counselling of smoking cessation to achieve better results in the treatment of periodontitis.", [["periodontal", "ANATOMY", 30, 41], ["Smoking", "DISEASE", 0, 7], ["periodontitis", "DISEASE", 186, 199], ["periodontal", "ORGAN", 30, 41], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["periodontal therapy", "TREATMENT", 30, 49], ["smoking cessation", "TREATMENT", 122, 139], ["periodontitis", "PROBLEM", 186, 199], ["periodontitis", "OBSERVATION", 186, 199]]], ["Objectives: Laminin (LN), which is a large multidomain glycoprotein of the extra cellular matrix, has attracted much attention because of its importance in many cellular functions, including induction of cell adhesion, growth promotion and mediation of cell communication.", [["cellular matrix", "ANATOMY", 81, 96], ["cellular", "ANATOMY", 161, 169], ["cell", "ANATOMY", 204, 208], ["cell", "ANATOMY", 253, 257], ["Laminin", "GENE_OR_GENE_PRODUCT", 12, 19], ["LN", "GENE_OR_GENE_PRODUCT", 21, 23], ["extra cellular matrix", "CELLULAR_COMPONENT", 75, 96], ["cellular", "CELL", 161, 169], ["cell", "CELL", 204, 208], ["cell", "CELL", 253, 257], ["Laminin", "PROTEIN", 12, 19], ["LN", "PROTEIN", 21, 23], ["multidomain glycoprotein", "PROTEIN", 43, 67], ["a large multidomain glycoprotein of the extra cellular matrix", "TREATMENT", 35, 96], ["cell adhesion", "TREATMENT", 204, 217], ["growth promotion", "TREATMENT", 219, 235], ["cell communication", "TREATMENT", 253, 271], ["LN", "ANATOMY", 21, 23], ["large", "OBSERVATION_MODIFIER", 37, 42], ["multidomain", "OBSERVATION_MODIFIER", 43, 54], ["glycoprotein", "OBSERVATION", 55, 67], ["extra cellular matrix", "OBSERVATION_MODIFIER", 75, 96], ["cellular functions", "OBSERVATION", 161, 179], ["cell adhesion", "OBSERVATION", 204, 217], ["cell communication", "OBSERVATION", 253, 271]]], ["The target of this study was to find out whether there is any relation between the levels of serum LN and the inflammatory activity of a microbial infection.", [["serum LN", "ANATOMY", 93, 101], ["microbial infection", "DISEASE", 137, 156], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["LN", "MULTI-TISSUE_STRUCTURE", 99, 101], ["this study", "TEST", 14, 24], ["serum LN", "TEST", 93, 101], ["a microbial infection", "PROBLEM", 135, 156], ["inflammatory", "OBSERVATION_MODIFIER", 110, 122], ["microbial", "OBSERVATION_MODIFIER", 137, 146], ["infection", "OBSERVATION", 147, 156]]], ["Patients/Methods: From June to October 2005, 48 immunocompetent adults, with confirmed bacterial infection were admitted to our hospital (17 with pneumonia, 24 with pyelonephritis and 8 with cholecystitis) (Group 1).", [["bacterial infection", "DISEASE", 87, 106], ["pneumonia", "DISEASE", 146, 155], ["pyelonephritis", "DISEASE", 165, 179], ["cholecystitis", "DISEASE", 191, 204], ["Patients", "ORGANISM", 0, 8], ["adults", "ORGANISM", 64, 70], ["Patients", "SPECIES", 0, 8], ["bacterial infection", "PROBLEM", 87, 106], ["pneumonia", "PROBLEM", 146, 155], ["pyelonephritis", "PROBLEM", 165, 179], ["cholecystitis", "PROBLEM", 191, 204], ["bacterial", "OBSERVATION_MODIFIER", 87, 96], ["infection", "OBSERVATION", 97, 106], ["pneumonia", "OBSERVATION", 146, 155], ["pyelonephritis", "OBSERVATION", 165, 179], ["cholecystitis", "OBSERVATION", 191, 204]]], ["At the same time 50 hospitalised patients for non-infectious causes (stroke, gastrointestinal bleeding, anaemia) were also studied (Group 2).", [["gastrointestinal", "ANATOMY", 77, 93], ["stroke", "DISEASE", 69, 75], ["gastrointestinal bleeding", "DISEASE", 77, 102], ["anaemia", "DISEASE", 104, 111], ["patients", "ORGANISM", 33, 41], ["gastrointestinal", "ORGANISM_SUBDIVISION", 77, 93], ["patients", "SPECIES", 33, 41], ["non-infectious causes", "PROBLEM", 46, 67], ["stroke", "PROBLEM", 69, 75], ["gastrointestinal bleeding", "PROBLEM", 77, 102], ["anaemia", "PROBLEM", 104, 111], ["non-infectious", "OBSERVATION", 46, 60], ["gastrointestinal", "ANATOMY", 77, 93], ["bleeding", "OBSERVATION", 94, 102]]], ["The levels of serum LN and CRP were measured on the day of admission in both groups.", [["serum LN", "ANATOMY", 14, 22], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["LN", "MULTI-TISSUE_STRUCTURE", 20, 22], ["CRP", "GENE_OR_GENE_PRODUCT", 27, 30], ["CRP", "PROTEIN", 27, 30], ["The levels", "TEST", 0, 10], ["serum LN", "TEST", 14, 22], ["CRP", "TEST", 27, 30]]], ["The levels of LN were measured using an enzyme immunoassay kit (TaKaRa LAMININ EIA Kit) and 100 healthy volunteers were used to determine its normal limits (130-520 ng/ml).", [["LN", "ANATOMY", 14, 16], ["LN", "MULTI-TISSUE_STRUCTURE", 14, 16], ["volunteers", "ORGANISM", 104, 114], ["The levels of LN", "TEST", 0, 16], ["an enzyme immunoassay kit", "TEST", 37, 62], ["TaKaRa LAMININ EIA Kit", "TREATMENT", 64, 86], ["LN", "ANATOMY", 14, 16]]], ["Plasma CRP concentration was assessed by immunoturbidometric method (using RANDOX, UK kits).", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["CRP", "GENE_OR_GENE_PRODUCT", 7, 10], ["CRP", "PROTEIN", 7, 10], ["Plasma CRP concentration", "TEST", 0, 24]]], ["Results: The mean serum LN levels of patients of Group 1 were 800.90 \u00b1 249.29 (much higher that the normal limits), while the mean CRP value was 117.53 \u00b1 87.78.", [["serum LN", "ANATOMY", 18, 26], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["LN", "MULTI-TISSUE_STRUCTURE", 24, 26], ["patients", "ORGANISM", 37, 45], ["CRP", "GENE_OR_GENE_PRODUCT", 131, 134], ["CRP", "PROTEIN", 131, 134], ["patients", "SPECIES", 37, 45], ["The mean serum LN levels", "TEST", 9, 33], ["the mean CRP value", "TEST", 122, 140]]], ["The mean corresponding values in Group 2 were 475.79 \u00b1 239.25 for LN (within normal limits) and 24.15 \u00b1 32.77 for CRP.", [["LN", "ANATOMY", 66, 68], ["CRP", "GENE_OR_GENE_PRODUCT", 114, 117], ["CRP", "PROTEIN", 114, 117], ["The mean corresponding values", "TEST", 0, 29], ["LN", "TEST", 66, 68], ["CRP", "TEST", 114, 117]]], ["There is a statistically significant difference between the mean LN levels of the two groups (p < 0.001).", [["LN", "ANATOMY", 65, 67], ["LN", "MULTI-TISSUE_STRUCTURE", 65, 67], ["statistically", "OBSERVATION_MODIFIER", 11, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["difference", "OBSERVATION_MODIFIER", 37, 47], ["mean LN", "OBSERVATION_MODIFIER", 60, 67]]], ["Additionally, there is a statistically significant correlation between the levels of LN and CRP (a well studied serum inflammatory marker) in patients with bacterial infection (Group 1) (Pearson correlation coefficient r = 0.565, p = 0.01).", [["LN", "ANATOMY", 85, 87], ["serum", "ANATOMY", 112, 117], ["bacterial infection", "DISEASE", 156, 175], ["LN", "MULTI-TISSUE_STRUCTURE", 85, 87], ["CRP", "GENE_OR_GENE_PRODUCT", 92, 95], ["serum", "ORGANISM_SUBSTANCE", 112, 117], ["patients", "ORGANISM", 142, 150], ["LN", "PROTEIN", 85, 87], ["CRP", "PROTEIN", 92, 95], ["patients", "SPECIES", 142, 150], ["CRP", "TEST", 92, 95], ["serum inflammatory marker", "TEST", 112, 137], ["bacterial infection", "PROBLEM", 156, 175], ["Pearson correlation coefficient r", "TEST", 187, 220], ["p", "TEST", 230, 231], ["statistically", "OBSERVATION_MODIFIER", 25, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["LN", "ANATOMY", 85, 87], ["bacterial", "OBSERVATION_MODIFIER", 156, 165], ["infection", "OBSERVATION", 166, 175]]], ["Conclusions: The definition of the LN levels could constitute a new reliable, simple, direct serum marker for the confirmation of an active bacterial infection.", [["LN", "ANATOMY", 35, 37], ["serum", "ANATOMY", 93, 98], ["bacterial infection", "DISEASE", 140, 159], ["LN", "MULTI-TISSUE_STRUCTURE", 35, 37], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["the LN levels", "TEST", 31, 44], ["a new reliable, simple, direct serum marker", "PROBLEM", 62, 105], ["the confirmation", "TEST", 110, 126], ["an active bacterial infection", "PROBLEM", 130, 159], ["LN", "ANATOMY", 35, 37], ["new", "OBSERVATION_MODIFIER", 64, 67], ["active", "OBSERVATION_MODIFIER", 133, 139], ["bacterial", "OBSERVATION_MODIFIER", 140, 149], ["infection", "OBSERVATION", 150, 159]]], ["Additionally, as the CRP levels are above normal in Group 2 too (patients without infection) while LN lies within normal limits, maybe LN is even more specific than CRP.", [["LN", "ANATOMY", 99, 101], ["LN", "ANATOMY", 135, 137], ["infection", "DISEASE", 82, 91], ["CRP", "GENE_OR_GENE_PRODUCT", 21, 24], ["patients", "ORGANISM", 65, 73], ["LN", "MULTI-TISSUE_STRUCTURE", 135, 137], ["CRP", "GENE_OR_GENE_PRODUCT", 165, 168], ["CRP", "PROTEIN", 21, 24], ["CRP", "PROTEIN", 165, 168], ["patients", "SPECIES", 65, 73], ["the CRP levels", "TEST", 17, 31], ["infection", "PROBLEM", 82, 91], ["CRP", "TEST", 165, 168], ["without", "UNCERTAINTY", 74, 81], ["infection", "OBSERVATION", 82, 91], ["normal limits", "OBSERVATION", 114, 127]]], ["More studies are required in the future, with more patients included, in order to confirm the outcome of this study.P1720Performance and clinical significance of a direct tube coagulase test using serum separator tubes for rapid identification of Staphylococcus aureus from blood culture broth D. Kwa, T. Sch\u00fc lin-Casonato, P. Sturm (Nijmegen, NL)P1720Objective: Blood cultures are important in the diagnosis of serious infections.", [["serum", "ANATOMY", 197, 202], ["blood", "ANATOMY", 274, 279], ["Blood cultures", "ANATOMY", 363, 377], ["Staphylococcus aureus", "DISEASE", 247, 268], ["infections", "DISEASE", 420, 430], ["patients", "ORGANISM", 51, 59], ["tube", "TISSUE", 171, 175], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["Staphylococcus aureus", "ORGANISM", 247, 268], ["blood", "ORGANISM_SUBSTANCE", 274, 279], ["Blood cultures", "CELL", 363, 377], ["patients", "SPECIES", 51, 59], ["Staphylococcus aureus", "SPECIES", 247, 268], ["Staphylococcus aureus", "SPECIES", 247, 268], ["T. Sch\u00fc lin-Casonato", "SPECIES", 302, 322], ["More studies", "TEST", 0, 12], ["this study", "TEST", 105, 115], ["a direct tube coagulase test", "TEST", 162, 190], ["serum separator tubes", "TREATMENT", 197, 218], ["Staphylococcus aureus", "PROBLEM", 247, 268], ["blood culture", "TEST", 274, 287], ["Kwa", "TEST", 297, 300], ["Blood cultures", "TEST", 363, 377], ["serious infections", "PROBLEM", 412, 430], ["Staphylococcus aureus", "OBSERVATION", 247, 268], ["serious", "OBSERVATION_MODIFIER", 412, 419], ["infections", "OBSERVATION", 420, 430]]], ["Early administration of effective antibiotics is associated with improved patient outcome.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["effective antibiotics", "TREATMENT", 24, 45]]], ["The performance of the direct tube coagulase (DTC) using serum separator tubes (SSTs) for rapid identification of S. aureus from blood culture broth (BCB) was investigated.", [["serum", "ANATOMY", 57, 62], ["blood", "ANATOMY", 129, 134], ["BCB", "ANATOMY", 150, 153], ["tube", "TISSUE", 30, 34], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["S. aureus", "ORGANISM", 114, 123], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["S. aureus", "SPECIES", 114, 123], ["S. aureus", "SPECIES", 114, 123], ["the direct tube coagulase (DTC)", "TREATMENT", 19, 50], ["serum separator tubes (SSTs", "TREATMENT", 57, 84], ["S. aureus", "PROBLEM", 114, 123], ["blood culture broth", "TEST", 129, 148], ["aureus", "OBSERVATION", 117, 123]]], ["The clinical significance of rapid identification was assessed.", [["rapid identification", "TEST", 29, 49]]], ["Methods: Consecutive blood cultures with gram-positive cocci in clusters were tested.", [["blood", "ANATOMY", 21, 26], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["Consecutive blood cultures", "TEST", 9, 35], ["gram", "TEST", 41, 45], ["positive cocci in clusters", "PROBLEM", 46, 72], ["positive cocci", "OBSERVATION", 46, 60]]], ["BCB was collected in SSTs using a subculture-venting unit.", [["BCB", "CANCER", 0, 3], ["BCB", "PROTEIN", 0, 3], ["BCB", "TEST", 0, 3], ["a subculture-venting unit", "TREATMENT", 32, 57]]], ["After centrifugation, the supernatant was discarded and 1 ml rabbit plasma was added to the remaining pellet of bacteria.", [["supernatant", "ANATOMY", 26, 37], ["plasma", "ANATOMY", 68, 74], ["rabbit", "ORGANISM", 61, 67], ["plasma", "ORGANISM_SUBSTANCE", 68, 74], ["rabbit", "SPECIES", 61, 67], ["rabbit", "SPECIES", 61, 67], ["centrifugation", "TREATMENT", 6, 20], ["the supernatant", "TREATMENT", 22, 37], ["1 ml rabbit plasma", "TREATMENT", 56, 74], ["bacteria", "PROBLEM", 112, 120], ["bacteria", "OBSERVATION", 112, 120]]], ["Coagulation was evaluated after 2 and 4 hours incubation at 37\u00b0C, and after overnight incubation at room temperature.", [["Coagulation", "TEST", 0, 11]]], ["In parallel, a direct tube coagulase test was performed using a 1:10 saline dilution of BCB as described previously.", [["BCB", "CHEMICAL", 88, 91], ["BCB", "CHEMICAL", 88, 91], ["tube", "TISSUE", 22, 26], ["BCB", "SIMPLE_CHEMICAL", 88, 91], ["a direct tube coagulase test", "TEST", 13, 41], ["a 1:10 saline dilution of BCB", "TREATMENT", 62, 91]]], ["Clinical significance was measured by comparison of antimicrobial prescription based on Gram stain results, direct coagulase results, and culture results.", [["antimicrobial prescription", "TREATMENT", 52, 78], ["Gram stain", "TEST", 88, 98], ["direct coagulase results", "TEST", 108, 132], ["culture", "TEST", 138, 145]]], ["Results: Over a 6-week period, 90 BCBs from 46 patients were tested.", [["BCBs", "ANATOMY", 34, 38], ["BCBs", "CANCER", 34, 38], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["BCBs", "TEST", 34, 38]]], ["S. aureus was present in 22 BCBs.", [["BCBs", "ANATOMY", 28, 32], ["S. aureus", "ORGANISM", 0, 9], ["BCBs", "CANCER", 28, 32], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["aureus", "OBSERVATION", 3, 9]]], ["Using the serum separator tube method and the saline dilution method, the sensitivity of the DTC after 2 hours incubation was 91% and 41%, and after 4 hours 100% and 88%, respectively.", [["serum", "ANATOMY", 10, 15], ["DTC", "DISEASE", 93, 96], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["tube", "TISSUE", 26, 30], ["the serum separator tube method", "TREATMENT", 6, 37], ["the saline dilution method", "TREATMENT", 42, 68]]], ["Rapid identification of S. aureus resulted in initiation (n = 1) or streamlining (n = 4) of antimicrobial therapy in 5 of 13 patients with S. aureus bacteremia.", [["S. aureus bacteremia", "DISEASE", 139, 159], ["S. aureus", "ORGANISM", 24, 33], ["patients", "ORGANISM", 125, 133], ["S. aureus", "ORGANISM", 139, 148], ["S. aureus", "SPECIES", 24, 33], ["patients", "SPECIES", 125, 133], ["S. aureus", "SPECIES", 139, 148], ["S. aureus", "SPECIES", 24, 33], ["S. aureus", "SPECIES", 139, 148], ["S. aureus", "PROBLEM", 24, 33], ["antimicrobial therapy", "TREATMENT", 92, 113], ["S. aureus bacteremia", "PROBLEM", 139, 159], ["aureus", "OBSERVATION", 27, 33], ["aureus", "OBSERVATION_MODIFIER", 142, 148], ["bacteremia", "OBSERVATION", 149, 159]]], ["Rapid identification of coagulase-negative staphylococci resulted in changes in antimicrobial therapy in 1 of 33 patients.", [["coagulase-negative staphylococci", "GENE_OR_GENE_PRODUCT", 24, 56], ["patients", "ORGANISM", 113, 121], ["coagulase", "PROTEIN", 24, 33], ["patients", "SPECIES", 113, 121], ["coagulase", "TEST", 24, 33], ["negative staphylococci", "PROBLEM", 34, 56], ["antimicrobial therapy", "TREATMENT", 80, 101], ["negative staphylococci", "OBSERVATION", 34, 56], ["antimicrobial therapy", "OBSERVATION", 80, 101]]], ["Conclusion: The DTC using SSTs for bacterial enrichment is a very reliable, rapid, cheap and easy to perform method for identification of S. aureus from BCB.", [["BCB", "ANATOMY", 153, 156], ["S. aureus", "ORGANISM", 138, 147], ["BCB", "CANCER", 153, 156], ["S. aureus", "SPECIES", 138, 147], ["S. aureus", "SPECIES", 138, 147], ["bacterial enrichment", "PROBLEM", 35, 55], ["S. aureus from BCB", "PROBLEM", 138, 156], ["aureus", "OBSERVATION", 141, 147]]], ["Implementation of this test can improve antimicrobial therapy.P1721Evaluation of the results of the Spanish SEIMC External Quality Control Program for the diagnosis of Enterococcus faecalis and Klebsiella pneumoniae infections R. Guna, J.L. P\u00e9rez, N. Orta, C. Gimeno on behalf of SEIMC Objectives: To evaluate the results obtained from four shipments of two different strains by the participants in the SEIMC External Quality Control Program (EQCP).", [["Enterococcus faecalis", "DISEASE", 168, 189], ["Klebsiella pneumoniae infections", "DISEASE", 194, 226], ["Enterococcus faecalis", "ORGANISM", 168, 189], ["Klebsiella pneumoniae", "ORGANISM", 194, 215], ["Enterococcus faecalis", "SPECIES", 168, 189], ["Klebsiella pneumoniae", "SPECIES", 194, 215], ["participants", "SPECIES", 383, 395], ["Enterococcus faecalis", "SPECIES", 168, 189], ["Klebsiella pneumoniae", "SPECIES", 194, 215], ["this test", "TEST", 18, 27], ["antimicrobial therapy", "TREATMENT", 40, 61], ["Enterococcus faecalis", "PROBLEM", 168, 189], ["Klebsiella pneumoniae infections", "PROBLEM", 194, 226], ["Enterococcus faecalis", "OBSERVATION", 168, 189], ["Klebsiella pneumoniae", "OBSERVATION", 194, 215]]], ["These controls were intended to analyse the percentages of correct species identification and the ability of the participants in detecting some special features of the control strains: vanB phenotype in the case of E. faecalis, and the production of extended spectrum betalactamase (ESBL) in K. pneumoniae.", [["vanB", "GENE_OR_GENE_PRODUCT", 185, 189], ["E. faecalis", "ORGANISM", 215, 226], ["extended spectrum betalactamase", "GENE_OR_GENE_PRODUCT", 250, 281], ["K. pneumoniae", "ORGANISM", 292, 305], ["extended spectrum betalactamase", "PROTEIN", 250, 281], ["ESBL", "PROTEIN", 283, 287], ["participants", "SPECIES", 113, 125], ["E. faecalis", "SPECIES", 215, 226], ["K. pneumoniae", "SPECIES", 292, 305], ["E. faecalis", "SPECIES", 215, 226], ["K. pneumoniae", "SPECIES", 292, 305], ["vanB phenotype", "PROBLEM", 185, 199], ["E. faecalis", "PROBLEM", 215, 226], ["extended spectrum betalactamase", "PROBLEM", 250, 281], ["ESBL", "PROBLEM", 283, 287], ["pneumoniae", "PROBLEM", 295, 305], ["pneumoniae", "OBSERVATION", 295, 305]]], ["Methods: The same strain of each microorganism was sent in two different shipments.", [["each microorganism", "PROBLEM", 28, 46]]], ["The vanB E. faecalis strain was sent both in a control of year 2002 as well as in other of 2004, while the ESBL-producing K. pneumoniae was sent in 1999 and in 2005 to an average of 200 laboratories.", [["vanB E. faecalis", "ORGANISM", 4, 20], ["K. pneumoniae", "ORGANISM", 122, 135], ["E. faecalis", "SPECIES", 9, 20], ["K. pneumoniae", "SPECIES", 122, 135], ["E. faecalis", "SPECIES", 9, 20], ["K. pneumoniae", "SPECIES", 122, 135], ["The vanB E. faecalis strain", "TEST", 0, 27], ["the ESBL", "TEST", 103, 111], ["K. pneumoniae", "PROBLEM", 122, 135], ["faecalis strain", "OBSERVATION", 12, 27]]], ["The results obtained were compared with those of a reference laboratory that certified both the species identification and the resistance features.", [["the resistance features", "PROBLEM", 123, 146]]], ["Results: In the 2002 control, 92.6% of participants identified correctly E. faecalis, while 97.8% did it in 2004.", [["participants", "ORGANISM", 39, 51], ["E. faecalis", "ORGANISM", 73, 84], ["participants", "SPECIES", 39, 51], ["E. faecalis", "SPECIES", 73, 84], ["E. faecalis", "SPECIES", 73, 84]]], ["As for the glycopeptide resistance pattern of the enterococcal strain, 39.9% and 53.3% of participants detected the vanB phenotype in 2002 and 2004, respectively.", [["participants", "ORGANISM", 90, 102], ["vanB", "GENE_OR_GENE_PRODUCT", 116, 120], ["participants", "SPECIES", 90, 102], ["the glycopeptide resistance pattern", "TEST", 7, 42], ["the enterococcal strain", "TEST", 46, 69], ["the vanB phenotype", "TEST", 112, 130], ["enterococcal strain", "OBSERVATION", 50, 69]]], ["Overall, the K. pneumoniae strain was correctly identified in both separate controls by most of the participants (97.1% and 98.6%, respectively).", [["K. pneumoniae", "ORGANISM", 13, 26], ["K. pneumoniae", "SPECIES", 13, 26], ["participants", "SPECIES", 100, 112], ["K. pneumoniae", "SPECIES", 13, 26], ["the K. pneumoniae strain", "PROBLEM", 9, 33], ["pneumoniae", "OBSERVATION", 16, 26]]], ["Interestingly, the percentage of laboratories that detected the presence of the ESBL in the K. pneumoniae strain sharply increased from 55.0% in 1999 to 89.4% in 2005.Conclusions:The overall percentages of correct species identification were high for the two microorganisms and for both control points.", [["ESBL", "GENE_OR_GENE_PRODUCT", 80, 84], ["K. pneumoniae", "ORGANISM", 92, 105], ["K. pneumoniae", "SPECIES", 92, 105], ["K. pneumoniae", "SPECIES", 92, 105], ["the ESBL", "TEST", 76, 84], ["the K. pneumoniae strain", "TEST", 88, 112], ["correct species identification", "TEST", 206, 236], ["the two microorganisms", "PROBLEM", 251, 273], ["ESBL", "OBSERVATION", 80, 84], ["pneumoniae", "OBSERVATION", 95, 105], ["sharply", "OBSERVATION_MODIFIER", 113, 120], ["increased", "OBSERVATION_MODIFIER", 121, 130]]], ["Most important, the ability of the Spanish clinical laboratories in detecting the special resistance features of these strains clearly improved along the study period.", [["these strains", "PROBLEM", 113, 126], ["the study", "TEST", 150, 159]]], ["These data confirm the importance of implement a continuous surveillance of the diagnostic training in the clinical laboratory, as well as the possible positive intervention of the SEIMC External Quality Control Program in such improvement, since the analysis of results is accompanied of updated reviews on the subject of each control.P1722 Evaluation of the RIDASCREEN \u00d2 Borrelia IgG and IgM for the serological diagnosis of Lyme borreliosisA.", [["Lyme borreliosisA", "DISEASE", 427, 444], ["Borrelia IgG", "GENE_OR_GENE_PRODUCT", 373, 385], ["IgM", "GENE_OR_GENE_PRODUCT", 390, 393], ["RIDASCREEN \u00d2 Borrelia IgG", "PROTEIN", 360, 385], ["IgM", "PROTEIN", 390, 393], ["Lyme borreliosisA", "SPECIES", 427, 444], ["the diagnostic training", "TEST", 76, 99], ["the analysis", "TEST", 247, 259], ["Evaluation", "TEST", 342, 352], ["the RIDASCREEN", "TEST", 356, 370], ["Borrelia IgG", "TEST", 373, 385], ["IgM", "TEST", 390, 393], ["Lyme borreliosisA", "PROBLEM", 427, 444], ["Lyme borreliosisA", "OBSERVATION", 427, 444]]], ["Bonnet-Pierroz, A. Resenterra, O. P\u00e9ter (Sion, CH)P1722 Evaluation of the RIDASCREEN \u00d2 Borrelia IgG and IgM for the serological diagnosis of Lyme borreliosisObjective: To evaluate 2 new ELISA RIDASCREEN \u00d2 Borrelia IgG and IgM for antibody response in patients with confirmed Lyme borreliosis and to compare to the results of VIDAS Lyme (IgG-IgM) and in-house immunoblots (B. garinii IgG and IgM for early cases or B. burgdorferi sensu stricto, B. afzelii, B. garinii, B. valaisiana IgG for late cases).", [["Lyme borreliosisObjective", "DISEASE", 141, 166], ["Lyme borreliosis", "DISEASE", 275, 291], ["Lyme", "DISEASE", 331, 335], ["Borrelia", "ORGANISM", 87, 95], ["IgG", "GENE_OR_GENE_PRODUCT", 96, 99], ["IgM", "GENE_OR_GENE_PRODUCT", 104, 107], ["Borrelia", "ORGANISM", 205, 213], ["IgG", "GENE_OR_GENE_PRODUCT", 214, 217], ["IgM", "GENE_OR_GENE_PRODUCT", 222, 225], ["patients", "ORGANISM", 251, 259], ["IgG-IgM", "GENE_OR_GENE_PRODUCT", 337, 344], ["B. garinii", "ORGANISM", 372, 382], ["IgG", "ORGANISM", 383, 386], ["IgM", "GENE_OR_GENE_PRODUCT", 391, 394], ["B. burgdorferi sensu stricto", "ORGANISM", 414, 442], ["B. afzelii", "ORGANISM", 444, 454], ["B. garinii", "ORGANISM", 456, 466], ["B. valaisiana", "ORGANISM", 468, 481], ["IgG", "ORGANISM", 482, 485], ["RIDASCREEN \u00d2 Borrelia IgG", "PROTEIN", 74, 99], ["IgM", "PROTEIN", 104, 107], ["ELISA RIDASCREEN", "PROTEIN", 186, 202], ["Borrelia IgG", "PROTEIN", 205, 217], ["IgM", "PROTEIN", 222, 225], ["IgG", "PROTEIN", 337, 340], ["IgM", "PROTEIN", 341, 344], ["B. garinii IgG", "PROTEIN", 372, 386], ["IgM", "PROTEIN", 391, 394], ["B. valaisiana IgG", "PROTEIN", 468, 485], ["patients", "SPECIES", 251, 259], ["B. garinii", "SPECIES", 372, 382], ["B. burgdorferi", "SPECIES", 414, 428], ["sensu stricto", "SPECIES", 429, 442], ["B. afzelii", "SPECIES", 444, 454], ["B. garinii", "SPECIES", 456, 466], ["B. valaisiana", "SPECIES", 468, 481], ["Borrelia", "SPECIES", 205, 213], ["B. garinii", "SPECIES", 372, 382], ["B. burgdorferi sensu stricto", "SPECIES", 414, 442], ["B. afzelii", "SPECIES", 444, 454], ["B. garinii", "SPECIES", 456, 466], ["B. valaisiana", "SPECIES", 468, 481], ["Evaluation", "TEST", 56, 66], ["the RIDASCREEN", "TEST", 70, 84], ["Borrelia IgG", "TEST", 87, 99], ["IgM", "TEST", 104, 107], ["new ELISA RIDASCREEN", "TEST", 182, 202], ["Borrelia IgG", "TEST", 205, 217], ["IgM", "TEST", 222, 225], ["antibody response", "TEST", 230, 247], ["Lyme borreliosis", "PROBLEM", 275, 291], ["VIDAS Lyme", "TEST", 325, 335], ["IgG", "TEST", 337, 340], ["IgM", "TEST", 341, 344], ["garinii IgG", "TEST", 375, 386], ["IgM", "TEST", 391, 394], ["early cases", "PROBLEM", 399, 410]]], ["Methods: ELISA RIDASCREEN \u00d2 Borrelia IgG and IgM was used to screen sera from patients with clinically confirmed Erythema migrans EM (N = 30).", [["sera", "ANATOMY", 68, 72], ["Erythema migrans", "DISEASE", 113, 129], ["Borrelia", "ORGANISM", 28, 36], ["IgG", "ORGANISM_SUBSTANCE", 37, 40], ["IgM", "GENE_OR_GENE_PRODUCT", 45, 48], ["sera", "ORGANISM_SUBSTANCE", 68, 72], ["patients", "ORGANISM", 78, 86], ["Borrelia IgG", "PROTEIN", 28, 40], ["IgM", "PROTEIN", 45, 48], ["patients", "SPECIES", 78, 86], ["ELISA RIDASCREEN", "TEST", 9, 25], ["Borrelia IgG", "TEST", 28, 40], ["IgM", "TEST", 45, 48], ["screen sera", "TEST", 61, 72], ["Erythema migrans EM", "TEST", 113, 132], ["Erythema", "OBSERVATION", 113, 121]]], ["Patients with confirmed neuroborreliosis by intrathecal antibody synthesis (N = 45) were evaluated for IgG antibodies to Borrelia.", [["neuroborreliosis", "DISEASE", 24, 40], ["Borrelia", "DISEASE", 121, 129], ["Patients", "ORGANISM", 0, 8], ["IgG antibodies", "PROTEIN", 103, 117], ["Patients", "SPECIES", 0, 8], ["neuroborreliosis", "PROBLEM", 24, 40], ["intrathecal antibody synthesis", "TEST", 44, 74], ["IgG antibodies to Borrelia", "PROBLEM", 103, 129], ["neuroborreliosis", "OBSERVATION", 24, 40]]], ["Sera from patients with Acrodermatitis chronica atrophicans ACA (N = 30) and sera and synovial fluids from patients with Lyme arthritis (N = 30) were also evaluated for IgG antibodies.", [["Sera", "ANATOMY", 0, 4], ["sera", "ANATOMY", 77, 81], ["synovial fluids", "ANATOMY", 86, 101], ["Acrodermatitis chronica atrophicans ACA", "DISEASE", 24, 63], ["Lyme arthritis", "DISEASE", 121, 135], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["patients", "ORGANISM", 10, 18], ["sera", "ORGANISM_SUBSTANCE", 77, 81], ["synovial fluids", "ORGANISM_SUBSTANCE", 86, 101], ["patients", "ORGANISM", 107, 115], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 169, 183], ["IgG antibodies", "PROTEIN", 169, 183], ["patients", "SPECIES", 10, 18], ["Acrodermatitis chronica atrophicans", "SPECIES", 24, 59], ["patients", "SPECIES", 107, 115], ["Acrodermatitis chronica atrophicans", "SPECIES", 24, 59], ["Sera", "TEST", 0, 4], ["Acrodermatitis chronica atrophicans ACA", "PROBLEM", 24, 63], ["sera and synovial fluids", "TEST", 77, 101], ["Lyme arthritis", "PROBLEM", 121, 135], ["IgG antibodies", "PROBLEM", 169, 183], ["synovial", "ANATOMY", 86, 94]]], ["Patients with syphilis (N = 10) and infectious mononucleosis (N = 10) were screened for IgG and IgM antibodies to Borrelia in order to estimate the specificity.Results:Conclusion: The ELISA RIDASCREEN \u00d2 Borrelia IgG and IgM have shown a good sensitivity for the serological diagnosis of Lyme borreliosis.", [["syphilis", "DISEASE", 14, 22], ["infectious mononucleosis", "DISEASE", 36, 60], ["Lyme borreliosis", "DISEASE", 287, 303], ["Patients", "ORGANISM", 0, 8], ["IgG", "GENE_OR_GENE_PRODUCT", 88, 91], ["Borrelia IgG", "ORGANISM", 203, 215], ["IgM", "GENE_OR_GENE_PRODUCT", 220, 223], ["IgG", "PROTEIN", 88, 91], ["IgM antibodies", "PROTEIN", 96, 110], ["RIDASCREEN", "PROTEIN", 190, 200], ["Borrelia IgG", "PROTEIN", 203, 215], ["IgM", "PROTEIN", 220, 223], ["Patients", "SPECIES", 0, 8], ["Lyme borreliosis", "SPECIES", 287, 303], ["syphilis", "PROBLEM", 14, 22], ["infectious mononucleosis", "PROBLEM", 36, 60], ["IgG", "TEST", 88, 91], ["IgM antibodies", "TEST", 96, 110], ["The ELISA RIDASCREEN", "TEST", 180, 200], ["Borrelia IgG", "TEST", 203, 215], ["IgM", "TEST", 220, 223], ["Lyme borreliosis", "PROBLEM", 287, 303], ["syphilis", "OBSERVATION", 14, 22], ["infectious", "OBSERVATION_MODIFIER", 36, 46], ["Lyme borreliosis", "OBSERVATION", 287, 303]]], ["The short evaluation for the specificity of the IgG test revealed a good assay with few false positive reactions, whereas the IgM assay was, as expected more prompt to give false positive results with sera from patients with infectious mononucleosis.", [["sera", "ANATOMY", 201, 205], ["infectious mononucleosis", "DISEASE", 225, 249], ["sera", "ORGANISM_SUBSTANCE", 201, 205], ["patients", "ORGANISM", 211, 219], ["IgG", "PROTEIN", 48, 51], ["IgM", "PROTEIN", 126, 129], ["patients", "SPECIES", 211, 219], ["The short evaluation", "TEST", 0, 20], ["the IgG test", "TEST", 44, 56], ["few false positive reactions", "PROBLEM", 84, 112], ["the IgM assay", "TEST", 122, 135], ["infectious mononucleosis", "PROBLEM", 225, 249], ["positive reactions", "OBSERVATION", 94, 112], ["infectious", "OBSERVATION_MODIFIER", 225, 235], ["mononucleosis", "OBSERVATION", 236, 249]]], ["So far any equivocal or positive tests should be confirmed by immunoblots.P1723Is it necessary to incubate the BacT/Alert blood culture bottles more than 3 days?", [["blood", "ANATOMY", 122, 127], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["positive tests", "PROBLEM", 24, 38], ["immunoblots", "TEST", 62, 73], ["blood culture", "TEST", 122, 135]]], ["Objective: To assess the incubation time reduction of the aerobic and anaerobic BacT/Alert system bottles from 5 to 3 days.", [["the incubation time reduction", "TREATMENT", 21, 50]]], ["Methods: From 1996 to 2004 we processed 94.303 blood culture sets and detected 9.432 (10%) positive blood cultures with clinical significance.", [["blood", "ANATOMY", 47, 52], ["blood cultures", "ANATOMY", 100, 114], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["blood culture sets", "TEST", 47, 65], ["blood cultures", "TEST", 100, 114]]], ["We retrospectively examined the detection time of positive bottles and assessed the clinical significance of the bottles that were positive between the fourth and fifth day.", [["positive bottles", "TREATMENT", 50, 66]]], ["Results: Out of 9432 positive blood cultures with clinical significance, 9238 (97.9%) were detected within the first 3 days of incubation.", [["blood cultures", "ANATOMY", 30, 44], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["blood cultures", "TEST", 30, 44], ["incubation", "TREATMENT", 127, 137]]], ["Out of the 194 positive blood cultures detected between the fourth and fifth incubation days, 105 were recovered in concurrent cultures within the first 3 days.", [["blood cultures", "ANATOMY", 24, 38], ["blood cultures", "CELL", 24, 38], ["blood cultures", "TEST", 24, 38], ["concurrent cultures", "TEST", 116, 135]]], ["Chart reviews were conducted from 78 patients with the remaining 89 isolates.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45]]], ["Only in 24 patients (0.3% positive blood cultures) changes in antimicrobial therapy based upon the positive blood culture results on day 4 to 5 were made, in the other patients the empirical treatment was adequate.", [["blood cultures", "ANATOMY", 35, 49], ["blood", "ANATOMY", 108, 113], ["patients", "ORGANISM", 11, 19], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 168, 176], ["blood cultures", "TEST", 35, 49], ["antimicrobial therapy", "TREATMENT", 62, 83], ["the positive blood culture", "TEST", 95, 121], ["the empirical treatment", "TREATMENT", 177, 200], ["antimicrobial therapy", "OBSERVATION", 62, 83]]], ["The isolated microorganisms in those 24 patients were: 7 Gram-positive cocci (3 Staphylococcus spp. not S. aureus, 1 Staphylococcus aureus, 2 Streptococcus viridans and 1 Streptococcus pyogenes), 5 Anaerobes, 3 Enterobacteriaceae, 2 Pseudomonas aeruginosa, 2 Campylobacter spp., 2 Candida spp.", [["Staphylococcus aureus", "DISEASE", 117, 138], ["Streptococcus viridans", "DISEASE", 142, 164], ["Streptococcus pyogenes", "DISEASE", 171, 193], ["Campylobacter spp.", "DISEASE", 259, 277], ["patients", "ORGANISM", 40, 48], ["Staphylococcus spp", "ORGANISM", 80, 98], ["S. aureus", "ORGANISM", 104, 113], ["1 Staphylococcus aureus", "ORGANISM", 115, 138], ["Streptococcus viridans", "ORGANISM", 142, 164], ["1", "ORGANISM", 169, 170], ["Streptococcus pyogenes", "ORGANISM", 171, 193], ["Pseudomonas aeruginosa", "ORGANISM", 233, 255], ["Campylobacter spp.", "ORGANISM", 259, 277], ["Candida spp", "ORGANISM", 281, 292], ["patients", "SPECIES", 40, 48], ["Staphylococcus spp", "SPECIES", 80, 98], ["S. aureus", "SPECIES", 104, 113], ["Staphylococcus aureus", "SPECIES", 117, 138], ["Streptococcus viridans", "SPECIES", 142, 164], ["Streptococcus pyogenes", "SPECIES", 171, 193], ["Pseudomonas aeruginosa", "SPECIES", 233, 255], ["Campylobacter spp.", "SPECIES", 259, 277], ["S. aureus", "SPECIES", 104, 113], ["Staphylococcus aureus", "SPECIES", 117, 138], ["Streptococcus viridans", "SPECIES", 142, 164], ["Streptococcus pyogenes", "SPECIES", 171, 193], ["Pseudomonas aeruginosa", "SPECIES", 233, 255], ["Campylobacter spp.", "SPECIES", 259, 277], ["The isolated microorganisms", "TEST", 0, 27], ["Gram-positive cocci", "PROBLEM", 57, 76], ["3 Staphylococcus spp", "PROBLEM", 78, 98], ["S. aureus", "PROBLEM", 104, 113], ["1 Staphylococcus aureus", "PROBLEM", 115, 138], ["Streptococcus viridans", "TEST", 142, 164], ["1 Streptococcus pyogenes", "PROBLEM", 169, 193], ["Anaerobes", "TEST", 198, 207], ["Enterobacteriaceae", "TEST", 211, 229], ["2 Pseudomonas aeruginosa", "PROBLEM", 231, 255], ["microorganisms", "OBSERVATION_MODIFIER", 13, 27], ["cocci", "OBSERVATION", 71, 76], ["Staphylococcus spp", "OBSERVATION", 80, 98], ["aureus", "OBSERVATION", 107, 113], ["Staphylococcus aureus", "OBSERVATION", 117, 138]]], ["1 Cryptococcus neoformans, 1 Brucella spp. and 1 Haemophilus influenzae.", [["Cryptococcus neoformans", "DISEASE", 2, 25], ["Haemophilus influenzae", "DISEASE", 49, 71], ["1", "ORGANISM", 0, 1], ["Cryptococcus neoformans", "ORGANISM", 2, 25], ["Brucella spp.", "ORGANISM", 29, 42], ["Haemophilus influenzae", "ORGANISM", 49, 71], ["Cryptococcus neoformans", "SPECIES", 2, 25], ["Brucella spp.", "SPECIES", 29, 42], ["Haemophilus influenzae", "SPECIES", 49, 71], ["Cryptococcus neoformans", "SPECIES", 2, 25], ["Brucella spp.", "SPECIES", 29, 42], ["Haemophilus influenzae", "SPECIES", 49, 71], ["Cryptococcus neoformans", "TEST", 2, 25], ["Brucella spp.", "TEST", 29, 42], ["1 Haemophilus influenzae", "PROBLEM", 47, 71], ["Cryptococcus neoformans", "OBSERVATION", 2, 25]]], ["Conclusions: Incubation of Bact/Alert blood cultures bottles only for 3 days would have represented a detection loss of 0.3% of the clinically significant isolates, which led to antimicrobial therapy changes.", [["blood cultures", "ANATOMY", 38, 52], ["Bact", "GENE_OR_GENE_PRODUCT", 27, 31], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["Bact/Alert blood cultures bottles", "TEST", 27, 60], ["a detection loss", "PROBLEM", 100, 116], ["the clinically significant isolates", "PROBLEM", 128, 163], ["antimicrobial therapy changes", "TREATMENT", 178, 207], ["antimicrobial therapy", "OBSERVATION", 178, 199]]], ["Although we keep employing a 5-day incubation for routine blood cultures, we could reduce the incubation time to 3 days depending on current instrument capacity.P1724An enzyme immunoassay for anti-diphtheria antibodies: a practical alternative to the Vero cell assay R. Budd, E. Harley, R. George, A. Efstratiou, K. Broughton, A. Bradwell (Birmingham, London, UK)P1724Introduction: In this extended study, results from an anti-Diphtheria toxoid enzyme immunoassay (EIA), specifically designed to detect higher affinity antibodies, were compared with those from a Vero cell assay (VCA).", [["blood cultures", "ANATOMY", 58, 72], ["Vero cell", "ANATOMY", 251, 260], ["Vero cell", "ANATOMY", 563, 572], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["P1724An", "GENE_OR_GENE_PRODUCT", 161, 168], ["anti-diphtheria antibodies", "GENE_OR_GENE_PRODUCT", 192, 218], ["Vero cell", "CELL", 251, 260], ["Vero cell", "CELL", 563, 572], ["P1724An enzyme", "PROTEIN", 161, 175], ["anti-diphtheria antibodies", "PROTEIN", 192, 218], ["affinity antibodies", "PROTEIN", 510, 529], ["VCA", "PROTEIN", 580, 583], ["routine blood cultures", "TEST", 50, 72], ["enzyme immunoassay", "TEST", 169, 187], ["anti-diphtheria antibodies", "PROBLEM", 192, 218], ["the Vero cell assay", "TEST", 247, 266], ["this extended study", "TEST", 385, 404], ["an anti-Diphtheria toxoid enzyme immunoassay", "TEST", 419, 463], ["EIA", "TEST", 465, 468], ["higher affinity antibodies", "PROBLEM", 503, 529], ["a Vero cell assay", "TEST", 561, 578]]], ["Methods and Results: 154 serum samples with antibody concentrations ranging from 0.008-8.000 IU/mL on the VCA from the Respiratory and Systemic Infectious laboratory (RSIL) were assayed by EIA (The Binding Site Ltd, UK).", [["serum samples", "ANATOMY", 25, 38], ["serum samples", "ORGANISM_SUBSTANCE", 25, 38], ["VCA", "PROTEIN", 106, 109], ["serum samples", "TEST", 25, 38], ["antibody concentrations", "TEST", 44, 67], ["Respiratory", "ANATOMY", 119, 130], ["Systemic", "OBSERVATION_MODIFIER", 135, 143], ["Infectious", "OBSERVATION", 144, 154]]], ["A further 100 samples from RSIL selected on the basis of being close to the protective level, were assayed to confirm the performance of the EIA.", [["samples", "ANATOMY", 14, 21], ["the EIA", "TEST", 137, 144]]], ["The EIA was calibrated, against the NIBSC reference material 00/496 and the assay measuring range was 0.004-3.0 IU/mL Results were compared using the WHO guidelines of 0.01-0.1 IU/mL as minimum protective level, and > 0.1 IU/mL as protective.", [["The EIA", "TEST", 0, 7], ["the assay", "TEST", 72, 81], ["minimum protective level", "TEST", 186, 210]]], ["Relative agreement, sensitivity and specificity for the first 154 samples were: 91.6%, 98.8% and 83.3% respectively, for the second set of 100 samples performance was: 90.0%, 84.5% and 97.6%, and for the combined 254 samples results were: 91.3%, 92.9% and 89.4% respectively.", [["samples", "ANATOMY", 66, 73], ["samples", "ANATOMY", 143, 150], ["samples", "ANATOMY", 217, 224], ["sensitivity", "TEST", 20, 31], ["specificity", "TEST", 36, 47]]], ["ROC analysis of the total 254 samples confirmed the highest sensitivity 92.9% and specificity 89.4% occurred at a cut-off of precisely 0.1 IU/mL for the ELISA assay.", [["samples", "ANATOMY", 30, 37], ["ROC analysis", "TEST", 0, 12], ["the highest sensitivity", "TEST", 48, 71], ["specificity", "TEST", 82, 93], ["the ELISA assay", "TEST", 149, 164]]], ["Conclusion: Of the total 22 discrepant samples, 14 had VCA and EIA values < 0.149 IU/ml, therefore we suggest the possibility of establishing an equivocal zone for the interpretation of the EIA results.", [["samples", "ANATOMY", 39, 46], ["samples", "CANCER", 39, 46], ["VCA", "GENE_OR_GENE_PRODUCT", 55, 58], ["VCA", "PROTEIN", 55, 58], ["VCA", "TEST", 55, 58], ["EIA values", "TEST", 63, 73], ["the EIA", "TEST", 186, 193], ["suggest the possibility of", "UNCERTAINTY", 102, 128]]], ["If the test is part of a general immune status assessment a grey zone is not required.", [["the test", "TEST", 3, 11], ["a general immune status assessment", "TEST", 23, 57]]], ["If undertaken to determine the requirement for immunization, the use of the equivocal zone is recommended.", [["immunization", "TREATMENT", 47, 59]]], ["By applying these criteria in the EIA, only one sample would have suggested inappropriate immunization, as indicated by a VCA result > 0.149 IU/mL.", [["VCA", "PROTEIN", 122, 125], ["the EIA", "TEST", 30, 37], ["inappropriate immunization", "TREATMENT", 76, 102], ["a VCA result", "TEST", 120, 132]]], ["Because of the > 90% agreement between the two assays, significant advantages of cost and speed, ease of use and the potential for automation, the EIA could therefore be considered as an alternative to the VCA.P1725Evaluation of accuracy limits of countable colony-forming units on agar plates J. Arbique, A. Rendell, K. Forward (Halifax, CA)P1725Objectives: Accurate colony counts are an essential component of many microbiology research projects and clinical laboratory processes.", [["colony", "ANATOMY", 258, 264], ["colony", "ANATOMY", 368, 374], ["VCA", "GENE_OR_GENE_PRODUCT", 206, 209], ["VCA", "PROTEIN", 206, 209], ["the two assays", "TEST", 39, 53], ["automation", "TEST", 131, 141], ["the EIA", "TEST", 143, 150], ["Evaluation", "TEST", 215, 225], ["accuracy", "TEST", 229, 237], ["countable colony", "TEST", 248, 264], ["Accurate colony counts", "TEST", 359, 381], ["essential", "OBSERVATION_MODIFIER", 389, 398], ["component", "OBSERVATION_MODIFIER", 399, 408]]], ["The suggested range of accuracy of colony-forming units (CFU) extends from 30 to 300 (Standard Methods for the Examination of Water and Wastewater).", [["colony", "ANATOMY", 35, 41], ["the Examination", "TEST", 107, 122], ["range", "OBSERVATION_MODIFIER", 14, 19]]], ["This recommendation dates to 1907, and fails to adequately address the numerous sources of inter-and intra-variability.", [["inter-and intra-variability", "PROBLEM", 91, 118]]], ["Without more detailed analysis it is difficult to estimate the sample size and number of replicates necessary to ensure accurate results.", [["more detailed analysis", "TEST", 8, 30], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["The purpose of this study was to determine the validity of accuracy limits for quantifying CFUs on agar plates.", [["this study", "TEST", 15, 25], ["quantifying CFUs on agar plates", "PROBLEM", 79, 110], ["CFUs", "OBSERVATION", 91, 95]]], ["Methods: Escherichia coli (ATCC 25922) and Staphylococcus epidermidis (ATCC 12228) were used to prepare series of four organism densities ranging from approximately 40-500 CFU, on three different days.", [["ATCC 12228", "ANATOMY", 71, 81], ["ATCC 25922", "CHEMICAL", 27, 37], ["Staphylococcus epidermidis", "DISEASE", 43, 69], ["ATCC 12228", "CHEMICAL", 71, 81], ["Escherichia coli", "ORGANISM", 9, 25], ["ATCC 25922", "CELL", 27, 37], ["Staphylococcus epidermidis", "ORGANISM", 43, 69], ["ATCC 12228", "CELL", 71, 81], ["Escherichia coli", "SPECIES", 9, 25], ["Staphylococcus epidermidis", "SPECIES", 43, 69], ["Escherichia coli", "SPECIES", 9, 25], ["ATCC 25922)", "SPECIES", 27, 38], ["Staphylococcus epidermidis (ATCC 12228)", "SPECIES", 43, 82], ["Escherichia coli", "PROBLEM", 9, 25], ["ATCC", "TEST", 27, 31], ["Staphylococcus epidermidis", "PROBLEM", 43, 69], ["ATCC", "TEST", 71, 75], ["four organism densities", "PROBLEM", 114, 137], ["Escherichia coli", "OBSERVATION", 9, 25], ["Staphylococcus epidermidis", "OBSERVATION", 43, 69]]], ["On each day, each of the 4 densities for both organisms was plated on SBA and viable organisms were counted following incubation.", [["SBA", "SIMPLE_CHEMICAL", 70, 73], ["the 4 densities", "PROBLEM", 21, 36], ["both organisms", "PROBLEM", 41, 55], ["SBA", "TEST", 70, 73], ["viable organisms", "PROBLEM", 78, 94]]], ["An average of the margins of error obtained over the 3 days of testing was used to determine the reproducibility of agar plate counts, and to estimate the optimum number of replicate plates (sample size) required for each organism at each concentration.", [["sample", "ANATOMY", 191, 197], ["testing", "TEST", 63, 70], ["agar plate counts", "TEST", 116, 133], ["replicate plates (sample size)", "TREATMENT", 173, 203], ["average", "OBSERVATION_MODIFIER", 3, 10], ["margins", "OBSERVATION_MODIFIER", 18, 25]]], ["Results: Margins of error for both organisms were greatest with suspensions yielding approximately 40 CFU, and lowest for suspensions yielding 300 and 500 CFU.", [["both organisms", "PROBLEM", 30, 44], ["Margins", "OBSERVATION_MODIFIER", 9, 16]]], ["Nine replicate plates were required for a suspension of S. epidermidis yielding 40 CFU to achieve the same margin of error as obtained with 3 replicate plates at concentrations yielding 100-300 CFU.", [["S. epidermidis", "ORGANISM", 56, 70], ["S. epidermidis", "SPECIES", 56, 70], ["S. epidermidis", "SPECIES", 56, 70], ["Nine replicate plates", "TREATMENT", 0, 21], ["S. epidermidis", "PROBLEM", 56, 70], ["epidermidis", "OBSERVATION", 59, 70]]], ["Seven replicates plates were required for a suspension of E. coli yielding 40 and 100 CFU to achieve similar margins of error to those obtained with 4 replicate plates at concentrations yielding 300 CFU, and 3 replicate plates at concentrations yielding 500 CFU.", [["E. coli", "ORGANISM", 58, 65], ["E. coli", "SPECIES", 58, 65], ["E. coli", "SPECIES", 58, 65], ["Seven replicates plates", "TREATMENT", 0, 23], ["E. coli", "PROBLEM", 58, 65], ["E. coli", "OBSERVATION", 58, 65]]], ["Conclusion: We found that the greater the concentration (300 and 500 CFU), the fewer replicate plates necessary to reliably estimate organism concentrations.", [["the fewer replicate plates", "TREATMENT", 75, 101], ["organism concentrations", "PROBLEM", 133, 156], ["greater", "OBSERVATION_MODIFIER", 30, 37]]], ["The lower the organism density (40 CFU), the more plates necessary to reliably estimate CFUs.", [["lower", "OBSERVATION_MODIFIER", 4, 9], ["organism", "OBSERVATION_MODIFIER", 14, 22], ["density", "OBSERVATION", 23, 30], ["40 CFU", "OBSERVATION_MODIFIER", 32, 38], ["CFUs", "OBSERVATION", 88, 92]]], ["Contrary to the recommendations described in Standard Methods for the Examination of Water and Wastewater, CFU of 500 were reliably reproducible.", [["the Examination", "TEST", 66, 81]]], ["For greatest accuracy, experiments should be conducted so as to assure that colony counts are in the range of 300-500.P1726Direct microscopy: a valuable instrument for diagnosis and prognosis of periodontal disease Objective: To appreciate the composition of micro flora from periodontal pockets, using light microscopy and to compare it with clinical status.", [["colony", "ANATOMY", 76, 82], ["periodontal", "ANATOMY", 195, 206], ["periodontal pockets", "ANATOMY", 276, 295], ["periodontal disease", "DISEASE", 195, 214], ["micro flora", "TISSUE", 259, 270], ["periodontal pockets", "MULTI-TISSUE_STRUCTURE", 276, 295], ["colony counts", "TEST", 76, 89], ["periodontal disease", "PROBLEM", 195, 214], ["micro flora", "PROBLEM", 259, 270], ["periodontal pockets", "PROBLEM", 276, 295], ["light microscopy", "TEST", 303, 319], ["periodontal", "ANATOMY", 195, 206], ["periodontal", "ANATOMY", 276, 287], ["pockets", "OBSERVATION", 288, 295]]], ["Introduction: It is generally accepted that periodontal disease occurs when anaerobic Gram-negative flora increase in number with the subsequent decrease of facultative anaerobe Grampositive bacteria.", [["periodontal", "ANATOMY", 44, 55], ["periodontal disease", "DISEASE", 44, 63], ["periodontal disease", "PROBLEM", 44, 63], ["anaerobic Gram", "TEST", 76, 90], ["negative flora", "PROBLEM", 91, 105], ["facultative anaerobe Grampositive bacteria", "PROBLEM", 157, 199], ["increase", "OBSERVATION_MODIFIER", 106, 114], ["decrease", "OBSERVATION_MODIFIER", 145, 153], ["facultative anaerobe Grampositive bacteria", "OBSERVATION", 157, 199]]], ["In other words, the switch from Gram-positive to Gram-negative of sub-gingival flora has a pathologic significance and could be observed using direct microscopy.", [["gingival flora", "ANATOMY", 70, 84], ["Gram-", "GENE_OR_GENE_PRODUCT", 32, 37], ["Gram", "GENE_OR_GENE_PRODUCT", 49, 53], ["Gram", "TEST", 49, 53], ["sub-gingival flora", "PROBLEM", 66, 84], ["direct microscopy", "TEST", 143, 160], ["gingival", "ANATOMY", 70, 78], ["flora", "OBSERVATION", 79, 84]]], ["Materials and methods: 30 specimens sampled with sterile paper points from periodontal pockets and 10 samples from clinical healthy persons were included in this study.", [["specimens", "ANATOMY", 26, 35], ["periodontal pockets", "ANATOMY", 75, 94], ["samples", "ANATOMY", 102, 109], ["periodontal pockets", "MULTI-TISSUE_STRUCTURE", 75, 94], ["persons", "ORGANISM", 132, 139], ["persons", "SPECIES", 132, 139], ["sterile paper points", "TREATMENT", 49, 69], ["periodontal pockets", "PROBLEM", 75, 94], ["this study", "TEST", 157, 167], ["periodontal", "ANATOMY", 75, 86], ["pockets", "OBSERVATION", 87, 94]]], ["Each sample was diluted in 0.5 ml saline solution and, with a calibrated loop, was taken 10 lL aliquots in order to prepare a smear for microscopic examination and for inoculation on solid media (Columbia with 5% sheep blood).", [["sample", "ANATOMY", 5, 11], ["blood", "ANATOMY", 219, 224], ["sheep", "ORGANISM", 213, 218], ["blood", "ORGANISM_SUBSTANCE", 219, 224], ["sheep", "SPECIES", 213, 218], ["sheep", "SPECIES", 213, 218], ["0.5 ml saline solution", "TREATMENT", 27, 49], ["a calibrated loop", "TREATMENT", 60, 77], ["a smear", "TEST", 124, 131], ["microscopic examination", "TEST", 136, 159], ["inoculation", "PROBLEM", 168, 179], ["5% sheep blood)", "TREATMENT", 210, 225]]], ["The smears were Gram stained and the culture plates were incubated in anaerobic conditions (72 h, 37\u00b0C) and in air (24 h, 37\u00b0C).", [["The smears", "TEST", 0, 10], ["Gram", "TEST", 16, 20], ["the culture plates", "TEST", 33, 51], ["air", "ANATOMY", 111, 114]]], ["Results: In 95% of samples from patients with periodontal disease, easily notable, high number of Gram-negative bacteria at direct microscopy, associated with abundant growth in anaerobic condition and poor growth in air.", [["samples", "ANATOMY", 19, 26], ["periodontal", "ANATOMY", 46, 57], ["periodontal disease", "DISEASE", 46, 65], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["samples", "TEST", 19, 26], ["periodontal disease", "PROBLEM", 46, 65], ["Gram-negative bacteria", "PROBLEM", 98, 120], ["direct microscopy", "TEST", 124, 141], ["abundant growth in anaerobic condition", "PROBLEM", 159, 197], ["poor growth in air", "PROBLEM", 202, 220], ["periodontal", "ANATOMY", 46, 57], ["disease", "OBSERVATION", 58, 65], ["negative bacteria", "OBSERVATION", 103, 120], ["abundant", "OBSERVATION_MODIFIER", 159, 167], ["growth", "OBSERVATION_MODIFIER", 168, 174], ["anaerobic condition", "OBSERVATION", 178, 197], ["poor", "OBSERVATION_MODIFIER", 202, 206], ["growth", "OBSERVATION_MODIFIER", 207, 213], ["air", "OBSERVATION", 217, 220]]], ["In 9 from 10 healthy patients, the Gram-negative flora was almost absent and Gram-positive bacteria were in high number, correlated with the absence of bacterial growth in anaerobiosis and some growth in air.The presence of Treponema spp. at direct microscopy was associated with deep and bleeding periodontal pockets.", [["periodontal", "ANATOMY", 298, 309], ["Treponema spp", "DISEASE", 224, 237], ["bleeding", "DISEASE", 289, 297], ["patients", "ORGANISM", 21, 29], ["Gram-", "GENE_OR_GENE_PRODUCT", 35, 40], ["Treponema spp", "ORGANISM", 224, 237], ["periodontal pockets", "PATHOLOGICAL_FORMATION", 298, 317], ["patients", "SPECIES", 21, 29], ["the Gram-negative flora", "TEST", 31, 54], ["Gram-positive bacteria", "PROBLEM", 77, 99], ["bacterial growth in anaerobiosis", "PROBLEM", 152, 184], ["some growth in air", "PROBLEM", 189, 207], ["Treponema spp", "PROBLEM", 224, 237], ["direct microscopy", "TEST", 242, 259], ["deep and bleeding periodontal pockets", "PROBLEM", 280, 317], ["positive bacteria", "OBSERVATION", 82, 99], ["high number", "OBSERVATION_MODIFIER", 108, 119], ["bacterial growth", "OBSERVATION", 152, 168], ["anaerobiosis", "OBSERVATION", 172, 184], ["some", "OBSERVATION_MODIFIER", 189, 193], ["growth", "OBSERVATION_MODIFIER", 194, 200], ["air", "OBSERVATION", 204, 207], ["Treponema spp", "OBSERVATION", 224, 237], ["deep", "ANATOMY_MODIFIER", 280, 284], ["bleeding", "OBSERVATION", 289, 297], ["periodontal", "ANATOMY", 298, 309], ["pockets", "OBSERVATION", 310, 317]]], ["After few days of proper therapy, the good clinical status was well correlated with an increasing number of gram-positive bacteria.", [["proper therapy", "TREATMENT", 18, 32], ["gram-positive bacteria", "PROBLEM", 108, 130], ["increasing", "OBSERVATION_MODIFIER", 87, 97], ["positive bacteria", "OBSERVATION", 113, 130]]], ["Conclusions: 1) Using a diluted sample for microscopic examination, the value of the method increase, offering important information about the composition of sub-gingival flora.2) The good correlation between the clinical status and microscopic finding recommend it as an easy to use diagnostic method in dentistry.P1727Identification of species and glycopeptide resistance among enterococcal isolates by BD Phoenix Objectives: Vancomycin resistant enterococci are emerging in Europe necessitating their fast and accurate identification by the Laboratory.", [["sample", "ANATOMY", 32, 38], ["gingival flora", "ANATOMY", 162, 176], ["Vancomycin", "CHEMICAL", 428, 438], ["Vancomycin", "CHEMICAL", 428, 438], ["gingival flora", "TISSUE", 162, 176], ["microscopic examination", "TEST", 43, 66], ["sub-gingival flora", "PROBLEM", 158, 176], ["species", "PROBLEM", 338, 345], ["glycopeptide resistance", "TREATMENT", 350, 373], ["enterococcal isolates", "TREATMENT", 380, 401], ["Vancomycin resistant enterococci", "PROBLEM", 428, 460], ["gingival", "ANATOMY", 162, 170], ["flora", "OBSERVATION", 171, 176], ["good", "OBSERVATION_MODIFIER", 184, 188], ["glycopeptide resistance", "OBSERVATION", 350, 373]]], ["There was an attempt to evaluate the performance of the BD Phoenix Automated Microbiology System (BD Diagnostic Systems, Sparks, Md.) for the correct identification of species and glycopeptide resistance in comparison to the gold standard of diagnosis, PCR, using a large collection of clinical strains.", [["species", "PROBLEM", 168, 175], ["glycopeptide resistance", "PROBLEM", 180, 203], ["PCR", "TEST", 253, 256], ["a large collection of clinical strains", "PROBLEM", 264, 302], ["glycopeptide resistance", "OBSERVATION", 180, 203], ["large", "OBSERVATION_MODIFIER", 266, 271]]], ["Methods: A total of 232 enterococcal isolates were tested by the BD Phoenix sytem.", [["enterococcal isolates", "TREATMENT", 24, 45]]], ["These strains were isolated from 145 faecal, 55 urine, 18 pus, 5 blood and 9 samples from other body sites cultures.", [["faecal", "ANATOMY", 37, 43], ["urine", "ANATOMY", 48, 53], ["pus", "ANATOMY", 58, 61], ["blood", "ANATOMY", 65, 70], ["samples", "ANATOMY", 77, 84], ["body sites", "ANATOMY", 96, 106], ["faecal", "ORGANISM_SUBSTANCE", 37, 43], ["urine", "ORGANISM_SUBSTANCE", 48, 53], ["pus", "ORGANISM_SUBSTANCE", 58, 61], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["These strains", "TEST", 0, 13], ["urine", "TEST", 48, 53], ["pus", "PROBLEM", 58, 61], ["blood", "TEST", 65, 70], ["other body sites cultures", "TEST", 90, 115], ["pus", "OBSERVATION", 58, 61]]], ["A multiplex PCR was applied using 8 different pairs of primers, specific for the identification of E. faecium, E. faecalis and the vanA, vanB, vanC, vanD, vanG, vanE glycopeptide resistance genotypes.", [["E. faecium", "ORGANISM", 99, 109], ["E. faecalis", "ORGANISM", 111, 122], ["vanA", "GENE_OR_GENE_PRODUCT", 131, 135], ["vanB", "GENE_OR_GENE_PRODUCT", 137, 141], ["vanC", "GENE_OR_GENE_PRODUCT", 143, 147], ["vanD", "GENE_OR_GENE_PRODUCT", 149, 153], ["vanG", "GENE_OR_GENE_PRODUCT", 155, 159], ["vanE", "GENE_OR_GENE_PRODUCT", 161, 165], ["E. faecium", "SPECIES", 99, 109], ["E. faecalis", "SPECIES", 111, 122], ["E. faecium", "SPECIES", 99, 109], ["E. faecalis", "SPECIES", 111, 122], ["A multiplex PCR", "TEST", 0, 15], ["E. faecium", "PROBLEM", 99, 109], ["E. faecalis", "PROBLEM", 111, 122], ["the vanA", "TREATMENT", 127, 135], ["vanB", "TREATMENT", 137, 141], ["vanC", "TREATMENT", 143, 147], ["vanD", "TREATMENT", 149, 153], ["vanG", "TREATMENT", 155, 159], ["vanE glycopeptide resistance genotypes", "TREATMENT", 161, 199]]], ["Susceptibility to the glycopeptides was also confirmed by the Etest (AB Biodisk, Solna, Sweden).", [["the glycopeptides", "TREATMENT", 18, 35], ["the Etest", "TEST", 58, 67]]], ["Results: According to the PCR, there were 101 E. faecium (including 85 vanA-positive strains), 72 E. faecalis (including 1 vanA-positive and 1 vanB-positive strains) and 58 E. cass/gall isolates.", [["strains", "ANATOMY", 85, 92], ["strains", "ANATOMY", 157, 164], ["E. faecium", "ORGANISM", 46, 56], ["vanA", "GENE_OR_GENE_PRODUCT", 71, 75], ["E. faecalis", "ORGANISM", 98, 109], ["vanA", "GENE_OR_GENE_PRODUCT", 123, 127], ["vanB", "GENE_OR_GENE_PRODUCT", 143, 147], ["E. cass", "ORGANISM", 173, 180], ["gall", "ORGAN", 181, 185], ["E. faecium", "SPECIES", 46, 56], ["E. faecalis", "SPECIES", 98, 109], ["E. cass", "SPECIES", 173, 180], ["E. faecium", "SPECIES", 46, 56], ["E. faecalis", "SPECIES", 98, 109], ["E. cass", "SPECIES", 173, 180], ["the PCR", "TEST", 22, 29], ["E. faecium", "TEST", 46, 56], ["vanA", "TEST", 71, 75], ["E. faecalis", "TEST", 98, 109], ["1 vanA", "TEST", 121, 127], ["vanB", "TEST", 143, 147], ["gall isolates", "PROBLEM", 181, 194], ["gall", "ANATOMY", 181, 185]]], ["Two strains were not identified and were excluded from the analysis.", [["Two strains", "PROBLEM", 0, 11], ["the analysis", "TEST", 55, 67]]], ["Discrepant results between the multiplex PCR and the Phoenix system were obtained for 23/232 isolates (10%) with similar rates amongst faecal (15/145, 10.4%) and the rest of the isolates (8/87, 9.4%).", [["faecal", "ORGANISM_SUBSTANCE", 135, 141], ["the multiplex PCR", "TEST", 27, 44], ["the Phoenix system", "TEST", 49, 67], ["isolates", "TEST", 93, 101], ["the isolates", "TEST", 174, 186]]], ["The most common discrepancies were the misidentification of 11 E. faecium vanA strains and 7 E. faecalis strains as E. cass/gall by Phoenix.", [["gall", "ANATOMY", 124, 128], ["E. faecium", "ORGANISM", 63, 73], ["E. faecalis", "ORGANISM", 93, 104], ["E. cass", "ORGANISM", 116, 123], ["gall", "ORGAN", 124, 128], ["E. faecium", "SPECIES", 63, 73], ["E. faecalis", "SPECIES", 93, 104], ["E. cass", "SPECIES", 116, 123], ["E. faecium", "SPECIES", 63, 73], ["E. faecalis", "SPECIES", 93, 104], ["E. cass", "SPECIES", 116, 123], ["the misidentification", "TEST", 35, 56], ["E. faecium vanA strains", "TREATMENT", 63, 86], ["7 E. faecalis strains", "TREATMENT", 91, 112], ["gall", "ANATOMY", 124, 128]]], ["Two E. faecalis strains were incorrectly characterized as vancomycin resistant, two E. faecium strains were misidentified as E. hirae and E.cass/gall, respectively, and one E.cass/gall strain was reported as E. faecium resistant to both glycopeptides.", [["gall", "ANATOMY", 145, 149], ["vancomycin", "CHEMICAL", 58, 68], ["vancomycin", "CHEMICAL", 58, 68], ["E. faecalis strains", "ORGANISM", 4, 23], ["vancomycin", "SIMPLE_CHEMICAL", 58, 68], ["E. faecium", "ORGANISM", 84, 94], ["E. hirae", "ORGANISM", 125, 133], ["gall", "ORGAN", 145, 149], ["gall", "ORGAN", 180, 184], ["E. faecium", "ORGANISM", 208, 218], ["E. faecalis", "SPECIES", 4, 15], ["E. faecium", "SPECIES", 84, 94], ["E. hirae", "SPECIES", 125, 133], ["E. faecium", "SPECIES", 208, 218], ["E. faecalis", "SPECIES", 4, 15], ["E. faecium", "SPECIES", 84, 94], ["E. hirae", "SPECIES", 125, 133], ["E. faecium", "SPECIES", 208, 218], ["Two E. faecalis strains", "PROBLEM", 0, 23], ["vancomycin", "TREATMENT", 58, 68], ["two E. faecium strains", "TEST", 80, 102], ["gall strain", "PROBLEM", 180, 191], ["both glycopeptides", "TREATMENT", 232, 250], ["faecalis strains", "OBSERVATION", 7, 23], ["gall", "ANATOMY", 145, 149], ["gall", "ANATOMY", 180, 184]]], ["Thus, the sensitivity and specificity for the identification of E.cass/gall by Phoenix were 98.3% (57/58 strains) and 88.4% (145/164 strains), respectively, while 12.8% of vanA strains (11/86 strains) were not recognized by this system.", [["gall", "ANATOMY", 71, 75], ["gall", "ORGAN", 71, 75], ["Phoenix", "GENE_OR_GENE_PRODUCT", 79, 86], ["vanA strains", "ORGANISM", 172, 184], ["the sensitivity", "TEST", 6, 21], ["E.cass", "TEST", 64, 70], ["Phoenix", "TEST", 79, 86], ["strains", "TEST", 105, 112], ["strains", "TEST", 133, 140], ["vanA strains", "TEST", 172, 184], ["strains", "PROBLEM", 192, 199], ["gall", "ANATOMY", 71, 75]]], ["Conclusion: This study demonstrates that the new identification system, Phoenix, similarly to other automated or manual systems, presents with problems regarding correct identifica-tion of enterococcal species and glycopeptide resistance.", [["enterococcal species", "SIMPLE_CHEMICAL", 189, 209], ["This study", "TEST", 12, 22], ["enterococcal species", "PROBLEM", 189, 209], ["glycopeptide resistance", "TREATMENT", 214, 237], ["enterococcal species", "OBSERVATION", 189, 209], ["glycopeptide resistance", "OBSERVATION", 214, 237]]], ["Specifically, Laboratories should be aware that clinically significant isolates identified as E.cass/gall should be confirmed by another method.P1728An audit of sputum requisition practices P. Lal, I. Balakrishnan (London, UK)P1728Objectives: To analyse the indications and rationale for the processing of sputum specimens in a London teaching hospital.", [["gall", "ANATOMY", 101, 105], ["sputum", "ANATOMY", 161, 167], ["sputum specimens", "ANATOMY", 306, 322], ["gall", "ORGAN", 101, 105], ["clinically significant isolates", "PROBLEM", 48, 79], ["sputum specimens", "TEST", 306, 322], ["gall", "ANATOMY", 101, 105]]], ["Methods: Sputum samples received from 01/12/2004 -28/02/ 2005 were included in this study.", [["Sputum samples", "ANATOMY", 9, 23], ["Sputum samples", "CANCER", 9, 23], ["Sputum samples", "TEST", 9, 23], ["this study", "TEST", 79, 89]]], ["Data were obtained from the patient requisition forms and the Winpath systems and were analysed further as per the objectives.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35]]], ["Results: A total of 1309 specimens were received during this period.", [["specimens", "ANATOMY", 25, 34], ["specimens", "CANCER", 25, 34]]], ["1202 (92%) from hospital in-patients and 107 (8%) from general practitioners.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]], ["Out of the total of 1202 samples received from hospital-in patients 167 (13.9%) had > 25 epithelial cells/ LPF.", [["samples", "ANATOMY", 25, 32], ["epithelial cells", "ANATOMY", 89, 105], ["samples", "CANCER", 25, 32], ["patients", "ORGANISM", 59, 67], ["epithelial cells", "CELL", 89, 105], ["LPF", "CELL", 107, 110], ["epithelial cells", "CELL_TYPE", 89, 105], ["LPF", "PROTEIN", 107, 110], ["patients", "SPECIES", 59, 67], ["25 epithelial cells/ LPF", "PROBLEM", 86, 110], ["epithelial cells", "OBSERVATION", 89, 105]]], ["No clinical details were mentioned in 258 (21.4%) and 388 (32.2%) were from patients already on antibiotics.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["antibiotics", "TREATMENT", 96, 107]]], ["Repeat specimens within one week were sent in 340 (28.2%) cases and 375 (33%) had atypical serology also sent.", [["specimens", "ANATOMY", 7, 16], ["Repeat specimens", "TEST", 0, 16], ["cases", "TEST", 58, 63], ["atypical serology", "TEST", 82, 99]]], ["Out of the 1202 hospital-in patient samples 372 (30.9%) had a significant isolate and 488 (40.5%) had normal respiratory tract flora isolated.", [["respiratory tract flora", "ANATOMY", 109, 132], ["respiratory tract flora", "DISEASE", 109, 132], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["normal respiratory tract flora", "PROBLEM", 102, 132], ["respiratory tract", "ANATOMY", 109, 126]]], ["Others were reported as: ''gross oral contamination'' [168 (13.9%)], ''no growth'' [29 (2.4%)] and ''no significant growth'' [37 (3.07%)].", [["oral", "ANATOMY", 33, 37], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["''gross oral contamination", "TEST", 25, 51], ["significant growth''", "PROBLEM", 104, 124], ["no", "UNCERTAINTY", 101, 103]]], ["There were a few specimens reported as ''inappropriate specimen -two days old'' [35 (2.9%)] and ''leaking'' or ''Saliva only' ' [22 (1.8%) ].", [["specimens", "ANATOMY", 17, 26], ["specimens", "CANCER", 17, 26], ["a few specimens", "TEST", 11, 26], ["''inappropriate specimen", "TEST", 39, 63], ["''leaking'' or ''Saliva", "PROBLEM", 96, 119]]], ["Out of a total of 107 samples received from GP patients 14 (13.1%) of samples had > 25 epithelial cells/LPF, 25 (23.3%) had no clinical details provided, 5 (4.6%) samples were sent while patients were on antibiotics and 9 (8.4%) samples were repeated within one week.", [["samples", "ANATOMY", 22, 29], ["samples", "ANATOMY", 70, 77], ["epithelial cells", "ANATOMY", 87, 103], ["samples", "ANATOMY", 163, 170], ["samples", "ANATOMY", 229, 236], ["samples", "CANCER", 22, 29], ["patients", "ORGANISM", 47, 55], ["samples", "CANCER", 70, 77], ["epithelial cells", "CELL", 87, 103], ["samples", "CANCER", 163, 170], ["patients", "ORGANISM", 187, 195], ["epithelial cells", "CELL_TYPE", 87, 103], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 187, 195], ["samples", "TEST", 70, 77], ["epithelial cells", "TEST", 87, 103], ["LPF", "TEST", 104, 107], ["samples", "TEST", 163, 170], ["antibiotics", "TREATMENT", 204, 215], ["samples", "TEST", 229, 236], ["epithelial cells", "OBSERVATION", 87, 103]]], ["Only 4 (3.9%) had atypical serology also sent.", [["atypical serology", "TEST", 18, 35]]], ["Conclusions: -Less than one-third of specimens yielded a significant pathogen.-Adequate clinical details were lacking in about one-fifth of specimens.-Nearly one-third of specimens were repeated within one week, without a clear indication.-About 16% of specimens were of poor quality.-Atypical serology was only performed in 3.9% of outpatients, as compared with 33% of in-patients.This audit brings forth the fact that the clinical indications for which sputa are being sent for culture need to be clearly defined and an educational campaign instituted amongst relevant healthcare professionals.", [["specimens", "ANATOMY", 37, 46], ["specimens", "ANATOMY", 140, 149], ["specimens", "ANATOMY", 171, 180], ["specimens", "ANATOMY", 253, 262], ["specimens", "CANCER", 37, 46], ["specimens", "CANCER", 140, 149], ["specimens", "CANCER", 171, 180], ["specimens", "CANCER", 253, 262], ["outpatients", "ORGANISM", 333, 344], ["patients", "ORGANISM", 373, 381], ["patients", "SPECIES", 373, 381], ["a significant pathogen", "PROBLEM", 55, 77], ["specimens", "TEST", 253, 262], ["Atypical serology", "TEST", 285, 302], ["sputa", "PROBLEM", 455, 460], ["culture", "TEST", 480, 487], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["pathogen", "OBSERVATION", 69, 77]]], ["Sputum collection techniques need to be rigorously applied if good-quality specimens are to be obtained.", [["Sputum", "ANATOMY", 0, 6], ["specimens", "ANATOMY", 75, 84], ["Sputum collection techniques", "TREATMENT", 0, 28]]], ["Indications for performing atypical serology need to be defined and reinforced, particularly in primary care.P1729A new approach to laboratory diagnostic of infectious gastroenteritis -a follow-up Objectives: In order to optimize use of laboratory facilities and ensure flexibility in relation to current epidemiology, a new approach to laboratory diagnosis of infectious gastroenteritis was applied: From an algorithm the decision of which organisms to test for was defined by the demographic, clinical and epidemiological information submitted to the laboratory on paper/electronic request forms.P1729Methods: From April 1, 2004 -June 30, 2005 , hospitals and general practitioners submitted a request form with the following information together with the stool sample (s): (1) acute or persistent diarrhoea (duration > 2 weeks); (2) bloody stools; (3) recent history of foreign travel; (4) > 2 patients within same epidemiological setting; and (5) nosocomial infection.", [["bloody stools", "ANATOMY", 836, 849], ["infectious gastroenteritis", "DISEASE", 157, 183], ["infectious gastroenteritis", "DISEASE", 361, 387], ["diarrhoea", "DISEASE", 800, 809], ["nosocomial infection", "DISEASE", 951, 971], ["patients", "ORGANISM", 897, 905], ["patients", "SPECIES", 897, 905], ["atypical serology", "TEST", 27, 44], ["infectious gastroenteritis", "PROBLEM", 157, 183], ["laboratory facilities", "TREATMENT", 237, 258], ["infectious gastroenteritis", "PROBLEM", 361, 387], ["acute or persistent diarrhoea", "PROBLEM", 780, 809], ["bloody stools", "PROBLEM", 836, 849], ["foreign travel", "PROBLEM", 873, 887], ["nosocomial infection", "PROBLEM", 951, 971], ["infectious", "OBSERVATION_MODIFIER", 157, 167], ["infectious", "OBSERVATION_MODIFIER", 361, 371], ["persistent", "OBSERVATION_MODIFIER", 789, 799], ["diarrhoea", "OBSERVATION", 800, 809], ["foreign travel", "OBSERVATION", 873, 887], ["infection", "OBSERVATION", 962, 971]]], ["Based on these data, analyses were performed according to an algorithm.", [["these data", "TEST", 9, 19], ["analyses", "TEST", 21, 29], ["an algorithm", "TEST", 58, 70]]], ["Examination for Salmonella, Shigella, Yersinia, Campylobacter, and Clostridium difficile was done by culturing.", [["Clostridium difficile", "DISEASE", 67, 88], ["Shigella, Yersinia", "ORGANISM", 28, 46], ["Clostridium difficile", "ORGANISM", 67, 88], ["Clostridium difficile", "SPECIES", 67, 88], ["Salmonella", "SPECIES", 16, 26], ["Clostridium difficile", "SPECIES", 67, 88], ["Examination", "TEST", 0, 11], ["Salmonella", "PROBLEM", 16, 26], ["Shigella", "PROBLEM", 28, 36], ["Yersinia", "PROBLEM", 38, 46], ["Campylobacter", "PROBLEM", 48, 61], ["Clostridium difficile", "PROBLEM", 67, 88], ["culturing", "TEST", 101, 110], ["Clostridium difficile", "OBSERVATION", 67, 88]]], ["Verotoxin producing E. coli (VTEC), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC) and enteroinvasive E. coli (EIEC) were identified by PCR for virulence genes and serotyping.", [["EIEC", "ANATOMY", 128, 132], ["Verotoxin", "CHEMICAL", 0, 9], ["enterotoxigenic E. coli", "DISEASE", 69, 92], ["Verotoxin", "GENE_OR_GENE_PRODUCT", 0, 9], ["E. coli", "ORGANISM", 20, 27], ["VTEC", "ORGANISM", 29, 33], ["enteropathogenic E. coli", "ORGANISM", 36, 60], ["EPEC", "ORGANISM", 62, 66], ["enterotoxigenic E. coli", "ORGANISM", 69, 92], ["ETEC", "ORGANISM", 94, 98], ["enteroinvasive E. coli", "ORGANISM", 104, 126], ["EIEC", "CANCER", 128, 132], ["virulence genes", "DNA", 161, 176], ["E. coli", "SPECIES", 20, 27], ["E. coli", "SPECIES", 53, 60], ["enterotoxigenic E. coli", "SPECIES", 69, 92], ["E. coli", "SPECIES", 119, 126], ["E. coli", "SPECIES", 20, 27], ["VTEC", "SPECIES", 29, 33], ["E. coli", "SPECIES", 53, 60], ["EPEC", "SPECIES", 62, 66], ["E. coli", "SPECIES", 85, 92], ["ETEC", "SPECIES", 94, 98], ["E. coli", "SPECIES", 119, 126], ["EIEC", "SPECIES", 128, 132], ["Verotoxin", "TEST", 0, 9], ["E. coli (VTEC", "PROBLEM", 20, 33], ["enteropathogenic E. coli", "PROBLEM", 36, 60], ["EPEC", "PROBLEM", 62, 66], ["enterotoxigenic E. coli", "PROBLEM", 69, 92], ["ETEC", "PROBLEM", 94, 98], ["enteroinvasive E. coli", "PROBLEM", 104, 126], ["EIEC", "PROBLEM", 128, 132], ["PCR", "TEST", 153, 156], ["virulence genes", "PROBLEM", 161, 176], ["serotyping", "PROBLEM", 181, 191], ["E. coli", "OBSERVATION", 20, 27], ["E. coli", "OBSERVATION_MODIFIER", 53, 60], ["E. coli", "OBSERVATION_MODIFIER", 85, 92], ["enteroinvasive", "OBSERVATION_MODIFIER", 104, 118], ["E. coli", "OBSERVATION_MODIFIER", 119, 126]]], ["Rota and adenovirus were detected by antigen tests and parasites by microscopy.", [["adenovirus", "ORGANISM", 9, 19], ["adenovirus", "SPECIES", 9, 19], ["adenovirus", "PROBLEM", 9, 19], ["antigen tests", "TEST", 37, 50], ["microscopy", "TEST", 68, 78], ["adenovirus", "OBSERVATION", 9, 19]]], ["Results: In total we examined 8,628 samples from 4,088 patients.", [["samples", "ANATOMY", 36, 43], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63]]], ["A pathogen was isolated in 19% of patients.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["A pathogen", "PROBLEM", 0, 10]]], ["In 673 cases (17%) clinical/epidemiological data were missing. \u2022 1,205 patients had diarrhoea < 2 weeks: 13% with Campylobacter, 5% with Salmonella, 4% with ETEC, 3% with Giardia, and 1% each with EIEC and VTEC \u2022 1,502 patients had diarrhoea > 2 weeks: 3% with Campylobacter, 2% with Giardia, 1% each with EPEC and VTEC \u2022 740 patients had a history of foreign travel: 7% with Campylobacter, 6% with ETEC, 4% with Salmonella, and 4% with Giardia \u2022 214 patients had bloody stools: 18% with Campylobacter, 3%P1729with Salmonella, and 2% with VTEC \u2022 896 patients were < 7 years: 4% with Campylobacter, 3% with EPEC, 2% each with Giardia, VTEC and Salmonella, and 1% with ETEC Conclusions: Campylobacter was the most common bacterial pathogens in all groups and rotavirus was the most common pathogen in children < 7 years.", [["diarrhoea", "DISEASE", 84, 93], ["Campylobacter", "DISEASE", 114, 127], ["ETEC", "DISEASE", 157, 161], ["Giardia", "DISEASE", 171, 178], ["EIEC", "DISEASE", 197, 201], ["VTEC", "DISEASE", 206, 210], ["diarrhoea", "DISEASE", 232, 241], ["Campylobacter", "DISEASE", 261, 274], ["Giardia", "DISEASE", 284, 291], ["VTEC", "DISEASE", 315, 319], ["Campylobacter", "DISEASE", 376, 389], ["ETEC", "DISEASE", 399, 403], ["bloody stools", "DISEASE", 464, 477], ["Campylobacter", "DISEASE", 488, 501], ["VTEC", "DISEASE", 539, 543], ["Campylobacter", "DISEASE", 583, 596], ["Giardia, VTEC", "DISEASE", 625, 638], ["rotavirus", "DISEASE", 757, 766], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 326, 334], ["patients", "ORGANISM", 451, 459], ["patients", "ORGANISM", 550, 558], ["rotavirus", "ORGANISM", 757, 766], ["children", "ORGANISM", 799, 807], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 326, 334], ["patients", "SPECIES", 451, 459], ["patients", "SPECIES", 550, 558], ["children", "SPECIES", 799, 807], ["Salmonella", "SPECIES", 137, 147], ["ETEC", "SPECIES", 157, 161], ["VTEC", "SPECIES", 206, 210], ["EPEC", "SPECIES", 306, 310], ["VTEC", "SPECIES", 315, 319], ["ETEC", "SPECIES", 399, 403], ["Salmonella", "SPECIES", 413, 423], ["Salmonella", "SPECIES", 515, 525], ["VTEC", "SPECIES", 539, 543], ["EPEC", "SPECIES", 606, 610], ["VTEC", "SPECIES", 634, 638], ["Salmonella", "SPECIES", 643, 653], ["ETEC", "SPECIES", 667, 671], ["rotavirus", "SPECIES", 757, 766], ["clinical/epidemiological data", "TEST", 19, 48], ["diarrhoea", "PROBLEM", 84, 93], ["Campylobacter", "PROBLEM", 114, 127], ["Salmonella", "PROBLEM", 137, 147], ["ETEC", "TEST", 157, 161], ["Giardia", "TEST", 171, 178], ["EIEC", "TEST", 197, 201], ["VTEC", "TEST", 206, 210], ["diarrhoea", "PROBLEM", 232, 241], ["Campylobacter", "PROBLEM", 261, 274], ["Giardia", "PROBLEM", 284, 291], ["EPEC", "PROBLEM", 306, 310], ["Campylobacter", "PROBLEM", 376, 389], ["ETEC", "TEST", 399, 403], ["Salmonella", "PROBLEM", 413, 423], ["Giardia", "TEST", 437, 444], ["bloody stools", "PROBLEM", 464, 477], ["Campylobacter", "TEST", 488, 501], ["Salmonella", "TEST", 515, 525], ["VTEC", "TEST", 539, 543], ["Campylobacter", "PROBLEM", 583, 596], ["EPEC", "TEST", 606, 610], ["Giardia", "PROBLEM", 625, 632], ["VTEC", "PROBLEM", 634, 638], ["Salmonella", "PROBLEM", 643, 653], ["Campylobacter", "PROBLEM", 685, 698], ["bacterial pathogens in all groups", "PROBLEM", 719, 752], ["rotavirus", "PROBLEM", 757, 766], ["Giardia", "OBSERVATION", 625, 632], ["Campylobacter", "OBSERVATION", 685, 698], ["most common", "OBSERVATION_MODIFIER", 707, 718], ["bacterial", "OBSERVATION_MODIFIER", 719, 728], ["pathogens", "OBSERVATION", 729, 738]]], ["The new approach had a number of advantages: more relevant microbiological analysis, collection of data on defined patient groups, and flexibility regarding adaptation to current epidemiological knowledge.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["microbiological analysis", "TEST", 59, 83], ["collection of data", "TEST", 85, 103], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Increasing use of electronic submission of request forms will optimize the approach used.", [["the approach", "TREATMENT", 71, 83]]], ["Objectives: Small colony variants (SCVs) are an emerging infectious disease problem, presenting as a naturally occurring, slow-growing subpopulation of Staphylococcus aureus that are characterized by tiny colonies on solid media.", [["colony", "ANATOMY", 18, 24], ["SCVs", "ANATOMY", 35, 39], ["colonies", "ANATOMY", 205, 213], ["Staphylococcus aureus", "DISEASE", 152, 173], ["Staphylococcus aureus", "ORGANISM", 152, 173], ["Staphylococcus aureus", "SPECIES", 152, 173], ["Staphylococcus aureus", "SPECIES", 152, 173], ["Small colony variants (SCVs", "PROBLEM", 12, 39], ["an emerging infectious disease problem", "PROBLEM", 45, 83], ["Staphylococcus aureus", "PROBLEM", 152, 173], ["tiny colonies on solid media", "PROBLEM", 200, 228], ["Small", "OBSERVATION_MODIFIER", 12, 17], ["colony variants", "OBSERVATION", 18, 33], ["infectious", "OBSERVATION_MODIFIER", 57, 67], ["growing", "OBSERVATION_MODIFIER", 127, 134], ["subpopulation", "OBSERVATION_MODIFIER", 135, 148], ["Staphylococcus aureus", "OBSERVATION", 152, 173], ["tiny", "OBSERVATION_MODIFIER", 200, 204], ["colonies", "OBSERVATION_MODIFIER", 205, 213], ["solid media", "OBSERVATION_MODIFIER", 217, 228]]], ["Studies on SCVs recovered from patients with persistent infections are hampered due to their frequent unstable phenotype.", [["infections", "DISEASE", 56, 66], ["SCVs", "CELL", 11, 15], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["SCVs", "TEST", 11, 15], ["persistent infections", "PROBLEM", 45, 66], ["their frequent unstable phenotype", "PROBLEM", 87, 120], ["persistent", "OBSERVATION_MODIFIER", 45, 55], ["infections", "OBSERVATION", 56, 66]]], ["In particular, SCVs are not easily distinguishable from the normal phenotype in broth media and a reversion of SCVs into the normal phenotype is not traceable.", [["SCVs", "ANATOMY", 15, 19], ["SCVs", "CELL", 15, 19], ["SCVs", "CELL", 111, 115], ["SCVs", "PROBLEM", 15, 19], ["SCVs", "OBSERVATION", 15, 19], ["normal phenotype", "OBSERVATION", 60, 76], ["SCVs", "OBSERVATION", 111, 115], ["normal phenotype", "OBSERVATION", 125, 141]]], ["Methods: A set of isogenic S. aureus isolates comprising the (i) normal and the (ii) SCV phenotype (isogenic to the isolate with normal phenotype) recovered from clinical specimens, as well as (iii) corresponding mutants mimicking the SCV phenotype (knock-out of hemB), and (iv) their complemented mutants were used to investigate the feasibility of Fourier-transform infrared (FTIR) spectroscopy to trace the expressed phenotype in broth media.", [["specimens", "ANATOMY", 171, 180], ["S. aureus", "ORGANISM", 27, 36], ["hemB", "GENE_OR_GENE_PRODUCT", 263, 267], ["hemB", "PROTEIN", 263, 267], ["S. aureus", "SPECIES", 27, 36], ["S. aureus", "SPECIES", 27, 36], ["isogenic S. aureus isolates", "PROBLEM", 18, 45], ["clinical specimens", "TEST", 162, 180], ["SCV", "ANATOMY", 235, 238]]], ["The respective isolates cultured on solid media served as controls.", [["The respective isolates", "TEST", 0, 23], ["solid media", "TREATMENT", 36, 47]]], ["In addition, all isolates were genotyped by pulsed-field gel electrophoresis and spa typing.", [["all isolates", "PROBLEM", 13, 25], ["pulsed-field gel electrophoresis", "TEST", 44, 76], ["spa typing", "TEST", 81, 91]]], ["Results: Using first-derivative infrared spectra to calculate spectral distances, hierarchical clustering based on spectral information in three different spectral ranges resulted in a dendrogram that showed a clear discrimination between both staphylococcal phenotypes.", [["first-derivative infrared spectra", "TREATMENT", 15, 48], ["hierarchical clustering", "PROBLEM", 82, 105], ["a dendrogram", "TEST", 183, 195], ["both staphylococcal phenotypes", "PROBLEM", 239, 269], ["clear", "OBSERVATION", 210, 215], ["staphylococcal phenotypes", "OBSERVATION", 244, 269]]], ["Distinct clusters comprising the clinical and mutant SCV phenotype on one hand and the normal phenotype (isolate with normal phenotype and complemented mutant) on the other hand were found.", [["hand", "ANATOMY", 74, 78], ["hand", "ANATOMY", 173, 177], ["hand", "ORGANISM_SUBDIVISION", 74, 78], ["hand", "ORGANISM_SUBDIVISION", 173, 177], ["Distinct clusters", "PROBLEM", 0, 17], ["mutant SCV phenotype", "PROBLEM", 46, 66], ["clusters", "OBSERVATION_MODIFIER", 9, 17], ["SCV phenotype", "OBSERVATION", 53, 66], ["normal phenotype", "OBSERVATION", 87, 103]]], ["Thus, SCVs from different clonal lineages gave spectra that were more similar to one another than to their normal growth parent.", [["SCVs", "ANATOMY", 6, 10], ["SCVs", "CELL", 6, 10], ["SCVs", "PROBLEM", 6, 10], ["SCVs", "OBSERVATION", 6, 10]]], ["Conclusion: FTIR spectroscopy allows a rapid, reproducible and clear discrimination of different phenotypes of S. aureus in fluid media for diagnostic and research purposes.", [["S. aureus", "ORGANISM", 111, 120], ["S. aureus", "SPECIES", 111, 120], ["S. aureus", "SPECIES", 111, 120], ["FTIR spectroscopy", "TEST", 12, 29], ["S. aureus", "PROBLEM", 111, 120], ["fluid media", "TREATMENT", 124, 135], ["diagnostic and research purposes", "TEST", 140, 172], ["aureus", "OBSERVATION", 114, 120], ["fluid media", "OBSERVATION", 124, 135]]], ["In contrast to genotyping approaches, FTIR staphylococcal fingerprinting is only reliable for typing purposes if the isolates exhibit the same phenotype.", [["genotyping approaches", "TEST", 15, 36], ["FTIR staphylococcal fingerprinting", "TEST", 38, 72], ["typing purposes", "TEST", 94, 109], ["the isolates", "TEST", 113, 125], ["the same phenotype", "PROBLEM", 134, 152]]], ["In future studies, this technique may also provide an approach for tracing the SCV phenotype in infected tissues.", [["tissues", "ANATOMY", 105, 112], ["tissues", "TISSUE", 105, 112], ["future studies", "TEST", 3, 17], ["this technique", "TREATMENT", 19, 33], ["an approach", "TEST", 51, 62], ["the SCV phenotype in infected tissues", "PROBLEM", 75, 112], ["SCV", "ANATOMY", 79, 82], ["phenotype", "OBSERVATION", 83, 92], ["infected tissues", "OBSERVATION", 96, 112]]], ["Objectives: Triggering receptor expressed on myeloid cells-1 (TREM-1) is a recently discovered cell surface molecule whose expression on phagocytes is up regulated by exposure to bacteria or fungi.", [["myeloid cells", "ANATOMY", 45, 58], ["cell surface", "ANATOMY", 95, 107], ["phagocytes", "ANATOMY", 137, 147], ["myeloid cells-1", "GENE_OR_GENE_PRODUCT", 45, 60], ["TREM-1", "GENE_OR_GENE_PRODUCT", 62, 68], ["cell", "CELL", 95, 99], ["phagocytes", "CELL", 137, 147], ["myeloid cells", "CELL_TYPE", 45, 58], ["phagocytes", "CELL_TYPE", 137, 147], ["myeloid cells", "TEST", 45, 58], ["TREM", "TEST", 62, 66], ["a recently discovered cell surface molecule", "PROBLEM", 73, 116], ["bacteria", "PROBLEM", 179, 187], ["fungi", "PROBLEM", 191, 196], ["myeloid cells", "OBSERVATION", 45, 58], ["fungi", "OBSERVATION", 191, 196]]], ["A soluble form of TREM-1 (sTREM-1) can be measured in various body fluids.", [["body fluids", "ANATOMY", 62, 73], ["TREM-1", "GENE_OR_GENE_PRODUCT", 18, 24], ["TREM-1", "GENE_OR_GENE_PRODUCT", 27, 33], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["TREM-1", "PROTEIN", 18, 24], ["TREM", "PROTEIN", 27, 31], ["TREM", "TEST", 18, 22], ["TREM", "TEST", 27, 31]]], ["We studied whether sTREM-1 in cerebrospinal fluid (CSF) could serve as a biomarker for the presence and outcome in patients with bacterial meningitis.", [["cerebrospinal fluid", "ANATOMY", 30, 49], ["bacterial meningitis", "DISEASE", 129, 149], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 19, 26], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 30, 49], ["CSF", "ORGANISM_SUBSTANCE", 51, 54], ["patients", "ORGANISM", 115, 123], ["sTREM-1", "PROTEIN", 19, 26], ["patients", "SPECIES", 115, 123], ["sTREM", "TEST", 19, 24], ["cerebrospinal fluid (CSF", "TEST", 30, 54], ["a biomarker", "TEST", 71, 82], ["bacterial meningitis", "PROBLEM", 129, 149], ["bacterial", "OBSERVATION_MODIFIER", 129, 138], ["meningitis", "OBSERVATION", 139, 149]]], ["Methods: In this retrospective study on diagnostic accuracy we used an ELISA to determine levels of sTREM-1 in CSF from 46 adults with bacterial meningitis, confirmed by CSF culture, who participated in the prospective Dutch Meningitis Cohort Study; 8 patients with viral meningitis, confirmed by polymerase chain reaction of CSF; and 9 healthy control subjects, who underwent lumbar puncture to exclude the diagnosis of subarachnoid haemorrhage.", [["lumbar", "ANATOMY", 377, 383], ["subarachnoid", "ANATOMY", 421, 433], ["bacterial meningitis", "DISEASE", 135, 155], ["Meningitis", "DISEASE", 225, 235], ["viral meningitis", "DISEASE", 266, 282], ["subarachnoid haemorrhage", "DISEASE", 421, 445], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 100, 107], ["CSF", "ORGANISM_SUBSTANCE", 111, 114], ["adults", "ORGANISM", 123, 129], ["patients", "ORGANISM", 252, 260], ["CSF", "GENE_OR_GENE_PRODUCT", 326, 329], ["subarachnoid haemorrhage", "PATHOLOGICAL_FORMATION", 421, 445], ["sTREM-1", "PROTEIN", 100, 107], ["patients", "SPECIES", 252, 260], ["diagnostic accuracy", "TEST", 40, 59], ["an ELISA", "TEST", 68, 76], ["sTREM", "TEST", 100, 105], ["bacterial meningitis", "PROBLEM", 135, 155], ["CSF culture", "TEST", 170, 181], ["Cohort Study", "TEST", 236, 248], ["viral meningitis", "PROBLEM", 266, 282], ["polymerase chain reaction of CSF", "PROBLEM", 297, 329], ["lumbar puncture", "TEST", 377, 392], ["subarachnoid haemorrhage", "PROBLEM", 421, 445], ["meningitis", "OBSERVATION", 145, 155], ["viral", "OBSERVATION_MODIFIER", 266, 271], ["meningitis", "OBSERVATION", 272, 282], ["lumbar", "ANATOMY", 377, 383], ["subarachnoid", "ANATOMY", 421, 433], ["haemorrhage", "OBSERVATION", 434, 445]]], ["The Mann-Whitney U test and the Chi-square test were used to identify differences between groups.", [["The Mann-Whitney U test", "TEST", 0, 23], ["the Chi-square test", "TEST", 28, 47]]], ["A receiveroperating-characteristic curve (ROC) was constructed to illustrate various cut-off CSF levels of sTREM-1 in differentiating between the presence and absence of bacterial meningitis and diagnostic accuracy was quantified by 95% confidence intervals (95% CI).", [["bacterial meningitis", "DISEASE", 170, 190], ["CSF", "GENE_OR_GENE_PRODUCT", 93, 96], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 107, 114], ["sTREM-1", "PROTEIN", 107, 114], ["CSF levels", "TEST", 93, 103], ["sTREM", "TEST", 107, 112], ["bacterial meningitis", "PROBLEM", 170, 190], ["diagnostic accuracy", "TEST", 195, 214], ["bacterial", "OBSERVATION_MODIFIER", 170, 179], ["meningitis", "OBSERVATION", 180, 190]]], ["Results: Levels of sTREM-1 in CSF were higher in patients with bacterial meningitis as compared to those with viral meningitis [median, 159 pg/mL (range, 0 to 988 pg/mL) versus 0.5 pg/mL (range, 0 to 48 pg/mL); P = 0.001] and controls [0 pg/mL (range, 0 to 36 pg/mL); P < 0.001; Fig].", [["bacterial meningitis", "DISEASE", 63, 83], ["viral meningitis", "DISEASE", 110, 126], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 19, 26], ["CSF", "GENE_OR_GENE_PRODUCT", 30, 33], ["patients", "ORGANISM", 49, 57], ["sTREM-1", "PROTEIN", 19, 26], ["CSF", "PROTEIN", 30, 33], ["patients", "SPECIES", 49, 57], ["Levels", "TEST", 9, 15], ["sTREM", "TEST", 19, 24], ["CSF", "TEST", 30, 33], ["bacterial meningitis", "PROBLEM", 63, 83], ["viral meningitis", "PROBLEM", 110, 126], ["P", "TEST", 211, 212], ["controls", "TEST", 226, 234], ["bacterial", "OBSERVATION_MODIFIER", 63, 72], ["meningitis", "OBSERVATION", 73, 83]]], ["Patients with viral meningitis and controls had similar CSF sTREM-1 levels.", [["viral meningitis", "DISEASE", 14, 30], ["Patients", "ORGANISM", 0, 8], ["CSF", "GENE_OR_GENE_PRODUCT", 56, 59], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 60, 67], ["sTREM", "PROTEIN", 60, 65], ["Patients", "SPECIES", 0, 8], ["viral meningitis", "PROBLEM", 14, 30], ["CSF sTREM", "TEST", 56, 65], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["meningitis", "OBSERVATION", 20, 30]]], ["The area under the ROC curve for discriminating between patients with and without bacterial meningitis was 0.88 (95% CI, 0.80 to 0.96; P < 0.001).", [["bacterial meningitis", "DISEASE", 82, 102], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["the ROC curve", "TEST", 15, 28], ["bacterial meningitis", "PROBLEM", 82, 102], ["CI", "TEST", 117, 119], ["P", "TEST", 135, 136], ["without", "UNCERTAINTY", 74, 81], ["meningitis", "OBSERVATION", 92, 102]]], ["At a cut-off level of 40 pg/mL, sTREM-1 yielded a sensitivity of 0.80 (95% CI, 0.69 to 0.88) and a specificity of 0.94 (95% CI, 0.77 to 0.99).", [["sTREM-1", "GENE_OR_GENE_PRODUCT", 32, 39], ["sTREM", "PROTEIN", 32, 37], ["sTREM", "TEST", 32, 37], ["a sensitivity", "TEST", 48, 61], ["CI", "TEST", 75, 77], ["a specificity", "TEST", 97, 110], ["CI", "TEST", 124, 126]]], ["In patients with bacterial meningitis, CSF sTREM-1 levels were associated with mortality [survivors versus nonsurvivors: median 99 pg/mL (range, 0 to 365 pg/mL) versus 214 pg/mL (range, 0 to 988 pg/mL); P = 0.02].P1729Conclusions: Measuring sTREM-1 in CSF may be a valuable new approach to accurately diagnose bacterial meningitis and identify patients at high risk for adverse outcome.", [["bacterial meningitis", "DISEASE", 17, 37], ["meningitis", "DISEASE", 320, 330], ["patients", "ORGANISM", 3, 11], ["CSF sTREM-1", "GENE_OR_GENE_PRODUCT", 39, 50], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 241, 248], ["CSF", "GENE_OR_GENE_PRODUCT", 252, 255], ["patients", "ORGANISM", 344, 352], ["sTREM", "PROTEIN", 43, 48], ["sTREM-1", "PROTEIN", 241, 248], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 344, 352], ["bacterial meningitis", "PROBLEM", 17, 37], ["CSF sTREM", "TEST", 39, 48], ["P", "TEST", 203, 204], ["Measuring sTREM", "TEST", 231, 246], ["bacterial meningitis", "PROBLEM", 310, 330], ["adverse outcome", "PROBLEM", 370, 385], ["bacterial", "OBSERVATION_MODIFIER", 17, 26], ["meningitis", "OBSERVATION", 27, 37]]], ["Therefore, a prospective study on sTREM-1 as biomarker in bacterial meningitis is needed.P1732Systematic review of rapid diagnostic tests for enterohaemorrhagic E. coli I. Abubakar, L. Irvine, L. Shepstone, S. Schelenz, C. Aldus, P. Hunter (Norwich, UK)P1732Objective: A variety of rapid tests for the detection of Enterohaemorrhagic Escherichia coli (EHEC) have recently emerged.", [["bacterial meningitis", "DISEASE", 58, 78], ["sTREM-1", "GENE_OR_GENE_PRODUCT", 34, 41], ["Enterohaemorrhagic Escherichia coli", "ORGANISM", 315, 350], ["EHEC", "ORGANISM", 352, 356], ["sTREM", "PROTEIN", 34, 39], ["E. coli", "SPECIES", 161, 168], ["Escherichia coli", "SPECIES", 334, 350], ["E. coli", "SPECIES", 161, 168], ["Escherichia coli", "SPECIES", 334, 350], ["EHEC", "SPECIES", 352, 356], ["a prospective study", "TEST", 11, 30], ["sTREM", "TEST", 34, 39], ["bacterial meningitis", "PROBLEM", 58, 78], ["rapid diagnostic tests", "TEST", 115, 137], ["enterohaemorrhagic E. coli", "PROBLEM", 142, 168], ["rapid tests", "TEST", 282, 293], ["Enterohaemorrhagic Escherichia coli", "PROBLEM", 315, 350], ["EHEC", "PROBLEM", 352, 356], ["bacterial", "OBSERVATION_MODIFIER", 58, 67], ["meningitis", "OBSERVATION", 68, 78], ["Enterohaemorrhagic Escherichia coli", "OBSERVATION", 315, 350]]], ["Culture on Sorbitol MacConkey (SMAC) agar and biochemical identification, while easy to use and inexpensive, is slow and lacks sensitivity in the detection of non O157:H7 serotypes.", [["Sorbitol MacConkey", "CHEMICAL", 11, 29], ["SMAC", "CHEMICAL", 31, 35], ["O157", "SPECIES", 163, 167], ["Culture", "TEST", 0, 7], ["Sorbitol MacConkey (SMAC) agar", "TREATMENT", 11, 41], ["biochemical identification", "TEST", 46, 72], ["the detection", "TEST", 142, 155]]], ["This study sought to determine the accuracy of rapid serological or polymerase chain reaction (PCR) assays which have been evaluated for the detection of all EHEC serotypes compared to culture.", [["EHEC", "SPECIES", 158, 162], ["This study", "TEST", 0, 10], ["rapid serological or polymerase chain reaction", "PROBLEM", 47, 93], ["PCR) assays", "TEST", 95, 106], ["the detection", "TEST", 137, 150], ["all EHEC serotypes", "PROBLEM", 154, 172], ["culture", "TEST", 185, 192]]], ["Methods: A systematic review and meta-analysis of 146 articles, identified via searches of electronic databases, hand searching of selected journals, and through contact with experts and commercial test manufacturers.", [["meta-analysis", "TEST", 33, 46], ["electronic databases", "TEST", 91, 111]]], ["The majority of these needed to be excluded due to low quality or lack of accuracy data.", [["low quality", "PROBLEM", 51, 62]]], ["Sensitivity and specificity of each method was calculated using full biochemical identification as the reference standard.", [["Sensitivity", "TEST", 0, 11], ["each method", "TEST", 31, 42]]], ["Twenty-one studies met the inclusion criteria, of which 7 used PCR methods and 10 used serological assays and 4 were based on culture.", [["PCR methods", "TEST", 63, 74], ["serological assays", "TEST", 87, 105], ["culture", "TEST", 126, 133]]], ["A summary receiver operator curve (SROC) was constructed from these data and the area under the curve (AUC) calculated (using the trapezium rule).", [["A summary receiver operator curve", "TEST", 0, 33], ["these data", "TEST", 62, 72], ["the curve (AUC", "TEST", 92, 106], ["the trapezium rule", "TEST", 126, 144], ["trapezium", "ANATOMY", 130, 139]]], ["Results: Serological tests had individual sensitivities ranging from 0.82 to 1.00 and specificities ranging from 0.67 to 1.00.", [["Serological tests", "TEST", 9, 26], ["individual sensitivities", "TEST", 31, 55], ["specificities", "TEST", 86, 99]]], ["PCR tests had individual sensitivities ranging from 0.94 to 1.00 and specificities ranging from 0.92 to 1.00.", [["PCR tests", "TEST", 0, 9], ["individual sensitivities", "TEST", 14, 38], ["specificities", "TEST", 69, 82]]], ["Additional analysis comparing SMAC agar culture with toxin detection methods showed poor sensitivity compared to PCR and serological tests (ranging from 0.24 to 0.38) yet the specificity was very good (1.00 for all 4 studies considered).Conclusions:Our results suggest that both molecular and serological tests may have a potential role in detecting EHEC infection.", [["infection", "DISEASE", 355, 364], ["SMAC", "GENE_OR_GENE_PRODUCT", 30, 34], ["EHEC", "SPECIES", 350, 354], ["Additional analysis", "TEST", 0, 19], ["SMAC agar culture", "TEST", 30, 47], ["toxin detection methods", "TEST", 53, 76], ["poor sensitivity", "PROBLEM", 84, 100], ["PCR", "TEST", 113, 116], ["serological tests", "TEST", 121, 138], ["the specificity", "TEST", 171, 186], ["all 4 studies", "TEST", 211, 224], ["serological tests", "TEST", 293, 310], ["EHEC infection", "PROBLEM", 350, 364], ["EHEC", "OBSERVATION_MODIFIER", 350, 354], ["infection", "OBSERVATION", 355, 364]]], ["Whilst there is very little difference in the effectiveness of these techniques, both are faster and have improved sensitivity when compared to traditional culture methods.", [["these techniques", "TEST", 63, 79], ["traditional culture methods", "TEST", 144, 171], ["very", "OBSERVATION_MODIFIER", 16, 20], ["little", "OBSERVATION_MODIFIER", 21, 27], ["difference", "OBSERVATION_MODIFIER", 28, 38], ["improved", "OBSERVATION_MODIFIER", 106, 114]]], ["Fast, reliable diagnosis could lead to more informed treatment choices and improved outbreak control measures.", [["informed treatment choices", "TREATMENT", 44, 70]]], ["However, given the substantial extra cost of these assays, an assessment of economic feasibility is necessary prior to use in everyday practice.P1733Antibodies against Bordetella pertussis detected by slow agglutination test and ELISA in two agerelated groups of vaccinated people suspected of acute pertussis: a comparative studyP1733Objective: The aim of presented study was to describe differences between results of two tests used for detection of antibodies against Bordetella pertussis (slow agglutination and ELISA) in two age-related groups of patients suffering from respiratory infection.", [["respiratory", "ANATOMY", 576, 587], ["Bordetella pertussis", "DISEASE", 168, 188], ["pertussis", "DISEASE", 300, 309], ["respiratory infection", "DISEASE", 576, 597], ["P1733Antibodies", "GENE_OR_GENE_PRODUCT", 144, 159], ["Bordetella pertussis", "ORGANISM", 168, 188], ["people", "ORGANISM", 274, 280], ["Bordetella pertussis", "ORGANISM", 471, 491], ["patients", "ORGANISM", 552, 560], ["antibodies", "PROTEIN", 452, 462], ["Bordetella pertussis", "SPECIES", 168, 188], ["people", "SPECIES", 274, 280], ["Bordetella pertussis", "SPECIES", 471, 491], ["patients", "SPECIES", 552, 560], ["Bordetella pertussis", "SPECIES", 168, 188], ["Bordetella pertussis", "SPECIES", 471, 491], ["these assays", "TEST", 45, 57], ["an assessment", "TEST", 59, 72], ["Bordetella pertussis", "PROBLEM", 168, 188], ["slow agglutination test", "TEST", 201, 224], ["ELISA", "TEST", 229, 234], ["acute pertussis", "PROBLEM", 294, 309], ["a comparative study", "TEST", 311, 330], ["two tests", "TEST", 420, 429], ["antibodies", "PROBLEM", 452, 462], ["Bordetella pertussis", "PROBLEM", 471, 491], ["slow agglutination", "PROBLEM", 493, 511], ["ELISA", "TEST", 516, 521], ["respiratory infection", "PROBLEM", 576, 597], ["acute", "OBSERVATION_MODIFIER", 294, 299], ["pertussis", "OBSERVATION", 300, 309], ["respiratory", "ANATOMY", 576, 587], ["infection", "OBSERVATION", 588, 597]]], ["Each of the people has undergone vaccination against B. pertussis.", [["people", "ORGANISM", 12, 18], ["B. pertussis", "ORGANISM", 53, 65], ["people", "SPECIES", 12, 18], ["B. pertussis", "SPECIES", 53, 65], ["B. pertussis", "SPECIES", 53, 65], ["vaccination", "TREATMENT", 33, 44], ["B. pertussis", "PROBLEM", 53, 65]]], ["Methods: Paired sera obtained from two age-related groups of patients [(1). age 0-6 years, n = 49; (2). age above 6 years, n = 455] suffering from acute respiratory infection were tested.", [["sera", "ANATOMY", 16, 20], ["respiratory", "ANATOMY", 153, 164], ["acute respiratory infection", "DISEASE", 147, 174], ["sera", "ORGANISM_SUBSTANCE", 16, 20], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["acute respiratory infection", "PROBLEM", 147, 174], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["respiratory", "ANATOMY", 153, 164], ["infection", "OBSERVATION", 165, 174]]], ["The first group comprised the children who were vaccinated earlier than one year before testing; the second group was determined by longer interval between the vaccination and the testing.", [["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38], ["testing", "TEST", 88, 95], ["the vaccination", "TREATMENT", 156, 171], ["the testing", "TEST", 176, 187]]], ["The criterion of positivity of the slow agglutination was based on quadruple increase/decrease of the titer of specific antibodies; the criterion of serodiagnosis of the illness was the same.", [["illness", "DISEASE", 170, 177], ["specific antibodies", "PROTEIN", 111, 130], ["the slow agglutination", "PROBLEM", 31, 53], ["quadruple increase", "PROBLEM", 67, 85], ["specific antibodies", "PROBLEM", 111, 130], ["the illness", "PROBLEM", 166, 177], ["slow", "OBSERVATION_MODIFIER", 35, 39], ["agglutination", "OBSERVATION", 40, 53], ["decrease", "OBSERVATION_MODIFIER", 86, 94]]], ["Each of the patients was tested by ELISA IgA,IgG,IgM (Virotech) during the same period, positive results of each of class of immunoglobulins were evaluated as positive ELISA.", [["patients", "ORGANISM", 12, 20], ["IgA", "GENE_OR_GENE_PRODUCT", 41, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 45, 48], ["IgM", "GENE_OR_GENE_PRODUCT", 49, 52], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 125, 140], ["IgA", "PROTEIN", 41, 44], ["IgG", "PROTEIN", 45, 48], ["IgM", "PROTEIN", 49, 52], ["Virotech", "PROTEIN", 54, 62], ["immunoglobulins", "PROTEIN", 125, 140], ["patients", "SPECIES", 12, 20], ["ELISA IgA", "TEST", 35, 44], ["IgG", "TEST", 45, 48], ["IgM", "TEST", 49, 52], ["immunoglobulins", "TEST", 125, 140]]], ["The differences of results obtained by the two tests were assessed inside and between the groups.", [["the two tests", "TEST", 39, 52]]], ["Results: There were found 12.2% (respective 16.9%) concordant positive and 36.7% (respective 19.6%) concordant negative results between the tests in the first (respective second) group.", [["respective", "TEST", 33, 43], ["the tests", "TEST", 136, 145]]], ["There were found the following discrepancies in the frame of non equal results: agglutination positive/ELISA negative sera were present in 8.2% (respective 13.2%) persons and agglutination negative/ELISA positive samples were present in 42.9% (respective 62.2%) persons.", [["sera", "ANATOMY", 118, 122], ["samples", "ANATOMY", 213, 220], ["sera", "ORGANISM_SUBSTANCE", 118, 122], ["persons", "ORGANISM", 163, 170], ["persons", "ORGANISM", 262, 269], ["persons", "SPECIES", 163, 170], ["persons", "SPECIES", 262, 269], ["agglutination", "TEST", 80, 93], ["ELISA", "TEST", 103, 108], ["sera", "TEST", 118, 122], ["respective", "TEST", 145, 155], ["agglutination", "TEST", 175, 188], ["ELISA positive samples", "TEST", 198, 220]]], ["The frequency of serologically confirmed infection based on results of slow agglutination is higher in the group of people older six; the interpretation of the results in the younger group is limited by the influence of actual vaccination.", [["infection", "DISEASE", 41, 50], ["people", "ORGANISM", 116, 122], ["people", "SPECIES", 116, 122], ["infection", "PROBLEM", 41, 50], ["slow agglutination", "PROBLEM", 71, 89], ["actual vaccination", "TREATMENT", 220, 238], ["infection", "OBSERVATION", 41, 50], ["slow", "OBSERVATION_MODIFIER", 71, 75], ["agglutination", "OBSERVATION", 76, 89], ["higher", "OBSERVATION_MODIFIER", 93, 99]]], ["The ELISA evaluated as described above shows extremely high frequency of positivity in both groups, thus, the usefulness for diagnostics of acute infection seems to be low.", [["infection", "DISEASE", 146, 155], ["The ELISA", "TEST", 0, 9], ["acute infection", "PROBLEM", 140, 155], ["high", "OBSERVATION_MODIFIER", 55, 59], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["infection", "OBSERVATION", 146, 155], ["low", "OBSERVATION_MODIFIER", 168, 171]]], ["The study will be continued to asses relationships between the positive results detected by slow agglutination and the positive ones detected by ELISA in separate classes of specific immunglobulins.P1734Accuracy of the MicroScan WalkAway system to identify coagulase-negative staphylococci A. S\u00e1ez, B. Ruiz, L. Mart\u00ednez-Mart\u00ednez (Santander, ES) Objective: To determine the reliability of the identification of coagulase-negative staphylococci (CoNS) with the MicroScan WalkAway 96 (WA, Dade Behring) system at species level when a > = 90% probability is obtained, considering as a reference the results of molecular identification.", [["immunglobulins", "GENE_OR_GENE_PRODUCT", 183, 197], ["coagulase-negative staphylococci", "GENE_OR_GENE_PRODUCT", 410, 442], ["L. Mart\u00ednez", "SPECIES", 308, 319], ["The study", "TEST", 0, 9], ["slow agglutination", "PROBLEM", 92, 110], ["the positive ones", "PROBLEM", 115, 132], ["ELISA", "TEST", 145, 150], ["coagulase", "TEST", 257, 266], ["staphylococci", "TEST", 276, 289], ["Ruiz", "TEST", 302, 306], ["coagulase", "TEST", 410, 419]]], ["Methods: One hundred and sixty-eight isolates of CoNS from clinical samples (October 2003 -May 2005 for which the identification with the WA system was \u2021 90%, and 9 ATCC type strains were evaluated.", [["samples", "ANATOMY", 68, 75], ["CoNS", "CELL", 49, 53], ["the WA system", "TEST", 134, 147], ["9 ATCC type strains", "TREATMENT", 163, 182]]], ["Bacteria were identified with the WA system using Pos Combo 1S panels.", [["Bacteria", "CELL", 0, 8], ["Bacteria", "PROBLEM", 0, 8], ["Pos Combo 1S panels", "TREATMENT", 50, 69]]], ["Absence of coagulase was determined with a latex assay (Pastorex \u00d2 staph-plus, Bio-Rad).", [["coagulase", "PROTEIN", 11, 20], ["coagulase", "PROBLEM", 11, 20], ["a latex assay", "TEST", 41, 54], ["Pastorex", "TEST", 56, 64], ["staph", "TEST", 67, 72], ["coagulase", "OBSERVATION", 11, 20]]], ["Reference identification was established by sequencing of the 16S rRNA; when identification with WA and 16S rRNA disagree, definitive identification was defined after sequencing of the sodA and tuf genes, as previously described (Drancourt et al. JCM 2000; 38: 3623-30 and Heikens el al. JCM 2005; 43: 2286-90) .", [["rRNA", "CELLULAR_COMPONENT", 66, 70], ["sodA", "GENE_OR_GENE_PRODUCT", 185, 189], ["tuf", "GENE_OR_GENE_PRODUCT", 194, 197], ["16S rRNA", "DNA", 62, 70], ["sodA and tuf genes", "DNA", 185, 203], ["WA", "TEST", 97, 99], ["the sodA and tuf genes", "PROBLEM", 181, 203]]], ["For identification, the sequences of 16S rRNA, sodA and tuf were compared with those in GeneBank.", [["16S", "GENE_OR_GENE_PRODUCT", 37, 40], ["rRNA", "CELLULAR_COMPONENT", 41, 45], ["sodA", "GENE_OR_GENE_PRODUCT", 47, 51], ["16S rRNA", "DNA", 37, 45], ["sodA", "DNA", 47, 51], ["tuf", "DNA", 56, 59], ["identification", "TEST", 4, 18], ["the sequences", "TEST", 20, 33], ["16S rRNA", "TEST", 37, 45]]], ["Homologies values above 97% were considered reliable.", [["Homologies values", "TEST", 0, 17]]], ["Results: All 9 type strains were correctly identified by 16S rRNA sequencing as named by the ATCC.", [["All 9 type strains", "PROBLEM", 9, 27], ["16S rRNA sequencing", "TEST", 57, 76]]], ["Among the 168 clinical isolates, the molecular method identified the following species (number): S. hominis (39), S. haemolyticus (35), S. saprophyticus (30), S. epidermidis (27), S. lugdunensis (12), S. schleiferi (7), S. capitis (7), S. simulans (4), S. pasteuri (2), S. warneri (2), S. intermedius (2) and S. equorum (1).", [["S. saprophyticus", "DISEASE", 136, 152], ["S. epidermidis", "DISEASE", 159, 173], ["S. lugdunensis", "DISEASE", 180, 194], ["S. capitis", "DISEASE", 220, 230], ["S. hominis", "ORGANISM", 97, 107], ["S. haemolyticus", "ORGANISM", 114, 129], ["S. saprophyticus", "ORGANISM", 136, 152], ["S. epidermidis", "ORGANISM", 159, 173], ["S. lugdunensis", "ORGANISM", 180, 194], ["S. schleiferi", "ORGANISM", 201, 214], ["S. capitis", "ORGANISM", 220, 230], ["S. simulans", "ORGANISM", 236, 247], ["S. pasteuri", "ORGANISM", 253, 264], ["S. warneri", "ORGANISM", 270, 280], ["S. intermedius", "ORGANISM", 286, 300], ["S. equorum", "ORGANISM", 309, 319], ["S. hominis", "SPECIES", 97, 107], ["S. haemolyticus", "SPECIES", 114, 129], ["S. saprophyticus", "SPECIES", 136, 152], ["S. epidermidis", "SPECIES", 159, 173], ["S. lugdunensis", "SPECIES", 180, 194], ["S. schleiferi", "SPECIES", 201, 214], ["S. capitis", "SPECIES", 220, 230], ["S. simulans", "SPECIES", 236, 247], ["S. pasteuri", "SPECIES", 253, 264], ["S. warneri", "SPECIES", 270, 280], ["S. intermedius", "SPECIES", 286, 300], ["S. equorum", "SPECIES", 309, 319], ["S. hominis", "SPECIES", 97, 107], ["S. haemolyticus", "SPECIES", 114, 129], ["S. saprophyticus", "SPECIES", 136, 152], ["S. epidermidis", "SPECIES", 159, 173], ["S. lugdunensis", "SPECIES", 180, 194], ["S. schleiferi", "SPECIES", 201, 214], ["S. capitis", "SPECIES", 220, 230], ["S. simulans", "SPECIES", 236, 247], ["S. pasteuri", "SPECIES", 253, 264], ["S. warneri", "SPECIES", 270, 280], ["S. intermedius", "SPECIES", 286, 300], ["S. equorum", "SPECIES", 309, 319], ["S. hominis", "TEST", 97, 107], ["S. haemolyticus", "TEST", 114, 129], ["S. saprophyticus", "TEST", 136, 152], ["S. epidermidis", "PROBLEM", 159, 173], ["S. lugdunensis", "PROBLEM", 180, 194], ["S. capitis", "PROBLEM", 220, 230], ["S. simulans", "PROBLEM", 236, 247], ["epidermidis", "OBSERVATION", 162, 173], ["lugdunensis", "OBSERVATION", 183, 194], ["capitis", "ANATOMY", 223, 230], ["intermedius", "ANATOMY", 289, 300]]], ["The WA system correctly identified 8 out of the 9 ATCC strains.", [["The WA system", "TEST", 0, 13], ["the 9 ATCC strains", "TREATMENT", 44, 62]]], ["S. pasteuri is not included in the WA database, and the corresponding ATCC strain was misidentified as S. warneri.", [["S. pasteuri", "ORGANISM", 0, 11], ["ATCC strain", "ORGANISM", 70, 81], ["S. warneri", "ORGANISM", 103, 113], ["S. pasteuri", "SPECIES", 0, 11], ["S. warneri", "SPECIES", 103, 113], ["S. pasteuri", "SPECIES", 0, 11], ["S. warneri", "SPECIES", 103, 113], ["the corresponding ATCC strain", "PROBLEM", 52, 81]]], ["One hundred and fiftyseven out of the 168 (93.4%) clinical isolates were correctly identified by the WA.", [["clinical isolates", "TEST", 50, 67]]], ["Five S. haemolyticus were identified by WA as S. auricularis (2), S. simulans (2) and S. warneri (1) .", [["S. haemolyticus", "ORGANISM", 5, 20], ["S. auricularis", "ORGANISM", 46, 60], ["S. simulans", "ORGANISM", 66, 77], ["S. warneri", "ORGANISM", 86, 96], ["S. haemolyticus", "SPECIES", 5, 20], ["S. auricularis", "SPECIES", 46, 60], ["S. simulans", "SPECIES", 66, 77], ["S. warneri", "SPECIES", 86, 96], ["S. haemolyticus", "SPECIES", 5, 20], ["S. auricularis", "SPECIES", 46, 60], ["S. simulans", "SPECIES", 66, 77], ["S. warneri", "SPECIES", 86, 96], ["Five S. haemolyticus", "PROBLEM", 0, 20], ["haemolyticus", "OBSERVATION", 8, 20]]], ["Other errors corresponded to: two S. pasteuri misidentified as S. warneri, one S. epidermidis as S. hominis, one S. lugdunensis as S. schleiferi, one S. hominis as S. haemolyticus and one S. equorum as S. cohnii.", [["S. pasteuri", "ORGANISM", 34, 45], ["S. warneri", "ORGANISM", 63, 73], ["S. epidermidis", "ORGANISM", 79, 93], ["S. hominis", "ORGANISM", 97, 107], ["S. lugdunensis", "ORGANISM", 113, 127], ["S. schleiferi", "ORGANISM", 131, 144], ["S. hominis", "ORGANISM", 150, 160], ["S. haemolyticus", "ORGANISM", 164, 179], ["S. equorum", "ORGANISM", 188, 198], ["S. cohnii", "ORGANISM", 202, 211], ["S. pasteuri", "SPECIES", 34, 45], ["S. warneri", "SPECIES", 63, 73], ["S. epidermidis", "SPECIES", 79, 93], ["S. hominis", "SPECIES", 97, 107], ["S. lugdunensis", "SPECIES", 113, 127], ["S. schleiferi", "SPECIES", 131, 144], ["S. hominis", "SPECIES", 150, 160], ["S. haemolyticus", "SPECIES", 164, 179], ["S. equorum", "SPECIES", 188, 198], ["S. cohnii", "SPECIES", 202, 211], ["S. pasteuri", "SPECIES", 34, 45], ["S. warneri", "SPECIES", 63, 73], ["S. epidermidis", "SPECIES", 79, 93], ["S. hominis", "SPECIES", 97, 107], ["S. lugdunensis", "SPECIES", 113, 127], ["S. schleiferi", "SPECIES", 131, 144], ["S. hominis", "SPECIES", 150, 160], ["S. haemolyticus", "SPECIES", 164, 179], ["S. equorum", "SPECIES", 188, 198], ["S. cohnii", "SPECIES", 202, 211], ["S. hominis", "PROBLEM", 97, 107], ["haemolyticus", "PROBLEM", 167, 179], ["epidermidis", "OBSERVATION", 82, 93], ["lugdunensis", "OBSERVATION", 116, 127], ["cohnii", "OBSERVATION", 205, 211]]], ["All isolates of S. saprophyticus, S. schleiferi, S. capitis, S. simulans, S. warneri and S. intermedius were correctly identified by the WA system.", [["S. capitis", "DISEASE", 49, 59], ["S. saprophyticus", "ORGANISM", 16, 32], ["S. schleiferi", "ORGANISM", 34, 47], ["S. capitis", "ORGANISM", 49, 59], ["S. simulans", "ORGANISM", 61, 72], ["S. warneri", "ORGANISM", 74, 84], ["S. intermedius", "ORGANISM", 89, 103], ["S. saprophyticus", "SPECIES", 16, 32], ["S. schleiferi", "SPECIES", 34, 47], ["S. capitis", "SPECIES", 49, 59], ["S. simulans", "SPECIES", 61, 72], ["S. warneri", "SPECIES", 74, 84], ["S. intermedius", "SPECIES", 89, 103], ["S. saprophyticus", "SPECIES", 16, 32], ["S. schleiferi", "SPECIES", 34, 47], ["S. capitis", "SPECIES", 49, 59], ["S. simulans", "SPECIES", 61, 72], ["S. warneri", "SPECIES", 74, 84], ["S. intermedius", "SPECIES", 89, 103], ["S. saprophyticus", "PROBLEM", 16, 32], ["S. capitis", "PROBLEM", 49, 59], ["S. intermedius", "TREATMENT", 89, 103], ["saprophyticus", "OBSERVATION_MODIFIER", 19, 32], ["capitis", "ANATOMY", 52, 59], ["intermedius", "ANATOMY", 92, 103]]], ["Conclusions: The MicroScan WalkAway 96 is reliable to identify CoNS at species level when a probability of > = 90% is obtained.", [["The MicroScan WalkAway", "TEST", 13, 35]]], ["S. pasteuri should be incorporated to the WA database in order to improve its performance.", [["S. pasteuri", "ORGANISM", 0, 11], ["S. pasteuri", "SPECIES", 0, 11], ["S. pasteuri", "SPECIES", 0, 11]]], ["Objectives: The aim of this study was to analyse the results of proficiency testing obtained by Polish microbiology laboratories participating in POLMICRO.", [["this study", "TEST", 23, 33], ["proficiency testing", "TEST", 64, 83]]], ["Haemophilus influenzae is an important pathogen causing a variety of community-acquired respiratory tract infections, acute otitis media and purulent meningitis.", [["respiratory tract", "ANATOMY", 88, 105], ["Haemophilus influenzae", "DISEASE", 0, 22], ["respiratory tract infections", "DISEASE", 88, 116], ["acute otitis media", "DISEASE", 118, 136], ["meningitis", "DISEASE", 150, 160], ["Haemophilus influenzae", "ORGANISM", 0, 22], ["Haemophilus influenzae", "SPECIES", 0, 22], ["Haemophilus influenzae", "SPECIES", 0, 22], ["Haemophilus influenzae", "PROBLEM", 0, 22], ["an important pathogen", "PROBLEM", 26, 47], ["community-acquired respiratory tract infections", "PROBLEM", 69, 116], ["acute otitis media", "PROBLEM", 118, 136], ["purulent meningitis", "PROBLEM", 141, 160], ["influenzae", "OBSERVATION", 12, 22], ["variety", "OBSERVATION_MODIFIER", 58, 65], ["respiratory tract", "ANATOMY", 88, 105], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["otitis", "OBSERVATION", 124, 130], ["purulent", "OBSERVATION_MODIFIER", 141, 149], ["meningitis", "OBSERVATION", 150, 160]]], ["Two mechanisms of ampicillin (AMP) resistance in this organism are described.", [["ampicillin", "CHEMICAL", 18, 28], ["AMP", "CHEMICAL", 30, 33], ["ampicillin", "CHEMICAL", 18, 28], ["AMP", "CHEMICAL", 30, 33], ["ampicillin", "SIMPLE_CHEMICAL", 18, 28], ["AMP", "SIMPLE_CHEMICAL", 30, 33], ["ampicillin (AMP) resistance", "TREATMENT", 18, 45], ["this organism", "PROBLEM", 49, 62]]], ["One is mediated by the production of beta-lactamases TEM-1 and ROB-1; these AMP-resistant strains are termed beta-lactamase-producing, AMP-resistant (BLPAR).", [["AMP", "CHEMICAL", 76, 79], ["AMP", "CHEMICAL", 135, 138], ["AMP", "CHEMICAL", 76, 79], ["AMP", "CHEMICAL", 135, 138], ["beta-lactamases TEM-1", "GENE_OR_GENE_PRODUCT", 37, 58], ["ROB-1", "GENE_OR_GENE_PRODUCT", 63, 68], ["AMP", "SIMPLE_CHEMICAL", 76, 79], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 109, 123], ["AMP", "SIMPLE_CHEMICAL", 135, 138], ["beta-lactamases TEM", "TEST", 37, 56], ["ROB", "TEST", 63, 66], ["these AMP", "TEST", 70, 79], ["resistant strains", "PROBLEM", 80, 97], ["beta-lactamase", "TEST", 109, 123], ["AMP", "TEST", 135, 138]]], ["The second mechanism involves development of altered penicillin-binding proteins (PBP) with decreased affinity to AMP and other beta-lectam agents.", [["penicillin", "CHEMICAL", 53, 63], ["AMP", "CHEMICAL", 114, 117], ["penicillin", "CHEMICAL", 53, 63], ["AMP", "CHEMICAL", 114, 117], ["beta-lectam", "CHEMICAL", 128, 139], ["penicillin-binding proteins", "GENE_OR_GENE_PRODUCT", 53, 80], ["PBP", "GENE_OR_GENE_PRODUCT", 82, 85], ["AMP", "SIMPLE_CHEMICAL", 114, 117], ["beta-lectam agents", "SIMPLE_CHEMICAL", 128, 146], ["penicillin-binding proteins", "PROTEIN", 53, 80], ["PBP", "PROTEIN", 82, 85], ["altered penicillin-binding proteins", "PROBLEM", 45, 80], ["decreased affinity", "PROBLEM", 92, 110], ["AMP", "TREATMENT", 114, 117], ["other beta-lectam agents", "TREATMENT", 122, 146], ["altered", "OBSERVATION_MODIFIER", 45, 52], ["penicillin", "OBSERVATION", 53, 63]]], ["Strains with resistance mechanisms mediated by PBP alterations are termed beta-lactamase-nonproducing, AMP-resistant (BLNAR) H. influenzae.", [["AMP", "CHEMICAL", 103, 106], ["AMP", "CHEMICAL", 103, 106], ["PBP", "GENE_OR_GENE_PRODUCT", 47, 50], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 74, 88], ["AMP", "SIMPLE_CHEMICAL", 103, 106], ["H. influenzae", "ORGANISM", 125, 138], ["PBP", "PROTEIN", 47, 50], ["H. influenzae", "SPECIES", 125, 138], ["H. influenzae", "SPECIES", 125, 138], ["resistance mechanisms", "PROBLEM", 13, 34], ["PBP alterations", "TEST", 47, 62], ["termed beta-lactamase", "TEST", 67, 88], ["AMP", "TEST", 103, 106], ["resistant (BLNAR)", "PROBLEM", 107, 124], ["H. influenzae", "PROBLEM", 125, 138], ["beta-lactamase", "OBSERVATION_MODIFIER", 74, 88], ["influenzae", "OBSERVATION", 128, 138]]], ["Each participating laboratory received Haemophilus influenzae (PM-63)-beta-lactamase negative, ampicillin-resistant strain (BLNAR).", [["Haemophilus influenzae", "DISEASE", 39, 61], ["PM-63)-beta-lactamase", "CHEMICAL", 63, 84], ["ampicillin", "CHEMICAL", 95, 105], ["ampicillin", "CHEMICAL", 95, 105], ["Haemophilus influenzae", "ORGANISM", 39, 61], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 70, 84], ["ampicillin", "SIMPLE_CHEMICAL", 95, 105], ["Haemophilus influenzae", "SPECIES", 39, 61], ["Haemophilus influenzae", "SPECIES", 39, 61], ["Haemophilus influenzae", "TEST", 39, 61], ["beta-lactamase", "TEST", 70, 84], ["ampicillin", "TREATMENT", 95, 105], ["resistant strain (BLNAR)", "PROBLEM", 106, 130]]], ["Thirteen laboratories reported the analysed strain as Haemophilus parainfluenzae.", [["Haemophilus parainfluenzae", "DISEASE", 54, 80], ["Haemophilus parainfluenzae", "ORGANISM", 54, 80], ["Haemophilus parainfluenzae", "SPECIES", 54, 80], ["Haemophilus parainfluenzae", "SPECIES", 54, 80], ["Thirteen laboratories", "TEST", 0, 21], ["Haemophilus parainfluenzae", "PROBLEM", 54, 80], ["Haemophilus parainfluenzae", "OBSERVATION", 54, 80]]], ["Three hundred ninety eight laboratories (88.1%) of 452 correctly detected the mechanism of resistance to beta-lactams.", [["beta-lactams", "SIMPLE_CHEMICAL", 105, 117], ["beta-lactams", "PROTEIN", 105, 117], ["beta-lactams", "TEST", 105, 117]]], ["Only three laboratories incorrectly reported the organism as beta-lactamase producer.", [["beta-lactamase", "GENE_OR_GENE_PRODUCT", 61, 75], ["beta", "PROTEIN", 61, 65], ["beta-lactamase producer", "TREATMENT", 61, 84]]], ["The greatest dispersion of inhibition zone was observed in the susceptibility of H. influenzae to ampicillin, amoxicillin-clavulanic acid and clarithromycin.", [["ampicillin", "CHEMICAL", 98, 108], ["amoxicillin-clavulanic acid", "CHEMICAL", 110, 137], ["clarithromycin", "CHEMICAL", 142, 156], ["ampicillin", "CHEMICAL", 98, 108], ["amoxicillin-clavulanic acid", "CHEMICAL", 110, 137], ["clarithromycin", "CHEMICAL", 142, 156], ["H. influenzae", "ORGANISM", 81, 94], ["ampicillin", "SIMPLE_CHEMICAL", 98, 108], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 110, 137], ["clarithromycin", "SIMPLE_CHEMICAL", 142, 156], ["H. influenzae", "SPECIES", 81, 94], ["H. influenzae", "SPECIES", 81, 94], ["inhibition zone", "PROBLEM", 27, 42], ["H. influenzae", "PROBLEM", 81, 94], ["ampicillin", "TREATMENT", 98, 108], ["amoxicillin", "TREATMENT", 110, 121], ["clavulanic acid", "TREATMENT", 122, 137], ["clarithromycin", "TREATMENT", 142, 156], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["dispersion", "OBSERVATION_MODIFIER", 13, 23], ["inhibition", "OBSERVATION_MODIFIER", 27, 37], ["zone", "OBSERVATION_MODIFIER", 38, 42]]], ["Conclusions: Over 90% of the laboratories correctly identified and interpreted beta-lactamase-nonproducing, AMP-resistant (BLNAR) H. influenzae strain.", [["AMP", "CHEMICAL", 108, 111], ["AMP", "CHEMICAL", 108, 111], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 79, 93], ["AMP", "SIMPLE_CHEMICAL", 108, 111], ["H. influenzae strain", "ORGANISM", 130, 150], ["H. influenzae", "SPECIES", 130, 143], ["H. influenzae", "SPECIES", 130, 143], ["the laboratories", "TEST", 25, 41], ["beta-lactamase", "TEST", 79, 93], ["AMP", "TEST", 108, 111], ["H. influenzae strain", "PROBLEM", 130, 150], ["influenzae strain", "OBSERVATION", 133, 150]]], ["Purpose and methods.The Architect Syphilis TP assay is a chemiluminescent EIA that employs three recombinant antigens of Treponema pallidum on the solid phase and an anti-human IgM and IgG conjugate.", [["TP", "GENE_OR_GENE_PRODUCT", 43, 45], ["Treponema pallidum", "ORGANISM", 121, 139], ["IgM", "GENE_OR_GENE_PRODUCT", 177, 180], ["IgG", "GENE_OR_GENE_PRODUCT", 185, 188], ["recombinant antigens", "PROTEIN", 97, 117], ["anti-human IgM", "PROTEIN", 166, 180], ["IgG conjugate", "PROTEIN", 185, 198], ["Treponema pallidum", "SPECIES", 121, 139], ["Treponema pallidum", "SPECIES", 121, 139], ["The Architect Syphilis TP assay", "TEST", 20, 51], ["a chemiluminescent EIA", "TEST", 55, 77], ["Treponema pallidum", "PROBLEM", 121, 139], ["the solid phase", "TEST", 143, 158], ["an anti-human IgM", "TEST", 163, 180], ["solid phase", "OBSERVATION_MODIFIER", 147, 158]]], ["We evaluated this assay in comparison with a conventional EIA (Diesse Enzywell Syphilis Screen Recombinant) on unselected routine serum samples and on repository specimens for whom the results for specific IgG and IgM and of the rapid plasma reagin (RPR) assay were already known.", [["serum samples", "ANATOMY", 130, 143], ["specimens", "ANATOMY", 162, 171], ["plasma", "ANATOMY", 235, 241], ["serum samples", "ORGANISM_SUBSTANCE", 130, 143], ["IgG", "GENE_OR_GENE_PRODUCT", 206, 209], ["IgM", "GENE_OR_GENE_PRODUCT", 214, 217], ["plasma", "ORGANISM_SUBSTANCE", 235, 241], ["IgG", "PROTEIN", 206, 209], ["IgM", "PROTEIN", 214, 217], ["RPR", "PROTEIN", 250, 253], ["this assay", "TEST", 13, 23], ["a conventional EIA", "TEST", 43, 61], ["unselected routine serum samples", "TEST", 111, 143], ["repository specimens", "TEST", 151, 171], ["specific IgG", "TEST", 197, 209], ["IgM", "TEST", 214, 217], ["the rapid plasma reagin", "TEST", 225, 248], ["RPR) assay", "TEST", 250, 260]]], ["In both instances an immunoblot (IB: Inno-LIATM Syphilis Score, Innogenetics) has been employed on discordant specimens as a confirmatory assay.", [["specimens", "ANATOMY", 110, 119], ["an immunoblot", "TEST", 18, 31], ["a confirmatory assay", "TEST", 123, 143]]], ["The precision and robustness of the Architect assay were also evaluated.Results.On 1.165 routine samples (975 from volunteer blood donors and 190 from in and outpatients) the concordance between Architect and EIA was high (1.155 samples, or 99.1%; 7 positives, 1,148 negatives).", [["samples", "ANATOMY", 97, 104], ["blood", "ANATOMY", 125, 130], ["blood donors", "MULTI-TISSUE_STRUCTURE", 125, 137], ["the Architect assay", "TEST", 32, 51], ["blood donors", "TEST", 125, 137], ["Architect", "TEST", 195, 204], ["EIA", "TEST", 209, 212]]], ["One of the discordant, positive by Architect and negative by EIA, was confirmed by IB.", [["Architect", "TEST", 35, 44], ["EIA", "TEST", 61, 64]]], ["The specificity of the Architect assay was 99.4% (95% confidence limits: 98.9-99.8).", [["the Architect assay", "TEST", 19, 38]]], ["The 177 repository samples assayed belonged to three groups: 1) 9 biological false positives from 6 subjects: all negative by Architect; 2) 134 true positives, all positive by Architect, with a significantly stronger signal (average S/CO: 26.19 vs. 14.53) on the 23 IgM positive samples, all of whom were also positive by RPR; 3) 34 samples positive by RPR and negative by EIA IgG: 32 of them were negative by Architect as well and for IgM, while two specimens were strongly positive by Architect and positive also for specific IgM and with three specific bands by Inno-LIA, suggesting a pattern of recent infection.", [["samples", "ANATOMY", 19, 26], ["samples", "ANATOMY", 279, 286], ["samples", "ANATOMY", 333, 340], ["specimens", "ANATOMY", 451, 460], ["infection", "DISEASE", 606, 615], ["samples", "CANCER", 333, 340], ["IgG", "GENE_OR_GENE_PRODUCT", 377, 380], ["IgM", "GENE_OR_GENE_PRODUCT", 436, 439], ["IgM", "GENE_OR_GENE_PRODUCT", 528, 531], ["IgM", "PROTEIN", 266, 269], ["RPR", "PROTEIN", 353, 356], ["EIA IgG", "PROTEIN", 373, 380], ["IgM", "PROTEIN", 436, 439], ["IgM", "PROTEIN", 528, 531], ["repository samples", "TEST", 8, 26], ["biological false positives", "TEST", 66, 92], ["true positives", "TEST", 144, 158], ["Architect", "TEST", 176, 185], ["S/CO", "TEST", 233, 237], ["the 23 IgM positive samples", "PROBLEM", 259, 286], ["RPR", "TEST", 322, 325], ["RPR", "TEST", 353, 356], ["EIA IgG", "TEST", 373, 380], ["IgM", "TEST", 436, 439], ["two specimens", "TEST", 447, 460], ["Architect", "TEST", 487, 496], ["specific IgM", "TEST", 519, 531], ["recent infection", "PROBLEM", 599, 615], ["LIA", "ANATOMY", 570, 573], ["infection", "OBSERVATION", 606, 615]]], ["The reproducibility of the Architect assay was good, with CVs of 7.78%, 5.71% and 5.51% on 28 replicates over 4 weeks of the assay's negative and positive control and of an internal control; finally, the S/CO distribution of negative specimens confirmed the robustness of the assay, with a mean of 0.09, a median of 0.06, 10 standard deviations between the mean and the cut-off value and the 99th percentile at a S/CO value of 0.53.Conclusion.The automated assay for anti-Treponema pallidum antibodies on the Architect system has an excellent sensitivity and a good specificity.", [["specimens", "ANATOMY", 234, 243], ["anti-Treponema pallidum", "ORGANISM", 467, 490], ["anti-Treponema pallidum antibodies", "PROTEIN", 467, 501], ["anti-Treponema pallidum", "SPECIES", 467, 490], ["anti-Treponema pallidum", "SPECIES", 467, 490], ["the Architect assay", "TEST", 23, 42], ["CVs", "TEST", 58, 61], ["the assay's", "TEST", 121, 132], ["the S/CO distribution", "TEST", 200, 221], ["the assay", "TEST", 272, 281], ["a S/CO value", "TEST", 411, 423], ["The automated assay", "TEST", 443, 462], ["anti-Treponema pallidum antibodies", "PROBLEM", 467, 501], ["the Architect system", "TEST", 505, 525]]], ["The analytical performances, coupled with the elevated throughput and minimal samples handling, make this method a first-choice option for syphilis screening and diagnosis in medium and large volume laboratories.", [["syphilis", "DISEASE", 139, 147], ["The analytical performances", "TEST", 0, 27], ["the elevated throughput", "PROBLEM", 42, 65], ["minimal samples handling", "PROBLEM", 70, 94], ["syphilis screening", "TEST", 139, 157], ["large volume laboratories", "TEST", 186, 211], ["minimal", "OBSERVATION_MODIFIER", 70, 77]]], ["Objective: Quantitative urine culture is the gold standard for defining the diagnosis of Urinary Tract Infection (UTI), because it allows identification of the uropathogenic species.", [["urine culture", "ANATOMY", 24, 37], ["Urinary Tract Infection", "DISEASE", 89, 112], ["UTI", "DISEASE", 114, 117], ["urine", "ORGANISM_SUBSTANCE", 24, 29], ["Quantitative urine culture", "TEST", 11, 37], ["Urinary Tract Infection", "PROBLEM", 89, 112], ["UTI", "PROBLEM", 114, 117], ["the uropathogenic species", "PROBLEM", 156, 181], ["Urinary Tract", "ANATOMY", 89, 102], ["Infection", "OBSERVATION", 103, 112], ["uropathogenic species", "OBSERVATION", 160, 181]]], ["Approximately, up to 70% of urine cultures are negative with high cost for unnecessary testing.", [["urine cultures", "ANATOMY", 28, 42], ["urine", "ORGANISM_SUBSTANCE", 28, 33], ["cultures", "CELL", 34, 42], ["urine cultures", "TEST", 28, 42], ["unnecessary testing", "TEST", 75, 94]]], ["Thus, we have evaluated the usefulness of two automated analysers for UTI screening to quickly identify the negative samples that can be prompt reported to the clinicians, improving in the quality of patient care and allowing the laboratory to direct more effort into positive samples.", [["samples", "ANATOMY", 277, 284], ["patient", "ORGANISM", 200, 207], ["patient", "SPECIES", 200, 207], ["UTI screening", "TEST", 70, 83]]], ["Methods: 1.165 of midstream urine samples submitted for microbiological examination were analysed by conventional urine culture plates (McConkey agar + Trypticase Soy agar + Bile Esculine Azide), Sysmex UF-100 (Sysmex, Japan) and Coral UTI Screen (Coral Biotechnology, CA, USA) automated analysers.", [["urine samples", "ANATOMY", 28, 41], ["urine samples", "ORGANISM_SUBSTANCE", 28, 41], ["urine", "ORGANISM_SUBSTANCE", 114, 119], ["midstream urine samples", "TEST", 18, 41], ["microbiological examination", "TEST", 56, 83], ["conventional urine culture plates", "TEST", 101, 134], ["McConkey", "TEST", 136, 144], ["agar", "TEST", 145, 149], ["Trypticase Soy", "TEST", 152, 166], ["agar", "TEST", 167, 171], ["Bile Esculine Azide", "TEST", 174, 193], ["Sysmex UF", "TEST", 196, 205], ["Sysmex", "TEST", 211, 217], ["Coral UTI Screen", "TEST", 230, 246]]], ["UTI was defined positive as follows: one or two strains of bacteria with at least 10 5 UFC/ml for the culture plates, more than 5.000 bacteria/ll and more than 15 WBC/ll for the UF-100 and/or an RLU value grater than 2% of the calibrator value for the Coral.", [["UTI", "DISEASE", 0, 3], ["UTI", "PROBLEM", 0, 3], ["bacteria", "PROBLEM", 59, 67], ["the culture plates", "TEST", 98, 116], ["5.000 bacteria/ll", "PROBLEM", 128, 145], ["WBC", "TEST", 163, 166], ["the UF", "TEST", 174, 180], ["an RLU value", "TEST", 192, 204], ["bacteria", "OBSERVATION", 59, 67], ["ll", "ANATOMY", 143, 145]]], ["When more than two strains of bacteria were found, the culture was classified as contamined.", [["bacteria", "PROBLEM", 30, 38], ["the culture", "TEST", 51, 62], ["bacteria", "OBSERVATION", 30, 38]]], ["Results: The diagnostic performance of Sysmex UF-100 and Coral UTI Screen are shown in table 1.Conclusion:The Sensitivity (95.8%) and Negative Predictive Value (96.4%) confirm that Sysmex UF-100 and Coral UTI screen are an excellent screening for UTI.", [["UTI", "DISEASE", 247, 250], ["Sysmex UF", "TEST", 39, 48], ["Coral UTI Screen", "TEST", 57, 73], ["The Sensitivity", "TEST", 106, 121], ["Predictive Value", "TEST", 143, 159], ["Sysmex UF", "TEST", 181, 190], ["Coral UTI screen", "TEST", 199, 215], ["UTI", "PROBLEM", 247, 250], ["UTI", "OBSERVATION", 247, 250]]], ["After this evaluation, we decide the use of the Sysmex UF-100 and Coral UTI Screen on our routine workflow for UTI screening.", [["UTI", "DISEASE", 111, 114], ["this evaluation", "TEST", 6, 21], ["the Sysmex UF", "TEST", 44, 57], ["Coral UTI Screen", "PROBLEM", 66, 82], ["our routine workflow", "TEST", 86, 106], ["UTI screening", "TEST", 111, 124]]], ["The results of both the analysers are sent to a software system (LabFinity Dasit, Italy) connected to the LIS.", [["the analysers", "TEST", 20, 33]]], ["If the results are lower than the cut-off values, UTI can be excluded and directly reported to the physician.", [["UTI", "DISEASE", 50, 53], ["UTI", "PROBLEM", 50, 53], ["lower", "OBSERVATION_MODIFIER", 19, 24]]], ["Positive results are submitted to microbiological culture and reported within 24 or 48 hours depending on negative or positive bacterial growth.", [["microbiological culture", "TEST", 34, 57], ["positive bacterial growth", "PROBLEM", 118, 143], ["positive bacterial", "OBSERVATION_MODIFIER", 118, 136], ["growth", "OBSERVATION_MODIFIER", 137, 143]]], ["In our experience, evaluated on further 2.955 samples, this means that 78% of samples are immediately reported within very few hours.", [["samples", "ANATOMY", 78, 85], ["samples", "CANCER", 78, 85]]], ["Of the 22% of positive samples, 222 (35%) were confirmed by culture and reported within 48 hours, 418 (65%) were not confirmed and reported within 24 hours.P1738Comparison of the blood and bone marrow culture positivity rates for the diagnosis of brucellosis Objectives: Brucellosis is a common disease, seen worldwide as well as in our country.", [["samples", "ANATOMY", 23, 30], ["blood", "ANATOMY", 179, 184], ["bone marrow", "ANATOMY", 189, 200], ["brucellosis", "DISEASE", 247, 258], ["Brucellosis", "DISEASE", 271, 282], ["samples", "CANCER", 23, 30], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 189, 200], ["positive samples", "TEST", 14, 30], ["culture", "TEST", 60, 67], ["the blood", "TEST", 175, 184], ["bone marrow culture", "TEST", 189, 208], ["brucellosis", "PROBLEM", 247, 258], ["Brucellosis", "PROBLEM", 271, 282], ["a common disease", "PROBLEM", 286, 302], ["blood", "ANATOMY", 179, 184], ["bone", "ANATOMY", 189, 193], ["marrow", "ANATOMY", 194, 200], ["brucellosis", "OBSERVATION", 247, 258], ["Brucellosis", "OBSERVATION", 271, 282]]], ["The diagnosis of brucellosis is made with certainly when brucellae are recovered from blood, bone marrow.", [["brucellae", "ANATOMY", 57, 66], ["blood", "ANATOMY", 86, 91], ["bone marrow", "ANATOMY", 93, 104], ["brucellosis", "DISEASE", 17, 28], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 93, 104], ["brucellosis", "PROBLEM", 17, 28], ["brucellae", "PROBLEM", 57, 66], ["blood, bone marrow", "TEST", 86, 104], ["brucellosis", "OBSERVATION", 17, 28], ["bone marrow", "ANATOMY", 93, 104]]], ["In our study, we aimed to compare the blood and bone marrow culture positivity rates in patient with brucellosis.", [["blood", "ANATOMY", 38, 43], ["bone marrow", "ANATOMY", 48, 59], ["brucellosis", "DISEASE", 101, 112], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 48, 59], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["our study", "TEST", 3, 12], ["the blood", "TEST", 34, 43], ["bone marrow culture", "TEST", 48, 67], ["brucellosis", "PROBLEM", 101, 112], ["bone", "ANATOMY", 48, 52], ["marrow", "ANATOMY", 53, 59], ["brucellosis", "OBSERVATION", 101, 112]]], ["Methods: This study was performed in the Infectious Diseases and Clinical Microbiology Department of Ankara Research and Training Hospital between 2002 and 2004.", [["This study", "TEST", 9, 19]]], ["The diagnosis of brucellosis was made on the history, physical findings, serologic findings and the isolation of the organism.", [["brucellosis", "DISEASE", 17, 28], ["brucellosis", "PROBLEM", 17, 28], ["physical findings", "TEST", 54, 71], ["serologic findings", "TEST", 73, 91], ["the organism", "PROBLEM", 113, 125], ["brucellosis", "OBSERVATION", 17, 28]]], ["The number of patients with brucellosis included to the study was 102.", [["brucellosis", "DISEASE", 28, 39], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["brucellosis", "PROBLEM", 28, 39], ["the study", "TEST", 52, 61], ["brucellosis", "OBSERVATION", 28, 39]]], ["Blood and bone marrow samples were taken from all of the patients on admission and cultured by using the BACTEC 9050 system.", [["Blood", "ANATOMY", 0, 5], ["bone marrow samples", "ANATOMY", 10, 29], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["bone marrow samples", "ORGANISM_SUBSTANCE", 10, 29], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["Blood and bone marrow samples", "TEST", 0, 29], ["bone", "ANATOMY", 10, 14], ["marrow", "ANATOMY", 15, 21]]], ["Results: Blood culture positivity for brucellosis was 48% (49/ 102), while bone marrow culture positivity was 34% (35/102).", [["Blood", "ANATOMY", 9, 14], ["bone marrow", "ANATOMY", 75, 86], ["brucellosis", "DISEASE", 38, 49], ["Blood", "ORGANISM_SUBSTANCE", 9, 14], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 75, 86], ["Blood culture positivity", "TEST", 9, 33], ["brucellosis", "PROBLEM", 38, 49], ["bone marrow culture positivity", "TEST", 75, 105], ["Blood", "ANATOMY", 9, 14], ["bone", "ANATOMY", 75, 79], ["marrow", "ANATOMY", 80, 86]]], ["The difference between those positivity rates was found to be statistically significant (p < 0.05).", [["those positivity rates", "TEST", 23, 45], ["significant", "OBSERVATION_MODIFIER", 76, 87]]], ["The isolation ratio from blood cultures among acute cases was 66% (40/61) while it was 31% (9/29) among subacute cases.", [["blood cultures", "ANATOMY", 25, 39], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["The isolation ratio", "TEST", 0, 19], ["blood cultures", "TEST", 25, 39], ["acute cases", "TEST", 46, 57], ["subacute", "OBSERVATION_MODIFIER", 104, 112]]], ["Brucella isolation from blood was not detected in 12 chronic cases.", [["blood", "ANATOMY", 24, 29], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["Brucella isolation", "PROBLEM", 0, 18], ["chronic", "OBSERVATION_MODIFIER", 53, 60]]], ["The isolation rates of the microorganism from bone marrow of acute, subacute and chronic cases were 45.9%, 20.7%, 0.9% respectively.", [["bone marrow", "ANATOMY", 46, 57], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 46, 57], ["The isolation rates", "TEST", 0, 19], ["the microorganism", "PROBLEM", 23, 40], ["acute, subacute and chronic cases", "PROBLEM", 61, 94], ["bone marrow", "ANATOMY", 46, 57], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["subacute", "OBSERVATION_MODIFIER", 68, 76], ["chronic", "OBSERVATION_MODIFIER", 81, 88]]], ["Among our patients, 32 had history of medical therapy for brucellosis before admission and 27 of them was treated inadequately.", [["brucellosis", "DISEASE", 58, 69], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["medical therapy", "TREATMENT", 38, 53], ["brucellosis", "PROBLEM", 58, 69]]], ["Of those 27 cases, the organism was isolated in 7 (25%) from blood and in 9 (33%) from bone marrow.In the cases with high standard tube agglutination titers, the rate of positivity was also high both in blood and bone marrow cultures.", [["blood", "ANATOMY", 61, 66], ["bone marrow", "ANATOMY", 87, 98], ["blood", "ANATOMY", 203, 208], ["bone marrow cultures", "ANATOMY", 213, 233], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 87, 98], ["tube", "TISSUE", 131, 135], ["blood", "ORGANISM_SUBSTANCE", 203, 208], ["bone marrow cultures", "CELL", 213, 233], ["the organism", "TEST", 19, 31], ["blood", "TEST", 61, 66], ["bone marrow", "TEST", 87, 98], ["high standard tube agglutination titers", "TREATMENT", 117, 156], ["the rate of positivity", "TEST", 158, 180], ["blood and bone marrow cultures", "TEST", 203, 233], ["bone marrow", "ANATOMY", 87, 98], ["tube agglutination", "OBSERVATION", 131, 149], ["bone", "ANATOMY", 213, 217]]], ["However when compared with low standard tube agglutination titers, that difference was not statistically significant.The mean growing time for the positivity of cultures was 4.2 days for bone marrow and was 5.8 days for blood cultures.", [["bone marrow", "ANATOMY", 187, 198], ["blood cultures", "ANATOMY", 220, 234], ["tube", "TISSUE", 40, 44], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 187, 198], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["low standard tube agglutination titers", "TREATMENT", 27, 65], ["cultures", "TEST", 161, 169], ["bone marrow", "TEST", 187, 198], ["blood cultures", "TEST", 220, 234], ["marrow", "ANATOMY", 192, 198]]], ["The difference between the mean growing times of two culture types was found statistically significant (t-test. p < 0.05).", [["two culture types", "TEST", 49, 66], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Conclusion: Premedication, subacute and especially chronic phases decrease the possibility of isolation of the microorganism from blood culture.", [["blood", "ANATOMY", 130, 135], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["Premedication", "TREATMENT", 12, 25], ["chronic phases", "PROBLEM", 51, 65], ["the microorganism", "PROBLEM", 107, 124], ["blood culture", "TEST", 130, 143], ["subacute", "OBSERVATION_MODIFIER", 27, 35]]], ["Therefore we suggest taking bone marrow culture only for these kinds of patients as it. is a traumatic process.P1739Serological findings in blood sera of patients with Yersinia-triggered arthritis E. Golkocheva, R. Stoilov, H. Najdenski (Sofia, BG)P1739Objectives: Immunoblot analysis of IgA and IgG antibody response of blood sera from patient with Yersinia triggered reactive arthritis and with undifferentiated arthritis were made.", [["bone marrow", "ANATOMY", 28, 39], ["blood sera", "ANATOMY", 140, 150], ["blood sera", "ANATOMY", 321, 331], ["Yersinia-triggered arthritis", "DISEASE", 168, 196], ["reactive arthritis", "DISEASE", 369, 387], ["undifferentiated arthritis", "DISEASE", 397, 423], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 28, 39], ["patients", "ORGANISM", 72, 80], ["blood sera", "ORGANISM_SUBSTANCE", 140, 150], ["patients", "ORGANISM", 154, 162], ["IgA", "GENE_OR_GENE_PRODUCT", 288, 291], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 296, 308], ["blood", "ORGANISM_SUBSTANCE", 321, 326], ["sera", "ORGANISM_SUBSTANCE", 327, 331], ["patient", "ORGANISM", 337, 344], ["IgA", "PROTEIN", 288, 291], ["IgG antibody", "PROTEIN", 296, 308], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 154, 162], ["patient", "SPECIES", 337, 344], ["bone marrow culture", "TEST", 28, 47], ["a traumatic process", "PROBLEM", 91, 110], ["blood sera", "TEST", 140, 150], ["Yersinia", "PROBLEM", 168, 176], ["arthritis", "PROBLEM", 187, 196], ["Immunoblot analysis", "TEST", 265, 284], ["IgA", "TEST", 288, 291], ["IgG antibody", "TEST", 296, 308], ["blood sera", "TEST", 321, 331], ["Yersinia", "PROBLEM", 350, 358], ["reactive arthritis", "PROBLEM", 369, 387], ["undifferentiated arthritis", "PROBLEM", 397, 423], ["traumatic", "OBSERVATION", 93, 102], ["Yersinia", "OBSERVATION", 168, 176], ["arthritis", "OBSERVATION", 187, 196], ["reactive arthritis", "OBSERVATION", 369, 387], ["undifferentiated", "OBSERVATION_MODIFIER", 397, 413], ["arthritis", "OBSERVATION", 414, 423]]], ["Patients and methods: Serum samples were obtained from patients admitted to Clinic of Rheumatology at Medical University, Sofia, Bulgaria with suspicion of Yersinia triggered reactive arthritis, based on diagnostic criteria.", [["Serum samples", "ANATOMY", 22, 35], ["Yersinia", "DISEASE", 156, 164], ["reactive arthritis", "DISEASE", 175, 193], ["Patients", "ORGANISM", 0, 8], ["Serum samples", "ORGANISM_SUBSTANCE", 22, 35], ["patients", "ORGANISM", 55, 63], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 55, 63], ["Serum samples", "TEST", 22, 35], ["Yersinia", "PROBLEM", 156, 164], ["reactive arthritis", "PROBLEM", 175, 193], ["diagnostic criteria", "TEST", 204, 223], ["Yersinia", "OBSERVATION", 156, 164], ["reactive", "OBSERVATION_MODIFIER", 175, 183], ["arthritis", "OBSERVATION", 184, 193]]], ["A total of 20 blood serum samples were analysed by immunoblot analysis with specific antigens-Yops (yersinia outermembrane proteins).", [["blood serum samples", "ANATOMY", 14, 33], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["serum samples", "ORGANISM_SUBSTANCE", 20, 33], ["Yops", "GENE_OR_GENE_PRODUCT", 94, 98], ["yersinia outermembrane proteins", "GENE_OR_GENE_PRODUCT", 100, 131], ["antigens", "PROTEIN", 85, 93], ["Yops", "PROTEIN", 94, 98], ["yersinia outermembrane proteins", "PROTEIN", 100, 131], ["blood serum samples", "TEST", 14, 33], ["immunoblot analysis", "TEST", 51, 70], ["specific antigens", "TEST", 76, 93]]], ["When Y. enterocolitica is cultivated at 37 o C under calcium restriction (0.2 mM Ca 2+ ), large amounts of Yops are secreted into medium.", [["Y. enterocolitica", "DISEASE", 5, 22], ["calcium", "CHEMICAL", 53, 60], ["Ca", "CHEMICAL", 81, 83], ["calcium", "CHEMICAL", 53, 60], ["Ca 2+", "CHEMICAL", 81, 86], ["Y. enterocolitica", "ORGANISM", 5, 22], ["calcium", "SIMPLE_CHEMICAL", 53, 60], ["Yops", "GENE_OR_GENE_PRODUCT", 107, 111], ["Yops", "PROTEIN", 107, 111], ["Y. enterocolitica", "SPECIES", 5, 22], ["Y. enterocolitica", "SPECIES", 5, 22], ["calcium restriction", "TEST", 53, 72], ["mM Ca", "TEST", 78, 83], ["large amounts of Yops", "PROBLEM", 90, 111], ["large", "OBSERVATION_MODIFIER", 90, 95], ["amounts", "OBSERVATION_MODIFIER", 96, 103], ["Yops", "OBSERVATION", 107, 111]]], ["These proteins were separated by 2D-SDSelectrophoresis.P1739Results: Immunoblot analysis of IgA and IgG antibody response against Yops in 20 blood sera from patients with arthralgias and polyarthropathies was carried out.", [["blood sera", "ANATOMY", 141, 151], ["arthralgias", "DISEASE", 171, 182], ["polyarthropathies", "DISEASE", 187, 204], ["IgA", "GENE_OR_GENE_PRODUCT", 92, 95], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 100, 112], ["blood sera", "ORGANISM_SUBSTANCE", 141, 151], ["patients", "ORGANISM", 157, 165], ["IgA", "PROTEIN", 92, 95], ["IgG antibody", "PROTEIN", 100, 112], ["patients", "SPECIES", 157, 165], ["Immunoblot analysis", "TEST", 69, 88], ["IgA", "TEST", 92, 95], ["IgG antibody", "TEST", 100, 112], ["Yops", "TEST", 130, 134], ["blood sera", "TEST", 141, 151], ["arthralgias", "PROBLEM", 171, 182], ["polyarthropathies", "PROBLEM", 187, 204], ["arthralgias", "OBSERVATION", 171, 182]]], ["Yersinia enterocolitica, serotype O: 8, was used as source for Yop.", [["Yersinia enterocolitica", "DISEASE", 0, 23], ["Yersinia enterocolitica", "ORGANISM", 0, 23], ["Yersinia enterocolitica", "SPECIES", 0, 23], ["Yersinia enterocolitica", "SPECIES", 0, 23], ["Yersinia enterocolitica", "PROBLEM", 0, 23], ["enterocolitica", "OBSERVATION", 9, 23]]], ["Seven strong bands of the molecular weights 26 kDa-YopE, 33 kDa-YopN, 36 kDa-YopD, 41 kDa -V-ag, 43 kDa-YopB, 46 kDa-YopM and 51 kDa-YopH were visualized.", [["kDa-YopH", "GENE_OR_GENE_PRODUCT", 129, 137], ["YopE", "PROTEIN", 51, 55], ["33 kDa", "PROTEIN", 57, 63], ["YopN", "PROTEIN", 64, 68], ["36 kDa", "PROTEIN", 70, 76], ["YopD", "PROTEIN", 77, 81], ["41 kDa", "PROTEIN", 83, 89], ["V-ag", "PROTEIN", 91, 95], ["43 kDa", "PROTEIN", 97, 103], ["YopB", "PROTEIN", 104, 108], ["46 kDa", "PROTEIN", 110, 116], ["YopM", "PROTEIN", 117, 121], ["51 kDa", "PROTEIN", 126, 132], ["YopH", "PROTEIN", 133, 137], ["the molecular weights", "TEST", 22, 43], ["kDa", "TEST", 60, 63], ["kDa", "TEST", 73, 76], ["kDa", "TEST", 86, 89], ["V-ag", "TEST", 91, 95], ["kDa", "TEST", 100, 103], ["YopB", "TEST", 104, 108], ["kDa", "TEST", 113, 116], ["kDa", "TEST", 129, 132], ["strong", "OBSERVATION_MODIFIER", 6, 12], ["bands", "OBSERVATION_MODIFIER", 13, 18], ["43 kDa", "OBSERVATION_MODIFIER", 97, 103], ["51 kDa", "OBSERVATION_MODIFIER", 126, 132]]], ["For immunoblot assay the optimal concentration of antigen was established by analytical electrophoresis.", [["immunoblot assay", "TEST", 4, 20], ["analytical electrophoresis", "TEST", 77, 103]]], ["Of the 10 blood sera from the patients with Yersinia triggered reactive arthritis IgG antibodies were detected against YopH, YopM, YopB, YopD, YopN and YopE.", [["blood sera", "ANATOMY", 10, 20], ["arthritis", "DISEASE", 72, 81], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["sera", "ORGANISM_SUBSTANCE", 16, 20], ["patients", "ORGANISM", 30, 38], ["YopH", "GENE_OR_GENE_PRODUCT", 119, 123], ["YopM", "GENE_OR_GENE_PRODUCT", 125, 129], ["YopB", "GENE_OR_GENE_PRODUCT", 131, 135], ["YopD", "GENE_OR_GENE_PRODUCT", 137, 141], ["YopN", "GENE_OR_GENE_PRODUCT", 143, 147], ["YopE", "GENE_OR_GENE_PRODUCT", 152, 156], ["arthritis IgG antibodies", "PROTEIN", 72, 96], ["YopH", "PROTEIN", 119, 123], ["YopM", "PROTEIN", 125, 129], ["YopB", "PROTEIN", 131, 135], ["YopD", "PROTEIN", 137, 141], ["YopN", "PROTEIN", 143, 147], ["YopE", "PROTEIN", 152, 156], ["patients", "SPECIES", 30, 38], ["blood sera", "TEST", 10, 20], ["Yersinia", "PROBLEM", 44, 52], ["reactive arthritis IgG antibodies", "PROBLEM", 63, 96], ["reactive", "OBSERVATION_MODIFIER", 63, 71], ["arthritis", "OBSERVATION", 72, 81]]], ["IgA antibodies were established against YopM, YopB, YopD, YopN and YopE.", [["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["YopM", "GENE_OR_GENE_PRODUCT", 40, 44], ["YopB", "GENE_OR_GENE_PRODUCT", 46, 50], ["YopD", "GENE_OR_GENE_PRODUCT", 52, 56], ["YopN", "GENE_OR_GENE_PRODUCT", 58, 62], ["YopE", "GENE_OR_GENE_PRODUCT", 67, 71], ["IgA antibodies", "PROTEIN", 0, 14], ["YopM", "PROTEIN", 40, 44], ["YopB", "PROTEIN", 46, 50], ["YopD", "PROTEIN", 52, 56], ["YopN", "PROTEIN", 58, 62], ["YopE", "PROTEIN", 67, 71], ["IgA antibodies", "TEST", 0, 14]]], ["All 5 sera from the patients with other rheumatic diseases were negative for the presence of anti-yersinia IgA antibodies and two of them were positive for IgG against YopD.", [["sera", "ANATOMY", 6, 10], ["rheumatic diseases", "DISEASE", 40, 58], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["patients", "ORGANISM", 20, 28], ["IgA", "GENE_OR_GENE_PRODUCT", 107, 110], ["IgG", "GENE_OR_GENE_PRODUCT", 156, 159], ["YopD", "GENE_OR_GENE_PRODUCT", 168, 172], ["anti-yersinia IgA antibodies", "PROTEIN", 93, 121], ["IgG", "PROTEIN", 156, 159], ["YopD", "PROTEIN", 168, 172], ["patients", "SPECIES", 20, 28], ["All 5 sera", "TEST", 0, 10], ["other rheumatic diseases", "PROBLEM", 34, 58], ["anti-yersinia IgA antibodies", "PROBLEM", 93, 121], ["IgG", "PROBLEM", 156, 159], ["YopD", "PROBLEM", 168, 172], ["rheumatic", "OBSERVATION", 40, 49]]], ["Antibodies from two classes were not detected in 5 sera samples from healthy people.", [["sera samples", "ANATOMY", 51, 63], ["sera samples", "ORGANISM_SUBSTANCE", 51, 63], ["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["Antibodies", "TEST", 0, 10]]], ["Conclusions: Yops are borne by the virulence plasmid, which mean that they are clearly associated with virulence properties of pathogenic strains.", [["Yops", "GENE_OR_GENE_PRODUCT", 13, 17], ["virulence plasmid", "DNA", 35, 52], ["pathogenic strains", "PROBLEM", 127, 145]]], ["Moreover, Yops is not restricted to single serotype and this made them a specific antigen in diagnosis of different Yersinia infections.", [["Yersinia infections", "DISEASE", 116, 135], ["Yersinia infections", "ORGANISM", 116, 135], ["Yops", "PROBLEM", 10, 14], ["single serotype", "PROBLEM", 36, 51], ["different Yersinia infections", "PROBLEM", 106, 135], ["Yersinia infections", "OBSERVATION", 116, 135]]], ["Conventional techniques such as culture and demonstration of serum agglutinins prove to be insufficient to demonstrate invasive or chronic yersiniosis in contrast with the determination of specific serum IgA and IgG antibodies by immunoblot analysis and antigen detection.", [["serum", "ANATOMY", 61, 66], ["serum", "ANATOMY", 198, 203], ["yersiniosis", "DISEASE", 139, 150], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["IgA", "GENE_OR_GENE_PRODUCT", 204, 207], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 212, 226], ["serum IgA", "PROTEIN", 198, 207], ["IgG antibodies", "PROTEIN", 212, 226], ["Conventional techniques", "TREATMENT", 0, 23], ["culture", "TEST", 32, 39], ["serum agglutinins", "TEST", 61, 78], ["invasive or chronic yersiniosis in contrast", "PROBLEM", 119, 162], ["specific serum IgA", "TEST", 189, 207], ["IgG antibodies", "TEST", 212, 226], ["immunoblot analysis", "TEST", 230, 249], ["antigen detection", "TEST", 254, 271], ["invasive", "OBSERVATION_MODIFIER", 119, 127], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["yersiniosis", "OBSERVATION", 139, 150]]], ["The detection of anti-Yops IgG and IgA antibodies by immunoblot can be used for diagnosis of Yersinia triggered arthritis.", [["Yersinia", "DISEASE", 93, 101], ["arthritis", "DISEASE", 112, 121], ["anti-Yops IgG", "GENE_OR_GENE_PRODUCT", 17, 30], ["IgA antibodies", "GENE_OR_GENE_PRODUCT", 35, 49], ["anti-Yops IgG", "PROTEIN", 17, 30], ["IgA antibodies", "PROTEIN", 35, 49], ["anti-Yops", "SPECIES", 17, 26], ["The detection", "TEST", 0, 13], ["anti-Yops IgG", "TREATMENT", 17, 30], ["IgA antibodies", "TEST", 35, 49], ["immunoblot", "TEST", 53, 63], ["Yersinia triggered arthritis", "PROBLEM", 93, 121], ["Yersinia", "OBSERVATION", 93, 101], ["arthritis", "OBSERVATION", 112, 121]]], ["Acknowledgements: This work was sponsored by NATOreintegration grant 981256.", [["NATOreintegration grant 981256", "CHEMICAL", 45, 75]]], ["Objectives: To evaluate the identification and susceptibility results by using suspensions obtained directly from positive blood cultures.", [["blood cultures", "ANATOMY", 123, 137], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["positive blood cultures", "CELL_LINE", 114, 137], ["the identification", "TEST", 24, 42], ["positive blood cultures", "TEST", 114, 137]]], ["Methods: During the period between 1st August and 31st October 2005 we selected all positive cultures grown in Bact/ Alert \u00d2 SA and SN bottles (bioM\u00e9rieux) from gram-negative bacilli.", [["all positive cultures", "TEST", 80, 101], ["gram", "TEST", 161, 165], ["negative bacilli", "OBSERVATION", 166, 182]]], ["Only the first culture positive from each patient was included.", [["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["the first culture", "TEST", 5, 22]]], ["We inoculated 5 mL fluid from a positive bottle into a serum separator tube (BD Vacutainer Systems, Plymouth, United Kingdom) and centrifuged at 1500 x g for 10 minutes and the supernatant was carefully aspirated.", [["serum", "ANATOMY", 55, 60], ["supernatant", "ANATOMY", 177, 188], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["tube", "TISSUE", 71, 75], ["a serum separator tube", "TREATMENT", 53, 75], ["BD Vacutainer Systems", "TREATMENT", 77, 98], ["the supernatant", "TREATMENT", 173, 188]]], ["Using a cotton swab the bacteria were removed from the top of the separator layer to be suspended in 0.45% saline solution to get 0.6 McFarland.", [["saline", "SIMPLE_CHEMICAL", 107, 113], ["cotton", "SPECIES", 8, 14], ["a cotton swab the bacteria", "TREATMENT", 6, 32], ["the separator layer", "TREATMENT", 62, 81], ["0.45% saline solution", "TREATMENT", 101, 122]]], ["The suspension was processed according to standard inoculation procedure for GN and AST-N020 Vitek \u00d2 2 cards.", [["The suspension", "TREATMENT", 0, 14], ["standard inoculation procedure", "TREATMENT", 42, 72], ["GN", "TEST", 77, 79], ["AST", "TEST", 84, 87]]], ["Positive Bact/Alert 3D bottles were also sub cultured and after an overnight incubation several colonies were used to make a 0.63 McFarland suspension in 0.45% saline.", [["colonies", "ANATOMY", 96, 104], ["Bact", "GENE_OR_GENE_PRODUCT", 9, 13], ["saline", "SIMPLE_CHEMICAL", 160, 166], ["an overnight incubation several colonies", "TREATMENT", 64, 104], ["a 0.63 McFarland suspension", "TREATMENT", 123, 150], ["0.45% saline", "TREATMENT", 154, 166], ["Bact", "OBSERVATION", 9, 13]]], ["The suspension was processed according to standard Vitek \u00d2 2 inoculation procedure for GN and AST-N020 cards.", [["AST", "PROTEIN", 94, 97], ["The suspension", "TREATMENT", 0, 14], ["2 inoculation procedure", "TREATMENT", 59, 82], ["GN", "TEST", 87, 89], ["AST", "TEST", 94, 97]]], ["Results: Identification: A total 56 gram-negative bacillus from positive blood cultures were investigated.", [["blood cultures", "ANATOMY", 73, 87], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["positive blood cultures", "CELL_LINE", 64, 87], ["positive blood cultures", "TEST", 64, 87]]], ["Fifty (89.2%) strains were correctly identified to the species level, four (7.1%) strains were not identified and two (3.6%) strains were misidentified.", [["strains", "PROBLEM", 14, 21]]], ["Antimicrobial susceptibility testing: In all, 1040 MICs were determined for 52 isolated by both methods.", [["Antimicrobial susceptibility testing", "TEST", 0, 36]]], ["The unidentified strains (4) were excluded.", [["strains", "OBSERVATION_MODIFIER", 17, 24]]], ["All individual antimicrobial agents scored > 90%.", [["All individual antimicrobial agents", "TREATMENT", 0, 35], ["antimicrobial", "OBSERVATION_MODIFIER", 15, 28]]], ["The overall minor error rate was 2.8% (30 of 1040).", [["The overall minor error rate", "TEST", 0, 28]]], ["The overall very major error rate was 2.1% (22 of 1040).", [["error rate", "TEST", 23, 33]]], ["The highest rate of MIC agreement was for amikacin, norfloxacin (100%), meropenem (98%), gentamicin and ofloxacin (96.1%).", [["amikacin", "CHEMICAL", 42, 50], ["norfloxacin", "CHEMICAL", 52, 63], ["meropenem", "CHEMICAL", 72, 81], ["gentamicin", "CHEMICAL", 89, 99], ["ofloxacin", "CHEMICAL", 104, 113], ["amikacin", "CHEMICAL", 42, 50], ["norfloxacin", "CHEMICAL", 52, 63], ["meropenem", "CHEMICAL", 72, 81], ["gentamicin", "CHEMICAL", 89, 99], ["ofloxacin", "CHEMICAL", 104, 113], ["amikacin", "SIMPLE_CHEMICAL", 42, 50], ["norfloxacin", "SIMPLE_CHEMICAL", 52, 63], ["meropenem", "SIMPLE_CHEMICAL", 72, 81], ["gentamicin", "SIMPLE_CHEMICAL", 89, 99], ["ofloxacin", "SIMPLE_CHEMICAL", 104, 113], ["amikacin", "TREATMENT", 42, 50], ["norfloxacin", "TREATMENT", 52, 63], ["meropenem", "TREATMENT", 72, 81], ["gentamicin", "TREATMENT", 89, 99], ["ofloxacin", "TREATMENT", 104, 113]]], ["Conclusion: The direct method from positive Bact/ Alert\uf0d2 cultures cannot totally replace the approved methods of identification and susceptibility but in some cases provides earlier information which allows a better patient management and also reduce cost in patient care.P1741Investigation of Listeria monocytogenes \"O\" antibodies in maternal and cord sera with the agglutination test E. Us, A.T. Cengiz, O. Gelisen (Ankara, TR)P1741Objectives: Listeria monocytogenes is a Gram-positive food borne pathogen that is responsible for listeriosis, a human infection with a mortality rate of 30%, which could cause severe motherto-child infections.", [["cord sera", "ANATOMY", 348, 357], ["Listeria monocytogenes", "DISEASE", 446, 468], ["listeriosis", "DISEASE", 532, 543], ["human infection", "DISEASE", 547, 562], ["motherto-child infections", "DISEASE", 618, 643], ["patient", "ORGANISM", 216, 223], ["patient", "ORGANISM", 259, 266], ["Listeria monocytogenes", "ORGANISM", 294, 316], ["O\" antibodies", "GENE_OR_GENE_PRODUCT", 318, 331], ["cord sera", "ORGANISM_SUBSTANCE", 348, 357], ["Ankara, TR)P1741Objectives", "ORGANISM", 418, 444], ["Listeria monocytogenes", "ORGANISM", 446, 468], ["Gram-", "GENE_OR_GENE_PRODUCT", 474, 479], ["human", "ORGANISM", 547, 552], ["positive Bact/ Alert\uf0d2 cultures", "CELL_LINE", 35, 65], ["Listeria monocytogenes \"O\" antibodies", "PROTEIN", 294, 331], ["patient", "SPECIES", 216, 223], ["patient", "SPECIES", 259, 266], ["Listeria monocytogenes", "SPECIES", 294, 316], ["Listeria monocytogenes", "SPECIES", 446, 468], ["human", "SPECIES", 547, 552], ["Listeria monocytogenes", "SPECIES", 294, 316], ["Listeria monocytogenes", "SPECIES", 446, 468], ["human", "SPECIES", 547, 552], ["The direct method", "TEST", 12, 29], ["positive Bact/ Alert\uf0d2 cultures", "PROBLEM", 35, 65], ["a better patient management", "TREATMENT", 207, 234], ["cost in patient care", "TREATMENT", 251, 271], ["Listeria monocytogenes", "PROBLEM", 294, 316], ["antibodies", "TEST", 321, 331], ["maternal and cord sera", "TEST", 335, 357], ["the agglutination test", "TEST", 363, 385], ["E. Us", "TEST", 386, 391], ["Listeria monocytogenes", "PROBLEM", 446, 468], ["a Gram-positive food borne pathogen", "PROBLEM", 472, 507], ["listeriosis", "PROBLEM", 532, 543], ["a human infection", "PROBLEM", 545, 562], ["a mortality rate", "TEST", 568, 584], ["severe motherto-child infections", "PROBLEM", 611, 643], ["Listeria monocytogenes", "OBSERVATION", 294, 316], ["cord", "ANATOMY", 348, 352], ["Listeria monocytogenes", "OBSERVATION", 446, 468], ["responsible for", "UNCERTAINTY", 516, 531], ["infection", "OBSERVATION", 553, 562], ["severe", "OBSERVATION_MODIFIER", 611, 617], ["infections", "OBSERVATION", 633, 643]]], ["This serious pathogen in pregnancy could be treated if diagnosed, but there is no routine screening test for susceptibility to listeriosis during pregnancy.", [["listeriosis", "DISEASE", 127, 138], ["This serious pathogen", "PROBLEM", 0, 21], ["routine screening test", "TEST", 82, 104], ["susceptibility", "PROBLEM", 109, 123], ["listeriosis", "PROBLEM", 127, 138], ["pregnancy", "PROBLEM", 146, 155], ["listeriosis", "OBSERVATION", 127, 138]]], ["Therefore, we investigate different L monocytogenes serotype O antibodies for diagnosis of listeriosis in 275 maternal sera with agglutination test.", [["sera", "ANATOMY", 119, 123], ["listeriosis", "DISEASE", 91, 102], ["L monocytogenes", "ORGANISM", 36, 51], ["serotype O antibodies", "GENE_OR_GENE_PRODUCT", 52, 73], ["sera", "ORGANISM_SUBSTANCE", 119, 123], ["L monocytogenes serotype O antibodies", "PROTEIN", 36, 73], ["L monocytogenes", "SPECIES", 36, 51], ["L monocytogenes", "SPECIES", 36, 51], ["listeriosis", "PROBLEM", 91, 102], ["maternal sera", "TEST", 110, 123], ["agglutination test", "TEST", 129, 147], ["listeriosis", "OBSERVATION", 91, 102]]], ["69 of them had spontaneous abortion, premature labour or stillbirth (group I), while 206 had no obstetric patology (group II) in their previous pregnancies.", [["abortion", "DISEASE", 27, 35], ["premature labour", "DISEASE", 37, 53], ["stillbirth", "DISEASE", 57, 67], ["obstetric patology", "DISEASE", 96, 114], ["spontaneous abortion", "PROBLEM", 15, 35], ["premature labour", "PROBLEM", 37, 53], ["spontaneous", "OBSERVATION_MODIFIER", 15, 26], ["abortion", "OBSERVATION", 27, 35]]], ["Cord bloods were also obtained at the delivery and tested.", [["Cord bloods", "ANATOMY", 0, 11], ["Cord bloods", "ORGANISM_SUBSTANCE", 0, 11], ["Cord bloods", "TEST", 0, 11]]], ["Methods: All sera were being tested against antigens with the O formulation of serotype 1/2c, 3b, 4ab, 4c and 4d.", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["serotype", "TEST", 79, 87]]], ["The antigens were prepared by the method of Osebold, and Larsen et all.", [["antigens", "PROTEIN", 4, 12]]], ["The bacterial suspensions were trypsinized for 15 min at 37\u00b0C to prevent cross-reactions and contaminations.", [["suspensions", "ANATOMY", 14, 25], ["The bacterial suspensions", "TREATMENT", 0, 25], ["cross-reactions", "PROBLEM", 73, 88], ["bacterial suspensions", "OBSERVATION", 4, 25]]], ["Sera were diluted by doubling serially in saline followed by addition of an equal volume of antigen.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["saline", "SIMPLE_CHEMICAL", 42, 48], ["Sera", "TREATMENT", 0, 4], ["saline", "TREATMENT", 42, 48], ["an equal volume of antigen", "TREATMENT", 73, 99]]], ["A positive titre of greater than or equal to 1:320 was chosen as positive test result to maximize the sensitivity and specificity.", [["A positive titre", "TEST", 0, 16], ["the sensitivity", "TEST", 98, 113], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["titre", "OBSERVATION_MODIFIER", 11, 16]]], ["Results: 4.36% of cases have ingested raw milk and diary products, 1.81% ready-to-eat foods, and 5.81% developed nonspecific febrile illness (NFI) during their pregnancies.", [["milk", "ANATOMY", 42, 46], ["febrile illness", "DISEASE", 125, 140], ["NFI", "DISEASE", 142, 145], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["diary products", "TREATMENT", 51, 65], ["nonspecific febrile illness", "PROBLEM", 113, 140], ["nonspecific", "OBSERVATION_MODIFIER", 113, 124]]], ["20% of group I were found positive (28.5% developed NFI) while at group II 22% had positive (26.6% developed NFI) agglutination titres to one ore more serotypes.", [["NFI", "PROTEIN", 52, 55], ["NFI", "PROTEIN", 109, 112], ["group I", "TEST", 7, 14], ["positive", "PROBLEM", 26, 34], ["NFI", "TEST", 52, 55], ["NFI", "TEST", 109, 112], ["agglutination titres", "TEST", 114, 134]]], ["All the cord blood sera of group I were found negative, whereas two in group II (all 4ab) were positive, with the positive maternal sera of the same serotype.", [["cord blood sera", "ANATOMY", 8, 23], ["sera", "ANATOMY", 132, 136], ["cord blood sera", "ORGANISM_SUBSTANCE", 8, 23], ["4ab", "GENE_OR_GENE_PRODUCT", 85, 88], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["All the cord blood sera", "TEST", 0, 23], ["the positive maternal sera of the same serotype", "PROBLEM", 110, 157], ["cord", "ANATOMY", 8, 12], ["positive", "OBSERVATION", 95, 103]]], ["It's evaluated as transmission of the antibody from mother to foetus.", [["foetus", "ANATOMY", 62, 68], ["foetus", "ORGANISM", 62, 68]]], ["At group I the frequent serotypes were 1/2c = 4ab, at group II 4ab, 1/2c, respectively.", [["the frequent serotypes", "TREATMENT", 11, 33]]], ["The newborns showed no symptoms or signs of listerial foeto-maternal infection.", [["infection", "DISEASE", 69, 78], ["newborns", "ORGANISM", 4, 12], ["symptoms", "PROBLEM", 23, 31], ["listerial foeto", "PROBLEM", 44, 59], ["maternal infection", "PROBLEM", 60, 78], ["no", "UNCERTAINTY", 20, 22], ["listerial foeto", "OBSERVATION", 44, 59], ["infection", "OBSERVATION", 69, 78]]], ["Conclusion: The women encountered the antigens of L monocytogenes in any period of their life time (most 21-25 years of age) and produce antibodies against this pathogen.", [["women", "ORGANISM", 16, 21], ["L monocytogenes", "ORGANISM", 50, 65], ["antibodies", "PROTEIN", 137, 147], ["women", "SPECIES", 16, 21], ["L monocytogenes", "SPECIES", 50, 65], ["L monocytogenes", "SPECIES", 50, 65], ["this pathogen", "PROBLEM", 156, 169]]], ["There is a relationship between NFI and positive titres.", [["NFI", "GENE_OR_GENE_PRODUCT", 32, 35], ["NFI", "PROTEIN", 32, 35], ["positive titres", "OBSERVATION", 40, 55]]], ["If the disease is recognized, it is possible to treat the mother and allow the birth of a healthy infant.", [["infant", "ORGANISM", 98, 104], ["infant", "SPECIES", 98, 104], ["the disease", "PROBLEM", 3, 14], ["disease", "OBSERVATION", 7, 14]]], ["We propose the less time consuming and easy to perform agglutination test as a routine screening test for susceptibility to listeriosis during pregnancy to prevent bad pregnancy outcomes.", [["listeriosis", "DISEASE", 124, 135], ["agglutination test", "TEST", 55, 73], ["a routine screening test", "TEST", 77, 101], ["susceptibility", "PROBLEM", 106, 120], ["listeriosis", "PROBLEM", 124, 135], ["bad pregnancy outcomes", "PROBLEM", 164, 186]]], ["Objectives: To evaluate the performance of a real time PCR assay (with a fluorogenic target-specific probe), MRSA-IDI (GeneOhm Sciences) for MRSA detection directly from mucocutaneous swabs in hospitalized patients.", [["mucocutaneous swabs", "ANATOMY", 170, 189], ["patients", "ORGANISM", 206, 214], ["MRSA", "SPECIES", 109, 113], ["MRSA", "SPECIES", 141, 145], ["patients", "SPECIES", 206, 214], ["MRSA", "SPECIES", 141, 145], ["a real time PCR assay", "TEST", 43, 64], ["a fluorogenic target", "TEST", 71, 91], ["MRSA", "PROBLEM", 109, 113], ["MRSA detection", "PROBLEM", 141, 155], ["mucocutaneous swabs", "TREATMENT", 170, 189]]], ["Methods: Clinical swabs (1 to 14 samples with a median of 2.1 samples per patient) from nares (n = 330) and skin (n = 326) were prospectively collected for MRSA screening from 321 patients admitted to a 858-bed teaching hospital.", [["swabs", "ANATOMY", 18, 23], ["samples", "ANATOMY", 33, 40], ["nares", "ANATOMY", 88, 93], ["skin", "ANATOMY", 108, 112], ["patient", "ORGANISM", 74, 81], ["nares", "ORGANISM_SUBDIVISION", 88, 93], ["skin", "ORGAN", 108, 112], ["patients", "ORGANISM", 180, 188], ["patient", "SPECIES", 74, 81], ["MRSA", "SPECIES", 156, 160], ["patients", "SPECIES", 180, 188], ["MRSA", "SPECIES", 156, 160], ["Clinical swabs", "TEST", 9, 23], ["MRSA screening", "TEST", 156, 170], ["nares", "ANATOMY", 88, 93], ["skin", "ANATOMY", 108, 112]]], ["Swabs were inoculated onto selective MRSA agar (MRSA-ID, Biom\u00e9rieux), into the buffer extraction solution for IDI-MRSA PCR assay and into enrichment broth (BHI with 7.5% NaCl).", [["Swabs", "ANATOMY", 0, 5], ["MRSA", "CHEMICAL", 37, 41], ["NaCl", "CHEMICAL", 170, 174], ["NaCl", "CHEMICAL", 170, 174], ["MRSA", "SPECIES", 37, 41], ["MRSA", "SPECIES", 48, 52], ["MRSA", "SPECIES", 114, 118], ["MRSA", "SPECIES", 37, 41], ["Swabs", "TEST", 0, 5], ["selective MRSA agar", "TEST", 27, 46], ["MRSA", "PROBLEM", 48, 52], ["the buffer extraction solution", "TREATMENT", 75, 105], ["IDI-MRSA PCR assay", "TEST", 110, 128], ["7.5% NaCl)", "TREATMENT", 165, 175]]], ["After 24h, BHI broths were subcultured onto MRSA-ID agar.", [["MRSA", "SPECIES", 44, 48], ["BHI broths", "TREATMENT", 11, 21], ["MRSA", "PROBLEM", 44, 48]]], ["Selective agars were incubated for 48 h at 35ordm;C and examinated daily.", [["Selective agars", "TEST", 0, 15]]], ["Suspected colonies were identified by coagulase testing; oxacillin resistance was tested by cefoxitin disk diffusion according to CLSI recommendations.", [["colonies", "ANATOMY", 10, 18], ["oxacillin", "CHEMICAL", 57, 66], ["cefoxitin", "CHEMICAL", 92, 101], ["oxacillin", "CHEMICAL", 57, 66], ["cefoxitin", "CHEMICAL", 92, 101], ["oxacillin", "SIMPLE_CHEMICAL", 57, 66], ["cefoxitin", "SIMPLE_CHEMICAL", 92, 101], ["Suspected colonies", "PROBLEM", 0, 18], ["coagulase testing", "TEST", 38, 55], ["oxacillin resistance", "TREATMENT", 57, 77], ["cefoxitin disk diffusion", "TREATMENT", 92, 116], ["colonies", "OBSERVATION", 10, 18]]], ["The PCR assay was performed according to the manufacturer's instructions.", [["The PCR assay", "TEST", 0, 13]]], ["PCR results were compared with phenotypic identification test results.", [["PCR", "TEST", 0, 3], ["phenotypic identification test", "TEST", 31, 61]]], ["In case of discordant results, the assay was repeated, but only results from first testing were considered for calculating test performance.", [["the assay", "TEST", 31, 40], ["first testing", "TEST", 77, 90], ["calculating test performance", "TEST", 111, 139]]], ["Results: MRSA was detected by culture in 74 specimen (11.3%) from 38 patients.", [["specimen", "ANATOMY", 44, 52], ["MRSA", "CANCER", 9, 13], ["patients", "ORGANISM", 69, 77], ["MRSA", "SPECIES", 9, 13], ["patients", "SPECIES", 69, 77], ["MRSA", "SPECIES", 9, 13], ["MRSA", "PROBLEM", 9, 13], ["culture", "TEST", 30, 37], ["MRSA", "OBSERVATION", 9, 13]]], ["The sensitivity and specificity of the PCR compared with culture was 82.4% and 96.9%, respectively.", [["The sensitivity", "TEST", 0, 15], ["the PCR", "TEST", 35, 42], ["culture", "TEST", 57, 64]]], ["The sensitivity of PCR (92%) was higher on nasal swabs than on swabs from other sites (77.5%, p < 0.001).", [["nasal swabs", "ANATOMY", 43, 54], ["swabs", "ANATOMY", 63, 68], ["sites", "ANATOMY", 80, 85], ["nasal swabs", "ORGANISM_SUBSTANCE", 43, 54], ["PCR", "TEST", 19, 22], ["nasal swabs", "TEST", 43, 54], ["swabs", "TEST", 63, 68], ["nasal", "ANATOMY", 43, 48]]], ["The PCR assay detected MRSA in 34 patients (89.5%).", [["patients", "ORGANISM", 34, 42], ["MRSA", "SPECIES", 23, 27], ["patients", "SPECIES", 34, 42], ["MRSA", "SPECIES", 23, 27], ["The PCR assay", "TEST", 0, 13], ["MRSA", "PROBLEM", 23, 27]]], ["The PCR assay provided results in 2 to 12 versus 48 to 72 hours for conventional method.", [["The PCR assay", "TEST", 0, 13], ["conventional method", "TREATMENT", 68, 87]]], ["Conclusion: In our hospital, the ID-MRSA PCR assay detected 89.5% MRSA carriers in less than 12 hours when performed on multiple specimen.", [["specimen", "ANATOMY", 129, 137], ["MRSA", "SPECIES", 36, 40], ["MRSA", "SPECIES", 66, 70], ["the ID-MRSA PCR assay", "TEST", 29, 50], ["MRSA carriers", "PROBLEM", 66, 79]]], ["The assay appeared more sensitive in testing nasal swabs than other clinical specimens.", [["nasal swabs", "ANATOMY", 45, 56], ["specimens", "ANATOMY", 77, 86], ["nasal swabs", "ORGANISM_SUBSTANCE", 45, 56], ["The assay", "TEST", 0, 9], ["testing nasal swabs", "TEST", 37, 56], ["other clinical specimens", "TEST", 62, 86]]], ["Prospective studies are needed to evaluate the impact of this assay for rapid implementation of infection control procedures and its global costs and benefits.", [["infection", "DISEASE", 96, 105], ["Prospective studies", "TEST", 0, 19], ["this assay", "TEST", 57, 67], ["infection control procedures", "TREATMENT", 96, 124], ["infection", "OBSERVATION", 96, 105]]], ["The purpose of this study was to establish a rapid and sensitive real-time polymerase chain reaction (PCR) method for detection of methicillin-resistant Staphylococcus aureus (MRSA) from blood culture bottle.", [["blood", "ANATOMY", 187, 192], ["methicillin", "CHEMICAL", 131, 142], ["methicillin", "CHEMICAL", 131, 142], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 131, 174], ["MRSA", "CANCER", 176, 180], ["blood", "ORGANISM_SUBSTANCE", 187, 192], ["Staphylococcus aureus", "SPECIES", 153, 174], ["MRSA", "SPECIES", 176, 180], ["Staphylococcus aureus", "SPECIES", 153, 174], ["MRSA", "SPECIES", 176, 180], ["this study", "TEST", 15, 25], ["a rapid and sensitive real-time polymerase chain reaction", "PROBLEM", 43, 100], ["methicillin-resistant Staphylococcus aureus", "PROBLEM", 131, 174], ["MRSA", "PROBLEM", 176, 180], ["blood culture bottle", "TEST", 187, 207], ["Staphylococcus aureus", "OBSERVATION", 153, 174]]], ["As a result of over use of broad-spectrum antibiotics after the 1960s in whole the world, an outbreak of MRSA infection has been seen.", [["MRSA infection", "DISEASE", 105, 119], ["MRSA", "CANCER", 105, 109], ["MRSA", "SPECIES", 105, 109], ["MRSA", "SPECIES", 105, 109], ["broad-spectrum antibiotics", "TREATMENT", 27, 53], ["MRSA infection", "PROBLEM", 105, 119], ["MRSA", "OBSERVATION_MODIFIER", 105, 109], ["infection", "OBSERVATION", 110, 119]]], ["Severe nosocomial infections with MRSA such as bacteraemia and sepsis may lead to multiple organ failure and high mortality in the hospital.", [["organ", "ANATOMY", 91, 96], ["nosocomial infections", "DISEASE", 7, 28], ["MRSA", "DISEASE", 34, 38], ["bacteraemia", "DISEASE", 47, 58], ["sepsis", "DISEASE", 63, 69], ["organ failure", "DISEASE", 91, 104], ["organ", "ORGAN", 91, 96], ["MRSA", "SPECIES", 34, 38], ["MRSA", "SPECIES", 34, 38], ["Severe nosocomial infections", "PROBLEM", 0, 28], ["MRSA", "PROBLEM", 34, 38], ["bacteraemia", "PROBLEM", 47, 58], ["sepsis", "PROBLEM", 63, 69], ["multiple organ failure", "PROBLEM", 82, 104], ["nosocomial", "OBSERVATION_MODIFIER", 7, 17], ["infections", "OBSERVATION", 18, 28], ["MRSA", "OBSERVATION", 34, 38], ["bacteraemia", "OBSERVATION", 47, 58], ["sepsis", "OBSERVATION", 63, 69], ["multiple", "OBSERVATION_MODIFIER", 82, 90], ["organ", "ANATOMY", 91, 96], ["failure", "OBSERVATION", 97, 104], ["high", "OBSERVATION_MODIFIER", 109, 113], ["mortality", "OBSERVATION_MODIFIER", 114, 123]]], ["Although standard method took at least 48 hours to identify MRSA by the blood culture method, the presence of mecA and nuc genes which is specific for methicillin resistance and S. aureus was determined by real-time PCR method within only 2 hours after blood culture signal positivity.", [["blood", "ANATOMY", 72, 77], ["blood", "ANATOMY", 253, 258], ["methicillin", "CHEMICAL", 151, 162], ["methicillin", "CHEMICAL", 151, 162], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["mecA", "GENE_OR_GENE_PRODUCT", 110, 114], ["nuc", "GENE_OR_GENE_PRODUCT", 119, 122], ["S. aureus", "ORGANISM", 178, 187], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["mecA and nuc genes", "DNA", 110, 128], ["MRSA", "SPECIES", 60, 64], ["S. aureus", "SPECIES", 178, 187], ["MRSA", "SPECIES", 60, 64], ["S. aureus", "SPECIES", 178, 187], ["MRSA", "PROBLEM", 60, 64], ["the blood culture method", "TEST", 68, 92], ["mecA and nuc genes", "PROBLEM", 110, 128], ["methicillin resistance", "PROBLEM", 151, 173], ["S. aureus", "PROBLEM", 178, 187], ["blood culture signal positivity", "TEST", 253, 284], ["MRSA", "OBSERVATION", 60, 64], ["aureus", "OBSERVATION", 181, 187]]], ["Nineteen S. aureus and 33 coagulase negative staphylococci positive blood culture bottles were studied retrospectively for detection of S. aureus and methicillin resistance.", [["blood", "ANATOMY", 68, 73], ["methicillin", "CHEMICAL", 150, 161], ["methicillin", "CHEMICAL", 150, 161], ["S. aureus", "ORGANISM", 9, 18], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["S. aureus", "ORGANISM", 136, 145], ["methicillin", "SIMPLE_CHEMICAL", 150, 161], ["S. aureus", "SPECIES", 9, 18], ["S. aureus", "SPECIES", 136, 145], ["S. aureus", "SPECIES", 9, 18], ["S. aureus", "SPECIES", 136, 145], ["Nineteen S. aureus", "TEST", 0, 18], ["33 coagulase negative staphylococci positive blood culture bottles", "PROBLEM", 23, 89], ["S. aureus", "PROBLEM", 136, 145], ["methicillin resistance", "PROBLEM", 150, 172], ["aureus", "OBSERVATION", 12, 18], ["aureus", "OBSERVATION", 139, 145], ["methicillin resistance", "OBSERVATION", 150, 172]]], ["Staphylococci were identified with classical methods and MICs of oxacillin were determined by Etest (AB Biodisk) on Mueller-Hinton agar supplemented with 2% NaCl.", [["oxacillin", "CHEMICAL", 65, 74], ["NaCl", "CHEMICAL", 157, 161], ["oxacillin", "CHEMICAL", 65, 74], ["NaCl", "CHEMICAL", 157, 161], ["oxacillin", "SIMPLE_CHEMICAL", 65, 74], ["Staphylococci", "PROBLEM", 0, 13], ["classical methods", "TREATMENT", 35, 52], ["oxacillin", "TREATMENT", 65, 74], ["Hinton agar", "TREATMENT", 124, 135], ["2% NaCl", "TREATMENT", 154, 161]]], ["Real-time PCR was performed to all positive blood culture samples for S. aureus and methicillin resistance determination.", [["blood culture samples", "ANATOMY", 44, 65], ["methicillin", "CHEMICAL", 84, 95], ["methicillin", "CHEMICAL", 84, 95], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["S. aureus", "ORGANISM", 70, 79], ["methicillin", "SIMPLE_CHEMICAL", 84, 95], ["S. aureus", "SPECIES", 70, 79], ["S. aureus", "SPECIES", 70, 79], ["Real-time PCR", "TEST", 0, 13], ["blood culture samples", "TEST", 44, 65], ["S. aureus", "PROBLEM", 70, 79], ["methicillin resistance determination", "PROBLEM", 84, 120], ["aureus", "OBSERVATION", 73, 79], ["methicillin resistance", "OBSERVATION", 84, 106]]], ["Nineteen (100%) S. aureus were determined correctly by real-time PCR method.", [["S. aureus", "ORGANISM", 16, 25], ["S. aureus", "SPECIES", 16, 25], ["S. aureus", "SPECIES", 16, 25], ["S. aureus", "PROBLEM", 16, 25], ["aureus", "OBSERVATION", 19, 25]]], ["Forty-four methicillin resistant and 8 methicillin sensitive staphylococci were detected by Etest.", [["methicillin", "CHEMICAL", 11, 22], ["methicillin", "CHEMICAL", 39, 50], ["staphylococci", "DISEASE", 61, 74], ["methicillin", "CHEMICAL", 11, 22], ["methicillin", "CHEMICAL", 39, 50], ["staphylococci", "CANCER", 61, 74], ["four methicillin resistant and 8 methicillin sensitive staphylococci", "PROBLEM", 6, 74], ["Etest", "TEST", 92, 97]]], ["Using the real-time PCR method, the mecA gene was detected in 47 Staphylococci except 3.", [["mecA", "GENE_OR_GENE_PRODUCT", 36, 40], ["mecA gene", "DNA", 36, 45], ["the mecA gene", "TEST", 32, 45], ["Staphylococci", "PROBLEM", 65, 78]]], ["When compared with Etest and realtime PCR method gave sensitivity, specificity, and positive and negative predictive values of 100%, 63%, 94%, 100% for both positive and negative tests, respectively.", [["Etest", "TEST", 19, 24], ["realtime PCR method", "TEST", 29, 48], ["sensitivity", "TEST", 54, 65], ["specificity", "TEST", 67, 78]]], ["Agreements between two methods were high (94%); there were 3 discrepant results among the 52 strains were tested.", [["two methods", "TEST", 19, 30], ["the 52 strains", "PROBLEM", 86, 100]]], ["Detection of MRSA bacteraemia and methicillin resistance with real-time PCR definitely is useful for reducing mortality and morbidity of this type infection.", [["bacteraemia", "DISEASE", 18, 29], ["methicillin", "CHEMICAL", 34, 45], ["infection", "DISEASE", 147, 156], ["methicillin", "CHEMICAL", 34, 45], ["MRSA", "SPECIES", 13, 17], ["MRSA", "SPECIES", 13, 17], ["MRSA bacteraemia", "PROBLEM", 13, 29], ["methicillin resistance", "PROBLEM", 34, 56], ["real-time PCR", "TEST", 62, 75], ["reducing mortality", "PROBLEM", 101, 119], ["this type infection", "PROBLEM", 137, 156], ["MRSA bacteraemia", "OBSERVATION", 13, 29], ["methicillin resistance", "OBSERVATION", 34, 56], ["infection", "OBSERVATION", 147, 156]]], ["In conclusion, this method, as many as sensitive and specific for detection of MRSA bacteraemia and clinically should be beneficial for prevention of unnecessary antibiotic use and determination of appropriate antibiotic treatments of MRSA infection.P1744PCR detection of Class B, C and D betalactamases in environmental and clinical Aeromonas strains T. Fosse, C. Giraud-Morin, F. La Louze (Nice, FR)P1744Objectives: Aeromonas spp. strains are waterborne opportunistic pathogens.", [["bacteraemia", "DISEASE", 84, 95], ["MRSA infection", "DISEASE", 235, 249], ["waterborne opportunistic pathogens", "DISEASE", 445, 479], ["Class B", "GENE_OR_GENE_PRODUCT", 272, 279], ["C", "GENE_OR_GENE_PRODUCT", 281, 282], ["D betalactamases", "SIMPLE_CHEMICAL", 287, 303], ["F. La Louze", "ORGANISM", 379, 390], ["Nice, FR)P1744Objectives", "ORGANISM", 392, 416], ["Aeromonas spp", "ORGANISM", 418, 431], ["Class B, C and D betalactamases", "PROTEIN", 272, 303], ["MRSA", "SPECIES", 79, 83], ["MRSA", "SPECIES", 235, 239], ["MRSA", "SPECIES", 79, 83], ["MRSA", "SPECIES", 235, 239], ["this method", "TEST", 15, 26], ["MRSA bacteraemia", "PROBLEM", 79, 95], ["unnecessary antibiotic use", "TREATMENT", 150, 176], ["appropriate antibiotic treatments", "TREATMENT", 198, 231], ["MRSA infection", "PROBLEM", 235, 249], ["Class B", "TEST", 272, 279], ["C", "TEST", 281, 282], ["and D betalactamases in environmental", "PROBLEM", 283, 320], ["clinical Aeromonas strains", "TEST", 325, 351], ["Fosse", "TEST", 355, 360], ["C.", "TEST", 362, 364], ["Giraud", "TEST", 365, 371], ["Aeromonas spp", "PROBLEM", 418, 431], ["waterborne opportunistic pathogens", "PROBLEM", 445, 479], ["MRSA", "OBSERVATION", 79, 83], ["MRSA", "OBSERVATION_MODIFIER", 235, 239], ["infection", "OBSERVATION", 240, 249], ["waterborne", "OBSERVATION_MODIFIER", 445, 455], ["opportunistic", "OBSERVATION_MODIFIER", 456, 469], ["pathogens", "OBSERVATION", 470, 479]]], ["They are able to produce different types of beta-lactamases (class B, C and D).", [["class B", "GENE_OR_GENE_PRODUCT", 61, 68], ["C", "GENE_OR_GENE_PRODUCT", 70, 71], ["D", "GENE_OR_GENE_PRODUCT", 76, 77], ["beta-lactamases", "PROBLEM", 44, 59]]], ["The determination of beta-lactamase content is not easy by phenotypic methods.", [["beta-lactamase", "GENE_OR_GENE_PRODUCT", 21, 35], ["beta", "PROTEIN", 21, 25], ["The determination of beta-lactamase content", "TEST", 0, 43], ["beta-lactamase", "OBSERVATION", 21, 35], ["not easy", "UNCERTAINTY", 47, 55]]], ["We have developed a PCR tool to study diversity and distribution of Class B, C and D beta-lactamases in a set of representative clinical and environmental Aeromonas species.", [["Class B", "GENE_OR_GENE_PRODUCT", 68, 75], ["C", "GENE_OR_GENE_PRODUCT", 77, 78], ["D beta-lactamases", "GENE_OR_GENE_PRODUCT", 83, 100], ["Class B, C and D beta-lactamases", "PROTEIN", 68, 100], ["a PCR", "TEST", 18, 23], ["Class B, C and D beta-lactamases", "PROBLEM", 68, 100], ["representative clinical and environmental Aeromonas species", "PROBLEM", 113, 172], ["environmental Aeromonas species", "OBSERVATION", 141, 172]]], ["Identification was realized by conventional tests and gyrB sequence analysis.", [["gyrB sequence", "DNA", 54, 67], ["conventional tests and gyrB sequence analysis", "TEST", 31, 76]]], ["Beta-lactam antibiotic susceptibility was determined by diffusion agar and micro broth dilution methods.", [["Beta-lactam", "CHEMICAL", 0, 11], ["Beta-lactam", "CHEMICAL", 0, 11], ["Beta-lactam", "SIMPLE_CHEMICAL", 0, 11], ["Beta-lactam antibiotic susceptibility", "TREATMENT", 0, 37], ["diffusion agar", "TEST", 56, 70], ["micro broth dilution methods", "TREATMENT", 75, 103]]], ["Three sets of specific primers were defined for the PCR amplification of the internal region of class B beta-lactamase (MEI1 and MEI2, 297 bp size), class C beta-lactamase (AERCP1 and AERCP2, 840 bp) and class D betalactamase (AERD1 and AERD2, 514 bp).", [["class B beta-lactamase", "GENE_OR_GENE_PRODUCT", 96, 118], ["MEI1", "GENE_OR_GENE_PRODUCT", 120, 124], ["class C beta-lactamase", "GENE_OR_GENE_PRODUCT", 149, 171], ["AERCP1", "GENE_OR_GENE_PRODUCT", 173, 179], ["AERCP2", "GENE_OR_GENE_PRODUCT", 184, 190], ["class D betalactamase", "GENE_OR_GENE_PRODUCT", 204, 225], ["class B beta-lactamase", "DNA", 96, 118], ["MEI1", "PROTEIN", 120, 124], ["MEI2", "PROTEIN", 129, 133], ["class C beta-lactamase", "DNA", 149, 171], ["AERCP1", "DNA", 173, 179], ["AERCP2", "DNA", 184, 190], ["class D betalactamase", "DNA", 204, 225], ["AERD1", "DNA", 227, 232], ["AERD2", "DNA", 237, 242], ["specific primers", "TEST", 14, 30], ["the PCR amplification", "TEST", 48, 69], ["MEI1", "TEST", 120, 124], ["MEI2", "TEST", 129, 133], ["bp size", "TEST", 139, 146], ["class C beta-lactamase", "PROBLEM", 149, 171], ["AERCP1", "TEST", 173, 179], ["AERCP2", "TEST", 184, 190], ["bp", "TEST", 196, 198], ["class D betalactamase", "TEST", 204, 225], ["AERD1", "TEST", 227, 232], ["AERD2", "TEST", 237, 242], ["bp", "TEST", 248, 250], ["internal", "ANATOMY_MODIFIER", 77, 85]]], ["All PCR products were sequenced.", [["PCR products", "DNA", 4, 16], ["All PCR products", "TREATMENT", 0, 16]]], ["Results: Class D PCR was positive with most strains except A. trota, a ticarcillin susceptible species (3 strains) .", [["ticarcillin", "CHEMICAL", 71, 82], ["ticarcillin", "CHEMICAL", 71, 82], ["Class D", "GENE_OR_GENE_PRODUCT", 9, 16], ["A. trota", "ORGANISM", 59, 67], ["ticarcillin", "SIMPLE_CHEMICAL", 71, 82], ["A. trota", "SPECIES", 59, 67], ["A. trota", "SPECIES", 59, 67], ["Class D PCR", "TEST", 9, 20], ["most strains", "PROBLEM", 39, 51], ["a ticarcillin susceptible species", "PROBLEM", 69, 102]]], ["Class C PCR was positive with most cephalothin resistant strains (MIC >16 mg/l; 61/67 strains, 91%) including A. hydrophila and A. caviae phenospecies.", [["cephalothin", "CHEMICAL", 35, 46], ["MIC", "CHEMICAL", 66, 69], ["cephalothin", "CHEMICAL", 35, 46], ["Class C", "GENE_OR_GENE_PRODUCT", 0, 7], ["cephalothin", "SIMPLE_CHEMICAL", 35, 46], ["A. hydrophila", "ORGANISM", 110, 123], ["A. caviae", "ORGANISM", 128, 137], ["A. hydrophila", "SPECIES", 110, 123], ["A. caviae", "SPECIES", 128, 137], ["A. hydrophila", "SPECIES", 110, 123], ["A. caviae", "SPECIES", 128, 137], ["Class C PCR", "TEST", 0, 11], ["most cephalothin resistant strains", "PROBLEM", 30, 64], ["MIC", "TEST", 66, 69], ["strains", "TEST", 86, 93], ["A. hydrophila", "PROBLEM", 110, 123], ["A. caviae phenospecies", "PROBLEM", 128, 150], ["caviae phenospecies", "OBSERVATION", 131, 150]]], ["Class B PCR was positive with most strains of A. hydrophila and A. veronii phenospecies (33/38; 87%) including three imipenem susceptible strains (MIC < 5 mg/l). beta-lactamase type distribution was species related and was particularly useful to better characterize environmental species such as A. bestiarum, A. popoffii and A. allosaccharophila.", [["imipenem", "CHEMICAL", 117, 125], ["MIC", "CHEMICAL", 147, 150], ["imipenem", "CHEMICAL", 117, 125], ["Class B", "GENE_OR_GENE_PRODUCT", 0, 7], ["A. hydrophila", "ORGANISM", 46, 59], ["A. veronii", "ORGANISM", 64, 74], ["phenospecies", "ORGANISM", 75, 87], ["imipenem", "SIMPLE_CHEMICAL", 117, 125], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 162, 176], ["A. bestiarum", "ORGANISM", 296, 308], ["A. popoffii", "ORGANISM", 310, 321], ["A. allosaccharophila", "ORGANISM", 326, 346], ["A. hydrophila", "SPECIES", 46, 59], ["A. veronii", "SPECIES", 64, 74], ["A. bestiarum", "SPECIES", 296, 308], ["A. popoffii", "SPECIES", 310, 321], ["A. allosaccharophila", "SPECIES", 326, 346], ["A. hydrophila", "SPECIES", 46, 59], ["A. veronii", "SPECIES", 64, 74], ["A. bestiarum", "SPECIES", 296, 308], ["A. popoffii", "SPECIES", 310, 321], ["A. allosaccharophila", "SPECIES", 326, 346], ["Class B PCR", "TEST", 0, 11], ["A. hydrophila", "PROBLEM", 46, 59], ["A. veronii phenospecies", "TEST", 64, 87], ["three imipenem susceptible strains", "TREATMENT", 111, 145], ["beta-lactamase type distribution", "PROBLEM", 162, 194], ["environmental species", "PROBLEM", 266, 287]]], ["Partial beta-lactamase gene sequence analysis allowed phylogenic studies.", [["beta-lactamase", "GENE_OR_GENE_PRODUCT", 8, 22], ["beta-lactamase gene sequence", "DNA", 8, 36], ["Partial beta-lactamase gene sequence analysis", "TEST", 0, 45], ["phylogenic studies", "TEST", 54, 72]]], ["Some cephalosporinase gene from environmental species was probable progenitor of ampC plasmidic beta-lactamase.", [["progenitor", "ANATOMY", 67, 77], ["cephalosporinase", "GENE_OR_GENE_PRODUCT", 5, 21], ["progenitor", "CELL", 67, 77], ["ampC plasmidic beta-lactamase", "GENE_OR_GENE_PRODUCT", 81, 110], ["cephalosporinase gene", "DNA", 5, 26], ["ampC plasmidic beta-lactamase", "PROTEIN", 81, 110], ["Some cephalosporinase gene", "PROBLEM", 0, 26], ["environmental species", "PROBLEM", 32, 53], ["ampC plasmidic beta-lactamase", "TREATMENT", 81, 110], ["cephalosporinase", "OBSERVATION", 5, 21]]], ["Conclusion: PCR with specific primers was a good method to detect class B, C and D beta-lactamase in Aeromonas species.", [["class B", "GENE_OR_GENE_PRODUCT", 66, 73], ["C", "GENE_OR_GENE_PRODUCT", 75, 76], ["D beta-lactamase", "GENE_OR_GENE_PRODUCT", 81, 97], ["Aeromonas species", "ORGANISM", 101, 118], ["class B, C and D beta-lactamase", "PROTEIN", 66, 97], ["PCR", "TEST", 12, 15], ["specific primers", "TEST", 21, 37], ["class B, C and D beta-lactamase in Aeromonas species", "PROBLEM", 66, 118], ["Aeromonas species", "OBSERVATION", 101, 118]]], ["Beta-lactamase type distribution and sequence analysis phylogeny were largely species related and could be helpful for molecular diagnostic and taxonomic purpose.", [["Beta-lactamase", "GENE_OR_GENE_PRODUCT", 0, 14], ["Beta-lactamase type distribution", "TEST", 0, 32], ["sequence analysis phylogeny", "TEST", 37, 64], ["molecular diagnostic", "TEST", 119, 139], ["taxonomic purpose", "TEST", 144, 161]]], ["Objectives: The aim of this study was to develop a convenient DNA extraction method and to optimise a PCR reaction in order to detect enterotoxin B producing S. aureus strains directly from milk.", [["milk", "ANATOMY", 190, 194], ["enterotoxin B", "CHEMICAL", 134, 147], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["enterotoxin B", "GENE_OR_GENE_PRODUCT", 134, 147], ["S. aureus", "ORGANISM", 158, 167], ["strains", "ORGANISM", 168, 175], ["milk", "ORGANISM_SUBSTANCE", 190, 194], ["enterotoxin B", "PROTEIN", 134, 147], ["S. aureus", "SPECIES", 158, 167], ["S. aureus", "SPECIES", 158, 167], ["this study", "TEST", 23, 33], ["a convenient DNA extraction method", "TREATMENT", 49, 83], ["a PCR reaction", "PROBLEM", 100, 114], ["enterotoxin B", "PROBLEM", 134, 147], ["S. aureus strains", "PROBLEM", 158, 175], ["aureus", "OBSERVATION", 161, 167]]], ["Methods: We applied a chemical extraction method of bacterial DNA from milk samples artificially inoculated with S. aureus.", [["milk samples", "ANATOMY", 71, 83], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["milk samples", "ORGANISM_SUBSTANCE", 71, 83], ["S. aureus", "ORGANISM", 113, 122], ["S. aureus", "SPECIES", 113, 122], ["S. aureus", "SPECIES", 113, 122], ["a chemical extraction method", "TREATMENT", 20, 48], ["bacterial DNA", "PROBLEM", 52, 65], ["milk samples", "TEST", 71, 83], ["S. aureus", "PROBLEM", 113, 122], ["aureus", "OBSERVATION", 116, 122]]], ["A PCR based method was used for the detection of seb gene (coding for enterotoxin B) and nuc gene (coding for termonuclease).", [["seb", "GENE_OR_GENE_PRODUCT", 49, 52], ["enterotoxin B", "GENE_OR_GENE_PRODUCT", 70, 83], ["nuc", "GENE_OR_GENE_PRODUCT", 89, 92], ["termonuclease", "GENE_OR_GENE_PRODUCT", 110, 123], ["seb gene", "DNA", 49, 57], ["enterotoxin B", "PROTEIN", 70, 83], ["nuc gene", "DNA", 89, 97], ["termonuclease", "DNA", 110, 123], ["A PCR based method", "TEST", 0, 18], ["seb gene", "TREATMENT", 49, 57], ["enterotoxin B)", "TREATMENT", 70, 84]]], ["A protocol for the multiplex PCR was developed and optimized.", [["A protocol", "TREATMENT", 0, 10], ["the multiplex PCR", "TEST", 15, 32]]], ["The sensitivity of the reaction was checked by determining the minimum number of organismsAEml -1 , which can be detected in the multiplex PCR and in each single PCR reaction.", [["AEml -1", "GENE_OR_GENE_PRODUCT", 90, 97], ["the reaction", "TEST", 19, 31], ["the multiplex PCR", "TEST", 125, 142], ["each single PCR reaction", "TEST", 150, 174]]], ["Amplification specificity of the seb gene was verified by amplicon digestion with restriction endonucleases.", [["seb", "GENE_OR_GENE_PRODUCT", 33, 36], ["seb gene", "DNA", 33, 41], ["restriction endonucleases", "PROTEIN", 82, 107], ["Amplification specificity", "TEST", 0, 25], ["restriction endonucleases", "TREATMENT", 82, 107]]], ["Results: The specific bands for both genes in the multiplex PCR were detected in samples containing a DNA quantity corresponding to 5000 organismsAEml )1 .", [["samples", "ANATOMY", 81, 88], ["DNA", "CELLULAR_COMPONENT", 102, 105], ["The specific bands", "TREATMENT", 9, 27], ["the multiplex PCR", "TEST", 46, 63]]], ["In the same reaction, the amplicon for nuc gene was visible for as little as the DNA concentration corresponding to 1000 organismsAEml )1 .", [["nuc", "GENE_OR_GENE_PRODUCT", 39, 42], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["nuc gene", "DNA", 39, 47], ["the amplicon", "TREATMENT", 22, 34]]], ["The sensitivity of each single PCR reaction was similar with those of multiplex PCR reaction.", [["each single PCR reaction", "TEST", 19, 43], ["multiplex PCR reaction", "PROBLEM", 70, 92]]], ["Conclusion: The applied DNA extraction method allowed us to obtain a good quality DNA and can be used for a direct milk extraction.", [["milk", "ANATOMY", 115, 119], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["milk", "ORGANISM_SUBSTANCE", 115, 119], ["The applied DNA extraction method", "TREATMENT", 12, 45], ["a direct milk extraction", "TREATMENT", 106, 130]]], ["Multiplex PCR reaction is a simple, rapid and reliable method for detecting enterotoxin B producing S. aureus strains from milk.", [["milk", "ANATOMY", 123, 127], ["enterotoxin B", "CHEMICAL", 76, 89], ["enterotoxin B", "GENE_OR_GENE_PRODUCT", 76, 89], ["S. aureus", "ORGANISM", 100, 109], ["strains", "ORGANISM", 110, 117], ["milk", "ORGANISM_SUBSTANCE", 123, 127], ["enterotoxin B", "PROTEIN", 76, 89], ["S. aureus", "SPECIES", 100, 109], ["milk", "SPECIES", 123, 127], ["S. aureus", "SPECIES", 100, 109], ["Multiplex PCR reaction", "TEST", 0, 22], ["enterotoxin B", "PROBLEM", 76, 89], ["S. aureus strains from milk", "PROBLEM", 100, 127], ["aureus", "OBSERVATION", 103, 109]]], ["Objective: To detect the resistance to fluoroquinolones in 30 Acinetobacter baumannii strains by a PCR-RFLP assay.P1744Methods: Thirty A. baumannii clinical isolates were obtained from different specimens (bronchial aspirates, blood-cultures, catheters, etc.) .", [["specimens", "ANATOMY", 195, 204], ["bronchial aspirates", "ANATOMY", 206, 225], ["blood", "ANATOMY", 227, 232], ["cultures", "ANATOMY", 233, 241], ["fluoroquinolones", "CHEMICAL", 39, 55], ["fluoroquinolones", "CHEMICAL", 39, 55], ["fluoroquinolones", "SIMPLE_CHEMICAL", 39, 55], ["Acinetobacter baumannii", "ORGANISM", 62, 85], ["A. baumannii", "ORGANISM", 135, 147], ["bronchial aspirates", "MULTI-TISSUE_STRUCTURE", 206, 225], ["blood", "ORGANISM_SUBSTANCE", 227, 232], ["Acinetobacter baumannii", "SPECIES", 62, 85], ["A. baumannii", "SPECIES", 135, 147], ["Acinetobacter baumannii", "SPECIES", 62, 85], ["A. baumannii", "SPECIES", 135, 147], ["fluoroquinolones", "TREATMENT", 39, 55], ["Acinetobacter baumannii strains", "PROBLEM", 62, 93], ["a PCR", "TEST", 97, 102], ["RFLP assay", "TEST", 103, 113], ["Thirty A. baumannii clinical isolates", "PROBLEM", 128, 165], ["different specimens", "TEST", 185, 204], ["bronchial aspirates", "TEST", 206, 225], ["blood", "TEST", 227, 232], ["cultures", "TEST", 233, 241], ["catheters", "TREATMENT", 243, 252], ["bronchial", "ANATOMY", 206, 215]]], ["The MICs (Minimal Inhibitory Concentrations) for ofloxacin were determined by agar dilution following standard methodology.A PCR-RFLP method using one primer pair for amplification of a 344 bp fragment related to gyrA gene (which codifies subunity A of DNA-gyrase) and using one restriction enzyme Hinf I was developed to study the resistance to ofloxacin in the different A. baumannii strains.", [["ofloxacin", "CHEMICAL", 49, 58], ["ofloxacin", "CHEMICAL", 346, 355], ["ofloxacin", "CHEMICAL", 49, 58], ["ofloxacin", "CHEMICAL", 346, 355], ["ofloxacin", "SIMPLE_CHEMICAL", 49, 58], ["gyrA", "GENE_OR_GENE_PRODUCT", 213, 217], ["DNA", "CELLULAR_COMPONENT", 253, 256], ["-gyrase", "GENE_OR_GENE_PRODUCT", 256, 263], ["Hinf I", "GENE_OR_GENE_PRODUCT", 298, 304], ["ofloxacin", "SIMPLE_CHEMICAL", 346, 355], ["A. baumannii strains", "ORGANISM", 373, 393], ["344 bp fragment", "DNA", 186, 201], ["gyrA gene", "DNA", 213, 222], ["subunity A", "DNA", 239, 249], ["restriction enzyme", "PROTEIN", 279, 297], ["Hinf I", "PROTEIN", 298, 304], ["A. baumannii", "SPECIES", 373, 385], ["A. baumannii", "SPECIES", 373, 385], ["The MICs (Minimal Inhibitory Concentrations)", "TREATMENT", 0, 44], ["ofloxacin", "TREATMENT", 49, 58], ["A PCR", "TEST", 123, 128], ["RFLP method", "TEST", 129, 140], ["a 344 bp fragment", "PROBLEM", 184, 201], ["gyrA gene", "PROBLEM", 213, 222], ["ofloxacin", "TREATMENT", 346, 355], ["baumannii strains", "PROBLEM", 376, 393], ["baumannii", "OBSERVATION", 376, 385]]], ["When an A. baumannii strain is resistant to fluoroquinolones, a mutation in the position Ser 83 of the DNA-gyrase has been detected, decreasing the affinity for the antimicrobial.", [["fluoroquinolones", "CHEMICAL", 44, 60], ["fluoroquinolones", "CHEMICAL", 44, 60], ["Ser", "CHEMICAL", 89, 92], ["A. baumannii strain", "ORGANISM", 8, 27], ["fluoroquinolones", "SIMPLE_CHEMICAL", 44, 60], ["Ser 83", "AMINO_ACID", 89, 95], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["-gyrase", "GENE_OR_GENE_PRODUCT", 106, 113], ["position Ser 83", "PROTEIN", 80, 95], ["DNA-gyrase", "PROTEIN", 103, 113], ["A. baumannii", "SPECIES", 8, 20], ["A. baumannii", "SPECIES", 8, 20], ["an A. baumannii strain", "TREATMENT", 5, 27], ["fluoroquinolones", "TREATMENT", 44, 60], ["a mutation", "PROBLEM", 62, 72], ["the antimicrobial", "TREATMENT", 161, 178]]], ["Agarosa gel was used to determine the DNA pattern: 2 fragments of 289 bp and 55 bp when there is not mutation and 1 fragment of 344 bp when the Ser 83 to Leu 83 mutation is present.", [["Ser", "CHEMICAL", 144, 147], ["Leu", "CHEMICAL", 154, 157], ["DNA", "CELLULAR_COMPONENT", 38, 41], ["Ser 83", "AMINO_ACID", 144, 150], ["Leu 83", "AMINO_ACID", 154, 160], ["Agarosa gel", "TREATMENT", 0, 11], ["bp", "TEST", 70, 72], ["bp", "TEST", 80, 82], ["mutation", "PROBLEM", 101, 109], ["1 fragment", "PROBLEM", 114, 124], ["bp", "TEST", 132, 134]]], ["Results: The relationship between the PCR-RFLP pattern and the MIC to ofloxacin is shown in the table 1.", [["ofloxacin", "CHEMICAL", 70, 79], ["ofloxacin", "CHEMICAL", 70, 79], ["ofloxacin", "SIMPLE_CHEMICAL", 70, 79], ["the PCR", "TEST", 34, 41], ["RFLP pattern", "TEST", 42, 54], ["the MIC to ofloxacin", "TREATMENT", 59, 79]]], ["The results of PCR-RFLP analysis of most strains were in agreement with the results of MIC.", [["RFLP", "DNA", 19, 23], ["PCR", "TEST", 15, 18], ["RFLP analysis", "TEST", 19, 32], ["most strains", "PROBLEM", 36, 48]]], ["One isolate was susceptible to ofloxacin by agar dilution (MIC = 0.25 mg/l) whereas by PCR-RFLP this isolate seems to be resistant because it presents the mutation in gyrA gene.", [["ofloxacin", "CHEMICAL", 31, 40], ["ofloxacin", "CHEMICAL", 31, 40], ["ofloxacin", "SIMPLE_CHEMICAL", 31, 40], ["gyrA", "GENE_OR_GENE_PRODUCT", 167, 171], ["gyrA gene", "DNA", 167, 176], ["ofloxacin", "TREATMENT", 31, 40], ["PCR", "TEST", 87, 90], ["RFLP", "TEST", 91, 95], ["the mutation in gyrA gene", "PROBLEM", 151, 176]]], ["Two isolates with intermediate MIC (4 mg/l) showed mutation in gyrA.Conclusion:The genotypic study by PCR-RFLP proved that ofloxacin resistant A. baumannii strains showed a punctual mutation in gyrA gene, in the same position inside the sequence of gene.P1747Evaluation of a rapid amplification-detection assay for the identification of vancomycinresistant enterococci J. Fuller, L. Turnbull, S. Shokoples, B. Lui, L. Rosmus, R. Rennie (Edmonton, CA)P1747Objective: The routine identification of vancomycin-resistant enterococci (VRE) in clinical laboratories often yields a lengthy turn-around-time that may impede infection control efforts, particularly in an outbreak situation.", [["MIC", "CHEMICAL", 31, 34], ["ofloxacin", "CHEMICAL", 123, 132], ["vancomycin", "CHEMICAL", 496, 506], ["VRE", "CHEMICAL", 530, 533], ["infection", "DISEASE", 616, 625], ["ofloxacin", "CHEMICAL", 123, 132], ["vancomycin", "CHEMICAL", 496, 506], ["ofloxacin", "SIMPLE_CHEMICAL", 123, 132], ["A. baumannii strains", "ORGANISM", 143, 163], ["gyrA", "GENE_OR_GENE_PRODUCT", 194, 198], ["B. Lui", "ORGANISM", 407, 413], ["L. Rosmus", "ORGANISM", 415, 424], ["R. Rennie", "ORGANISM", 426, 435], ["Edmonton, CA", "ORGANISM", 437, 449], ["vancomycin-resistant enterococci", "SIMPLE_CHEMICAL", 496, 528], ["gyrA", "DNA", 63, 67], ["RFLP", "DNA", 106, 110], ["gyrA gene", "DNA", 194, 203], ["A. baumannii", "SPECIES", 143, 155], ["L. Rosmus", "SPECIES", 415, 424], ["A. baumannii", "SPECIES", 143, 155], ["intermediate MIC", "TREATMENT", 18, 34], ["mutation in gyrA", "PROBLEM", 51, 67], ["The genotypic study", "TEST", 79, 98], ["PCR", "TEST", 102, 105], ["RFLP", "TEST", 106, 110], ["ofloxacin resistant A. baumannii strains", "PROBLEM", 123, 163], ["a punctual mutation", "PROBLEM", 171, 190], ["a rapid amplification", "TEST", 273, 294], ["vancomycinresistant enterococci", "PROBLEM", 337, 368], ["vancomycin", "TREATMENT", 496, 506], ["resistant enterococci", "PROBLEM", 507, 528], ["VRE", "PROBLEM", 530, 533], ["impede infection control efforts", "PROBLEM", 609, 641], ["gyrA", "ANATOMY", 63, 67], ["punctual mutation", "OBSERVATION", 173, 190], ["infection", "OBSERVATION", 616, 625]]], ["In search of an improved VRE test, we evaluated the GenoType \u00d2 Enterococcus assay (Hain Lifescience, Germany), which provides both species and van gene identification for VRE, and compared the results to conventional methods.", [["an improved VRE test", "TEST", 13, 33], ["VRE", "PROBLEM", 171, 174]]], ["Methods: Forty clinical enterococcal strains isolated on VREscreen agar media were selected for study.", [["strains", "ANATOMY", 37, 44], ["Forty clinical enterococcal strains", "PROBLEM", 9, 44], ["VREscreen agar media", "TREATMENT", 57, 77], ["study", "TEST", 96, 101], ["enterococcal strains", "OBSERVATION", 24, 44]]], ["Lactococcus and Pediococcus were used as negative controls.", [["Lactococcus", "TREATMENT", 0, 11], ["Pediococcus", "TREATMENT", 16, 27]]], ["Conventional testing involved basic culture and identification tests, E-test susceptibility testing for vancomycin and teichoplanin, and PCR for vanA, B, and C genes.", [["vancomycin", "CHEMICAL", 104, 114], ["teichoplanin", "CHEMICAL", 119, 131], ["vancomycin", "CHEMICAL", 104, 114], ["teichoplanin", "CHEMICAL", 119, 131], ["vancomycin", "SIMPLE_CHEMICAL", 104, 114], ["teichoplanin", "SIMPLE_CHEMICAL", 119, 131], ["vanA", "GENE_OR_GENE_PRODUCT", 145, 149], ["B", "GENE_OR_GENE_PRODUCT", 151, 152], ["C", "GENE_OR_GENE_PRODUCT", 158, 159], ["vanA", "DNA", 145, 149], ["B, and C genes", "DNA", 151, 165], ["Conventional testing", "TEST", 0, 20], ["basic culture", "TEST", 30, 43], ["identification tests", "TEST", 48, 68], ["E-test susceptibility testing", "TEST", 70, 99], ["vancomycin", "TREATMENT", 104, 114], ["teichoplanin", "TREATMENT", 119, 131], ["PCR", "TEST", 137, 140], ["vanA", "PROBLEM", 145, 149]]], ["The GenoType \u00d2 Enterococcus assay involved multiplex DNA amplification and reverse hybridization of amplified product on an immobilized DNA strip-blot containing probes for E. faecium, E. faecalis, E. casseliflavus, E. gallinarum, vanA, vanB, vanC1, and vanC2/3.Results:The GenoType \u00d2 Enterococcus assay produced correct species and van gene identification for all 40 (100%) VRE isolates, including 7 E. faecalis vanB, 12 E. faecium vanA, 12 E. faecium vanB, 6 E. gallinarum vanC1, 1 E. gallinarum vanA-vanC1, and 2 E. casseliflavus vanC2/3.", [["DNA", "CELLULAR_COMPONENT", 53, 56], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["E. faecium", "ORGANISM", 173, 183], ["E. faecalis", "ORGANISM", 185, 196], ["E. casseliflavus", "ORGANISM", 198, 214], ["E. gallinarum", "ORGANISM", 216, 229], ["vanA", "GENE_OR_GENE_PRODUCT", 231, 235], ["vanB", "GENE_OR_GENE_PRODUCT", 237, 241], ["vanC1", "GENE_OR_GENE_PRODUCT", 243, 248], ["3", "GENE_OR_GENE_PRODUCT", 260, 261], ["E. faecalis vanB", "ORGANISM", 401, 417], ["E. faecium vanA", "ORGANISM", 422, 437], ["E. faecium vanB", "ORGANISM", 442, 457], ["E. gallinarum", "ORGANISM", 461, 474], ["vanC1", "ORGANISM", 475, 480], ["E. gallinarum", "ORGANISM", 484, 497], ["vanA-vanC1", "ORGANISM", 498, 508], ["E. casseliflavus", "ORGANISM", 516, 532], ["vanA", "DNA", 231, 235], ["E. faecium", "SPECIES", 173, 183], ["E. faecalis", "SPECIES", 185, 196], ["E. casseliflavus", "SPECIES", 198, 214], ["E. gallinarum", "SPECIES", 216, 229], ["E. faecalis", "SPECIES", 401, 412], ["E. faecium", "SPECIES", 422, 432], ["E. faecium", "SPECIES", 442, 452], ["E. gallinarum", "SPECIES", 461, 474], ["E. gallinarum", "SPECIES", 484, 497], ["E. casseliflavus", "SPECIES", 516, 532], ["E. faecium", "SPECIES", 173, 183], ["E. faecalis", "SPECIES", 185, 196], ["E. casseliflavus", "SPECIES", 198, 214], ["E. gallinarum", "SPECIES", 216, 229], ["E. faecalis", "SPECIES", 401, 412], ["E. faecium", "SPECIES", 422, 432], ["E. faecium", "SPECIES", 442, 452], ["E. gallinarum", "SPECIES", 461, 474], ["E. gallinarum vanA-vanC1", "SPECIES", 484, 508], ["E. casseliflavus", "SPECIES", 516, 532], ["The GenoType \u00d2 Enterococcus assay", "TEST", 0, 33], ["multiplex DNA amplification", "TREATMENT", 43, 70], ["reverse hybridization of amplified product", "TREATMENT", 75, 117], ["an immobilized DNA strip", "TREATMENT", 121, 145], ["E. faecium", "PROBLEM", 173, 183], ["E. faecalis", "PROBLEM", 185, 196], ["vanB", "TREATMENT", 237, 241], ["vanC1", "TREATMENT", 243, 248], ["vanC2", "TREATMENT", 254, 259], ["The GenoType \u00d2 Enterococcus assay", "TEST", 270, 303], ["van gene identification", "TEST", 333, 356], ["VRE isolates", "TEST", 375, 387], ["faecium vanB", "TREATMENT", 445, 457], ["vanC1", "TREATMENT", 503, 508]]], ["The only minor discrepancy was an E. casseliflavus that hybridized very weakly with the vanC1 probe in addition to the expected vanC2/C3 probe.", [["E. casseliflavus", "ORGANISM", 34, 50], ["vanC2", "GENE_OR_GENE_PRODUCT", 128, 133], ["vanC1 probe", "DNA", 88, 99], ["vanC2/C3 probe", "DNA", 128, 142], ["E. casseliflavus", "SPECIES", 34, 50], ["E. casseliflavus", "SPECIES", 34, 50], ["an E. casseliflavus", "PROBLEM", 31, 50], ["the vanC1 probe", "TREATMENT", 84, 99], ["the expected vanC2/C3 probe", "TREATMENT", 115, 142], ["minor", "OBSERVATION_MODIFIER", 9, 14], ["discrepancy", "OBSERVATION", 15, 26]]], ["The costs per specimen were comparable for each test method.", [["specimen", "ANATOMY", 14, 22], ["each test method", "TEST", 43, 59]]], ["However, the GenoType \u00d2 Enterococcus assay could be completed within a normal working day in contrast to conventional testing, which required a minimum of two days from the point of isolation on the vancomycin-screen media.", [["vancomycin", "CHEMICAL", 199, 209], ["vancomycin", "CHEMICAL", 199, 209], ["vancomycin", "SIMPLE_CHEMICAL", 199, 209], ["the GenoType \u00d2 Enterococcus assay", "TEST", 9, 42], ["conventional testing", "TEST", 105, 125], ["the vancomycin", "TREATMENT", 195, 209]]], ["Conclusion: From this preliminary evaluation, the GenoType \u00d2 Enterococcus amplification-detection assay provides VRE species and van genotype identification in a rapid and costeffective manner, superior to conventional culture methods.", [["this preliminary evaluation", "TEST", 17, 44], ["the GenoType \u00d2 Enterococcus amplification", "TEST", 46, 87], ["detection assay", "TEST", 88, 103], ["VRE species", "PROBLEM", 113, 124], ["van genotype identification", "TEST", 129, 156], ["a rapid and costeffective manner", "TREATMENT", 160, 192], ["conventional culture methods", "TEST", 206, 234]]], ["Although further study is required, this kit may have clinical utility during a VRE outbreak.P1748Application of minimal sequence quality values prevents misidentification of blashv type in single bacterial isolates carrying different SHV extended-spectrum beta-lactamase genes Background: Detection of extended spectrum beta-lactamase (ESBL) genes by PCR and sequence analysis is the gold standard for detection of SHV-type beta lactamases.", [["blashv", "GENE_OR_GENE_PRODUCT", 175, 181], ["extended spectrum beta-lactamase", "GENE_OR_GENE_PRODUCT", 303, 335], ["ESBL", "GENE_OR_GENE_PRODUCT", 337, 341], ["SHV-type beta lactamases", "GENE_OR_GENE_PRODUCT", 416, 440], ["SHV extended-spectrum beta-lactamase genes", "DNA", 235, 277], ["extended spectrum beta-lactamase (ESBL) genes", "DNA", 303, 348], ["SHV-type beta lactamases", "PROTEIN", 416, 440], ["further study", "TEST", 9, 22], ["a VRE outbreak", "PROBLEM", 78, 92], ["minimal sequence quality values", "TEST", 113, 144], ["blashv type", "PROBLEM", 175, 186], ["single bacterial isolates", "PROBLEM", 190, 215], ["extended spectrum beta-lactamase", "TEST", 303, 335], ["ESBL) genes", "TEST", 337, 348], ["PCR", "TEST", 352, 355], ["sequence analysis", "TEST", 360, 377], ["SHV", "TEST", 416, 419], ["type beta lactamases", "PROBLEM", 420, 440]]], ["Usually, quality values of sequence analyses are not reported.", [["sequence analyses", "TEST", 27, 44]]], ["During a study on ESBL epidemiology, three strains for which the default sequence assembly showed an SHV)2 or SHV-5 gene, showed low quality values at certain positions in individual sequence traces.", [["SHV)2", "GENE_OR_GENE_PRODUCT", 101, 106], ["SHV-5", "GENE_OR_GENE_PRODUCT", 110, 115], ["SHV-5 gene", "DNA", 110, 120], ["a study", "TEST", 7, 14], ["the default sequence", "TEST", 61, 81], ["an SHV", "TEST", 98, 104], ["SHV", "TEST", 110, 113], ["low quality values", "PROBLEM", 129, 147], ["low quality", "OBSERVATION_MODIFIER", 129, 140]]], ["We investigated the reason for these lower values.", [["these lower values", "PROBLEM", 31, 49]]], ["Methods: SHV genes were amplified by PCR from three isolates (Escherichia coli, Enterobacter cloacae and Pseudomonas aeruginosa).", [["SHV", "GENE_OR_GENE_PRODUCT", 9, 12], ["Escherichia coli", "ORGANISM", 62, 78], ["Enterobacter cloacae", "ORGANISM", 80, 100], ["Pseudomonas aeruginosa", "ORGANISM", 105, 127], ["SHV genes", "DNA", 9, 18], ["Escherichia coli", "SPECIES", 62, 78], ["Enterobacter cloacae", "SPECIES", 80, 100], ["Pseudomonas aeruginosa", "SPECIES", 105, 127], ["Escherichia coli", "SPECIES", 62, 78], ["Enterobacter cloacae", "SPECIES", 80, 100], ["Pseudomonas aeruginosa", "SPECIES", 105, 127], ["SHV genes", "PROBLEM", 9, 18], ["PCR", "TEST", 37, 40], ["Escherichia coli", "PROBLEM", 62, 78], ["Enterobacter cloacae", "PROBLEM", 80, 100], ["Pseudomonas aeruginosa", "PROBLEM", 105, 127]]], ["Individual sequence traces were analysed with the computer programs PHRED and Codon Code.", [["PHRED", "DNA", 68, 73], ["Codon Code", "DNA", 78, 88], ["Individual sequence traces", "TEST", 0, 26]]], ["PCR products were ligated in vector pCR2.1 and transformed to E. coli.", [["pCR2.1", "GENE_OR_GENE_PRODUCT", 36, 42], ["E. coli", "ORGANISM", 62, 69], ["PCR products", "DNA", 0, 12], ["vector pCR2.1", "DNA", 29, 42], ["E. coli", "SPECIES", 62, 69], ["E. coli", "SPECIES", 62, 69], ["PCR products", "TREATMENT", 0, 12], ["E. coli", "PROBLEM", 62, 69], ["E. coli", "OBSERVATION", 62, 69]]], ["Sequence analysis was performed on eight individual clones from each transformation.", [["Sequence analysis", "TEST", 0, 17]]], ["Results: Visual inspection of the low quality positions in the sequence traces showed signals for two different nucleotides at three positions in the SHV sequence: A or T at position 92, A or G at position 402 and A or G at position 703.", [["nucleotides", "CHEMICAL", 112, 123], ["A", "GENE_OR_GENE_PRODUCT", 164, 165], ["SHV sequence", "DNA", 150, 162], ["position 703", "DNA", 224, 236], ["Visual inspection", "TEST", 9, 26], ["the sequence traces", "TEST", 59, 78], ["two different nucleotides", "PROBLEM", 98, 123], ["low quality", "OBSERVATION_MODIFIER", 34, 45]]], ["The polymorphisms at positions 92 and 703 lead to aminoacid substitutions, the four different combinations would give SHV types 2, 2a, 5 or 12.", [["aminoacid", "CHEMICAL", 50, 59], ["aminoacid", "AMINO_ACID", 50, 59], ["The polymorphisms at positions", "PROBLEM", 0, 30], ["aminoacid substitutions", "TREATMENT", 50, 73], ["aminoacid substitutions", "OBSERVATION", 50, 73]]], ["The double signals suggested that two or more blaSHV alleles were amplified.", [["blaSHV", "GENE_OR_GENE_PRODUCT", 46, 52], ["blaSHV alleles", "DNA", 46, 60], ["more blaSHV alleles", "PROBLEM", 41, 60]]], ["PCR amplicons were cloned in E. coli, in the sequences of individual clones only two combinations of the three polymorphisms were present: A92G402A703 and T92A402G703.", [["clones", "ANATOMY", 69, 75], ["E. coli", "ORGANISM", 29, 36], ["clones", "CELL", 69, 75], ["PCR amplicons", "DNA", 0, 13], ["E. coli", "SPECIES", 29, 36], ["E. coli", "SPECIES", 29, 36], ["PCR amplicons", "TEST", 0, 13], ["E. coli", "PROBLEM", 29, 36], ["individual clones", "PROBLEM", 58, 75], ["E. coli", "OBSERVATION_MODIFIER", 29, 36]]], ["These two combinations correspond to SHV-2 and SHV-12, respectively.", [["SHV-2", "GENE_OR_GENE_PRODUCT", 37, 42], ["SHV-12", "GENE_OR_GENE_PRODUCT", 47, 53], ["SHV", "DNA", 37, 40], ["SHV", "DNA", 47, 50], ["SHV", "TEST", 37, 40], ["SHV", "TEST", 47, 50]]], ["Conclusions: (i) In isolates of three different species, two different SHV genes were present: SHV-2 and SHV-12. (ii) Genotypic detection with default sequence assembly parameters may lead to misidentification of the number and type of SHV genes carried by a single strain. (iii) Careful interpretation of sequence data of SHV genes, including analysis of low quality positions, may further improve our understanding of the epidemiology and evolution of these ESBL genes.P1749Antimicrobial susceptibilities and epidemiological analysis of Salmonella typhimurium human isolates in Slovakia by phage typing and pulsed-field gel electrophoresis V. Majt\u00e1n, L. Majt\u00e1nova, M. Szab\u00f3 ov\u00e1 (Bratislava, SK)P1749Objectives: Salmonella Typhimurium is a common cause of salmonellosis among humans and animals in many countries.", [["Salmonella Typhimurium", "DISEASE", 713, 735], ["salmonellosis", "DISEASE", 757, 770], ["SHV", "GENE_OR_GENE_PRODUCT", 71, 74], ["SHV-2", "GENE_OR_GENE_PRODUCT", 95, 100], ["SHV-12", "GENE_OR_GENE_PRODUCT", 105, 111], ["SHV", "GENE_OR_GENE_PRODUCT", 236, 239], ["SHV", "GENE_OR_GENE_PRODUCT", 323, 326], ["ESBL", "GENE_OR_GENE_PRODUCT", 460, 464], ["Salmonella typhimurium", "ORGANISM", 539, 561], ["human", "ORGANISM", 562, 567], ["Salmonella Typhimurium", "ORGANISM", 713, 735], ["humans", "ORGANISM", 777, 783], ["SHV genes", "DNA", 71, 80], ["SHV-12", "DNA", 105, 111], ["SHV genes", "DNA", 236, 245], ["SHV genes", "DNA", 323, 332], ["ESBL genes", "DNA", 460, 470], ["Salmonella typhimurium", "SPECIES", 539, 561], ["human", "SPECIES", 562, 567], ["Salmonella Typhimurium", "SPECIES", 713, 735], ["humans", "SPECIES", 777, 783], ["SHV-12", "SPECIES", 105, 111], ["Salmonella typhimurium", "SPECIES", 539, 561], ["human", "SPECIES", 562, 567], ["M. Szab\u00f3 ov\u00e1", "SPECIES", 667, 679], ["Salmonella Typhimurium", "SPECIES", 713, 735], ["salmonellosis", "SPECIES", 757, 770], ["humans", "SPECIES", 777, 783], ["three different species", "PROBLEM", 32, 55], ["SHV", "TEST", 95, 98], ["SHV", "TEST", 105, 108], ["Genotypic detection", "TEST", 118, 137], ["default sequence", "TEST", 143, 159], ["SHV genes", "PROBLEM", 236, 245], ["a single strain", "PROBLEM", 257, 272], ["sequence data", "TEST", 306, 319], ["SHV genes", "TEST", 323, 332], ["these ESBL genes", "PROBLEM", 454, 470], ["P1749Antimicrobial susceptibilities", "TEST", 471, 506], ["epidemiological analysis", "TEST", 511, 535], ["Salmonella typhimurium human isolates", "PROBLEM", 539, 576], ["phage typing", "TEST", 592, 604], ["pulsed-field gel electrophoresis", "TEST", 609, 641], ["Majt\u00e1n", "TEST", 645, 651], ["Salmonella Typhimurium", "PROBLEM", 713, 735], ["salmonellosis", "PROBLEM", 757, 770], ["low quality", "OBSERVATION_MODIFIER", 356, 367], ["ESBL genes", "OBSERVATION", 460, 470], ["Salmonella Typhimurium", "OBSERVATION", 713, 735], ["salmonellosis", "OBSERVATION", 757, 770]]], ["In the last few decades the incidence of multidrug-resistant S. Typhimurium infections appears to pose a particular health risk.", [["S. Typhimurium infections", "DISEASE", 61, 86], ["multidrug", "ORGANISM", 41, 50], ["S. Typhimurium", "ORGANISM", 61, 75], ["S. Typhimurium", "SPECIES", 61, 75], ["S. Typhimurium", "SPECIES", 61, 75], ["multidrug-resistant S. Typhimurium infections", "PROBLEM", 41, 86], ["Typhimurium infections", "OBSERVATION", 64, 86]]], ["The objectives of this study were analysis by antibiotic susceptibility, phage typing and pulsed-field gel electrophoresis (PFGE) of S. Typhimurium human isolates.", [["S. Typhimurium", "ORGANISM", 133, 147], ["human", "ORGANISM", 148, 153], ["S. Typhimurium", "SPECIES", 133, 147], ["human", "SPECIES", 148, 153], ["S. Typhimurium", "SPECIES", 133, 147], ["human", "SPECIES", 148, 153], ["this study", "TEST", 18, 28], ["antibiotic susceptibility", "TEST", 46, 71], ["phage typing", "TEST", 73, 85], ["pulsed-field gel electrophoresis", "TEST", 90, 122], ["S. Typhimurium human isolates", "PROBLEM", 133, 162]]], ["The susceptibility of isolates to ten antibiotics was evaluated by a disk diffusion method.", [["ten antibiotics", "TREATMENT", 34, 49], ["a disk diffusion method", "TEST", 67, 90]]], ["The phage types were identified according to Anderson et al. (1977) in the National Reference Center for phage typing of Salmonellae.", [["phage typing", "TEST", 105, 117], ["Salmonellae", "PROBLEM", 121, 132], ["Salmonellae", "OBSERVATION", 121, 132]]], ["PFGE was used to resolve XbaI macro restriction fragments from all strains.", [["XbaI", "GENE_OR_GENE_PRODUCT", 25, 29], ["XbaI macro restriction fragments", "DNA", 25, 57], ["PFGE", "TREATMENT", 0, 4], ["XbaI macro restriction fragments", "PROBLEM", 25, 57], ["all strains", "PROBLEM", 63, 74], ["fragments", "OBSERVATION_MODIFIER", 48, 57]]], ["Results: Of human isolates 88 (60.7%) were resistant to more than two antibiotics.", [["human", "ORGANISM", 12, 17], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["human isolates", "TEST", 12, 26], ["two antibiotics", "TREATMENT", 66, 81]]], ["Sixty-three of isolates (43.4%) showed a classic DT104 resistance profile to ampicillin, chloramphenicol, streptomycin, sulfonamides, tetracycline (ACSSuT).", [["DT104", "CHEMICAL", 49, 54], ["ampicillin", "CHEMICAL", 77, 87], ["chloramphenicol", "CHEMICAL", 89, 104], ["streptomycin", "CHEMICAL", 106, 118], ["sulfonamides", "CHEMICAL", 120, 132], ["tetracycline", "CHEMICAL", 134, 146], ["ACSSuT", "CHEMICAL", 148, 154], ["ampicillin", "CHEMICAL", 77, 87], ["chloramphenicol", "CHEMICAL", 89, 104], ["streptomycin", "CHEMICAL", 106, 118], ["sulfonamides", "CHEMICAL", 120, 132], ["tetracycline", "CHEMICAL", 134, 146], ["ACSSuT", "CHEMICAL", 148, 154], ["ampicillin", "SIMPLE_CHEMICAL", 77, 87], ["chloramphenicol", "SIMPLE_CHEMICAL", 89, 104], ["streptomycin", "SIMPLE_CHEMICAL", 106, 118], ["sulfonamides", "SIMPLE_CHEMICAL", 120, 132], ["tetracycline", "SIMPLE_CHEMICAL", 134, 146], ["ACSSuT", "SIMPLE_CHEMICAL", 148, 154], ["DT104", "SPECIES", 49, 54], ["DT104", "SPECIES", 49, 54], ["isolates", "TEST", 15, 23], ["a classic DT104 resistance profile", "PROBLEM", 39, 73], ["ampicillin", "TREATMENT", 77, 87], ["chloramphenicol", "TREATMENT", 89, 104], ["streptomycin", "TREATMENT", 106, 118], ["sulfonamides", "TREATMENT", 120, 132], ["tetracycline", "TREATMENT", 134, 146]]], ["Among this resistance type 37.2% were DT104, 7.6% were DT120 and one strain was DT20a.", [["DT104", "SPECIES", 38, 43], ["DT104", "SPECIES", 38, 43], ["this resistance type", "TEST", 6, 26], ["DT104", "TEST", 38, 43], ["DT120", "TEST", 55, 60]]], ["Isolates encompassed 18 phage types.", [["Isolates", "TEST", 0, 8], ["18 phage", "OBSERVATION_MODIFIER", 21, 29]]], ["The majority of isolates was found to be definitive phage type DT104, representing 62.8% of all isolates.", [["DT104", "SPECIES", 63, 68], ["DT104", "SPECIES", 63, 68], ["definitive phage type DT104", "PROBLEM", 41, 68]]], ["Other phage types were mainly DT120, DT41 and DT20a.", [["DT20a", "GENE_OR_GENE_PRODUCT", 46, 51], ["DT120", "PROTEIN", 30, 35], ["DT41", "PROTEIN", 37, 41], ["DT20a", "PROTEIN", 46, 51], ["DT41", "TEST", 37, 41], ["DT20a", "TEST", 46, 51]]], ["Nine pulsotypes and 18 subpulsotypes were obtained using XbaI restriction enzyme, but pattern X1 with its subtypes predominated (86.9%).", [["XbaI", "GENE_OR_GENE_PRODUCT", 57, 61], ["XbaI restriction enzyme", "PROTEIN", 57, 80], ["Nine pulsotypes", "TEST", 0, 15], ["XbaI restriction enzyme", "TEST", 57, 80]]], ["A major pulsotype X1 was represented by 51.7% of DT104 isolates and was also found among DT120 isolates.", [["pulsotype X1", "GENE_OR_GENE_PRODUCT", 8, 20], ["DT104", "ORGANISM", 49, 54], ["major pulsotype X1", "DNA", 2, 20], ["DT104", "SPECIES", 49, 54], ["DT104", "SPECIES", 49, 54], ["A major pulsotype X1", "PROBLEM", 0, 20], ["DT104 isolates", "TEST", 49, 63]]], ["Conclusion: Results indicated the spread of different clones of the multidrug-resistant S. Typhimurium in the Slovakia, but with predominance of one clone represented mainly by DT104 isolates.", [["multidrug", "ORGANISM", 68, 77], ["S. Typhimurium", "ORGANISM", 88, 102], ["clone", "CELL", 149, 154], ["DT104 isolates", "ORGANISM", 177, 191], ["S. Typhimurium", "SPECIES", 88, 102], ["DT104", "SPECIES", 177, 182], ["S. Typhimurium", "SPECIES", 88, 102], ["DT104", "SPECIES", 177, 182], ["the multidrug-resistant S. Typhimurium", "PROBLEM", 64, 102], ["one clone", "PROBLEM", 145, 154]]], ["The phage typing as well as PFGE may offer an improved level of discrimination for the epidemiological investigation of S. Typhimurium human strains.P1750Novel reverse hybridisation assay to identify CTX-M genotype in cephalosporin-resistant isolates from UK and India To validate the assay results by DNA sequencing.", [["strains", "ANATOMY", 141, 148], ["CTX", "CHEMICAL", 200, 203], ["cephalosporin", "CHEMICAL", 218, 231], ["cephalosporin", "CHEMICAL", 218, 231], ["S. Typhimurium", "ORGANISM", 120, 134], ["human", "ORGANISM", 135, 140], ["P1750", "GENE_OR_GENE_PRODUCT", 149, 154], ["CTX-M", "GENE_OR_GENE_PRODUCT", 200, 205], ["cephalosporin", "SIMPLE_CHEMICAL", 218, 231], ["DNA", "CELLULAR_COMPONENT", 302, 305], ["S. Typhimurium", "SPECIES", 120, 134], ["human", "SPECIES", 135, 140], ["S. Typhimurium", "SPECIES", 120, 134], ["human", "SPECIES", 135, 140], ["The phage typing", "TREATMENT", 0, 16], ["PFGE", "TREATMENT", 28, 32], ["the epidemiological investigation", "TEST", 83, 116], ["S. Typhimurium human strains", "PROBLEM", 120, 148], ["Novel reverse hybridisation assay", "TEST", 154, 187], ["CTX", "TEST", 200, 203], ["cephalosporin", "TREATMENT", 218, 231], ["resistant isolates", "PROBLEM", 232, 250], ["the assay", "TEST", 281, 290]]], ["Methods: Isolate collection 1: 110 Enterobacteriaceae resistant to extended-spectrum cephalosporins, isolated in London and South-East England.", [["cephalosporins", "CHEMICAL", 85, 99], ["cephalosporins", "CHEMICAL", 85, 99], ["extended-spectrum cephalosporins", "SIMPLE_CHEMICAL", 67, 99], ["Enterobacteriaceae", "PROBLEM", 35, 53], ["extended-spectrum cephalosporins", "TREATMENT", 67, 99]]], ["These isolates were known to carry phylogenetic group 1 blaCTX-M, but precise genotypes had not been determined.", [["blaCTX-M", "GENE_OR_GENE_PRODUCT", 56, 64]]], ["Isolate collection 2: 130 Enterobacteriaceae resistant to extended-spectrum cephalosporins, isolated in Aligarh, North India.", [["cephalosporins", "CHEMICAL", 76, 90], ["cephalosporins", "CHEMICAL", 76, 90], ["extended-spectrum cephalosporins", "SIMPLE_CHEMICAL", 58, 90], ["Isolate collection", "TEST", 0, 18], ["Enterobacteriaceae", "PROBLEM", 26, 44], ["extended-spectrum cephalosporins", "TREATMENT", 58, 90], ["Enterobacteriaceae resistant", "OBSERVATION_MODIFIER", 26, 54]]], ["A novel multiplex PCR was used to amplify blaCTX-M.", [["blaCTX-M.", "GENE_OR_GENE_PRODUCT", 42, 51], ["blaCTX", "PROTEIN", 42, 48], ["A novel multiplex PCR", "TEST", 0, 21]]], ["Reverse hybridisation was carried out using biotinylated PCR amplicon and sequence-specific oligonucleotides designed to identify members of CTX-M phylogenetic group 1.", [["biotinylated PCR amplicon", "DNA", 44, 69], ["Reverse hybridisation", "PROBLEM", 0, 21], ["biotinylated PCR amplicon", "TREATMENT", 44, 69], ["CTX", "TEST", 141, 144]]], ["Hybridisation results were validated by DNA sequencing for 20 representative isolates from each collection.", [["DNA", "CELLULAR_COMPONENT", 40, 43], ["Hybridisation results", "TEST", 0, 21], ["DNA sequencing", "TEST", 40, 54]]], ["Results: 109/110 London and SE England isolates known to carry group 1 blaCTX-M gave a consistent profile, corresponding to that for CTX-M-15 and CTX-M-28; 1/110 gave a profile corresponding to CTX-M-3 and CTX-M-22.", [["SE", "DISEASE", 28, 30], ["CTX-M-15", "CHEMICAL", 133, 141], ["CTX-M-28", "CHEMICAL", 146, 154], ["CTX-M-3", "CHEMICAL", 194, 201], ["CTX-M-22", "CHEMICAL", 206, 214], ["blaCTX-M", "GENE_OR_GENE_PRODUCT", 71, 79], ["CTX-M-15", "GENE_OR_GENE_PRODUCT", 133, 141], ["CTX-M-28", "SIMPLE_CHEMICAL", 146, 154], ["1/110", "SIMPLE_CHEMICAL", 156, 161], ["CTX-M-3", "GENE_OR_GENE_PRODUCT", 194, 201], ["CTX-M-22", "SIMPLE_CHEMICAL", 206, 214], ["CTX", "TEST", 133, 136], ["CTX", "TEST", 146, 149], ["CTX", "TEST", 194, 197], ["CTX", "TEST", 206, 209]]], ["82/130 Indian isolates had blaCTX-M genes, all of which belonged to group 1, and all these gave a hybridisation profile corresponding to CTX-M-15 or CTX-M-28.", [["CTX-M-15", "CHEMICAL", 137, 145], ["CTX-M-28", "CHEMICAL", 149, 157], ["blaCTX-M", "GENE_OR_GENE_PRODUCT", 27, 35], ["CTX-M-15", "GENE_OR_GENE_PRODUCT", 137, 145], ["CTX-M-28", "SIMPLE_CHEMICAL", 149, 157], ["blaCTX-M genes", "DNA", 27, 41], ["Indian isolates", "TEST", 7, 22], ["CTX", "TEST", 137, 140], ["CTX", "TEST", 149, 152]]], ["CTX-M-28 and CTX-M-22 are rare variants, suggesting that the enzymes present were more likely to be CTX-M-15 and CTX-M-3, and this was confirmed by DNA sequencing.", [["CTX-M-28", "CHEMICAL", 0, 8], ["CTX-M-22", "CHEMICAL", 13, 21], ["CTX", "CHEMICAL", 100, 103], ["CTX-M-28", "GENE_OR_GENE_PRODUCT", 0, 8], ["CTX-M-22", "GENE_OR_GENE_PRODUCT", 13, 21], ["CTX-M-15", "GENE_OR_GENE_PRODUCT", 100, 108], ["CTX-M-3", "GENE_OR_GENE_PRODUCT", 113, 120], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["CTX", "TEST", 0, 3], ["CTX", "TEST", 13, 16], ["rare variants", "PROBLEM", 26, 39], ["the enzymes", "TEST", 57, 68], ["CTX", "TEST", 100, 103], ["CTX", "TEST", 113, 116], ["rare variants", "OBSERVATION", 26, 39]]], ["Conclusions: This is the first reported application of this novel reverse hybridisation assay to the analysis of large numbers of cephalosporin-resistant Enterobacteriaceae.", [["cephalosporin", "CHEMICAL", 130, 143], ["cephalosporin", "CHEMICAL", 130, 143], ["cephalosporin", "SIMPLE_CHEMICAL", 130, 143], ["Enterobacteriaceae", "CANCER", 154, 172], ["the analysis", "TEST", 97, 109], ["cephalosporin", "TREATMENT", 130, 143], ["resistant Enterobacteriaceae", "PROBLEM", 144, 172], ["large", "OBSERVATION_MODIFIER", 113, 118], ["resistant", "OBSERVATION_MODIFIER", 144, 153], ["Enterobacteriaceae", "OBSERVATION", 154, 172]]], ["Results were validated by DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 26, 29]]], ["The assay is cheap and convenient, enables reasonable throughput, provides results within one day and can be used in place of DNA sequencing.", [["DNA", "CELLULAR_COMPONENT", 126, 129], ["DNA sequencing", "TREATMENT", 126, 140]]], ["We believe it will be valuable for monitoring the prevalence and genotypes of blaCTX-M genes in Enterobacteriaceae.P1751Detection of mexA and mexX efflux genes in P. aeruginosa: correlation between QC-RT-PCR and real-time PCR Objectives: Efflux systems are rarely identified as such in clinical microbiology laboratories.", [["blaCTX-M", "GENE_OR_GENE_PRODUCT", 78, 86], ["Enterobacteriaceae", "CANCER", 96, 114], ["mexA", "GENE_OR_GENE_PRODUCT", 133, 137], ["mexX", "GENE_OR_GENE_PRODUCT", 142, 146], ["P. aeruginosa", "ORGANISM", 163, 176], ["blaCTX-M genes", "DNA", 78, 92], ["mexA and mexX efflux genes", "DNA", 133, 159], ["P. aeruginosa", "SPECIES", 163, 176], ["P. aeruginosa", "SPECIES", 163, 176], ["Enterobacteriaceae", "PROBLEM", 96, 114], ["mexA", "TREATMENT", 133, 137], ["QC", "TEST", 198, 200], ["RT", "TEST", 201, 203], ["PCR", "TEST", 204, 207], ["Efflux systems", "PROBLEM", 238, 252], ["Enterobacteriaceae", "OBSERVATION", 96, 114]]], ["Yet, over expression of transporters such as MexAB-OprM and MexXY-OprM are likely to cause antibiotic multi-and cross-resistance in Pseudomonas aeruginosa, leading to potential clinical treatment failures because of their inducible character.", [["MexAB", "GENE_OR_GENE_PRODUCT", 45, 50], ["OprM", "GENE_OR_GENE_PRODUCT", 51, 55], ["MexXY-OprM", "GENE_OR_GENE_PRODUCT", 60, 70], ["Pseudomonas aeruginosa", "ORGANISM", 132, 154], ["MexAB", "PROTEIN", 45, 50], ["OprM", "PROTEIN", 51, 55], ["MexXY", "PROTEIN", 60, 65], ["OprM", "PROTEIN", 66, 70], ["Pseudomonas aeruginosa", "SPECIES", 132, 154], ["Pseudomonas aeruginosa", "SPECIES", 132, 154], ["transporters", "TREATMENT", 24, 36], ["MexAB", "TEST", 45, 50], ["MexXY", "TREATMENT", 60, 65], ["OprM", "TREATMENT", 66, 70], ["antibiotic multi-and cross-resistance in Pseudomonas aeruginosa", "PROBLEM", 91, 154], ["potential clinical treatment failures", "PROBLEM", 167, 204], ["their inducible character", "PROBLEM", 216, 241]]], ["We have previously developed and validated with reference strains a QC-RT-PCR method to quantify mexA and mexX expression levels (ECCMID 2005 .", [["mexA", "GENE_OR_GENE_PRODUCT", 97, 101], ["mexX", "GENE_OR_GENE_PRODUCT", 106, 110], ["mexX", "PROTEIN", 106, 110], ["PCR method", "TEST", 74, 84]]], ["In the present study, we have developed a Real-Time-PCR assay and present here the correlation between both methods using control strains and clinical isolates.", [["PCR assay", "TEST", 52, 61], ["control strains", "TREATMENT", 122, 137]]], ["Methods: Expression levels of mexA and mexX were measured by both techniques in (i) 4 reference strains expressing only one of these efflux mechanisms [mexA (2) or mexX (2) ]; and (ii) 8 clinical isolates, in comparison with the wild-type strain PAO1 (basal mexA and mexX expression levels).", [["mexA", "GENE_OR_GENE_PRODUCT", 30, 34], ["mexX", "GENE_OR_GENE_PRODUCT", 39, 43], ["mexA (2)", "GENE_OR_GENE_PRODUCT", 152, 160], ["mexX (2)", "GENE_OR_GENE_PRODUCT", 164, 172], ["PAO1", "CELL", 246, 250], ["mexX", "GENE_OR_GENE_PRODUCT", 267, 271], ["mexA", "PROTEIN", 30, 34], ["mexX", "PROTEIN", 39, 43], ["mexX", "PROTEIN", 267, 271], ["mexA and mexX", "TREATMENT", 30, 43], ["these efflux mechanisms", "PROBLEM", 127, 150], ["mexA", "TEST", 152, 156], ["type strain PAO1", "PROBLEM", 234, 250], ["basal mexA", "TEST", 252, 262]]], ["Results: Real-Time PCR showed an inter-day reproducibility of 95 \u00b1 5.3% (triplicates of 10 strains).", [["Time PCR", "TEST", 14, 22], ["an inter-day reproducibility", "TEST", 30, 58]]], ["Among the clinical strains, 5 over expressed mexA and 3 mexX.", [["mexA", "GENE_OR_GENE_PRODUCT", 45, 49], ["mexX", "GENE_OR_GENE_PRODUCT", 56, 60], ["mexA", "PROTEIN", 45, 49], ["mexX", "PROTEIN", 56, 60], ["the clinical strains", "PROBLEM", 6, 26]]], ["The Table shows (i) the mean level of overexpression of mexA and mexX in comparison with the wild type strain PAO1 (set at 1), as detected by Real-time PCR for all strains; (ii) the ratio of these values to those observed by QC-RT-PCR for the corresponding transporters.P1751Conclusions: Both QC-RT-PCR and Real-Time-PCR are potentially useful in clinical laboratories as sensitive and rapid diagnostic tools to quantify the expression level of mexA and mexX in P. aeruginosa.", [["mexA", "GENE_OR_GENE_PRODUCT", 56, 60], ["mexX", "GENE_OR_GENE_PRODUCT", 65, 69], ["wild type strain PAO1", "ORGANISM", 93, 114], ["mexA", "GENE_OR_GENE_PRODUCT", 445, 449], ["mexX", "GENE_OR_GENE_PRODUCT", 454, 458], ["P. aeruginosa", "ORGANISM", 462, 475], ["mexA", "PROTEIN", 56, 60], ["mexX", "PROTEIN", 65, 69], ["mexA", "PROTEIN", 445, 449], ["mexX", "PROTEIN", 454, 458], ["P. aeruginosa", "SPECIES", 462, 475], ["P. aeruginosa", "SPECIES", 462, 475], ["overexpression of mexA", "PROBLEM", 38, 60], ["the wild type strain PAO1", "PROBLEM", 89, 114], ["all strains", "PROBLEM", 160, 171], ["QC", "TEST", 225, 227], ["PCR", "TEST", 231, 234], ["PCR", "TEST", 299, 302], ["Real-Time-PCR", "TEST", 307, 320], ["clinical laboratories", "TEST", 347, 368], ["rapid diagnostic tools", "TEST", 386, 408], ["mexA", "TEST", 445, 449], ["mexX in P. aeruginosa", "PROBLEM", 454, 475]]], ["Combined with phenotypic characterization, this approach may help in a better understanding of the resistance mechanisms and epidemiology of resistance in this difficult-to-treat nosocomial pathogen.P1752Molecular detection of penicillin resistance in Streptococcus pneumomiae N.G. Rizk, N.A. Abo Khadr, S.M. Abdel Salam, N.M. Gamil, M. Hassan (Alexandria, EG) Objectives: The aim of the study was to detect penicillin resistant Streptococcus pneumoniae by using seminested polymerase chain reaction (PCR) and to compare it with minimum inhibitory concentration (MIC) of penicillin G. Methods: Fifty clinical isolates of Streptococcus pneumoniae where isolated from patients admitted to Alexandria Main University Hospital in Egypt and were recovered from sputum (36 strains), throat swabs (11 strains), and pleural effusion (3 strains) .", [["sputum", "ANATOMY", 756, 762], ["strains", "ANATOMY", 767, 774], ["throat swabs", "ANATOMY", 777, 789], ["strains", "ANATOMY", 794, 801], ["pleural effusion", "ANATOMY", 808, 824], ["penicillin", "CHEMICAL", 227, 237], ["penicillin", "CHEMICAL", 408, 418], ["Streptococcus pneumoniae", "DISEASE", 429, 453], ["penicillin", "CHEMICAL", 571, 581], ["Streptococcus pneumoniae", "DISEASE", 621, 645], ["pleural effusion", "DISEASE", 808, 824], ["penicillin", "CHEMICAL", 227, 237], ["penicillin", "CHEMICAL", 408, 418], ["penicillin", "CHEMICAL", 571, 581], ["penicillin", "SIMPLE_CHEMICAL", 227, 237], ["Streptococcus pneumomiae", "ORGANISM", 252, 276], ["penicillin", "SIMPLE_CHEMICAL", 408, 418], ["Streptococcus pneumoniae", "ORGANISM", 429, 453], ["Streptococcus pneumoniae", "ORGANISM", 621, 645], ["patients", "ORGANISM", 666, 674], ["sputum", "ORGANISM_SUBSTANCE", 756, 762], ["pleural effusion", "CANCER", 808, 824], ["Streptococcus pneumomiae", "SPECIES", 252, 276], ["Streptococcus pneumoniae", "SPECIES", 429, 453], ["Streptococcus pneumoniae", "SPECIES", 621, 645], ["patients", "SPECIES", 666, 674], ["Streptococcus pneumomiae", "SPECIES", 252, 276], ["Streptococcus pneumoniae", "SPECIES", 429, 453], ["Streptococcus pneumoniae", "SPECIES", 621, 645], ["phenotypic characterization", "TEST", 14, 41], ["the resistance mechanisms", "PROBLEM", 95, 120], ["nosocomial pathogen", "PROBLEM", 179, 198], ["penicillin resistance", "PROBLEM", 227, 248], ["Streptococcus pneumomiae", "PROBLEM", 252, 276], ["the study", "TEST", 384, 393], ["penicillin resistant Streptococcus pneumoniae", "PROBLEM", 408, 453], ["seminested polymerase chain reaction", "PROBLEM", 463, 499], ["PCR", "TEST", 501, 504], ["Streptococcus pneumoniae", "PROBLEM", 621, 645], ["sputum", "TEST", 756, 762], ["throat swabs", "TEST", 777, 789], ["pleural effusion", "PROBLEM", 808, 824], ["penicillin resistance", "OBSERVATION", 227, 248], ["Streptococcus pneumomiae", "OBSERVATION", 252, 276], ["Streptococcus pneumoniae", "OBSERVATION", 621, 645], ["pleural", "ANATOMY", 808, 815], ["effusion", "OBSERVATION", 816, 824]]], ["Two species-specific primers 1A-1 and 1A-2, which amplified 1043 bp region of the pbp1A penicillin-binding gene, were used for pneumococcal detection.", [["penicillin", "CHEMICAL", 88, 98], ["penicillin", "CHEMICAL", 88, 98], ["1A-1", "GENE_OR_GENE_PRODUCT", 29, 33], ["1A-2", "GENE_OR_GENE_PRODUCT", 38, 42], ["pbp1A penicillin", "GENE_OR_GENE_PRODUCT", 82, 98], ["primers 1A-1 and 1A-2", "DNA", 21, 42], ["1043 bp region", "DNA", 60, 74], ["pbp1A penicillin-binding gene", "DNA", 82, 111], ["pneumococcal", "SPECIES", 127, 139], ["Two species", "TEST", 0, 11], ["specific primers", "TEST", 12, 28], ["the pbp1A penicillin", "TREATMENT", 78, 98], ["pneumococcal detection", "PROBLEM", 127, 149]]], ["Two resistance primers, 1A-R1 and 1A-R2, were used to bind to altered areas of pbp1A gene which, together with the down stream primer 1A-2, amplify DNA sequences of 224 bp and 569 bp from isolates with penicillin MIC > 0.", [["penicillin", "CHEMICAL", 202, 212], ["penicillin", "CHEMICAL", 202, 212], ["1A-R2", "GENE_OR_GENE_PRODUCT", 34, 39], ["pbp1A", "GENE_OR_GENE_PRODUCT", 79, 84], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["penicillin", "SIMPLE_CHEMICAL", 202, 212], ["R1", "DNA", 27, 29], ["1A", "DNA", 34, 36], ["R2", "DNA", 37, 39], ["pbp1A gene", "DNA", 79, 89], ["down stream primer 1A-2", "DNA", 115, 138], ["DNA sequences", "DNA", 148, 161], ["Two resistance primers", "TEST", 0, 22], ["1A", "TEST", 24, 26], ["DNA sequences", "TEST", 148, 161], ["bp", "TEST", 169, 171], ["bp", "TEST", 180, 182], ["isolates", "TEST", 188, 196], ["penicillin MIC", "TREATMENT", 202, 216], ["resistance primers", "OBSERVATION", 4, 22]]], ["Objective: Lipopolysaccharide-binding protein (LBP) is an acute phase protein produced in the liver.", [["liver", "ANATOMY", 94, 99], ["Lipopolysaccharide", "CHEMICAL", 11, 29], ["Lipopolysaccharide-binding protein", "GENE_OR_GENE_PRODUCT", 11, 45], ["LBP", "GENE_OR_GENE_PRODUCT", 47, 50], ["liver", "ORGAN", 94, 99], ["Lipopolysaccharide-binding protein", "PROTEIN", 11, 45], ["LBP", "PROTEIN", 47, 50], ["acute phase protein", "PROTEIN", 58, 77], ["Lipopolysaccharide-binding protein (LBP", "TEST", 11, 50], ["an acute phase protein", "TEST", 55, 77], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["phase", "OBSERVATION_MODIFIER", 64, 69], ["protein", "OBSERVATION", 70, 77], ["liver", "ANATOMY", 94, 99]]], ["The objective of our study was to evaluate LBP as a marker of severity and prognosis in patients with bacteraemia.", [["LBP", "DISEASE", 43, 46], ["bacteraemia", "DISEASE", 102, 113], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["our study", "TEST", 17, 26], ["LBP", "PROBLEM", 43, 46], ["bacteraemia", "PROBLEM", 102, 113], ["bacteraemia", "OBSERVATION", 102, 113]]], ["Methods: 42 adult patients with community-acquired bacteraemia were included in a prospective manner.", [["bacteraemia", "DISEASE", 51, 62], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["community-acquired bacteraemia", "PROBLEM", 32, 62], ["bacteraemia", "OBSERVATION", 51, 62]]], ["Daily blood sampling for LBP and Interleukin-6 (IL-6) was performed.", [["blood", "ANATOMY", 6, 11], ["LBP", "DISEASE", 25, 28], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["Interleukin-6", "GENE_OR_GENE_PRODUCT", 33, 46], ["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["Interleukin-6", "PROTEIN", 33, 46], ["IL", "PROTEIN", 48, 50], ["Daily blood sampling", "TEST", 0, 20], ["LBP", "PROBLEM", 25, 28], ["Interleukin", "TEST", 33, 44]]], ["The patients were classified according to the Systemic Inflammatory Response Syndrome (SIRS) criteria.", [["SIRS", "DISEASE", 87, 91], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the Systemic Inflammatory Response Syndrome", "PROBLEM", 42, 85], ["Systemic", "OBSERVATION_MODIFIER", 46, 54], ["Inflammatory Response Syndrome", "OBSERVATION", 55, 85]]], ["Demographic data, co-morbidity, microbiological aaetiology, routine biochemical parameters, focus of infection, severity score and mortality on day 28 were recorded.", [["infection", "DISEASE", 101, 110], ["Demographic data", "TEST", 0, 16], ["co-morbidity", "PROBLEM", 18, 30], ["microbiological aaetiology", "TEST", 32, 58], ["routine biochemical parameters", "TEST", 60, 90], ["infection", "PROBLEM", 101, 110], ["severity score", "PROBLEM", 112, 126], ["infection", "OBSERVATION", 101, 110]]], ["LBP and IL-6 levels were analysed on plasma samples with a chemiluminescent immunometric assay (Immulite-1000 \u00d2 ).", [["plasma samples", "ANATOMY", 37, 51], ["LBP", "DISEASE", 0, 3], ["IL-6", "GENE_OR_GENE_PRODUCT", 8, 12], ["plasma samples", "ORGANISM_SUBSTANCE", 37, 51], ["IL", "PROTEIN", 8, 10], ["LBP", "TEST", 0, 3], ["IL", "TEST", 8, 10], ["plasma samples", "TEST", 37, 51], ["a chemiluminescent immunometric assay", "TEST", 57, 94], ["Immulite", "TEST", 96, 104]]], ["The mortality rate on day 28 was 16.6%.", [["The mortality rate", "TEST", 0, 18]]], ["5 patients had bacteraemia without SIRS, 17 patients had sepsis and 20 patients had severe sepsis.", [["bacteraemia", "DISEASE", 15, 26], ["SIRS", "DISEASE", 35, 39], ["sepsis", "DISEASE", 57, 63], ["sepsis", "DISEASE", 91, 97], ["patients", "ORGANISM", 2, 10], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 2, 10], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 71, 79], ["bacteraemia", "PROBLEM", 15, 26], ["SIRS", "PROBLEM", 35, 39], ["sepsis", "PROBLEM", 57, 63], ["severe sepsis", "PROBLEM", 84, 97], ["bacteraemia", "OBSERVATION", 15, 26], ["without", "UNCERTAINTY", 27, 34], ["sepsis", "OBSERVATION", 57, 63], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["sepsis", "OBSERVATION", 91, 97]]], ["LBP concentrations are presented as medians and range: 32.2 lg/ml (28.", [["LBP", "DISEASE", 0, 3], ["LBP concentrations", "PROBLEM", 0, 18]]], ["2-34.1) in patients without SIRS, ) in patients with sepsis and 50.9 lg/ml (22.9-96.5) in patients with severe sepsis (P < 0.05).", [["SIRS", "DISEASE", 28, 32], ["sepsis", "DISEASE", 53, 59], ["sepsis", "DISEASE", 111, 117], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 90, 98], ["SIRS", "PROBLEM", 28, 32], ["sepsis", "PROBLEM", 53, 59], ["lg/ml", "TEST", 69, 74], ["severe sepsis", "PROBLEM", 104, 117], ["sepsis", "OBSERVATION", 53, 59], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["sepsis", "OBSERVATION", 111, 117]]], ["LBP levels correlated to levels of IL-6 (rs 0.52), C-reactive protein (rs 0.68), leukocytes (rs 0.44) and neutrophils (rs 0.46) (P < 0.01).", [["leukocytes", "ANATOMY", 81, 91], ["neutrophils", "ANATOMY", 106, 117], ["LBP", "DISEASE", 0, 3], ["LBP", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-6", "GENE_OR_GENE_PRODUCT", 35, 39], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 51, 69], ["leukocytes", "CELL", 81, 91], ["neutrophils", "CELL", 106, 117], ["IL-6", "PROTEIN", 35, 39], ["C-reactive protein", "PROTEIN", 51, 69], ["leukocytes", "CELL_TYPE", 81, 91], ["neutrophils", "CELL_TYPE", 106, 117], ["LBP levels", "TEST", 0, 10], ["levels", "TEST", 25, 31], ["IL", "TEST", 35, 37], ["rs", "TEST", 41, 43], ["C-reactive protein", "TEST", 51, 69], ["rs", "TEST", 71, 73], ["leukocytes", "TEST", 81, 91], ["rs", "TEST", 93, 95], ["neutrophils", "TEST", 106, 117], ["rs", "TEST", 119, 121], ["P", "TEST", 129, 130], ["leukocytes", "ANATOMY", 81, 91]]], ["LBP did not predict the outcome of the patients with bacteraemia.", [["LBP", "DISEASE", 0, 3], ["bacteraemia", "DISEASE", 53, 64], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["LBP", "PROBLEM", 0, 3], ["bacteraemia", "PROBLEM", 53, 64], ["bacteraemia", "OBSERVATION", 53, 64]]], ["Conclusion: LBP levels increased with the severity of sepsis in patients with bacteraemia.", [["sepsis", "DISEASE", 54, 60], ["bacteraemia", "DISEASE", 78, 89], ["LBP", "GENE_OR_GENE_PRODUCT", 12, 15], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["LBP levels", "PROBLEM", 12, 22], ["sepsis", "PROBLEM", 54, 60], ["bacteraemia", "PROBLEM", 78, 89], ["LBP", "OBSERVATION", 12, 15], ["sepsis", "OBSERVATION", 54, 60], ["bacteraemia", "OBSERVATION", 78, 89]]], ["LBP correlated to IL-6, C-reactive protein, leukocytes and neutrophils.", [["leukocytes", "ANATOMY", 44, 54], ["neutrophils", "ANATOMY", 59, 70], ["LBP", "DISEASE", 0, 3], ["IL-6", "GENE_OR_GENE_PRODUCT", 18, 22], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 24, 42], ["leukocytes", "CELL", 44, 54], ["neutrophils", "CELL", 59, 70], ["IL-6", "PROTEIN", 18, 22], ["C-reactive protein", "PROTEIN", 24, 42], ["leukocytes", "CELL_TYPE", 44, 54], ["neutrophils", "CELL_TYPE", 59, 70], ["LBP", "PROBLEM", 0, 3], ["IL", "TEST", 18, 20], ["C-reactive protein", "TEST", 24, 42], ["leukocytes", "TEST", 44, 54], ["neutrophils", "TEST", 59, 70], ["leukocytes", "ANATOMY", 44, 54], ["neutrophils", "ANATOMY", 59, 70]]], ["LBP did not predict the outcome of the patients in this small cohort.P1754Pyrosequencing of the GRA6 gene to discriminate type I, II and III Toxoplasma gondii in clinical samples B. Edvinsson, B. Eveng\u00e5rd on behalf of the ESGT Objectives: Infection with Toxoplasma gondii in immunocompromised transplant recipients is rare but often fatal.", [["LBP", "DISEASE", 0, 3], ["Toxoplasma gondii", "DISEASE", 141, 158], ["Toxoplasma gondii", "DISEASE", 254, 271], ["patients", "ORGANISM", 39, 47], ["GRA6", "GENE_OR_GENE_PRODUCT", 96, 100], ["Toxoplasma gondii", "ORGANISM", 141, 158], ["Toxoplasma gondii", "ORGANISM", 254, 271], ["recipients", "ORGANISM", 304, 314], ["GRA6 gene", "DNA", 96, 105], ["patients", "SPECIES", 39, 47], ["Toxoplasma gondii", "SPECIES", 141, 158], ["Toxoplasma gondii", "SPECIES", 254, 271], ["type I", "SPECIES", 122, 128], ["Toxoplasma gondii", "SPECIES", 141, 158], ["Toxoplasma gondii", "SPECIES", 254, 271], ["LBP", "PROBLEM", 0, 3], ["type I, II and III Toxoplasma gondii", "PROBLEM", 122, 158], ["Infection", "PROBLEM", 239, 248], ["Toxoplasma gondii", "PROBLEM", 254, 271], ["immunocompromised transplant recipients", "TREATMENT", 275, 314], ["small", "OBSERVATION_MODIFIER", 56, 61], ["cohort", "OBSERVATION", 62, 68], ["Infection", "OBSERVATION", 239, 248]]], ["To increase our knowledge about the significance of the genotype of the parasite during infection, methods suitable for routine use need to be developed.", [["infection", "DISEASE", 88, 97], ["the parasite during infection", "PROBLEM", 68, 97], ["methods", "TREATMENT", 99, 106], ["infection", "OBSERVATION", 88, 97]]], ["Pyrosequencing is a rapid sequencing-bysynthesis method performed in real-time.", [["a rapid sequencing", "TEST", 18, 36], ["bysynthesis method", "TEST", 37, 55]]], ["It is developed for detection of short nucleotide polymorphisms (SNPs), and is suitable for molecular genotyping of microorganisms.", [["short nucleotide polymorphisms", "DNA", 33, 63], ["short nucleotide polymorphisms (SNPs)", "PROBLEM", 33, 70], ["molecular genotyping of microorganisms", "PROBLEM", 92, 130]]], ["We here present a pyrosequencing assay for rapid and reliable discrimination of Toxoplasma gondii type I, II and III in clinical samples.", [["samples", "ANATOMY", 129, 136], ["Toxoplasma gondii", "DISEASE", 80, 97], ["Toxoplasma gondii", "ORGANISM", 80, 97], ["samples", "CANCER", 129, 136], ["Toxoplasma gondii", "SPECIES", 80, 97], ["Toxoplasma gondii type I", "SPECIES", 80, 104], ["a pyrosequencing assay", "TEST", 16, 38], ["Toxoplasma gondii type I, II and III in clinical samples", "PROBLEM", 80, 136]]], ["Methods: Twenty-two isolates of T. gondii were used for pyrosequencing analysis of the GRA6 gene.", [["T. gondii", "ORGANISM", 32, 41], ["GRA6", "GENE_OR_GENE_PRODUCT", 87, 91], ["GRA6 gene", "DNA", 87, 96], ["T. gondii", "SPECIES", 32, 41], ["T. gondii", "SPECIES", 32, 41], ["T. gondii", "TEST", 32, 41], ["pyrosequencing analysis", "TEST", 56, 79]]], ["Real-time PCR was performed using a LightCycler 2.0 instrument to amplify a 176 bp fragment of the GRA6 gene.", [["GRA6", "GENE_OR_GENE_PRODUCT", 99, 103], ["176 bp fragment", "DNA", 76, 91], ["GRA6 gene", "DNA", 99, 108], ["a LightCycler 2.0 instrument", "TREATMENT", 34, 62], ["a 176 bp fragment of the GRA6 gene", "TREATMENT", 74, 108]]], ["Pyrosequencing analysis of two different SNPs contained within a 10 bp fragment of the amplified product was preformed to identify T. gondii type I, by detection of nucleotides G and A at these respective positions.", [["T. gondii type I", "ORGANISM", 131, 147], ["SNPs", "DNA", 41, 45], ["10 bp fragment", "DNA", 65, 79], ["T. gondii", "SPECIES", 131, 140], ["T. gondii", "SPECIES", 131, 140], ["Pyrosequencing analysis", "TEST", 0, 23], ["two different SNPs", "PROBLEM", 27, 45], ["a 10 bp fragment", "TREATMENT", 63, 79], ["nucleotides G", "TREATMENT", 165, 178]]], ["Type II was G and G, and type III was A and A. To test the assay in a clinical context, blood samples and lung tissue from an immunocompromised patient was analysed.", [["blood samples", "ANATOMY", 88, 101], ["lung tissue", "ANATOMY", 106, 117], ["G", "GENE_OR_GENE_PRODUCT", 12, 13], ["blood samples", "ORGANISM_SUBSTANCE", 88, 101], ["lung tissue", "TISSUE", 106, 117], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["the assay", "TEST", 55, 64], ["blood samples", "TEST", 88, 101], ["lung tissue", "PROBLEM", 106, 117], ["lung", "ANATOMY", 106, 110], ["immunocompromised", "OBSERVATION", 126, 143]]], ["Results: The detection limit of the assay is 10 parasitic genomes in a sample.", [["the assay", "TEST", 32, 41]]], ["Reproducibility (R) was calculated as R = Nr/N (Nr = the number of isolates assigned the same type on repeat testing and N = the number of isolates tested).", [["Reproducibility", "TEST", 0, 15], ["repeat testing", "TEST", 102, 116]]], ["R was determined using three independent runs, and was 1, suggesting clearly interpretable results with little variation.", [["R", "GENE_OR_GENE_PRODUCT", 0, 1], ["little variation", "OBSERVATION", 104, 120]]], ["Typeablility (T) of the assay was calculated as T = Nt/N (Nt = the number of typeable strains and N = the number of isolates tested).", [["the assay", "TEST", 20, 29], ["T", "TEST", 48, 49], ["Nt", "PROBLEM", 58, 60], ["typeable strains", "PROBLEM", 77, 93]]], ["T was determined using three independent runs, each including four atypical isolates.", [["T", "GENE_OR_GENE_PRODUCT", 0, 1]]], ["T was 0.82, suggesting that the assay discriminates correctly between the three main genotypes of T. gondii, but does not detect atypical strains.", [["T. gondii", "ORGANISM", 98, 107], ["T. gondii", "SPECIES", 98, 107], ["T. gondii", "SPECIES", 98, 107], ["T", "TEST", 0, 1], ["the assay", "TEST", 28, 37], ["T. gondii", "PROBLEM", 98, 107], ["atypical strains", "PROBLEM", 129, 145]]], ["Analysis of the clinical samples revealed type II T. gondii in blood samples and lung tissue.", [["samples", "ANATOMY", 25, 32], ["blood samples", "ANATOMY", 63, 76], ["lung tissue", "ANATOMY", 81, 92], ["gondii", "ORGANISM", 53, 59], ["blood samples", "ORGANISM_SUBSTANCE", 63, 76], ["lung tissue", "TISSUE", 81, 92], ["T. gondii", "SPECIES", 50, 59], ["T. gondii", "SPECIES", 50, 59], ["the clinical samples", "TEST", 12, 32], ["type II T. gondii in blood samples and lung tissue", "PROBLEM", 42, 92], ["lung", "ANATOMY", 81, 85], ["tissue", "OBSERVATION", 86, 92]]], ["Conclusion: When preceded by real-time PCR, pyrosequencing is a rapid process with a high reproducibility and throughput.", [["a rapid process", "PROBLEM", 62, 77], ["a high reproducibility", "PROBLEM", 83, 105], ["high reproducibility", "OBSERVATION", 85, 105]]], ["The method does, however, not detect atypical or recombinant strains.", [["atypical or recombinant strains", "PROBLEM", 37, 68]]], ["Acknowledgement: In particular, we want to thank Marie-Laure Dard\u00e9 and Herv\u00e9 Pelloux for provision of the T. gondii isolates.P1755Virulence genes in Escherichia coli isolates from calves in Shahrekord area, Iran Shiga toxin-producing Escherichia coli (STEC) strains, also called verotoxin-producing E. coli (VTEC) strains, represent the most important recently emerged group of food-borne pathogens around the world.", [["Shiga toxin-producing Escherichia coli", "CHEMICAL", 212, 250], ["STEC", "CHEMICAL", 252, 256], ["T. gondii", "ORGANISM", 106, 115], ["P1755", "GENE_OR_GENE_PRODUCT", 125, 130], ["Escherichia coli", "ORGANISM", 149, 165], ["calves", "ORGANISM", 180, 186], ["Iran", "ORGANISM", 207, 211], ["Shiga toxin-producing Escherichia coli", "ORGANISM", 212, 250], ["STEC) strains", "ORGANISM", 252, 265], ["verotoxin-producing E. coli", "ORGANISM", 279, 306], ["VTEC", "ORGANISM", 308, 312], ["T. gondii", "SPECIES", 106, 115], ["Escherichia coli", "SPECIES", 149, 165], ["calves", "SPECIES", 180, 186], ["Escherichia coli", "SPECIES", 234, 250], ["E. coli", "SPECIES", 299, 306], ["T. gondii", "SPECIES", 106, 115], ["Escherichia coli", "SPECIES", 149, 165], ["Escherichia coli", "SPECIES", 234, 250], ["STEC", "SPECIES", 252, 256], ["E. coli", "SPECIES", 299, 306], ["VTEC", "SPECIES", 308, 312], ["the T. gondii isolates", "PROBLEM", 102, 124], ["Virulence genes in Escherichia coli isolates from calves in Shahrekord area", "PROBLEM", 130, 205], ["Iran Shiga toxin", "TEST", 207, 223], ["Escherichia coli (STEC) strains", "PROBLEM", 234, 265], ["verotoxin", "TEST", 279, 288], ["E. coli (VTEC) strains", "PROBLEM", 299, 321], ["Escherichia coli", "OBSERVATION", 149, 165], ["Escherichia coli", "OBSERVATION", 234, 250], ["E. coli", "OBSERVATION_MODIFIER", 299, 306]]], ["Members of this group are a major cause of gastroenteritis that may be complicated by hemorrhagic colitis (HC) or the hemolytic uremic syndrome (HUS), which is the main cause of acute renal failure in children.", [["renal", "ANATOMY", 184, 189], ["gastroenteritis", "DISEASE", 43, 58], ["hemorrhagic colitis", "DISEASE", 86, 105], ["HC", "DISEASE", 107, 109], ["hemolytic uremic syndrome", "DISEASE", 118, 143], ["HUS", "DISEASE", 145, 148], ["acute renal failure", "DISEASE", 178, 197], ["colitis", "PATHOLOGICAL_FORMATION", 98, 105], ["renal", "ORGAN", 184, 189], ["children", "ORGANISM", 201, 209], ["children", "SPECIES", 201, 209], ["gastroenteritis", "PROBLEM", 43, 58], ["hemorrhagic colitis", "PROBLEM", 86, 105], ["the hemolytic uremic syndrome", "PROBLEM", 114, 143], ["HUS", "TEST", 145, 148], ["acute renal failure", "PROBLEM", 178, 197], ["gastroenteritis", "OBSERVATION", 43, 58], ["may be", "UNCERTAINTY", 64, 70], ["hemorrhagic", "OBSERVATION_MODIFIER", 86, 97], ["colitis", "OBSERVATION", 98, 105], ["hemolytic", "OBSERVATION_MODIFIER", 118, 127], ["uremic", "OBSERVATION_MODIFIER", 128, 134], ["syndrome", "OBSERVATION", 135, 143], ["main cause of", "UNCERTAINTY", 164, 177], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["renal", "ANATOMY", 184, 189], ["failure", "OBSERVATION", 190, 197]]], ["Domestic ruminants, mainly cattle, sheep, and goats, have been implicated as the principal reservoir.", [["sheep", "ORGANISM", 35, 40], ["goats", "ORGANISM", 46, 51], ["cattle", "SPECIES", 27, 33], ["sheep", "SPECIES", 35, 40], ["goats", "SPECIES", 46, 51], ["cattle", "SPECIES", 27, 33], ["sheep", "SPECIES", 35, 40], ["goats", "SPECIES", 46, 51]]], ["Transmission occurs through consumption of undercooked meat, unpasteurized dairy products and vegetables, or water contaminated by feces of carriers because STEC strains are found as part of the normal intestinal floras of the animals.We studied the prevalence of Shiga toxinproducing Escherichia coli (STEC) in stool specimens of calves with diarrhoea or other gastrointestinal alterations from 10 dairy cattle farms of Shahrekord City (central of Iran).", [["meat", "ANATOMY", 55, 59], ["vegetables", "ANATOMY", 94, 104], ["intestinal floras", "ANATOMY", 202, 219], ["stool specimens", "ANATOMY", 312, 327], ["calves", "ANATOMY", 331, 337], ["gastrointestinal", "ANATOMY", 362, 378], ["STEC", "CHEMICAL", 157, 161], ["diarrhoea", "DISEASE", 343, 352], ["gastrointestinal alterations", "DISEASE", 362, 390], ["meat", "ORGANISM_SUBDIVISION", 55, 59], ["vegetables", "ORGANISM_SUBDIVISION", 94, 104], ["feces", "ORGANISM_SUBDIVISION", 131, 136], ["STEC strains", "ORGANISM", 157, 169], ["intestinal floras", "MULTI-TISSUE_STRUCTURE", 202, 219], ["Shiga toxinproducing Escherichia coli", "GENE_OR_GENE_PRODUCT", 264, 301], ["STEC", "CANCER", 303, 307], ["stool specimens", "ORGANISM_SUBSTANCE", 312, 327], ["calves", "ORGANISM", 331, 337], ["gastrointestinal", "ORGAN", 362, 378], ["meat", "SPECIES", 55, 59], ["Escherichia coli", "SPECIES", 285, 301], ["calves", "SPECIES", 331, 337], ["cattle", "SPECIES", 405, 411], ["STEC", "SPECIES", 157, 161], ["Escherichia coli", "SPECIES", 285, 301], ["STEC", "SPECIES", 303, 307], ["cattle", "SPECIES", 405, 411], ["STEC strains", "PROBLEM", 157, 169], ["Shiga toxinproducing Escherichia coli", "PROBLEM", 264, 301], ["STEC", "PROBLEM", 303, 307], ["stool specimens", "TEST", 312, 327], ["diarrhoea", "PROBLEM", 343, 352], ["other gastrointestinal alterations", "PROBLEM", 356, 390], ["normal", "OBSERVATION", 195, 201], ["intestinal", "ANATOMY", 202, 212], ["Escherichia coli", "OBSERVATION", 285, 301], ["calves", "ANATOMY", 331, 337], ["diarrhoea", "OBSERVATION", 343, 352], ["gastrointestinal", "ANATOMY", 362, 378]]], ["The virulence genes, stx1, stx2, eae, Intimin Hly, enterohemolysin, ST, LT, were detected by multiplex PCR method.", [["stx1", "GENE_OR_GENE_PRODUCT", 21, 25], ["stx2", "GENE_OR_GENE_PRODUCT", 27, 31], ["eae", "GENE_OR_GENE_PRODUCT", 33, 36], ["Intimin Hly", "GENE_OR_GENE_PRODUCT", 38, 49], ["enterohemolysin", "GENE_OR_GENE_PRODUCT", 51, 66], ["ST", "GENE_OR_GENE_PRODUCT", 68, 70], ["LT", "GENE_OR_GENE_PRODUCT", 72, 74], ["virulence genes", "DNA", 4, 19], ["stx1", "DNA", 21, 25], ["stx2", "DNA", 27, 31], ["eae", "DNA", 33, 36], ["Intimin Hly", "DNA", 38, 49], ["enterohemolysin", "DNA", 51, 66], ["ST", "DNA", 68, 70], ["LT", "DNA", 72, 74], ["stx1", "PROBLEM", 21, 25], ["stx2", "PROBLEM", 27, 31], ["eae", "PROBLEM", 33, 36], ["Intimin Hly", "TEST", 38, 49], ["enterohemolysin", "PROBLEM", 51, 66], ["ST, LT", "PROBLEM", 68, 74], ["multiplex PCR method", "TEST", 93, 113], ["LT", "ANATOMY", 72, 74]]], ["STEC strains were detected in 7 (11.5%) of 61 E. coli from 180 cases investigated.", [["E. coli", "ORGANISM", 46, 53], ["E. coli", "SPECIES", 46, 53], ["STEC", "SPECIES", 0, 4], ["E. coli", "SPECIES", 46, 53], ["STEC strains", "TEST", 0, 12], ["E. coli", "TEST", 46, 53], ["E. coli", "OBSERVATION_MODIFIER", 46, 53]]], ["STEC O157 was isolated in 7 cases (11.5%), whereas non-O157 STEC strains were isolated from 4 animals (6%).", [["strains", "ANATOMY", 65, 72], ["STEC", "CHEMICAL", 0, 4], ["STEC O157", "ORGANISM", 0, 9], ["STEC O157", "SPECIES", 0, 9], ["O157", "SPECIES", 55, 59], ["STEC O157", "TEST", 0, 9], ["O157 STEC strains", "PROBLEM", 55, 72]]], ["STEC strains were the most frequently recovered enteropathogenic bacteria.", [["STEC", "CHEMICAL", 0, 4], ["STEC", "SPECIES", 0, 4], ["STEC strains", "PROBLEM", 0, 12], ["enteropathogenic bacteria", "PROBLEM", 48, 73], ["enteropathogenic bacteria", "OBSERVATION", 48, 73]]], ["PCR showed that 5 (8.2%) isolates carried st gene.", [["st", "GENE_OR_GENE_PRODUCT", 42, 44], ["st gene", "DNA", 42, 49], ["PCR", "TEST", 0, 3]]], ["None of isolates carried an ehxA, eae, and LT (labile toxin) genes.", [["ehxA", "GENE_OR_GENE_PRODUCT", 28, 32], ["eae", "GENE_OR_GENE_PRODUCT", 34, 37], ["LT (labile toxin", "GENE_OR_GENE_PRODUCT", 43, 59], ["ehxA, eae, and LT (labile toxin) genes", "DNA", 28, 66], ["an ehxA", "TEST", 25, 32], ["eae", "PROBLEM", 34, 37], ["LT (labile toxin) genes", "PROBLEM", 43, 66], ["LT", "ANATOMY", 43, 45]]], ["Our results suggest that STEC strains are a significant cause of calf infections in this area and confirm that, infections caused by STEC non-O157 strains are more common than those caused by O157:H7 isolates.", [["STEC", "CHEMICAL", 25, 29], ["infections", "DISEASE", 70, 80], ["infections", "DISEASE", 112, 122], ["STEC", "CHEMICAL", 133, 137], ["STEC strains", "ORGANISM", 25, 37], ["calf", "ORGANISM_SUBDIVISION", 65, 69], ["STEC non-O157 strains", "ORGANISM", 133, 154], ["calf", "SPECIES", 65, 69], ["STEC", "SPECIES", 25, 29], ["calf", "SPECIES", 65, 69], ["STEC", "SPECIES", 133, 137], ["O157", "SPECIES", 142, 146], ["O157", "SPECIES", 192, 196], ["STEC strains", "PROBLEM", 25, 37], ["calf infections", "PROBLEM", 65, 80], ["infections", "PROBLEM", 112, 122], ["STEC", "PROBLEM", 133, 137], ["O157 strains", "PROBLEM", 142, 154], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["calf", "ANATOMY", 65, 69], ["infections", "OBSERVATION", 70, 80], ["infections", "OBSERVATION", 112, 122]]], ["The high prevalence of STEC strains (both O157 and non-O157 strains) also found in human patients by other investigators, and their association with serious complications, strongly supports the utilization of protocols for detection of all serotypes of STEC in Spanish clinical microbiology laboratories.", [["STEC", "DISEASE", 23, 27], ["STEC", "DISEASE", 253, 257], ["STEC strains", "ORGANISM", 23, 35], ["human", "ORGANISM", 83, 88], ["patients", "ORGANISM", 89, 97], ["human", "SPECIES", 83, 88], ["patients", "SPECIES", 89, 97], ["STEC", "SPECIES", 23, 27], ["O157", "SPECIES", 42, 46], ["O157", "SPECIES", 55, 59], ["human", "SPECIES", 83, 88], ["STEC", "SPECIES", 253, 257], ["STEC strains", "PROBLEM", 23, 35], ["non-O157 strains", "PROBLEM", 51, 67], ["serious complications", "PROBLEM", 149, 170], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["STEC strains", "OBSERVATION", 23, 35]]], ["Objectives: Shiga toxins are A-B holotoxin including one enzymatically active A subunit associated non-covalently to five identical receptor binding B subunits.", [["Shiga toxins", "SIMPLE_CHEMICAL", 12, 24], ["A-B holotoxin", "SIMPLE_CHEMICAL", 29, 42], ["receptor binding B subunits", "GENE_OR_GENE_PRODUCT", 132, 159], ["enzymatically active A subunit", "PROTEIN", 57, 87], ["receptor binding B subunits", "PROTEIN", 132, 159], ["Shiga toxins", "PROBLEM", 12, 24], ["A-B holotoxin", "TREATMENT", 29, 42]]], ["Each subunit can cause different signalling pathways in different cells.", [["cells", "ANATOMY", 66, 71], ["cells", "CELL", 66, 71], ["different signalling pathways in different cells", "PROBLEM", 23, 71], ["different cells", "OBSERVATION", 56, 71]]], ["To assess the effect of each single subunit the specific clones for expressing the single subunit was designed.", [["clones", "CELL", 57, 63]]], ["Periplasmic expression yielded native AB5 holotoxin or B5 pentamer.", [["AB5 holotoxin", "GENE_OR_GENE_PRODUCT", 38, 51], ["B5 pentamer", "GENE_OR_GENE_PRODUCT", 55, 66], ["AB5 holotoxin", "PROTEIN", 38, 51], ["B5 pentamer", "PROTEIN", 55, 66], ["Periplasmic expression", "TEST", 0, 22], ["native AB5 holotoxin", "TREATMENT", 31, 51], ["B5 pentamer", "TREATMENT", 55, 66]]], ["Methods: O157 was used as bacterial strain for PCR amplification of shiga toxin gene.", [["O157", "ORGANISM", 9, 13], ["shiga toxin", "GENE_OR_GENE_PRODUCT", 68, 79], ["shiga toxin gene", "DNA", 68, 84], ["O157", "SPECIES", 9, 13], ["bacterial strain", "PROBLEM", 26, 42], ["PCR amplification", "TEST", 47, 64], ["shiga toxin gene", "PROBLEM", 68, 84]]], ["Each subunit was amplified by specific primers and the amplified genes were cloned in pBAD expression vector.", [["pBAD", "GENE_OR_GENE_PRODUCT", 86, 90], ["amplified genes", "DNA", 55, 70], ["pBAD expression vector", "DNA", 86, 108]]], ["The expression of the cloned genes was induced and optimized by different concentration of arabinose.", [["arabinose", "CHEMICAL", 91, 100], ["arabinose", "CHEMICAL", 91, 100], ["arabinose", "SIMPLE_CHEMICAL", 91, 100], ["cloned genes", "DNA", 22, 34]]], ["The expressed proteins was assessed on SDS-PAGE and detected by ELISA and western blotting.", [["SDS", "TEST", 39, 42]]], ["The expressed recombinant AB5 holotoxin and B subunit were purified and assessed for its biological activity on cells.", [["cells", "ANATOMY", 112, 117], ["AB5 holotoxin", "GENE_OR_GENE_PRODUCT", 26, 39], ["B subunit", "GENE_OR_GENE_PRODUCT", 44, 53], ["cells", "CELL", 112, 117], ["recombinant AB5 holotoxin", "PROTEIN", 14, 39], ["B subunit", "PROTEIN", 44, 53], ["The expressed recombinant AB5 holotoxin", "TREATMENT", 0, 39], ["B subunit", "TREATMENT", 44, 53]]], ["Cell cytotoxicity was shown by the expressed (AB5) holotoxin.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["holotoxin", "GENE_OR_GENE_PRODUCT", 51, 60], ["AB5", "PROTEIN", 46, 49], ["Cell cytotoxicity", "TEST", 0, 17], ["holotoxin", "TREATMENT", 51, 60]]], ["Moreover inhibition was observed by B subunit and antibody against it.", [["B subunit", "GENE_OR_GENE_PRODUCT", 36, 45], ["B subunit", "PROTEIN", 36, 45]]], ["Results: E. coli clones expressing recombinant shiga toxin A and recombinant shiga toxin B subunits were established to release the toxin to periplasmic space.", [["clones", "ANATOMY", 17, 23], ["E. coli", "ORGANISM", 9, 16], ["clones", "CELL", 17, 23], ["shiga toxin A", "GENE_OR_GENE_PRODUCT", 47, 60], ["shiga toxin B subunits", "GENE_OR_GENE_PRODUCT", 77, 99], ["recombinant shiga toxin A", "PROTEIN", 35, 60], ["recombinant shiga toxin B subunits", "PROTEIN", 65, 99], ["toxin", "PROTEIN", 132, 137], ["E. coli", "SPECIES", 9, 16], ["E. coli", "SPECIES", 9, 16], ["E. coli clones", "PROBLEM", 9, 23], ["recombinant shiga toxin A", "PROBLEM", 35, 60], ["recombinant shiga toxin B subunits", "TREATMENT", 65, 99], ["coli clones", "OBSERVATION", 12, 23]]], ["The whole structure of these expressed subunits was checked in native gel.", [["these expressed subunits", "TREATMENT", 23, 47]]], ["Active AB5 structure expressed in periplasmic space was extracted by polymyxine B. The biological activity of the constructed recombinant shiga toxin showed both Vero cell Cytotoxicity and inhibition of in vitro protein synthesis.P1755Conclusion: In this study it was shown that for B subunit assembly and secretion to periplasmic space as B5 pentamer homologous leader sequence is not needed.", [["periplasmic space", "ANATOMY", 34, 51], ["Vero cell", "ANATOMY", 162, 171], ["polymyxine", "CHEMICAL", 69, 79], ["AB5", "GENE_OR_GENE_PRODUCT", 7, 10], ["shiga toxin", "GENE_OR_GENE_PRODUCT", 138, 149], ["Vero cell", "CELL", 162, 171], ["B subunit", "GENE_OR_GENE_PRODUCT", 283, 292], ["AB5 structure", "PROTEIN", 7, 20], ["recombinant shiga toxin", "PROTEIN", 126, 149], ["B subunit", "PROTEIN", 283, 292], ["B5 pentamer homologous leader sequence", "DNA", 340, 378], ["Active AB5 structure", "PROBLEM", 0, 20], ["periplasmic space", "PROBLEM", 34, 51], ["the constructed recombinant shiga toxin", "TEST", 110, 149], ["both Vero cell Cytotoxicity", "PROBLEM", 157, 184], ["vitro protein synthesis", "TREATMENT", 206, 229], ["this study", "TEST", 250, 260], ["B subunit assembly", "TREATMENT", 283, 301], ["secretion to periplasmic space", "PROBLEM", 306, 336], ["B5 pentamer homologous leader sequence", "TREATMENT", 340, 378], ["periplasmic space", "OBSERVATION", 34, 51], ["Vero cell Cytotoxicity", "OBSERVATION", 162, 184], ["protein synthesis", "OBSERVATION", 212, 229]]], ["Although for biological active holotoxin (AB5) secretion to periplasmic space the presence of homologous leader sequence of gene is essential.", [["periplasmic space", "ANATOMY", 60, 77], ["holotoxin", "GENE_OR_GENE_PRODUCT", 31, 40], ["AB5", "GENE_OR_GENE_PRODUCT", 42, 45], ["AB5", "PROTEIN", 42, 45], ["biological active holotoxin (AB5)", "TREATMENT", 13, 46], ["secretion to periplasmic space", "PROBLEM", 47, 77]]], ["These subunits can be used for studying on cell cytotoxicity and also as a vector for antigen presentation in immunotherapeutic approaches.P1757Characterisation of Gram-positive anaerobic cocci by biochemical tests and partial 16S rRNA sequencing A. Bryk, A. Kanervo-Nordstrom, M. Hyvonen, E. Kononen (Helsinki, FI) Objective: Gram-positive anaerobic cocci, which are common findings in various infections, are difficult to identify in clinical microbiology laboratories, where identification is based only on few phenotypic tests.", [["cell", "ANATOMY", 43, 47], ["infections", "DISEASE", 395, 405], ["cell", "CELL", 43, 47], ["These subunits", "TREATMENT", 0, 14], ["cell cytotoxicity", "TEST", 43, 60], ["immunotherapeutic approaches", "TREATMENT", 110, 138], ["Gram-positive anaerobic cocci", "PROBLEM", 164, 193], ["biochemical tests", "TEST", 197, 214], ["partial 16S rRNA", "TEST", 219, 235], ["Bryk", "TEST", 250, 254], ["Gram-positive anaerobic cocci", "PROBLEM", 327, 356], ["various infections", "PROBLEM", 387, 405], ["few phenotypic tests", "TEST", 510, 530], ["Gram-positive", "OBSERVATION_MODIFIER", 164, 177], ["anaerobic cocci", "OBSERVATION", 178, 193], ["anaerobic cocci", "OBSERVATION", 341, 356], ["various", "OBSERVATION_MODIFIER", 387, 394], ["infections", "OBSERVATION", 395, 405]]], ["In recent years, this group of organisms (traditionally known as peptostreptococci) has encountered several taxonomic changes.", [["peptostreptococci", "CANCER", 65, 82], ["organisms", "PROBLEM", 31, 40], ["peptostreptococci", "TEST", 65, 82], ["several taxonomic changes", "PROBLEM", 100, 125], ["several", "OBSERVATION_MODIFIER", 100, 107], ["taxonomic", "OBSERVATION", 108, 117]]], ["The aim of the present study was to compare the characterization made by a selection of key phenotypic tests to that by partial sequencing of the 16S rRNA gene.", [["16S", "GENE_OR_GENE_PRODUCT", 146, 149], ["rRNA", "CELLULAR_COMPONENT", 150, 154], ["16S rRNA gene", "DNA", 146, 159], ["the present study", "TEST", 11, 28], ["the characterization", "TEST", 44, 64], ["partial sequencing", "TEST", 120, 138]]], ["Methods: Fifty-nine clinical isolates sent to our laboratory as gram-positive anaerobic cocci were examined for their colony and cell morphologies and biochemically characterized using spot catalase and indole reaction, 8 enzyme reactions by individual diagnostic tablets (Rosco), sodium polyanethol sulphate susceptibility, glucose fermentation, and determination of metabolic end products.", [["colony", "ANATOMY", 118, 124], ["cell", "ANATOMY", 129, 133], ["indole", "CHEMICAL", 203, 209], ["sodium polyanethol sulphate", "CHEMICAL", 281, 308], ["glucose", "CHEMICAL", 325, 332], ["indole", "CHEMICAL", 203, 209], ["sodium polyanethol sulphate", "CHEMICAL", 281, 308], ["glucose", "CHEMICAL", 325, 332], ["cell", "CELL", 129, 133], ["catalase", "SIMPLE_CHEMICAL", 190, 198], ["indole", "SIMPLE_CHEMICAL", 203, 209], ["Rosco", "SIMPLE_CHEMICAL", 273, 278], ["sodium polyanethol sulphate", "SIMPLE_CHEMICAL", 281, 308], ["glucose", "SIMPLE_CHEMICAL", 325, 332], ["catalase", "PROTEIN", 190, 198], ["metabolic end products", "PROTEIN", 368, 390], ["gram", "TEST", 64, 68], ["positive anaerobic cocci", "PROBLEM", 69, 93], ["their colony and cell morphologies", "TEST", 112, 146], ["spot catalase", "TEST", 185, 198], ["indole reaction", "TEST", 203, 218], ["enzyme reactions", "TEST", 222, 238], ["Rosco", "TEST", 273, 278], ["sodium polyanethol sulphate susceptibility", "TEST", 281, 323], ["glucose fermentation", "TEST", 325, 345], ["metabolic end products", "TREATMENT", 368, 390], ["anaerobic cocci", "OBSERVATION", 78, 93], ["cell morphologies", "OBSERVATION", 129, 146]]], ["In addition, commercial identification test kit (Rapid ID 32A) patterns were performed.", [["commercial identification test kit", "TEST", 13, 47], ["Rapid ID 32A) patterns", "TEST", 49, 71]]], ["The sequencing of the 16S rRNA gene of the 59 clinical isolates and 4 reference strains comprised of about 470 bp, and the sequences obtained were compared to those in GenBank database by using the multisequence Advanced BLAST comparison software from the National Center of Biotechnology Information.", [["rRNA", "CELLULAR_COMPONENT", 26, 30], ["16S rRNA gene", "DNA", 22, 35], ["The sequencing", "TEST", 0, 14], ["the 16S rRNA", "TEST", 18, 30], ["bp", "TEST", 111, 113], ["the sequences", "TEST", 119, 132]]], ["Results: The biochemical characteristics of the isolates were consistent with those of Peptostreptococcus anaerobius (n = 8), Peptostreptococcus (Micromonas) micros (n = 6), Finegoldia magna (n = 25), Peptoniphilus asaccharolyticus (n = 8), Peptoniphilus sp. (n = 8) and Anaerococcus sp. (n = 2), whereas 2 isolates remained as unidentified gram-positive anaerobic cocci.", [["Finegoldia magna", "DISEASE", 174, 190], ["Peptoniphilus asaccharolyticus", "DISEASE", 201, 231], ["Peptostreptococcus anaerobius", "ORGANISM", 87, 116], ["Peptostreptococcus", "ORGANISM", 126, 144], ["Micromonas) micros", "ORGANISM", 146, 164], ["Finegoldia magna", "ORGANISM", 174, 190], ["Peptoniphilus asaccharolyticus", "ORGANISM", 201, 231], ["Peptoniphilus sp", "ORGANISM", 241, 257], ["Anaerococcus sp", "ORGANISM", 271, 286], ["Peptostreptococcus anaerobius", "SPECIES", 87, 116], ["Micromonas", "SPECIES", 146, 156], ["Finegoldia magna", "SPECIES", 174, 190], ["Peptoniphilus asaccharolyticus", "SPECIES", 201, 231], ["Peptostreptococcus anaerobius", "SPECIES", 87, 116], ["Finegoldia magna", "SPECIES", 174, 190], ["Peptoniphilus asaccharolyticus", "SPECIES", 201, 231], ["the isolates", "TEST", 44, 56], ["Peptostreptococcus anaerobius", "PROBLEM", 87, 116], ["Peptostreptococcus", "TEST", 126, 144], ["micros", "TEST", 158, 164], ["Finegoldia magna", "TEST", 174, 190], ["Peptoniphilus asaccharolyticus", "TEST", 201, 231], ["gram", "TEST", 341, 345], ["positive anaerobic cocci", "PROBLEM", 346, 370], ["consistent with", "UNCERTAINTY", 62, 77], ["Peptostreptococcus", "OBSERVATION", 87, 105], ["anaerobic cocci", "OBSERVATION", 355, 370]]], ["Biochemical identification correlated with that obtained by partial 16S rRNA sequencing in 56/59 (95%) isolates at genus level and in 40/59 (68%) isolates at species level.", [["Biochemical identification", "TEST", 0, 26], ["partial 16S rRNA sequencing", "TEST", 60, 87], ["genus level", "TEST", 115, 126]]], ["The agreement of the biochemical and sequence-based identification was 100% for P. micros and F. magna.", [["F. magna", "ORGANISM", 94, 102], ["F. magna", "SPECIES", 94, 102], ["P. micros", "SPECIES", 80, 89], ["F. magna", "SPECIES", 94, 102]]], ["Of 8 isolates biochemically identified as P. asaccharolyticus, 2 isolates were identified as Peptoniphilus harei and 6 remained as Peptoniphilus sp. by sequencing.", [["P. asaccharolyticus", "DISEASE", 42, 61], ["P. asaccharolyticus", "ORGANISM", 42, 61], ["Peptoniphilus harei", "ORGANISM", 93, 112], ["Peptoniphilus sp", "ORGANISM", 131, 147], ["P. asaccharolyticus", "SPECIES", 42, 61], ["Peptoniphilus harei", "SPECIES", 93, 112], ["P. asaccharolyticus", "SPECIES", 42, 61], ["Peptoniphilus harei", "SPECIES", 93, 112], ["Peptoniphilus harei", "TEST", 93, 112]]], ["According to the sequence data, the 2 unidentified isolates were Peptoniphilus ivorii.", [["Peptoniphilus ivorii", "ORGANISM", 65, 85], ["Peptoniphilus ivorii", "SPECIES", 65, 85], ["Peptoniphilus ivorii", "SPECIES", 65, 85], ["the sequence data", "TEST", 13, 30]]], ["Conclusion: Most isolates from human infections proved to be F. magna.", [["infections", "DISEASE", 37, 47], ["F. magna", "DISEASE", 61, 69], ["human", "ORGANISM", 31, 36], ["F. magna", "ORGANISM", 61, 69], ["human", "SPECIES", 31, 36], ["F. magna", "SPECIES", 61, 69], ["human", "SPECIES", 31, 36], ["F. magna", "SPECIES", 61, 69], ["human infections", "PROBLEM", 31, 47], ["infections", "OBSERVATION", 37, 47]]], ["A relatively good agreement of identification was obtained using biochemical testing and partial 16S rRNA sequencing.", [["biochemical testing", "TEST", 65, 84], ["partial 16S rRNA sequencing", "TEST", 89, 116]]], ["Objectives: Molecular methods for identification of infectious agents in patients with clinical infectious disease are increasingly being used.", [["infectious disease", "DISEASE", 96, 114], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["infectious agents", "TREATMENT", 52, 69], ["clinical infectious disease", "PROBLEM", 87, 114], ["infectious", "OBSERVATION", 52, 62]]], ["Especially in cases where antibiotics have been given prior to sampling or when fastidious bacteria difficult to grow are the aaetiology of the infection.", [["infection", "DISEASE", 144, 153], ["antibiotics", "TREATMENT", 26, 37], ["fastidious bacteria", "PROBLEM", 80, 99], ["the infection", "PROBLEM", 140, 153], ["infection", "OBSERVATION", 144, 153]]], ["Infectious arthritis is a serious disease where identification of the etiological agent is mandatory for optimal antibiotic treatment as well as indication of the primary focus if not the joint it self.", [["Infectious arthritis", "DISEASE", 0, 20], ["Infectious arthritis", "PROBLEM", 0, 20], ["a serious disease", "PROBLEM", 24, 41], ["optimal antibiotic treatment", "TREATMENT", 105, 133], ["arthritis", "OBSERVATION", 11, 20], ["serious", "OBSERVATION_MODIFIER", 26, 33], ["joint", "ANATOMY", 188, 193]]], ["Methods: In the present prospective study, 227 synovial fluids taken from patients in elucidation of affected joints and sent to a Clinical Microbiological laboratory in the Copenhagen area, Denmark, were examined by conventional (culture, phenotypic tests) and molecular methods (PCR/sequencing of 23S ribosomal genes).", [["synovial fluids", "ANATOMY", 47, 62], ["joints", "ANATOMY", 110, 116], ["synovial fluids", "ORGANISM_SUBSTANCE", 47, 62], ["patients", "ORGANISM", 74, 82], ["joints", "MULTI-TISSUE_STRUCTURE", 110, 116], ["23S", "GENE_OR_GENE_PRODUCT", 299, 302], ["ribosomal", "CELLULAR_COMPONENT", 303, 312], ["23S ribosomal genes", "DNA", 299, 318], ["patients", "SPECIES", 74, 82], ["synovial fluids", "TEST", 47, 62], ["affected joints", "PROBLEM", 101, 116], ["culture", "TEST", 231, 238], ["phenotypic tests", "TEST", 240, 256], ["molecular methods", "TEST", 262, 279], ["PCR/sequencing", "TEST", 281, 295], ["23S ribosomal genes", "PROBLEM", 299, 318], ["joints", "ANATOMY", 110, 116]]], ["Conventional methods included Gramstaining and microscopy, aerobic and anaerobic culture and identification.", [["Conventional methods", "TEST", 0, 20], ["Gramstaining", "TEST", 30, 42], ["microscopy", "TEST", 47, 57], ["aerobic", "TEST", 59, 66], ["anaerobic culture", "TEST", 71, 88], ["identification", "TEST", 93, 107]]], ["PCR/sequencing included DNA extraction, PCR assay which produced a 700 bp fragment of 23S rDNA, and sequencing of both DNA strands of the amplicons.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["23S", "GENE_OR_GENE_PRODUCT", 86, 89], ["rDNA", "CELLULAR_COMPONENT", 90, 94], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["700 bp fragment", "DNA", 67, 82], ["23S rDNA", "DNA", 86, 94], ["PCR", "TEST", 0, 3], ["DNA extraction", "TEST", 24, 38], ["PCR assay", "TEST", 40, 49], ["a 700 bp fragment of 23S rDNA", "PROBLEM", 65, 94]]], ["Sequencing data were edited and a BLAST search in the NCBI database was done.", [["Sequencing data", "TEST", 0, 15], ["a BLAST search", "TEST", 32, 46], ["the NCBI database", "TEST", 50, 67]]], ["Results: Overall a microorganism was identified in 24 of the 227 synovial fluids (10.6%).", [["synovial fluids", "ANATOMY", 65, 80], ["synovial fluids", "TISSUE", 65, 80], ["a microorganism", "TEST", 17, 32], ["synovial fluids", "TEST", 65, 80]]], ["In 14 synovial fluids from nine patients bacteria were identified by either methods [Staphylococcus aureus (n = 8), Streptococcus pneumoniae (n = 3), Streptococcus dysgalactiae (n = 2), Citrobacter freundii (n = 1)].", [["synovial fluids", "ANATOMY", 6, 21], ["Staphylococcus aureus", "DISEASE", 85, 106], ["Streptococcus pneumoniae", "DISEASE", 116, 140], ["Streptococcus dysgalactiae", "DISEASE", 150, 176], ["Citrobacter freundii", "DISEASE", 186, 206], ["synovial fluids", "ORGANISM_SUBSTANCE", 6, 21], ["patients", "ORGANISM", 32, 40], ["Staphylococcus aureus", "ORGANISM", 85, 106], ["Streptococcus pneumoniae", "ORGANISM", 116, 140], ["Streptococcus dysgalactiae", "ORGANISM", 150, 176], ["Citrobacter freundii", "ORGANISM", 186, 206], ["patients", "SPECIES", 32, 40], ["Staphylococcus aureus", "SPECIES", 85, 106], ["Streptococcus pneumoniae", "SPECIES", 116, 140], ["Streptococcus dysgalactiae", "SPECIES", 150, 176], ["Citrobacter freundii", "SPECIES", 186, 206], ["Staphylococcus aureus", "SPECIES", 85, 106], ["Streptococcus pneumoniae", "SPECIES", 116, 140], ["Streptococcus dysgalactiae", "SPECIES", 150, 176], ["Citrobacter freundii", "SPECIES", 186, 206], ["nine patients bacteria", "PROBLEM", 27, 49], ["Staphylococcus aureus", "PROBLEM", 85, 106], ["Streptococcus pneumoniae", "PROBLEM", 116, 140], ["Streptococcus dysgalactiae", "PROBLEM", 150, 176], ["Citrobacter freundii", "PROBLEM", 186, 206], ["synovial", "ANATOMY", 6, 14], ["Streptococcus dysgalactiae", "OBSERVATION", 150, 176]]], ["Six synovial fluids were only culture positive; in four of those six specimens coagulase negative staphylococci were isolated.", [["synovial fluids", "ANATOMY", 4, 19], ["specimens", "ANATOMY", 69, 78], ["synovial fluids", "ORGANISM_SUBSTANCE", 4, 19], ["Six synovial fluids", "TEST", 0, 19], ["culture", "TEST", 30, 37], ["those six specimens coagulase", "TEST", 59, 88], ["staphylococci", "PROBLEM", 98, 111], ["synovial", "ANATOMY", 4, 12], ["fluids", "OBSERVATION", 13, 19]]], ["In three of the 227 synovial fluids a microorganism was identified by 23S PCR only.", [["synovial fluids", "ANATOMY", 20, 35], ["synovial fluids", "ORGANISM_SUBSTANCE", 20, 35], ["a microorganism", "TEST", 36, 51], ["23S PCR", "TEST", 70, 77]]], ["In two synovial fluids 23S PCR identified only one microorganism, whereas culturing resulted in two isolates.", [["synovial fluids", "ANATOMY", 7, 22], ["two synovial fluids 23S PCR", "TEST", 3, 30], ["one microorganism", "PROBLEM", 47, 64], ["culturing", "TEST", 74, 83], ["synovial", "ANATOMY", 7, 15], ["fluids 23S", "OBSERVATION", 16, 26], ["one microorganism", "OBSERVATION_MODIFIER", 47, 64]]], ["Conclusion: The present study indicates a significant contribution by molecular methods (PCR/sequencing of 23S ribosomal genes) in recognizing and identification of microorganisms from foci normally considered sterile like synovial fluids.", [["foci", "ANATOMY", 185, 189], ["synovial fluids", "ANATOMY", 223, 238], ["23S", "GENE_OR_GENE_PRODUCT", 107, 110], ["ribosomal", "CELLULAR_COMPONENT", 111, 120], ["synovial fluids", "ORGANISM_SUBSTANCE", 223, 238], ["23S ribosomal genes", "DNA", 107, 126], ["The present study", "TEST", 12, 29], ["molecular methods (PCR/sequencing of 23S ribosomal genes", "PROBLEM", 70, 126], ["microorganisms", "PROBLEM", 165, 179], ["foci", "PROBLEM", 185, 189], ["sterile like synovial fluids", "TREATMENT", 210, 238], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["microorganisms", "OBSERVATION", 165, 179], ["foci", "OBSERVATION", 185, 189], ["synovial", "ANATOMY", 223, 231], ["fluids", "OBSERVATION", 232, 238]]], ["Continued suspicion of infected arthritis despite of negative cultures should result in use of molecular diagnostics.P1759Direct detection of Cardiobacterium hominis by broad-range 16S rRNA PCR and sequencing in the serum of a patient with infective endocarditis E. Malli, D. Klapsa, A. Vasdeki, M. Morava, M. Pitsitaki, E. Petinaki, A. Maniatis (Larissa, GR) Objectives: To describe the detection of Cardiobacterium hominis directly in the serum of a patient with infective endocarditis, by employment of broad-range 16S rRNA PCR followed by sequencing.", [["serum", "ANATOMY", 216, 221], ["serum", "ANATOMY", 441, 446], ["infected arthritis", "DISEASE", 23, 41], ["infective endocarditis", "DISEASE", 240, 262], ["infective endocarditis", "DISEASE", 465, 487], ["Cardiobacterium hominis", "ORGANISM", 142, 165], ["serum", "ORGANISM_SUBSTANCE", 216, 221], ["patient", "ORGANISM", 227, 234], ["Cardiobacterium hominis", "ORGANISM", 401, 424], ["serum", "ORGANISM_SUBSTANCE", 441, 446], ["patient", "ORGANISM", 452, 459], ["Cardiobacterium hominis", "SPECIES", 142, 165], ["patient", "SPECIES", 227, 234], ["Cardiobacterium hominis", "SPECIES", 401, 424], ["patient", "SPECIES", 452, 459], ["Cardiobacterium hominis", "SPECIES", 142, 165], ["Cardiobacterium hominis", "SPECIES", 401, 424], ["infected arthritis", "PROBLEM", 23, 41], ["negative cultures", "PROBLEM", 53, 70], ["molecular diagnostics", "TEST", 95, 116], ["Cardiobacterium hominis", "PROBLEM", 142, 165], ["rRNA PCR", "TEST", 185, 193], ["sequencing in the serum", "TEST", 198, 221], ["infective endocarditis", "PROBLEM", 240, 262], ["Cardiobacterium hominis", "PROBLEM", 401, 424], ["infective endocarditis", "PROBLEM", 465, 487], ["rRNA PCR", "TEST", 522, 530], ["suspicion of", "UNCERTAINTY", 10, 22], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["arthritis", "OBSERVATION", 32, 41], ["infective", "OBSERVATION_MODIFIER", 240, 249], ["endocarditis", "OBSERVATION", 250, 262], ["infective", "OBSERVATION_MODIFIER", 465, 474], ["endocarditis", "OBSERVATION", 475, 487]]], ["Methods: A series of blood cultures were taken from the patient before starting empirical treatment.", [["blood cultures", "ANATOMY", 21, 35], ["blood cultures", "CELL", 21, 35], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["blood cultures", "TEST", 21, 35], ["empirical treatment", "TREATMENT", 80, 99]]], ["In addition, 10 ml whole blood was collected in rubber sealed pyrogen-free tubes for direct detection of bacterial DNA.", [["whole blood", "ANATOMY", 19, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["bacterial DNA", "DNA", 105, 118], ["rubber sealed pyrogen-free tubes", "TREATMENT", 48, 80], ["direct detection", "TEST", 85, 101], ["bacterial DNA", "PROBLEM", 105, 118], ["free tubes", "OBSERVATION", 70, 80], ["bacterial DNA", "OBSERVATION", 105, 118]]], ["Bacterial DNA was detected by a broad range PCR reaction and sequencing process allowed identification of bacteria species.", [["DNA", "CELLULAR_COMPONENT", 10, 13], ["Bacterial DNA", "PROBLEM", 0, 13], ["a broad range PCR reaction", "PROBLEM", 30, 56], ["sequencing process", "TEST", 61, 79], ["bacteria species", "PROBLEM", 106, 122], ["DNA", "OBSERVATION", 10, 13], ["bacteria species", "OBSERVATION", 106, 122]]], ["Results: Cardiobacterium hominis was identified as the causative agent of infective endocarditis, on two days after the serum collection.", [["serum", "ANATOMY", 120, 125], ["infective endocarditis", "DISEASE", 74, 96], ["Cardiobacterium hominis", "ORGANISM", 9, 32], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["Cardiobacterium hominis", "SPECIES", 9, 32], ["Cardiobacterium hominis", "SPECIES", 9, 32], ["Cardiobacterium hominis", "PROBLEM", 9, 32], ["infective endocarditis", "PROBLEM", 74, 96], ["the serum collection", "TEST", 116, 136], ["infective", "OBSERVATION_MODIFIER", 74, 83], ["endocarditis", "OBSERVATION", 84, 96]]], ["Blood cultures, simultaneously obtained with the serum sample, remained negative after 5 days of routine incubation; however, after a prolonged incubation of twelve days a gram negative bacterium was isolated from the aerobic bottles, that was identified as C. hominis species, by the usual phenotypic studies (catalase, oxidase reaction, indole, nitrate, etc) which are time-consuming.", [["Blood cultures", "ANATOMY", 0, 14], ["serum sample", "ANATOMY", 49, 61], ["indole", "CHEMICAL", 339, 345], ["nitrate", "CHEMICAL", 347, 354], ["indole", "CHEMICAL", 339, 345], ["nitrate", "CHEMICAL", 347, 354], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["C. hominis", "ORGANISM", 258, 268], ["catalase", "SIMPLE_CHEMICAL", 311, 319], ["oxidase", "SIMPLE_CHEMICAL", 321, 328], ["indole", "SIMPLE_CHEMICAL", 339, 345], ["nitrate", "SIMPLE_CHEMICAL", 347, 354], ["catalase", "PROTEIN", 311, 319], ["C. hominis", "SPECIES", 258, 268], ["C. hominis", "SPECIES", 258, 268], ["Blood cultures", "TEST", 0, 14], ["the serum sample", "TEST", 45, 61], ["routine incubation", "TREATMENT", 97, 115], ["a gram negative bacterium", "PROBLEM", 170, 195], ["the aerobic bottles", "PROBLEM", 214, 233], ["C. hominis species", "PROBLEM", 258, 276], ["the usual phenotypic studies", "TEST", 281, 309], ["catalase, oxidase reaction", "TREATMENT", 311, 337], ["indole, nitrate", "TREATMENT", 339, 354], ["negative", "OBSERVATION", 72, 80], ["hominis species", "OBSERVATION", 261, 276]]], ["Conclusions: To our knowledge this is the first report of direct detection of C. hominis in the serum using molecular methods, emphasizing the need for the establishment of such methods especially for infections caused by fastidious organisms.P1760Identification of dangerous bacterial pathogens by 16S ribosomal RNA gene sequence analysis W. Ruppitsch, A. Stoeger, A. Indra, D. Schmid, K. Grif, C. Schabereiter-Gurtner, A. Hirschl, F. Allerberger (Vienna, AT) To assess the usefulness of partial 16S rRNA sequence analysis for identification of dangerous bacterial pathogens, a total of 28 isolates comprising Bacillus anthracis, Brucella melitensis, Biovars melitensis, Suis, Abortus and Bovis, Burkholderia mallei, Burkholderia pseudomallei, Francisella tularensis, Yersinia pestis, and 9 genus-related and unrelated control strains were sequenced and analysed using the GenBank database (Blast 2.2.10, National Institute of Health, U.S.A), the MicroSeq500 database (version 1.4.1 and V1.0, Applied Biosystems, Foster City, U.S.A.) , The Ribosomal Database Project-II database (RDP-II, release 9, update 26, Michigan State University, U.S.A), and the Ribosomal Differentiation of Medical Microorganisms database (RIDOM, University of Wuerzburg, Germany).", [["serum", "ANATOMY", 96, 101], ["infections", "DISEASE", 201, 211], ["Brucella melitensis", "DISEASE", 631, 650], ["Biovars melitensis", "DISEASE", 652, 670], ["Yersinia pestis", "DISEASE", 769, 784], ["C. hominis", "ORGANISM", 78, 88], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["Bacillus anthracis", "ORGANISM", 611, 629], ["Brucella melitensis", "ORGANISM", 631, 650], ["Biovars melitensis", "ORGANISM", 652, 670], ["Suis, Abortus", "ORGANISM", 672, 685], ["Bovis", "ORGANISM", 690, 695], ["Burkholderia mallei", "ORGANISM", 697, 716], ["Burkholderia pseudomallei", "ORGANISM", 718, 743], ["Francisella tularensis", "ORGANISM", 745, 767], ["Yersinia pestis", "ORGANISM", 769, 784], ["16S ribosomal RNA gene sequence", "DNA", 299, 330], ["16S rRNA sequence", "DNA", 497, 514], ["C. hominis", "SPECIES", 78, 88], ["Bacillus anthracis", "SPECIES", 611, 629], ["Brucella melitensis", "SPECIES", 631, 650], ["Biovars melitensis", "SPECIES", 652, 670], ["Burkholderia mallei", "SPECIES", 697, 716], ["Burkholderia pseudomallei", "SPECIES", 718, 743], ["Francisella tularensis", "SPECIES", 745, 767], ["Yersinia pestis", "SPECIES", 769, 784], ["C. hominis", "SPECIES", 78, 88], ["Bacillus anthracis", "SPECIES", 611, 629], ["Brucella melitensis", "SPECIES", 631, 650], ["Biovars melitensis", "SPECIES", 652, 670], ["Burkholderia mallei", "SPECIES", 697, 716], ["Burkholderia pseudomallei", "SPECIES", 718, 743], ["Francisella tularensis", "SPECIES", 745, 767], ["Yersinia pestis", "SPECIES", 769, 784], ["direct detection", "TEST", 58, 74], ["C. hominis", "PROBLEM", 78, 88], ["such methods", "TREATMENT", 173, 185], ["infections", "PROBLEM", 201, 211], ["fastidious organisms", "PROBLEM", 222, 242], ["dangerous bacterial pathogens", "PROBLEM", 266, 295], ["16S ribosomal RNA gene sequence analysis", "TEST", 299, 339], ["partial 16S rRNA sequence analysis", "TEST", 489, 523], ["dangerous bacterial pathogens", "PROBLEM", 546, 575], ["Bacillus anthracis", "PROBLEM", 611, 629], ["Brucella melitensis", "PROBLEM", 631, 650], ["Biovars melitensis", "PROBLEM", 652, 670], ["Suis", "PROBLEM", 672, 676], ["Abortus", "PROBLEM", 678, 685], ["Bovis", "PROBLEM", 690, 695], ["Burkholderia mallei", "PROBLEM", 697, 716], ["Burkholderia pseudomallei", "PROBLEM", 718, 743], ["Francisella tularensis", "PROBLEM", 745, 767], ["Yersinia pestis", "PROBLEM", 769, 784], ["unrelated control strains", "PROBLEM", 810, 835], ["the GenBank database", "TEST", 870, 890], ["Blast", "TEST", 892, 897], ["Brucella melitensis", "OBSERVATION", 631, 650], ["Francisella tularensis", "OBSERVATION", 745, 767]]], ["On genus level all isolates were identified using GenBank, RDP-II, and MicroSeq V1.0.", [["RDP-II, and MicroSeq V1.0", "DNA", 59, 84], ["genus level", "TEST", 3, 14], ["GenBank", "TEST", 50, 57], ["RDP", "TEST", 59, 62]]], ["The older MicroSeq 1.4.1 database identified 92% of the tested samples correctly on genus level.", [["samples", "ANATOMY", 63, 70], ["samples", "CANCER", 63, 70], ["the tested samples", "TEST", 52, 70]]], ["The RIDOM database did not include sequence data of the tested species even on genus level, the RIDOM database none (''there seems to be, at least currently, no close relative available'').", [["RIDOM database", "DNA", 4, 18], ["The RIDOM database", "TEST", 0, 18], ["sequence data", "TEST", 35, 48], ["the tested species", "PROBLEM", 52, 70], ["genus level", "TEST", 79, 90]]], ["Genbank and RDP-II identified all dangerous pathogens correctly.", [["RDP-II", "CHEMICAL", 12, 18], ["RDP-II", "GENE_OR_GENE_PRODUCT", 12, 18], ["all dangerous pathogens", "PROBLEM", 30, 53]]], ["The MicroSeq V 1.0 database identified four of the six species of dangerous pathogens.", [["dangerous pathogens", "PROBLEM", 66, 85], ["dangerous pathogens", "OBSERVATION", 66, 85]]], ["On species level none of the dangerous pathogens was correctly identified using MicroSeq 1.4.1 or RIDOM.", [["the dangerous pathogens", "PROBLEM", 25, 48], ["MicroSeq", "TEST", 80, 88]]], ["As previously noted by various other authors, the most important reason for failure of databases in identifying a bacterium is a lack of the 16 S rRNA gene sequence of the particular bacterium in the database rather than misidentification because of poor sequence quality.", [["16 S rRNA gene sequence", "DNA", 141, 164], ["failure of databases", "PROBLEM", 76, 96], ["a bacterium", "PROBLEM", 112, 123], ["the 16 S rRNA gene sequence", "PROBLEM", 137, 164], ["poor sequence quality", "PROBLEM", 250, 271]]], ["One must also be aware that the following bacterial species or subspecies have the same 16S rRNA gene sequence, which makes differentiation by sequence analysis impossible: B. anthracis and B. cereus, Y. pestis and Y. pseudotuberculosis, all Brucella subspecies, and Francisella tularensis ssp. holarctica and mediasiatica.", [["Y. pestis", "DISEASE", 201, 210], ["Y. pseudotuberculosis", "DISEASE", 215, 236], ["B. anthracis", "ORGANISM", 173, 185], ["B. cereus", "ORGANISM", 190, 199], ["Y. pestis", "ORGANISM", 201, 210], ["Y. pseudotuberculosis", "ORGANISM", 215, 236], ["Brucella subspecies", "ORGANISM", 242, 261], ["Francisella tularensis", "ORGANISM", 267, 289], ["ssp", "ORGANISM", 290, 293], ["holarctica", "ORGANISM", 295, 305], ["16S rRNA gene sequence", "DNA", 88, 110], ["B. anthracis", "SPECIES", 173, 185], ["B. cereus", "SPECIES", 190, 199], ["Y. pestis", "SPECIES", 201, 210], ["Y. pseudotuberculosis", "SPECIES", 215, 236], ["Brucella subspecies", "SPECIES", 242, 261], ["Francisella tularensis", "SPECIES", 267, 289], ["ssp", "SPECIES", 290, 293], ["holarctica", "SPECIES", 295, 305], ["B. anthracis", "SPECIES", 173, 185], ["B. cereus", "SPECIES", 190, 199], ["Y. pestis", "SPECIES", 201, 210], ["Y. pseudotuberculosis", "SPECIES", 215, 236], ["Brucella subspecies", "SPECIES", 242, 261], ["Francisella tularensis ssp", "SPECIES", 267, 293], ["the following bacterial species", "PROBLEM", 28, 59], ["the same 16S rRNA gene sequence", "PROBLEM", 79, 110], ["sequence analysis", "TEST", 143, 160], ["B. anthracis", "PROBLEM", 173, 185], ["B. cereus", "PROBLEM", 190, 199], ["Y. pseudotuberculosis", "PROBLEM", 215, 236], ["all Brucella subspecies", "PROBLEM", 238, 261], ["Francisella tularensis ssp", "PROBLEM", 267, 293], ["holarctica", "PROBLEM", 295, 305], ["mediasiatica", "PROBLEM", 310, 322], ["pseudotuberculosis", "OBSERVATION", 218, 236], ["Francisella tularensis", "OBSERVATION", 267, 289], ["mediasiatica", "ANATOMY", 310, 322]]], ["In addition to 16S rRNA gene analysis complementary methods are essential to discriminate between these bacteria on species or subspecies level.P1761Identification of nontuberculous mycobacteria by sequence analysis of the 16S ribosomal RNA, the heat-shock protein 65 and the RNA polymerase beta-subunit genes S. Shin, J.H. Yoon, E.C. Kim (Seoul, KR)P1761Objectives: The diagnosis of diseases caused by nontuberculous mycobacteria (NTM) is difficult because NTM are prevalent in the environment such as soil and water and because they have fastidious properties.", [["nontuberculous mycobacteria", "DISEASE", 403, 430], ["NTM", "DISEASE", 432, 435], ["NTM", "DISEASE", 458, 461], ["16S", "GENE_OR_GENE_PRODUCT", 223, 226], ["ribosomal", "CELLULAR_COMPONENT", 227, 236], ["heat-shock protein 65", "GENE_OR_GENE_PRODUCT", 246, 267], ["16S rRNA gene", "DNA", 15, 28], ["16S ribosomal RNA", "RNA", 223, 240], ["heat-shock protein 65", "PROTEIN", 246, 267], ["RNA polymerase beta-subunit genes", "DNA", 276, 309], ["16S rRNA gene analysis", "TEST", 15, 37], ["complementary methods", "TEST", 38, 59], ["these bacteria on species", "PROBLEM", 98, 123], ["nontuberculous mycobacteria", "PROBLEM", 167, 194], ["sequence analysis", "TEST", 198, 215], ["the 16S ribosomal RNA", "TEST", 219, 240], ["the heat", "TEST", 242, 250], ["shock protein", "TEST", 251, 264], ["diseases", "PROBLEM", 384, 392], ["nontuberculous mycobacteria (NTM", "PROBLEM", 403, 435], ["NTM", "PROBLEM", 458, 461], ["bacteria", "OBSERVATION", 104, 112], ["nontuberculous mycobacteria", "OBSERVATION", 167, 194], ["Shin", "ANATOMY", 313, 317], ["diseases", "OBSERVATION", 384, 392], ["nontuberculous mycobacteria", "OBSERVATION", 403, 430]]], ["In this study, we investigated the distribution pattern of NTM clinical isolates and the identification to the species level.", [["NTM", "DISEASE", 59, 62], ["this study", "TEST", 3, 13], ["NTM clinical isolates", "PROBLEM", 59, 80], ["the species level", "PROBLEM", 107, 124], ["NTM", "OBSERVATION", 59, 62]]], ["Methods: Among the presumptive NTM clinical isolates, cultured in a third referral hospital from 21-Jan-2003 to 20-Jan-2004 in Seoul, South Korea, which were negative by probe hybridization method for Mycobacterium tuberculosis complex, we selected those of more than 10 colonies or those cultured more than twice in a same patient.", [["colonies", "ANATOMY", 271, 279], ["NTM", "DISEASE", 31, 34], ["Mycobacterium tuberculosis", "DISEASE", 201, 227], ["Mycobacterium tuberculosis", "GENE_OR_GENE_PRODUCT", 201, 227], ["patient", "ORGANISM", 324, 331], ["Mycobacterium tuberculosis", "SPECIES", 201, 227], ["patient", "SPECIES", 324, 331], ["Mycobacterium tuberculosis", "SPECIES", 201, 227], ["Mycobacterium tuberculosis complex", "PROBLEM", 201, 235]]], ["A total of 120 isolates were studied for the distribution of NTM including 97 isolates recruited for species identification by direct sequencing of 16S rRNA, hsp65 and rpoB gene segments.", [["NTM", "DISEASE", 61, 64], ["16S", "GENE_OR_GENE_PRODUCT", 148, 151], ["rRNA", "CELLULAR_COMPONENT", 152, 156], ["hsp65", "GENE_OR_GENE_PRODUCT", 158, 163], ["rpoB", "GENE_OR_GENE_PRODUCT", 168, 172], ["16S rRNA, hsp65 and rpoB gene segments", "DNA", 148, 186], ["A total of 120 isolates", "TREATMENT", 0, 23], ["NTM", "PROBLEM", 61, 64], ["species identification", "TEST", 101, 123], ["direct sequencing", "TEST", 127, 144], ["16S rRNA", "TEST", 148, 156], ["hsp65", "TEST", 158, 163], ["rpoB gene segments", "PROBLEM", 168, 186], ["NTM", "OBSERVATION", 61, 64], ["segments", "ANATOMY_MODIFIER", 178, 186]]], ["(2.5%) were also identified in the presumptive NTM isolates.", [["NTM", "DISEASE", 47, 50], ["NTM isolates", "OBSERVATION", 47, 59]]], ["The identification rate by sequencing of 16S rRNA, rpoB, and hsp65 were 65%, 82% and 87%, respectively. hsp65 or rpoB gene was more efficient than 16S rRNA in identification of NTM by sequencing.", [["NTM", "DISEASE", 177, 180], ["16S rRNA", "GENE_OR_GENE_PRODUCT", 41, 49], ["rpoB", "GENE_OR_GENE_PRODUCT", 51, 55], ["hsp65", "GENE_OR_GENE_PRODUCT", 61, 66], ["hsp65", "GENE_OR_GENE_PRODUCT", 104, 109], ["rpoB", "GENE_OR_GENE_PRODUCT", 113, 117], ["16S rRNA", "DNA", 41, 49], ["rpoB", "DNA", 51, 55], ["hsp65", "DNA", 61, 66], ["hsp65", "DNA", 104, 109], ["rpoB gene", "DNA", 113, 122], ["16S rRNA", "DNA", 147, 155], ["The identification rate", "TEST", 0, 23], ["16S rRNA", "TEST", 41, 49], ["rpoB", "TEST", 51, 55], ["hsp65", "TEST", 61, 66], ["hsp65", "TEST", 104, 109], ["rpoB gene", "TEST", 113, 122], ["NTM", "PROBLEM", 177, 180], ["NTM", "OBSERVATION", 177, 180]]], ["Conclusions: Some NTM are considered to be the causative organisms of clinical diseases even in the countries with intermediate burden of tuberculosis, so accurate identification method by direct sequencing can be adapted to clinical laboratories.P1762Evaluation of the genotype MTBDR assay for the simultaneous detection of resistance to rifampicin and isoniazid of Mycobacterium tuberculosis clinical strains F. Brossier, C. Truffot-Pernot, N. Veziris, V. Jarlier, W. Sougakoff (Paris, FR)P1762Objectives: The rapid determination of drug resistance in Mycobacterium tuberculosis is an important challenge to ensure a rapid effective chemotherapy.", [["NTM", "DISEASE", 18, 21], ["tuberculosis", "DISEASE", 138, 150], ["rifampicin", "CHEMICAL", 339, 349], ["isoniazid", "CHEMICAL", 354, 363], ["Mycobacterium tuberculosis", "DISEASE", 367, 393], ["Mycobacterium tuberculosis", "DISEASE", 554, 580], ["rifampicin", "CHEMICAL", 339, 349], ["isoniazid", "CHEMICAL", 354, 363], ["rifampicin", "SIMPLE_CHEMICAL", 339, 349], ["isoniazid", "SIMPLE_CHEMICAL", 354, 363], ["Mycobacterium tuberculosis", "ORGANISM", 367, 393], ["Mycobacterium tuberculosis", "ORGANISM", 554, 580], ["Mycobacterium tuberculosis", "SPECIES", 367, 393], ["Mycobacterium tuberculosis", "SPECIES", 554, 580], ["Mycobacterium tuberculosis", "SPECIES", 367, 393], ["C. Truffot-Pernot", "SPECIES", 424, 441], ["Mycobacterium tuberculosis", "SPECIES", 554, 580], ["Some NTM", "PROBLEM", 13, 21], ["clinical diseases", "PROBLEM", 70, 87], ["tuberculosis", "PROBLEM", 138, 150], ["the genotype MTBDR assay", "TEST", 266, 290], ["resistance", "PROBLEM", 325, 335], ["rifampicin", "TREATMENT", 339, 349], ["isoniazid", "TREATMENT", 354, 363], ["Mycobacterium tuberculosis", "PROBLEM", 367, 393], ["drug resistance", "PROBLEM", 535, 550], ["Mycobacterium tuberculosis", "PROBLEM", 554, 580], ["a rapid effective chemotherapy", "TREATMENT", 617, 647], ["NTM", "OBSERVATION", 18, 21], ["tuberculosis", "OBSERVATION", 138, 150], ["drug resistance", "OBSERVATION", 535, 550], ["Mycobacterium tuberculosis", "OBSERVATION", 554, 580]]], ["The Genotype MTBDR test is a commercially available DNA strip assay enabling the molecular genetic identification of the M. tuberculosis complex and its resistance to rifampicin (RIF-R) and isoniazid (INH-R) by detecting the most commonly found mutations in the genes rpoB (Asp516Val, His526Tyr, His526Asp, Ser531Leu) and katG (Ser315Thr).", [["tuberculosis", "DISEASE", 124, 136], ["rifampicin", "CHEMICAL", 167, 177], ["RIF-R", "CHEMICAL", 179, 184], ["isoniazid", "CHEMICAL", 190, 199], ["INH-R", "CHEMICAL", 201, 206], ["rifampicin", "CHEMICAL", 167, 177], ["RIF-R", "CHEMICAL", 179, 184], ["isoniazid", "CHEMICAL", 190, 199], ["INH-R", "CHEMICAL", 201, 206], ["Asp", "CHEMICAL", 274, 277], ["His", "CHEMICAL", 285, 288], ["His", "CHEMICAL", 296, 299], ["Ser", "CHEMICAL", 307, 310], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["M. tuberculosis", "ORGANISM", 121, 136], ["rifampicin", "SIMPLE_CHEMICAL", 167, 177], ["RIF-R", "SIMPLE_CHEMICAL", 179, 184], ["isoniazid", "SIMPLE_CHEMICAL", 190, 199], ["INH-R", "SIMPLE_CHEMICAL", 201, 206], ["rpoB", "GENE_OR_GENE_PRODUCT", 268, 272], ["Asp516Val, His526Tyr", "GENE_OR_GENE_PRODUCT", 274, 294], ["His526Asp, Ser531Leu", "GENE_OR_GENE_PRODUCT", 296, 316], ["katG", "GENE_OR_GENE_PRODUCT", 322, 326], ["Ser315Thr", "AMINO_ACID", 328, 337], ["rpoB", "DNA", 268, 272], ["Ser531Leu", "DNA", 307, 316], ["katG", "DNA", 322, 326], ["Ser315Thr", "DNA", 328, 337], ["M. tuberculosis", "SPECIES", 121, 136], ["M. tuberculosis", "SPECIES", 121, 136], ["The Genotype MTBDR test", "TEST", 0, 23], ["DNA strip assay", "TEST", 52, 67], ["the M. tuberculosis complex", "PROBLEM", 117, 144], ["rifampicin", "TREATMENT", 167, 177], ["RIF", "TEST", 179, 182], ["isoniazid", "TREATMENT", 190, 199], ["Asp", "TEST", 274, 277], ["His", "TEST", 285, 288], ["His", "TEST", 296, 299], ["katG", "TEST", 322, 326], ["tuberculosis", "OBSERVATION", 124, 136]]], ["Here, we report the evaluation of the Genotype MTBDR assay from a set of 106 clinical isolates of M. tuberculosis.", [["tuberculosis", "DISEASE", 101, 113], ["M. tuberculosis", "ORGANISM", 98, 113], ["M. tuberculosis", "SPECIES", 98, 113], ["M. tuberculosis", "SPECIES", 98, 113], ["the evaluation", "TEST", 16, 30], ["the Genotype MTBDR assay", "TEST", 34, 58], ["M. tuberculosis", "PROBLEM", 98, 113], ["tuberculosis", "OBSERVATION", 101, 113]]], ["Methods: 106 clinical isolates were collected in France over a 2 years period (2003) (2004) and were included in the study: 77 were RIF-R, 96 were INH-R (of which 73 were also RIF-R) and 6 were susceptible to both drugs.", [["RIF", "CHEMICAL", 132, 135], ["INH", "CHEMICAL", 147, 150], ["INH-R", "GENE_OR_GENE_PRODUCT", 147, 152], ["RIF-R", "GENE_OR_GENE_PRODUCT", 176, 181], ["the study", "TEST", 113, 122], ["RIF", "TEST", 132, 135]]], ["The susceptibility tests were carried out by the standard proportion method.", [["The susceptibility tests", "TEST", 0, 24]]], ["The mutations involved in RIF-R and INH-R in rpoB, katG, inhA and his promoter region, were characterized by DNA sequencing.", [["RIF-R", "GENE_OR_GENE_PRODUCT", 26, 31], ["INH-R", "GENE_OR_GENE_PRODUCT", 36, 41], ["rpoB", "GENE_OR_GENE_PRODUCT", 45, 49], ["katG", "GENE_OR_GENE_PRODUCT", 51, 55], ["inhA", "GENE_OR_GENE_PRODUCT", 57, 61], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["RIF-R and INH-R", "DNA", 26, 41], ["rpoB", "DNA", 45, 49], ["katG", "DNA", 51, 55], ["inhA", "DNA", 57, 61], ["his promoter region", "DNA", 66, 85], ["The mutations", "PROBLEM", 0, 13], ["RIF", "TEST", 26, 29]]], ["Results: The Genotype MTBDR assay identified 100% of the 77 RIF-R strains harbouring mutations in the rpoB gene, of which 37 (48%) showed a Ser531Leu mutation and 14 (18%) a His526Asp or Tyr mutation.", [["Tyr", "CHEMICAL", 187, 190], ["RIF-R", "GENE_OR_GENE_PRODUCT", 60, 65], ["rpoB", "GENE_OR_GENE_PRODUCT", 102, 106], ["Ser531Leu", "GENE_OR_GENE_PRODUCT", 140, 149], ["His526Asp", "GENE_OR_GENE_PRODUCT", 174, 183], ["Tyr", "AMINO_ACID", 187, 190], ["rpoB gene", "DNA", 102, 111], ["The Genotype MTBDR assay", "TEST", 9, 33], ["R strains harbouring mutations", "PROBLEM", 64, 94], ["the rpoB gene", "TEST", 98, 111], ["a Ser531Leu mutation", "TEST", 138, 158], ["a His526Asp or Tyr mutation", "PROBLEM", 172, 199], ["Tyr mutation", "OBSERVATION", 187, 199]]], ["61 of the 96 INH-R strains (63%) harboured a Ser315Thr mutation in katG, all identified by the Genotype MTBDR assay.", [["INH", "CHEMICAL", 13, 16], ["Thr", "CHEMICAL", 51, 54], ["INH-R", "GENE_OR_GENE_PRODUCT", 13, 18], ["Ser315", "GENE_OR_GENE_PRODUCT", 45, 51], ["katG", "GENE_OR_GENE_PRODUCT", 67, 71], ["katG", "DNA", 67, 71], ["a Ser315Thr mutation", "TREATMENT", 43, 63]]], ["58 of this 61 strains displayed a high level of INH-R.", [["INH", "CHEMICAL", 48, 51], ["this 61 strains", "PROBLEM", 6, 21], ["R.", "ANATOMY", 52, 54]]], ["Among the other INH-R strains, 3 showed a katG mutation at the level of the 315 regions, which was different from Ser315Thr (2 of which showing a low level of INH-R), and one harboured a deletion in katG (with a high level of INH-R).", [["INH", "CHEMICAL", 16, 19], ["Ser", "CHEMICAL", 114, 117], ["Thr", "CHEMICAL", 120, 123], ["INH-R", "GENE_OR_GENE_PRODUCT", 16, 21], ["katG", "GENE_OR_GENE_PRODUCT", 42, 46], ["Ser315Thr", "AMINO_ACID", 114, 123], ["INH-R", "GENE_OR_GENE_PRODUCT", 159, 164], ["katG", "GENE_OR_GENE_PRODUCT", 199, 203], ["INH-R", "GENE_OR_GENE_PRODUCT", 226, 231], ["315 regions", "DNA", 76, 87], ["INH", "PROTEIN", 159, 162], ["katG", "DNA", 199, 203], ["the other INH-R strains", "TEST", 6, 29], ["a katG mutation", "PROBLEM", 40, 55], ["a deletion in katG", "PROBLEM", 185, 203]]], ["These 4 mutations were also detected by the strip.", [["These 4 mutations", "PROBLEM", 0, 17]]], ["Finally, among the 31 remaining INH-R strains not detected by the MTBDR assay, 13 were characterized by a mutation in position -15 of the promoter region for the mabA-inhA regulon (10 with a low level of INH-R), 7 by a Ser94Ala mutation in InhA (all with a low level of resistance) and 11 by other mutations.", [["INH", "CHEMICAL", 32, 35], ["INH-R", "GENE_OR_GENE_PRODUCT", 32, 37], ["mabA-inhA", "GENE_OR_GENE_PRODUCT", 162, 171], ["INH-R", "GENE_OR_GENE_PRODUCT", 204, 209], ["Ser94Ala", "GENE_OR_GENE_PRODUCT", 219, 227], ["MTBDR", "DNA", 66, 71], ["position -15", "DNA", 118, 130], ["promoter region", "DNA", 138, 153], ["mabA", "DNA", 162, 166], ["inhA regulon", "DNA", 167, 179], ["Ser94Ala mutation", "DNA", 219, 236], ["InhA", "DNA", 240, 244], ["the MTBDR assay", "TEST", 62, 77], ["a mutation in position", "PROBLEM", 104, 126], ["the mabA-inhA regulon", "TEST", 158, 179], ["a Ser94Ala mutation in InhA", "PROBLEM", 217, 244]]], ["Conclusions: The MTBDR assay, which can readily be included in a routine laboratory workflow, identified 100% and 68% of the strains resistant to RIF and INH, respectively.", [["RIF", "CHEMICAL", 146, 149], ["INH", "CHEMICAL", 154, 157], ["RIF", "CHEMICAL", 146, 149], ["INH", "CHEMICAL", 154, 157], ["INH", "SIMPLE_CHEMICAL", 154, 157], ["The MTBDR assay", "TEST", 13, 28], ["a routine laboratory workflow", "TEST", 63, 92], ["the strains", "PROBLEM", 121, 132], ["RIF", "TEST", 146, 149], ["INH", "TEST", 154, 157], ["RIF", "OBSERVATION_MODIFIER", 146, 149]]], ["Interestingly, 60 of the 68 INH-R strains showing a high level of resistance (88%), but only 5 of the 28 INH-R strains with a low level of resistance (18%), were detected by the MTBDR assay, indicating that complementary tests are necessary for detection of the M. tuberculosis strains having a low level of resistance to INH.P1763Variation in the streptococcal 16S rDNA detected by pyrosequencing M. Haanper\u00e4, P. Huovinen, J. Jalava (Turku, FI) Originally the aim of this study was to identify alpha-haemolytic streptococcal isolates to the species level by pyrosequencing the v1 and v2 regions of the 16S rDNA and comparing the results to the sequences of type strains that have been determined earlier.", [["INH", "CHEMICAL", 28, 31], ["tuberculosis", "DISEASE", 265, 277], ["INH", "CHEMICAL", 322, 325], ["P1763Variation", "CHEMICAL", 326, 340], ["INH", "CHEMICAL", 322, 325], ["INH-R", "GENE_OR_GENE_PRODUCT", 28, 33], ["INH-R", "GENE_OR_GENE_PRODUCT", 105, 110], ["M. tuberculosis strains", "ORGANISM", 262, 285], ["INH", "SIMPLE_CHEMICAL", 322, 325], ["rDNA", "CELLULAR_COMPONENT", 366, 370], ["rDNA", "CELLULAR_COMPONENT", 607, 611], ["P1763Variation", "DNA", 326, 340], ["streptococcal 16S rDNA", "DNA", 348, 370], ["v1 and v2 regions", "DNA", 578, 595], ["16S rDNA", "DNA", 603, 611], ["M. tuberculosis", "SPECIES", 262, 277], ["M. tuberculosis", "SPECIES", 262, 277], ["R strains", "PROBLEM", 32, 41], ["a high level of resistance", "PROBLEM", 50, 76], ["R strains", "PROBLEM", 109, 118], ["a low level of resistance", "PROBLEM", 124, 149], ["the MTBDR assay", "TEST", 174, 189], ["complementary tests", "TEST", 207, 226], ["the M. tuberculosis strains", "PROBLEM", 258, 285], ["the streptococcal 16S rDNA", "TEST", 344, 370], ["this study", "TEST", 468, 478], ["alpha-haemolytic streptococcal isolates", "PROBLEM", 495, 534], ["the 16S rDNA", "TEST", 599, 611], ["type strains", "PROBLEM", 658, 670], ["high level", "OBSERVATION_MODIFIER", 52, 62], ["low level", "OBSERVATION_MODIFIER", 126, 135], ["tuberculosis", "OBSERVATION", 265, 277]]], ["However, the isolates could not be unambiguously identified due to sequence variations detected in the alpha-haemolytic isolates.", [["the isolates", "PROBLEM", 9, 21], ["sequence variations", "TEST", 67, 86]]], ["Materials and methods: Invasive S. pneumoniae isolates (n = 17), alpha-haemolytic streptococcal blood culture isolates (n = 16) and alpha-haemolytic streptococcal isolates from the normal pharyngeal microbiota (n = 34) of six elderly persons were analysed by pyrosequencing the v1 and v2 regions.", [["blood", "ANATOMY", 96, 101], ["pharyngeal microbiota", "ANATOMY", 188, 209], ["S. pneumoniae", "ORGANISM", 32, 45], ["pharyngeal microbiota", "MULTI-TISSUE_STRUCTURE", 188, 209], ["persons", "ORGANISM", 234, 241], ["v1 and v2 regions", "DNA", 278, 295], ["S. pneumoniae", "SPECIES", 32, 45], ["persons", "SPECIES", 234, 241], ["S. pneumoniae", "SPECIES", 32, 45], ["Invasive S. pneumoniae isolates", "TEST", 23, 54], ["alpha-haemolytic streptococcal blood culture isolates", "TEST", 65, 118], ["alpha-haemolytic streptococcal isolates", "PROBLEM", 132, 171], ["streptococcal isolates", "OBSERVATION", 149, 171], ["pharyngeal microbiota", "ANATOMY", 188, 209], ["v2", "ANATOMY_MODIFIER", 285, 287], ["regions", "ANATOMY_MODIFIER", 288, 295]]], ["Results: Varying degree of genetic variation was found in different types of streptococcal isolates.", [["genetic variation", "PROBLEM", 27, 44], ["streptococcal isolates", "PROBLEM", 77, 99], ["genetic variation", "OBSERVATION", 27, 44], ["streptococcal isolates", "OBSERVATION", 77, 99]]], ["In the pneumococcal isolates, no sequence variation was detected as all the isolates contained the sequence specific for S. pneumoniae in both regions.", [["S. pneumoniae", "ORGANISM", 121, 134], ["S. pneumoniae", "SPECIES", 121, 134], ["pneumococcal", "SPECIES", 7, 19], ["S. pneumoniae", "SPECIES", 121, 134], ["the pneumococcal isolates", "TREATMENT", 3, 28], ["sequence variation", "TEST", 33, 51], ["the sequence", "TEST", 95, 107], ["S. pneumoniae", "PROBLEM", 121, 134], ["pneumococcal isolates", "OBSERVATION", 7, 28], ["pneumoniae", "OBSERVATION", 124, 134], ["both", "ANATOMY_MODIFIER", 138, 142], ["regions", "ANATOMY_MODIFIER", 143, 150]]], ["Also the sequences of the alpha-haemolytic blood culture isolates were well in agreement with the sequences of the streptococcal type strains.", [["blood", "ANATOMY", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["the alpha-haemolytic blood culture isolates", "TEST", 22, 65], ["the sequences", "TEST", 94, 107], ["the streptococcal type strains", "PROBLEM", 111, 141]]], ["However, most of these isolates could not be unambiguously identified, as they contained sequences belonging to different species in the v1 and v2 region.", [["v1 and v2 region", "DNA", 137, 153], ["v1", "ANATOMY_MODIFIER", 137, 139], ["v2", "ANATOMY_MODIFIER", 144, 146], ["region", "ANATOMY_MODIFIER", 147, 153]]], ["Consequently, only five of the isolates could be unequivocally identified as S. gallolyticus (n = 2), S. anginosus (n = 1), S. mitis (n = 1) and S. sanguinis (n = 1).", [["S. gallolyticus", "DISEASE", 77, 92], ["S. anginosus", "DISEASE", 102, 114], ["S. mitis", "DISEASE", 124, 132], ["S. sanguinis", "DISEASE", 145, 157], ["S. gallolyticus", "ORGANISM", 77, 92], ["S. anginosus", "ORGANISM", 102, 114], ["S. mitis", "ORGANISM", 124, 132], ["S. sanguinis", "ORGANISM", 145, 157], ["S. gallolyticus", "SPECIES", 77, 92], ["S. anginosus", "SPECIES", 102, 114], ["S. mitis", "SPECIES", 124, 132], ["S. sanguinis", "SPECIES", 145, 157], ["S. gallolyticus", "SPECIES", 77, 92], ["S. anginosus", "SPECIES", 102, 114], ["S. mitis", "SPECIES", 124, 132], ["S. sanguinis", "SPECIES", 145, 157], ["the isolates", "TEST", 27, 39], ["S. gallolyticus", "TEST", 77, 92], ["S. anginosus", "PROBLEM", 102, 114], ["S. mitis", "PROBLEM", 124, 132], ["S. sanguinis", "PROBLEM", 145, 157], ["anginosus", "OBSERVATION", 105, 114], ["mitis", "OBSERVATION", 127, 132]]], ["The commensal streptococci contained numerous sequences to which an identical type sequence could not be found.", [["commensal streptococci", "CELL", 4, 26], ["The commensal streptococci", "PROBLEM", 0, 26], ["an identical type sequence", "TEST", 65, 91], ["commensal", "OBSERVATION_MODIFIER", 4, 13], ["streptococci", "OBSERVATION", 14, 26]]], ["Also sequences identical to type strains were found; but similarly to the blood culture isolates, the results enabled the identification of only four isolates: S. mitis (n = 2), S. parasanguinis (n = 1), and S. salivarius or S. vestibularis (n = 1).", [["blood culture", "ANATOMY", 74, 87], ["S. parasanguinis", "DISEASE", 178, 194], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["S. mitis", "ORGANISM", 160, 168], ["S. parasanguinis", "ORGANISM", 178, 194], ["S. salivarius", "ORGANISM", 208, 221], ["S. vestibularis", "ORGANISM", 225, 240], ["S. mitis", "SPECIES", 160, 168], ["S. parasanguinis", "SPECIES", 178, 194], ["S. salivarius", "SPECIES", 208, 221], ["S. vestibularis", "SPECIES", 225, 240], ["S. mitis", "SPECIES", 160, 168], ["S. parasanguinis", "SPECIES", 178, 194], ["S. salivarius", "SPECIES", 208, 221], ["S. vestibularis", "SPECIES", 225, 240], ["type strains", "PROBLEM", 28, 40], ["the blood culture isolates", "TEST", 70, 96], ["four isolates", "TEST", 145, 158], ["S. mitis", "PROBLEM", 160, 168], ["S. parasanguinis", "TEST", 178, 194], ["mitis", "OBSERVATION", 163, 168]]], ["Moreover, the pyrograms of three blood culture isolates and ten pharyngeal isolates indicated heterogeneous 16S rDNA alleles.", [["blood", "ANATOMY", 33, 38], ["pharyngeal isolates", "ANATOMY", 64, 83], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["rDNA", "CELLULAR_COMPONENT", 112, 116], ["16S rDNA alleles", "DNA", 108, 124], ["three blood culture isolates", "TEST", 27, 55], ["ten pharyngeal isolates", "TEST", 60, 83], ["heterogeneous 16S rDNA alleles", "PROBLEM", 94, 124], ["pharyngeal", "ANATOMY", 64, 74], ["heterogeneous", "OBSERVATION_MODIFIER", 94, 107]]], ["One such pyrogram of the v1 region is presented in the figure.", [["v1 region", "DNA", 25, 34], ["v1", "ANATOMY", 25, 27], ["region", "ANATOMY_MODIFIER", 28, 34]]], ["Interestingly, four of the eight different nonheterogeneous v1 and v2 sequence combinations of the blood culture isolates were also present among the pharyngeal isolates.Conclusions:The results of this study indicate that the variation in commensal streptococci is greater than that of the streptococcal type strains and pathogenic isolates.", [["blood culture", "ANATOMY", 99, 112], ["pharyngeal isolates", "ANATOMY", 150, 169], ["v1", "GENE_OR_GENE_PRODUCT", 60, 62], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["commensal streptococci", "CELL", 239, 261], ["streptococcal type strains", "ORGANISM", 290, 316], ["nonheterogeneous v1 and v2 sequence", "DNA", 43, 78], ["the blood culture isolates", "TEST", 95, 121], ["this study", "TEST", 197, 207], ["the variation", "PROBLEM", 222, 235], ["commensal streptococci", "PROBLEM", 239, 261], ["the streptococcal type strains", "PROBLEM", 286, 316], ["pathogenic isolates", "PROBLEM", 321, 340], ["pharyngeal", "ANATOMY", 150, 160], ["commensal streptococci", "OBSERVATION", 239, 261], ["greater", "OBSERVATION_MODIFIER", 265, 272]]], ["The presence of identical sequence combinations among the blood culture and pharyngeal isolates supports the assumption that potentially pathogenic isolates are present in the normal microbiota.P1764Evaluation of partial 16S rRNA gene sequencing for identification of clinical isolates of Nocardia species M. Mar\u00edn, M. S\u00e1nchez, M. del Rosal, E. Cercenado, P. Mart\u00edn-Rabad\u00e1n, E. Bouza (Madrid, ES) New species of Nocardia are being described.", [["blood culture", "ANATOMY", 58, 71], ["pharyngeal isolates", "ANATOMY", 76, 95], ["Nocardia", "DISEASE", 412, 420], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["pharyngeal", "ORGANISM_SUBDIVISION", 76, 86], ["16S rRNA gene", "DNA", 221, 234], ["the blood culture", "TEST", 54, 71], ["pharyngeal isolates", "TEST", 76, 95], ["potentially pathogenic isolates", "PROBLEM", 125, 156], ["partial 16S rRNA gene sequencing", "TREATMENT", 213, 245], ["Nocardia species", "PROBLEM", 289, 305], ["New species of Nocardia", "PROBLEM", 397, 420], ["pharyngeal", "ANATOMY", 76, 86], ["pathogenic isolates", "OBSERVATION", 137, 156], ["normal microbiota", "OBSERVATION", 176, 193], ["species", "OBSERVATION_MODIFIER", 401, 408], ["Nocardia", "OBSERVATION", 412, 420]]], ["Conventional identification based on biochemical characteristics and PCRrestriction enzyme analysis is frequently unable to distinguish them.", [["Conventional identification", "TEST", 0, 27], ["biochemical characteristics", "TEST", 37, 64], ["PCRrestriction enzyme analysis", "TEST", 69, 99]]], ["Partial sequencing of 16S rRNA gene has proven useful in the identification of bacteria.", [["16S", "GENE_OR_GENE_PRODUCT", 22, 25], ["rRNA", "CELLULAR_COMPONENT", 26, 30], ["16S rRNA gene", "DNA", 22, 35], ["Partial sequencing of 16S rRNA gene", "PROBLEM", 0, 35], ["bacteria", "PROBLEM", 79, 87], ["bacteria", "OBSERVATION", 79, 87]]], ["Objective: To evaluate the utility of 5'end 16S rRNA gene PCR and sequencing in the identification of clinical isolates of Nocardia sp. compared with conventional methods and PCR-RFLP of hsp65.", [["Nocardia sp", "DISEASE", 123, 134], ["Nocardia sp", "ORGANISM", 123, 134], ["hsp65", "GENE_OR_GENE_PRODUCT", 187, 192], ["5'end 16S rRNA gene", "DNA", 38, 57], ["RFLP", "DNA", 179, 183], ["hsp65", "DNA", 187, 192], ["5'end 16S rRNA gene PCR", "PROBLEM", 38, 61], ["Nocardia sp", "PROBLEM", 123, 134], ["conventional methods", "TEST", 150, 170], ["PCR", "TEST", 175, 178], ["hsp65", "TEST", 187, 192]]], ["Methods: 48 clinical isolates of Nocardia sp. were characterized by biochemical reactions and disk diffusion susceptibility testing.", [["Nocardia sp", "ORGANISM", 33, 44], ["biochemical reactions", "PROBLEM", 68, 89], ["disk diffusion susceptibility testing", "TEST", 94, 131], ["biochemical reactions", "OBSERVATION", 68, 89]]], ["Molecular identification was performed by hsp65 PCR-RFLP and PCR of 5'end of 16S rRNA gene followed by sequencing.", [["hsp", "GENE_OR_GENE_PRODUCT", 42, 45], ["16S", "GENE_OR_GENE_PRODUCT", 77, 80], ["rRNA", "CELLULAR_COMPONENT", 81, 85], ["RFLP", "DNA", 52, 56], ["16S rRNA gene", "DNA", 77, 90], ["Molecular identification", "TEST", 0, 24], ["hsp", "TEST", 42, 45], ["PCR", "TEST", 48, 51], ["RFLP", "TEST", 52, 56], ["PCR", "TEST", 61, 64]]], ["The sequences obtained were compared with those included in Genebank.", [["The sequences", "TEST", 0, 13]]], ["Only alignments with similarities higher than 99% were considered.", [["higher", "OBSERVATION_MODIFIER", 34, 40]]], ["A comparison of sequences of our Nocardia isolates with those deposited in Genebank and well characterized phenotypically was performed using Clustal X 1.8 software.P1764Results: Distribution of species after PCR-RFLP of hsp65 was N. asteroides VI (22), N. farcinica (11), N. nova (6), N. asteroides I (4), N. otitidiscaviarum (4) and N. asteroides IV (1) .", [["N. asteroides I", "DISEASE", 286, 301], ["hsp65", "GENE_OR_GENE_PRODUCT", 221, 226], ["N. asteroides VI", "ORGANISM", 231, 247], ["N. farcinica", "ORGANISM", 254, 266], ["N. nova", "ORGANISM", 273, 280], ["N. asteroides I", "ORGANISM", 286, 301], ["N. otitidiscaviarum", "ORGANISM", 307, 326], ["N. asteroides IV", "ORGANISM", 335, 351], ["RFLP", "DNA", 213, 217], ["hsp65", "DNA", 221, 226], ["N. asteroides", "SPECIES", 231, 244], ["N. farcinica", "SPECIES", 254, 266], ["N. nova", "SPECIES", 273, 280], ["N. asteroides", "SPECIES", 286, 299], ["N. otitidiscaviarum", "SPECIES", 307, 326], ["N. asteroides", "SPECIES", 335, 348], ["N. asteroides", "SPECIES", 231, 244], ["N. farcinica", "SPECIES", 254, 266], ["N. nova", "SPECIES", 273, 280], ["N. asteroides I", "SPECIES", 286, 301], ["N. otitidiscaviarum", "SPECIES", 307, 326], ["N. asteroides IV (1", "SPECIES", 335, 354], ["our Nocardia isolates", "TEST", 29, 50], ["species", "PROBLEM", 195, 202], ["PCR", "TEST", 209, 212], ["RFLP", "TEST", 213, 217], ["hsp65", "TEST", 221, 226], ["asteroides VI", "TEST", 234, 247], ["N. farcinica", "TEST", 254, 266], ["farcinica", "OBSERVATION", 257, 266]]], ["Partial sequence analysis of 16S rRNA revealed a great heterogeneity between the isolates of N. asteroides VI, as follows: N. cyriacigeorgica (15 isolates), N. abscessus (3 isolates) and N. carnea (1 isolate).", [["N. asteroides VI", "DISEASE", 93, 109], ["N. abscessus", "DISEASE", 157, 169], ["N. asteroides VI", "ORGANISM", 93, 109], ["N. cyriacigeorgica", "ORGANISM", 123, 141], ["N. abscessus", "ORGANISM", 157, 169], ["N. carnea", "ORGANISM", 187, 196], ["16S rRNA", "DNA", 29, 37], ["N. asteroides", "SPECIES", 93, 106], ["N. cyriacigeorgica", "SPECIES", 123, 141], ["N. abscessus", "SPECIES", 157, 169], ["N. carnea", "SPECIES", 187, 196], ["N. asteroides VI", "SPECIES", 93, 109], ["N. cyriacigeorgica", "SPECIES", 123, 141], ["N. abscessus", "SPECIES", 157, 169], ["N. carnea", "SPECIES", 187, 196], ["Partial sequence analysis", "TEST", 0, 25], ["16S rRNA", "TEST", 29, 37], ["a great heterogeneity", "PROBLEM", 47, 68], ["N. abscessus", "PROBLEM", 157, 169], ["great", "OBSERVATION_MODIFIER", 49, 54], ["heterogeneity", "OBSERVATION", 55, 68], ["abscessus", "OBSERVATION", 160, 169], ["carnea", "ANATOMY", 190, 196]]], ["For 3 isolates, no Genebank sequence was found with more than 99% similarity.", [["Genebank sequence", "DNA", 19, 36], ["Genebank sequence", "TEST", 19, 36]]], ["All N. farcinica isolates had the same sequence and showed 100% similarity with those deposited in Genebank.", [["N. farcinica", "ORGANISM", 4, 16], ["N. farcinica", "SPECIES", 4, 16], ["N. farcinica", "SPECIES", 4, 16], ["All N. farcinica isolates", "TEST", 0, 25], ["farcinica", "OBSERVATION", 7, 16]]], ["N. nova, N. asteroides I and N. otitidiscaviarum also showed sequence heterogeneity.", [["N. nova", "ORGANISM", 0, 7], ["N. asteroides I", "ORGANISM", 9, 24], ["N. otitidiscaviarum", "ORGANISM", 29, 48], ["N. asteroides", "SPECIES", 9, 22], ["N. otitidiscaviarum", "SPECIES", 29, 48], ["N. nova", "SPECIES", 0, 7], ["N. asteroides I", "SPECIES", 9, 24], ["N. otitidiscaviarum", "SPECIES", 29, 48], ["sequence heterogeneity", "PROBLEM", 61, 83], ["heterogeneity", "OBSERVATION", 70, 83]]], ["Three N. nova isolates matched with the recently described N. veterana and 3 with N. nova.", [["N. veterana", "SPECIES", 59, 70], ["N. nova", "SPECIES", 6, 13], ["N. veterana", "SPECIES", 59, 70], ["N. nova", "SPECIES", 82, 89], ["nova isolates", "OBSERVATION", 9, 22]]], ["N. asteroides I isolates were identified as N. abscessus (1) and N. beijingensis (3) .", [["N. asteroides I", "ORGANISM", 0, 15], ["N. abscessus", "ORGANISM", 44, 56], ["N. beijingensis", "ORGANISM", 65, 80], ["N. asteroides", "SPECIES", 0, 13], ["N. abscessus", "SPECIES", 44, 56], ["N. beijingensis", "SPECIES", 65, 80], ["N. asteroides I", "SPECIES", 0, 15], ["N. abscessus", "SPECIES", 44, 56], ["N. beijingensis", "SPECIES", 65, 80], ["asteroides I isolates", "PROBLEM", 3, 24], ["N. abscessus", "PROBLEM", 44, 56], ["asteroides", "OBSERVATION", 3, 13], ["abscessus", "OBSERVATION", 47, 56]]], ["All N. otitidiscaviarum were identified properly.", [["N. otitidiscaviarum", "ORGANISM", 4, 23], ["N. otitidiscaviarum", "SPECIES", 4, 23], ["N. otitidiscaviarum", "SPECIES", 4, 23], ["otitidiscaviarum", "OBSERVATION", 7, 23]]], ["The isolate of N. asteroides IV was identified as N. transvalensis.", [["N. asteroides IV", "ORGANISM", 15, 31], ["N. transvalensis", "ORGANISM", 50, 66], ["N. asteroides", "SPECIES", 15, 28], ["N. transvalensis", "SPECIES", 50, 66], ["N. asteroides IV", "SPECIES", 15, 31], ["N. transvalensis", "SPECIES", 50, 66], ["N. asteroides IV", "TREATMENT", 15, 31], ["N. asteroides", "OBSERVATION", 15, 28], ["N. transvalensis", "OBSERVATION", 50, 66]]], ["Conclusions: Sequencing of 5'end 16S rRNA gene is a useful and rapid molecular tool for the identification of Nocardia clinical isolates.", [["5'end 16S rRNA gene", "DNA", 27, 46], ["Sequencing of 5'end 16S rRNA gene", "TEST", 13, 46], ["Nocardia clinical isolates", "PROBLEM", 110, 136]]], ["Sequence analysis of the 5'end 16S rRNA has enabled us to recognize great diversity and new species among our Nocardia isolates.", [["Nocardia", "DISEASE", 110, 118], ["5'end 16S rRNA", "DNA", 25, 39], ["Sequence analysis", "TEST", 0, 17], ["great diversity", "PROBLEM", 68, 83], ["new species", "PROBLEM", 88, 99], ["great diversity", "OBSERVATION", 68, 83]]], ["Several species would have gone unnoticed using non-sequencing-based methods.P1764Antibacterial susceptibility studies-III P1765 Anaerobic bacteraemia due to Fusobacterium necrophorum and Clostiridium cadaveris: a case report M. Panopoulou, E. Alepopoulou, E. Chrisafidou, A. Tsaroucha, C. Simopoulos, S. Kartali (Alexandroupolis, GR) Introduction: Anaerobic bacteremia is uncommon accounting 0.5-9% of bacteremias and it is associated with a high mortality rate, which is strongly and independently associated with underlying liver disease.", [["liver", "ANATOMY", 527, 532], ["P1764Antibacterial", "CHEMICAL", 77, 95], ["bacteraemia", "DISEASE", 139, 150], ["Fusobacterium necrophorum", "DISEASE", 158, 183], ["Anaerobic bacteremia", "DISEASE", 349, 369], ["bacteremias", "DISEASE", 403, 414], ["liver disease", "DISEASE", 527, 540], ["Fusobacterium necrophorum", "ORGANISM", 158, 183], ["Clostiridium cadaveris", "ORGANISM", 188, 210], ["liver", "ORGAN", 527, 532], ["Fusobacterium necrophorum", "SPECIES", 158, 183], ["Clostiridium cadaveris", "SPECIES", 188, 210], ["Fusobacterium necrophorum", "SPECIES", 158, 183], ["Clostiridium cadaveris", "SPECIES", 188, 210], ["Several species", "PROBLEM", 0, 15], ["non-sequencing-based methods", "TREATMENT", 48, 76], ["P1764Antibacterial susceptibility studies", "TEST", 77, 118], ["Anaerobic bacteraemia", "PROBLEM", 129, 150], ["Fusobacterium necrophorum", "PROBLEM", 158, 183], ["S. Kartali (Alexandroupolis, GR)", "TREATMENT", 302, 334], ["Anaerobic bacteremia", "PROBLEM", 349, 369], ["bacteremias", "PROBLEM", 403, 414], ["a high mortality rate", "PROBLEM", 441, 462], ["underlying liver disease", "PROBLEM", 516, 540], ["bacteremia", "OBSERVATION", 359, 369], ["bacteremias", "OBSERVATION", 403, 414], ["liver", "ANATOMY", 527, 532], ["disease", "OBSERVATION", 533, 540]]], ["Case report: A 62 year-old man presented to our hospital with a 2-day fever and rigor.", [["fever", "DISEASE", 70, 75], ["man", "ORGANISM", 27, 30], ["man", "SPECIES", 27, 30], ["fever", "PROBLEM", 70, 75], ["rigor", "PROBLEM", 80, 85]]], ["He had a history of cancer of the extrahepatic biliary tree, which was found incidentally during an operation for the treatment of echinococcal cyst of the liver.", [["cancer", "ANATOMY", 20, 26], ["extrahepatic biliary tree", "ANATOMY", 34, 59], ["echinococcal cyst", "ANATOMY", 131, 148], ["liver", "ANATOMY", 156, 161], ["cancer of the extrahepatic biliary tree", "DISEASE", 20, 59], ["echinococcal cyst of the liver", "DISEASE", 131, 161], ["cancer", "CANCER", 20, 26], ["extrahepatic biliary tree", "MULTI-TISSUE_STRUCTURE", 34, 59], ["echinococcal cyst", "CANCER", 131, 148], ["liver", "ORGAN", 156, 161], ["cancer of the extrahepatic biliary tree", "PROBLEM", 20, 59], ["an operation", "TREATMENT", 97, 109], ["echinococcal cyst of the liver", "PROBLEM", 131, 161], ["cancer", "OBSERVATION", 20, 26], ["extrahepatic", "ANATOMY_MODIFIER", 34, 46], ["biliary tree", "ANATOMY", 47, 59], ["echinococcal", "OBSERVATION_MODIFIER", 131, 143], ["cyst", "OBSERVATION", 144, 148], ["liver", "ANATOMY", 156, 161]]], ["Physical examination reveals high fever (39 C) and tachycardia.", [["fever", "DISEASE", 34, 39], ["tachycardia", "DISEASE", 51, 62], ["Physical examination", "TEST", 0, 20], ["high fever", "PROBLEM", 29, 39], ["tachycardia", "PROBLEM", 51, 62]]], ["Blood tests showed the following results: Hb: 9.9 gr/dl, WBC: 22.500 /ul, PLT: 296.000 /ul, TPROT: 5.9 Each colony type subcultured to blood agar plates and incubated aerobically and anaerobically (aerotolerance test).", [["Blood", "ANATOMY", 0, 5], ["colony", "ANATOMY", 108, 114], ["blood", "ANATOMY", 135, 140], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Hb", "GENE_OR_GENE_PRODUCT", 42, 44], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["Blood tests", "TEST", 0, 11], ["Hb", "TEST", 42, 44], ["gr", "TEST", 50, 52], ["dl", "TEST", 53, 55], ["WBC", "TEST", 57, 60], ["ul", "TEST", 70, 72], ["PLT", "TEST", 74, 77], ["ul", "TEST", 88, 90], ["TPROT", "TEST", 92, 97], ["Each colony type", "TEST", 103, 119], ["blood agar plates", "TEST", 135, 152], ["aerotolerance test", "TEST", 198, 216]]], ["After 24 hours of incubation the two organisms grew only in anaerobic conditions.", [["incubation", "TREATMENT", 18, 28], ["the two organisms", "TEST", 29, 46], ["anaerobic conditions", "OBSERVATION", 60, 80]]], ["They identified by the Api 20A system (Bio-Merieux-France) as Fusobacterium necrophorum and Clostiridium cadaveris.", [["Fusobacterium necrophorum", "ORGANISM", 62, 87], ["Clostiridium cadaveris", "ORGANISM", 92, 114], ["Fusobacterium necrophorum", "SPECIES", 62, 87], ["Clostiridium cadaveris", "SPECIES", 92, 114], ["Fusobacterium necrophorum", "SPECIES", 62, 87], ["Clostiridium cadaveris", "SPECIES", 92, 114], ["Fusobacterium necrophorum", "PROBLEM", 62, 87], ["Clostiridium cadaveris", "TREATMENT", 92, 114]]], ["The patient's treatment started with metronidazole, amikacin and ceftriaxone and followed by metronidazole and imipenem.", [["metronidazole", "CHEMICAL", 37, 50], ["amikacin", "CHEMICAL", 52, 60], ["ceftriaxone", "CHEMICAL", 65, 76], ["metronidazole", "CHEMICAL", 93, 106], ["imipenem", "CHEMICAL", 111, 119], ["metronidazole", "CHEMICAL", 37, 50], ["amikacin", "CHEMICAL", 52, 60], ["ceftriaxone", "CHEMICAL", 65, 76], ["metronidazole", "CHEMICAL", 93, 106], ["imipenem", "CHEMICAL", 111, 119], ["patient", "ORGANISM", 4, 11], ["metronidazole", "SIMPLE_CHEMICAL", 37, 50], ["amikacin", "SIMPLE_CHEMICAL", 52, 60], ["ceftriaxone", "SIMPLE_CHEMICAL", 65, 76], ["metronidazole", "SIMPLE_CHEMICAL", 93, 106], ["imipenem", "SIMPLE_CHEMICAL", 111, 119], ["patient", "SPECIES", 4, 11], ["The patient's treatment", "TREATMENT", 0, 23], ["metronidazole", "TREATMENT", 37, 50], ["amikacin", "TREATMENT", 52, 60], ["ceftriaxone", "TREATMENT", 65, 76], ["metronidazole", "TREATMENT", 93, 106], ["imipenem", "TREATMENT", 111, 119]]], ["Conclusions: Although anaerobic bacteremia is rare, there is value in performing separate anaerobic blood cultures.", [["blood", "ANATOMY", 100, 105], ["bacteremia", "DISEASE", 32, 42], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["anaerobic blood cultures", "CELL_LINE", 90, 114], ["anaerobic bacteremia", "PROBLEM", 22, 42], ["separate anaerobic blood cultures", "TEST", 81, 114], ["bacteremia", "OBSERVATION", 32, 42]]], ["The early recognition of anaerobic bacteremia and administration of the appropriate antimicrobial therapy play a major role in preventing mortality especially in patients with underlying disease.P1766Fluoroquinolone resistance among Enterobacteriaceae strains isolated from urinary tract infections V. Skandami-Epitropaki, P. Fostira, A. Tsiringa, A. Xanthaki, K. Zampitha, M. Toutouza (Athens, GR)P1766Objectives: To study the frequency and antibiotic susceptibility of quinolone resistant bacterial stains isolated from patients with community-aquired bacteriuria and compare it with urinary pathogens from hospitalized patients.", [["urinary tract", "ANATOMY", 274, 287], ["urinary", "ANATOMY", 586, 593], ["bacteremia", "DISEASE", 35, 45], ["P1766Fluoroquinolone", "CHEMICAL", 195, 215], ["urinary tract infections", "DISEASE", 274, 298], ["quinolone", "CHEMICAL", 471, 480], ["bacteriuria", "DISEASE", 554, 565], ["urinary pathogens", "DISEASE", 586, 603], ["P1766Fluoroquinolone", "CHEMICAL", 195, 215], ["quinolone", "CHEMICAL", 471, 480], ["patients", "ORGANISM", 162, 170], ["P1766Fluoroquinolone", "SIMPLE_CHEMICAL", 195, 215], ["Enterobacteriaceae strains", "ORGANISM", 233, 259], ["urinary tract", "ORGANISM_SUBDIVISION", 274, 287], ["quinolone", "SIMPLE_CHEMICAL", 471, 480], ["patients", "ORGANISM", 522, 530], ["urinary", "ORGANISM_SUBSTANCE", 586, 593], ["patients", "ORGANISM", 622, 630], ["patients", "SPECIES", 162, 170], ["patients", "SPECIES", 522, 530], ["patients", "SPECIES", 622, 630], ["V. Skandami-Epitropaki", "SPECIES", 299, 321], ["anaerobic bacteremia", "PROBLEM", 25, 45], ["the appropriate antimicrobial therapy", "TREATMENT", 68, 105], ["underlying disease", "PROBLEM", 176, 194], ["P1766Fluoroquinolone resistance", "TREATMENT", 195, 226], ["Enterobacteriaceae strains", "PROBLEM", 233, 259], ["urinary tract infections", "PROBLEM", 274, 298], ["Epitropaki", "PROBLEM", 311, 321], ["antibiotic susceptibility", "TEST", 442, 467], ["quinolone resistant bacterial stains", "PROBLEM", 471, 507], ["community-aquired bacteriuria", "PROBLEM", 536, 565], ["urinary pathogens", "PROBLEM", 586, 603], ["anaerobic bacteremia", "OBSERVATION", 25, 45], ["disease", "OBSERVATION", 187, 194], ["Enterobacteriaceae strains", "OBSERVATION", 233, 259], ["urinary tract", "ANATOMY", 274, 287], ["bacteriuria", "OBSERVATION", 554, 565], ["urinary", "ANATOMY", 586, 593], ["pathogens", "OBSERVATION", 594, 603]]], ["Methods: During a 12-month period (October 2004 -October 2005 a total of 772 bacterial strains were isolated out of 8369 urine samples submitted for culture in our hospital laboratory from the community and from hospitalized patients with urinary tract infection symptoms.", [["urine samples", "ANATOMY", 121, 134], ["urinary tract", "ANATOMY", 239, 252], ["urinary tract infection", "DISEASE", 239, 262], ["urine samples", "ORGANISM_SUBSTANCE", 121, 134], ["patients", "ORGANISM", 225, 233], ["urinary tract", "ORGANISM_SUBDIVISION", 239, 252], ["patients", "SPECIES", 225, 233], ["bacterial strains", "PROBLEM", 77, 94], ["urine samples", "TEST", 121, 134], ["culture", "TEST", 149, 156], ["urinary tract infection symptoms", "PROBLEM", 239, 271], ["urinary tract", "ANATOMY", 239, 252]]], ["Cultures and bacterial identification were obtained by conventional methods.", [["Cultures", "TEST", 0, 8], ["bacterial identification", "TEST", 13, 37]]], ["Antibiotic susceptibility testing was done by Kirby-Bauer disk diffusion method according NCCLS criteria.", [["Antibiotic susceptibility testing", "TEST", 0, 33]]], ["Results: Of the 772 bactrial strains studied (Escherichia coli 604, Klebsiella pneumoniae 97, Proteus mirabilis 71), 14.6% of them were found to be quinolone resistant.", [["quinolone", "CHEMICAL", 148, 157], ["quinolone", "CHEMICAL", 148, 157], ["Escherichia coli 604,", "ORGANISM", 46, 67], ["Klebsiella pneumoniae 97", "ORGANISM", 68, 92], ["Proteus mirabilis 71", "ORGANISM", 94, 114], ["quinolone", "SIMPLE_CHEMICAL", 148, 157], ["Escherichia coli", "SPECIES", 46, 62], ["Klebsiella pneumoniae", "SPECIES", 68, 89], ["Proteus mirabilis", "SPECIES", 94, 111], ["Escherichia coli", "SPECIES", 46, 62], ["Klebsiella pneumoniae", "SPECIES", 68, 89], ["Proteus mirabilis 71", "SPECIES", 94, 114], ["the 772 bactrial strains", "TEST", 12, 36], ["Escherichia coli", "TEST", 46, 62], ["Klebsiella pneumoniae", "TEST", 68, 89], ["Proteus mirabilis", "TEST", 94, 111], ["quinolone resistant", "PROBLEM", 148, 167], ["Escherichia coli", "OBSERVATION", 46, 62], ["quinolone resistant", "OBSERVATION", 148, 167]]], ["The percentage of quinolone resistance was 19.9% for hospitalized patients (HP) and 5.7% for community patients (CP).", [["quinolone", "CHEMICAL", 18, 27], ["quinolone", "CHEMICAL", 18, 27], ["quinolone", "SIMPLE_CHEMICAL", 18, 27], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 103, 111], ["quinolone resistance", "TEST", 18, 38], ["HP", "TEST", 76, 78], ["CP", "PROBLEM", 113, 115], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["quinolone resistance", "OBSERVATION", 18, 38]]], ["The quinolone resistance for E. coli was 11.3% (16.5% for HP and 4.3% for CP), for K. pneumoniae 24.7% (28.0% for HP and 6.7% for CP) and for P. mirabilis 29.6% (29.6% for HP, 29.4% for CP).", [["quinolone", "CHEMICAL", 4, 13], ["quinolone", "CHEMICAL", 4, 13], ["quinolone", "SIMPLE_CHEMICAL", 4, 13], ["E. coli", "ORGANISM", 29, 36], ["K. pneumoniae", "ORGANISM", 83, 96], ["P. mirabilis", "ORGANISM", 142, 154], ["E. coli", "SPECIES", 29, 36], ["K. pneumoniae", "SPECIES", 83, 96], ["P. mirabilis", "SPECIES", 142, 154], ["E. coli", "SPECIES", 29, 36], ["K. pneumoniae", "SPECIES", 83, 96], ["P. mirabilis", "SPECIES", 142, 154], ["The quinolone resistance", "TEST", 0, 24], ["E. coli", "TEST", 29, 36], ["HP", "TEST", 58, 60], ["CP", "PROBLEM", 74, 76], ["K. pneumoniae", "TEST", 83, 96], ["HP", "TEST", 114, 116], ["CP", "PROBLEM", 130, 132], ["P. mirabilis", "TEST", 142, 154], ["HP", "TEST", 172, 174], ["CP", "PROBLEM", 186, 188], ["quinolone resistance", "OBSERVATION", 4, 24]]], ["Susceptibility pattern of the 113 quinolone resistant isolates to other antimicrobial agents was for hospitalized patients and community patients respectively as following: For E. coli ampicillin (AM) 7%-9.1%, amoxicillinclavulanate (AMC) 45.6%-54.5%, piperacillin-tazobactam (TZP) 69.4%-81.8%, cefuroxime (CXM) 64.9%-72.7%, trimethoprimsulfamethoxazole (SXT) 15.8%-18.2%, ceftazidime (CAZ) 66.7%-72.7%, cefepime (FEP) 66.7%-81.8%, gentamicin (GM) 80.7%-72.7%.", [["quinolone", "CHEMICAL", 34, 43], ["ampicillin", "CHEMICAL", 185, 195], ["AM", "CHEMICAL", 197, 199], ["amoxicillinclavulanate", "CHEMICAL", 210, 232], ["AMC", "CHEMICAL", 234, 237], ["piperacillin-tazobactam", "CHEMICAL", 252, 275], ["TZP", "CHEMICAL", 277, 280], ["cefuroxime", "CHEMICAL", 295, 305], ["CXM", "CHEMICAL", 307, 310], ["trimethoprimsulfamethoxazole", "CHEMICAL", 325, 353], ["SXT", "CHEMICAL", 355, 358], ["ceftazidime", "CHEMICAL", 373, 384], ["CAZ", "CHEMICAL", 386, 389], ["cefepime", "CHEMICAL", 404, 412], ["FEP", "CHEMICAL", 414, 417], ["gentamicin", "CHEMICAL", 432, 442], ["GM", "CHEMICAL", 444, 446], ["quinolone", "CHEMICAL", 34, 43], ["ampicillin", "CHEMICAL", 185, 195], ["amoxicillinclavulanate", "CHEMICAL", 210, 232], ["piperacillin-tazobactam", "CHEMICAL", 252, 275], ["TZP", "CHEMICAL", 277, 280], ["cefuroxime", "CHEMICAL", 295, 305], ["CXM", "CHEMICAL", 307, 310], ["trimethoprimsulfamethoxazole", "CHEMICAL", 325, 353], ["SXT", "CHEMICAL", 355, 358], ["ceftazidime", "CHEMICAL", 373, 384], ["CAZ", "CHEMICAL", 386, 389], ["cefepime", "CHEMICAL", 404, 412], ["gentamicin", "CHEMICAL", 432, 442], ["patients", "ORGANISM", 114, 122], ["patients", "ORGANISM", 137, 145], ["E. coli", "ORGANISM", 177, 184], ["ampicillin", "SIMPLE_CHEMICAL", 185, 195], ["AM", "SIMPLE_CHEMICAL", 197, 199], ["amoxicillinclavulanate", "SIMPLE_CHEMICAL", 210, 232], ["AMC", "SIMPLE_CHEMICAL", 234, 237], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 252, 275], ["TZP", "SIMPLE_CHEMICAL", 277, 280], ["cefuroxime", "SIMPLE_CHEMICAL", 295, 305], ["CXM", "SIMPLE_CHEMICAL", 307, 310], ["trimethoprimsulfamethoxazole", "SIMPLE_CHEMICAL", 325, 353], ["SXT", "SIMPLE_CHEMICAL", 355, 358], ["ceftazidime", "SIMPLE_CHEMICAL", 373, 384], ["CAZ", "SIMPLE_CHEMICAL", 386, 389], ["cefepime", "SIMPLE_CHEMICAL", 404, 412], ["FEP", "SIMPLE_CHEMICAL", 414, 417], ["gentamicin", "SIMPLE_CHEMICAL", 432, 442], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 137, 145], ["E. coli", "SPECIES", 177, 184], ["E. coli", "SPECIES", 177, 184], ["Susceptibility pattern", "TEST", 0, 22], ["the 113 quinolone resistant isolates", "TREATMENT", 26, 62], ["antimicrobial agents", "TREATMENT", 72, 92], ["E. coli ampicillin", "TREATMENT", 177, 195], ["amoxicillinclavulanate (AMC)", "TREATMENT", 210, 238], ["piperacillin-tazobactam (TZP)", "TREATMENT", 252, 281], ["cefuroxime (CXM", "TREATMENT", 295, 310], ["trimethoprimsulfamethoxazole (SXT)", "TREATMENT", 325, 359], ["ceftazidime (CAZ)", "TREATMENT", 373, 390], ["cefepime (FEP", "TREATMENT", 404, 417], ["gentamicin", "TREATMENT", 432, 442]]], ["For K. pneumoniae AM 0%-0%, AMC 25%-0%, TZP 68.4%-100%, CXM 37.5%-100%, SXT 15.8%-100%, CAZ 37.5%-100%, FEP 41.7%-100%, GM 79.2%-100%.", [["TZP", "CHEMICAL", 40, 43], ["SXT", "CHEMICAL", 72, 75], ["CAZ", "CHEMICAL", 88, 91], ["GM", "CHEMICAL", 120, 122], ["K. pneumoniae", "SPECIES", 4, 17], ["K. pneumoniae", "SPECIES", 4, 17], ["K. pneumoniae", "TEST", 4, 17], ["AMC", "TEST", 28, 31], ["TZP", "TEST", 40, 43], ["CXM", "TEST", 56, 59], ["SXT", "TEST", 72, 75], ["CAZ", "TEST", 88, 91], ["FEP", "TEST", 104, 107], ["GM", "TEST", 120, 122], ["pneumoniae", "OBSERVATION", 7, 17]]], ["For P. mirabilis AM 9.5%-20%, AMC 23.8%-40%, TZP 90.5%-100%, CXM 25%-40%, SXT 4.8%-0%, CAZ 23.8%-40%, FEP 100%-100%, GM 56.3%-60%.", [["TZP", "CHEMICAL", 45, 48], ["SXT", "CHEMICAL", 74, 77], ["GM", "CHEMICAL", 117, 119], ["P. mirabilis AM", "ORGANISM", 4, 19], ["P. mirabilis", "SPECIES", 4, 16], ["P. mirabilis", "SPECIES", 4, 16], ["P. mirabilis", "TEST", 4, 16], ["AMC", "TEST", 30, 33], ["TZP", "TEST", 45, 48], ["CXM", "TEST", 61, 64], ["SXT", "TEST", 74, 77], ["CAZ", "TEST", 87, 90], ["FEP", "TEST", 102, 105]]], ["Seven strains of K. pneumoniae (29.2%) were carbapenem resistant and metallo-beta lactamase producing.", [["K. pneumoniae", "DISEASE", 17, 30], ["carbapenem", "CHEMICAL", 44, 54], ["metallo-beta lactamase", "CHEMICAL", 69, 91], ["carbapenem", "CHEMICAL", 44, 54], ["K. pneumoniae", "ORGANISM", 17, 30], ["metallo-beta lactamase", "SIMPLE_CHEMICAL", 69, 91], ["K. pneumoniae", "SPECIES", 17, 30], ["K. pneumoniae", "SPECIES", 17, 30], ["K. pneumoniae", "PROBLEM", 17, 30], ["carbapenem", "TREATMENT", 44, 54], ["metallo-beta lactamase", "TEST", 69, 91], ["pneumoniae", "OBSERVATION", 20, 30]]], ["Conclusions: High resistance rates to fluoroquinolones were observed in uropathogen bacteria isolated not only from hospitalized patients but also from patients with communityacquired urinary tract infections in Greece.", [["urinary tract", "ANATOMY", 184, 197], ["fluoroquinolones", "CHEMICAL", 38, 54], ["urinary tract infections", "DISEASE", 184, 208], ["fluoroquinolones", "CHEMICAL", 38, 54], ["fluoroquinolones", "SIMPLE_CHEMICAL", 38, 54], ["uropathogen bacteria", "CELL", 72, 92], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 152, 160], ["urinary tract", "ORGANISM_SUBDIVISION", 184, 197], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 152, 160], ["High resistance rates", "PROBLEM", 13, 34], ["fluoroquinolones", "TREATMENT", 38, 54], ["uropathogen bacteria", "PROBLEM", 72, 92], ["communityacquired urinary tract infections", "PROBLEM", 166, 208], ["High resistance", "OBSERVATION", 13, 28], ["urinary tract", "ANATOMY", 184, 197], ["infections", "OBSERVATION", 198, 208]]], ["Increasing resistance rates to the rest antibiotic agents make the treatment of urinary tract infections a very difficult problem.P1767Susceptibility of Pseudomonas aeruginosa isolated from the MYSTIC Programme to the carbapenems: meropenem and imipenem P.J. Turner (Macclesfield, UK)P1767Objectives: The Meropenem Yearly Susceptibility Test Information Collection Programme (MYSTIC) was initiated in 1997 in order to track the susceptibility of organisms in centres that were prescribing meropenem.", [["urinary tract", "ANATOMY", 80, 93], ["urinary tract infections", "DISEASE", 80, 104], ["carbapenems", "CHEMICAL", 218, 229], ["meropenem", "CHEMICAL", 231, 240], ["imipenem", "CHEMICAL", 245, 253], ["Meropenem", "CHEMICAL", 305, 314], ["meropenem", "CHEMICAL", 489, 498], ["carbapenems", "CHEMICAL", 218, 229], ["meropenem", "CHEMICAL", 231, 240], ["imipenem", "CHEMICAL", 245, 253], ["meropenem", "CHEMICAL", 489, 498], ["urinary tract", "ORGANISM_SUBDIVISION", 80, 93], ["Pseudomonas aeruginosa", "ORGANISM", 153, 175], ["meropenem", "SIMPLE_CHEMICAL", 231, 240], ["imipenem", "SIMPLE_CHEMICAL", 245, 253], ["meropenem", "SIMPLE_CHEMICAL", 489, 498], ["Pseudomonas aeruginosa", "SPECIES", 153, 175], ["Pseudomonas aeruginosa", "SPECIES", 153, 175], ["Increasing resistance rates", "PROBLEM", 0, 27], ["the rest antibiotic agents", "TREATMENT", 31, 57], ["urinary tract infections", "PROBLEM", 80, 104], ["a very difficult problem", "PROBLEM", 105, 129], ["Pseudomonas aeruginosa", "PROBLEM", 153, 175], ["the carbapenems", "TREATMENT", 214, 229], ["meropenem", "TREATMENT", 231, 240], ["imipenem", "TREATMENT", 245, 253], ["The Meropenem", "TREATMENT", 301, 314], ["meropenem", "TREATMENT", 489, 498], ["resistance", "OBSERVATION", 11, 21], ["urinary tract", "ANATOMY", 80, 93], ["Pseudomonas", "OBSERVATION", 153, 164]]], ["This poster seeks to examine the susceptibility of Pseudomonas aeruginosa isolates over this period to the carbapenems; meropenem and imipenem and, in particular, records the susceptibility of imipenem-resistant isolates to meropenem and vice versa.", [["carbapenems", "CHEMICAL", 107, 118], ["meropenem", "CHEMICAL", 120, 129], ["imipenem", "CHEMICAL", 134, 142], ["imipenem", "CHEMICAL", 193, 201], ["meropenem", "CHEMICAL", 224, 233], ["carbapenems", "CHEMICAL", 107, 118], ["meropenem", "CHEMICAL", 120, 129], ["imipenem", "CHEMICAL", 134, 142], ["imipenem", "CHEMICAL", 193, 201], ["meropenem", "CHEMICAL", 224, 233], ["Pseudomonas aeruginosa", "ORGANISM", 51, 73], ["carbapenems", "SIMPLE_CHEMICAL", 107, 118], ["meropenem", "SIMPLE_CHEMICAL", 120, 129], ["imipenem", "SIMPLE_CHEMICAL", 134, 142], ["imipenem", "SIMPLE_CHEMICAL", 193, 201], ["meropenem", "SIMPLE_CHEMICAL", 224, 233], ["Pseudomonas aeruginosa", "SPECIES", 51, 73], ["Pseudomonas aeruginosa", "SPECIES", 51, 73], ["Pseudomonas aeruginosa isolates", "PROBLEM", 51, 82], ["the carbapenems", "TREATMENT", 103, 118], ["meropenem", "TREATMENT", 120, 129], ["imipenem", "TREATMENT", 134, 142], ["imipenem", "TREATMENT", 193, 201], ["meropenem", "TREATMENT", 224, 233]]], ["Methods: Pseudomonas aeruginosa isolates were speciated by the methods in current use at the participating centres.", [["Pseudomonas aeruginosa", "ORGANISM", 9, 31], ["Pseudomonas aeruginosa", "SPECIES", 9, 31], ["Pseudomonas aeruginosa", "SPECIES", 9, 31], ["Pseudomonas aeruginosa isolates", "PROBLEM", 9, 40]]], ["Minimum Inhibitory Concentrations of meropenem and imipenem were determined using reference methods described by CLSI.", [["meropenem", "CHEMICAL", 37, 46], ["imipenem", "CHEMICAL", 51, 59], ["meropenem", "CHEMICAL", 37, 46], ["imipenem", "CHEMICAL", 51, 59], ["meropenem", "SIMPLE_CHEMICAL", 37, 46], ["imipenem", "SIMPLE_CHEMICAL", 51, 59], ["meropenem", "TREATMENT", 37, 46], ["imipenem", "TREATMENT", 51, 59]]], ["Results: A total of 15709 isolates of Pseudomonas aeruginosa have been tested globally, of these 78.2% were susceptible to meropenem at the breakpoint of < 4 mg/L and 70.1% to imipenem.", [["meropenem", "CHEMICAL", 123, 132], ["imipenem", "CHEMICAL", 176, 184], ["meropenem", "CHEMICAL", 123, 132], ["imipenem", "CHEMICAL", 176, 184], ["Pseudomonas aeruginosa", "ORGANISM", 38, 60], ["meropenem", "SIMPLE_CHEMICAL", 123, 132], ["imipenem", "SIMPLE_CHEMICAL", 176, 184], ["Pseudomonas aeruginosa", "SPECIES", 38, 60], ["Pseudomonas aeruginosa", "SPECIES", 38, 60], ["Pseudomonas aeruginosa", "PROBLEM", 38, 60], ["meropenem", "TREATMENT", 123, 132], ["imipenem", "TREATMENT", 176, 184]]], ["Globally, susceptibility to the two carbapenems has remained stable over the period 1997-2005, however when imipenem-resistant isolates were examined (n = 4625) 32.7% proved to be susceptible to meropenem, conversely of the 3359 meropenem-resistant isolates only 7.8% proved to be susceptible to imipenem.", [["carbapenems", "CHEMICAL", 36, 47], ["imipenem", "CHEMICAL", 108, 116], ["meropenem", "CHEMICAL", 195, 204], ["meropenem", "CHEMICAL", 229, 238], ["imipenem", "CHEMICAL", 296, 304], ["carbapenems", "CHEMICAL", 36, 47], ["imipenem", "CHEMICAL", 108, 116], ["meropenem", "CHEMICAL", 195, 204], ["meropenem", "CHEMICAL", 229, 238], ["imipenem", "CHEMICAL", 296, 304], ["imipenem", "SIMPLE_CHEMICAL", 108, 116], ["meropenem", "SIMPLE_CHEMICAL", 195, 204], ["meropenem", "SIMPLE_CHEMICAL", 229, 238], ["imipenem", "SIMPLE_CHEMICAL", 296, 304], ["the two carbapenems", "PROBLEM", 28, 47], ["imipenem", "TEST", 108, 116], ["resistant isolates", "PROBLEM", 117, 135], ["meropenem", "TREATMENT", 195, 204], ["meropenem", "TREATMENT", 229, 238], ["resistant isolates", "PROBLEM", 239, 257], ["imipenem", "TREATMENT", 296, 304], ["carbapenems", "OBSERVATION", 36, 47], ["stable", "OBSERVATION_MODIFIER", 61, 67]]], ["A similar pattern was seen when isolates were separated into global regions:USA 425 imipenem-resistant isolates, 25.4% susceptible to meropenemUSA 346 meropenem- Results: Bacteroides fragilis group (BAFG) accounted for 53% of the isolates, Fusobacterium spp. for 7%, other gram negative bacilli (OGNB) for 11%, Clostridia (CLOS) for 14%, nonsporeforming Gram-positive bacilli (NSFGPB) for 7% and cocci for 8%.", [["imipenem", "CHEMICAL", 84, 92], ["meropenemUSA 346", "CHEMICAL", 134, 150], ["meropenem", "CHEMICAL", 151, 160], ["imipenem", "CHEMICAL", 84, 92], ["meropenem", "CHEMICAL", 151, 160], ["imipenem", "SIMPLE_CHEMICAL", 84, 92], ["Bacteroides fragilis", "ORGANISM", 171, 191], ["BAFG", "CANCER", 199, 203], ["Fusobacterium spp.", "ORGANISM", 240, 258], ["Gram-positive bacilli", "GENE_OR_GENE_PRODUCT", 354, 375], ["Bacteroides fragilis group", "SPECIES", 171, 197], ["Fusobacterium spp.", "SPECIES", 240, 258], ["Bacteroides fragilis", "SPECIES", 171, 191], ["Fusobacterium spp.", "SPECIES", 240, 258], ["imipenem", "TEST", 84, 92], ["resistant isolates", "PROBLEM", 93, 111], ["meropenemUSA", "TEST", 134, 146], ["meropenem", "TREATMENT", 151, 160], ["Bacteroides fragilis", "PROBLEM", 171, 191], ["the isolates", "TEST", 226, 238], ["Fusobacterium spp.", "TEST", 240, 258], ["other gram negative bacilli", "TEST", 267, 294], ["OGNB", "TEST", 296, 300], ["Clostridia (CLOS)", "TEST", 311, 328], ["nonsporeforming Gram-positive bacilli", "PROBLEM", 338, 375], ["NSFGPB", "TEST", 377, 383], ["cocci", "TEST", 396, 401], ["bacilli", "OBSERVATION", 287, 294], ["cocci", "OBSERVATION", 396, 401]]], ["Beta-lactamases (BL) were detected in 61% of isolates.", [["Beta-lactamases", "CHEMICAL", 0, 15], ["Beta-lactamases", "GENE_OR_GENE_PRODUCT", 0, 15], ["BL", "CANCER", 17, 19], ["Beta-lactamases (BL)", "TEST", 0, 20]]], ["Most BL + strains belonged to BAFG (98%) and OGNB (70%).", [["BL + strains", "ANATOMY", 5, 17], ["BL + strains", "CELL", 5, 17], ["BAFG", "CANCER", 30, 34], ["strains", "PROBLEM", 10, 17], ["BAFG", "TEST", 30, 34], ["OGNB", "TEST", 45, 49]]], ["At NCCLS-recommended breakpoints, more than 95% of isolates were susceptible to TZP, MTZ, CHL and MEM, 92% to AMC but only 77%, 70%, 62% and 33% to FOX, CTT, CLI and PEN respectively.", [["TZP", "CHEMICAL", 80, 83], ["MTZ", "CHEMICAL", 85, 88], ["CHL", "CHEMICAL", 90, 93], ["MEM", "CHEMICAL", 98, 101], ["CLI", "DISEASE", 158, 161], ["PEN", "CHEMICAL", 166, 169], ["TZP", "CHEMICAL", 80, 83], ["MTZ", "CHEMICAL", 85, 88], ["CHL", "CHEMICAL", 90, 93], ["MEM", "CHEMICAL", 98, 101], ["TZP", "SIMPLE_CHEMICAL", 80, 83], ["MTZ", "SIMPLE_CHEMICAL", 85, 88], ["CHL", "SIMPLE_CHEMICAL", 90, 93], ["NCCLS", "TEST", 3, 8], ["breakpoints", "PROBLEM", 21, 32], ["isolates", "PROBLEM", 51, 59], ["TZP", "TREATMENT", 80, 83], ["MTZ", "TREATMENT", 85, 88], ["AMC", "TEST", 110, 113], ["CTT", "TEST", 153, 156]]], ["No NCCLS-breakpoints for anaerobes are available for MXF, LZD and TIG.", [["MXF", "CHEMICAL", 53, 56], ["LZD", "CHEMICAL", 58, 61], ["TIG", "CHEMICAL", 66, 69], ["MXF", "CHEMICAL", 53, 56], ["LZD", "CHEMICAL", 58, 61], ["TIG", "CHEMICAL", 66, 69], ["MXF", "SIMPLE_CHEMICAL", 53, 56], ["LZD", "SIMPLE_CHEMICAL", 58, 61], ["TIG", "SIMPLE_CHEMICAL", 66, 69], ["NCCLS", "PROBLEM", 3, 8], ["anaerobes", "PROBLEM", 25, 34], ["MXF", "TREATMENT", 53, 56], ["LZD", "TREATMENT", 58, 61], ["TIG", "TREATMENT", 66, 69], ["NCCLS", "OBSERVATION", 3, 8]]], ["MIC 50 and MIC 90 for MXF were 1 and 64 mg/L, for LZD 2 and 4 mg/L and for TIG 0.5-8 mg/L. In comparison with similar surveys conducted in 1987 and 1993 -1994 susceptibility of BAFG to clindamycin decreased from 83% in 1987 , to 66% in 1993 -1994 and 48% in 2004 In BAFG 92% of B. fragilis and 78% of non-B. fragilis were susceptible to AMC in this study; in 1993-1994 susceptibility in these groups was 95% and 89% and in 1987-97% and 94% respectively.", [["MIC", "CHEMICAL", 0, 3], ["MIC", "CHEMICAL", 11, 14], ["MXF", "CHEMICAL", 22, 25], ["LZD", "CHEMICAL", 50, 53], ["TIG", "CHEMICAL", 75, 78], ["BAFG", "CHEMICAL", 177, 181], ["clindamycin", "CHEMICAL", 185, 196], ["AMC", "CHEMICAL", 337, 340], ["clindamycin", "CHEMICAL", 185, 196], ["MXF", "SIMPLE_CHEMICAL", 22, 25], ["clindamycin", "SIMPLE_CHEMICAL", 185, 196], ["B. fragilis", "ORGANISM", 278, 289], ["non-B. fragilis", "ORGANISM", 301, 316], ["B. fragilis", "SPECIES", 278, 289], ["non-B. fragilis", "SPECIES", 301, 316], ["B. fragilis", "SPECIES", 278, 289], ["non-B. fragilis", "SPECIES", 301, 316], ["MXF", "TEST", 22, 25], ["LZD", "TREATMENT", 50, 53], ["TIG", "TREATMENT", 75, 78], ["BAFG", "TEST", 177, 181], ["clindamycin", "TEST", 185, 196], ["BAFG", "TEST", 266, 270], ["B. fragilis", "TEST", 278, 289], ["non-B. fragilis", "PROBLEM", 301, 316], ["this study", "TEST", 344, 354]]], ["All isolates, except 6 BAFG and 1 CLOS, were susceptible to MEM.", [["MEM", "CHEMICAL", 60, 63]]], ["98% of the isolates were susceptible to CHL.", [["CHL", "CHEMICAL", 40, 43], ["CHL", "CHEMICAL", 40, 43], ["CHL", "CANCER", 40, 43], ["the isolates", "TEST", 7, 19]]], ["Susceptibility to MTZ remains stable and is high in all groups except NSFGPB where MTZ is active on merely 35% of the isolates.", [["MTZ", "CHEMICAL", 18, 21], ["MTZ", "CHEMICAL", 83, 86], ["MTZ", "CHEMICAL", 18, 21], ["MTZ", "CHEMICAL", 83, 86], ["MTZ", "SIMPLE_CHEMICAL", 18, 21], ["MTZ", "SIMPLE_CHEMICAL", 83, 86], ["MTZ", "TEST", 18, 21], ["stable", "OBSERVATION_MODIFIER", 30, 36], ["high", "OBSERVATION_MODIFIER", 44, 48], ["MTZ", "OBSERVATION_MODIFIER", 83, 86], ["active", "OBSERVATION_MODIFIER", 90, 96]]], ["Conclusions: TZP, MEM and MTZ remain very potent antimicrobial agents in the treatment of anaerobic infections.", [["TZP", "CHEMICAL", 13, 16], ["MEM", "CHEMICAL", 18, 21], ["MTZ", "CHEMICAL", 26, 29], ["anaerobic infections", "DISEASE", 90, 110], ["TZP", "CHEMICAL", 13, 16], ["MEM", "CHEMICAL", 18, 21], ["MTZ", "CHEMICAL", 26, 29], ["TZP", "SIMPLE_CHEMICAL", 13, 16], ["MEM", "SIMPLE_CHEMICAL", 18, 21], ["MTZ", "SIMPLE_CHEMICAL", 26, 29], ["TZP, MEM and MTZ", "TREATMENT", 13, 29], ["antimicrobial agents", "TREATMENT", 49, 69], ["anaerobic infections", "PROBLEM", 90, 110], ["anaerobic infections", "OBSERVATION", 90, 110]]], ["Although still rare, resistant organisms were detected to each of them.", [["resistant organisms", "PROBLEM", 21, 40], ["resistant", "OBSERVATION_MODIFIER", 21, 30], ["organisms", "OBSERVATION", 31, 40]]], ["Therefore susceptibility testing of anaerobic isolates is indicated in severe infections to confirm appropriateness of antimicrobial therapy.", [["infections", "DISEASE", 78, 88], ["susceptibility testing of anaerobic isolates", "TEST", 10, 54], ["severe infections", "PROBLEM", 71, 88], ["antimicrobial therapy", "TREATMENT", 119, 140], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["infections", "OBSERVATION", 78, 88], ["antimicrobial therapy", "OBSERVATION", 119, 140]]], ["Further monitoring of background susceptibility is necessary to guide empiric treatment.P1769Comparative in vitro activity of levofloxacin against Escherichia coli isolated from acute pyelonephritis in france in 2005 C.J. Soussy, C. Lascols, C. Dib-Smahi and The Multicenter Group Study.P1769Objectives: The objective of this study was to evaluate the in vitro activity of levofloxacin (LVX) comparatively to other antibiotics against Escherichia coli strains isolated from acute pyelonephritis in women consulting Emerging rooms by 23 French hospitals in 2005.", [["levofloxacin", "CHEMICAL", 126, 138], ["pyelonephritis", "DISEASE", 184, 198], ["levofloxacin", "CHEMICAL", 373, 385], ["LVX", "CHEMICAL", 387, 390], ["acute pyelonephritis", "DISEASE", 474, 494], ["levofloxacin", "CHEMICAL", 126, 138], ["levofloxacin", "CHEMICAL", 373, 385], ["LVX", "CHEMICAL", 387, 390], ["levofloxacin", "SIMPLE_CHEMICAL", 126, 138], ["Escherichia coli", "ORGANISM", 147, 163], ["levofloxacin", "SIMPLE_CHEMICAL", 373, 385], ["LVX", "SIMPLE_CHEMICAL", 387, 390], ["Escherichia coli", "ORGANISM", 435, 451], ["women", "ORGANISM", 498, 503], ["Escherichia coli", "SPECIES", 147, 163], ["Escherichia coli", "SPECIES", 435, 451], ["women", "SPECIES", 498, 503], ["Escherichia coli", "SPECIES", 147, 163], ["Escherichia coli", "SPECIES", 435, 451], ["Further monitoring", "TEST", 0, 18], ["background susceptibility", "PROBLEM", 22, 47], ["empiric treatment", "TREATMENT", 70, 87], ["levofloxacin", "TREATMENT", 126, 138], ["Escherichia coli", "PROBLEM", 147, 163], ["acute pyelonephritis", "PROBLEM", 178, 198], ["The Multicenter Group Study", "TEST", 259, 286], ["this study", "TEST", 321, 331], ["levofloxacin (LVX)", "TREATMENT", 373, 391], ["other antibiotics", "TREATMENT", 409, 426], ["Escherichia coli strains", "PROBLEM", 435, 459], ["acute pyelonephritis", "PROBLEM", 474, 494], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["pyelonephritis", "OBSERVATION", 184, 198], ["acute", "OBSERVATION_MODIFIER", 474, 479], ["pyelonephritis", "OBSERVATION", 480, 494]]], ["Methods: MICs of LVX, ofloxacin (OFX), ciprofloxacin (CIP), nalidixic acid (NAL), amoxicillin-clavulanic acid (AMC), ceftriaxone (CRO), cefixime (CFM), amikacin (AN), gentamicin (GM) and cotrimoxazole (SXT) were determined by agar dilution according to the EUCAST breakpoints approved by 2005 recommendations of the Comit\u00e9 de l'Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie.", [["LVX", "CHEMICAL", 17, 20], ["ofloxacin", "CHEMICAL", 22, 31], ["OFX", "CHEMICAL", 33, 36], ["ciprofloxacin", "CHEMICAL", 39, 52], ["CIP", "CHEMICAL", 54, 57], ["nalidixic acid", "CHEMICAL", 60, 74], ["NAL", "CHEMICAL", 76, 79], ["amoxicillin-clavulanic acid", "CHEMICAL", 82, 109], ["AMC", "CHEMICAL", 111, 114], ["ceftriaxone", "CHEMICAL", 117, 128], ["CRO", "CHEMICAL", 130, 133], ["cefixime", "CHEMICAL", 136, 144], ["CFM", "CHEMICAL", 146, 149], ["amikacin", "CHEMICAL", 152, 160], ["AN", "CHEMICAL", 162, 164], ["gentamicin", "CHEMICAL", 167, 177], ["GM", "CHEMICAL", 179, 181], ["cotrimoxazole", "CHEMICAL", 187, 200], ["SXT", "CHEMICAL", 202, 205], ["LVX", "CHEMICAL", 17, 20], ["ofloxacin", "CHEMICAL", 22, 31], ["OFX", "CHEMICAL", 33, 36], ["ciprofloxacin", "CHEMICAL", 39, 52], ["CIP", "CHEMICAL", 54, 57], ["nalidixic acid", "CHEMICAL", 60, 74], ["NAL", "CHEMICAL", 76, 79], ["amoxicillin-clavulanic acid", "CHEMICAL", 82, 109], ["AMC", "CHEMICAL", 111, 114], ["ceftriaxone", "CHEMICAL", 117, 128], ["CRO", "CHEMICAL", 130, 133], ["cefixime", "CHEMICAL", 136, 144], ["CFM", "CHEMICAL", 146, 149], ["amikacin", "CHEMICAL", 152, 160], ["gentamicin", "CHEMICAL", 167, 177], ["cotrimoxazole", "CHEMICAL", 187, 200], ["SXT", "CHEMICAL", 202, 205], ["LVX", "SIMPLE_CHEMICAL", 17, 20], ["ofloxacin", "SIMPLE_CHEMICAL", 22, 31], ["OFX", "SIMPLE_CHEMICAL", 33, 36], ["ciprofloxacin", "SIMPLE_CHEMICAL", 39, 52], ["CIP", "SIMPLE_CHEMICAL", 54, 57], ["nalidixic acid", "SIMPLE_CHEMICAL", 60, 74], ["NAL", "SIMPLE_CHEMICAL", 76, 79], ["amoxicillin-clavulanic acid", "SIMPLE_CHEMICAL", 82, 109], ["AMC", "SIMPLE_CHEMICAL", 111, 114], ["ceftriaxone", "SIMPLE_CHEMICAL", 117, 128], ["CRO", "SIMPLE_CHEMICAL", 130, 133], ["cefixime", "SIMPLE_CHEMICAL", 136, 144], ["CFM", "SIMPLE_CHEMICAL", 146, 149], ["amikacin", "SIMPLE_CHEMICAL", 152, 160], ["AN", "SIMPLE_CHEMICAL", 162, 164], ["gentamicin", "SIMPLE_CHEMICAL", 167, 177], ["GM", "SIMPLE_CHEMICAL", 179, 181], ["cotrimoxazole", "SIMPLE_CHEMICAL", 187, 200], ["SXT", "SIMPLE_CHEMICAL", 202, 205], ["MICs of LVX", "TREATMENT", 9, 20], ["ofloxacin (OFX)", "TREATMENT", 22, 37], ["ciprofloxacin (CIP)", "TREATMENT", 39, 58], ["nalidixic acid (NAL)", "TREATMENT", 60, 80], ["amoxicillin", "TREATMENT", 82, 93], ["clavulanic acid (AMC)", "TREATMENT", 94, 115], ["ceftriaxone (CRO)", "TREATMENT", 117, 134], ["cefixime (CFM)", "TREATMENT", 136, 150], ["amikacin", "TREATMENT", 152, 160], ["gentamicin (GM)", "TREATMENT", 167, 182], ["cotrimoxazole (SXT", "TREATMENT", 187, 205]]], ["Quality control was performed with E. coli strain ATCC 25922.", [["E. coli", "ORGANISM", 35, 42], ["ATCC 25922", "CELL", 50, 60], ["E. coli", "SPECIES", 35, 42], ["E. coli", "SPECIES", 35, 42], ["ATCC 25922", "SPECIES", 50, 60], ["E. coli strain ATCC", "PROBLEM", 35, 54]]], ["46.3% of strains were isolated from urinary samples, 10.8 % from blood culture and 42.9% from the two specimens.", [["strains", "ANATOMY", 9, 16], ["urinary samples", "ANATOMY", 36, 51], ["blood culture", "ANATOMY", 65, 78], ["specimens", "ANATOMY", 102, 111], ["urinary samples", "ORGANISM_SUBSTANCE", 36, 51], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["strains", "PROBLEM", 9, 16], ["urinary samples", "TEST", 36, 51], ["blood culture", "TEST", 65, 78], ["the two specimens", "TEST", 94, 111], ["urinary", "ANATOMY", 36, 43]]], ["MICs 50/90 (mg/L), the range of MICs and the percentage of susceptibility (%) are presented in the following table: Concerning the fluoroquinolones, MICs50/90 of LVX were one/two dilution lower than those of OFX and two/one dilution higher than those of CIP.", [["MICs", "CHEMICAL", 0, 4], ["fluoroquinolones", "CHEMICAL", 131, 147], ["MICs50/90", "CHEMICAL", 149, 158], ["LVX", "CHEMICAL", 162, 165], ["OFX", "CHEMICAL", 208, 211], ["fluoroquinolones", "CHEMICAL", 131, 147], ["LVX", "CHEMICAL", 162, 165], ["fluoroquinolones", "SIMPLE_CHEMICAL", 131, 147], ["MICs50/90", "SIMPLE_CHEMICAL", 149, 158], ["LVX", "SIMPLE_CHEMICAL", 162, 165], ["OFX", "SIMPLE_CHEMICAL", 208, 211], ["MICs", "TEST", 0, 4], ["MICs", "TREATMENT", 32, 36], ["the fluoroquinolones", "TREATMENT", 127, 147], ["LVX", "TREATMENT", 162, 165], ["OFX", "TREATMENT", 208, 211], ["CIP", "TREATMENT", 254, 257]]], ["For the other antibiotics, a higher percentage of susceptibility was observed with CRO and AN, when a lower percentage of susceptibility was observed with AMC and SXT.P1769Conclusions: Levofloxacin exhibited good in vitro activity against E. coli strains isolated from acute pyelonephritis with 93.1% of susceptible strains.P1770In vitro activity of double and triple combinations of colistin, imipenem, rifampicin and linezolid against epidemic strains of multidrug-resistant Acinetobacter baumannii producing OXA carbapenamases D.W. Wareham, D.C. Bean (London, UK)P1770Objectives: A. baumannii has emerged as an important cause of nosocomial infection in critically ill patients worldwide.", [["CRO", "CHEMICAL", 83, 86], ["SXT", "CHEMICAL", 163, 166], ["Levofloxacin", "CHEMICAL", 185, 197], ["pyelonephritis", "DISEASE", 275, 289], ["colistin", "CHEMICAL", 384, 392], ["imipenem", "CHEMICAL", 394, 402], ["rifampicin", "CHEMICAL", 404, 414], ["linezolid", "CHEMICAL", 419, 428], ["OXA", "CHEMICAL", 511, 514], ["nosocomial infection", "DISEASE", 633, 653], ["critically ill", "DISEASE", 657, 671], ["SXT", "CHEMICAL", 163, 166], ["Levofloxacin", "CHEMICAL", 185, 197], ["colistin", "CHEMICAL", 384, 392], ["imipenem", "CHEMICAL", 394, 402], ["rifampicin", "CHEMICAL", 404, 414], ["linezolid", "CHEMICAL", 419, 428], ["CRO", "SIMPLE_CHEMICAL", 83, 86], ["SXT", "SIMPLE_CHEMICAL", 163, 166], ["Levofloxacin", "SIMPLE_CHEMICAL", 185, 197], ["E. coli", "ORGANISM", 239, 246], ["strains", "ORGANISM", 247, 254], ["colistin", "SIMPLE_CHEMICAL", 384, 392], ["imipenem", "SIMPLE_CHEMICAL", 394, 402], ["rifampicin", "SIMPLE_CHEMICAL", 404, 414], ["linezolid", "SIMPLE_CHEMICAL", 419, 428], ["multidrug-resistant", "ORGANISM", 457, 476], ["Acinetobacter baumannii", "ORGANISM", 477, 500], ["OXA carbapenamases", "SIMPLE_CHEMICAL", 511, 529], ["A. baumannii", "ORGANISM", 583, 595], ["patients", "ORGANISM", 672, 680], ["E. coli", "SPECIES", 239, 246], ["Acinetobacter baumannii", "SPECIES", 477, 500], ["A. baumannii", "SPECIES", 583, 595], ["patients", "SPECIES", 672, 680], ["E. coli", "SPECIES", 239, 246], ["Acinetobacter baumannii", "SPECIES", 477, 500], ["A. baumannii", "SPECIES", 583, 595], ["the other antibiotics", "TREATMENT", 4, 25], ["Levofloxacin", "TREATMENT", 185, 197], ["E. coli strains", "PROBLEM", 239, 254], ["acute pyelonephritis", "PROBLEM", 269, 289], ["susceptible strains", "PROBLEM", 304, 323], ["double and triple combinations", "TREATMENT", 350, 380], ["colistin", "TREATMENT", 384, 392], ["imipenem", "TREATMENT", 394, 402], ["rifampicin", "TREATMENT", 404, 414], ["linezolid", "TREATMENT", 419, 428], ["multidrug-resistant Acinetobacter baumannii", "PROBLEM", 457, 500], ["baumannii", "PROBLEM", 586, 595], ["nosocomial infection", "PROBLEM", 633, 653], ["acute", "OBSERVATION_MODIFIER", 269, 274], ["pyelonephritis", "OBSERVATION", 275, 289], ["nosocomial", "OBSERVATION_MODIFIER", 633, 643], ["infection", "OBSERVATION", 644, 653]]], ["In the UK three strains in particular exhibiting multi-drug resistance and producing OXA carbapenamases have been responsible for ongoing outbreaks.", [["OXA", "CHEMICAL", 85, 88], ["OXA", "CHEMICAL", 85, 88], ["OXA carbapenamases", "SIMPLE_CHEMICAL", 85, 103], ["multi-drug resistance", "PROBLEM", 49, 70], ["OXA carbapenamases", "PROBLEM", 85, 103], ["drug resistance", "OBSERVATION", 55, 70]]], ["Treatment options for infection with these organisms are limited as only colistin and tigecycline retaining significant activity in vitro.", [["infection", "DISEASE", 22, 31], ["colistin", "CHEMICAL", 73, 81], ["tigecycline", "CHEMICAL", 86, 97], ["colistin", "CHEMICAL", 73, 81], ["tigecycline", "CHEMICAL", 86, 97], ["colistin", "SIMPLE_CHEMICAL", 73, 81], ["tigecycline", "SIMPLE_CHEMICAL", 86, 97], ["Treatment options", "TREATMENT", 0, 17], ["infection", "PROBLEM", 22, 31], ["these organisms", "PROBLEM", 37, 52], ["colistin", "TREATMENT", 73, 81], ["tigecycline", "TREATMENT", 86, 97]]], ["Animal models and in vitro studies using other multi-resistant strains suggest that drugs in combination with colistin may be effective.", [["colistin", "CHEMICAL", 110, 118], ["colistin", "CHEMICAL", 110, 118], ["colistin", "SIMPLE_CHEMICAL", 110, 118], ["Animal models", "TEST", 0, 13], ["vitro studies", "TEST", 21, 34], ["other multi-resistant strains", "PROBLEM", 41, 70], ["drugs", "TREATMENT", 84, 89], ["colistin", "TREATMENT", 110, 118]]], ["We assessed the activity of colistin in combinations including imipenem, rifampicin and linezolid against epidemic strains from a recent UK outbreak.", [["colistin", "CHEMICAL", 28, 36], ["imipenem", "CHEMICAL", 63, 71], ["rifampicin", "CHEMICAL", 73, 83], ["linezolid", "CHEMICAL", 88, 97], ["colistin", "CHEMICAL", 28, 36], ["imipenem", "CHEMICAL", 63, 71], ["rifampicin", "CHEMICAL", 73, 83], ["linezolid", "CHEMICAL", 88, 97], ["colistin", "SIMPLE_CHEMICAL", 28, 36], ["imipenem", "SIMPLE_CHEMICAL", 63, 71], ["rifampicin", "SIMPLE_CHEMICAL", 73, 83], ["linezolid", "SIMPLE_CHEMICAL", 88, 97], ["colistin", "TREATMENT", 28, 36], ["imipenem", "TREATMENT", 63, 71], ["rifampicin", "TREATMENT", 73, 83], ["linezolid", "TREATMENT", 88, 97], ["epidemic strains", "PROBLEM", 106, 122]]], ["Methods: Isolates of A. baumannii exhibiting resistance to carbapenems were recovered from patients at Barts and The London NHS.", [["carbapenems", "CHEMICAL", 59, 70], ["carbapenems", "CHEMICAL", 59, 70], ["A. baumannii", "ORGANISM", 21, 33], ["carbapenems", "SIMPLE_CHEMICAL", 59, 70], ["patients", "ORGANISM", 91, 99], ["A. baumannii", "SPECIES", 21, 33], ["patients", "SPECIES", 91, 99], ["A. baumannii", "SPECIES", 21, 33], ["A. baumannii", "PROBLEM", 21, 33], ["carbapenems", "TREATMENT", 59, 70]]], ["Isolates were referred to the Health Protection Agency and confirmed as belonging to clones producing OXA carbapenemases.", [["OXA", "CHEMICAL", 102, 105], ["clones", "CELL", 85, 91], ["OXA carbapenemases", "SIMPLE_CHEMICAL", 102, 120], ["OXA carbapenemases", "PROTEIN", 102, 120], ["OXA carbapenemases", "PROBLEM", 102, 120]]], ["Activities of polymyxin, imipenem, rifampicin and linezolid alone and in double and triple combinations were determined using standard chequerboard assays with increasing concentrations of drug 1 on the x axis, drug 2 on the y axis and drug three in multiple replicate plates.", [["polymyxin", "CHEMICAL", 14, 23], ["imipenem", "CHEMICAL", 25, 33], ["rifampicin", "CHEMICAL", 35, 45], ["linezolid", "CHEMICAL", 50, 59], ["polymyxin", "CHEMICAL", 14, 23], ["imipenem", "CHEMICAL", 25, 33], ["rifampicin", "CHEMICAL", 35, 45], ["linezolid", "CHEMICAL", 50, 59], ["polymyxin", "SIMPLE_CHEMICAL", 14, 23], ["imipenem", "SIMPLE_CHEMICAL", 25, 33], ["rifampicin", "SIMPLE_CHEMICAL", 35, 45], ["linezolid", "SIMPLE_CHEMICAL", 50, 59], ["polymyxin", "TREATMENT", 14, 23], ["imipenem", "TREATMENT", 25, 33], ["rifampicin", "TREATMENT", 35, 45], ["linezolid", "TREATMENT", 50, 59], ["double and triple combinations", "TREATMENT", 73, 103], ["standard chequerboard assays", "TEST", 126, 154], ["increasing concentrations of drug", "TREATMENT", 160, 193], ["drug", "TREATMENT", 211, 215], ["drug", "TREATMENT", 236, 240], ["replicate plates", "OBSERVATION", 259, 275]]], ["After incubation at 24 hours wells were examined for growth and MIC's determined for each combination.", [["MIC's", "TEST", 64, 69]]], ["Synergy between agents was defined as a fixed inhibitory concentration index (FICI) of < 0.5.", [["Synergy between agents", "TREATMENT", 0, 22], ["a fixed inhibitory concentration index", "TEST", 38, 76]]], ["Results: The isolates tested belonged to the OXA-23 clone 1, OXA-23 clone 2 and the South East Clone, as confired by the HPA.", [["OXA", "CHEMICAL", 45, 48], ["OXA", "CHEMICAL", 61, 64], ["OXA-23 clone 2", "CELL", 61, 75], ["The isolates", "TEST", 9, 21], ["the OXA", "TEST", 41, 48], ["OXA", "TEST", 61, 64]]], ["Colistin was the most active agent alone with MICs from 1-2 mg/L. Imipenem MIC's varied from 4-32 mg/L. The most active combinations were colistin plus rifampicin (FICI = 0.38) and colistin, rifampicin and imipenem (FICI = 0.39).", [["Colistin", "CHEMICAL", 0, 8], ["MICs", "CHEMICAL", 46, 50], ["Imipenem", "CHEMICAL", 66, 74], ["MIC", "CHEMICAL", 75, 78], ["colistin", "CHEMICAL", 138, 146], ["rifampicin", "CHEMICAL", 152, 162], ["FICI", "CHEMICAL", 164, 168], ["colistin", "CHEMICAL", 181, 189], ["rifampicin", "CHEMICAL", 191, 201], ["imipenem", "CHEMICAL", 206, 214], ["FICI", "CHEMICAL", 216, 220], ["Colistin", "CHEMICAL", 0, 8], ["Imipenem", "CHEMICAL", 66, 74], ["colistin", "CHEMICAL", 138, 146], ["rifampicin", "CHEMICAL", 152, 162], ["colistin", "CHEMICAL", 181, 189], ["rifampicin", "CHEMICAL", 191, 201], ["imipenem", "CHEMICAL", 206, 214], ["Colistin", "SIMPLE_CHEMICAL", 0, 8], ["MICs", "SIMPLE_CHEMICAL", 46, 50], ["Imipenem MIC", "SIMPLE_CHEMICAL", 66, 78], ["colistin", "SIMPLE_CHEMICAL", 138, 146], ["rifampicin", "SIMPLE_CHEMICAL", 152, 162], ["FICI", "SIMPLE_CHEMICAL", 164, 168], ["colistin", "SIMPLE_CHEMICAL", 181, 189], ["rifampicin", "SIMPLE_CHEMICAL", 191, 201], ["imipenem", "SIMPLE_CHEMICAL", 206, 214], ["Colistin", "TREATMENT", 0, 8], ["MICs", "TREATMENT", 46, 50], ["Imipenem MIC's", "TREATMENT", 66, 80], ["colistin", "TREATMENT", 138, 146], ["rifampicin", "TREATMENT", 152, 162], ["FICI", "TREATMENT", 164, 168], ["colistin", "TREATMENT", 181, 189], ["rifampicin", "TREATMENT", 191, 201], ["imipenem", "TREATMENT", 206, 214], ["FICI", "TEST", 216, 220]]], ["Synergy was not seen with colistin in combination with imipenem alone.", [["colistin", "CHEMICAL", 26, 34], ["imipenem", "CHEMICAL", 55, 63], ["colistin", "CHEMICAL", 26, 34], ["imipenem", "CHEMICAL", 55, 63], ["colistin", "SIMPLE_CHEMICAL", 26, 34], ["imipenem", "SIMPLE_CHEMICAL", 55, 63], ["Synergy", "TREATMENT", 0, 7], ["colistin", "TREATMENT", 26, 34], ["imipenem", "TREATMENT", 55, 63]]], ["Linezolid in combination with colistin (FICI = 0.37), or imipenem (FICI = 0.38) was synergistic but at therapeutically unobtainable linezolid concentrations (64 mg/L).", [["Linezolid", "CHEMICAL", 0, 9], ["colistin", "CHEMICAL", 30, 38], ["FICI", "CHEMICAL", 40, 44], ["imipenem", "CHEMICAL", 57, 65], ["FICI", "CHEMICAL", 67, 71], ["linezolid", "CHEMICAL", 132, 141], ["Linezolid", "CHEMICAL", 0, 9], ["colistin", "CHEMICAL", 30, 38], ["imipenem", "CHEMICAL", 57, 65], ["linezolid", "CHEMICAL", 132, 141], ["Linezolid", "SIMPLE_CHEMICAL", 0, 9], ["colistin", "SIMPLE_CHEMICAL", 30, 38], ["FICI", "SIMPLE_CHEMICAL", 40, 44], ["imipenem", "SIMPLE_CHEMICAL", 57, 65], ["linezolid", "SIMPLE_CHEMICAL", 132, 141], ["Linezolid", "TREATMENT", 0, 9], ["colistin", "TREATMENT", 30, 38], ["FICI", "TEST", 40, 44], ["imipenem", "TREATMENT", 57, 65], ["FICI", "TEST", 67, 71], ["unobtainable linezolid concentrations", "TREATMENT", 119, 156]]], ["Conclusion: Multidrug resistant strains of A. baumannii from the UK producing OXA carbapenemases remain susceptible to polymyxin in vitro.", [["OXA", "CHEMICAL", 78, 81], ["polymyxin", "CHEMICAL", 119, 128], ["polymyxin", "CHEMICAL", 119, 128], ["A. baumannii", "ORGANISM", 43, 55], ["UK", "GENE_OR_GENE_PRODUCT", 65, 67], ["OXA", "GENE_OR_GENE_PRODUCT", 78, 81], ["polymyxin", "SIMPLE_CHEMICAL", 119, 128], ["A. baumannii", "SPECIES", 43, 55], ["A. baumannii", "SPECIES", 43, 55], ["Multidrug resistant strains", "PROBLEM", 12, 39], ["A. baumannii", "PROBLEM", 43, 55], ["OXA carbapenemases", "TREATMENT", 78, 96], ["polymyxin in vitro", "TREATMENT", 119, 137]]], ["Polymyxin exerts its effect on the bacterial cell wall; theoretically assisting other antibiotics to reach their respective targets, and seems a logical choice for inclusion in combination therapy.", [["cell wall", "ANATOMY", 45, 54], ["Polymyxin", "CHEMICAL", 0, 9], ["Polymyxin", "CHEMICAL", 0, 9], ["Polymyxin", "SIMPLE_CHEMICAL", 0, 9], ["cell wall", "TISSUE", 45, 54], ["Polymyxin", "TREATMENT", 0, 9], ["the bacterial cell wall", "PROBLEM", 31, 54], ["other antibiotics", "TREATMENT", 80, 97], ["combination therapy", "TREATMENT", 177, 196], ["bacterial cell", "OBSERVATION", 35, 49], ["wall", "ANATOMY_MODIFIER", 50, 54]]], ["We have shown that rifampicin is synergistic with polymyxin against these isolates in vitro and may be effective in treating severe A. baumannii infections in man.P1771A comparative in vitro evaluation of resistance development after exposure to teicoplanin, vancomycin, linezolid and quinupristin/ dalfopristin in Staphylococcus spp. and Enterococcus spp.", [["rifampicin", "CHEMICAL", 19, 29], ["polymyxin", "CHEMICAL", 50, 59], ["A. baumannii infections", "DISEASE", 132, 155], ["teicoplanin", "CHEMICAL", 246, 257], ["vancomycin", "CHEMICAL", 259, 269], ["linezolid", "CHEMICAL", 271, 280], ["quinupristin", "CHEMICAL", 285, 297], ["dalfopristin", "CHEMICAL", 299, 311], ["Staphylococcus spp.", "CHEMICAL", 315, 334], ["rifampicin", "CHEMICAL", 19, 29], ["polymyxin", "CHEMICAL", 50, 59], ["teicoplanin", "CHEMICAL", 246, 257], ["vancomycin", "CHEMICAL", 259, 269], ["linezolid", "CHEMICAL", 271, 280], ["quinupristin", "CHEMICAL", 285, 297], ["dalfopristin", "CHEMICAL", 299, 311], ["rifampicin", "SIMPLE_CHEMICAL", 19, 29], ["polymyxin", "SIMPLE_CHEMICAL", 50, 59], ["A. baumannii", "ORGANISM", 132, 144], ["man", "ORGANISM", 159, 162], ["teicoplanin", "SIMPLE_CHEMICAL", 246, 257], ["vancomycin", "SIMPLE_CHEMICAL", 259, 269], ["linezolid", "SIMPLE_CHEMICAL", 271, 280], ["quinupristin", "SIMPLE_CHEMICAL", 285, 297], ["dalfopristin", "SIMPLE_CHEMICAL", 299, 311], ["Staphylococcus spp.", "ORGANISM", 315, 334], ["Enterococcus spp", "ORGANISM", 339, 355], ["A. baumannii", "SPECIES", 132, 144], ["man", "SPECIES", 159, 162], ["Staphylococcus spp.", "SPECIES", 315, 334], ["A. baumannii", "SPECIES", 132, 144], ["Staphylococcus spp.", "SPECIES", 315, 334], ["rifampicin", "TREATMENT", 19, 29], ["polymyxin", "TREATMENT", 50, 59], ["severe A. baumannii infections", "PROBLEM", 125, 155], ["vitro evaluation", "TEST", 185, 201], ["resistance development", "PROBLEM", 205, 227], ["teicoplanin", "TREATMENT", 246, 257], ["vancomycin", "TREATMENT", 259, 269], ["linezolid", "TREATMENT", 271, 280], ["quinupristin", "TREATMENT", 285, 297], ["dalfopristin", "TREATMENT", 299, 311], ["Staphylococcus spp.", "PROBLEM", 315, 334], ["Enterococcus spp", "PROBLEM", 339, 355], ["rifampicin", "OBSERVATION", 19, 29], ["baumannii", "OBSERVATION", 135, 144], ["Staphylococcus spp.", "OBSERVATION", 315, 334], ["Enterococcus spp", "OBSERVATION", 339, 355]]], ["MSSA, MRSE, MSSE, E. faecium and E. faecalis strains was determined on agar plates containing each antibiotic at CLSI resistance breakpoints and at peak blood concentrations.", [["blood", "ANATOMY", 153, 158], ["MSSA", "CHEMICAL", 0, 4], ["E. faecium", "ORGANISM", 18, 28], ["E. faecalis", "ORGANISM", 33, 44], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["E. faecium", "SPECIES", 18, 28], ["E. faecalis", "SPECIES", 33, 44], ["E. faecium", "SPECIES", 18, 28], ["E. faecalis", "SPECIES", 33, 44], ["MSSA", "PROBLEM", 0, 4], ["MRSE", "TEST", 6, 10], ["MSSE", "TEST", 12, 16], ["E. faecium", "PROBLEM", 18, 28], ["E. faecalis strains", "PROBLEM", 33, 52], ["agar plates", "TREATMENT", 71, 82], ["each antibiotic at CLSI resistance breakpoints", "TREATMENT", 94, 140], ["peak blood concentrations", "TEST", 148, 173], ["MRSE", "OBSERVATION", 6, 10], ["faecalis strains", "OBSERVATION", 36, 52]]], ["After incubation at 37\u00b0C for 48 h colonies were counted and compared to the inoculum to calculate frequency of mutation.", [["colonies", "ANATOMY", 34, 42], ["mutation", "PROBLEM", 111, 119]]], ["Colonies grown in plates containing antibiotics were sampled for determination of MIC values.", [["Colonies", "ANATOMY", 0, 8], ["MIC", "SIMPLE_CHEMICAL", 82, 85], ["antibiotics", "TREATMENT", 36, 47], ["MIC values", "TEST", 82, 92], ["plates", "OBSERVATION_MODIFIER", 18, 24]]], ["Results: Frequency of mutation was less than 10-9 for all the tested antibiotics at peak blood concentrations.", [["blood", "ANATOMY", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["mutation", "TEST", 22, 30], ["the tested antibiotics", "TREATMENT", 58, 80], ["peak blood concentrations", "TEST", 84, 109]]], ["Same results were obtained when breakpoint concentrations for each drug were used.", [["breakpoint concentrations", "PROBLEM", 32, 57], ["each drug", "TREATMENT", 62, 71]]], ["Conclusion: This one-step in vitro study demonstrated the ability of teicoplanin, vancomycin, linezolid and quinupristin/ dalfopristin to prevent growth of resistant mutants of staphylococci and enterococci, thus suggesting no occurrence of mutational events leading to resistance when bacteria are exposed to blood concentrations of these drugs.", [["staphylococci", "ANATOMY", 177, 190], ["blood", "ANATOMY", 310, 315], ["teicoplanin", "CHEMICAL", 69, 80], ["vancomycin", "CHEMICAL", 82, 92], ["linezolid", "CHEMICAL", 94, 103], ["quinupristin", "CHEMICAL", 108, 120], ["dalfopristin", "CHEMICAL", 122, 134], ["staphylococci", "DISEASE", 177, 190], ["teicoplanin", "CHEMICAL", 69, 80], ["vancomycin", "CHEMICAL", 82, 92], ["linezolid", "CHEMICAL", 94, 103], ["quinupristin", "CHEMICAL", 108, 120], ["dalfopristin", "CHEMICAL", 122, 134], ["teicoplanin", "SIMPLE_CHEMICAL", 69, 80], ["vancomycin", "SIMPLE_CHEMICAL", 82, 92], ["linezolid", "SIMPLE_CHEMICAL", 94, 103], ["quinupristin", "SIMPLE_CHEMICAL", 108, 120], ["dalfopristin", "SIMPLE_CHEMICAL", 122, 134], ["staphylococci", "CANCER", 177, 190], ["enterococci", "CANCER", 195, 206], ["blood", "ORGANISM_SUBSTANCE", 310, 315], ["vitro study", "TEST", 29, 40], ["teicoplanin", "TREATMENT", 69, 80], ["vancomycin", "TREATMENT", 82, 92], ["linezolid", "TREATMENT", 94, 103], ["quinupristin", "TREATMENT", 108, 120], ["dalfopristin", "TREATMENT", 122, 134], ["resistant mutants", "PROBLEM", 156, 173], ["staphylococci", "PROBLEM", 177, 190], ["enterococci", "PROBLEM", 195, 206], ["mutational events", "PROBLEM", 241, 258], ["bacteria", "PROBLEM", 286, 294], ["these drugs", "TREATMENT", 334, 345], ["staphylococci", "OBSERVATION", 177, 190], ["enterococci", "OBSERVATION", 195, 206], ["no occurrence", "UNCERTAINTY", 224, 237]]], ["In order to establish the development of resistance after in vitro serial exposure to the same antibiotics simulating different in vivo concentrations, further studies are needed and are now in progress (multi step induction of resistance).P1772In vitro activity of antimicrobial agents against Legionella obtained from hotel water systems in Turkey Objectives: The aim of this study was to evaluate the in vitro activity of colistin against endemic pan-resistant Acinetobacter baumannii (including resistance to imipenem) isolated during a 4 year period in a university hospital.", [["colistin", "CHEMICAL", 425, 433], ["imipenem", "CHEMICAL", 513, 521], ["colistin", "CHEMICAL", 425, 433], ["imipenem", "CHEMICAL", 513, 521], ["P1772In", "SIMPLE_CHEMICAL", 240, 247], ["Legionella", "ORGANISM", 295, 305], ["colistin", "SIMPLE_CHEMICAL", 425, 433], ["Acinetobacter baumannii", "ORGANISM", 464, 487], ["imipenem", "SIMPLE_CHEMICAL", 513, 521], ["Acinetobacter baumannii", "SPECIES", 464, 487], ["Acinetobacter baumannii", "SPECIES", 464, 487], ["resistance", "PROBLEM", 41, 51], ["vitro serial exposure", "TREATMENT", 61, 82], ["the same antibiotics", "TREATMENT", 86, 106], ["further studies", "TEST", 152, 167], ["antimicrobial agents", "TREATMENT", 266, 286], ["Legionella", "PROBLEM", 295, 305], ["this study", "TEST", 373, 383], ["colistin", "TREATMENT", 425, 433], ["endemic pan-resistant Acinetobacter baumannii", "PROBLEM", 442, 487], ["imipenem", "TREATMENT", 513, 521], ["resistance", "OBSERVATION", 41, 51], ["Acinetobacter baumannii", "OBSERVATION", 464, 487]]], ["Methods: 150 imipenem-resistant Acinetobacter spp. isolates were collected between January 2001 and October 2004, from a variety of clinical specimens of different patients attending distinct wards in a university teaching hospital.", [["specimens", "ANATOMY", 141, 150], ["imipenem", "CHEMICAL", 13, 21], ["imipenem", "CHEMICAL", 13, 21], ["imipenem", "SIMPLE_CHEMICAL", 13, 21], ["Acinetobacter spp.", "ORGANISM", 32, 50], ["patients", "ORGANISM", 164, 172], ["Acinetobacter spp.", "SPECIES", 32, 50], ["patients", "SPECIES", 164, 172], ["Acinetobacter spp.", "SPECIES", 32, 50], ["imipenem", "TREATMENT", 13, 21], ["resistant Acinetobacter spp. isolates", "PROBLEM", 22, 59]]], ["Isolates were identified by API32GN and by sequencing the 16S rRNA gene.", [["16S", "GENE_OR_GENE_PRODUCT", 58, 61], ["rRNA", "CELLULAR_COMPONENT", 62, 66], ["API32GN", "DNA", 28, 35], ["16S rRNA gene", "DNA", 58, 71], ["Isolates", "TEST", 0, 8]]], ["MICs of colistin were determined by agar dilution method, according to NCCLS susceptible breakpoint (\u00a3 2 mg/L).", [["colistin", "CHEMICAL", 8, 16], ["colistin", "CHEMICAL", 8, 16], ["colistin", "SIMPLE_CHEMICAL", 8, 16], ["colistin", "TREATMENT", 8, 16]]], ["PFGE (ApaI restriction enzyme) was performed.", [["ApaI restriction enzyme", "GENE_OR_GENE_PRODUCT", 6, 29], ["ApaI restriction enzyme", "PROTEIN", 6, 29], ["PFGE (ApaI restriction enzyme", "TEST", 0, 29]]], ["Results: 141 of 150 A. baumannii isolates (94%) were susceptible to colistin.", [["colistin", "CHEMICAL", 68, 76], ["colistin", "CHEMICAL", 68, 76], ["A. baumannii", "ORGANISM", 20, 32], ["colistin", "SIMPLE_CHEMICAL", 68, 76], ["A. baumannii", "SPECIES", 20, 32], ["A. baumannii", "SPECIES", 20, 32], ["baumannii isolates", "TEST", 23, 41], ["colistin", "TREATMENT", 68, 76]]], ["Colistin resistance (MIC \u2021 4 mg/L) was observed in 9 isolates (5 isolates with a MIC of \u2021 16 mg/L and 4 isolates with a MIC of 4 mg/L) recovered from different patients in distinct wards.", [["Colistin", "CHEMICAL", 0, 8], ["Colistin", "CHEMICAL", 0, 8], ["Colistin", "SIMPLE_CHEMICAL", 0, 8], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["Colistin resistance (MIC \u2021 4 mg/L)", "TREATMENT", 0, 34], ["a MIC", "TREATMENT", 79, 84], ["a MIC", "TREATMENT", 118, 123]]], ["Among these imipenem-and colistin-resistant isolates, 3 distinct PFGE patterns were identified (clones A, B, and C).", [["imipenem", "CHEMICAL", 12, 20], ["colistin", "CHEMICAL", 25, 33], ["imipenem", "CHEMICAL", 12, 20], ["colistin", "CHEMICAL", 25, 33], ["imipenem", "SIMPLE_CHEMICAL", 12, 20], ["colistin", "SIMPLE_CHEMICAL", 25, 33], ["B", "GENE_OR_GENE_PRODUCT", 106, 107], ["these imipenem", "TREATMENT", 6, 20], ["colistin", "TREATMENT", 25, 33], ["resistant isolates", "PROBLEM", 34, 52], ["distinct PFGE patterns", "TEST", 56, 78]]], ["Resistance to almost all beta-lactams (including carbapenems) and variable susceptibility to aztreonam, amikacin and tobramycin was a common feature of clone A. Isolates belonging to clone B showed resistance to imipenem, amoxicillin and its association with clavulanic acid (AMC), ureidopenicillins and their associations; susceptibility to ceftazidime; and variable behaviour to meropenem, cefepime, cefpirome and aztreonam.", [["carbapenems", "CHEMICAL", 49, 60], ["aztreonam", "CHEMICAL", 93, 102], ["amikacin", "CHEMICAL", 104, 112], ["tobramycin", "CHEMICAL", 117, 127], ["imipenem", "CHEMICAL", 212, 220], ["amoxicillin", "CHEMICAL", 222, 233], ["clavulanic acid", "CHEMICAL", 259, 274], ["AMC", "CHEMICAL", 276, 279], ["ureidopenicillins", "CHEMICAL", 282, 299], ["ceftazidime", "CHEMICAL", 342, 353], ["meropenem", "CHEMICAL", 381, 390], ["cefepime", "CHEMICAL", 392, 400], ["cefpirome", "CHEMICAL", 402, 411], ["aztreonam", "CHEMICAL", 416, 425], ["beta-lactams", "CHEMICAL", 25, 37], ["carbapenems", "CHEMICAL", 49, 60], ["aztreonam", "CHEMICAL", 93, 102], ["amikacin", "CHEMICAL", 104, 112], ["tobramycin", "CHEMICAL", 117, 127], ["imipenem", "CHEMICAL", 212, 220], ["amoxicillin", "CHEMICAL", 222, 233], ["clavulanic acid", "CHEMICAL", 259, 274], ["AMC", "CHEMICAL", 276, 279], ["ureidopenicillins", "CHEMICAL", 282, 299], ["ceftazidime", "CHEMICAL", 342, 353], ["meropenem", "CHEMICAL", 381, 390], ["cefepime", "CHEMICAL", 392, 400], ["cefpirome", "CHEMICAL", 402, 411], ["aztreonam", "CHEMICAL", 416, 425], ["beta-lactams", "GENE_OR_GENE_PRODUCT", 25, 37], ["carbapenems", "SIMPLE_CHEMICAL", 49, 60], ["aztreonam", "SIMPLE_CHEMICAL", 93, 102], ["amikacin", "SIMPLE_CHEMICAL", 104, 112], ["tobramycin", "SIMPLE_CHEMICAL", 117, 127], ["clone A. Isolates", "ORGANISM", 152, 169], ["clone B", "CELL", 183, 190], ["imipenem", "SIMPLE_CHEMICAL", 212, 220], ["amoxicillin", "SIMPLE_CHEMICAL", 222, 233], ["clavulanic acid", "SIMPLE_CHEMICAL", 259, 274], ["AMC", "SIMPLE_CHEMICAL", 276, 279], ["ureidopenicillins", "SIMPLE_CHEMICAL", 282, 299], ["ceftazidime", "SIMPLE_CHEMICAL", 342, 353], ["meropenem", "SIMPLE_CHEMICAL", 381, 390], ["cefepime", "SIMPLE_CHEMICAL", 392, 400], ["cefpirome", "SIMPLE_CHEMICAL", 402, 411], ["aztreonam", "SIMPLE_CHEMICAL", 416, 425], ["all beta-lactams", "TEST", 21, 37], ["carbapenems", "TREATMENT", 49, 60], ["variable susceptibility", "PROBLEM", 66, 89], ["aztreonam", "TREATMENT", 93, 102], ["amikacin", "TREATMENT", 104, 112], ["tobramycin", "TREATMENT", 117, 127], ["clone B", "TEST", 183, 190], ["imipenem", "TREATMENT", 212, 220], ["amoxicillin", "TREATMENT", 222, 233], ["clavulanic acid", "TREATMENT", 259, 274], ["ureidopenicillins", "TREATMENT", 282, 299], ["ceftazidime", "TREATMENT", 342, 353], ["meropenem", "TREATMENT", 381, 390], ["cefepime", "TREATMENT", 392, 400], ["cefpirome", "TREATMENT", 402, 411], ["aztreonam", "TREATMENT", 416, 425]]], ["The susceptibility profile to aminoglycosides was variable, differing from clone A in its susceptibility to netilmicin and minocycline.", [["aminoglycosides", "CHEMICAL", 30, 45], ["netilmicin", "CHEMICAL", 108, 118], ["minocycline", "CHEMICAL", 123, 134], ["aminoglycosides", "CHEMICAL", 30, 45], ["netilmicin", "CHEMICAL", 108, 118], ["minocycline", "CHEMICAL", 123, 134], ["aminoglycosides", "SIMPLE_CHEMICAL", 30, 45], ["netilmicin", "SIMPLE_CHEMICAL", 108, 118], ["minocycline", "SIMPLE_CHEMICAL", 123, 134], ["clone A", "CELL_LINE", 75, 82], ["aminoglycosides", "TREATMENT", 30, 45], ["netilmicin", "TREATMENT", 108, 118], ["minocycline", "TREATMENT", 123, 134]]], ["Clone C was resistant to imipenem, amoxicillin, AMC, piperacillin, piperacillin + tazobactam, ticarcillin and ticarcillin + clavulanic acid, but remained susceptible to meropenem, aztreonam, cefpirome, ceftazidime and cefepime.", [["imipenem", "CHEMICAL", 25, 33], ["amoxicillin", "CHEMICAL", 35, 46], ["AMC", "CHEMICAL", 48, 51], ["piperacillin", "CHEMICAL", 53, 65], ["piperacillin", "CHEMICAL", 67, 79], ["tazobactam", "CHEMICAL", 82, 92], ["ticarcillin", "CHEMICAL", 94, 105], ["ticarcillin + clavulanic acid", "CHEMICAL", 110, 139], ["meropenem", "CHEMICAL", 169, 178], ["aztreonam", "CHEMICAL", 180, 189], ["cefpirome", "CHEMICAL", 191, 200], ["ceftazidime", "CHEMICAL", 202, 213], ["cefepime", "CHEMICAL", 218, 226], ["imipenem", "CHEMICAL", 25, 33], ["amoxicillin", "CHEMICAL", 35, 46], ["AMC", "CHEMICAL", 48, 51], ["piperacillin", "CHEMICAL", 53, 65], ["piperacillin", "CHEMICAL", 67, 79], ["tazobactam", "CHEMICAL", 82, 92], ["ticarcillin", "CHEMICAL", 94, 105], ["ticarcillin", "CHEMICAL", 110, 121], ["clavulanic acid", "CHEMICAL", 124, 139], ["meropenem", "CHEMICAL", 169, 178], ["aztreonam", "CHEMICAL", 180, 189], ["cefpirome", "CHEMICAL", 191, 200], ["ceftazidime", "CHEMICAL", 202, 213], ["cefepime", "CHEMICAL", 218, 226], ["Clone C", "GENE_OR_GENE_PRODUCT", 0, 7], ["imipenem", "SIMPLE_CHEMICAL", 25, 33], ["amoxicillin", "SIMPLE_CHEMICAL", 35, 46], ["AMC", "SIMPLE_CHEMICAL", 48, 51], ["piperacillin", "SIMPLE_CHEMICAL", 53, 65], ["piperacillin + tazobactam", "SIMPLE_CHEMICAL", 67, 92], ["ticarcillin", "SIMPLE_CHEMICAL", 94, 105], ["ticarcillin + clavulanic acid", "SIMPLE_CHEMICAL", 110, 139], ["meropenem", "SIMPLE_CHEMICAL", 169, 178], ["aztreonam", "SIMPLE_CHEMICAL", 180, 189], ["cefpirome", "SIMPLE_CHEMICAL", 191, 200], ["ceftazidime", "SIMPLE_CHEMICAL", 202, 213], ["cefepime", "SIMPLE_CHEMICAL", 218, 226], ["Clone C", "PROBLEM", 0, 7], ["imipenem", "TREATMENT", 25, 33], ["amoxicillin", "TREATMENT", 35, 46], ["AMC", "TREATMENT", 48, 51], ["piperacillin", "TREATMENT", 53, 65], ["piperacillin", "TREATMENT", 67, 79], ["tazobactam", "TREATMENT", 82, 92], ["ticarcillin", "TREATMENT", 94, 105], ["ticarcillin", "TREATMENT", 110, 121], ["clavulanic acid", "TREATMENT", 124, 139], ["meropenem", "TREATMENT", 169, 178], ["aztreonam", "TREATMENT", 180, 189], ["cefpirome", "TREATMENT", 191, 200], ["ceftazidime", "TREATMENT", 202, 213], ["cefepime", "TREATMENT", 218, 226]]], ["Conclusion: Only colistin, one of the few effective drugs available against multi-drug-resistant Acinetobacter infections, showed in vitro activity against the majority of Acinetobacter spp. strains isolated within the sampled hospital.", [["colistin", "CHEMICAL", 17, 25], ["Acinetobacter infections", "DISEASE", 97, 121], ["colistin", "CHEMICAL", 17, 25], ["colistin", "SIMPLE_CHEMICAL", 17, 25], ["multi-drug", "ORGANISM", 76, 86], ["Acinetobacter infections", "ORGANISM", 97, 121], ["Acinetobacter spp", "ORGANISM", 172, 189], ["Acinetobacter spp", "SPECIES", 172, 189], ["colistin", "TREATMENT", 17, 25], ["the few effective drugs", "TREATMENT", 34, 57], ["multi-drug-resistant Acinetobacter infections", "PROBLEM", 76, 121], ["Acinetobacter spp", "PROBLEM", 172, 189], ["strains", "PROBLEM", 191, 198], ["resistant", "OBSERVATION_MODIFIER", 87, 96], ["Acinetobacter", "OBSERVATION", 97, 110], ["Acinetobacter spp", "OBSERVATION", 172, 189]]], ["The observed 6% A. baumannii resistance to the recently re-introduced colistin seems like the first chapter of a novel repeatedly told for several antibiotics.P1774Emergence of high-level gentamicin resistance in clinical enterococcal isolates of companion animals in Portugal Objectives: To characterize in vitro gentamicin susceptibility among enterococci causing infections in cats and dogs, in order to evaluate the impact of high-level gentamicin resistance in small animal therapeutics.", [["colistin", "CHEMICAL", 70, 78], ["gentamicin", "CHEMICAL", 188, 198], ["gentamicin", "CHEMICAL", 314, 324], ["infections", "DISEASE", 366, 376], ["gentamicin", "CHEMICAL", 441, 451], ["colistin", "CHEMICAL", 70, 78], ["gentamicin", "CHEMICAL", 188, 198], ["gentamicin", "CHEMICAL", 314, 324], ["gentamicin", "CHEMICAL", 441, 451], ["A. baumannii", "ORGANISM", 16, 28], ["colistin", "SIMPLE_CHEMICAL", 70, 78], ["gentamicin", "SIMPLE_CHEMICAL", 188, 198], ["gentamicin", "SIMPLE_CHEMICAL", 314, 324], ["cats", "ORGANISM", 380, 384], ["dogs", "ORGANISM", 389, 393], ["gentamicin", "SIMPLE_CHEMICAL", 441, 451], ["A. baumannii", "SPECIES", 16, 28], ["cats", "SPECIES", 380, 384], ["dogs", "SPECIES", 389, 393], ["A. baumannii", "SPECIES", 16, 28], ["cats", "SPECIES", 380, 384], ["6% A. baumannii resistance", "TREATMENT", 13, 39], ["colistin", "TREATMENT", 70, 78], ["several antibiotics", "TREATMENT", 139, 158], ["high-level gentamicin resistance", "TREATMENT", 177, 209], ["vitro gentamicin susceptibility", "PROBLEM", 308, 339], ["enterococci", "PROBLEM", 346, 357], ["infections in cats and dogs", "PROBLEM", 366, 393], ["high-level gentamicin resistance", "TREATMENT", 430, 462], ["small animal therapeutics", "TREATMENT", 466, 491], ["baumannii resistance", "OBSERVATION", 19, 39], ["gentamicin resistance", "OBSERVATION", 441, 462], ["small", "OBSERVATION_MODIFIER", 466, 471]]], ["Methods: The samples were collected at the Veterinary Teaching Hospital of the Faculty of Veterinary Medicine and at veterinary private practices in the Lisbon area.", [["samples", "ANATOMY", 13, 20], ["Veterinary Medicine", "TREATMENT", 90, 109]]], ["From January 1998 until November 2005, a total of 43 enterococci were isolated from dogs and cats with urinary tract infection (UTI), otitis externa (OE) and pioderma.", [["urinary tract", "ANATOMY", 103, 116], ["OE", "ANATOMY", 150, 152], ["pioderma", "ANATOMY", 158, 166], ["urinary tract infection", "DISEASE", 103, 126], ["UTI", "DISEASE", 128, 131], ["otitis externa (OE) and pioderma", "DISEASE", 134, 166], ["enterococci", "CANCER", 53, 64], ["dogs", "ORGANISM", 84, 88], ["cats", "ORGANISM", 93, 97], ["urinary tract", "ORGANISM_SUBDIVISION", 103, 116], ["dogs", "SPECIES", 84, 88], ["cats", "SPECIES", 93, 97], ["43 enterococci", "PROBLEM", 50, 64], ["urinary tract infection", "PROBLEM", 103, 126], ["UTI", "PROBLEM", 128, 131], ["otitis externa (OE)", "PROBLEM", 134, 153], ["pioderma", "PROBLEM", 158, 166], ["urinary tract", "ANATOMY", 103, 116], ["infection", "OBSERVATION", 117, 126], ["UTI", "OBSERVATION", 128, 131]]], ["BBL Crystal Gram Positive ID System was used for identification at the species level.", [["BBL Crystal Gram", "TEST", 0, 16]]], ["Minimal inhibitory concentrations (MIC) were determined by the microdilution method according to NCCLS (1) .", [["Minimal inhibitory concentrations", "PROBLEM", 0, 33], ["the microdilution method", "TEST", 59, 83], ["NCCLS", "TEST", 97, 102], ["inhibitory", "OBSERVATION_MODIFIER", 8, 18], ["concentrations", "OBSERVATION_MODIFIER", 19, 33]]], ["The bifuntional enzyme gene that confers high-level gentamicin resistance (HLGR) was detected using PCR (2) .", [["gentamicin", "CHEMICAL", 52, 62], ["gentamicin", "CHEMICAL", 52, 62], ["bifuntional enzyme", "GENE_OR_GENE_PRODUCT", 4, 22], ["gentamicin", "SIMPLE_CHEMICAL", 52, 62], ["bifuntional enzyme gene", "DNA", 4, 27], ["The bifuntional enzyme gene", "TEST", 0, 27], ["high-level gentamicin resistance", "TREATMENT", 41, 73], ["PCR", "TEST", 100, 103]]], ["Results: Enterococcus faecalis was the predominant isolate (n = 35), followed in frequency by Enterococcus faecium (n = 6).", [["Enterococcus faecium", "DISEASE", 94, 114], ["Enterococcus faecalis", "ORGANISM", 9, 30], ["Enterococcus faecium", "ORGANISM", 94, 114], ["Enterococcus faecalis", "SPECIES", 9, 30], ["Enterococcus faecium", "SPECIES", 94, 114], ["Enterococcus faecalis", "SPECIES", 9, 30], ["Enterococcus faecium", "SPECIES", 94, 114], ["Enterococcus faecalis", "PROBLEM", 9, 30], ["Enterococcus faecium", "PROBLEM", 94, 114], ["Enterococcus faecalis", "OBSERVATION", 9, 30], ["Enterococcus faecium", "OBSERVATION", 94, 114]]], ["MIC cumulative data analysis showed that MIC50 values were 8 lg/ ml and MIC90 1024 lg/ml.", [["MIC50", "CHEMICAL", 41, 46], ["MIC50", "SIMPLE_CHEMICAL", 41, 46], ["MIC cumulative data analysis", "TEST", 0, 28], ["MIC50 values", "TEST", 41, 53], ["MIC90", "TEST", 72, 77]]], ["Six (14%) HLGR clinical enterococcal isolates were detected, with MIC ranges between 1024-2048 lg/ml.", [["HLGR", "ORGANISM", 10, 14], ["enterococcal", "ORGANISM", 24, 36], ["HLGR clinical enterococcal isolates", "PROBLEM", 10, 45], ["MIC ranges", "TEST", 66, 76], ["enterococcal isolates", "OBSERVATION", 24, 45]]], ["Four of these enterococci were isolated from UTI and 2 from OE.", [["OE", "ANATOMY", 60, 62], ["UTI", "DISEASE", 45, 48], ["enterococci", "CANCER", 14, 25], ["these enterococci", "PROBLEM", 8, 25], ["UTI", "PROBLEM", 45, 48], ["enterococci", "OBSERVATION", 14, 25], ["UTI", "OBSERVATION", 45, 48]]], ["Four of the phenotypically high-level gentamicin resistant isolates carried the aac(6')-Ie-aph(2'')-Ia gene.", [["gentamicin", "CHEMICAL", 38, 48], ["gentamicin", "CHEMICAL", 38, 48], ["gentamicin", "SIMPLE_CHEMICAL", 38, 48], ["aph(2'')-Ia", "GENE_OR_GENE_PRODUCT", 91, 102], ["aph(2'')-Ia gene", "DNA", 91, 107], ["the phenotypically high-level gentamicin resistant isolates", "TREATMENT", 8, 67], ["the aac", "TREATMENT", 76, 83], ["high", "OBSERVATION_MODIFIER", 27, 31]]], ["Conclusions: The importance of enterococcal infection in small animal clinical samples has increased over the last years.", [["samples", "ANATOMY", 79, 86], ["enterococcal infection", "DISEASE", 31, 53], ["enterococcal", "ORGANISM", 31, 43], ["enterococcal infection", "PROBLEM", 31, 53], ["small animal clinical samples", "PROBLEM", 57, 86], ["enterococcal", "OBSERVATION_MODIFIER", 31, 43], ["infection", "OBSERVATION", 44, 53], ["small", "OBSERVATION_MODIFIER", 57, 62], ["increased", "OBSERVATION_MODIFIER", 91, 100]]], ["MIC cumulative data points out low-level gentamicin resistance among clinical enterococci isolates of veterinary origin and the emergence of high-level isolates, as previously detected (2).", [["gentamicin", "CHEMICAL", 41, 51], ["gentamicin", "CHEMICAL", 41, 51], ["gentamicin", "SIMPLE_CHEMICAL", 41, 51], ["MIC cumulative data", "TEST", 0, 19], ["low-level gentamicin resistance", "PROBLEM", 31, 62], ["clinical enterococci isolates of veterinary origin", "PROBLEM", 69, 119], ["high-level isolates", "PROBLEM", 141, 160], ["veterinary origin", "OBSERVATION", 102, 119]]], ["This fact compromises cell-wall active agents (such as ampicillin or vancomicin) and aminoglicoside in vivo synergy.", [["cell", "ANATOMY", 22, 26], ["wall", "ANATOMY", 27, 31], ["ampicillin", "CHEMICAL", 55, 65], ["vancomicin", "CHEMICAL", 69, 79], ["aminoglicoside", "CHEMICAL", 85, 99], ["ampicillin", "CHEMICAL", 55, 65], ["vancomicin", "CHEMICAL", 69, 79], ["aminoglicoside", "CHEMICAL", 85, 99], ["cell", "CELL", 22, 26], ["ampicillin", "SIMPLE_CHEMICAL", 55, 65], ["vancomicin", "SIMPLE_CHEMICAL", 69, 79], ["aminoglicoside", "SIMPLE_CHEMICAL", 85, 99], ["cell-wall active agents", "TREATMENT", 22, 45], ["ampicillin", "TREATMENT", 55, 65], ["vancomicin", "TREATMENT", 69, 79], ["aminoglicoside", "TREATMENT", 85, 99], ["compromises cell", "OBSERVATION", 10, 26], ["active agents", "OBSERVATION", 32, 45]]], ["The aac (6')-Ieaph(2'')-Ia gene carriage is of concern because its expression confers resistance also to tobramicin, netilmicin, amikacin and kanamicin.", [["tobramicin", "CHEMICAL", 105, 115], ["netilmicin", "CHEMICAL", 117, 127], ["amikacin", "CHEMICAL", 129, 137], ["kanamicin", "CHEMICAL", 142, 151], ["tobramicin", "CHEMICAL", 105, 115], ["netilmicin", "CHEMICAL", 117, 127], ["amikacin", "CHEMICAL", 129, 137], ["kanamicin", "CHEMICAL", 142, 151], ["aac (6')-Ieaph(2'')-Ia", "GENE_OR_GENE_PRODUCT", 4, 26], ["tobramicin", "SIMPLE_CHEMICAL", 105, 115], ["netilmicin", "SIMPLE_CHEMICAL", 117, 127], ["amikacin", "SIMPLE_CHEMICAL", 129, 137], ["kanamicin", "SIMPLE_CHEMICAL", 142, 151], ["Ieaph(2'')-Ia gene", "DNA", 13, 31], ["The aac", "TREATMENT", 0, 7], ["tobramicin", "TREATMENT", 105, 115], ["netilmicin", "TREATMENT", 117, 127], ["amikacin", "TREATMENT", 129, 137], ["kanamicin", "TREATMENT", 142, 151]]], ["Our findings are of critical importance, as they may have a direct impact in therapeutic decision in the management of companion animal's infections by enterococci.", [["infections", "DISEASE", 138, 148], ["enterococci", "CANCER", 152, 163], ["the management", "TREATMENT", 101, 115], ["animal's infections", "PROBLEM", 129, 148], ["enterococci", "PROBLEM", 152, 163]]], ["Furthermore, transfer of resistance genes and resistance strains between animals and owners/caretakers by direct contact is a concerning probability.", [["resistance genes", "DNA", 25, 41], ["resistance genes", "PROBLEM", 25, 41], ["resistance strains", "PROBLEM", 46, 64]]], ["References: (1) Results: Interpretative criteria were used according to NCCLS 2002.During the study period penicillin resistant strains of S. pneumoniae was noted as follows: 67% in sputum or TA,19% in blood,12%in CSF,and 75% in others,against cefuroxim resistant strains:15% in sputum or TA,10% in blood,4% in CSF.Regarding the susceptibility to Ofx,penicillin resistant S. pneumoniae strains from sputum or TA revealed 97.9%.The penicillin resistant strains coming from sputum or TA showed resistance as follows; 48% to Em and 78% to Sxt,against strains isolated from others: 58% to Em and 49% to Sxt.No resistant strain to Va was found.", [["sputum", "ANATOMY", 182, 188], ["blood", "ANATOMY", 202, 207], ["sputum", "ANATOMY", 279, 285], ["blood", "ANATOMY", 299, 304], ["sputum", "ANATOMY", 399, 405], ["sputum", "ANATOMY", 472, 478], ["penicillin", "CHEMICAL", 107, 117], ["S. pneumoniae", "DISEASE", 139, 152], ["cefuroxim", "CHEMICAL", 244, 253], ["Ofx", "CHEMICAL", 347, 350], ["penicillin", "CHEMICAL", 351, 361], ["penicillin", "CHEMICAL", 431, 441], ["TA", "CHEMICAL", 482, 484], ["penicillin", "CHEMICAL", 107, 117], ["cefuroxim", "CHEMICAL", 244, 253], ["penicillin", "CHEMICAL", 351, 361], ["penicillin", "CHEMICAL", 431, 441], ["penicillin", "SIMPLE_CHEMICAL", 107, 117], ["S. pneumoniae", "ORGANISM", 139, 152], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["CSF", "ORGANISM_SUBSTANCE", 214, 217], ["cefuroxim", "SIMPLE_CHEMICAL", 244, 253], ["sputum", "ORGANISM_SUBSTANCE", 279, 285], ["blood", "ORGANISM_SUBSTANCE", 299, 304], ["CSF", "ORGANISM_SUBSTANCE", 311, 314], ["Ofx", "SIMPLE_CHEMICAL", 347, 350], ["penicillin", "SIMPLE_CHEMICAL", 351, 361], ["S. pneumoniae", "ORGANISM", 372, 385], ["sputum", "ORGANISM_SUBSTANCE", 399, 405], ["penicillin", "SIMPLE_CHEMICAL", 431, 441], ["sputum", "ORGANISM_SUBSTANCE", 472, 478], ["Sxt", "GENE_OR_GENE_PRODUCT", 536, 539], ["Va", "GENE_OR_GENE_PRODUCT", 626, 628], ["Va", "PROTEIN", 626, 628], ["S. pneumoniae", "SPECIES", 139, 152], ["S. pneumoniae", "SPECIES", 372, 385], ["S. pneumoniae", "SPECIES", 139, 152], ["S. pneumoniae", "SPECIES", 372, 385], ["the study", "TEST", 90, 99], ["penicillin resistant strains", "PROBLEM", 107, 135], ["S. pneumoniae", "PROBLEM", 139, 152], ["sputum", "TEST", 182, 188], ["TA", "TEST", 192, 194], ["blood", "TEST", 202, 207], ["CSF", "TEST", 214, 217], ["cefuroxim resistant strains", "PROBLEM", 244, 271], ["sputum", "TEST", 279, 285], ["TA", "TEST", 289, 291], ["blood", "TEST", 299, 304], ["CSF", "TEST", 311, 314], ["the susceptibility to Ofx", "PROBLEM", 325, 350], ["penicillin resistant S. pneumoniae strains", "PROBLEM", 351, 393], ["sputum", "TEST", 399, 405], ["TA", "TEST", 409, 411], ["The penicillin resistant strains", "TREATMENT", 427, 459], ["Em", "TEST", 522, 524], ["Sxt", "TEST", 536, 539], ["strains", "PROBLEM", 548, 555], ["Em", "TEST", 585, 587], ["resistant strain to Va", "PROBLEM", 606, 628], ["pneumoniae", "OBSERVATION", 142, 152], ["resistant", "OBSERVATION_MODIFIER", 606, 615], ["strain", "OBSERVATION", 616, 622]]], ["Conclusion: The percentage of the penicillin resistant S. pneumoniae isolates from the lower respiratory tract, middle ear fluid, eye fluid and sinus was markedly higher than that of the isolates from blood and CSF.", [["lower respiratory tract", "ANATOMY", 87, 110], ["middle ear fluid", "ANATOMY", 112, 128], ["eye fluid", "ANATOMY", 130, 139], ["sinus", "ANATOMY", 144, 149], ["blood", "ANATOMY", 201, 206], ["penicillin", "CHEMICAL", 34, 44], ["penicillin", "CHEMICAL", 34, 44], ["penicillin resistant", "ORGANISM", 34, 54], ["S. pneumoniae", "ORGANISM", 55, 68], ["lower", "ORGANISM_SUBDIVISION", 87, 92], ["respiratory tract", "ORGANISM_SUBDIVISION", 93, 110], ["ear fluid", "MULTI-TISSUE_STRUCTURE", 119, 128], ["eye fluid", "MULTI-TISSUE_STRUCTURE", 130, 139], ["sinus", "ORGAN", 144, 149], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["CSF", "ORGANISM_SUBSTANCE", 211, 214], ["S. pneumoniae", "SPECIES", 55, 68], ["S. pneumoniae", "SPECIES", 55, 68], ["the penicillin resistant S. pneumoniae isolates", "PROBLEM", 30, 77], ["the lower respiratory tract", "PROBLEM", 83, 110], ["middle ear fluid, eye fluid", "TEST", 112, 139], ["the isolates from blood and CSF", "TEST", 183, 214], ["pneumoniae", "OBSERVATION", 58, 68], ["lower", "ANATOMY_MODIFIER", 87, 92], ["respiratory tract", "ANATOMY", 93, 110], ["middle ear", "ANATOMY", 112, 122], ["fluid", "OBSERVATION", 123, 128], ["eye", "ANATOMY", 130, 133], ["fluid", "OBSERVATION", 134, 139], ["sinus", "ANATOMY", 144, 149], ["markedly", "OBSERVATION_MODIFIER", 154, 162], ["higher", "OBSERVATION_MODIFIER", 163, 169]]], ["The most efficient drugs against penicillin resistant pneumococci were cefuroxim and ofloxacin.", [["penicillin", "CHEMICAL", 33, 43], ["pneumococci", "DISEASE", 54, 65], ["cefuroxim", "CHEMICAL", 71, 80], ["ofloxacin", "CHEMICAL", 85, 94], ["penicillin", "CHEMICAL", 33, 43], ["cefuroxim", "CHEMICAL", 71, 80], ["ofloxacin", "CHEMICAL", 85, 94], ["penicillin", "SIMPLE_CHEMICAL", 33, 43], ["pneumococci", "SIMPLE_CHEMICAL", 54, 65], ["cefuroxim", "SIMPLE_CHEMICAL", 71, 80], ["ofloxacin", "SIMPLE_CHEMICAL", 85, 94], ["The most efficient drugs", "TREATMENT", 0, 24], ["penicillin resistant pneumococci", "TREATMENT", 33, 65], ["cefuroxim", "TREATMENT", 71, 80], ["ofloxacin", "TREATMENT", 85, 94]]], ["These results from Romania also underline the previous observations regarding the higher emerging rates of resistance in S. pneumoniae worldwide.P1776Penicillin resistance in Streptococcus agalactiae Objectives: Streptococcus agalactiae has become recognized as a cause of serious illness in newborns, pregnant women, and adults with chronic medical conditions.", [["S. pneumoniae", "DISEASE", 121, 134], ["P1776Penicillin", "CHEMICAL", 145, 160], ["Streptococcus agalactiae", "DISEASE", 175, 199], ["Streptococcus agalactiae", "DISEASE", 212, 236], ["S. pneumoniae", "ORGANISM", 121, 134], ["P1776Penicillin", "SIMPLE_CHEMICAL", 145, 160], ["Streptococcus agalactiae", "ORGANISM", 175, 199], ["Streptococcus agalactiae", "ORGANISM", 212, 236], ["newborns", "ORGANISM", 292, 300], ["women", "ORGANISM", 311, 316], ["S. pneumoniae", "SPECIES", 121, 134], ["Streptococcus agalactiae", "SPECIES", 175, 199], ["Streptococcus agalactiae", "SPECIES", 212, 236], ["women", "SPECIES", 311, 316], ["S. pneumoniae", "SPECIES", 121, 134], ["Streptococcus agalactiae", "SPECIES", 175, 199], ["Streptococcus agalactiae", "SPECIES", 212, 236], ["S. pneumoniae", "PROBLEM", 121, 134], ["Streptococcus agalactiae", "PROBLEM", 175, 199], ["Streptococcus agalactiae", "PROBLEM", 212, 236], ["chronic medical conditions", "PROBLEM", 334, 360], ["pneumoniae", "OBSERVATION", 124, 134], ["Streptococcus agalactiae", "OBSERVATION", 175, 199], ["Streptococcus agalactiae", "OBSERVATION", 212, 236]]], ["Heavy colonization of the genital tract with Streptococcus agalactiae also increases the risk that a woman will deliver a preterm low-birthweight infant.", [["genital tract", "ANATOMY", 26, 39], ["Streptococcus agalactiae", "DISEASE", 45, 69], ["genital tract", "ORGANISM_SUBDIVISION", 26, 39], ["Streptococcus agalactiae", "ORGANISM", 45, 69], ["woman", "ORGANISM", 101, 106], ["Streptococcus agalactiae", "SPECIES", 45, 69], ["woman", "SPECIES", 101, 106], ["Streptococcus agalactiae", "SPECIES", 45, 69], ["Heavy colonization of the genital tract", "PROBLEM", 0, 39], ["Streptococcus agalactiae", "PROBLEM", 45, 69], ["a preterm low-birthweight infant", "TREATMENT", 120, 152], ["colonization", "OBSERVATION", 6, 18], ["genital tract", "ANATOMY", 26, 39], ["Streptococcus agalactiae", "OBSERVATION", 45, 69]]], ["Early-onset infections (occurring at < 7 days of age) are associated with much lower fatality than when they were first described, and their incidence is finally decreasing as the use of preventive antibiotics during childbirth increases among women at risk.", [["infections", "DISEASE", 12, 22], ["women", "ORGANISM", 244, 249], ["women", "SPECIES", 244, 249], ["Early-onset infections", "PROBLEM", 0, 22], ["preventive antibiotics", "TREATMENT", 187, 209], ["onset", "OBSERVATION_MODIFIER", 6, 11], ["infections", "OBSERVATION", 12, 22]]], ["Penicillin or ampicillin remains the drug of choice for intrapartum antibiotic prophylaxis for Streptococcus agalactiae colonization in pregnant women.", [["Penicillin", "CHEMICAL", 0, 10], ["ampicillin", "CHEMICAL", 14, 24], ["Streptococcus agalactiae colonization", "DISEASE", 95, 132], ["Penicillin", "CHEMICAL", 0, 10], ["ampicillin", "CHEMICAL", 14, 24], ["Penicillin", "SIMPLE_CHEMICAL", 0, 10], ["ampicillin", "SIMPLE_CHEMICAL", 14, 24], ["Streptococcus agalactiae", "ORGANISM", 95, 119], ["women", "ORGANISM", 145, 150], ["Streptococcus agalactiae", "SPECIES", 95, 119], ["women", "SPECIES", 145, 150], ["Streptococcus agalactiae", "SPECIES", 95, 119], ["Penicillin", "TREATMENT", 0, 10], ["ampicillin", "TREATMENT", 14, 24], ["the drug of choice", "TREATMENT", 33, 51], ["intrapartum antibiotic prophylaxis", "TREATMENT", 56, 90], ["Streptococcus agalactiae colonization", "PROBLEM", 95, 132]]], ["Erythromycin and clindamycin are the drugs of choice for women with serious penicillin allergy who are colonized with Streptococcus agalactiae.", [["Erythromycin", "CHEMICAL", 0, 12], ["clindamycin", "CHEMICAL", 17, 28], ["penicillin", "CHEMICAL", 76, 86], ["allergy", "DISEASE", 87, 94], ["Streptococcus agalactiae", "DISEASE", 118, 142], ["Erythromycin", "CHEMICAL", 0, 12], ["clindamycin", "CHEMICAL", 17, 28], ["penicillin", "CHEMICAL", 76, 86], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["clindamycin", "SIMPLE_CHEMICAL", 17, 28], ["women", "ORGANISM", 57, 62], ["Streptococcus agalactiae", "ORGANISM", 118, 142], ["women", "SPECIES", 57, 62], ["Streptococcus agalactiae", "SPECIES", 118, 142], ["Streptococcus agalactiae", "SPECIES", 118, 142], ["Erythromycin", "TREATMENT", 0, 12], ["clindamycin", "TREATMENT", 17, 28], ["serious penicillin allergy", "PROBLEM", 68, 94], ["Streptococcus agalactiae", "PROBLEM", 118, 142], ["Streptococcus agalactiae", "OBSERVATION", 118, 142]]], ["The objective of this study is to estimate the insorgence of penicillin resistance among Streptococcus agalactiae.", [["penicillin", "CHEMICAL", 61, 71], ["Streptococcus agalactiae", "DISEASE", 89, 113], ["penicillin", "CHEMICAL", 61, 71], ["penicillin", "SIMPLE_CHEMICAL", 61, 71], ["Streptococcus agalactiae", "ORGANISM", 89, 113], ["Streptococcus agalactiae", "SPECIES", 89, 113], ["Streptococcus agalactiae", "SPECIES", 89, 113], ["this study", "TEST", 17, 27], ["penicillin resistance", "PROBLEM", 61, 82], ["Streptococcus agalactiae", "PROBLEM", 89, 113], ["Streptococcus agalactiae", "OBSERVATION", 89, 113]]], ["Methods: All streptococcus agalactiae were tested against penicillin by agar dilution method according to Clinical and Laboratory Standards Institute 2005 (CLSI); breakpoints for resistance were those recommended by the CLSI.", [["streptococcus agalactiae", "DISEASE", 13, 37], ["penicillin", "CHEMICAL", 58, 68], ["penicillin", "CHEMICAL", 58, 68], ["streptococcus agalactiae", "ORGANISM", 13, 37], ["penicillin", "SIMPLE_CHEMICAL", 58, 68], ["streptococcus agalactiae", "SPECIES", 13, 37], ["streptococcus agalactiae", "SPECIES", 13, 37], ["All streptococcus agalactiae", "TREATMENT", 9, 37], ["penicillin", "TREATMENT", 58, 68], ["resistance", "PROBLEM", 179, 189]]], ["Antimicrobial agents were obtained from their manufacture as laboratory grade powder.", [["Antimicrobial agents", "TREATMENT", 0, 20], ["laboratory grade powder", "TREATMENT", 61, 84]]], ["Streptococcus agalactiae resulted resistant to Penicillin in 1 case; and about 2% resulted borderlines.The present findings indicate a probable evolution in S. agalactiae toward penicillin resistance this finding suggest the need a continuous national and international surveillance programs to provide timely data on the evolution of incidence of penicillin resistance in this pathogen.P1777Ciprofloxacin susceptibility of the most common isolates at bacterial conuctivitis Conclusion: According to the average numerals we concluded that all the isolated strains are highly susceptible at ciprofloxacin.", [["Streptococcus agalactiae", "DISEASE", 0, 24], ["Penicillin", "CHEMICAL", 47, 57], ["penicillin", "CHEMICAL", 178, 188], ["penicillin", "CHEMICAL", 348, 358], ["P1777Ciprofloxacin", "CHEMICAL", 387, 405], ["ciprofloxacin", "CHEMICAL", 590, 603], ["Penicillin", "CHEMICAL", 47, 57], ["penicillin", "CHEMICAL", 178, 188], ["penicillin", "CHEMICAL", 348, 358], ["P1777Ciprofloxacin", "CHEMICAL", 387, 405], ["ciprofloxacin", "CHEMICAL", 590, 603], ["Streptococcus agalactiae", "ORGANISM", 0, 24], ["Penicillin", "SIMPLE_CHEMICAL", 47, 57], ["S. agalactiae", "ORGANISM", 157, 170], ["penicillin", "SIMPLE_CHEMICAL", 178, 188], ["penicillin", "SIMPLE_CHEMICAL", 348, 358], ["P1777Ciprofloxacin", "SIMPLE_CHEMICAL", 387, 405], ["ciprofloxacin", "SIMPLE_CHEMICAL", 590, 603], ["Streptococcus agalactiae", "SPECIES", 0, 24], ["S. agalactiae", "SPECIES", 157, 170], ["Streptococcus agalactiae", "SPECIES", 0, 24], ["S. agalactiae", "SPECIES", 157, 170], ["Streptococcus agalactiae", "PROBLEM", 0, 24], ["Penicillin", "TREATMENT", 47, 57], ["S. agalactiae", "PROBLEM", 157, 170], ["penicillin resistance", "TREATMENT", 178, 199], ["international surveillance programs", "TREATMENT", 256, 291], ["penicillin resistance", "PROBLEM", 348, 369], ["this pathogen", "PROBLEM", 373, 386], ["all the isolated strains", "PROBLEM", 539, 563], ["ciprofloxacin", "TREATMENT", 590, 603], ["indicate a probable", "UNCERTAINTY", 124, 143], ["penicillin resistance", "OBSERVATION", 348, 369]]], ["Its application in the conuctivial saccus is especially important in curing the conuctivial infections with resistent strains like Pseudomonas aeruginosa.", [["conuctivial saccus", "ANATOMY", 23, 41], ["infections", "DISEASE", 92, 102], ["conuctivial saccus", "ORGANISM", 23, 41], ["Pseudomonas aeruginosa", "ORGANISM", 131, 153], ["Pseudomonas aeruginosa", "SPECIES", 131, 153], ["conuctivial saccus", "SPECIES", 23, 41], ["Pseudomonas aeruginosa", "SPECIES", 131, 153], ["the conuctivial infections", "PROBLEM", 76, 102], ["resistent strains like Pseudomonas aeruginosa", "PROBLEM", 108, 153], ["Pseudomonas aeruginosa", "OBSERVATION", 131, 153]]], ["We successfully cure the bacteria chronic conuctivitis with the adequately used therapy according to antibiogram.P1778Antimicrobial resistance patterns of Acinetobacter baumannii in clinical isolates G.T. Tsilika, V.P. Pliatsika, M.T. Tsivitanidou, D.S. Sofianou (Thessaloniki, GR)P1778Objectives: A. baumannii is a nosocomial pathogen, commonly isolated from critically ill and immunocompromised patients.", [["conuctivitis", "DISEASE", 42, 54], ["Acinetobacter baumannii", "DISEASE", 155, 178], ["nosocomial pathogen", "DISEASE", 316, 335], ["critically ill", "DISEASE", 360, 374], ["Acinetobacter baumannii", "ORGANISM", 155, 178], ["A. baumannii", "ORGANISM", 298, 310], ["patients", "ORGANISM", 397, 405], ["Acinetobacter baumannii", "SPECIES", 155, 178], ["A. baumannii", "SPECIES", 298, 310], ["patients", "SPECIES", 397, 405], ["Acinetobacter baumannii", "SPECIES", 155, 178], ["A. baumannii", "SPECIES", 298, 310], ["the bacteria chronic conuctivitis", "PROBLEM", 21, 54], ["therapy", "TREATMENT", 80, 87], ["antibiogram", "TEST", 101, 112], ["Acinetobacter baumannii", "PROBLEM", 155, 178], ["clinical isolates", "TEST", 182, 199], ["Tsilika", "TEST", 205, 212], ["a nosocomial pathogen", "PROBLEM", 314, 335], ["critically ill", "PROBLEM", 360, 374], ["bacteria", "OBSERVATION_MODIFIER", 25, 33], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["conuctivitis", "OBSERVATION", 42, 54], ["Acinetobacter baumannii", "OBSERVATION", 155, 178]]], ["The aim of the present study was to evaluate the antimicrobial resistance of A. baumannii strains isolated in a tertiary care hospital througout a three-year period.", [["A. baumannii strains", "ORGANISM", 77, 97], ["A. baumannii", "SPECIES", 77, 89], ["A. baumannii", "SPECIES", 77, 89], ["the present study", "TEST", 11, 28], ["A. baumannii strains", "PROBLEM", 77, 97], ["baumannii", "OBSERVATION", 80, 89]]], ["Methods: A total of 1311 A. baumannii strains were selected from January 2002 to December 2004.The specimens were obtained from inpatients hospitalized in intensive care unit (ICU) and pediatric intensive care unit (PICU) and other departments of our hospital.The identification and the antimicrobial susceptibility testing were performed using the Vitek 2 automated system(bioMerieux,France Conclusions: The emergance and rapid spread of multidrug resistant A. baumannii isolates are of a great concern worldwide.Imipenem was one of the most potent agents for treatment of those infections caused by multiresistant strains.The increasing prevalence of imipenem resistance limits therapeutic options and leads to outbreaks of carbapenems resistant strains.P1778Tigecycline in vivo studies Objectives: Antibacterial agents disrupt the ecological balance of the normal human microflora.", [["specimens", "ANATOMY", 99, 108], ["strains", "ANATOMY", 616, 623], ["Imipenem", "CHEMICAL", 514, 522], ["infections", "DISEASE", 580, 590], ["imipenem", "CHEMICAL", 653, 661], ["carbapenems", "CHEMICAL", 726, 737], ["P1778Tigecycline", "CHEMICAL", 756, 772], ["Imipenem", "CHEMICAL", 514, 522], ["imipenem", "CHEMICAL", 653, 661], ["carbapenems", "CHEMICAL", 726, 737], ["A. baumannii", "ORGANISM", 25, 37], ["specimens", "CANCER", 99, 108], ["A. baumannii", "ORGANISM", 459, 471], ["Imipenem", "SIMPLE_CHEMICAL", 514, 522], ["imipenem", "SIMPLE_CHEMICAL", 653, 661], ["carbapenems", "SIMPLE_CHEMICAL", 726, 737], ["P1778Tigecycline", "SIMPLE_CHEMICAL", 756, 772], ["human", "ORGANISM", 867, 872], ["A. baumannii", "SPECIES", 25, 37], ["A. baumannii", "SPECIES", 459, 471], ["human", "SPECIES", 867, 872], ["A. baumannii", "SPECIES", 25, 37], ["A. baumannii", "SPECIES", 459, 471], ["human", "SPECIES", 867, 872], ["A. baumannii strains", "PROBLEM", 25, 45], ["The specimens", "TEST", 95, 108], ["The identification", "TEST", 260, 278], ["the antimicrobial susceptibility testing", "TEST", 283, 323], ["the Vitek", "TEST", 345, 354], ["The emergance", "TREATMENT", 405, 418], ["multidrug resistant A. baumannii isolates", "TREATMENT", 439, 480], ["Imipenem", "TREATMENT", 514, 522], ["those infections", "PROBLEM", 574, 590], ["multiresistant strains", "PROBLEM", 601, 623], ["imipenem resistance", "TREATMENT", 653, 672], ["therapeutic options", "TREATMENT", 680, 699], ["carbapenems resistant strains", "PROBLEM", 726, 755], ["Antibacterial agents", "TREATMENT", 801, 821], ["infections", "OBSERVATION", 580, 590], ["multiresistant strains", "OBSERVATION", 601, 623], ["increasing", "OBSERVATION_MODIFIER", 628, 638], ["imipenem resistance", "OBSERVATION", 653, 672], ["normal human microflora", "OBSERVATION", 860, 883]]], ["Disturbances may lead to the emergence of antibiotic resistance and/or to infections by potentially pathogenic bacteria.", [["infections", "DISEASE", 74, 84], ["Disturbances", "PROBLEM", 0, 12], ["antibiotic resistance", "TREATMENT", 42, 63], ["infections", "PROBLEM", 74, 84], ["pathogenic bacteria", "PROBLEM", 100, 119]]], ["Tigecycline, a member of a new class of antibiotics (glycylcyclines), has been shown to have a potent expanded broad-spectrum activity against most grampositive and gram-negative aerobic and anaerobic bacteria.", [["Tigecycline", "CHEMICAL", 0, 11], ["glycylcyclines", "CHEMICAL", 53, 67], ["Tigecycline", "CHEMICAL", 0, 11], ["glycylcyclines", "CHEMICAL", 53, 67], ["Tigecycline", "SIMPLE_CHEMICAL", 0, 11], ["glycylcyclines", "SIMPLE_CHEMICAL", 53, 67], ["Tigecycline", "TREATMENT", 0, 11], ["antibiotics (glycylcyclines", "TREATMENT", 40, 67], ["gram", "TEST", 165, 169], ["anaerobic bacteria", "PROBLEM", 191, 209], ["negative aerobic", "OBSERVATION_MODIFIER", 170, 186], ["anaerobic bacteria", "OBSERVATION", 191, 209]]], ["The aim of the study was to investigate the ecological effects of tigecycline on the normal oropharyngeal and intestinal microflora in healthy subjects.", [["oropharyngeal", "ANATOMY", 92, 105], ["intestinal microflora", "ANATOMY", 110, 131], ["tigecycline", "CHEMICAL", 66, 77], ["tigecycline", "CHEMICAL", 66, 77], ["tigecycline", "SIMPLE_CHEMICAL", 66, 77], ["oropharyngeal", "ORGANISM_SUBDIVISION", 92, 105], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 110, 131], ["the study", "TEST", 11, 20], ["tigecycline", "TREATMENT", 66, 77], ["oropharyngeal", "ANATOMY", 92, 105], ["intestinal microflora", "ANATOMY", 110, 131]]], ["Methods: Thirteen (13) white subjects (6 women, 7 men) aged 20 to 31 years, received 100 mg of tigecycline in the morning on day 1 as a 30-minute intravenous (IV) infusion, followed by 50mg doses of tigecycline given every 12 hours as a 30-minute infusion for 10 days.", [["intravenous", "ANATOMY", 146, 157], ["tigecycline", "CHEMICAL", 95, 106], ["tigecycline", "CHEMICAL", 199, 210], ["tigecycline", "CHEMICAL", 95, 106], ["tigecycline", "CHEMICAL", 199, 210], ["subjects", "ORGANISM", 29, 37], ["women", "ORGANISM", 41, 46], ["men", "ORGANISM", 50, 53], ["tigecycline", "SIMPLE_CHEMICAL", 95, 106], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 146, 157], ["tigecycline", "SIMPLE_CHEMICAL", 199, 210], ["women", "SPECIES", 41, 46], ["men", "SPECIES", 50, 53], ["tigecycline", "TREATMENT", 95, 106], ["a 30-minute intravenous (IV) infusion", "TREATMENT", 134, 171], ["tigecycline", "TREATMENT", 199, 210]]], ["One (1) subject was withdrawn on day 2 because of an adverse event.", [["an adverse event", "PROBLEM", 50, 66]]], ["Serum, saliva, and faecal samples were collected before, during, and after administration for microbiologic cultivation and for assays of tigecycline.", [["Serum", "ANATOMY", 0, 5], ["saliva", "ANATOMY", 7, 13], ["faecal samples", "ANATOMY", 19, 33], ["tigecycline", "CHEMICAL", 138, 149], ["tigecycline", "CHEMICAL", 138, 149], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["saliva", "ORGANISM_SUBSTANCE", 7, 13], ["faecal samples", "ORGANISM_SUBSTANCE", 19, 33], ["tigecycline", "SIMPLE_CHEMICAL", 138, 149], ["Serum, saliva", "TEST", 0, 13], ["faecal samples", "TEST", 19, 33], ["microbiologic cultivation", "TEST", 94, 119], ["assays", "TEST", 128, 134], ["tigecycline", "TREATMENT", 138, 149], ["saliva", "ANATOMY", 7, 13], ["faecal", "ANATOMY", 19, 25]]], ["All new colonizing bacteria were tested for susceptibility (resistance >8 mg/L) during the investigation period.", [["All new colonizing bacteria", "PROBLEM", 0, 27], ["susceptibility", "PROBLEM", 44, 58], ["resistance", "TEST", 60, 70], ["new", "OBSERVATION_MODIFIER", 4, 7], ["colonizing bacteria", "OBSERVATION", 8, 27]]], ["Results: The serum concentrations on day 9, 12 hours after dosing, were 0.2 to 2.1 mg/L (mean value 0.4 mg/L, median value 0.2 mg/L, and SD 0.5 mg/L).", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["The serum concentrations", "TEST", 9, 33]]], ["The faecal concentrations on day 8 were 3.0 to 14.1 mg/kg (mean value 6.0 mg/kg, median value 5.6 mg/kg, and SD 2.9 mg/L).", [["faecal", "ANATOMY", 4, 10], ["faecal", "ORGANISM_SUBSTANCE", 4, 10], ["The faecal concentrations", "TEST", 0, 25]]], ["Saliva concentrations were generally low, with highest mean value 0.18 mg/L, median value 0.22 mg/L, on day 10, 3 hours after dosing.", [["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["Saliva concentrations", "TREATMENT", 0, 21]]], ["A minor effect on the oropharyngeal microflora was observed.", [["oropharyngeal microflora", "ANATOMY", 22, 46], ["oropharyngeal microflora", "PATHOLOGICAL_FORMATION", 22, 46], ["A minor effect on the oropharyngeal microflora", "PROBLEM", 0, 46], ["minor", "OBSERVATION_MODIFIER", 2, 7], ["effect", "OBSERVATION_MODIFIER", 8, 14], ["oropharyngeal microflora", "ANATOMY", 22, 46]]], ["The numbers of Enterococci and Escherichia coli in the intestinal microflora were reduced at day 8, while other enterobacteria and yeasts increased.", [["intestinal microflora", "ANATOMY", 55, 76], ["Enterococci", "CELL", 15, 26], ["Escherichia coli", "ORGANISM", 31, 47], ["intestinal microflora", "ORGAN", 55, 76], ["Escherichia coli", "SPECIES", 31, 47], ["Escherichia coli", "SPECIES", 31, 47], ["Enterococci", "PROBLEM", 15, 26], ["Escherichia coli", "PROBLEM", 31, 47], ["the intestinal microflora", "PROBLEM", 51, 76], ["other enterobacteria", "PROBLEM", 106, 126], ["yeasts", "PROBLEM", 131, 137], ["Enterococci", "OBSERVATION", 15, 26], ["Escherichia coli", "OBSERVATION", 31, 47], ["intestinal microflora", "ANATOMY", 55, 76], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["enterobacteria", "OBSERVATION", 112, 126], ["yeasts increased", "OBSERVATION", 131, 147]]], ["There was a marked reduction of lactobacilli and bifidobacteria but no impact on bacteroides.", [["lactobacilli", "CHEMICAL", 32, 44], ["bifidobacteria", "CHEMICAL", 49, 63], ["lactobacilli", "SIMPLE_CHEMICAL", 32, 44], ["bifidobacteria", "SIMPLE_CHEMICAL", 49, 63], ["bacteroides", "SIMPLE_CHEMICAL", 81, 92], ["a marked reduction of lactobacilli", "PROBLEM", 10, 44], ["bifidobacteria", "PROBLEM", 49, 63], ["bacteroides", "PROBLEM", 81, 92], ["marked", "OBSERVATION_MODIFIER", 12, 18], ["reduction", "OBSERVATION_MODIFIER", 19, 28], ["lactobacilli", "OBSERVATION", 32, 44], ["no", "UNCERTAINTY", 68, 70], ["impact", "OBSERVATION_MODIFIER", 71, 77], ["bacteroides", "OBSERVATION", 81, 92]]], ["No Clostridium difficile strains were isolated.", [["Clostridium difficile", "DISEASE", 3, 24], ["Clostridium difficile strains", "ORGANISM", 3, 32], ["Clostridium difficile", "SPECIES", 3, 24], ["Clostridium difficile", "SPECIES", 3, 24], ["Clostridium difficile strains", "PROBLEM", 3, 32], ["Clostridium", "OBSERVATION_MODIFIER", 3, 14], ["difficile", "OBSERVATION", 15, 24]]], ["Two (2) Klebsiella strains and 5 Enterobacter strains resistant to tigecycline were found.", [["tigecycline", "CHEMICAL", 67, 78], ["tigecycline", "CHEMICAL", 67, 78], ["5", "ORGANISM", 31, 32], ["Enterobacter strains", "ORGANISM", 33, 53], ["tigecycline", "SIMPLE_CHEMICAL", 67, 78], ["Two (2) Klebsiella strains", "PROBLEM", 0, 26], ["5 Enterobacter strains", "PROBLEM", 31, 53], ["tigecycline", "TREATMENT", 67, 78]]], ["Conclusion: Tigecycline had a minor effect on the oropharyngeal microflora.", [["oropharyngeal microflora", "ANATOMY", 50, 74], ["Tigecycline", "CHEMICAL", 12, 23], ["Tigecycline", "CHEMICAL", 12, 23], ["Tigecycline", "SIMPLE_CHEMICAL", 12, 23], ["oropharyngeal microflora", "PATHOLOGICAL_FORMATION", 50, 74], ["Tigecycline", "TREATMENT", 12, 23], ["a minor effect on the oropharyngeal microflora", "PROBLEM", 28, 74], ["oropharyngeal microflora", "ANATOMY", 50, 74]]], ["Tigecycline's effect on the intestinal microflora was due to its spectrum of antibacterial activity and intestinal concentrations.", [["intestinal microflora", "ANATOMY", 28, 49], ["intestinal", "ANATOMY", 104, 114], ["Tigecycline", "CHEMICAL", 0, 11], ["Tigecycline", "CHEMICAL", 0, 11], ["Tigecycline", "SIMPLE_CHEMICAL", 0, 11], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 28, 49], ["intestinal", "ORGAN", 104, 114], ["Tigecycline", "TREATMENT", 0, 11], ["the intestinal microflora", "PROBLEM", 24, 49], ["antibacterial activity", "TREATMENT", 77, 99], ["intestinal concentrations", "PROBLEM", 104, 129], ["intestinal", "ANATOMY", 28, 38], ["antibacterial activity", "OBSERVATION", 77, 99], ["intestinal", "ANATOMY", 104, 114]]], ["Objectives: To examine and report the use of Tigecycline (Wyeth) in the treatment of multidrug resistant acinetobacter (MDRA) culture positive sepsis in 11 patients requiring mutiorgan support.", [["Tigecycline", "CHEMICAL", 45, 56], ["acinetobacter", "CHEMICAL", 105, 118], ["sepsis", "DISEASE", 143, 149], ["Tigecycline", "CHEMICAL", 45, 56], ["Tigecycline", "SIMPLE_CHEMICAL", 45, 56], ["Wyeth", "ORGANISM", 58, 63], ["acinetobacter", "SIMPLE_CHEMICAL", 105, 118], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["Tigecycline (Wyeth)", "TREATMENT", 45, 64], ["multidrug resistant acinetobacter", "PROBLEM", 85, 118], ["culture", "TEST", 126, 133], ["sepsis", "PROBLEM", 143, 149], ["mutiorgan support", "TREATMENT", 175, 192], ["sepsis", "OBSERVATION", 143, 149]]], ["Methods: All patients were managed within the Liver Intensive Care Unit.", [["Liver", "ANATOMY", 46, 51], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["Liver", "ANATOMY", 46, 51]]], ["Physiological data was collected prospectively and entered onto a specialist database.", [["Physiological data", "TEST", 0, 18]]], ["Patients received standard intensive care management; antibiotic and antifungal therapy administered as indicated by microbiological cultures.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["standard intensive care management", "TREATMENT", 18, 52], ["antibiotic", "TREATMENT", 54, 64], ["antifungal therapy", "TREATMENT", 69, 87], ["microbiological cultures", "TEST", 117, 141]]], ["Systemic inflammatory response (SIRS) features initiated blood cultures (vascular lines and peripheral), drain fluid culture and broncoalveolar lavage (BAL).", [["blood cultures", "ANATOMY", 57, 71], ["vascular lines", "ANATOMY", 73, 87], ["drain fluid", "ANATOMY", 105, 116], ["broncoalveolar lavage", "ANATOMY", 129, 150], ["BAL", "ANATOMY", 152, 155], ["SIRS", "DISEASE", 32, 36], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["vascular lines", "CELL", 73, 87], ["peripheral", "TISSUE", 92, 102], ["broncoalveolar lavage", "ORGANISM_SUBSTANCE", 129, 150], ["Systemic inflammatory response (SIRS) features", "PROBLEM", 0, 46], ["blood cultures", "TEST", 57, 71], ["vascular lines and peripheral)", "TREATMENT", 73, 103], ["drain fluid culture", "TEST", 105, 124], ["broncoalveolar lavage", "TEST", 129, 150], ["inflammatory", "OBSERVATION", 9, 21], ["vascular", "ANATOMY", 73, 81], ["broncoalveolar lavage", "OBSERVATION", 129, 150]]], ["Screening swabs were undertaken weekly and samples sent for culture at laparotomy.", [["swabs", "ANATOMY", 10, 15], ["samples", "ANATOMY", 43, 50], ["Screening swabs", "TEST", 0, 15], ["samples", "TEST", 43, 50], ["culture", "TEST", 60, 67], ["laparotomy", "TEST", 71, 81]]], ["MDRA positive cultures from blood, BAL, drain fluid or samples taken at laparotomy in the context of SIRS resulted in the initiation of tigecycline treatment.", [["cultures", "ANATOMY", 14, 22], ["blood", "ANATOMY", 28, 33], ["BAL", "ANATOMY", 35, 38], ["drain fluid", "ANATOMY", 40, 51], ["samples", "ANATOMY", 55, 62], ["SIRS", "DISEASE", 101, 105], ["tigecycline", "CHEMICAL", 136, 147], ["tigecycline", "CHEMICAL", 136, 147], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["BAL", "ORGANISM_SUBSTANCE", 35, 38], ["tigecycline", "SIMPLE_CHEMICAL", 136, 147], ["MDRA positive cultures", "CELL_LINE", 0, 22], ["positive cultures", "PROBLEM", 5, 22], ["blood", "TEST", 28, 33], ["BAL", "TEST", 35, 38], ["drain fluid or samples", "TEST", 40, 62], ["laparotomy", "TREATMENT", 72, 82], ["SIRS", "PROBLEM", 101, 105], ["tigecycline treatment", "TREATMENT", 136, 157], ["SIRS", "OBSERVATION", 101, 105]]], ["Results: 11 patients received Tigecycline treatment for MDRA infections.", [["Tigecycline", "CHEMICAL", 30, 41], ["MDRA infections", "DISEASE", 56, 71], ["Tigecycline", "CHEMICAL", 30, 41], ["patients", "ORGANISM", 12, 20], ["Tigecycline", "SIMPLE_CHEMICAL", 30, 41], ["patients", "SPECIES", 12, 20], ["Tigecycline treatment", "TREATMENT", 30, 51], ["MDRA infections", "PROBLEM", 56, 71], ["infections", "OBSERVATION", 61, 71]]], ["The underlying disease states were necrotizing pancreatitis (1), post hepatectomy (1), polytrauma (1), all with postive intra-abdominal cultures.", [["intra-abdominal cultures", "ANATOMY", 120, 144], ["pancreatitis", "DISEASE", 47, 59], ["polytrauma", "DISEASE", 87, 97], ["The underlying disease", "PROBLEM", 0, 22], ["necrotizing pancreatitis", "PROBLEM", 35, 59], ["hepatectomy", "TREATMENT", 70, 81], ["polytrauma", "PROBLEM", 87, 97], ["postive intra-abdominal cultures", "TEST", 112, 144], ["disease", "OBSERVATION", 15, 22], ["necrotizing", "OBSERVATION_MODIFIER", 35, 46], ["pancreatitis", "OBSERVATION", 47, 59], ["hepatectomy", "OBSERVATION", 70, 81], ["polytrauma", "OBSERVATION", 87, 97], ["intra-abdominal", "ANATOMY", 120, 135]]], ["Acute and acute on chronic liver failure (4), MDRA +ive broncho-alveolar lavage \u00b1 blood cultures and 4 post liver transplant patients (necrotising pancreatitis in one, 2 with recurrent small bowel perforation and 1 with retroperitoneal haemorrhage) all with positive blood cultures and in 3 positive intra-abdominal tissue/clot.", [["liver", "ANATOMY", 27, 32], ["blood", "ANATOMY", 82, 87], ["liver", "ANATOMY", 108, 113], ["bowel", "ANATOMY", 191, 196], ["retroperitoneal", "ANATOMY", 220, 235], ["blood cultures", "ANATOMY", 267, 281], ["intra-abdominal tissue", "ANATOMY", 300, 322], ["clot", "ANATOMY", 323, 327], ["chronic liver failure", "DISEASE", 19, 40], ["pancreatitis", "DISEASE", 147, 159], ["bowel perforation", "DISEASE", 191, 208], ["retroperitoneal haemorrhage", "DISEASE", 220, 247], ["liver", "ORGAN", 27, 32], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["liver", "ORGAN", 108, 113], ["patients", "ORGANISM", 125, 133], ["bowel", "ORGAN", 191, 196], ["blood", "ORGANISM_SUBSTANCE", 267, 272], ["intra-abdominal tissue", "TISSUE", 300, 322], ["clot", "ORGANISM_SUBSTANCE", 323, 327], ["patients", "SPECIES", 125, 133], ["Acute and acute on chronic liver failure", "PROBLEM", 0, 40], ["MDRA", "TEST", 46, 50], ["broncho", "TEST", 56, 63], ["alveolar lavage", "TEST", 64, 79], ["blood cultures", "TEST", 82, 96], ["liver transplant", "TREATMENT", 108, 124], ["necrotising pancreatitis", "PROBLEM", 135, 159], ["recurrent small bowel perforation", "PROBLEM", 175, 208], ["retroperitoneal haemorrhage", "PROBLEM", 220, 247], ["blood cultures", "TEST", 267, 281], ["3 positive intra-abdominal tissue", "PROBLEM", 289, 322], ["clot", "PROBLEM", 323, 327], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["liver", "ANATOMY", 27, 32], ["failure", "OBSERVATION", 33, 40], ["alveolar", "ANATOMY", 64, 72], ["lavage", "OBSERVATION", 73, 79], ["liver", "ANATOMY", 108, 113], ["transplant", "OBSERVATION", 114, 124], ["necrotising", "OBSERVATION_MODIFIER", 135, 146], ["pancreatitis", "OBSERVATION", 147, 159], ["small", "OBSERVATION_MODIFIER", 185, 190], ["bowel", "ANATOMY", 191, 196], ["perforation", "OBSERVATION", 197, 208], ["retroperitoneal", "ANATOMY", 220, 235], ["haemorrhage", "OBSERVATION", 236, 247], ["intra-abdominal tissue", "ANATOMY", 300, 322], ["clot", "OBSERVATION", 323, 327]]], ["Mean time from admission to treatment for MDRA was 25 days.", [["MDRA", "DISEASE", 42, 46], ["treatment", "TREATMENT", 28, 37], ["MDRA", "TREATMENT", 42, 46]]], ["Mean duration of treatment was 10 days (range 4-15).", [["treatment", "TREATMENT", 17, 26]]], ["Mean APACHE II score at initiation of therapy was 18 (range 13-26); 4/11 patients survived to intensive care discharge and 3/11 to hospital discharge.", [["patients", "ORGANISM", 73, 81], ["APACHE II", "PROTEIN", 5, 14], ["patients", "SPECIES", 73, 81], ["Mean APACHE II score", "TEST", 0, 20], ["therapy", "TREATMENT", 38, 45]]], ["Microbiological clearance of MDRA was observed in 8/11 cases.", [["MDRA", "GENE_OR_GENE_PRODUCT", 29, 33], ["MDRA", "PROTEIN", 29, 33], ["Microbiological clearance", "TEST", 0, 25], ["MDRA", "TEST", 29, 33]]], ["In those who did not achieve microbiological clearance cause of death was intra-abdominal haemorrhage, recalcitrant organ failure with recurrent small bowel perforation and vasopressor resistant shock.", [["intra-abdominal", "ANATOMY", 74, 89], ["organ", "ANATOMY", 116, 121], ["bowel", "ANATOMY", 151, 156], ["death", "DISEASE", 64, 69], ["intra-abdominal haemorrhage", "DISEASE", 74, 101], ["organ failure", "DISEASE", 116, 129], ["bowel perforation", "DISEASE", 151, 168], ["shock", "DISEASE", 195, 200], ["organ", "ORGAN", 116, 121], ["bowel", "ORGAN", 151, 156], ["microbiological clearance", "TEST", 29, 54], ["death", "PROBLEM", 64, 69], ["intra-abdominal haemorrhage", "PROBLEM", 74, 101], ["recalcitrant organ failure", "PROBLEM", 103, 129], ["recurrent small bowel perforation", "PROBLEM", 135, 168], ["vasopressor resistant shock", "PROBLEM", 173, 200], ["intra-abdominal", "ANATOMY", 74, 89], ["haemorrhage", "OBSERVATION", 90, 101], ["recurrent", "OBSERVATION_MODIFIER", 135, 144], ["small", "OBSERVATION_MODIFIER", 145, 150], ["bowel", "ANATOMY", 151, 156], ["perforation", "OBSERVATION", 157, 168], ["vasopressor resistant shock", "OBSERVATION", 173, 200]]], ["In these patients one remained culture positive for intraabdominal sepsis despite full treatment (small bowel perforation x5).", [["intraabdominal", "ANATOMY", 52, 66], ["bowel", "ANATOMY", 104, 109], ["intraabdominal sepsis", "DISEASE", 52, 73], ["patients", "ORGANISM", 9, 17], ["bowel", "ORGAN", 104, 109], ["patients", "SPECIES", 9, 17], ["culture", "TEST", 31, 38], ["intraabdominal sepsis", "PROBLEM", 52, 73], ["full treatment", "TREATMENT", 82, 96], ["small bowel perforation", "PROBLEM", 98, 121], ["intraabdominal", "ANATOMY", 52, 66], ["sepsis", "OBSERVATION", 67, 73], ["small", "OBSERVATION_MODIFIER", 98, 103], ["bowel", "ANATOMY", 104, 109], ["perforation", "OBSERVATION", 110, 121]]], ["The drug was well tolerated with the only side effect being that of hypercalcaemia observed in 5/12 patients, mean corrected calcium 2.59 mMol/l, range 2.32-2.81.", [["hypercalcaemia", "DISEASE", 68, 82], ["calcium", "CHEMICAL", 125, 132], ["calcium", "CHEMICAL", 125, 132], ["patients", "ORGANISM", 100, 108], ["calcium", "SIMPLE_CHEMICAL", 125, 132], ["patients", "SPECIES", 100, 108], ["hypercalcaemia", "PROBLEM", 68, 82], ["mean", "TEST", 110, 114], ["calcium", "TEST", 125, 132], ["range", "TEST", 146, 151], ["hypercalcaemia", "OBSERVATION", 68, 82]]], ["In all cases this resolved on drug discontinuation.P1778Conclusion: Tigecycline appears to be an efficacious agent in the treatment of deep seated MDRA infections.", [["Tigecycline", "CHEMICAL", 68, 79], ["infections", "DISEASE", 152, 162], ["Tigecycline", "CHEMICAL", 68, 79], ["Tigecycline", "SIMPLE_CHEMICAL", 68, 79], ["drug discontinuation", "TREATMENT", 30, 50], ["Tigecycline", "TREATMENT", 68, 79], ["deep seated MDRA infections", "PROBLEM", 135, 162], ["deep seated", "OBSERVATION", 135, 146], ["infections", "OBSERVATION", 152, 162]]], ["Objectives: Nausea (N) and vomiting (V) have been reported with tigecycline, a new glycylcycline with expanded broad spectrum activity.", [["Nausea (N) and vomiting", "DISEASE", 12, 35], ["tigecycline", "CHEMICAL", 64, 75], ["glycylcycline", "CHEMICAL", 83, 96], ["tigecycline", "CHEMICAL", 64, 75], ["glycylcycline", "CHEMICAL", 83, 96], ["tigecycline", "SIMPLE_CHEMICAL", 64, 75], ["glycylcycline", "SIMPLE_CHEMICAL", 83, 96], ["Nausea (N)", "PROBLEM", 12, 22], ["vomiting (V", "PROBLEM", 27, 38], ["tigecycline", "TREATMENT", 64, 75], ["a new glycylcycline", "TREATMENT", 77, 96], ["expanded broad spectrum activity", "TREATMENT", 102, 134], ["broad spectrum", "OBSERVATION_MODIFIER", 111, 125], ["activity", "OBSERVATION_MODIFIER", 126, 134]]], ["Exposure-response relationships and patient covariates predictive of the first N and V occurrence were evaluated in patients with complicated intra-abdominal infections (cIAI).", [["intra-abdominal", "ANATOMY", 142, 157], ["intra-abdominal infections", "DISEASE", 142, 168], ["cIAI", "DISEASE", 170, 174], ["patient", "ORGANISM", 36, 43], ["patients", "ORGANISM", 116, 124], ["patient", "SPECIES", 36, 43], ["patients", "SPECIES", 116, 124], ["complicated intra-abdominal infections", "PROBLEM", 130, 168], ["intra-abdominal", "ANATOMY", 142, 157], ["infections", "OBSERVATION", 158, 168]]], ["Methods: Data from patients from 3 cIAI trials (one phase 2 and two phase 3), receiving 100 mg loading dose and 50 mg every 12 hours, were pooled for analysis.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["analysis", "TEST", 150, 158]]], ["N and V (definitely, possibly, or probably related to tigecycline) reported from the start of infusion until 24 hours after the last dose were included.", [["tigecycline", "CHEMICAL", 54, 65], ["tigecycline", "CHEMICAL", 54, 65], ["tigecycline", "SIMPLE_CHEMICAL", 54, 65], ["tigecycline", "TREATMENT", 54, 65], ["infusion", "TREATMENT", 94, 102]]], ["Individual exposure measures [AUC0-12 and Cmax] were calculated using a previously developed population PK model.", [["AUC0", "TEST", 30, 34]]], ["Logistic regression was used to evaluate predictors of first N and V occurrence.", [["Logistic regression", "TEST", 0, 19], ["first N and V occurrence", "PROBLEM", 55, 79]]], ["Covariates included age, weight, sex, region of treatment, and baseline N and V. Results: The dataset included 928 patients (218 with PK).", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["treatment", "TREATMENT", 48, 57], ["PK", "TEST", 134, 136]]], ["Mean (SD) age and weight were 46 (18) years and 73 (16) kg.", [["Mean", "TEST", 0, 4], ["weight", "TEST", 18, 24]]], ["64% of patients were men and 24%, 37%, and 18% were enrolled in North America, Europe, and Latin America, respectively.", [["patients", "ORGANISM", 7, 15], ["men", "ORGANISM", 21, 24], ["patients", "SPECIES", 7, 15], ["men", "SPECIES", 21, 24]]], ["Baseline nausea or vomiting was reported in 47% and 35%.", [["nausea", "DISEASE", 9, 15], ["vomiting", "DISEASE", 19, 27], ["Baseline nausea", "PROBLEM", 0, 15], ["vomiting", "PROBLEM", 19, 27], ["nausea", "OBSERVATION", 9, 15]]], ["Overall, N and V occurred in 18% and 13% of patients receiving tigecycline, however most (62%; 67%) of first N and V events were mild in nature.", [["tigecycline", "CHEMICAL", 63, 74], ["tigecycline", "CHEMICAL", 63, 74], ["patients", "ORGANISM", 44, 52], ["tigecycline", "SIMPLE_CHEMICAL", 63, 74], ["patients", "SPECIES", 44, 52], ["tigecycline", "TREATMENT", 63, 74], ["first N and V events", "PROBLEM", 103, 123], ["mild", "OBSERVATION_MODIFIER", 129, 133]]], ["Women had more N and V (23%; 17%) than men (15%; 11%).", [["Women", "ORGANISM", 0, 5], ["men", "ORGANISM", 39, 42], ["Women", "SPECIES", 0, 5], ["men", "SPECIES", 39, 42]]], ["N and V were lower in Europe (10%; 6%) than in other regions.", [["lower", "OBSERVATION_MODIFIER", 13, 18]]], ["AUC0-12 and Cmax were not predictive.", [["AUC0-12", "GENE_OR_GENE_PRODUCT", 0, 7], ["Cmax", "SIMPLE_CHEMICAL", 12, 16], ["AUC0", "TEST", 0, 4]]], ["The final nausea model included weight, sex, region, baseline nausea, and the interaction of weight/region as predictors of the first nausea occurrence (p = 0.671, 0.0006, 0.205, 0.033, & 0.023, respectively Objective: Because hospitalisation for community-acquired pneumonia (CAP) is associated with substantial morbidity and health resource utilisation, we evaluated the predictors of prolonged hospital length of stay (LOS) and treatment duration.", [["nausea", "DISEASE", 10, 16], ["nausea", "DISEASE", 62, 68], ["nausea", "DISEASE", 134, 140], ["pneumonia", "DISEASE", 266, 275], ["CAP", "DISEASE", 277, 280], ["baseline nausea", "PROBLEM", 53, 68], ["the first nausea occurrence", "PROBLEM", 124, 151], ["community-acquired pneumonia (CAP)", "PROBLEM", 247, 281], ["substantial morbidity", "PROBLEM", 301, 322], ["treatment duration", "TREATMENT", 431, 449], ["nausea", "OBSERVATION", 62, 68], ["pneumonia", "OBSERVATION", 266, 275], ["substantial", "OBSERVATION_MODIFIER", 301, 312], ["morbidity", "OBSERVATION", 313, 322]]], ["Methods: We conducted a retrospective analysis of data from a double-blind, randomised, multicentre clinical study that compared the efficacy and safety of tigecycline with that of levofloxacin in the treatment of patients with CAP requiring hospitalisation.", [["tigecycline", "CHEMICAL", 156, 167], ["levofloxacin", "CHEMICAL", 181, 193], ["CAP", "DISEASE", 228, 231], ["tigecycline", "CHEMICAL", 156, 167], ["levofloxacin", "CHEMICAL", 181, 193], ["tigecycline", "SIMPLE_CHEMICAL", 156, 167], ["levofloxacin", "SIMPLE_CHEMICAL", 181, 193], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 214, 222], ["multicentre clinical study", "TEST", 88, 114], ["tigecycline", "TREATMENT", 156, 167], ["levofloxacin", "TREATMENT", 181, 193], ["CAP", "PROBLEM", 228, 231]]], ["Patients were stratified by the FINE Pneumonia Severity Index and randomly assigned to receive tigecycline or levofloxacin via IV administration for at least 7 days.", [["Pneumonia", "DISEASE", 37, 46], ["tigecycline", "CHEMICAL", 95, 106], ["levofloxacin", "CHEMICAL", 110, 122], ["tigecycline", "CHEMICAL", 95, 106], ["levofloxacin", "CHEMICAL", 110, 122], ["Patients", "ORGANISM", 0, 8], ["tigecycline", "SIMPLE_CHEMICAL", 95, 106], ["levofloxacin", "SIMPLE_CHEMICAL", 110, 122], ["Patients", "SPECIES", 0, 8], ["the FINE Pneumonia Severity Index", "PROBLEM", 28, 61], ["tigecycline", "TREATMENT", 95, 106], ["levofloxacin", "TREATMENT", 110, 122], ["IV administration", "TREATMENT", 127, 144], ["FINE", "OBSERVATION_MODIFIER", 32, 36], ["Pneumonia", "OBSERVATION", 37, 46]]], ["Treatment duration and hospital discharge were based on physician assessment of signs and symptoms of infection and patient condition.", [["infection", "DISEASE", 102, 111], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 116, 123], ["physician assessment", "TEST", 56, 76], ["signs", "PROBLEM", 80, 85], ["symptoms", "PROBLEM", 90, 98], ["infection and patient condition", "PROBLEM", 102, 133], ["infection", "OBSERVATION", 102, 111]]], ["We used Cox proportional hazards modelling with stepwise selection to identify statistically significant predictors (p < 0.05) of treatment duration and hospital LOS.", [["Cox proportional hazards modelling", "TREATMENT", 8, 42], ["stepwise selection", "TREATMENT", 48, 66]]], ["Results: Among 426 patients with CAP in the clinical intent-totreat population with complete hospitalisation data, mean age was 49.8 years (range 17-92) and 22.8% of patients were aged \u202165 years.", [["CAP", "DISEASE", 33, 36], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 166, 174], ["CAP", "PROBLEM", 33, 36]]], ["Diabetes (11.5%), chronic obstructive pulmonary disease (7.8%), and congestive heart failure (7.0%) were leading co-morbidities.", [["pulmonary", "ANATOMY", 38, 47], ["heart", "ANATOMY", 79, 84], ["Diabetes", "DISEASE", 0, 8], ["chronic obstructive pulmonary disease", "DISEASE", 18, 55], ["congestive heart failure", "DISEASE", 68, 92], ["pulmonary", "ORGAN", 38, 47], ["heart", "ORGAN", 79, 84], ["Diabetes", "PROBLEM", 0, 8], ["chronic obstructive pulmonary disease", "PROBLEM", 18, 55], ["congestive heart failure", "PROBLEM", 68, 92], ["co-morbidities", "PROBLEM", 113, 127], ["chronic", "OBSERVATION_MODIFIER", 18, 25], ["obstructive", "OBSERVATION_MODIFIER", 26, 37], ["pulmonary", "ANATOMY", 38, 47], ["disease", "OBSERVATION", 48, 55], ["congestive", "OBSERVATION_MODIFIER", 68, 78], ["heart", "ANATOMY", 79, 84], ["failure", "OBSERVATION", 85, 92]]], ["About 37.1% of patients were smokers and 5.6% were characterised by alcohol abuse.", [["alcohol abuse", "DISEASE", 68, 81], ["alcohol", "CHEMICAL", 68, 75], ["patients", "ORGANISM", 15, 23], ["alcohol", "SIMPLE_CHEMICAL", 68, 75], ["patients", "SPECIES", 15, 23]]], ["Median FINE Pneumonia Severity Index score was 3; 21.1% of patients had a score >4. .", [["Pneumonia", "DISEASE", 12, 21], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Median FINE Pneumonia Severity Index score", "TEST", 0, 42], ["a score", "TEST", 72, 79], ["Pneumonia", "OBSERVATION", 12, 21]]], ["There were no significant differences between the 2 groups in treatment duration or LOS.", [["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37]]], ["Conclusions: Tigecycline, a first-in-class glycylcycline, was associated with treatment duration and LOS similar to that of levofloxacin, adjusting for several identified risk factors.P1783Tigecycline effective in treating patients with intra-abdominal or skin/skin structure infections who have bacteraemia E.J. Ellis-Grosse, R. Maroko (Collegeville, US)P1783Objectives: The treatment of bacteraemia, which is a potentially fatal complication of infections originating at other body sites, is complicated by increasing resistance.", [["intra-abdominal", "ANATOMY", 237, 252], ["skin", "ANATOMY", 256, 260], ["skin", "ANATOMY", 261, 265], ["body sites", "ANATOMY", 479, 489], ["Tigecycline", "CHEMICAL", 13, 24], ["glycylcycline", "CHEMICAL", 43, 56], ["levofloxacin", "CHEMICAL", 124, 136], ["P1783Tigecycline", "CHEMICAL", 184, 200], ["intra-abdominal or skin/skin structure infections", "DISEASE", 237, 286], ["bacteraemia", "DISEASE", 296, 307], ["bacteraemia", "DISEASE", 389, 400], ["infections", "DISEASE", 447, 457], ["Tigecycline", "CHEMICAL", 13, 24], ["glycylcycline", "CHEMICAL", 43, 56], ["levofloxacin", "CHEMICAL", 124, 136], ["P1783Tigecycline", "CHEMICAL", 184, 200], ["Tigecycline", "SIMPLE_CHEMICAL", 13, 24], ["glycylcycline", "SIMPLE_CHEMICAL", 43, 56], ["levofloxacin", "SIMPLE_CHEMICAL", 124, 136], ["P1783Tigecycline", "SIMPLE_CHEMICAL", 184, 200], ["patients", "ORGANISM", 223, 231], ["intra-abdominal", "ORGANISM_SUBDIVISION", 237, 252], ["skin", "ORGAN", 256, 260], ["skin", "ORGAN", 261, 265], ["body sites", "MULTI-TISSUE_STRUCTURE", 479, 489], ["patients", "SPECIES", 223, 231], ["Tigecycline", "TREATMENT", 13, 24], ["levofloxacin", "TREATMENT", 124, 136], ["P1783Tigecycline", "TREATMENT", 184, 200], ["intra-abdominal or skin/skin structure infections", "PROBLEM", 237, 286], ["bacteraemia", "PROBLEM", 296, 307], ["bacteraemia", "PROBLEM", 389, 400], ["infections", "PROBLEM", 447, 457], ["increasing resistance", "PROBLEM", 509, 530], ["Tigecycline", "OBSERVATION", 13, 24], ["intra-abdominal", "ANATOMY", 237, 252], ["skin", "ANATOMY", 256, 260], ["skin", "ANATOMY", 261, 265], ["bacteraemia", "OBSERVATION", 389, 400], ["fatal", "OBSERVATION_MODIFIER", 425, 430], ["complication", "OBSERVATION", 431, 443], ["infections", "OBSERVATION", 447, 457], ["increasing", "OBSERVATION_MODIFIER", 509, 519], ["resistance", "OBSERVATION", 520, 530]]], ["Tigecycline, a first-in-class glycylcycline, has an expanded spectrum of activity against Gram-positive, Gram-negative, anaerobic, and atypical bacteria including resistant strains.", [["strains", "ANATOMY", 173, 180], ["Tigecycline", "CHEMICAL", 0, 11], ["glycylcycline", "CHEMICAL", 30, 43], ["Tigecycline", "CHEMICAL", 0, 11], ["glycylcycline", "CHEMICAL", 30, 43], ["Tigecycline", "SIMPLE_CHEMICAL", 0, 11], ["glycylcycline", "SIMPLE_CHEMICAL", 30, 43], ["Gram", "GENE_OR_GENE_PRODUCT", 90, 94], ["Gram", "GENE_OR_GENE_PRODUCT", 105, 109], ["Tigecycline", "TREATMENT", 0, 11], ["Gram", "TEST", 90, 94], ["Gram", "TEST", 105, 109], ["anaerobic", "PROBLEM", 120, 129], ["atypical bacteria", "PROBLEM", 135, 152], ["resistant strains", "PROBLEM", 163, 180], ["atypical bacteria", "OBSERVATION", 135, 152], ["resistant strains", "OBSERVATION", 163, 180]]], ["Tigecycline is safe and effective in treating complicated skin and skin structure (cSSSI) and intraabdominal infections (cIAI).", [["skin", "ANATOMY", 58, 62], ["skin", "ANATOMY", 67, 71], ["intraabdominal", "ANATOMY", 94, 108], ["Tigecycline", "CHEMICAL", 0, 11], ["skin and skin structure", "DISEASE", 58, 81], ["cSSSI", "DISEASE", 83, 88], ["intraabdominal infections", "DISEASE", 94, 119], ["cIAI", "DISEASE", 121, 125], ["Tigecycline", "CHEMICAL", 0, 11], ["Tigecycline", "SIMPLE_CHEMICAL", 0, 11], ["skin", "ORGAN", 58, 62], ["skin", "ORGAN", 67, 71], ["intraabdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 108], ["Tigecycline", "TREATMENT", 0, 11], ["complicated skin and skin structure", "PROBLEM", 46, 81], ["intraabdominal infections", "PROBLEM", 94, 119], ["skin", "ANATOMY", 58, 62], ["skin", "ANATOMY", 67, 71], ["intraabdominal", "ANATOMY", 94, 108], ["infections", "OBSERVATION", 109, 119]]], ["This analysis examines tigecycline clinical trial experience in patients with cIAI or cSSSI who had bacteraemia (presence of bacteria in blood) at baseline.", [["blood", "ANATOMY", 137, 142], ["tigecycline", "CHEMICAL", 23, 34], ["cIAI", "DISEASE", 78, 82], ["cSSSI", "DISEASE", 86, 91], ["bacteraemia", "DISEASE", 100, 111], ["tigecycline", "CHEMICAL", 23, 34], ["patients", "ORGANISM", 64, 72], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["patients", "SPECIES", 64, 72], ["This analysis", "TEST", 0, 13], ["tigecycline", "TREATMENT", 23, 34], ["bacteraemia", "PROBLEM", 100, 111], ["bacteria in blood", "PROBLEM", 125, 142], ["bacteraemia", "OBSERVATION", 100, 111], ["bacteria", "OBSERVATION", 125, 133]]], ["Objectives: Treatment of complicated intra-abdominal infections (cIAI) is challenging due to diverse bacteriology and bacterial resistance.", [["intra-abdominal", "ANATOMY", 37, 52], ["intra-abdominal infections", "DISEASE", 37, 63], ["cIAI", "DISEASE", 65, 69], ["complicated intra-abdominal infections", "PROBLEM", 25, 63], ["diverse bacteriology", "PROBLEM", 93, 113], ["bacterial resistance", "PROBLEM", 118, 138], ["intra-abdominal", "ANATOMY", 37, 52], ["infections", "OBSERVATION", 53, 63], ["bacterial resistance", "OBSERVATION", 118, 138]]], ["The efficacy and safety of Tigecycline (TGC), a first-in-class glycylcycline approved in Mexico, Brazil, Peru, Colombia and USA for treating cIAI and complicated skin and skin structure infections, was compared with Imipenem/Cilastatin (IMI/CIS) in adult hospitalised patients with cIAI in two double-blind, Phase 3 multinational trials.", [["skin", "ANATOMY", 162, 166], ["skin", "ANATOMY", 171, 175], ["Tigecycline", "CHEMICAL", 27, 38], ["TGC", "CHEMICAL", 40, 43], ["glycylcycline", "CHEMICAL", 63, 76], ["cIAI", "DISEASE", 141, 145], ["skin and skin structure infections", "DISEASE", 162, 196], ["Imipenem", "CHEMICAL", 216, 224], ["Cilastatin", "CHEMICAL", 225, 235], ["IMI", "CHEMICAL", 237, 240], ["cIAI", "DISEASE", 282, 286], ["Tigecycline", "CHEMICAL", 27, 38], ["glycylcycline", "CHEMICAL", 63, 76], ["Imipenem", "CHEMICAL", 216, 224], ["Cilastatin", "CHEMICAL", 225, 235], ["Tigecycline", "SIMPLE_CHEMICAL", 27, 38], ["TGC", "SIMPLE_CHEMICAL", 40, 43], ["glycylcycline", "SIMPLE_CHEMICAL", 63, 76], ["skin", "ORGAN", 162, 166], ["skin", "ORGAN", 171, 175], ["Imipenem", "SIMPLE_CHEMICAL", 216, 224], ["Cilastatin", "SIMPLE_CHEMICAL", 225, 235], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["Tigecycline (TGC", "TREATMENT", 27, 43], ["treating cIAI", "TREATMENT", 132, 145], ["complicated skin and skin structure infections", "PROBLEM", 150, 196], ["Imipenem", "TREATMENT", 216, 224], ["Cilastatin", "TREATMENT", 225, 235], ["IMI/CIS", "TREATMENT", 237, 244], ["cIAI", "TREATMENT", 282, 286], ["Phase 3 multinational trials", "TREATMENT", 308, 336], ["complicated", "OBSERVATION_MODIFIER", 150, 161], ["skin", "ANATOMY", 162, 166], ["skin", "ANATOMY", 171, 175], ["structure infections", "OBSERVATION", 176, 196]]], ["This analysis evaluated TGC efficacy and safety in the European region of the integrated results of these two trials.", [["This analysis", "TEST", 0, 13]]], ["Methods: One study was conducted in 96 centres (17 countries) and the other study was conducted in 94 centres (27 countries).", [["One study", "TEST", 9, 18], ["the other study", "TEST", 66, 81]]], ["Patients were stratified by disease severity (APACHE II score \u00a315 vs >15 but \u00a330), and randomly assigned to IV TGC (100 mg loading, then 500 mg q12h) or IV IMI/CIS (500/500 mg q6h) for 5-14 days.", [["IMI", "CHEMICAL", 156, 159], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["disease severity", "TEST", 28, 44], ["APACHE II score", "TEST", 46, 61], ["IV TGC", "TREATMENT", 108, 114], ["IV IMI/CIS", "TREATMENT", 153, 163]]], ["Clinical response at test-of-cure (TOC, 12-44 days after therapy) for microbiological evaluable (ME) and microbiological modified intent-to-treat (m-mITT) were co-primary efficacy endpoints where cure/failure responses were determined.", [["Clinical response at test", "TEST", 0, 25], ["TOC", "TEST", 35, 38], ["therapy", "TREATMENT", 57, 64], ["microbiological evaluable", "TEST", 70, 95], ["co-primary efficacy endpoints", "PROBLEM", 160, 189], ["failure responses", "PROBLEM", 201, 218]]], ["Safety was assessed by physical examination, laboratory results, and adverse event (AE) reporting.", [["physical examination", "TEST", 23, 43]]], ["Results: In the European analysis, 703 patients were mITT (received \u20211 dose), 556 m-mITT (283 TGC, 273 IMI/CIS) and 460 ME (237 TGC, 223 IMI/CIS).", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["mITT", "TEST", 53, 57], ["TGC", "TEST", 94, 97], ["IMI/CIS", "TEST", 103, 110], ["TGC", "TEST", 128, 131], ["IMI/CIS", "TEST", 137, 144]]], ["Patients were mostly white (98.2%) men (58%) with a mean age of 50 years.", [["Patients", "ORGANISM", 0, 8], ["men", "ORGANISM", 35, 38], ["Patients", "SPECIES", 0, 8], ["men", "SPECIES", 35, 38], ["white", "TEST", 21, 26]]], ["For ME, clinical cure rates at TOC were 92.4% (219/237) for TGC vs 88.8% (198/ 223) for IMI/CIS (95% CI = )2.", [["clinical cure rates", "TEST", 8, 27], ["TOC", "TEST", 31, 34], ["TGC vs", "TEST", 60, 66], ["IMI", "TEST", 88, 91], ["CIS", "TEST", 92, 95], ["CI", "TEST", 101, 103]]], ["2, 9.4 ; test for non-inferiority p < 0.0001).", [["test", "TEST", 9, 13], ["non-inferiority", "TEST", 18, 33]]], ["Clinical cure rates for m-mITT were 87.3% (247/283) for TGC vs 83.5% (228/273) for IMI/CIS (95% CI = )2.5, 10.0; test for non-inferiority p < 0.0001).", [["mITT", "TEST", 26, 30], ["TGC vs", "TEST", 56, 62], ["IMI", "TEST", 83, 86], ["CIS", "TEST", 87, 90], ["CI", "TEST", 96, 98], ["test", "TEST", 113, 117], ["non-inferiority", "TEST", 122, 137]]], ["Most commonly reported treatment emergent AEs (TEAEs, mITT) for TGC and IMI/CIS were nausea (14.7% and 11.8%, p = 0.267) and vomiting (10.7% and 7.3%, p = 0.146).", [["IMI", "DISEASE", 72, 75], ["CIS", "DISEASE", 76, 79], ["nausea", "DISEASE", 85, 91], ["vomiting", "DISEASE", 125, 133], ["emergent AEs", "PROBLEM", 33, 45], ["TEAEs", "TEST", 47, 52], ["TGC", "TEST", 64, 67], ["IMI/CIS", "TEST", 72, 79], ["nausea", "PROBLEM", 85, 91], ["p", "TEST", 110, 111], ["vomiting", "PROBLEM", 125, 133]]], ["The IMI/CIS group had significantly higher TEAEs of fever (7.3% IMI/CIS vs 3.2% TGC, p = 0.017), hyperglycaemia (1.7% IMI/CIS vs 0 TGC, p = 0.031) and dyspnoea (2.8% IMI/CIS vs 0.3% TGC, p = 0.011) where TGC had significantly higher amylase increase (3.2% TGC vs 0.6% IMI/CIS, p = 0.011) and BUN increase (2.3% TGC vs 0 IMI/CIS, p = 0.003).", [["fever", "DISEASE", 52, 57], ["hyperglycaemia", "DISEASE", 97, 111], ["dyspnoea", "DISEASE", 151, 159], ["amylase", "GENE_OR_GENE_PRODUCT", 233, 240], ["BUN", "SIMPLE_CHEMICAL", 292, 295], ["amylase", "PROTEIN", 233, 240], ["significantly higher TEAEs", "PROBLEM", 22, 48], ["fever", "PROBLEM", 52, 57], ["IMI", "TEST", 64, 67], ["CIS", "TEST", 68, 71], ["TGC", "TEST", 80, 83], ["p", "TEST", 85, 86], ["hyperglycaemia", "PROBLEM", 97, 111], ["IMI", "TEST", 118, 121], ["CIS", "TEST", 122, 125], ["TGC", "TEST", 131, 134], ["p", "TEST", 136, 137], ["dyspnoea", "PROBLEM", 151, 159], ["IMI", "TEST", 166, 169], ["CIS", "TEST", 170, 173], ["TGC", "TEST", 182, 185], ["p", "TEST", 187, 188], ["TGC", "TEST", 204, 207], ["significantly higher amylase increase", "PROBLEM", 212, 249], ["TGC", "TEST", 256, 259], ["IMI", "TEST", 268, 271], ["CIS", "TEST", 272, 275], ["p", "TEST", 277, 278], ["BUN", "TEST", 292, 295], ["TGC", "TEST", 311, 314], ["IMI", "TEST", 320, 323], ["CIS", "TEST", 324, 327], ["p", "TEST", 329, 330]]], ["Conclusions: Similar to the overall integrated analysis of the two Phase 3 trails, in the European analysis, TGC was safe and effective in the treatment of hospitalised patients with cIAI in comparison with IMI/CIS.P1785Tigecycline is safe and effective in the treatment of complicated skin and skin structure infections: European experience of two double-blind phase 3 comparison studies with vancomycin/aztreonam R. Maroko, N. Dartois, D. Sarkozy, J. Goodrich, E.J. Ellis-Grosse on behalf of the Tigecycline 300 and 305 Study GroupsP1785Objectives: Tigecycline (TGC) a first-in-class expanded spectrum glycylcycline, has been approved in Mexico, Brazil, Peru, Colombia and USA for treating complicated skin and skin structure infections (cSSSI) and complicated intraabdominal infections.", [["skin", "ANATOMY", 286, 290], ["skin", "ANATOMY", 295, 299], ["skin", "ANATOMY", 704, 708], ["skin", "ANATOMY", 713, 717], ["intraabdominal", "ANATOMY", 763, 777], ["cIAI", "DISEASE", 183, 187], ["IMI", "CHEMICAL", 207, 210], ["P1785Tigecycline", "CHEMICAL", 215, 231], ["skin and skin structure infections", "DISEASE", 286, 320], ["vancomycin", "CHEMICAL", 394, 404], ["aztreonam", "CHEMICAL", 405, 414], ["Tigecycline", "CHEMICAL", 498, 509], ["Tigecycline", "CHEMICAL", 551, 562], ["TGC", "CHEMICAL", 564, 567], ["glycylcycline", "CHEMICAL", 604, 617], ["skin and skin structure infections", "DISEASE", 704, 738], ["cSSSI", "DISEASE", 740, 745], ["intraabdominal infections", "DISEASE", 763, 788], ["P1785Tigecycline", "CHEMICAL", 215, 231], ["vancomycin", "CHEMICAL", 394, 404], ["aztreonam", "CHEMICAL", 405, 414], ["Tigecycline", "CHEMICAL", 551, 562], ["glycylcycline", "CHEMICAL", 604, 617], ["patients", "ORGANISM", 169, 177], ["P1785Tigecycline", "SIMPLE_CHEMICAL", 215, 231], ["skin", "ORGAN", 286, 290], ["skin", "ORGAN", 295, 299], ["vancomycin", "SIMPLE_CHEMICAL", 394, 404], ["Tigecycline", "SIMPLE_CHEMICAL", 551, 562], ["TGC", "SIMPLE_CHEMICAL", 564, 567], ["glycylcycline", "SIMPLE_CHEMICAL", 604, 617], ["skin", "ORGAN", 704, 708], ["skin", "ORGAN", 713, 717], ["intraabdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 763, 777], ["patients", "SPECIES", 169, 177], ["the European analysis", "TEST", 86, 107], ["TGC", "TEST", 109, 112], ["P1785Tigecycline", "TREATMENT", 215, 231], ["complicated skin and skin structure infections", "PROBLEM", 274, 320], ["comparison studies", "TEST", 370, 388], ["vancomycin", "TREATMENT", 394, 404], ["aztreonam", "TREATMENT", 405, 414], ["the Tigecycline", "TREATMENT", 494, 509], ["Tigecycline (TGC", "TREATMENT", 551, 567], ["spectrum glycylcycline", "TREATMENT", 595, 617], ["complicated skin and skin structure infections", "PROBLEM", 692, 738], ["complicated intraabdominal infections", "PROBLEM", 751, 788], ["complicated", "OBSERVATION_MODIFIER", 274, 285], ["skin", "ANATOMY", 286, 290], ["skin", "ANATOMY", 295, 299], ["infections", "OBSERVATION", 310, 320], ["skin", "ANATOMY", 704, 708], ["skin", "ANATOMY", 713, 717], ["infections", "OBSERVATION", 728, 738], ["intraabdominal", "ANATOMY", 763, 777], ["infections", "OBSERVATION", 778, 788]]], ["Two phase 3, randomised, double-blind studies were conducted in hospitalised men and women with cSSSI to determine TGC safety and efficacy compared with vancomycin/aztreonam (V/A).", [["vancomycin", "CHEMICAL", 153, 163], ["aztreonam", "CHEMICAL", 164, 173], ["vancomycin", "CHEMICAL", 153, 163], ["aztreonam", "CHEMICAL", 164, 173], ["men", "ORGANISM", 77, 80], ["women", "ORGANISM", 85, 90], ["vancomycin", "SIMPLE_CHEMICAL", 153, 163], ["aztreonam", "SIMPLE_CHEMICAL", 164, 173], ["V/A", "SIMPLE_CHEMICAL", 175, 178], ["men", "SPECIES", 77, 80], ["women", "SPECIES", 85, 90], ["blind studies", "TEST", 32, 45], ["cSSSI", "TREATMENT", 96, 101], ["vancomycin", "TREATMENT", 153, 163], ["aztreonam", "TREATMENT", 164, 173]]], ["The objective of this analysis was to evaluate the efficacy and safety seen in the European population of the integrated analysis of these 2 Phase 3 trials.", [["this analysis", "TEST", 17, 30]]], ["Methods: One study was conducted in 53 centres in 8 countries while the other study was conducted in 65 centres in 21 countries.", [["One study", "TEST", 9, 18], ["the other study", "TEST", 68, 83]]], ["Patients were randomly assigned (1:1) to receive either TGC (100 mg, followed by 50 mg IV twice daily) or vancomycin (1 g IV twice daily) plus aztreonam (2 g IV twice daily) for up to 14 days.", [["TGC", "CHEMICAL", 56, 59], ["vancomycin", "CHEMICAL", 106, 116], ["aztreonam", "CHEMICAL", 143, 152], ["vancomycin", "CHEMICAL", 106, 116], ["aztreonam", "CHEMICAL", 143, 152], ["Patients", "ORGANISM", 0, 8], ["TGC", "SIMPLE_CHEMICAL", 56, 59], ["vancomycin", "SIMPLE_CHEMICAL", 106, 116], ["aztreonam", "SIMPLE_CHEMICAL", 143, 152], ["Patients", "SPECIES", 0, 8], ["TGC", "TREATMENT", 56, 59], ["vancomycin", "TREATMENT", 106, 116], ["aztreonam", "TREATMENT", 143, 152]]], ["Clinical response at test-of-cure (TOC, 12-92 days after therapy) for clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) populations were coprimary efficacy endpoints in which cure/failure responses were determined.", [["Clinical response at test", "TEST", 0, 25], ["TOC", "TEST", 35, 38], ["therapy", "TREATMENT", 57, 64], ["c-mITT) populations", "TREATMENT", 135, 154], ["coprimary efficacy endpoints", "PROBLEM", 160, 188], ["failure responses", "PROBLEM", 203, 220]]], ["Secondary objectives included determination of in vitro susceptibility to TGC of a range of bacteria that cause cSSSI and microbiological efficacy.", [["cSSSI", "DISEASE", 112, 117], ["Secondary objectives", "PROBLEM", 0, 20], ["bacteria", "PROBLEM", 92, 100]]], ["Safety was assessed by physical examination, laboratory results, and adverse event (AE) reporting.", [["physical examination", "TEST", 23, 43]]], ["Results: In the European analysis, 385 patients comprise mITT (received \u20211 dose of study drug), 326 comprised CE (167 TGC, 159 V/A/CIS) and 376 comprised c-mITT (189 TGC, 187 V/A/ CIS).", [["mITT", "DISEASE", 57, 61], ["CE", "CHEMICAL", 110, 112], ["patients", "ORGANISM", 39, 47], ["c-mITT", "GENE_OR_GENE_PRODUCT", 154, 160], ["patients", "SPECIES", 39, 47], ["study drug", "TEST", 83, 93], ["CE", "TEST", 110, 112], ["TGC", "TEST", 118, 121], ["V/A/CIS", "TEST", 127, 134], ["c", "TEST", 154, 155], ["mITT", "TEST", 156, 160], ["TGC", "TEST", 166, 169], ["V/A/ CIS", "TEST", 175, 183]]], ["Patients were mostly white (99.7%) men (63.6%) with a mean age of 50 years.", [["Patients", "ORGANISM", 0, 8], ["men", "ORGANISM", 35, 38], ["Patients", "SPECIES", 0, 8], ["men", "SPECIES", 35, 38], ["white", "TEST", 21, 26]]], ["In the European region, clinical responses to TGC and V/A at test-of-cure were similar: c-mITT, 84.7% (160/ 189) versus 86.6% (162/187), difference TGC-V/A was -2.0% (95% CI -9.5, 5.6).", [["c-mITT", "GENE_OR_GENE_PRODUCT", 88, 94], ["TGC", "TEST", 46, 49], ["V/A at test", "TEST", 54, 65], ["mITT", "TEST", 90, 94], ["TGC", "TEST", 148, 151], ["A", "TEST", 154, 155], ["CI", "TEST", 171, 173]]], ["Similar results were noted in the CE population with TGC curing 89.8% (150/167) and V/A curing 95.0% (151/ 159), difference TGC-V/A was -5.1% (95% CI -11.6, 1.2).Most commonly reported treatment emergent AEs (TEAEs, mITT) for TGC and V/A were nausea (17.3% and 3.2%, p < 0.001) and vomiting (6.1% and 1.6%, p = 0.032).", [["nausea", "DISEASE", 243, 249], ["vomiting", "DISEASE", 282, 290], ["TGC curing", "TEST", 53, 63], ["V", "TEST", 84, 85], ["TGC", "TEST", 124, 127], ["V", "TEST", 128, 129], ["A", "TEST", 130, 131], ["CI", "TEST", 147, 149], ["emergent AEs", "PROBLEM", 195, 207], ["TEAEs", "TEST", 209, 214], ["TGC", "TEST", 226, 229], ["nausea", "PROBLEM", 243, 249], ["vomiting", "PROBLEM", 282, 290]]], ["The V/A group had significantly higher TEAEs of SGPT increase (6.9% V/A vs 2.0% TGC, p = 0.025) and rash (2.6% V/A vs 0 TGC, p = 0.028).", [["rash", "DISEASE", 100, 104], ["SGPT", "SIMPLE_CHEMICAL", 48, 52], ["significantly higher TEAEs of SGPT increase", "PROBLEM", 18, 61], ["V", "TEST", 68, 69], ["A", "TEST", 70, 71], ["TGC", "TEST", 80, 83], ["p", "TEST", 85, 86], ["rash", "TEST", 100, 104], ["TGC", "TEST", 120, 123], ["p", "TEST", 125, 126]]], ["Conclusion: In the European analysis of the integrated Phase 3 worldwide clinical studies, TGC monotherapy is as safe and efficacious as the combination of V/A in the treatment of patients with cSSSI.P1786Safety and tolerability of tigecycline R. Maroko, N. Dartois, G. Rose, E.J. Ellis-Grosse (Collegeville, US; Paris, FR)P1786Objectives: Tigecycline (TGC), a glycylcycline, is a first-in-class, extended, broad-spectrum IV antibiotic that has demonstrated clinical activity in patients with complicated intra-abdominal infections (cIAI) and complicated skin and skin-structure infections (cSSSI).", [["intra-abdominal", "ANATOMY", 505, 520], ["skin", "ANATOMY", 555, 559], ["skin", "ANATOMY", 564, 568], ["cSSSI", "DISEASE", 194, 199], ["tigecycline", "CHEMICAL", 232, 243], ["Tigecycline", "CHEMICAL", 340, 351], ["TGC", "CHEMICAL", 353, 356], ["glycylcycline", "CHEMICAL", 361, 374], ["intra-abdominal infections", "DISEASE", 505, 531], ["cIAI", "DISEASE", 533, 537], ["skin and skin-structure infections", "DISEASE", 555, 589], ["SSSI", "DISEASE", 592, 596], ["Tigecycline", "CHEMICAL", 340, 351], ["glycylcycline", "CHEMICAL", 361, 374], ["TGC", "SIMPLE_CHEMICAL", 91, 94], ["V/A", "GENE_OR_GENE_PRODUCT", 156, 159], ["patients", "ORGANISM", 180, 188], ["Tigecycline", "SIMPLE_CHEMICAL", 340, 351], ["TGC", "SIMPLE_CHEMICAL", 353, 356], ["glycylcycline", "SIMPLE_CHEMICAL", 361, 374], ["patients", "ORGANISM", 479, 487], ["skin", "ORGAN", 555, 559], ["skin", "ORGAN", 564, 568], ["patients", "SPECIES", 180, 188], ["patients", "SPECIES", 479, 487], ["clinical studies", "TEST", 73, 89], ["TGC monotherapy", "TREATMENT", 91, 106], ["V/A", "TREATMENT", 156, 159], ["cSSSI", "TREATMENT", 194, 199], ["P1786Safety", "TEST", 200, 211], ["tigecycline", "TREATMENT", 232, 243], ["Collegeville", "TEST", 295, 307], ["Tigecycline (TGC", "TREATMENT", 340, 356], ["a glycylcycline", "TREATMENT", 359, 374], ["broad-spectrum IV antibiotic", "TREATMENT", 407, 435], ["complicated intra-abdominal infections (cIAI)", "PROBLEM", 493, 538], ["complicated skin and skin-structure infections", "PROBLEM", 543, 589], ["Dartois", "ANATOMY", 258, 265], ["intra-abdominal", "ANATOMY", 505, 520], ["infections", "OBSERVATION", 521, 531], ["complicated", "OBSERVATION_MODIFIER", 543, 554], ["skin", "ANATOMY", 555, 559], ["skin", "ANATOMY", 564, 568], ["structure", "OBSERVATION_MODIFIER", 569, 578], ["infections", "OBSERVATION", 579, 589]]], ["The safety of tigecycline was evaluated in four Phase III trials.", [["tigecycline", "CHEMICAL", 14, 25], ["tigecycline", "CHEMICAL", 14, 25], ["tigecycline", "SIMPLE_CHEMICAL", 14, 25], ["tigecycline", "TREATMENT", 14, 25]]], ["Methods: A total of 1415 hospitalized patients from these trials were pooled and evaluable for safety analysis.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["these trials", "TEST", 52, 64], ["safety analysis", "TEST", 95, 110]]], ["In the cIAI trial, patients received TGC 50 mg q 12 hrs (following a 100-mg loading dose) or imipenem 500 mg and cilastin 500 mg q 6 hrs.", [["imipenem", "CHEMICAL", 93, 101], ["cilastin", "CHEMICAL", 113, 121], ["imipenem", "CHEMICAL", 93, 101], ["cilastin", "CHEMICAL", 113, 121], ["patients", "ORGANISM", 19, 27], ["imipenem", "SIMPLE_CHEMICAL", 93, 101], ["cilastin", "SIMPLE_CHEMICAL", 113, 121], ["patients", "SPECIES", 19, 27], ["TGC", "TREATMENT", 37, 40], ["imipenem", "TREATMENT", 93, 101], ["cilastin", "TREATMENT", 113, 121]]], ["Those in the cSSSI study were treated with either TGC (same dose/schedule) or vancomycin 1 gm with or without aztreonam 2 gm q 12 hrs.", [["TGC", "CHEMICAL", 50, 53], ["vancomycin", "CHEMICAL", 78, 88], ["aztreonam", "CHEMICAL", 110, 119], ["vancomycin", "CHEMICAL", 78, 88], ["aztreonam", "CHEMICAL", 110, 119], ["TGC", "SIMPLE_CHEMICAL", 50, 53], ["aztreonam", "SIMPLE_CHEMICAL", 110, 119], ["the cSSSI study", "TEST", 9, 24], ["TGC (same dose/schedule", "TREATMENT", 50, 73], ["vancomycin", "TREATMENT", 78, 88], ["aztreonam", "TREATMENT", 110, 119]]], ["Results: The most frequently reported adverse events (AEs) in both TGC-treated groups were nausea (N) and vomiting (V).", [["nausea", "DISEASE", 91, 97], ["vomiting", "DISEASE", 106, 114], ["TGC", "SIMPLE_CHEMICAL", 67, 70], ["adverse events", "PROBLEM", 38, 52], ["nausea", "PROBLEM", 91, 97], ["vomiting", "PROBLEM", 106, 114]]], ["The incidence of N was 29.5% while V was approximately 19.5%; these were generally mild to moderate in severity.", [["N", "TEST", 17, 18], ["V", "TEST", 35, 36], ["generally mild to moderate in severity", "PROBLEM", 73, 111], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["moderate", "OBSERVATION_MODIFIER", 91, 99]]], ["Infection-related serious AEs were slightly more frequent with TGC versus comparators (6.7% vs 4.6%).", [["Infection", "PROBLEM", 0, 9], ["serious AEs", "PROBLEM", 18, 29], ["TGC", "TEST", 63, 66], ["comparators", "TEST", 74, 85], ["serious", "OBSERVATION_MODIFIER", 18, 25], ["slightly", "OBSERVATION_MODIFIER", 35, 43], ["more frequent", "OBSERVATION_MODIFIER", 44, 57]]], ["Discontinuations due to treatment-emergent AEs (including N/V) occurred at similar rates with TGC and comparators (5.0% vs 4.7%).", [["Discontinuations", "TREATMENT", 0, 16], ["treatment", "TREATMENT", 24, 33], ["emergent AEs", "PROBLEM", 34, 46], ["N/V)", "PROBLEM", 58, 62], ["TGC", "TEST", 94, 97], ["comparators", "TEST", 102, 113]]], ["Six patients (0.36%) treated with TGC presented with intestinal perforations and developed sepsis/septic shock compared with 2 (0.12%) for imipenem/cilastatin, with higher baseline Apache II scores in the TGC group; the relationship to treatment could not be determined.", [["intestinal", "ANATOMY", 53, 63], ["intestinal perforations", "DISEASE", 53, 76], ["sepsis", "DISEASE", 91, 97], ["septic shock", "DISEASE", 98, 110], ["imipenem", "CHEMICAL", 139, 147], ["cilastatin", "CHEMICAL", 148, 158], ["imipenem", "CHEMICAL", 139, 147], ["cilastatin", "CHEMICAL", 148, 158], ["patients", "ORGANISM", 4, 12], ["intestinal", "ORGAN", 53, 63], ["imipenem", "SIMPLE_CHEMICAL", 139, 147], ["cilastatin", "SIMPLE_CHEMICAL", 148, 158], ["patients", "SPECIES", 4, 12], ["TGC", "TREATMENT", 34, 37], ["intestinal perforations", "PROBLEM", 53, 76], ["sepsis", "PROBLEM", 91, 97], ["septic shock", "PROBLEM", 98, 110], ["imipenem", "TREATMENT", 139, 147], ["cilastatin", "TREATMENT", 148, 158], ["higher baseline Apache II scores in the TGC group", "PROBLEM", 165, 214], ["treatment", "TREATMENT", 236, 245], ["intestinal", "ANATOMY", 53, 63], ["perforations", "OBSERVATION", 64, 76], ["sepsis", "OBSERVATION", 91, 97], ["septic shock", "OBSERVATION", 98, 110]]], ["In the overall efficacy analysis, subjects with ''perforation of the intestines'' were balanced between the two groups, and overall efficacy was not statistically different.", [["intestines", "ANATOMY", 69, 79], ["intestines", "ORGAN", 69, 79], ["''perforation of the intestines''", "PROBLEM", 48, 81], ["perforation", "OBSERVATION", 50, 61], ["intestines", "ANATOMY", 69, 79]]], ["No clinically significant renal, hepatic, cardiac (QTc), bone marrow, or CNS toxicities were noted with TGC.P1786Conclusion: TGC appears to be safe and tolerable for patients with cIAI and cSSSI.", [["renal", "ANATOMY", 26, 31], ["hepatic", "ANATOMY", 33, 40], ["cardiac", "ANATOMY", 42, 49], ["bone marrow", "ANATOMY", 57, 68], ["CNS", "ANATOMY", 73, 76], ["renal, hepatic, cardiac (QTc), bone marrow, or CNS toxicities", "DISEASE", 26, 87], ["cIAI", "DISEASE", 180, 184], ["cSSSI", "DISEASE", 189, 194], ["renal", "MULTI-TISSUE_STRUCTURE", 26, 31], ["hepatic", "MULTI-TISSUE_STRUCTURE", 33, 40], ["cardiac", "ORGAN", 42, 49], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 57, 68], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["clinically significant renal, hepatic, cardiac (QTc), bone marrow", "PROBLEM", 3, 68], ["CNS toxicities", "PROBLEM", 73, 87], ["TGC", "TEST", 104, 107], ["cIAI", "TREATMENT", 180, 184], ["cSSSI", "TREATMENT", 189, 194], ["clinically", "OBSERVATION_MODIFIER", 3, 13], ["significant", "OBSERVATION", 14, 25], ["renal", "ANATOMY", 26, 31], ["hepatic", "ANATOMY", 33, 40], ["cardiac", "ANATOMY", 42, 49], ["bone marrow", "ANATOMY", 57, 68], ["CNS", "ANATOMY", 73, 76], ["toxicities", "OBSERVATION", 77, 87]]], ["N/V were generally mild to moderate in severity, self-limiting, and did not result in increased overall drug discontinuation.", [["V", "PROBLEM", 2, 3], ["generally mild to moderate in severity", "PROBLEM", 9, 47], ["increased overall drug discontinuation", "PROBLEM", 86, 124], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["moderate", "OBSERVATION_MODIFIER", 27, 35], ["self-limiting", "OBSERVATION_MODIFIER", 49, 62]]], ["There did not appear to be clinically significant renal, hepatic, cardiac, bone marrow, or neurological toxicities related to TGC treatment.", [["renal", "ANATOMY", 50, 55], ["hepatic", "ANATOMY", 57, 64], ["cardiac", "ANATOMY", 66, 73], ["bone marrow", "ANATOMY", 75, 86], ["neurological", "ANATOMY", 91, 103], ["renal, hepatic, cardiac, bone marrow, or neurological toxicities", "DISEASE", 50, 114], ["TGC", "CHEMICAL", 126, 129], ["renal", "ORGAN", 50, 55], ["hepatic", "MULTI-TISSUE_STRUCTURE", 57, 64], ["cardiac", "ORGAN", 66, 73], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 75, 86], ["clinically significant renal, hepatic, cardiac, bone marrow", "PROBLEM", 27, 86], ["neurological toxicities", "PROBLEM", 91, 114], ["TGC treatment", "TREATMENT", 126, 139], ["not appear to be", "UNCERTAINTY", 10, 26], ["clinically", "OBSERVATION_MODIFIER", 27, 37], ["significant", "OBSERVATION", 38, 49], ["renal", "ANATOMY", 50, 55], ["hepatic", "ANATOMY", 57, 64], ["cardiac", "ANATOMY", 66, 73], ["bone marrow", "ANATOMY", 75, 86]]], ["All-cause mortality rates did not statistically differ between those treated with TGC and the comparators.", [["TGC", "TREATMENT", 82, 85]]], ["Its demonstrated efficacy and favourable toxicity profile make TGC a good monotherapy option for selected serious infections.P1787Tigecycline as effective as imipenem/cilastatin in the treatment of complicated intra-abdominal infections: experience in India Objective: Due to diverse bacteriology and bacterial resistance, treatment of complicated intra-abdominal infections (cIAI) is a challenge.", [["intra-abdominal", "ANATOMY", 210, 225], ["intra-abdominal", "ANATOMY", 348, 363], ["toxicity", "DISEASE", 41, 49], ["infections", "DISEASE", 114, 124], ["P1787Tigecycline", "CHEMICAL", 125, 141], ["imipenem", "CHEMICAL", 158, 166], ["cilastatin", "CHEMICAL", 167, 177], ["intra-abdominal infections", "DISEASE", 210, 236], ["intra-abdominal infections", "DISEASE", 348, 374], ["cIAI", "DISEASE", 376, 380], ["P1787Tigecycline", "CHEMICAL", 125, 141], ["imipenem", "CHEMICAL", 158, 166], ["cilastatin", "CHEMICAL", 167, 177], ["TGC", "SIMPLE_CHEMICAL", 63, 66], ["P1787Tigecycline", "SIMPLE_CHEMICAL", 125, 141], ["imipenem", "SIMPLE_CHEMICAL", 158, 166], ["cilastatin", "SIMPLE_CHEMICAL", 167, 177], ["intra-abdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 348, 363], ["favourable toxicity profile", "PROBLEM", 30, 57], ["TGC a good monotherapy option", "TREATMENT", 63, 92], ["selected serious infections", "PROBLEM", 97, 124], ["P1787Tigecycline", "TREATMENT", 125, 141], ["imipenem", "TREATMENT", 158, 166], ["cilastatin", "TREATMENT", 167, 177], ["complicated intra-abdominal infections", "PROBLEM", 198, 236], ["diverse bacteriology", "PROBLEM", 276, 296], ["bacterial resistance", "PROBLEM", 301, 321], ["complicated intra-abdominal infections", "PROBLEM", 336, 374], ["favourable", "OBSERVATION_MODIFIER", 30, 40], ["toxicity", "OBSERVATION", 41, 49], ["serious", "OBSERVATION_MODIFIER", 106, 113], ["infections", "OBSERVATION", 114, 124], ["intra-abdominal", "ANATOMY", 210, 225], ["infections", "OBSERVATION", 226, 236], ["bacterial resistance", "OBSERVATION", 301, 321], ["complicated", "OBSERVATION_MODIFIER", 336, 347], ["intra-abdominal", "ANATOMY", 348, 363], ["infections", "OBSERVATION", 364, 374]]], ["In a double-blind, phase 3, multinational trial, the efficacy of tigecycline, a first-in-class glycylcycline, was compared with imipenem/cilastatin (IMI/CIS) in hospitalised patients with cIAI.", [["tigecycline", "CHEMICAL", 65, 76], ["glycylcycline", "CHEMICAL", 95, 108], ["imipenem", "CHEMICAL", 128, 136], ["cilastatin", "CHEMICAL", 137, 147], ["IMI", "CHEMICAL", 149, 152], ["cIAI", "DISEASE", 188, 192], ["tigecycline", "CHEMICAL", 65, 76], ["glycylcycline", "CHEMICAL", 95, 108], ["imipenem", "CHEMICAL", 128, 136], ["cilastatin", "CHEMICAL", 137, 147], ["tigecycline", "SIMPLE_CHEMICAL", 65, 76], ["glycylcycline", "SIMPLE_CHEMICAL", 95, 108], ["imipenem", "SIMPLE_CHEMICAL", 128, 136], ["cilastatin", "SIMPLE_CHEMICAL", 137, 147], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["tigecycline", "TREATMENT", 65, 76], ["imipenem", "TREATMENT", 128, 136], ["cilastatin", "TREATMENT", 137, 147], ["IMI/CIS", "TREATMENT", 149, 156]]], ["This subanalysis evaluated tigecycline safety and efficacy from 12 investigational sites in India.", [["tigecycline", "CHEMICAL", 27, 38], ["tigecycline", "CHEMICAL", 27, 38], ["tigecycline", "SIMPLE_CHEMICAL", 27, 38], ["This subanalysis", "TEST", 0, 16], ["tigecycline safety", "TREATMENT", 27, 45]]], ["Methods: Patients were stratified by disease severity (APACHE II score \u00a315 vs >15 but <31), and randomly assigned to IV tigecycline (100 mg loading, 50 mg q12h) or IV IMI/CIS adjusted for body weight (500/500 mg q6h for \u202170 kg) for 5-14 days.", [["body", "ANATOMY", 188, 192], ["tigecycline", "CHEMICAL", 120, 131], ["IMI", "CHEMICAL", 167, 170], ["tigecycline", "CHEMICAL", 120, 131], ["Patients", "ORGANISM", 9, 17], ["tigecycline", "SIMPLE_CHEMICAL", 120, 131], ["body", "ORGANISM_SUBDIVISION", 188, 192], ["Patients", "SPECIES", 9, 17], ["disease severity", "TEST", 37, 53], ["APACHE II score", "TEST", 55, 70], ["IV tigecycline", "TREATMENT", 117, 131], ["IV IMI/CIS", "TREATMENT", 164, 174], ["body weight", "TREATMENT", 188, 199]]], ["Clinical response at test-of-cure (TOC, 12-44 days after therapy) for microbiological evaluable (ME) and microbiological modified intent-to-treat (m-mITT) populations were co-primary efficacy endpoints where cure/failure responses were determined.", [["Clinical response at test", "TEST", 0, 25], ["TOC", "TEST", 35, 38], ["therapy", "TREATMENT", 57, 64], ["microbiological evaluable", "TEST", 70, 95], ["failure responses", "PROBLEM", 213, 230]]], ["Safety evaluations included vital signs, laboratory tests and record of adverse events (AEs).", [["Safety evaluations", "TEST", 0, 18], ["vital signs", "TEST", 28, 39], ["laboratory tests", "TEST", 41, 57], ["adverse events", "PROBLEM", 72, 86]]], ["Results: In India, 167 patients received at least 1 dose (mITT, 84 tigecycline, 83 IMI/CIS), 149 patients were clinically evaluable (CE), 85 were ME, 120 were m-mITT.", [["tigecycline", "CHEMICAL", 67, 78], ["tigecycline", "CHEMICAL", 67, 78], ["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 97, 105], ["mITT", "TEST", 58, 62], ["tigecycline", "TREATMENT", 67, 78], ["CE", "TEST", 133, 135]]], ["Primary diagnoses (mITT) were complicated appendicitis (31%), gastric/duodenal perforation (26%), perforation of intestine (18%), cholecystitis (12%), peritonitis (6%), and intraabdominal abscess (5%).", [["gastric", "ANATOMY", 62, 69], ["duodenal", "ANATOMY", 70, 78], ["intestine", "ANATOMY", 113, 122], ["intraabdominal abscess", "ANATOMY", 173, 195], ["mITT", "DISEASE", 19, 23], ["appendicitis", "DISEASE", 42, 54], ["gastric/duodenal perforation", "DISEASE", 62, 90], ["perforation of intestine", "DISEASE", 98, 122], ["cholecystitis", "DISEASE", 130, 143], ["peritonitis", "DISEASE", 151, 162], ["intraabdominal abscess", "DISEASE", 173, 195], ["gastric", "ORGAN", 62, 69], ["duodenal", "ORGAN", 70, 78], ["intestine", "ORGAN", 113, 122], ["intraabdominal abscess", "PATHOLOGICAL_FORMATION", 173, 195], ["complicated appendicitis", "PROBLEM", 30, 54], ["gastric/duodenal perforation", "PROBLEM", 62, 90], ["perforation of intestine", "PROBLEM", 98, 122], ["cholecystitis", "PROBLEM", 130, 143], ["peritonitis", "PROBLEM", 151, 162], ["intraabdominal abscess", "PROBLEM", 173, 195], ["appendicitis", "OBSERVATION", 42, 54], ["gastric", "ANATOMY", 62, 69], ["duodenal", "ANATOMY", 70, 78], ["perforation", "OBSERVATION", 79, 90], ["perforation", "OBSERVATION", 98, 109], ["intestine", "ANATOMY", 113, 122], ["cholecystitis", "OBSERVATION", 130, 143], ["peritonitis", "OBSERVATION", 151, 162], ["intraabdominal", "ANATOMY", 173, 187], ["abscess", "OBSERVATION", 188, 195]]], ["Cure rates at TOC in ME in India were 36/41 (87.8%) tigecycline and 40/44 (90.9%) IMI/ CIS, which are consistent with overall ME results [80.6% (199/ 247) tigecycline vs 82.4% (210/255) IMI/CIS (95% CI = )8.4, 5.1; non-inferiority p < 0.001)].", [["TOC", "CHEMICAL", 14, 17], ["tigecycline", "CHEMICAL", 52, 63], ["tigecycline", "CHEMICAL", 155, 166], ["tigecycline", "CHEMICAL", 52, 63], ["tigecycline", "CHEMICAL", 155, 166], ["tigecycline", "SIMPLE_CHEMICAL", 52, 63], ["Cure rates", "TEST", 0, 10], ["tigecycline", "TEST", 52, 63], ["IMI/ CIS", "TEST", 82, 90], ["tigecycline vs", "TEST", 155, 169], ["IMI", "TEST", 186, 189], ["CIS", "TEST", 190, 193], ["CI", "TEST", 199, 201]]], ["In India m-mITT, cure rates at TOC were 47/59 (79.7%) tigecycline and 54/61 (88.5%) IMI/CIS, similar to the overall m-mITT results [73.5% (227/309) tigecycline vs 78.2% (244/312) IMI/CIS (95% CI = )11.0, 2.5; non-inferiority p < 0.001)].", [["TOC", "CHEMICAL", 31, 34], ["tigecycline", "CHEMICAL", 54, 65], ["tigecycline", "CHEMICAL", 148, 159], ["tigecycline", "CHEMICAL", 54, 65], ["tigecycline", "CHEMICAL", 148, 159], ["tigecycline", "SIMPLE_CHEMICAL", 54, 65], ["cure rates", "TEST", 17, 27], ["TOC", "TEST", 31, 34], ["tigecycline", "TEST", 54, 65], ["IMI/CIS", "TEST", 84, 91], ["tigecycline vs", "TEST", 148, 162], ["IMI", "TEST", 179, 182], ["CIS", "TEST", 183, 186], ["CI", "TEST", 192, 194]]], ["Noninferiority of tigecycline among India patients could not be statistically demonstrated because of insufficient sample sizes, however, magnitude of response to study drugs in patients treated in India was comparable to that in overall patients.", [["tigecycline", "CHEMICAL", 18, 29], ["tigecycline", "CHEMICAL", 18, 29], ["tigecycline", "SIMPLE_CHEMICAL", 18, 29], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 178, 186], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 238, 246], ["tigecycline", "TREATMENT", 18, 29], ["insufficient sample sizes", "PROBLEM", 102, 127], ["study drugs", "TREATMENT", 163, 174], ["tigecycline", "OBSERVATION", 18, 29], ["sizes", "OBSERVATION_MODIFIER", 122, 127]]], ["In India, treatment AEs were similar with significantly higher incidence of dyspnoea in tigecycline (9.5%) vs IMI/CIS (0.0%), p = 0.007.", [["dyspnoea", "DISEASE", 76, 84], ["tigecycline", "CHEMICAL", 88, 99], ["IMI", "CHEMICAL", 110, 113], ["tigecycline", "CHEMICAL", 88, 99], ["tigecycline", "SIMPLE_CHEMICAL", 88, 99], ["dyspnoea", "PROBLEM", 76, 84], ["tigecycline", "TEST", 88, 99], ["IMI", "TEST", 110, 113], ["CIS", "TEST", 114, 117], ["dyspnoea", "OBSERVATION", 76, 84]]], ["Conclusions: Efficacy results in India are consistent with findings from the overall study and results at other centres, suggesting tigecycline is noninferior to comparator in treating cIAI.P1787Nosocomial infection: control of environment, viral infections P1788 Bacterial flora contamination of blood pressure cuffs in use on hospital wards N. Walker, R. Gupta, J. Cheesbrough (Preston, UK)P1787Blood pressure cuffs are a plausbile vehicle for the transmission of nosocomial infection between patients.", [["blood", "ANATOMY", 297, 302], ["tigecycline", "CHEMICAL", 132, 143], ["cIAI", "DISEASE", 185, 189], ["P1787Nosocomial infection", "DISEASE", 190, 215], ["viral infections", "DISEASE", 241, 257], ["nosocomial infection", "DISEASE", 466, 486], ["tigecycline", "CHEMICAL", 132, 143], ["tigecycline", "SIMPLE_CHEMICAL", 132, 143], ["blood", "ORGANISM_SUBSTANCE", 297, 302], ["patients", "ORGANISM", 495, 503], ["patients", "SPECIES", 495, 503], ["the overall study", "TEST", 73, 90], ["tigecycline", "TREATMENT", 132, 143], ["P1787Nosocomial infection", "PROBLEM", 190, 215], ["viral infections", "PROBLEM", 241, 257], ["Bacterial flora", "PROBLEM", 264, 279], ["blood pressure cuffs", "TREATMENT", 297, 317], ["P1787Blood pressure cuffs", "TREATMENT", 392, 417], ["a plausbile vehicle", "TREATMENT", 422, 441], ["nosocomial infection", "PROBLEM", 466, 486], ["consistent with", "UNCERTAINTY", 43, 58], ["tigecycline", "OBSERVATION", 132, 143], ["infection", "OBSERVATION", 206, 215], ["nosocomial", "OBSERVATION_MODIFIER", 466, 476], ["infection", "OBSERVATION", 477, 486]]], ["Despite this, few studies have examined the level of bacterial contamination and tested for the presence of common nosocomial pathogens on their surface.", [["surface", "ANATOMY", 145, 152], ["surface", "CELLULAR_COMPONENT", 145, 152], ["few studies", "TEST", 14, 25], ["bacterial contamination", "PROBLEM", 53, 76], ["common nosocomial pathogens on their surface", "PROBLEM", 108, 152], ["bacterial contamination", "OBSERVATION", 53, 76]]], ["Using sterile gloves, a disposable template measuring 10 \u00b7 10 cms was placed onto the cuff and a moistened sterile swab was rubbed onto the defined area for 1 minute and then transported in 10 mls of buffer medium.", [["cuff", "ANATOMY", 86, 90], ["swab", "ANATOMY", 115, 119], ["sterile gloves", "TREATMENT", 6, 20], ["a disposable template", "TREATMENT", 22, 43], ["a moistened sterile swab", "TREATMENT", 95, 119], ["buffer medium", "TREATMENT", 200, 213], ["cuff", "ANATOMY", 86, 90]]], ["From each sample, 0.5 mls of the buffer was plated onto 6 different media which included a non-selective agar medium for total viable count (TVC) and selective media for S. aureus, MRSA, C. difficile, coliforms and Vancomycin resistant enterococci (VRE.)", [["sample", "ANATOMY", 10, 16], ["MRSA", "CHEMICAL", 181, 185], ["C. difficile", "DISEASE", 187, 199], ["coliforms", "CHEMICAL", 201, 210], ["Vancomycin", "CHEMICAL", 215, 225], ["Vancomycin", "CHEMICAL", 215, 225], ["S. aureus", "ORGANISM", 170, 179], ["C. difficile", "ORGANISM", 187, 199], ["Vancomycin resistant enterococci", "SIMPLE_CHEMICAL", 215, 247], ["S. aureus", "SPECIES", 170, 179], ["MRSA", "SPECIES", 181, 185], ["C. difficile", "SPECIES", 187, 199], ["S. aureus", "SPECIES", 170, 179], ["MRSA", "SPECIES", 181, 185], ["C. difficile", "SPECIES", 187, 199], ["the buffer", "TREATMENT", 29, 39], ["a non-selective agar medium", "TREATMENT", 89, 116], ["total viable count", "TEST", 121, 139], ["selective media", "TREATMENT", 150, 165], ["S. aureus", "PROBLEM", 170, 179], ["MRSA", "PROBLEM", 181, 185], ["C. difficile", "PROBLEM", 187, 199], ["coliforms", "PROBLEM", 201, 210], ["Vancomycin resistant enterococci", "PROBLEM", 215, 247], ["VRE", "PROBLEM", 249, 252], ["aureus", "OBSERVATION", 173, 179], ["MRSA", "OBSERVATION", 181, 185]]], ["Bacterial growth was recovered from all 24 cuffs.", [["Bacterial growth", "PROBLEM", 0, 16], ["growth", "OBSERVATION_MODIFIER", 10, 16], ["cuffs", "OBSERVATION_MODIFIER", 43, 48]]], ["Pathogenic organisms were isolated from 14 cuffs (58%).", [["Pathogenic organisms", "PROBLEM", 0, 20]]], ["MSSA from 5, MRSA from 1 and C. difficile from 5.", [["MSSA", "CHEMICAL", 0, 4], ["C. difficile", "ORGANISM", 29, 41], ["MRSA", "SPECIES", 13, 17], ["C. difficile", "SPECIES", 29, 41], ["C. difficile", "SPECIES", 29, 41], ["MSSA", "PROBLEM", 0, 4], ["MRSA", "PROBLEM", 13, 17], ["C. difficile", "PROBLEM", 29, 41], ["difficile", "OBSERVATION", 32, 41]]], ["The remaining three cuffs grew more than one pathogenic organism; MSSA + MRSA + C. difficile from one and MSSA + C. difficile from 2 cuffs.", [["MSSA", "CHEMICAL", 66, 70], ["MRSA", "CHEMICAL", 73, 77], ["C. difficile", "DISEASE", 80, 92], ["MSSA", "CHEMICAL", 106, 110], ["C. difficile", "DISEASE", 113, 125], ["MSSA + MRSA + C. difficile", "ORGANISM", 66, 92], ["MRSA", "SPECIES", 73, 77], ["C. difficile", "SPECIES", 80, 92], ["C. difficile", "SPECIES", 113, 125], ["C. difficile", "SPECIES", 80, 92], ["C. difficile", "SPECIES", 113, 125], ["The remaining three cuffs", "TEST", 0, 25], ["one pathogenic organism", "PROBLEM", 41, 64], ["MSSA", "PROBLEM", 66, 70], ["MRSA", "PROBLEM", 73, 77], ["C. difficile", "PROBLEM", 80, 92], ["MSSA", "PROBLEM", 106, 110], ["C. difficile", "PROBLEM", 113, 125], ["MSSA", "OBSERVATION", 66, 70], ["MRSA", "OBSERVATION", 73, 77], ["C. difficile", "OBSERVATION", 80, 92], ["C. difficile", "OBSERVATION", 113, 125]]], ["Colifroms and VRE were not isolated from any of the cuffs.", [["Colifroms", "CHEMICAL", 0, 9], ["Colifroms", "SIMPLE_CHEMICAL", 0, 9], ["cuffs", "TISSUE", 52, 57], ["Colifroms", "PROBLEM", 0, 9], ["VRE", "PROBLEM", 14, 17], ["VRE", "OBSERVATION", 14, 17], ["cuffs", "OBSERVATION", 52, 57]]], ["The range of total viable counts recovered per 100 cm 2 area of the cuff varied from 1000 > 20000 cfu and the cuffs with the highest counts tended to have more pathogens present.", [["total viable counts", "TEST", 13, 32], ["the cuff", "TEST", 64, 72], ["the cuffs", "TEST", 106, 115], ["the highest counts", "TEST", 121, 139], ["range", "OBSERVATION_MODIFIER", 4, 9], ["100 cm", "OBSERVATION_MODIFIER", 47, 53], ["cuff", "ANATOMY", 68, 72], ["varied", "OBSERVATION_MODIFIER", 73, 79], ["pathogens", "OBSERVATION", 160, 169]]], ["MSSA and C. difficile were isolated from 33% of the cuffs sampled and MRSA from 8%.", [["MSSA", "CHEMICAL", 0, 4], ["MRSA", "DISEASE", 70, 74], ["C. difficile", "ORGANISM", 9, 21], ["C. difficile", "SPECIES", 9, 21], ["MRSA", "SPECIES", 70, 74], ["C. difficile", "SPECIES", 9, 21], ["MSSA", "PROBLEM", 0, 4], ["C. difficile", "PROBLEM", 9, 21], ["the cuffs", "TEST", 48, 57], ["MRSA", "PROBLEM", 70, 74], ["C.", "OBSERVATION_MODIFIER", 9, 11], ["difficile", "OBSERVATION", 12, 21]]], ["While the actual importance of this potential route of transmission for nosocomial pathogens remains unclear, it can not be dismissed.", [["nosocomial pathogens", "DISEASE", 72, 92], ["nosocomial pathogens", "PROBLEM", 72, 92]]], ["The impracticality of decontaminating blood pressure cuffs between patients suggests that single patient use cuffs or a barrier between cuff and skin would be a more viable option on a busy general ward.P1789Needlestick and sharp injuries of health care personnel in a newly founded tertiary hospital: a prospective study M. Falagas, I. Karydis, G. Georgoulias, P. Hatzopoulou, D. Nikita, I. Kostogiannou (Athens, GR)P1789Objectives: Needlestick and sharp injuries of health care workers are a major cause of anxiety and may expose susceptible employees to the risk of infectious diseases.", [["blood", "ANATOMY", 38, 43], ["cuff", "ANATOMY", 136, 140], ["skin", "ANATOMY", 145, 149], ["injuries", "DISEASE", 230, 238], ["injuries", "DISEASE", 456, 464], ["anxiety", "DISEASE", 509, 516], ["infectious diseases", "DISEASE", 569, 588], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["patients", "ORGANISM", 67, 75], ["patient", "ORGANISM", 97, 104], ["cuff", "MULTI-TISSUE_STRUCTURE", 136, 140], ["skin", "ORGAN", 145, 149], ["patients", "SPECIES", 67, 75], ["patient", "SPECIES", 97, 104], ["decontaminating blood pressure cuffs", "TREATMENT", 22, 58], ["cuffs", "TREATMENT", 109, 114], ["a barrier between cuff", "TREATMENT", 118, 140], ["anxiety", "PROBLEM", 509, 516], ["infectious diseases", "PROBLEM", 569, 588], ["pressure cuffs", "OBSERVATION", 44, 58], ["skin", "ANATOMY", 145, 149], ["infectious", "OBSERVATION", 569, 579]]], ["However, the incidence of such injuries has not been examined in a newly founded hospital while preventive programmes are taking place.", [["injuries", "DISEASE", 31, 39], ["such injuries", "PROBLEM", 26, 39], ["preventive programmes", "TREATMENT", 96, 117]]], ["Methods: We prospectively studied the needlestick and sharp injuries of employees in a newly founded tertiary hospital in Athens, Greece while a vaccination program against hepatitis B virus as well as educational activities for avoidance of injuries were taking place.", [["injuries", "DISEASE", 60, 68], ["hepatitis B", "DISEASE", 173, 184], ["injuries", "DISEASE", 242, 250], ["hepatitis B virus", "ORGANISM", 173, 190], ["hepatitis B virus", "SPECIES", 173, 190], ["hepatitis B virus", "SPECIES", 173, 190], ["a vaccination program", "TREATMENT", 143, 164], ["hepatitis B virus", "PROBLEM", 173, 190], ["injuries", "PROBLEM", 242, 250]]], ["Serologic studies for hepatitis B and C virus as well as human immunodeficiency virus (HIV) were performed in all injured employees and the source patients (when known).", [["hepatitis B", "DISEASE", 22, 33], ["human immunodeficiency virus (HIV)", "DISEASE", 57, 91], ["hepatitis B and C virus", "ORGANISM", 22, 45], ["human immunodeficiency virus", "ORGANISM", 57, 85], ["HIV", "ORGANISM", 87, 90], ["patients", "ORGANISM", 147, 155], ["hepatitis B and C virus", "SPECIES", 22, 45], ["human immunodeficiency virus (HIV", "SPECIES", 57, 90], ["patients", "SPECIES", 147, 155], ["hepatitis B", "SPECIES", 22, 33], ["C virus", "SPECIES", 38, 45], ["human immunodeficiency virus", "SPECIES", 57, 85], ["HIV", "SPECIES", 87, 90], ["Serologic studies", "TEST", 0, 17], ["hepatitis B", "PROBLEM", 22, 33], ["C virus", "PROBLEM", 38, 45], ["human immunodeficiency virus", "PROBLEM", 57, 85]]], ["Results: Sixty-eight needlestick, 8 sharp injuries, and 3 splashes were reported during the study period (01/10/2002 to 28/02/ 2005) in 71 nurses, 2 housekeepers, 3 technicians, and 3 ambulance workers.", [["injuries", "DISEASE", 42, 50], ["8 sharp injuries", "PROBLEM", 34, 50], ["3 splashes", "PROBLEM", 56, 66], ["sharp", "OBSERVATION_MODIFIER", 36, 41], ["injuries", "OBSERVATION", 42, 50]]], ["The overall incidence (percutaneous injuries and splashes) per 100full-time employment-years (100 FTEYs) was 2.4% whereas the incidence of percutaneous injuries alone per 100 FTEYs was 2.3%.", [["percutaneous", "ANATOMY", 23, 35], ["percutaneous", "ANATOMY", 139, 151], ["injuries", "DISEASE", 152, 160], ["The overall incidence (percutaneous injuries", "PROBLEM", 0, 44], ["splashes", "PROBLEM", 49, 57], ["percutaneous injuries", "PROBLEM", 139, 160], ["percutaneous", "OBSERVATION_MODIFIER", 23, 35], ["injuries", "OBSERVATION", 36, 44], ["percutaneous", "OBSERVATION_MODIFIER", 139, 151], ["injuries", "OBSERVATION", 152, 160]]], ["A higher incidence of injuries was noted during the first than the second half of the study period (3.8% versus 1.8%, p = 0.003).", [["injuries", "DISEASE", 22, 30], ["injuries", "PROBLEM", 22, 30], ["the study", "TEST", 82, 91], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["incidence", "OBSERVATION_MODIFIER", 9, 18], ["injuries", "OBSERVATION", 22, 30]]], ["No source patient was found positive for hepatitis C or HIV.", [["hepatitis C or HIV", "DISEASE", 41, 59], ["patient", "ORGANISM", 10, 17], ["hepatitis C", "ORGANISM", 41, 52], ["HIV", "ORGANISM", 56, 59], ["patient", "SPECIES", 10, 17], ["HIV", "SPECIES", 56, 59], ["HIV", "SPECIES", 56, 59], ["hepatitis C", "PROBLEM", 41, 52], ["HIV", "PROBLEM", 56, 59]]], ["The use of high-titre immunoglobulin after adjustment for the incidence of injuries was higher in the first than the second half of the study period (22.6% vs 3.8%, p = 0.05).", [["injuries", "DISEASE", 75, 83], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 22, 36], ["immunoglobulin", "PROTEIN", 22, 36], ["high-titre immunoglobulin", "TREATMENT", 11, 36], ["injuries", "PROBLEM", 75, 83], ["injuries", "OBSERVATION", 75, 83], ["higher", "OBSERVATION_MODIFIER", 88, 94]]], ["Conclusion: Although we did not adjust for possible confounders, our data show that educational and vaccination preventive programs for needlestick and sharp injuries led to a statistically significant decrease in the incidence of such injuries and use of high-titre immunoglobulin.P1790Epidemiology of occupational needlestick and sharps injury among healthcare-workers in Turkey S. Hosoglu on behalf of the Occupational Infections study group, TurkeyP1790Background: Health care workers (HCWs) are frequently exposed to the danger of infectious agents through needle stick and sharps injury (NSSI) in their occupational efforts.", [["injuries", "DISEASE", 158, 166], ["injuries", "DISEASE", 236, 244], ["sharps injury", "DISEASE", 332, 345], ["Infections", "DISEASE", 422, 432], ["sharps injury", "DISEASE", 579, 592], ["NSSI", "DISEASE", 594, 598], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 267, 281], ["high-titre immunoglobulin", "PROTEIN", 256, 281], ["our data", "TEST", 65, 73], ["educational and vaccination preventive programs", "TREATMENT", 84, 131], ["needlestick", "PROBLEM", 136, 147], ["sharp injuries", "PROBLEM", 152, 166], ["such injuries", "PROBLEM", 231, 244], ["high-titre immunoglobulin", "TREATMENT", 256, 281], ["infectious agents", "TREATMENT", 536, 553], ["needle stick", "TEST", 562, 574], ["sharps injury", "PROBLEM", 579, 592], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["decrease", "OBSERVATION_MODIFIER", 202, 210]]], ["In Turkey, the hepatitis B and C viruses cause an essential threat to the HCWs because of their prevalence rate (2%-4% and 0.5%-1%, respectively).Method:A cross-sectional countrywide survey study was performed on the epidemiology of NSSI among HCWs at 30 hospitals in 19 cities throughout the country.", [["hepatitis B", "DISEASE", 15, 26], ["NSSI", "DISEASE", 233, 237], ["hepatitis B and C viruses", "ORGANISM", 15, 40], ["hepatitis B", "SPECIES", 15, 26], ["the hepatitis B", "PROBLEM", 11, 26], ["C viruses", "PROBLEM", 31, 40], ["their prevalence rate", "TEST", 90, 111], ["A cross-sectional countrywide survey study", "TEST", 153, 195], ["hepatitis", "OBSERVATION", 15, 24]]], ["Data relating to the epidemiology of NSSIs were collected using a standard questionnaire in 2004.", [["NSSIs", "DISEASE", 37, 42], ["NSSIs", "CANCER", 37, 42]]], ["Results: Totally 5048 HCWs completed the questionnaire forms.", [["HCWs", "ORGANISM", 22, 26]]], ["Nurses are the leading group (2016 persons) that joined into the study were followed by doctors (1452 persons) andlaboratory technicians (475).", [["persons", "SPECIES", 35, 42], ["persons", "SPECIES", 102, 109]]], ["Totally 2498 of them (49.5%) declared an occupational exposure or NSSI in the last 12 months related their job.", [["NSSI", "DISEASE", 66, 70]]], ["Needle stick injury was reported in 1698 of them (33.6%), splash into the eye in 1132 (22.4%), sharp injury in 737 (14.6%), and the other injuries in 419 (7.0%).", [["eye", "ANATOMY", 74, 77], ["Needle stick injury", "DISEASE", 0, 19], ["sharp injury", "DISEASE", 95, 107], ["injuries", "DISEASE", 138, 146], ["eye", "ORGAN", 74, 77], ["Needle stick injury", "PROBLEM", 0, 19], ["splash into the eye", "TEST", 58, 77], ["sharp injury", "PROBLEM", 95, 107], ["the other injuries", "PROBLEM", 128, 146], ["eye", "ANATOMY", 74, 77], ["sharp", "OBSERVATION_MODIFIER", 95, 100], ["injury", "OBSERVATION", 101, 107], ["injuries", "OBSERVATION", 138, 146]]], ["The hepatitis positivity was reported in 567 cases (2.27%) Objectives: To assess the microbiological status of reprocessed single-use devices for interventional cardiology by testing bioburden, sterility and pyrogenic load.", [["hepatitis", "DISEASE", 4, 13], ["The hepatitis positivity", "TEST", 0, 24], ["interventional cardiology", "TREATMENT", 146, 171], ["sterility", "PROBLEM", 194, 203], ["pyrogenic load", "PROBLEM", 208, 222], ["hepatitis", "OBSERVATION", 4, 13], ["pyrogenic load", "OBSERVATION", 208, 222]]], ["Methods: A total amount of 154 electrophysiology non-lumen catheters (EP) were collected after the first clinical use on patient.", [["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128], ["electrophysiology non-lumen catheters", "TREATMENT", 31, 68], ["catheters", "OBSERVATION", 59, 68]]], ["20 devices were contaminated with bacteria spiked human blood and underwent four different pre-sterilization protocols including chlorine, polyphenol, and enzymatic agents.", [["blood", "ANATOMY", 56, 61], ["chlorine", "CHEMICAL", 129, 137], ["polyphenol", "CHEMICAL", 139, 149], ["chlorine", "CHEMICAL", 129, 137], ["polyphenol", "CHEMICAL", 139, 149], ["human", "ORGANISM", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["chlorine", "SIMPLE_CHEMICAL", 129, 137], ["polyphenol", "SIMPLE_CHEMICAL", 139, 149], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["20 devices", "TREATMENT", 0, 10], ["bacteria spiked human blood", "PROBLEM", 34, 61], ["four different pre-sterilization protocols", "TREATMENT", 76, 118], ["chlorine", "TREATMENT", 129, 137], ["polyphenol", "TREATMENT", 139, 149], ["enzymatic agents", "TREATMENT", 155, 171]]], ["Treated samples were assayed by cultural quantitative methods (CQM) for bactericidal properties and electron microscopy (EM) for biologic residuals.", [["samples", "ANATOMY", 8, 15], ["bactericidal properties", "TREATMENT", 72, 95], ["electron microscopy", "TEST", 100, 119], ["biologic residuals", "TEST", 129, 147]]], ["73 EP were tested for sterility.", [["sterility", "PROBLEM", 22, 31]]], ["By the repetition of simulated-use (bacteria spiked blood) and regeneration (enzymatic and chlorine treatment, gas plasma sterilization) we obtained 54, 39, 26, 28, 36, 22 samples respectively reprocessed 1, 2, 3, 4, 5, 6 times.", [["blood", "ANATOMY", 52, 57], ["plasma", "ANATOMY", 115, 121], ["chlorine", "CHEMICAL", 91, 99], ["chlorine", "CHEMICAL", 91, 99], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["chlorine", "SIMPLE_CHEMICAL", 91, 99], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["bacteria spiked blood", "PROBLEM", 36, 57], ["regeneration (enzymatic and chlorine treatment", "TREATMENT", 63, 109], ["gas plasma sterilization", "TEST", 111, 135]]], ["Devices were cultured for 28 days in trypticase soy broth.", [["Devices", "TREATMENT", 0, 7]]], ["The pyrogenic status of 61 EP was monitored after clinical use, after decontamination-cleaning treatments and after complete reprocessing by LAL test.", [["LAL", "PROTEIN", 141, 144], ["The pyrogenic status", "TEST", 0, 20], ["decontamination", "TREATMENT", 70, 85], ["cleaning treatments", "TREATMENT", 86, 105], ["LAL test", "TEST", 141, 149], ["pyrogenic", "OBSERVATION_MODIFIER", 4, 13]]], ["Results: High-resolution EM and CQM confirmed the superior properties of chlorine releasing agent added to enzymatic detergent for devices treatment before sterilization.", [["chlorine", "CHEMICAL", 73, 81], ["chlorine", "CHEMICAL", 73, 81], ["chlorine", "SIMPLE_CHEMICAL", 73, 81], ["chlorine releasing agent", "TREATMENT", 73, 97], ["enzymatic detergent", "TREATMENT", 107, 126], ["devices treatment", "TREATMENT", 131, 148], ["sterilization", "TREATMENT", 156, 169]]], ["Hypochlorous acid based protocols were more biocide (>3.1 log CFU reduction) than polyphenolic (3.2-1.9 log CFU reduction).", [["Hypochlorous acid", "CHEMICAL", 0, 17], ["Hypochlorous acid", "CHEMICAL", 0, 17], ["polyphenolic", "CHEMICAL", 82, 94], ["Hypochlorous acid", "SIMPLE_CHEMICAL", 0, 17], ["Hypochlorous acid based protocols", "TREATMENT", 0, 33], ["polyphenolic", "TEST", 82, 94]]], ["Sterility tests showed no positive sample to inoculated strain until the fourth cycle of reprocessing.", [["Sterility tests", "TEST", 0, 15], ["positive sample to inoculated strain", "PROBLEM", 26, 62], ["no", "UNCERTAINTY", 23, 25]]], ["Catheters showed the growth of the inoculated strain, Bacillus subtilis in 1/35 and 1/22 samples after five cycles and six cycles respectively.", [["strain", "ANATOMY", 46, 52], ["samples", "ANATOMY", 89, 96], ["Bacillus subtilis", "ORGANISM", 54, 71], ["Bacillus subtilis", "SPECIES", 54, 71], ["Bacillus subtilis", "SPECIES", 54, 71], ["Catheters", "TREATMENT", 0, 9], ["the inoculated strain", "PROBLEM", 31, 52], ["Bacillus subtilis", "TEST", 54, 71], ["growth", "OBSERVATION_MODIFIER", 21, 27], ["inoculated strain", "OBSERVATION", 35, 52], ["Bacillus subtilis", "OBSERVATION", 54, 71]]], ["Every reprocessed device was non-pyrogenic (<20 EU/catheter).", [["Every reprocessed device", "TREATMENT", 0, 24], ["non-pyrogenic", "PROBLEM", 29, 42], ["EU/catheter", "TREATMENT", 48, 59], ["catheter", "OBSERVATION", 51, 59]]], ["In addition, tests conducted on in-vitro spiked catheters showed that pyrogenic loads of 200 EU/device were reduced to less than 11 EU/device.", [["tests", "TEST", 13, 18], ["pyrogenic loads", "PROBLEM", 70, 85], ["EU/device", "TREATMENT", 93, 102], ["EU/device", "TREATMENT", 132, 141], ["pyrogenic loads", "OBSERVATION", 70, 85]]], ["Conclusions: Reprocessing procedures following the adopted regeneration protocol were able to satisfy the fundamental microbiological requirements until five in-vitro reuses.", [["Reprocessing procedures", "TREATMENT", 13, 36], ["the adopted regeneration protocol", "TREATMENT", 47, 80]]], ["Sterility tests showed that devices' sterility was not guaranteed after five reuses.", [["Sterility tests", "TEST", 0, 15], ["devices' sterility", "TREATMENT", 28, 46]]], ["Pre-sterilization treatments including enzymatic solutions and chlorine revealed high cleaning properties with effective bioburden reduction.", [["chlorine", "CHEMICAL", 63, 71], ["chlorine", "CHEMICAL", 63, 71], ["chlorine", "SIMPLE_CHEMICAL", 63, 71], ["Pre-sterilization treatments", "TREATMENT", 0, 28], ["enzymatic solutions", "TREATMENT", 39, 58], ["chlorine", "TREATMENT", 63, 71], ["high cleaning properties", "TREATMENT", 81, 105], ["effective bioburden reduction", "TREATMENT", 111, 140], ["high cleaning", "OBSERVATION", 81, 94], ["effective", "OBSERVATION_MODIFIER", 111, 120], ["bioburden reduction", "OBSERVATION", 121, 140]]], ["Storage intervals among reprocessing steps longer than 24 hours should be avoided in order to limit contamination and pyrogenic load.", [["pyrogenic load", "PROBLEM", 118, 132]]], ["Technical considerations suggest to consider the introduction of reprocessing procedure only in hospitals with a considerable workload.P1792Room disinfection in the hospital setting using Akacid plus \u00d2 C. Kratzer, S. Tobudic, W. Graninger, A. Buxbaum, A. Georgopoulos (Vienna, AT)P1792Objectives: Akacid plus \u00d2 , a novel polymeric guanidine with broad antimicrobial activity also against multi-resistant bacterial strains, was used in the present study as room disinfectant.", [["strains", "ANATOMY", 414, 421], ["P1792Room", "CHEMICAL", 135, 144], ["Akacid", "CHEMICAL", 188, 194], ["Akacid", "CHEMICAL", 297, 303], ["polymeric guanidine", "CHEMICAL", 321, 340], ["guanidine", "CHEMICAL", 331, 340], ["P1792Room", "SIMPLE_CHEMICAL", 135, 144], ["Akacid", "SIMPLE_CHEMICAL", 297, 303], ["\u00d2", "SIMPLE_CHEMICAL", 309, 310], ["polymeric guanidine", "SIMPLE_CHEMICAL", 321, 340], ["reprocessing procedure", "TREATMENT", 65, 87], ["Akacid", "TREATMENT", 188, 194], ["a novel polymeric guanidine", "TREATMENT", 313, 340], ["broad antimicrobial activity", "TREATMENT", 346, 374], ["multi-resistant bacterial strains", "PROBLEM", 388, 421]]], ["Methods: Disinfection of closed rooms experimentally contaminated with antibiotic-susceptible and multi-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa and Escherichia coli was performed using Akacid plus \u00d2 at concentrations of 0.1%, 0.25% and 0.5% for 100 minutes.", [["Staphylococcus aureus", "DISEASE", 114, 135], ["Akacid", "CHEMICAL", 208, 214], ["multi-resistant Staphylococcus aureus", "ORGANISM", 98, 135], ["MRSA", "ORGANISM", 137, 141], ["Pseudomonas aeruginosa", "ORGANISM", 144, 166], ["Escherichia coli", "ORGANISM", 171, 187], ["Akacid", "SIMPLE_CHEMICAL", 208, 214], ["Staphylococcus aureus", "SPECIES", 114, 135], ["MRSA", "SPECIES", 137, 141], ["Pseudomonas aeruginosa", "SPECIES", 144, 166], ["Escherichia coli", "SPECIES", 171, 187], ["Staphylococcus aureus", "SPECIES", 114, 135], ["MRSA", "SPECIES", 137, 141], ["Pseudomonas aeruginosa", "SPECIES", 144, 166], ["Escherichia coli", "SPECIES", 171, 187], ["antibiotic", "TREATMENT", 71, 81], ["multi-resistant Staphylococcus aureus", "PROBLEM", 98, 135], ["MRSA", "PROBLEM", 137, 141], ["Pseudomonas aeruginosa", "PROBLEM", 144, 166], ["Escherichia coli", "PROBLEM", 171, 187], ["Akacid", "TREATMENT", 208, 214], ["multi-resistant", "OBSERVATION_MODIFIER", 98, 113], ["Staphylococcus aureus", "OBSERVATION", 114, 135], ["Escherichia coli", "OBSERVATION", 171, 187]]], ["Bacterial suspensions were distributed on stainless steel plates and placed in a test and control room.", [["suspensions", "ANATOMY", 10, 21], ["Bacterial suspensions", "TREATMENT", 0, 21], ["stainless steel plates", "TREATMENT", 42, 64], ["a test", "TEST", 79, 85], ["suspensions", "OBSERVATION", 10, 21], ["stainless steel plates", "OBSERVATION_MODIFIER", 42, 64]]], ["Recovery of the test bacteria was determinedbefore nebulizing, 60 and 100 minutes after the beginning and 4 hours after the end of room disinfection by a modified simple swab-rinse technique.", [["the test bacteria", "TEST", 12, 29], ["a modified simple swab-rinse technique", "TREATMENT", 152, 190]]], ["For the detection of MRSA in isolation units, surface samples were collected by direct swab and enrichment culture.", [["surface samples", "ANATOMY", 46, 61], ["MRSA", "DISEASE", 21, 25], ["surface samples", "ORGANISM_SUBSTANCE", 46, 61], ["MRSA", "SPECIES", 21, 25], ["MRSA", "SPECIES", 21, 25], ["MRSA in isolation units", "TREATMENT", 21, 44], ["surface samples", "TEST", 46, 61], ["direct swab", "TEST", 80, 91], ["enrichment culture", "TEST", 96, 114], ["MRSA", "OBSERVATION", 21, 25]]], ["Results: The swab-rinse method demonstrated a dose-and time-dependent effectiveness of Akacid plus \u00d2 in eradicating S. aureus, E. coli and P. aeruginosa on stainless steel plates.", [["Akacid", "CHEMICAL", 87, 93], ["Akacid", "CHEMICAL", 87, 93], ["Akacid", "SIMPLE_CHEMICAL", 87, 93], ["S. aureus", "ORGANISM", 116, 125], ["E. coli", "ORGANISM", 127, 134], ["P. aeruginosa", "ORGANISM", 139, 152], ["S. aureus", "SPECIES", 116, 125], ["E. coli", "SPECIES", 127, 134], ["P. aeruginosa", "SPECIES", 139, 152], ["S. aureus", "SPECIES", 116, 125], ["E. coli", "SPECIES", 127, 134], ["P. aeruginosa", "SPECIES", 139, 152], ["The swab", "TEST", 9, 17], ["Akacid", "TREATMENT", 87, 93], ["eradicating S. aureus", "PROBLEM", 104, 125], ["E. coli", "PROBLEM", 127, 134], ["P. aeruginosa", "PROBLEM", 139, 152], ["stainless steel plates", "TREATMENT", 156, 178], ["aureus", "OBSERVATION", 119, 125], ["E. coli", "OBSERVATION", 127, 134]]], ["Nebulizing of 0.5% Akacid plus was successful in eliminating all hospital pathogens in 340 min contact time, while MRSA was still detectable after use of 0.25% Akacid plus \u00d2 .", [["Akacid", "CHEMICAL", 19, 25], ["MRSA", "CHEMICAL", 115, 119], ["Akacid", "CHEMICAL", 160, 166], ["Akacid", "CHEMICAL", 160, 166], ["Akacid", "SIMPLE_CHEMICAL", 19, 25], ["Akacid", "SIMPLE_CHEMICAL", 160, 166], ["MRSA", "SPECIES", 115, 119], ["MRSA", "SPECIES", 115, 119], ["Nebulizing", "TREATMENT", 0, 10], ["MRSA", "PROBLEM", 115, 119]]], ["0.1% Akacid plus \u00d2 achieved a reduction >100 CFU of S. aureus and P. aeruginosa, but was only able to eradicate E. coli during the observation time.Conclusion:The results suggest that nebulized Akacid plus \u00d2 at a concentration of 0.5% is a potent substance for eradication of pathogenic organisms in the hospital setting.P1793Study on the antiviral efficacy of Citrofresh \u00d2 , a flavonoid based organic acid complex sanitizer Z. Nack (North-Geelong, AU)P1793Objective: Determine the antiviral efficacy of this organic sanitizer against enveloped and non-enveloped viruses using a carrier based method.", [["Akacid", "CHEMICAL", 5, 11], ["Akacid", "CHEMICAL", 194, 200], ["P1793Study", "CHEMICAL", 321, 331], ["Citrofresh", "CHEMICAL", 361, 371], ["flavonoid", "CHEMICAL", 378, 387], ["Citrofresh", "CHEMICAL", 361, 371], ["flavonoid", "CHEMICAL", 378, 387], ["Akacid", "SIMPLE_CHEMICAL", 5, 11], ["S. aureus", "ORGANISM", 52, 61], ["P. aeruginosa", "ORGANISM", 66, 79], ["E. coli", "ORGANISM", 112, 119], ["Akacid", "SIMPLE_CHEMICAL", 194, 200], ["Citrofresh \u00d2", "SIMPLE_CHEMICAL", 361, 373], ["flavonoid", "SIMPLE_CHEMICAL", 378, 387], ["organic acid", "SIMPLE_CHEMICAL", 394, 406], ["S. aureus", "SPECIES", 52, 61], ["P. aeruginosa", "SPECIES", 66, 79], ["E. coli", "SPECIES", 112, 119], ["S. aureus", "SPECIES", 52, 61], ["P. aeruginosa", "SPECIES", 66, 79], ["E. coli", "SPECIES", 112, 119], ["a reduction", "TREATMENT", 28, 39], ["S. aureus", "PROBLEM", 52, 61], ["P. aeruginosa", "PROBLEM", 66, 79], ["E. coli", "PROBLEM", 112, 119], ["nebulized Akacid", "TREATMENT", 184, 200], ["a potent substance", "TREATMENT", 238, 256], ["pathogenic organisms", "PROBLEM", 276, 296], ["Citrofresh", "TREATMENT", 361, 371], ["a flavonoid based organic acid complex sanitizer", "TREATMENT", 376, 424], ["this organic sanitizer", "TREATMENT", 504, 526], ["non-enveloped viruses", "PROBLEM", 549, 570], ["a carrier based method", "TREATMENT", 577, 599], ["aureus", "OBSERVATION", 55, 61], ["coli", "OBSERVATION", 115, 119]]], ["Seeking registration for Citrofresh \u00d2 in Australia and in the EU as a Hospital Grade antiviral sanitizer.", [["a Hospital Grade antiviral sanitizer", "TREATMENT", 68, 104], ["antiviral sanitizer", "OBSERVATION", 85, 104]]], ["Methods: The study was performed according to the American Society of Testing and Materials (ASTM) Designation (E 1053-85) recommended by the Australian Therapeutic Goods Administration (TGA) to determine the efficacy of a disinfectant intended to use on inanimate, environmental surfaces.", [["The study", "TEST", 9, 18], ["a disinfectant", "TREATMENT", 221, 235]]], ["We tested Citrofresh \u00d2 (diluted in standard hard water) in three different concentrations: 1%, 2% and 4% on adherent cell lines (PK-15, MRC-5, MDCK, A549, L929) in four replicates against five different viruses including: Porcine Parvovirus (non-enveloped, high resistant against sanitizer); Human Rhinovirus-16 (non-enveloped, high resistant against sanitizer); Human Adenovirus-4 (non-enveloped, moderate resistant against sanitizer); Human Influenza Type A (H3N2) virus (enveloped, moderate resistant against sanitizer); Human Herpes simplex virus Type 1 (enveloped, low resistant against sanitizers).", [["cell lines", "ANATOMY", 117, 127], ["MRC-5", "ANATOMY", 136, 141], ["MDCK", "ANATOMY", 143, 147], ["A549", "ANATOMY", 149, 153], ["L929", "ANATOMY", 155, 159], ["Citrofresh", "CHEMICAL", 10, 20], ["PK-15, MRC-5", "CHEMICAL", 129, 141], ["Porcine Parvovirus", "DISEASE", 222, 240], ["sanitizer", "CHEMICAL", 351, 360], ["Adenovirus-4", "CHEMICAL", 369, 381], ["sanitizer", "CHEMICAL", 425, 434], ["Influenza Type A (H3N2) virus", "DISEASE", 443, 472], ["Herpes simplex virus", "DISEASE", 530, 550], ["cell lines", "CELL", 117, 127], ["PK-15", "CELL", 129, 134], ["MRC-5", "CELL", 136, 141], ["MDCK", "CELL", 143, 147], ["A549", "CELL", 149, 153], ["L929", "CELL", 155, 159], ["Porcine Parvovirus", "ORGANISM", 222, 240], ["Human", "ORGANISM", 292, 297], ["Rhinovirus-16", "ORGANISM", 298, 311], ["Human", "ORGANISM", 363, 368], ["Adenovirus-4", "ORGANISM", 369, 381], ["Human", "ORGANISM", 437, 442], ["Influenza Type A (H3N2) virus", "ORGANISM", 443, 472], ["Human", "ORGANISM", 524, 529], ["Herpes simplex virus Type 1", "ORGANISM", 530, 557], ["adherent cell lines", "CELL_LINE", 108, 127], ["MDCK", "CELL_LINE", 143, 147], ["A549", "CELL_LINE", 149, 153], ["L929", "CELL_LINE", 155, 159], ["Porcine", "SPECIES", 222, 229], ["Human", "SPECIES", 292, 297], ["Human", "SPECIES", 363, 368], ["Adenovirus-4", "SPECIES", 369, 381], ["Human", "SPECIES", 437, 442], ["Influenza", "SPECIES", 443, 452], ["H3N2) virus", "SPECIES", 461, 472], ["Human", "SPECIES", 524, 529], ["Herpes simplex virus", "SPECIES", 530, 550], ["Porcine Parvovirus", "SPECIES", 222, 240], ["Human Rhinovirus-16", "SPECIES", 292, 311], ["Human Adenovirus-4", "SPECIES", 363, 381], ["Human Influenza Type A (H3N2) virus", "SPECIES", 437, 472], ["Human Herpes simplex virus Type 1", "SPECIES", 524, 557], ["Citrofresh \u00d2 (diluted in standard hard water)", "TREATMENT", 10, 55], ["adherent cell lines", "TREATMENT", 108, 127], ["PK", "TEST", 129, 131], ["MRC", "TEST", 136, 139], ["MDCK", "TEST", 143, 147], ["A549", "TEST", 149, 153], ["five different viruses", "PROBLEM", 188, 210], ["Porcine Parvovirus", "PROBLEM", 222, 240], ["high resistant against sanitizer", "TREATMENT", 257, 289], ["Human Rhinovirus", "TEST", 292, 308], ["high resistant against sanitizer", "TREATMENT", 328, 360], ["Human Adenovirus", "TREATMENT", 363, 379], ["Human Influenza Type A (H3N2) virus", "PROBLEM", 437, 472], ["moderate resistant against sanitizer", "TREATMENT", 485, 521], ["Human Herpes simplex virus Type 1", "PROBLEM", 524, 557], ["cell lines", "OBSERVATION", 117, 127], ["viruses", "OBSERVATION", 203, 210], ["low resistant", "OBSERVATION_MODIFIER", 570, 583]]], ["Prior to the viral testings, acute toxicity assay was carried out to determine the adherent cells viability against Citrofresh \u00d2 .", [["cells", "ANATOMY", 92, 97], ["toxicity", "DISEASE", 35, 43], ["cells", "CELL", 92, 97], ["adherent cells", "CELL_TYPE", 83, 97], ["the viral testings", "TEST", 9, 27], ["acute toxicity assay", "PROBLEM", 29, 49], ["acute", "OBSERVATION_MODIFIER", 29, 34]]], ["Results: Cell lines exhibited >80% viability after exposure to all three concentration.", [["Cell lines", "ANATOMY", 9, 19], ["Cell lines", "CELL", 9, 19], ["Cell lines", "CELL_LINE", 9, 19], ["Cell lines", "TREATMENT", 9, 19], ["Cell lines", "OBSERVATION", 9, 19]]], ["Herpes simplex Type 1, Human Influenza Type A and Human Adenovirus-4 exhibited the most significant viral log reduction of log10 4 to 5 at 4% concentration of Citrofresh \u00d2 followed by the Human Rhinovirus-16 and Porcine Parvovirus log10 4 reduction at 4% concentration.", [["Herpes simplex Type", "DISEASE", 0, 19], ["Influenza", "DISEASE", 29, 38], ["Citrofresh", "CHEMICAL", 159, 169], ["Herpes simplex Type 1", "ORGANISM", 0, 21], ["Human", "ORGANISM", 23, 28], ["Influenza", "ORGANISM", 29, 38], ["Human", "ORGANISM", 50, 55], ["Adenovirus-4", "ORGANISM", 56, 68], ["Citrofresh", "SIMPLE_CHEMICAL", 159, 169], ["Human", "ORGANISM", 188, 193], ["Rhinovirus-16", "ORGANISM", 194, 207], ["Porcine Parvovirus", "ORGANISM", 212, 230], ["Herpes simplex", "SPECIES", 0, 14], ["Human", "SPECIES", 23, 28], ["Influenza", "SPECIES", 29, 38], ["Human", "SPECIES", 50, 55], ["Human", "SPECIES", 188, 193], ["Porcine", "SPECIES", 212, 219], ["Human Influenza", "SPECIES", 23, 38], ["Human Adenovirus-4", "SPECIES", 50, 68], ["Human Rhinovirus-16", "SPECIES", 188, 207], ["Herpes simplex Type 1", "PROBLEM", 0, 21], ["Human Influenza", "PROBLEM", 23, 38], ["Type A and Human Adenovirus", "PROBLEM", 39, 66], ["Citrofresh", "TREATMENT", 159, 169], ["the Human Rhinovirus", "TREATMENT", 184, 204], ["Porcine Parvovirus log10 4 reduction", "TREATMENT", 212, 248]]], ["The reduction of viable virus load was exhibited after 1 minute exposure time to Citrofresh \u00d2 , which means no time-dependant activity.", [["viable virus load", "PROBLEM", 17, 34], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["virus load", "OBSERVATION", 24, 34]]], ["Citrofresh \u00d2 clearly exhibited concentration and pH dependent viral load reduction activity against Influenza Type A and the Human Adenovirus -4 and Human Herpes simplex Type 1 virus.", [["Citrofresh", "CHEMICAL", 0, 10], ["Influenza Type A", "DISEASE", 100, 116], ["Herpes simplex Type 1 virus", "DISEASE", 155, 182], ["Citrofresh", "SIMPLE_CHEMICAL", 0, 10], ["Influenza Type A", "ORGANISM", 100, 116], ["Human", "ORGANISM", 125, 130], ["Adenovirus -4", "ORGANISM", 131, 144], ["Human", "ORGANISM", 149, 154], ["Herpes simplex Type 1 virus", "ORGANISM", 155, 182], ["Influenza", "SPECIES", 100, 109], ["Human", "SPECIES", 125, 130], ["Human", "SPECIES", 149, 154], ["Herpes simplex Type 1 virus", "SPECIES", 155, 182], ["Influenza Type A", "SPECIES", 100, 116], ["Human Adenovirus -4", "SPECIES", 125, 144], ["Human Herpes simplex Type 1 virus", "SPECIES", 149, 182], ["Citrofresh", "TREATMENT", 0, 10], ["pH dependent viral load reduction activity", "PROBLEM", 49, 91], ["Influenza Type A", "PROBLEM", 100, 116], ["the Human Adenovirus", "TEST", 121, 141], ["Human Herpes simplex Type 1 virus", "PROBLEM", 149, 182], ["pH dependent", "OBSERVATION_MODIFIER", 49, 61], ["viral load", "OBSERVATION", 62, 72]]], ["The reduction in viral titre for Porcine Parvovirus and Human Rhinovirus-16 is probably pH dependent (the pH of 1% Citrofresh \u00d2 is 6.5, 2% is 4.5 and 4% is 3.5).", [["Porcine Parvovirus", "DISEASE", 33, 51], ["Porcine Parvovirus", "ORGANISM", 33, 51], ["Human", "ORGANISM", 56, 61], ["Rhinovirus-16", "ORGANISM", 62, 75], ["Porcine", "SPECIES", 33, 40], ["Human", "SPECIES", 56, 61], ["Porcine Parvovirus", "SPECIES", 33, 51], ["Human Rhinovirus-16", "SPECIES", 56, 75], ["The reduction", "TREATMENT", 0, 13], ["viral titre", "TEST", 17, 28], ["Porcine Parvovirus", "PROBLEM", 33, 51], ["Human Rhinovirus", "TEST", 56, 72], ["pH dependent", "PROBLEM", 88, 100], ["the pH", "TEST", 102, 108], ["Citrofresh", "TEST", 115, 125], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["viral titre", "OBSERVATION", 17, 28], ["probably", "UNCERTAINTY", 79, 87], ["pH dependent", "OBSERVATION_MODIFIER", 88, 100]]], ["Conclusion: Our investigation shows that Citrofresh \u00d2 is an effective disinfectant on environmental surfaces, eliminating enveloped and non-enveloped viruses and sufficient to achieve the minimum 4-log reduction with complete viral inactivation which is prerequisite for registration.P1794Rapid environmental recontamination of an intensive care unit after decontamination with hydrogen peroxide vapour Objectives: To evaluate the effectiveness of hydrogen peroxide vapour (HPV) to reduce the levels of total bacterial and methicillin resistant Staphylococcus aureus (MRSA) environmental contamination on an Intensive Care Unit (ICU), and to establish the rate of environmental recontamination.", [["Citrofresh", "CHEMICAL", 41, 51], ["P1794Rapid", "CHEMICAL", 284, 294], ["hydrogen peroxide", "CHEMICAL", 378, 395], ["hydrogen peroxide", "CHEMICAL", 448, 465], ["methicillin", "CHEMICAL", 523, 534], ["hydrogen peroxide", "CHEMICAL", 378, 395], ["hydrogen peroxide", "CHEMICAL", 448, 465], ["methicillin", "CHEMICAL", 523, 534], ["Citrofresh", "SIMPLE_CHEMICAL", 41, 51], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 378, 395], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 448, 465], ["HPV", "ORGANISM", 474, 477], ["methicillin resistant Staphylococcus aureus", "ORGANISM", 523, 566], ["Staphylococcus aureus", "SPECIES", 545, 566], ["MRSA", "SPECIES", 568, 572], ["Staphylococcus aureus", "SPECIES", 545, 566], ["MRSA", "SPECIES", 568, 572], ["Our investigation", "TEST", 12, 29], ["Citrofresh", "TREATMENT", 41, 51], ["environmental surfaces", "TREATMENT", 86, 108], ["non-enveloped viruses", "PROBLEM", 136, 157], ["log reduction", "TREATMENT", 198, 211], ["complete viral inactivation", "TREATMENT", 217, 244], ["hydrogen peroxide vapour", "TREATMENT", 378, 402], ["hydrogen peroxide vapour (HPV", "TREATMENT", 448, 477], ["the levels", "TEST", 489, 499], ["total bacterial and methicillin resistant Staphylococcus aureus", "PROBLEM", 503, 566], ["MRSA", "PROBLEM", 568, 572], ["environmental recontamination", "TREATMENT", 664, 693], ["viral inactivation", "OBSERVATION", 226, 244], ["methicillin resistant Staphylococcus aureus", "OBSERVATION", 523, 566]]], ["Methods: The study took place on a 9 bed open plan ICU.", [["The study", "TEST", 9, 18]]], ["On each environmental screen 3 sites in each bed space (under the bed, the workstation and the monitor) were examined using broth enrichment for the detection of MRSA.", [["MRSA", "DISEASE", 162, 166], ["MRSA", "SPECIES", 162, 166], ["MRSA", "SPECIES", 162, 166], ["each environmental screen", "TEST", 3, 28], ["the monitor", "TEST", 91, 102], ["broth enrichment", "TREATMENT", 124, 140], ["MRSA", "PROBLEM", 162, 166], ["MRSA", "OBSERVATION", 162, 166]]], ["In addition total bacterial counts were determined for under the bed and workstation using RODAC plates.", [["total bacterial counts", "TEST", 12, 34], ["RODAC plates", "TREATMENT", 91, 103]]], ["Environmental screening was carried out monthly for the 3 months preceding the usage of HPV, increasing to weekly for the 4 weeks prior to usage.", [["HPV", "ORGANISM", 88, 91], ["HPV", "SPECIES", 88, 91], ["Environmental screening", "TEST", 0, 23], ["HPV", "TREATMENT", 88, 91]]], ["Additional sampling was carried out immediately before patients were discharged from ICU, following the subsequent terminal clean and then immediately after HPV use.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["HPV", "SPECIES", 157, 160], ["Additional sampling", "TEST", 0, 19], ["the subsequent terminal clean", "TREATMENT", 100, 129], ["clean", "OBSERVATION", 124, 129]]], ["After readmission of patients sampling was carried out at 24 h, 48 h and then weekly for a period of 8 weeks.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["patients sampling", "TEST", 21, 38]]], ["Patients were screened for MRSA on admission and then weekly.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["MRSA", "SPECIES", 27, 31], ["MRSA", "SPECIES", 27, 31], ["MRSA", "PROBLEM", 27, 31]]], ["Results: Sampling of the environment prior to the usage of HPV revealed contamination of the environment with MRSA on 6/7 occasions, with MRSA colonised patients being present on only 3/7 occasions.", [["HPV", "ORGANISM", 59, 62], ["patients", "ORGANISM", 153, 161], ["MRSA", "SPECIES", 110, 114], ["MRSA", "SPECIES", 138, 142], ["patients", "SPECIES", 153, 161], ["HPV", "SPECIES", 59, 62], ["MRSA", "SPECIES", 110, 114], ["MRSA", "SPECIES", 138, 142], ["HPV", "TEST", 59, 62], ["MRSA", "PROBLEM", 110, 114], ["MRSA", "PROBLEM", 138, 142], ["contamination", "OBSERVATION", 72, 85], ["MRSA", "OBSERVATION", 110, 114]]], ["After discharge of the patients and terminal cleaning of the environment, MRSA was isolated from 5 (13%) environmental sites.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["MRSA", "SPECIES", 74, 78], ["MRSA", "SPECIES", 74, 78], ["MRSA", "PROBLEM", 74, 78], ["MRSA", "OBSERVATION", 74, 78]]], ["After the use of HPV, MRSA was not isolated from any environmental sites upon immediate sampling, but 24 h after patients were readmitted, including 2 patients known to be colonised with MRSA, MRSA was isolated from 5 sites.", [["MRSA", "DISEASE", 187, 191], ["MRSA", "DISEASE", 193, 197], ["HPV", "ORGANISM", 17, 20], ["MRSA", "CANCER", 22, 26], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 151, 159], ["MRSA", "SPECIES", 22, 26], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 151, 159], ["MRSA", "SPECIES", 187, 191], ["MRSA", "SPECIES", 193, 197], ["HPV", "SPECIES", 17, 20], ["MRSA", "SPECIES", 22, 26], ["MRSA", "SPECIES", 187, 191], ["MRSA", "SPECIES", 193, 197], ["HPV", "PROBLEM", 17, 20], ["MRSA", "PROBLEM", 22, 26], ["MRSA", "PROBLEM", 187, 191], ["MRSA", "PROBLEM", 193, 197], ["MRSA", "OBSERVATION", 22, 26], ["MRSA", "OBSERVATION", 187, 191], ["MRSA", "OBSERVATION", 193, 197]]], ["These sites were not clustered around the colonised patients but were widespread across the ICU.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["widespread", "OBSERVATION_MODIFIER", 70, 80]]], ["In the 8 weeks post HPV usage MRSA has been isolated every week.", [["MRSA", "CHEMICAL", 30, 34], ["HPV", "ORGANISM", 20, 23], ["MRSA", "SPECIES", 30, 34], ["HPV", "SPECIES", 20, 23], ["MRSA", "SPECIES", 30, 34], ["MRSA", "PROBLEM", 30, 34]]], ["The mean total bacterial counts prior to the use of HPV were 22.0/10 cm 2 underneath the beds and 3.8/10 cm 2 on the workstations, this was reduced after HPV to 0.1/10 cm 2 and 0.2/10 cm 2 respectively.", [["HPV", "ORGANISM", 52, 55], ["HPV", "SPECIES", 52, 55], ["HPV", "SPECIES", 154, 157], ["The mean total bacterial counts", "TEST", 0, 31], ["HPV", "TEST", 52, 55], ["HPV", "TEST", 154, 157], ["bacterial counts", "OBSERVATION", 15, 31], ["beds", "ANATOMY", 89, 93]]], ["After patients readmission the counts were 4.1/ 10 cm 2 underneath the beds and 1.2/10 cm 2 on the workstations after 48 h and returned to pre-HPV levels of 16.9/10 cm 2 and 4.8/10 cm 2 at each site respectively after 1 week.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["the counts", "TEST", 27, 37], ["pre-HPV levels", "TEST", 139, 153], ["beds", "ANATOMY", 71, 75]]], ["Conclusion: Hydrogen peroxide vapour is effective in eliminating bacteria from the environment.", [["Hydrogen peroxide", "CHEMICAL", 12, 29], ["Hydrogen peroxide", "CHEMICAL", 12, 29], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 12, 29], ["Hydrogen peroxide vapour", "TREATMENT", 12, 36], ["bacteria", "PROBLEM", 65, 73], ["bacteria", "OBSERVATION", 65, 73]]], ["The rapid rate of recontamination of the environment suggests that the use of HPV is not an effective means of maintaining low levels of environmental contamination on an open plan ICU.", [["HPV", "ORGANISM", 78, 81], ["HPV", "SPECIES", 78, 81], ["HPV", "PROBLEM", 78, 81], ["rapid", "OBSERVATION_MODIFIER", 4, 9]]], ["Objectives: The nosocomial infections are more serious and dangerous than community acquired infections since they have high rate of morbidity and mortality as well as they increase the cost of therapy.", [["nosocomial infections", "DISEASE", 16, 37], ["infections", "DISEASE", 93, 103], ["The nosocomial infections", "PROBLEM", 12, 37], ["community acquired infections", "PROBLEM", 74, 103], ["therapy", "TREATMENT", 194, 201], ["nosocomial", "OBSERVATION_MODIFIER", 16, 26], ["infections", "OBSERVATION", 27, 37]]], ["Recently many precautions have been taken to prevent these infections.", [["infections", "DISEASE", 59, 69], ["many precautions", "TREATMENT", 9, 25], ["these infections", "PROBLEM", 53, 69], ["infections", "OBSERVATION", 59, 69]]], ["One of these applications is that covering of the floor of the wards, clinics, intensive care units and operating rooms of the hospitals with vinyl flooring material, which is believed to be cleaned easily and effectively.", [["vinyl", "CHEMICAL", 142, 147], ["vinyl flooring material", "TREATMENT", 142, 165]]], ["In this study it was aimed to determine the duration of survive of the Staphylococcus aureus, Enterococcus feacalis, Escherichia coli and Pseudomonas aeruginosa, which were most common encountered as nosocomial infection agents, on the surface of flooring materials such as vinyl flooring, ceramic laminated wood and galvanized sheet at room temperature.", [["surface", "ANATOMY", 236, 243], ["wood", "ANATOMY", 308, 312], ["Staphylococcus aureus", "DISEASE", 71, 92], ["nosocomial infection", "DISEASE", 200, 220], ["vinyl flooring", "CHEMICAL", 274, 288], ["vinyl", "CHEMICAL", 274, 279], ["Staphylococcus aureus", "ORGANISM", 71, 92], ["Enterococcus feacalis", "ORGANISM", 94, 115], ["Escherichia coli", "ORGANISM", 117, 133], ["Pseudomonas aeruginosa", "ORGANISM", 138, 160], ["Staphylococcus aureus", "SPECIES", 71, 92], ["Enterococcus feacalis", "SPECIES", 94, 115], ["Escherichia coli", "SPECIES", 117, 133], ["Pseudomonas aeruginosa", "SPECIES", 138, 160], ["Staphylococcus aureus", "SPECIES", 71, 92], ["Enterococcus feacalis", "SPECIES", 94, 115], ["Escherichia coli", "SPECIES", 117, 133], ["Pseudomonas aeruginosa", "SPECIES", 138, 160], ["this study", "TEST", 3, 13], ["the Staphylococcus aureus", "PROBLEM", 67, 92], ["Enterococcus feacalis", "PROBLEM", 94, 115], ["Escherichia coli", "PROBLEM", 117, 133], ["Pseudomonas aeruginosa", "PROBLEM", 138, 160], ["nosocomial infection agents", "TREATMENT", 200, 227], ["the surface of flooring materials", "TREATMENT", 232, 265], ["vinyl flooring", "TREATMENT", 274, 288], ["ceramic laminated wood", "TREATMENT", 290, 312], ["Staphylococcus aureus", "OBSERVATION", 71, 92], ["Escherichia coli", "OBSERVATION", 117, 133], ["laminated wood", "OBSERVATION", 298, 312]]], ["Methods: Four kinds of flooring materials were prepared approximately in 4-6 cm 2 coupons and sterilized.", [["flooring materials", "TREATMENT", 23, 41]]], ["Separate bacterial suspensions equal to Mc Farland 1 turbidity were swapped to the surface of each flooring materials by sterile cotton swabs.", [["surface", "ANATOMY", 83, 90], ["cotton", "SPECIES", 129, 135], ["Separate bacterial suspensions", "TREATMENT", 0, 30], ["sterile cotton swabs", "TREATMENT", 121, 141], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["suspensions", "OBSERVATION_MODIFIER", 19, 30], ["equal", "OBSERVATION_MODIFIER", 31, 36], ["to Mc", "OBSERVATION_MODIFIER", 37, 42]]], ["All contaminated test materials were put in sterile petri dishes with cover and kept at room temperature without subjecting to the direct sunlight.", [["All contaminated test materials", "TEST", 0, 31], ["sterile petri dishes", "TREATMENT", 44, 64]]], ["On the third day, culture samples were taken from the surface of each material by sterile cotton swaps soaked with sterile saline and streaked on the blood agar surface.", [["culture samples", "ANATOMY", 18, 33], ["surface", "ANATOMY", 54, 61], ["blood", "ANATOMY", 150, 155], ["surface", "ANATOMY", 161, 168], ["saline", "SIMPLE_CHEMICAL", 123, 129], ["blood", "ORGANISM_SUBSTANCE", 150, 155], ["cotton", "SPECIES", 90, 96], ["culture samples", "TEST", 18, 33], ["sterile cotton swaps", "TREATMENT", 82, 102], ["sterile saline", "TREATMENT", 115, 129], ["blood", "ANATOMY", 150, 155]]], ["Culturing procedure was repeated every other day until no growth detected.", [["Culturing procedure", "TREATMENT", 0, 19], ["growth", "PROBLEM", 58, 64]]], ["In case of three consequently, negative culture results obtained culturing was ended.", [["culturing", "TEST", 65, 74]]], ["Results: Overall results of the study were presented on table 1.P1794Conclusions: Among the four flooring materials, galvanised sheet seemed to be the most unsuitable one for the bacteria to survive long period.", [["the study", "TEST", 28, 37], ["galvanised sheet", "TREATMENT", 117, 133], ["the bacteria", "PROBLEM", 175, 187]]], ["In other words this material should be preferred as to laminated wood for covering benches and laboratory tables.", [["wood", "ANATOMY", 65, 69]]], ["As for the flooring of the floors the vinyl flooring material is better than ceramic. covering the complete CMV IE-1 and pp65 proteins.Results: CMV seropositive transplant recipients had significantly hightened IE-1 and pp65 specific T cell frequencies compared to seronegative individuals.", [["T cell", "ANATOMY", 234, 240], ["vinyl", "CHEMICAL", 38, 43], ["vinyl", "CHEMICAL", 38, 43], ["CMV", "ORGANISM", 108, 111], ["IE-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["pp65", "GENE_OR_GENE_PRODUCT", 121, 125], ["CMV", "ORGANISM", 144, 147], ["recipients", "ORGANISM", 172, 182], ["IE-1", "GENE_OR_GENE_PRODUCT", 211, 215], ["pp65", "GENE_OR_GENE_PRODUCT", 220, 224], ["T cell", "CELL", 234, 240], ["CMV IE-1 and pp65 proteins", "PROTEIN", 108, 134], ["pp65", "PROTEIN", 220, 224], ["CMV", "SPECIES", 144, 147], ["the vinyl flooring material", "TREATMENT", 34, 61], ["the complete CMV IE", "TEST", 95, 114], ["pp65 proteins", "TEST", 121, 134], ["CMV seropositive transplant recipients", "TREATMENT", 144, 182], ["significantly hightened IE", "PROBLEM", 187, 213], ["pp65 specific T cell frequencies", "TEST", 220, 252], ["seronegative individuals", "PROBLEM", 265, 289]]], ["Patients withevidence of CMV antigenemia or DNAemia could not be discriminated based on CMV-and donor-reactive T cells or serum creatinine.", [["donor-reactive T cells", "ANATOMY", 96, 118], ["serum", "ANATOMY", 122, 127], ["CMV antigenemia", "DISEASE", 25, 40], ["DNAemia", "DISEASE", 44, 51], ["creatinine", "CHEMICAL", 128, 138], ["creatinine", "CHEMICAL", 128, 138], ["Patients", "ORGANISM", 0, 8], ["CMV", "ORGANISM", 25, 28], ["CMV", "ORGANISM", 88, 91], ["donor-reactive T cells", "CELL", 96, 118], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["creatinine", "SIMPLE_CHEMICAL", 128, 138], ["donor-reactive T cells", "CELL_TYPE", 96, 118], ["Patients", "SPECIES", 0, 8], ["CMV", "SPECIES", 25, 28], ["CMV", "SPECIES", 88, 91], ["CMV antigenemia", "PROBLEM", 25, 40], ["DNAemia", "PROBLEM", 44, 51], ["CMV", "TEST", 88, 91], ["donor-reactive T cells", "PROBLEM", 96, 118], ["serum creatinine", "TEST", 122, 138], ["CMV antigenemia", "OBSERVATION", 25, 40], ["DNAemia", "OBSERVATION", 44, 51]]], ["However, recipients of seropositive grafts with low IE1 response showed a tendency towards more frequent CMV infection.", [["grafts", "ANATOMY", 36, 42], ["CMV infection", "DISEASE", 105, 118], ["recipients", "ORGANISM", 9, 19], ["grafts", "TISSUE", 36, 42], ["IE1", "GENE_OR_GENE_PRODUCT", 52, 55], ["CMV", "ORGANISM", 105, 108], ["IE1", "PROTEIN", 52, 55], ["CMV", "SPECIES", 105, 108], ["seropositive grafts", "TREATMENT", 23, 42], ["low IE1 response", "PROBLEM", 48, 64], ["a tendency", "PROBLEM", 72, 82], ["more frequent CMV infection", "PROBLEM", 91, 118], ["seropositive grafts", "OBSERVATION", 23, 42], ["more frequent", "OBSERVATION_MODIFIER", 91, 104], ["CMV infection", "OBSERVATION", 105, 118]]], ["CMV disease was observed in only 3/64 individuals.", [["CMV disease", "DISEASE", 0, 11], ["CMV", "ORGANISM", 0, 3], ["CMV", "SPECIES", 0, 3], ["CMV disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["2 had no detectable IE1or pp65-T cell response, the third presented with a dominant pp65 response.", [["pp65-T cell", "ANATOMY", 26, 37], ["IE1", "GENE_OR_GENE_PRODUCT", 20, 23], ["pp65", "GENE_OR_GENE_PRODUCT", 26, 30], ["pp65", "GENE_OR_GENE_PRODUCT", 84, 88], ["IE1", "PROTEIN", 20, 23], ["pp65", "PROTEIN", 26, 30], ["pp65", "PROTEIN", 84, 88], ["detectable IE1", "PROBLEM", 9, 23], ["pp65", "TEST", 26, 30], ["no detectable", "UNCERTAINTY", 6, 19], ["dominant", "OBSERVATION_MODIFIER", 75, 83], ["pp65 response", "OBSERVATION", 84, 97]]], ["Interestingly, IE1-specific T cells correlated inversely with early post-Tx donor-reactive T cell frequencies during weeks 1-2 post-Tx.", [["T cells", "ANATOMY", 28, 35], ["T cell", "ANATOMY", 91, 97], ["IE1", "GENE_OR_GENE_PRODUCT", 15, 18], ["T cells", "CELL", 28, 35], ["T cell", "CELL", 91, 97], ["IE1", "PROTEIN", 15, 18], ["T cells", "CELL_TYPE", 28, 35], ["IE1", "TEST", 15, 18], ["Tx donor-reactive T cell frequencies", "TREATMENT", 73, 109]]], ["Most importantly, IE1-specific T cell frequencies correlated inversely with serum creatinine at 6 and 12 months at several times post-Tx.", [["T cell", "ANATOMY", 31, 37], ["serum", "ANATOMY", 76, 81], ["creatinine", "CHEMICAL", 82, 92], ["creatinine", "CHEMICAL", 82, 92], ["IE1", "GENE_OR_GENE_PRODUCT", 18, 21], ["T cell", "CELL", 31, 37], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["creatinine", "SIMPLE_CHEMICAL", 82, 92], ["IE1", "PROTEIN", 18, 21], ["IE1", "TEST", 18, 21], ["serum creatinine", "TEST", 76, 92], ["Tx", "TREATMENT", 134, 136]]], ["In patients without acute rejection, even pre-transplant IE-1 specific T cells correlated inversely with 6 and 12 months creatinine.", [["T cells", "ANATOMY", 71, 78], ["creatinine", "CHEMICAL", 121, 131], ["creatinine", "CHEMICAL", 121, 131], ["patients", "ORGANISM", 3, 11], ["IE-1", "GENE_OR_GENE_PRODUCT", 57, 61], ["T cells", "CELL", 71, 78], ["T cells", "CELL_TYPE", 71, 78], ["patients", "SPECIES", 3, 11], ["acute rejection", "PROBLEM", 20, 35], ["pre-transplant IE", "TEST", 42, 59], ["creatinine", "TEST", 121, 131], ["without", "UNCERTAINTY", 12, 19], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["rejection", "OBSERVATION", 26, 35]]], ["Conclusion: These data suggest subclinical control of CMV infection by IE-1 specific T cells and subsequently less graft injury by (CMV-induced) alloimmunity.P1799Universal precautions: knowledge, attitude and practice of healthcare workers regarding HIV, hepatitis B and C V. Gupta, S. Bhoi, A. Goel, P. Aggarwal (New Delhi, IN)P1799Objectives: Increasing incidence of HIV, Hepatitis B (HBV) and Hepatitis C (HCV) in the patients expose the healthcare professionals of acquiring these infections during occupational exposure.", [["T cells", "ANATOMY", 85, 92], ["graft", "ANATOMY", 115, 120], ["CMV infection", "DISEASE", 54, 67], ["HIV, hepatitis B", "DISEASE", 251, 267], ["HIV, Hepatitis B (HBV) and Hepatitis C (HCV)", "DISEASE", 370, 414], ["infections", "DISEASE", 486, 496], ["CMV", "ORGANISM", 54, 57], ["IE-1", "GENE_OR_GENE_PRODUCT", 71, 75], ["T cells", "CELL", 85, 92], ["graft", "TISSUE", 115, 120], ["CMV", "ORGANISM", 132, 135], ["HIV", "ORGANISM", 251, 254], ["hepatitis B", "ORGANISM", 256, 267], ["HIV", "ORGANISM", 370, 373], ["Hepatitis B", "ORGANISM", 375, 386], ["HBV", "ORGANISM", 388, 391], ["Hepatitis C", "ORGANISM", 397, 408], ["HCV", "ORGANISM", 410, 413], ["patients", "ORGANISM", 422, 430], ["T cells", "CELL_TYPE", 85, 92], ["HIV", "SPECIES", 251, 254], ["HIV", "SPECIES", 370, 373], ["patients", "SPECIES", 422, 430], ["CMV", "SPECIES", 54, 57], ["HIV", "SPECIES", 251, 254], ["HIV", "SPECIES", 370, 373], ["Hepatitis B", "SPECIES", 375, 386], ["HBV", "SPECIES", 388, 391], ["HCV", "SPECIES", 410, 413], ["These data", "TEST", 12, 22], ["CMV infection", "PROBLEM", 54, 67], ["1 specific T cells", "PROBLEM", 74, 92], ["subsequently less graft injury", "PROBLEM", 97, 127], ["alloimmunity", "PROBLEM", 145, 157], ["HIV", "PROBLEM", 251, 254], ["hepatitis B", "PROBLEM", 256, 267], ["HIV", "PROBLEM", 370, 373], ["Hepatitis B (HBV)", "PROBLEM", 375, 392], ["Hepatitis C (HCV)", "PROBLEM", 397, 414], ["these infections", "PROBLEM", 480, 496], ["CMV infection", "OBSERVATION", 54, 67], ["less", "OBSERVATION_MODIFIER", 110, 114], ["graft injury", "OBSERVATION", 115, 127], ["alloimmunity", "OBSERVATION", 145, 157], ["Hepatitis", "OBSERVATION", 375, 384], ["infections", "OBSERVATION", 486, 496]]], ["We studied the knowledge, attitudes and practices of healthcare workers regarding HIV, HBV, HCV and the risk of occupational transmission of these diseases.", [["HIV, HBV, HCV", "DISEASE", 82, 95], ["HIV", "ORGANISM", 82, 85], ["HBV", "ORGANISM", 87, 90], ["HCV", "ORGANISM", 92, 95], ["HIV", "SPECIES", 82, 85], ["HIV", "SPECIES", 82, 85], ["HBV", "SPECIES", 87, 90], ["HCV", "SPECIES", 92, 95], ["HIV", "PROBLEM", 82, 85], ["HBV", "PROBLEM", 87, 90], ["HCV", "PROBLEM", 92, 95], ["these diseases", "PROBLEM", 141, 155], ["diseases", "OBSERVATION", 147, 155]]], ["Data analysis (Bivariate and multivariate analysis) was done using SPSS version 10.", [["Data analysis", "TEST", 0, 13], ["Bivariate", "TEST", 15, 24], ["multivariate analysis", "TEST", 29, 50], ["SPSS version", "TEST", 67, 79]]], ["Results: 170 (response rate: 80%) HCW participated in the study.", [["response rate", "TEST", 14, 27], ["the study", "TEST", 54, 63]]], ["The study population comprised of 40% doctors, 23% nurses, 25% lab technicians and 12% support staff.", [["The study", "TEST", 0, 9]]], ["Respondents had adequate knowledge about causative (65%) usual transmission (63%), symptoms (69%) of AIDS but poor knowledge about HBV and HCV (43%, 41% and 30% respectively).", [["AIDS", "DISEASE", 101, 105], ["HCV", "DISEASE", 139, 142], ["HBV", "ORGANISM", 131, 134], ["HBV", "SPECIES", 131, 134], ["HCV", "SPECIES", 139, 142], ["usual transmission", "TEST", 57, 75], ["symptoms", "PROBLEM", 83, 91], ["AIDS", "PROBLEM", 101, 105], ["HBV", "TEST", 131, 134], ["HCV", "TEST", 139, 142]]], ["Inadequate knowledge was also revealed about the infectious bodyfluids (31%), disinfection of equipments (32%), pregnancy in HCW as a susceptibility factor (22%), post exposure prophylaxis (34%) and comparative infectivity of HIV and Hepatitis (38%).", [["bodyfluids", "DISEASE", 60, 70], ["HIV and Hepatitis", "DISEASE", 226, 243], ["HIV", "ORGANISM", 226, 229], ["HIV", "SPECIES", 226, 229], ["HIV", "SPECIES", 226, 229], ["the infectious bodyfluids", "PROBLEM", 45, 70], ["pregnancy in HCW", "PROBLEM", 112, 128], ["a susceptibility factor", "PROBLEM", 132, 155], ["exposure prophylaxis", "TREATMENT", 168, 188], ["HIV", "PROBLEM", 226, 229], ["Hepatitis", "PROBLEM", 234, 243], ["infectious", "OBSERVATION_MODIFIER", 49, 59], ["Hepatitis", "OBSERVATION", 234, 243]]], ["70% of HCW became anxious while treating these patients.", [["HCW", "ORGANISM", 7, 10], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["anxious", "PROBLEM", 18, 25]]], ["Poor compliance with Universal Precautions was noticed.", [["Universal Precautions", "TREATMENT", 21, 42]]], ["High compliance was reported for wearing masks (72%) and wearing gloves (53%).", [["gloves", "TREATMENT", 65, 71]]], ["Doctors were more likely to suffer needlestick injury (p = 0.04) Occupational exposures was found to be high (48%) with poor declaration rate (10%).", [["needlestick injury", "DISEASE", 35, 53], ["needlestick injury", "PROBLEM", 35, 53], ["more likely", "UNCERTAINTY", 13, 24], ["high", "OBSERVATION_MODIFIER", 104, 108]]], ["Conclusions: Results from this study reveal that there is a fair level of knowledge about HIV/AIDS but Hepatitis B and C have not generated adequate concern among the HCW.", [["HIV/AIDS", "DISEASE", 90, 98], ["Hepatitis B", "DISEASE", 103, 114], ["HIV", "ORGANISM", 90, 93], ["Hepatitis B", "ORGANISM", 103, 114], ["HIV", "SPECIES", 90, 93], ["HIV", "SPECIES", 90, 93], ["this study", "TEST", 26, 36], ["HIV/AIDS", "PROBLEM", 90, 98], ["Hepatitis B and C", "PROBLEM", 103, 120]]], ["Incongruity between perceived knowledge and reported practice suggests that there is a need for an interactive awareness course about the universal precautions.", [["the universal precautions", "TREATMENT", 134, 159]]], ["Objectives: The sero-prevalence of hepatitis A (HAV) antibodies are known to be low in young adults in Korea.", [["hepatitis A", "DISEASE", 35, 46], ["hepatitis A", "ORGANISM", 35, 46], ["HAV", "ORGANISM", 48, 51], ["hepatitis A (HAV) antibodies", "PROTEIN", 35, 63], ["hepatitis A", "SPECIES", 35, 46], ["HAV", "SPECIES", 48, 51], ["hepatitis A (HAV) antibodies", "PROBLEM", 35, 63], ["hepatitis", "OBSERVATION", 35, 44]]], ["Recently, seventeen cases of hepatitis A have been reported in health-care workers (HCW) of ICU in a University hospital from May 2005 to July 2005.", [["hepatitis A", "DISEASE", 29, 40], ["hepatitis A", "CANCER", 29, 40], ["hepatitis A", "SPECIES", 29, 40], ["hepatitis A", "PROBLEM", 29, 40], ["hepatitis", "OBSERVATION", 29, 38]]], ["We performed surveillance, and determined molecular identification of outbreaks.", [["surveillance", "TEST", 13, 25], ["outbreaks", "PROBLEM", 70, 79]]], ["We checked the HAV IgM from all the patients of SICU with elevated AST/ALT retrospectively and screened AST/ALT level from all the nurses and the doctors in contact with suspicious index case.", [["HAV", "ORGANISM", 15, 18], ["patients", "ORGANISM", 36, 44], ["AST", "SIMPLE_CHEMICAL", 67, 70], ["ALT", "SIMPLE_CHEMICAL", 71, 74], ["HAV IgM", "PROTEIN", 15, 22], ["AST", "PROTEIN", 67, 70], ["ALT", "PROTEIN", 71, 74], ["AST", "PROTEIN", 104, 107], ["ALT", "PROTEIN", 108, 111], ["patients", "SPECIES", 36, 44], ["HAV", "SPECIES", 15, 18], ["elevated AST", "PROBLEM", 58, 70], ["ALT retrospectively", "TEST", 71, 90], ["AST", "TEST", 104, 107], ["ALT level", "TEST", 108, 117]]], ["When we determined the existence of outbreak, the molecular subtypes of HAV from a blood of HCW were determined to provide the data for epidemiologic study.", [["blood", "ANATOMY", 83, 88], ["HAV", "DISEASE", 72, 75], ["HAV", "ORGANISM", 72, 75], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["HAV", "SPECIES", 72, 75], ["outbreak", "PROBLEM", 36, 44], ["HAV", "PROBLEM", 72, 75], ["epidemiologic study", "TEST", 136, 155]]], ["We determined the index case, a transmission route and the intervention for control an outbreak were planned.", [["a transmission route", "TREATMENT", 30, 50], ["the intervention", "TREATMENT", 55, 71]]], ["Seventeen HCW including 13 nurses and 4 doctors who are 22 to 32 years old, suffered from acute HAV over 7 weeks period.", [["HAV", "DISEASE", 96, 99], ["HAV", "SPECIES", 96, 99], ["acute HAV", "PROBLEM", 90, 99], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["HAV", "OBSERVATION", 96, 99]]], ["The possible transmission of HAV was fecaloral route from the bed-ridden patients with diarrhea to the exposed HCW.", [["HAV", "DISEASE", 29, 32], ["diarrhea", "DISEASE", 87, 95], ["HAV", "ORGANISM", 29, 32], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["HAV", "SPECIES", 29, 32], ["HAV", "PROBLEM", 29, 32], ["diarrhea", "PROBLEM", 87, 95]]], ["The eight HCW had a positive HAV RNA.", [["HAV", "ORGANISM", 29, 32], ["positive HAV RNA", "RNA", 20, 36], ["HAV", "SPECIES", 29, 32], ["a positive HAV RNA", "PROBLEM", 18, 36], ["positive", "OBSERVATION_MODIFIER", 20, 28], ["HAV RNA", "OBSERVATION", 29, 36]]], ["Analysis of the VP1-P2A region of each isolate showed genotype 1A in five strains and co-circulation of 1A and 1B in others.P1799Conclusions: The occurrence of HAV outbreak highlights the importance of standard precaution in a hospital.", [["HAV", "DISEASE", 160, 163], ["VP1-P2A", "GENE_OR_GENE_PRODUCT", 16, 23], ["HAV", "ORGANISM", 160, 163], ["VP1-P2A region", "DNA", 16, 30], ["HAV", "SPECIES", 160, 163], ["Analysis", "TEST", 0, 8], ["the VP1", "TEST", 12, 19], ["genotype 1A in five strains", "PROBLEM", 54, 81], ["standard precaution", "TREATMENT", 202, 221]]], ["The HAV vaccination is considered in young aged-HCW.", [["HAV", "ORGANISM", 4, 7], ["HAV", "SPECIES", 4, 7], ["The HAV vaccination", "TREATMENT", 0, 19]]], ["The genotype identification of blood would be useful for the epidemiologic study of suspicious HAV outbreak in a hospital.P1801Management of a norovirus-associated gastroenteritis outbreak on two psychiatric wards A. Buehling, U. Arnold (Magdeburg, DE)P1801Objectives: We report a norovirus-associated outbreak of gastroenteritis on a closed psychiatric and a gerontopsychiatric wards from December 2004 to February 2005.", [["blood", "ANATOMY", 31, 36], ["HAV", "DISEASE", 95, 98], ["P1801", "CHEMICAL", 122, 127], ["norovirus", "DISEASE", 143, 152], ["gastroenteritis", "DISEASE", 164, 179], ["psychiatric", "DISEASE", 196, 207], ["norovirus", "DISEASE", 281, 290], ["gastroenteritis", "DISEASE", 314, 329], ["psychiatric", "DISEASE", 342, 353], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["HAV", "ORGANISM", 95, 98], ["HAV", "SPECIES", 95, 98], ["the epidemiologic study", "TEST", 57, 80], ["a norovirus", "PROBLEM", 141, 152], ["gastroenteritis", "PROBLEM", 164, 179], ["a norovirus", "PROBLEM", 279, 290], ["gastroenteritis", "PROBLEM", 314, 329], ["norovirus", "OBSERVATION", 143, 152], ["gastroenteritis", "OBSERVATION", 164, 179], ["norovirus", "OBSERVATION", 281, 290], ["gastroenteritis", "OBSERVATION", 314, 329]]], ["During this time 46 patients and 25 healthcare workers (HCWs) were affected.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Introduction and results of hygiene measures based on published guidelines on psychiatric wards are described.", [["psychiatric", "DISEASE", 78, 89], ["hygiene measures", "TREATMENT", 28, 44]]], ["Methods: Effective and adapted measures had to be implemented to stop the outbreak and to prevent the spread of disease to other areas of our hospital.", [["adapted measures", "TREATMENT", 23, 39], ["disease", "PROBLEM", 112, 119]]], ["Isolation or cohorting of the psychiatric patients was excluded for therapeutic reasons.", [["psychiatric", "DISEASE", 30, 41], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Isolation", "TREATMENT", 0, 9]]], ["Regular hand disinfection in patient rooms was impossible because of the high risk of abuse.", [["hand", "ANATOMY", 8, 12], ["hand", "ORGANISM_SUBDIVISION", 8, 12], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["hand", "ANATOMY", 8, 12], ["disinfection", "OBSERVATION", 13, 25]]], ["The following measures have been introduced: use of gowns, masks and gloves by HCWs during care of infected patients-frequent hand disinfections with alcohol-based disinfectants by HCWs using ''pocket bottles''; recommendation for all persons entering the station to use gowns, gloves and masks and to disinfect their hands frequently, distribution of handouts describing the measures; hand disinfection by all patients after using toilet, before and after taking meals (distribution of disinfectants by HCW); increased frequency of routine surface disinfection (3 times daily) instead of routine cleaning once daily; routine disinfection of door handles, handrails, wash-basins and -fittings and light switches 3-4 times a shift; avoidance of patient transfer via hospital; visitor restriction during outbreak time; daily evaluation of recommended measures and adaptation to the current situation; exclusion of affected staff from the ward until 48 h symptom free.", [["hand", "ANATOMY", 126, 130], ["hand", "ANATOMY", 386, 390], ["surface", "ANATOMY", 541, 548], ["alcohol", "CHEMICAL", 150, 157], ["alcohol", "CHEMICAL", 150, 157], ["patients", "ORGANISM", 108, 116], ["hand", "ORGANISM_SUBDIVISION", 126, 130], ["alcohol", "SIMPLE_CHEMICAL", 150, 157], ["hand", "ORGANISM_SUBDIVISION", 386, 390], ["patients", "ORGANISM", 411, 419], ["patient", "ORGANISM", 744, 751], ["patients", "SPECIES", 108, 116], ["persons", "SPECIES", 235, 242], ["patients", "SPECIES", 411, 419], ["patient", "SPECIES", 744, 751], ["gowns", "TREATMENT", 52, 57], ["gloves", "TREATMENT", 69, 75], ["''pocket bottles", "TREATMENT", 192, 208], ["gowns", "TREATMENT", 271, 276], ["gloves and masks", "TREATMENT", 278, 294], ["hand disinfection", "PROBLEM", 386, 403], ["toilet", "TREATMENT", 432, 438], ["routine surface disinfection", "TREATMENT", 533, 561], ["routine cleaning", "TREATMENT", 589, 605], ["routine disinfection of door handles", "TREATMENT", 618, 654], ["handrails", "TREATMENT", 656, 665], ["wash-basins", "TREATMENT", 667, 678], ["fittings", "TREATMENT", 684, 692], ["light switches", "TREATMENT", 697, 711], ["daily evaluation", "TEST", 817, 833]]], ["They have been fully accepted only after a severe staff shortage in the fifth week of outbreak because of 3 new cases of gastroenteritis during HCWs and 14 newly infected patients.", [["gastroenteritis", "DISEASE", 121, 136], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["gastroenteritis", "PROBLEM", 121, 136], ["gastroenteritis", "OBSERVATION", 121, 136]]], ["Because of the restrictive application of the adapted guidelines for these special wards the outbreak has been stopped within 4 further weeks.", [["the adapted guidelines", "TREATMENT", 42, 64], ["restrictive", "OBSERVATION_MODIFIER", 15, 26]]], ["Conclusion: In case of norovirus-based gastroenteritis outbreaks on closed psychiatric wards hygienic measures which are adapted to the concrete situation are necessary.", [["norovirus", "DISEASE", 23, 32], ["gastroenteritis", "DISEASE", 39, 54], ["psychiatric", "DISEASE", 75, 86], ["norovirus", "ORGANISM", 23, 32], ["norovirus", "PROBLEM", 23, 32], ["based gastroenteritis", "PROBLEM", 33, 54], ["closed psychiatric wards hygienic measures", "TREATMENT", 68, 110], ["norovirus", "OBSERVATION", 23, 32], ["gastroenteritis", "OBSERVATION", 39, 54]]], ["Especially in these cases the compliance with guidelines can be increased by daily meetings and daily evaluation of recommendations.", [["daily evaluation", "TEST", 96, 112]]], ["Staff shortage during the outbreak forced the strict compliance with the recommended measures.P1801Regional spread of antibiotic resistance Methods: We performed surveillance of patients, healthcare stuff and ICU environment and we registered the infections of Ab during 3 periods of 21 days each one.", [["infections", "DISEASE", 247, 257], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["ICU environment", "TREATMENT", 209, 224], ["Ab", "TREATMENT", 261, 263], ["antibiotic resistance", "OBSERVATION", 118, 139], ["infections", "OBSERVATION", 247, 257]]], ["Rectal, oropharyngeal swabs tracheal aspirates from patients, handswabs from stuff and samples from environment were taken weekly.", [["Rectal", "ANATOMY", 0, 6], ["oropharyngeal swabs tracheal aspirates", "ANATOMY", 8, 46], ["handswabs", "ANATOMY", 62, 71], ["samples", "ANATOMY", 87, 94], ["Rectal", "MULTI-TISSUE_STRUCTURE", 0, 6], ["oropharyngeal swabs tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 8, 46], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Rectal, oropharyngeal swabs tracheal aspirates", "TEST", 0, 46], ["oropharyngeal", "ANATOMY", 8, 21], ["tracheal", "ANATOMY", 28, 36], ["aspirates", "OBSERVATION", 37, 46]]], ["The identification of Ab was performed using Vitek II system the susceptibility was tested by Kirby-Bauer and MIC methods and the <>obtained by pulsed field gel electrophoresis (PFGE).", [["Ab", "GENE_OR_GENE_PRODUCT", 22, 24], ["MIC methods", "TEST", 110, 121], ["pulsed field gel electrophoresis", "TEST", 144, 176]]], ["Results: During the 1st 2nd and 3rd period, 19 patients (14 men, 5 women), 13 patients (7 men, 6 women) and 12 patients (8 men, 4 women) were hospitalized in ICU respectively.", [["patients", "ORGANISM", 47, 55], ["men", "ORGANISM", 60, 63], ["women", "ORGANISM", 67, 72], ["patients", "ORGANISM", 78, 86], ["men", "ORGANISM", 90, 93], ["women", "ORGANISM", 97, 102], ["patients", "ORGANISM", 111, 119], ["men", "ORGANISM", 123, 126], ["women", "ORGANISM", 130, 135], ["patients", "SPECIES", 47, 55], ["men", "SPECIES", 60, 63], ["women", "SPECIES", 67, 72], ["patients", "SPECIES", 78, 86], ["men", "SPECIES", 90, 93], ["women", "SPECIES", 97, 102], ["patients", "SPECIES", 111, 119], ["men", "SPECIES", 123, 126], ["women", "SPECIES", 130, 135]]], ["Ab was isolated in 74 from 250 samples (29.6%) at the 1st period, 59 from 336 (17.5%) at the 2nd and 62 from 260 (24%) at the 3rd period.", [["samples", "ANATOMY", 31, 38], ["Ab", "GENE_OR_GENE_PRODUCT", 0, 2], ["Ab", "TEST", 0, 2]]], ["Totally Ab was isolated in 195 from 846 specimens (23%) At the 1st 2nd and 3rd period among the patients carrying Ab, 7/14 (50%), 7/10 (70%) and 5/8 (62%) were infected respectively.", [["specimens", "ANATOMY", 40, 49], ["Ab", "GENE_OR_GENE_PRODUCT", 8, 10], ["patients", "ORGANISM", 96, 104], ["Ab", "GENE_OR_GENE_PRODUCT", 114, 116], ["patients", "SPECIES", 96, 104], ["Totally Ab", "TEST", 0, 10], ["specimens", "TEST", 40, 49]]], ["The infections observed during the study period were: sepsis (8), urinary tract infection (1), pneumonia (11), meningitis (1), thrombophlebitis (2) .", [["urinary tract", "ANATOMY", 66, 79], ["infections", "DISEASE", 4, 14], ["sepsis", "DISEASE", 54, 60], ["urinary tract infection", "DISEASE", 66, 89], ["pneumonia", "DISEASE", 95, 104], ["meningitis", "DISEASE", 111, 121], ["thrombophlebitis", "DISEASE", 127, 143], ["urinary tract", "ORGANISM_SUBDIVISION", 66, 79], ["The infections", "PROBLEM", 0, 14], ["the study", "TEST", 31, 40], ["sepsis", "PROBLEM", 54, 60], ["urinary tract infection", "PROBLEM", 66, 89], ["pneumonia", "PROBLEM", 95, 104], ["meningitis", "PROBLEM", 111, 121], ["thrombophlebitis", "PROBLEM", 127, 143], ["infections", "OBSERVATION", 4, 14], ["sepsis", "OBSERVATION", 54, 60], ["urinary tract", "ANATOMY", 66, 79], ["infection", "OBSERVATION", 80, 89], ["pneumonia", "OBSERVATION", 95, 104], ["meningitis", "OBSERVATION", 111, 121], ["thrombophlebitis", "OBSERVATION", 127, 143]]], ["All the isolated Ab strains were multiresistant to antimicrobial agents.", [["Ab", "GENE_OR_GENE_PRODUCT", 17, 19], ["All the isolated Ab strains", "PROBLEM", 0, 27], ["antimicrobial agents", "TREATMENT", 51, 71], ["Ab strains", "OBSERVATION", 17, 27]]], ["Molecular analysis of 169 isolated strains by PFGE distinguished the following types: A (64, subtypes A1-A7), B (10) at the 1st period A(6), C(7), D(22), E(2), F(1), G(1), H(2), I(1).", [["D(22)", "SIMPLE_CHEMICAL", 147, 152], ["G(1)", "SIMPLE_CHEMICAL", 166, 170], ["Molecular analysis", "TEST", 0, 18], ["isolated strains", "PROBLEM", 26, 42], ["PFGE", "TEST", 46, 50], ["G", "TEST", 166, 167]]], ["J(1) at the 2nd period A(25), B (16), D(1), H(3), K(2).", [["H(3), K(2)", "CHEMICAL", 44, 54], ["D(1)", "SIMPLE_CHEMICAL", 38, 42], ["H(3)", "SIMPLE_CHEMICAL", 44, 48], ["K", "TEST", 50, 51]]], ["Infections were caused mainly by A and D types while the same types were isolated from the environment and the hands of the ICU stuff.", [["Infections", "DISEASE", 0, 10], ["hands", "ORGANISM_SUBDIVISION", 111, 116], ["Infections", "PROBLEM", 0, 10], ["A and D types", "PROBLEM", 33, 46]]], ["Conclusion: There was a high rate of colonization and infection of ICU patients by multiresistant clones of Ab.", [["infection", "DISEASE", 54, 63], ["Ab.", "CHEMICAL", 108, 111], ["patients", "ORGANISM", 71, 79], ["Ab.", "ORGANISM", 108, 111], ["patients", "SPECIES", 71, 79], ["a high rate of colonization", "PROBLEM", 22, 49], ["infection", "PROBLEM", 54, 63], ["colonization", "OBSERVATION", 37, 49], ["infection", "OBSERVATION", 54, 63]]], ["The persistence of clone A of A. baumannii and the appearance of B type at the 3rd period after its disappearance at the 2nd period despite the application hygiene measures, indicates the need for more strict reinforced infection control in ICU.", [["infection", "DISEASE", 220, 229], ["A. baumannii", "ORGANISM", 30, 42], ["B type", "CELL", 65, 71], ["A. baumannii", "SPECIES", 30, 42], ["A. baumannii", "SPECIES", 30, 42], ["A. baumannii", "PROBLEM", 30, 42], ["the application hygiene measures", "TREATMENT", 140, 172], ["strict reinforced infection control", "TREATMENT", 202, 237], ["clone", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 220, 229]]], ["The transmission via the hands of stuff to patients has become the most important contributor factor in patient colonization and/or infection.", [["infection", "DISEASE", 132, 141], ["patients", "ORGANISM", 43, 51], ["patient", "ORGANISM", 104, 111], ["patients", "SPECIES", 43, 51], ["patient", "SPECIES", 104, 111], ["patient colonization", "PROBLEM", 104, 124], ["infection", "PROBLEM", 132, 141], ["infection", "OBSERVATION", 132, 141]]], ["Objectives: The antibiotic resistance and its mechanism of group A streptococci (GAS) varies according to nations or study period.", [["group A streptococci", "ORGANISM", 59, 79], ["The antibiotic resistance", "TREATMENT", 12, 37], ["group A streptococci", "PROBLEM", 59, 79]]], ["We have investigated antibiotic resistance and mechanism of macrolide resistance for the strains isolated from Korean children and compared to the previous (2002) results.", [["macrolide", "CHEMICAL", 60, 69], ["macrolide", "CHEMICAL", 60, 69], ["macrolide", "SIMPLE_CHEMICAL", 60, 69], ["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["antibiotic resistance", "TREATMENT", 21, 42], ["macrolide resistance", "TREATMENT", 60, 80], ["the strains", "PROBLEM", 85, 96], ["antibiotic resistance", "OBSERVATION", 21, 42], ["macrolide resistance", "OBSERVATION", 60, 80]]], ["Methods: Throat cultures were taken from 2351 elementary school children in Jinju, Korea from October to December, 2004 to isolate GAS.", [["Throat cultures", "ANATOMY", 9, 24], ["Throat cultures", "CELL", 9, 24], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["Throat cultures", "TEST", 9, 24], ["Throat", "ANATOMY", 9, 15]]], ["Antibiotic susceptibility test to erythromycin (EM), clindamycin (CC), and tetracycline (TC) was performed by disk diffusion method.", [["erythromycin", "CHEMICAL", 34, 46], ["EM", "CHEMICAL", 48, 50], ["clindamycin", "CHEMICAL", 53, 64], ["CC", "CHEMICAL", 66, 68], ["tetracycline", "CHEMICAL", 75, 87], ["TC", "CHEMICAL", 89, 91], ["erythromycin", "CHEMICAL", 34, 46], ["clindamycin", "CHEMICAL", 53, 64], ["tetracycline", "CHEMICAL", 75, 87], ["erythromycin", "SIMPLE_CHEMICAL", 34, 46], ["EM", "SIMPLE_CHEMICAL", 48, 50], ["clindamycin", "SIMPLE_CHEMICAL", 53, 64], ["CC", "SIMPLE_CHEMICAL", 66, 68], ["tetracycline", "SIMPLE_CHEMICAL", 75, 87], ["TC", "SIMPLE_CHEMICAL", 89, 91], ["Antibiotic susceptibility test", "TEST", 0, 30], ["erythromycin (EM)", "TREATMENT", 34, 51], ["clindamycin (CC)", "TREATMENT", 53, 69], ["tetracycline (TC)", "TREATMENT", 75, 92], ["disk diffusion method", "TEST", 110, 131]]], ["Macrolide resistance phenotype and genotype as well as emm genotype were studied.", [["Macrolide", "CHEMICAL", 0, 9], ["Macrolide", "CHEMICAL", 0, 9], ["Macrolide", "SIMPLE_CHEMICAL", 0, 9], ["Macrolide resistance phenotype and genotype", "PROBLEM", 0, 43], ["emm genotype", "TEST", 55, 67]]], ["Results: Isolation rate of GAS was 14.0% (328/2351).", [["Isolation rate", "TEST", 9, 23], ["GAS", "TEST", 27, 30]]], ["Resistance rates of EM, CC, and TC were 9.8%, 8.8%, and 18.3% respectively, which were dramatically decreased from 51%, 34%, and 30% in 2002 at the same area.", [["CC", "CHEMICAL", 24, 26], ["Resistance rates", "TEST", 0, 16], ["EM", "TEST", 20, 22], ["CC", "TEST", 24, 26], ["TC", "TEST", 32, 34], ["dramatically", "OBSERVATION_MODIFIER", 87, 99], ["decreased", "OBSERVATION_MODIFIER", 100, 109]]], ["Emm44/61 was prevalent (29%), while emm12 was the most common type (34%) in 2002. cMLSB, M, and iMLSB were observed in 87.5%, 9.4%, and 3.1% respectively, compared to 64%, 34%, and 2% in 2002.", [["Emm44/61", "GENE_OR_GENE_PRODUCT", 0, 8]]], ["The strains with cMLSB and iMLSB had ermB gene and the ones with M phenotype were positive with mefA gene.", [["cMLSB", "GENE_OR_GENE_PRODUCT", 17, 22], ["iMLSB", "GENE_OR_GENE_PRODUCT", 27, 32], ["ermB", "GENE_OR_GENE_PRODUCT", 37, 41], ["mefA", "GENE_OR_GENE_PRODUCT", 96, 100], ["cMLSB", "DNA", 17, 22], ["iMLSB", "DNA", 27, 32], ["ermB gene", "DNA", 37, 46], ["mefA gene", "DNA", 96, 105], ["The strains with cMLSB", "PROBLEM", 0, 22], ["M phenotype", "TEST", 65, 76]]], ["Conclusion: The resistance rates to EM and CC were dramatically decreased compared to the past (2002).", [["CC", "CHEMICAL", 43, 45], ["The resistance rates", "TEST", 12, 32], ["dramatically", "OBSERVATION_MODIFIER", 51, 63], ["decreased", "OBSERVATION_MODIFIER", 64, 73]]], ["Education to the public and physicians, decreased consumption of antibiotics, acquisition of immunity to the resistant strains, or change of prevalent emm types could be considered to explain the reason of decrease of antibiotic resistance.", [["antibiotics", "TREATMENT", 65, 76], ["immunity", "TREATMENT", 93, 101], ["the resistant strains", "PROBLEM", 105, 126], ["antibiotic resistance", "TREATMENT", 218, 239], ["antibiotic resistance", "OBSERVATION", 218, 239]]], ["Although antibiotic resistance rate was decreased, cMLSB type which has high MIC was prevalent suggesting treatment failure for those children carrying these resistant strains in Jinju, Korea.P1804Analysis of skin and soft tissue infections in European medical centres: report from the SENTRY Antimicrobial Surveillance Program (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) G. Moet, P. Strabala, H. Sader, T. Fritsche, R. Jones (North Liberty, US)P1804Objective: To analyse the skin and soft tissue infections (SSTI) or wound infections in hospitalized patients in the SENTRY Program for pathogen prevalence and resistance (R) variations in European (EU) medical centres for the years 1998 to 2005 (8 years).", [["skin", "ANATOMY", 209, 213], ["soft tissue", "ANATOMY", 218, 229], ["skin", "ANATOMY", 488, 492], ["soft tissue", "ANATOMY", 497, 508], ["wound", "ANATOMY", 530, 535], ["MIC", "CHEMICAL", 77, 80], ["skin and soft tissue infections", "DISEASE", 209, 240], ["skin and soft tissue infections", "DISEASE", 488, 519], ["SSTI", "DISEASE", 521, 525], ["wound infections", "DISEASE", 530, 546], ["children", "ORGANISM", 134, 142], ["skin", "ORGAN", 209, 213], ["soft tissue", "TISSUE", 218, 229], ["skin", "ORGAN", 488, 492], ["soft tissue", "TISSUE", 497, 508], ["wound", "PATHOLOGICAL_FORMATION", 530, 535], ["patients", "ORGANISM", 563, 571], ["children", "SPECIES", 134, 142], ["patients", "SPECIES", 563, 571], ["antibiotic resistance rate", "TEST", 9, 35], ["high MIC", "PROBLEM", 72, 80], ["treatment failure", "PROBLEM", 106, 123], ["these resistant strains in Jinju", "PROBLEM", 152, 184], ["skin and soft tissue infections", "PROBLEM", 209, 240], ["the skin", "PROBLEM", 484, 492], ["soft tissue infections", "PROBLEM", 497, 519], ["SSTI", "PROBLEM", 521, 525], ["wound infections", "PROBLEM", 530, 546], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["skin", "ANATOMY", 209, 213], ["soft tissue", "OBSERVATION_MODIFIER", 218, 229], ["infections", "OBSERVATION", 230, 240], ["skin", "ANATOMY", 488, 492], ["soft tissue", "ANATOMY", 497, 508], ["infections", "OBSERVATION", 509, 519], ["wound", "ANATOMY", 530, 535], ["infections", "OBSERVATION", 536, 546]]], ["This program also included North America (NA) and Latin America (LA) for the same years, except 2003.", [["LA", "CHEMICAL", 65, 67]]], ["Methods: 50 consecutively isolated pathogens/site were collected from each centre per year and varied in number of sites each year in EU: 1998 EU: (23), 1999 EU: (6), 2000 EU: (16), 2002 EU: (3), 2003 EU: (25), 2004 EU: (23), and 2005 .", [["isolated pathogens/site", "PROBLEM", 26, 49], ["EU", "TEST", 216, 218]]], ["Susceptibility testing was determined by CLSI (formerly the NCCLS) broth microdilution methods and interpreted by current (2005) breakpoints.P1804Results: Table of all years total of SSTI pathogens.", [["Susceptibility testing", "TEST", 0, 22], ["SSTI pathogens", "PROBLEM", 183, 197]]], ["(See Table) SA was the predominant pathogen in EU ranging from 35.7% of SSTI isolates in 1998 to 47.5% in 2005.", [["SSTI", "DISEASE", 72, 76], ["SSTI isolates", "TEST", 72, 85], ["predominant", "OBSERVATION_MODIFIER", 23, 34], ["pathogen", "OBSERVATION", 35, 43]]], ["The top 5 most prevalent organisms accounted for 80.0% of isolates in all years with PSA and EC ranking second and third, respectively with 22.5% combined, and ENC and ENT ranked fourth and fifth with 10.7% of the total isolates.", [["EC", "ANATOMY", 93, 95], ["EC", "CELL", 93, 95], ["PSA", "PROTEIN", 85, 88], ["PSA", "TEST", 85, 88], ["the total isolates", "TREATMENT", 210, 228], ["most prevalent", "OBSERVATION_MODIFIER", 10, 24]]], ["Compared to the Americas, MRSA and VRE isolation was at a lower occurrence rate in the EU; but between the rates of other monitored continents for CTZ-R PSA, CIPRO-R EC and CTZ-R ENT (AmpC).", [["VRE", "DISEASE", 35, 38], ["CTZ-R", "CHEMICAL", 147, 152], ["CTZ-R PSA", "GENE_OR_GENE_PRODUCT", 147, 156], ["CIPRO-R EC", "GENE_OR_GENE_PRODUCT", 158, 168], ["CTZ-R ENT", "GENE_OR_GENE_PRODUCT", 173, 182], ["AmpC", "GENE_OR_GENE_PRODUCT", 184, 188], ["CTZ", "PROTEIN", 147, 150], ["PSA", "PROTEIN", 153, 156], ["CIPRO", "PROTEIN", 158, 163], ["CTZ", "PROTEIN", 173, 176], ["MRSA", "SPECIES", 26, 30], ["MRSA", "SPECIES", 26, 30], ["MRSA", "PROBLEM", 26, 30], ["VRE isolation", "PROBLEM", 35, 48], ["CTZ", "TEST", 147, 150], ["R PSA", "TEST", 151, 156], ["CIPRO", "TREATMENT", 158, 163], ["CTZ", "TEST", 173, 176], ["R ENT (AmpC)", "TREATMENT", 177, 189], ["MRSA", "OBSERVATION", 26, 30]]], ["VRE increased in EU over the 8 year.P1804Conclusions: Pathogen prevalence in SSTI for EU has been consistent over the 8 monitored years although SA (with MRSA) appears to be increasing.", [["MRSA", "SPECIES", 154, 158], ["VRE", "PROBLEM", 0, 3], ["SSTI", "PROBLEM", 77, 81], ["SA", "PROBLEM", 145, 147], ["MRSA", "PROBLEM", 154, 158], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["MRSA", "OBSERVATION", 154, 158], ["increasing", "OBSERVATION_MODIFIER", 174, 184]]], ["However, the R rates are evolving which suggests continued need for surveillance programs at regular intervals to detect mobile genetic R elements.", [["mobile genetic R elements", "DNA", 121, 146], ["surveillance programs", "TREATMENT", 68, 89], ["mobile genetic R elements", "PROBLEM", 121, 146]]], ["Objectives: Carbapenems play an important role in the therapy of Pseudomonas aeruginosa infections.", [["Carbapenems", "CHEMICAL", 12, 23], ["Pseudomonas aeruginosa infections", "DISEASE", 65, 98], ["Pseudomonas aeruginosa", "ORGANISM", 65, 87], ["Pseudomonas aeruginosa", "SPECIES", 65, 87], ["Pseudomonas aeruginosa", "SPECIES", 65, 87], ["Carbapenems", "TREATMENT", 12, 23], ["Pseudomonas aeruginosa infections", "PROBLEM", 65, 98]]], ["The aim of our study was to characterize the molecular alteration responsible for changed susceptibility towards carbapenems in multiresistant P. aeruginosa strains from Germany.", [["carbapenems", "CHEMICAL", 113, 124], ["carbapenems", "CHEMICAL", 113, 124], ["carbapenems", "SIMPLE_CHEMICAL", 113, 124], ["P. aeruginosa", "ORGANISM", 143, 156], ["P. aeruginosa", "SPECIES", 143, 156], ["P. aeruginosa", "SPECIES", 143, 156], ["our study", "TEST", 11, 20], ["the molecular alteration", "PROBLEM", 41, 65], ["carbapenems", "TREATMENT", 113, 124], ["multiresistant P. aeruginosa strains", "PROBLEM", 128, 164]]], ["Methods: 19 multiresistant P. aeruginosa strains from 9 cystic fibrosis and 9 non cystic fibrosis patients were collected in 3 German hospitals in 2004.", [["cystic", "ANATOMY", 56, 62], ["cystic fibrosis", "DISEASE", 56, 71], ["fibrosis", "DISEASE", 89, 97], ["P. aeruginosa", "ORGANISM", 27, 40], ["cystic fibrosis", "PATHOLOGICAL_FORMATION", 56, 71], ["patients", "ORGANISM", 98, 106], ["P. aeruginosa", "SPECIES", 27, 40], ["patients", "SPECIES", 98, 106], ["P. aeruginosa", "SPECIES", 27, 40], ["Methods", "TEST", 0, 7], ["multiresistant P. aeruginosa strains", "PROBLEM", 12, 48], ["9 cystic fibrosis", "PROBLEM", 54, 71], ["9 non cystic fibrosis", "PROBLEM", 76, 97], ["cystic", "OBSERVATION_MODIFIER", 56, 62], ["fibrosis", "OBSERVATION", 63, 71], ["cystic", "OBSERVATION_MODIFIER", 82, 88], ["fibrosis", "OBSERVATION", 89, 97]]], ["The strains showed reduced susceptibility (intermediate or resistant; DIN guidelines) to imipenem, piperacillin, ciprofloxacin and gentamicin.", [["imipenem", "CHEMICAL", 89, 97], ["piperacillin", "CHEMICAL", 99, 111], ["ciprofloxacin", "CHEMICAL", 113, 126], ["gentamicin", "CHEMICAL", 131, 141], ["imipenem", "CHEMICAL", 89, 97], ["piperacillin", "CHEMICAL", 99, 111], ["ciprofloxacin", "CHEMICAL", 113, 126], ["gentamicin", "CHEMICAL", 131, 141], ["imipenem", "SIMPLE_CHEMICAL", 89, 97], ["piperacillin", "SIMPLE_CHEMICAL", 99, 111], ["ciprofloxacin", "SIMPLE_CHEMICAL", 113, 126], ["gentamicin", "SIMPLE_CHEMICAL", 131, 141], ["The strains", "PROBLEM", 0, 11], ["reduced susceptibility", "PROBLEM", 19, 41], ["imipenem", "TREATMENT", 89, 97], ["piperacillin", "TREATMENT", 99, 111], ["ciprofloxacin", "TREATMENT", 113, 126], ["gentamicin", "TREATMENT", 131, 141], ["reduced", "OBSERVATION_MODIFIER", 19, 26], ["susceptibility", "OBSERVATION_MODIFIER", 27, 41]]], ["A PCR screening for VIM and IMP was carried out.", [["VIM", "GENE_OR_GENE_PRODUCT", 20, 23], ["IMP", "SIMPLE_CHEMICAL", 28, 31], ["VIM", "PROTEIN", 20, 23], ["A PCR screening", "TEST", 0, 15], ["VIM", "TEST", 20, 23], ["IMP", "TEST", 28, 31]]], ["Effluxpump overexpression was detected using an effluxpump inhibitor (EPI) test.", [["Effluxpump", "GENE_OR_GENE_PRODUCT", 0, 10], ["Effluxpump overexpression", "PROBLEM", 0, 25], ["an effluxpump inhibitor", "TREATMENT", 45, 68], ["EPI) test", "TEST", 70, 79]]], ["OprD and for strains with positive results in the EPI test the effluxpump repressorgenes mexR and nfxB were sequenced.", [["OprD", "GENE_OR_GENE_PRODUCT", 0, 4], ["mexR", "GENE_OR_GENE_PRODUCT", 89, 93], ["nfxB", "GENE_OR_GENE_PRODUCT", 98, 102], ["OprD", "DNA", 0, 4], ["effluxpump repressorgenes", "DNA", 63, 88], ["mexR", "DNA", 89, 93], ["nfxB", "DNA", 98, 102], ["OprD", "TREATMENT", 0, 4], ["strains", "PROBLEM", 13, 20], ["the EPI test", "TEST", 46, 58]]], ["Results: PFGE patterns revealed no clonal relationship among the multiresistant strains.", [["strains", "ANATOMY", 80, 87], ["PFGE patterns", "TEST", 9, 22], ["clonal relationship", "PROBLEM", 35, 54], ["the multiresistant strains", "PROBLEM", 61, 87], ["no", "UNCERTAINTY", 32, 34], ["multiresistant strains", "OBSERVATION", 65, 87]]], ["Neither VIM nor IMP was detected.", [["IMP", "CHEMICAL", 16, 19], ["IMP", "CHEMICAL", 16, 19], ["VIM", "GENE_OR_GENE_PRODUCT", 8, 11], ["IMP", "SIMPLE_CHEMICAL", 16, 19], ["VIM", "PROTEIN", 8, 11]]], ["Defective oprD genes caused by premature stopcodons or frameshifts were found in 17 strains.", [["premature stopcodons", "DISEASE", 31, 51], ["oprD", "GENE_OR_GENE_PRODUCT", 10, 14], ["oprD genes", "DNA", 10, 20], ["Defective oprD genes", "PROBLEM", 0, 20], ["premature stopcodons", "PROBLEM", 31, 51], ["frameshifts", "PROBLEM", 55, 66], ["premature", "OBSERVATION_MODIFIER", 31, 40], ["stopcodons", "OBSERVATION", 41, 51]]], ["Among those 11 had no mutations in mexR or nfxB and showed the highest MICs found ranging from 8 to >32 and 4 to 32 mg/L of imipenem and meropenem, respectively.", [["imipenem", "CHEMICAL", 124, 132], ["meropenem", "CHEMICAL", 137, 146], ["imipenem", "CHEMICAL", 124, 132], ["meropenem", "CHEMICAL", 137, 146], ["mexR", "GENE_OR_GENE_PRODUCT", 35, 39], ["nfxB", "GENE_OR_GENE_PRODUCT", 43, 47], ["imipenem", "SIMPLE_CHEMICAL", 124, 132], ["meropenem", "SIMPLE_CHEMICAL", 137, 146], ["mexR", "DNA", 35, 39], ["nfxB", "DNA", 43, 47], ["mutations in mexR", "PROBLEM", 22, 39], ["the highest MICs", "TEST", 59, 75], ["imipenem", "TREATMENT", 124, 132], ["meropenem", "TREATMENT", 137, 146]]], ["3 additionally had defective mexR genes, but intact nfxB genes, 2 also had modifications in mexR and nfxB, and 1 showed only in nfxB additional alterations.", [["mexR", "GENE_OR_GENE_PRODUCT", 29, 33], ["nfxB", "GENE_OR_GENE_PRODUCT", 52, 56], ["mexR", "GENE_OR_GENE_PRODUCT", 92, 96], ["nfxB", "GENE_OR_GENE_PRODUCT", 101, 105], ["nfxB", "GENE_OR_GENE_PRODUCT", 128, 132], ["mexR genes", "DNA", 29, 39], ["nfxB genes", "DNA", 52, 62], ["mexR", "DNA", 92, 96], ["nfxB", "DNA", 101, 105], ["nfxB", "DNA", 128, 132], ["defective mexR genes", "PROBLEM", 19, 39], ["defective", "OBSERVATION_MODIFIER", 19, 28], ["mexR genes", "OBSERVATION", 29, 39], ["alterations", "OBSERVATION", 144, 155]]], ["For 2 strains no alterations in oprD but in mexR were proven.", [["oprD", "GENE_OR_GENE_PRODUCT", 32, 36], ["mexR", "GENE_OR_GENE_PRODUCT", 44, 48], ["oprD", "DNA", 32, 36], ["mexR", "DNA", 44, 48], ["alterations in oprD", "PROBLEM", 17, 36]]], ["Conclusions: The predominating mechanism of carbapenem resistance in multiresistant P. aeruginosa strains from Germany was the loss of OprD.", [["carbapenem", "CHEMICAL", 44, 54], ["P. aeruginosa", "DISEASE", 84, 97], ["carbapenem", "CHEMICAL", 44, 54], ["carbapenem", "SIMPLE_CHEMICAL", 44, 54], ["P. aeruginosa", "ORGANISM", 84, 97], ["P. aeruginosa", "SPECIES", 84, 97], ["P. aeruginosa", "SPECIES", 84, 97], ["carbapenem resistance", "PROBLEM", 44, 65], ["multiresistant P. aeruginosa strains", "PROBLEM", 69, 105], ["carbapenem resistance", "OBSERVATION", 44, 65]]], ["Accessory overexpression of MexABOprM due to modifications in mexR did not result in significantly elevated MICs of meropenem.", [["meropenem", "CHEMICAL", 116, 125], ["meropenem", "CHEMICAL", 116, 125], ["MexABOprM", "GENE_OR_GENE_PRODUCT", 28, 37], ["mexR", "GENE_OR_GENE_PRODUCT", 62, 66], ["meropenem", "SIMPLE_CHEMICAL", 116, 125], ["MexABOprM", "PROTEIN", 28, 37], ["mexR", "DNA", 62, 66], ["MexABOprM", "TREATMENT", 28, 37], ["modifications in mexR", "PROBLEM", 45, 66], ["significantly elevated MICs", "PROBLEM", 85, 112], ["meropenem", "TREATMENT", 116, 125], ["overexpression", "OBSERVATION", 10, 24]]], ["Moreover, the additional overexpression of MexCDOprJ did not lower the MIC of imipenem.", [["MexCDOprJ", "CHEMICAL", 43, 52], ["imipenem", "CHEMICAL", 78, 86], ["imipenem", "CHEMICAL", 78, 86], ["MexCDOprJ", "GENE_OR_GENE_PRODUCT", 43, 52], ["imipenem", "SIMPLE_CHEMICAL", 78, 86], ["MexCDOprJ", "PROTEIN", 43, 52], ["MexCDOprJ", "TREATMENT", 43, 52], ["imipenem", "TREATMENT", 78, 86]]], ["In 2 strains with modifications only in mexR only elevated MICs of imipenem indicate a reduced expression of OprD accompanied by overexpression of MexEFOprN as conferred by nfxC-type mutants.", [["imipenem", "CHEMICAL", 67, 75], ["imipenem", "CHEMICAL", 67, 75], ["mexR", "SIMPLE_CHEMICAL", 40, 44], ["imipenem", "SIMPLE_CHEMICAL", 67, 75], ["OprD", "GENE_OR_GENE_PRODUCT", 109, 113], ["MexEFOprN", "GENE_OR_GENE_PRODUCT", 147, 156], ["nfxC-type", "GENE_OR_GENE_PRODUCT", 173, 182], ["OprD", "PROTEIN", 109, 113], ["MexEFOprN", "PROTEIN", 147, 156], ["nfxC", "PROTEIN", 173, 177], ["imipenem", "TREATMENT", 67, 75], ["MexEFOprN", "TREATMENT", 147, 156]]], ["Objective: MART (Study for Monitoring Antimicrobial Resistance Trends) is an ongoing global antimicrobial surveillance program focused on clinical isolates from intraabdominal infections (IAI).", [["intraabdominal", "ANATOMY", 161, 175], ["intraabdominal infections", "DISEASE", 161, 186], ["IAI", "DISEASE", 188, 191], ["intraabdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 161, 175], ["an ongoing global antimicrobial surveillance program", "TREATMENT", 74, 126], ["intraabdominal infections", "PROBLEM", 161, 186], ["intraabdominal", "ANATOMY", 161, 175], ["infections", "OBSERVATION", 176, 186]]], ["The aim of this sub-analysis was to assess antimicrobial susceptibility patterns among Gramnegative bacilli from 5 different regions of the world during 2004.", [["this sub-analysis", "TEST", 11, 28], ["antimicrobial susceptibility patterns", "PROBLEM", 43, 80], ["Gramnegative bacilli", "PROBLEM", 87, 107], ["Gramnegative bacilli", "OBSERVATION", 87, 107]]], ["Methods: 6pA total of 81 major medical centres in North America, Latin America, Europe, Middle East/Africa, & Asia/ Pacific tested the in vitro activity of antimicrobial agents commonly used to treat IAI against consecutive unique aerobic and facultative Gram-negative bacilli from IAI using microdilution techniques according to CLSI guidelines & breakpoints.", [["IAI", "DISEASE", 200, 203], ["antimicrobial agents", "TREATMENT", 156, 176], ["IAI", "PROBLEM", 200, 203], ["microdilution techniques", "TREATMENT", 292, 316]]], ["Results: Enterobacteriaceae were recovered from 4905 (88%) & non-Enterobacteriaceae were recovered from 826 (15%) of the 5596 patients in the study worldwide, constituting 5317 (86%) & 839 (14%) of the 6156 total isolates, respectively.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["Enterobacteriaceae", "TEST", 9, 27], ["non-Enterobacteriaceae", "TEST", 61, 83], ["the study", "TEST", 138, 147], ["Enterobacteriaceae", "OBSERVATION", 9, 27]]], ["E. coli (n = 2979; 56%) and Klebsiella spp. (n = 978; 18%) were the most commonly isolated Enterobacteriaceae.", [["Klebsiella spp.", "DISEASE", 28, 43], ["E. coli", "ORGANISM", 0, 7], ["Klebsiella spp.", "ORGANISM", 28, 43], ["E. coli", "SPECIES", 0, 7], ["Klebsiella spp.", "SPECIES", 28, 43], ["E. coli", "SPECIES", 0, 7], ["Klebsiella spp.", "SPECIES", 28, 43], ["E. coli", "TEST", 0, 7], ["Klebsiella spp.", "PROBLEM", 28, 43], ["Enterobacteriaceae", "PROBLEM", 91, 109], ["coli", "OBSERVATION", 3, 7], ["Klebsiella", "OBSERVATION_MODIFIER", 28, 38], ["Enterobacteriaceae", "OBSERVATION", 91, 109]]], ["Pseudomonas spp. (n = 605; 72%) and Acinetobacter spp. (n = 110; 13%) were the most commonly isolated non-Enterobacteriaceae.", [["Acinetobacter spp.", "DISEASE", 36, 54], ["Pseudomonas spp.", "ORGANISM", 0, 16], ["Acinetobacter spp.", "ORGANISM", 36, 54], ["non-Enterobacteriaceae", "CANCER", 102, 124], ["Pseudomonas spp.", "SPECIES", 0, 16], ["Acinetobacter spp.", "SPECIES", 36, 54], ["Pseudomonas spp.", "SPECIES", 0, 16], ["Acinetobacter spp.", "SPECIES", 36, 54], ["Pseudomonas spp.", "PROBLEM", 0, 16], ["Acinetobacter spp.", "TEST", 36, 54], ["non-Enterobacteriaceae", "OBSERVATION", 102, 124]]], ["Isolates from Asia/Pacific and Latin America were generally more resistant.", [["Pacific and Latin America", "TREATMENT", 19, 44]]], ["2267 (43%) of the Enterobacteriaceae & 272 (32%) of the non-Enterobacteriaceae were recovered <48 hours after hospitalization.", [["non-Enterobacteriaceae", "CANCER", 56, 78], ["the Enterobacteriaceae", "TEST", 14, 36], ["the non-Enterobacteriaceae", "TREATMENT", 52, 78]]], ["The % susceptible isolates are reported below:P1805Conclusion: In this study, Enterobacteriaceae were the predominant intraabdominal isolates recovered both <48 h and >48 h after hospitalization.", [["intraabdominal", "ANATOMY", 118, 132], ["Enterobacteriaceae", "CANCER", 78, 96], ["this study", "TEST", 66, 76], ["Enterobacteriaceae", "PROBLEM", 78, 96], ["intraabdominal", "ANATOMY", 118, 132]]], ["Carbapenems were overall the most active agents against Enterobacteriaceae worldwide.", [["Carbapenems", "CHEMICAL", 0, 11], ["Carbapenems", "CHEMICAL", 0, 11], ["Carbapenems", "SIMPLE_CHEMICAL", 0, 11], ["Enterobacteriaceae", "CANCER", 56, 74], ["Carbapenems", "TREATMENT", 0, 11], ["Enterobacteriaceae worldwide", "TREATMENT", 56, 84], ["most active", "OBSERVATION_MODIFIER", 29, 40]]], ["Resistance rates varied among geographic regions, with the Asia/Pacific and Latin America regions generally having the most resistance.P1808Characterisation of streptogramin resistance genes among Enterococcus faecium isolates from Austrian animal husbandry A. Eisner, G. Gorkiewicz, G. Feierl, F. Dieber, E. Marth, J. K\u00f6 fer (Graz, AT)P1808Objectives: The streptogramin virginiamycin has been widely used as a growth promoter in animal husbandry in the European Union but was banned in 1998 because of concerns about evolving cross-resistance to the streptogramin quinupristin-dalfopristin used in human medicine.", [["streptogramin", "CHEMICAL", 160, 173], ["streptogramin", "CHEMICAL", 357, 370], ["virginiamycin", "CHEMICAL", 371, 384], ["streptogramin quinupristin-dalfopristin", "CHEMICAL", 551, 590], ["virginiamycin", "CHEMICAL", 371, 384], ["quinupristin", "CHEMICAL", 565, 577], ["dalfopristin", "CHEMICAL", 578, 590], ["streptogramin", "GENE_OR_GENE_PRODUCT", 160, 173], ["Enterococcus faecium", "ORGANISM", 197, 217], ["streptogramin virginiamycin", "SIMPLE_CHEMICAL", 357, 384], ["streptogramin quinupristin-dalfopristin", "SIMPLE_CHEMICAL", 551, 590], ["human", "ORGANISM", 599, 604], ["streptogramin resistance genes", "DNA", 160, 190], ["growth promoter", "DNA", 411, 426], ["Enterococcus faecium", "SPECIES", 197, 217], ["human", "SPECIES", 599, 604], ["Enterococcus faecium", "SPECIES", 197, 217], ["human", "SPECIES", 599, 604], ["Resistance rates", "TEST", 0, 16], ["the Asia/Pacific and Latin America regions", "TREATMENT", 55, 97], ["streptogramin resistance genes", "PROBLEM", 160, 190], ["Enterococcus faecium", "PROBLEM", 197, 217], ["The streptogramin virginiamycin", "TREATMENT", 353, 384], ["a growth promoter", "TREATMENT", 409, 426], ["the streptogramin quinupristin", "TREATMENT", 547, 577], ["dalfopristin", "TREATMENT", 578, 590], ["human medicine", "TREATMENT", 599, 613], ["most resistance", "OBSERVATION", 119, 134], ["streptogramin resistance", "OBSERVATION", 160, 184]]], ["The aim of the present study was to investigate the prevalence of streptogramin resistance genes of Enterococcus faecium recovered from animal faecal specimens collected in Southeast Austria.", [["faecal specimens", "ANATOMY", 143, 159], ["streptogramin", "CHEMICAL", 66, 79], ["streptogramin", "GENE_OR_GENE_PRODUCT", 66, 79], ["Enterococcus faecium", "ORGANISM", 100, 120], ["streptogramin resistance genes", "DNA", 66, 96], ["Enterococcus faecium", "SPECIES", 100, 120], ["Enterococcus faecium", "SPECIES", 100, 120], ["the present study", "TEST", 11, 28], ["streptogramin resistance genes", "PROBLEM", 66, 96], ["Enterococcus faecium", "PROBLEM", 100, 120], ["animal faecal specimens", "TEST", 136, 159], ["Enterococcus faecium", "OBSERVATION", 100, 120]]], ["Methods: We analysed 300 E. faecium isolates of cattle (n = 100), pig (n = 100), and poultry (n = 100) for the presence of streptogramin resistance genes.", [["streptogramin", "CHEMICAL", 123, 136], ["cattle", "ORGANISM", 48, 54], ["pig", "ORGANISM", 66, 69], ["streptogramin", "GENE_OR_GENE_PRODUCT", 123, 136], ["streptogramin resistance genes", "DNA", 123, 153], ["E. faecium", "SPECIES", 25, 35], ["cattle", "SPECIES", 48, 54], ["pig", "SPECIES", 66, 69], ["E. faecium", "SPECIES", 25, 35], ["cattle", "SPECIES", 48, 54], ["pig", "SPECIES", 66, 69], ["poultry", "SPECIES", 85, 92], ["pig (n", "TREATMENT", 66, 72], ["streptogramin resistance genes", "PROBLEM", 123, 153], ["streptogramin resistance", "OBSERVATION", 123, 147]]], ["We used selective enterococcal broth for isolation.", [["selective enterococcal broth", "TREATMENT", 8, 36], ["isolation", "TREATMENT", 41, 50], ["selective", "OBSERVATION_MODIFIER", 8, 17], ["enterococcal", "OBSERVATION", 18, 30]]], ["Species identification was done on basis of Gram stain, catalase and pyrrolidonyl arylamidase activity, motility, Lancefield group D antigen typing, and by the 20 Strep Apitest (bioM\u00e9rieux).", [["pyrrolidonyl", "CHEMICAL", 69, 81], ["pyrrolidonyl", "CHEMICAL", 69, 81], ["catalase", "SIMPLE_CHEMICAL", 56, 64], ["pyrrolidonyl arylamidase", "SIMPLE_CHEMICAL", 69, 93], ["catalase", "PROTEIN", 56, 64], ["Species identification", "TEST", 0, 22], ["Gram stain", "TEST", 44, 54], ["catalase", "TEST", 56, 64], ["pyrrolidonyl arylamidase activity", "TREATMENT", 69, 102], ["Lancefield group D antigen typing", "TEST", 114, 147]]], ["Detection of the resistance genes vat(E), vat(D), and erm(B) was done by PCR.", [["vat(E)", "GENE_OR_GENE_PRODUCT", 34, 40], ["vat(D)", "GENE_OR_GENE_PRODUCT", 42, 48], ["erm(B)", "GENE_OR_GENE_PRODUCT", 54, 60], ["resistance genes", "DNA", 17, 33], ["vat", "DNA", 34, 37], ["E", "DNA", 38, 39], ["vat", "DNA", 42, 45], ["D", "DNA", 46, 47], ["erm(B)", "DNA", 54, 60], ["vat(D)", "TEST", 42, 48]]], ["Results: The erm(B) gene encoding macrolide, lincosamine, and streptogramin B (MLSB) resistance was found in each 2 E. faecium isolates recovered from pig and cattle, none of the isolates from these animals carried genes coding for streptogramin A resistance.", [["macrolide", "CHEMICAL", 34, 43], ["lincosamine", "CHEMICAL", 45, 56], ["streptogramin B", "CHEMICAL", 62, 77], ["MLSB", "CHEMICAL", 79, 83], ["streptogramin A", "CHEMICAL", 232, 247], ["macrolide", "CHEMICAL", 34, 43], ["lincosamine", "CHEMICAL", 45, 56], ["streptogramin B", "CHEMICAL", 62, 77], ["MLSB", "CHEMICAL", 79, 83], ["streptogramin A", "CHEMICAL", 232, 247], ["erm(B)", "GENE_OR_GENE_PRODUCT", 13, 19], ["macrolide", "SIMPLE_CHEMICAL", 34, 43], ["lincosamine", "SIMPLE_CHEMICAL", 45, 56], ["streptogramin B", "GENE_OR_GENE_PRODUCT", 62, 77], ["MLSB", "SIMPLE_CHEMICAL", 79, 83], ["E. faecium", "ORGANISM", 116, 126], ["pig", "ORGANISM", 151, 154], ["cattle", "ORGANISM", 159, 165], ["streptogramin A", "SIMPLE_CHEMICAL", 232, 247], ["erm(B) gene", "DNA", 13, 24], ["E. faecium", "SPECIES", 116, 126], ["pig", "SPECIES", 151, 154], ["cattle", "SPECIES", 159, 165], ["E. faecium", "SPECIES", 116, 126], ["pig", "SPECIES", 151, 154], ["cattle", "SPECIES", 159, 165], ["The erm(B) gene encoding macrolide", "TREATMENT", 9, 43], ["lincosamine", "TREATMENT", 45, 56], ["streptogramin B (MLSB) resistance", "TREATMENT", 62, 95], ["pig and cattle", "TREATMENT", 151, 165], ["streptogramin A resistance", "PROBLEM", 232, 258]]], ["On the contrary, 14 E. faecium isolates from broiler specimens contained the vat(E) gene and one isolate contained the vat(D) gene.", [["specimens", "ANATOMY", 53, 62], ["E. faecium", "ORGANISM", 20, 30], ["broiler specimens", "CANCER", 45, 62], ["vat(E)", "GENE_OR_GENE_PRODUCT", 77, 83], ["vat(D)", "GENE_OR_GENE_PRODUCT", 119, 125], ["vat(E) gene", "DNA", 77, 88], ["vat(D) gene", "DNA", 119, 130], ["E. faecium", "SPECIES", 20, 30], ["E. faecium", "SPECIES", 20, 30], ["E. faecium isolates", "TREATMENT", 20, 39], ["broiler specimens", "TEST", 45, 62], ["the vat(E) gene", "TREATMENT", 73, 88], ["the vat(D) gene", "TREATMENT", 115, 130]]], ["All of these isolates also contained the erm(B) gene.", [["erm(B)", "GENE_OR_GENE_PRODUCT", 41, 47], ["erm(B) gene", "DNA", 41, 52], ["these isolates", "TREATMENT", 7, 21]]], ["Conclusion: Our data indicate that the use of the meanwhile banned antimicrobial feed additive virginiamycin has created a reservoir of streptogramin-resistant E. faecium in Southeast Austrian poultry.P1809Characterisation of macrolide-resistant Streptococcus pneumoniae isolates from Russia Objectives: Streptococcus pneumoniae (Spn) resistance to macrolide antibiotics continues to be of major concern.", [["virginiamycin", "CHEMICAL", 95, 108], ["streptogramin", "CHEMICAL", 136, 149], ["P1809", "CHEMICAL", 201, 206], ["macrolide", "CHEMICAL", 226, 235], ["Streptococcus pneumoniae", "DISEASE", 246, 270], ["Streptococcus pneumoniae", "DISEASE", 304, 328], ["macrolide", "CHEMICAL", 349, 358], ["virginiamycin", "CHEMICAL", 95, 108], ["streptogramin", "CHEMICAL", 136, 149], ["macrolide", "CHEMICAL", 226, 235], ["macrolide", "CHEMICAL", 349, 358], ["virginiamycin", "SIMPLE_CHEMICAL", 95, 108], ["streptogramin", "GENE_OR_GENE_PRODUCT", 136, 149], ["E. faecium", "ORGANISM", 160, 170], ["macrolide", "SIMPLE_CHEMICAL", 226, 235], ["Streptococcus pneumoniae", "ORGANISM", 246, 270], ["Streptococcus pneumoniae", "ORGANISM", 304, 328], ["Spn", "ORGANISM", 330, 333], ["macrolide", "SIMPLE_CHEMICAL", 349, 358], ["E. faecium", "SPECIES", 160, 170], ["Streptococcus pneumoniae", "SPECIES", 246, 270], ["Streptococcus pneumoniae", "SPECIES", 304, 328], ["E. faecium", "SPECIES", 160, 170], ["Streptococcus pneumoniae", "SPECIES", 246, 270], ["Streptococcus pneumoniae", "SPECIES", 304, 328], ["Our data", "TEST", 12, 20], ["the meanwhile banned antimicrobial feed additive virginiamycin", "TREATMENT", 46, 108], ["a reservoir of streptogramin", "TREATMENT", 121, 149], ["resistant E. faecium", "PROBLEM", 150, 170], ["macrolide", "TEST", 226, 235], ["resistant Streptococcus pneumoniae isolates", "PROBLEM", 236, 279], ["Streptococcus pneumoniae", "PROBLEM", 304, 328], ["macrolide antibiotics", "TREATMENT", 349, 370], ["faecium", "OBSERVATION_MODIFIER", 163, 170], ["resistant", "OBSERVATION_MODIFIER", 236, 245], ["Streptococcus pneumoniae", "OBSERVATION", 246, 270], ["Streptococcus pneumoniae", "OBSERVATION", 304, 328]]], ["The aim of present study was to analyse phenotypic and genotypic characteristics of macrolide resistant Spn isolates.", [["macrolide", "CHEMICAL", 84, 93], ["macrolide", "CHEMICAL", 84, 93], ["macrolide", "SIMPLE_CHEMICAL", 84, 93], ["present study", "TEST", 11, 24], ["macrolide resistant Spn isolates", "PROBLEM", 84, 116]]], ["Methods: Eighty one macrolide resistant Spn isolates were collected in Moscow, 2003 Moscow, -2005 .", [["macrolide", "CHEMICAL", 20, 29], ["macrolide", "CHEMICAL", 20, 29], ["Spn", "ORGANISM", 40, 43]]], ["The susceptibility testing was performed according to the CLSI guidelines.", [["The susceptibility testing", "TEST", 0, 26]]], ["Macrolide resistance phenotypes were characterized by triple-disk diffusion test, using erythromycin, clindamycin and rokitamycin disks.", [["Macrolide", "CHEMICAL", 0, 9], ["erythromycin", "CHEMICAL", 88, 100], ["clindamycin", "CHEMICAL", 102, 113], ["rokitamycin", "CHEMICAL", 118, 129], ["Macrolide", "CHEMICAL", 0, 9], ["erythromycin", "CHEMICAL", 88, 100], ["clindamycin", "CHEMICAL", 102, 113], ["rokitamycin", "CHEMICAL", 118, 129], ["Macrolide", "SIMPLE_CHEMICAL", 0, 9], ["erythromycin", "SIMPLE_CHEMICAL", 88, 100], ["clindamycin", "SIMPLE_CHEMICAL", 102, 113], ["rokitamycin", "SIMPLE_CHEMICAL", 118, 129], ["Macrolide resistance phenotypes", "PROBLEM", 0, 31], ["triple-disk diffusion test", "TEST", 54, 80], ["erythromycin", "TREATMENT", 88, 100], ["clindamycin", "TREATMENT", 102, 113], ["rokitamycin disks", "TREATMENT", 118, 135]]], ["Detection of genes, coding resistance to macrolides, was done by RT-PCR.", [["macrolides", "CHEMICAL", 41, 51], ["macrolides", "CHEMICAL", 41, 51], ["macrolides", "TREATMENT", 41, 51], ["PCR", "TEST", 68, 71]]], ["Sequencing for QRDR mutations was performed on levofloxacin resistant Spn isolates.", [["levofloxacin", "CHEMICAL", 47, 59], ["levofloxacin", "CHEMICAL", 47, 59], ["QRDR", "GENE_OR_GENE_PRODUCT", 15, 19], ["levofloxacin", "SIMPLE_CHEMICAL", 47, 59], ["QRDR mutations", "DNA", 15, 29], ["QRDR mutations", "PROBLEM", 15, 29], ["levofloxacin", "TREATMENT", 47, 59]]], ["Selected isolates were analysed by MLST.", [["Selected isolates", "TEST", 0, 17]]], ["Results: By the triple-disk test, 21 isolates were assigned to the M phenotype, 20 of them were carrying mefA gene, and one was negative.", [["mefA", "GENE_OR_GENE_PRODUCT", 105, 109], ["mefA gene", "DNA", 105, 114], ["the triple-disk test", "TEST", 12, 32], ["the M phenotype", "TEST", 63, 78], ["negative", "OBSERVATION", 128, 136]]], ["Twenty eight isolates were cMLSB-phenotype, 25 of them were carrying both ermB and mefA genes, in two isolates only ermB was detected, and one isolate was negative for both genes. iMcLSB phenotype was demonstrated by 29 isolates, both ermB and mefA genes were detected in 6 of them, and only ermB in 23.", [["ermB", "GENE_OR_GENE_PRODUCT", 74, 78], ["mefA", "GENE_OR_GENE_PRODUCT", 83, 87], ["ermB", "GENE_OR_GENE_PRODUCT", 116, 120], ["iMcLSB", "GENE_OR_GENE_PRODUCT", 180, 186], ["ermB", "GENE_OR_GENE_PRODUCT", 235, 239], ["mefA", "GENE_OR_GENE_PRODUCT", 244, 248], ["ermB and mefA genes", "DNA", 74, 93], ["ermB", "DNA", 116, 120], ["ermB and mefA genes", "DNA", 235, 254], ["ermB", "DNA", 292, 296], ["cMLSB", "TEST", 27, 32], ["ermB", "PROBLEM", 116, 120], ["iMcLSB phenotype", "TEST", 180, 196]]], ["Three isolates didn't demonstrated blunting of zone of inhibition around rokitamycin disk.", [["rokitamycin", "CHEMICAL", 73, 84], ["rokitamycin", "CHEMICAL", 73, 84], ["rokitamycin", "SIMPLE_CHEMICAL", 73, 84], ["Three isolates", "TEST", 0, 14], ["blunting of zone of inhibition around rokitamycin disk", "PROBLEM", 35, 89], ["blunting", "OBSERVATION", 35, 43], ["zone", "OBSERVATION_MODIFIER", 47, 51], ["rokitamycin disk", "OBSERVATION", 73, 89]]], ["Associated resistance to penicillin G, tetracycline, chloramphenicol and co-trimoxazole was observed in 67.9%, 86.4%, 42.0% and 75.3% of Spn isolates respectively.", [["penicillin G", "CHEMICAL", 25, 37], ["tetracycline", "CHEMICAL", 39, 51], ["chloramphenicol", "CHEMICAL", 53, 68], ["co-trimoxazole", "CHEMICAL", 73, 87], ["penicillin G", "CHEMICAL", 25, 37], ["tetracycline", "CHEMICAL", 39, 51], ["chloramphenicol", "CHEMICAL", 53, 68], ["co-trimoxazole", "CHEMICAL", 73, 87], ["penicillin G", "SIMPLE_CHEMICAL", 25, 37], ["tetracycline", "SIMPLE_CHEMICAL", 39, 51], ["chloramphenicol", "SIMPLE_CHEMICAL", 53, 68], ["co-trimoxazole", "SIMPLE_CHEMICAL", 73, 87], ["penicillin G", "TREATMENT", 25, 37], ["tetracycline", "TREATMENT", 39, 51], ["chloramphenicol", "TREATMENT", 53, 68], ["co-trimoxazole", "TREATMENT", 73, 87], ["Spn isolates", "TEST", 137, 149]]], ["Nine multidrug resistant isolates, harbouring both mefA and ermB genes, were subjected to MLST.", [["mefA", "GENE_OR_GENE_PRODUCT", 51, 55], ["ermB", "GENE_OR_GENE_PRODUCT", 60, 64], ["mefA and ermB genes", "DNA", 51, 70], ["Nine multidrug resistant isolates", "PROBLEM", 0, 33], ["harbouring both mefA and ermB genes", "PROBLEM", 35, 70], ["multidrug resistant isolates", "OBSERVATION", 5, 33], ["ermB genes", "OBSERVATION", 60, 70]]], ["Among them one isolate was found to share the allelic profile ST 81 (Spain23F-1 clone), and four isolates were single-allele variants of ST 81.", [["Spain23F-1", "GENE_OR_GENE_PRODUCT", 69, 79], ["ST 81", "DNA", 62, 67], ["Spain23F-1 clone", "DNA", 69, 85], ["ST 81", "DNA", 137, 142], ["Spain23F", "TEST", 69, 77], ["four isolates", "TEST", 92, 105]]], ["In four isolates new allelic profiles were detected.", [["new allelic profiles", "PROBLEM", 17, 37], ["isolates", "OBSERVATION_MODIFIER", 8, 16], ["new", "OBSERVATION_MODIFIER", 17, 20], ["allelic profiles", "OBSERVATION", 21, 37]]], ["Three isolates were resistant to levofloxacin (MIC \u20214 mg/L), in two of them with levofloxacin MIC > 32 mg/L (ST81 single-allele variants) E85K, S79F and I460V substitutions were detected in GyrA, ParC and ParE, respectively.", [["levofloxacin", "CHEMICAL", 33, 45], ["MIC", "CHEMICAL", 47, 50], ["levofloxacin", "CHEMICAL", 81, 93], ["MIC", "CHEMICAL", 94, 97], ["levofloxacin", "CHEMICAL", 33, 45], ["levofloxacin", "CHEMICAL", 81, 93], ["levofloxacin", "SIMPLE_CHEMICAL", 33, 45], ["levofloxacin", "SIMPLE_CHEMICAL", 81, 93], ["E85K", "GENE_OR_GENE_PRODUCT", 138, 142], ["GyrA", "AMINO_ACID", 190, 194], ["ParC", "GENE_OR_GENE_PRODUCT", 196, 200], ["ParE", "GENE_OR_GENE_PRODUCT", 205, 209], ["ParC", "PROTEIN", 196, 200], ["ParE", "PROTEIN", 205, 209], ["Three isolates", "PROBLEM", 0, 14], ["levofloxacin", "TREATMENT", 33, 45], ["levofloxacin MIC", "TREATMENT", 81, 97], ["I460V substitutions", "PROBLEM", 153, 172]]], ["D83N and I460V substitutions were detected in ParC and ParE of one isolate with new allelic profile.", [["D83N", "GENE_OR_GENE_PRODUCT", 0, 4], ["I460V", "GENE_OR_GENE_PRODUCT", 9, 14], ["ParC", "GENE_OR_GENE_PRODUCT", 46, 50], ["ParC", "PROTEIN", 46, 50], ["ParE", "PROTEIN", 55, 59], ["D83N", "TREATMENT", 0, 4], ["I460V substitutions", "TREATMENT", 9, 28], ["new allelic profile", "PROBLEM", 80, 99]]], ["Conclusion: High prevalence of macrolide resistant Spn, harboring both ermB and mefA genes is observed in Moscow, macrolide resistance is associated with resistance to other groups of antibacterials.", [["macrolide", "CHEMICAL", 31, 40], ["macrolide", "CHEMICAL", 114, 123], ["macrolide", "CHEMICAL", 31, 40], ["macrolide", "CHEMICAL", 114, 123], ["macrolide", "SIMPLE_CHEMICAL", 31, 40], ["Spn", "GENE_OR_GENE_PRODUCT", 51, 54], ["ermB", "GENE_OR_GENE_PRODUCT", 71, 75], ["mefA", "GENE_OR_GENE_PRODUCT", 80, 84], ["macrolide", "SIMPLE_CHEMICAL", 114, 123], ["ermB and mefA genes", "DNA", 71, 90], ["macrolide resistant Spn", "PROBLEM", 31, 54], ["harboring both ermB and mefA genes", "PROBLEM", 56, 90], ["macrolide resistance", "PROBLEM", 114, 134], ["antibacterials", "TREATMENT", 184, 198], ["High prevalence", "OBSERVATION_MODIFIER", 12, 27], ["both ermB", "OBSERVATION", 66, 75], ["macrolide resistance", "OBSERVATION", 114, 134]]], ["Some multidrug resistant isolates are highly related to internationally disseminated multiresistant clone Spain23F-1.", [["Spain23F-1", "GENE_OR_GENE_PRODUCT", 106, 116], ["Some multidrug resistant isolates", "PROBLEM", 0, 33], ["multidrug resistant isolates", "OBSERVATION", 5, 33], ["disseminated", "OBSERVATION_MODIFIER", 72, 84], ["multiresistant", "OBSERVATION_MODIFIER", 85, 99]]], ["Strains with fluoroquinolone resistance in Moscow were all single locus variants of the Spain23F-1 clone.P1810Occurrence of tet(W) gene in a Clostridium difficile clinical isolate P. Mastrantonio, F. Barbanti, P. Spigaglia (Rome, IT)P1810Objectives: To investigate the presence of tet(W), a tetracycline resistance gene recently identified in anaerobic commensal bacteria from animals and humans, in C. difficile clinical isolates.", [["fluoroquinolone", "CHEMICAL", 13, 28], ["Clostridium difficile", "DISEASE", 141, 162], ["tetracycline", "CHEMICAL", 291, 303], ["C. difficile", "DISEASE", 400, 412], ["fluoroquinolone", "CHEMICAL", 13, 28], ["tetracycline", "CHEMICAL", 291, 303], ["fluoroquinolone", "SIMPLE_CHEMICAL", 13, 28], ["Spain23F-1", "GENE_OR_GENE_PRODUCT", 88, 98], ["tet(W)", "GENE_OR_GENE_PRODUCT", 124, 130], ["Clostridium difficile", "ORGANISM", 141, 162], ["P. Spigaglia", "ORGANISM", 210, 222], ["tet(W)", "GENE_OR_GENE_PRODUCT", 281, 287], ["tetracycline", "SIMPLE_CHEMICAL", 291, 303], ["humans", "ORGANISM", 389, 395], ["C. difficile", "ORGANISM", 400, 412], ["Spain23F-1 clone", "DNA", 88, 104], ["tet(W) gene", "DNA", 124, 135], ["tet(W)", "DNA", 281, 287], ["tetracycline resistance gene", "DNA", 291, 319], ["Clostridium difficile", "SPECIES", 141, 162], ["humans", "SPECIES", 389, 395], ["C. difficile", "SPECIES", 400, 412], ["Clostridium difficile", "SPECIES", 141, 162], ["P. Mastrantonio", "SPECIES", 180, 195], ["humans", "SPECIES", 389, 395], ["C. difficile", "SPECIES", 400, 412], ["fluoroquinolone resistance", "TREATMENT", 13, 39], ["tet(W) gene", "TREATMENT", 124, 135], ["a Clostridium difficile", "PROBLEM", 139, 162], ["tet(W)", "TREATMENT", 281, 287], ["a tetracycline resistance gene", "TREATMENT", 289, 319], ["anaerobic commensal bacteria", "PROBLEM", 343, 371], ["C. difficile clinical isolates", "PROBLEM", 400, 430], ["fluoroquinolone resistance", "OBSERVATION", 13, 39], ["commensal bacteria", "OBSERVATION", 353, 371]]], ["Methods: Several C. difficile clinical isolates from different Italian hospitals were analysed for the presence of a tet(W) gene by PCR assays.", [["C. difficile", "DISEASE", 17, 29], ["C. difficile", "ORGANISM", 17, 29], ["tet(W)", "GENE_OR_GENE_PRODUCT", 117, 123], ["tet(W) gene", "DNA", 117, 128], ["C. difficile", "SPECIES", 17, 29], ["C. difficile", "SPECIES", 17, 29], ["Several C. difficile clinical isolates", "PROBLEM", 9, 47], ["a tet(W) gene", "TREATMENT", 115, 128], ["PCR assays", "TEST", 132, 142]]], ["The primers used were designed on the tet(W) sequences available in GenBank.", [["tet(W) sequences", "DNA", 38, 54], ["The primers", "TREATMENT", 0, 11], ["the tet(W) sequences", "TREATMENT", 34, 54]]], ["PCR fragments obtained by these amplifications were sequenced. tet(W) DNA flanking regions were also examined with a set of PCRs constructed on the sequence of the conjugative transposon TnB1230 of Butyrivibrio fibrisolvens 1.230, that is the only element carrying a tet(W) partially characterized so far. tet(W) positive isolates were also examined for the tet(M) gene and for the presence of int and tndX, markers for the Tn916 and the Tn5397like elements, respectively.", [["tet(W)", "GENE_OR_GENE_PRODUCT", 63, 69], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["Butyrivibrio fibrisolvens", "ORGANISM", 198, 223], ["tet(W)", "GENE_OR_GENE_PRODUCT", 267, 273], ["tet(W)", "GENE_OR_GENE_PRODUCT", 306, 312], ["tet(M)", "GENE_OR_GENE_PRODUCT", 358, 364], ["tndX", "GENE_OR_GENE_PRODUCT", 402, 406], ["Tn916", "GENE_OR_GENE_PRODUCT", 424, 429], ["PCR fragments", "DNA", 0, 13], ["tet(W) DNA flanking regions", "DNA", 63, 90], ["conjugative transposon TnB1230", "DNA", 164, 194], ["tet(W)", "DNA", 267, 273], ["tet(M) gene", "DNA", 358, 369], ["int", "DNA", 394, 397], ["tndX", "DNA", 402, 406], ["Tn916 and the Tn5397like elements", "DNA", 424, 457], ["Butyrivibrio fibrisolvens", "SPECIES", 198, 223], ["Butyrivibrio fibrisolvens", "SPECIES", 198, 223], ["PCR fragments", "TEST", 0, 13], ["these amplifications", "TEST", 26, 46], ["tet(W) DNA flanking regions", "TREATMENT", 63, 90], ["a set of PCRs", "TEST", 115, 128], ["the conjugative transposon", "TREATMENT", 160, 186], ["Butyrivibrio fibrisolvens", "TREATMENT", 198, 223], ["tet(W) positive isolates", "TREATMENT", 306, 330], ["markers", "TEST", 408, 415], ["the Tn916", "TEST", 420, 429]]], ["The Tn916-like elements were further characterized by PCRs designed on Enteroccus faecalis Tn916 sequence.", [["Tn916", "GENE_OR_GENE_PRODUCT", 4, 9], ["Enteroccus faecalis", "ORGANISM", 71, 90], ["Tn916-like elements", "DNA", 4, 23], ["Enteroccus faecalis Tn916 sequence", "DNA", 71, 105], ["Enteroccus faecalis", "SPECIES", 71, 90], ["Enteroccus faecalis", "SPECIES", 71, 90], ["The Tn916", "TEST", 0, 9], ["PCRs", "TEST", 54, 58], ["Enteroccus faecalis Tn916 sequence", "TEST", 71, 105]]], ["Tetracycline MIC values were determined by the E-test method.", [["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline MIC", "SIMPLE_CHEMICAL", 0, 16], ["Tetracycline MIC values", "TEST", 0, 23]]], ["Tetracycline resistance gene transfer was evaluated by filter mating experiments, using C. difficile p881R strain as recipient.", [["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "SIMPLE_CHEMICAL", 0, 12], ["C. difficile p881R", "ORGANISM", 88, 106], ["C. difficile", "SPECIES", 88, 100], ["C. difficile", "SPECIES", 88, 100], ["Tetracycline resistance gene transfer", "TREATMENT", 0, 37], ["C. difficile", "PROBLEM", 88, 100]]], ["Results: A tet(W) gene was found in only one isolate, C. difficile cd5, also positive for the tet(M) gene.", [["tet(W)", "GENE_OR_GENE_PRODUCT", 11, 17], ["C. difficile", "ORGANISM", 54, 66], ["cd5", "GENE_OR_GENE_PRODUCT", 67, 70], ["tet(M)", "GENE_OR_GENE_PRODUCT", 94, 100], ["tet(W) gene", "DNA", 11, 22], ["tet(M) gene", "DNA", 94, 105], ["C. difficile", "SPECIES", 54, 66], ["C. difficile", "SPECIES", 54, 66], ["A tet(W) gene", "TREATMENT", 9, 22], ["C. difficile cd5", "PROBLEM", 54, 70], ["difficile cd5", "OBSERVATION", 57, 70]]], ["This isolate was resistant to tetracycline with a MIC of 8 mg/L. Sequence analysis of the tet(W) PCR fragment (about 1860 bp) showed that this gene had an identity of 99% with the genes found in Clostridium spp strain K10, Mitsuokella multacida and Butyrivibrio fibrisolvens.", [["tetracycline", "CHEMICAL", 30, 42], ["tetracycline", "CHEMICAL", 30, 42], ["tetracycline", "SIMPLE_CHEMICAL", 30, 42], ["tet(W)", "GENE_OR_GENE_PRODUCT", 90, 96], ["Clostridium spp", "ORGANISM", 195, 210], ["strain", "ORGANISM", 211, 217], ["K10", "ORGANISM", 218, 221], ["Mitsuokella multacida", "ORGANISM", 223, 244], ["Butyrivibrio fibrisolvens", "ORGANISM", 249, 274], ["tet(W) PCR fragment", "DNA", 90, 109], ["Clostridium spp", "SPECIES", 195, 210], ["Mitsuokella multacida", "SPECIES", 223, 244], ["Butyrivibrio fibrisolvens", "SPECIES", 249, 274], ["Clostridium spp strain K10", "SPECIES", 195, 221], ["Mitsuokella multacida", "SPECIES", 223, 244], ["Butyrivibrio fibrisolvens", "SPECIES", 249, 274], ["tetracycline", "TREATMENT", 30, 42], ["a MIC", "TREATMENT", 48, 53], ["the tet(W) PCR fragment", "TREATMENT", 86, 109], ["bp", "TEST", 122, 124], ["an identity", "TEST", 152, 163], ["Mitsuokella multacida", "TREATMENT", 223, 244], ["Butyrivibrio fibrisolvens", "TREATMENT", 249, 274]]], ["No amplifications were obtained with the primers designed on TnB1230, indicating the presence of a different genetic support for tet(W) in C. difficile. tet(M) gene of C. difficile cd5 was carried by a Tn916-like element that showed nucleotide sequence mutations in the region containing orf 17-20 compared to the element of E. faecalis.", [["C. difficile", "DISEASE", 139, 151], ["nucleotide", "CHEMICAL", 233, 243], ["nucleotide", "CHEMICAL", 233, 243], ["TnB1230", "GENE_OR_GENE_PRODUCT", 61, 68], ["tet(W)", "GENE_OR_GENE_PRODUCT", 129, 135], ["C. difficile", "ORGANISM", 139, 151], ["tet(M)", "GENE_OR_GENE_PRODUCT", 153, 159], ["C. difficile", "ORGANISM", 168, 180], ["cd5", "GENE_OR_GENE_PRODUCT", 181, 184], ["Tn916", "GENE_OR_GENE_PRODUCT", 202, 207], ["E. faecalis", "ORGANISM", 325, 336], ["TnB1230", "DNA", 61, 68], ["tet(W)", "DNA", 129, 135], ["tet(M) gene", "DNA", 153, 164], ["cd5", "DNA", 181, 184], ["Tn916-like element", "DNA", 202, 220], ["orf 17-20", "DNA", 288, 297], ["C. difficile", "SPECIES", 139, 151], ["C. difficile", "SPECIES", 168, 180], ["E. faecalis", "SPECIES", 325, 336], ["C. difficile", "SPECIES", 139, 151], ["C. difficile", "SPECIES", 168, 180], ["E. faecalis", "SPECIES", 325, 336], ["the primers", "TEST", 37, 48], ["a different genetic support", "TREATMENT", 97, 124], ["C. difficile", "PROBLEM", 139, 151], ["C. difficile cd5", "PROBLEM", 168, 184], ["a Tn916-like element", "PROBLEM", 200, 220], ["nucleotide sequence mutations", "PROBLEM", 233, 262], ["difficile", "OBSERVATION", 142, 151], ["difficile cd5", "OBSERVATION", 171, 184], ["E. faecalis", "OBSERVATION", 325, 336]]], ["Conjugative transfer of tet(W) was not observed, whereas the tet(M) gene was transferred to the recipient strain.", [["tet(W)", "GENE_OR_GENE_PRODUCT", 24, 30], ["tet(M)", "GENE_OR_GENE_PRODUCT", 61, 67], ["tet(W)", "DNA", 24, 30], ["tet(M) gene", "DNA", 61, 72], ["tet(W)", "TREATMENT", 24, 30]]], ["C. difficile transconjugants were resistant to tetracycline with a MIC of 8 mg/L. Conclusion: The results obtained in this study demonstrate for the first time the presence of a tet(W) gene in a clinical isolate of C. difficile, providing further evidence of the spread of this resistance determinant among gastrointestinal bacteria.P1811Macrolide resistance determinants are prevalent and readily selected for in viridans group streptococci among healthy Norwegian adults Background: Norway has a low prevalence of antimicrobialresistant bacteria including macrolide resistant (MR) respiratory tract pathogens.", [["gastrointestinal bacteria", "ANATOMY", 307, 332], ["tetracycline", "CHEMICAL", 47, 59], ["C. difficile", "DISEASE", 215, 227], ["P1811", "CHEMICAL", 333, 338], ["Macrolide", "CHEMICAL", 338, 347], ["macrolide", "CHEMICAL", 558, 567], ["MR) respiratory tract pathogens", "DISEASE", 579, 610], ["tetracycline", "CHEMICAL", 47, 59], ["Macrolide", "CHEMICAL", 338, 347], ["macrolide", "CHEMICAL", 558, 567], ["C. difficile", "ORGANISM", 0, 12], ["transconjugants", "CELL", 13, 28], ["tetracycline", "SIMPLE_CHEMICAL", 47, 59], ["tet(W)", "GENE_OR_GENE_PRODUCT", 178, 184], ["C. difficile", "ORGANISM", 215, 227], ["P1811", "GENE_OR_GENE_PRODUCT", 333, 338], ["viridans group streptococci", "ORGANISM", 414, 441], ["macrolide", "SIMPLE_CHEMICAL", 558, 567], ["tet(W) gene", "DNA", 178, 189], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "SPECIES", 215, 227], ["C. difficile", "SPECIES", 0, 12], ["C. difficile", "SPECIES", 215, 227], ["C. difficile transconjugants", "PROBLEM", 0, 28], ["tetracycline", "TREATMENT", 47, 59], ["a MIC", "TREATMENT", 65, 70], ["this study", "TEST", 118, 128], ["a tet(W) gene", "TREATMENT", 176, 189], ["C. difficile", "PROBLEM", 215, 227], ["gastrointestinal bacteria", "PROBLEM", 307, 332], ["Macrolide resistance", "TEST", 338, 358], ["viridans group streptococci", "PROBLEM", 414, 441], ["antimicrobialresistant bacteria", "PROBLEM", 516, 547], ["macrolide resistant (MR) respiratory tract pathogens", "PROBLEM", 558, 610], ["difficile", "OBSERVATION", 3, 12], ["difficile", "OBSERVATION", 218, 227], ["low prevalence", "OBSERVATION_MODIFIER", 498, 512], ["respiratory tract", "ANATOMY", 583, 600]]], ["We have observed an increase in macrolide consumption in Norway and there is a lack of knowledge on the reservoir of macrolide resistance determinants among viridans group of streptococci (VGS) in the pharyngeal flora.", [["VGS", "ANATOMY", 189, 192], ["pharyngeal flora", "ANATOMY", 201, 217], ["macrolide", "CHEMICAL", 32, 41], ["macrolide", "CHEMICAL", 117, 126], ["viridans", "CHEMICAL", 157, 165], ["macrolide", "CHEMICAL", 32, 41], ["macrolide", "CHEMICAL", 117, 126], ["macrolide", "SIMPLE_CHEMICAL", 32, 41], ["macrolide", "SIMPLE_CHEMICAL", 117, 126], ["VGS", "CANCER", 189, 192], ["pharyngeal flora", "PATHOLOGICAL_FORMATION", 201, 217], ["macrolide consumption", "TREATMENT", 32, 53], ["macrolide resistance", "TREATMENT", 117, 137], ["streptococci (VGS) in the pharyngeal flora", "PROBLEM", 175, 217], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["macrolide consumption", "OBSERVATION", 32, 53], ["pharyngeal flora", "ANATOMY", 201, 217]]], ["Objectives: Examine the occurrence, selection and persistence of macrolide resistance determinants in VGS pharyngeal flora in healthy Norwegian adults before and after treatment with azithromycin.", [["VGS pharyngeal flora", "ANATOMY", 102, 122], ["macrolide", "CHEMICAL", 65, 74], ["azithromycin", "CHEMICAL", 183, 195], ["macrolide", "CHEMICAL", 65, 74], ["azithromycin", "CHEMICAL", 183, 195], ["macrolide", "SIMPLE_CHEMICAL", 65, 74], ["pharyngeal flora", "PATHOLOGICAL_FORMATION", 106, 122], ["azithromycin", "SIMPLE_CHEMICAL", 183, 195], ["macrolide resistance determinants", "PROBLEM", 65, 98], ["treatment", "TREATMENT", 168, 177], ["azithromycin", "TREATMENT", 183, 195], ["macrolide resistance", "OBSERVATION", 65, 85], ["pharyngeal flora", "ANATOMY", 106, 122]]], ["Methods: Throat samples were collected before (day 1), after treatment (day 7) and after 3 months (day 90) from 20 healthy volunteers.", [["Throat samples", "ANATOMY", 9, 23], ["Throat samples", "CANCER", 9, 23], ["volunteers", "ORGANISM", 123, 133], ["Throat samples", "TEST", 9, 23], ["Throat", "ANATOMY", 9, 15]]], ["The samples were plated directly as a lawn on PDMII agar plates with 5% defibrinated blood with an erythromycin Etest strip.", [["samples", "ANATOMY", 4, 11], ["blood", "ANATOMY", 85, 90], ["erythromycin", "CHEMICAL", 99, 111], ["erythromycin", "CHEMICAL", 99, 111], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["erythromycin", "SIMPLE_CHEMICAL", 99, 111], ["The samples", "TEST", 0, 11], ["PDMII agar plates", "TREATMENT", 46, 63], ["an erythromycin Etest strip", "TREATMENT", 96, 123]]], ["Photos were used as quantitative comparisons.", [["quantitative comparisons", "TEST", 20, 44]]], ["Up to 10 morphological different colonies with erythromycin Etest MIC \u20211lg/ml from each specimen were collected; day1 (n = 59), day 7 (n = 157) and day 90 (n = 76).", [["colonies", "ANATOMY", 33, 41], ["specimen", "ANATOMY", 88, 96], ["erythromycin", "CHEMICAL", 47, 59], ["erythromycin", "CHEMICAL", 47, 59], ["erythromycin", "SIMPLE_CHEMICAL", 47, 59], ["erythromycin Etest MIC", "TREATMENT", 47, 69]]], ["In total 86 representatives MR, VGS-isolates were selected for further studies: (i) MICs of erythromycin, tetracycline and penicillin were determined by Etest. (ii) PCR's for erm(B), erm(TR), and mef(A/E), and subsequent sequence-typing of mef.", [["erythromycin", "CHEMICAL", 92, 104], ["tetracycline", "CHEMICAL", 106, 118], ["penicillin", "CHEMICAL", 123, 133], ["erythromycin", "CHEMICAL", 92, 104], ["tetracycline", "CHEMICAL", 106, 118], ["penicillin", "CHEMICAL", 123, 133], ["erythromycin", "SIMPLE_CHEMICAL", 92, 104], ["tetracycline", "SIMPLE_CHEMICAL", 106, 118], ["penicillin", "SIMPLE_CHEMICAL", 123, 133], ["erm(B)", "GENE_OR_GENE_PRODUCT", 175, 181], ["erm(TR)", "GENE_OR_GENE_PRODUCT", 183, 190], ["MR", "PROTEIN", 28, 30], ["TR", "PROTEIN", 187, 189], ["mef", "DNA", 196, 199], ["mef", "DNA", 240, 243], ["MR", "TEST", 28, 30], ["VGS", "TEST", 32, 35], ["further studies", "TEST", 63, 78], ["erythromycin", "TREATMENT", 92, 104], ["tetracycline", "TREATMENT", 106, 118], ["penicillin", "TREATMENT", 123, 133], ["PCR's", "TEST", 165, 170], ["erm", "PROBLEM", 175, 178], ["subsequent sequence", "TEST", 210, 229], ["mef", "PROBLEM", 240, 243]]], ["Species identification was performed by sodA sequencing.", [["sodA", "GENE_OR_GENE_PRODUCT", 40, 44], ["sodA", "DNA", 40, 44], ["Species identification", "TEST", 0, 22]]], ["Results: A total of 17/20 persons carried a low number (<5) of MR VGS in day1 specimens, while 20/20 had a significant higher number (>100) of MR strains in day2 specimens.", [["specimens", "ANATOMY", 78, 87], ["day2 specimens", "ANATOMY", 157, 171], ["persons", "ORGANISM", 26, 33], ["MR", "PROTEIN", 63, 65], ["MR", "PROTEIN", 143, 145], ["persons", "SPECIES", 26, 33], ["MR VGS", "TEST", 63, 69], ["day1 specimens", "TEST", 73, 87], ["MR strains in day2 specimens", "PROBLEM", 143, 171]]], ["In day90 specimens, 20/20 carried a low number of MR, resembling day1.", [["day90 specimens", "ANATOMY", 3, 18], ["MR", "DISEASE", 50, 52], ["day90 specimens", "CELL", 3, 18], ["MR", "PROTEIN", 50, 52], ["day1", "PROTEIN", 65, 69]]], ["Reduced susceptibility to penicillin was observed in 32/86 (34%) isolates.", [["penicillin", "CHEMICAL", 26, 36], ["penicillin", "CHEMICAL", 26, 36], ["penicillin", "SIMPLE_CHEMICAL", 26, 36], ["Reduced susceptibility", "PROBLEM", 0, 22], ["penicillin", "TREATMENT", 26, 36]]], ["Tetracycline resistance was found in 43/86 (57%), and mainly in erm(B)-positive strains. mef(A/E)-positive dominated day1 (53%) and erm(B) day2 specimens 52%.", [["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "CHEMICAL", 0, 12], ["Tetracycline", "SIMPLE_CHEMICAL", 0, 12], ["erm(B)", "GENE_OR_GENE_PRODUCT", 64, 70], ["mef", "GENE_OR_GENE_PRODUCT", 89, 92], ["A/E", "GENE_OR_GENE_PRODUCT", 93, 96], ["Tetracycline resistance", "TEST", 0, 23], ["positive strains", "PROBLEM", 71, 87], ["mef(A/E)", "TEST", 89, 97], ["erm(B) day2 specimens", "TEST", 132, 153]]], ["Sequence typing revealed mef(E) (n = 41) and mef(A) (n = 3).", [["Sequence typing", "TEST", 0, 15]]], ["SodA sequence; S. mitis (n = 42), S. oralis (n = 9), S. parasanguinis (n = 12), S. salivarius (n = 22), and S. sanguinis (n = 1).", [["S. parasanguinis", "DISEASE", 53, 69], ["S. sanguinis", "DISEASE", 108, 120], ["SodA", "GENE_OR_GENE_PRODUCT", 0, 4], ["S. mitis", "ORGANISM", 15, 23], ["S. oralis", "ORGANISM", 34, 43], ["S. parasanguinis", "ORGANISM", 53, 69], ["S. salivarius", "ORGANISM", 80, 93], ["S. sanguinis", "ORGANISM", 108, 120], ["SodA sequence", "DNA", 0, 13], ["S. mitis", "SPECIES", 15, 23], ["S. oralis", "SPECIES", 34, 43], ["S. parasanguinis", "SPECIES", 53, 69], ["S. salivarius", "SPECIES", 80, 93], ["S. sanguinis", "SPECIES", 108, 120], ["S. mitis", "SPECIES", 15, 23], ["S. oralis", "SPECIES", 34, 43], ["S. parasanguinis", "SPECIES", 53, 69], ["S. salivarius", "SPECIES", 80, 93], ["S. sanguinis", "SPECIES", 108, 120], ["SodA sequence", "TEST", 0, 13], ["S. mitis", "TEST", 15, 23], ["S. oralis (n", "TEST", 34, 46], ["S. parasanguinis", "PROBLEM", 53, 69], ["mitis", "OBSERVATION", 18, 23], ["oralis", "ANATOMY", 37, 43]]], ["Conclusion: There is a pool of VGS carrying macrolide resistance determinants in the normal pharyngeal flora of healthy adults that are readily selected for during azithromycin exposure.", [["pharyngeal flora", "ANATOMY", 92, 108], ["macrolide", "CHEMICAL", 44, 53], ["azithromycin", "CHEMICAL", 164, 176], ["macrolide", "CHEMICAL", 44, 53], ["azithromycin", "CHEMICAL", 164, 176], ["VGS", "GENE_OR_GENE_PRODUCT", 31, 34], ["macrolide", "SIMPLE_CHEMICAL", 44, 53], ["pharyngeal flora", "ORGAN", 92, 108], ["azithromycin", "SIMPLE_CHEMICAL", 164, 176], ["macrolide resistance", "TREATMENT", 44, 64], ["azithromycin exposure", "TREATMENT", 164, 185], ["macrolide resistance", "OBSERVATION", 44, 64], ["normal", "OBSERVATION_MODIFIER", 85, 91], ["pharyngeal flora", "ANATOMY", 92, 108]]], ["The mef(E) and erm(B) were the most prevalent resistance genes and co-resistance to tetracycline was frequently observed, resembling the findings in Norwegian clinical isolates of S. pneumoniae.", [["tetracycline", "CHEMICAL", 84, 96], ["tetracycline", "CHEMICAL", 84, 96], ["mef(E)", "GENE_OR_GENE_PRODUCT", 4, 10], ["erm(B)", "GENE_OR_GENE_PRODUCT", 15, 21], ["tetracycline", "SIMPLE_CHEMICAL", 84, 96], ["S. pneumoniae", "ORGANISM", 180, 193], ["mef", "DNA", 4, 7], ["E", "DNA", 8, 9], ["resistance genes", "DNA", 46, 62], ["S. pneumoniae", "SPECIES", 180, 193], ["S. pneumoniae", "SPECIES", 180, 193], ["tetracycline", "TREATMENT", 84, 96], ["S. pneumoniae", "PROBLEM", 180, 193], ["pneumoniae", "OBSERVATION", 183, 193]]], ["These VGS may provide a pool of resistant bacteria that may transfer resistance determinants to more pathogenic organisms.P1812Relationships in genotype, phenotype, T type and PFGE type among macrolide-resistant Streptococcus pyogenes strains isolated in the Czech Republic V. Jakub\u00f9 , P. Urb\u00e1\u0161kov\u00e1, L. Strakov\u00e1 (Prague, CZ)P1812Objectives: To determine relationships between phenotypic and genotypic methods among erythromycin-resistant S. pyogenes strains.", [["VGS", "CHEMICAL", 6, 9], ["macrolide", "CHEMICAL", 192, 201], ["Streptococcus pyogenes", "DISEASE", 212, 234], ["erythromycin", "CHEMICAL", 415, 427], ["macrolide", "CHEMICAL", 192, 201], ["erythromycin", "CHEMICAL", 415, 427], ["VGS", "CANCER", 6, 9], ["T type", "GENE_OR_GENE_PRODUCT", 165, 171], ["macrolide", "SIMPLE_CHEMICAL", 192, 201], ["Streptococcus pyogenes strains", "ORGANISM", 212, 242], ["erythromycin", "SIMPLE_CHEMICAL", 415, 427], ["S. pyogenes strains", "ORGANISM", 438, 457], ["Streptococcus pyogenes", "SPECIES", 212, 234], ["S. pyogenes", "SPECIES", 438, 449], ["Streptococcus pyogenes", "SPECIES", 212, 234], ["S. pyogenes", "SPECIES", 438, 449], ["resistant bacteria", "PROBLEM", 32, 50], ["P1812Relationships", "TEST", 122, 140], ["genotype", "TEST", 144, 152], ["phenotype", "TEST", 154, 163], ["PFGE type", "TEST", 176, 185], ["macrolide", "TEST", 192, 201], ["resistant Streptococcus pyogenes strains", "PROBLEM", 202, 242], ["genotypic methods", "TEST", 391, 408], ["erythromycin", "TREATMENT", 415, 427], ["resistant S. pyogenes strains", "PROBLEM", 428, 457], ["Streptococcus pyogenes", "OBSERVATION", 212, 234]]], ["Methods: A total of 1331 clinical isolates of S. pyogenes resistant to erythromycin were collected in 39 microbiology laboratories during 2001-2003.", [["S. pyogenes", "DISEASE", 46, 57], ["erythromycin", "CHEMICAL", 71, 83], ["erythromycin", "CHEMICAL", 71, 83], ["S. pyogenes", "ORGANISM", 46, 57], ["erythromycin", "SIMPLE_CHEMICAL", 71, 83], ["S. pyogenes", "SPECIES", 46, 57], ["S. pyogenes", "SPECIES", 46, 57], ["S. pyogenes", "PROBLEM", 46, 57], ["erythromycin", "TREATMENT", 71, 83]]], ["Erythromycin susceptibility was tested by the disk diffusion method.", [["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "CHEMICAL", 0, 12], ["Erythromycin", "SIMPLE_CHEMICAL", 0, 12], ["Erythromycin susceptibility", "TREATMENT", 0, 27], ["the disk diffusion method", "TEST", 42, 67]]], ["Strains with an inhibition zone <21 mm around the erythromycin disk (15 lg) were sent to the National Reference Laboratory for Antibiotics (NRL).", [["erythromycin", "CHEMICAL", 50, 62], ["erythromycin", "CHEMICAL", 50, 62], ["erythromycin", "SIMPLE_CHEMICAL", 50, 62], ["an inhibition zone", "TEST", 13, 31], ["the erythromycin disk", "TREATMENT", 46, 67], ["Antibiotics (NRL", "TREATMENT", 127, 143]]], ["Presences of MLSB resistance genes (ermTR, ermB and mefA) were tested by PCR.", [["MLSB", "GENE_OR_GENE_PRODUCT", 13, 17], ["ermTR", "GENE_OR_GENE_PRODUCT", 36, 41], ["ermB", "GENE_OR_GENE_PRODUCT", 43, 47], ["mefA", "GENE_OR_GENE_PRODUCT", 52, 56], ["MLSB resistance genes", "DNA", 13, 34], ["ermTR", "DNA", 36, 41], ["ermB", "DNA", 43, 47], ["mefA", "DNA", 52, 56], ["MLSB resistance genes", "PROBLEM", 13, 34], ["MLSB resistance", "OBSERVATION", 13, 28]]], ["T serotypes were determined in randomly selected representatives of each phenotype (n = 370).", [["T serotypes", "GENE_OR_GENE_PRODUCT", 0, 11], ["T serotypes", "PROBLEM", 0, 11]]], ["PFGE type were determined in strains from year 2003 only (n = 68).", [["PFGE type", "TEST", 0, 9]]], ["Results: The rate of the most prevalent phenotype (constitutive MLSB resistance) was 63%, 55% in the year 2001 and 2003, respectively.", [["The rate", "TEST", 9, 17], ["constitutive MLSB resistance", "TEST", 51, 79]]], ["The major prevalent T types among the analysed strains were serotype T 28 (58%), T 12 (10%), T 4 (8%) and T B3264 (8%).", [["T", "CANCER", 20, 21], ["serotype T 28", "ORGANISM", 60, 73], ["T 4", "GENE_OR_GENE_PRODUCT", 93, 96], ["T B3264", "CANCER", 106, 113], ["serotype T 28", "SPECIES", 60, 73], ["T B3264", "SPECIES", 106, 113], ["the analysed strains", "TEST", 34, 54], ["serotype T", "TEST", 60, 70], ["T", "TEST", 81, 82], ["T", "TEST", 93, 94], ["T B3264", "TEST", 106, 113]]], ["Gene ermB was the most frequent (54%).", [["ermB", "GENE_OR_GENE_PRODUCT", 5, 9], ["Gene ermB", "DNA", 0, 9], ["Gene ermB", "PROBLEM", 0, 9], ["ermB", "OBSERVATION", 5, 9]]], ["The results of PCR method was highly congruent with observed phenotype of resistance.", [["PCR method", "TEST", 15, 25]]], ["PFGE patterns of strains with constitutive MLSB resistance were highly identical.", [["MLSB", "GENE_OR_GENE_PRODUCT", 43, 47], ["strains", "PROBLEM", 17, 24], ["constitutive MLSB resistance", "PROBLEM", 30, 58], ["MLSB resistance", "OBSERVATION", 43, 58]]], ["Conclusion: M phenotypes, constitutive and inducible resistance to MLSB antibiotics were found and ermTR, ermB and mefA genes were detected among the analysed strains.", [["MLSB", "CHEMICAL", 67, 71], ["MLSB", "CHEMICAL", 67, 71], ["MLSB", "GENE_OR_GENE_PRODUCT", 67, 71], ["ermTR", "GENE_OR_GENE_PRODUCT", 99, 104], ["ermB", "GENE_OR_GENE_PRODUCT", 106, 110], ["mefA", "GENE_OR_GENE_PRODUCT", 115, 119], ["ermTR, ermB and mefA genes", "DNA", 99, 125], ["M phenotypes", "PROBLEM", 12, 24], ["constitutive and inducible resistance", "PROBLEM", 26, 63], ["MLSB antibiotics", "TREATMENT", 67, 83], ["ermB and mefA genes", "PROBLEM", 106, 125]]], ["The T serotype 28 was identified the mainly prevalent in our collection.", [["T serotype 28", "ORGANISM", 4, 17], ["T serotype 28", "SPECIES", 4, 17], ["The T serotype", "TEST", 0, 14], ["collection", "OBSERVATION", 61, 71]]], ["The majority of strains harbouring T serotype 28 were constitutively resistant to macrolides.", [["macrolides", "CHEMICAL", 82, 92], ["macrolides", "CHEMICAL", 82, 92], ["T serotype 28", "ORGANISM", 35, 48], ["macrolides", "SIMPLE_CHEMICAL", 82, 92], ["T serotype", "SPECIES", 35, 45], ["T serotype 28", "SPECIES", 35, 48], ["strains harbouring T serotype", "PROBLEM", 16, 45], ["macrolides", "TREATMENT", 82, 92]]], ["The study showed close relationships among genotypes, T types, specific resistotypes (phenotype) and PFGE types.", [["The study", "TEST", 0, 9]]], ["Objectives: Since recognition of transferable clindamycin and tetracycline resistance in Bacteroides, we have undertaken a US national survey on the susceptibility of B. fragilis group to analyse emergence of resistance and trends, since these species are not routinely tested for susceptibility in hospital clinical laboratories.", [["clindamycin", "CHEMICAL", 46, 57], ["tetracycline", "CHEMICAL", 62, 74], ["clindamycin", "CHEMICAL", 46, 57], ["tetracycline", "CHEMICAL", 62, 74], ["clindamycin", "SIMPLE_CHEMICAL", 46, 57], ["tetracycline", "SIMPLE_CHEMICAL", 62, 74], ["B. fragilis", "ORGANISM", 167, 178], ["B. fragilis group", "SPECIES", 167, 184], ["B. fragilis", "SPECIES", 167, 178], ["transferable clindamycin", "TREATMENT", 33, 57], ["tetracycline resistance in Bacteroides", "TREATMENT", 62, 100], ["B. fragilis", "PROBLEM", 167, 178], ["these species", "PROBLEM", 238, 251]]], ["Methods: Agar dilution MICs were determined for 5225 isolates from 1997-2004 for B. fragilis and related species from 9 geographically diverse centers in the US.", [["B. fragilis", "ORGANISM", 81, 92], ["B. fragilis", "SPECIES", 81, 92], ["B. fragilis", "SPECIES", 81, 92], ["Agar dilution MICs", "TREATMENT", 9, 27], ["B. fragilis", "PROBLEM", 81, 92], ["related species", "PROBLEM", 97, 112]]], ["Antibiotics included 3 carbapenems, 3 B-lactam/B-lactamase inhibitors, 2 quinolones, a tetracycline, clindamycin, metronidazole, chloramphenicol, a glycylcycline and linezolid.", [["carbapenems", "CHEMICAL", 23, 34], ["B-lactam", "CHEMICAL", 38, 46], ["quinolones", "CHEMICAL", 73, 83], ["tetracycline", "CHEMICAL", 87, 99], ["clindamycin", "CHEMICAL", 101, 112], ["metronidazole", "CHEMICAL", 114, 127], ["chloramphenicol", "CHEMICAL", 129, 144], ["glycylcycline", "CHEMICAL", 148, 161], ["linezolid", "CHEMICAL", 166, 175], ["carbapenems", "CHEMICAL", 23, 34], ["3 B-lactam", "CHEMICAL", 36, 46], ["quinolones", "CHEMICAL", 73, 83], ["tetracycline", "CHEMICAL", 87, 99], ["clindamycin", "CHEMICAL", 101, 112], ["metronidazole", "CHEMICAL", 114, 127], ["chloramphenicol", "CHEMICAL", 129, 144], ["glycylcycline", "CHEMICAL", 148, 161], ["linezolid", "CHEMICAL", 166, 175], ["B-lactam", "SIMPLE_CHEMICAL", 38, 46], ["B-lactamase", "SIMPLE_CHEMICAL", 47, 58], ["quinolones", "SIMPLE_CHEMICAL", 73, 83], ["tetracycline", "SIMPLE_CHEMICAL", 87, 99], ["clindamycin", "SIMPLE_CHEMICAL", 101, 112], ["metronidazole", "SIMPLE_CHEMICAL", 114, 127], ["chloramphenicol", "SIMPLE_CHEMICAL", 129, 144], ["glycylcycline", "SIMPLE_CHEMICAL", 148, 161], ["linezolid", "SIMPLE_CHEMICAL", 166, 175], ["Antibiotics", "TREATMENT", 0, 11], ["3 carbapenems", "TREATMENT", 21, 34], ["3 B-lactam", "TREATMENT", 36, 46], ["B-lactamase inhibitors", "TREATMENT", 47, 69], ["2 quinolones", "TREATMENT", 71, 83], ["a tetracycline", "TREATMENT", 85, 99], ["clindamycin", "TREATMENT", 101, 112], ["metronidazole", "TREATMENT", 114, 127], ["chloramphenicol", "TREATMENT", 129, 144], ["a glycylcycline", "TREATMENT", 146, 161], ["linezolid", "TREATMENT", 166, 175]]], ["Results: Analysis of resistance trends from 1997-2004 showed a decrease in geometric mean MIC's (geoMIC) for imipenem (0.80 mcg/ml to 0.32 mcg/ml, p < 0.001) and meropenem (0.52 mcg/ml-0.42 mcg/ml, p = 0.003) for the Bacteroides species.", [["imipenem", "CHEMICAL", 109, 117], ["meropenem", "CHEMICAL", 162, 171], ["imipenem", "CHEMICAL", 109, 117], ["meropenem", "CHEMICAL", 162, 171], ["imipenem", "SIMPLE_CHEMICAL", 109, 117], ["meropenem", "SIMPLE_CHEMICAL", 162, 171], ["geometric mean MIC's", "TREATMENT", 75, 95], ["imipenem", "TREATMENT", 109, 117], ["meropenem", "TREATMENT", 162, 171], ["the Bacteroides species", "PROBLEM", 213, 236], ["decrease", "OBSERVATION_MODIFIER", 63, 71]]], ["Ertapenem geoMIC remained unchanged (0.99 mcg/ ml).", [["Ertapenem", "CHEMICAL", 0, 9], ["Ertapenem", "CHEMICAL", 0, 9], ["Ertapenem", "SIMPLE_CHEMICAL", 0, 9], ["Ertapenem geoMIC", "TREATMENT", 0, 16], ["unchanged", "OBSERVATION_MODIFIER", 26, 35]]], ["For the B-lactamase inhibitors, piperacillin-tazobactam geoMIC declined from 2.56 mcg/ml to 2.22 mcg/ml (p < 0.001).", [["piperacillin-tazobactam", "CHEMICAL", 32, 55], ["piperacillin", "CHEMICAL", 32, 44], ["tazobactam", "CHEMICAL", 45, 55], ["B-lactamase", "SIMPLE_CHEMICAL", 8, 19], ["piperacillin-tazobactam", "SIMPLE_CHEMICAL", 32, 55], ["the B-lactamase inhibitors", "TREATMENT", 4, 30], ["piperacillin-tazobactam geoMIC", "TREATMENT", 32, 62]]], ["Ampicillin-sulbactam geoMIC did not change.", [["Ampicillin", "CHEMICAL", 0, 10], ["sulbactam", "CHEMICAL", 11, 20], ["Ampicillin", "CHEMICAL", 0, 10], ["sulbactam", "CHEMICAL", 11, 20], ["Ampicillin-sulbactam", "SIMPLE_CHEMICAL", 0, 20], ["Ampicillin", "TREATMENT", 0, 10], ["sulbactam geoMIC", "TREATMENT", 11, 27]]], ["Few isolates were resistant to any carbapenem or B-lactamase inhibitor combination.", [["carbapenem", "CHEMICAL", 35, 45], ["carbapenem", "CHEMICAL", 35, 45], ["carbapenem", "SIMPLE_CHEMICAL", 35, 45], ["B-lactamase", "SIMPLE_CHEMICAL", 49, 60], ["Few isolates", "PROBLEM", 0, 12], ["any carbapenem", "TREATMENT", 31, 45], ["B-lactamase inhibitor", "TREATMENT", 49, 70]]], ["Clindamycin resistance increased, especially for B. fragilis, B. ovatus and B. thetaiotaomicron (all p < 0.001).", [["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["B. fragilis", "ORGANISM", 49, 60], ["B. ovatus", "ORGANISM", 62, 71], ["B. thetaiotaomicron", "ORGANISM", 76, 95], ["B. fragilis", "SPECIES", 49, 60], ["B. ovatus", "SPECIES", 62, 71], ["B. thetaiotaomicron", "SPECIES", 76, 95], ["B. fragilis", "SPECIES", 49, 60], ["B. ovatus", "SPECIES", 62, 71], ["B. thetaiotaomicron", "SPECIES", 76, 95], ["Clindamycin resistance", "TREATMENT", 0, 22], ["B. fragilis", "PROBLEM", 49, 60], ["B. thetaiotaomicron", "TREATMENT", 76, 95]]], ["Among quinolones, resistance of Bacteroides to moxifloxacin increased (geoMIC went from 2 mcg/ml to 3.5 mcg/ml, p < 0.001).", [["quinolones", "CHEMICAL", 6, 16], ["Bacteroides", "CHEMICAL", 32, 43], ["moxifloxacin", "CHEMICAL", 47, 59], ["quinolones", "CHEMICAL", 6, 16], ["moxifloxacin", "CHEMICAL", 47, 59], ["quinolones", "SIMPLE_CHEMICAL", 6, 16], ["Bacteroides", "SIMPLE_CHEMICAL", 32, 43], ["moxifloxacin", "SIMPLE_CHEMICAL", 47, 59], ["Among quinolones", "TREATMENT", 0, 16], ["Bacteroides", "TREATMENT", 32, 43], ["moxifloxacin", "TREATMENT", 47, 59]]], ["B. fragilis remains the most sensitive Bacteroides species to moxifloxacin, although approximately 45% of stains have MIC's \u2021to 4 mcg/ml in 2004.", [["moxifloxacin", "CHEMICAL", 62, 74], ["moxifloxacin", "CHEMICAL", 62, 74], ["B. fragilis", "ORGANISM", 0, 11], ["moxifloxacin", "SIMPLE_CHEMICAL", 62, 74], ["B. fragilis", "SPECIES", 0, 11], ["B. fragilis", "SPECIES", 0, 11], ["B. fragilis", "PROBLEM", 0, 11], ["the most sensitive Bacteroides species", "PROBLEM", 20, 58], ["moxifloxacin", "TREATMENT", 62, 74], ["stains", "TEST", 106, 112], ["MIC's \u2021to", "TREATMENT", 118, 127], ["fragilis", "OBSERVATION", 3, 11], ["most sensitive", "OBSERVATION_MODIFIER", 24, 38]]], ["Tigecycline susceptibility, tested over 5 years, did not change.", [["Tigecycline", "CHEMICAL", 0, 11], ["Tigecycline", "CHEMICAL", 0, 11], ["Tigecycline", "SIMPLE_CHEMICAL", 0, 11], ["Tigecycline susceptibility", "TEST", 0, 26]]], ["The first confirmed metronidazole-resistant isolate (MIC = 64 mcg/ml) obtained in the US was noted in 2002 but none were noted in 2003 or 2004.", [["metronidazole", "CHEMICAL", 20, 33], ["metronidazole", "CHEMICAL", 20, 33], ["metronidazole", "SIMPLE_CHEMICAL", 20, 33], ["metronidazole-resistant isolate (MIC", "TREATMENT", 20, 56], ["the US", "TEST", 82, 88]]], ["Conclusion: Improved susceptibility of Bacteroides species to some carbapenems and the B-lactamase inhibitor combinations is unexplained but significant.", [["carbapenems", "CHEMICAL", 67, 78], ["carbapenems", "CHEMICAL", 67, 78], ["Bacteroides species", "ORGANISM", 39, 58], ["carbapenems", "SIMPLE_CHEMICAL", 67, 78], ["B-lactamase", "GENE_OR_GENE_PRODUCT", 87, 98], ["Bacteroides species", "PROBLEM", 39, 58], ["some carbapenems", "TREATMENT", 62, 78], ["the B-lactamase inhibitor", "TREATMENT", 83, 108], ["Bacteroides species", "OBSERVATION", 39, 58], ["significant", "OBSERVATION_MODIFIER", 141, 152]]], ["Clindamycin resistance continues to increase, especially for B. fragilis.", [["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["B. fragilis", "ORGANISM", 61, 72], ["B. fragilis", "SPECIES", 61, 72], ["B. fragilis", "SPECIES", 61, 72], ["Clindamycin resistance", "TREATMENT", 0, 22], ["B. fragilis", "PROBLEM", 61, 72], ["fragilis", "OBSERVATION", 64, 72]]], ["Moxifloxacin susceptibility for the non fragilis species shows that the majority of strains are resistant.", [["Moxifloxacin", "CHEMICAL", 0, 12], ["Moxifloxacin", "CHEMICAL", 0, 12], ["Moxifloxacin", "SIMPLE_CHEMICAL", 0, 12], ["non fragilis species", "ORGANISM", 36, 56], ["Moxifloxacin susceptibility", "TEST", 0, 27], ["the non fragilis species", "PROBLEM", 32, 56], ["strains", "PROBLEM", 84, 91]]], ["The first metronidazole resistant isolate has been reported from the US.", [["metronidazole", "CHEMICAL", 10, 23], ["metronidazole", "CHEMICAL", 10, 23], ["metronidazole", "SIMPLE_CHEMICAL", 10, 23], ["The first metronidazole resistant isolate", "TREATMENT", 0, 41], ["the US", "TEST", 65, 71]]], ["Since resistance trends are associated with species, the differentiation within the species is of extreme importance, since it may impact the choice of antimicrobial agent for the treatment of infections caused by this group of anaerobes.P1814Observed duration of nasopharyngeal carriage of penicillin-resistant pneumococci: relations to age and serogroup P. Geli, L. H\u00f6 gberg, H. Ringberg, E. Melander, M. Lipsitch, K. Ekdahl (Solna, Malm\u00f6, Lund, Stockholm, SE; Boston, US) Background and objectives: Knowledge of how the duration of pneumococcal carriage varies with age and serogroup is essential to understanding how immunity to carriage arises throughout the course of life, and designing appropriate models for the effects of vaccination or other public health initiatives aiming to reduce the pneumococcal transmission in the community.", [["nasopharyngeal", "ANATOMY", 264, 278], ["infections", "DISEASE", 193, 203], ["penicillin", "CHEMICAL", 291, 301], ["pneumococci", "DISEASE", 312, 323], ["penicillin", "CHEMICAL", 291, 301], ["nasopharyngeal", "ORGAN", 264, 278], ["penicillin", "SIMPLE_CHEMICAL", 291, 301], ["pneumococci", "ORGANISM", 312, 323], ["pneumococcal", "ORGANISM", 535, 547], ["L. H\u00f6 gberg", "SPECIES", 365, 376], ["pneumococcal", "SPECIES", 535, 547], ["pneumococcal", "SPECIES", 800, 812], ["species", "PROBLEM", 44, 51], ["antimicrobial agent", "TREATMENT", 152, 171], ["infections", "PROBLEM", 193, 203], ["this group of anaerobes", "PROBLEM", 214, 237], ["nasopharyngeal carriage", "PROBLEM", 264, 287], ["penicillin", "TREATMENT", 291, 301], ["resistant pneumococci", "PROBLEM", 302, 323], ["pneumococcal carriage varies", "PROBLEM", 535, 563], ["vaccination", "TREATMENT", 732, 743], ["the pneumococcal transmission", "TREATMENT", 796, 825], ["infections", "OBSERVATION", 193, 203], ["anaerobes", "OBSERVATION", 228, 237], ["nasopharyngeal", "ANATOMY", 264, 278]]], ["Using data from an ongoing Swedish intervention project, the duration of nasopharyngeal carriage of penicillinresistant pneumococci (MIC PcG >0.5 mg/L) stratified by both serogroup and age of the carrier were estimated.", [["nasopharyngeal", "ANATOMY", 73, 87], ["penicillinresistant", "CHEMICAL", 100, 119], ["MIC", "CHEMICAL", 133, 136], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 73, 87], ["PcG", "PROTEIN", 137, 140], ["an ongoing Swedish intervention", "TREATMENT", 16, 47], ["nasopharyngeal carriage", "PROBLEM", 73, 96], ["penicillinresistant pneumococci", "TREATMENT", 100, 131], ["MIC PcG", "TREATMENT", 133, 140], ["nasopharyngeal", "ANATOMY", 73, 87]]], ["Results: The mean duration of carriage for all cases was 37 days (95% CI 35-38).", [["CI", "TEST", 70, 72]]], ["Children below the age of 5 years carried PRP for significantly longer periods (43 days, 95% CI 41-45) compared with older individuals (25 days, 95% CI 24-27).", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["CI", "TEST", 93, 95], ["CI", "TEST", 149, 151]]], ["Serogroup 9 and 14 were carried for significantly shorter periods compared with serogroup 6.", [["Serogroup", "TEST", 0, 9]]], ["Serogroup 9 also had significantly shorter carriage duration compared with serogroups 19 and 23 for cases 0-4 years.", [["significantly shorter carriage duration", "PROBLEM", 21, 60], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["shorter", "OBSERVATION_MODIFIER", 35, 42]]], ["For cases 5 years or older, no significant difference in carriage duration for different ages or serogroups could be noted.", [["serogroups", "PROBLEM", 97, 107], ["no", "UNCERTAINTY", 28, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["Conclusions: Even though the estimate does not cover any correction for the censored carriage duration and therefore not yield an estimate of the total length of carriage, the results highlight the importance to take both serogroup and age of the P1823 Exploring the molecular basis for differences in phenotype of Salmonella enteritidis typing phage N. DeLappe, D. Morris, M. Cormican (Galway, IE)P1814Objectives: The Salmonella enteritidis phage tying scheme of the Laboratory of Enteric Pathogens, Health Protection Agency, UK, is a widely used method for subtyping this important pathogen.", [["Salmonella enteritidis", "DISEASE", 315, 337], ["Salmonella enteritidis", "DISEASE", 419, 441], ["Enteric Pathogens", "DISEASE", 482, 499], ["Salmonella enteritidis", "ORGANISM", 315, 337], ["Salmonella enteritidis", "ORGANISM", 419, 441], ["Salmonella enteritidis", "SPECIES", 315, 337], ["Salmonella enteritidis", "SPECIES", 419, 441], ["Salmonella enteritidis", "SPECIES", 315, 337], ["Salmonella enteritidis", "SPECIES", 419, 441], ["the censored carriage duration", "PROBLEM", 72, 102], ["Salmonella enteritidis", "TREATMENT", 315, 337], ["The Salmonella enteritidis phage", "TREATMENT", 415, 447], ["Enteric", "ANATOMY", 482, 489]]], ["The method is rapid and highly discriminatory.", [["rapid", "OBSERVATION_MODIFIER", 14, 19]]], ["Interpretation of results can be subjective and the typing phage which are central to the method have not been well characterised.", [["the typing phage", "TEST", 48, 64]]], ["Complete sequence data is available for the Salmonella typhimurium podovirus phage P22.", [["Salmonella typhimurium podovirus phage P22", "ORGANISM", 44, 86], ["Salmonella typhimurium podovirus", "SPECIES", 44, 76], ["Salmonella typhimurium", "SPECIES", 44, 66], ["Complete sequence data", "TEST", 0, 22], ["the Salmonella typhimurium podovirus phage P22", "TREATMENT", 40, 86]]], ["Methods: The 16 typing phage were propagated on S. enteritidis PT1b (PB406).", [["S. enteritidis", "ORGANISM", 48, 62], ["PT1b", "ORGANISM", 63, 67], ["PB406", "CANCER", 69, 74], ["S. enteritidis", "SPECIES", 48, 62], ["S. enteritidis PT1b", "SPECIES", 48, 67], ["The 16 typing phage", "TREATMENT", 9, 28]]], ["Phage were visualised by electron microscopy.", [["electron microscopy", "TEST", 25, 44]]], ["Phage DNA was extracted and digested with HindIII.", [["DNA", "CELLULAR_COMPONENT", 6, 9], ["HindIII", "GENE_OR_GENE_PRODUCT", 42, 49], ["Phage DNA", "DNA", 0, 9], ["HindIII", "DNA", 42, 49], ["Phage DNA", "PROBLEM", 0, 9], ["HindIII", "TREATMENT", 42, 49]]], ["Consensus PCR primers were designed based on sequences of P22 and other S. typhimurium phage.", [["S. typhimurium phage", "ORGANISM", 72, 92], ["PCR primers", "DNA", 10, 21], ["P22", "DNA", 58, 61], ["S. typhimurium", "SPECIES", 72, 86], ["S. typhimurium", "SPECIES", 72, 86], ["Consensus PCR primers", "TEST", 0, 21], ["P22", "TREATMENT", 58, 61]]], ["Additional primers were designed based on the sequence of the S. enterititidis typing phage 3 (a siphovirus).", [["S. enterititidis", "ORGANISM", 62, 78], ["phage 3", "GENE_OR_GENE_PRODUCT", 86, 93], ["siphovirus", "CANCER", 97, 107], ["S. enterititidis", "SPECIES", 62, 78], ["S. enterititidis", "SPECIES", 62, 78], ["Additional primers", "TEST", 0, 18], ["the sequence", "TEST", 42, 54]]], ["Amplification, sequencing and DNA probe hybridisation of various phage genes were performed using standard techniques.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["phage genes", "DNA", 65, 76], ["DNA probe hybridisation of various phage genes", "TREATMENT", 30, 76]]], ["Results: On EM the 16 typing phage comprise 6 podoviridae (phage 1, 8, 10, 14, 15 and 16) , 6 siphoviridae (phage 3, 5, 7, 11, 12 and 13) and 4 myoviridae (phage 2, 4, 6 and 9).", [["phage 3", "ORGANISM", 108, 115], ["podoviridae (phage", "TREATMENT", 46, 64], ["siphoviridae (phage", "TREATMENT", 94, 113], ["4 myoviridae (phage", "TREATMENT", 142, 161]]], ["Digestion with HindIII subdivided each morphotype into 3 groups.", [["HindIII", "GENE_OR_GENE_PRODUCT", 15, 22], ["HindIII", "DNA", 15, 22], ["Digestion with HindIII", "TREATMENT", 0, 22]]], ["The podoviridae contained genes homologous to P22 while the siphoviridae contained genes homologous to the sequenced S. enteritidis typing phage 3.", [["podoviridae", "CANCER", 4, 15], ["P22", "GENE_OR_GENE_PRODUCT", 46, 49], ["siphoviridae", "GENE_OR_GENE_PRODUCT", 60, 72], ["S. enteritidis", "ORGANISM", 117, 131], ["typing phage 3", "GENE_OR_GENE_PRODUCT", 132, 146], ["podoviridae", "DNA", 4, 15], ["P22", "DNA", 46, 49], ["siphoviridae", "DNA", 60, 72], ["S. enteritidis", "SPECIES", 117, 131], ["S. enteritidis", "SPECIES", 117, 131], ["The podoviridae", "TREATMENT", 0, 15], ["genes homologous to P22", "TREATMENT", 26, 49], ["the siphoviridae", "TREATMENT", 56, 72], ["genes homologous", "TREATMENT", 83, 99]]], ["Some sequence variation was detected in podovirus and siphovirus genes however in some cases phage, which differ in their phenotype had no difference detected in HindIII digestion pattern or partial sequence.", [["podovirus", "CANCER", 40, 49], ["siphovirus", "GENE_OR_GENE_PRODUCT", 54, 64], ["HindIII", "GENE_OR_GENE_PRODUCT", 162, 169], ["podovirus and siphovirus genes", "DNA", 40, 70], ["Some sequence variation", "PROBLEM", 0, 23]]], ["Conclusions: The S. enteritidis typing phage set comprise 3 distinct phage morphotypes.", [["S. enteritidis", "ORGANISM", 17, 31], ["S. enteritidis", "SPECIES", 17, 31], ["S. enteritidis", "SPECIES", 17, 31], ["The S. enteritidis typing phage", "TREATMENT", 13, 44]]], ["In some instances distinct phage that contribute to differentiation between S. enteritidis phage types had no DNA sequence variation detected.", [["S. enteritidis phage", "ORGANISM", 76, 96], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["S. enteritidis", "SPECIES", 76, 90], ["S. enteritidis", "SPECIES", 76, 90], ["some instances distinct phage", "PROBLEM", 3, 32], ["S. enteritidis phage types", "PROBLEM", 76, 102], ["DNA sequence variation", "PROBLEM", 110, 132], ["distinct phage", "OBSERVATION", 18, 32]]], ["Variations in phage typing reactions may in part be due to epigenetic difference in typing phage, e.g. due to methylation of phage DNA.", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["phage DNA", "DNA", 125, 134], ["Variations in phage typing reactions", "PROBLEM", 0, 36], ["epigenetic difference in typing phage", "PROBLEM", 59, 96], ["methylation of phage DNA", "PROBLEM", 110, 134]]], ["Salmonella enteritidis typing phage biology could provide a model for developing approaches to phage therapy.", [["Salmonella enteritidis", "ORGANISM", 0, 22], ["Salmonella enteritidis", "SPECIES", 0, 22], ["Salmonella enteritidis", "SPECIES", 0, 22], ["Salmonella enteritidis typing phage", "TREATMENT", 0, 35], ["phage therapy", "TREATMENT", 95, 108]]], ["Tularemia is a zoonotic bacterial disease.", [["Tularemia", "DISEASE", 0, 9], ["zoonotic bacterial disease", "DISEASE", 15, 41], ["Tularemia", "PROBLEM", 0, 9], ["a zoonotic bacterial disease", "PROBLEM", 13, 41], ["zoonotic", "OBSERVATION_MODIFIER", 15, 23], ["bacterial disease", "OBSERVATION", 24, 41]]], ["The causative agent, Francisella tularensis, is spread to humans by direct contact with infected rodents, inhalation, ingestion of contaminated water or by arthropod bites.", [["Francisella tularensis", "DISEASE", 21, 43], ["arthropod bites", "DISEASE", 156, 171], ["Francisella tularensis", "ORGANISM", 21, 43], ["humans", "ORGANISM", 58, 64], ["Francisella tularensis", "SPECIES", 21, 43], ["humans", "SPECIES", 58, 64], ["Francisella tularensis", "SPECIES", 21, 43], ["humans", "SPECIES", 58, 64], ["Francisella tularensis", "PROBLEM", 21, 43], ["Francisella tularensis", "OBSERVATION", 21, 43]]], ["In some endemic regions, outbreaks occur frequently, whereas nearby rural parts may be completely free.", [["some", "OBSERVATION_MODIFIER", 3, 7], ["endemic", "OBSERVATION_MODIFIER", 8, 15], ["outbreaks", "OBSERVATION_MODIFIER", 25, 34]]], ["We presented two cases of tularemia in non endemic region of the Turkey.", [["tularemia", "DISEASE", 26, 35], ["tularemia", "PROBLEM", 26, 35], ["tularemia", "OBSERVATION", 26, 35], ["non endemic", "OBSERVATION_MODIFIER", 39, 50]]], ["Case 1: A 46 year old female patient referred to tertiary hospital due to swollen on the neck for 2 months.", [["neck", "ANATOMY", 89, 93], ["female", "ORGANISM", 22, 28], ["patient", "ORGANISM", 29, 36], ["neck", "ORGANISM_SUBDIVISION", 89, 93], ["patient", "SPECIES", 29, 36], ["swollen on the neck", "PROBLEM", 74, 93], ["swollen", "OBSERVATION", 74, 81], ["neck", "ANATOMY", 89, 93]]], ["Before admission beta lactam antibiotics had been prescribed to her for tonsilopharyngitidis.", [["beta lactam", "CHEMICAL", 17, 28], ["tonsilopharyngitidis", "DISEASE", 72, 92], ["beta lactam", "CHEMICAL", 17, 28], ["beta lactam", "SIMPLE_CHEMICAL", 17, 28], ["beta lactam antibiotics", "TREATMENT", 17, 40], ["tonsilopharyngitidis", "PROBLEM", 72, 92]]], ["But her complaints had been continued.", [["her complaints", "PROBLEM", 4, 18]]], ["She had been suffered fever sore throat and neck pain.", [["neck", "ANATOMY", 44, 48], ["fever sore throat", "DISEASE", 22, 39], ["neck pain", "DISEASE", 44, 53], ["throat", "ORGANISM_SUBDIVISION", 33, 39], ["neck", "ORGANISM_SUBDIVISION", 44, 48], ["fever sore throat", "PROBLEM", 22, 39], ["neck pain", "PROBLEM", 44, 53], ["throat", "ANATOMY", 33, 39], ["neck", "ANATOMY", 44, 48], ["pain", "OBSERVATION", 49, 53]]], ["She had a palpable and painfull cervical lymphadenopathy which was not suppurated.", [["cervical", "ANATOMY", 32, 40], ["lymphadenopathy", "DISEASE", 41, 56], ["cervical lymphadenopathy", "CANCER", 32, 56], ["a palpable and painfull cervical lymphadenopathy", "PROBLEM", 8, 56], ["palpable", "OBSERVATION", 10, 18], ["cervical", "ANATOMY", 32, 40], ["lymphadenopathy", "OBSERVATION", 41, 56]]], ["Leukocytosis and elevated C reactive protein were predominant.", [["Leukocytosis", "DISEASE", 0, 12], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 26, 44], ["C reactive protein", "PROTEIN", 26, 44], ["Leukocytosis", "PROBLEM", 0, 12], ["elevated C reactive protein", "PROBLEM", 17, 44], ["elevated", "OBSERVATION_MODIFIER", 17, 25], ["reactive protein", "OBSERVATION", 28, 44], ["predominant", "OBSERVATION_MODIFIER", 50, 61]]], ["At screening there were not any lymphadenopathy detected elsewhere.", [["lymphadenopathy", "DISEASE", 32, 47], ["any lymphadenopathy", "PROBLEM", 28, 47], ["lymphadenopathy", "OBSERVATION", 32, 47]]], ["She had been examined about Cytomegalovirus Epstein Barr virus and brucellosis.", [["Cytomegalovirus Epstein Barr virus", "DISEASE", 28, 62], ["brucellosis", "DISEASE", 67, 78], ["Cytomegalovirus", "ORGANISM", 28, 43], ["Epstein Barr virus", "ORGANISM", 44, 62], ["Epstein Barr virus", "SPECIES", 44, 62], ["Cytomegalovirus Epstein Barr virus", "PROBLEM", 28, 62], ["brucellosis", "PROBLEM", 67, 78], ["Epstein Barr virus", "OBSERVATION", 44, 62], ["brucellosis", "OBSERVATION", 67, 78]]], ["They were negative.", [["negative", "OBSERVATION", 10, 18]]], ["Fine needle aspiration from neck was negative considered as malignancy.", [["neck", "ANATOMY", 28, 32], ["malignancy", "DISEASE", 60, 70], ["Fine needle", "MULTI-TISSUE_STRUCTURE", 0, 11], ["neck", "ORGAN", 28, 32], ["malignancy", "CANCER", 60, 70], ["Fine needle aspiration from neck", "TEST", 0, 32], ["malignancy", "PROBLEM", 60, 70], ["aspiration", "OBSERVATION", 12, 22], ["neck", "ANATOMY", 28, 32], ["negative considered", "UNCERTAINTY", 37, 56], ["malignancy", "OBSERVATION", 60, 70]]], ["Cultures were negative for routine bacteriologic examination.", [["Cultures", "TEST", 0, 8], ["routine bacteriologic examination", "TEST", 27, 60]]], ["Microagglutination test for tularemia was 1/320 positive.", [["tularemia", "DISEASE", 28, 37], ["Microagglutination test", "TEST", 0, 23], ["tularemia", "PROBLEM", 28, 37]]], ["Then we decided to treat her with gentamycin for 10 days.", [["gentamycin", "CHEMICAL", 34, 44], ["gentamycin", "CHEMICAL", 34, 44], ["gentamycin", "SIMPLE_CHEMICAL", 34, 44], ["gentamycin", "TREATMENT", 34, 44]]], ["After treatment cervical lymphadenopathy became small.", [["cervical", "ANATOMY", 16, 24], ["lymphadenopathy", "DISEASE", 25, 40], ["cervical lymphadenopathy", "PATHOLOGICAL_FORMATION", 16, 40], ["treatment cervical lymphadenopathy", "PROBLEM", 6, 40], ["cervical", "ANATOMY", 16, 24], ["lymphadenopathy", "OBSERVATION", 25, 40], ["small", "OBSERVATION_MODIFIER", 48, 53]]], ["Leukocyte count and C reactive protein levels were reach normal range.", [["Leukocyte", "ANATOMY", 0, 9], ["Leukocyte", "CELL", 0, 9], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 20, 38], ["C reactive protein", "PROTEIN", 20, 38], ["Leukocyte count", "TEST", 0, 15], ["C reactive protein levels", "TEST", 20, 45], ["reactive", "OBSERVATION_MODIFIER", 22, 30]]], ["Case 2: A 29 year old female patient referred to university hospital due to cervical lymphadenopathy and fever and sore throat.", [["cervical", "ANATOMY", 76, 84], ["cervical lymphadenopathy", "DISEASE", 76, 100], ["fever", "DISEASE", 105, 110], ["sore throat", "DISEASE", 115, 126], ["female", "ORGANISM", 22, 28], ["patient", "ORGANISM", 29, 36], ["cervical", "ORGAN", 76, 84], ["patient", "SPECIES", 29, 36], ["cervical lymphadenopathy", "PROBLEM", 76, 100], ["fever", "PROBLEM", 105, 110], ["sore throat", "PROBLEM", 115, 126], ["cervical", "ANATOMY", 76, 84], ["lymphadenopathy", "OBSERVATION", 85, 100], ["fever", "OBSERVATION", 105, 110], ["sore throat", "ANATOMY", 115, 126]]], ["Before admission beta lactam antibiotics were prescribed to her for 2 weeks.", [["beta lactam", "CHEMICAL", 17, 28], ["beta lactam", "CHEMICAL", 17, 28], ["beta lactam antibiotics", "SIMPLE_CHEMICAL", 17, 40], ["beta lactam antibiotics", "TREATMENT", 17, 40]]], ["But no apparent benefits had been detected.", [["no apparent", "UNCERTAINTY", 4, 15]]], ["There was a palpable and fistulated cervical lymphdenopathy.", [["cervical lymphdenopathy", "ANATOMY", 36, 59], ["lymphdenopathy", "DISEASE", 45, 59], ["cervical lymphdenopathy", "CANCER", 36, 59], ["a palpable and fistulated cervical lymphdenopathy", "PROBLEM", 10, 59], ["palpable", "OBSERVATION_MODIFIER", 12, 20], ["fistulated", "OBSERVATION_MODIFIER", 25, 35], ["cervical", "ANATOMY", 36, 44], ["lymphdenopathy", "OBSERVATION", 45, 59]]], ["Drainage was examined microscopically and cultured for bacteria, mycobacteria and fungi.", [["Drainage", "TREATMENT", 0, 8], ["bacteria", "PROBLEM", 55, 63], ["mycobacteria", "PROBLEM", 65, 77], ["fungi", "PROBLEM", 82, 87], ["mycobacteria", "OBSERVATION", 65, 77]]], ["On routine cultures no microorganisms were grown.", [["routine cultures", "TEST", 3, 19], ["microorganisms", "PROBLEM", 23, 37]]], ["Fine needle aspiration was done.", [["Fine needle aspiration", "TEST", 0, 22], ["aspiration", "OBSERVATION", 12, 22]]], ["It was reported that suppurative granulamatous lympadenitis.", [["suppurative granulamatous lympadenitis", "DISEASE", 21, 59], ["suppurative granulamatous lympadenitis", "PROBLEM", 21, 59], ["suppurative", "OBSERVATION_MODIFIER", 21, 32], ["granulamatous lympadenitis", "OBSERVATION", 33, 59]]], ["So we were examined for tularemia, cat scratch disease.Interesting case reportsMicroaggltunation test for tularemia was 1/320 positive.", [["tularemia", "DISEASE", 24, 33], ["cat scratch disease", "DISEASE", 35, 54], ["tularemia", "DISEASE", 106, 115], ["cat", "ORGANISM", 35, 38], ["tularemia", "PROBLEM", 24, 33], ["cat scratch disease", "PROBLEM", 35, 54], ["Microaggltunation test", "TEST", 79, 101], ["tularemia", "PROBLEM", 106, 115], ["scratch disease", "OBSERVATION", 39, 54]]], ["Then streptomycin had been given for 10 days and excision of lymphadenopathy had been done.", [["streptomycin", "CHEMICAL", 5, 17], ["lymphadenopathy", "DISEASE", 61, 76], ["streptomycin", "CHEMICAL", 5, 17], ["streptomycin", "SIMPLE_CHEMICAL", 5, 17], ["streptomycin", "TREATMENT", 5, 17], ["excision", "TREATMENT", 49, 57], ["lymphadenopathy", "PROBLEM", 61, 76], ["lymphadenopathy", "OBSERVATION", 61, 76]]], ["No complications or recurrence occur.", [["complications", "PROBLEM", 3, 16], ["recurrence", "PROBLEM", 20, 30], ["complications", "OBSERVATION", 3, 16], ["recurrence", "OBSERVATION", 20, 30]]], ["Results: Both patients were applied to us from non endemic and different regions of the Turkey.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["They had no known insect bite history.", [["insect bite", "DISEASE", 18, 29], ["no known", "UNCERTAINTY", 9, 17]]], ["Both of them were diagnosed by serological tests.", [["serological tests", "TEST", 31, 48]]], ["Conclusions: In the differential diagnosis of tonsillopharyngitidis, tularemia also must be considered in the non endemic regions.P1825Tularaemia presenting with tonsillopharyngitis and cervical lymphadenitis: two case reports B. Kandemir, I. Erayman, M. Bitirgen, E. Turk Aribas, A.C. Inkaya, S. Guler (Konya, TR)P1825Tularemia is a zoonotic disease caused by Francisella tularensis.", [["cervical lymphadenitis", "ANATOMY", 186, 208], ["tonsillopharyngitidis", "DISEASE", 46, 67], ["tularemia", "DISEASE", 69, 78], ["P1825Tularaemia", "CHEMICAL", 130, 145], ["tonsillopharyngitis", "DISEASE", 162, 181], ["cervical lymphadenitis", "DISEASE", 186, 208], ["P1825Tularemia", "CHEMICAL", 314, 328], ["zoonotic disease", "DISEASE", 334, 350], ["cervical lymphadenitis", "CANCER", 186, 208], ["Konya, TR)P1825Tularemia", "ORGANISM", 304, 328], ["Francisella tularensis", "ORGANISM", 361, 383], ["Francisella tularensis", "SPECIES", 361, 383], ["Francisella tularensis", "SPECIES", 361, 383], ["tonsillopharyngitidis", "PROBLEM", 46, 67], ["tularemia", "PROBLEM", 69, 78], ["tonsillopharyngitis", "PROBLEM", 162, 181], ["cervical lymphadenitis", "PROBLEM", 186, 208], ["a zoonotic disease", "PROBLEM", 332, 350], ["Francisella tularensis", "PROBLEM", 361, 383], ["tularemia", "OBSERVATION", 69, 78], ["must be considered", "UNCERTAINTY", 84, 102], ["cervical", "ANATOMY", 186, 194], ["lymphadenitis", "OBSERVATION", 195, 208], ["zoonotic disease", "OBSERVATION", 334, 350], ["Francisella tularensis", "OBSERVATION", 361, 383]]], ["Francisella tularensis is transmitted to humans by direct contact or ingestion of infected animal tissues, through the bite of infected arthropods, by consumption of contaminated food or water, or from inhalation of aerosolized bacteria.", [["tissues", "ANATOMY", 98, 105], ["Francisella tularensis", "DISEASE", 0, 22], ["infected arthropods", "DISEASE", 127, 146], ["Francisella tularensis", "ORGANISM", 0, 22], ["humans", "ORGANISM", 41, 47], ["tissues", "TISSUE", 98, 105], ["Francisella tularensis", "SPECIES", 0, 22], ["humans", "SPECIES", 41, 47], ["Francisella tularensis", "SPECIES", 0, 22], ["humans", "SPECIES", 41, 47], ["Francisella tularensis", "PROBLEM", 0, 22], ["infected animal tissues", "PROBLEM", 82, 105], ["infected arthropods", "PROBLEM", 127, 146], ["aerosolized bacteria", "PROBLEM", 216, 236], ["tularensis", "OBSERVATION", 12, 22], ["infected", "OBSERVATION", 82, 90], ["infected", "OBSERVATION", 127, 135], ["aerosolized bacteria", "OBSERVATION", 216, 236]]], ["In this report we describe two cases of oropharyngeal tularemia who presented with tonsillopharyngitis and cervical lymphadenitis.", [["oropharyngeal", "ANATOMY", 40, 53], ["cervical lymphadenitis", "ANATOMY", 107, 129], ["oropharyngeal tularemia", "DISEASE", 40, 63], ["tonsillopharyngitis", "DISEASE", 83, 102], ["cervical lymphadenitis", "DISEASE", 107, 129], ["cervical lymphadenitis", "CANCER", 107, 129], ["oropharyngeal tularemia", "PROBLEM", 40, 63], ["tonsillopharyngitis", "PROBLEM", 83, 102], ["cervical lymphadenitis", "PROBLEM", 107, 129], ["oropharyngeal", "ANATOMY", 40, 53], ["tularemia", "OBSERVATION", 54, 63], ["cervical", "ANATOMY", 107, 115], ["lymphadenitis", "OBSERVATION", 116, 129]]], ["Case I: A 43 years old woman with multiple cervical lymphadenitis has been admitted to our clinic.", [["cervical lymphadenitis", "ANATOMY", 43, 65], ["cervical lymphadenitis", "DISEASE", 43, 65], ["woman", "ORGANISM", 23, 28], ["cervical lymphadenitis", "CANCER", 43, 65], ["woman", "SPECIES", 23, 28], ["multiple cervical lymphadenitis", "PROBLEM", 34, 65], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["cervical", "ANATOMY", 43, 51], ["lymphadenitis", "OBSERVATION", 52, 65]]], ["Her complaints started 2 months ago with signs and symptoms of tonsillopharyngitis.", [["tonsillopharyngitis", "DISEASE", 63, 82], ["Her complaints", "PROBLEM", 0, 14], ["signs and symptoms of tonsillopharyngitis", "PROBLEM", 41, 82], ["tonsillopharyngitis", "OBSERVATION", 63, 82]]], ["She had received non specific treatment (ampicillin+sulbactam) and ten days later cervical lymph nodes appeared.", [["cervical lymph nodes", "ANATOMY", 82, 102], ["ampicillin", "CHEMICAL", 41, 51], ["sulbactam", "CHEMICAL", 52, 61], ["ampicillin", "CHEMICAL", 41, 51], ["sulbactam", "CHEMICAL", 52, 61], ["ampicillin+sulbactam", "SIMPLE_CHEMICAL", 41, 61], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 82, 102], ["non specific treatment", "TREATMENT", 17, 39], ["ampicillin+sulbactam", "TREATMENT", 41, 61], ["cervical lymph nodes", "PROBLEM", 82, 102], ["cervical", "ANATOMY", 82, 90], ["lymph nodes", "OBSERVATION", 91, 102]]], ["The diagnosis was made serologically.", [["serologically", "PROBLEM", 23, 36]]], ["The antimicrobial therapy (streptomycin 1 \u00b7 1 g im) was given for fourteen days.", [["streptomycin", "CHEMICAL", 27, 39], ["streptomycin", "CHEMICAL", 27, 39], ["streptomycin", "SIMPLE_CHEMICAL", 27, 39], ["The antimicrobial therapy", "TREATMENT", 0, 25], ["streptomycin", "TREATMENT", 27, 39]]], ["The patient recovered completely.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Case II: A 16 years old girl with multiple cervical lymphadenitis was admitted to hospital.", [["cervical lymphadenitis", "ANATOMY", 43, 65], ["cervical lymphadenitis", "DISEASE", 43, 65], ["girl", "ORGANISM", 24, 28], ["cervical lymphadenitis", "CANCER", 43, 65], ["girl", "SPECIES", 24, 28], ["multiple cervical lymphadenitis", "PROBLEM", 34, 65], ["multiple", "OBSERVATION_MODIFIER", 34, 42], ["cervical", "ANATOMY", 43, 51], ["lymphadenitis", "OBSERVATION", 52, 65]]], ["Her complaints started 3 months ago with throat ache after which multiple cervical lymphadenitis appeared.", [["throat", "ANATOMY", 41, 47], ["cervical lymphadenitis", "ANATOMY", 74, 96], ["throat ache", "DISEASE", 41, 52], ["lymphadenitis", "DISEASE", 83, 96], ["throat", "ORGANISM_SUBDIVISION", 41, 47], ["ache", "ORGANISM_SUBDIVISION", 48, 52], ["cervical lymphadenitis", "CANCER", 74, 96], ["Her complaints", "PROBLEM", 0, 14], ["throat ache", "PROBLEM", 41, 52], ["multiple cervical lymphadenitis", "PROBLEM", 65, 96], ["throat ache", "ANATOMY", 41, 52], ["cervical", "ANATOMY", 74, 82], ["lymphadenitis", "OBSERVATION", 83, 96]]], ["She was admitted to our out patient clinics and diagnosed to have tularemia.", [["tularemia", "DISEASE", 66, 75], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["tularemia", "PROBLEM", 66, 75], ["tularemia", "OBSERVATION", 66, 75]]], ["Anti-microbial therapy (streptomycin 1 \u00b7 1 g im+doxycyciline 2 \u00b7 100 mg) was given for four weeks but no clinical response was achieved.", [["streptomycin", "CHEMICAL", 24, 36], ["doxycyciline", "CHEMICAL", 48, 60], ["streptomycin", "CHEMICAL", 24, 36], ["doxycyciline", "CHEMICAL", 48, 60], ["streptomycin", "SIMPLE_CHEMICAL", 24, 36], ["Anti-microbial therapy", "TREATMENT", 0, 22], ["streptomycin", "TREATMENT", 24, 36], ["doxycyciline", "TREATMENT", 48, 60]]], ["Patient was admitted to the hospital and surgical drainage was performed.", [["Patient", "SPECIES", 0, 7], ["surgical drainage", "TREATMENT", 41, 58], ["drainage", "OBSERVATION", 50, 58]]], ["Treatment against tularemia was prolonged.", [["tularemia", "DISEASE", 18, 27], ["Treatment", "TREATMENT", 0, 9], ["tularemia", "PROBLEM", 18, 27], ["tularemia", "OBSERVATION", 18, 27]]], ["Patient was finally recovered at the end of nine weeks of therapy.", [["Patient", "ORGANISM", 0, 7], ["Patient", "SPECIES", 0, 7], ["therapy", "TREATMENT", 58, 65]]], ["It can be concluded that early diagnosis and treatment of tularemia are important.", [["tularemia", "DISEASE", 58, 67], ["treatment", "TREATMENT", 45, 54], ["tularemia", "PROBLEM", 58, 67], ["tularemia", "OBSERVATION", 58, 67]]], ["Some patients may benefit from surgical drainage and prolonged therapy.P1826A case of nonclostridial crepitant cellulitis which is due to Escherichia coli C. Ayaz, M. Ulug, M.K. Celen, M.F. Geyik, S. Hosoglu (Diyarbakir, TR)P1826Objectives: This condition is caused by gas forming bacteria that involve the skin, either or as an extension from deeper structures.", [["skin", "ANATOMY", 307, 311], ["cellulitis", "DISEASE", 111, 121], ["patients", "ORGANISM", 5, 13], ["Escherichia coli", "ORGANISM", 138, 154], ["skin", "ORGAN", 307, 311], ["patients", "SPECIES", 5, 13], ["Escherichia coli", "SPECIES", 138, 154], ["Escherichia coli", "SPECIES", 138, 154], ["surgical drainage", "TREATMENT", 31, 48], ["prolonged therapy", "TREATMENT", 53, 70], ["nonclostridial crepitant cellulitis", "PROBLEM", 86, 121], ["Escherichia coli", "PROBLEM", 138, 154], ["gas forming bacteria", "PROBLEM", 269, 289], ["surgical drainage", "OBSERVATION", 31, 48], ["cellulitis", "OBSERVATION", 111, 121], ["Escherichia coli", "OBSERVATION", 138, 154], ["skin", "ANATOMY", 307, 311]]], ["The origin of infection is an abdominal wound, perianal disease, or operative incisions that have become secondarily infected.", [["abdominal wound", "ANATOMY", 30, 45], ["perianal", "ANATOMY", 47, 55], ["infection", "DISEASE", 14, 23], ["perianal disease", "DISEASE", 47, 63], ["abdominal wound", "PATHOLOGICAL_FORMATION", 30, 45], ["infection", "PROBLEM", 14, 23], ["an abdominal wound", "PROBLEM", 27, 45], ["perianal disease", "PROBLEM", 47, 63], ["operative incisions", "PROBLEM", 68, 87], ["origin", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 14, 23], ["abdominal", "ANATOMY", 30, 39], ["wound", "OBSERVATION", 40, 45], ["perianal", "ANATOMY", 47, 55], ["disease", "OBSERVATION", 56, 63], ["operative incisions", "OBSERVATION", 68, 87], ["secondarily", "OBSERVATION_MODIFIER", 105, 116], ["infected", "OBSERVATION", 117, 125]]], ["Tracking of gas-forming organisms from deeper sites of infection may also present as crepitant cellulitis without a break in the skin.", [["sites", "ANATOMY", 46, 51], ["skin", "ANATOMY", 129, 133], ["infection", "DISEASE", 55, 64], ["cellulitis", "DISEASE", 95, 105], ["skin", "ORGAN", 129, 133], ["forming organisms", "PROBLEM", 16, 33], ["deeper sites of infection", "PROBLEM", 39, 64], ["crepitant cellulitis", "PROBLEM", 85, 105], ["a break in the skin", "PROBLEM", 114, 133], ["gas", "OBSERVATION_MODIFIER", 12, 15], ["deeper sites", "OBSERVATION_MODIFIER", 39, 51], ["infection", "OBSERVATION", 55, 64], ["cellulitis", "OBSERVATION", 95, 105], ["break", "OBSERVATION_MODIFIER", 116, 121], ["skin", "ANATOMY", 129, 133]]], ["Diabetics are more likely to acquire such infections, especially in the lower extremites.", [["infections", "DISEASE", 42, 52], ["Diabetics", "PROBLEM", 0, 9], ["such infections", "PROBLEM", 37, 52], ["more likely", "UNCERTAINTY", 14, 25], ["infections", "OBSERVATION", 42, 52], ["lower extremites", "ANATOMY", 72, 88]]], ["Among the bacteria isolated are anaerobic organisms such as Bacteriodes or anaerobic streptococci, or coliform bacteria, especially Escherichia coli and Klebsiella.", [["Bacteriodes", "SIMPLE_CHEMICAL", 60, 71], ["Escherichia coli", "ORGANISM", 132, 148], ["Escherichia coli", "SPECIES", 132, 148], ["Escherichia coli", "SPECIES", 132, 148], ["the bacteria", "PROBLEM", 6, 18], ["anaerobic organisms", "PROBLEM", 32, 51], ["Bacteriodes", "PROBLEM", 60, 71], ["anaerobic streptococci", "PROBLEM", 75, 97], ["coliform bacteria", "PROBLEM", 102, 119], ["Escherichia coli", "PROBLEM", 132, 148], ["Klebsiella", "PROBLEM", 153, 163], ["bacteria", "OBSERVATION_MODIFIER", 10, 18], ["anaerobic streptococci", "OBSERVATION", 75, 97], ["coliform bacteria", "OBSERVATION", 102, 119], ["Escherichia coli", "OBSERVATION", 132, 148], ["Klebsiella", "OBSERVATION_MODIFIER", 153, 163]]], ["Because of this reason we reported a case of a nonclostridial crepitant cellulitis which is due to Escherichia coli.", [["cellulitis", "DISEASE", 72, 82], ["Escherichia coli", "ORGANISM", 99, 115], ["Escherichia coli", "SPECIES", 99, 115], ["Escherichia coli", "SPECIES", 99, 115], ["a nonclostridial crepitant cellulitis", "PROBLEM", 45, 82], ["Escherichia coli", "PROBLEM", 99, 115], ["cellulitis", "OBSERVATION", 72, 82], ["Escherichia coli", "OBSERVATION", 99, 115]]], ["Case: A 40 year old man who was previously healthy, has come with fever, pain, oedema, erythema, crepitant and limitation of movement at the right lower extremity.", [["right lower extremity", "ANATOMY", 141, 162], ["fever", "DISEASE", 66, 71], ["pain", "DISEASE", 73, 77], ["oedema", "DISEASE", 79, 85], ["erythema", "DISEASE", 87, 95], ["crepitant", "DISEASE", 97, 106], ["man", "ORGANISM", 20, 23], ["right", "ORGANISM_SUBDIVISION", 141, 146], ["lower extremity", "ORGANISM_SUBDIVISION", 147, 162], ["man", "SPECIES", 20, 23], ["fever", "PROBLEM", 66, 71], ["pain", "PROBLEM", 73, 77], ["oedema", "PROBLEM", 79, 85], ["erythema", "PROBLEM", 87, 95], ["crepitant", "PROBLEM", 97, 106], ["oedema", "OBSERVATION", 79, 85], ["erythema", "OBSERVATION", 87, 95], ["movement", "OBSERVATION", 125, 133], ["right", "ANATOMY_MODIFIER", 141, 146], ["lower extremity", "ANATOMY", 147, 162]]], ["Perianal abscess has developed at this time and it has drainged spontaneously 3 days later.", [["Perianal abscess", "ANATOMY", 0, 16], ["abscess", "DISEASE", 9, 16], ["Perianal abscess", "PROBLEM", 0, 16], ["abscess", "OBSERVATION", 9, 16]]], ["On physical examination, the temperature was 38.9\u00b0C, pulse rate 116/ minute, respiratory rate 42/minute and blood pressure was 90/50 mmHg.", [["blood", "ANATOMY", 108, 113], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["C", "TEST", 50, 51], ["pulse rate", "TEST", 53, 63], ["respiratory rate", "TEST", 77, 93], ["blood pressure", "TEST", 108, 122]]], ["Laboratory evaluation showed a haemoglobin 8.1 g/dl, leucocyte count of 32700/mm 3 (neutrophils 92%).", [["leucocyte", "ANATOMY", 53, 62], ["neutrophils", "ANATOMY", 84, 95], ["leucocyte", "CELL", 53, 62], ["neutrophils", "CELL", 84, 95], ["neutrophils", "CELL_TYPE", 84, 95], ["Laboratory evaluation", "TEST", 0, 21], ["a haemoglobin", "TEST", 29, 42], ["leucocyte count", "TEST", 53, 68], ["neutrophils", "TEST", 84, 95]]], ["Serum electrolytes, renal and liver function tests were within normal limits.", [["Serum", "ANATOMY", 0, 5], ["renal", "ANATOMY", 20, 25], ["liver", "ANATOMY", 30, 35], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["renal", "ORGAN", 20, 25], ["liver", "ORGAN", 30, 35], ["Serum electrolytes", "TEST", 0, 18], ["renal and liver function tests", "TEST", 20, 50], ["renal", "ANATOMY", 20, 25], ["liver", "ANATOMY", 30, 35], ["normal limits", "OBSERVATION", 63, 76]]], ["C reactive protein was elevated up to 354 mg/dl, ESR was 77 mm/h.", [["C reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["C reactive protein", "PROTEIN", 0, 18], ["C reactive protein", "TEST", 0, 18], ["elevated", "PROBLEM", 23, 31], ["ESR", "TEST", 49, 52], ["reactive protein", "OBSERVATION", 2, 18]]], ["Escherichia coli was isolated from wound and blood cultures.", [["wound", "ANATOMY", 35, 40], ["blood cultures", "ANATOMY", 45, 59], ["Escherichia coli", "ORGANISM", 0, 16], ["wound", "PATHOLOGICAL_FORMATION", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "PROBLEM", 0, 16], ["wound", "PROBLEM", 35, 40], ["blood cultures", "TEST", 45, 59], ["coli", "OBSERVATION", 12, 16], ["wound", "OBSERVATION", 35, 40]]], ["He was treated initially with ampicilinsulbactam (6 g/day) and required attempt.", [["ampicilinsulbactam", "CHEMICAL", 30, 48], ["ampicilinsulbactam", "CHEMICAL", 30, 48], ["He", "ORGANISM", 0, 2], ["ampicilinsulbactam", "SIMPLE_CHEMICAL", 30, 48], ["ampicilinsulbactam", "TREATMENT", 30, 48]]], ["Even with optimal surgical and medical therapy, he dies at the third day of the treatment from septic shock.", [["septic shock", "DISEASE", 95, 107], ["optimal surgical", "TREATMENT", 10, 26], ["medical therapy", "TREATMENT", 31, 46], ["the treatment", "TREATMENT", 76, 89], ["septic shock", "PROBLEM", 95, 107], ["septic shock", "OBSERVATION", 95, 107]]], ["Conclusion: The onset is generally gradual, and there is usually mild local pain and systemic toxicity, allowing clinical differentiation from the more fulminant clostridial myonecrosis.", [["pain", "DISEASE", 76, 80], ["toxicity", "DISEASE", 94, 102], ["myonecrosis", "DISEASE", 174, 185], ["usually mild local pain", "PROBLEM", 57, 80], ["systemic toxicity", "PROBLEM", 85, 102], ["the more fulminant clostridial myonecrosis", "PROBLEM", 143, 185], ["generally", "OBSERVATION_MODIFIER", 25, 34], ["gradual", "OBSERVATION_MODIFIER", 35, 42], ["mild", "OBSERVATION_MODIFIER", 65, 69], ["local", "OBSERVATION_MODIFIER", 70, 75], ["pain", "OBSERVATION", 76, 80], ["systemic", "OBSERVATION_MODIFIER", 85, 93], ["toxicity", "OBSERVATION", 94, 102], ["more", "OBSERVATION_MODIFIER", 147, 151], ["fulminant", "OBSERVATION_MODIFIER", 152, 161], ["clostridial", "OBSERVATION_MODIFIER", 162, 173], ["myonecrosis", "OBSERVATION", 174, 185]]], ["The surgical approach should be aggressive, but tailored specifically to the underlying cause of infection.", [["infection", "DISEASE", 97, 106], ["The surgical approach", "TREATMENT", 0, 21], ["infection", "PROBLEM", 97, 106], ["surgical", "OBSERVATION", 4, 12], ["infection", "OBSERVATION", 97, 106]]], ["Antibiotic therapy is directed at a mixed aerobic-anaerobic flora, until culture reports are available.P1827A case of iliopsoas abscess which is due to Pseudomonas aeruginosa Objectives: Pyogenic psoas abscess, a rare but life-threatening infection, results from primary suppuration or is secondary to the spread of infection from an adjacent structure.", [["iliopsoas abscess", "ANATOMY", 118, 135], ["Pyogenic psoas abscess", "ANATOMY", 187, 209], ["iliopsoas abscess", "DISEASE", 118, 135], ["Pyogenic psoas abscess", "DISEASE", 187, 209], ["infection", "DISEASE", 239, 248], ["suppuration", "DISEASE", 271, 282], ["infection", "DISEASE", 316, 325], ["iliopsoas abscess", "PATHOLOGICAL_FORMATION", 118, 135], ["Pseudomonas aeruginosa", "ORGANISM", 152, 174], ["psoas", "PATHOLOGICAL_FORMATION", 196, 201], ["Pseudomonas aeruginosa", "SPECIES", 152, 174], ["Pseudomonas aeruginosa", "SPECIES", 152, 174], ["Antibiotic therapy", "TREATMENT", 0, 18], ["a mixed aerobic-anaerobic flora", "PROBLEM", 34, 65], ["culture", "TEST", 73, 80], ["iliopsoas abscess", "PROBLEM", 118, 135], ["Pseudomonas aeruginosa", "PROBLEM", 152, 174], ["Pyogenic psoas abscess", "PROBLEM", 187, 209], ["life-threatening infection", "PROBLEM", 222, 248], ["primary suppuration", "PROBLEM", 263, 282], ["infection", "PROBLEM", 316, 325], ["iliopsoas", "ANATOMY", 118, 127], ["abscess", "OBSERVATION", 128, 135], ["due to", "UNCERTAINTY", 145, 151], ["Pyogenic", "OBSERVATION_MODIFIER", 187, 195], ["psoas", "ANATOMY", 196, 201], ["abscess", "OBSERVATION", 202, 209], ["threatening", "OBSERVATION_MODIFIER", 227, 238], ["infection", "OBSERVATION", 239, 248], ["primary", "OBSERVATION_MODIFIER", 263, 270], ["suppuration", "OBSERVATION", 271, 282], ["infection", "OBSERVATION", 316, 325]]], ["Primary iliopsoas abscess occurs probably as a result of hematogenous spread of an infectious process from an occult source in the body.", [["iliopsoas abscess", "ANATOMY", 8, 25], ["body", "ANATOMY", 131, 135], ["abscess", "DISEASE", 18, 25], ["iliopsoas abscess", "PATHOLOGICAL_FORMATION", 8, 25], ["body", "ORGANISM_SUBDIVISION", 131, 135], ["Primary iliopsoas abscess", "PROBLEM", 0, 25], ["hematogenous spread", "PROBLEM", 57, 76], ["an infectious process", "PROBLEM", 80, 101], ["an occult source in the body", "PROBLEM", 107, 135], ["iliopsoas", "ANATOMY", 8, 17], ["abscess", "OBSERVATION", 18, 25], ["hematogenous", "OBSERVATION_MODIFIER", 57, 69], ["infectious", "OBSERVATION", 83, 93], ["occult", "OBSERVATION_MODIFIER", 110, 116], ["source", "OBSERVATION", 117, 123], ["body", "ANATOMY", 131, 135]]], ["Primary iliopsoas abscess can occur in diabetus mellitus, intravenous drug abuse, AIDS, renal failure and immunosupression.", [["iliopsoas abscess", "ANATOMY", 8, 25], ["intravenous", "ANATOMY", 58, 69], ["renal", "ANATOMY", 88, 93], ["abscess", "DISEASE", 18, 25], ["diabetus mellitus", "DISEASE", 39, 56], ["intravenous drug abuse", "DISEASE", 58, 80], ["AIDS", "DISEASE", 82, 86], ["renal failure", "DISEASE", 88, 101], ["immunosupression", "DISEASE", 106, 122], ["iliopsoas abscess", "PATHOLOGICAL_FORMATION", 8, 25], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 69], ["renal", "ORGAN", 88, 93], ["Primary iliopsoas abscess", "PROBLEM", 0, 25], ["diabetus mellitus", "PROBLEM", 39, 56], ["AIDS", "PROBLEM", 82, 86], ["renal failure", "PROBLEM", 88, 101], ["immunosupression", "TREATMENT", 106, 122], ["iliopsoas", "ANATOMY", 8, 17], ["abscess", "OBSERVATION", 18, 25], ["renal", "ANATOMY", 88, 93], ["failure", "OBSERVATION", 94, 101]]], ["Ultrasound is diagnostic in only 60% of the cases.", [["Ultrasound", "TEST", 0, 10]]], ["Computed tomography should be done for definitive diagnosis and is considered the gold standard.", [["Computed tomography", "TEST", 0, 19], ["definitive diagnosis", "TEST", 39, 59]]], ["Stapylococcus aureus is the causative organism in patients with primary iliopsoas abscess, but pyogenic psoas abscess caused by Pseudomonas aeruginosa is uncommon.", [["primary iliopsoas abscess", "ANATOMY", 64, 89], ["pyogenic psoas abscess", "ANATOMY", 95, 117], ["Stapylococcus aureus", "DISEASE", 0, 20], ["primary iliopsoas abscess", "DISEASE", 64, 89], ["psoas abscess", "DISEASE", 104, 117], ["Pseudomonas aeruginosa", "DISEASE", 128, 150], ["Stapylococcus aureus", "ORGANISM", 0, 20], ["patients", "ORGANISM", 50, 58], ["iliopsoas abscess", "PATHOLOGICAL_FORMATION", 72, 89], ["psoas abscess", "PATHOLOGICAL_FORMATION", 104, 117], ["Pseudomonas aeruginosa", "ORGANISM", 128, 150], ["Stapylococcus aureus", "SPECIES", 0, 20], ["patients", "SPECIES", 50, 58], ["Pseudomonas aeruginosa", "SPECIES", 128, 150], ["Stapylococcus aureus", "SPECIES", 0, 20], ["Pseudomonas aeruginosa", "SPECIES", 128, 150], ["Stapylococcus aureus", "PROBLEM", 0, 20], ["the causative organism", "PROBLEM", 24, 46], ["primary iliopsoas abscess", "PROBLEM", 64, 89], ["pyogenic psoas abscess", "PROBLEM", 95, 117], ["Pseudomonas aeruginosa", "PROBLEM", 128, 150], ["aureus", "OBSERVATION", 14, 20], ["causative organism", "OBSERVATION", 28, 46], ["iliopsoas", "ANATOMY", 72, 81], ["abscess", "OBSERVATION", 82, 89], ["pyogenic", "OBSERVATION_MODIFIER", 95, 103], ["psoas", "ANATOMY", 104, 109], ["abscess", "OBSERVATION", 110, 117], ["Pseudomonas aeruginosa", "OBSERVATION", 128, 150]]], ["Case: A previously well 67 year old woman presented with a month history of right loin to groin pain, limping or limitation of hip movement, fever and nausea.", [["right loin", "ANATOMY", 76, 86], ["groin", "ANATOMY", 90, 95], ["hip", "ANATOMY", 127, 130], ["groin pain", "DISEASE", 90, 100], ["limping", "DISEASE", 102, 109], ["fever", "DISEASE", 141, 146], ["nausea", "DISEASE", 151, 157], ["woman", "ORGANISM", 36, 41], ["loin", "ORGANISM_SUBDIVISION", 82, 86], ["groin", "ORGANISM_SUBDIVISION", 90, 95], ["hip", "ORGANISM_SUBDIVISION", 127, 130], ["woman", "SPECIES", 36, 41], ["right loin to groin pain", "PROBLEM", 76, 100], ["limping", "PROBLEM", 102, 109], ["hip movement", "PROBLEM", 127, 139], ["fever", "PROBLEM", 141, 146], ["nausea", "PROBLEM", 151, 157], ["right", "ANATOMY_MODIFIER", 76, 81], ["loin", "ANATOMY", 82, 86], ["groin", "ANATOMY", 90, 95], ["pain", "OBSERVATION", 96, 100], ["hip", "ANATOMY", 127, 130], ["movement", "OBSERVATION", 131, 139], ["fever", "OBSERVATION", 141, 146]]], ["She was a diabetus mellitus patient for 7 years.", [["diabetus mellitus", "DISEASE", 10, 27], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["a diabetus mellitus", "PROBLEM", 8, 27]]], ["On her physical examination, the temperature was 38.1\u00b0C, pulse rate 104/minute, respiratory rate 28/minute and blood pressure was 140/90 mmHg.", [["respiratory", "ANATOMY", 80, 91], ["blood", "ANATOMY", 111, 116], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["her physical examination", "TEST", 3, 27], ["the temperature", "TEST", 29, 44], ["C", "TEST", 54, 55], ["pulse rate", "TEST", 57, 67], ["respiratory rate", "TEST", 80, 96], ["blood pressure", "TEST", 111, 125]]], ["Examination of the respiratory system, cardiovascular system and abdomen were found to be normal.", [["respiratory system", "ANATOMY", 19, 37], ["cardiovascular system", "ANATOMY", 39, 60], ["abdomen", "ANATOMY", 65, 72], ["cardiovascular", "ANATOMICAL_SYSTEM", 39, 53], ["system", "ANATOMICAL_SYSTEM", 54, 60], ["abdomen", "ORGAN", 65, 72], ["Examination of the respiratory system", "TEST", 0, 37], ["respiratory system", "ANATOMY", 19, 37], ["cardiovascular system", "ANATOMY", 39, 60], ["abdomen", "ANATOMY", 65, 72], ["normal", "OBSERVATION", 90, 96]]], ["Laboratory investigations revealed total leucocyte count of 17800/mm 3 (polymorphs 88%), C reactive protein was elevated up to 168 mg/dl, ESR was 77 mm/h.", [["leucocyte", "ANATOMY", 41, 50], ["leucocyte", "CELL", 41, 50], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 89, 107], ["C reactive protein", "PROTEIN", 89, 107], ["Laboratory investigations", "TEST", 0, 25], ["total leucocyte count", "TEST", 35, 56], ["polymorphs", "TEST", 72, 82], ["C reactive protein", "TEST", 89, 107], ["elevated", "PROBLEM", 112, 120], ["ESR", "TEST", 138, 141], ["total", "OBSERVATION_MODIFIER", 35, 40], ["leucocyte count", "OBSERVATION", 41, 56]]], ["Serum electrolytes, renal and liver function tests were within normal limits, but serum glucose level was elevated to 351 mg/dl.", [["Serum", "ANATOMY", 0, 5], ["renal", "ANATOMY", 20, 25], ["liver", "ANATOMY", 30, 35], ["serum", "ANATOMY", 82, 87], ["glucose", "CHEMICAL", 88, 95], ["glucose", "CHEMICAL", 88, 95], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["renal", "ORGAN", 20, 25], ["liver", "ORGAN", 30, 35], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["glucose", "SIMPLE_CHEMICAL", 88, 95], ["Serum electrolytes", "TEST", 0, 18], ["liver function tests", "TEST", 30, 50], ["serum glucose level", "TEST", 82, 101], ["elevated", "PROBLEM", 106, 114], ["renal", "ANATOMY", 20, 25], ["liver", "ANATOMY", 30, 35]]], ["Her blood cultures were sterile, but abscess culture yielded Pseudomonas aeruginosa which was taken during the surgery.", [["blood cultures", "ANATOMY", 4, 18], ["abscess", "DISEASE", 37, 44], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["Pseudomonas aeruginosa", "ORGANISM", 61, 83], ["Pseudomonas aeruginosa", "SPECIES", 61, 83], ["Pseudomonas aeruginosa", "SPECIES", 61, 83], ["Her blood cultures", "TEST", 0, 18], ["abscess culture", "TEST", 37, 52], ["Pseudomonas aeruginosa", "PROBLEM", 61, 83], ["the surgery", "TREATMENT", 107, 118], ["abscess", "OBSERVATION", 37, 44]]], ["She was treated imipenem (2 g/ day) + amicasin (1.5 g/day) and required surgical drainage.", [["imipenem", "CHEMICAL", 16, 24], ["amicasin", "CHEMICAL", 38, 46], ["imipenem", "CHEMICAL", 16, 24], ["amicasin", "CHEMICAL", 38, 46], ["imipenem", "SIMPLE_CHEMICAL", 16, 24], ["amicasin", "SIMPLE_CHEMICAL", 38, 46], ["imipenem", "TREATMENT", 16, 24], ["amicasin", "TREATMENT", 38, 46], ["surgical drainage", "TREATMENT", 72, 89], ["surgical drainage", "OBSERVATION", 72, 89]]], ["She was treated and followed up 21 days, and discharged at the end of the treatment.", [["the treatment", "TREATMENT", 70, 83]]], ["Conclusion: In these patients treatment involves the use of appropriate antibiotics along with drainage of the abscess.", [["abscess", "ANATOMY", 111, 118], ["abscess", "DISEASE", 111, 118], ["patients", "ORGANISM", 21, 29], ["abscess", "PATHOLOGICAL_FORMATION", 111, 118], ["patients", "SPECIES", 21, 29], ["appropriate antibiotics", "TREATMENT", 60, 83], ["drainage", "TREATMENT", 95, 103], ["the abscess", "PROBLEM", 107, 118], ["abscess", "OBSERVATION", 111, 118]]], ["An adequate knowledge of the causative organisms should guide the initial choice of antibiotics.", [["the causative organisms", "PROBLEM", 25, 48], ["antibiotics", "TREATMENT", 84, 95], ["adequate", "OBSERVATION_MODIFIER", 3, 11]]], ["Depending on the results of the abscess fluid culture and sensitivity, adjustments should be made.", [["abscess fluid", "ANATOMY", 32, 45], ["abscess", "DISEASE", 32, 39], ["the abscess fluid culture", "TEST", 28, 53], ["sensitivity", "TEST", 58, 69], ["abscess", "OBSERVATION", 32, 39]]], ["Percutaneous drainage or surgical drainage may be done in them.", [["Percutaneous", "ANATOMY", 0, 12], ["Percutaneous drainage", "TREATMENT", 0, 21], ["surgical drainage", "TREATMENT", 25, 42], ["drainage", "OBSERVATION", 13, 21], ["surgical drainage", "OBSERVATION", 25, 42]]], ["In conclusion early recognition, empiric antimicrobial coverage and aggressive drainage or debriment are indicated in these patients.P1828Cervical lymphadenitis in a diabetic woman F. \u00c7 ok\u00e7a, A. Azap, S. G\u00f6 \u00e7men, H. Erdi Sanli, S. G\u00fc l (Ankara, Kirikkale, TR)P1828Objective: Rhodococcus equi infections are commonly seen in immunocompromised patients.", [["lymphadenitis", "DISEASE", 147, 160], ["diabetic", "DISEASE", 166, 174], ["Rhodococcus equi infections", "DISEASE", 275, 302], ["patients", "ORGANISM", 124, 132], ["S. G\u00fc l", "ORGANISM", 228, 235], ["Kirikkale, TR)P1828Objective", "ORGANISM", 245, 273], ["Rhodococcus equi", "ORGANISM", 275, 291], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 124, 132], ["woman", "SPECIES", 175, 180], ["Rhodococcus equi", "SPECIES", 275, 291], ["patients", "SPECIES", 342, 350], ["Rhodococcus equi", "SPECIES", 275, 291], ["empiric antimicrobial coverage", "TREATMENT", 33, 63], ["aggressive drainage", "TREATMENT", 68, 87], ["debriment", "TREATMENT", 91, 100], ["P1828Cervical lymphadenitis", "PROBLEM", 133, 160], ["Rhodococcus equi infections", "PROBLEM", 275, 302], ["lymphadenitis", "OBSERVATION", 147, 160], ["Rhodococcus", "OBSERVATION", 275, 286], ["equi infections", "OBSERVATION", 287, 302], ["immunocompromised", "OBSERVATION", 324, 341]]], ["Exposure to domestic animals, such as horses and pigs may play a role in some cases.", [["horses", "ORGANISM_SUBDIVISION", 38, 44], ["pigs", "ORGANISM", 49, 53], ["pigs", "SPECIES", 49, 53], ["horses", "SPECIES", 38, 44], ["pigs", "SPECIES", 49, 53]]], ["Two thirds of the R. equi infections in immunocompromised were reported in HIV infected patients, and the rest divided between transplant recipients, immunosupressive medications and other kinds of immunosupression.", [["equi infections", "DISEASE", 21, 36], ["HIV infected", "DISEASE", 75, 87], ["R. equi", "ORGANISM", 18, 25], ["HIV", "ORGANISM", 75, 78], ["patients", "ORGANISM", 88, 96], ["recipients", "ORGANISM", 138, 148], ["R. equi", "SPECIES", 18, 25], ["HIV", "SPECIES", 75, 78], ["patients", "SPECIES", 88, 96], ["R. equi", "SPECIES", 18, 25], ["HIV", "SPECIES", 75, 78], ["the R. equi infections", "PROBLEM", 14, 36], ["immunocompromised", "PROBLEM", 40, 57], ["transplant recipients", "TREATMENT", 127, 148], ["immunosupressive medications", "TREATMENT", 150, 178], ["immunosupression", "TREATMENT", 198, 214], ["R.", "OBSERVATION_MODIFIER", 18, 20], ["equi", "OBSERVATION_MODIFIER", 21, 25], ["infections", "OBSERVATION", 26, 36], ["immunocompromised", "OBSERVATION", 40, 57]]], ["The clinical picture presents with pulmonary infection in 80% of patients.", [["pulmonary", "ANATOMY", 35, 44], ["pulmonary infection", "DISEASE", 35, 54], ["pulmonary", "ORGAN", 35, 44], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["pulmonary infection", "PROBLEM", 35, 54], ["pulmonary", "ANATOMY", 35, 44], ["infection", "OBSERVATION", 45, 54]]], ["Here, we report a rare case of cervical lymphadenitis in a diabetic women due to R. equi.", [["cervical lymphadenitis", "ANATOMY", 31, 53], ["cervical lymphadenitis", "DISEASE", 31, 53], ["diabetic", "DISEASE", 59, 67], ["cervical lymphadenitis", "CANCER", 31, 53], ["women", "ORGANISM", 68, 73], ["R. equi", "ORGANISM", 81, 88], ["women", "SPECIES", 68, 73], ["R. equi", "SPECIES", 81, 88], ["R. equi", "SPECIES", 81, 88], ["cervical lymphadenitis", "PROBLEM", 31, 53], ["R. equi", "PROBLEM", 81, 88], ["cervical", "ANATOMY", 31, 39], ["lymphadenitis", "OBSERVATION", 40, 53]]], ["Case: A sixty-year-old diabetic woman was admitted with the complaints of fever, right cervical erythematous swelling with tenderness and warmth.", [["right cervical", "ANATOMY", 81, 95], ["diabetic", "DISEASE", 23, 31], ["fever", "DISEASE", 74, 79], ["swelling", "DISEASE", 109, 117], ["tenderness", "DISEASE", 123, 133], ["woman", "ORGANISM", 32, 37], ["cervical", "ORGANISM_SUBDIVISION", 87, 95], ["woman", "SPECIES", 32, 37], ["fever", "PROBLEM", 74, 79], ["right cervical erythematous swelling", "PROBLEM", 81, 117], ["tenderness", "PROBLEM", 123, 133], ["warmth", "PROBLEM", 138, 144], ["fever", "OBSERVATION", 74, 79], ["right", "ANATOMY_MODIFIER", 81, 86], ["cervical", "ANATOMY", 87, 95], ["erythematous", "OBSERVATION_MODIFIER", 96, 108], ["swelling", "OBSERVATION", 109, 117], ["tenderness", "OBSERVATION", 123, 133], ["warmth", "OBSERVATION", 138, 144]]], ["On physical examination; inflammation beginning from the right submandibular region and descending to the upper chest was detected.", [["right submandibular region", "ANATOMY", 57, 83], ["upper chest", "ANATOMY", 106, 117], ["inflammation", "DISEASE", 25, 37], ["submandibular region", "MULTI-TISSUE_STRUCTURE", 63, 83], ["upper chest", "ORGANISM_SUBDIVISION", 106, 117], ["physical examination", "TEST", 3, 23], ["inflammation", "PROBLEM", 25, 37], ["inflammation", "OBSERVATION", 25, 37], ["right", "ANATOMY_MODIFIER", 57, 62], ["submandibular", "ANATOMY", 63, 76], ["region", "ANATOMY_MODIFIER", 77, 83], ["descending", "ANATOMY_MODIFIER", 88, 98], ["upper", "ANATOMY_MODIFIER", 106, 111], ["chest", "ANATOMY", 112, 117]]], ["A tender mass of 8 \u00b7 5 \u00b7 cm. was palpated on the right cervical region.", [["right cervical region", "ANATOMY", 49, 70], ["cervical", "ORGAN", 55, 63], ["A tender mass", "PROBLEM", 0, 13], ["tender", "OBSERVATION_MODIFIER", 2, 8], ["mass", "OBSERVATION", 9, 13], ["8 \u00b7 5 \u00b7 cm", "OBSERVATION_MODIFIER", 17, 27], ["right", "ANATOMY_MODIFIER", 49, 54], ["cervical", "ANATOMY", 55, 63], ["region", "ANATOMY_MODIFIER", 64, 70]]], ["Ampicillin/sulbactam 4 g/day was given emprically for a week with no improvement.", [["Ampicillin", "CHEMICAL", 0, 10], ["sulbactam", "CHEMICAL", 11, 20], ["Ampicillin", "CHEMICAL", 0, 10], ["sulbactam", "CHEMICAL", 11, 20], ["Ampicillin", "SIMPLE_CHEMICAL", 0, 10], ["sulbactam", "SIMPLE_CHEMICAL", 11, 20], ["Ampicillin", "TREATMENT", 0, 10], ["sulbactam", "TREATMENT", 11, 20]]], ["The CT scan of the neck showed conglomerated lymphadenopathy extending from the submandibular area to the supraclaviculary region with 10.5 \u00b7 3 cm in size.", [["neck", "ANATOMY", 19, 23], ["submandibular area", "ANATOMY", 80, 98], ["supraclaviculary region", "ANATOMY", 106, 129], ["lymphadenopathy", "DISEASE", 45, 60], ["neck", "ORGAN", 19, 23], ["lymphadenopathy", "CANCER", 45, 60], ["submandibular area", "MULTI-TISSUE_STRUCTURE", 80, 98], ["The CT scan of the neck", "TEST", 0, 23], ["conglomerated lymphadenopathy", "PROBLEM", 31, 60], ["neck", "ANATOMY", 19, 23], ["conglomerated", "OBSERVATION_MODIFIER", 31, 44], ["lymphadenopathy", "OBSERVATION", 45, 60], ["submandibular", "ANATOMY", 80, 93], ["area", "ANATOMY_MODIFIER", 94, 98], ["supraclaviculary", "ANATOMY_MODIFIER", 106, 122], ["region", "ANATOMY_MODIFIER", 123, 129], ["10.5 \u00b7 3 cm", "OBSERVATION_MODIFIER", 135, 146], ["size", "OBSERVATION_MODIFIER", 150, 154]]], ["The mass began to fluctuate and 500 cc abscess material was drained surgically.", [["mass", "ANATOMY", 4, 8], ["abscess", "DISEASE", 39, 46], ["The mass", "PROBLEM", 0, 8], ["abscess material", "PROBLEM", 39, 55], ["mass", "OBSERVATION", 4, 8], ["fluctuate", "OBSERVATION_MODIFIER", 18, 27], ["500 cc", "OBSERVATION_MODIFIER", 32, 38], ["abscess", "OBSERVATION", 39, 46], ["drained", "OBSERVATION_MODIFIER", 60, 67], ["surgically", "OBSERVATION", 68, 78]]], ["Gram's stain of the purulent material showed polymorphonuclear leukocytes with pleomorphic gram positive coccobacilli.", [["purulent material", "ANATOMY", 20, 37], ["polymorphonuclear leukocytes", "ANATOMY", 45, 73], ["pleomorphic gram positive coccobacilli", "ANATOMY", 79, 117], ["polymorphonuclear leukocytes", "CELL", 45, 73], ["polymorphonuclear leukocytes", "CELL_TYPE", 45, 73], ["Gram's stain", "TEST", 0, 12], ["the purulent material", "TEST", 16, 37], ["polymorphonuclear leukocytes", "PROBLEM", 45, 73], ["pleomorphic gram positive coccobacilli", "PROBLEM", 79, 117], ["purulent", "OBSERVATION_MODIFIER", 20, 28], ["polymorphonuclear leukocytes", "OBSERVATION", 45, 73], ["pleomorphic", "OBSERVATION_MODIFIER", 79, 90], ["positive coccobacilli", "OBSERVATION", 96, 117]]], ["The cultures of the material grew R. equi.", [["R. equi", "ORGANISM", 34, 41], ["R. equi", "SPECIES", 34, 41], ["R. equi", "SPECIES", 34, 41], ["The cultures", "TEST", 0, 12], ["R. equi", "PROBLEM", 34, 41]]], ["Therapy was changed to teicoplanin and ciprofloxacin combination and surgical care of the wound with antiseptics was performed.", [["wound", "ANATOMY", 90, 95], ["teicoplanin", "CHEMICAL", 23, 34], ["ciprofloxacin", "CHEMICAL", 39, 52], ["teicoplanin", "CHEMICAL", 23, 34], ["ciprofloxacin", "CHEMICAL", 39, 52], ["teicoplanin", "SIMPLE_CHEMICAL", 23, 34], ["ciprofloxacin", "SIMPLE_CHEMICAL", 39, 52], ["wound", "PATHOLOGICAL_FORMATION", 90, 95], ["Therapy", "TREATMENT", 0, 7], ["teicoplanin", "TREATMENT", 23, 34], ["ciprofloxacin", "TREATMENT", 39, 52], ["surgical care", "TREATMENT", 69, 82], ["the wound", "PROBLEM", 86, 95], ["antiseptics", "TREATMENT", 101, 112], ["wound", "ANATOMY", 90, 95]]], ["After a month, intrevenous medical therapy was changed to oral route with roxythromycin and ciprofloxacin and was continued to 2 months with complete resolution.", [["oral", "ANATOMY", 58, 62], ["roxythromycin", "CHEMICAL", 74, 87], ["ciprofloxacin", "CHEMICAL", 92, 105], ["roxythromycin", "CHEMICAL", 74, 87], ["ciprofloxacin", "CHEMICAL", 92, 105], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["roxythromycin", "SIMPLE_CHEMICAL", 74, 87], ["ciprofloxacin", "SIMPLE_CHEMICAL", 92, 105], ["intrevenous medical therapy", "TREATMENT", 15, 42], ["oral route", "TREATMENT", 58, 68], ["roxythromycin", "TREATMENT", 74, 87], ["ciprofloxacin", "TREATMENT", 92, 105]]], ["Conclusion: Increased awareness and improved laboratory techniques help for the early diagnosis of rhodococcal infections.", [["rhodococcal infections", "DISEASE", 99, 121], ["Increased awareness", "PROBLEM", 12, 31], ["rhodococcal infections", "PROBLEM", 99, 121], ["Increased", "OBSERVATION_MODIFIER", 12, 21], ["infections", "OBSERVATION", 111, 121]]], ["Timely diagnosis is important because the microorganism is usually resistant to penicillin G, oxacillin, ampicillin, carbenicillin and cefazolin.", [["penicillin G", "CHEMICAL", 80, 92], ["oxacillin", "CHEMICAL", 94, 103], ["ampicillin", "CHEMICAL", 105, 115], ["carbenicillin", "CHEMICAL", 117, 130], ["cefazolin", "CHEMICAL", 135, 144], ["penicillin G", "CHEMICAL", 80, 92], ["oxacillin", "CHEMICAL", 94, 103], ["ampicillin", "CHEMICAL", 105, 115], ["carbenicillin", "CHEMICAL", 117, 130], ["cefazolin", "CHEMICAL", 135, 144], ["penicillin G", "SIMPLE_CHEMICAL", 80, 92], ["oxacillin", "SIMPLE_CHEMICAL", 94, 103], ["ampicillin", "SIMPLE_CHEMICAL", 105, 115], ["carbenicillin", "SIMPLE_CHEMICAL", 117, 130], ["cefazolin", "SIMPLE_CHEMICAL", 135, 144], ["the microorganism", "PROBLEM", 38, 55], ["penicillin G", "TREATMENT", 80, 92], ["oxacillin", "TREATMENT", 94, 103], ["ampicillin", "TREATMENT", 105, 115], ["carbenicillin", "TREATMENT", 117, 130], ["cefazolin", "TREATMENT", 135, 144]]], ["The use of at least one antibiotic with intracellular activity is necessary in the treatment of R. equi infections.", [["intracellular", "ANATOMY", 40, 53], ["R. equi infections", "DISEASE", 96, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 53], ["R. equi", "ORGANISM", 96, 103], ["R. equi", "SPECIES", 96, 103], ["R. equi", "SPECIES", 96, 103], ["intracellular activity", "TREATMENT", 40, 62], ["R. equi infections", "PROBLEM", 96, 114], ["equi", "OBSERVATION_MODIFIER", 99, 103], ["infections", "OBSERVATION", 104, 114]]], ["Empirical two drug regimens with erythromycin, rifampin and/or ciprofloxacin are recommended.", [["erythromycin", "CHEMICAL", 33, 45], ["rifampin", "CHEMICAL", 47, 55], ["ciprofloxacin", "CHEMICAL", 63, 76], ["erythromycin", "CHEMICAL", 33, 45], ["rifampin", "CHEMICAL", 47, 55], ["ciprofloxacin", "CHEMICAL", 63, 76], ["erythromycin", "SIMPLE_CHEMICAL", 33, 45], ["rifampin", "SIMPLE_CHEMICAL", 47, 55], ["ciprofloxacin", "SIMPLE_CHEMICAL", 63, 76], ["Empirical two drug regimens", "TREATMENT", 0, 27], ["erythromycin", "TREATMENT", 33, 45], ["rifampin", "TREATMENT", 47, 55], ["ciprofloxacin", "TREATMENT", 63, 76]]], ["Objectives: To analysed the features of spondylodiscitis (SD), their clinical presentation, the commonest diagnostic methods and the kind of treatment applied according to the different groups of the study.", [["spondylodiscitis", "DISEASE", 40, 56], ["SD", "DISEASE", 58, 60], ["spondylodiscitis", "PROBLEM", 40, 56], ["treatment", "TREATMENT", 141, 150], ["the study", "TEST", 196, 205], ["spondylodiscitis", "OBSERVATION", 40, 56]]], ["Methods: A retrospective and descriptive study taking place amongst the patients diagnosed as having SD from 1998 till 2003.", [["SD", "DISEASE", 101, 103], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["descriptive study", "TEST", 29, 46]]], ["In each case we studied the presence of underlying disease, primary infectious sources in the prior 6 months, the way symptoms started, location, diagnostic methods, treatment and evolution, comparing between different aetiologies.P1828Results: 67 patients with SD were studied.53 of them had pyogenic SD,(35 had spontaneous SD and 18 had an SD after spinal surgery) and 14 patients had tuberculous SD.", [["spinal", "ANATOMY", 351, 357], ["SD", "DISEASE", 262, 264], ["SD", "DISEASE", 302, 304], ["SD", "DISEASE", 325, 327], ["SD", "DISEASE", 342, 344], ["SD", "DISEASE", 399, 401], ["patients", "ORGANISM", 248, 256], ["patients", "ORGANISM", 374, 382], ["patients", "SPECIES", 248, 256], ["patients", "SPECIES", 374, 382], ["underlying disease", "PROBLEM", 40, 58], ["primary infectious sources", "PROBLEM", 60, 86], ["the way symptoms", "PROBLEM", 110, 126], ["diagnostic methods", "TEST", 146, 164], ["treatment", "TREATMENT", 166, 175], ["SD", "PROBLEM", 262, 264], ["pyogenic SD", "PROBLEM", 293, 304], ["spinal surgery", "TREATMENT", 351, 365], ["tuberculous SD", "PROBLEM", 387, 401], ["disease", "OBSERVATION", 51, 58], ["primary", "OBSERVATION_MODIFIER", 60, 67], ["infectious", "OBSERVATION", 68, 78], ["pyogenic", "OBSERVATION_MODIFIER", 293, 301], ["spinal", "ANATOMY", 351, 357], ["tuberculous SD", "OBSERVATION", 387, 401]]], ["45 were men (16 to 84 years; mean 51.8).", [["men", "ORGANISM", 8, 11], ["men", "SPECIES", 8, 11]]], ["Patients with postoperative SD were the youngest (mean 42.17 y, p = 0.001).", [["postoperative SD", "DISEASE", 14, 30], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Underlying diseases were found in 75% of patients, mainly in postoperative SD (50% of cases) (p = 0.009).", [["postoperative SD", "DISEASE", 61, 77], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Underlying diseases", "PROBLEM", 0, 19], ["diseases", "OBSERVATION", 11, 19]]], ["An episode of previous bacteremia or infectious source was found in 40% and 63% respectively of patients with spontaneous pyogenic SD, significantly higher than in surgical SD (6% had bacteremia and 11% other infectious source, p < 0.01).", [["bacteremia", "DISEASE", 23, 33], ["SD", "DISEASE", 131, 133], ["SD", "DISEASE", 173, 175], ["bacteremia", "DISEASE", 184, 194], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["previous bacteremia", "PROBLEM", 14, 33], ["infectious source", "PROBLEM", 37, 54], ["spontaneous pyogenic SD", "PROBLEM", 110, 133], ["surgical SD", "TEST", 164, 175], ["bacteremia", "PROBLEM", 184, 194], ["11% other infectious source", "PROBLEM", 199, 226], ["bacteremia", "OBSERVATION", 23, 33], ["infectious", "OBSERVATION_MODIFIER", 37, 47], ["spontaneous", "OBSERVATION_MODIFIER", 110, 121], ["pyogenic", "OBSERVATION", 122, 130], ["significantly", "OBSERVATION_MODIFIER", 135, 148], ["higher", "OBSERVATION_MODIFIER", 149, 155]]], ["The most common presenting symptoms were back pain (98.5%) and neurological deficits (54%).", [["back", "ANATOMY", 41, 45], ["neurological", "ANATOMY", 63, 75], ["back pain", "DISEASE", 41, 50], ["neurological deficits", "DISEASE", 63, 84], ["The most common presenting symptoms", "PROBLEM", 0, 35], ["back pain", "PROBLEM", 41, 50], ["neurological deficits", "PROBLEM", 63, 84]]], ["Frank fever occurred in 29% of cases, being more frequent in spontaneous SD (49%) than in postoperative SD (6%) or tuberculous SD (7%), p \u00a3 0.002.", [["fever", "DISEASE", 6, 11], ["SD", "DISEASE", 73, 75], ["postoperative SD", "DISEASE", 90, 106], ["tuberculous SD", "DISEASE", 115, 129], ["Frank fever", "PROBLEM", 0, 11], ["spontaneous SD", "PROBLEM", 61, 75], ["tuberculous SD", "PROBLEM", 115, 129], ["fever", "OBSERVATION", 6, 11], ["tuberculous", "OBSERVATION", 115, 126]]], ["Leukocytosis was found only in 28% of patients.", [["Leukocytosis", "DISEASE", 0, 12], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Leukocytosis", "PROBLEM", 0, 12]]], ["Postoperative SD presented the lowest levels of ESR (p = 0.008).", [["SD", "DISEASE", 14, 16], ["Postoperative SD", "PROBLEM", 0, 16], ["ESR", "TEST", 48, 51]]], ["S. aureus was the most frequent bacteria isolated (31%) in pyogenic spontaneous SD, as coagulase negative staphylococci was in surgical SD.", [["SD", "DISEASE", 80, 82], ["coagulase negative staphylococci", "DISEASE", 87, 119], ["SD", "DISEASE", 136, 138], ["S. aureus", "ORGANISM", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["the most frequent bacteria", "PROBLEM", 14, 40], ["pyogenic spontaneous SD", "PROBLEM", 59, 82], ["coagulase negative staphylococci", "PROBLEM", 87, 119], ["surgical SD", "PROBLEM", 127, 138], ["aureus", "OBSERVATION", 3, 9], ["most frequent", "OBSERVATION_MODIFIER", 18, 31], ["bacteria", "OBSERVATION_MODIFIER", 32, 40], ["pyogenic", "OBSERVATION_MODIFIER", 59, 67], ["spontaneous SD", "OBSERVATION", 68, 82], ["staphylococci", "OBSERVATION_MODIFIER", 106, 119], ["surgical SD", "OBSERVATION", 127, 138]]], ["Lumbosacral localization was detected in 45% of spontaneous pyogenic SD and in 95% of postoperative SD.", [["Lumbosacral", "ANATOMY", 0, 11], ["SD", "DISEASE", 69, 71], ["SD", "DISEASE", 100, 102], ["Lumbosacral localization", "TEST", 0, 24], ["spontaneous pyogenic SD", "PROBLEM", 48, 71], ["postoperative SD", "PROBLEM", 86, 102], ["pyogenic", "OBSERVATION_MODIFIER", 60, 68]]], ["Tuberculous SD predominate in dorsolumbar region.", [["dorsolumbar region", "ANATOMY", 30, 48], ["SD", "DISEASE", 12, 14], ["Tuberculous SD predominate in dorsolumbar region", "PROBLEM", 0, 48], ["dorsolumbar", "ANATOMY_MODIFIER", 30, 41], ["region", "ANATOMY_MODIFIER", 42, 48]]], ["Paravertebral abscess formation was observed in 39% of pyogenic SD and in 93% of tuberculous SD (p = 0.001).", [["Paravertebral abscess", "ANATOMY", 0, 21], ["Paravertebral abscess", "DISEASE", 0, 21], ["SD", "DISEASE", 64, 66], ["SD", "DISEASE", 93, 95], ["Paravertebral abscess", "PATHOLOGICAL_FORMATION", 0, 21], ["Paravertebral abscess formation", "PROBLEM", 0, 31], ["pyogenic SD", "PROBLEM", 55, 66], ["tuberculous SD", "PROBLEM", 81, 95], ["abscess", "OBSERVATION", 14, 21], ["pyogenic", "OBSERVATION_MODIFIER", 55, 63], ["tuberculous SD", "OBSERVATION", 81, 95]]], ["Surgical treatment was required in 46.2% of tuberculous SD and in 9% of pyogenic SD (p = 0.005).", [["SD", "DISEASE", 56, 58], ["SD", "DISEASE", 81, 83], ["Surgical treatment", "TREATMENT", 0, 18], ["tuberculous SD", "PROBLEM", 44, 58], ["pyogenic SD", "PROBLEM", 72, 83], ["tuberculous SD", "OBSERVATION", 44, 58], ["pyogenic", "OBSERVATION_MODIFIER", 72, 80]]], ["Outcome of patients with spontaneous SD was worse (sequelae in 62%), than in patients with surgical SD (38.2%) or tuberculous SD (14%) (p = 0.015).", [["SD", "DISEASE", 37, 39], ["SD", "DISEASE", 100, 102], ["SD", "DISEASE", 126, 128], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 77, 85], ["spontaneous SD", "PROBLEM", 25, 39], ["surgical SD", "PROBLEM", 91, 102], ["tuberculous SD", "PROBLEM", 114, 128], ["tuberculous", "OBSERVATION", 114, 125]]], ["Conclusions: 1) Spontaneous SD was the most frequent and it occurred mainly in patients suffering from underlying diseases; 2) Nearly all patients had pain but only in 1/3 of them was accompanied by fever; 3) The lumbar zone was the most frequent location; 4) The majority of patients had a complete resolution of their symptoms only with medical treatment.", [["lumbar zone", "ANATOMY", 213, 224], ["SD", "DISEASE", 28, 30], ["pain", "DISEASE", 151, 155], ["fever", "DISEASE", 199, 204], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 138, 146], ["lumbar zone", "MULTI-TISSUE_STRUCTURE", 213, 224], ["patients", "ORGANISM", 276, 284], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 276, 284], ["Spontaneous SD", "PROBLEM", 16, 30], ["underlying diseases", "PROBLEM", 103, 122], ["pain", "PROBLEM", 151, 155], ["fever", "PROBLEM", 199, 204], ["The lumbar zone", "PROBLEM", 209, 224], ["their symptoms", "PROBLEM", 314, 328], ["medical treatment", "TREATMENT", 339, 356], ["most frequent", "OBSERVATION_MODIFIER", 39, 52], ["diseases", "OBSERVATION", 114, 122], ["fever", "OBSERVATION", 199, 204], ["lumbar", "ANATOMY", 213, 219]]], ["Background: The ethiopathogenesis of CNS abscess includes a broad spectrum of pathogens and predisposing conditions, so that a polymicrobial flora is a quite frequent event.", [["CNS abscess", "ANATOMY", 37, 48], ["abscess", "DISEASE", 41, 48], ["polymicrobial", "DISEASE", 127, 140], ["CNS abscess", "PATHOLOGICAL_FORMATION", 37, 48], ["CNS abscess", "PROBLEM", 37, 48], ["pathogens", "PROBLEM", 78, 87], ["predisposing conditions", "PROBLEM", 92, 115], ["a polymicrobial flora", "PROBLEM", 125, 146], ["CNS", "ANATOMY", 37, 40], ["abscess", "OBSERVATION", 41, 48], ["pathogens", "OBSERVATION", 78, 87], ["polymicrobial", "OBSERVATION_MODIFIER", 127, 140], ["flora", "OBSERVATION", 141, 146]]], ["Capnocytophaga spp. includes fastidious Gram-negative organisms, usually underestimated in the common clinical practice, and poorly tested in vitro for antimicrobial susceptibility.", [["Capnocytophaga spp.", "SPECIES", 0, 19], ["Capnocytophaga spp.", "TREATMENT", 0, 19], ["fastidious Gram-negative organisms", "PROBLEM", 29, 63], ["antimicrobial susceptibility", "PROBLEM", 152, 180], ["negative organisms", "OBSERVATION", 45, 63], ["antimicrobial susceptibility", "OBSERVATION", 152, 180]]], ["Surprisingly, also agents usually active on Gram-positive pathogens demonstrated some efficacy against Capnocytophaga spp. (i.e. erythromycin, rifampin, tetracyclines, cotrimoxazole, chloramphenicol, and glycopeptides), which is usually responsible of anecdotal episodes of CNS infection (meningitis, brain abscess, and subdural empyema).", [["CNS", "ANATOMY", 274, 277], ["brain", "ANATOMY", 301, 306], ["subdural", "ANATOMY", 320, 328], ["erythromycin", "CHEMICAL", 129, 141], ["rifampin", "CHEMICAL", 143, 151], ["tetracyclines", "CHEMICAL", 153, 166], ["cotrimoxazole", "CHEMICAL", 168, 181], ["chloramphenicol", "CHEMICAL", 183, 198], ["CNS infection", "DISEASE", 274, 287], ["meningitis", "DISEASE", 289, 299], ["brain abscess", "DISEASE", 301, 314], ["subdural empyema", "DISEASE", 320, 336], ["erythromycin", "CHEMICAL", 129, 141], ["rifampin", "CHEMICAL", 143, 151], ["tetracyclines", "CHEMICAL", 153, 166], ["cotrimoxazole", "CHEMICAL", 168, 181], ["chloramphenicol", "CHEMICAL", 183, 198], ["erythromycin", "SIMPLE_CHEMICAL", 129, 141], ["rifampin", "SIMPLE_CHEMICAL", 143, 151], ["tetracyclines", "SIMPLE_CHEMICAL", 153, 166], ["cotrimoxazole", "SIMPLE_CHEMICAL", 168, 181], ["chloramphenicol", "SIMPLE_CHEMICAL", 183, 198], ["CNS", "ANATOMICAL_SYSTEM", 274, 277], ["brain", "ORGAN", 301, 306], ["subdural empyema", "PATHOLOGICAL_FORMATION", 320, 336], ["Capnocytophaga spp.", "SPECIES", 103, 122], ["Capnocytophaga spp.", "SPECIES", 103, 122], ["Gram-positive pathogens", "PROBLEM", 44, 67], ["Capnocytophaga spp.", "PROBLEM", 103, 122], ["erythromycin", "TREATMENT", 129, 141], ["rifampin", "TREATMENT", 143, 151], ["tetracyclines", "TREATMENT", 153, 166], ["cotrimoxazole", "TREATMENT", 168, 181], ["chloramphenicol", "TREATMENT", 183, 198], ["glycopeptides", "TREATMENT", 204, 217], ["CNS infection", "PROBLEM", 274, 287], ["meningitis", "PROBLEM", 289, 299], ["brain abscess", "PROBLEM", 301, 314], ["subdural empyema", "PROBLEM", 320, 336], ["CNS", "ANATOMY", 274, 277], ["infection", "OBSERVATION", 278, 287], ["meningitis", "OBSERVATION", 289, 299], ["brain", "ANATOMY", 301, 306], ["abscess", "OBSERVATION", 307, 314], ["subdural", "ANATOMY", 320, 328], ["empyema", "OBSERVATION", 329, 336]]], ["Methods and results: The fourth case report of Capnocytophaga spp. brain abscess is herewith reported.", [["brain abscess", "ANATOMY", 67, 80], ["brain abscess", "DISEASE", 67, 80], ["Capnocytophaga spp", "ORGANISM", 47, 65], ["brain", "ORGAN", 67, 72], ["Capnocytophaga spp", "PROBLEM", 47, 65], ["brain abscess", "PROBLEM", 67, 80], ["Capnocytophaga spp", "OBSERVATION", 47, 65], ["abscess", "OBSERVATION", 73, 80]]], ["A probable origin from a recent cat bite and a mandibular granuloma is suspected.", [["mandibular granuloma", "ANATOMY", 47, 67], ["cat bite", "DISEASE", 32, 40], ["mandibular granuloma", "DISEASE", 47, 67], ["cat", "ORGANISM", 32, 35], ["mandibular granuloma", "CANCER", 47, 67], ["a recent cat bite", "PROBLEM", 23, 40], ["a mandibular granuloma", "PROBLEM", 45, 67], ["probable", "UNCERTAINTY", 2, 10], ["origin", "ANATOMY_MODIFIER", 11, 17], ["cat bite", "OBSERVATION", 32, 40], ["mandibular", "ANATOMY", 47, 57], ["granuloma", "OBSERVATION", 58, 67]]], ["Due to the lack of clinical and neuroradiological response to neurosurgical debridement and an association therapy including imipenem, amikacin, clindamycin and fluconazole, empiric administration of linezolid (1200 mg/day) was attempted, and a rapidly favorable clinical, microbiological, and neuroradiological response was achieved.Conclusions:Notwithstanding the identification of Capnocytophaga spp. as the sole microorganism yielded by purulent drainage of a CNS abscess, patients with multiple risk factors and recent surgery are expected to suffer from a polymicrobial CNS infection.", [["CNS abscess", "ANATOMY", 464, 475], ["CNS", "ANATOMY", 576, 579], ["imipenem", "CHEMICAL", 125, 133], ["amikacin", "CHEMICAL", 135, 143], ["clindamycin", "CHEMICAL", 145, 156], ["fluconazole", "CHEMICAL", 161, 172], ["linezolid", "CHEMICAL", 200, 209], ["abscess", "DISEASE", 468, 475], ["infection", "DISEASE", 580, 589], ["imipenem", "CHEMICAL", 125, 133], ["amikacin", "CHEMICAL", 135, 143], ["clindamycin", "CHEMICAL", 145, 156], ["fluconazole", "CHEMICAL", 161, 172], ["linezolid", "CHEMICAL", 200, 209], ["imipenem", "SIMPLE_CHEMICAL", 125, 133], ["amikacin", "SIMPLE_CHEMICAL", 135, 143], ["clindamycin", "SIMPLE_CHEMICAL", 145, 156], ["fluconazole", "SIMPLE_CHEMICAL", 161, 172], ["linezolid", "SIMPLE_CHEMICAL", 200, 209], ["Capnocytophaga spp", "ORGANISM", 384, 402], ["CNS abscess", "PATHOLOGICAL_FORMATION", 464, 475], ["patients", "ORGANISM", 477, 485], ["CNS", "ANATOMICAL_SYSTEM", 576, 579], ["patients", "SPECIES", 477, 485], ["neurosurgical debridement", "TREATMENT", 62, 87], ["an association therapy", "TREATMENT", 92, 114], ["imipenem", "TREATMENT", 125, 133], ["amikacin", "TREATMENT", 135, 143], ["clindamycin", "TREATMENT", 145, 156], ["fluconazole", "TREATMENT", 161, 172], ["linezolid", "TREATMENT", 200, 209], ["Capnocytophaga spp", "PROBLEM", 384, 402], ["the sole microorganism", "PROBLEM", 407, 429], ["purulent drainage", "TREATMENT", 441, 458], ["a CNS abscess", "PROBLEM", 462, 475], ["multiple risk factors", "PROBLEM", 491, 512], ["recent surgery", "TREATMENT", 517, 531], ["a polymicrobial CNS infection", "PROBLEM", 560, 589], ["Capnocytophaga spp", "OBSERVATION", 384, 402], ["purulent", "OBSERVATION_MODIFIER", 441, 449], ["drainage", "OBSERVATION", 450, 458], ["CNS", "ANATOMY", 464, 467], ["abscess", "OBSERVATION", 468, 475], ["polymicrobial", "OBSERVATION_MODIFIER", 562, 575], ["CNS", "ANATOMY", 576, 579], ["infection", "OBSERVATION", 580, 589]]], ["Due to its favourable CNS penetration and its dual mode of administration (both i.v. and oral), linezolid may represent an alternative option in the event of CNS diseases borne by numerous risk factors and a suspected polymicrobial origin, especially when a lack of response to first therapeutic attempts is of concern.", [["CNS", "ANATOMY", 22, 25], ["oral", "ANATOMY", 89, 93], ["CNS", "ANATOMY", 158, 161], ["linezolid", "CHEMICAL", 96, 105], ["linezolid", "CHEMICAL", 96, 105], ["CNS", "ANATOMICAL_SYSTEM", 22, 25], ["oral", "ORGANISM_SUBDIVISION", 89, 93], ["linezolid", "SIMPLE_CHEMICAL", 96, 105], ["CNS", "ANATOMICAL_SYSTEM", 158, 161], ["its favourable CNS penetration", "PROBLEM", 7, 37], ["linezolid", "TREATMENT", 96, 105], ["an alternative option", "TREATMENT", 120, 141], ["CNS diseases", "PROBLEM", 158, 170], ["a suspected polymicrobial origin", "PROBLEM", 206, 238], ["favourable", "OBSERVATION_MODIFIER", 11, 21], ["CNS penetration", "OBSERVATION", 22, 37], ["CNS", "ANATOMY", 158, 161], ["diseases", "OBSERVATION", 162, 170], ["polymicrobial origin", "OBSERVATION", 218, 238]]], ["In the management of a CNS abscess where the role of microorganisms with an unpredictable sensitivity profile remains of concern, chemotherapy should be directed also against potentially multiresistant organisms.", [["CNS abscess", "ANATOMY", 23, 34], ["abscess", "DISEASE", 27, 34], ["CNS abscess", "PATHOLOGICAL_FORMATION", 23, 34], ["a CNS abscess", "PROBLEM", 21, 34], ["microorganisms", "PROBLEM", 53, 67], ["an unpredictable sensitivity profile", "TEST", 73, 109], ["chemotherapy", "TREATMENT", 130, 142], ["multiresistant organisms", "PROBLEM", 187, 211], ["CNS", "ANATOMY", 23, 26], ["abscess", "OBSERVATION", 27, 34]]], ["Considering also the relevant limitations given by the often poor CNS penetration, the activity of glycopeptide agents is limited, compared with that of linezolid.P1831Aetiologies and antimicrobial resistance profiles of purulent meningitis study carried out in a hospital of infectious diseases, Algiers Objectives: Bacterial meningitis is a serious clinical and medicolegal consequences if management is incorrect.", [["CNS", "ANATOMY", 66, 69], ["linezolid", "CHEMICAL", 153, 162], ["purulent meningitis", "DISEASE", 221, 240], ["infectious diseases", "DISEASE", 276, 295], ["meningitis", "DISEASE", 327, 337], ["linezolid", "CHEMICAL", 153, 162], ["CNS", "ANATOMICAL_SYSTEM", 66, 69], ["linezolid", "SIMPLE_CHEMICAL", 153, 162], ["the often poor CNS penetration", "PROBLEM", 51, 81], ["glycopeptide agents", "TREATMENT", 99, 118], ["linezolid", "TREATMENT", 153, 162], ["P1831Aetiologies", "TEST", 163, 179], ["antimicrobial resistance profiles", "TEST", 184, 217], ["purulent meningitis study", "PROBLEM", 221, 246], ["Bacterial meningitis", "PROBLEM", 317, 337], ["antimicrobial resistance", "OBSERVATION", 184, 208], ["purulent", "OBSERVATION_MODIFIER", 221, 229], ["meningitis", "OBSERVATION", 230, 240], ["infectious", "OBSERVATION", 276, 286], ["Bacterial", "OBSERVATION_MODIFIER", 317, 326], ["meningitis", "OBSERVATION", 327, 337]]], ["Meningitis protocols have recently been published by the British Infection Society/Meningitis Research Foundation and are widely disseminated in our institution.", [["Meningitis", "DISEASE", 0, 10], ["Meningitis", "DISEASE", 83, 93], ["Meningitis protocols", "TREATMENT", 0, 20], ["Meningitis", "PROBLEM", 83, 93], ["Infection", "OBSERVATION", 65, 74], ["Meningitis", "OBSERVATION", 83, 93], ["widely", "OBSERVATION_MODIFIER", 122, 128], ["disseminated", "OBSERVATION_MODIFIER", 129, 141]]], ["This study investigated the level of understanding about meningitis and knowledge of the guidelines in medical staff of different grades working in the emergency Department and the Acute Medical Admissions Unit in a large teaching and emergency hospital.", [["meningitis", "DISEASE", 57, 67], ["This study", "TEST", 0, 10], ["meningitis", "PROBLEM", 57, 67], ["meningitis", "OBSERVATION", 57, 67]]], ["Methods: 90 medical staff were interviewed faced to face and asked a series of questions on the management of meningitis.", [["meningitis", "DISEASE", 110, 120], ["the management", "TREATMENT", 92, 106], ["meningitis", "PROBLEM", 110, 120], ["meningitis", "OBSERVATION", 110, 120]]], ["Results were stored on a database and responses were analysed.", [["a database", "TEST", 23, 33]]], ["Results: General knowledge about meningitis was variable.", [["meningitis", "DISEASE", 33, 43], ["meningitis", "PROBLEM", 33, 43], ["meningitis", "OBSERVATION", 33, 43]]], ["Although 96% knew that bacterial meningitis was a notifiable disease only 40% knew the procedure for informing the Health Protection Agency and only 43% would notify viral meningitis.", [["meningitis", "DISEASE", 33, 43], ["meningitis", "DISEASE", 172, 182], ["bacterial meningitis", "PROBLEM", 23, 43], ["a notifiable disease", "PROBLEM", 48, 68], ["the procedure", "TREATMENT", 83, 96], ["viral meningitis", "PROBLEM", 166, 182], ["bacterial", "OBSERVATION_MODIFIER", 23, 32], ["meningitis", "OBSERVATION", 33, 43], ["meningitis", "OBSERVATION", 172, 182]]], ["Only 41% correctly identified the indications and cautions for lumbar puncture.", [["lumbar", "ANATOMY", 63, 69], ["lumbar puncture", "TEST", 63, 78], ["lumbar", "ANATOMY", 63, 69]]], ["Although the majority recognised the need for urgent administration of antibiotics 18% would omit antibiotics until further assessment and lumbar puncture results.", [["lumbar", "ANATOMY", 139, 145], ["lumbar puncture", "MULTI-TISSUE_STRUCTURE", 139, 154], ["urgent administration of antibiotics", "TREATMENT", 46, 82], ["antibiotics", "TREATMENT", 98, 109], ["further assessment", "TEST", 116, 134], ["lumbar puncture", "TEST", 139, 154], ["lumbar", "ANATOMY", 139, 145]]], ["Only 30% were aware of the need to consider adding ampicillin to cover listeria in patients over 55 years of age and there was uncertainty about the management of patients with penicillin resistance.", [["ampicillin", "CHEMICAL", 51, 61], ["penicillin", "CHEMICAL", 177, 187], ["ampicillin", "CHEMICAL", 51, 61], ["penicillin", "CHEMICAL", 177, 187], ["ampicillin", "SIMPLE_CHEMICAL", 51, 61], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 163, 171], ["penicillin", "SIMPLE_CHEMICAL", 177, 187], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 163, 171], ["ampicillin", "TREATMENT", 51, 61], ["listeria", "PROBLEM", 71, 79], ["the management", "TREATMENT", 145, 159], ["penicillin resistance", "TREATMENT", 177, 198], ["penicillin resistance", "OBSERVATION", 177, 198]]], ["Conclusions: Although protocols and guidelines for meningitis have been produced and are easily accessible the majority of medical staff were uncertain how to access and utilise this information.", [["meningitis", "DISEASE", 51, 61], ["protocols", "TEST", 22, 31], ["meningitis", "PROBLEM", 51, 61]]], ["The level of knowledge and expertise in managing meningitis amongst medical staff working in A and E and the Acute Medical Unit was poor and there is a need for further education to improve patient management.", [["meningitis", "DISEASE", 49, 59], ["patient", "ORGANISM", 190, 197], ["patient", "SPECIES", 190, 197], ["meningitis", "PROBLEM", 49, 59], ["further education", "TREATMENT", 161, 178], ["patient management", "TREATMENT", 190, 208]]], ["Objectives: The aim of this study was to evaluate the prevalence of penicillin resistant and multi-drug resistant pneumococci isolates in Streptococcus pneumoniae meningitis.", [["penicillin", "CHEMICAL", 68, 78], ["Streptococcus pneumoniae meningitis", "DISEASE", 138, 173], ["penicillin", "CHEMICAL", 68, 78], ["penicillin", "SIMPLE_CHEMICAL", 68, 78], ["pneumococci", "ORGANISM", 114, 125], ["Streptococcus pneumoniae", "ORGANISM", 138, 162], ["Streptococcus pneumoniae", "SPECIES", 138, 162], ["Streptococcus pneumoniae", "SPECIES", 138, 162], ["this study", "TEST", 23, 33], ["penicillin resistant and multi-drug resistant pneumococci isolates", "PROBLEM", 68, 134], ["Streptococcus pneumoniae meningitis", "PROBLEM", 138, 173], ["Streptococcus pneumoniae", "OBSERVATION", 138, 162]]], ["Methods: A retrospective study was carried out on 46 clinical records between January 2001 and October 2005.", [["A retrospective study", "TEST", 9, 30]]], ["Among the 46 CSF samples the pneumococcal ethiology was confirmed by 55% positive cultures and 70% Latex agglutination.", [["CSF samples", "ANATOMY", 13, 24], ["CSF samples", "CANCER", 13, 24], ["pneumococcal", "ORGANISM", 29, 41], ["pneumococcal", "SPECIES", 29, 41], ["CSF samples", "TEST", 13, 24], ["the pneumococcal ethiology", "TEST", 25, 51], ["positive cultures", "TEST", 73, 90], ["Latex agglutination", "TEST", 99, 118], ["Latex agglutination", "OBSERVATION", 99, 118]]], ["Antibiotic susceptibility testing was performed by disk diffusion method according to NCCLS standards.", [["Antibiotic susceptibility testing", "TEST", 0, 33], ["disk diffusion method", "TEST", 51, 72]]], ["Isolates of pneumococci with oxacillin zone sides of >20 mm are susceptible (MIC < 0.06 microg/ml) to penicillin, while at those of <19 mm the MIC has to be determined (by E -test).", [["oxacillin", "CHEMICAL", 29, 38], ["penicillin", "CHEMICAL", 102, 112], ["penicillin", "CHEMICAL", 102, 112], ["pneumococci", "CELL", 12, 23], ["penicillin", "SIMPLE_CHEMICAL", 102, 112], ["pneumococci", "PROBLEM", 12, 23], ["oxacillin zone sides", "TREATMENT", 29, 49], ["susceptible (MIC", "TREATMENT", 64, 80], ["penicillin", "TREATMENT", 102, 112], ["pneumococci", "OBSERVATION", 12, 23], ["20 mm", "OBSERVATION_MODIFIER", 54, 59]]], ["Results: Isolates from 12 patients (26%) were found with penicillin-resistance (PRP) -of which 67% were multi-drug resistant-and 34 (84%) with penicillin susceptibility -of which 35% were resistant to other drugs.", [["penicillin", "CHEMICAL", 57, 67], ["penicillin", "CHEMICAL", 143, 153], ["penicillin", "CHEMICAL", 57, 67], ["penicillin", "CHEMICAL", 143, 153], ["patients", "ORGANISM", 26, 34], ["penicillin", "SIMPLE_CHEMICAL", 57, 67], ["penicillin", "SIMPLE_CHEMICAL", 143, 153], ["patients", "SPECIES", 26, 34], ["Isolates", "TEST", 9, 17], ["penicillin", "TREATMENT", 57, 67], ["PRP", "TEST", 80, 83], ["penicillin susceptibility", "TEST", 143, 168], ["other drugs", "TREATMENT", 201, 212]]], ["An abrupt onset of disease was found in 58% PRP patients and 79% from non-PRP ones.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["An abrupt onset of disease", "PROBLEM", 0, 26], ["abrupt", "OBSERVATION_MODIFIER", 3, 9], ["onset", "OBSERVATION_MODIFIER", 10, 15], ["disease", "OBSERVATION", 19, 26]]], ["Chest X ray pulmonary determinations were found in 50% PRP patients and 35% non-PRP ones.", [["pulmonary", "ANATOMY", 12, 21], ["pulmonary", "ORGAN", 12, 21], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["Chest X ray pulmonary determinations", "TEST", 0, 36], ["35% non-PRP ones", "TREATMENT", 72, 88], ["pulmonary", "ANATOMY", 12, 21]]], ["Sixty-six per cent of PRP patients and 29% of non-PRP ones had a prior hospitalization.", [["PRP", "ORGANISM", 22, 25], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["Only 8% of non PRP patients had a positive blood culture.", [["blood", "ANATOMY", 43, 48], ["patients", "ORGANISM", 19, 27], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["patients", "SPECIES", 19, 27], ["a positive blood culture", "PROBLEM", 32, 56]]], ["Antibiotic switch was made in 41% cases with PRP isolates and 29% cases with non PRP ones.", [["Antibiotic switch", "TREATMENT", 0, 17], ["PRP isolates", "TREATMENT", 45, 57], ["non PRP ones", "TREATMENT", 77, 89]]], ["The overall rate of mortality was 8%, with 16% for PRP patients and 6% for non-PRP ones.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["PRP patients", "TREATMENT", 51, 63], ["non-PRP ones", "TREATMENT", 75, 87]]], ["Conclusions: Non-PRP isolates were the prevalent ethiology of S. pneumoniae meningitis.", [["S. pneumoniae meningitis", "DISEASE", 62, 86], ["Non-PRP", "GENE_OR_GENE_PRODUCT", 13, 20], ["S. pneumoniae", "ORGANISM", 62, 75], ["S. pneumoniae", "SPECIES", 62, 75], ["S. pneumoniae", "SPECIES", 62, 75], ["Non-PRP isolates", "TREATMENT", 13, 29], ["S. pneumoniae meningitis", "PROBLEM", 62, 86], ["pneumoniae", "OBSERVATION_MODIFIER", 65, 75], ["meningitis", "OBSERVATION", 76, 86]]], ["35% of non -PRP strains developed other drug resistance, and 67% PRP strains were multi -drug resistant.", [["other drug resistance", "PROBLEM", 34, 55], ["PRP strains", "TEST", 65, 76], ["drug resistance", "OBSERVATION", 40, 55]]], ["PRP meningites evolved more as a hospital-related pathology, with an abrupt onset, frequently associated with pulmonary determinations and higher mortality rate.", [["pulmonary", "ANATOMY", 110, 119], ["pulmonary", "ORGAN", 110, 119], ["PRP meningites", "PROBLEM", 0, 14], ["pulmonary determinations", "PROBLEM", 110, 134], ["higher mortality rate", "PROBLEM", 139, 160], ["abrupt", "OBSERVATION_MODIFIER", 69, 75], ["pulmonary", "ANATOMY", 110, 119]]], ["Background: Although vaccination strategies have shifted the age distribution of meningitis to older age groups, few studies have specifically examined bacterial meningitis in the older adult.", [["meningitis", "DISEASE", 81, 91], ["meningitis", "DISEASE", 162, 172], ["vaccination strategies", "TREATMENT", 21, 43], ["meningitis", "PROBLEM", 81, 91], ["few studies", "TEST", 113, 124], ["bacterial meningitis", "PROBLEM", 152, 172], ["meningitis", "OBSERVATION", 81, 91], ["bacterial", "OBSERVATION_MODIFIER", 152, 161], ["meningitis", "OBSERVATION", 162, 172]]], ["Methods: From October 1998 to April 2002, we prospectively included 696 episodes of community-acquired bacterial meningitis, confirmed by culture of cerebrospinal fluid, which occurred in patients aged >16 years.", [["cerebrospinal fluid", "ANATOMY", 149, 168], ["bacterial meningitis", "DISEASE", 103, 123], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 149, 168], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["community-acquired bacterial meningitis", "PROBLEM", 84, 123], ["cerebrospinal fluid", "PROBLEM", 149, 168], ["bacterial", "OBSERVATION_MODIFIER", 103, 112], ["meningitis", "OBSERVATION", 113, 123], ["cerebrospinal fluid", "OBSERVATION", 149, 168]]], ["We dichotomized the cohort with respect to age: patients aged \u202160 years were defined as older adults and patients aged 17-59 years as younger adults.", [["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 105, 113]]], ["Predictors for an unfavourable outcome (defined as score 1-4 on the Glasgow Outcome Scale) were determined by logistic regression.", [["an unfavourable outcome", "PROBLEM", 15, 38]]], ["The Mann-Whitney U test and the Chi-square test were used to identify differences between groups.", [["The Mann-Whitney U test", "TEST", 0, 23], ["the Chi-square test", "TEST", 28, 47]]], ["Streptococcus pneumoniae was the most common pathogen in older adults (69%).", [["Streptococcus pneumoniae", "DISEASE", 0, 24], ["Streptococcus pneumoniae", "ORGANISM", 0, 24], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "SPECIES", 0, 24], ["Streptococcus pneumoniae", "PROBLEM", 0, 24], ["pneumoniae", "OBSERVATION", 14, 24], ["most common", "OBSERVATION_MODIFIER", 33, 44]]], ["Meningitis in younger adults was caused by Neisseria meningitidis and S. pneumoniae in 50% and 40% of the episodes, respectively.", [["Meningitis", "DISEASE", 0, 10], ["Neisseria meningitidis and S. pneumoniae", "DISEASE", 43, 83], ["Neisseria meningitidis", "ORGANISM", 43, 65], ["S. pneumoniae", "ORGANISM", 70, 83], ["Neisseria meningitidis", "SPECIES", 43, 65], ["S. pneumoniae", "SPECIES", 70, 83], ["Neisseria meningitidis", "SPECIES", 43, 65], ["S. pneumoniae", "SPECIES", 70, 83], ["Meningitis", "PROBLEM", 0, 10], ["Neisseria meningitidis", "PROBLEM", 43, 65], ["S. pneumoniae", "PROBLEM", 70, 83], ["Neisseria meningitidis", "OBSERVATION", 43, 65], ["pneumoniae", "OBSERVATION", 73, 83]]], ["Older adults were more likely to present with the classic triad of bacterial meningitis (fever, neck stiffness and altered mental status) than younger adults (58% versus 36%; P < 0.001).", [["neck", "ANATOMY", 96, 100], ["bacterial meningitis", "DISEASE", 67, 87], ["fever", "DISEASE", 89, 94], ["neck stiffness", "DISEASE", 96, 110], ["adults", "ORGANISM", 6, 12], ["neck", "ORGANISM_SUBDIVISION", 96, 100], ["bacterial meningitis", "PROBLEM", 67, 87], ["fever", "PROBLEM", 89, 94], ["neck stiffness", "PROBLEM", 96, 110], ["altered mental status", "PROBLEM", 115, 136], ["bacterial", "OBSERVATION_MODIFIER", 67, 76], ["meningitis", "OBSERVATION", 77, 87], ["neck", "ANATOMY", 96, 100]]], ["The prognostic value of independent risk factors for unfavourable outcome was similar in both age groups.", [["independent risk factors", "PROBLEM", 24, 48], ["unfavourable outcome", "PROBLEM", 53, 73]]], ["Older adults had more complications during clinical course, resulting in a higher mortality rate than in younger adults (34% versus 13%; P < 0.001).", [["a higher mortality rate", "PROBLEM", 73, 96]]], ["Sepsis was the most common cause of death in both age groups (30% in older adults versus 32% in younger adults; Fig) .", [["Sepsis", "DISEASE", 0, 6], ["death", "DISEASE", 36, 41], ["Sepsis", "PROBLEM", 0, 6], ["death", "PROBLEM", 36, 41], ["most common", "OBSERVATION_MODIFIER", 15, 26]]], ["Whereas older adults tended to die more often due to cardiorespiratory failure (25% versus 11%; P = 0.06), younger adults more often died due to brain herniation (23% versus 2%; P = 0.004).P1831Conclusions: Bacterial meningitis in older adults is associated with high morbidity and mortality rates.", [["brain", "ANATOMY", 145, 150], ["cardiorespiratory failure", "DISEASE", 53, 78], ["brain herniation", "DISEASE", 145, 161], ["meningitis", "DISEASE", 217, 227], ["adults", "ORGANISM", 14, 20], ["brain", "ORGAN", 145, 150], ["cardiorespiratory failure", "PROBLEM", 53, 78], ["P", "TEST", 96, 97], ["brain herniation", "PROBLEM", 145, 161], ["Bacterial meningitis", "PROBLEM", 207, 227], ["high morbidity", "PROBLEM", 263, 277], ["mortality rates", "PROBLEM", 282, 297], ["cardiorespiratory", "ANATOMY", 53, 70], ["failure", "OBSERVATION", 71, 78], ["brain", "ANATOMY", 145, 150], ["herniation", "OBSERVATION", 151, 161], ["Bacterial", "OBSERVATION_MODIFIER", 207, 216], ["meningitis", "OBSERVATION", 217, 227], ["high", "OBSERVATION_MODIFIER", 263, 267], ["morbidity", "OBSERVATION", 268, 277]]], ["Elderly patients often present with classic symptoms and S. pneumoniae is the most common pathogen within this age group.", [["S. pneumoniae", "DISEASE", 57, 70], ["patients", "ORGANISM", 8, 16], ["S. pneumoniae", "ORGANISM", 57, 70], ["patients", "SPECIES", 8, 16], ["S. pneumoniae", "SPECIES", 57, 70], ["S. pneumoniae", "SPECIES", 57, 70], ["classic symptoms", "PROBLEM", 36, 52], ["S. pneumoniae", "PROBLEM", 57, 70], ["pneumoniae", "OBSERVATION", 60, 70], ["most common", "OBSERVATION_MODIFIER", 78, 89]]], ["Whereas older adults often die due to cardiorespiratory failure, younger adults more often die due to brain herniation.P1835Incidence of serogroups and penicillin susceptibility in Neisseria meningitidis isolates (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) Objective: The aim of this study was to analyse the serogroup incidence and penicillin susceptibility in N. meningitidis before and after Spanish epidemic outbreak in 1997.", [["brain", "ANATOMY", 102, 107], ["cardiorespiratory failure", "DISEASE", 38, 63], ["brain herniation", "DISEASE", 102, 118], ["penicillin", "CHEMICAL", 152, 162], ["penicillin", "CHEMICAL", 352, 362], ["penicillin", "CHEMICAL", 152, 162], ["penicillin", "CHEMICAL", 352, 362], ["adults", "ORGANISM", 14, 20], ["brain", "ORGAN", 102, 107], ["penicillin", "SIMPLE_CHEMICAL", 152, 162], ["Neisseria meningitidis isolates", "ORGANISM", 181, 212], ["penicillin", "SIMPLE_CHEMICAL", 352, 362], ["N. meningitidis", "ORGANISM", 381, 396], ["Neisseria meningitidis", "SPECIES", 181, 203], ["N. meningitidis", "SPECIES", 381, 396], ["Neisseria meningitidis", "SPECIES", 181, 203], ["N. meningitidis", "SPECIES", 381, 396], ["cardiorespiratory failure", "PROBLEM", 38, 63], ["brain herniation", "PROBLEM", 102, 118], ["serogroups", "PROBLEM", 137, 147], ["penicillin susceptibility in Neisseria meningitidis isolates", "PROBLEM", 152, 212], ["this study", "TEST", 298, 308], ["the serogroup incidence", "PROBLEM", 324, 347], ["penicillin susceptibility", "PROBLEM", 352, 377], ["meningitidis", "PROBLEM", 384, 396], ["cardiorespiratory", "ANATOMY", 38, 55], ["failure", "OBSERVATION", 56, 63], ["brain", "ANATOMY", 102, 107], ["herniation", "OBSERVATION", 108, 118], ["serogroups", "OBSERVATION_MODIFIER", 137, 147], ["penicillin susceptibility", "OBSERVATION_MODIFIER", 152, 177]]], ["In this year the Public Health Service decided a massive vaccination in our sanitary area (Galicia, north-west of Spain, 459.180 inhabitants) and in autum of 2000 the inclusion of vaccine against N. meningitidis serogroup C in vaccination programme.P1835Methods: Retrospective study of all cases of meningococcal disease confirmed by culture and/or PCR in the Health Care Area of Santiago de Compostela (Galicia) from 1996 to 2004.", [["meningococcal disease", "DISEASE", 299, 320], ["N. meningitidis serogroup C", "ORGANISM", 196, 223], ["N. meningitidis serogroup", "SPECIES", 196, 221], ["N. meningitidis", "SPECIES", 196, 211], ["meningococcal", "SPECIES", 299, 312], ["a massive vaccination", "TREATMENT", 47, 68], ["vaccine", "TREATMENT", 180, 187], ["N. meningitidis serogroup C in vaccination programme", "TREATMENT", 196, 248], ["Retrospective study", "TEST", 263, 282], ["meningococcal disease", "PROBLEM", 299, 320], ["culture", "TEST", 334, 341], ["PCR", "PROBLEM", 349, 352], ["massive", "OBSERVATION_MODIFIER", 49, 56], ["meningococcal disease", "OBSERVATION", 299, 320]]], ["Results: In the period 1996-2004 we identified 151 meningococcal disease episodes by microbiologic diagnosis (56.3%, 41.7% and 2.0% to B, C and W135 respectively).", [["meningococcal disease", "DISEASE", 51, 72], ["151 meningococcal disease episodes", "PROBLEM", 47, 81], ["microbiologic diagnosis", "TEST", 85, 108], ["B", "TEST", 135, 136], ["C", "TEST", 138, 139], ["meningococcal disease", "OBSERVATION", 51, 72]]], ["In 1996, serogroup C were the 80% of the isolates.", [["serogroup C", "ORGANISM", 9, 20], ["serogroup C", "TEST", 9, 20]]], ["In 1997 and 1998 the serogroup incidence was almost the same (B = 45.7%, C = 48.6%).", [["C", "TEST", 73, 74]]], ["From 1999 an increase in B serogroup cases were detected, in 1999 (66.6%), in 2000 (88.9%) and in 2003 (76.9%).", [["B serogroup cases", "TEST", 25, 42], ["increase", "OBSERVATION_MODIFIER", 13, 21]]], ["During this period an increase in penicillin susceptibility was observed (in B serogroup 0% in 1996 and 44% in 2004 of the isolates were susceptible and in C serogroup 0% in 1996 and 50% in 2004).", [["penicillin", "CHEMICAL", 34, 44], ["penicillin", "CHEMICAL", 34, 44], ["penicillin", "SIMPLE_CHEMICAL", 34, 44], ["an increase in penicillin susceptibility", "PROBLEM", 19, 59], ["the isolates", "TEST", 119, 131], ["increase", "OBSERVATION_MODIFIER", 22, 30], ["penicillin susceptibility", "OBSERVATION", 34, 59]]], ["Conclusions: The B serogroup is the most frecuent isolate during this period except in the years 1996 and 1997.", [["B", "GENE_OR_GENE_PRODUCT", 17, 18], ["B serogroup", "SPECIES", 17, 28]]], ["The strain that cause the epidemic outbreak in 1997 (C:2b P1:2.5) was not isolated since 2000.", [["The strain", "PROBLEM", 0, 10], ["epidemic", "OBSERVATION_MODIFIER", 26, 34]]], ["In our Health Care Area, C:2a serotype, was isolated for first time in 2000, and since then, is the unique serotype isolated in C serogroup.", [["C serogroup", "ORGANISM", 128, 139], ["a serotype", "PROBLEM", 28, 38]]], ["Incidence rate in C serogroup has changed from 3.34/100.000 in 1997 to 1.09/100.000 in 2004.", [["Incidence rate in C serogroup", "PROBLEM", 0, 29]]], ["The incidence rate in B serogroup during these years was modified from 1.48/100.000 in 1997 to 2.17/100.000 in 2004.P1836A four-year retrospective analysis of infective endocarditis in a Belgian university hospital N. de Visscher, B. Delaere, B. Krug, Y. Glupczynski (Yvoir, BE)P1836Objectives: To establish the epidemiology of infective endocarditis (IE) and determine the prognostic factors for adverse outcome in patients admitted to a university hospital with a cardiovascular surgery department.", [["cardiovascular", "ANATOMY", 466, 480], ["infective endocarditis", "DISEASE", 159, 181], ["infective endocarditis", "DISEASE", 328, 350], ["IE", "DISEASE", 352, 354], ["B serogroup", "ORGANISM", 22, 33], ["patients", "ORGANISM", 416, 424], ["patients", "SPECIES", 416, 424], ["The incidence rate in B serogroup", "PROBLEM", 0, 33], ["infective endocarditis", "PROBLEM", 159, 181], ["infective endocarditis", "PROBLEM", 328, 350], ["a cardiovascular surgery", "TREATMENT", 464, 488], ["infective", "OBSERVATION_MODIFIER", 159, 168], ["endocarditis", "OBSERVATION", 169, 181], ["infective", "OBSERVATION_MODIFIER", 328, 337], ["endocarditis", "OBSERVATION", 338, 350]]], ["Methods: Between 01/00 and 12/04, the clinical and laboratory features of all consecutive adult patients with a definite diagnosis of IE (Duke criteria) were evaluated retrospectively by two infectious diseases physicians on the basis of clinical data charts and microbiological laboratory.", [["IE", "DISEASE", 134, 136], ["infectious diseases", "DISEASE", 191, 210], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104]]], ["Results: 45 patients (24 men, 21 women) presented with a definite diagnosis of IE.", [["IE", "DISEASE", 79, 81], ["patients", "ORGANISM", 12, 20], ["men", "ORGANISM", 25, 28], ["women", "ORGANISM", 33, 38], ["patients", "SPECIES", 12, 20], ["men", "SPECIES", 25, 28], ["women", "SPECIES", 33, 38]]], ["Mean age was 64, 6 yrs; 34 cases (76%) were native valve endocarditis (NVE) and 11 (24%) were prosthetic valve endocarditis (PVE); 30% of patients with NVE had underlying valvular abnormalities (3 bicuspidies, 4 mitral prolapsus or regurgitation, 3 others).", [["valve", "ANATOMY", 51, 56], ["valve", "ANATOMY", 105, 110], ["valvular", "ANATOMY", 171, 179], ["bicuspidies", "ANATOMY", 197, 208], ["mitral", "ANATOMY", 212, 218], ["valve endocarditis", "DISEASE", 51, 69], ["NVE", "DISEASE", 71, 74], ["prosthetic valve endocarditis", "DISEASE", 94, 123], ["PVE", "DISEASE", 125, 128], ["NVE", "DISEASE", 152, 155], ["valvular abnormalities", "DISEASE", 171, 193], ["bicuspidies", "DISEASE", 197, 208], ["mitral prolapsus or regurgitation", "DISEASE", 212, 245], ["valve", "PATHOLOGICAL_FORMATION", 105, 110], ["patients", "ORGANISM", 138, 146], ["valvular", "ORGAN", 171, 179], ["patients", "SPECIES", 138, 146], ["Mean age", "TEST", 0, 8], ["cases", "TEST", 27, 32], ["native valve endocarditis", "PROBLEM", 44, 69], ["prosthetic valve endocarditis", "PROBLEM", 94, 123], ["PVE", "TEST", 125, 128], ["NVE", "PROBLEM", 152, 155], ["underlying valvular abnormalities", "PROBLEM", 160, 193], ["3 bicuspidies", "PROBLEM", 195, 208], ["4 mitral prolapsus", "PROBLEM", 210, 228], ["regurgitation", "PROBLEM", 232, 245], ["native valve", "ANATOMY", 44, 56], ["endocarditis", "OBSERVATION", 57, 69], ["prosthetic valve endocarditis", "OBSERVATION", 94, 123], ["valvular", "ANATOMY", 171, 179], ["abnormalities", "OBSERVATION", 180, 193], ["mitral prolapsus", "ANATOMY", 212, 228], ["regurgitation", "OBSERVATION", 232, 245]]], ["Ten out of 11 cases of PVE were late-onset episodes (>1 year after surgery).", [["PVE", "DISEASE", 23, 26], ["PVE", "PROBLEM", 23, 26], ["late-onset episodes", "PROBLEM", 32, 51], ["surgery", "TREATMENT", 67, 74]]], ["Global mortality was 42% (18/45 pts), including 15 patients (33%) still under antibiotic therapy.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Global mortality", "TEST", 0, 16], ["antibiotic therapy", "TREATMENT", 78, 96]]], ["A higher mortality rate was observed in PVE [7/11; (64%)] than in NVE [11/34; (32%)].", [["NVE", "DISEASE", 66, 69], ["A higher mortality rate", "PROBLEM", 0, 23], ["PVE", "TEST", 40, 43], ["higher", "OBSERVATION_MODIFIER", 2, 8]]], ["Overall, 18 pts (42%) underwent surgery (mean: 18 days following admission).", [["surgery", "TREATMENT", 32, 39]]], ["Valvular replacement was contra-indicated in 11 pts because of critical status and/or major co-morbidities.", [["Valvular", "ANATOMY", 0, 8], ["Valvular", "MULTI-TISSUE_STRUCTURE", 0, 8], ["Valvular replacement", "TREATMENT", 0, 20], ["major co-morbidities", "PROBLEM", 86, 106], ["replacement", "OBSERVATION", 9, 20]]], ["The distribution of isolated pathogens was: streptococci: 20 cases (44%) including 4 cases of S. bovis, S. aureus: 14 cases (31%, including 2 MRSA), Enterococci: 3 cases (7%), miscellaneous: 8 cases.", [["S. bovis", "DISEASE", 94, 102], ["S. aureus", "DISEASE", 104, 113], ["MRSA", "DISEASE", 142, 146], ["S. bovis", "ORGANISM", 94, 102], ["S. aureus", "ORGANISM", 104, 113], ["S. bovis", "SPECIES", 94, 102], ["S. aureus", "SPECIES", 104, 113], ["MRSA", "SPECIES", 142, 146], ["S. bovis", "SPECIES", 94, 102], ["S. aureus", "SPECIES", 104, 113], ["isolated pathogens", "PROBLEM", 20, 38], ["streptococci", "TEST", 44, 56], ["S. bovis", "TEST", 94, 102], ["S. aureus", "TEST", 104, 113], ["Enterococci", "TEST", 149, 160], ["isolated", "OBSERVATION_MODIFIER", 20, 28], ["pathogens", "OBSERVATION", 29, 38], ["bovis", "ANATOMY", 97, 102]]], ["The affected valves were: only aortic: 19 (43%), only mitral: 15 (33%), only tricuspidal: 1, aortic and mitral: 4, mitral and tricuspidal: 2, aortic, mitral and tricuspidal: 2.", [["valves", "ANATOMY", 13, 19], ["aortic", "ANATOMY", 31, 37], ["mitral", "ANATOMY", 54, 60], ["tricuspidal", "ANATOMY", 77, 88], ["aortic", "ANATOMY", 93, 99], ["mitral", "ANATOMY", 104, 110], ["mitral", "ANATOMY", 115, 121], ["tricuspidal", "ANATOMY", 126, 137], ["aortic", "ANATOMY", 142, 148], ["mitral", "ANATOMY", 150, 156], ["valves", "MULTI-TISSUE_STRUCTURE", 13, 19], ["aortic", "MULTI-TISSUE_STRUCTURE", 31, 37], ["mitral", "MULTI-TISSUE_STRUCTURE", 54, 60], ["aortic", "MULTI-TISSUE_STRUCTURE", 93, 99], ["mitral", "MULTI-TISSUE_STRUCTURE", 115, 121], ["aortic", "MULTI-TISSUE_STRUCTURE", 142, 148], ["mitral", "MULTI-TISSUE_STRUCTURE", 150, 156], ["aortic", "TEST", 31, 37], ["mitral", "TEST", 54, 60], ["affected valves", "ANATOMY", 4, 19], ["aortic", "ANATOMY", 31, 37], ["mitral", "ANATOMY", 54, 60], ["aortic", "ANATOMY", 93, 99], ["mitral", "OBSERVATION", 104, 110], ["mitral", "OBSERVATION", 115, 121], ["aortic", "ANATOMY", 142, 148], ["mitral", "OBSERVATION", 150, 156]]], ["A high mortality rate was observed in S. aureus IE (9/14 [64%]), especially in the subgroup of patients with a PVE (4/5 pts [80%] ).", [["S. aureus IE", "DISEASE", 38, 50], ["PVE", "DISEASE", 111, 114], ["S. aureus IE", "ORGANISM", 38, 50], ["patients", "ORGANISM", 95, 103], ["S. aureus", "SPECIES", 38, 47], ["patients", "SPECIES", 95, 103], ["S. aureus", "SPECIES", 38, 47], ["A high mortality rate", "PROBLEM", 0, 21], ["S. aureus IE", "PROBLEM", 38, 50], ["a PVE", "TEST", 109, 114], ["aureus", "OBSERVATION", 41, 47]]], ["The mortality rate in patients with IE episodes caused by Streptococci amounted 21% (5/24 pts).P1836Clinical Microbiology and Infection, Volume 12, Supplement 4, 2006 related, 20% (n = 40) had previous surgery and 9% (n = 19) were related to urinary or digestive tract procedures.", [["urinary", "ANATOMY", 242, 249], ["digestive tract", "ANATOMY", 253, 268], ["IE", "DISEASE", 36, 38], ["Infection", "DISEASE", 126, 135], ["urinary or digestive tract", "DISEASE", 242, 268], ["patients", "ORGANISM", 22, 30], ["urinary", "ORGANISM_SUBDIVISION", 242, 249], ["digestive tract", "ORGANISM_SUBDIVISION", 253, 268], ["patients", "SPECIES", 22, 30], ["The mortality rate", "TEST", 0, 18], ["IE episodes", "PROBLEM", 36, 47], ["Streptococci", "TEST", 58, 70], ["P1836Clinical Microbiology", "TEST", 95, 121], ["Infection", "PROBLEM", 126, 135], ["Volume", "TEST", 137, 143], ["previous surgery", "TREATMENT", 193, 209], ["urinary or digestive tract procedures", "PROBLEM", 242, 279], ["Infection", "OBSERVATION", 126, 135], ["urinary", "ANATOMY", 242, 249], ["digestive tract", "ANATOMY", 253, 268]]], ["Only 2 patients had illegal substance abuse.", [["substance abuse", "DISEASE", 28, 43], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["substance abuse", "OBSERVATION", 28, 43]]], ["The most frequent predisposing acquired cardiac condition for native valve endocarditis was degenerative valvular disease in 55% (71/ 129).", [["cardiac", "ANATOMY", 40, 47], ["valve", "ANATOMY", 69, 74], ["valvular", "ANATOMY", 105, 113], ["valve endocarditis", "DISEASE", 69, 87], ["degenerative valvular disease", "DISEASE", 92, 121], ["cardiac", "ORGAN", 40, 47], ["valvular", "ORGAN", 105, 113], ["The most frequent predisposing acquired cardiac condition", "PROBLEM", 0, 57], ["native valve endocarditis", "PROBLEM", 62, 87], ["degenerative valvular disease", "PROBLEM", 92, 121], ["cardiac", "ANATOMY", 40, 47], ["condition", "OBSERVATION", 48, 57], ["native valve", "ANATOMY", 62, 74], ["endocarditis", "OBSERVATION", 75, 87], ["degenerative", "OBSERVATION_MODIFIER", 92, 104], ["valvular", "ANATOMY", 105, 113]]], ["Twelve percentage (n = 24) had prior IE.", [["IE", "DISEASE", 37, 39], ["Twelve percentage", "TEST", 0, 17]]], ["The most frequent predisposing congenital cardiac condition was a bicuspid aortic valve in 5% (n = 11).", [["cardiac", "ANATOMY", 42, 49], ["aortic", "ANATOMY", 75, 81], ["congenital cardiac condition", "DISEASE", 31, 59], ["bicuspid aortic valve", "DISEASE", 66, 87], ["cardiac", "ORGAN", 42, 49], ["aortic valve", "PATHOLOGICAL_FORMATION", 75, 87], ["The most frequent predisposing congenital cardiac condition", "PROBLEM", 0, 59], ["a bicuspid aortic valve", "TREATMENT", 64, 87], ["congenital", "OBSERVATION", 31, 41], ["cardiac", "ANATOMY", 42, 49], ["condition", "OBSERVATION", 50, 59], ["bicuspid", "OBSERVATION", 66, 74], ["aortic valve", "ANATOMY", 75, 87]]], ["In 16% (n = 32), no predisposing heart disease was discernible.", [["heart", "ANATOMY", 33, 38], ["heart disease", "DISEASE", 33, 46], ["heart", "ORGAN", 33, 38], ["predisposing heart disease", "PROBLEM", 20, 46], ["no", "UNCERTAINTY", 17, 19], ["heart", "ANATOMY", 33, 38], ["disease", "OBSERVATION", 39, 46]]], ["Causative microorganisms included: Staphylococci in 43% (n = 87) with S. aureus in 31% (n = 62), CoNS in 12% (n = 25), Streptococci in 26% (n = 52) with S. viridans in 12% (n = 25), S. bovis in 8% (n = 16), Enterococci in 17% (n = 34) and other pathogens in 3% (n = 7).", [["Staphylococci", "DISEASE", 35, 48], ["S. aureus", "DISEASE", 70, 79], ["CoNS", "DISEASE", 97, 101], ["Streptococci", "DISEASE", 119, 131], ["S. viridans", "DISEASE", 153, 164], ["S. aureus", "ORGANISM", 70, 79], ["S. viridans", "ORGANISM", 153, 164], ["S. bovis", "ORGANISM", 182, 190], ["S. aureus", "SPECIES", 70, 79], ["S. viridans", "SPECIES", 153, 164], ["S. bovis", "SPECIES", 182, 190], ["S. aureus", "SPECIES", 70, 79], ["S. viridans", "SPECIES", 153, 164], ["S. bovis", "SPECIES", 182, 190], ["Causative microorganisms", "PROBLEM", 0, 24], ["Staphylococci", "PROBLEM", 35, 48], ["S. aureus", "TEST", 70, 79], ["CoNS", "TEST", 97, 101], ["Streptococci", "TEST", 119, 131], ["S. viridans", "TEST", 153, 164], ["S. bovis", "TEST", 182, 190], ["Enterococci", "TEST", 207, 218], ["other pathogens", "TEST", 239, 254], ["Staphylococci", "OBSERVATION", 35, 48], ["aureus", "OBSERVATION", 73, 79]]], ["Culture negative IE was reported in 11% (n = 23).", [["Culture", "TEST", 0, 7]]], ["Both in community-acquired and nosocomial IE, S. aureus was the most frequent causative agent.", [["nosocomial IE", "DISEASE", 31, 44], ["S. aureus", "ORGANISM", 46, 55], ["S. aureus", "SPECIES", 46, 55], ["S. aureus", "SPECIES", 46, 55], ["S. aureus", "PROBLEM", 46, 55], ["aureus", "OBSERVATION", 49, 55]]], ["Twenty-three percentage (14/62) were methicillin-resistant S. aureus.", [["methicillin", "CHEMICAL", 37, 48], ["methicillin", "CHEMICAL", 37, 48], ["S. aureus", "ORGANISM", 59, 68], ["S. aureus", "SPECIES", 59, 68], ["S. aureus", "SPECIES", 59, 68], ["methicillin-resistant S. aureus", "PROBLEM", 37, 68], ["aureus", "OBSERVATION", 62, 68]]], ["S. viridans IE was mainly community-acquired while enterococcal IE was nearly equally distributed between community and nosocomial origin.", [["S. viridans IE", "ORGANISM", 0, 14], ["S. viridans", "SPECIES", 0, 11], ["S. viridans", "SPECIES", 0, 11], ["S. viridans IE", "PROBLEM", 0, 14], ["enterococcal IE", "TREATMENT", 51, 66], ["viridans", "OBSERVATION", 3, 11], ["enterococcal", "OBSERVATION", 51, 63], ["nosocomial origin", "OBSERVATION", 120, 137]]], ["Conclusion: Compared to older series, we observed a high proportion of nosocomial IE and of prosthetic valve IE.", [["valve", "ANATOMY", 103, 108], ["IE", "DISEASE", 82, 84], ["prosthetic valve IE", "DISEASE", 92, 111], ["nosocomial IE", "TREATMENT", 71, 84], ["prosthetic valve IE", "TREATMENT", 92, 111], ["nosocomial", "OBSERVATION", 71, 81], ["prosthetic valve", "OBSERVATION", 92, 108]]], ["S. aureus and E. faecalis were the most prevalent causative microorganisms.", [["S. aureus", "ORGANISM", 0, 9], ["E. faecalis", "ORGANISM", 14, 25], ["S. aureus", "SPECIES", 0, 9], ["E. faecalis", "SPECIES", 14, 25], ["S. aureus", "SPECIES", 0, 9], ["E. faecalis", "SPECIES", 14, 25], ["S. aureus", "PROBLEM", 0, 9], ["E. faecalis", "PROBLEM", 14, 25], ["aureus", "OBSERVATION", 3, 9], ["E. faecalis", "OBSERVATION", 14, 25], ["most prevalent", "OBSERVATION_MODIFIER", 35, 49]]], ["Enterococci were nearly equally distributed between community and nosocomial origin, suggesting that nosocomial enterococcemia should be added as a major criterion, as proposed before for S. aureus.P1840The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials M. Falagas, D. Matthaiou, P. Papastamataki, I. Bliziotis (Athens, GR)P1840Objectives: The addition of an aminoglycoside to a beta-lactam for the treatment of patients with infective endocarditis has been supported mainly from data from laboratory and animal studies.", [["nosocomial", "DISEASE", 66, 76], ["nosocomial enterococcemia", "DISEASE", 101, 126], ["P1840", "CHEMICAL", 198, 203], ["aminoglycosides", "CHEMICAL", 215, 230], ["beta-lactam", "CHEMICAL", 253, 264], ["bacterial endocarditis", "DISEASE", 286, 308], ["aminoglycoside", "CHEMICAL", 453, 467], ["beta-lactam", "CHEMICAL", 473, 484], ["infective endocarditis", "DISEASE", 520, 542], ["P1840", "CHEMICAL", 198, 203], ["aminoglycosides", "CHEMICAL", 215, 230], ["beta-lactam", "CHEMICAL", 253, 264], ["aminoglycoside", "CHEMICAL", 453, 467], ["beta-lactam", "CHEMICAL", 473, 484], ["Enterococci", "ORGANISM_SUBSTANCE", 0, 11], ["S. aureus", "ORGANISM", 188, 197], ["aminoglycosides", "SIMPLE_CHEMICAL", 215, 230], ["beta-lactam", "SIMPLE_CHEMICAL", 253, 264], ["aminoglycoside", "SIMPLE_CHEMICAL", 453, 467], ["beta-lactam", "SIMPLE_CHEMICAL", 473, 484], ["patients", "ORGANISM", 506, 514], ["P1840", "PROTEIN", 198, 203], ["S. aureus", "SPECIES", 188, 197], ["patients", "SPECIES", 506, 514], ["S. aureus", "SPECIES", 188, 197], ["Enterococci", "PROBLEM", 0, 11], ["nosocomial enterococcemia", "PROBLEM", 101, 126], ["S. aureus", "PROBLEM", 188, 197], ["aminoglycosides", "TREATMENT", 215, 230], ["a beta-lactam", "TREATMENT", 251, 264], ["bacterial endocarditis", "PROBLEM", 286, 308], ["an aminoglycoside", "TREATMENT", 450, 467], ["a beta-lactam", "TREATMENT", 471, 484], ["the treatment", "TREATMENT", 489, 502], ["infective endocarditis", "PROBLEM", 520, 542], ["animal studies", "TEST", 599, 613], ["nosocomial origin", "OBSERVATION", 66, 83], ["nosocomial", "OBSERVATION", 101, 111], ["aureus", "OBSERVATION", 191, 197], ["bacterial", "OBSERVATION_MODIFIER", 286, 295], ["endocarditis", "OBSERVATION", 296, 308], ["infective", "OBSERVATION_MODIFIER", 520, 529], ["endocarditis", "OBSERVATION", 530, 542]]], ["We sought to review the evidence from the available comparative clinical trials regarding the role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis due to Gram-positive cocci.", [["aminoglycosides", "CHEMICAL", 102, 117], ["beta-lactam", "CHEMICAL", 140, 151], ["bacterial endocarditis", "DISEASE", 173, 195], ["aminoglycosides", "CHEMICAL", 102, 117], ["beta-lactam", "CHEMICAL", 140, 151], ["aminoglycosides", "SIMPLE_CHEMICAL", 102, 117], ["beta-lactam", "SIMPLE_CHEMICAL", 140, 151], ["aminoglycosides", "TREATMENT", 102, 117], ["a beta-lactam", "TREATMENT", 138, 151], ["bacterial endocarditis", "PROBLEM", 173, 195], ["Gram-positive cocci", "PROBLEM", 203, 222], ["bacterial endocarditis", "OBSERVATION", 173, 195], ["positive cocci", "OBSERVATION", 208, 222]]], ["Methods: The studies for our meta-analysis were retrieved from searches of the PubMed database and from references of relevant articles.", [["The studies", "TEST", 9, 20], ["our meta-analysis", "TEST", 25, 42], ["the PubMed database", "TEST", 75, 94]]], ["Included studies were trials that provided comparative data regarding the effectiveness of the treatment and/or mortality in patients receiving monotherapy with a betalactam or beta-lactam/aminoglycoside combination therapy.", [["betalactam", "CHEMICAL", 163, 173], ["beta-lactam", "CHEMICAL", 177, 188], ["aminoglycoside", "CHEMICAL", 189, 203], ["betalactam", "CHEMICAL", 163, 173], ["beta-lactam", "CHEMICAL", 177, 188], ["aminoglycoside", "CHEMICAL", 189, 203], ["patients", "ORGANISM", 125, 133], ["betalactam", "SIMPLE_CHEMICAL", 163, 173], ["beta-lactam", "SIMPLE_CHEMICAL", 177, 188], ["aminoglycoside", "SIMPLE_CHEMICAL", 189, 203], ["patients", "SPECIES", 125, 133], ["Included studies", "TEST", 0, 16], ["comparative data", "TEST", 43, 59], ["the treatment", "TREATMENT", 91, 104], ["monotherapy", "TREATMENT", 144, 155], ["a betalactam", "TREATMENT", 161, 173], ["beta-lactam", "TREATMENT", 177, 188], ["aminoglycoside combination therapy", "TREATMENT", 189, 223]]], ["Two independent reviewers performed the literature search, study selection, and extraction of data from relevant studies published in English during the period 01/1975-08/2005.", [["study selection", "TEST", 59, 74]]], ["Results: No clinical trial comparing beta-lactam monotherapy to beta-lactam/aminoglycoside combination therapy for the treatment of enterococcal endocarditis was found.", [["beta-lactam", "CHEMICAL", 37, 48], ["beta-lactam", "CHEMICAL", 64, 75], ["aminoglycoside", "CHEMICAL", 76, 90], ["enterococcal endocarditis", "DISEASE", 132, 157], ["beta-lactam", "CHEMICAL", 37, 48], ["beta-lactam", "CHEMICAL", 64, 75], ["aminoglycoside", "CHEMICAL", 76, 90], ["beta-lactam", "SIMPLE_CHEMICAL", 37, 48], ["beta-lactam", "SIMPLE_CHEMICAL", 64, 75], ["aminoglycoside", "SIMPLE_CHEMICAL", 76, 90], ["beta-lactam monotherapy", "TREATMENT", 37, 60], ["beta-lactam", "TREATMENT", 64, 75], ["aminoglycoside combination therapy", "TREATMENT", 76, 110], ["enterococcal endocarditis", "PROBLEM", 132, 157], ["No", "UNCERTAINTY", 9, 11], ["enterococcal", "OBSERVATION_MODIFIER", 132, 144], ["endocarditis", "OBSERVATION", 145, 157]]], ["We performed a meta-analysis of 5 available comparative trials (4 randomized controlled trials and 1 comparative prospective trial) that included 261 patients with bacterial endocarditis in native valves due to Staphylococcus. aureus (4 studies) or Streptococcus viridans (1 study).", [["bacterial endocarditis", "DISEASE", 164, 186], ["Streptococcus viridans", "DISEASE", 249, 271], ["patients", "ORGANISM", 150, 158], ["valves", "PATHOLOGICAL_FORMATION", 197, 203], ["aureus", "ORGANISM", 227, 233], ["Streptococcus viridans", "ORGANISM", 249, 271], ["patients", "SPECIES", 150, 158], ["aureus", "SPECIES", 227, 233], ["Streptococcus viridans", "SPECIES", 249, 271], ["aureus", "SPECIES", 227, 233], ["Streptococcus viridans", "SPECIES", 249, 271], ["a meta-analysis", "TEST", 13, 28], ["4 randomized controlled trials", "TREATMENT", 64, 94], ["bacterial endocarditis in native valves", "PROBLEM", 164, 203], ["Staphylococcus", "PROBLEM", 211, 225], ["aureus", "PROBLEM", 227, 233], ["Streptococcus viridans", "PROBLEM", 249, 271], ["bacterial", "OBSERVATION_MODIFIER", 164, 173], ["endocarditis", "OBSERVATION", 174, 186], ["native valves", "OBSERVATION", 190, 203], ["Staphylococcus", "OBSERVATION", 211, 225]]], ["There was no statistically significant difference between the compared arms regarding mortality (OR 0.59, CI 95% 0.21-1.66), treatment success (OR = 1.25, CI 95% 0.49-3.05), treatment success without surgery (OR = 1.66, , and relapse of endocarditis (OR = 0.79, .", [["endocarditis", "DISEASE", 237, 249], ["mortality", "TEST", 86, 95], ["CI", "TEST", 106, 108], ["CI", "TEST", 155, 157], ["surgery", "TREATMENT", 200, 207], ["endocarditis", "PROBLEM", 237, 249], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49], ["endocarditis", "OBSERVATION", 237, 249]]], ["Nephrotoxicity was less common in the beta-lactam monotherapy arm compared to the beta-lactam/aminoglycoside combination therapy (OR = 0.38, CI 95% 0.16-0.88, p = 0.024).", [["Nephrotoxicity", "DISEASE", 0, 14], ["beta-lactam", "CHEMICAL", 38, 49], ["beta-lactam", "CHEMICAL", 82, 93], ["aminoglycoside", "CHEMICAL", 94, 108], ["beta-lactam", "CHEMICAL", 38, 49], ["aminoglycoside", "CHEMICAL", 94, 108], ["beta-lactam", "SIMPLE_CHEMICAL", 38, 49], ["beta-lactam", "SIMPLE_CHEMICAL", 82, 93], ["aminoglycoside", "SIMPLE_CHEMICAL", 94, 108], ["Nephrotoxicity", "PROBLEM", 0, 14], ["the beta-lactam monotherapy arm", "TREATMENT", 34, 65], ["the beta-lactam/aminoglycoside combination therapy", "TREATMENT", 78, 128], ["CI", "TEST", 141, 143], ["less common", "OBSERVATION_MODIFIER", 19, 30]]], ["Conclusion: The limited evidence from the available prospective comparative studies does not offer support for the addition of an aminoglycoside to beta-lactam treatment of patients with endocarditis due to Gram-positive cocci.", [["aminoglycoside", "CHEMICAL", 130, 144], ["beta-lactam", "CHEMICAL", 148, 159], ["endocarditis", "DISEASE", 187, 199], ["aminoglycoside", "CHEMICAL", 130, 144], ["beta-lactam", "CHEMICAL", 148, 159], ["aminoglycoside", "SIMPLE_CHEMICAL", 130, 144], ["beta-lactam", "SIMPLE_CHEMICAL", 148, 159], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["the available prospective comparative studies", "TEST", 38, 83], ["support", "TREATMENT", 99, 106], ["an aminoglycoside", "TREATMENT", 127, 144], ["beta-lactam treatment", "TREATMENT", 148, 169], ["endocarditis", "PROBLEM", 187, 199], ["Gram-positive cocci", "PROBLEM", 207, 226], ["endocarditis", "OBSERVATION", 187, 199], ["positive cocci", "OBSERVATION", 212, 226]]], ["A large multicenter randomized controlled trial may be necessary to reach a definitive conclusion on this issue.P1841Outpatient antimicrobial therapy for infective endocarditis.", [["P1841Outpatient", "CHEMICAL", 112, 127], ["infective endocarditis", "DISEASE", 154, 176], ["A large multicenter randomized controlled trial", "TREATMENT", 0, 47], ["antimicrobial therapy", "TREATMENT", 128, 149], ["infective endocarditis", "PROBLEM", 154, 176], ["large", "OBSERVATION_MODIFIER", 2, 7], ["infective", "OBSERVATION_MODIFIER", 154, 163], ["endocarditis", "OBSERVATION", 164, 176]]], ["Single-centre experience Objectives: To evaluate the characteristics and outcome of infective endocarditis (IE) patients included in a Outpatient antimicrobial therapy (OPAT) program.", [["infective endocarditis", "DISEASE", 84, 106], ["IE", "DISEASE", 108, 110], ["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["infective endocarditis", "PROBLEM", 84, 106], ["a Outpatient antimicrobial therapy", "TREATMENT", 133, 167], ["infective", "OBSERVATION_MODIFIER", 84, 93], ["endocarditis", "OBSERVATION", 94, 106]]], ["Methods: From January 1997 to May 2005 all patients who received OPAT therapy for an IE were prospectively evaluated.", [["OPAT", "CHEMICAL", 65, 69], ["OPAT", "CHEMICAL", 65, 69], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["OPAT therapy", "TREATMENT", 65, 77]]], ["Inclusion in OPAT program require clinical stability and agreement of patients.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["Active drug addiction was contraindicated for inclusion.", [["drug addiction", "DISEASE", 7, 21]]], ["Antibiotic treatment was administered in bolus for once-daily antibiotics regimens.", [["Antibiotic treatment", "TREATMENT", 0, 20], ["daily antibiotics regimens", "TREATMENT", 56, 82]]], ["USA) portable infusion system for either continuous or intermittentprogrammed bolus infusion.", [["portable infusion system", "TREATMENT", 5, 29], ["continuous or intermittentprogrammed bolus infusion", "TREATMENT", 41, 92]]], ["Results: We included 65 patients, 51 male (78%), mean age 60 years old (SD: 19.3 years).", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32]]], ["The diagnostic of IE was definite in 45 cases (13 with pathologic diagnosis), 15 probable and 5 possible.", [["IE", "DISEASE", 18, 20], ["pathologic diagnosis", "TEST", 55, 75]]], ["Mostly of the cases were community-acquired IE (83%).", [["IE", "DISEASE", 44, 46]]], ["Mitral valve IE was the most frequent anatomical site involved (46%), followed by aortic (32%).", [["Mitral valve", "ANATOMY", 0, 12], ["site", "ANATOMY", 49, 53], ["aortic", "ANATOMY", 82, 88], ["aortic", "MULTI-TISSUE_STRUCTURE", 82, 88], ["Mitral valve IE", "TREATMENT", 0, 15], ["aortic", "TEST", 82, 88], ["valve", "ANATOMY", 7, 12], ["aortic", "ANATOMY", 82, 88]]], ["Native-valve IE represent the majority of cases (55%), but 32% were prostheticvalve and 12% were pacemaker lead IE.", [["prostheticvalve", "DISEASE", 68, 83], ["prostheticvalve", "CANCER", 68, 83], ["Native-valve", "TREATMENT", 0, 12], ["pacemaker lead IE", "TREATMENT", 97, 114], ["valve", "OBSERVATION", 7, 12]]], ["Viridans group streptococci was the most frequent isolate (31 patients, 48%) with 4 cases of S. bovis IE.", [["Viridans", "CHEMICAL", 0, 8], ["S. bovis IE", "DISEASE", 93, 104], ["patients", "ORGANISM", 62, 70], ["S. bovis", "ORGANISM", 93, 101], ["Viridans group streptococci", "SPECIES", 0, 27], ["patients", "SPECIES", 62, 70], ["S. bovis", "SPECIES", 93, 101], ["S. bovis", "SPECIES", 93, 101], ["Viridans group streptococci", "PROBLEM", 0, 27], ["group streptococci", "OBSERVATION", 9, 27], ["bovis", "OBSERVATION", 96, 101]]], ["Eleven patients had S. aureus IE (17%).", [["S. aureus IE", "DISEASE", 20, 32], ["patients", "ORGANISM", 7, 15], ["S. aureus IE", "ORGANISM", 20, 32], ["patients", "SPECIES", 7, 15], ["S. aureus", "SPECIES", 20, 29], ["S. aureus", "SPECIES", 20, 29], ["S. aureus IE", "PROBLEM", 20, 32], ["aureus", "OBSERVATION", 23, 29]]], ["At the time of the diagnosis, 10 patients had valve rupture and 4 patients had periannular abscess.", [["valve", "ANATOMY", 46, 51], ["periannular abscess", "ANATOMY", 79, 98], ["valve rupture", "DISEASE", 46, 59], ["abscess", "DISEASE", 91, 98], ["patients", "ORGANISM", 33, 41], ["valve", "PATHOLOGICAL_FORMATION", 46, 51], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 66, 74], ["valve rupture", "PROBLEM", 46, 59], ["periannular abscess", "PROBLEM", 79, 98], ["valve", "ANATOMY", 46, 51], ["rupture", "OBSERVATION", 52, 59], ["periannular", "ANATOMY", 79, 90], ["abscess", "OBSERVATION", 91, 98]]], ["A total of 15 patients required some surgical intervention for the IE [9 valvular replacement (2 of them associated with aortic graft), 5 pacemaker extraction and 1 aortic graft].", [["valvular", "ANATOMY", 73, 81], ["aortic", "ANATOMY", 121, 127], ["aortic", "ANATOMY", 165, 171], ["IE", "DISEASE", 67, 69], ["patients", "ORGANISM", 14, 22], ["aortic graft", "MULTI-TISSUE_STRUCTURE", 121, 133], ["aortic graft", "TISSUE", 165, 177], ["patients", "SPECIES", 14, 22], ["some surgical intervention", "TREATMENT", 32, 58], ["the IE [9 valvular replacement", "TREATMENT", 63, 93], ["aortic graft", "TREATMENT", 121, 133], ["5 pacemaker extraction", "TREATMENT", 136, 158], ["1 aortic graft", "TREATMENT", 163, 177], ["valvular", "ANATOMY", 73, 81], ["replacement", "OBSERVATION", 82, 93], ["aortic", "ANATOMY", 121, 127], ["graft", "OBSERVATION", 128, 133], ["aortic", "ANATOMY", 165, 171], ["graft", "OBSERVATION", 172, 177]]], ["The majority of the patients received outpatient monotherapy (65%).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["outpatient monotherapy", "TREATMENT", 38, 60], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["The most frequent antibiotic used was Ceftriaxone (55% of the cases), followed by cloxacillin 20%, gentamycin 20%, vancomycin 14%, teicoplanin 14%, ampicillin 8% and other antibiotics in 14%.", [["Ceftriaxone", "CHEMICAL", 38, 49], ["cloxacillin", "CHEMICAL", 82, 93], ["gentamycin", "CHEMICAL", 99, 109], ["vancomycin", "CHEMICAL", 115, 125], ["teicoplanin", "CHEMICAL", 131, 142], ["ampicillin", "CHEMICAL", 148, 158], ["Ceftriaxone", "CHEMICAL", 38, 49], ["cloxacillin", "CHEMICAL", 82, 93], ["gentamycin", "CHEMICAL", 99, 109], ["vancomycin", "CHEMICAL", 115, 125], ["teicoplanin", "CHEMICAL", 131, 142], ["ampicillin", "CHEMICAL", 148, 158], ["Ceftriaxone", "SIMPLE_CHEMICAL", 38, 49], ["cloxacillin", "SIMPLE_CHEMICAL", 82, 93], ["gentamycin", "SIMPLE_CHEMICAL", 99, 109], ["vancomycin", "SIMPLE_CHEMICAL", 115, 125], ["teicoplanin", "SIMPLE_CHEMICAL", 131, 142], ["ampicillin", "SIMPLE_CHEMICAL", 148, 158], ["The most frequent antibiotic", "TREATMENT", 0, 28], ["Ceftriaxone", "TREATMENT", 38, 49], ["cloxacillin", "TREATMENT", 82, 93], ["gentamycin", "TREATMENT", 99, 109], ["vancomycin", "TREATMENT", 115, 125], ["teicoplanin", "TREATMENT", 131, 142], ["ampicillin", "TREATMENT", 148, 158], ["other antibiotics", "TREATMENT", 166, 183]]], ["In 60% of the patients the vascular access was a perifericallyinserted venous central catheter and in 26% we used a portable infusion system.", [["vascular", "ANATOMY", 27, 35], ["venous", "ANATOMY", 71, 77], ["patients", "ORGANISM", 14, 22], ["vascular", "MULTI-TISSUE_STRUCTURE", 27, 35], ["patients", "SPECIES", 14, 22], ["a perifericallyinserted venous central catheter", "TREATMENT", 47, 94], ["a portable infusion system", "TREATMENT", 114, 140], ["vascular", "ANATOMY", 27, 35], ["venous", "ANATOMY", 71, 77], ["central catheter", "OBSERVATION", 78, 94]]], ["Twelve patients (18%) had some complication during OPAT that require hospital readmission, of which 5 could return to OPAT program.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["some complication", "PROBLEM", 26, 43], ["complication", "OBSERVATION", 31, 43]]], ["Three patients had a fatal outcome (deaths) during admission, not related to IE complications.", [["deaths", "DISEASE", 36, 42], ["IE", "DISEASE", 77, 79], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["IE complications", "PROBLEM", 77, 93]]], ["The mean duration of OPAT was 18.9 days per patient, and globally supposed 1.230 days of hospital admission savings.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["hospital admission savings", "TREATMENT", 89, 115], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Conclusion: OPAT for IE can be a good therapeutic option for IE stable patients.", [["OPAT", "CHEMICAL", 12, 16], ["IE", "DISEASE", 21, 23], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79]]], ["This procedure can represent a considerable amount of hospital admissions savings, improving also patients' well-being, and must be take into account for the treatment of this disease.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["This procedure", "TREATMENT", 0, 14], ["this disease", "PROBLEM", 171, 183], ["considerable", "OBSERVATION_MODIFIER", 31, 43], ["amount", "OBSERVATION_MODIFIER", 44, 50], ["disease", "OBSERVATION", 176, 183]]], ["Objectives: Botulism, a neuroparalytic illness, is caused by toxin produced by clostridium botulinum.", [["Botulism", "DISEASE", 12, 20], ["neuroparalytic illness", "DISEASE", 24, 46], ["clostridium botulinum", "ORGANISM", 79, 100], ["clostridium botulinum", "SPECIES", 79, 100], ["clostridium botulinum", "SPECIES", 79, 100], ["Botulism", "PROBLEM", 12, 20], ["a neuroparalytic illness", "PROBLEM", 22, 46], ["clostridium botulinum", "PROBLEM", 79, 100], ["Botulism", "OBSERVATION", 12, 20]]], ["Food born botulism, a potentially lethal neuroparalytic disease, is caused by ingestion of preformed toxin.", [["botulism", "DISEASE", 10, 18], ["neuroparalytic disease", "DISEASE", 41, 63], ["Food born botulism", "PROBLEM", 0, 18], ["a potentially lethal neuroparalytic disease", "PROBLEM", 20, 63], ["botulism", "OBSERVATION", 10, 18]]], ["Clinical illness is characterised by cranial nerve paralysis, followed by descending flaccid muscle paralysis.", [["cranial nerve", "ANATOMY", 37, 50], ["muscle", "ANATOMY", 93, 99], ["illness", "DISEASE", 9, 16], ["cranial nerve paralysis", "DISEASE", 37, 60], ["muscle paralysis", "DISEASE", 93, 109], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 37, 50], ["muscle", "ORGAN", 93, 99], ["Clinical illness", "PROBLEM", 0, 16], ["cranial nerve paralysis", "PROBLEM", 37, 60], ["descending flaccid muscle paralysis", "PROBLEM", 74, 109], ["cranial nerve", "ANATOMY", 37, 50], ["paralysis", "OBSERVATION", 51, 60], ["descending", "ANATOMY_MODIFIER", 74, 84], ["flaccid muscle", "ANATOMY", 85, 99], ["paralysis", "OBSERVATION", 100, 109]]], ["In this article we report a case series including a family group of type E botulism after ingestion of an Iranian traditional soup.", [["botulism", "DISEASE", 75, 83], ["type E botulism", "PROBLEM", 68, 83]]], ["Methods: In January 2005, 11 patients of a family group developed clinical manifestations of botulism 1-2 hours following ingestion of a traditional soup.", [["botulism", "DISEASE", 93, 101], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["botulism", "PROBLEM", 93, 101], ["a traditional soup", "TREATMENT", 135, 153]]], ["Their main clinical presentations were severe weakness (90.9%-10 case) and lethargy (72.8%-8 case).", [["weakness", "DISEASE", 46, 54], ["lethargy", "DISEASE", 75, 83], ["severe weakness", "PROBLEM", 39, 54], ["lethargy", "PROBLEM", 75, 83], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["weakness", "OBSERVATION", 46, 54]]], ["Other signs and symptoms were blurred vision, fixed and dilated pupils, diplopia, dry mouth and decreased gag reflex.", [["mouth", "ANATOMY", 86, 91], ["blurred vision", "DISEASE", 30, 44], ["diplopia", "DISEASE", 72, 80], ["dry mouth", "DISEASE", 82, 91], ["decreased gag reflex", "DISEASE", 96, 116], ["mouth", "ORGANISM_SUBDIVISION", 86, 91], ["Other signs and symptoms", "PROBLEM", 0, 24], ["blurred vision", "PROBLEM", 30, 44], ["fixed and dilated pupils", "PROBLEM", 46, 70], ["diplopia", "PROBLEM", 72, 80], ["dry mouth", "PROBLEM", 82, 91], ["decreased gag reflex", "PROBLEM", 96, 116], ["dilated", "OBSERVATION_MODIFIER", 56, 63], ["pupils", "OBSERVATION", 64, 70], ["diplopia", "OBSERVATION", 72, 80], ["mouth", "ANATOMY", 86, 91], ["decreased", "OBSERVATION_MODIFIER", 96, 105], ["gag reflex", "OBSERVATION", 106, 116]]], ["Based on clinical finding, all patients received 3 monovalent antitoxins (A, B, C).", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["3 monovalent antitoxins", "TREATMENT", 49, 72]]], ["Stool, gastric fluid and serum samples were sent for toxicological evaluation using the standard mouse bioassay.", [["Stool", "ANATOMY", 0, 5], ["gastric fluid", "ANATOMY", 7, 20], ["serum samples", "ANATOMY", 25, 38], ["Stool", "ORGANISM_SUBSTANCE", 0, 5], ["gastric fluid", "ORGANISM_SUBSTANCE", 7, 20], ["serum samples", "ORGANISM_SUBSTANCE", 25, 38], ["mouse", "ORGANISM", 97, 102], ["mouse", "SPECIES", 97, 102], ["mouse", "SPECIES", 97, 102], ["Stool, gastric fluid", "TEST", 0, 20], ["serum samples", "TEST", 25, 38], ["toxicological evaluation", "TEST", 53, 77], ["the standard mouse bioassay", "TREATMENT", 84, 111], ["gastric", "ANATOMY", 7, 14], ["fluid", "OBSERVATION", 15, 20]]], ["Results: Type E toxin was detected in the stool and serum sample of only one patient.", [["stool", "ANATOMY", 42, 47], ["serum sample", "ANATOMY", 52, 64], ["Type E toxin", "GENE_OR_GENE_PRODUCT", 9, 21], ["stool", "ORGANISM_SUBSTANCE", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["patient", "ORGANISM", 77, 84], ["Type E toxin", "PROTEIN", 9, 21], ["patient", "SPECIES", 77, 84], ["Type E toxin", "TEST", 9, 21], ["serum sample", "TEST", 52, 64], ["stool", "ANATOMY", 42, 47]]], ["All patients recovered and discharged one week after admission.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Conclusion: This study confirmed that prompt administration of antitoxin can prevent progression of disease based on clinical judgment and also may be life saving.", [["antitoxin", "PROTEIN", 63, 72], ["This study", "TEST", 12, 22], ["antitoxin", "TREATMENT", 63, 72], ["disease", "PROBLEM", 100, 107], ["clinical judgment", "TEST", 117, 134]]], ["In this case series study, we observed a short incubation period of 1-2 hours only in type E botulism.P1843An outbreak of group G streptococcal pharyngitis among hospital personnel considered to be foodborne N. Karabiber, A. Gurbuz Ertas, M. Karahan, E. Aykut Arca, Z.C. Karahan, A. Tekeli (Ankara, TR) Introduction: Food-born outbreaks of streptococcal pharyngitis are relatively rarely reported,and while Group A streptococci are the main causative agents, only a few epidemics caused by Group G streptococci have been published.", [["botulism", "DISEASE", 93, 101], ["streptococcal pharyngitis", "DISEASE", 130, 155], ["streptococcal pharyngitis", "DISEASE", 340, 365], ["Group A streptococci", "ORGANISM", 407, 427], ["Group G streptococci", "ORGANISM", 490, 510], ["series study", "TEST", 13, 25], ["type E botulism", "PROBLEM", 86, 101], ["group G streptococcal pharyngitis", "PROBLEM", 122, 155], ["streptococcal pharyngitis", "PROBLEM", 340, 365], ["a few epidemics", "PROBLEM", 464, 479], ["Group G streptococci", "PROBLEM", 490, 510], ["botulism", "OBSERVATION", 93, 101], ["Arca", "ANATOMY", 260, 264], ["streptococcal pharyngitis", "OBSERVATION", 340, 365]]], ["We describe here an outbreak of Group G streptococcal pharyngitis occurred among the staff of a teaching hospital in Ankara.The outbreak: An explosive outbreak of pharyngitis occured mainly among the staff working in certain departments (i.e. Intensive Care Units, Operation Rooms) of T\u00fc rkiye Y\u00fc ksek Ihtisas Teaching Hospital, in 29 January 2004.", [["streptococcal pharyngitis", "DISEASE", 40, 65], ["pharyngitis", "DISEASE", 163, 174], ["Group G streptococcal pharyngitis", "PROBLEM", 32, 65], ["pharyngitis", "PROBLEM", 163, 174], ["streptococcal", "OBSERVATION_MODIFIER", 40, 53], ["pharyngitis", "OBSERVATION", 54, 65], ["explosive", "OBSERVATION_MODIFIER", 141, 150], ["outbreak", "OBSERVATION_MODIFIER", 151, 159], ["pharyngitis", "OBSERVATION", 163, 174]]], ["Methods: A total of 377 (111 and 266; 3 and 47 from catering firm personel) throat cultures were evaluated in 2 days,and 124 BHS strains were isolated, 65 and 59 on the first and the second days, respectively.", [["throat cultures", "ANATOMY", 76, 91], ["throat cultures", "TEST", 76, 91], ["BHS strains", "TEST", 125, 136], ["throat", "ANATOMY", 76, 82]]], ["Presumptive identification by nbacitracin and trimethoprim/sulfametoxazole disk diffusion test showed that 121 strains were non-Group A, 3 strains were Group A streptococci.", [["nbacitracin", "CHEMICAL", 30, 41], ["trimethoprim", "CHEMICAL", 46, 58], ["sulfametoxazole", "CHEMICAL", 59, 74], ["nbacitracin", "CHEMICAL", 30, 41], ["trimethoprim", "CHEMICAL", 46, 58], ["sulfametoxazole", "CHEMICAL", 59, 74], ["nbacitracin", "SIMPLE_CHEMICAL", 30, 41], ["trimethoprim", "SIMPLE_CHEMICAL", 46, 58], ["sulfametoxazole", "SIMPLE_CHEMICAL", 59, 74], ["nbacitracin", "TREATMENT", 30, 41], ["trimethoprim/sulfametoxazole disk diffusion test", "TEST", 46, 94], ["121 strains", "PROBLEM", 107, 118], ["non-Group A", "PROBLEM", 124, 135], ["3 strains", "PROBLEM", 137, 146], ["Group A streptococci", "PROBLEM", 152, 172]]], ["In definite grouping by Streptococcus Grouping Kit (Avipath-Strep,OMEGA),121 strains were found to be Lancefield Group G,3 strains were found to be Group A streptococci (GAS).", [["GAS", "CANCER", 170, 173], ["Streptococcus Grouping Kit", "TEST", 24, 50], ["Avipath", "TEST", 52, 59], ["121 strains", "PROBLEM", 73, 84], ["Lancefield Group G", "TEST", 102, 120], ["3 strains", "PROBLEM", 121, 130], ["streptococci", "OBSERVATION", 156, 168]]], ["One of the GAS strains was isolated from a catering staff on the first day, the other two were isolated from two health care personnels on the second day.", [["the GAS strains", "PROBLEM", 7, 22], ["GAS strains", "OBSERVATION", 11, 22]]], ["During the outbreak, 16 of 50 catering firm personel (32%) were found to positive for Group G streptococci.", [["Group G streptococci", "PROBLEM", 86, 106]]], ["All the BHS tested were found sensitive to penicillin G and erythromycin by agar disc diffusion method.", [["penicillin", "CHEMICAL", 43, 53], ["erythromycin", "CHEMICAL", 60, 72], ["penicillin G", "CHEMICAL", 43, 55], ["erythromycin", "CHEMICAL", 60, 72], ["penicillin G", "SIMPLE_CHEMICAL", 43, 55], ["erythromycin", "SIMPLE_CHEMICAL", 60, 72], ["All the BHS", "TEST", 0, 11], ["penicillin G", "TREATMENT", 43, 55], ["erythromycin", "TREATMENT", 60, 72]]], ["Conclusions: The configuration of the epidemic curve suggested a common source of exposure.", [["the epidemic curve", "TEST", 34, 52]]], ["Since respiratory spread of streptococci in such a rapid fashion would be highly unlikely and that 16 of 121 positive throat culture were from the staff of the catering firm that provide all the food services for the hospital, and that most of them were working at the departments in which the outbreak occurred, we considered that the outbreak might be food-borne.", [["respiratory", "ANATOMY", 6, 17], ["streptococci", "PROBLEM", 28, 40], ["positive throat culture", "TEST", 109, 132], ["streptococci", "OBSERVATION", 28, 40]]], ["Prompt treatment with penicillin all the ill personnel and 9-day holiday coming consequently 30 January, terminated the outbreak.", [["penicillin", "CHEMICAL", 22, 32], ["penicillin", "CHEMICAL", 22, 32], ["penicillin", "SIMPLE_CHEMICAL", 22, 32], ["penicillin", "TREATMENT", 22, 32]]], ["All the strains were cryopreserved for further typing studies.We are now typing these strains by Pulsed Field Gel Electophoresis (PFGE) after digestion with SmaI restriction endonuclease.", [["SmaI restriction endonuclease", "GENE_OR_GENE_PRODUCT", 157, 186], ["SmaI restriction endonuclease", "PROTEIN", 157, 186], ["further typing studies", "TEST", 39, 61], ["SmaI restriction endonuclease", "TREATMENT", 157, 186]]], ["Our initial results show that these strains are of the same origin.P1844Outbreak of acute gastroenteritis in an air force base in Western Greece E. Jelastopulu, T. Constantinidis, T. Kolokotronis, D. Venieri, G. Komninou, C. Bantias (Patras, Andravida, GR)P1844Objectives: On 20 September 2005, an operative training day at the Air Force base in Western Greece, soldiers and staff experienced an outbreak of acute gastroenteritis.", [["gastroenteritis", "DISEASE", 90, 105], ["gastroenteritis", "DISEASE", 414, 429], ["these strains", "PROBLEM", 30, 43], ["acute gastroenteritis", "PROBLEM", 84, 105], ["an operative training", "TREATMENT", 295, 316], ["acute gastroenteritis", "PROBLEM", 408, 429], ["strains", "OBSERVATION", 36, 43], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["gastroenteritis", "OBSERVATION", 90, 105], ["air force", "OBSERVATION", 112, 121], ["acute", "OBSERVATION_MODIFIER", 408, 413], ["gastroenteritis", "OBSERVATION", 414, 429]]], ["The purpose of this study was to determine the causes of the outbreak and develop control measures.", [["this study", "TEST", 15, 25], ["the outbreak", "PROBLEM", 57, 69]]], ["Methods: Following the assessment of descriptive epidemiology, a case-control analytic approach was utilized with 100 randomly selected cases and 66 controls.", [["the assessment", "TEST", 19, 33], ["a case-control analytic approach", "TREATMENT", 63, 95]]], ["Patients completed a questionnaire pertaining to the presence and severity of gastrointestinal disturbances, date and time of symptoms onset and consumption of food items served in the base on the implied training day.", [["gastrointestinal", "ANATOMY", 78, 94], ["gastrointestinal disturbances", "DISEASE", 78, 107], ["Patients", "ORGANISM", 0, 8], ["gastrointestinal", "ORGAN", 78, 94], ["Patients", "SPECIES", 0, 8], ["gastrointestinal disturbances", "PROBLEM", 78, 107], ["symptoms", "PROBLEM", 126, 134], ["gastrointestinal", "ANATOMY", 78, 94], ["base", "ANATOMY_MODIFIER", 185, 189]]], ["Odds ratios were calculated and statistical significance was determined using x2 test.", [["Odds ratios", "TEST", 0, 11], ["x2 test", "TEST", 78, 85]]], ["Samples of food items were collected for bacteriological examination.", [["Samples", "ANATOMY", 0, 7], ["Samples of food items", "TEST", 0, 21], ["bacteriological examination", "TEST", 41, 68]]], ["Results: The overall attack rate was at least 50% among the approximately 1050 attendees.", [["The overall attack rate", "TEST", 9, 32]]], ["From the interviews and the analysis it was established that the lunch (beef, macaroni, tomato sauce and grated cheese) consumed several hours prior to onset of symptoms by affected military personnel was the likely source of the outbreak with a strong statistical association.", [["macaroni, tomato sauce", "CHEMICAL", 78, 100], ["beef", "ORGANISM_SUBDIVISION", 72, 76], ["tomato", "ORGANISM", 88, 94], ["sauce", "ORGANISM_SUBDIVISION", 95, 100], ["cheese", "ORGANISM_SUBDIVISION", 112, 118], ["beef", "SPECIES", 72, 76], ["tomato", "SPECIES", 88, 94], ["sauce", "SPECIES", 95, 100], ["beef", "SPECIES", 72, 76], ["tomato", "SPECIES", 88, 94], ["the analysis", "TEST", 24, 36], ["macaroni, tomato sauce", "TREATMENT", 78, 100], ["symptoms", "PROBLEM", 161, 169], ["the outbreak", "PROBLEM", 226, 238]]], ["Among the symptoms the most prominent were watery diarrhoea (96%) and abdominal pain (73%).", [["abdominal", "ANATOMY", 70, 79], ["watery diarrhoea", "DISEASE", 43, 59], ["abdominal pain", "DISEASE", 70, 84], ["abdominal", "ORGANISM_SUBDIVISION", 70, 79], ["the symptoms", "PROBLEM", 6, 18], ["watery diarrhoea", "PROBLEM", 43, 59], ["abdominal pain", "PROBLEM", 70, 84], ["most prominent", "OBSERVATION_MODIFIER", 23, 37], ["watery", "OBSERVATION_MODIFIER", 43, 49], ["diarrhoea", "OBSERVATION", 50, 59], ["abdominal", "ANATOMY", 70, 79]]], ["Relatively few indicated vomiting (8%) and nausea (7%).", [["vomiting", "DISEASE", 25, 33], ["nausea", "DISEASE", 43, 49], ["vomiting", "PROBLEM", 25, 33], ["nausea", "PROBLEM", 43, 49], ["few", "OBSERVATION_MODIFIER", 11, 14], ["vomiting", "OBSERVATION", 25, 33]]], ["In the bacteriological examination, Staphylococcus aureus was detected in a sample of raw beef and in two samples of grated cheese (rest-cheese from lunch and an unopened package).", [["samples", "ANATOMY", 106, 113], ["Staphylococcus aureus", "DISEASE", 36, 57], ["Staphylococcus aureus", "ORGANISM", 36, 57], ["Staphylococcus aureus", "SPECIES", 36, 57], ["beef", "SPECIES", 90, 94], ["Staphylococcus aureus", "SPECIES", 36, 57], ["beef", "SPECIES", 90, 94], ["the bacteriological examination", "TEST", 3, 34], ["Staphylococcus aureus", "PROBLEM", 36, 57], ["Staphylococcus aureus", "OBSERVATION", 36, 57]]], ["Conclusion: The short incubation period with abrupt onset, the symptomatology and the short, self-limiting nature of the illness, are suggestive of gastroenteritis caused by an enterotoxin-producing bacterium.", [["illness", "DISEASE", 121, 128], ["gastroenteritis", "DISEASE", 148, 163], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 177, 188], ["enterotoxin", "PROTEIN", 177, 188], ["abrupt onset", "PROBLEM", 45, 57], ["the symptomatology", "PROBLEM", 59, 77], ["the illness", "PROBLEM", 117, 128], ["gastroenteritis", "PROBLEM", 148, 163], ["an enterotoxin-producing bacterium", "PROBLEM", 174, 208], ["abrupt", "OBSERVATION_MODIFIER", 45, 51], ["suggestive of", "UNCERTAINTY", 134, 147], ["gastroenteritis", "OBSERVATION", 148, 163]]], ["S. aureus is considered to be the most likely cause.", [["S. aureus", "DISEASE", 0, 9], ["S. aureus", "ORGANISM", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["aureus", "OBSERVATION", 3, 9], ["considered to be the most likely", "UNCERTAINTY", 13, 45]]], ["Although mortality and longer-term morbidity are uncommon with food poisoning caused by enterotoxin-producing bacteria, this outbreak highlights its capacity to cause short term, moderately-severe illness in a young and healthy population.", [["food poisoning", "DISEASE", 63, 77], ["illness", "DISEASE", 197, 204], ["enterotoxin", "GENE_OR_GENE_PRODUCT", 88, 99], ["enterotoxin", "PROTEIN", 88, 99], ["mortality and longer-term morbidity", "PROBLEM", 9, 44], ["food poisoning", "PROBLEM", 63, 77], ["enterotoxin", "PROBLEM", 88, 99], ["bacteria", "PROBLEM", 110, 118], ["moderately-severe illness", "PROBLEM", 179, 204], ["short term", "OBSERVATION_MODIFIER", 167, 177], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["illness", "OBSERVATION", 197, 204]]], ["It underscores the need for proper food handling practices and reinforces the importance of appropriate microbiological specimen collection from cases, as well as the public health importance of timely notification of such outbreaks.P1845Occurrence, characterisation and antimicrobial resistance pattern of Staphylococcus aureus strains isolated from dairy products in southern Italy G. La Salandra, E. Goffredo, C. Pedarra, M.C. Nardella, A. Parisi, A. Dambrosio, N.C. Quaglia, G.V. Celano, G. Normanno (Foggia, Valenzano, IT)P1845Objectives: The ingestion of food contaminated by enterotoxins (SEs) synthesized by Staphylococcus aureus is responsible of one of the most common foodborne diseases (Staphylococcal Food Poisoning-SFP).", [["specimen", "ANATOMY", 120, 128], ["Staphylococcus aureus", "DISEASE", 307, 328], ["Staphylococcus aureus", "DISEASE", 616, 637], ["foodborne diseases", "DISEASE", 679, 697], ["Staphylococcal Food Poisoning-SFP", "DISEASE", 699, 732], ["Staphylococcus aureus strains", "ORGANISM", 307, 336], ["Staphylococcus aureus", "ORGANISM", 616, 637], ["enterotoxins", "PROTEIN", 582, 594], ["Staphylococcus aureus", "SPECIES", 307, 328], ["Staphylococcus aureus", "SPECIES", 616, 637], ["Staphylococcus aureus", "SPECIES", 307, 328], ["Staphylococcus aureus", "SPECIES", 616, 637], ["proper food handling practices", "TREATMENT", 28, 58], ["antimicrobial resistance pattern", "TEST", 271, 303], ["Staphylococcus aureus strains", "PROBLEM", 307, 336], ["Staphylococcus aureus", "PROBLEM", 616, 637], ["antimicrobial resistance", "OBSERVATION", 271, 295], ["Staphylococcus aureus", "OBSERVATION", 307, 328], ["Staphylococcus aureus", "OBSERVATION", 616, 637]]], ["Since S. aureus is often involved in cases of subclinical mastitis of ruminants, milk may results contaminated.", [["milk", "ANATOMY", 81, 85], ["S. aureus", "DISEASE", 6, 15], ["mastitis of ruminants", "DISEASE", 58, 79], ["S. aureus", "ORGANISM", 6, 15], ["milk", "ORGANISM_SUBSTANCE", 81, 85], ["S. aureus", "SPECIES", 6, 15], ["S. aureus", "SPECIES", 6, 15], ["ruminants", "SPECIES", 70, 79], ["S. aureus", "PROBLEM", 6, 15], ["subclinical mastitis of ruminants", "PROBLEM", 46, 79], ["aureus", "OBSERVATION", 9, 15], ["subclinical", "OBSERVATION_MODIFIER", 46, 57], ["mastitis", "OBSERVATION", 58, 66]]], ["Infact, the dairy products are frequently related to cases of SFP, expecially in areas characterized by a high level of consumption of these products.", [["the dairy products", "TREATMENT", 8, 26], ["SFP", "PROBLEM", 62, 65], ["these products", "TREATMENT", 135, 149]]], ["Consequently an active microbiological surveillance is needed in order to control the risk of SFP and to allow the improvement of the public health standards.", [["an active microbiological surveillance", "TEST", 13, 51], ["SFP", "PROBLEM", 94, 97], ["active", "OBSERVATION_MODIFIER", 16, 22]]], ["S. aureus also show a large antimicrobial resistance pattern.", [["S. aureus", "ORGANISM", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["a large antimicrobial resistance pattern", "PROBLEM", 20, 60], ["aureus", "OBSERVATION", 3, 9], ["large", "OBSERVATION_MODIFIER", 22, 27], ["antimicrobial resistance pattern", "OBSERVATION", 28, 60]]], ["In this work are reported the results of a survey conducted on the occurrence of S. aureus in dairy products from Apulia region (Southern Italy).", [["S. aureus", "ORGANISM", 81, 90], ["S. aureus", "SPECIES", 81, 90], ["S. aureus", "SPECIES", 81, 90], ["a survey", "TEST", 41, 49], ["S. aureus", "PROBLEM", 81, 90], ["aureus", "OBSERVATION", 84, 90]]], ["Furthermore, the isolated strains were characterized in order to determine their ability in synthesizing SEs and to evaluate their antimicrobial resistance pattern.", [["the isolated strains", "PROBLEM", 13, 33], ["antimicrobial resistance", "OBSERVATION", 131, 155]]], ["Methods: 250 samples of dairy products (milk, cheese, mozzarella cheese, ricotta cheeses) were analysed for the detection of S. aureus.", [["samples", "ANATOMY", 13, 20], ["milk", "ANATOMY", 40, 44], ["milk", "ORGANISM_SUBDIVISION", 40, 44], ["cheese", "ORGANISM_SUBDIVISION", 46, 52], ["cheese", "ORGANISM_SUBDIVISION", 65, 71], ["ricotta cheeses", "ORGANISM", 73, 88], ["S. aureus", "ORGANISM", 125, 134], ["milk", "SPECIES", 40, 44], ["cheese", "SPECIES", 46, 52], ["cheese", "SPECIES", 65, 71], ["S. aureus", "SPECIES", 125, 134], ["S. aureus", "SPECIES", 125, 134], ["dairy products", "TREATMENT", 24, 38], ["milk, cheese", "TREATMENT", 40, 52], ["mozzarella cheese, ricotta cheeses", "TREATMENT", 54, 88], ["S. aureus", "PROBLEM", 125, 134], ["aureus", "OBSERVATION", 128, 134]]], ["The isolated strains were tested for the detection of SEs, using the reverse passive latex agglutination test (SEA to SED) and submitted to PCR to detect entA, entB, entC, entD and entE genes.", [["entA", "GENE_OR_GENE_PRODUCT", 154, 158], ["entB", "GENE_OR_GENE_PRODUCT", 160, 164], ["entC", "GENE_OR_GENE_PRODUCT", 166, 170], ["entD", "GENE_OR_GENE_PRODUCT", 172, 176], ["entE", "GENE_OR_GENE_PRODUCT", 181, 185], ["entA, entB, entC, entD and entE genes", "DNA", 154, 191], ["The isolated strains", "PROBLEM", 0, 20], ["the reverse passive latex agglutination test", "TEST", 65, 109], ["PCR", "TEST", 140, 143], ["entA", "TEST", 154, 158], ["entB", "TEST", 160, 164], ["entC", "TEST", 166, 170]]], ["Furthermore, the strains were tested for susceptibility to ampicillin, tetracycline, gentamicin, eritromycin, enrofloxacin, co-trimoxazole, teicoplanin and vancomycin, by the agar diffusion method.", [["ampicillin", "CHEMICAL", 59, 69], ["tetracycline", "CHEMICAL", 71, 83], ["gentamicin", "CHEMICAL", 85, 95], ["eritromycin", "CHEMICAL", 97, 108], ["enrofloxacin", "CHEMICAL", 110, 122], ["co-trimoxazole", "CHEMICAL", 124, 138], ["teicoplanin", "CHEMICAL", 140, 151], ["vancomycin", "CHEMICAL", 156, 166], ["ampicillin", "CHEMICAL", 59, 69], ["tetracycline", "CHEMICAL", 71, 83], ["gentamicin", "CHEMICAL", 85, 95], ["eritromycin", "CHEMICAL", 97, 108], ["enrofloxacin", "CHEMICAL", 110, 122], ["co-trimoxazole", "CHEMICAL", 124, 138], ["teicoplanin", "CHEMICAL", 140, 151], ["vancomycin", "CHEMICAL", 156, 166], ["ampicillin", "SIMPLE_CHEMICAL", 59, 69], ["tetracycline", "SIMPLE_CHEMICAL", 71, 83], ["gentamicin", "SIMPLE_CHEMICAL", 85, 95], ["eritromycin", "SIMPLE_CHEMICAL", 97, 108], ["enrofloxacin", "SIMPLE_CHEMICAL", 110, 122], ["co-trimoxazole", "SIMPLE_CHEMICAL", 124, 138], ["teicoplanin", "SIMPLE_CHEMICAL", 140, 151], ["vancomycin", "SIMPLE_CHEMICAL", 156, 166], ["the strains", "PROBLEM", 13, 24], ["susceptibility", "PROBLEM", 41, 55], ["ampicillin", "TREATMENT", 59, 69], ["tetracycline", "TREATMENT", 71, 83], ["gentamicin", "TREATMENT", 85, 95], ["eritromycin", "TREATMENT", 97, 108], ["enrofloxacin", "TREATMENT", 110, 122], ["co-trimoxazole", "TREATMENT", 124, 138], ["teicoplanin", "TREATMENT", 140, 151], ["vancomycin", "TREATMENT", 156, 166]]], ["Results: Out of 250 samples analysed, 36 (14.4%) resulted contaminated with S. aureus and, among these, 19 (52.7%) have been recognized as enterotoxigenic strains (10 samples of milk, 5 samples of mozzarella cheese, 3 samples of cheese from ovine milk and 1 sample of cheese).", [["samples", "ANATOMY", 20, 27], ["strains", "ANATOMY", 155, 162], ["samples", "ANATOMY", 167, 174], ["milk", "ANATOMY", 178, 182], ["samples", "ANATOMY", 186, 193], ["samples", "ANATOMY", 218, 225], ["milk", "ANATOMY", 247, 251], ["sample", "ANATOMY", 258, 264], ["S. aureus", "ORGANISM", 76, 85], ["milk", "ORGANISM_SUBSTANCE", 178, 182], ["cheese", "ORGANISM_SUBDIVISION", 229, 235], ["ovine", "ORGANISM", 241, 246], ["milk", "ORGANISM_SUBDIVISION", 247, 251], ["cheese", "ORGANISM_SUBDIVISION", 268, 274], ["S. aureus", "SPECIES", 76, 85], ["milk", "SPECIES", 178, 182], ["cheese", "SPECIES", 229, 235], ["milk", "SPECIES", 247, 251], ["S. aureus", "SPECIES", 76, 85], ["cheese", "SPECIES", 229, 235], ["ovine", "SPECIES", 241, 246], ["S. aureus", "PROBLEM", 76, 85], ["enterotoxigenic strains", "PROBLEM", 139, 162], ["milk", "TEST", 178, 182], ["mozzarella cheese", "TREATMENT", 197, 214], ["ovine milk", "TREATMENT", 241, 251], ["aureus", "OBSERVATION", 79, 85]]], ["All the strains tested (one per each positive sample) showed antimicrobial resistance properties but none of these was resistant to teicoplanin and vancomicin.", [["sample", "ANATOMY", 46, 52], ["teicoplanin", "CHEMICAL", 132, 143], ["vancomicin", "CHEMICAL", 148, 158], ["teicoplanin", "CHEMICAL", 132, 143], ["vancomicin", "CHEMICAL", 148, 158], ["teicoplanin", "SIMPLE_CHEMICAL", 132, 143], ["vancomicin", "SIMPLE_CHEMICAL", 148, 158], ["All the strains", "TEST", 0, 15], ["antimicrobial resistance properties", "PROBLEM", 61, 96], ["teicoplanin", "TREATMENT", 132, 143], ["vancomicin", "TREATMENT", 148, 158], ["antimicrobial resistance", "OBSERVATION", 61, 85]]], ["Conclusions: The results obtained from this survey show that milk and dairy products from Southern Italy are frequently contaminated by enterotoxigenic strains of S. aureus and highlighted the need to implement strict hygienic control measures along the food chain in order to decrease the risk of SPF.", [["milk", "ANATOMY", 61, 65], ["milk", "ORGANISM_SUBSTANCE", 61, 65], ["S. aureus", "ORGANISM", 163, 172], ["S. aureus", "SPECIES", 163, 172], ["S. aureus", "SPECIES", 163, 172], ["SPF", "SPECIES", 298, 301], ["this survey", "TEST", 39, 50], ["milk and dairy products", "TREATMENT", 61, 84], ["enterotoxigenic strains", "PROBLEM", 136, 159], ["S. aureus", "PROBLEM", 163, 172], ["strict hygienic control measures", "TREATMENT", 211, 243], ["SPF", "PROBLEM", 298, 301], ["aureus", "OBSERVATION", 166, 172]]], ["Furthermore, the presence of antimicrobial-resistant strains of S. aureus in food may be considered a source of communityacquired infections, with the direct risk of transfer of the antimicrobial-resistance to intestinal human microflora.", [["intestinal", "ANATOMY", 210, 220], ["S. aureus", "DISEASE", 64, 73], ["infections", "DISEASE", 130, 140], ["S. aureus", "ORGANISM", 64, 73], ["human", "ORGANISM", 221, 226], ["S. aureus", "SPECIES", 64, 73], ["human", "SPECIES", 221, 226], ["S. aureus", "SPECIES", 64, 73], ["human", "SPECIES", 221, 226], ["antimicrobial", "TREATMENT", 29, 42], ["S. aureus in food", "PROBLEM", 64, 81], ["communityacquired infections", "PROBLEM", 112, 140], ["the antimicrobial", "TREATMENT", 178, 195], ["intestinal human microflora", "TREATMENT", 210, 237], ["antimicrobial", "OBSERVATION_MODIFIER", 29, 42], ["aureus", "OBSERVATION", 67, 73], ["infections", "OBSERVATION", 130, 140], ["intestinal", "ANATOMY", 210, 220], ["human microflora", "OBSERVATION", 221, 237]]], ["Objectives: Infection accounts for about one-third of cases of fever of unknown origin (FUO), which remains a major diagnostic challenge.", [["fever", "DISEASE", 63, 68], ["FUO", "DISEASE", 88, 91], ["Infection", "PROBLEM", 12, 21], ["fever", "PROBLEM", 63, 68], ["Infection", "OBSERVATION", 12, 21], ["fever", "OBSERVATION", 63, 68]]], ["Recently, F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) has entered the field of clinical infectious diseases.", [["F-18-fluorodeoxyglucose", "CHEMICAL", 10, 33], ["infectious diseases", "DISEASE", 109, 128], ["F-18-fluorodeoxyglucose", "CHEMICAL", 10, 33], ["FDG", "CHEMICAL", 35, 38], ["F-18-fluorodeoxyglucose", "SIMPLE_CHEMICAL", 10, 33], ["FDG", "SIMPLE_CHEMICAL", 35, 38], ["positron emission tomography", "TEST", 40, 68], ["clinical infectious diseases", "PROBLEM", 100, 128], ["infectious", "OBSERVATION", 109, 119]]], ["FDG accumulates in tissues with a high rate of glycolysis, which is present in malignant cells and in all activated leukocytes.", [["tissues", "ANATOMY", 19, 26], ["malignant cells", "ANATOMY", 79, 94], ["leukocytes", "ANATOMY", 116, 126], ["FDG", "SIMPLE_CHEMICAL", 0, 3], ["tissues", "TISSUE", 19, 26], ["malignant cells", "CELL", 79, 94], ["leukocytes", "CELL", 116, 126], ["malignant cells", "CELL_TYPE", 79, 94], ["activated leukocytes", "CELL_TYPE", 106, 126], ["FDG accumulates in tissues", "PROBLEM", 0, 26], ["a high rate of glycolysis", "PROBLEM", 32, 57], ["malignant cells", "PROBLEM", 79, 94], ["all activated leukocytes", "PROBLEM", 102, 126], ["tissues", "ANATOMY", 19, 26], ["high", "OBSERVATION_MODIFIER", 34, 38], ["malignant cells", "OBSERVATION", 79, 94], ["all", "OBSERVATION_MODIFIER", 102, 105], ["activated leukocytes", "OBSERVATION", 106, 126]]], ["The aim of this prospective multi-centre study was to validate the use of FDG-PET as part of a structured diagnostic protocol in the general patient population with FUO.", [["FUO", "DISEASE", 165, 168], ["FDG", "SIMPLE_CHEMICAL", 74, 77], ["patient", "ORGANISM", 141, 148], ["patient", "SPECIES", 141, 148], ["this prospective multi-centre study", "TEST", 11, 46], ["FDG-PET", "TREATMENT", 74, 81], ["a structured diagnostic protocol", "TEST", 93, 125], ["FUO", "PROBLEM", 165, 168], ["FUO", "OBSERVATION", 165, 168]]], ["Methods: From December 2003 to July 2005, 70 patients with FUO, defined according to the revised Petersdorf criteria, were recruited from one university hospital and five community hospitals.", [["FUO", "DISEASE", 59, 62], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["FUO", "PROBLEM", 59, 62]]], ["A structured diagnostic protocol was used.", [["A structured diagnostic protocol", "TEST", 0, 32]]], ["FDG-PET was performed after certain obligatory laboratory tests, chest Xray and abdominal ultrasound.", [["chest", "ANATOMY", 65, 70], ["abdominal", "ANATOMY", 80, 89], ["FDG", "CHEMICAL", 0, 3], ["FDG", "SIMPLE_CHEMICAL", 0, 3], ["abdominal", "ORGANISM_SUBDIVISION", 80, 89], ["FDG-PET", "TEST", 0, 7], ["laboratory tests", "TEST", 47, 63], ["chest Xray", "TEST", 65, 75], ["abdominal ultrasound", "TEST", 80, 100], ["chest", "ANATOMY", 65, 70], ["abdominal", "ANATOMY", 80, 89]]], ["The final clinical diagnosis was used for comparison with the FDG-PET results.", [["FDG", "SIMPLE_CHEMICAL", 62, 65], ["the FDG", "TEST", 58, 65]]], ["Results: A final diagnosis was established in 35 patients (50%): 12 infections, 5 malignancies, 16 non-infectious inflammatory disorders and 2 miscellaneous causes.", [["malignancies", "ANATOMY", 82, 94], ["infections", "DISEASE", 68, 78], ["malignancies", "DISEASE", 82, 94], ["inflammatory disorders", "DISEASE", 114, 136], ["patients", "ORGANISM", 49, 57], ["malignancies", "CANCER", 82, 94], ["patients", "SPECIES", 49, 57], ["12 infections", "PROBLEM", 65, 78], ["5 malignancies", "PROBLEM", 80, 94], ["16 non-infectious inflammatory disorders", "PROBLEM", 96, 136], ["2 miscellaneous causes", "PROBLEM", 141, 163], ["infectious", "OBSERVATION_MODIFIER", 103, 113], ["inflammatory", "OBSERVATION", 114, 126]]], ["Of the total number of FDG-PET-scans, 33% were helpful.", [["FDG", "SIMPLE_CHEMICAL", 23, 26], ["FDG-PET-scans", "TEST", 23, 36]]], ["Positive predictive value of FDG-PET was 70% and negative predictive value was 95%.", [["FDG", "SIMPLE_CHEMICAL", 29, 32], ["FDG-PET", "TEST", 29, 36]]], ["FDG-PET was helpful in all patients diagnosed with an infection except for one case of pyelonephritis.", [["infection", "DISEASE", 54, 63], ["pyelonephritis", "DISEASE", 87, 101], ["FDG", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 27, 35], ["pyelonephritis", "PATHOLOGICAL_FORMATION", 87, 101], ["patients", "SPECIES", 27, 35], ["FDG-PET", "TEST", 0, 7], ["an infection", "PROBLEM", 51, 63], ["pyelonephritis", "PROBLEM", 87, 101], ["infection", "OBSERVATION", 54, 63], ["pyelonephritis", "OBSERVATION", 87, 101]]], ["Contribution of FDG-PET to the final diagnosis did not differ significantly between the university hospital and the community hospitals.", [["FDG", "SIMPLE_CHEMICAL", 16, 19]]], ["FDG-PET was not helpful in any of the patients with normal erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).", [["erythrocyte", "ANATOMY", 59, 70], ["FDG", "CHEMICAL", 0, 3], ["FDG", "SIMPLE_CHEMICAL", 0, 3], ["patients", "ORGANISM", 38, 46], ["erythrocyte", "CELL", 59, 70], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 100, 118], ["CRP", "GENE_OR_GENE_PRODUCT", 120, 123], ["C-reactive protein", "PROTEIN", 100, 118], ["CRP", "PROTEIN", 120, 123], ["patients", "SPECIES", 38, 46], ["FDG-PET", "TEST", 0, 7], ["erythrocyte sedimentation rate", "TEST", 59, 89], ["ESR", "TEST", 91, 94], ["C", "TEST", 100, 101], ["CRP", "TEST", 120, 123]]], ["Conclusion: In addition to the apparent value of FDG-PET in diagnosing different infectious diseases as described in several case series, FDG-PET is a valuable imaging technique as part of a diagnostic protocol in the general patient population with FUO and a raised ESR or CRP.", [["infectious diseases", "DISEASE", 81, 100], ["FUO", "DISEASE", 250, 253], ["FDG", "SIMPLE_CHEMICAL", 49, 52], ["FDG", "SIMPLE_CHEMICAL", 138, 141], ["patient", "ORGANISM", 226, 233], ["CRP", "GENE_OR_GENE_PRODUCT", 274, 277], ["ESR", "PROTEIN", 267, 270], ["CRP", "PROTEIN", 274, 277], ["patient", "SPECIES", 226, 233], ["FDG-PET", "TEST", 49, 56], ["different infectious diseases", "PROBLEM", 71, 100], ["FDG-PET", "TEST", 138, 145], ["a valuable imaging technique", "TEST", 149, 177], ["a diagnostic protocol", "TEST", 189, 210], ["FUO", "PROBLEM", 250, 253], ["a raised ESR", "TEST", 258, 270], ["CRP", "TEST", 274, 277], ["infectious", "OBSERVATION", 81, 91]]], ["Based on previous studies comparing Gallium-67-citrate or labelled leukocyte scintigraphy and FDG-PET in patients with FUO and resulting from favourable characteristics of FDG-PET, conventional scintigraphic techniques may be replaced by FDG-PET in institutions where PET is available.P1863Emergence of clindamycin-resistant Streptococcus pyogenes causing cellulitis", [["leukocyte", "ANATOMY", 67, 76], ["Gallium-67-citrate", "CHEMICAL", 36, 54], ["FUO", "DISEASE", 119, 122], ["P1863Emergence", "CHEMICAL", 285, 299], ["clindamycin", "CHEMICAL", 303, 314], ["Streptococcus pyogenes", "DISEASE", 325, 347], ["cellulitis", "DISEASE", 356, 366], ["Gallium-67-citrate", "CHEMICAL", 36, 54], ["clindamycin", "CHEMICAL", 303, 314], ["Gallium-67-citrate", "SIMPLE_CHEMICAL", 36, 54], ["leukocyte", "CELL", 67, 76], ["FDG", "SIMPLE_CHEMICAL", 94, 97], ["patients", "ORGANISM", 105, 113], ["FDG", "SIMPLE_CHEMICAL", 172, 175], ["FDG", "SIMPLE_CHEMICAL", 238, 241], ["clindamycin", "SIMPLE_CHEMICAL", 303, 314], ["Streptococcus pyogenes", "ORGANISM", 325, 347], ["cellulitis", "PATHOLOGICAL_FORMATION", 356, 366], ["patients", "SPECIES", 105, 113], ["Streptococcus pyogenes", "SPECIES", 325, 347], ["Streptococcus pyogenes", "SPECIES", 325, 347], ["previous studies", "TEST", 9, 25], ["Gallium", "TEST", 36, 43], ["labelled leukocyte scintigraphy", "TEST", 58, 89], ["FDG-PET", "TEST", 94, 101], ["FUO", "PROBLEM", 119, 122], ["FDG-PET", "TEST", 172, 179], ["conventional scintigraphic techniques", "TREATMENT", 181, 218], ["FDG-PET", "TEST", 238, 245], ["PET", "TEST", 268, 271], ["clindamycin", "TREATMENT", 303, 314], ["resistant Streptococcus pyogenes", "PROBLEM", 315, 347], ["cellulitis", "PROBLEM", 356, 366], ["FUO", "OBSERVATION", 119, 122], ["Streptococcus pyogenes", "OBSERVATION", 325, 347], ["cellulitis", "OBSERVATION", 356, 366]]]], "PMC7346995": [["INTRODUCTIONThe coronavirus disease 2019 (COVID-19) outbreak has started from Wuhan in China in late December 2019; the World Health Organization (WHO) named this new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["coronavirus", "DISEASE", 167, 178], ["acute respiratory syndrome coronavirus", "DISEASE", 186, 224], ["coronavirus", "ORGANISM", 167, 178], ["SARS-CoV-2", "ORGANISM", 228, 238], ["coronavirus", "SPECIES", 167, 178], ["coronavirus severe acute respiratory syndrome coronavirus", "SPECIES", 167, 224], ["SARS-CoV-2", "SPECIES", 228, 238], ["coronavirus disease", "PROBLEM", 16, 35], ["COVID", "TEST", 42, 47], ["this new coronavirus severe acute respiratory syndrome coronavirus", "PROBLEM", 158, 224], ["CoV", "TEST", 233, 236], ["coronavirus disease", "OBSERVATION", 16, 35], ["coronavirus", "OBSERVATION_MODIFIER", 167, 178], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["acute", "OBSERVATION_MODIFIER", 186, 191], ["respiratory syndrome", "OBSERVATION", 192, 212]]], ["The first case of person-to-person transmission was confirmed in January 2020, and the first wave of the pandemic has started across the globe, including in Asian countries.1 The case-fatality rate among infected patients varies in our region: 5.5% in China, 2.2% in Korea, 2.5% in Japan and 0.1% in Singapore, which is lower than in the US and European countries.2 Higher mortality rates (8%\u201315%) were reported in elderly patients and patients with comorbid conditions such as hypertension and metabolic diseases.13 In addition, an important issue is the spreading of this infection to healthcare workers (HCWs).", [["hypertension", "DISEASE", 478, 490], ["metabolic diseases", "DISEASE", 495, 513], ["infection", "DISEASE", 574, 583], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 423, 431], ["patients", "ORGANISM", 436, 444], ["person", "SPECIES", 18, 24], ["person", "SPECIES", 28, 34], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 423, 431], ["patients", "SPECIES", 436, 444], ["the pandemic", "PROBLEM", 101, 113], ["mortality rates", "TEST", 373, 388], ["comorbid conditions", "PROBLEM", 450, 469], ["hypertension", "PROBLEM", 478, 490], ["metabolic diseases", "PROBLEM", 495, 513], ["this infection", "PROBLEM", 569, 583], ["globe", "ANATOMY", 137, 142], ["lower", "OBSERVATION_MODIFIER", 320, 325], ["hypertension", "OBSERVATION", 478, 490], ["metabolic diseases", "OBSERVATION", 495, 513]]], ["In China, 3.8% of the cases were found in HCWs (14.8% among them were severe or critical) with a mortality of 0.3%; moreover, 63% of the affected HCWs were reported in Wuhan.4INTRODUCTIONThe prevalence of allergic diseases, including asthma and allergic rhinitis (AR), is increasing in Asian countries, especially in the elderly,56 in which viral infections are major triggering factors.", [["allergic diseases", "DISEASE", 205, 222], ["asthma", "DISEASE", 234, 240], ["allergic rhinitis", "DISEASE", 245, 262], ["viral infections", "DISEASE", 341, 357], ["HCWs", "ORGANISM", 146, 150], ["HCWs", "TEST", 42, 46], ["a mortality", "TEST", 95, 106], ["the affected HCWs", "PROBLEM", 133, 150], ["allergic diseases", "PROBLEM", 205, 222], ["asthma", "PROBLEM", 234, 240], ["allergic rhinitis", "PROBLEM", 245, 262], ["AR", "PROBLEM", 264, 266], ["viral infections", "PROBLEM", 341, 357], ["allergic diseases", "OBSERVATION", 205, 222], ["asthma", "OBSERVATION", 234, 240], ["allergic rhinitis", "OBSERVATION", 245, 262], ["increasing", "OBSERVATION_MODIFIER", 272, 282], ["infections", "OBSERVATION", 347, 357]]], ["Although the initial starting point for COVID-19 appears to have been successful in controlling epidemics to the appropriate initial response in this region, there is constantly the possibility that a new virus subtype outbreak will begin.78 Therefore, we report our consensus on how to manage allergic patients during this pandemic as well as how to protect HCWs.INTRODUCTIONTo prevent the spread of this viral infection, the specified preventive measures have been applied to the general public and HCWs.", [["allergic", "DISEASE", 294, 302], ["viral infection", "DISEASE", 406, 421], ["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 303, 311], ["COVID", "TEST", 40, 45], ["a new virus subtype outbreak", "PROBLEM", 199, 227], ["allergic", "PROBLEM", 294, 302], ["this viral infection", "PROBLEM", 401, 421], ["constantly the possibility", "UNCERTAINTY", 167, 193], ["new", "OBSERVATION_MODIFIER", 201, 204], ["virus", "OBSERVATION", 205, 210], ["viral", "OBSERVATION_MODIFIER", 406, 411], ["infection", "OBSERVATION", 412, 421]]], ["The WHO recommended basic protective measures, including frequent hand washing, maintaining a social distance of 2 m and practicing respiratory hygiene for the public.9 During the COVID-19 pandemic, hospital authorities in Korea have restricted entrance to the hospital through strict screening of people by checking recent travel history, clinical symptoms and body temperature.", [["hand", "ANATOMY", 66, 70], ["respiratory", "ANATOMY", 132, 143], ["body", "ANATOMY", 362, 366], ["hand", "ORGANISM_SUBDIVISION", 66, 70], ["people", "ORGANISM", 298, 304], ["body", "ORGANISM_SUBDIVISION", 362, 366], ["people", "SPECIES", 298, 304], ["basic protective measures", "TREATMENT", 20, 45], ["frequent hand washing", "TREATMENT", 57, 78], ["practicing respiratory hygiene", "TREATMENT", 121, 151], ["clinical symptoms", "PROBLEM", 340, 357], ["body temperature", "PROBLEM", 362, 378]]], ["Furthermore, all the patients have been asked to wear a disposable facial mask with careful monitoring of symptoms and temperatures during their stay in the hospital.", [["facial", "ANATOMY", 67, 73], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["a disposable facial mask", "TREATMENT", 54, 78], ["symptoms", "PROBLEM", 106, 114]]], ["The American Centers for Disease Control and Prevention (CDC) recommended appropriate personal protective equipment for healthcare providers, including gowns, gloves, N95 respirators and goggles.110THE RISK OF COVID-19 IN PATIENTS WITH ASTHMA AND ALLERGIC DISEASESAlthough a respiratory viral infection is a major contributing factor to asthma exacerbation as well as a triggering factor, information about the influence of SARS-CoV-2 on asthma and allergic diseases is limited.", [["respiratory viral infection", "DISEASE", 275, 302], ["asthma", "DISEASE", 337, 343], ["SARS", "DISEASE", 424, 428], ["asthma", "DISEASE", 438, 444], ["allergic diseases", "DISEASE", 449, 466], ["SARS-CoV-2", "ORGANISM", 424, 434], ["Disease Control", "TREATMENT", 25, 40], ["ASTHMA", "PROBLEM", 236, 242], ["ALLERGIC DISEASESAlthough", "PROBLEM", 247, 272], ["a respiratory viral infection", "PROBLEM", 273, 302], ["asthma exacerbation", "PROBLEM", 337, 356], ["a triggering factor", "PROBLEM", 368, 387], ["SARS", "PROBLEM", 424, 428], ["asthma", "PROBLEM", 438, 444], ["allergic diseases", "PROBLEM", 449, 466], ["ASTHMA", "OBSERVATION", 236, 242], ["ALLERGIC", "OBSERVATION", 247, 255], ["respiratory", "ANATOMY", 275, 286], ["viral infection", "OBSERVATION", 287, 302], ["asthma", "OBSERVATION", 337, 343], ["asthma", "OBSERVATION", 438, 444], ["allergic diseases", "OBSERVATION", 449, 466]]], ["It was reported that none of the 140 patients who were hospitalized due to confirmed COVID-19 in Wuhan, China had asthma or other allergic diseases such as AR, atopic dermatitis (AD) and food allergy.11 Drug hypersensitivity and urticaria were found in 11.4% and 1.4% of the patients, respectively, in that study; their relationships to COVID-19 remain unclear.", [["asthma", "DISEASE", 114, 120], ["allergic diseases", "DISEASE", 130, 147], ["atopic dermatitis", "DISEASE", 160, 177], ["AD", "DISEASE", 179, 181], ["food allergy", "DISEASE", 187, 199], ["Drug hypersensitivity", "DISEASE", 203, 224], ["urticaria", "DISEASE", 229, 238], ["COVID-19", "CHEMICAL", 337, 345], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 275, 283], ["COVID-19", "GENE_OR_GENE_PRODUCT", 337, 345], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 275, 283], ["asthma", "PROBLEM", 114, 120], ["other allergic diseases", "PROBLEM", 124, 147], ["AR", "PROBLEM", 156, 158], ["atopic dermatitis", "PROBLEM", 160, 177], ["food allergy", "PROBLEM", 187, 199], ["Drug hypersensitivity", "PROBLEM", 203, 224], ["urticaria", "PROBLEM", 229, 238], ["that study", "TEST", 302, 312], ["COVID", "TEST", 337, 342], ["allergic diseases", "OBSERVATION", 130, 147], ["atopic dermatitis", "OBSERVATION", 160, 177], ["urticaria", "OBSERVATION", 229, 238]]], ["Another report from Wuhan observed a markedly lower prevalence of asthma (5 asthmatics among 548 patients with confirmed COVID-19, 0.9%) compared to the prevalence of adult asthma in Wuhan (6.4%).12 In another recent study of the 1,099 patients with COVID-19 admitted, no asthmatics were found among the study subjects.13 Korean data demonstrated that none of the 22 patients who died of COVID-19 were suffering from asthma or other allergic diseases.3 However, the possibility of under-diagnosis or under-reporting exists in those studies.", [["asthma", "DISEASE", 66, 72], ["asthma", "DISEASE", 173, 179], ["asthma", "DISEASE", 417, 423], ["allergic diseases", "DISEASE", 433, 450], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 367, 375], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 367, 375], ["asthma", "PROBLEM", 66, 72], ["COVID", "TEST", 121, 126], ["adult asthma", "PROBLEM", 167, 179], ["COVID", "TEST", 250, 255], ["asthmatics", "PROBLEM", 272, 282], ["Korean data", "TEST", 322, 333], ["COVID", "TEST", 388, 393], ["asthma", "PROBLEM", 417, 423], ["other allergic diseases", "PROBLEM", 427, 450], ["those studies", "TEST", 526, 539], ["asthma", "OBSERVATION", 66, 72], ["asthma", "OBSERVATION", 173, 179], ["asthma", "OBSERVATION", 417, 423], ["allergic diseases", "OBSERVATION", 433, 450]]], ["Although it has not been determined whether allergy or asthma may predispose patients to COVID-19, non-pandemic coronavirus infections have aggravated asthma both in adults and children.141516 Thus, the probability of the aggravation of asthma and other allergic diseases by COVID-19 should be considered.", [["allergy", "DISEASE", 44, 51], ["asthma", "DISEASE", 55, 61], ["coronavirus infections", "DISEASE", 112, 134], ["asthma", "DISEASE", 151, 157], ["asthma", "DISEASE", 237, 243], ["allergic diseases", "DISEASE", 254, 271], ["COVID-19", "CHEMICAL", 275, 283], ["patients", "ORGANISM", 77, 85], ["non-pandemic coronavirus", "ORGANISM", 99, 123], ["children", "ORGANISM", 177, 185], ["patients", "SPECIES", 77, 85], ["children", "SPECIES", 177, 185], ["non-pandemic coronavirus", "SPECIES", 99, 123], ["allergy", "PROBLEM", 44, 51], ["asthma", "PROBLEM", 55, 61], ["COVID", "TEST", 89, 94], ["non-pandemic coronavirus infections", "PROBLEM", 99, 134], ["asthma", "PROBLEM", 151, 157], ["asthma", "PROBLEM", 237, 243], ["other allergic diseases", "PROBLEM", 248, 271], ["COVID", "TEST", 275, 280], ["asthma", "OBSERVATION", 55, 61], ["coronavirus infections", "OBSERVATION", 112, 134], ["asthma", "OBSERVATION", 237, 243]]], ["Furthermore, as pediatric patients with asthma are at higher risk of respiratory viral infections, most experts advise extreme caution in such cases.17THE RISK OF COVID-19 IN PATIENTS WITH ASTHMA AND ALLERGIC DISEASESImmunosuppressive agents are frequently used to achieve a well-controlled status in patients with asthma or severe allergic diseases.", [["asthma", "DISEASE", 40, 46], ["respiratory viral infections", "DISEASE", 69, 97], ["asthma", "DISEASE", 315, 321], ["allergic diseases", "DISEASE", 332, 349], ["COVID-19", "CHEMICAL", 163, 171], ["patients", "ORGANISM", 26, 34], ["patients", "ORGANISM", 301, 309], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 301, 309], ["asthma", "PROBLEM", 40, 46], ["respiratory viral infections", "PROBLEM", 69, 97], ["COVID", "TEST", 163, 168], ["ASTHMA", "PROBLEM", 189, 195], ["ALLERGIC DISEASESImmunosuppressive agents", "TREATMENT", 200, 241], ["asthma", "PROBLEM", 315, 321], ["severe allergic diseases", "PROBLEM", 325, 349], ["respiratory", "ANATOMY", 69, 80], ["viral infections", "OBSERVATION", 81, 97], ["ASTHMA", "OBSERVATION", 189, 195], ["severe", "OBSERVATION_MODIFIER", 325, 331], ["allergic diseases", "OBSERVATION", 332, 349]]], ["Systemic corticosteroid, one of the most widely used rescue medications in allergic diseases, is known to increase the risk for systemic infections, and so do other immunosuppressive agents such as methotrexate and cyclosporin.18 Fortunately, the advent of biologic agents, such as anti-immunoglobulin E (IgE), anti-interleukin (IL)-5 and anti-IL-4 antibodies, has improved treatment outcomes with reduction in medications including systemic corticosteroids.", [["allergic diseases", "DISEASE", 75, 92], ["systemic infections", "DISEASE", 128, 147], ["methotrexate", "CHEMICAL", 198, 210], ["cyclosporin", "CHEMICAL", 215, 226], ["methotrexate", "CHEMICAL", 198, 210], ["cyclosporin", "CHEMICAL", 215, 226], ["methotrexate", "SIMPLE_CHEMICAL", 198, 210], ["cyclosporin", "SIMPLE_CHEMICAL", 215, 226], ["anti-immunoglobulin E", "SIMPLE_CHEMICAL", 282, 303], ["IgE", "GENE_OR_GENE_PRODUCT", 305, 308], ["anti-interleukin (IL)-5", "GENE_OR_GENE_PRODUCT", 311, 334], ["anti-IL-4", "GENE_OR_GENE_PRODUCT", 339, 348], ["anti-immunoglobulin E", "PROTEIN", 282, 303], ["IgE", "PROTEIN", 305, 308], ["anti-interleukin (IL)-5 and anti-IL-4 antibodies", "PROTEIN", 311, 359], ["Systemic corticosteroid", "TREATMENT", 0, 23], ["rescue medications", "TREATMENT", 53, 71], ["allergic diseases", "PROBLEM", 75, 92], ["systemic infections", "PROBLEM", 128, 147], ["other immunosuppressive agents", "TREATMENT", 159, 189], ["methotrexate", "TREATMENT", 198, 210], ["cyclosporin", "TREATMENT", 215, 226], ["biologic agents", "TREATMENT", 257, 272], ["anti-immunoglobulin E (IgE)", "TREATMENT", 282, 309], ["anti-interleukin (IL)", "TREATMENT", 311, 332], ["anti-IL", "TEST", 339, 346], ["reduction in medications", "TREATMENT", 398, 422], ["systemic corticosteroids", "TREATMENT", 433, 457], ["corticosteroid", "OBSERVATION", 9, 23], ["most widely", "OBSERVATION_MODIFIER", 36, 47], ["allergic diseases", "OBSERVATION", 75, 92], ["systemic", "OBSERVATION_MODIFIER", 128, 136], ["infections", "OBSERVATION", 137, 147]]], ["As it is not clear whether biologics may increase the susceptibility to serious infections, further studies are needed to draw conclusions.", [["infections", "DISEASE", 80, 90], ["serious infections", "PROBLEM", 72, 90], ["further studies", "TEST", 92, 107], ["serious", "OBSERVATION_MODIFIER", 72, 79], ["infections", "OBSERVATION", 80, 90]]], ["Taken together, we should consider the possibility of bidirectional influences between COVID-19 and asthma/allergic diseases, which can be influenced by patients' clinical characteristics such as age, comorbid illnesses, and profiles of the medications.PRACTICE OF ALLERGEN IMMUNOETHERAPYAllergen-specific immunotherapy (AIT), including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), is widely applied to patients with asthma or AR in Asia.19202122 AIT, especially SCIT, requires long-term regular contacts between HCWs and patients (>3 years).", [["subcutaneous", "ANATOMY", 337, 349], ["sublingual", "ANATOMY", 375, 385], ["asthma", "DISEASE", 100, 106], ["allergic diseases", "DISEASE", 107, 124], ["asthma", "DISEASE", 443, 449], ["19202122", "CHEMICAL", 464, 472], ["patients", "ORGANISM", 153, 161], ["patients", "ORGANISM", 429, 437], ["patients", "ORGANISM", 548, 556], ["patients", "SPECIES", 153, 161], ["patients", "SPECIES", 429, 437], ["patients", "SPECIES", 548, 556], ["COVID", "TEST", 87, 92], ["asthma", "PROBLEM", 100, 106], ["allergic diseases", "PROBLEM", 107, 124], ["comorbid illnesses", "PROBLEM", 201, 219], ["the medications", "TREATMENT", 237, 252], ["ALLERGEN IMMUNOETHERAPYAllergen", "TREATMENT", 265, 296], ["specific immunotherapy (AIT", "TREATMENT", 297, 324], ["subcutaneous immunotherapy (SCIT", "TREATMENT", 337, 369], ["sublingual immunotherapy (SLIT)", "TREATMENT", 375, 406], ["asthma", "PROBLEM", 443, 449], ["AR", "PROBLEM", 453, 455], ["allergic diseases", "OBSERVATION", 107, 124], ["asthma", "OBSERVATION", 443, 449]]], ["During the COVID-19 pandemic, home isolation strategy is necessary to control this highly contagious disease, and frequent hospital visits may increase the risk of exposure to the virus.PRACTICE OF ALLERGEN IMMUNOETHERAPYTo prevent the risk of infection and to provide safe medical services, the following control measures have been suggested to patients undergoing SCIT in each allergy center.23 Whenever the patients visit the hospital, they should be asked to take strict screening of COVID-19 at the entrance and exit.", [["infection", "DISEASE", 244, 253], ["allergy", "DISEASE", 379, 386], ["patients", "ORGANISM", 346, 354], ["patients", "ORGANISM", 410, 418], ["patients", "SPECIES", 346, 354], ["patients", "SPECIES", 410, 418], ["the COVID", "TEST", 7, 16], ["home isolation strategy", "TREATMENT", 30, 53], ["this highly contagious disease", "PROBLEM", 78, 108], ["the virus", "PROBLEM", 176, 185], ["ALLERGEN IMMUNOETHERAPYTo", "TREATMENT", 198, 223], ["infection", "PROBLEM", 244, 253], ["safe medical services", "TREATMENT", 269, 290], ["the following control measures", "TREATMENT", 292, 322], ["COVID", "TEST", 488, 493], ["infection", "OBSERVATION", 244, 253]]], ["Only patients with a normal temperature are allowed to enter the outpatient clinic.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["They should wear a disposable surgical mask during their stay in the hospital.", [["a disposable surgical mask", "TREATMENT", 17, 43]]], ["Any confirmed cases of COVID-19 should stop AIT until this infection completely resolves and the viral test result becomes negative.23PRACTICE OF ALLERGEN IMMUNOETHERAPYA good piece of advice is for HCWs, including physicians, nurses and the administrative staff contacting with patients, to wear appropriate personal protective equipment such as N94/95 protective masks and latex gloves in Korea, while additional protective equipment, including waterproof medical caps, anti-fog protective goggles and protective face shields, is required in allergy centers in Beijing.PRACTICE OF ALLERGEN IMMUNOETHERAPYInjections for SCIT should be modified after case-by-case assessment.", [["COVID-19", "CHEMICAL", 23, 31], ["AIT", "DISEASE", 44, 47], ["infection", "DISEASE", 59, 68], ["allergy", "DISEASE", 544, 551], ["COVID-19", "CHEMICAL", 23, 31], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 279, 287], ["COVID", "TEST", 23, 28], ["AIT", "TREATMENT", 44, 47], ["this infection", "PROBLEM", 54, 68], ["the viral test", "TEST", 93, 107], ["personal protective equipment", "TREATMENT", 309, 338], ["N94/95 protective masks", "TREATMENT", 347, 370], ["latex gloves", "TREATMENT", 375, 387], ["additional protective equipment", "TREATMENT", 404, 435], ["waterproof medical caps", "TREATMENT", 447, 470], ["anti-fog protective goggles", "TREATMENT", 472, 499], ["protective face shields", "TREATMENT", 504, 527], ["ALLERGEN IMMUNOETHERAPYInjections", "TREATMENT", 583, 616], ["SCIT", "TREATMENT", 621, 625], ["case assessment", "TEST", 659, 674]]], ["At the up-dose phase, discontinuation of SCIT is recommended if regular visits to the allergy center are difficult.", [["allergy", "DISEASE", 86, 93], ["discontinuation of SCIT", "TREATMENT", 22, 45]]], ["In patients who are at the maintenance phase of SCIT, the injection protocol can be adjusted later, and the next dose can be administered again as recalculated according to the authoritative guidelines.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["SCIT", "TREATMENT", 48, 52], ["the injection protocol", "TREATMENT", 54, 76]]], ["SLIT can be continued without interruption.23 Online consultation and medicine delivery services are recommended to reduce the need for patients to visit or stay in an allergy center during the COVID-19 pandemic.Asthma (adult and childhood) and AR ::: PHARMACOLOGIC TREATMENTIt is well known that common coronaviruses are associated with the worsening of asthma symptoms.1415 Recent reports have suggested that asthma does not increase the risk of COVID-19 infection or related complications.31113 However, these data have been obtained from hospitalized patients with COVID-19; therefore, the actual risk has not yet been accurately determined.", [["allergy", "DISEASE", 168, 175], ["Asthma", "DISEASE", 212, 218], ["asthma", "DISEASE", 355, 361], ["asthma", "DISEASE", 411, 417], ["infection", "DISEASE", 457, 466], ["patients", "ORGANISM", 136, 144], ["coronaviruses", "ORGANISM", 304, 317], ["patients", "ORGANISM", 555, 563], ["AR", "PROTEIN", 245, 247], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 555, 563], ["medicine delivery services", "TREATMENT", 70, 96], ["the COVID", "TEST", 190, 199], ["pandemic", "PROBLEM", 203, 211], ["Asthma", "PROBLEM", 212, 218], ["AR", "PROBLEM", 245, 247], ["PHARMACOLOGIC TREATMENTIt", "TREATMENT", 252, 277], ["common coronaviruses", "PROBLEM", 297, 317], ["asthma symptoms", "PROBLEM", 355, 370], ["asthma", "PROBLEM", 411, 417], ["COVID-19 infection", "PROBLEM", 448, 466], ["related complications", "PROBLEM", 470, 491], ["COVID", "TEST", 569, 574], ["asthma", "OBSERVATION", 355, 361], ["asthma", "OBSERVATION", 411, 417], ["infection", "OBSERVATION", 457, 466]]], ["The WHO recommends avoiding systemic steroid use in patients with COVID-19 (not limited to asthmatic patients), except in some situations such as septic shock and acute respiratory distress syndrome.11242526 All asthmatic patients should be treated with inhaled corticosteroids (ICSs) with/without long-acting beta2-agonists as controllers according to the Global Initiative for Asthma (GINA) guidelines.27 It would be better to use a metered-dose inhaler or dry-powder inhaler rather than a nebulizer in order to prevent the risk of the spread of the virus via the device.28 If patients with mild-to-moderate asthma are well controlled and have sufficient maintenance medications, it would be better to postpone face-to-face visits along with online consultations.29 Considerable efforts should be made to reduce the prescribed dose of systemic corticosteroids in order to avoid an immuno-compromised status in the management of severe asthma.", [["respiratory", "ANATOMY", 169, 180], ["steroid", "CHEMICAL", 37, 44], ["asthmatic", "DISEASE", 91, 100], ["septic shock", "DISEASE", 146, 158], ["acute respiratory distress syndrome", "DISEASE", 163, 198], ["asthmatic", "DISEASE", 212, 221], ["Asthma", "DISEASE", 379, 385], ["asthma", "DISEASE", 610, 616], ["asthma", "DISEASE", 937, 943], ["steroid", "CHEMICAL", 37, 44], ["COVID-19", "CHEMICAL", 66, 74], ["corticosteroids", "CHEMICAL", 262, 277], ["steroid", "SIMPLE_CHEMICAL", 37, 44], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 222, 230], ["inhaled corticosteroids", "SIMPLE_CHEMICAL", 254, 277], ["beta2-agonists", "GENE_OR_GENE_PRODUCT", 310, 324], ["patients", "ORGANISM", 579, 587], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 222, 230], ["patients", "SPECIES", 579, 587], ["systemic steroid use", "TREATMENT", 28, 48], ["COVID", "TEST", 66, 71], ["septic shock", "PROBLEM", 146, 158], ["acute respiratory distress syndrome", "PROBLEM", 163, 198], ["inhaled corticosteroids (ICSs", "TREATMENT", 254, 283], ["long-acting beta2-agonists", "TREATMENT", 298, 324], ["Asthma", "PROBLEM", 379, 385], ["a metered-dose inhaler", "TREATMENT", 433, 455], ["dry-powder inhaler", "TREATMENT", 459, 477], ["a nebulizer", "TREATMENT", 490, 501], ["the virus", "PROBLEM", 548, 557], ["the device", "TREATMENT", 562, 572], ["mild-to-moderate asthma", "PROBLEM", 593, 616], ["sufficient maintenance medications", "TREATMENT", 646, 680], ["systemic corticosteroids", "TREATMENT", 837, 861], ["severe asthma", "PROBLEM", 930, 943], ["septic shock", "OBSERVATION", 146, 158], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory distress", "OBSERVATION", 169, 189], ["syndrome", "OBSERVATION", 190, 198], ["asthmatic", "OBSERVATION", 212, 221], ["mild", "OBSERVATION_MODIFIER", 593, 597], ["moderate", "OBSERVATION_MODIFIER", 601, 609], ["asthma", "OBSERVATION", 610, 616], ["severe", "OBSERVATION_MODIFIER", 930, 936], ["asthma", "OBSERVATION", 937, 943]]], ["Elderly patients with asthma or comorbid conditions should be more strictly monitored.", [["asthma", "DISEASE", 22, 28], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["asthma", "PROBLEM", 22, 28], ["comorbid conditions", "PROBLEM", 32, 51], ["asthma", "OBSERVATION", 22, 28]]], ["Additionally, it is recommended that regular Ig replacement treatment be maintained in asthmatic patients with IgG subclass deficiency suffering from frequent asthma exacerbations.30 Such patients should receive IgG replacement treatment during the pandemic, even though they have the risk of exposure to the virus during their visits in order to prevent asthma exacerbation.31 Taken together, it is important to maintain each patient in an optimal controlled status, and it is not recommended to step-down controller medications that are maintained.2932 If patients have asthma exacerbations, they should be managed according to the GINA guidelines.", [["asthmatic", "DISEASE", 87, 96], ["IgG subclass deficiency", "DISEASE", 111, 134], ["asthma exacerbations", "DISEASE", 159, 179], ["asthma", "DISEASE", 355, 361], ["asthma exacerbations", "DISEASE", 572, 592], ["Ig", "GENE_OR_GENE_PRODUCT", 45, 47], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 188, 196], ["IgG", "GENE_OR_GENE_PRODUCT", 212, 215], ["patient", "ORGANISM", 427, 434], ["patients", "ORGANISM", 558, 566], ["IgG subclass", "PROTEIN", 111, 123], ["IgG", "PROTEIN", 212, 215], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 188, 196], ["patient", "SPECIES", 427, 434], ["patients", "SPECIES", 558, 566], ["regular Ig replacement treatment", "TREATMENT", 37, 69], ["IgG subclass deficiency", "PROBLEM", 111, 134], ["frequent asthma exacerbations", "PROBLEM", 150, 179], ["IgG replacement treatment", "TREATMENT", 212, 237], ["the virus", "PROBLEM", 305, 314], ["asthma exacerbation", "PROBLEM", 355, 374], ["controller medications", "TREATMENT", 507, 529], ["asthma exacerbations", "PROBLEM", 572, 592], ["frequent", "OBSERVATION_MODIFIER", 150, 158], ["asthma", "OBSERVATION", 159, 165], ["asthma", "OBSERVATION", 355, 361], ["asthma", "OBSERVATION", 572, 578]]], ["When conducting lung function tests to monitor control status, the clinical necessity and potential risk of droplet infection are compared carefully based on the judgment of the clinician.", [["lung", "ANATOMY", 16, 20], ["infection", "DISEASE", 116, 125], ["lung", "ORGAN", 16, 20], ["conducting lung function tests", "TEST", 5, 35], ["droplet infection", "PROBLEM", 108, 125], ["lung", "ANATOMY", 16, 20], ["droplet infection", "OBSERVATION", 108, 125]]], ["It is recommended to perform spirometry only when its results can draw an immediate treatment descision.33Asthma (adult and childhood) and AR ::: PHARMACOLOGIC TREATMENTNo specific documents are available for the management of AR during the COVID-19 pandemic; therefore, stepwise treatment should be performed according to symptom severity.", [["AR", "GENE_OR_GENE_PRODUCT", 227, 229], ["AR", "PROTEIN", 139, 141], ["spirometry", "TEST", 29, 39], ["an immediate treatment descision", "TREATMENT", 71, 103], ["AR", "PROBLEM", 227, 229], ["the COVID", "TEST", 237, 246], ["pandemic", "PROBLEM", 250, 258], ["stepwise treatment", "TREATMENT", 271, 289]]], ["However, given the benefits of controlling AR in patients who also have asthma, AR should also be treated more actively.34 In cases of mild/intermittent AR or seasonal rhinitis, face-to-face consultation should be postponed, and instead non-face-to-face consultation (online consultation) is advisable.Asthma (adult and childhood) and AR ::: PHARMACOLOGIC TREATMENTFrom the data available, it is currently clear that children are far less affected by COVID-19 than adults and that clinical symptoms are usually milder in children than in adults.35 Moreover, according to data from the American CDC, it is found that the prevalence of asthma in children (n = 345) with COVID-19 is about 11.5%, which is lower than that in the general population (20%).", [["asthma", "DISEASE", 72, 78], ["rhinitis", "DISEASE", 168, 176], ["Asthma", "DISEASE", 302, 308], ["asthma", "DISEASE", 634, 640], ["AR", "GENE_OR_GENE_PRODUCT", 43, 45], ["patients", "ORGANISM", 49, 57], ["AR", "GENE_OR_GENE_PRODUCT", 80, 82], ["children", "ORGANISM", 417, 425], ["adults", "ORGANISM", 465, 471], ["children", "ORGANISM", 521, 529], ["children", "ORGANISM", 644, 652], ["AR", "PROTEIN", 43, 45], ["AR", "PROTEIN", 80, 82], ["AR", "PROTEIN", 335, 337], ["patients", "SPECIES", 49, 57], ["children", "SPECIES", 417, 425], ["children", "SPECIES", 521, 529], ["children", "SPECIES", 644, 652], ["asthma", "PROBLEM", 72, 78], ["AR", "PROBLEM", 80, 82], ["mild/intermittent AR", "PROBLEM", 135, 155], ["seasonal rhinitis", "PROBLEM", 159, 176], ["Asthma", "PROBLEM", 302, 308], ["AR", "PROBLEM", 335, 337], ["clinical symptoms", "PROBLEM", 481, 498], ["asthma", "PROBLEM", 634, 640], ["COVID", "TEST", 668, 673], ["asthma", "OBSERVATION", 72, 78], ["mild", "OBSERVATION_MODIFIER", 135, 139], ["seasonal", "OBSERVATION_MODIFIER", 159, 167], ["rhinitis", "OBSERVATION", 168, 176], ["asthma", "OBSERVATION", 634, 640], ["lower", "OBSERVATION_MODIFIER", 702, 707]]], ["However, these data must be interpreted with caution because the total number of children included in the study was relatively small, and there was a considerable amount of missing data.36 Although specific studies on the effect of COVID-19 in asthmatic children have not been published yet, COVID-19 may not be an asthmogenic virus in children.", [["COVID-19", "CHEMICAL", 232, 240], ["asthmatic", "DISEASE", 244, 253], ["COVID-19", "CHEMICAL", 292, 300], ["COVID-19", "CHEMICAL", 232, 240], ["children", "ORGANISM", 81, 89], ["COVID-19", "GENE_OR_GENE_PRODUCT", 232, 240], ["children", "ORGANISM", 254, 262], ["children", "ORGANISM", 336, 344], ["children", "SPECIES", 81, 89], ["children", "SPECIES", 254, 262], ["children", "SPECIES", 336, 344], ["the study", "TEST", 102, 111], ["specific studies", "TEST", 198, 214], ["COVID", "TEST", 232, 237], ["small", "OBSERVATION_MODIFIER", 127, 132], ["virus", "OBSERVATION", 327, 332]]], ["In a review article, it is suggested that pediatric allergists should treat patients with asthma, AR or other allergic conditions according to the usual guidelines.", [["asthma", "DISEASE", 90, 96], ["allergic conditions", "DISEASE", 110, 129], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["pediatric allergists", "TREATMENT", 42, 62], ["asthma", "PROBLEM", 90, 96], ["AR", "PROBLEM", 98, 100], ["other allergic conditions", "PROBLEM", 104, 129]]], ["In addition, there is no evidence that currently available asthma and allergy medications, including antihistamines, ICSs and bronchodilators, increase the risk of disease exacerbation by COVID-19.", [["asthma", "DISEASE", 59, 65], ["allergy", "DISEASE", 70, 77], ["ICSs", "CHEMICAL", 117, 121], ["COVID-19", "CHEMICAL", 188, 196], ["COVID-19", "CHEMICAL", 188, 196], ["antihistamines", "SIMPLE_CHEMICAL", 101, 115], ["ICSs", "SIMPLE_CHEMICAL", 117, 121], ["asthma", "PROBLEM", 59, 65], ["allergy medications", "TREATMENT", 70, 89], ["antihistamines", "TREATMENT", 101, 115], ["ICSs", "TREATMENT", 117, 121], ["bronchodilators", "TREATMENT", 126, 141], ["disease exacerbation", "PROBLEM", 164, 184], ["COVID", "TEST", 188, 193], ["no evidence", "UNCERTAINTY", 22, 33], ["asthma", "OBSERVATION", 59, 65], ["disease", "OBSERVATION", 164, 171]]], ["It is also not advisable to stop oral steroids in the management of asthma if the patient is already taking these medications or to avoid oral steroids for the treatment of an acute asthma attack even if it is due to COVID-19.31 Although additional studies are needed in patients with pediatric asthma, it seems that COVID-19 is not a risk for asthma exacerbation in healthy or asthmatic children.", [["oral", "ANATOMY", 33, 37], ["oral", "ANATOMY", 138, 142], ["steroids", "CHEMICAL", 38, 46], ["asthma", "DISEASE", 68, 74], ["steroids", "CHEMICAL", 143, 151], ["asthma", "DISEASE", 182, 188], ["COVID-19.31", "CHEMICAL", 217, 228], ["asthma", "DISEASE", 295, 301], ["asthma", "DISEASE", 344, 350], ["asthmatic", "DISEASE", 378, 387], ["steroids", "CHEMICAL", 38, 46], ["steroids", "CHEMICAL", 143, 151], ["COVID-19.31", "CHEMICAL", 217, 228], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["patient", "ORGANISM", 82, 89], ["oral", "ORGANISM_SUBDIVISION", 138, 142], ["patients", "ORGANISM", 271, 279], ["children", "ORGANISM", 388, 396], ["patient", "SPECIES", 82, 89], ["patients", "SPECIES", 271, 279], ["children", "SPECIES", 388, 396], ["oral steroids", "TREATMENT", 33, 46], ["the management", "TREATMENT", 50, 64], ["asthma", "PROBLEM", 68, 74], ["these medications", "TREATMENT", 108, 125], ["oral steroids", "TREATMENT", 138, 151], ["the treatment", "TREATMENT", 156, 169], ["an acute asthma attack", "PROBLEM", 173, 195], ["COVID", "TEST", 217, 222], ["additional studies", "TEST", 238, 256], ["pediatric asthma", "PROBLEM", 285, 301], ["asthma exacerbation", "PROBLEM", 344, 363], ["asthma", "OBSERVATION", 68, 74], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["asthma", "OBSERVATION", 182, 188], ["asthma", "OBSERVATION", 344, 350]]], ["During the current pandemic, asthmatic children should continue to receive preventive treatment in order to be under good control.", [["asthmatic", "DISEASE", 29, 38], ["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["preventive treatment", "TREATMENT", 75, 95]]], ["There have been no studies on the effect of COVID-19 on AR in children yet.", [["COVID-19", "CHEMICAL", 44, 52], ["COVID-19", "CHEMICAL", 44, 52], ["COVID-19", "GENE_OR_GENE_PRODUCT", 44, 52], ["AR", "GENE_OR_GENE_PRODUCT", 56, 58], ["children", "ORGANISM", 62, 70], ["AR", "PROTEIN", 56, 58], ["children", "SPECIES", 62, 70], ["studies", "TEST", 19, 26], ["COVID", "TEST", 44, 49]]], ["The Allergic Rhinitis and its Impact on Asthma (ARIA)-European Academy of Allergology and Clinical Immunology (EAACI) mentioned that patients with common allergic conditions do not develop additional distinct symptoms or seem to be at increased risk of severe disease when infected with COVID-19.37Atopic dermatitis ::: PHARMACOLOGIC TREATMENTAD is a chronic inflammatory skin disease characterized by recurrent eczematous skin lesions and pruritus.", [["skin", "ANATOMY", 372, 376], ["skin lesions", "ANATOMY", 423, 435], ["Allergic Rhinitis", "DISEASE", 4, 21], ["Asthma", "DISEASE", 40, 46], ["allergic conditions", "DISEASE", 154, 173], ["Atopic dermatitis", "DISEASE", 298, 315], ["skin disease", "DISEASE", 372, 384], ["eczematous skin lesions", "DISEASE", 412, 435], ["pruritus", "DISEASE", 440, 448], ["patients", "ORGANISM", 133, 141], ["skin", "ORGAN", 372, 376], ["eczematous", "PATHOLOGICAL_FORMATION", 412, 422], ["skin lesions", "PATHOLOGICAL_FORMATION", 423, 435], ["patients", "SPECIES", 133, 141], ["The Allergic Rhinitis", "PROBLEM", 0, 21], ["Asthma", "PROBLEM", 40, 46], ["common allergic conditions", "PROBLEM", 147, 173], ["additional distinct symptoms", "PROBLEM", 189, 217], ["severe disease", "PROBLEM", 253, 267], ["COVID", "TEST", 287, 292], ["Atopic dermatitis", "PROBLEM", 298, 315], ["a chronic inflammatory skin disease", "PROBLEM", 349, 384], ["recurrent eczematous skin lesions", "PROBLEM", 402, 435], ["pruritus", "PROBLEM", 440, 448], ["Allergic", "OBSERVATION_MODIFIER", 4, 12], ["Rhinitis", "OBSERVATION", 13, 21], ["Asthma", "OBSERVATION", 40, 46], ["severe", "OBSERVATION_MODIFIER", 253, 259], ["disease", "OBSERVATION", 260, 267], ["chronic", "OBSERVATION_MODIFIER", 351, 358], ["inflammatory", "OBSERVATION_MODIFIER", 359, 371], ["skin", "ANATOMY", 372, 376], ["disease", "OBSERVATION", 377, 384], ["recurrent", "OBSERVATION_MODIFIER", 402, 411], ["eczematous", "OBSERVATION_MODIFIER", 412, 422], ["skin", "ANATOMY", 423, 427], ["lesions", "OBSERVATION", 428, 435], ["pruritus", "OBSERVATION", 440, 448]]], ["Not only is AD associated with airway diseases such as asthma and AR, but patients with severe AD are also likely to be vulnerable to respiratory infections because of their systemic immunosuppressive treatment.38 However, discontinuation of immunosuppressive agents should not be applied in all AD cases, since it can lead to the aggravation of AD and even to disseminated viral skin diseases such as eczema herpeticum.39 Maintenance of skin hygiene and the use of moisturizers and topical immunosuppressive agents would be preferable options in the treatment of AD.", [["airway", "ANATOMY", 31, 37], ["respiratory", "ANATOMY", 134, 145], ["skin", "ANATOMY", 380, 384], ["skin", "ANATOMY", 438, 442], ["AD", "DISEASE", 12, 14], ["airway diseases", "DISEASE", 31, 46], ["asthma", "DISEASE", 55, 61], ["AD", "DISEASE", 95, 97], ["respiratory infections", "DISEASE", 134, 156], ["AD", "DISEASE", 296, 298], ["AD", "DISEASE", 346, 348], ["viral skin diseases", "DISEASE", 374, 393], ["eczema herpeticum", "DISEASE", 402, 419], ["AD", "DISEASE", 564, 566], ["airway", "MULTI-TISSUE_STRUCTURE", 31, 37], ["AR", "GENE_OR_GENE_PRODUCT", 66, 68], ["patients", "ORGANISM", 74, 82], ["skin", "ORGAN", 380, 384], ["skin", "ORGAN", 438, 442], ["patients", "SPECIES", 74, 82], ["airway diseases", "PROBLEM", 31, 46], ["asthma", "PROBLEM", 55, 61], ["AR", "PROBLEM", 66, 68], ["severe AD", "PROBLEM", 88, 97], ["respiratory infections", "PROBLEM", 134, 156], ["their systemic immunosuppressive treatment", "TREATMENT", 168, 210], ["immunosuppressive agents", "TREATMENT", 242, 266], ["the aggravation of AD", "PROBLEM", 327, 348], ["disseminated viral skin diseases", "PROBLEM", 361, 393], ["eczema herpeticum", "PROBLEM", 402, 419], ["skin hygiene", "TREATMENT", 438, 450], ["moisturizers", "TREATMENT", 466, 478], ["topical immunosuppressive agents", "TREATMENT", 483, 515], ["AD", "PROBLEM", 564, 566], ["airway", "ANATOMY", 31, 37], ["diseases", "OBSERVATION", 38, 46], ["asthma", "OBSERVATION", 55, 61], ["respiratory", "ANATOMY", 134, 145], ["infections", "OBSERVATION", 146, 156], ["disseminated", "OBSERVATION_MODIFIER", 361, 373], ["viral", "OBSERVATION_MODIFIER", 374, 379], ["skin", "ANATOMY", 380, 384], ["diseases", "OBSERVATION", 385, 393], ["eczema", "OBSERVATION", 402, 408], ["skin", "ANATOMY", 438, 442], ["hygiene", "OBSERVATION", 443, 450]]], ["However, systemic immunosuppressant or immune-modulating agents, such as dupilumab, seem unlikely to elevate the risk of COVID-19.", [["dupilumab", "CHEMICAL", 73, 82], ["dupilumab", "CHEMICAL", 73, 82], ["COVID-19", "CHEMICAL", 121, 129], ["dupilumab", "SIMPLE_CHEMICAL", 73, 82], ["systemic immunosuppressant", "TREATMENT", 9, 35], ["immune-modulating agents", "TREATMENT", 39, 63], ["COVID", "TEST", 121, 126]]], ["A recent Italian study reported that only 2 (0.82%) of 245 AD patients treated with dupilumab developed COVID-19, and they successfully recovered from COVID-19 while maintaining dupilumab therapy.40 Taken together, to maintain optimal skincare, topical immunosuppressant and immune-modulating therapies should not be deferred or stopped if needed on the basis of physicians' judgment to prevent flares of AD.Chronic urticaria (CU) and drug allergy ::: PHARMACOLOGIC TREATMENTCU is defined as urticaria that has been present for at least 6 weeks and required long-term maintenance therapy because symptoms can last for years in many cases.41 In healthy subjects without any underlying diseases, CU symptoms are not usually life-threatening, and visiting healthcare facilities needs to be delayed and rescheduled (a few weeks to a few months) during the COVID-19 pandemic.", [["AD", "DISEASE", 59, 61], ["dupilumab", "CHEMICAL", 84, 93], ["COVID-19", "CHEMICAL", 151, 159], ["dupilumab", "CHEMICAL", 178, 187], ["AD", "DISEASE", 405, 407], ["Chronic urticaria", "DISEASE", 408, 425], ["CU", "DISEASE", 427, 429], ["drug allergy", "DISEASE", 435, 447], ["urticaria", "DISEASE", 492, 501], ["dupilumab", "CHEMICAL", 84, 93], ["COVID-19", "CHEMICAL", 151, 159], ["dupilumab", "CHEMICAL", 178, 187], ["patients", "ORGANISM", 62, 70], ["dupilumab", "SIMPLE_CHEMICAL", 84, 93], ["dupilumab", "SIMPLE_CHEMICAL", 178, 187], ["patients", "SPECIES", 62, 70], ["A recent Italian study", "TEST", 0, 22], ["dupilumab", "TREATMENT", 84, 93], ["COVID", "TEST", 104, 109], ["COVID", "TEST", 151, 156], ["dupilumab therapy", "TREATMENT", 178, 195], ["topical immunosuppressant", "TREATMENT", 245, 270], ["immune-modulating therapies", "TREATMENT", 275, 302], ["flares of AD", "PROBLEM", 395, 407], ["Chronic urticaria", "PROBLEM", 408, 425], ["urticaria", "PROBLEM", 492, 501], ["long-term maintenance therapy", "TREATMENT", 558, 587], ["symptoms", "PROBLEM", 596, 604], ["any underlying diseases", "PROBLEM", 669, 692], ["CU symptoms", "PROBLEM", 694, 705], ["the COVID", "TEST", 848, 857], ["pandemic", "PROBLEM", 861, 869], ["urticaria", "OBSERVATION", 416, 425], ["urticaria", "OBSERVATION", 492, 501], ["long-term", "OBSERVATION_MODIFIER", 558, 567], ["diseases", "OBSERVATION", 684, 692]]], ["To avoid this highly contagious disease, it is necessary to reduce unnecessary visits to hospitals and to be isolated at home.", [["this highly contagious disease", "PROBLEM", 9, 39]]], ["In particular, older patients with comorbidities, such as hypertension, diabetes, cardiovascular disease and chronic respiratory disease, are vulnerable to infections and are more cautious in visiting hospitals.4243 However, visiting healthcare facilities would be of some benefit in patients experiencing significant deterioration in the quality of life without regular medication.", [["cardiovascular", "ANATOMY", 82, 96], ["respiratory", "ANATOMY", 117, 128], ["hypertension", "DISEASE", 58, 70], ["diabetes", "DISEASE", 72, 80], ["cardiovascular disease", "DISEASE", 82, 104], ["chronic respiratory disease", "DISEASE", 109, 136], ["infections", "DISEASE", 156, 166], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 284, 292], ["comorbidities", "PROBLEM", 35, 48], ["hypertension", "PROBLEM", 58, 70], ["diabetes", "PROBLEM", 72, 80], ["cardiovascular disease", "PROBLEM", 82, 104], ["chronic respiratory disease", "PROBLEM", 109, 136], ["infections", "PROBLEM", 156, 166], ["significant deterioration", "PROBLEM", 306, 331], ["regular medication", "TREATMENT", 363, 381], ["hypertension", "OBSERVATION", 58, 70], ["diabetes", "OBSERVATION", 72, 80], ["cardiovascular", "ANATOMY", 82, 96], ["disease", "OBSERVATION", 97, 104], ["chronic", "OBSERVATION_MODIFIER", 109, 116], ["respiratory disease", "OBSERVATION", 117, 136], ["infections", "OBSERVATION", 156, 166], ["significant", "OBSERVATION_MODIFIER", 306, 317], ["deterioration", "OBSERVATION", 318, 331]]], ["When patients develop severe symptoms, such as anaphylaxis, angioedema, bronchospasm, dizziness, and hypotension accompanying urticaria, they should visit the emergency department to treat symptoms.", [["anaphylaxis", "DISEASE", 47, 58], ["angioedema", "DISEASE", 60, 70], ["bronchospasm", "DISEASE", 72, 84], ["dizziness", "DISEASE", 86, 95], ["hypotension", "DISEASE", 101, 112], ["urticaria", "DISEASE", 126, 135], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["severe symptoms", "PROBLEM", 22, 37], ["anaphylaxis", "PROBLEM", 47, 58], ["angioedema", "PROBLEM", 60, 70], ["bronchospasm", "PROBLEM", 72, 84], ["dizziness", "PROBLEM", 86, 95], ["hypotension", "PROBLEM", 101, 112], ["urticaria", "PROBLEM", 126, 135], ["symptoms", "PROBLEM", 189, 197], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["symptoms", "OBSERVATION", 29, 37], ["bronchospasm", "OBSERVATION", 72, 84]]], ["Patients are required to follow all the policies for infection control.", [["infection", "DISEASE", 53, 62], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infection control", "TREATMENT", 53, 70], ["infection", "OBSERVATION", 53, 62]]], ["Physicians should delay the evaluation of the causes of CU and reschedule patient outpatient visits until the pandemic is over.Chronic urticaria (CU) and drug allergy ::: PHARMACOLOGIC TREATMENTDrug allergy can be managed according to similar basic principles.", [["CU", "DISEASE", 56, 58], ["Chronic urticaria", "DISEASE", 127, 144], ["CU", "DISEASE", 146, 148], ["drug allergy", "DISEASE", 154, 166], ["allergy", "DISEASE", 199, 206], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["the evaluation", "TEST", 24, 38], ["Chronic urticaria", "PROBLEM", 127, 144], ["PHARMACOLOGIC TREATMENTDrug allergy", "TREATMENT", 171, 206], ["urticaria", "OBSERVATION", 135, 144]]], ["Drug allergy should be immediately treated especially in the presence of symptoms, such as generalized urticaria, angioedema, bronchospasm and hypotension.", [["Drug allergy", "DISEASE", 0, 12], ["urticaria", "DISEASE", 103, 112], ["angioedema", "DISEASE", 114, 124], ["bronchospasm", "DISEASE", 126, 138], ["hypotension", "DISEASE", 143, 154], ["Drug allergy", "PROBLEM", 0, 12], ["symptoms", "PROBLEM", 73, 81], ["generalized urticaria", "PROBLEM", 91, 112], ["angioedema", "PROBLEM", 114, 124], ["bronchospasm", "PROBLEM", 126, 138], ["hypotension", "PROBLEM", 143, 154], ["generalized", "OBSERVATION_MODIFIER", 91, 102], ["urticaria", "OBSERVATION", 103, 112], ["angioedema", "OBSERVATION", 114, 124], ["bronchospasm", "OBSERVATION", 126, 138], ["hypotension", "OBSERVATION", 143, 154]]], ["Epinephrine injection is contemplated in cases of suspected anaphylaxis.", [["Epinephrine", "CHEMICAL", 0, 11], ["anaphylaxis", "DISEASE", 60, 71], ["Epinephrine", "CHEMICAL", 0, 11], ["Epinephrine", "SIMPLE_CHEMICAL", 0, 11], ["Epinephrine injection", "TREATMENT", 0, 21], ["anaphylaxis", "PROBLEM", 60, 71], ["anaphylaxis", "OBSERVATION", 60, 71]]], ["Diagnostic procedures, such as drug challenge and drug skin tests, are required to be delayed until the pandemic is over.", [["skin", "ANATOMY", 55, 59], ["skin", "ORGAN", 55, 59], ["Diagnostic procedures", "TEST", 0, 21], ["drug challenge", "TREATMENT", 31, 45], ["drug skin tests", "TEST", 50, 65]]], ["Drug desensitization is actively considered in patients who need immediate administration of hypersensitivity drugs.", [["hypersensitivity", "DISEASE", 93, 109], ["Drug", "SIMPLE_CHEMICAL", 0, 4], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["Drug desensitization", "TREATMENT", 0, 20], ["hypersensitivity drugs", "TREATMENT", 93, 115]]], ["In principle, desensitization needs to be performed in the hospital according to the infection control procedure.44BIOLOGIC TREATMENTRegular administration of biologics, such as anti-IL-5, anti-IL-4 and anti-IgE antibodies, has become a common treatment option for severe asthma as well as for uncontrolled cases of CU and AD.", [["infection", "DISEASE", 85, 94], ["asthma", "DISEASE", 272, 278], ["CU", "DISEASE", 316, 318], ["AD", "DISEASE", 323, 325], ["anti-IL-5", "GENE_OR_GENE_PRODUCT", 178, 187], ["anti-IL-4", "GENE_OR_GENE_PRODUCT", 189, 198], ["anti-IgE antibodies", "GENE_OR_GENE_PRODUCT", 203, 222], ["anti-IL-5, anti-IL-4", "PROTEIN", 178, 198], ["anti-IgE antibodies", "PROTEIN", 203, 222], ["desensitization", "TREATMENT", 14, 29], ["the infection control procedure", "TREATMENT", 81, 112], ["BIOLOGIC TREATMENTRegular administration of biologics", "TREATMENT", 115, 168], ["anti-IL", "TREATMENT", 178, 185], ["anti-IL", "TREATMENT", 189, 196], ["anti-IgE antibodies", "TREATMENT", 203, 222], ["a common treatment option", "TREATMENT", 235, 260], ["severe asthma", "PROBLEM", 265, 278], ["infection", "OBSERVATION", 85, 94], ["asthma", "OBSERVATION", 272, 278]]], ["It is critical to control disease activity through the prevention of exacerbations.45 In addition, there have been no studies showing that biological agents may induce immune suppression and increase the risk of COVID-19.", [["COVID-19", "CHEMICAL", 212, 220], ["exacerbations", "PROBLEM", 69, 82], ["studies", "TEST", 118, 125], ["biological agents", "TREATMENT", 139, 156], ["immune suppression", "PROBLEM", 168, 186], ["COVID", "TEST", 212, 217], ["exacerbations", "OBSERVATION", 69, 82]]], ["For these reasons, there is no need to stop or reduce the dosage of biologics scheduled.29 However, most of the biologics require periodic parenteral/subcutaneous administration, for which such patients have to visit an allergy clinic to receive medications according to a treatment protocol.", [["subcutaneous", "ANATOMY", 150, 162], ["allergy", "DISEASE", 220, 227], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["the dosage of biologics", "TREATMENT", 54, 77], ["periodic parenteral/subcutaneous administration", "TREATMENT", 130, 177], ["medications", "TREATMENT", 246, 257], ["a treatment protocol", "TREATMENT", 271, 291]]], ["In these patients, it is advisable to provide required protective equipment to both HCWs and patients and to administer the medication with minimal contact.910BIOLOGIC TREATMENTIn allergic children, biologics are mainly used in patients with severe eczema or severe asthma.", [["allergic", "DISEASE", 180, 188], ["eczema", "DISEASE", 249, 255], ["asthma", "DISEASE", 266, 272], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 93, 101], ["children", "ORGANISM", 189, 197], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 93, 101], ["children", "SPECIES", 189, 197], ["patients", "SPECIES", 228, 236], ["protective equipment", "TREATMENT", 55, 75], ["the medication", "TREATMENT", 120, 134], ["biologics", "TREATMENT", 199, 208], ["severe eczema", "PROBLEM", 242, 255], ["severe asthma", "PROBLEM", 259, 272], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["eczema", "OBSERVATION", 249, 255], ["severe", "OBSERVATION_MODIFIER", 259, 265], ["asthma", "OBSERVATION", 266, 272]]], ["There have been no studies or guidelines on the usage of biologics in allergic children during the COVID-19 pandemic.", [["allergic", "DISEASE", 70, 78], ["children", "ORGANISM", 79, 87], ["children", "SPECIES", 79, 87], ["studies", "TEST", 19, 26], ["the COVID", "TEST", 95, 104], ["pandemic", "PROBLEM", 108, 116]]], ["A case report suggested that immunosuppressive therapy with biologics might be effective in COVID-19 patients with an overactive immune response, cytokine storm; however, there have been no systematic studies on this.46 When children under treatment with biologics are infected with COVID-19 and present with only mild symptoms, the treatment can be continued.", [["patients", "ORGANISM", 101, 109], ["children", "ORGANISM", 225, 233], ["cytokine", "PROTEIN", 146, 154], ["patients", "SPECIES", 101, 109], ["children", "SPECIES", 225, 233], ["immunosuppressive therapy", "TREATMENT", 29, 54], ["biologics", "TREATMENT", 60, 69], ["an overactive immune response", "PROBLEM", 115, 144], ["systematic studies", "TEST", 190, 208], ["treatment", "TREATMENT", 240, 249], ["biologics", "TREATMENT", 255, 264], ["COVID", "TREATMENT", 283, 288], ["mild symptoms", "PROBLEM", 314, 327], ["the treatment", "TREATMENT", 329, 342], ["mild", "OBSERVATION_MODIFIER", 314, 318], ["symptoms", "OBSERVATION", 319, 327]]], ["However, when either adults or children who develop severe COVID-19 symptoms, the treatment should be delayed until they completely recover.CONCLUSIONIt is still uncertain whether COVID-19 increases the risk of aggravating asthma or allergic diseases.", [["COVID", "DISEASE", 59, 64], ["asthma", "DISEASE", 223, 229], ["allergic diseases", "DISEASE", 233, 250], ["COVID-19", "CHEMICAL", 180, 188], ["children", "ORGANISM", 31, 39], ["COVID-19", "GENE_OR_GENE_PRODUCT", 180, 188], ["children", "SPECIES", 31, 39], ["severe COVID-19 symptoms", "PROBLEM", 52, 76], ["the treatment", "TREATMENT", 78, 91], ["COVID", "TEST", 180, 185], ["aggravating asthma", "PROBLEM", 211, 229], ["allergic diseases", "PROBLEM", 233, 250], ["aggravating", "OBSERVATION_MODIFIER", 211, 222], ["asthma", "OBSERVATION", 223, 229], ["allergic diseases", "OBSERVATION", 233, 250]]], ["Detailed monitoring and optimal treatment with AIT, ICS and biologics need to be continued in all patients suffering from asthma and allergic diseases.", [["ICS", "CHEMICAL", 52, 55], ["asthma", "DISEASE", 122, 128], ["allergic diseases", "DISEASE", 133, 150], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["Detailed monitoring", "TEST", 0, 19], ["AIT", "TREATMENT", 47, 50], ["ICS", "TREATMENT", 52, 55], ["biologics", "TREATMENT", 60, 69], ["asthma", "PROBLEM", 122, 128], ["allergic diseases", "PROBLEM", 133, 150], ["asthma", "OBSERVATION", 122, 128], ["allergic diseases", "OBSERVATION", 133, 150]]], ["This can be achieved in a safe condition using optimal protective measures.", [["optimal protective measures", "TREATMENT", 47, 74]]], ["Patients at high risk (older age and comorbid conditions) should be monitored more strictly.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["comorbid conditions", "PROBLEM", 37, 56]]], ["We applaud all the allergy/immunology specialists who strive to stay up for optimal health protection by focusing on patient management during the COVID-19 pandemic.", [["allergy", "DISEASE", 19, 26], ["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["patient management", "TREATMENT", 117, 135], ["the COVID", "TEST", 143, 152], ["pandemic", "PROBLEM", 156, 164]]]], "PMC7511853": [["IntroductionIn December 2019, another outbreak of acute respiratory disease caused by a novel coronavirus (CoV) was reported in Wuhan, China [1,2].", [["respiratory", "ANATOMY", 56, 67], ["respiratory disease", "DISEASE", 56, 75], ["coronavirus", "ORGANISM", 94, 105], ["CoV", "ORGANISM", 107, 110], ["coronavirus", "SPECIES", 94, 105], ["CoV", "SPECIES", 107, 110], ["acute respiratory disease", "PROBLEM", 50, 75], ["a novel coronavirus (CoV", "PROBLEM", 86, 110], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory disease", "OBSERVATION", 56, 75]]], ["Analysis of the complete genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) demonstrated that it belongs to betacoronavirus, but it is different from severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory coronavirus (MERS-CoV), which caused previous epidemics [1].", [["acute respiratory syndrome coronavirus", "DISEASE", 42, 80], ["acute respiratory syndrome coronavirus", "DISEASE", 176, 214], ["SARS-CoV)", "DISEASE", 216, 225], ["Respiratory coronavirus", "DISEASE", 242, 265], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 35, 82], ["SARS-CoV2", "ORGANISM", 84, 93], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 127, 142], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 169, 214], ["SARS-CoV", "ORGANISM", 216, 224], ["Middle East Respiratory coronavirus", "ORGANISM", 230, 265], ["MERS-CoV", "ORGANISM", 267, 275], ["severe acute respiratory syndrome coronavirus", "SPECIES", 35, 80], ["SARS-CoV2", "SPECIES", 84, 93], ["severe acute respiratory syndrome coronavirus", "SPECIES", 169, 214], ["SARS-CoV", "SPECIES", 216, 224], ["Middle East Respiratory coronavirus", "SPECIES", 230, 265], ["MERS-CoV", "SPECIES", 267, 275], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 35, 80], ["betacoronavirus", "PROBLEM", 127, 142], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 169, 214], ["Middle East Respiratory coronavirus", "PROBLEM", 230, 265], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory syndrome", "OBSERVATION", 48, 68], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["acute", "OBSERVATION_MODIFIER", 176, 181], ["respiratory syndrome coronavirus", "OBSERVATION", 182, 214], ["Middle", "ANATOMY_MODIFIER", 230, 236], ["Respiratory coronavirus", "ANATOMY", 242, 265]]], ["This new disease was named coronavirus disease 2019 (COVID-19), previously known as novel coronavirus [2019-nCoV], by the World Health Organization.", [["coronavirus disease", "DISEASE", 27, 46], ["coronavirus", "ORGANISM", 27, 38], ["coronavirus", "ORGANISM", 90, 101], ["coronavirus disease 2019 (COVID-19", "SPECIES", 27, 61], ["This new disease", "PROBLEM", 0, 16], ["coronavirus disease", "PROBLEM", 27, 46], ["COVID", "TEST", 53, 58], ["novel coronavirus", "PROBLEM", 84, 101], ["new", "OBSERVATION_MODIFIER", 5, 8], ["disease", "OBSERVATION", 9, 16], ["coronavirus disease", "OBSERVATION", 27, 46]]], ["COVID-19 was first reported in China, and it has now spread quickly to distant nations, including France and the USA.", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5]]], ["The number of cases within and outside China are increasing abruptly, and no drug has proved to be effective.", [["increasing", "OBSERVATION_MODIFIER", 49, 59]]], ["Therefore, it is crucial to discover and develop drugs to treat the disease.", [["drugs", "TREATMENT", 49, 54], ["the disease", "PROBLEM", 64, 75], ["disease", "OBSERVATION", 68, 75]]], ["An alternative treatment for COVID-19 is the combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, which was an effective therapy previously used against SARS-CoV [3].", [["COVID-19", "CHEMICAL", 29, 37], ["lopinavir", "CHEMICAL", 91, 100], ["ritonavir", "CHEMICAL", 105, 114], ["SARS", "DISEASE", 171, 175], ["COVID-19", "CHEMICAL", 29, 37], ["lopinavir", "CHEMICAL", 91, 100], ["ritonavir", "CHEMICAL", 105, 114], ["COVID-19", "SIMPLE_CHEMICAL", 29, 37], ["HIV-1", "ORGANISM", 64, 69], ["lopinavir", "SIMPLE_CHEMICAL", 91, 100], ["ritonavir", "SIMPLE_CHEMICAL", 105, 114], ["SARS-CoV", "ORGANISM", 171, 179], ["HIV-1", "SPECIES", 64, 69], ["HIV-1", "SPECIES", 64, 69], ["SARS-CoV", "SPECIES", 171, 179], ["An alternative treatment", "TREATMENT", 0, 24], ["COVID", "TEST", 29, 34], ["two HIV-1 protease inhibitors", "TREATMENT", 60, 89], ["lopinavir", "TREATMENT", 91, 100], ["ritonavir", "TREATMENT", 105, 114], ["an effective therapy", "TREATMENT", 126, 146]]], ["Previous theoretical studies demonstrated that lopinavir and ritonavir form stable complexes with the SARS-CoV main proteinase (SARS-CoV Mpro), with similar affinity [4].", [["lopinavir", "CHEMICAL", 47, 56], ["ritonavir", "CHEMICAL", 61, 70], ["lopinavir", "CHEMICAL", 47, 56], ["ritonavir", "CHEMICAL", 61, 70], ["lopinavir", "SIMPLE_CHEMICAL", 47, 56], ["ritonavir", "SIMPLE_CHEMICAL", 61, 70], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 128, 141], ["SARS-CoV main proteinase", "PROTEIN", 102, 126], ["SARS-CoV Mpro", "PROTEIN", 128, 141], ["SARS-CoV", "SPECIES", 102, 110], ["Previous theoretical studies", "TEST", 0, 28], ["lopinavir", "TREATMENT", 47, 56], ["ritonavir", "TREATMENT", 61, 70], ["the SARS", "TEST", 98, 106]]], ["Similar to SARS-CoV Mpro, the main proteinase of SARS-CoV2 (SARS-CoV2 Mpro) exhibits a crucial role in the proteolytic activity of replicase polyproteins, which are indispensable for viral replication.", [["SARS", "DISEASE", 11, 15], ["SARS-CoV Mpro", "ORGANISM", 11, 24], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 49, 58], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 60, 74], ["proteinase", "PROTEIN", 35, 45], ["SARS-CoV2", "PROTEIN", 49, 58], ["SARS-CoV2 Mpro", "DNA", 60, 74], ["replicase polyproteins", "PROTEIN", 131, 153], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "TEST", 11, 15], ["SARS", "TEST", 49, 53], ["SARS", "TEST", 60, 64], ["replicase polyproteins", "PROBLEM", 131, 153], ["viral replication", "PROBLEM", 183, 200], ["main", "OBSERVATION_MODIFIER", 30, 34], ["SARS", "OBSERVATION", 49, 53], ["crucial", "OBSERVATION_MODIFIER", 87, 94], ["replicase polyproteins", "OBSERVATION", 131, 153], ["viral replication", "OBSERVATION", 183, 200]]], ["In addition, an alignment of SARS-CoV Mpro and SARS-CoV2 Mpro shows that they share a high percentage of sequence identity (\u226595%).", [["SARS", "DISEASE", 29, 33], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 29, 42], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 47, 61], ["SARS-CoV Mpro and SARS-CoV2 Mpro", "DNA", 29, 61], ["SARS-CoV", "SPECIES", 29, 37], ["an alignment of SARS", "TEST", 13, 33], ["CoV Mpro", "TEST", 34, 42], ["SARS-CoV2 Mpro", "TEST", 47, 61]]], ["Several theoretical studies have been performed to identify inhibitors against SARS-CoV Mpro.", [["SARS", "DISEASE", 79, 83], ["SARS-CoV Mpro", "ORGANISM", 79, 92], ["SARS-CoV", "SPECIES", 79, 87], ["Several theoretical studies", "TEST", 0, 27], ["SARS", "PROBLEM", 79, 83]]], ["Xu et al. constructed a three-dimensional homology model of SARS-CoV2 Mpro based on SARS-CoV Mpro and screened it against 1903 drug inhibitors via protein modeling and virtual screening, highlighting nelfinavir as a potential inhibitor against SARS-CoV2 Mpro [5].", [["SARS", "DISEASE", 60, 64], ["nelfinavir", "CHEMICAL", 200, 210], ["nelfinavir", "CHEMICAL", 200, 210], ["SARS-CoV Mpro", "ORGANISM", 84, 97], ["nelfinavir", "SIMPLE_CHEMICAL", 200, 210], ["SARS-CoV", "SPECIES", 84, 92], ["SARS", "PROBLEM", 60, 64], ["SARS", "PROBLEM", 84, 88], ["protein modeling", "TEST", 147, 163], ["virtual screening", "TEST", 168, 185], ["nelfinavir", "TREATMENT", 200, 210], ["a potential inhibitor", "TREATMENT", 214, 235], ["SARS", "PROBLEM", 244, 248]]], ["Using X-ray crystallography, the structure of SARS-CoV2 Mpro has recently been solved in complex with the inhibitor N3 (PDB ID: 6LU7), revealing that its structural topology is similar to that of other CoV proteinases.", [["SARS", "DISEASE", 46, 50], ["Mpro", "CHEMICAL", 56, 60], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 46, 60], ["CoV proteinases", "GENE_OR_GENE_PRODUCT", 202, 217], ["Mpro", "PROTEIN", 56, 60], ["6LU7", "PROTEIN", 128, 132], ["CoV proteinases", "PROTEIN", 202, 217], ["X-ray crystallography", "TEST", 6, 27], ["SARS", "PROBLEM", 46, 50], ["the inhibitor N3", "TREATMENT", 102, 118], ["other CoV proteinases", "PROBLEM", 196, 217], ["SARS", "OBSERVATION", 46, 50]]], ["SARS-CoV2 Mpro is built in a homodimer conformation, formed of three domains: domains 1 (residues 8\u2013101) and 2 (residues 102\u2013184) are \u03b2-barrels, and domain 3 (residues 201\u2013306) comprises mainly \u03b1-helices, and it is connected to domain 2 by an elongated loop region (residues 185\u2013200).", [["SARS", "DISEASE", 0, 4], ["\u03b2-barrels", "GENE_OR_GENE_PRODUCT", 134, 143], ["\u2013306", "AMINO_ACID", 171, 175], ["\u03b1-helices", "GENE_OR_GENE_PRODUCT", 194, 203], ["SARS-CoV2 Mpro", "DNA", 0, 14], ["domains 1", "PROTEIN", 78, 87], ["residues 8\u2013101) and 2", "PROTEIN", 89, 110], ["residues 102\u2013184", "PROTEIN", 112, 128], ["\u03b2-barrels", "PROTEIN", 134, 143], ["domain 3", "PROTEIN", 149, 157], ["residues 201\u2013306", "PROTEIN", 159, 175], ["\u03b1-helices", "PROTEIN", 194, 203], ["domain 2", "PROTEIN", 228, 236], ["elongated loop region", "PROTEIN", 243, 264], ["an elongated loop region", "TREATMENT", 240, 264], ["elongated", "OBSERVATION_MODIFIER", 243, 252], ["loop", "OBSERVATION", 253, 257]]], ["The substrate-binding site of SARS-CoV2 Mpro is situated in a cleft between domain 1 and domain 2.", [["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 30, 39], ["substrate-binding site", "DNA", 4, 26], ["SARS-CoV2 Mpro", "DNA", 30, 44], ["domain 1", "PROTEIN", 76, 84], ["domain 2", "PROTEIN", 89, 97], ["SARS", "PROBLEM", 30, 34], ["SARS", "OBSERVATION", 30, 34], ["cleft", "OBSERVATION", 62, 67]]], ["Inhibitor N3 was developed using theoretical methods and it can specifically inhibit Mpro from multiple coronaviruses, including SARS-CoV, SARS-CoV2 and MERS-CoV [6, 7, 8, 9, 10, 11].", [["Mpro", "GENE_OR_GENE_PRODUCT", 85, 89], ["SARS-CoV", "ORGANISM", 129, 137], ["SARS-CoV2", "ORGANISM", 139, 148], ["MERS-CoV", "ORGANISM", 153, 161], ["Mpro", "PROTEIN", 85, 89], ["SARS-CoV", "SPECIES", 129, 137], ["MERS-CoV", "SPECIES", 153, 161], ["Inhibitor N3", "TREATMENT", 0, 12], ["theoretical methods", "TREATMENT", 33, 52], ["multiple coronaviruses", "PROBLEM", 95, 117], ["SARS", "PROBLEM", 129, 133], ["CoV", "TEST", 134, 137], ["SARS", "PROBLEM", 139, 143], ["CoV2", "TEST", 144, 148], ["MERS", "TEST", 153, 157], ["multiple", "OBSERVATION_MODIFIER", 95, 103], ["coronaviruses", "OBSERVATION", 104, 117]]], ["Inhibitor N3 is stabilized at the substrate binding site in an extended conformation by conserved residues (H41 and C145) involved in the catalytic activity of the enzyme, in a similar manner to that observed for other CoV proteinases [4].", [["substrate binding site", "PROTEIN", 34, 56], ["enzyme", "PROTEIN", 164, 170], ["CoV proteinases", "PROTEIN", 219, 234], ["Inhibitor N3", "TREATMENT", 0, 12], ["the enzyme", "TEST", 160, 170], ["other CoV proteinases", "PROBLEM", 213, 234]]], ["The backbone atoms of inhibitor form an antiparallel sheet with some residues of the long strand (residues 155\u2013168), and with residues 189\u2013191 of the loop that connects domain 2 to domain 3. (see Scheme 1)IntroductionProteases are typical targets for drug development because of their recognized enzymatic mechanism, however, many new potential drugs have been ineffective either because of a lack of ligand specificity or because of our incomplete understanding of the conformational state under a biological context of the targeted protease [12].", [["domain 2", "PROTEIN", 169, 177], ["domain 3", "PROTEIN", 181, 189], ["The backbone atoms of inhibitor", "TREATMENT", 0, 31], ["an antiparallel sheet", "TREATMENT", 37, 58], ["IntroductionProteases", "TREATMENT", 205, 226], ["drug development", "TREATMENT", 251, 267], ["the targeted protease", "TREATMENT", 521, 542]]], ["In order to successfully develop or identify new protease inhibitors, it is necessary to understand important structural features of the protease functions to expand the platform of inhibitor development.", [["protease", "PROTEIN", 137, 145], ["new protease inhibitors", "TREATMENT", 45, 68], ["the protease functions", "PROBLEM", 133, 155], ["inhibitor development", "TREATMENT", 182, 203]]], ["Although previous studies have considered the monomeric state of SARS-CoV Mpro or SARS-CoV2 Mpro to search for new inhibitors [5,13] or to understand the molecular basis of inhibitor recognition [4], kinetic studies have indicated that the active form of the SARS CoV main proteinase corresponds to a homodimer [14], suggesting significant conformational differences between the monomer and dimeric states and indicating that drug discovery combining docking and MD simulations should be performed using the homodimeric conformation instead of the monomer.", [["SARS", "DISEASE", 65, 69], ["SARS", "DISEASE", 259, 263], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 82, 96], ["SARS-CoV2 Mpro", "PROTEIN", 82, 96], ["SARS CoV main proteinase", "PROTEIN", 259, 283], ["dimeric states", "PROTEIN", 391, 405], ["SARS-CoV", "SPECIES", 65, 73], ["SARS CoV", "SPECIES", 259, 267], ["previous studies", "TEST", 9, 25], ["SARS", "PROBLEM", 65, 69], ["SARS", "PROBLEM", 82, 86], ["new inhibitors", "PROBLEM", 111, 125], ["kinetic studies", "TEST", 200, 215], ["the SARS CoV main proteinase", "PROBLEM", 255, 283], ["significant", "OBSERVATION_MODIFIER", 328, 339], ["conformational", "OBSERVATION", 340, 354]]], ["In the present research, the crystallographic dimeric structure of SARS-CoV2 Mpro, the first released structure of this enzyme available at the protein data bank (PDB ID: 6LU7), was docked against 15 Food and Drug Administration (FDA) approved drugs identified in a previous study [5] and then submitted to MD simulations coupled to the MM/GBSA approach to dissect the structural and energetic basis of molecular recognition considering the monomeric and dimeric states.", [["SARS", "DISEASE", 67, 71], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 67, 81], ["enzyme", "PROTEIN", 120, 126], ["monomeric and dimeric states", "PROTEIN", 441, 469], ["this enzyme", "TEST", 115, 126], ["drugs", "TREATMENT", 244, 249], ["a previous study", "TEST", 264, 280], ["the MM/GBSA approach", "TREATMENT", 333, 353]]], ["In addition, comparative analysis was performed for dimeric SARS-CoV2 Mpro and SARS-CoV Mpro coupling to lopinavir and ritonavir, which have been shown to be an effective therapy against SARS-CoV Mpro.Starting data and preparation systems ::: MethodsSeventeen FDA-approved small drugs (scheme), indomethacin (DB00328), naftazone (DB13680), ofloxacin (DB01165), zopiclone (DB01198), sofosbuvir (DB08934), pitavastatin (DB08860), eszopiclone (DB00402), perampanel (DB08883), fenoterol (DB01288), azelastine (DB00972), celecoxib (DB00482), nelfinavir (DB00220), praziquantel (DB01058), ondansetron (DB00904), lemborexant (DB11951), lopinavir (DB01601) and ritonavir (DB00503), were downloaded from DrugBank version 5.0 [15] and optimized at the AM1 level employing Gaussian 09W [16].", [["lopinavir", "CHEMICAL", 105, 114], ["ritonavir", "CHEMICAL", 119, 128], ["SARS", "DISEASE", 187, 191], ["indomethacin", "CHEMICAL", 295, 307], ["DB00328", "CHEMICAL", 309, 316], ["naftazone", "CHEMICAL", 319, 328], ["DB13680", "CHEMICAL", 330, 337], ["ofloxacin", "CHEMICAL", 340, 349], ["DB01165", "CHEMICAL", 351, 358], ["zopiclone", "CHEMICAL", 361, 370], ["DB01198", "CHEMICAL", 372, 379], ["sofosbuvir", "CHEMICAL", 382, 392], ["DB08934", "CHEMICAL", 394, 401], ["pitavastatin", "CHEMICAL", 404, 416], ["DB08860", "CHEMICAL", 418, 425], ["eszopiclone", "CHEMICAL", 428, 439], ["DB00402", "CHEMICAL", 441, 448], ["perampanel", "CHEMICAL", 451, 461], ["DB08883", "CHEMICAL", 463, 470], ["fenoterol", "CHEMICAL", 473, 482], ["DB01288", "CHEMICAL", 484, 491], ["azelastine", "CHEMICAL", 494, 504], ["DB00972", "CHEMICAL", 506, 513], ["celecoxib", "CHEMICAL", 516, 525], ["DB00482", "CHEMICAL", 527, 534], ["nelfinavir", "CHEMICAL", 537, 547], ["DB00220", "CHEMICAL", 549, 556], ["praziquantel", "CHEMICAL", 559, 571], ["DB01058", "CHEMICAL", 573, 580], ["ondansetron", "CHEMICAL", 583, 594], ["DB00904", "CHEMICAL", 596, 603], ["lemborexant", "CHEMICAL", 606, 617], ["DB11951", "CHEMICAL", 619, 626], ["lopinavir", "CHEMICAL", 629, 638], ["DB01601", "CHEMICAL", 640, 647], ["ritonavir", "CHEMICAL", 653, 662], ["DB00503", "CHEMICAL", 664, 671], ["lopinavir", "CHEMICAL", 105, 114], ["ritonavir", "CHEMICAL", 119, 128], ["indomethacin", "CHEMICAL", 295, 307], ["DB00328", "CHEMICAL", 309, 316], ["naftazone", "CHEMICAL", 319, 328], ["DB13680", "CHEMICAL", 330, 337], ["ofloxacin", "CHEMICAL", 340, 349], ["DB01165", "CHEMICAL", 351, 358], ["zopiclone", "CHEMICAL", 361, 370], ["DB01198", "CHEMICAL", 372, 379], ["sofosbuvir", "CHEMICAL", 382, 392], ["DB08934", "CHEMICAL", 394, 401], ["pitavastatin", "CHEMICAL", 404, 416], ["DB08860", "CHEMICAL", 418, 425], ["eszopiclone", "CHEMICAL", 428, 439], ["DB00402", "CHEMICAL", 441, 448], ["perampanel", "CHEMICAL", 451, 461], ["DB08883", "CHEMICAL", 463, 470], ["fenoterol", "CHEMICAL", 473, 482], ["DB01288", "CHEMICAL", 484, 491], ["azelastine", "CHEMICAL", 494, 504], ["DB00972", "CHEMICAL", 506, 513], ["celecoxib", "CHEMICAL", 516, 525], ["DB00482", "CHEMICAL", 527, 534], ["nelfinavir", "CHEMICAL", 537, 547], ["DB00220", "CHEMICAL", 549, 556], ["praziquantel", "CHEMICAL", 559, 571], ["DB01058", "CHEMICAL", 573, 580], ["ondansetron", "CHEMICAL", 583, 594], ["DB00904", "CHEMICAL", 596, 603], ["lemborexant", "CHEMICAL", 606, 617], ["DB11951", "CHEMICAL", 619, 626], ["lopinavir", "CHEMICAL", 629, 638], ["DB01601", "CHEMICAL", 640, 647], ["ritonavir", "CHEMICAL", 653, 662], ["DB00503", "CHEMICAL", 664, 671], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 79, 92], ["lopinavir", "SIMPLE_CHEMICAL", 105, 114], ["ritonavir", "SIMPLE_CHEMICAL", 119, 128], ["SARS-CoV Mpro", "ORGANISM", 187, 200], ["indomethacin", "SIMPLE_CHEMICAL", 295, 307], ["DB00328", "SIMPLE_CHEMICAL", 309, 316], ["naftazone", "SIMPLE_CHEMICAL", 319, 328], ["DB13680", "SIMPLE_CHEMICAL", 330, 337], ["ofloxacin", "SIMPLE_CHEMICAL", 340, 349], ["DB01165", "SIMPLE_CHEMICAL", 351, 358], ["zopiclone", "SIMPLE_CHEMICAL", 361, 370], ["DB01198", "SIMPLE_CHEMICAL", 372, 379], ["sofosbuvir", "SIMPLE_CHEMICAL", 382, 392], ["DB08934", "SIMPLE_CHEMICAL", 394, 401], ["pitavastatin", "SIMPLE_CHEMICAL", 404, 416], ["DB08860", "SIMPLE_CHEMICAL", 418, 425], ["eszopiclone", "SIMPLE_CHEMICAL", 428, 439], ["DB00402", "SIMPLE_CHEMICAL", 441, 448], ["perampanel", "SIMPLE_CHEMICAL", 451, 461], ["DB08883", "SIMPLE_CHEMICAL", 463, 470], ["fenoterol", "SIMPLE_CHEMICAL", 473, 482], ["DB01288", "SIMPLE_CHEMICAL", 484, 491], ["azelastine", "SIMPLE_CHEMICAL", 494, 504], ["DB00972", "SIMPLE_CHEMICAL", 506, 513], ["celecoxib", "SIMPLE_CHEMICAL", 516, 525], ["DB00482", "SIMPLE_CHEMICAL", 527, 534], ["nelfinavir", "SIMPLE_CHEMICAL", 537, 547], ["DB00220", "SIMPLE_CHEMICAL", 549, 556], ["praziquantel", "SIMPLE_CHEMICAL", 559, 571], ["DB01058", "SIMPLE_CHEMICAL", 573, 580], ["ondansetron", "SIMPLE_CHEMICAL", 583, 594], ["DB00904", "SIMPLE_CHEMICAL", 596, 603], ["lemborexant", "SIMPLE_CHEMICAL", 606, 617], ["DB11951", "SIMPLE_CHEMICAL", 619, 626], ["lopinavir", "SIMPLE_CHEMICAL", 629, 638], ["DB01601", "SIMPLE_CHEMICAL", 640, 647], ["ritonavir", "SIMPLE_CHEMICAL", 653, 662], ["DB00503", "SIMPLE_CHEMICAL", 664, 671], ["SARS-CoV", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 187, 195], ["comparative analysis", "TEST", 13, 33], ["dimeric SARS", "TEST", 52, 64], ["CoV2 Mpro", "TREATMENT", 65, 74], ["SARS", "PROBLEM", 79, 83], ["CoV Mpro coupling", "TREATMENT", 84, 101], ["lopinavir", "TREATMENT", 105, 114], ["ritonavir", "TREATMENT", 119, 128], ["an effective therapy", "TREATMENT", 158, 178], ["SARS", "PROBLEM", 187, 191], ["CoV Mpro", "TREATMENT", 192, 200], ["MethodsSeventeen FDA", "TREATMENT", 243, 263], ["small drugs (scheme)", "TREATMENT", 273, 293], ["indomethacin (DB00328)", "TREATMENT", 295, 317], ["naftazone (DB13680)", "TREATMENT", 319, 338], ["ofloxacin (DB01165)", "TREATMENT", 340, 359], ["zopiclone (DB01198)", "TREATMENT", 361, 380], ["sofosbuvir (DB08934)", "TREATMENT", 382, 402], ["pitavastatin (DB08860)", "TREATMENT", 404, 426], ["eszopiclone (DB00402)", "TREATMENT", 428, 449], ["perampanel (DB08883)", "TREATMENT", 451, 471], ["fenoterol (DB01288)", "TREATMENT", 473, 492], ["azelastine (DB00972)", "TREATMENT", 494, 514], ["celecoxib (DB00482)", "TREATMENT", 516, 535], ["nelfinavir (DB00220)", "TREATMENT", 537, 557], ["praziquantel (DB01058)", "TREATMENT", 559, 581], ["ondansetron (DB00904)", "TREATMENT", 583, 604], ["lemborexant (DB11951)", "TREATMENT", 606, 627], ["lopinavir (DB01601)", "TREATMENT", 629, 648], ["ritonavir (DB00503)", "TREATMENT", 653, 672]]], ["The X-ray crystallography structures of SARS-CoV2 Mpro (PDB ID: 6LU7, 2.16 \u00c5) and SARS-CoV Mpro (PDB ID: 2GX4, 1.93 \u00c5) were used to construct the protein-ligand complexes.", [["SARS", "DISEASE", 40, 44], ["CoV Mpro", "PROTEIN", 87, 95], ["2GX4", "PROTEIN", 105, 109], ["protein-ligand complexes", "PROTEIN", 146, 170], ["The X-ray crystallography", "TEST", 0, 25], ["SARS", "TEST", 40, 44], ["SARS", "TEST", 82, 86], ["ligand complexes", "OBSERVATION", 154, 170]]], ["PDB structures employed for this research were selected based on their availability (PDB ID: 6LU7, 2.16 \u00c5), high resolution, without mutations and missing residues.Molecular docking ::: MethodsThe seventeen FDA-approved small drugs were docked on monomeric and dimeric SARS-CoV2 Mpro using AutoDock Tools 1.5.6 and AutoDock 4.2 programs [17].", [["mutations", "PROBLEM", 133, 142], ["missing residues", "PROBLEM", 147, 163], ["Methods", "TREATMENT", 186, 193], ["small drugs", "TREATMENT", 220, 231], ["AutoDock Tools", "TEST", 290, 304], ["AutoDock", "TEST", 315, 323]]], ["Lopinavir and ritonavir were docked on monomeric and dimeric SARS-CoV Mpro.", [["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 14, 23], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 14, 23], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["ritonavir", "SIMPLE_CHEMICAL", 14, 23], ["dimeric SARS-CoV Mpro", "PROTEIN", 53, 74], ["SARS-CoV", "SPECIES", 61, 69], ["Lopinavir", "TREATMENT", 0, 9], ["ritonavir", "TREATMENT", 14, 23], ["CoV Mpro", "TREATMENT", 66, 74]]], ["In the previous docking calculation, hydrogen atoms were added to the ligand, and protein atoms and Kollman and Gasteiger partial charges were assigned for the receptor and ligand, respectively.", [["hydrogen", "CHEMICAL", 37, 45], ["hydrogen", "CHEMICAL", 37, 45], ["hydrogen atoms", "SIMPLE_CHEMICAL", 37, 51], ["Kollman", "SIMPLE_CHEMICAL", 100, 107], ["hydrogen atoms", "TREATMENT", 37, 51], ["protein atoms", "TREATMENT", 82, 95], ["Kollman and Gasteiger partial charges", "TREATMENT", 100, 137]]], ["The grid box was centered on the substrate-binding site of each monomeric subunit with grid points in the x, y and z of 70 x 70 x 70 \u00c5, respectively, with a grid spacing of 0.375 \u00c5.", [["grid box", "DNA", 4, 12], ["substrate-binding site", "DNA", 33, 55], ["monomeric subunit", "PROTEIN", 64, 81], ["The grid box", "PROBLEM", 0, 12], ["a grid spacing", "TEST", 155, 169]]], ["The ligand place was optimized using a Lamarckian genetic algorithm.", [["a Lamarckian genetic algorithm", "TREATMENT", 37, 67]]], ["The compounds reached the substrate binding site of SARS-CoV Mpro and SARS-CoV2 Mpro, obtaining a root-mean-square deviation (RMSD) of 0.5 \u00c5 to 2.0 \u00c5 with respect to the co-crystallized compound.", [["substrate binding site", "PROTEIN", 26, 48], ["SARS-CoV2 Mpro", "DNA", 70, 84], ["SARS-CoV", "SPECIES", 52, 60], ["a root", "TEST", 96, 102], ["RMSD", "TEST", 126, 130], ["root", "ANATOMY", 98, 102]]], ["The docking protocol was validated by reproducing the experimental binding mode of inhibitor N3 and TG-0205221 (scheme) on SARS-CoV2 Mpro (PDB ID: 6LU7) and SARS-CoV Mpro (PDB ID: 2GX4), respectively.", [["TG-0205221", "CHEMICAL", 100, 110], ["N3", "CHEMICAL", 93, 95], ["TG-0205221", "CHEMICAL", 100, 110], ["N3", "SIMPLE_CHEMICAL", 93, 95], ["TG-0205221", "SIMPLE_CHEMICAL", 100, 110], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 157, 170], ["PDB ID: 2GX4", "GENE_OR_GENE_PRODUCT", 172, 184], ["6LU7", "PROTEIN", 147, 151], ["CoV Mpro", "PROTEIN", 162, 170], ["2GX4", "PROTEIN", 180, 184], ["SARS-CoV", "SPECIES", 157, 165], ["The docking protocol", "TREATMENT", 0, 20], ["inhibitor N3", "TREATMENT", 83, 95], ["TG", "TEST", 100, 102], ["SARS", "PROBLEM", 157, 161]]], ["By using this methodology, we identified that our docking methodology was able to reproduce the experimental binding mode of both compounds with RMSD values lower than 1.0 \u00c5.MD simulations ::: MethodsMD simulations were carried out using the AMBER16 package [18] and the ff14SB force field [19].", [["RMSD values", "TEST", 145, 156], ["MethodsMD simulations", "TREATMENT", 193, 214], ["the AMBER16 package", "TREATMENT", 238, 257]]], ["The force field of ligands was performed considering AM1-BCC atomic charges and the general Amber force field (GAFF) [20].", [["The force field of ligands", "TEST", 0, 26], ["AM1", "TEST", 53, 56]]], ["Each complex generated through docking was neutralized with 0.10 M NaCl and then solvated using the TIP3P water model [21] in a dodecadic box of 12.0 \u00c5.", [["NaCl", "CHEMICAL", 67, 71], ["NaCl", "CHEMICAL", 67, 71], ["0.10 M NaCl", "TREATMENT", 60, 71], ["the TIP3P water model", "TREATMENT", 96, 117], ["a dodecadic box", "TREATMENT", 126, 141]]], ["Previously, MD simulations for each complex were minimized through 1000 steps for the steepest descent and 3000 steps for the conjugate gradient.", [["the conjugate gradient", "TEST", 122, 144]]], ["Then, the systems were heated through 200 ps, the density was equilibrated through 200 ps, and finally, the systems were equilibrated by 600 ps of constant pressure equilibration at 310 K. Once the systems were equilibrated, MD simulations were run for 100 ns with triplicate experiments using an NPT ensemble at 310 K. The electrostatic forces were described by the particle mesh Ewald method [22], and a 10 \u00c5 cutoff was chosen for the van der Waals interactions.", [["constant pressure equilibration", "TREATMENT", 147, 178], ["triplicate experiments", "TREATMENT", 265, 287], ["an NPT ensemble", "TREATMENT", 294, 309], ["a 10 \u00c5 cutoff", "TREATMENT", 404, 417], ["the van der Waals interactions", "TREATMENT", 433, 463], ["density", "OBSERVATION", 50, 57]]], ["The SHAKE algorithm [23] was used to constrain bond lengths at their equilibrium values.", [["The SHAKE algorithm", "TEST", 0, 19]]], ["Temperature and pressure were maintained using the weak-coupling algorithm [24].", [["Temperature", "TEST", 0, 11], ["pressure", "TEST", 16, 24], ["pressure", "OBSERVATION_MODIFIER", 16, 24]]], ["The results were analyzed using AmberTools16.", [["AmberTools", "TEST", 32, 42]]], ["Images were built using PyMOL [25].Binding free energy and per-residue decomposition calculations ::: MethodsThe MM/GBSA [26,27] method was employed to calculate the binding free energy (\u0394Gbind) values between the receptor and ligand and to calculate per-residue decomposition analysis.", [["Images", "TEST", 0, 6], ["The MM/GBSA", "TEST", 109, 120], ["per-residue decomposition analysis", "TEST", 251, 285]]], ["To this end, 500 snapshots at time intervals of 100 ps were selected over the equilibrated time, removing all counterions and water molecules with a salt concentration of 0.10 M [28].", [["salt", "SIMPLE_CHEMICAL", 149, 153], ["all counterions and water molecules", "TREATMENT", 106, 141], ["a salt concentration", "TREATMENT", 147, 167]]], ["\u0394Gbind and per-residue decomposition calculations were determined as described elsewhere [29], and the \u0394Gbind values represent the average values of triplicate simulation experiments.", [["\u0394Gbind and per-residue decomposition calculations", "PROBLEM", 0, 49], ["the \u0394Gbind values", "TEST", 99, 116]]], ["Similar experiments were performed using compounds with known experimental affinity to SARS-CoV2 Mpro or SARS-CoV Mpro to validate the ability of MM/GBSA approach to reproduce the experimental binding affinity trend.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["SARS-CoV", "SPECIES", 105, 113], ["SARS", "PROBLEM", 105, 109], ["MM/GBSA approach", "TREATMENT", 146, 162]]], ["We observed that the approach was able to reproduce the experimental tendency previously observed for two inhibitors (Chloroquine and niclosamide) of SARS-CoV2 Mpro [30], for which niclosamide showed higher affinity for SARS-CoV2 Mpro in comparison to chloroquine (supplementary material, Table S1).", [["Chloroquine", "CHEMICAL", 118, 129], ["niclosamide", "CHEMICAL", 134, 145], ["SARS", "DISEASE", 150, 154], ["niclosamide", "CHEMICAL", 181, 192], ["chloroquine", "CHEMICAL", 252, 263], ["Chloroquine", "CHEMICAL", 118, 129], ["niclosamide", "CHEMICAL", 134, 145], ["niclosamide", "CHEMICAL", 181, 192], ["chloroquine", "CHEMICAL", 252, 263], ["Chloroquine", "SIMPLE_CHEMICAL", 118, 129], ["niclosamide", "SIMPLE_CHEMICAL", 134, 145], ["niclosamide", "SIMPLE_CHEMICAL", 181, 192], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 220, 234], ["chloroquine", "SIMPLE_CHEMICAL", 252, 263], ["the experimental tendency", "PROBLEM", 52, 77], ["two inhibitors", "TREATMENT", 102, 116], ["Chloroquine", "TREATMENT", 118, 129], ["niclosamide", "TREATMENT", 134, 145], ["SARS", "PROBLEM", 150, 154], ["niclosamide", "TREATMENT", 181, 192], ["SARS", "PROBLEM", 220, 224], ["CoV2 Mpro", "TREATMENT", 225, 234], ["chloroquine (supplementary material", "TREATMENT", 252, 287]]], ["Similarly, TG-0205221, a SARS-CoV Mpro inhibitor, showed a higher affinity for SARS-Cov Mpro (supplementary material, Table S1) in comparison to lopinavir (table 2), in line with experimental reports [31,32].Docking of lopinavir or ritonavir with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: Docking between ligands and monomeric SARS-CoV2 Mpro ::: Results and DiscussionDocking studies show that lopinavir and ritonavir on SARS-CoV2 Mpro and SARS-CoV Mpro reached the catalytic site of both systems (supplementary material, Figs.", [["TG-0205221", "CHEMICAL", 11, 21], ["lopinavir", "CHEMICAL", 145, 154], ["lopinavir", "CHEMICAL", 219, 228], ["ritonavir", "CHEMICAL", 232, 241], ["lopinavir", "CHEMICAL", 399, 408], ["ritonavir", "CHEMICAL", 413, 422], ["TG-0205221", "CHEMICAL", 11, 21], ["lopinavir", "CHEMICAL", 145, 154], ["lopinavir", "CHEMICAL", 219, 228], ["ritonavir", "CHEMICAL", 232, 241], ["lopinavir", "CHEMICAL", 399, 408], ["ritonavir", "CHEMICAL", 413, 422], ["TG-0205221", "SIMPLE_CHEMICAL", 11, 21], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 25, 38], ["lopinavir", "SIMPLE_CHEMICAL", 145, 154], ["lopinavir", "SIMPLE_CHEMICAL", 219, 228], ["ritonavir", "SIMPLE_CHEMICAL", 232, 241], ["SARS-CoV", "ORGANISM", 276, 284], ["lopinavir", "SIMPLE_CHEMICAL", 399, 408], ["ritonavir", "SIMPLE_CHEMICAL", 413, 422], ["SARS-CoV2 Mpro", "ORGANISM", 426, 440], ["SARS-CoV Mpro", "ORGANISM", 445, 458], ["SARS-CoV Mpro", "DNA", 445, 458], ["catalytic site", "DNA", 471, 485], ["SARS-CoV", "SPECIES", 276, 284], ["SARS-CoV", "SPECIES", 445, 453], ["TG", "TEST", 11, 13], ["a SARS", "TEST", 23, 29], ["CoV Mpro inhibitor", "TREATMENT", 30, 48], ["a higher affinity", "PROBLEM", 57, 74], ["SARS", "PROBLEM", 79, 83], ["Cov Mpro (supplementary material", "TREATMENT", 84, 116], ["lopinavir", "TREATMENT", 145, 154], ["lopinavir", "TREATMENT", 219, 228], ["ritonavir", "TREATMENT", 232, 241], ["Docking studies", "TEST", 373, 388], ["lopinavir", "TREATMENT", 399, 408], ["ritonavir", "TREATMENT", 413, 422], ["SARS", "TEST", 426, 430], ["CoV2 Mpro", "TREATMENT", 431, 440], ["SARS", "PROBLEM", 445, 449], ["CoV Mpro", "TREATMENT", 450, 458]]], ["S3D\u2013G and Table S2).", [["S3D\u2013G", "GENE_OR_GENE_PRODUCT", 0, 5], ["Table S2", "GENE_OR_GENE_PRODUCT", 10, 18], ["S3D", "PROTEIN", 0, 3]]], ["On SARS-CoV2, lopinavir (Fig. S3D) and ritonavir (Fig. S3E) were mostly stabilized by T25, T26, H41, F140, L141, N142, G143, H163, E166, D187, Q189 and R188 residues through nonpolar interactions, whereas ritonavir established polar interactions with the side chain of S46 (Fig. S3E).", [["lopinavir", "CHEMICAL", 14, 23], ["ritonavir", "CHEMICAL", 39, 48], ["ritonavir", "CHEMICAL", 205, 214], ["lopinavir", "CHEMICAL", 14, 23], ["ritonavir", "CHEMICAL", 39, 48], ["T25, T26, H41, F140, L141, N142, G143, H163, E166, D187, Q189 and R188", "CHEMICAL", 86, 156], ["ritonavir", "CHEMICAL", 205, 214], ["SARS-CoV2", "SIMPLE_CHEMICAL", 3, 12], ["lopinavir", "SIMPLE_CHEMICAL", 14, 23], ["ritonavir", "SIMPLE_CHEMICAL", 39, 48], ["S3E", "GENE_OR_GENE_PRODUCT", 55, 58], ["T26", "GENE_OR_GENE_PRODUCT", 91, 94], ["H41", "GENE_OR_GENE_PRODUCT", 96, 99], ["F140", "GENE_OR_GENE_PRODUCT", 101, 105], ["ritonavir", "SIMPLE_CHEMICAL", 205, 214], ["S3E", "PROTEIN", 55, 58], ["S46", "PROTEIN", 269, 272], ["Fig. S3E", "PROTEIN", 274, 282], ["SARS", "TREATMENT", 3, 7], ["CoV2", "TREATMENT", 8, 12], ["lopinavir (Fig", "TREATMENT", 14, 28], ["ritonavir (Fig", "TREATMENT", 39, 53], ["ritonavir", "TREATMENT", 205, 214]]], ["On SARS-CoV Mpro, lopinavir (Fig. S3F) and ritonavir (Fig. S3G) are mostly stabilized by T25, A46, M49, L141, S144, E166 and Q189 through nonpolar interactions, while ritonavir formed polar interactions with the side chain of Q189 (Fig. S3G).Docking of lopinavir or ritonavir with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: Docking between ligands and monomeric SARS-CoV2 Mpro ::: Results and DiscussionComparative analysis between the coupling of lopinavir or ritonavir on SARS-CoV2 Mpro and SARS-CoV Mpro showed that T25, S/A46, Y/M49, L141, S144, E166 and Q189 are present in the stabilization of ligands on SARS-CoV2 Mpro and SARS-CoV Mpro.", [["lopinavir", "CHEMICAL", 18, 27], ["ritonavir", "CHEMICAL", 43, 52], ["ritonavir", "CHEMICAL", 167, 176], ["lopinavir", "CHEMICAL", 253, 262], ["ritonavir", "CHEMICAL", 266, 275], ["lopinavir", "CHEMICAL", 452, 461], ["ritonavir", "CHEMICAL", 465, 474], ["lopinavir", "CHEMICAL", 18, 27], ["ritonavir", "CHEMICAL", 43, 52], ["T25, A46, M49, L141, S144, E166 and Q189", "CHEMICAL", 89, 129], ["ritonavir", "CHEMICAL", 167, 176], ["lopinavir", "CHEMICAL", 253, 262], ["ritonavir", "CHEMICAL", 266, 275], ["lopinavir", "CHEMICAL", 452, 461], ["ritonavir", "CHEMICAL", 465, 474], ["lopinavir", "SIMPLE_CHEMICAL", 18, 27], ["ritonavir", "SIMPLE_CHEMICAL", 43, 52], ["S3G", "GENE_OR_GENE_PRODUCT", 59, 62], ["A46", "GENE_OR_GENE_PRODUCT", 94, 97], ["M49", "GENE_OR_GENE_PRODUCT", 99, 102], ["Q189", "AMINO_ACID", 125, 129], ["ritonavir", "SIMPLE_CHEMICAL", 167, 176], ["Q189", "SIMPLE_CHEMICAL", 226, 230], ["lopinavir", "SIMPLE_CHEMICAL", 253, 262], ["ritonavir", "SIMPLE_CHEMICAL", 266, 275], ["SARS-CoV", "ORGANISM", 310, 318], ["lopinavir", "SIMPLE_CHEMICAL", 452, 461], ["ritonavir", "SIMPLE_CHEMICAL", 465, 474], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 478, 492], ["SARS-CoV Mpro", "ORGANISM", 497, 510], ["Y/M49", "ORGANISM", 535, 540], ["L141", "GENE_OR_GENE_PRODUCT", 542, 546], ["S144", "GENE_OR_GENE_PRODUCT", 548, 552], ["E166", "GENE_OR_GENE_PRODUCT", 554, 558], ["Q189", "GENE_OR_GENE_PRODUCT", 563, 567], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 615, 629], ["SARS-CoV Mpro", "ORGANISM", 634, 647], ["S3G", "PROTEIN", 59, 62], ["Q189", "PROTEIN", 226, 230], ["SARS-CoV Mpro", "DNA", 634, 647], ["SARS-CoV", "SPECIES", 3, 11], ["SARS-CoV", "SPECIES", 310, 318], ["SARS-CoV", "SPECIES", 497, 505], ["SARS-CoV", "SPECIES", 634, 642], ["CoV Mpro", "TREATMENT", 8, 16], ["lopinavir (Fig", "TREATMENT", 18, 32], ["ritonavir (Fig", "TREATMENT", 43, 57], ["ritonavir formed polar interactions", "TREATMENT", 167, 202], ["lopinavir", "TREATMENT", 253, 262], ["ritonavir", "TREATMENT", 266, 275], ["DiscussionComparative analysis", "TEST", 397, 427], ["lopinavir", "TREATMENT", 452, 461], ["ritonavir", "TREATMENT", 465, 474], ["SARS", "TEST", 478, 482], ["SARS", "TEST", 497, 501], ["CoV Mpro", "TEST", 502, 510], ["T25", "TEST", 523, 526], ["SARS", "TEST", 615, 619], ["SARS", "PROBLEM", 634, 638], ["mostly", "OBSERVATION_MODIFIER", 68, 74], ["stabilized", "OBSERVATION", 75, 85]]], ["In addition, these compounds are better stabilized on SARS-CoV2 Mpro than on SARS-CoV Mpro.", [["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 54, 68], ["SARS-CoV Mpro", "ORGANISM", 77, 90], ["SARS-CoV", "SPECIES", 77, 85]]], ["All these docking-predicted complexes were submitted to MD simulation in the monomeric and dimeric states to validate their stabilization at the catalytic sites of SARS-CoV2 Mpro and SARS-CoV Mpro.Convergence of MD simulations ::: Results and DiscussionRMSD and radius of gyration (Rg) studies showed that monomeric SARS-CoV2 Mpro and SARS-CoV Mpro in their free and bound states reached equilibrium between 10 and 20 ns with average values that oscillated between 1.6 \u00b1 0.2 and 3.8 \u00b1 0.2 \u00c5 for RMSD and 21.9 \u00b1 0.2 and 23.1 \u00b1 0.2 \u00c5 for RG (Table S3, supplementary material).", [["SARS", "DISEASE", 316, 320], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 183, 196], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 335, 348], ["catalytic sites", "PROTEIN", 145, 160], ["SARS-CoV Mpro", "PROTEIN", 183, 196], ["Mpro", "PROTEIN", 326, 330], ["SARS-CoV Mpro", "PROTEIN", 335, 348], ["RG", "PROTEIN", 536, 538], ["SARS-CoV", "SPECIES", 183, 191], ["SARS-CoV", "SPECIES", 335, 343], ["SARS", "PROBLEM", 164, 168], ["SARS", "PROBLEM", 183, 187], ["radius of gyration (Rg) studies", "TEST", 262, 293], ["monomeric SARS", "PROBLEM", 306, 320], ["CoV2 Mpro", "TEST", 321, 330], ["SARS", "PROBLEM", 335, 339], ["CoV Mpro", "TEST", 340, 348], ["average values", "TEST", 426, 440], ["RMSD", "TEST", 495, 499], ["RG", "TEST", 536, 538]]], ["Dimeric SARS-CoV2 Mpro and SARS-CoV Mpro in their free and bound states reached equilibrium among 10 to 30 ns with average values that ranged between 1.5 \u00b1 0.1 and 2.2 \u00b1 0.2 \u00c5 for RMSD and 25.8 \u00b1 0.2 and 26.1 \u00b1 0.2 \u00c5 for RG (Table S4, supplementary material).", [["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 27, 40], ["Dimeric SARS-CoV2 Mpro", "PROTEIN", 0, 22], ["SARS-CoV Mpro", "DNA", 27, 40], ["RG", "PROTEIN", 221, 223], ["SARS-CoV", "SPECIES", 27, 35], ["Dimeric SARS", "TEST", 0, 12], ["CoV2 Mpro", "TREATMENT", 13, 22], ["SARS", "PROBLEM", 27, 31], ["CoV Mpro", "TEST", 32, 40], ["average values", "TEST", 115, 129], ["RMSD", "TEST", 180, 184], ["RG", "TEST", 221, 223], ["SARS", "OBSERVATION", 8, 12]]], ["Therefore, for further analyses, the first 30 ns were discarded from the 100 ns simulation for each monomer and dimer simulations.MD simulations of lopinavir or ritonavir with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: MD simulations of ligands with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: Results and DiscussionMD simulations showed that ritonavir lost interactions with the catalytic site of SARS-CoV2, whereas lopinavir maintained the interactions with the catalytic site (Fig. 2E).", [["lopinavir", "CHEMICAL", 148, 157], ["ritonavir", "CHEMICAL", 161, 170], ["ritonavir", "CHEMICAL", 350, 359], ["lopinavir", "CHEMICAL", 424, 433], ["lopinavir", "CHEMICAL", 148, 157], ["ritonavir", "CHEMICAL", 161, 170], ["ritonavir", "CHEMICAL", 350, 359], ["lopinavir", "CHEMICAL", 424, 433], ["lopinavir", "SIMPLE_CHEMICAL", 148, 157], ["ritonavir", "SIMPLE_CHEMICAL", 161, 170], ["SARS-CoV", "ORGANISM", 205, 213], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 283, 291], ["ritonavir", "SIMPLE_CHEMICAL", 350, 359], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 405, 414], ["lopinavir", "SIMPLE_CHEMICAL", 424, 433], ["monomeric SARS-CoV2 Mpro", "PROTEIN", 254, 278], ["catalytic site", "PROTEIN", 387, 401], ["catalytic site", "DNA", 471, 485], ["SARS-CoV", "SPECIES", 205, 213], ["SARS-CoV", "SPECIES", 283, 291], ["further analyses", "TEST", 15, 31], ["the 100 ns simulation", "TREATMENT", 69, 90], ["each monomer and dimer simulations", "TREATMENT", 95, 129], ["lopinavir", "TREATMENT", 148, 157], ["ritonavir", "TREATMENT", 161, 170], ["DiscussionMD simulations", "TEST", 313, 337], ["ritonavir", "TREATMENT", 350, 359], ["SARS", "PROBLEM", 405, 409], ["lopinavir", "TREATMENT", 424, 433]]], ["Lopinavir was mostly stabilized by hydrophobic residues (M49, M165 and Q189) similar to those present in the fifteen repositioned compounds (Figs.", [["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "CHEMICAL", 0, 9], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["Lopinavir", "TREATMENT", 0, 9]]], ["1 and 2), while it established polar interactions with the side chain of S46 (Fig. 2E).", [["S46", "PROTEIN", 73, 76], ["polar", "OBSERVATION_MODIFIER", 31, 36]]], ["On SARS-CoV Mpro, lopinavir and ritonavir were mainly stabilized by L27, H41, A46, M49 and C145 through hydrophobic interactions, whereas lopinavir formed polar interactions with backbone atoms of A46 (Fig. 2F), and ritonavir formed polar interactions with the side chain of N142 (Fig. 2G).MD simulations of lopinavir or ritonavir with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: MD simulations of ligands with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: Results and DiscussionAnalyses between the coupling of lopinavir or ritonavir on SARS-CoV2 Mpro and SARS-CoV Mpro showed that only hydrophobic contacts with M49 were shared in the stabilization of the fifteen repositioned compounds on SARS-CoV2 Mpro and SARS-CoV Mpro.", [["lopinavir", "CHEMICAL", 18, 27], ["ritonavir", "CHEMICAL", 32, 41], ["lopinavir", "CHEMICAL", 138, 147], ["ritonavir", "CHEMICAL", 216, 225], ["lopinavir", "CHEMICAL", 308, 317], ["ritonavir", "CHEMICAL", 321, 330], ["lopinavir", "CHEMICAL", 516, 525], ["ritonavir", "CHEMICAL", 529, 538], ["M49", "CHEMICAL", 618, 621], ["lopinavir", "CHEMICAL", 18, 27], ["ritonavir", "CHEMICAL", 32, 41], ["L27, H41, A46, M49 and C145", "CHEMICAL", 68, 95], ["lopinavir", "CHEMICAL", 138, 147], ["ritonavir", "CHEMICAL", 216, 225], ["lopinavir", "CHEMICAL", 308, 317], ["ritonavir", "CHEMICAL", 321, 330], ["lopinavir", "CHEMICAL", 516, 525], ["ritonavir", "CHEMICAL", 529, 538], ["M49", "CHEMICAL", 618, 621], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 3, 16], ["lopinavir", "SIMPLE_CHEMICAL", 18, 27], ["ritonavir", "SIMPLE_CHEMICAL", 32, 41], ["L27", "SIMPLE_CHEMICAL", 68, 71], ["H41", "SIMPLE_CHEMICAL", 73, 76], ["M49", "GENE_OR_GENE_PRODUCT", 83, 86], ["C145", "SIMPLE_CHEMICAL", 91, 95], ["lopinavir", "SIMPLE_CHEMICAL", 138, 147], ["A46", "SIMPLE_CHEMICAL", 197, 200], ["Fig. 2F", "SIMPLE_CHEMICAL", 202, 209], ["ritonavir", "SIMPLE_CHEMICAL", 216, 225], ["N142", "SIMPLE_CHEMICAL", 275, 279], ["lopinavir", "SIMPLE_CHEMICAL", 308, 317], ["ritonavir", "SIMPLE_CHEMICAL", 321, 330], ["SARS-CoV", "ORGANISM", 365, 373], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 443, 451], ["lopinavir", "SIMPLE_CHEMICAL", 516, 525], ["ritonavir", "SIMPLE_CHEMICAL", 529, 538], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 542, 556], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 561, 569], ["M49", "SIMPLE_CHEMICAL", 618, 621], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 696, 710], ["SARS-CoV Mpro", "ORGANISM", 715, 728], ["N142", "PROTEIN", 275, 279], ["monomeric SARS-CoV2 Mpro", "PROTEIN", 414, 438], ["SARS-CoV", "SPECIES", 3, 11], ["SARS-CoV", "SPECIES", 365, 373], ["SARS-CoV", "SPECIES", 443, 451], ["SARS-CoV", "SPECIES", 561, 569], ["SARS-CoV", "SPECIES", 715, 723], ["CoV Mpro", "TREATMENT", 8, 16], ["lopinavir", "TREATMENT", 18, 27], ["ritonavir", "TREATMENT", 32, 41], ["hydrophobic interactions", "PROBLEM", 104, 128], ["backbone atoms of A46", "TREATMENT", 179, 200], ["ritonavir formed polar interactions", "TREATMENT", 216, 251], ["the side chain", "TREATMENT", 257, 271], ["lopinavir", "TREATMENT", 308, 317], ["ritonavir", "TREATMENT", 321, 330], ["lopinavir", "TREATMENT", 516, 525], ["ritonavir", "TREATMENT", 529, 538], ["CoV Mpro", "TEST", 566, 574], ["SARS", "TEST", 696, 700], ["SARS", "PROBLEM", 715, 719], ["CoV Mpro", "TREATMENT", 720, 728], ["polar interactions", "OBSERVATION", 233, 251]]], ["In addition, the stabilization of these compounds was better on SARS-CoV2 Mpro than on SARS-CoV2 Mpro.MD simulations of ligands with dimeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: MD simulations of ligands with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: Results and DiscussionIn contrast, with the observations with monomeric SARS-CoV2 and SARS-CoV Mpro, MD simulations for most of the dimeric systems showed that all the ligands remained on both subunits of the dimer, except for the complexes between indomethacin, ofloxacin and lemborexant with SARS-CoV2 Mpro, in which these compounds only remained at one of the catalytic sites of SARS-CoV2 Mpro.", [["SARS", "DISEASE", 328, 332], ["indomethacin", "CHEMICAL", 505, 517], ["ofloxacin", "CHEMICAL", 519, 528], ["indomethacin", "CHEMICAL", 505, 517], ["ofloxacin", "CHEMICAL", 519, 528], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 64, 78], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 160, 168], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 238, 246], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 342, 350], ["indomethacin", "SIMPLE_CHEMICAL", 505, 517], ["ofloxacin", "SIMPLE_CHEMICAL", 519, 528], ["lemborexant", "SIMPLE_CHEMICAL", 533, 544], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 550, 564], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 638, 652], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 133, 155], ["monomeric SARS-CoV2 Mpro", "PROTEIN", 209, 233], ["dimer", "PROTEIN", 465, 470], ["catalytic sites", "PROTEIN", 619, 634], ["SARS-CoV2 Mpro", "PROTEIN", 638, 652], ["SARS-CoV", "SPECIES", 160, 168], ["SARS-CoV", "SPECIES", 238, 246], ["SARS-CoV", "SPECIES", 342, 350], ["dimeric SARS", "PROBLEM", 133, 145], ["monomeric SARS", "TEST", 318, 332], ["the dimeric systems", "TEST", 384, 403], ["indomethacin", "TREATMENT", 505, 517], ["ofloxacin", "TREATMENT", 519, 528], ["lemborexant", "TREATMENT", 533, 544], ["SARS", "PROBLEM", 550, 554], ["CoV2 Mpro", "TREATMENT", 555, 564]]], ["Indomethacin coupled to subunit 2 (Fig. 3A), naftazone bound to subunits 1 and 2 (Fig. 3B and 3C), ofloxacin bound to subunit 1 (Fig. 3D), and zopiclone coupled to subunits 1 and 2 (Fig. 3E and 3F).", [["Indomethacin", "CHEMICAL", 0, 12], ["naftazone", "CHEMICAL", 45, 54], ["ofloxacin", "CHEMICAL", 99, 108], ["zopiclone", "CHEMICAL", 143, 152], ["Indomethacin", "CHEMICAL", 0, 12], ["naftazone", "CHEMICAL", 45, 54], ["ofloxacin", "CHEMICAL", 99, 108], ["zopiclone", "CHEMICAL", 143, 152], ["Indomethacin", "SIMPLE_CHEMICAL", 0, 12], ["Fig. 3A", "GENE_OR_GENE_PRODUCT", 35, 42], ["naftazone", "SIMPLE_CHEMICAL", 45, 54], ["Fig. 3B", "GENE_OR_GENE_PRODUCT", 82, 89], ["3C", "GENE_OR_GENE_PRODUCT", 94, 96], ["ofloxacin", "SIMPLE_CHEMICAL", 99, 108], ["zopiclone", "SIMPLE_CHEMICAL", 143, 152], ["subunit 2", "PROTEIN", 24, 33], ["subunits 1 and 2", "PROTEIN", 64, 80], ["Fig. 3B and 3C", "PROTEIN", 82, 96], ["subunit 1", "PROTEIN", 118, 127], ["subunits 1 and 2", "PROTEIN", 164, 180], ["Fig. 3E and 3F", "PROTEIN", 182, 196], ["Indomethacin", "TREATMENT", 0, 12], ["naftazone bound to subunits", "TREATMENT", 45, 72], ["ofloxacin bound to subunit", "TREATMENT", 99, 125], ["zopiclone", "TREATMENT", 143, 152]]], ["Sofosbuvir bound at subunits 1 and 2 (Fig. 4A and 4B), pitavastatin bound at subunits 1 and 2 (Fig. 4C and 4D), and eszopiclone bound at subunits 1 and 2 (Fig. 4E and 4F).", [["Sofosbuvir", "CHEMICAL", 0, 10], ["pitavastatin", "CHEMICAL", 55, 67], ["eszopiclone", "CHEMICAL", 116, 127], ["Sofosbuvir", "CHEMICAL", 0, 10], ["pitavastatin", "CHEMICAL", 55, 67], ["eszopiclone", "CHEMICAL", 116, 127], ["Sofosbuvir", "SIMPLE_CHEMICAL", 0, 10], ["Fig. 4A", "GENE_OR_GENE_PRODUCT", 38, 45], ["4B", "GENE_OR_GENE_PRODUCT", 50, 52], ["pitavastatin", "SIMPLE_CHEMICAL", 55, 67], ["eszopiclone", "SIMPLE_CHEMICAL", 116, 127], ["4F", "GENE_OR_GENE_PRODUCT", 167, 169], ["subunits 1 and 2", "PROTEIN", 20, 36], ["Fig. 4A and 4B", "PROTEIN", 38, 52], ["subunits 1 and 2", "PROTEIN", 77, 93], ["4D", "PROTEIN", 107, 109], ["eszopiclone", "PROTEIN", 116, 127], ["subunits 1 and 2", "PROTEIN", 137, 153], ["4F", "PROTEIN", 167, 169], ["Sofosbuvir bound at subunits", "TREATMENT", 0, 28], ["pitavastatin bound at subunits", "TREATMENT", 55, 85], ["eszopiclone bound at subunits", "TREATMENT", 116, 145]]], ["Perampanel coupled at subunit 1 or 2 (Fig. 5A and 5B), fenoterol bound at subunit 1 or 2 (Fig. 5C and 5D), and azelastine bound at subunits 1 and 2 (Fig. 5E and 5F).", [["Perampanel", "CHEMICAL", 0, 10], ["fenoterol", "CHEMICAL", 55, 64], ["azelastine", "CHEMICAL", 111, 121], ["Perampanel", "CHEMICAL", 0, 10], ["fenoterol", "CHEMICAL", 55, 64], ["azelastine", "CHEMICAL", 111, 121], ["Perampanel", "SIMPLE_CHEMICAL", 0, 10], ["fenoterol", "SIMPLE_CHEMICAL", 55, 64], ["azelastine", "SIMPLE_CHEMICAL", 111, 121], ["subunits 1 and 2", "PROTEIN", 131, 147], ["5F", "PROTEIN", 161, 163], ["Perampanel", "TREATMENT", 0, 10], ["fenoterol bound at subunit", "TREATMENT", 55, 81], ["azelastine bound at subunits", "TREATMENT", 111, 139]]], ["Celecoxib coupled at subunits 1 and 2 (Fig. 6A and 6B), nelfinavir bound at subunits 1 and 2 (Fig. 6C and 6D), and praziquantel bound at subunits 1 and 2 (Fig. 6E and 6F).", [["Celecoxib", "CHEMICAL", 0, 9], ["nelfinavir", "CHEMICAL", 56, 66], ["praziquantel", "CHEMICAL", 115, 127], ["Celecoxib", "CHEMICAL", 0, 9], ["nelfinavir", "CHEMICAL", 56, 66], ["praziquantel", "CHEMICAL", 115, 127], ["Celecoxib", "SIMPLE_CHEMICAL", 0, 9], ["Fig. 6A", "GENE_OR_GENE_PRODUCT", 39, 46], ["6B", "GENE_OR_GENE_PRODUCT", 51, 53], ["nelfinavir", "SIMPLE_CHEMICAL", 56, 66], ["praziquantel", "SIMPLE_CHEMICAL", 115, 127], ["subunits 1 and 2", "PROTEIN", 21, 37], ["Fig. 6A and 6B", "PROTEIN", 39, 53], ["subunits 1 and 2", "PROTEIN", 76, 92], ["6D", "PROTEIN", 106, 108], ["subunits 1 and 2", "PROTEIN", 137, 153], ["6F", "PROTEIN", 167, 169], ["Celecoxib coupled at subunits", "TREATMENT", 0, 29], ["nelfinavir bound at subunits", "TREATMENT", 56, 84], ["praziquantel bound at subunits", "TREATMENT", 115, 145]]], ["Ondansetron bound at subunits 1 and 2 (Fig. 7A and 7B), and lemborexant bound at subunit 2 (Fig. 7C).", [["Ondansetron", "CHEMICAL", 0, 11], ["Ondansetron", "CHEMICAL", 0, 11], ["Ondansetron", "SIMPLE_CHEMICAL", 0, 11], ["Fig. 7A", "GENE_OR_GENE_PRODUCT", 39, 46], ["7B", "GENE_OR_GENE_PRODUCT", 51, 53], ["subunits 1 and 2", "PROTEIN", 21, 37], ["Fig. 7A and 7B", "PROTEIN", 39, 53], ["lemborexant", "PROTEIN", 60, 71], ["subunit 2", "PROTEIN", 81, 90], ["Ondansetron bound at subunits", "TREATMENT", 0, 29]]], ["These compounds were mainly stabilized by L27, H41, M49, N142, C145 and M165 through nonpolar interactions.", [["L27", "CHEMICAL", 42, 45], ["H41", "CHEMICAL", 47, 50], ["M49", "CHEMICAL", 52, 55], ["N142", "CHEMICAL", 57, 61], ["C145", "CHEMICAL", 63, 67], ["M165", "CHEMICAL", 72, 76], ["L27", "SIMPLE_CHEMICAL", 42, 45], ["H41", "SIMPLE_CHEMICAL", 47, 50], ["C145", "SIMPLE_CHEMICAL", 63, 67], ["M165", "SIMPLE_CHEMICAL", 72, 76]]], ["T25, H41, T45, S46, L141, N142, G143, F140, S144, H163, H164, M165, E166, Q192, and Q189 formed polar interactions with backbone or side chain atoms with some of these compounds: naftazone (Fig. 3B), ofloxacin (Fig. 3D), zopiclone (Fig. 3E and 3F), sofosbuvir (Fig. 4A and 4B), pitavastatin (Fig. 4C and 4D), eszopiclone (Fig. 4E and 4F), perampanel (Fig. 5A and 5B), fenoterol (Fig. 5C and 5D), azelastine (Fig. 5F), celecoxib (Fig. 6A and 6B), nelfinavir (Fig. 6C and 6D), praziquantel (Fig. 6E and 6F), ondansetron (Fig. 7A and 7B) and lemborexant (Fig. 7C).", [["naftazone", "CHEMICAL", 179, 188], ["ofloxacin", "CHEMICAL", 200, 209], ["zopiclone", "CHEMICAL", 221, 230], ["sofosbuvir", "CHEMICAL", 249, 259], ["pitavastatin", "CHEMICAL", 278, 290], ["eszopiclone", "CHEMICAL", 309, 320], ["perampanel", "CHEMICAL", 339, 349], ["fenoterol", "CHEMICAL", 368, 377], ["azelastine", "CHEMICAL", 396, 406], ["celecoxib", "CHEMICAL", 418, 427], ["nelfinavir", "CHEMICAL", 446, 456], ["praziquantel", "CHEMICAL", 475, 487], ["ondansetron", "CHEMICAL", 506, 517], ["T25, H41, T45, S46, L141, N142, G143, F140, S144, H163, H164, M165, E166, Q192, and Q189", "CHEMICAL", 0, 88], ["naftazone", "CHEMICAL", 179, 188], ["ofloxacin", "CHEMICAL", 200, 209], ["zopiclone", "CHEMICAL", 221, 230], ["sofosbuvir", "CHEMICAL", 249, 259], ["pitavastatin", "CHEMICAL", 278, 290], ["eszopiclone", "CHEMICAL", 309, 320], ["perampanel", "CHEMICAL", 339, 349], ["fenoterol", "CHEMICAL", 368, 377], ["azelastine", "CHEMICAL", 396, 406], ["celecoxib", "CHEMICAL", 418, 427], ["nelfinavir", "CHEMICAL", 446, 456], ["praziquantel", "CHEMICAL", 475, 487], ["ondansetron", "CHEMICAL", 506, 517], ["lemborexant", "CHEMICAL", 539, 550], ["naftazone", "SIMPLE_CHEMICAL", 179, 188], ["Fig. 3B", "SIMPLE_CHEMICAL", 190, 197], ["ofloxacin", "SIMPLE_CHEMICAL", 200, 209], ["Fig. 3D", "SIMPLE_CHEMICAL", 211, 218], ["zopiclone", "SIMPLE_CHEMICAL", 221, 230], ["3F", "SIMPLE_CHEMICAL", 244, 246], ["sofosbuvir", "SIMPLE_CHEMICAL", 249, 259], ["pitavastatin", "SIMPLE_CHEMICAL", 278, 290], ["eszopiclone", "SIMPLE_CHEMICAL", 309, 320], ["4F", "SIMPLE_CHEMICAL", 334, 336], ["perampanel", "SIMPLE_CHEMICAL", 339, 349], ["Fig. 5A", "SIMPLE_CHEMICAL", 351, 358], ["5B", "SIMPLE_CHEMICAL", 363, 365], ["fenoterol", "SIMPLE_CHEMICAL", 368, 377], ["5D", "SIMPLE_CHEMICAL", 391, 393], ["azelastine", "SIMPLE_CHEMICAL", 396, 406], ["Fig. 5F", "SIMPLE_CHEMICAL", 408, 415], ["celecoxib", "SIMPLE_CHEMICAL", 418, 427], ["nelfinavir", "SIMPLE_CHEMICAL", 446, 456], ["praziquantel", "SIMPLE_CHEMICAL", 475, 487], ["ondansetron", "SIMPLE_CHEMICAL", 506, 517], ["H41", "TEST", 5, 8], ["T45", "TEST", 10, 13], ["S46", "TEST", 15, 18], ["backbone or side chain atoms", "PROBLEM", 120, 148], ["naftazone (Fig. 3B", "TREATMENT", 179, 197], ["ofloxacin", "TREATMENT", 200, 209], ["zopiclone", "TREATMENT", 221, 230], ["sofosbuvir (Fig. 4A", "TREATMENT", 249, 268], ["pitavastatin (Fig. 4C", "TREATMENT", 278, 299], ["eszopiclone (Fig. 4E", "TREATMENT", 309, 329], ["perampanel (Fig. 5A and 5B)", "TREATMENT", 339, 366], ["fenoterol (Fig. 5C", "TREATMENT", 368, 386], ["azelastine (Fig. 5F", "TREATMENT", 396, 415], ["celecoxib (Fig. 6A", "TREATMENT", 418, 436], ["nelfinavir (Fig. 6C", "TREATMENT", 446, 465], ["praziquantel (Fig. 6E", "TREATMENT", 475, 496], ["ondansetron (Fig", "TREATMENT", 506, 522], ["lemborexant (Fig", "TREATMENT", 539, 555]]], ["Comparison of the residues stabilizing these ligands in the monomeric (Fig. 1 and 2) versus dimeric SARS-CoV2 Mpro and SARS-CoV Mpro (Figs.", [["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 100, 114], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 119, 132], ["SARS-CoV", "SPECIES", 119, 127], ["the residues", "PROBLEM", 14, 26], ["dimeric SARS", "TEST", 92, 104], ["SARS", "PROBLEM", 119, 123]]], ["3 and 7) revealed that the repositioned compounds were better stabilized in the dimeric state than in the monomeric state.", [["the repositioned compounds", "PROBLEM", 23, 49]]], ["In addition, only in the complexes using the dimeric system, the presence of interactions with conserved residues (H41 and C145) involved in the catalytic activity was observed [33].MD simulations of lopinavir or ritonavir with dimeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: MD simulations of ligands with monomeric SARS-CoV2 Mpro and SARS-CoV Mpro ::: Results and DiscussionMD simulations showed that lopinavir at subunits 1 (Fig. 7D) and 2 (Fig. 7E) and ritonavir at subunits 1 (Fig. 7F) and 2 (Fig. 8A) were maintained interactions at the catalytic site of SARS-CoV2.", [["lopinavir", "CHEMICAL", 200, 209], ["ritonavir", "CHEMICAL", 213, 222], ["lopinavir", "CHEMICAL", 400, 409], ["ritonavir", "CHEMICAL", 454, 463], ["lopinavir", "CHEMICAL", 200, 209], ["ritonavir", "CHEMICAL", 213, 222], ["lopinavir", "CHEMICAL", 400, 409], ["ritonavir", "CHEMICAL", 454, 463], ["lopinavir", "SIMPLE_CHEMICAL", 200, 209], ["ritonavir", "SIMPLE_CHEMICAL", 213, 222], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 255, 263], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 333, 341], ["lopinavir", "SIMPLE_CHEMICAL", 400, 409], ["ritonavir", "SIMPLE_CHEMICAL", 454, 463], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 558, 567], ["C145", "PROTEIN", 123, 127], ["catalytic site", "PROTEIN", 540, 554], ["CoV2", "PROTEIN", 563, 567], ["SARS-CoV", "SPECIES", 255, 263], ["SARS-CoV", "SPECIES", 333, 341], ["lopinavir", "TREATMENT", 200, 209], ["ritonavir", "TREATMENT", 213, 222], ["dimeric SARS", "PROBLEM", 228, 240], ["monomeric SARS", "PROBLEM", 304, 318], ["lopinavir at subunits", "TREATMENT", 400, 421], ["ritonavir at subunits", "TREATMENT", 454, 475]]], ["Ritonavir and lopinavir were generally stabilized by four residues (M49, M165, L167 and Q189), whereas only lopinavir formed polar interactions with backbone atoms and side chain atoms of T90 and Q189 (Fig. 7E).", [["Ritonavir", "CHEMICAL", 0, 9], ["lopinavir", "CHEMICAL", 14, 23], ["lopinavir", "CHEMICAL", 108, 117], ["Ritonavir", "CHEMICAL", 0, 9], ["lopinavir", "CHEMICAL", 14, 23], ["lopinavir", "CHEMICAL", 108, 117], ["Q189", "CHEMICAL", 196, 200], ["Ritonavir", "SIMPLE_CHEMICAL", 0, 9], ["lopinavir", "SIMPLE_CHEMICAL", 14, 23], ["lopinavir", "SIMPLE_CHEMICAL", 108, 117], ["T90", "SIMPLE_CHEMICAL", 188, 191], ["Ritonavir", "TREATMENT", 0, 9], ["lopinavir", "TREATMENT", 14, 23], ["backbone atoms", "TREATMENT", 149, 163]]], ["On SARS-CoV Mpro, lopinavir coupled at subunits 1 (Fig. 8B) and 2 (Fig. 8C) and ritonavir coupled at subunit 1 (Fig. 8D) were mostly stabilized by H41, M49, M165 and Q189 through hydrophobic interactions.", [["lopinavir", "CHEMICAL", 18, 27], ["ritonavir", "CHEMICAL", 80, 89], ["lopinavir", "CHEMICAL", 18, 27], ["ritonavir", "CHEMICAL", 80, 89], ["H41, M49, M165 and Q189", "CHEMICAL", 147, 170], ["lopinavir", "SIMPLE_CHEMICAL", 18, 27], ["ritonavir", "SIMPLE_CHEMICAL", 80, 89], ["H41", "SIMPLE_CHEMICAL", 147, 150], ["Q189", "SIMPLE_CHEMICAL", 166, 170], ["subunit 1", "PROTEIN", 101, 110], ["SARS-CoV", "SPECIES", 3, 11], ["CoV Mpro", "TREATMENT", 8, 16], ["lopinavir coupled at subunits", "TREATMENT", 18, 47], ["ritonavir", "TREATMENT", 80, 89]]], ["Similar nonpolar and polar interactions were observed for the fifteen repositioned compounds (Fig. 3, Fig. 4, Fig. 5, Fig. 6, Fig. 7), except for L167.", [["the fifteen repositioned compounds", "TREATMENT", 58, 92], ["Fig.", "TEST", 94, 98], ["Fig.", "TEST", 102, 106], ["nonpolar", "OBSERVATION_MODIFIER", 8, 16], ["polar", "OBSERVATION_MODIFIER", 21, 26]]], ["Comparative analysis of the residues stabilizing ritonavir and lopinavir in the monomeric (Fig. 2) versus dimer SARS-CoV2 Mpro and SARS-CoV Mpro (Figs.", [["ritonavir", "CHEMICAL", 49, 58], ["lopinavir", "CHEMICAL", 63, 72], ["ritonavir", "CHEMICAL", 49, 58], ["lopinavir", "CHEMICAL", 63, 72], ["ritonavir", "SIMPLE_CHEMICAL", 49, 58], ["lopinavir", "SIMPLE_CHEMICAL", 63, 72], ["SARS-CoV Mpro", "ORGANISM", 131, 144], ["SARS-CoV", "SPECIES", 131, 139], ["Comparative analysis", "TEST", 0, 20], ["the residues", "PROBLEM", 24, 36], ["ritonavir", "TREATMENT", 49, 58], ["lopinavir", "TREATMENT", 63, 72], ["dimer SARS", "TEST", 106, 116], ["CoV2 Mpro", "TREATMENT", 117, 126], ["SARS", "PROBLEM", 131, 135]]], ["7 and 8) showed that ritonavir is stabilized by similar hydrophobic residues (M49 and M165) in the monomeric and dimeric states, whereas only two residues (H41 and M49) are shared in the stabilization of lopinavir in the monomeric and dimeric SARS-CoV2 Mpro and SARS-CoV Mpro.Binding free energy calculations ::: Results and DiscussionDifferences in affinity for the complexes between ligands and monomeric and dimeric SARS-CoV2 Mpro and SARS-CoV Mpro systems were calculated using the MM/GBSA approach, showing that all the bindings are energetically favorable and guided through nonpolar interactions, van der Waals energy (\u0394Evdw) and the nonpolar free energy of desolvation (\u0394Gnpol,sol).", [["ritonavir", "CHEMICAL", 21, 30], ["lopinavir", "CHEMICAL", 204, 213], ["ritonavir", "CHEMICAL", 21, 30], ["lopinavir", "CHEMICAL", 204, 213], ["ritonavir", "SIMPLE_CHEMICAL", 21, 30], ["lopinavir", "SIMPLE_CHEMICAL", 204, 213], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 262, 275], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 438, 446], ["monomeric and dimeric states", "PROTEIN", 99, 127], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 235, 257], ["SARS-CoV Mpro", "PROTEIN", 262, 275], ["SARS-CoV", "SPECIES", 262, 270], ["SARS-CoV", "SPECIES", 438, 446], ["ritonavir", "TREATMENT", 21, 30], ["lopinavir", "TREATMENT", 204, 213], ["SARS", "PROBLEM", 262, 266], ["CoV Mpro", "TREATMENT", 267, 275], ["the complexes between ligands", "TEST", 363, 392], ["monomeric and dimeric SARS", "TEST", 397, 423], ["SARS", "PROBLEM", 438, 442], ["CoV Mpro systems", "TEST", 443, 459], ["the MM/GBSA approach", "TREATMENT", 482, 502], ["hydrophobic residues", "OBSERVATION", 56, 76]]], ["Binding free energy (\u0394Gbind) values for the ligands coupled at the monomeric SARS-CoV2 Mpro show the following tendency: perampanel > lopinavir > ondansetron > pitavastatin > zopiclone > azelastine > sofosbuvir = eszopiclone > celecoxib > lemborexant (table 1).", [["perampanel", "CHEMICAL", 121, 131], ["lopinavir", "CHEMICAL", 134, 143], ["ondansetron", "CHEMICAL", 146, 157], ["pitavastatin", "CHEMICAL", 160, 172], ["zopiclone", "CHEMICAL", 175, 184], ["azelastine", "CHEMICAL", 187, 197], ["sofosbuvir", "CHEMICAL", 200, 210], ["eszopiclone", "CHEMICAL", 213, 224], ["celecoxib", "CHEMICAL", 227, 236], ["perampanel", "CHEMICAL", 121, 131], ["lopinavir", "CHEMICAL", 134, 143], ["ondansetron", "CHEMICAL", 146, 157], ["pitavastatin", "CHEMICAL", 160, 172], ["zopiclone", "CHEMICAL", 175, 184], ["azelastine", "CHEMICAL", 187, 197], ["sofosbuvir", "CHEMICAL", 200, 210], ["eszopiclone", "CHEMICAL", 213, 224], ["celecoxib", "CHEMICAL", 227, 236], ["lemborexant", "CHEMICAL", 239, 250], ["perampanel", "SIMPLE_CHEMICAL", 121, 131], ["lopinavir", "SIMPLE_CHEMICAL", 134, 143], ["ondansetron", "SIMPLE_CHEMICAL", 146, 157], ["pitavastatin", "SIMPLE_CHEMICAL", 160, 172], ["zopiclone", "SIMPLE_CHEMICAL", 175, 184], ["azelastine", "SIMPLE_CHEMICAL", 187, 197], ["sofosbuvir", "SIMPLE_CHEMICAL", 200, 210], ["eszopiclone", "SIMPLE_CHEMICAL", 213, 224], ["celecoxib", "SIMPLE_CHEMICAL", 227, 236], ["the ligands", "PROBLEM", 40, 51], ["the monomeric SARS", "TEST", 63, 81], ["perampanel", "TEST", 121, 131], ["lopinavir", "TREATMENT", 134, 143], ["ondansetron", "TREATMENT", 146, 157], ["pitavastatin", "TREATMENT", 160, 172], ["zopiclone", "TREATMENT", 175, 184], ["azelastine", "TREATMENT", 187, 197], ["sofosbuvir", "TREATMENT", 200, 210], ["eszopiclone", "TREATMENT", 213, 224], ["celecoxib", "TREATMENT", 227, 236]]], ["However, a higher affinity towards monomeric SARS-CoV Mpro was exhibited by lopinavir than by ritonavir.", [["SARS", "DISEASE", 45, 49], ["lopinavir", "CHEMICAL", 76, 85], ["ritonavir", "CHEMICAL", 94, 103], ["lopinavir", "CHEMICAL", 76, 85], ["ritonavir", "CHEMICAL", 94, 103], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 45, 53], ["lopinavir", "SIMPLE_CHEMICAL", 76, 85], ["ritonavir", "SIMPLE_CHEMICAL", 94, 103], ["SARS-CoV", "SPECIES", 45, 53], ["a higher affinity", "PROBLEM", 9, 26], ["monomeric SARS", "PROBLEM", 35, 49], ["CoV Mpro", "TREATMENT", 50, 58], ["lopinavir", "TREATMENT", 76, 85], ["ritonavir", "TREATMENT", 94, 103]]], ["Comparison of \u0394Gbind values for the affinity of repositioned compounds with ritonavir or lopinavir shows that perampanel was able to inhibit monomeric SARS-CoV Mpro in a similar manner to lopinavir and ritonavir, which diffuses in the first nanoseconds of MD simulations (see section 3.3.1).", [["ritonavir", "CHEMICAL", 76, 85], ["lopinavir", "CHEMICAL", 89, 98], ["perampanel", "CHEMICAL", 110, 120], ["lopinavir", "CHEMICAL", 188, 197], ["ritonavir", "CHEMICAL", 202, 211], ["ritonavir", "CHEMICAL", 76, 85], ["lopinavir", "CHEMICAL", 89, 98], ["perampanel", "CHEMICAL", 110, 120], ["lopinavir", "CHEMICAL", 188, 197], ["ritonavir", "CHEMICAL", 202, 211], ["ritonavir", "SIMPLE_CHEMICAL", 76, 85], ["lopinavir", "SIMPLE_CHEMICAL", 89, 98], ["perampanel", "SIMPLE_CHEMICAL", 110, 120], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 151, 159], ["lopinavir", "SIMPLE_CHEMICAL", 188, 197], ["ritonavir", "SIMPLE_CHEMICAL", 202, 211], ["\u0394Gbind", "PROTEIN", 14, 20], ["SARS-CoV", "SPECIES", 151, 159], ["\u0394Gbind values", "TEST", 14, 27], ["repositioned compounds", "TREATMENT", 48, 70], ["ritonavir", "TREATMENT", 76, 85], ["lopinavir", "TREATMENT", 89, 98], ["perampanel", "TREATMENT", 110, 120], ["monomeric SARS", "PROBLEM", 141, 155], ["CoV Mpro", "TREATMENT", 156, 164], ["lopinavir", "TREATMENT", 188, 197], ["ritonavir", "TREATMENT", 202, 211]]], ["Comparisons between the affinity of lopinavir or ritonavir for monomeric SARS-CoV2 Mpro and SARS-CoV Mpro systems showed that these two compounds exhibit a higher affinity by monomeric SARS-CoV Mpro than by SARS-CoV2 Mpro.Binding free energy calculations ::: Results and Discussion\u0394Gbind values for the ligands coupled on the first subunit of dimeric SARS-CoV2 Mpro show the following tendency: perampanel > lopinavir > praziquantel > ritonavir > ofloxacin > azelastine > zopiclone > eszopiclone > fenoterol > pitavastatin> nelfinavir = celecoxib > sofosbuvir > ondansetron > naftazone.", [["lopinavir", "CHEMICAL", 36, 45], ["ritonavir", "CHEMICAL", 49, 58], ["perampanel", "CHEMICAL", 395, 405], ["lopinavir", "CHEMICAL", 408, 417], ["praziquantel", "CHEMICAL", 420, 432], ["ritonavir", "CHEMICAL", 435, 444], ["ofloxacin", "CHEMICAL", 447, 456], ["azelastine", "CHEMICAL", 459, 469], ["zopiclone", "CHEMICAL", 472, 481], ["eszopiclone", "CHEMICAL", 484, 495], ["fenoterol", "CHEMICAL", 498, 507], ["pitavastatin", "CHEMICAL", 510, 522], ["nelfinavir", "CHEMICAL", 524, 534], ["celecoxib", "CHEMICAL", 537, 546], ["sofosbuvir", "CHEMICAL", 549, 559], ["ondansetron", "CHEMICAL", 562, 573], ["naftazone", "CHEMICAL", 576, 585], ["lopinavir", "CHEMICAL", 36, 45], ["ritonavir", "CHEMICAL", 49, 58], ["perampanel", "CHEMICAL", 395, 405], ["lopinavir", "CHEMICAL", 408, 417], ["praziquantel", "CHEMICAL", 420, 432], ["ritonavir", "CHEMICAL", 435, 444], ["ofloxacin", "CHEMICAL", 447, 456], ["azelastine", "CHEMICAL", 459, 469], ["zopiclone", "CHEMICAL", 472, 481], ["eszopiclone", "CHEMICAL", 484, 495], ["fenoterol", "CHEMICAL", 498, 507], ["pitavastatin", "CHEMICAL", 510, 522], ["nelfinavir", "CHEMICAL", 524, 534], ["celecoxib", "CHEMICAL", 537, 546], ["sofosbuvir", "CHEMICAL", 549, 559], ["ondansetron", "CHEMICAL", 562, 573], ["naftazone", "CHEMICAL", 576, 585], ["lopinavir", "SIMPLE_CHEMICAL", 36, 45], ["ritonavir", "SIMPLE_CHEMICAL", 49, 58], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 185, 193], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 207, 221], ["perampanel", "SIMPLE_CHEMICAL", 395, 405], ["lopinavir", "SIMPLE_CHEMICAL", 408, 417], ["praziquantel", "SIMPLE_CHEMICAL", 420, 432], ["ritonavir", "SIMPLE_CHEMICAL", 435, 444], ["ofloxacin", "SIMPLE_CHEMICAL", 447, 456], ["azelastine", "SIMPLE_CHEMICAL", 459, 469], ["zopiclone", "SIMPLE_CHEMICAL", 472, 481], ["eszopiclone", "SIMPLE_CHEMICAL", 484, 495], ["fenoterol", "SIMPLE_CHEMICAL", 498, 507], ["pitavastatin", "SIMPLE_CHEMICAL", 510, 522], ["nelfinavir", "SIMPLE_CHEMICAL", 524, 534], ["celecoxib", "SIMPLE_CHEMICAL", 537, 546], ["sofosbuvir", "SIMPLE_CHEMICAL", 549, 559], ["ondansetron", "SIMPLE_CHEMICAL", 562, 573], ["naftazone", "SIMPLE_CHEMICAL", 576, 585], ["SARS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 185, 193], ["lopinavir", "TREATMENT", 36, 45], ["ritonavir", "TREATMENT", 49, 58], ["monomeric SARS", "TEST", 63, 77], ["SARS", "PROBLEM", 92, 96], ["CoV Mpro systems", "TEST", 97, 113], ["these two compounds", "PROBLEM", 126, 145], ["a higher affinity", "PROBLEM", 154, 171], ["monomeric SARS", "PROBLEM", 175, 189], ["the ligands", "PROBLEM", 299, 310], ["dimeric SARS", "TEST", 343, 355], ["perampanel", "TEST", 395, 405], ["lopinavir", "TREATMENT", 408, 417], ["praziquantel", "TREATMENT", 420, 432], ["ritonavir", "TREATMENT", 435, 444], ["ofloxacin", "TREATMENT", 447, 456], ["azelastine", "TREATMENT", 459, 469], ["zopiclone", "TREATMENT", 472, 481], ["eszopiclone", "TREATMENT", 484, 495], ["fenoterol", "TREATMENT", 498, 507], ["pitavastatin", "TREATMENT", 510, 522], ["nelfinavir", "TREATMENT", 524, 534], ["celecoxib", "TREATMENT", 537, 546], ["sofosbuvir", "TREATMENT", 549, 559], ["ondansetron", "TREATMENT", 562, 573], ["naftazone", "TREATMENT", 576, 585]]], ["The ligands coupled at the second subunit showed the following order: nelfinavir > lopinavir > praziquantel > perampanel > azelastine > ritonavir > eszopiclone > fenoterol > ondansetron > pitavastatin> zopiclone > sofosbuvir > celecoxib > lemborexant > indomethacin > naftazone (table 2).", [["nelfinavir", "CHEMICAL", 70, 80], ["lopinavir", "CHEMICAL", 83, 92], ["praziquantel", "CHEMICAL", 95, 107], ["perampanel", "CHEMICAL", 110, 120], ["azelastine", "CHEMICAL", 123, 133], ["ritonavir", "CHEMICAL", 136, 145], ["eszopiclone", "CHEMICAL", 148, 159], ["fenoterol", "CHEMICAL", 162, 171], ["ondansetron", "CHEMICAL", 174, 185], ["pitavastatin", "CHEMICAL", 188, 200], ["zopiclone", "CHEMICAL", 202, 211], ["sofosbuvir", "CHEMICAL", 214, 224], ["celecoxib", "CHEMICAL", 227, 236], ["lemborexant", "CHEMICAL", 239, 250], ["indomethacin", "CHEMICAL", 253, 265], ["naftazone", "CHEMICAL", 268, 277], ["nelfinavir", "CHEMICAL", 70, 80], ["lopinavir", "CHEMICAL", 83, 92], ["praziquantel", "CHEMICAL", 95, 107], ["perampanel", "CHEMICAL", 110, 120], ["azelastine", "CHEMICAL", 123, 133], ["ritonavir", "CHEMICAL", 136, 145], ["eszopiclone", "CHEMICAL", 148, 159], ["fenoterol", "CHEMICAL", 162, 171], ["ondansetron", "CHEMICAL", 174, 185], ["pitavastatin", "CHEMICAL", 188, 200], ["zopiclone", "CHEMICAL", 202, 211], ["sofosbuvir", "CHEMICAL", 214, 224], ["celecoxib", "CHEMICAL", 227, 236], ["lemborexant", "CHEMICAL", 239, 250], ["indomethacin", "CHEMICAL", 253, 265], ["naftazone", "CHEMICAL", 268, 277], ["nelfinavir", "SIMPLE_CHEMICAL", 70, 80], ["lopinavir", "SIMPLE_CHEMICAL", 83, 92], ["praziquantel", "SIMPLE_CHEMICAL", 95, 107], ["perampanel", "SIMPLE_CHEMICAL", 110, 120], ["azelastine", "SIMPLE_CHEMICAL", 123, 133], ["ritonavir", "SIMPLE_CHEMICAL", 136, 145], ["eszopiclone", "SIMPLE_CHEMICAL", 148, 159], ["fenoterol", "SIMPLE_CHEMICAL", 162, 171], ["ondansetron", "SIMPLE_CHEMICAL", 174, 185], ["pitavastatin", "SIMPLE_CHEMICAL", 188, 200], ["zopiclone", "SIMPLE_CHEMICAL", 202, 211], ["sofosbuvir", "SIMPLE_CHEMICAL", 214, 224], ["celecoxib", "SIMPLE_CHEMICAL", 227, 236], ["lemborexant", "SIMPLE_CHEMICAL", 239, 250], ["indomethacin", "SIMPLE_CHEMICAL", 253, 265], ["naftazone", "SIMPLE_CHEMICAL", 268, 277], ["nelfinavir", "TREATMENT", 70, 80], ["lopinavir", "TREATMENT", 83, 92], ["praziquantel", "TREATMENT", 95, 107], ["perampanel", "TREATMENT", 110, 120], ["azelastine", "TREATMENT", 123, 133], ["ritonavir", "TREATMENT", 136, 145], ["eszopiclone", "TREATMENT", 148, 159], ["fenoterol", "TREATMENT", 162, 171], ["ondansetron", "TREATMENT", 174, 185], ["pitavastatin", "TREATMENT", 188, 200], ["zopiclone", "TREATMENT", 202, 211], ["sofosbuvir", "TREATMENT", 214, 224], ["celecoxib", "TREATMENT", 227, 236], ["lemborexant", "TREATMENT", 239, 250], ["indomethacin > naftazone", "TREATMENT", 253, 277]]], ["Based on this analysis, it is evident that perampanel, and praziquantel can be proposed as anti-COVID-19 clinical drugs, whereas nelfinavir could also exhibit moderate activities against COVID-19.", [["perampanel", "CHEMICAL", 43, 53], ["praziquantel", "CHEMICAL", 59, 71], ["nelfinavir", "CHEMICAL", 129, 139], ["COVID-19", "CHEMICAL", 187, 195], ["perampanel", "CHEMICAL", 43, 53], ["praziquantel", "CHEMICAL", 59, 71], ["nelfinavir", "CHEMICAL", 129, 139], ["COVID-19", "CHEMICAL", 187, 195], ["perampanel", "SIMPLE_CHEMICAL", 43, 53], ["praziquantel", "SIMPLE_CHEMICAL", 59, 71], ["nelfinavir", "SIMPLE_CHEMICAL", 129, 139], ["this analysis", "TEST", 9, 22], ["perampanel", "TREATMENT", 43, 53], ["praziquantel", "TREATMENT", 59, 71], ["anti-COVID-19 clinical drugs", "TREATMENT", 91, 119], ["nelfinavir", "TREATMENT", 129, 139], ["COVID", "TEST", 187, 192], ["moderate", "OBSERVATION_MODIFIER", 159, 167]]], ["Perampanel is a drug currently employed in epilepsy, with an innovative mechanism of action through AMPA ([2-amino-3- (3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid) glutamate receptors.", [["Perampanel", "CHEMICAL", 0, 10], ["epilepsy", "DISEASE", 43, 51], ["AMPA", "CHEMICAL", 100, 104], ["[2-amino-3- (3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid", "CHEMICAL", 106, 167], ["glutamate", "CHEMICAL", 169, 178], ["Perampanel", "CHEMICAL", 0, 10], ["AMPA", "CHEMICAL", 100, 104], ["[2-amino-3- (3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid", "CHEMICAL", 106, 167], ["glutamate", "CHEMICAL", 169, 178], ["Perampanel", "SIMPLE_CHEMICAL", 0, 10], ["AMPA", "SIMPLE_CHEMICAL", 100, 104], ["[2-amino-3- (3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid", "SIMPLE_CHEMICAL", 106, 167], ["glutamate receptors", "PROTEIN", 169, 188], ["Perampanel", "TREATMENT", 0, 10], ["epilepsy", "PROBLEM", 43, 51], ["action through AMPA", "TREATMENT", 85, 104], ["amino", "TREATMENT", 109, 114], ["hydroxy", "TREATMENT", 121, 128], ["methyl", "TREATMENT", 131, 137], ["isoxazol", "TREATMENT", 138, 146], ["propanoic acid) glutamate receptors", "TREATMENT", 153, 188]]], ["Praziquantel is an anthelmintic drug used to treat several sorts of parasitic worm infections, and nelfinavir is a strong HIV1 protease inhibitor used with other antiviral medications to treat HIV.", [["worm", "ANATOMY", 78, 82], ["Praziquantel", "CHEMICAL", 0, 12], ["parasitic worm infections", "DISEASE", 68, 93], ["nelfinavir", "CHEMICAL", 99, 109], ["HIV", "DISEASE", 193, 196], ["Praziquantel", "CHEMICAL", 0, 12], ["nelfinavir", "CHEMICAL", 99, 109], ["Praziquantel", "SIMPLE_CHEMICAL", 0, 12], ["worm", "ORGANISM_SUBDIVISION", 78, 82], ["nelfinavir", "SIMPLE_CHEMICAL", 99, 109], ["HIV1", "GENE_OR_GENE_PRODUCT", 122, 126], ["HIV", "ORGANISM", 193, 196], ["HIV", "SPECIES", 193, 196], ["HIV1", "SPECIES", 122, 126], ["HIV", "SPECIES", 193, 196], ["Praziquantel", "TREATMENT", 0, 12], ["an anthelmintic drug", "TREATMENT", 16, 36], ["parasitic worm infections", "PROBLEM", 68, 93], ["nelfinavir", "TREATMENT", 99, 109], ["a strong HIV1 protease inhibitor", "TREATMENT", 113, 145], ["other antiviral medications", "TREATMENT", 156, 183], ["HIV", "PROBLEM", 193, 196], ["parasitic worm infections", "OBSERVATION", 68, 93]]], ["Interestingly, perampanel and praziquantel also exhibit a similar affinity to lopinavir and a higher affinity than ritonavir, both known inhibitors of SARS-CoV Mpro [3].", [["perampanel", "CHEMICAL", 15, 25], ["praziquantel", "CHEMICAL", 30, 42], ["lopinavir", "CHEMICAL", 78, 87], ["ritonavir", "CHEMICAL", 115, 124], ["perampanel", "CHEMICAL", 15, 25], ["praziquantel", "CHEMICAL", 30, 42], ["lopinavir", "CHEMICAL", 78, 87], ["ritonavir", "CHEMICAL", 115, 124], ["perampanel", "SIMPLE_CHEMICAL", 15, 25], ["praziquantel", "SIMPLE_CHEMICAL", 30, 42], ["lopinavir", "SIMPLE_CHEMICAL", 78, 87], ["ritonavir", "SIMPLE_CHEMICAL", 115, 124], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 151, 159], ["SARS-CoV", "SPECIES", 151, 159], ["perampanel", "TREATMENT", 15, 25], ["praziquantel", "TREATMENT", 30, 42], ["lopinavir", "TREATMENT", 78, 87], ["a higher affinity", "TREATMENT", 92, 109], ["ritonavir", "TREATMENT", 115, 124], ["SARS", "PROBLEM", 151, 155]]], ["A comparison of the \u0394Gbind values of lopinavir and ritonavir on dimeric SARS-CoV Mpro versus SARS-CoV2 Mpro indicated that these compounds exhibit a higher affinity for dimeric SARS-CoV2 Mpro than for SARS-CoV2 Mpro.", [["lopinavir", "CHEMICAL", 37, 46], ["ritonavir", "CHEMICAL", 51, 60], ["lopinavir", "CHEMICAL", 37, 46], ["ritonavir", "CHEMICAL", 51, 60], ["lopinavir", "SIMPLE_CHEMICAL", 37, 46], ["ritonavir", "SIMPLE_CHEMICAL", 51, 60], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 93, 107], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 201, 215], ["SARS-CoV2 Mpro", "PROTEIN", 93, 107], ["SARS-CoV", "SPECIES", 72, 80], ["the \u0394Gbind values", "TEST", 16, 33], ["lopinavir", "TREATMENT", 37, 46], ["ritonavir", "TREATMENT", 51, 60], ["dimeric SARS", "TEST", 64, 76], ["CoV Mpro", "TEST", 77, 85], ["these compounds", "PROBLEM", 123, 138], ["dimeric SARS", "PROBLEM", 169, 181], ["SARS", "PROBLEM", 201, 205]]], ["In addition, a comparison between the monomeric versus dimeric SARS-CoV2 Mpro and SARS-CoV Mpro systems shows that although the employment of the monomeric system allowed us to identify perampanel and lopinavir as good inhibitors of SARS-CoV2, it did not permit to the identification with praziquantel nelfinavir and ritonavir, highlighting the suitability of employing the dimeric system for drug discovery.Per-residue free energy decomposition ::: Results and DiscussionAn analysis of the residues contributing to the \u0394Gbind values for complexes with monomeric and dimeric SARS-CoV2 Mpro and SARS-CoV Mpro systems resulted in 5 to 11 residues (Table 3, Table 4, Table 5, Table 6).", [["perampanel", "CHEMICAL", 186, 196], ["lopinavir", "CHEMICAL", 201, 210], ["SARS", "DISEASE", 233, 237], ["praziquantel", "CHEMICAL", 289, 301], ["nelfinavir", "CHEMICAL", 302, 312], ["ritonavir", "CHEMICAL", 317, 326], ["perampanel", "CHEMICAL", 186, 196], ["lopinavir", "CHEMICAL", 201, 210], ["praziquantel", "CHEMICAL", 289, 301], ["nelfinavir", "CHEMICAL", 302, 312], ["ritonavir", "CHEMICAL", 317, 326], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["perampanel", "SIMPLE_CHEMICAL", 186, 196], ["lopinavir", "SIMPLE_CHEMICAL", 201, 210], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 233, 242], ["praziquantel", "SIMPLE_CHEMICAL", 289, 301], ["nelfinavir", "SIMPLE_CHEMICAL", 302, 312], ["ritonavir", "SIMPLE_CHEMICAL", 317, 326], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 594, 602], ["\u0394Gbind", "PROTEIN", 520, 526], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 594, 602], ["the monomeric", "TEST", 34, 47], ["SARS-CoV Mpro systems", "TEST", 82, 103], ["perampanel", "TREATMENT", 186, 196], ["lopinavir", "TREATMENT", 201, 210], ["praziquantel nelfinavir", "TREATMENT", 289, 312], ["ritonavir", "TREATMENT", 317, 326], ["the residues", "PROBLEM", 487, 499], ["the \u0394Gbind values", "TEST", 516, 533], ["monomeric and dimeric SARS", "PROBLEM", 553, 579], ["CoV2 Mpro", "TREATMENT", 580, 589], ["SARS", "PROBLEM", 594, 598], ["CoV Mpro systems", "TEST", 599, 615]]], ["An analysis of the residue stabilizing complexes between ligands and monomeric SARS-CoV2 Mpro and SARS-CoV Mpro systems showed that H41, M49, M165 and Q189 were present in most of the complexes (table 3), but only H41 and M165 were present for perampanel, the compound with the highest affinity for monomeric SARS-CoV2 (table 1); instead, it was stabilized by N142, G143, S144 and C145, which together with M165, contributed the most to the \u0394Gbind value.", [["perampanel", "CHEMICAL", 244, 254], ["M165", "CHEMICAL", 407, 411], ["H41", "CHEMICAL", 132, 135], ["M49", "CHEMICAL", 137, 140], ["M165", "CHEMICAL", 142, 146], ["Q189", "CHEMICAL", 151, 155], ["perampanel", "CHEMICAL", 244, 254], ["N142", "CHEMICAL", 360, 364], ["G143", "CHEMICAL", 366, 370], ["S144", "CHEMICAL", 372, 376], ["C145", "CHEMICAL", 381, 385], ["M165", "CHEMICAL", 407, 411], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 98, 106], ["H41", "SIMPLE_CHEMICAL", 132, 135], ["M165", "SIMPLE_CHEMICAL", 222, 226], ["perampanel", "SIMPLE_CHEMICAL", 244, 254], ["N142", "SIMPLE_CHEMICAL", 360, 364], ["G143", "SIMPLE_CHEMICAL", 366, 370], ["S144", "SIMPLE_CHEMICAL", 372, 376], ["C145", "SIMPLE_CHEMICAL", 381, 385], ["CoV2", "PROTEIN", 314, 318], ["\u0394Gbind", "PROTEIN", 441, 447], ["SARS-CoV", "SPECIES", 98, 106], ["An analysis", "TEST", 0, 11], ["the residue stabilizing complexes between ligands", "PROBLEM", 15, 64], ["monomeric SARS", "TEST", 69, 83], ["CoV2 Mpro", "TEST", 84, 93], ["SARS", "TEST", 98, 102], ["CoV Mpro systems", "TEST", 103, 119], ["M49", "TEST", 137, 140], ["perampanel", "TREATMENT", 244, 254], ["monomeric SARS", "TEST", 299, 313]]], ["M49 and M165 were present in the stabilization of lopinavir, the second-best compound, in the monomeric SARS-CoV2 Mpro and SARS-CoV Mpro systems.Per-residue free energy decomposition ::: Results and DiscussionFor the dimeric SARS-CoV2 Mpro and SARS-CoV Mpro systems, H41, M49 and M165 were present in the stabilization of almost all the complexes (Table 4, Table 5, Table 6).", [["lopinavir", "CHEMICAL", 50, 59], ["lopinavir", "CHEMICAL", 50, 59], ["lopinavir", "SIMPLE_CHEMICAL", 50, 59], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 244, 252], ["H41", "SIMPLE_CHEMICAL", 267, 270], ["SARS-CoV", "SPECIES", 123, 131], ["SARS-CoV", "SPECIES", 244, 252], ["lopinavir", "TREATMENT", 50, 59], ["the monomeric SARS", "TEST", 90, 108], ["the dimeric SARS", "TEST", 213, 229], ["SARS", "TEST", 244, 248], ["CoV Mpro systems", "TEST", 249, 265], ["stabilization", "OBSERVATION", 305, 318]]], ["From these three residues, the energetic contribution of H41 and M49 was only present in one of the subunits for the complex between dimeric SARS-CoV2 Mpro and perampanel (table 5).", [["H41", "CHEMICAL", 57, 60], ["H41", "CHEMICAL", 57, 60], ["perampanel", "CHEMICAL", 160, 170], ["H41", "GENE_OR_GENE_PRODUCT", 57, 60], ["perampanel", "SIMPLE_CHEMICAL", 160, 170], ["H41", "PROTEIN", 57, 60], ["M49", "PROTEIN", 65, 68], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 133, 155], ["perampanel", "PROTEIN", 160, 170], ["dimeric SARS", "TEST", 133, 145], ["three residues", "OBSERVATION", 11, 25], ["energetic", "OBSERVATION_MODIFIER", 31, 40]]], ["H41 was present in both subunits of the complex between SARS-CoV2 Mpro and praziquantel, and M49 was present only in subunit 1 for perampanel (table 5).", [["praziquantel", "CHEMICAL", 75, 87], ["praziquantel", "CHEMICAL", 75, 87], ["perampanel", "CHEMICAL", 131, 141], ["H41", "GENE_OR_GENE_PRODUCT", 0, 3], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 56, 70], ["praziquantel", "SIMPLE_CHEMICAL", 75, 87], ["perampanel", "SIMPLE_CHEMICAL", 131, 141], ["H41", "PROTEIN", 0, 3], ["subunit 1", "PROTEIN", 117, 126], ["praziquantel", "TREATMENT", 75, 87]]], ["H41 and M49 were present in the complexes of dimeric SARS-CoV2 Mpro with nelfinavir (table 5) and lopinavir (table 6).", [["nelfinavir", "CHEMICAL", 73, 83], ["lopinavir", "CHEMICAL", 98, 107], ["nelfinavir", "CHEMICAL", 73, 83], ["lopinavir", "CHEMICAL", 98, 107], ["H41", "GENE_OR_GENE_PRODUCT", 0, 3], ["M49", "GENE_OR_GENE_PRODUCT", 8, 11], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 53, 67], ["nelfinavir", "SIMPLE_CHEMICAL", 73, 83], ["lopinavir", "SIMPLE_CHEMICAL", 98, 107], ["H41", "PROTEIN", 0, 3], ["M49", "PROTEIN", 8, 11], ["dimeric SARS", "PROBLEM", 45, 57], ["CoV2 Mpro", "TREATMENT", 58, 67], ["nelfinavir (table", "TREATMENT", 73, 90], ["lopinavir (table", "TREATMENT", 98, 114]]], ["M49 was present in the complex of dimeric SARS-CoV2 Mpro with ritonavir (table 6).Per-residue free energy decomposition ::: Results and DiscussionAs observed for the complex between perampanel and monomeric SARS-CoV2 Mpro (table 3), N142, G143, S144 and C145, together with M165, contributed the most to the \u0394Gbind value (table 2) on both subunits of dimeric SARS-CoV2 Mpro (table 5).", [["SARS", "DISEASE", 42, 46], ["ritonavir", "CHEMICAL", 62, 71], ["perampanel", "CHEMICAL", 182, 192], ["SARS", "DISEASE", 207, 211], ["M165", "CHEMICAL", 274, 278], ["ritonavir", "CHEMICAL", 62, 71], ["perampanel", "CHEMICAL", 182, 192], ["N142", "CHEMICAL", 233, 237], ["G143", "CHEMICAL", 239, 243], ["S144", "CHEMICAL", 245, 249], ["C145", "CHEMICAL", 254, 258], ["ritonavir", "SIMPLE_CHEMICAL", 62, 71], ["perampanel", "SIMPLE_CHEMICAL", 182, 192], ["SARS-CoV2 Mpro (table 3", "GENE_OR_GENE_PRODUCT", 207, 230], ["M49", "PROTEIN", 0, 3], ["M165", "PROTEIN", 274, 278], ["\u0394Gbind", "PROTEIN", 308, 314], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 351, 373], ["table 5", "PROTEIN", 375, 382], ["dimeric SARS", "PROBLEM", 34, 46], ["CoV2 Mpro", "TREATMENT", 47, 56], ["ritonavir", "TREATMENT", 62, 71], ["dimeric SARS", "TEST", 351, 363]]], ["For praziquantel, the energetic contribution of M49 was only observed for one of the subunits, whereas participation of H41 and M165 was observed for both subunits, and as observed for perampanel, in which N142, G143, S144, C145 and M165 contributed importantly to the \u0394Gbind value (table 2).", [["praziquantel", "CHEMICAL", 4, 16], ["M49", "CHEMICAL", 48, 51], ["perampanel", "CHEMICAL", 185, 195], ["praziquantel", "CHEMICAL", 4, 16], ["perampanel", "CHEMICAL", 185, 195], ["N142", "CHEMICAL", 206, 210], ["G143", "CHEMICAL", 212, 216], ["S144", "CHEMICAL", 218, 222], ["C145", "CHEMICAL", 224, 228], ["M165", "CHEMICAL", 233, 237], ["praziquantel", "SIMPLE_CHEMICAL", 4, 16], ["M49", "GENE_OR_GENE_PRODUCT", 48, 51], ["H41", "GENE_OR_GENE_PRODUCT", 120, 123], ["M165", "GENE_OR_GENE_PRODUCT", 128, 132], ["perampanel", "SIMPLE_CHEMICAL", 185, 195], ["M49", "PROTEIN", 48, 51], ["H41", "PROTEIN", 120, 123], ["M165", "PROTEIN", 128, 132], ["\u0394Gbind", "PROTEIN", 269, 275], ["praziquantel", "TREATMENT", 4, 16], ["perampanel", "TEST", 185, 195]]], ["For nelfinavir, the participation of H41, M49 and M165 was seen only in one of the subunits, the one with the higher affinity (table 2), where it was also observed for the energetic contribution of D187, Q189, T190, A191 and Q192, which contributed importantly to the \u0394Gbind value (table 2).", [["nelfinavir", "CHEMICAL", 4, 14], ["nelfinavir", "CHEMICAL", 4, 14], ["H41, M49 and M165", "CHEMICAL", 37, 54], ["D187, Q189, T190, A191 and Q192", "CHEMICAL", 198, 229], ["nelfinavir", "SIMPLE_CHEMICAL", 4, 14], ["H41", "GENE_OR_GENE_PRODUCT", 37, 40], ["\u0394Gbind", "PROTEIN", 268, 274], ["nelfinavir", "TREATMENT", 4, 14]]], ["Energetic contributions of H41, M49 and M165 residues were observed for complexes of lopinavir with the dimeric SARS-CoV2 Mpro and SARS-CoV Mpro (table 6).", [["lopinavir", "CHEMICAL", 85, 94], ["H41, M49 and M165", "CHEMICAL", 27, 44], ["lopinavir", "CHEMICAL", 85, 94], ["H41", "GENE_OR_GENE_PRODUCT", 27, 30], ["M49", "SIMPLE_CHEMICAL", 32, 35], ["lopinavir", "SIMPLE_CHEMICAL", 85, 94], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 131, 139], ["SARS-CoV Mpro", "PROTEIN", 131, 144], ["table 6", "PROTEIN", 146, 153], ["SARS-CoV", "SPECIES", 131, 139], ["lopinavir", "TREATMENT", 85, 94], ["the dimeric SARS", "TEST", 100, 116], ["SARS", "PROBLEM", 131, 135]]], ["Significant participation of P168, D187, Q189 and T190 was also observed but only for interactions at subunit 2 of the dimeric SARS-CoV2 Mpro in complex with lopinavir (table 6), whereas Q189 contributed importantly to the \u0394Gbind value in both subunits of the dimeric SARS-CoV Mpro (table 6).Per-residue free energy decomposition ::: Results and DiscussionEnergetic contributions of M49 and M165 were observed for complexes of ritonavir with dimeric SARS-CoV2 Mpro and of H41 M49 and M165 with dimeric SARS-CoV Mpro (table 6).", [["lopinavir", "CHEMICAL", 158, 167], ["ritonavir", "CHEMICAL", 427, 436], ["P168, D187, Q189 and T190", "CHEMICAL", 29, 54], ["lopinavir", "CHEMICAL", 158, 167], ["ritonavir", "CHEMICAL", 427, 436], ["P168", "GENE_OR_GENE_PRODUCT", 29, 33], ["D187", "GENE_OR_GENE_PRODUCT", 35, 39], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 127, 141], ["lopinavir", "SIMPLE_CHEMICAL", 158, 167], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 268, 276], ["M165", "GENE_OR_GENE_PRODUCT", 391, 395], ["ritonavir", "SIMPLE_CHEMICAL", 427, 436], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 450, 464], ["P168", "PROTEIN", 29, 33], ["D187", "PROTEIN", 35, 39], ["Q189", "PROTEIN", 41, 45], ["T190", "PROTEIN", 50, 54], ["subunit 2", "PROTEIN", 102, 111], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 119, 141], ["Q189", "PROTEIN", 187, 191], ["\u0394Gbind", "PROTEIN", 223, 229], ["dimeric SARS-CoV Mpro", "PROTEIN", 260, 281], ["table 6", "PROTEIN", 283, 290], ["M165", "PROTEIN", 484, 488], ["dimeric SARS-CoV Mpro", "PROTEIN", 494, 515], ["table 6", "PROTEIN", 517, 524], ["SARS-CoV", "SPECIES", 268, 276], ["D187", "TREATMENT", 35, 39], ["the dimeric SARS", "PROBLEM", 115, 131], ["CoV2 Mpro", "TREATMENT", 132, 141], ["lopinavir (table", "TREATMENT", 158, 174], ["ritonavir", "TREATMENT", 427, 436], ["dimeric SARS", "TEST", 442, 454], ["dimeric SARS", "TEST", 494, 506]]], ["It was also observed that there was significant participation of P168, Q189 and A191 for interactions of ritonavir at subunit 1 of dimeric SARS-CoV2 Mpro and of D166, L167, P168, and Q189 for ritonavir at subunit 1 of dimeric SARS-CoV Mpro.", [["ritonavir", "CHEMICAL", 105, 114], ["ritonavir", "CHEMICAL", 192, 201], ["ritonavir", "CHEMICAL", 105, 114], ["D166, L167, P168, and Q189", "CHEMICAL", 161, 187], ["ritonavir", "CHEMICAL", 192, 201], ["P168", "GENE_OR_GENE_PRODUCT", 65, 69], ["Q189", "GENE_OR_GENE_PRODUCT", 71, 75], ["A191", "GENE_OR_GENE_PRODUCT", 80, 84], ["ritonavir", "SIMPLE_CHEMICAL", 105, 114], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 139, 153], ["ritonavir", "SIMPLE_CHEMICAL", 192, 201], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 226, 239], ["P168", "PROTEIN", 65, 69], ["subunit 1", "PROTEIN", 118, 127], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 131, 153], ["D166", "PROTEIN", 161, 165], ["P168", "PROTEIN", 173, 177], ["Q189", "PROTEIN", 183, 187], ["subunit 1", "PROTEIN", 205, 214], ["dimeric SARS-CoV Mpro", "PROTEIN", 218, 239], ["SARS-CoV", "SPECIES", 226, 234], ["ritonavir", "TREATMENT", 105, 114], ["dimeric SARS", "TEST", 131, 143], ["D166", "TEST", 161, 165], ["ritonavir", "TREATMENT", 192, 201], ["CoV Mpro", "TREATMENT", 231, 239]]], ["Overall, this analysis supports the importance of two conserved residues (H41 and C145) [4] in the stabilization of different inhibitors and highlights the importance of other residues (M49, N142, G143, S144, M165, D187, Q189, T190, A191 and Q192) in ligand stabilization.", [["M49", "CHEMICAL", 186, 189], ["N142", "CHEMICAL", 191, 195], ["G143", "CHEMICAL", 197, 201], ["S144", "CHEMICAL", 203, 207], ["M165, D187, Q189, T190, A191 and Q192", "CHEMICAL", 209, 246], ["this analysis", "TEST", 9, 22], ["the stabilization of different inhibitors", "TREATMENT", 95, 136]]], ["The identification of these 12 hot-spot residues allow to explain the differences in ligand affinity in the monomeric, dimeric and between each subunit of dimer.", [["dimer", "PROTEIN", 155, 160], ["these 12 hot-spot residues", "PROBLEM", 22, 48], ["the differences in ligand affinity", "PROBLEM", 66, 100]]], ["Although these residues do not form part of the protein-protein interface: domain 1 (residues 10-11 and14), domain 2 (122-127, 137-141, 166, 170 and 172) and domain 3 (280, 283, 285, 286, 290, 298, 299 and 303), they are in close distance of residues forming the protein-protein interface.", [["domain 1", "PROTEIN", 75, 83], ["residues 10-11 and14", "PROTEIN", 85, 105], ["domain 2", "PROTEIN", 108, 116], ["domain 3", "PROTEIN", 158, 166], ["protein-protein interface", "PROTEIN", 263, 288], ["residues", "TEST", 85, 93], ["the protein", "TEST", 259, 270], ["protein interface", "OBSERVATION", 271, 288]]], ["Therefore, the ligand binding in dimer is impacted not only by the modulating of these key residues, but also by the induced fit binding of ligand.Principal component analysis ::: Results and DiscussionPCA was performed to provide a quantified estimation of the differences in mobility.", [["dimer", "PROTEIN", 33, 38], ["impacted", "OBSERVATION", 42, 50], ["key residues", "OBSERVATION", 87, 99]]], ["To this end, the trace of the diagonalized covariance matrix of the backbone atomic positional fluctuations was determined for the free and bound SARS-CoV2 Mpro and SARS-CoV Mpro in the monomeric (Table S5, supplementary material) and dimeric states (table 7and Fig. S4, supplementary material).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 165, 173], ["SARS-CoV Mpro", "PROTEIN", 165, 178], ["S5", "PROTEIN", 203, 205], ["dimeric states", "PROTEIN", 235, 249], ["SARS-CoV", "SPECIES", 165, 173], ["the diagonalized covariance matrix", "TREATMENT", 26, 60], ["the backbone atomic positional fluctuations", "PROBLEM", 64, 107], ["the free and bound SARS", "TEST", 127, 150], ["CoV2 Mpro", "TEST", 151, 160], ["SARS", "PROBLEM", 165, 169], ["CoV Mpro", "TEST", 170, 178], ["trace", "OBSERVATION_MODIFIER", 17, 22]]], ["Based on this analysis, the values for free and bound monomeric SARS-CoV2 Mpro and SARS-CoV Mpro systems suggested that only the binding of sofosbuvir and lopinavir to monomeric SARS-CoV2 Mpro was not coupled to conformational changes of monomeric SARS-CoV2 Mpro.", [["sofosbuvir", "CHEMICAL", 140, 150], ["lopinavir", "CHEMICAL", 155, 164], ["SARS", "DISEASE", 178, 182], ["sofosbuvir", "CHEMICAL", 140, 150], ["lopinavir", "CHEMICAL", 155, 164], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["sofosbuvir", "SIMPLE_CHEMICAL", 140, 150], ["lopinavir", "SIMPLE_CHEMICAL", 155, 164], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 248, 262], ["monomeric SARS-CoV2 Mpro", "PROTEIN", 238, 262], ["SARS-CoV", "SPECIES", 83, 91], ["this analysis", "TEST", 9, 22], ["the values", "TEST", 24, 34], ["bound monomeric SARS", "TEST", 48, 68], ["SARS", "PROBLEM", 83, 87], ["CoV Mpro systems", "TEST", 88, 104], ["sofosbuvir", "TREATMENT", 140, 150], ["lopinavir", "TREATMENT", 155, 164], ["monomeric SARS", "PROBLEM", 168, 182], ["monomeric SARS", "PROBLEM", 238, 252], ["CoV2 Mpro", "TREATMENT", 253, 262]]], ["The binding of naftazone, pitavastatin, eszopiclone, perampanel, azelastine, celecoxib, ondansetron and lemborexant was linked to a decrease in the conformational mobility of monomeric SARS-CoV2 Mpro, and the conformational reduction would be coupled to an increase in the \u0394Gbind value (table 1), due to an unfavorable entropy component.", [["naftazone", "CHEMICAL", 15, 24], ["pitavastatin", "CHEMICAL", 26, 38], ["eszopiclone", "CHEMICAL", 40, 51], ["perampanel", "CHEMICAL", 53, 63], ["azelastine", "CHEMICAL", 65, 75], ["celecoxib", "CHEMICAL", 77, 86], ["ondansetron", "CHEMICAL", 88, 99], ["lemborexant", "CHEMICAL", 104, 115], ["naftazone", "CHEMICAL", 15, 24], ["pitavastatin", "CHEMICAL", 26, 38], ["eszopiclone", "CHEMICAL", 40, 51], ["perampanel", "CHEMICAL", 53, 63], ["azelastine", "CHEMICAL", 65, 75], ["celecoxib", "CHEMICAL", 77, 86], ["ondansetron", "CHEMICAL", 88, 99], ["lemborexant", "CHEMICAL", 104, 115], ["naftazone", "SIMPLE_CHEMICAL", 15, 24], ["pitavastatin", "SIMPLE_CHEMICAL", 26, 38], ["eszopiclone", "SIMPLE_CHEMICAL", 40, 51], ["perampanel", "SIMPLE_CHEMICAL", 53, 63], ["azelastine", "SIMPLE_CHEMICAL", 65, 75], ["celecoxib", "SIMPLE_CHEMICAL", 77, 86], ["ondansetron", "SIMPLE_CHEMICAL", 88, 99], ["lemborexant", "SIMPLE_CHEMICAL", 104, 115], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 185, 199], ["monomeric SARS-CoV2 Mpro", "PROTEIN", 175, 199], ["\u0394Gbind", "PROTEIN", 273, 279], ["naftazone", "TREATMENT", 15, 24], ["pitavastatin", "TREATMENT", 26, 38], ["eszopiclone", "TREATMENT", 40, 51], ["perampanel", "TREATMENT", 53, 63], ["azelastine", "TREATMENT", 65, 75], ["celecoxib", "TREATMENT", 77, 86], ["ondansetron", "TREATMENT", 88, 99], ["lemborexant", "TREATMENT", 104, 115], ["the conformational reduction", "TREATMENT", 205, 233], ["an unfavorable entropy component", "PROBLEM", 304, 336], ["decrease", "OBSERVATION_MODIFIER", 132, 140], ["increase", "OBSERVATION_MODIFIER", 257, 265], ["unfavorable", "OBSERVATION_MODIFIER", 307, 318], ["entropy", "OBSERVATION", 319, 326]]], ["The binding of zopiclone was coupled to an increase in the conformational mobility, which contributed to a decrease in the \u0394Gbind value due to a favorable entropy component.", [["zopiclone", "CHEMICAL", 15, 24], ["zopiclone", "CHEMICAL", 15, 24], ["zopiclone", "SIMPLE_CHEMICAL", 15, 24], ["zopiclone", "TREATMENT", 15, 24], ["a decrease in the \u0394Gbind value", "PROBLEM", 105, 135], ["a favorable entropy component", "PROBLEM", 143, 172], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["decrease", "OBSERVATION_MODIFIER", 107, 115], ["favorable", "OBSERVATION_MODIFIER", 145, 154], ["entropy", "OBSERVATION", 155, 162]]], ["The binding of lopinavir and ritonavir was linked to a decrease in the conformational mobility of monomeric SARS-CoV Mpro, which would also be linked to an increase in the \u0394Gbind value observed in table 1.Principal component analysis ::: Results and DiscussionAnalysis of the covariance values for free and bound dimeric SARS-CoV2 Mpro and SARS-CoV Mpro systems indicates that the binding of naftazone, zopiclone, sofosbuvir, eszopiclone, perampanel, azelastine, nelfinavir, praziquantel, lemborexant and lopinavir was not linked to important conformational changes of dimeric SARS-CoV2 Mpro, which means that their coupling with receptors would not impact the affinity observed in table 2.", [["lopinavir", "CHEMICAL", 15, 24], ["ritonavir", "CHEMICAL", 29, 38], ["naftazone", "CHEMICAL", 392, 401], ["zopiclone", "CHEMICAL", 403, 412], ["sofosbuvir", "CHEMICAL", 414, 424], ["eszopiclone", "CHEMICAL", 426, 437], ["perampanel", "CHEMICAL", 439, 449], ["azelastine", "CHEMICAL", 451, 461], ["nelfinavir", "CHEMICAL", 463, 473], ["praziquantel", "CHEMICAL", 475, 487], ["lemborexant", "CHEMICAL", 489, 500], ["lopinavir", "CHEMICAL", 505, 514], ["lopinavir", "CHEMICAL", 15, 24], ["ritonavir", "CHEMICAL", 29, 38], ["naftazone", "CHEMICAL", 392, 401], ["zopiclone", "CHEMICAL", 403, 412], ["sofosbuvir", "CHEMICAL", 414, 424], ["eszopiclone", "CHEMICAL", 426, 437], ["perampanel", "CHEMICAL", 439, 449], ["azelastine", "CHEMICAL", 451, 461], ["nelfinavir", "CHEMICAL", 463, 473], ["praziquantel", "CHEMICAL", 475, 487], ["lemborexant", "CHEMICAL", 489, 500], ["lopinavir", "CHEMICAL", 505, 514], ["lopinavir", "SIMPLE_CHEMICAL", 15, 24], ["ritonavir", "SIMPLE_CHEMICAL", 29, 38], ["SARS-CoV Mpro", "GENE_OR_GENE_PRODUCT", 108, 121], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 340, 348], ["naftazone", "SIMPLE_CHEMICAL", 392, 401], ["zopiclone", "SIMPLE_CHEMICAL", 403, 412], ["sofosbuvir", "SIMPLE_CHEMICAL", 414, 424], ["eszopiclone", "SIMPLE_CHEMICAL", 426, 437], ["perampanel", "SIMPLE_CHEMICAL", 439, 449], ["azelastine", "SIMPLE_CHEMICAL", 451, 461], ["nelfinavir", "SIMPLE_CHEMICAL", 463, 473], ["praziquantel", "SIMPLE_CHEMICAL", 475, 487], ["lemborexant", "SIMPLE_CHEMICAL", 489, 500], ["lopinavir", "SIMPLE_CHEMICAL", 505, 514], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 577, 591], ["\u0394Gbind", "PROTEIN", 172, 178], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 569, 591], ["SARS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 340, 348], ["lopinavir", "TREATMENT", 15, 24], ["ritonavir", "TREATMENT", 29, 38], ["CoV Mpro", "TREATMENT", 113, 121], ["the covariance values", "TEST", 272, 293], ["free and bound dimeric SARS", "TEST", 298, 325], ["CoV2 Mpro", "TREATMENT", 326, 335], ["SARS", "PROBLEM", 340, 344], ["CoV Mpro systems", "TEST", 345, 361], ["naftazone", "TREATMENT", 392, 401], ["zopiclone", "TREATMENT", 403, 412], ["sofosbuvir", "TREATMENT", 414, 424], ["eszopiclone", "TREATMENT", 426, 437], ["perampanel", "TREATMENT", 439, 449], ["azelastine", "TREATMENT", 451, 461], ["nelfinavir", "TREATMENT", 463, 473], ["praziquantel", "TREATMENT", 475, 487], ["lemborexant", "TREATMENT", 489, 500], ["lopinavir", "TREATMENT", 505, 514], ["dimeric SARS", "PROBLEM", 569, 581], ["CoV2 Mpro", "TREATMENT", 582, 591], ["receptors", "TREATMENT", 630, 639], ["the affinity", "PROBLEM", 657, 669], ["decrease", "OBSERVATION_MODIFIER", 55, 63], ["increase", "OBSERVATION_MODIFIER", 156, 164]]], ["The binding of ofloxacin, pitavastatin and fenoterol contributed to a decrease in conformational mobility, and the coupling of indomethacin, celecoxib, ondansetron and ritonavir was linked to an increase in dimeric SARS-CoV2 Mpro.", [["ofloxacin", "CHEMICAL", 15, 24], ["pitavastatin", "CHEMICAL", 26, 38], ["fenoterol", "CHEMICAL", 43, 52], ["indomethacin", "CHEMICAL", 127, 139], ["celecoxib", "CHEMICAL", 141, 150], ["ondansetron", "CHEMICAL", 152, 163], ["ritonavir", "CHEMICAL", 168, 177], ["ofloxacin", "CHEMICAL", 15, 24], ["pitavastatin", "CHEMICAL", 26, 38], ["fenoterol", "CHEMICAL", 43, 52], ["indomethacin", "CHEMICAL", 127, 139], ["celecoxib", "CHEMICAL", 141, 150], ["ondansetron", "CHEMICAL", 152, 163], ["ritonavir", "CHEMICAL", 168, 177], ["ofloxacin", "SIMPLE_CHEMICAL", 15, 24], ["pitavastatin", "SIMPLE_CHEMICAL", 26, 38], ["fenoterol", "SIMPLE_CHEMICAL", 43, 52], ["indomethacin", "SIMPLE_CHEMICAL", 127, 139], ["celecoxib", "SIMPLE_CHEMICAL", 141, 150], ["ondansetron", "SIMPLE_CHEMICAL", 152, 163], ["ritonavir", "SIMPLE_CHEMICAL", 168, 177], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 215, 229], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 207, 229], ["ofloxacin", "TREATMENT", 15, 24], ["pitavastatin", "TREATMENT", 26, 38], ["fenoterol", "TREATMENT", 43, 52], ["a decrease in conformational mobility", "PROBLEM", 68, 105], ["indomethacin", "TREATMENT", 127, 139], ["celecoxib", "TREATMENT", 141, 150], ["ondansetron", "TREATMENT", 152, 163], ["ritonavir", "TREATMENT", 168, 177], ["an increase in dimeric SARS", "PROBLEM", 192, 219], ["CoV2 Mpro", "TREATMENT", 220, 229], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["increase", "OBSERVATION_MODIFIER", 195, 203]]], ["However, the binding of lopinavir and ritonavir on dimeric SARS-CoV Mpro was not linked to conformational changes for lopinavir and an increase in the mobility of this receptor, which also means that their coupling on dimeric SARS-CoV Mpro did not impact the affinity observed in table 2.", [["lopinavir", "CHEMICAL", 24, 33], ["ritonavir", "CHEMICAL", 38, 47], ["lopinavir", "CHEMICAL", 118, 127], ["lopinavir", "CHEMICAL", 24, 33], ["ritonavir", "CHEMICAL", 38, 47], ["lopinavir", "CHEMICAL", 118, 127], ["lopinavir", "SIMPLE_CHEMICAL", 24, 33], ["ritonavir", "SIMPLE_CHEMICAL", 38, 47], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["lopinavir", "SIMPLE_CHEMICAL", 118, 127], ["SARS-CoV", "SPECIES", 59, 67], ["lopinavir", "TREATMENT", 24, 33], ["ritonavir", "TREATMENT", 38, 47], ["CoV Mpro", "TREATMENT", 64, 72], ["lopinavir", "TREATMENT", 118, 127], ["dimeric SARS", "PROBLEM", 218, 230], ["CoV Mpro", "TREATMENT", 231, 239], ["the affinity", "PROBLEM", 255, 267], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["Overall, this analysis shows that the binding of the best compounds on monomeric SARS-CoV2 Mpro or SARS-CoV Mpro more importantly impacts the \u0394Gbind value estimated for each ligand due to the conformational changes coupled to the binding, whereas the affinity trends observed for the best compounds on the dimeric systems were not affected.ConclusionIn this research, we first performed the docking of 15 FDA-approved drugs, which were previously identified as potential inhibitors of monomeric SARS-CoV2 Mpro, by employing the recently elucidated crystallographic structure of monomer and dimeric SARS-CoV2 Mpro; then, 100-ns-long MD simulations coupled to the MM/GBSA approach were performed to compare results using both monomeric versus dimeric states, where the latter corresponds to the functional state.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 99, 107], ["monomeric SARS-CoV2 Mpro", "PROTEIN", 71, 95], ["SARS-CoV Mpro", "PROTEIN", 99, 112], ["\u0394Gbind", "PROTEIN", 142, 148], ["dimeric SARS-CoV2 Mpro", "PROTEIN", 590, 612], ["SARS-CoV", "SPECIES", 99, 107], ["this analysis", "TEST", 9, 22], ["SARS", "PROBLEM", 99, 103], ["the conformational changes", "PROBLEM", 188, 214], ["drugs", "TREATMENT", 418, 423], ["the MM/GBSA approach", "TREATMENT", 658, 678]]], ["Additionally, similar studies were performed, including two known HIV-1 protease inhibitors, lopinavir and ritonavir, which have been previously employed as an effective therapy against SARS-CoV Mpro, to compare the inhibitory differences.", [["lopinavir", "CHEMICAL", 93, 102], ["ritonavir", "CHEMICAL", 107, 116], ["lopinavir", "CHEMICAL", 93, 102], ["ritonavir", "CHEMICAL", 107, 116], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 66, 80], ["lopinavir", "SIMPLE_CHEMICAL", 93, 102], ["ritonavir", "SIMPLE_CHEMICAL", 107, 116], ["SARS-CoV Mpro", "ORGANISM", 186, 199], ["HIV-1", "SPECIES", 66, 71], ["HIV-1", "SPECIES", 66, 71], ["SARS-CoV", "SPECIES", 186, 194], ["similar studies", "TEST", 14, 29], ["HIV-1 protease inhibitors", "TREATMENT", 66, 91], ["lopinavir", "TREATMENT", 93, 102], ["ritonavir", "TREATMENT", 107, 116], ["an effective therapy", "TREATMENT", 157, 177], ["SARS", "PROBLEM", 186, 190]]], ["Our results identified perampanel (best compound), praziquantel (second best compound) and nelfinavir (third best compound) as potential inhibitors of dimeric SARS-CoV2 Mpro, and these ligands also showed similar inhibitory properties than those of lopinavir and better inhibitory properties than those of ritonavir.", [["perampanel", "CHEMICAL", 23, 33], ["praziquantel", "CHEMICAL", 51, 63], ["nelfinavir", "CHEMICAL", 91, 101], ["lopinavir", "CHEMICAL", 249, 258], ["ritonavir", "CHEMICAL", 306, 315], ["perampanel", "CHEMICAL", 23, 33], ["praziquantel", "CHEMICAL", 51, 63], ["nelfinavir", "CHEMICAL", 91, 101], ["lopinavir", "CHEMICAL", 249, 258], ["ritonavir", "CHEMICAL", 306, 315], ["perampanel", "SIMPLE_CHEMICAL", 23, 33], ["praziquantel", "SIMPLE_CHEMICAL", 51, 63], ["nelfinavir", "SIMPLE_CHEMICAL", 91, 101], ["SARS-CoV2 Mpro", "SIMPLE_CHEMICAL", 159, 173], ["lopinavir", "SIMPLE_CHEMICAL", 249, 258], ["ritonavir", "SIMPLE_CHEMICAL", 306, 315], ["perampanel", "TEST", 23, 33], ["praziquantel", "TREATMENT", 51, 63], ["nelfinavir", "TREATMENT", 91, 101], ["dimeric SARS", "PROBLEM", 151, 163], ["CoV2 Mpro", "TREATMENT", 164, 173], ["lopinavir", "TREATMENT", 249, 258], ["ritonavir", "TREATMENT", 306, 315]]], ["Furthermore, comparative analysis of the affinity of lopinavir and ritonavir on SARS-CoV2 Mpro and SARS-CoV Mpro revealed that both compounds showed a higher affinity to SARS-CoV2 Mpro.", [["lopinavir", "CHEMICAL", 53, 62], ["ritonavir", "CHEMICAL", 67, 76], ["SARS", "DISEASE", 170, 174], ["lopinavir", "CHEMICAL", 53, 62], ["ritonavir", "CHEMICAL", 67, 76], ["lopinavir", "SIMPLE_CHEMICAL", 53, 62], ["ritonavir", "SIMPLE_CHEMICAL", 67, 76], ["SARS-CoV2 Mpro", "ORGANISM", 80, 94], ["SARS-CoV Mpro", "ORGANISM", 99, 112], ["SARS-CoV2 Mpro", "GENE_OR_GENE_PRODUCT", 170, 184], ["SARS-CoV Mpro", "PROTEIN", 99, 112], ["SARS-CoV", "SPECIES", 99, 107], ["comparative analysis", "TEST", 13, 33], ["lopinavir", "TREATMENT", 53, 62], ["ritonavir", "TREATMENT", 67, 76], ["SARS", "TEST", 80, 84], ["CoV Mpro", "TEST", 104, 112]]], ["On the basis of per-residue free energy decomposition, we identified the hot-spot residues (H41, M49, N142, G143, S144, C145, M165, D187, Q189, T190, A191 and Q192) which contribute significantly high to the total binding affinity.", [["per-residue free energy decomposition", "PROBLEM", 16, 53], ["spot residues", "TEST", 77, 90], ["M49", "TEST", 97, 100]]], ["Among these residues H41 and C145 are conserved residues.", [["C145", "AMINO_ACID", 29, 33], ["residues", "OBSERVATION_MODIFIER", 48, 56]]], ["Therefore, these key residues are important for drug binding.", [["drug binding", "PROBLEM", 48, 60]]], ["This study demonstrates for the first time that the coupling of ligands on dimeric SARS-CoV2 Mpro is linked to differences in the binding affinity in both subunits that may be characteristic of cooperativity.", [["dimeric SARS-CoV2 Mpro", "PROTEIN", 75, 97], ["This study", "TEST", 0, 10], ["dimeric SARS", "TEST", 75, 87], ["the binding affinity", "PROBLEM", 126, 146], ["may be characteristic of", "UNCERTAINTY", 169, 193], ["cooperativity", "OBSERVATION", 194, 207]]], ["Our study also demonstrates that to obtain more confident drug discovery results, it is better to employ the dimeric state than the monomeric state since ligand binding on the monomer is coupled to conformational changes that contribute to the impact of the \u0394Gbind value.Declaration of competing interest\u2612 The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.Declaration of competing interest\u25a1 The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:", [["\u0394Gbind", "GENE_OR_GENE_PRODUCT", 258, 264], ["\u0394Gbind", "PROTEIN", 258, 264], ["Our study", "TEST", 0, 9], ["ligand binding", "PROBLEM", 154, 168]]]], "PMC7151974": [["General IntroductionMonoclonal antibodies are protein molecules made from hybridoma cells by recombinant DNA technology.", [["hybridoma cells", "ANATOMY", 74, 89], ["hybridoma cells", "CELL", 74, 89], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["Monoclonal antibodies", "PROTEIN", 20, 41], ["protein molecules", "PROTEIN", 46, 63], ["hybridoma cells", "CELL_LINE", 74, 89], ["General IntroductionMonoclonal antibodies", "TREATMENT", 0, 41], ["protein molecules", "PROBLEM", 46, 63], ["hybridoma cells", "TREATMENT", 74, 89], ["hybridoma cells", "OBSERVATION", 74, 89]]], ["When applied as a therapeutic, a particular monoclonal antibody is referred to as Mab.", [["Mab", "GENE_OR_GENE_PRODUCT", 82, 85], ["monoclonal antibody", "PROTEIN", 44, 63], ["Mab", "PROTEIN", 82, 85], ["a particular monoclonal antibody", "TREATMENT", 31, 63]]], ["The Mabs are defined as \u201cmonospecific antibodies that are made by identical immune cells that are all clones of a unique parent cell.\u201d", [["immune cells", "ANATOMY", 76, 88], ["cell", "ANATOMY", 128, 132], ["Mabs", "GENE_OR_GENE_PRODUCT", 4, 8], ["immune cells", "CELL", 76, 88], ["cell", "CELL", 128, 132], ["Mabs", "PROTEIN", 4, 8], ["\u201cmonospecific antibodies", "PROTEIN", 24, 48], ["immune cells", "CELL_TYPE", 76, 88], ["unique parent cell", "CELL_LINE", 114, 132], ["The Mabs", "TREATMENT", 0, 8], ["\u201cmonospecific antibodies", "PROBLEM", 24, 48], ["identical immune cells", "PROBLEM", 66, 88], ["immune cells", "OBSERVATION", 76, 88]]], ["Mabs are far superior to polyclonal antibodies with respect to their controlled manufacturing procedures and their reproducible affinity for specific target antigens.", [["Mabs", "PROTEIN", 0, 4], ["polyclonal antibodies", "PROTEIN", 25, 46], ["target antigens", "PROTEIN", 150, 165], ["Mabs", "TREATMENT", 0, 4], ["polyclonal antibodies", "TREATMENT", 25, 46], ["their controlled manufacturing procedures", "TREATMENT", 63, 104]]]], "PMC7309522": [["A 44-year-old right-handed woman reported a gradual onset of right hand incoordination seven days after the onset of minor respiratory symptoms and pruritus due to COVID-19 infection.", [["right hand", "ANATOMY", 61, 71], ["respiratory", "ANATOMY", 123, 134], ["right hand incoordination", "DISEASE", 61, 86], ["respiratory symptoms", "DISEASE", 123, 143], ["pruritus", "DISEASE", 148, 156], ["COVID-19", "CHEMICAL", 164, 172], ["infection", "DISEASE", 173, 182], ["woman", "ORGANISM", 27, 32], ["hand", "ORGANISM_SUBDIVISION", 67, 71], ["woman", "SPECIES", 27, 32], ["right hand incoordination", "PROBLEM", 61, 86], ["minor respiratory symptoms", "PROBLEM", 117, 143], ["pruritus", "PROBLEM", 148, 156], ["COVID-19 infection", "PROBLEM", 164, 182], ["right", "ANATOMY_MODIFIER", 14, 19], ["right", "ANATOMY_MODIFIER", 61, 66], ["hand", "ANATOMY", 67, 71], ["incoordination", "OBSERVATION", 72, 86], ["respiratory", "ANATOMY", 123, 134], ["symptoms", "OBSERVATION", 135, 143], ["infection", "OBSERVATION", 173, 182]]], ["Over 48 hours, the patient developed word-finding difficulties and progression in right arm weakness leading to presentation to the emergency department as a suspected stroke.", [["right arm", "ANATOMY", 82, 91], ["right arm weakness", "DISEASE", 82, 100], ["stroke", "DISEASE", 168, 174], ["patient", "ORGANISM", 19, 26], ["arm", "ORGANISM_SUBDIVISION", 88, 91], ["patient", "SPECIES", 19, 26], ["word-finding difficulties", "PROBLEM", 37, 62], ["right arm weakness", "PROBLEM", 82, 100], ["a suspected stroke", "PROBLEM", 156, 174], ["right", "ANATOMY_MODIFIER", 82, 87], ["arm", "ANATOMY", 88, 91], ["weakness", "OBSERVATION", 92, 100], ["stroke", "OBSERVATION", 168, 174]]]], "PMC6492653": [["IntroductionRespiratory failure is the major complication in patients hospitalized with severe viral infections such as influenza, severe acute respiratory syndrome (SARS), and the novel coronavirus (CoV) infection.", [["IntroductionRespiratory failure", "DISEASE", 0, 31], ["viral infections", "DISEASE", 95, 111], ["influenza", "DISEASE", 120, 129], ["acute respiratory syndrome", "DISEASE", 138, 164], ["SARS", "DISEASE", 166, 170], ["coronavirus (CoV) infection", "DISEASE", 187, 214], ["patients", "ORGANISM", 61, 69], ["coronavirus", "ORGANISM", 187, 198], ["CoV", "ORGANISM", 200, 203], ["patients", "SPECIES", 61, 69], ["CoV", "SPECIES", 200, 203], ["IntroductionRespiratory failure", "PROBLEM", 0, 31], ["the major complication", "PROBLEM", 35, 57], ["severe viral infections", "PROBLEM", 88, 111], ["influenza", "PROBLEM", 120, 129], ["severe acute respiratory syndrome", "PROBLEM", 131, 164], ["SARS", "PROBLEM", 166, 170], ["the novel coronavirus (CoV) infection", "PROBLEM", 177, 214], ["failure", "OBSERVATION", 24, 31], ["major", "OBSERVATION_MODIFIER", 39, 44], ["complication", "OBSERVATION", 45, 57], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["viral", "OBSERVATION_MODIFIER", 95, 100], ["infections", "OBSERVATION", 101, 111], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["respiratory syndrome", "OBSERVATION", 144, 164], ["coronavirus", "OBSERVATION", 187, 198], ["infection", "OBSERVATION", 205, 214]]], ["Affected patients may progress rapidly to acute respiratory distress syndrome (ARDS) and multi\u2010organ failure.1, 2, 3, 4 Excessive cytokine and chemokine responses have been proposed as central to disease pathogenesis and end\u2010organ damage in such patients.2, 4 Dysregulated responses with marked elevations of blood IL\u20106, CXCL8/IL\u20108, CCL2/MCP\u20101, CXCL10/IP\u201010, and CXCL9/MIG have been observed in patients infected with avian influenza A(H5N1) virus; these responses are correlated with high levels of viral replication in the respiratory tract.2, 5 Higher plasma levels of proinflammatory IL\u20106, CXCL8/IL\u20108, CCL2/MCP\u20101, and sTNFR\u20101 have been observed in patients with severe A(H1N1)pdm09 infection than those with mild disease, and the levels correlate with the extent and progression of pneumonia.6, 7 While neuraminidase inhibitor (NAI) therapy is useful in improving clinical outcome if administered to patients hospitalized with influenza within 4\u20135 days of illness onset, there is often delay in initiation of NAI therapy and progressive disease sometimes occurs despite early administration.8 In SARS, there were marked increases in Th1 cytokine interferon (IFN)\u2010\u03b3, inflammatory cytokines IL\u20101, IL\u20106 and IL\u201012, and chemokines IL\u20108, MCP\u20101 and IP\u201010, and these changes confirmed the activation of Th1 cell\u2010mediated immunity (CMI) and hyperinnate inflammatory response through the accumulation of monocytes/macrophages and neutrophils.9", [["respiratory", "ANATOMY", 48, 59], ["end\u2010organ", "ANATOMY", 221, 230], ["blood", "ANATOMY", 309, 314], ["respiratory tract", "ANATOMY", 525, 542], ["plasma", "ANATOMY", 555, 561], ["monocytes", "ANATOMY", 1398, 1407], ["macrophages", "ANATOMY", 1408, 1419], ["neutrophils", "ANATOMY", 1424, 1435], ["acute respiratory distress syndrome", "DISEASE", 42, 77], ["ARDS", "DISEASE", 79, 83], ["multi\u2010organ failure", "DISEASE", 89, 108], ["end\u2010organ damage", "DISEASE", 221, 237], ["avian influenza A(H5N1) virus", "DISEASE", 418, 447], ["infection", "DISEASE", 686, 695], ["pneumonia", "DISEASE", 786, 795], ["neuraminidase inhibitor", "CHEMICAL", 807, 830], ["NAI", "CHEMICAL", 832, 835], ["influenza", "DISEASE", 931, 940], ["illness", "DISEASE", 960, 967], ["NAI", "CHEMICAL", 1013, 1016], ["SARS", "DISEASE", 1100, 1104], ["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 246, 254], ["blood", "ORGANISM_SUBSTANCE", 309, 314], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 315, 319], ["CXCL8", "GENE_OR_GENE_PRODUCT", 321, 326], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 327, 331], ["CCL2", "GENE_OR_GENE_PRODUCT", 333, 337], ["MCP\u20101", "GENE_OR_GENE_PRODUCT", 338, 343], ["CXCL10", "GENE_OR_GENE_PRODUCT", 345, 351], ["IP\u201010", "GENE_OR_GENE_PRODUCT", 352, 357], ["CXCL9", "GENE_OR_GENE_PRODUCT", 363, 368], ["MIG", "GENE_OR_GENE_PRODUCT", 369, 372], ["patients", "ORGANISM", 395, 403], ["avian influenza A(H5N1) virus", "ORGANISM", 418, 447], ["respiratory tract", "ORGANISM_SUBDIVISION", 525, 542], ["plasma", "ORGANISM_SUBSTANCE", 555, 561], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 588, 592], ["CXCL8", "GENE_OR_GENE_PRODUCT", 594, 599], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 600, 604], ["CCL2", "GENE_OR_GENE_PRODUCT", 606, 610], ["MCP\u20101", "GENE_OR_GENE_PRODUCT", 611, 616], ["sTNFR\u20101", "GENE_OR_GENE_PRODUCT", 622, 629], ["patients", "ORGANISM", 652, 660], ["A(H1N1)pdm09", "ORGANISM", 673, 685], ["neuraminidase inhibitor", "SIMPLE_CHEMICAL", 807, 830], ["NAI", "SIMPLE_CHEMICAL", 832, 835], ["patients", "ORGANISM", 904, 912], ["interferon (IFN)\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 1150, 1168], ["IL\u20101", "GENE_OR_GENE_PRODUCT", 1193, 1197], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 1199, 1203], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 1208, 1213], ["IL\u20108", "GENE_OR_GENE_PRODUCT", 1230, 1234], ["MCP\u20101", "GENE_OR_GENE_PRODUCT", 1236, 1241], ["IP\u201010", "GENE_OR_GENE_PRODUCT", 1246, 1251], ["monocytes", "CELL", 1398, 1407], ["macrophages", "CELL", 1408, 1419], ["neutrophils", "CELL", 1424, 1435], ["cytokine", "PROTEIN", 130, 138], ["chemokine", "PROTEIN", 143, 152], ["blood IL\u20106", "PROTEIN", 309, 319], ["CXCL8", "PROTEIN", 321, 326], ["IL\u20108", "PROTEIN", 327, 331], ["CCL2", "PROTEIN", 333, 337], ["MCP\u20101", "PROTEIN", 338, 343], ["CXCL10", "PROTEIN", 345, 351], ["IP\u201010", "PROTEIN", 352, 357], ["CXCL9", "PROTEIN", 363, 368], ["MIG", "PROTEIN", 369, 372], ["proinflammatory IL\u20106", "PROTEIN", 572, 592], ["CXCL8", "PROTEIN", 594, 599], ["CCL2", "PROTEIN", 606, 610], ["MCP\u20101", "PROTEIN", 611, 616], ["sTNFR\u20101", "PROTEIN", 622, 629], ["Th1 cytokine interferon (IFN)\u2010\u03b3", "PROTEIN", 1137, 1168], ["inflammatory cytokines", "PROTEIN", 1170, 1192], ["IL\u20106", "PROTEIN", 1199, 1203], ["IL\u201012", "PROTEIN", 1208, 1213], ["chemokines", "PROTEIN", 1219, 1229], ["IL\u20108", "PROTEIN", 1230, 1234], ["MCP\u20101", "PROTEIN", 1236, 1241], ["IP\u201010", "PROTEIN", 1246, 1251], ["monocytes", "CELL_TYPE", 1398, 1407], ["macrophages", "CELL_TYPE", 1408, 1419], ["neutrophils", "CELL_TYPE", 1424, 1435], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 246, 254], ["patients", "SPECIES", 395, 403], ["avian influenza A(H5N1", "SPECIES", 418, 440], ["patients", "SPECIES", 652, 660], ["patients", "SPECIES", 904, 912], ["avian influenza A(H5N1) virus", "SPECIES", 418, 447], ["acute respiratory distress syndrome", "PROBLEM", 42, 77], ["ARDS", "PROBLEM", 79, 83], ["multi\u2010organ failure", "PROBLEM", 89, 108], ["central to disease pathogenesis", "PROBLEM", 185, 216], ["end\u2010organ damage", "PROBLEM", 221, 237], ["marked elevations", "PROBLEM", 288, 305], ["blood IL", "TEST", 309, 317], ["CXCL8", "TEST", 321, 326], ["IL", "TEST", 327, 329], ["CCL2", "TEST", 333, 337], ["MCP", "TEST", 338, 341], ["CXCL10/IP\u2010", "TEST", 345, 355], ["CXCL9", "TEST", 363, 368], ["/MIG", "TEST", 368, 372], ["avian influenza A(H5N1) virus", "PROBLEM", 418, 447], ["viral replication in the respiratory tract", "PROBLEM", 500, 542], ["Higher plasma levels", "TEST", 548, 568], ["proinflammatory IL\u2010", "TEST", 572, 591], ["CXCL8/IL\u2010", "TEST", 594, 603], ["CCL2", "TEST", 606, 610], ["MCP", "TEST", 611, 614], ["sTNFR", "TEST", 622, 627], ["severe A(H1N1)pdm09 infection", "PROBLEM", 666, 695], ["mild disease", "PROBLEM", 712, 724], ["the levels", "TEST", 730, 740], ["pneumonia", "PROBLEM", 786, 795], ["neuraminidase inhibitor (NAI) therapy", "TREATMENT", 807, 844], ["influenza", "PROBLEM", 931, 940], ["NAI therapy", "TREATMENT", 1013, 1024], ["progressive disease", "PROBLEM", 1029, 1048], ["marked increases", "PROBLEM", 1117, 1133], ["Th1 cytokine interferon (IFN)", "TREATMENT", 1137, 1166], ["inflammatory cytokines IL", "TREATMENT", 1170, 1195], ["IL\u2010", "TREATMENT", 1199, 1202], ["chemokines IL", "TEST", 1219, 1232], ["MCP", "TEST", 1236, 1239], ["IP\u2010", "TEST", 1246, 1249], ["these changes", "TEST", 1257, 1270], ["CMI", "PROBLEM", 1327, 1330], ["hyperinnate inflammatory response", "PROBLEM", 1336, 1369], ["monocytes", "TEST", 1398, 1407], ["macrophages", "PROBLEM", 1408, 1419], ["neutrophils", "TEST", 1424, 1435], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["respiratory distress", "OBSERVATION", 48, 68], ["ARDS", "OBSERVATION", 79, 83], ["failure", "OBSERVATION", 101, 108], ["disease", "OBSERVATION", 196, 203], ["marked", "OBSERVATION_MODIFIER", 288, 294], ["elevations", "OBSERVATION_MODIFIER", 295, 305], ["viral replication", "OBSERVATION", 500, 517], ["respiratory tract", "ANATOMY", 525, 542], ["proinflammatory", "OBSERVATION_MODIFIER", 572, 587], ["severe", "OBSERVATION_MODIFIER", 666, 672], ["mild", "OBSERVATION_MODIFIER", 712, 716], ["disease", "OBSERVATION", 717, 724], ["progression", "OBSERVATION_MODIFIER", 771, 782], ["pneumonia", "OBSERVATION", 786, 795], ["progressive", "OBSERVATION_MODIFIER", 1029, 1040], ["disease", "OBSERVATION", 1041, 1048], ["marked", "OBSERVATION_MODIFIER", 1117, 1123], ["increases", "OBSERVATION_MODIFIER", 1124, 1133], ["Th1 cytokine interferon", "OBSERVATION", 1137, 1160], ["inflammatory", "OBSERVATION_MODIFIER", 1170, 1182], ["inflammatory response", "OBSERVATION", 1348, 1369], ["accumulation of monocytes", "OBSERVATION", 1382, 1407], ["macrophages", "ANATOMY", 1408, 1419]]]], "17283ed26d54e432f633c6053090952ff4d3a6f7": []}